<?xml version="1.0"?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
      <journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
      <journal-title-group>
        <journal-title>Frontiers in Immunology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1664-3224</issn>
      <publisher>
        <publisher-name>Frontiers Media S.A.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32296436</article-id>
      <article-id pub-id-type="pmc">7136553</article-id>
      <article-id pub-id-type="doi">10.3389/fimmu.2020.00530</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Immunology</subject>
          <subj-group>
            <subject>Original Research</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Assessment of the Role of C3(H<sub>2</sub>O) in the Alternative Pathway</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Fromell</surname>
            <given-names>Karin</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/878414/overview"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Adler</surname>
            <given-names>Anna</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/880958/overview"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>&#xC5;man</surname>
            <given-names>Amanda</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/880203/overview"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Manivel</surname>
            <given-names>Vivek Anand</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/878964/overview"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>Shan</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>D&#xFC;hrkop</surname>
            <given-names>Claudia</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sandholm</surname>
            <given-names>Kerstin</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/616729/overview"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ekdahl</surname>
            <given-names>Kristina N.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/579730/overview"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nilsson</surname>
            <given-names>Bo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c001">
            <sup>*</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/289238/overview"/>
        </contrib>
      </contrib-group>
      <aff id="aff1"><sup>1</sup><institution>Rudbeck Laboratory, Department of Immunology, Genetics and Pathology</institution>, <addr-line>Uppsala</addr-line>, <country>Sweden</country></aff>
      <aff id="aff2"><sup>2</sup><institution>Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg</institution>, <addr-line>Gothenburg</addr-line>, <country>Sweden</country></aff>
      <aff id="aff3"><sup>3</sup><institution>Linnaeus Center of Biomaterials Chemistry, Linnaeus University</institution>, <addr-line>Kalmar</addr-line>, <country>Sweden</country></aff>
      <author-notes>
        <fn fn-type="edited-by">
          <p>Edited by: Nicole Thielens, UMR5075 Institut de Biologie Structurale (IBS), France</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Reviewed by: Brian V. Geisbrecht, University of Missouri&#x2013;Kansas City, United States; Mih&#xE1;ly J&#xF3;zsi, E&#xF6;tv&#xF6;s Lor&#xE1;nd University, Hungary</p>
        </fn>
        <corresp id="c001">*Correspondence: Bo Nilsson <email>bo.nilsson@igp.uu.se</email></corresp>
        <fn fn-type="other" id="fn001">
          <p>This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>31</day>
        <month>3</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>11</volume>
      <elocation-id>530</elocation-id>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>12</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>3</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2020 Fromell, Adler, &#xC5;man, Manivel, Huang, D&#xFC;hrkop, Sandholm, Ekdahl and Nilsson.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder>Fromell, Adler, &#xC5;man, Manivel, Huang, D&#xFC;hrkop, Sandholm, Ekdahl and Nilsson</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>In this study we investigate the hydrolysis of C3 to C3(H<sub>2</sub>O) and its ability to initiate activation via the alternative pathway (AP) of the complement system. The internal thioester bond within C3 is hydrolyzed by water in plasma because of its inherent lability. This results in the formation of non-proteolytically activated C3(H<sub>2</sub>O) which is believed have C3b-like properties and be able to form an active initial fluid phase C3 convertase together with Factor B (FB). The generation of C3(H<sub>2</sub>O) occurs at a low but constant rate in blood, but the formation can be greatly accelerated by the interaction with various surfaces or nucleophilic and chaotropic agents. In order to more specifically elucidate the relevance of the C3(H<sub>2</sub>O) for AP activation, formation was induced in solution by repeated freeze/thawing, methylamine or KCSN treatment and named C3(x) where the x can be any of the reactive nucleophilic or chaotropic agents. Isolation and characterization of C3(x) showed that it exists in several forms with varying attributes, where some have more C3b-like properties and can be cleaved by Factor I in the presence of Factor H. However, in common for all these variants is that they are less active partners in initial formation of the AP convertase compared with the corresponding activity of C3b. These observations support the idea that formation of C3(x) in the fluid phase is not a strong initiator of the AP. It is rather likely that the AP mainly acts as an amplification mechanism of complement activation that is triggered by deposition of target-bound C3b molecules generated by other means.</p>
      </abstract>
      <kwd-group>
        <kwd>complement</kwd>
        <kwd>C3</kwd>
        <kwd>C3(H<sub>2</sub>O)</kwd>
        <kwd>C3b</kwd>
        <kwd>alternative pathway</kwd>
        <kwd>C3 convertase</kwd>
      </kwd-group>
      <counts>
        <fig-count count="7"/>
        <table-count count="2"/>
        <equation-count count="0"/>
        <ref-count count="34"/>
        <page-count count="13"/>
        <word-count count="9379"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>The alternative pathway of complement (AP) is initiated by C3b and factor B forming a Mg<sup>2+</sup>-dependent complex as reviewed in Lachmann (<xref rid="B1" ref-type="bibr">1</xref>) and Harrison (<xref rid="B2" ref-type="bibr">2</xref>). This initial complex formation is followed by the cleavage of factor B by factor D into Ba and Bb to form the active labile enzymatic complex C3bBb, the AP C3 convertase, which in the fluid phase has a half-life of 90s as determined <italic>in vitro</italic> using purified components (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). The C3bBb convertase can then cleave native C3 molecules into C3a and C3b. These C3b molecules trigger a positive feedback loop reaction, with each new C3b molecule potentially being able to form a new AP convertase complex.</p>
      <p>Thus, in order for the AP to commence and form an initial AP convertase, C3b needs to be available in the fluid phase. As an indication of C3b formation, the anaphylatoxin C3a/C3a<sub>desArg</sub> is constantly generated with a half-life in plasma of ~30 min (<xref rid="B5" ref-type="bibr">5</xref>). The C3a levels are elevated in proportion to the concentration of C3 (i.e., the C3a/C3 ratio is constant) which was evident in a normal/obese population with a wide range of C3 concentrations in the blood plasma (<xref rid="B6" ref-type="bibr">6</xref>). This turn-over of C3 has been explained by the tick-over theory, put forward by Lachmann et al. in the early 1970s (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). This theory states that low amounts of C3b are constantly generated in sufficient quantity to be able to interact with Factor B (FB) and initiate an initial fluid-phase AP convertase. The origin and configuration of this C3 species has not been fully elucidated, but in the early 1980s Pangburn et al. described the continuous hydrolysis of the internal thioester in C3, generating a &#x201C;C3b-like&#x201D; molecule with no hemolytic activity (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Based on these findings, the tick-over of native C3 to C3(H<sub>2</sub>O) has been the prevailing mechanism explaining the tick-over theory and activation of the AP.</p>
      <p>The C3b-like activity of C3(H<sub>2</sub>O) was linked to its ability to bind FB and form an AP convertase and to its susceptibility to cleavage by Factor I in the presence of Factor H. The convertase forming properties were assessed in a purified system by mixing C3(H<sub>2</sub>O), FB and Factor D (FD) to form AP convertases. The generated AP convertases were allowed to cleave native C3. The remaining native C3 after cleavage of C3 to C3a and C3b with C3(H<sub>2</sub>O)Bb was measured in a sensitive hemolytic assay (<xref rid="B10" ref-type="bibr">10</xref>).</p>
      <p>One of the caveats in the earlier studies was that in all the presented experiments, the reaction was amplified by either isolated C3 nephritic factor (C3Nef) or by purified properdin, which both stabilize the AP convertase. None of these components are present under physiological conditions. C3Nef is related to C3 glomerulonephritidis (C3GN) and, as later shown, purified properdin preparations contain a large fraction of aggregates (P<sub>n</sub>), which cause fluid phase complement consumption when added to serum in contrast to the physiological oligomer forms (P<sub>2</sub>, P<sub>3</sub>, and P<sub>4</sub>) (<xref rid="B11" ref-type="bibr">11</xref>). More recently, the non-physiological activity of the aggregates of properdin were confirmed since P<sub>n</sub> and unseparated properdin were shown to bind to numerous surfaces, in contrast to the P<sub>2</sub>-P<sub>4</sub> forms which showed selectivity for zymosan and necrotic cells (<xref rid="B12" ref-type="bibr">12</xref>).</p>
      <p>Also, in later studies it was shown that C3(H<sub>2</sub>O) consists of a mixture of C3 populations; one which has a native C3-like configuration C3(H<sub>2</sub>O<sup>*</sup>) and one that has a &#x201C;C3b-like&#x201D; form (<xref rid="B13" ref-type="bibr">13</xref>). The former one can return to the shape of native C3 with hemolytic activity, while the latter one is in an irreversible &#x201C;C3b-like&#x201D; state. This means that the preparation will contain various forms of C3 including contaminating native C3 that allows cleavage of C3 into C3b which will be able to participate in the generation of AP convertases thereby distorting an accurate evaluation of the true properties of C3(H<sub>2</sub>O).</p>
      <p>In order to more precisely elucidate the relevance of C3(H<sub>2</sub>O) for AP activation we prepared different forms of C3(H<sub>2</sub>O), which from now on will be called C3(x) where the x is the reactive nucleophilic or chaotropic agent. We separated the various populations of C3(x), and demonstrated that the conditions previously described to create C3b-like molecules were variable and insufficient in order to convert all native C3 to C3(x). Confirming previous studies (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>), different fractions of C3(x) were identified and it was also shown that different agents [methylamine, KSCN, repeated cycles of freezing/thawing (F/T)] generated its distinctive populations. A schematic illustration of the structural rearrangement of the different forms of C3(x) is shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. In general, we show that all forms of C3(x) were able to form C3(x)Bb convertases and were susceptible to cleavage to Factor I in the presence of Factor H, but all forms were much more sluggish compared to C3b and no AP convertase activity was observed in the presence of Factor I and Factor H. Theoretically, only one initial C3(x) molecule is needed to start the positive feedback loop and to commence AP activation, but due to its inefficiency, this mechanism as demonstrated on various activating surfaces, is likely to be largely overruled by C3b generation mediated by the surface-bound classical pathway (CP) lectin pathway (LP) convertase. This implies that the AP mainly is an amplification mechanism (<xref rid="B15" ref-type="bibr">15</xref>), apart from situations when activation is dependent on insufficient regulation as in paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), etc.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Schematic illustration of the different forms of non-proteolytically activated C3 i.e., C3(x).</p>
        </caption>
        <graphic xlink:href="fimmu-11-00530-g0001"/>
      </fig>
    </sec>
    <sec sec-type="materials and methods" id="s2">
      <title>Materials and Methods</title>
      <sec>
        <title>Construction and Validation of an Assay for Detection of Non-proteolytically Activated C3 [C3(x)]</title>
        <p>We have previously generated monoclonal antibodies (mAbs) to specific epitopes along the C3 polypeptide chains (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). One of those is mAb 4SD17.3, which is specific for a neoepitope in the C3a fragment. In addition to free C3a, mAb 4SD17.3 also reacts with the C3a moiety exposed in C3 where the thioester has been disrupted, but not with intact, non-activated C3 in the fluid phase. The generated C3(x) was detected in three different ways: (1) by ELISA using monoclonal antibody (mAb) 4SD17.3 toward a neo-epitope in C3a for capture and biotinylated polyclonal (pAb) anti-C3d (Dako, Glostrup, Denmark) together with streptavidin-HRP (GE Healthcare, Uppsala, Sweden) for detection; (2) by Magpix&#xAE; Luminex technology, using MagPlexC&#xAE; Microspheres (Luminex, Bio-Rad Laboratories, Hercules, CA, USA) pre-coupled with mAb mouse anti-human C3a (4SD17.3) for capture (3 &#x3BC;g/1.25 &#xD7; 10<sup>6</sup> beads) and 4 &#x3BC;g/mL biotinylated pAb anti-C3c (Dako, Glostrup, Denmark) followed by PE-conjugated streptavidin (Bio-Rad Laboratories, USA) for detection, and (3) using the same assay but biotinylated pAb rabbit anti-human C3d (Agilent Technologies, Inc., Santa Clara, CA, USA) instead of anti-C3c.</p>
        <p>Purified C3 (<xref rid="B18" ref-type="bibr">18</xref>) in which the thioester had been disrupted by repeated (10 times) freezing (&#x2212;20&#xB0;C) and thawing [room temperature (RT)] was dissolved in PBS (Phosphate buffered saline, pH 7.4) and used as standard in these assays. In hemolytic tests for the CP and the AP (<xref rid="B19" ref-type="bibr">19</xref>) this preparation of C3 was found to be devoid of activity, confirming that the thioester was disrupted.</p>
      </sec>
      <sec>
        <title>Assessment of the Rate of C3(x) Generation</title>
        <p>The C3(x) ELISA was then used to measure the rate at which C3(H<sub>2</sub>O) is formed in plasma. Freshly drawn human whole blood in K<sub>2</sub>-EDTA Vacutainers&#xAE; (BD, Plymouth, UK) from healthy volunteers was centrifuged to obtain plasma. The plasma was then incubated continuously rotating at 20 rpm at 37&#xB0;C in PVC tubes pre-coated with heparin (Corline Systems AB, Sweden) without a bubble and samples were collected for C3(x) ELISA analysis at different time points from 0 to 180 min.</p>
      </sec>
      <sec>
        <title>Preparation of C3(x) With Nucleophilic and Chaotropic Agents</title>
        <p>Native C3 [purified in-house from human plasma, according to Hammer et al. (<xref rid="B18" ref-type="bibr">18</xref>)] was incubated with the nucleophilic agent methylamine (0.2 M) or potassium thiocyanate (KSCN; 0.33 M) for 30 min at 37&#xB0;C in VB<sup>++</sup> (Veronal-buffered saline containing 5 mM Na-barbiturate, pH 7.4; 145 mM NaCl; 0.15 mM Ca<sup>2+</sup>; 0.5 mM Mg<sup>2+</sup>) adjusted to pH 8.0. After the incubation the C3 was dialyzed back to VB<sup>++</sup> pH 7.3. Some of the methylamine treated C3 was subjected to repeated F/T cycles (10 times from &#x2212;20&#xB0;C to RT) to remove any traces of native C3.</p>
      </sec>
      <sec>
        <title>Size Exclusion Chromatography</title>
        <p>The binding of the mAbs 7D84.1 (0.25 &#x3BC;M) or 4SD17.3 (0.25 &#x3BC;M) (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>) to C3b (0.5 &#x3BC;M) and F/T C3 methylamine (0.5 &#x3BC;M) was analyzed using Size Exclusion Chromatography (SEC). Human fibrinogen 3 (FIB 3, Enzyme research, IN, USA) was used as a positive control for complex formation. The C3b/C3 methylamine was incubated in VB<sup>++</sup> for 60 min at 37&#xB0;C together with the mAb, followed by SEC using ENrich&#x2122; SEC 650 10 &#xD7; 300 Column coupled to an NGC<sup>TM</sup> Chromatography System (Bio-Rad, USA). VB<sup>++</sup> was used as elution buffer. The collected fractions were further analyzed with ELISA by incubation in wells of high-binding microtiter plates, followed by detection using either a rabbit anti-mouse IgG HRP-conjugated antibody (Dako, Glostrup, Denmark) or rabbit-anti-hu-C3c HRP-conjugated antibody (Dako, Glostrup, Denmark).</p>
      </sec>
      <sec>
        <title>Ion Exchange Chromatography</title>
        <p>Cation-exchange chromatography was used to identify different C3 populations within native C3, C3 (methylamine), C3 (methylamine F/T), and C3(KSCN). The chromatography was performed using a Mono S 5/50 GL column (GE Healthcare, Bio-Sciences AB, Uppsala, Sweden) coupled to the NGC<sup>TM</sup> Chromatography System. The flow-rate was set to 0.5 mL/min at RT and a gradient was established from 0 to 0.85 M NaCl in 20 mM Phosphate buffer pH 6.8. Fractions were collected for further analysis.</p>
      </sec>
      <sec>
        <title>Identification of C3(x) Forms in Human Serum</title>
        <p>Human whole blood from a healthy volunteer was collected in Serum/Cat BD Vacutainers&#xAE; (BD, Plymouth, UK). The collected serum was incubated at 37&#xB0;C for 24 h, followed by protein precipitation using 15% polyethylene glycol (PEG)-4000 at 4&#xB0;C for 60 min and then centrifuged at 13,000 &#xD7; g for 10 min. Finally, the pellet was resuspended in 20 mM PBS pH 6.8. The protein solution was diluted 1:3 before adding it to the NGC<sup>TM</sup> Chromatography System with the MonoS column. The same &#x201C;Cation exchange MonoS C3&#x201D; protocol as described above was used (Flow-rate 0.5 mL/ min, 85% gradient (0&#x2013;0.85 M NaCl in 20 mM Phosphate buffer pH 6.8). The fractions were collected (25 fractions), for further analysis of C3 and C3(x). The C3c-ELISA was performed according to the protocol for detection of C3 levels described in Henningsson et al. (<xref rid="B22" ref-type="bibr">22</xref>). The fractions were diluted 1/200 and added to 96-well plate coated with polyclonal antibody anti-C3c (Dako, Glostrup, Denmark). This was followed by detection using biotinylated anti-C3c diluted 1/6,400 and streptavidin conjugated to HRP (GE Healthcare, Chicago, IL, US). A serum pool (consisting of 46 donors' serum) at a concentration of 500 &#x3BC;g/L was used as a standard. The C3(x) analysis was performed according to the assay described above.</p>
      </sec>
      <sec>
        <title>Wes Capillary Electrophoresis/Blotting Immunoassay</title>
        <p>An automated Western blot-like assay was used. Simple Western 12&#x2013;230 kDa size assay cartridges under reducing conditions were carried out using a Wes&#xAE; analyzer (Protein Simple, Santa Clara, CA, USA) according to the manufacturer's manual. In brief, C3/C3b/C3(met)/C3(KSCN) (2.8 &#x3BC;g) were incubated together with Factor B (4 &#x3BC;g) and Factor D (0.02 &#x3BC;g) (Complement Technology Inc, Tyler, TX, USA) in VB<sup>++</sup> at 37&#xB0;C and samples were collected after 1, 5, 15, 30, 60, and 120 min. Following incubation, the samples were diluted 5x in 0.1 x Wes Sample Buffer to the final concentrations seen in <xref rid="T1" ref-type="table">Table 1</xref>. In order to follow the cleavage of FB to Bb and Ba, a mAb mouse anti-human complement factor Bb (10 &#x3BC;g/mL) (Bio-Rad, Kidlington, UK) detecting both intact FB and the Bb cleavage product, was used as primary antibody for the Wes analysis together with the Wes anti-mouse detection module. The following electrophoretic protein separation and immunodetection were performed using the default SimpleWestern&#x2122; settings. The quantified immune-detected signal, i.e., area under the curve, was analyzed using the Compass software (version 4.0.0, ProteinSimple&#x2122;), which also converted the electropherograms into virtual blots. The experiments are repeated four times.</p>
        <table-wrap id="T1" position="float">
          <label>Table 1</label>
          <caption>
            <p>The molecular weight, and final concentration of complement proteins used in Wes immunoassay for analysis of C3 convertase formation.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th valign="top" align="left" rowspan="1" colspan="1">
                  <bold>Protein</bold>
                </th>
                <th valign="top" align="center" rowspan="1" colspan="1">
                  <bold>Molecular weight (kDa)</bold>
                </th>
                <th valign="top" align="center" rowspan="1" colspan="1">
                  <bold>Concentration for incubation at 37<sup><bold>&#xB0;</bold></sup>C (&#x3BC;g/mL). Diluted in VB<sup><bold>++</bold></sup></bold>
                </th>
                <th valign="top" align="center" rowspan="1" colspan="1">
                  <bold>Final concentration in Wes Diluted 1:5 in 0.1 x Wes Sample Buffer (&#x3BC;g/mL)</bold>
                </th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Native C3</td>
                <td valign="top" align="center" rowspan="1" colspan="1">185</td>
                <td valign="top" align="center" rowspan="1" colspan="1">70</td>
                <td valign="top" align="center" rowspan="1" colspan="1">14</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">C3b</td>
                <td valign="top" align="center" rowspan="1" colspan="1">176</td>
                <td valign="top" align="center" rowspan="1" colspan="1">70</td>
                <td valign="top" align="center" rowspan="1" colspan="1">14</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">C3 methylamine</td>
                <td valign="top" align="center" rowspan="1" colspan="1">185</td>
                <td valign="top" align="center" rowspan="1" colspan="1">70</td>
                <td valign="top" align="center" rowspan="1" colspan="1">14</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">C3 KSCN</td>
                <td valign="top" align="center" rowspan="1" colspan="1">185</td>
                <td valign="top" align="center" rowspan="1" colspan="1">70</td>
                <td valign="top" align="center" rowspan="1" colspan="1">14</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Factor B</td>
                <td valign="top" align="center" rowspan="1" colspan="1">93</td>
                <td valign="top" align="center" rowspan="1" colspan="1">100</td>
                <td valign="top" align="center" rowspan="1" colspan="1">20</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Factor D</td>
                <td valign="top" align="center" rowspan="1" colspan="1">24</td>
                <td valign="top" align="center" rowspan="1" colspan="1">0.5</td>
                <td valign="top" align="center" rowspan="1" colspan="1">0.1</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec>
        <title>Factor I Cleavage Analysis</title>
        <p>Cleavage of native C3, C3b, C3(met), F/T C3(met) (167 &#x3BC;g/mL) by Factor I (17 &#x3BC;g/mL, Complement Technology Inc) in the presence of Factor H (33 &#x3BC;g/mL, purified in-house from human serum), was analyzed by SDS-PAGE electrophoresis on a 4&#x2013;20% gradient gel (Mini-PROTEAN&#xAE; TXG&#x2122; Precast Gels, Hercules, CA, USA, Bio-Rad), essentially according to Hammer et al. (<xref rid="B18" ref-type="bibr">18</xref>). The samples were boiled under reducing conditions using 100 mM DTT, and the proteins were visualized on the gel using Coomassie brilliant blue staining.</p>
      </sec>
      <sec>
        <title>Hemolytic Assay of the Alternative Pathway</title>
        <p>The hemolytic tests for the AP were performed as in Nilsson and Nilsson (<xref rid="B19" ref-type="bibr">19</xref>). In short, 50 &#x3BC;L of C3 depleted serum (Complement Technologies Inc., USA), were carefully mixed with 25 &#x3BC;L of C3 (positive control), C3b (negative control) or the C3(x) preparations, i.e., after treatment with methylamine and F/T. Native C3 was tested at 5 different concentrations (75&#x2013;365 &#x3BC;g/mL final concentration) and C3b, C3(x) methylamine and C3(x) F/T were added at a final concentration that was in the middle of this concentration range (see <xref rid="T2" ref-type="table">Table 2</xref>). The serum samples were then added to 100 &#x3BC;L 50% rabbit erythrocytes (v/v) and agitated at 37&#xB0;C for 20 min and then stopped by the addition of VB-EDTA. The activity of the test serum was compared to that of a reference serum and the activity was expressed in percent.</p>
        <table-wrap id="T2" position="float">
          <label>Table 2</label>
          <caption>
            <p>Hemolytic assay of AP with C3 added to C3 depleted serum as indicated.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th valign="top" align="left" rowspan="1" colspan="1">
                  <bold>Sample</bold>
                </th>
                <th valign="top" align="center" rowspan="1" colspan="1">
                  <bold>Concentration (&#x3BC;g/mL)</bold>
                </th>
                <th valign="top" align="center" rowspan="1" colspan="1">
                  <bold>Activity (%)</bold>
                </th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Native C3</td>
                <td valign="top" align="center" rowspan="1" colspan="1">365</td>
                <td valign="top" align="center" rowspan="1" colspan="1">95</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td valign="top" align="center" rowspan="1" colspan="1">295</td>
                <td valign="top" align="center" rowspan="1" colspan="1">80</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td valign="top" align="center" rowspan="1" colspan="1">225</td>
                <td valign="top" align="center" rowspan="1" colspan="1">55</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td valign="top" align="center" rowspan="1" colspan="1">145</td>
                <td valign="top" align="center" rowspan="1" colspan="1">51</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td valign="top" align="center" rowspan="1" colspan="1">75</td>
                <td valign="top" align="center" rowspan="1" colspan="1">22</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">C3(x) methylamine</td>
                <td valign="top" align="center" rowspan="1" colspan="1">150&#x2013;165</td>
                <td valign="top" align="center" rowspan="1" colspan="1">2</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">C3(x) F/T</td>
                <td valign="top" align="center" rowspan="1" colspan="1">230</td>
                <td valign="top" align="center" rowspan="1" colspan="1">0</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">C3b</td>
                <td valign="top" align="center" rowspan="1" colspan="1">145</td>
                <td valign="top" align="center" rowspan="1" colspan="1">0</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Control (VBS<sup>++</sup>)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">0</td>
                <td valign="top" align="center" rowspan="1" colspan="1">0</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec>
        <title>Estimation of C3(x) Formation at Different pH</title>
        <p>C3 (100 &#x3BC;g/mL) was incubated in Sodium Phosphate buffers with pH ranging from 4.3 to 7.3 for 60 min at 37&#xB0;C. The level of C3(x) formation was measured using multiplex xMAP according to the protocol described above. The ability of these preparations to cleave FB after addition of FD was measured by Wes immunoassay. Similarly, FB consumption was also measured after first neutralizing the C3 preparations to pH 7.4. The samples were prepared for the Wes immunoassay by mixing the C3 preparations treated at pH 4.3&#x2013;7.3 (70 &#x3BC;g/mL), FB (100 &#x3BC;g/mL), and FD (0.5 &#x3BC;g/mL) and followed by incubation at 37&#xB0;C for 5, 30, and 60 min and a 5x dilution in 0.1 x Wes Sample Buffer. Wes immunoassay was performed under reducing conditions and for detection, the primary mAb mouse anti-human complement factor Bb (1 &#x3BC;g/mL) was used together with the Wes anti-mouse detection module.</p>
      </sec>
      <sec>
        <title>Generation of C3(x) in Plasma by Incubation With Nucleophilic Agents</title>
        <p>Blood from healthy volunteers, who had not been receiving any medication for a minimum of 10 days prior to donation, was collected in Vacutainer&#xAE; tubes (BD, Plymouth, UK) in the presence of the specific thrombin inhibitor lepirudin (50 &#x3BC;g/mL, Refludan<sup>TM</sup>, Aventis Pharma) and centrifuged to obtain plasma. Aliquots (20 &#x3BC;L) of physiological relevant final concentrations of ammonium hydroxide solution (0&#x2013;3.2 mM) were added to 480 &#x3BC;L of lepirudin plasma and incubated for 60 min at 37&#xB0;C. The levels of generated C3(x), C3a and sC5b-9 in the samples were analyzed by ELISA. C3a and sC5b-9 were assessed according to Nilsson et al. (<xref rid="B21" ref-type="bibr">21</xref>) and Mollnes et al. (<xref rid="B23" ref-type="bibr">23</xref>). Each experiment was performed separately using blood from different donors.</p>
      </sec>
      <sec>
        <title>Activation of the Alternative Pathway on Different Surfaces</title>
        <p>Four different surfaces, i.e., lipopolysaccharide (LPS) coated polystyrene (PS), bare PS, glass, and polypropylene (PP) tubes were selected for the evaluation of surface-induced activation of the AP in lepirudin plasma. The LPS coated tubes were prepared by adsorption of LPS (1 mg/mL) from <italic>Escherichia coli</italic> O55:B5 (Sigma Aldrich) to clean PS tubes during 1h at RT, followed by careful washing with PBS. All tubes were dried before use. The lepirudin plasma was added to the four different types of tubes and incubated stationary at 37&#xB0;C. Two parallel series of experiments were performed; one with the addition of Mg-EGTA (0.5 and 10 mM final concentration, respectively) and the other without, where the volume was compensated with the corresponding amount of PBS. Samples were collected after 0, 15, 30, 60, and 120 min. EDTA (10 mM final concentration) was immediately added to stop further activation. The surface mediated complement activation was monitored as the generation of C3a measured by sandwich ELISA. The experiment was repeated with three different blood donors.</p>
      </sec>
      <sec>
        <title>Statistics</title>
        <p>All experiments have been repeated at least 3 times. Data are presented as mean values &#xB1; SEM or as a representative image. Statistical calculations (one-way ANOVA with Bonferroni's multiple comparisons test) were made using GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA USA). <italic>P</italic> &lt; 0.05 was considered significant. Correlation between the different parameters was calculated with the non-parametric Spearman correlation test. Differences between groups (patients vs. controls) were calculated using the Mann-Whitney U-test.</p>
      </sec>
      <sec>
        <title>Ethics</title>
        <p>Ethical approval for blood collection was obtained from the regional ethics committee in Uppsala with the diary number 2008/264.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s3">
      <title>Results</title>
      <sec>
        <title>Validation of an Assay for Non-proteolytically Activated C3 [C3(x)]</title>
        <p>An ELISA for detection of C3(x) (<xref rid="B24" ref-type="bibr">24</xref>) was used employing the monoclonal mAb 4SD17.3 against a neo-epitope in C3a for capture and polyclonal antibody anti-C3d for detection (<xref ref-type="fig" rid="F2">Figures 2A,B</xref>). Since the epitope for mAb 4SD17.3 is exposed both in high molecular weight C3(x) and low molecular weight C3a, a mix-up between C3(x) and C3a is possible. Although this interaction occurs only to a small extent, an initial PEG precipitation step was included prior to analysis. In this study, the assay was transferred to the Mag-pix platform using the same pair of antibodies. Good correlation was found between the results obtained with the two techniques (r<sub>s</sub> = 0.976, <italic>p</italic> &lt; 0.0001), albeit with higher nominal values found for the ELISA. When fully optimized, the intra-CV for the assay was 2.7% and the inter-CV 6.0%. Next, we tested whether the choice of detection antibody (anti-C3d or anti-C3c depicted in <xref ref-type="fig" rid="F2">Figure 2B</xref>) would affect the levels of detection. The rationale is that bound C3b and C3(x) are susceptible to cleavage by Factor I in plasma which ultimately may cleave off C3c. This can potentially result in lower nominal values if anti-C3d is used for detection. As this was not the case, the values correlated closely (r<sub>s</sub> = 0.918, <italic>p</italic> &lt; 0.0001) with only slightly higher values obtained when anti-C3c was used for detection (<xref ref-type="fig" rid="F2">Figure 2C</xref>).</p>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p><bold>(A)</bold> An illustration of the newly developed assay to measure non-proteolytically activated C3. <bold>(B)</bold> Schematic linear representation of native C3 [&#x3B1;-chain alone with indicated cleavage sites for convertases and Factor I appointed 1&#x2013;3 (top of the figure) and the intact C3 molecule with a mark for the position of the thioester (below)], non-proteolytically activated C3 i.e., C3(x) (left) and C3 activated by convertases i.e., C3b (right) and their degradation fragments. The figure is adapted from Ekdahl et al. (<xref rid="B25" ref-type="bibr">25</xref>) with permission from the publisher. <bold>(C)</bold> Correlation between measured levels of C3(x) using anti-C3d or anti-C3c polyclonal antibodies for detection. <bold>(D)</bold> Measured C3(x) formation in plasma over time from 0 to 180 min.</p>
          </caption>
          <graphic xlink:href="fimmu-11-00530-g0002"/>
        </fig>
        <p>The ELISA was then used to monitor the spontaneous formation of C3(x) in plasma. The formation of C3(x) is easily affected by external factors such as the activating surfaces e.g., those presented by the walls of the reaction tubes or at the air-liquid interface. We therefore carefully selected low-adsorbing polypropylene tubing and removed all air bubbles before onset of the experiment to ensure that it actually was the spontaneous formation of C3(x) that was analyzed with minimal influence from other factors. This may explain the slower rate of C3(x) formation obtained in our experiments compared to values previously published (<xref rid="B10" ref-type="bibr">10</xref>). There was an initial faster C3(x) generation which tended to reach a slower, stationary stage within 60 min. Overall it showed a slow but continuous C3(x) formation of ~3 nM per hour (<xref ref-type="fig" rid="F2">Figure 2D</xref>).</p>
      </sec>
      <sec>
        <title>Characterization of C3(x) Preparations</title>
        <p>Nucleophilic and chaotropic agents have been proven to accelerate C3 conversion to C3(x) in selected composition buffers (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). C3(x) was prepared by treatment with either the chaotropic agent KSCN [C3(KSCN)] or the nucleophilic agent methylamine [C3(met)]. In addition, C3(x) prepared by repeated F/T and C3(met) also exposed to repeated F/T were included in the study.</p>
        <sec>
          <title>Size Exclusion Chromatography</title>
          <p>In order to characterize the C3(x) preparations, C3(x) prepared by methylamine treatment and repeated F/T were allowed to bind to mAb 4SD17.3. This antibody is directed toward a neo-epitope of C3a only exposed on C3(x), but not in native C3. The proteins before and after complex formation were analyzed on a SEC column. Fibrinogen (molecular weight of 300 kDa) was used as a molecular weight marker as it eluted at approximately the same potential volume as the formed complexes. As seen in the <xref ref-type="fig" rid="F3">Figure 3A</xref> (upper panel), C3(x) with a molecular weight of 180 kDa is eluted slightly before the antibody (150 kDa). However, after incubating C3(x) with mAb 4SD17.3, complexes were formed which appeared as a distinct peak near the 300 kDa molecular weight marker proving that the C3a domain was exposed and available for binding. It was confirmed that the 300 kDa peak contained complexes between C3(x) and mAb 4SD17.3, by detection of both C3 and IgG in the fractions collected from the SEC analysis using ELISAs (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figures 1B&#x2013;E</xref>). C3b, lacking the C3a fragment, was used as a negative control (<xref ref-type="fig" rid="F3">Figure 3A</xref>, lower panel) and as expected, no complexes were formed after incubation with the mAb 4SD17.3. Similarly, complexes were allowed to form between C3(x)/C3b and mAb 7D84.1, which is directed against a neo-epitope in C3d,g, only available in the denatured form of C3. Separation of the SEC column shows no traces of complexes at the 300 kDa elution point, indicated by fibrinogen (red trace). Instead, C3 (blue trace), mAb 7D84.1 (green trace) and the mixture of the two after incubation (dark blue trace), were all eluted at the same position. The same pattern was seen for the corresponding analysis of C3b and mAb 7D84.1 (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 1A</xref>). These results show that the C3a epitope is available in the C3(met) preparation, but the molecule has not undergone a conformational change that exposes the neo-epitope in C3d,g.</p>
          <fig id="F3" position="float">
            <label>Figure 3</label>
            <caption>
              <p><bold>(A)</bold> SEC analysis of complexes formed between anti-C3a mAb 4SD17.3 and F/T C3 (upper panel) and C3b (lower panel). Fibrinogen with a molecular weight of ca 300 kDa was used as a molecular weight marker with approximately the same size as formed complexes. <bold>(B)</bold> MonoS cation exchange chromatography analysis of native C3 (red line) and C3 after repeated F/T (blue line). <bold>(C)</bold> The corresponding MonoS analysis of native C3 (red line), methylamine treated C3 (darkblue line), methylamine treated C3 after repeated F/T (green line) and KSCN treated C3 (lightblue line). The identified main peaks are marked in the chromatogram. <bold>(D)</bold> C3(x) ELISA for identification of C3(x) in the fractions containing C3 collected from MonoS cation exchange chromatography separation of human serum sample after incubation at 37&#xB0;Cover night (24 h). The serum sample was precipitated with PEG 4000 prior to application on the column.</p>
            </caption>
            <graphic xlink:href="fimmu-11-00530-g0003"/>
          </fig>
        </sec>
        <sec>
          <title>Ion Exchange Chromatography</title>
          <p>The elution profile of native C3 (<xref ref-type="fig" rid="F3">Figure 3B</xref>, red line) separated on a MonoS cation exchange chromatography column shows one distinct peak (peak 1) that contains native C3 followed by two small peaks (peak 2 and 3) that contain C3(x) since a small part of the C3 population usually undergoes spontaneous hydrolysis. In the corresponding analysis of a sample where C3(x) had been formed by repeated F/T (<xref ref-type="fig" rid="F3">Figure 3B</xref>, blue line), the vast majority of the sample population was instead eluted in peak 3, a small part still appeared in the second peak, while only a minor part remained in the first peak. Separation profiles of the different C3(x) preparations, i.e., C3(met), F/T C3(met), and C3(KSCN) on the MonoS column are shown in <xref ref-type="fig" rid="F3">Figure 3C</xref>. The methylamine treated C3 was mainly eluted in peak 2 and peak 3, but repeated F/T of this sample caused most of the population in peak 2 to be transferred into peak 3. In addition, there is a small peak between peak 1 and 2. This peak increases slightly after freezing/thawing cycles, while peak 1 that contains native C3 disappears (<xref ref-type="fig" rid="F3">Figure 3C</xref>, green line). Although this peak has not been characterized due to the small amount, it is assumed to contain C3(x) or a derivative thereof. A similar pattern was detected for KSCN treated C3, with the difference that this preparation also contained a 4th peak at the end of the elution profile. However, further analysis showed that this peak contained C3(KSCN) with similar functional properties as those in peak 3 in the same preparation (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 3C</xref>). Since this analysis of C3(x) indicates that there are two different populations C3(x) formed initially, separated as peak 2 and peak 3 on the MonoS column, these two fractions were collected for further characterization and will in the following text be named C3(x)<sub>1</sub> and C3(x)<sub>2</sub> respectively.</p>
        </sec>
      </sec>
      <sec>
        <title>Identification of C3(x) Forms in Human Serum</title>
        <p>In addition to studying C3(x) formation in a purified system, C3(x) generation in human serum was also analyzed after incubation at 37&#xB0;C overnight followed by PEG 4000 precipitation before separation on the cation exchange (MonoS) chromatography column (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 2A</xref>). All collected fractions were analyzed for the total amount of C3 using a C3c ELISA. The complete analysis of all the fractions from the MonoS separation is found in <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 2B</xref>. As illustrated in this figure, most of the C3 was eluted in fraction 2&#x2013;9. In order to identify the amount of C3(x) in these fractions the C3(x) assay was used. It turned out that C3(x) was mainly found in fraction 6&#x2013;8 and to some extent also in fraction 9, but only traces in later fractions (<xref ref-type="fig" rid="F3">Figure 3D</xref>). This indicates that mainly the first form of C3(x) i.e., C3(x)<sub>1</sub> is present in the serum sample and only minute amounts, if any, of C3(x)<sub>2</sub>. One reason for this may be that, in contrast to C3(x)<sub>1</sub>, C3(x)<sub>2</sub> is easily cleaved by Factor I in the presence of Factor H and the split products will be both PEG precipitated and separated differently on MonoS columns compared to the intact C3(x)<sub>2</sub> molecules.</p>
      </sec>
      <sec>
        <title>Generation of Bb in Presence of Different C3(x) Preparations</title>
        <p>To get an idea of the properties of the two forms of C3(x) [i.e., C3(x)<sub>1</sub> and C3(x)<sub>2</sub>] identified by the cation exchange (MonoS) chromatography separation, their ability to bind FB allowing its subsequent cleavage by FD into Bb and Ba and thereby forming a C3 convertase, was evaluated using a new method, similar to that employed by Pangburn previously (<xref rid="B9" ref-type="bibr">9</xref>), but which was modified in the detection stage. In our method, the cleavage of FB and the ensuing generation of Bb was measured with Wes immunoassay after 1, 5, 15, 30, 60, and 120 min. For comparison, native C3 and C3b were also included in the study. The results are summarized in <xref ref-type="fig" rid="F4">Figure 4A</xref>. As expected, C3b readily binds FB which in the presence of FD is cleaved to Bb and Ba. Already after 1 min the amount of FB was reduced to 90%, after 5 min to ca. 60%, after 15 min only 25% remained and after 30 min almost all FB was consumed. The same scenario was seen in the native C3 sample, which can be explained by C3b contamination in the C3 preparation. Immediately after addition of FB and FD a C3 convertase forms that cleaves C3 and generates more C3b, leading to an efficient positive feedback cleavage of FB, demonstrating the accelerating nature of the AP. However, much slower FB cleavage profiles were observed with both C3(x)<sub>1</sub> and C3(x)<sub>2</sub> from the methylamine treated C3 samples separated on the MonoS column. In C3(x)<sub>1</sub>, practically all FB remains after 1 min, 85% after 5 min, 60% after 15 min and there are still 30&#x2013;40% FB in the sample after 60&#x2013;120 min. An even slower FB reduction was obtained in the sample with C3(x)<sub>2</sub>. In this case, all FB remains after 1&#x2013;5 min, 90% after 15 min, and as much as 60% still has not been consumed after 120 min. It should be noted that the ability of the different C3, C3b, and C3(x) preparations to bind and cleave FB is easily affected by different factors that change the conformation of the C3 preparations. This is particularly true if the preparations are stored (e.g., at +4&#xB0;C or frozen/thawed), which is illustrated in <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 3A</xref>. It presents the corresponding blot views of Wes immunoassays in four serially repeated experiments performed over a week. The FB cleavage was increasingly slower for all C3 preparations, but the relative difference between native C3/C3b and C3(x)<sub>1</sub>/ C3(x)<sub>2</sub> was similar in all cases, where C3(x)<sub>2</sub> was by far the least effective.</p>
        <fig id="F4" position="float">
          <label>Figure 4</label>
          <caption>
            <p><bold>(A)</bold> Wes immunoassay monitoring the consumption of FB due to cleavage to Bb and Ba after the addition of FD to native C3, C3b and peak 2 and 3 isolated after separation of methylamine treated C3 on a MonoS chromatography column at different time points from 1 to 120 min. The decrease in FB due to cleavage to Bb and Ba was measured by Wes immunoassay using a specific mAb for Bb. The data is presented as mean &#xB1; SEM. <bold>(B)</bold> Cleavage by Factor I in the presence of Factor H of native C3, C3b and peak 2 and 3 isolated after separation of methylamine treated C3 on a MonoS chromatography analyzed by SDS-PAGE under reducing conditions. The samples before incubation are marked with &#x201C;1&#x201D; and the same samples after incubation with Factor I and Factor H are marked with &#x201C;2&#x201D; below each lane in the panel.</p>
          </caption>
          <graphic xlink:href="fimmu-11-00530-g0004"/>
        </fig>
        <p>KSCN treatment of C3 did not result in any C3(x)<sub>1</sub>, but a large population of C3(x)<sub>2</sub>, which was collected from the MonoS chromatography separation and tested for its capacity to bind FB, which subsequently may be cleaved to Bb and Ba in the presence of FD (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 3B</xref>). As expected, a very slow FB consumption was obtained with C3(x)<sub>2</sub> from C3(KSCN), almost identical to that observed with C3(x)<sub>2</sub> from C3(met), which confirms that this population of C3(x) is a poor initiator of the AP.</p>
      </sec>
      <sec>
        <title>Susceptibility of C3(x) to Factor I and Factor H Cleavage</title>
        <p>To further evaluate the specific properties of C3(x), the inactivation by Factor I in the presence of Factor H was analyzed by SDS-PAGE electrophoresis under reducing conditions and stained with Coomassie Brilliant Blue. <xref ref-type="fig" rid="F4">Figure 4B</xref> shows the results from Factor I + Factor H cleavage of native C3, C3b, and C3(x)<sub>1</sub> and C3(x)<sub>2</sub> collected as peak 2 and 3 on the MonoS column. Native C3 was used as a control, since it should not be cleaved by Factor I in the presence of Factor H, but despite this, a weak 40 kDa band was visible after incubation. This indicated that the native C3 preparation contains a small amount of C3(x), which was clearly visible in the MonoS chromatogram. Here, in addition to the first large peak with native C3, there were also several succeeding small peaks containing C3(x) (<xref ref-type="fig" rid="F3">Figure 3B</xref>). An almost complete cleavage of the &#x3B1;-chain to a 76 kDa and a 40 kDa fragment was seen in the C3(x)<sub>2</sub> sample as well as with C3b (67 and 40 kDa). On the other hand, C3(x)<sub>1</sub> was only partly cleaved, since some intact &#x3B1;-chains remained after the incubation with Factor I and Factor H, although a weak 40 kDa band also started to appear. The same was observed in the methylamine treated C3 sample before F/T, whereas C3(KSCN) and C3(met) preparations that had been exposed to repeated F/T showed a complete cleavage of the &#x3B1;-chain to a 76 kDa and a 40 kDa fragment after incubation with Factor I and Factor H (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 3C</xref>). Moreover, the addition of Factor I and Factor H to native C3 and C3b followed by addition of FB and FD completely inhibited the conversion of FB to Bb (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 3D</xref>).</p>
      </sec>
      <sec>
        <title>Hemolytic Activity</title>
        <p>In the AP hemolytic assay, native C3 added at fixed concentrations ranging from 75 to 365 &#x3BC;g/mL to C3 depleted serum, showed a linear relationship between the increasing C3 concentration and an upturn in activity, where the highest added C3 concentration reached 95% activity. But the C3(x) prepared either by treatment with methylamine [C3(met)] or by repeated F/T [C3(x)] was found to be devoid of activity, confirming that the thioester bond had been disrupted. The same was found for C3b. The results from the hemolytic assay are summarized in <xref rid="T2" ref-type="table">Table 2</xref>.</p>
      </sec>
      <sec>
        <title>C3(x) Formation as a Function of pH</title>
        <p>To evaluate the sensitivity of the C3 thioester integrity to changes in pH, the generation of C3(x) was measured after incubating C3 in phosphate buffers with pH ranging from 4.3 to 7.3, which were selected to cover a range from an acidic intracellular milieu (e.g., lysosomes) to the neutral pH of blood plasma. The lowest pH (4.3 and 4.6) induced significant levels of C3(x) formation, while the pH of 4.9 and above did not seem to affect the C3 conformation to any measurable extent (<xref ref-type="fig" rid="F5">Figure 5A</xref>). Also, the ability of these C3 preparations to form a C3 convertase and cleave FB to Bb after addition of FD within the same pH intervals was evaluated using Wes immunoassay (<xref ref-type="fig" rid="F5">Figure 5B</xref>). As described above, a few molecules of C3b in the native C3 preparation are sufficient to start the convertase formation, which rapidly leads to the formation of more C3b by cleavage of C3 and a fast-continued convertase formation, measured as the conversion of FB to Bb. If there is a large proportion of C3(x) in the sample, it cannot be cleaved by the convertase and generate more C3b, which results in a slower conversion of FB to Bb. Interestingly, the most efficient generation of Bb was found at a pH between 6.3 and 6.8. The slightly higher pH (7.3) still generated Bb, but at a slower rate, whereas a pH of 5.8 and below seemed to prevent Bb formation. The lack of activity at low pH may be due to both a large formed proportion of C3(x) or that the convertase activity and complex formation is not functioning in that environment. In addition, low pH may affect the enzymatic properties of the serine proteases Bb and FD, since their active sites are likely exhibit pH sensitivity. Therefore, the same experiment was performed after first neutralizing the C3 preparations, and thereby only the correlation between C3(x) formation and the efficiency of FB cleavage/Bb generation was studied (<xref ref-type="fig" rid="F5">Figure 5C</xref>). After incubation at the lowest pH (4.3) more C3 was transformed to C3(x), which resulted in slower FB cleavage/Bb generation. When the pH increased, less C3(x) was formed and the rate of FB reduction became faster. No measurable difference was seen in the C3 samples after treatment in pH 5.8, 6.3, 6.8, and 7.3, and in these cases most of the FB had been converted to Bb after 5 min.</p>
        <fig id="F5" position="float">
          <label>Figure 5</label>
          <caption>
            <p><bold>(A)</bold> Measurement of C3(x) formation at different pH using the C3(x) ELISA. <bold>(B)</bold> Virtual blot view of Wes immunoassay analysis of Bb generation after addition of FD to C3 at different pH. <bold>(C)</bold> The corresponding virtual blots for Bb generation after addition of FD to C3 incubated at different pH, followed by re-neutralization back to neutral pH (7.4).</p>
          </caption>
          <graphic xlink:href="fimmu-11-00530-g0005"/>
        </fig>
      </sec>
      <sec>
        <title>Generation of C3(x) in Plasma During Incubation With Nucleophilic Agents</title>
        <p>As our initial experiment pointed to C3(x) in solution being a poor initiator of AP in a pure system, we decided to further investigate its functionality in plasma. This was tested by the addition of physiologically relevant amounts of ammonia (0&#x2013;3.2 mM) in our model with human lepirudin plasma followed by immediate measurement of C3(x) generation. The C3(x) generation was induced by the presence of ammonia in a dose dependent manner, and a distinct increase of C3(x) was already detected at 0.2 mM ammonia (<xref ref-type="fig" rid="F6">Figure 6A</xref>), which was a clinically relevant level that can be found in acute liver failure patients (<xref rid="B26" ref-type="bibr">26</xref>). However, a small increase in the level of complement activation marker C3a was induced (<italic>p</italic> = 0.0324) by the highest amount of ammonia (3.2 mM) (<xref ref-type="fig" rid="F6">Figure 6B</xref>) while no effect was detected by measuring sC5b-9 (<xref ref-type="fig" rid="F6">Figure 6C</xref>), suggesting that C3(x) formed by ammonia is a poor trigger of complement activation.</p>
        <fig id="F6" position="float">
          <label>Figure 6</label>
          <caption>
            <p>Generation of C3(x) and complement activation induced by ammonia in human lepirudin plasma. Serial amount of ammonia (0&#x2013;3.2 mM) was incubated together with human plasma, and thereafter, C3(x) <bold>(A)</bold>, C3a <bold>(B)</bold>, and sC5b-9 <bold>(C)</bold> levels were examined. Data was collected from 3 donors and presented as mean &#xB1; SEM. Significant difference compared to control plasma without addition are indicated as *<italic>P</italic> &lt; 0.05 and ****<italic>P</italic> &lt; 0.0001.</p>
          </caption>
          <graphic xlink:href="fimmu-11-00530-g0006"/>
        </fig>
      </sec>
      <sec>
        <title>Surface Induced Complement Activation in Plasma</title>
        <p>Initiation of complement activation in human plasma after contact with a number of different types of surfaces was studied by measuring the generation of C3a at different time points from 0 to 60 min. In order to evaluate how much AP contributes to this activation, the C3a levels in lepirudin plasma after surface contact were compared with corresponding plasma samples where CP and LP had been turned off by the addition of EGTA. As seen in <xref ref-type="fig" rid="F7">Figure 7</xref>, the C3a levels generated after incubation with solid surfaces were generally higher at all time points in the samples where activation was allowed via CP and LP, compared to those where activation was via AP (+ EGTA). As expected, highest C3a levels were elicited by the LPS surface, a well-known complement trigger. Even though the values were significantly elevated in the EGTA-plasma, they were twice as high in plasma without EGTA. The other three tested solid surfaces, i.e., glass, PS and PP, resulted in an increase in C3a generation over time, and the measured concentrations were slightly lower when activation occurred via AP in all cases.</p>
        <fig id="F7" position="float">
          <label>Figure 7</label>
          <caption>
            <p>C3a generation after incubation (0&#x2013;60 min) of human lepirudin plasma with different types of surfaces, with and without the addition of Mg<sup>2+</sup>-EGTA.</p>
          </caption>
          <graphic xlink:href="fimmu-11-00530-g0007"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s4">
      <title>Discussion</title>
      <p>In the present study, we investigate C3(x) both in purified systems and in serum and plasma and we confirm that C3(x) exists in several forms (<xref rid="B13" ref-type="bibr">13</xref>). The AP convertase-forming properties and the sensitivity to inactivation by Factor I of C3(x) is much more sluggish and varies between all of these forms compared with the corresponding activity of C3b both in purified systems and in plasma. These observations support the idea that formation of C3(x) in the fluid phase is not the main mechanism by which C3b is made available during AP activation (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B25" ref-type="bibr">25</xref>).</p>
      <p>A crucial question at issue was how &#x201C;C3b-like&#x201D; C3(H<sub>2</sub>O) [i.e., C3(x)] is. A caveat in the early studies is that in all the presented experiments, the reaction was amplified either by C3 nephritic factor (C3Nef), properdin or by using Ni<sup>2+</sup> instead of Mg<sup>2+</sup> (<xref rid="B3" ref-type="bibr">3</xref>). All these actions taken were natural in order to be able to characterize the C3(x)Bb convertase but make the assessment of the C3b-like activity difficult. The conclusion from these early studies is that C3(x) obtains &#x201C;C3b-like&#x201D; properties and that this molecule has similar activity as C3b (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>), giving the impression that it is a sufficient mechanism for generating C3b and initiating AP activation. There is clear evidence that C3(x) forms a complex with FB but except for the original observations using C3Nef or purified properdin, only few examples exist that it alone actually forms an efficient active convertase (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>).</p>
      <p>In the initial studies, the rate at which the thioester was hydrolyzed was estimated to be 0.2&#x2013;0.4% per hour (<xref rid="B10" ref-type="bibr">10</xref>) which has been confirmed in later studies including in this paper using specific ELISAs (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B29" ref-type="bibr">29</xref>). However, we found a lower rate of C3(x) formation in plasma (ca 3 nM/h), most likely by minimizing the influence of interfering surfaces such as the walls of the reaction tubes and the air-liquid interface. In the present study we used two western blot-like assays: first capillary electrophoresis in order to test C3(x)'s ability to bind FB, which subsequently can be cleaved by FD into Bb and Ba, and thereby form an AP convertase and secondly SDS-PAGE in order to test its inactivation by Factor I in the presence of Factor H. We found that C3b and native C3 (being converted to C3b by the formed AP convertases) both were able to almost completely convert factor B to Bb within 1 min in a fluid-phase assay. By contrast, using fully converted C3(x) i.e., no hemolytic activity, only sluggish convertase activity (without the presence of C3Nef or properdin) and Factor I inactivation was obtained with methylamine, F/T and KSCN-treated C3 compared with C3b.</p>
      <p>Another issue in the previous literature is that &#x201C;C3(x)&#x201D; was generated by incubating the native C3 in the presence of 0.1 M methylamine, pH 7.4 at 37&#xB0;C for 60 min, which may be a too mild condition for full conversion to C3(x) (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). Supporting the hypothesis that native C3 may be remaining in the mixture is that the experiments showed a large proportion of remaining C3 &#x3B1;-chain after cleavage with Factor I in the presence of Factor H, given that cleavage of the &#x3B1;-chain by Factor I is a way to differentiate native C3 from C3(x). In the present paper, we confirm that C3 treated with methylamine according to older protocols only leads to partial cleavage in the &#x3B1;-chain by Factor I. Similarly, KSCN treatment of native C3 generates a similar preparation. This implicates that previous protocols do not allow full conversion of native C3 to C3(x), although this was contradicted by the low hemolytic function of the preparation.</p>
      <p>This issue was clarified in later studies by Pangburn et al. (<xref rid="B13" ref-type="bibr">13</xref>) where they show that C3(NH<sub>3</sub>) preparations contain two major populations of C3(x); one which is able to return back to native C3 [C3(x)<sub>1</sub>], and the other that remains irreversibly in a C3(x) state [C3(x)<sub>2</sub>]. These forms have been demonstrated to have the anaphylatoxin domain (ANA) at different positions (<xref rid="B14" ref-type="bibr">14</xref>). The first one has properties that makes it elute at close to the same position as the native C3 position in the cation exchange (MonoS) chromatogram while the latter one, with the ANA sliding through a gap formed by the macroglobulin domains, is eluted much later (<xref rid="B13" ref-type="bibr">13</xref>). In our investigation we find similar populations in all C3(x) preparations in addition to smaller widely distributed populations and to native C3.</p>
      <p>The fact that C3(x)<sub>1</sub> can be converted back into native C3 makes it possible that C3b can be present or formed in the C3(x) preparations and thereby could link the C3b-like property to C3b instead of C3(x). In order to clarify if this was the case we made a similar separation on MonoS and tested the activity of the C3(x)<sub>1</sub> and C3(x)<sub>2</sub> population derived from the methylamine treated C3. It revealed that C3(x)<sub>1</sub> had AP convertase forming capacity although to a lower extent than C3b, while it was fairly resistant to cleavage by I and H. C3(x)<sub>2</sub> had even slower AP convertase activity but was much easier to cleave by Factor I and H. These experiments imply that C3(x) has C3b-like activity but is less active. This was confirmed in serum during forced C3(x) formation by adding ammonia, where only a small amount of C3a was generated. These results indicate that fluid-phase C3(x) is not a very efficient partner in the AP convertase and therefore may be a slow contributor of C3b activity.</p>
      <p>AP activation is a surface-oriented reaction and the tick-over of C3 to C3(x) in the fluid phase would theoretically only be able to provide minute amounts of C3b to the surface, since the deposition is highly dependent on the distance during which nascent C3b is active for covalent binding. However, in order to avoid a long lag phase before the activation takes off, a large amount of initial C3b molecules bound to the target surface is needed to speed up the activation. Without available C3b molecules, the lag phase would be very extended since the C3b generation is exponentially starting from one potential molecule (<xref rid="B30" ref-type="bibr">30</xref>). This is very well illustrated on a biomaterial surface both <italic>in vitro</italic> and <italic>in vivo</italic> where this lag phase may last up to 5&#x2013;10 min (<xref rid="B31" ref-type="bibr">31</xref>&#x2013;<xref rid="B33" ref-type="bibr">33</xref>).</p>
      <p>It is also important to take the target surface into consideration. The surface needs to allow AP activation, a function that is regulated by Factor H, Factor H-related (FHR) proteins, properdin etc. If it does not, there will be no AP activation (<xref rid="B34" ref-type="bibr">34</xref>). But if these molecules bind to the surface in a favorable proportion, disrupting the homeostasis between activation and regulation, AP activation may be triggered, which is the case in PNH, aHUS, AMD etc. Here a long lag phase does not have any importance for the pathology.</p>
      <p>CP and LP activation is part of the specific attack initiated by antibodies, pentraxins, collectins, and ficolins. They are able to provide the necessary C3b molecules, which allows AP activation to start immediately as part of our defense against foreign substances such as bacteria, viruses etc. They also provide specificity to the AP which is governed by the specificity of the CP and the LP and the properties of the target surface. This also explains that the vast majority of C3b molecules, particularly in inflammatory reactions, are generated by the AP convertases, even if complement activation is initiated by the CP or LP. This indicates that the AP is mainly an amplification loop which is the essence of the AP and to a lesser extent an activation pathway <italic>per se</italic> (<xref rid="B15" ref-type="bibr">15</xref>). This notion is illustrated in <xref ref-type="fig" rid="F7">Figure 7</xref> and has recently been discussed in Ekdahl et al. (<xref rid="B25" ref-type="bibr">25</xref>).</p>
    </sec>
    <sec sec-type="data-availability" id="s5">
      <title>Data Availability Statement</title>
      <p>The datasets generated for this study are available on request to the corresponding author.</p>
    </sec>
    <sec id="s6">
      <title>Ethics Statement</title>
      <p>The studies involving human participants were reviewed and approved by the Regional Ethics Board in Uppsala with the diary number 2008/264. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.</p>
    </sec>
    <sec id="s7">
      <title>Author Contributions</title>
      <p>KF, KE, and BN designed the research project. AA, A&#xC5;, VM, SH, and KS performed the experiments. KF, AA, KE, and BN wrote the manuscript with editorial assistance from A&#xC5;, VM, and CD. CD drew the graphical illustrations. All authors participated in editing the final manuscript and have read and approved the final manuscript.</p>
      <sec>
        <title>Conflict of Interest</title>
        <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="financial-disclosure">
        <p><bold>Funding.</bold> This work was supported by grants 2016-2075-5.1 and 2016-04519 from the Swedish Research Council (VR), and by faculty grants from the Linnaeus university.</p>
      </fn>
    </fn-group>
    <sec sec-type="supplementary-material" id="s8">
      <title>Supplementary Material</title>
      <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2020.00530/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2020.00530/full#supplementary-material</ext-link></p>
      <supplementary-material content-type="local-data" id="SM1">
        <media xlink:href="Data_Sheet_1.PDF">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachmann</surname><given-names>PJ</given-names></name></person-group>. <article-title>The amplification loop of the complement pathways</article-title>. <source>Adv Immunol.</source> (<year>2009</year>) <volume>104</volume>:<fpage>115</fpage>&#x2013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1016/S0065-2776(08)04004-2</pub-id><pub-id pub-id-type="pmid">20457117</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>RA</given-names></name></person-group>
<article-title>The properdin pathway: an &#x201C;alternative activation pathway&#x201D; or a &#x201C;critical amplification loop&#x201D; for C3 and C5 activation?</article-title>
<source>Semin Immunopathol.</source> (<year>2018</year>) <volume>40</volume>:<fpage>15</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1007/s00281-017-0661-x</pub-id><pub-id pub-id-type="pmid">29167939</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fishelson</surname><given-names>Z</given-names></name><name><surname>Pangburn</surname><given-names>MK</given-names></name><name><surname>M&#xFC;ller-Eberhard</surname><given-names>HJ</given-names></name></person-group>. <article-title>Characterization of the initial C3 convertase of the alternative pathway of human complement</article-title>. <source>J Immunol.</source> (<year>1984</year>) <volume>132</volume>:<fpage>1430</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="pmid">6559201</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pangburn</surname><given-names>MK</given-names></name><name><surname>M&#xFC;ller-Eberhard</surname><given-names>HJ</given-names></name></person-group>. <article-title>The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase</article-title>. <source>Biochem J.</source> (<year>1986</year>) <volume>235</volume>:<fpage>723</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1042/bj2350723</pub-id><pub-id pub-id-type="pmid">3638964</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norda</surname><given-names>R</given-names></name><name><surname>Schott</surname><given-names>U</given-names></name><name><surname>Berseus</surname><given-names>O</given-names></name><name><surname>Akerblom</surname><given-names>O</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Ekdahl</surname><given-names>KN</given-names></name><etal/></person-group>. <article-title>Complement activation products in liquid stored plasma and C3a kinetics after transfusion of autologous plasma</article-title>. <source>Vox sanguinis.</source> (<year>2012</year>) <volume>102</volume>:<fpage>125</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1111/j.1423-0410.2011.01522.x</pub-id><pub-id pub-id-type="pmid">21770955</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Hamad</surname><given-names>OA</given-names></name><name><surname>Ahlstrom</surname><given-names>H</given-names></name><name><surname>Kullberg</surname><given-names>J</given-names></name><name><surname>Johansson</surname><given-names>L</given-names></name><name><surname>Lindhagen</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors</article-title>. <source>Eur J Clin Investig.</source> (<year>2014</year>) <volume>44</volume>:<fpage>587</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1111/eci.12275</pub-id><pub-id pub-id-type="pmid">24754458</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicol</surname><given-names>PA</given-names></name><name><surname>Lachmann</surname><given-names>PJ</given-names></name></person-group>. <article-title>The alternate pathway of complement activation. The role of C3 and its inactivator (KAF)</article-title>. <source>Immunology.</source> (<year>1973</year>) <volume>24</volume>:<fpage>259</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="pmid">4632688</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachmann</surname><given-names>PJ</given-names></name><name><surname>Nicol</surname><given-names>P</given-names></name></person-group>. <article-title>Reaction mechanism of the alternative pathway of complement fixation</article-title>. <source>Lancet.</source> (<year>1973</year>) <volume>1</volume>:<fpage>465</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(73)91886-2</pub-id><pub-id pub-id-type="pmid">4120372</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pangburn</surname><given-names>MK</given-names></name><name><surname>M&#xFC;ller-Eberhard</surname><given-names>HJ</given-names></name></person-group>. <article-title>Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement</article-title>. <source>J Exp Med.</source> (<year>1980</year>) <volume>152</volume>:<fpage>1102</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1084/jem.152.4.1102</pub-id><pub-id pub-id-type="pmid">6903192</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pangburn</surname><given-names>MK</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>M&#xFC;ller-Eberhard</surname><given-names>HJ</given-names></name></person-group>. <article-title>Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3</article-title>. <source>J Exp Med.</source> (<year>1981</year>) <volume>154</volume>:<fpage>856</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1084/jem.154.3.856</pub-id><pub-id pub-id-type="pmid">6912277</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pangburn</surname><given-names>MK</given-names></name></person-group>. <article-title>Analysis of the natural polymeric forms of human properdin and their functions in complement activation</article-title>. <source>J Immunol.</source> (<year>1989</year>) <volume>142</volume>:<fpage>202</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="pmid">2909614</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>VP</given-names></name><name><surname>Cortes</surname><given-names>C</given-names></name><name><surname>Pangburn</surname><given-names>MK</given-names></name></person-group>. <article-title>Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement</article-title>. <source>Immunobiology.</source> (<year>2010</year>) <volume>215</volume>:<fpage>932</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.imbio.2010.02.002</pub-id><pub-id pub-id-type="pmid">20382442</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pangburn</surname><given-names>MK</given-names></name></person-group>. <article-title>Spontaneous reformation of the intramolecular thioester in complement protein C3 and low temperature capture of a conformational intermediate capable of reformation</article-title>. <source>J Biol Chem.</source> (<year>1992</year>) <volume>267</volume>:<fpage>8584</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="pmid">1569104</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishida</surname><given-names>N</given-names></name><name><surname>Walz</surname><given-names>T</given-names></name><name><surname>Springer</surname><given-names>TA</given-names></name></person-group>. <article-title>Structural transitions of complement component C3 and its activation products</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2006</year>) <volume>103</volume>:<fpage>19737</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0609791104</pub-id><pub-id pub-id-type="pmid">17172439</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harboe</surname><given-names>M</given-names></name><name><surname>Mollnes</surname><given-names>TE</given-names></name></person-group>. <article-title>The alternative complement pathway revisited</article-title>. <source>J Cell Mol Med.</source> (<year>2008</year>) <volume>12</volume>:<fpage>1074</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1111/j.1582-4934.2008.00350.x</pub-id><pub-id pub-id-type="pmid">18419792</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Svensson</surname><given-names>KE</given-names></name><name><surname>Borwell</surname><given-names>P</given-names></name><name><surname>Nilsson</surname><given-names>UR</given-names></name></person-group>
<article-title>Production of mouse monoclonal antibodies that detect distinct neoantigenic epitopes on bound C3b and iC3b but not on the corresponding soluble fragments</article-title>. <source>Mol Immunol.</source> (<year>1987</year>) <volume>24</volume>:<fpage>487</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/0161-5890(87)90023-X</pub-id><pub-id pub-id-type="pmid">2443836</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Grossberger</surname><given-names>D</given-names></name><name><surname>Nilsson Ekdahl</surname><given-names>K</given-names></name><name><surname>Riegert</surname><given-names>P</given-names></name><name><surname>Becherer</surname><given-names>DJ</given-names></name><name><surname>Nilsson</surname><given-names>UR</given-names></name><etal/></person-group>. <article-title>Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression</article-title>. <source>Biochem J.</source> (<year>1992</year>) <volume>282</volume> (<issue>Pt 3</issue>):<fpage>715</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1042/bj2820715</pub-id><pub-id pub-id-type="pmid">1372802</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammer</surname><given-names>CH</given-names></name><name><surname>Wirtz</surname><given-names>GH</given-names></name><name><surname>Renfer</surname><given-names>L</given-names></name><name><surname>Gresham</surname><given-names>HD</given-names></name><name><surname>Tack</surname><given-names>BF</given-names></name></person-group>. <article-title>Large scale isolation of functionally active components of the human complement system</article-title>. <source>J Biol Chem.</source> (<year>1981</year>) <volume>256</volume>:<fpage>3995</fpage>&#x2013;<lpage>4006</lpage>. <pub-id pub-id-type="pmid">6783652</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>UR</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name></person-group>. <article-title>Simplified assays of hemolytic activity of the classical and alternative complement pathways</article-title>. <source>J Immunol Methods.</source> (<year>1984</year>) <volume>72</volume>:<fpage>49</fpage>&#x2013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/0022-1759(84)90432-0</pub-id><pub-id pub-id-type="pmid">6747305</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Nilsson Ekdahl</surname><given-names>K</given-names></name><name><surname>Avila</surname><given-names>D</given-names></name><name><surname>Nilsson</surname><given-names>UR</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name></person-group>. <article-title>Neoantigens in complement component C3 as detected by monoclonal antibodies. Mapping of the recognized epitopes by synthetic peptides</article-title>. <source>Biochem J.</source> (<year>1990</year>) <volume>268</volume>:<fpage>55</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1042/bj2680055</pub-id><pub-id pub-id-type="pmid">1693076</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Svensson</surname><given-names>KE</given-names></name><name><surname>Inganas</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>UR</given-names></name></person-group>. <article-title>A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3</article-title>. <source>J Immunol Methods.</source> (<year>1988</year>) <volume>107</volume>:<fpage>281</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/0022-1759(88)90229-3</pub-id><pub-id pub-id-type="pmid">3257998</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henningsson</surname><given-names>AJ</given-names></name><name><surname>Ernerudh</surname><given-names>J</given-names></name><name><surname>Sandholm</surname><given-names>K</given-names></name><name><surname>Carlsson</surname><given-names>S-A</given-names></name><name><surname>Granlund</surname><given-names>H</given-names></name><name><surname>Jansson</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Complement activation in Lyme neuroborreliosis&#x2013;increased levels of C1q and C3a in cerebrospinal fluid indicate complement activation in the CNS</article-title>. <source>J Neuroimmunol.</source> (<year>2007</year>) <volume>183</volume>:<fpage>200</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2006.10.022</pub-id><pub-id pub-id-type="pmid">17157926</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollnes</surname><given-names>TE</given-names></name><name><surname>Lea</surname><given-names>T</given-names></name><name><surname>Fr&#xF8;land</surname><given-names>SS</given-names></name><name><surname>Harboe</surname><given-names>M</given-names></name></person-group>. <article-title>Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex</article-title>. <source>Scand J Immunol.</source> (<year>1985</year>) <volume>22</volume>:<fpage>197</fpage>&#x2013;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-3083.1985.tb01871.x</pub-id><pub-id pub-id-type="pmid">2412280</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson Ekdahl</surname><given-names>K</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Pekna</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>UR</given-names></name></person-group>. <article-title>Generation of iC3 at the interface between blood and gas</article-title>. <source>Scand J Immunol.</source> (<year>1992</year>) <volume>35</volume>:<fpage>85</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-3083.1992.tb02837.x</pub-id><pub-id pub-id-type="pmid">1734499</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekdahl</surname><given-names>KN</given-names></name><name><surname>Mohlin</surname><given-names>C</given-names></name><name><surname>Adler</surname><given-names>A</given-names></name><name><surname>&#xC5;man</surname><given-names>A</given-names></name><name><surname>Manivel</surname><given-names>VA</given-names></name><name><surname>Sandholm</surname><given-names>K</given-names></name><name><surname>Huber-Lang</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Is generation of C3(H<sub>2</sub>O) necessary for activation of the alternative pathway in real life?</article-title>
<source>Mol Immunol.</source> (<year>2019</year>) <volume>114</volume>:<fpage>353</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2019.07.032</pub-id><pub-id pub-id-type="pmid">31446306</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>V</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Acharya</surname><given-names>SK</given-names></name></person-group>. <article-title>Predictive value of arterial ammonia for complications and outcome in acute liver failure</article-title>. <source>Gut.</source> (<year>2006</year>) <volume>55</volume>:<fpage>98</fpage>&#x2013;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1136/gut.2004.061754</pub-id><pub-id pub-id-type="pmid">16024550</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isenman</surname><given-names>DE</given-names></name><name><surname>Kells</surname><given-names>DI</given-names></name><name><surname>Cooper</surname><given-names>NR</given-names></name><name><surname>M&#xFC;ller-Eberhard</surname><given-names>HJ</given-names></name><name><surname>Pangburn</surname><given-names>MK</given-names></name></person-group>. <article-title>Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties</article-title>. <source>Biochemistry.</source> (<year>1981</year>) <volume>20</volume>:<fpage>4458</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1021/bi00518a034</pub-id><pub-id pub-id-type="pmid">7284336</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bexborn</surname><given-names>F</given-names></name><name><surname>Andersson</surname><given-names>PO</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Ekdahl</surname><given-names>KN</given-names></name></person-group>. <article-title>The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H<sub>2</sub>O)Bb)</article-title>. <source>Mol Immunol.</source> (<year>2008</year>) <volume>45</volume>:<fpage>2370</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2007.11.003</pub-id><pub-id pub-id-type="pmid">18096230</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elvington</surname><given-names>M</given-names></name><name><surname>Liszewski</surname><given-names>MK</given-names></name><name><surname>Liszewski</surname><given-names>AR</given-names></name><name><surname>Kulkarni</surname><given-names>HS</given-names></name><name><surname>Hachem</surname><given-names>RR</given-names></name><name><surname>Mohanakumar</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Development and optimization of an ELISA to quantitate C3(H<sub>2</sub>O) as a marker of human disease</article-title>. <source>Front Immunol.</source> (<year>2019</year>) <volume>10</volume>:<fpage>703</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2019.00703</pub-id><pub-id pub-id-type="pmid">31019515</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Pangburn</surname><given-names>MK</given-names></name><name><surname>Lesavre</surname><given-names>PH</given-names></name><name><surname>M&#xFC;ller-Eberhard</surname><given-names>HJ</given-names></name></person-group>. <article-title>Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>1978</year>) <volume>75</volume>:<fpage>3948</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.75.8.3948</pub-id><pub-id pub-id-type="pmid">279011</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lhotta</surname><given-names>K</given-names></name><name><surname>Wurzner</surname><given-names>R</given-names></name><name><surname>Kronenberg</surname><given-names>F</given-names></name><name><surname>Oppermann</surname><given-names>M</given-names></name><name><surname>K&#xF6;nig</surname><given-names>P</given-names></name></person-group>. <article-title>Rapid activation of the complement system by cuprophane depends on complement component C4</article-title>. <source>Kidney Int.</source> (<year>1998</year>) <volume>53</volume>:<fpage>1044</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/j.1523-1755.1998.00836.x</pub-id><pub-id pub-id-type="pmid">9551416</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>UR</given-names></name><name><surname>Storm</surname><given-names>KE</given-names></name><name><surname>Elwing</surname><given-names>H</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name></person-group>. <article-title>Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface</article-title>. <source>Mol Immunol.</source> (<year>1993</year>) <volume>30</volume>:<fpage>211</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/0161-5890(93)90050-L</pub-id><pub-id pub-id-type="pmid">7679465</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>UR</given-names></name></person-group>. <article-title>Deposition of C3b/iC3b leads to the concealment of antigens, immunoglobulins and bound C1q in complement-activating immune complexes</article-title>. <source>Mol Immunol.</source> (<year>2001</year>) <volume>38</volume>:<fpage>151</fpage>&#x2013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/S0161-5890(01)00039-6</pub-id><pub-id pub-id-type="pmid">11532277</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trojn&#xE1;r</surname><given-names>E</given-names></name><name><surname>J&#xF3;zsi</surname><given-names>M</given-names></name><name><surname>Uray</surname><given-names>K</given-names></name><name><surname>Csuka</surname><given-names>D</given-names></name><name><surname>Szil&#xE1;gyi</surname><given-names>&#xC1;</given-names></name><name><surname>Milosevic</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Analysis of linear antibody epitopes on factor H and CFHR1 using sera of patients with autoimmune atypical hemolytic uremic syndrome</article-title>. <source>Front Immunol.</source> (<year>2017</year>) <volume>8</volume>:<fpage>302</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.00302</pub-id><pub-id pub-id-type="pmid">28424685</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Mediators Inflamm</journal-id>
      <journal-id journal-id-type="iso-abbrev">Mediators Inflamm</journal-id>
      <journal-id journal-id-type="publisher-id">MI</journal-id>
      <journal-title-group>
        <journal-title>Mediators of Inflammation</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0962-9351</issn>
      <issn pub-type="epub">1466-1861</issn>
      <publisher>
        <publisher-name>Hindawi</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33299378</article-id>
      <article-id pub-id-type="pmc">7707968</article-id>
      <article-id pub-id-type="doi">10.1155/2020/8831389</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>P-MAPA, a Fungi-Derived Immunomodulatory Compound, Induces a Proinflammatory Response in a Human Whole Blood Model</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Gon&#xE7;alves</surname>
            <given-names>Mariana Torrente</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Squaiella-Baptist&#xE3;o</surname>
            <given-names>Carla Cristina</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pidde</surname>
            <given-names>Giselle</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lopes</surname>
            <given-names>Priscila Hess</given-names>
          </name>
          <xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>da Silva Nunes</surname>
            <given-names>Iseu</given-names>
          </name>
          <xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1896-9074</contrib-id>
          <name>
            <surname>Tambourgi</surname>
            <given-names>Denise V.</given-names>
          </name>
          <email>denise.tambourgi@butantan.gov.br</email>
          <xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="I1">
<sup>1</sup>Immunochemistry Laboratory, Instituto Butantan, S&#xE3;o Paulo, Brazil</aff>
      <aff id="I2">
<sup>2</sup>Farmabrasilis, Campinas, Brazil</aff>
      <author-notes>
        <fn fn-type="other">
          <p>Academic Editor: Fumio Tsuji</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>11</month>
        <year>2020</year>
      </pub-date>
      <volume>2020</volume>
      <elocation-id>8831389</elocation-id>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>8</month>
          <year>2020</year>
        </date>
        <date date-type="rev-recd">
          <day>29</day>
          <month>10</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>6</day>
          <month>11</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2020 Mariana Torrente Gon&#xE7;alves et al.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>P-MAPA is a complex compound, derived from <italic>Aspergillus oryzae</italic> cultures, that has shown immunomodulatory properties in infection and cancer animal models. Despite promising results in these models, the mechanisms of cellular activation by P-MAPA, suggested to be Toll-like receptor- (TLR-) dependent, and its effect on human immune cells, remain unclear. Using an <italic>ex vivo</italic> model of human whole blood, the effects of P-MAPA on complement system activation, production of cytokines, and the expression of complement receptors (CD11b, C5aR, and C3aR), TLR2, TLR4, and the coreceptor CD14 were analyzed in neutrophils and monocytes. P-MAPA induced complement activation in human blood, detected by increased levels of C3a, C5a, and SC5b-9 in plasma. As a consequence, CD11b expression increased and C5aR decreased upon activation, while C3aR expression remained unchanged in leukocytes. TLR2 and TLR4 expressions were not modulated by P-MAPA treatment on neutrophils, but TLR4 expression was reduced in monocytes, while CD14 expression increased in both cell types. P-MAPA also induced the production of TNF-<italic>&#x3B1;</italic>, IL-8, and IL-12 and oxidative burst, measured by peroxynitrite levels, in human leukocytes. Complement inhibition with compstatin showed that P-MAPA-induced complement activation drives modulation of C5aR, but not of CD11b, suggesting that P-MAPA acts through both complement-dependent and complement-independent mechanisms. Compstatin also significantly reduced the peroxynitrite generation. Altogether, our results show that P-MAPA induced proinflammatory response in human leukocytes, which is partially mediated by complement activation. Our data contribute to elucidate the complement-dependent and complement-independent mechanisms of P-MAPA, which ultimately result in immune cell activation and in its immunomodulatory properties in infection and cancer animal models.</p>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source>Funda&#xE7;&#xE3;o de Amparo &#xE0; Pesquisa do Estado de S&#xE3;o Paulo</funding-source>
          <award-id>2012/05306-8</award-id>
          <award-id>2013/07467-1</award-id>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>1. Introduction</title>
      <p>P-MAPA, a compound obtained from the fermentation of <italic>Aspergillus oryzae</italic> fungus cultures [<xref rid="B1" ref-type="bibr">1</xref>], developed by Farmabrasilis research network, has shown positive immunomodulatory properties in various pathologic conditions. This compound has a complex composition of magnesium, ammonium, phosphate, linoleic acid, and a 16&#x2009;kDa protein fraction, with a total molecular weight of 316&#x2009;kDa [<xref rid="B2" ref-type="bibr">2</xref>], and it is obtained in the form of crystals.</p>
      <p>Experimental studies have shown that the use of P-MAPA, in the form of crystals, improved the rate of cancer survival, by inhibiting tumor growth in mice and rats bearing Ehrlich ascites tumor (EAT) [<xref rid="B3" ref-type="bibr">3</xref>] or bladder cancer [<xref rid="B1" ref-type="bibr">1</xref>], respectively. The load of intracellular pathogens was also reduced after P-MAPA treatment, as showed in mice infected with Punta Toro virus [<xref rid="B4" ref-type="bibr">4</xref>] or with <italic>Mycobacterium tuberculosis</italic> [<xref rid="B1" ref-type="bibr">1</xref>] and also in dogs infected with <italic>Leishmania infantum</italic> [<xref rid="B5" ref-type="bibr">5</xref>]. P-MAPA has also been shown to partially inhibit apoptosis in cell lines infected by Zika virus [<xref rid="B6" ref-type="bibr">6</xref>]. Recently, the FDA granted P-MAPA the status of orphan drug for the treatment of schistosomiasis, caused by <italic>Schistosoma mansoni</italic> [<xref rid="B7" ref-type="bibr">7</xref>]. Still, the mechanism by which P-MAPA activates cells is still unclear.</p>
      <p>It has been suggested that the antitumor and pathogen-resistant properties of P-MAPA are related to its immunomodulatory effects, such as the ability to increase, in a dose-dependent manner, the number of bone marrow CFU-GM (colony forming unit-granulocyte/macrophage), as observed in murine models of EAT [<xref rid="B3" ref-type="bibr">3</xref>] and <italic>Listeria monocytogenes</italic> infection [<xref rid="B8" ref-type="bibr">8</xref>]. It was also reported that treatment of <italic>Leishmania</italic>-infected dogs with P-MAPA crystals increased the percentage of circulating CD8<sup>+</sup> T lymphocytes, as well as the production of IFN-<italic>&#x3B3;</italic> and IL-2. Moreover, it induced a decrease of IL-10 levels, produced by peripheral blood mononuclear cells [<xref rid="B5" ref-type="bibr">5</xref>].</p>
      <p>It has been proposed that P-MAPA interacts with Toll-like receptors (TLR) 2 and 4, as demonstrated by the <italic>in vitro</italic> activation of NF-<italic>&#x3BA;</italic>B in HEK293 cells expressing human TLR2 or TLR4, but not in cells expressing TLR3, TLR5, TLR7, TLR8, or TLR9 [<xref rid="B1" ref-type="bibr">1</xref>]. <italic>In vivo</italic>, P-MAPA also increased the expression of TLR2 in macrophages from <italic>Leishmania chagasi</italic>-infected dogs [<xref rid="B8" ref-type="bibr">8</xref>], and of TLR2 and TLR4 in urothelial cells from female rats treated for bladder cancer [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>]. Moreover, P-MAPA induced phosphorylation of IKK and p38 MAPK in macrophages from <italic>L. chagasi</italic>-infected dogs, as well as the production of reactive oxygen species (ROS) and nitric oxide (NO), suggesting its interaction with TLR2 [<xref rid="B8" ref-type="bibr">8</xref>].</p>
      <p>TLR2 and TLR4 are key proinflammatory pattern recognition receptors, which can crosstalk with the complement system, thus reinforcing or controlling inflammation by regulating the expression of cellular receptors and cytokine production [<xref rid="B11" ref-type="bibr">11</xref>]. Although inflammation is a natural process during infection and tissue damage, imbalance of the inflammatory processes can lead to depletive consequences, as observed in sepsis or in immunosuppression.</p>
      <p>Although much work has been done in animal models, there is no evidence of the effect of P-MAPA in human cells. Moreover, <italic>in vivo</italic> studies have used P-MAPA in the form of insoluble crystals, resuspended in saline buffer or DMSO. In light of the immunomodulatory properties of P-MAPA observed in cell lines and animal models, here we have analyzed the effect of this compound in human whole blood model. The aim was to examine the P-MAPA effect on the complement system and modulation of the surface receptors involved in leukocyte activation during inflammation.</p>
    </sec>
    <sec id="sec2">
      <title>2. Materials and Methods</title>
      <sec id="sec2.1">
        <title>2.1. P-MAPA Solubilization and Preparation</title>
        <p>P-MAPA was produced and kindly supplied by Farmabrasilis (Campinas, SP, Brazil), in the form of crystals [<xref rid="B2" ref-type="bibr">2</xref>]. The crystals were solubilized in 0.25% formic acid in deionized water (for 1&#x2009;mg of P-MAPA) and then dried under vacuum and resuspended in sterile PBS (8.1&#x2009;mM Na<sub>2</sub>HPO<sub>4</sub>; 1.5&#x2009;mM KH<sub>2</sub>PO<sub>4</sub>; 137&#x2009;mM NaCl; 2.7&#x2009;mM KCl, pH 7.4). After solubilization, samples of P-MAPA were tested for LPS contamination using PYROGENT&#x2122; Plus Gel Clot LAL Assays (Lonza, MD, USA) by the Microbial Control Unity of Butantan Institute (S&#xE3;o Paulo, SP, Brazil). Endotoxin contamination was below detection level (0.125&#x2009;EU/mL), indicating that the results obtained in this study were due to P-MAPA's effect.</p>
      </sec>
      <sec id="sec2.2">
        <title>2.2. Blood and Plasma Collection</title>
        <p>This study was approved by the National Commission on Research Ethics under the protocol number CAAE: 02211512.5.0000.0082. Peripheral blood was collected from 6 healthy adult volunteers (21-24 years old) in polypropylene tubes containing lepirudin anticoagulant (Refludan, Celgene, NY, USA) (50&#x2009;<italic>&#x3BC;</italic>g/mL), an anticoagulant that does not interfere with complement activation [<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>].</p>
      </sec>
      <sec id="sec2.3">
        <title>2.3. Complement Activation by P-MAPA</title>
        <p>The effect of P-MAPA on the activation of the classical alternative and lectin complement pathways was evaluated <italic>in vitro</italic>, as previously described [<xref rid="B14" ref-type="bibr">14</xref>]. Briefly, normal human serum (NHS) obtained from healthy donors was incubated with PBS or P-MAPA at 37&#xB0;C, for 30 minutes for classical and lectin pathways or for 1 hour for the alternative pathway activation. The residual hemolytic activity was evaluated on sheep erythrocytes for the classical pathway or on rabbit erythrocytes for the alternative pathway. The use of sheep and rabbit erythrocytes was approved by the Animal Ethics Committee from Butantan Institute (CEUA 1145/13). The activation of the lectin pathway was evaluated by ELISA, as described [<xref rid="B14" ref-type="bibr">14</xref>].</p>
      </sec>
      <sec id="sec2.4">
        <title>2.4. Stimulation of Human Whole Blood with P-MAPA</title>
        <p>The following protocol was based on previous whole blood models for the study of the complement system [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>]. Aliquots of fresh blood (72% of total volume of the reaction) were immediately added in sterile polypropylene tubes containing PBS (14% of total volume). Blood samples were then stimulated with PBS (negative control), LPS from <italic>Escherichia coli</italic> (0111:B4, Sigma, MO, USA) (positive control, 100&#x2009;<italic>&#x3BC;</italic>g/mL), or P-MAPA (125, 250, 500, or 1000&#x2009;<italic>&#x3BC;</italic>g/mL) (14% of total volume) and incubated in water bath at 37&#xB0;C for 30 minutes. The amount of LPS used in this study was based on previous data showing that high concentrations of LPS (10 to 1000&#x2009;<italic>&#x3BC;</italic>g/mL) are necessary to achieve complement activation in lepirudin-treated plasma [<xref rid="B15" ref-type="bibr">15</xref>].</p>
        <p>After incubation, samples were immediately placed on ice. An aliquot of each experimental treatment was collected for analysis by flow cytometry, and the remaining volume was centrifuged (400<italic>g</italic>, 4&#xB0;C, 10&#x2009;min) for plasma collection. EDTA (10&#x2009;mM) (Sigma) was added to plasma, in order to stop complement activation, and stored at -80&#xB0;C for further analysis.</p>
      </sec>
      <sec id="sec2.5">
        <title>2.5. Measurement of Complement Factors and Cytokines in Plasma</title>
        <p>Plasma collected from human whole blood stimulated with different concentrations of P-MAPA was tested in commercial kits, for measurement of anaphylatoxins C3a/C3a desArg and C5a/C5a desArg, using BD OptEIA Human C3a and C5a ELISA Kits (BD Biosciences) or Cytometric Bead Array (CBA) Human Anaphylatoxin Kit (BD Biosciences), and sC5b-9, using MicroVue sC5b-9 Plus EIA Kit (Quidel Corporation). Cytokines IL-1<italic>&#x3B2;</italic>, IL-6, IL-8, IL-10, IL-12(p70), TNF-<italic>&#x3B1;</italic>, and IFN-<italic>&#x3B3;</italic> were measured using BD OptEIA Human cytokine ELISA Sets (BD Biosciences) or CBA Human Inflammatory Cytokines Kit (BD Biosciences). All assays were performed according to the manufacturer's instructions.</p>
      </sec>
      <sec id="sec2.6">
        <title>2.6. Analysis of Neutrophil and Monocyte Receptors by Flow Cytometry</title>
        <p>After treatment with P-MAPA or controls, blood was incubated with BD FACS Lysing Solution (BD Biosciences, San Jose, CA, USA), for 20&#x2003;min, at room temperature, for erythrocytes lysis. Samples were centrifuged (720&#x2003;<italic>g</italic>, 4&#xB0;C, 10&#x2003;min), the supernatants were discarded, and cells were washed in FACS buffer (BSA 1%; sodium azide 0.01% in PBS). Cells were then resuspended in FACS buffer containing paraformaldehyde 0.5%, distributed in FACS tubes and stained with anti-CD11b (ICRF44) PE, anti-CD14 (61D3) FITC (both from eBioscience, San Diego, CA, USA), anti-TLR2 (TL2.1) PE, anti-TLR4 (HTA125) PE (both from Life Technologies, San Diego, CA, USA), anti-C3aR (17) FITC, or anti-C5aR FITC (8D6) (both from Santa Cruz Biotechnology, Dallas, TX, USA) at room temperature for 15 minutes. Samples were soon analyzed using BD FACSCanto II flow cytometer, with BD FACSDiVa software, version 4.1 (all from BD Biosciences). Expression of surface receptors was analyzed by gating at neutrophils and monocytes within the total leukocyte population and acquiring 10,000 events (Supplemental Figure <xref ref-type="supplementary-material" rid="supplementary-material-1">1</xref>). The size (FSC-A) and complexity (SSC-A) patterns of cells suggest that LPS or P-MAPA treatments did not induce significant toxicity (Supplemental Figure <xref ref-type="supplementary-material" rid="supplementary-material-1">1</xref>). Data were expressed as median fluorescence intensity (MFI), after subtraction of background MFI from isotype-matched controls (all from Dako, Glostrup, Denmark). Additionally, the effects of solubilized P-MAPA or P-MAPA in the form of crystals were compared, using the whole blood model and analyzing the expression of surface markers in the whole leukocyte population.</p>
      </sec>
      <sec id="sec2.7">
        <title>2.7. Inhibition of Complement Activation by Compstatin</title>
        <p>Blood samples collected as in <xref ref-type="sec" rid="sec2.4">Section 2.4</xref> were preincubated with PBS or compstatin (1&#x2009;mM) for 10&#x2009;min at room temperature. Compstatin (Ac-ICVVQDWGHHRCT-NH2) was synthesized at the Butantan Institute (S&#xE3;o Paulo, SP, Brazil), according to sequences described previously [<xref rid="B13" ref-type="bibr">13</xref>]. Following preincubation with inhibitor or control, blood was then stimulated with LPS (100&#x2009;<italic>&#x3BC;</italic>g/mL) or P-MAPA (1000&#x2009;<italic>&#x3BC;</italic>g/mL) and incubated for 30&#x2009;min at 37&#xB0;C. Once incubation ended, samples were processed for flow cytometry analysis as described in <xref ref-type="sec" rid="sec2.6">Section 2.6</xref>.</p>
      </sec>
      <sec id="sec2.8">
        <title>2.8. Measurement of Reactive Oxygen and Nitrogen Species</title>
        <p>Analysis of superoxide and peroxynitrite production by total leukocytes was performed as previously described [<xref rid="B17" ref-type="bibr">17</xref>]. Following preincubation of blood samples with compstatin (1&#x2003;mM) for 10&#x2003;min at room temperature and stimulation with PBS, LPS, or P-MAPA (described in <xref ref-type="sec" rid="sec2.4">Section 2.4</xref>), aliquots of blood (50&#x2009;<italic>&#x3BC;</italic>L) were incubated with 1&#x2003;<italic>&#x3BC;</italic>L of dihydroethidium (DHE) or dihydrorhodamine 123 (DHR) (5&#x2003;<italic>&#x3BC;</italic>M) (both from Sigma) at 5% CO<sub>2</sub> for 1&#x2003;h at 37&#xB0;C, for DHE, or 30&#xB0;C, for DHR. Following incubation, erythrocytes were lysed with BD FACS Lysing Solution, according to the manufacturer's instructions, and samples were centrifuged (720&#x2003;<italic>g</italic>, 4&#xB0;C, 10&#x2003;min). Supernatants were discarded and cells were washed in FACS buffer, fixed with 0.5% paraformaldehyde and analyzed by flow cytometry.</p>
      </sec>
      <sec id="sec2.9">
        <title>2.9. Statistics</title>
        <p>Statistical analysis was performed using GraphPad Prism 7.00 software (GraphPad Software, CA, USA). Data distribution was checked using the D'Agostino-Pearson normality test. For comparison of three or more groups, one-way ANOVA followed by Tukey's posttest was used, and for comparison between two groups, Student's <italic>t</italic>-test was used. Differences were taken as statistically significant when <italic>p</italic> &lt; 0.05.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>3. Results</title>
      <sec id="sec3.1">
        <title>3.1. P-MAPA Promotes Complement Activation in Human Whole Blood</title>
        <p>The effect of P-MAPA on complement activation was first investigated in normal human sera, using hemolytic assays for the classical and alternative pathways, and ELISA for the lectin pathway. P-MAPA was able to promote a dose-dependent consumption of components from both classical and alternative pathways, inducing about 10-30% reduction of hemolytic activity of NHS with different P-MAPA concentrations (50-500&#x2009;<italic>&#x3BC;</italic>g/mL) (Supplemental Figure <xref ref-type="supplementary-material" rid="supplementary-material-1">2</xref>). The lectin pathway was not activated by P-MAPA (data not shown).</p>
        <p>The effect of P-MAPA on complement activation in human whole blood was measured in samples treated with increased concentrations of the immunomodulator. Complement activation was detected by the significant increase of anaphylatoxins C3a and C5a in plasma, posttreatment with P-MAPA, compared to PBS-treated blood (Figures <xref ref-type="fig" rid="fig1">1(a)</xref> and <xref ref-type="fig" rid="fig1">1(b)</xref>). To confirm if P-MAPA-induced complement activation leads to the formation of the terminal complement complex (TCC), soluble C5b-9 complex (sC5b-9) was measured in plasma samples from whole blood assays. <xref ref-type="fig" rid="fig1"> Figure 1(c)</xref> shows that total complement activation was detected after stimulation of blood with increased concentrations of P-MAPA.</p>
      </sec>
      <sec id="sec3.2">
        <title>3.2. P-MAPA Modulates Surface Receptors in Neutrophils and Monocytes</title>
        <p>After blood samples were stimulated with PBS, LPS, or increased concentrations of P-MAPA, erythrocytes were lysed and leukocytes stained for CD11b, CD14, C3aR, C5aR, TLR2, and TLR4 expressions. A 30-minute incubation was sufficient to induce CD11b upregulation by both LPS and P-MAPA stimulations, in monocytes (<xref ref-type="fig" rid="fig2">Figure 2(a)</xref>) and neutrophils (<xref ref-type="fig" rid="fig3">Figure 3(a)</xref>). CD14 was also upregulated by P-MAPA in both cell types (Figures <xref ref-type="fig" rid="fig2">2(b)</xref> and <xref ref-type="fig" rid="fig3">3(b)</xref>), mainly with the concentration of 1000&#x2009;<italic>&#x3BC;</italic>g/mL. C3aR expression (Figures <xref ref-type="fig" rid="fig2">2(c)</xref> and <xref ref-type="fig" rid="fig3">3(c)</xref>) remained unchanged in both cell types after treatments; however, C5aR expression was downregulated in a dose-dependent manner by P-MAPA, in both cell types (Figures <xref ref-type="fig" rid="fig2">2(d)</xref> and <xref ref-type="fig" rid="fig3">3(d)</xref>), with 1000&#x2009;<italic>&#x3BC;</italic>g/mL of P-MAPA inducing the same downregulation of LPS. Changes in TLR2 expression were not statistically significant (Figures <xref ref-type="fig" rid="fig2">2(e)</xref> and <xref ref-type="fig" rid="fig3">3(e)</xref>), but TLR4 expression was shown to be decreased in monocyte poststimulation with LPS or P-MAPA, compared to PBS (<xref ref-type="fig" rid="fig2">Figure 2(f)</xref>), whereas no change in TLR4 expression was observed in neutrophils (<xref ref-type="fig" rid="fig3">Figure 3(f)</xref>). Moreover, Supplemental Figure <xref ref-type="supplementary-material" rid="supplementary-material-1">3</xref> presents the comparison of the P-MAPA action, in the solubilized or crystal forms (nonsolubilized), in human blood. Data obtained showed similar results in the expression of leukocytes cell surface markers induced by the two P-MAPA forms.</p>
      </sec>
      <sec id="sec3.3">
        <title>3.3. P-MAPA Induces the Production of Proinflammatory Cytokines</title>
        <p>Having observed the modulation of leucocyte surface receptors within 30 minutes of stimulation with P-MAPA, the levels of cytokines in plasma from blood samples treated with P-MAPA were measured. P-MAPA, at concentrations of 500 and 1000&#x2009;<italic>&#x3BC;</italic>g/mL, induced production of TNF-<italic>&#x3B1;</italic> (<xref ref-type="fig" rid="fig4">Figure 4(a)</xref>); IL-8 was also detected in a dose-dependent manner, although levels of this cytokine were not as high as of LPS treatment (<xref ref-type="fig" rid="fig4">Figure 4(b)</xref>). P-MAPA promoted a significant increase of IL-12(p70) production at the concentration of 1000&#x2009;<italic>&#x3BC;</italic>g/mL, compared to PBS and LPS controls (<xref ref-type="fig" rid="fig4">Figure 4(c)</xref>). In contrast, levels of IFN-<italic>&#x3B3;</italic> showed a trend towards a dose-dependent decrease upon treatment with P-MAPA, although these differences were not statistically significant (<xref ref-type="fig" rid="fig4">Figure 4(d)</xref>). Although plasma was also tested for the presence of IL-6, IL-1<italic>&#x3B2;</italic>, and IL-10 productions, levels of these cytokines were not detected in any of the experimental treatments (data not shown), likely due to the length of incubation used (30 minutes).</p>
      </sec>
      <sec id="sec3.4">
        <title>3.4. Inhibition of Complement Activation by Compstatin</title>
        <p>Having shown that P-MAPA could activate the complement system in human blood, we investigated if the complement activation by this compound was responsible for modulation of cellular receptors. Firstly, complement inhibition by compstatin, a protein inhibitor of the C3 protein, was tested in hemolytic assay, in which inhibition of complement activity was successfully achieved after preincubation of sera with 1&#x2009;mM compstatin (data not shown). Blood samples were then preincubated with compstatin (1&#x2009;mM) and stimulated with LPS or P-MAPA. For these experiments, the concentration of 1000&#x2009;<italic>&#x3BC;</italic>g/mL of P-MAPA was chosen, once this concentration induced statistically significant changes in receptor expression in previous experiments. In these experiments, the expression of cell markers was evaluated in the whole population of leukocytes. Compstatin partially controlled the increased expression of CD11b on LPS blood treated samples, but not on P-MAPA treatment (<xref ref-type="fig" rid="fig5">Figure 5(a)</xref>). However, compstatin completely inhibited the downregulation of C5aR by P-MAPA treatment but only exerted a partial effect on its expression by LPS treatment (<xref ref-type="fig" rid="fig5">Figure 5(d)</xref>). Moreover, complement inhibition ahead of P-MAPA treatment induced an increase in TLR2 expression (<xref ref-type="fig" rid="fig5">Figure 5(e)</xref>).</p>
      </sec>
      <sec id="sec3.5">
        <title>3.5. Leukocytes Activated by P-MAPA Produce Peroxynitrite, Which Is Reduced upon Complement Inhibition</title>
        <p>In order to verify if P-MAPA induced the production of reactive oxygen and nitrogen species (ROS and RNS, respectively) in human leukocytes, and if complement activation was involved, blood samples were pretreated or not with compstatin (1&#x2009;mM), ahead of incubation with LPS or P-MAPA (1000&#x2009;<italic>&#x3BC;</italic>g/mL). Following treatments, cells were incubated with substrates DHR or DHE for analysis of production of superoxide and peroxynitrite, respectively, by the whole population of leukocytes. The production of superoxide was below baseline (PBS) levels, poststimulation with LPS or P-MAPA, with no changes promoted by compstatin (<xref ref-type="fig" rid="fig6">Figure 6(a)</xref>). In contrast, P-MAPA induced the production of peroxynitrite by leukocytes, and generation of this nitrogen species was reduced in the presence of compstatin (<xref ref-type="fig" rid="fig6">Figure 6(b)</xref>).</p>
      </sec>
    </sec>
    <sec id="sec4">
      <title>4. Discussion</title>
      <p>The immunomodulatory effects of P-MAPA have been described in animal models, but its effects on human cells had never been assessed. Besides, its molecular mechanisms are still poorly understood. P-MAPA was also granted status of orphan drug by the FDA, for the treatment of schistosomiasis [<xref rid="B7" ref-type="bibr">7</xref>]; thus, understanding the effect of P-MAPA on immune cells will contribute to novel therapeutic applications of this compound. Here, we reported the first data of P-MAPA treatment in human cells. Specifically, our results demonstrated that P-MAPA can induce complement activation in human blood and modulate surface receptors in neutrophils and monocytes and the production of proinflammatory cytokines by these cells. Also, here we achieved solubilization of P-MAPA crystals with formic acid solution, in contrast with previous studies, where insoluble crystals were resuspended in saline solution or DMSO. Further studies with soluble P-MAPA are required to understand how solubilization alters its structure, but herein we have demonstrated that the most consistent data of surface molecule expressions, which were CD11b, CD14, and C5aR, were similar when comparing solubilized P-MAPA or in the form of crystals (Supplemental Figure <xref ref-type="supplementary-material" rid="supplementary-material-1">3</xref>).</p>
      <p>In order to access complement activity in whole blood, we chose a short incubation time and used a lepirudin-based anticoagulant that has no adverse effect on complement activation [<xref rid="B13" ref-type="bibr">13</xref>]. A high concentration of LPS was used as a positive control for complement activation in the whole blood model, based on previous data [<xref rid="B15" ref-type="bibr">15</xref>]. Similar activation was observed by <italic>in vitro</italic> treatment of whole blood with P-MAPA that produced increased levels of anaphylatoxins C3a and C5a, and of sC5b-9, indicating activation of the terminal complement cascades. Complement activation by P-MAPA was also demonstrated in functional assays of classical, alternative, and lectin pathways. Classical and alternative pathway components were shown to be consumed by P-MAPA in NHS (Supplemental Figure <xref ref-type="supplementary-material" rid="supplementary-material-1">2</xref>). These effects may be related to linoleic acid and magnesium ions in its composition, once that linoleic acid is required for binding of low-density lipoprotein to complement C1q [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B18" ref-type="bibr">18</xref>]. However, activation of the alternative pathway by P-MAPA may be spontaneous and related with the high concentration of magnesium ions in the compound, as magnesium is an essential cation for activation of this pathway [<xref rid="B19" ref-type="bibr">19</xref>].</p>
      <p>Anaphylatoxins are proinflammatory mediators that can induce the production of TNF-<italic>&#x3B1;</italic>, IL-1<italic>&#x3B2;</italic>, IL-6, and IL-8 in monocytes [<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>] and neutrophils [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>], upon activation of complement receptors C3aR, CD11b/CD18 (CR3), and C5aR in leukocytes [<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>]. Indeed, following LPS (positive control) or P-MAPA stimulation of human blood, increased levels of TNF-<italic>&#x3B1;</italic> and IL-8 were found in plasma, as well as increased levels of IL-12 in blood treated with 1000&#x2009;<italic>&#x3BC;</italic>g/mL of P-MAPA. Although there are evidences showing that high concentrations of LPS can downmodulate cytokine production or cell activation [<xref rid="B26" ref-type="bibr">26</xref>], herein we were still able to observe TNF-<italic>&#x3B1;</italic> and IL-8 release by blood cells treated with LPS in the concentration of 100&#x2009;<italic>&#x3BC;</italic>g/mL.</p>
      <p>Additionally, flow cytometry analysis showed that, similar to LPS, P-MAPA treatment promoted increase of CD11b and decrease of C5aR expression in neutrophils and monocytes, which indicate activation of these receptors [<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>], suggesting their involvement in the production of the cytokines found in plasma. Again, despite the high concentration of LPS used as a positive control, we were still able to observe cell activation by LPS in our model, as shown by CD11b upregulation and C5aR downregulation in both cell populations (monocytes and neutrophils).</p>
      <p>In addition, inhibition of C3 cleavage by compstatin showed P-MAPA-induced complement activation drives modulation of C5aR, but not of CD11b, suggesting that P-MAPA acts through both complement-dependent and complement-independent mechanisms.</p>
      <p>Expression of CD14 also increased following P-MAPA treatment in neutrophils and monocytes, as seen with LPS stimulation, which is known to upregulate CD14 [<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>]. CD14 works as a coreceptor for TLR4 and TLR2, transferring LPS to TLRs to initiate signaling [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>]. Whether P-MAPA binds to CD14 directly is not known. CD14 is involved in triggering oxidative burst in leukocytes [<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>], alongside complement receptors, TLR2 and TLR4 [<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>].</p>
      <p>Indeed, P-MAPA induced oxidative burst in human leukocytes, as demonstrated by the production of peroxynitrite (OONO<sup>&#x2212;</sup>), which occurs upon reaction between superoxide anion (O<sub>2</sub><sup>&#x2212;</sup>) and nitric oxide (NO) [<xref rid="B34" ref-type="bibr">34</xref>]. Therefore, it is possible that the observed decrease in superoxide anion may be a consequence of its chemical reaction with NO, resulting in the formation of peroxynitrite. The oxidative burst had already been observed in neutrophils after only 10 minutes of incubation with <italic>E. coli</italic>, in lepirudin-treated whole blood model [<xref rid="B15" ref-type="bibr">15</xref>]. In the referred manuscript, the oxidative burst was evaluated by using dihydrorhodamine 123 (DHR), which readily detects peroxynitrite. Our results are in accordance to a study in which P-MAPA increased ROS production by macrophages from <italic>Leishmania chagasi</italic>-infected dogs [<xref rid="B8" ref-type="bibr">8</xref>]. As demonstrated by complement inhibition, reduction in peroxynitrite generation by P-MAPA suggests the compound can promote indirect generation of RNS via complement activation, in human leukocytes.</p>
      <p>Studies suggest that P-MAPA directly activates TLR2 and TLR4, as demonstrated by the increased expression of these TLRs in HEK293 cells <italic>in vitro</italic> [<xref rid="B1" ref-type="bibr">1</xref>], and in animal models of ovarian [<xref rid="B35" ref-type="bibr">35</xref>] and invasive bladder cancer [<xref rid="B10" ref-type="bibr">10</xref>], as well as by increased cytosolic levels of TLR-associated downstream signaling molecules MyD88, TRIF, and NF-<italic>&#x3BA;</italic>B p65 [<xref rid="B35" ref-type="bibr">35</xref>]. To this date, there are no studies on how P-MAPA activates TLRs, but it is possible that the lipids present in P-MAPA's composition, such as palmitoleic acid and linoleic acid [<xref rid="B2" ref-type="bibr">2</xref>], may be involved in human complement and TLR activation. Of these lipids, palmitoleic acid can enhance TLR4 expression <italic>in vitro</italic> [<xref rid="B36" ref-type="bibr">36</xref>] and linoleic acid has been reported to promote phosphorylation of ERK 1/2 and p38 MAPK and increase of IL-8 mRNA in neutrophils after <italic>in vitro</italic> stimulation [<xref rid="B37" ref-type="bibr">37</xref>]. These kinases are involved in TLR2 and TLR4 signaling pathways and known to promote neutrophil activation via these receptors [<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>].</p>
      <p>Upregulation of TLR2 and TLR4 by P-MAPA was previously reported in neoplastic tissues [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B35" ref-type="bibr">35</xref>] and in macrophages from infected animals [<xref rid="B8" ref-type="bibr">8</xref>]. In contrast, our study of human neutrophils and monocytes showed no changes in TLR2 expression following P-MAPA treatment, while TLR4 expression was reduced in monocytes. It is possible that significant increase of TLRs could have been observed if our samples were incubated for longer [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>]. Furthermore, here we achieved solubilization of P-MAPA crystals with a formic acid solution, in contrast with previous studies, in which P-MAPA was resuspended in saline [<xref rid="B35" ref-type="bibr">35</xref>], partially diluted in DMSO [<xref rid="B1" ref-type="bibr">1</xref>] or sonicated and resuspended in RPMI-1640 [<xref rid="B8" ref-type="bibr">8</xref>]. All these factors could have contributed for contrasting data.</p>
      <p>The downregulation of TLR4 expression overserved in monocytes after P-MAPA treatment could be associated with the modulation of CD14. Here, we report that P-MAPA increased the surface expression of CD14 in neutrophils and monocytes. CD14-dependent TLR4 endocytosis has been reported in mononuclear phagocytes and dendritic cells stimulated with LPS for short periods [<xref rid="B42" ref-type="bibr">42</xref>]. Interestingly, the authors showed that mature dendritic cells stimulated with TNF or CpG and then treated with LPS expressed higher levels of CD14 surface staining, while lower percentage of surface TLR4, similar to our data. Thus, CD14 may be important for the internalization of TLR4, but CD14 itself may not necessarily be internalized. This mechanism is essential for internalization of TLR4 into the endosome and consequent activation of TRIF/TRAM-dependent signaling pathway, which culminates in the production of type I interferons [<xref rid="B42" ref-type="bibr">42</xref>]. Type I interferons are mostly known for their ability to render cells resistant to virus infection, but they have also been implicated in the immune responses against tumor cells [<xref rid="B43" ref-type="bibr">43</xref>] and bacterial infections [<xref rid="B44" ref-type="bibr">44</xref>]. We thus hypothesize that TLR4 downregulation observed in human blood monocytes treated with P-MAPA could be a consequence of CD14-dependent TLR4 endocytosis, since the direct action of P-MAPA on TLR4 has already been demonstrated [<xref rid="B1" ref-type="bibr">1</xref>]. Herein, we did not analyze the production of type I interferons by P-MAPA, but it is possible that the interaction between CD14 and TLR4 may be related to the antiviral, antitumor, and antimicrobial effects previously attributed to P-MAPA treatment [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B5" ref-type="bibr">5</xref>].</p>
      <p>The production of a number of proinflammatory mediators by P-MAPA in human whole blood demonstrates its potential in enhancing the immune response. For instance, the generation of chemoattractants IL-8, C5a, and C3a could potentially drive neutrophils and monocytes to infected or damaged tissues, and TNF-<italic>&#x3B1;</italic> production could also promote inflammation, cell proliferation, and host defense [<xref rid="B45" ref-type="bibr">45</xref>]. All these mediators could therefore be related to the previously reported immunomodulatory effects of P-MAPA.</p>
      <p>In human blood, IFN-<italic>&#x3B3;</italic> levels decreased below baseline levels following treatment with P-MAPA. Conversely, in previous reports of <italic>in vivo models</italic>, PBMCs of dogs infected with <italic>L. chagasi</italic> and treated with P-MAPA produced higher levels of IFN-<italic>&#x3B3;</italic> than untreated animals [<xref rid="B5" ref-type="bibr">5</xref>] and high IFN-<italic>&#x3B3;</italic> levels were present in urinary bladder neoplastic tissue [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>] and ovarian carcinoma of rats treated with P-MAPA [<xref rid="B35" ref-type="bibr">35</xref>]. IFN-<italic>&#x3B3;</italic> is considered to be mainly produced by NK cells and CD4<sup>+</sup> T cells, although its production has been also attributed to other cell types [<xref rid="B46" ref-type="bibr">46</xref>]. Considering the short period of our model, it is reasonable to suggest that basal levels of IFN-<italic>&#x3B3;</italic>, detected in plasma, might be derived from NK cells. These cells usually produce IFN-<italic>&#x3B3;</italic> in response to IL-12 released by activated monocytes/macrophages [<xref rid="B47" ref-type="bibr">47</xref>]. Intriguingly, in our model, the marked impairment of IFN-<italic>&#x3B3;</italic> release in P-MAPA-treated blood was not accompanied by a decrease in IL-12 production. Thus, it seems that P-MAPA probably induced a regulation mechanism of IFN-<italic>&#x3B3;</italic> release. TGF-<italic>&#x3B2;</italic> is a known negative regulator of IFN-<italic>&#x3B3;</italic> release [<xref rid="B47" ref-type="bibr">47</xref>], but it was not increased by P-MAPA in our model (data not shown). Another possible explanation for the decrease of IFN-<italic>&#x3B3;</italic> is the short period of incubation (30 minutes). It is possible that this is a temporary effect, which could be reversible with longer periods of treatment, as already demonstrated in animal models [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B35" ref-type="bibr">35</xref>]. Thus, the effects of P-MAPA in the release of IFN-<italic>&#x3B3;</italic> in our model remain to be investigated.</p>
      <p>Altogether, our findings show that P-MAPA induces complement activation, with consequent release of C3a and C5a, and production of proinflammatory mediators, namely, TNF-<italic>&#x3B1;</italic>, IL-8, IL-12, and oxidative burst in human leukocytes. P-MAPA also modulates CD11b, CD14, and C5aR expressions in neutrophils and monocytes, and TLR4 in monocytes. Some of these effects are partially mediated by the complement system, while others are probably induced via TLR activation. Our data contribute to elucidate the complement-dependent and complement-independent mechanisms of P-MAPA, which ultimately result in a proinflammatory profile. This promotes immune cell activation, resulting in the previously shown immunomodulatory properties of P-MAPA in infection and cancer animal models.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>This work was supported by the S&#xE3;o Paulo Research Foundation (FAPESP) funding to the Centre of Toxins, Immune Response and Cell Signalling (CeTICS) (grant 2013/07467-1) and to Mariana Torrente Gon&#xE7;alves (fellowship grant 2012/05306-8). Denise V. Tambourgi is a recipient of the CNPq Research Productivity Fellowship. We thank Farmabrasilis for kindly providing P-MAPA.</p>
    </ack>
    <sec sec-type="data-availability">
      <title>Data Availability</title>
      <p>The data used to support the findings of this study are included within the article.</p>
    </sec>
    <sec>
      <title>Disclosure</title>
      <p>The funders had no role in study design, data collection and analysis, decisions to publish, or preparation of the manuscript.</p>
    </sec>
    <sec sec-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors declare that they have no conflict of interest.</p>
    </sec>
    <sec>
      <title>Authors' Contributions</title>
      <p>DVT conceived and supervised this project. MTG, CCSB, GP, and PHL performed the experiments. MTG, CCSB, ISN, and DVT analyzed the data. DVT and ISN contributed reagents/materials/analysis tools. MTG, CCSB, ISN, and DVT wrote the paper.</p>
    </sec>
    <sec sec-type="supplementary-material" id="supplementary-material-1">
      <title>Supplementary Materials</title>
      <supplementary-material content-type="local-data" id="supp-1">
        <label>Supplementary Materials</label>
        <caption>
          <p>Supplemental Figure 1 flow cytometry gating strategy for neutrophils and monocytes. Representative forward/side scatter plot showing (A) the total leukocyte population and (B) within this gate, identification of neutrophils and monocytes. Supplemental Figure 2 effect of P-MAPA on the complement pathways. Samples of normal human serum (NHS) were incubated with PBS or P-MAPA at 37&#xB0;C, for 30 minutes for classical (A) or for 1 hour for alternative pathway (B). The residual hemolytic activity relative to the PBS control was evaluated on sheep erythrocytes for the classical pathway (A) or on rabbit erythrocytes for the alternative pathway (B) and the absorbance of the supernatants determined at <italic>&#x3BB;</italic> = 414&#x2009;nm. Data were expressed as the mean &#xB1; standard&#x2009;deviation of duplicates, representative of 3 independent experiments. Statistical analysis performed by one-way ANOVA, complemented with the Tukey test. <sup>*</sup><italic>p</italic> &lt; 0.05, <sup>**</sup><italic>p</italic> &lt; 0.01, and <sup>***</sup><italic>p</italic> &lt; 0.001: statistically significant difference in relation to the control (PBS). <sup>&#xA2;</sup><italic>p</italic> &lt; 0.05 and <sup>&#xA2;&#xA2;</sup><italic>p</italic> &lt; 0.01: statistically significant difference between treatments with P-MAPA. Supplemental Figure 3 eEffect of solubilized and non-solubilized P-MAPA on the expression of surface markers in leukocytes. Human blood samples were treated with PBS, P-MAPA (1000&#x2009;<italic>&#x3BC;</italic>g/mL) solubilized or not, or LPS (100&#x2009;<italic>&#x3BC;</italic>g/mL), for 5 minutes, at room temperature, followed by incubation for 30 minutes at 37&#xB0;C. After incubation, leukocytes were collected and analyzed for expression of surface markers. (A) Expression of CD11b. (B) Expression of CD14. (C) Expression of TLR2. (D) Expression of TLR4. (E) C3aR expression. (F) C5aR expression. Data expressed as the mean &#xB1; standard&#x2009;deviation of duplicates from 2 independent experiments. MFI: median fluorescence intensity. Statistical analysis performed by one-way ANOVA, complemented with the Tukey test. <sup>*</sup><italic>p</italic> &lt; 0.05, <sup>**</sup><italic>p</italic> &lt; 0.01, <sup>***</sup><italic>p</italic> &lt; 0.001: statistically significant difference in relation to PBS. <sup>#</sup><italic>p</italic> &lt; 0.05 and <sup>##</sup><italic>p</italic> &lt; 0.01: statistical difference in relation to LPS. <sup>&#xA2;&#xA2;</sup><italic>p</italic> &lt; 0.01: statistically significant difference between treatments with P-MAPA.</p>
        </caption>
        <media xlink:href="8831389.f1.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Favaro</surname>
              <given-names>W. J.</given-names>
            </name>
            <name>
              <surname>Nunes</surname>
              <given-names>O. S.</given-names>
            </name>
            <name>
              <surname>Seiva</surname>
              <given-names>F. R.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of P-MAPA immunomodulator on Toll-like receptors and p53: potential therapeutic strategies for infectious diseases and cancer</article-title>
          <source>
            <italic toggle="yes">Infect Agent Cancer</italic>
          </source>
          <year>2012</year>
          <volume>7</volume>
          <issue>1</issue>
          <pub-id pub-id-type="doi">10.1186/1750-9378-7-14</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84862259318</pub-id>
          <pub-id pub-id-type="pmid">22709446</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="other">
          <person-group person-group-type="author">
            <name>
              <surname>Nunes</surname>
              <given-names>I. D. S.</given-names>
            </name>
            <name>
              <surname>Justo</surname>
              <given-names>G. Z.</given-names>
            </name>
            <name>
              <surname>Caballero</surname>
              <given-names>N. E. D.</given-names>
            </name>
          </person-group>
          <article-title>Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride immonomodulator, its production process and formulation</article-title>
          <comment>US patent US2006093628, (2004)</comment>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Justo</surname>
              <given-names>G. Z.</given-names>
            </name>
            <name>
              <surname>Dur&#xE1;n</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Queiroz</surname>
              <given-names>M. L. S.</given-names>
            </name>
          </person-group>
          <article-title>Myelopoietic response in tumour-bearing mice by an aggregated polymer isolated from Aspergillus oryzae</article-title>
          <source>
            <italic toggle="yes">European Journal of Pharmacology</italic>
          </source>
          <year>2000</year>
          <volume>388</volume>
          <issue>3</issue>
          <fpage>219</fpage>
          <lpage>226</lpage>
          <pub-id pub-id-type="doi">10.1016/s0014-2999(99)00851-1</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0033983915</pub-id>
          <pub-id pub-id-type="pmid">10675729</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dur&#xE1;n</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Gowen</surname>
              <given-names>B. B.</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>F. T. M.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A biotechnological product and its potential as a new immunomodulator for treatment of animal phlebovirus infection: Punta Toro virus</article-title>
          <source>
            <italic toggle="yes">Antiviral Research</italic>
          </source>
          <year>2009</year>
          <volume>83</volume>
          <issue>2</issue>
          <fpage>143</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="doi">10.1016/j.antiviral.2009.04.006</pub-id>
          <pub-id pub-id-type="other">2-s2.0-67449126846</pub-id>
          <pub-id pub-id-type="pmid">19393266</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santiago</surname>
              <given-names>M. E. B.</given-names>
            </name>
            <name>
              <surname>Neto</surname>
              <given-names>L. S.</given-names>
            </name>
            <name>
              <surname>Alexandre</surname>
              <given-names>E. C.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Improvement in clinical signs and cellular immunity of dogs with visceral leishmaniasis using the immunomodulator P-MAPA</article-title>
          <source>
            <italic toggle="yes">Acta Tropica</italic>
          </source>
          <year>2013</year>
          <volume>127</volume>
          <issue>3</issue>
          <fpage>174</fpage>
          <lpage>180</lpage>
          <pub-id pub-id-type="doi">10.1016/j.actatropica.2013.04.005</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84878395018</pub-id>
          <pub-id pub-id-type="pmid">23639468</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lima</surname>
              <given-names>M. C.</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>E. A. N.</given-names>
            </name>
            <name>
              <surname>de Morais</surname>
              <given-names>C. N. L.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The P-MAPA immunomodulator partially prevents apoptosis induced by Zika virus infection in THP-1 cells</article-title>
          <source>
            <italic toggle="yes">Current Pharmaceutical Biotechnology</italic>
          </source>
          <year>2020</year>
          <volume>21</volume>
          <pub-id pub-id-type="doi">10.2174/1389201021666200602140005</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="book">
          <collab>U S Food &amp; Drug Administration</collab>
          <source>
            <italic toggle="yes">Aggregated polymer of protein magnesium ammonium phospholinoleate-palmitoleate anhydride</italic>
          </source>
          <year>2020</year>
          <publisher-name>Orphan Drug Designations and Approvals</publisher-name>
          <comment>October 2020 <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=721319">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=721319</ext-link></comment>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melo</surname>
              <given-names>L. M.</given-names>
            </name>
            <name>
              <surname>Perosso</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>B. F. M.</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>K. L. O.</given-names>
            </name>
            <name>
              <surname>Somenzari</surname>
              <given-names>M. A.</given-names>
            </name>
            <name>
              <surname>de Lima</surname>
              <given-names>V. M. F.</given-names>
            </name>
          </person-group>
          <article-title>Effects of P-MAPA immunomodulator on Toll-like receptor 2, ROS, nitric oxide, MAPKp38 and IKK in PBMC and macrophages from dogs with visceral leishmaniasis</article-title>
          <source>
            <italic toggle="yes">International Immunopharmacology</italic>
          </source>
          <year>2014</year>
          <volume>18</volume>
          <issue>2</issue>
          <fpage>373</fpage>
          <lpage>378</lpage>
          <pub-id pub-id-type="doi">10.1016/j.intimp.2013.12.012</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84892690789</pub-id>
          <pub-id pub-id-type="pmid">24374021</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia</surname>
              <given-names>P. V.</given-names>
            </name>
            <name>
              <surname>Apolinario</surname>
              <given-names>L. M.</given-names>
            </name>
            <name>
              <surname>Bockelmann</surname>
              <given-names>P. K.</given-names>
            </name>
            <name>
              <surname>da Silva Nunes</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Duran</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Favaro</surname>
              <given-names>W. J.</given-names>
            </name>
          </person-group>
          <article-title>Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer</article-title>
          <source>
            <italic toggle="yes">International Journal of Clinical and Experimental Pathology</italic>
          </source>
          <year>2015</year>
          <volume>8</volume>
          <fpage>4427</fpage>
          <lpage>4443</lpage>
          <pub-id pub-id-type="pmid">26191134</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia</surname>
              <given-names>P. V.</given-names>
            </name>
            <name>
              <surname>Seiva</surname>
              <given-names>F. R. F.</given-names>
            </name>
            <name>
              <surname>Carniato</surname>
              <given-names>A. P.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased Toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier</article-title>
          <source>
            <italic toggle="yes">BMC Cancer</italic>
          </source>
          <year>2016</year>
          <volume>16</volume>
          <issue>1</issue>
          <pub-id pub-id-type="doi">10.1186/s12885-016-2474-z</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84978378755</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hajishengallis</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lambris</surname>
              <given-names>J. D.</given-names>
            </name>
          </person-group>
          <article-title>More than complementing tolls: complement-Toll-like receptor synergy and crosstalk in innate immunity and inflammation</article-title>
          <source>
            <italic toggle="yes">Immunological Reviews</italic>
          </source>
          <year>2016</year>
          <volume>274</volume>
          <issue>1</issue>
          <fpage>233</fpage>
          <lpage>244</lpage>
          <pub-id pub-id-type="doi">10.1111/imr.12467</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84992445194</pub-id>
          <pub-id pub-id-type="pmid">27782328</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bexborn</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Engberg</surname>
              <given-names>A. E.</given-names>
            </name>
            <name>
              <surname>Sandholm</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Mollnes</surname>
              <given-names>T. E.</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Nilsson Ekdahl</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Hirudin versus heparin for use in whole blood in vitro biocompatibility models</article-title>
          <source>
            <italic toggle="yes">Journal of Biomedical Materials Research. Part A</italic>
          </source>
          <year>2009</year>
          <volume>89A</volume>
          <issue>4</issue>
          <fpage>951</fpage>
          <lpage>959</lpage>
          <pub-id pub-id-type="doi">10.1002/jbm.a.32034</pub-id>
          <pub-id pub-id-type="other">2-s2.0-66249103690</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mollnes</surname>
              <given-names>T. E.</given-names>
            </name>
            <name>
              <surname>Brekke</surname>
              <given-names>O. L.</given-names>
            </name>
            <name>
              <surname>Fung</surname>
              <given-names>M.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation</article-title>
          <source>
            <italic toggle="yes">Blood</italic>
          </source>
          <year>2002</year>
          <volume>100</volume>
          <fpage>1869</fpage>
          <lpage>1877</lpage>
          <pub-id pub-id-type="pmid">12176911</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tanaka</surname>
              <given-names>G. D.</given-names>
            </name>
            <name>
              <surname>Pidde-Queiroz</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Furtado</surname>
              <given-names>M. D. F. D.</given-names>
            </name>
            <name>
              <surname>Van den Berg</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Tambourgi</surname>
              <given-names>D. V.</given-names>
            </name>
          </person-group>
          <article-title>Micrurus snake venoms activate human complement system and generate anaphylatoxins</article-title>
          <source>
            <italic toggle="yes">BMC Immunology</italic>
          </source>
          <year>2012</year>
          <volume>13</volume>
          <issue>1</issue>
          <fpage>p. 4</fpage>
          <pub-id pub-id-type="doi">10.1186/1471-2172-13-4</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84855771661</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brekke</surname>
              <given-names>O. L.</given-names>
            </name>
            <name>
              <surname>Christiansen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Fure</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Fung</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mollnes</surname>
              <given-names>T. E.</given-names>
            </name>
          </person-group>
          <article-title>The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood</article-title>
          <source>
            <italic toggle="yes">Journal of Leukocyte Biology</italic>
          </source>
          <year>2007</year>
          <volume>81</volume>
          <issue>6</issue>
          <fpage>1404</fpage>
          <lpage>1413</lpage>
          <pub-id pub-id-type="doi">10.1189/jlb.0806538</pub-id>
          <pub-id pub-id-type="other">2-s2.0-34249681296</pub-id>
          <pub-id pub-id-type="pmid">17389579</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brekke</surname>
              <given-names>O. L.</given-names>
            </name>
            <name>
              <surname>Christiansen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Fure</surname>
              <given-names>H.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combined inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokine- and growth factor-synthesis in human whole blood</article-title>
          <source>
            <italic toggle="yes">Molecular Immunology</italic>
          </source>
          <year>2008</year>
          <volume>45</volume>
          <issue>14</issue>
          <fpage>3804</fpage>
          <lpage>3813</lpage>
          <pub-id pub-id-type="doi">10.1016/j.molimm.2008.05.017</pub-id>
          <pub-id pub-id-type="other">2-s2.0-48049089596</pub-id>
          <pub-id pub-id-type="pmid">18606453</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernardshaw</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lyberg</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Hetland</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Effect of an extract of the mushroom Agaricus blazei Murill on expression of adhesion molecules and production of reactive oxygen species in monocytes and granulocytes in human whole blood ex vivo</article-title>
          <source>
            <italic toggle="yes">APMIS</italic>
          </source>
          <year>2007</year>
          <volume>115</volume>
          <issue>6</issue>
          <fpage>719</fpage>
          <lpage>725</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0463.2007.apm_619.x</pub-id>
          <pub-id pub-id-type="other">2-s2.0-34249778961</pub-id>
          <pub-id pub-id-type="pmid">17550380</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Biro</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ling</surname>
              <given-names>W. L.</given-names>
            </name>
            <name>
              <surname>Arlaud</surname>
              <given-names>G. J.</given-names>
            </name>
          </person-group>
          <article-title>Complement protein C1q recognizes enzymatically modified low-density lipoprotein through unesterified fatty acids generated by cholesterol esterase</article-title>
          <source>
            <italic toggle="yes">Biochemistry</italic>
          </source>
          <year>2010</year>
          <volume>49</volume>
          <issue>10</issue>
          <fpage>2167</fpage>
          <lpage>2176</lpage>
          <pub-id pub-id-type="doi">10.1021/bi9021022</pub-id>
          <pub-id pub-id-type="other">2-s2.0-77949376177</pub-id>
          <pub-id pub-id-type="pmid">20166680</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sandberg</surname>
              <given-names>A. L.</given-names>
            </name>
            <name>
              <surname>Osler</surname>
              <given-names>A. G.</given-names>
            </name>
          </person-group>
          <article-title>Dual pathways of complement interaction with guinea pig immunoglobulins</article-title>
          <source>
            <italic toggle="yes">Journal of Immunology</italic>
          </source>
          <year>1971</year>
          <volume>107</volume>
          <fpage>1268</fpage>
          <lpage>1273</lpage>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takabayashi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Vannier</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>B. D.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis</article-title>
          <source>
            <italic toggle="yes">Journal of Immunology</italic>
          </source>
          <year>1996</year>
          <volume>156</volume>
          <fpage>3455</fpage>
          <lpage>3460</lpage>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>W. H.</given-names>
            </name>
            <name>
              <surname>Jagels</surname>
              <given-names>M. A.</given-names>
            </name>
            <name>
              <surname>Hugli</surname>
              <given-names>T. E.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg)</article-title>
          <source>
            <italic toggle="yes">Journal of Immunology</italic>
          </source>
          <year>1999</year>
          <volume>162</volume>
          <fpage>453</fpage>
          <lpage>459</lpage>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strieter</surname>
              <given-names>R. M.</given-names>
            </name>
            <name>
              <surname>Kasahara</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>R. M.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cytokine-induced neutrophil-derived interleukin-8</article-title>
          <source>
            <italic toggle="yes">The American Journal of Pathology</italic>
          </source>
          <year>1992</year>
          <volume>141</volume>
          <fpage>397</fpage>
          <lpage>407</lpage>
          <pub-id pub-id-type="pmid">1497091</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hopken</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Mohr</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Struber</surname>
              <given-names>A.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies</article-title>
          <source>
            <italic toggle="yes">European Journal of Immunology</italic>
          </source>
          <year>1996</year>
          <volume>26</volume>
          <issue>5</issue>
          <fpage>1103</fpage>
          <lpage>1109</lpage>
          <pub-id pub-id-type="doi">10.1002/eji.1830260522</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0029980816</pub-id>
          <pub-id pub-id-type="pmid">8647174</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zwirner</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Gotze</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Begemann</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Kapp</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kirchhoff</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Werfel</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies</article-title>
          <source>
            <italic toggle="yes">Immunology</italic>
          </source>
          <year>2001</year>
          <volume>97</volume>
          <issue>1</issue>
          <fpage>166</fpage>
          <lpage>172</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2567.1999.00764.x</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0032941977</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lukacsi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Nagy-Balo</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Erdei</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sandor</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Bajtay</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>The role of CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in complement-mediated phagocytosis and podosome formation by human phagocytes</article-title>
          <source>
            <italic toggle="yes">Immunology Letters</italic>
          </source>
          <year>2017</year>
          <volume>189</volume>
          <fpage>64</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="doi">10.1016/j.imlet.2017.05.014</pub-id>
          <pub-id pub-id-type="other">2-s2.0-85019656025</pub-id>
          <pub-id pub-id-type="pmid">28554712</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Adhikari</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Dose-dependent immunomodulating effects of endotoxin in allergic airway inflammation</article-title>
          <source>
            <italic toggle="yes">Innate Immunity</italic>
          </source>
          <year>2016</year>
          <volume>23</volume>
          <issue>3</issue>
          <fpage>249</fpage>
          <lpage>257</lpage>
          <pub-id pub-id-type="doi">10.1177/1753425917690443</pub-id>
          <pub-id pub-id-type="other">2-s2.0-85016765537</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Unnewehr</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Rittirsch</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Sarma</surname>
              <given-names>J. V.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Changes and regulation of the C5a receptor on neutrophils during septic shock in humans</article-title>
          <source>
            <italic toggle="yes">Journal of Immunology</italic>
          </source>
          <year>2013</year>
          <volume>190</volume>
          <issue>8</issue>
          <fpage>4215</fpage>
          <lpage>4225</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.1200534</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84875994477</pub-id>
          <pub-id pub-id-type="pmid">23479227</pub-id>
        </element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riedemann</surname>
              <given-names>N. C.</given-names>
            </name>
            <name>
              <surname>Neff</surname>
              <given-names>T. A.</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>R. F.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression</article-title>
          <source>
            <italic toggle="yes">Journal of Immunology</italic>
          </source>
          <year>2003</year>
          <volume>170</volume>
          <issue>1</issue>
          <fpage>503</fpage>
          <lpage>507</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.170.1.503</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0037218519</pub-id>
          <pub-id pub-id-type="pmid">12496437</pub-id>
        </element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marchant</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Duchow</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Delville</surname>
              <given-names>J. P.</given-names>
            </name>
            <name>
              <surname>Goldman</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Lipopolysaccharide induces up-regulation of CD14 molecule on monocytes in human whole blood</article-title>
          <source>
            <italic toggle="yes">European Journal of Immunology</italic>
          </source>
          <year>1992</year>
          <volume>22</volume>
          <issue>6</issue>
          <fpage>1663</fpage>
          <lpage>1665</lpage>
          <pub-id pub-id-type="doi">10.1002/eji.1830220650</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0026551423</pub-id>
          <pub-id pub-id-type="pmid">1376269</pub-id>
        </element-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Landmann</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ludwig</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Obrist</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Obrecht</surname>
              <given-names>J. P.</given-names>
            </name>
          </person-group>
          <article-title>Effect of cytokines and lipopolysaccharide on CD14 antigen expression in human monocytes and macrophages</article-title>
          <source>
            <italic toggle="yes">Journal of Cellular Biochemistry</italic>
          </source>
          <year>1991</year>
          <volume>47</volume>
          <issue>4</issue>
          <fpage>317</fpage>
          <lpage>329</lpage>
          <pub-id pub-id-type="doi">10.1002/jcb.240470406</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0026337944</pub-id>
          <pub-id pub-id-type="pmid">1724447</pub-id>
        </element-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chow</surname>
              <given-names>J. C.</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>D. W.</given-names>
            </name>
            <name>
              <surname>Golenbock</surname>
              <given-names>D. T.</given-names>
            </name>
            <name>
              <surname>Christ</surname>
              <given-names>W. J.</given-names>
            </name>
            <name>
              <surname>Gusovsky</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction</article-title>
          <source>
            <italic toggle="yes">The Journal of Biological Chemistry</italic>
          </source>
          <year>1999</year>
          <volume>274</volume>
          <issue>16</issue>
          <fpage>10689</fpage>
          <lpage>10692</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.274.16.10689</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0033574415</pub-id>
          <pub-id pub-id-type="pmid">10196138</pub-id>
        </element-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>R. B.</given-names>
            </name>
            <name>
              <surname>Mark</surname>
              <given-names>M. R.</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>A.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling</article-title>
          <source>
            <italic toggle="yes">Nature</italic>
          </source>
          <year>1998</year>
          <volume>395</volume>
          <issue>6699</issue>
          <fpage>284</fpage>
          <lpage>288</lpage>
          <pub-id pub-id-type="doi">10.1038/26239</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0032541661</pub-id>
          <pub-id pub-id-type="pmid">9751057</pub-id>
        </element-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lau</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Nygard</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fure</surname>
              <given-names>H.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CD14 and complement crosstalk and largely mediate the transcriptional response to Escherichia coli in human whole blood as revealed by DNA microarray</article-title>
          <source>
            <italic toggle="yes">PLoS One</italic>
          </source>
          <year>2015</year>
          <volume>10</volume>
          <issue>2, article e0117261</issue>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0117261</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84923792613</pub-id>
        </element-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nathan</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Cunningham-Bussel</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Beyond oxidative stress: an immunologist&#x2019;s guide to reactive oxygen species</article-title>
          <source>
            <italic toggle="yes">Nature Reviews. Immunology</italic>
          </source>
          <year>2013</year>
          <volume>13</volume>
          <issue>5</issue>
          <fpage>349</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="doi">10.1038/nri3423</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84876931396</pub-id>
          <pub-id pub-id-type="pmid">23618831</pub-id>
        </element-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Almeida Chuffa</surname>
              <given-names>L. G.</given-names>
            </name>
            <name>
              <surname>de Moura Ferreira</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lupi</surname>
              <given-names>L. A.</given-names>
            </name>
            <name>
              <surname>da Silva Nunes</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>F&#xE1;varo</surname>
              <given-names>W. J.</given-names>
            </name>
          </person-group>
          <article-title>P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling</article-title>
          <source>
            <italic toggle="yes">Journal of Ovarian Research</italic>
          </source>
          <year>2018</year>
          <volume>11</volume>
          <issue>1</issue>
          <fpage>p. 8</fpage>
          <pub-id pub-id-type="doi">10.1186/s13048-018-0380-5</pub-id>
          <pub-id pub-id-type="other">2-s2.0-85040794713</pub-id>
          <pub-id pub-id-type="pmid">29343281</pub-id>
        </element-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schaeffler</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Buettner</surname>
              <given-names>R.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-<italic>&#x3BA;</italic>B pathway in adipocytes links nutritional signalling with innate immunity</article-title>
          <source>
            <italic toggle="yes">Immunology</italic>
          </source>
          <year>2009</year>
          <volume>126</volume>
          <issue>2</issue>
          <fpage>233</fpage>
          <lpage>245</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2567.2008.02892.x</pub-id>
          <pub-id pub-id-type="other">2-s2.0-58149310977</pub-id>
          <pub-id pub-id-type="pmid">18624726</pub-id>
        </element-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mena</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Manosalva</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ramirez</surname>
              <given-names>R.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Linoleic acid increases adhesion, chemotaxis, granule release, intracellular calcium mobilisation, MAPK phosphorylation and gene expression in bovine neutrophils</article-title>
          <source>
            <italic toggle="yes">Veterinary Immunology and Immunopathology</italic>
          </source>
          <year>2013</year>
          <volume>151</volume>
          <issue>3-4</issue>
          <fpage>275</fpage>
          <lpage>284</lpage>
          <pub-id pub-id-type="doi">10.1016/j.vetimm.2012.11.017</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84872795221</pub-id>
          <pub-id pub-id-type="pmid">23267746</pub-id>
        </element-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aomatsu</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>H.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Toll-like receptor agonists stimulate human neutrophil migration via activation of mitogen-activated protein kinases</article-title>
          <source>
            <italic toggle="yes">Immunology</italic>
          </source>
          <year>2008</year>
          <volume>123</volume>
          <issue>2</issue>
          <fpage>171</fpage>
          <lpage>180</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2567.2007.02684.x</pub-id>
          <pub-id pub-id-type="other">2-s2.0-37849039746</pub-id>
          <pub-id pub-id-type="pmid">17662043</pub-id>
        </element-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sabroe</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Dower</surname>
              <given-names>S. K.</given-names>
            </name>
            <name>
              <surname>Whyte</surname>
              <given-names>M. K. B.</given-names>
            </name>
          </person-group>
          <article-title>The role of Toll-like receptors in the regulation of neutrophil migration, activation, and apoptosis</article-title>
          <source>
            <italic toggle="yes">Clinical Infectious Diseases</italic>
          </source>
          <year>2005</year>
          <volume>41</volume>
          <issue>Supplement 7</issue>
          <fpage>S421</fpage>
          <lpage>S426</lpage>
          <pub-id pub-id-type="doi">10.1086/431992</pub-id>
          <pub-id pub-id-type="other">2-s2.0-27744558575</pub-id>
          <pub-id pub-id-type="pmid">16237641</pub-id>
        </element-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hayashi</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Means</surname>
              <given-names>T. K.</given-names>
            </name>
            <name>
              <surname>Luster</surname>
              <given-names>A. D.</given-names>
            </name>
          </person-group>
          <article-title>Toll-like receptors stimulate human neutrophil function</article-title>
          <source>
            <italic toggle="yes">Blood</italic>
          </source>
          <year>2003</year>
          <volume>102</volume>
          <issue>7</issue>
          <fpage>2660</fpage>
          <lpage>2669</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2003-04-1078</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0141705297</pub-id>
          <pub-id pub-id-type="pmid">12829592</pub-id>
        </element-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zarember</surname>
              <given-names>K. A.</given-names>
            </name>
            <name>
              <surname>Godowski</surname>
              <given-names>P. J.</given-names>
            </name>
          </person-group>
          <article-title>Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines</article-title>
          <source>
            <italic toggle="yes">Journal of Immunology</italic>
          </source>
          <year>2002</year>
          <volume>168</volume>
          <issue>2</issue>
          <fpage>554</fpage>
          <lpage>561</lpage>
          <pub-id pub-id-type="doi">10.4049/jimmunol.168.2.554</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0037080024</pub-id>
          <pub-id pub-id-type="pmid">11777946</pub-id>
        </element-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zanoni</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Ostuni</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Marek</surname>
              <given-names>L. R.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CD14 controls the LPS-induced endocytosis of Toll-like receptor 4</article-title>
          <source>
            <italic toggle="yes">Cell</italic>
          </source>
          <year>2011</year>
          <volume>147</volume>
          <issue>4</issue>
          <fpage>868</fpage>
          <lpage>880</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2011.09.051</pub-id>
          <pub-id pub-id-type="other">2-s2.0-81055129630</pub-id>
          <pub-id pub-id-type="pmid">22078883</pub-id>
        </element-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Snell</surname>
              <given-names>L. M.</given-names>
            </name>
            <name>
              <surname>McGaha</surname>
              <given-names>T. L.</given-names>
            </name>
            <name>
              <surname>Brooks</surname>
              <given-names>D. G.</given-names>
            </name>
          </person-group>
          <article-title>Type I interferon in chronic virus infection and cancer</article-title>
          <source>
            <italic toggle="yes">Trends in Immunology</italic>
          </source>
          <year>2017</year>
          <volume>38</volume>
          <issue>8</issue>
          <fpage>542</fpage>
          <lpage>557</lpage>
          <pub-id pub-id-type="doi">10.1016/j.it.2017.05.005</pub-id>
          <pub-id pub-id-type="other">2-s2.0-85019977333</pub-id>
          <pub-id pub-id-type="pmid">28579323</pub-id>
        </element-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Donovan</surname>
              <given-names>M. L.</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>T. E.</given-names>
            </name>
            <name>
              <surname>Duke</surname>
              <given-names>T. J.</given-names>
            </name>
            <name>
              <surname>Blumenthal</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Type I interferons in the pathogenesis of tuberculosis: molecular drivers and immunological consequences</article-title>
          <source>
            <italic toggle="yes">Frontiers in Immunology</italic>
          </source>
          <year>2017</year>
          <volume>8</volume>
          <pub-id pub-id-type="doi">10.3389/fimmu.2017.01633</pub-id>
          <pub-id pub-id-type="other">2-s2.0-85035057308</pub-id>
        </element-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalliolias</surname>
              <given-names>G. D.</given-names>
            </name>
            <name>
              <surname>Ivashkiv</surname>
              <given-names>L. B.</given-names>
            </name>
          </person-group>
          <article-title>TNF biology, pathogenic mechanisms and emerging therapeutic strategies</article-title>
          <source>
            <italic toggle="yes">Nature Reviews Rheumatology</italic>
          </source>
          <year>2016</year>
          <volume>12</volume>
          <issue>1</issue>
          <fpage>49</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="doi">10.1038/nrrheum.2015.169</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84954197918</pub-id>
          <pub-id pub-id-type="pmid">26656660</pub-id>
        </element-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bao</surname>
              <given-names>Z. J.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Haq</surname>
              <given-names>I. U.</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>S. M.</given-names>
            </name>
          </person-group>
          <article-title>Recombinant bovine interferon-<italic>&#x3C4;</italic> enhances in vitro development of bovine embryos by upregulating expression of connexin 43 and E-cadherin</article-title>
          <source>
            <italic toggle="yes">Journal of Dairy Science</italic>
          </source>
          <year>2014</year>
          <volume>97</volume>
          <issue>11</issue>
          <fpage>6917</fpage>
          <lpage>6925</lpage>
          <pub-id pub-id-type="doi">10.3168/jds.2014-8106</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84908327199</pub-id>
          <pub-id pub-id-type="pmid">25242422</pub-id>
        </element-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adib-Conquy</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Scott-Algara</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Cavaillon</surname>
              <given-names>J. M.</given-names>
            </name>
            <name>
              <surname>Souza-Fonseca-Guimaraes</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>TLR-mediated activation of NK cells and their role in bacterial/viral immune responses in mammals</article-title>
          <source>
            <italic toggle="yes">Immunology and Cell Biology</italic>
          </source>
          <year>2014</year>
          <volume>92</volume>
          <issue>3</issue>
          <fpage>256</fpage>
          <lpage>262</lpage>
          <pub-id pub-id-type="doi">10.1038/icb.2013.99</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84898972548</pub-id>
          <pub-id pub-id-type="pmid">24366517</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="fig1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Activation of the complement system by P-MAPA in human whole blood. Complement activation products were measured in plasma from blood samples (720&#x2009;<italic>&#x3BC;</italic>L) incubated with PBS, LPS (100&#x2009;<italic>&#x3BC;</italic>g/mL), or increasing concentrations of P-MAPA, at 37&#xB0;C for 30 minutes. (a) Levels of C3a/C3a desArg in plasma, posttreatment, were measured using the OptEIA Human C3a ELISA Kit or BD CBA Anaphylatoxin Kit. (b) Levels of C5a/C5a desArg were measured using the OptEIA Human C5a ELISA or BD CBA Anaphylatoxin Kit. (c) sC5b-9 complex levels in plasma, following incubation with P-MAPA, were measured by EIA detection kit. Data are the mean of three independent experiments, from three different blood donors, performed in duplicate, and the results are expressed as the mean &#xB1; SEM. Statistical analysis was performed by one-way ANOVA, complemented with the Tukey test. <sup>&#x2217;</sup><italic>p</italic> &lt; 0.05, <sup>&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.01, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.001, and <sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.0001: significant differences between the mean values with PBS control. <sup>#</sup><italic>p</italic> &lt; 0.05, <sup>##</sup><italic>p</italic> &lt; 0.01, <sup>###</sup><italic>p</italic> &lt; 0.001, and <sup>####</sup><italic>p</italic> &lt; 0.0001: significant differences between the mean values with LPS.</p>
      </caption>
      <graphic xlink:href="MI2020-8831389.001"/>
    </fig>
    <fig id="fig2" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Modulation of surface receptors in monocytes after P-MAPA treatment. After incubation of blood samples with PBS, LPS (100&#x2009;<italic>&#x3BC;</italic>g/mL), or P-MAPA (125, 250, 500, or 1000&#x2009;<italic>&#x3BC;</italic>g/mL) for 30 minutes at 37&#xB0;C, erythrocytes were lysed, and leukocytes were stained for flow cytometry analysis. (a) CD11b, (b) CD14, (c) C3aR, (d) C5aR, (e) TLR2, and (f) TLR4 expressions in monocyte population. Data are representative of six separate experiments, from six different donors, performed in duplicate, and the results are expressed as the mean &#xB1; SEM. Statistical analysis was performed by one-way ANOVA, complemented with the Tukey test. <sup>&#x2217;</sup><italic>p</italic> &lt; 0.05, <sup>&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.01, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.001, and <sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.0001: significant differences between the mean values with PBS control. <sup>#</sup><italic>p</italic> &lt; 0.05, <sup>##</sup><italic>p</italic> &lt; 0.01, <sup>###</sup><italic>p</italic> &lt; 0.001, and <sup>####</sup><italic>p</italic> &lt; 0.0001: significant differences between the mean values with LPS.</p>
      </caption>
      <graphic xlink:href="MI2020-8831389.002"/>
    </fig>
    <fig id="fig3" orientation="portrait" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Modulation of surface receptors in neutrophils after P-MAPA treatment. After incubation of blood samples with PBS, LPS (100&#x2009;<italic>&#x3BC;</italic>g/mL), or P-MAPA (125, 250, 500, or 1000&#x2009;<italic>&#x3BC;</italic>g/mL) for 30 minutes at 37&#xB0;C, erythrocytes were lysed, and leukocytes were stained for flow cytometry analysis. (a) CD11b, (b) CD14, (c) C3aR, (d) C5aR, (e) TLR2, and (f) TLR4 expressions in neutrophil population. Data are representative of six separate experiments, from six different donors, performed in duplicate, and the results are expressed as the mean &#xB1; SEM. Statistical analysis was performed by one-way ANOVA, complemented with the Tukey test. <sup>&#x2217;</sup><italic>p</italic> &lt; 0.05, <sup>&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.01, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.001, and <sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.0001: significant differences between the mean values with PBS control. <sup>#</sup><italic>p</italic> &lt; 0.05, <sup>##</sup><italic>p</italic> &lt; 0.01, <sup>###</sup><italic>p</italic> &lt; 0.001, and <sup>####</sup><italic>p</italic> &lt; 0.0001: significant differences between the mean values with LPS.</p>
      </caption>
      <graphic xlink:href="MI2020-8831389.003"/>
    </fig>
    <fig id="fig4" orientation="portrait" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Cytokine production poststimulation of human whole blood with P-MAPA. Cytokines were measured in plasma collected from blood stimulated with PBS, LPS (100&#x2009;<italic>&#x3BC;</italic>g/mL), or P-MAPA for 30 minutes at 37&#xB0;C. (a) TNF-<italic>&#x3B1;</italic> (assay detection limit 7.8&#x2009;pg/mL), (b) IL-8 (assay detection limit: 3.1&#x2009;pg/mL), (c) IL-12(p70) (assay detection limit: 7.8&#x2009;pg/mL), and (d) IFN-<italic>&#x3B3;</italic> (assay detection limit: 4.7&#x2009;pg/mL) productions are expressed as the mean &#xB1; SEM. Data are the mean of three separate experiments, from three different donors, performed in duplicate, and the results are expressed as concentration of each cytokine per mL of human plasma (pg/mL). Statistical analysis was performed by one-way ANOVA, complemented with the Tukey test. <sup>&#x2217;</sup><italic>p</italic> &lt; 0.05, <sup>&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.01, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.001, and <sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.0001: significant differences between the mean values with PBS control. <sup>#</sup><italic>p</italic> &lt; 0.05, <sup>##</sup><italic>p</italic> &lt; 0.01, <sup>###</sup><italic>p</italic> &lt; 0.001, and <sup>####</sup><italic>p</italic> &lt; 0.0001: significant differences between the mean values with LPS.</p>
      </caption>
      <graphic xlink:href="MI2020-8831389.004"/>
    </fig>
    <fig id="fig5" orientation="portrait" position="float">
      <label>Figure 5</label>
      <caption>
        <p>Expression of surface receptors following inhibition of complement activation by compstatin. Blood samples were incubated with compstatin (1&#x2009;mM) (10&#x2009;min, RT) ahead of stimulation with PBS, LPS (100&#x2009;<italic>&#x3BC;</italic>g/mL), or P-MAPA (1000&#x2009;<italic>&#x3BC;</italic>g/mL) for 30 minutes at 37&#xB0;C. Next, erythrocytes were lysed, and leukocytes were stained for flow cytometry analysis. (a) CD11b, (b) CD14, (c) C3aR, (d) C5aR, (e) TLR2, and (f) TLR4 expressions. Data are representative of three separate experiments, from three different donors, performed in duplicate, and the results are expressed as the mean &#xB1; SEM. Comparison between treatments was analyzed using ANOVA and Tukey's posttest. <sup>&#x2217;</sup><italic>p</italic> &lt; 0.05, <sup>&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.01, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.001, and <sup>&#x2217;&#x2217;&#x2217;&#x2217;</sup><italic>p</italic> &lt; 0.0001: significant differences between the mean values with PBS control. Comparison between samples treated with compstatin or not (buffer) was analyzed using Student's <italic>t</italic>-test, and significant differences are represented by <sup>&amp;</sup><italic>p</italic> &lt; 0.05, <sup>&amp;&amp;</sup><italic>p</italic> &lt; 0.01, and <sup>&amp;&amp;&amp;</sup><italic>p</italic> &lt; 0.001.</p>
      </caption>
      <graphic xlink:href="MI2020-8831389.005"/>
    </fig>
    <fig id="fig6" orientation="portrait" position="float">
      <label>Figure 6</label>
      <caption>
        <p>Production of oxygen and nitrogen of reactive species production after complement inhibition and P-MAPA stimulation. Blood samples were preincubated with compstatin (1&#x2009;mM) (10&#x2009;min, RT) or left untreated, ahead of stimulation with PBS, LPS (100&#x2009;<italic>&#x3BC;</italic>g/ml), or P-MAPA (1000&#x2009;<italic>&#x3BC;</italic>g/ml) for 1 h with DHE at 37&#xB0;C for the detection of superoxide (a) or with DHR at 30&#xB0;C for detection of peroxynitrite (b), in 5% CO<sub>2</sub> incubator. Erythrocytes were lysed and samples analysed by flow cytometry. Data are the mean of three separate experiments, from three independent donors, performed in duplicate, and results are expressed as the fold change of median fluorescence intensity (MFI) compared to the control group&#x2009;&#xB1;&#x2009;SEM. Comparison between compstatin-treated and compstatin-untreated samples were analysed using the Mann-Whitney test. <sup>&#x2217;</sup><italic>p</italic> &lt; 0.05: significant differences between the mean values with PBS control. <sup>&amp;&amp;</sup><italic>p</italic> &lt; 0.01: significant differences between compstatin-treated and compstatin-untreated groups.</p>
      </caption>
      <graphic xlink:href="MI2020-8831389.006"/>
    </fig>
  </floats-group>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
      <journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
      <journal-title-group>
        <journal-title>Frontiers in Immunology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1664-3224</issn>
      <publisher>
        <publisher-name>Frontiers Media S.A.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32983087</article-id>
      <article-id pub-id-type="pmc">7492592</article-id>
      <article-id pub-id-type="doi">10.3389/fimmu.2020.01789</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Immunology</subject>
          <subj-group>
            <subject>Original Research</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Complement C5a Induces Pro-inflammatory Microvesicle Shedding in Severely Injured Patients</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Karasu</surname>
            <given-names>Ebru</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Demmelmaier</surname>
            <given-names>Julia</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kellermann</surname>
            <given-names>Stephanie</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Holzmann</surname>
            <given-names>Karlheinz</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>K&#xF6;hl</surname>
            <given-names>J&#xF6;rg</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/25318/overview"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schmidt</surname>
            <given-names>Christoph Q.</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/640601/overview"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kalbitz</surname>
            <given-names>Miriam</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/700268/overview"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gebhard</surname>
            <given-names>Florian</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Huber-Lang</surname>
            <given-names>Markus S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/378510/overview"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Halbgebauer</surname>
            <given-names>Rebecca</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="c001">
            <sup>*</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/990954/overview"/>
        </contrib>
      </contrib-group>
      <aff id="aff1"><sup>1</sup><institution>Institute of Clinical and Experimental Trauma Immunology, University Hospital Ulm</institution>, <addr-line>Ulm</addr-line>, <country>Germany</country></aff>
      <aff id="aff2"><sup>2</sup><institution>Center for Biomedical Research, Genomics-Core Facility, Ulm University</institution>, <addr-line>Ulm</addr-line>, <country>Germany</country></aff>
      <aff id="aff3"><sup>3</sup><institution>Institute for Systemic Inflammation Research (ISEF), University of L&#xFC;beck</institution>, <addr-line>L&#xFC;beck</addr-line>, <country>Germany</country></aff>
      <aff id="aff4"><sup>4</sup><institution>Division of Immunobiology, Cincinnati Children's Hospital</institution>, <addr-line>Cincinnati, OH</addr-line>, <country>United States</country></aff>
      <aff id="aff5"><sup>5</sup><institution>Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University</institution>, <addr-line>Ulm</addr-line>, <country>Germany</country></aff>
      <aff id="aff6"><sup>6</sup><institution>Department of Traumatology, Hand-, Plastic- and Reconstructive Surgery, Center of Surgery, University of Ulm Medical School</institution>, <addr-line>Ulm</addr-line>, <country>Germany</country></aff>
      <author-notes>
        <fn fn-type="edited-by">
          <p>Edited by: Uday Kishore, Brunel University London, United Kingdom</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Reviewed by: Roberta Bulla, University of Trieste, Italy; Lubka T. Roumenina, INSERM U1138 Centre de Recherche des Cordeliers (CRC), France</p>
        </fn>
        <corresp id="c001">*Correspondence: Rebecca Halbgebauer <email>rebecca.halbgebauer@uniklinik-ulm.de</email></corresp>
        <fn fn-type="other" id="fn001">
          <p>This article was submitted to Molecular Innate Immunity, a section of the journal Frontiers in Immunology</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>02</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>11</volume>
      <elocation-id>1789</elocation-id>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>5</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>06</day>
          <month>7</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2020 Karasu, Demmelmaier, Kellermann, Holzmann, K&#xF6;hl, Schmidt, Kalbitz, Gebhard, Huber-Lang and Halbgebauer.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder>Karasu, Demmelmaier, Kellermann, Holzmann, K&#xF6;hl, Schmidt, Kalbitz, Gebhard, Huber-Lang and Halbgebauer</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Initially underestimated as platelet dust, extracellular vesicles are continuously gaining interest in the field of inflammation. Various studies addressing inflammatory diseases have shown that microvesicles (MVs) originating from different cell types are systemic transport vehicles carrying distinct cargoes to modulate immune responses. In this study, we focused on the clinical setting of multiple trauma, which is characterized by activation and dysfunction of both, the fluid-phase and the cellular component of innate immunity. Given the sensitivity of neutrophils for the complement anaphylatoxin C5a, we hypothesized that increased C5a production induces alterations in MV shedding of neutrophils resulting in neutrophil dysfunction that fuels posttraumatic inflammation. In a mono-centered prospective clinical study with polytraumatized patients, we found significantly increased granulocyte-derived MVs containing the C5a receptor (C5aR1, CD88) on their surface. This finding was accompanied by a concomitant loss of C5aR1 on granulocytes indicative of an impaired cellular chemotactic and pro-inflammatory neutrophil functions. Furthermore, <italic>in vitro</italic> exposure of human neutrophils (from healthy volunteers) to C5a significantly increased MV shedding and C5aR1 loss on neutrophils, which could be blocked using the C5aR1 antagonist PMX53. Mechanistic analyses revealed that the interaction between C5aR1 signaling and the small GTPase Arf6 acts as a molecular switch for MV shedding. When neutrophil derived, C5a-induced MV were exposed to a complex <italic>ex vivo</italic> whole blood model significant pro-inflammatory properties (NADPH activity, ROS and MPO generation) of the MVs became evident. C5a-induced MVs activated resting neutrophils and significantly induced IL-6 secretion. These data suggest a novel role of the C5a-C5aR1 axis: C5a-induced MV shedding from neutrophils results in decreased C5aR1 surface expression on the one hand, on the other hand it leads to profound inflammatory signals which likely are both key drivers of the neutrophil dysfunction which is regularly observed in patients suffering from multiple traumatic injuries.</p>
      </abstract>
      <kwd-group>
        <kwd>multiple trauma</kwd>
        <kwd>microvesicle shedding</kwd>
        <kwd>anaphylatoxin C5a</kwd>
        <kwd>C5aR1</kwd>
        <kwd>neutrophils</kwd>
        <kwd>polymorphonuclear neutrophils (PMNs)</kwd>
        <kwd>inflammation</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source id="cn001">Deutsche Forschungsgemeinschaft<named-content content-type="fundref-id">10.13039/501100001659</named-content></funding-source>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="8"/>
        <table-count count="1"/>
        <equation-count count="0"/>
        <ref-count count="90"/>
        <page-count count="17"/>
        <word-count count="9816"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>In patients with severe injury, sepsis, and septic shock (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>) early and excessive complement activation may be responsible for subsequent innate immune dysfunction (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Neutrophils as first-line cellular defense of innate immunity showed major changes in their function driven by an imbalanced complement activity. Equipped with a broad receptor repertoire for complement activation products including the anaphylatoxin receptors as well as membrane-bound complement regulators, neutrophils quickly sense micro-environmental changes. Our previous study showed altered expression profiles of complement receptors and membrane-bound complement regulators on immune cells from polytraumatized patients (<xref rid="B5" ref-type="bibr">5</xref>). So far, it is well-established that the anaphylatoxin C5a exerts its effects through the two complement anaphylatoxin C5a receptors, C5aR1 (CD88) and C5aR2. While C5aR1 is a classical G-protein coupled receptor, C5aR2 is deficient in G-protein coupling. Especially, dysfunction of C5aR1 has been implicated in various pathological conditions such as sepsis, autoimmunity and inflammation (<xref rid="B6" ref-type="bibr">6</xref>&#x2013;<xref rid="B8" ref-type="bibr">8</xref>). Neutrophils, as first cellular line of defense, constitutively express C5aR1 (<xref rid="B9" ref-type="bibr">9</xref>), which represents the major receptor for the anaphylatoxin. C5aR1 acts as switch to induce multiple functions of neutrophils including chemotaxis, adhesion, intracellular pH changes and electrophysiological changes (<xref rid="B10" ref-type="bibr">10</xref>&#x2013;<xref rid="B12" ref-type="bibr">12</xref>). C5aR1 dysfunction negatively influences cellular effector functions and is associated with poor clinical outcome in sepsis patients (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B13" ref-type="bibr">13</xref>&#x2013;<xref rid="B15" ref-type="bibr">15</xref>).</p>
      <p>There is increasing evidence that MVs are involved in the loss of cellular C5aR1. In a previous study, we showed a significant reduction of the C5aR1 on neutrophils from septic shock patients and simultaneously increased plasma levels of a circulating form of C5aR1, suggesting that cells lose their receptors through MV shedding (<xref rid="B3" ref-type="bibr">3</xref>). However, a direct linkage among C5aR1 loss and MV shedding has not been demonstrated so far. MV shaping involves a dynamic interplay between phospholipid redistribution and cytoskeletal proteins. MV formation is induced by translocation of phosphatidylserine to the outer membrane through the activity of aminophospholipid translocases. It is well-established that the small and ubiquitously expressed GTP-binding proteins ADP-ribosylation factor (Arf) proteins possess important roles in membrane trafficking including vesicle formation (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). In principle, MVs can transfer information from the MV-generating donor cell to a wide range of remote target cells (<xref rid="B18" ref-type="bibr">18</xref>). Besides communication and transport vehicles, MVs are highly relevant in the context of inflammation. These packages actively contribute in inflammatory processes by interacting with immune cells, epithelial and endothelial cells, and bridging innate and adaptive immunity (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Several studies showed that MV numbers and their origin are altered in trauma and sepsis (<xref rid="B21" ref-type="bibr">21</xref>&#x2013;<xref rid="B23" ref-type="bibr">23</xref>). Patients with major burn injury showed elevated numbers of granulocyte- and monocyte- derived MVs, and this increase was associated with injury severity (<xref rid="B24" ref-type="bibr">24</xref>).</p>
      <p>In our present study, we focused on the anaphylatoxin C5a in MV shedding, because (i) increased concentrations are present early after multiple trauma and correlates with clinical severity, and (ii) the C5a-C5aR1 axis has already been shown to lead to a paralyzed innate immune response but underlying mechanisms remain mostly unexplained. We hypothesized that a link between C5aR1 signaling and Arf6-mediated MV shedding in neutrophils is responsible for altered C5aR1 levels on neutrophils under systemic inflammatory conditions.</p>
    </sec>
    <sec sec-type="materials and methods" id="s2">
      <title>Materials and Methods</title>
      <sec>
        <title>Clinical Study on Polytraumatized Patients</title>
        <p>A prospective clinical study was conducted in patients after severe trauma (Injury Severity Score &#x2265; 32, <italic>n</italic> = 11) and healthy volunteers of similar sex and age distribution (<italic>n</italic> = 8) (<xref rid="T1" ref-type="table">Table 1</xref>). The study was approved by the Independent Local Ethics Committee of the University of Ulm (number 94/14). Written informed consent was collected for each subject. Blood was obtained upon admission to the emergency room (ER) or 0 h, and 4, 12, 24, 48, 120, and 240 h after trauma. Citrate and EDTA blood from PT patients were centrifuged at 800 &#xD7; g for 15 min at 4&#xB0;C, followed by a second centrifugation at 16,000 &#xD7; g for 2 min at 4&#xB0;C. The supernatant was transferred into a new tube and was stored at &#x2212;80&#xB0;C.</p>
        <table-wrap id="T1" position="float">
          <label>Table 1</label>
          <caption>
            <p>Study participants.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th rowspan="1" colspan="1"/>
                <th valign="top" align="center" rowspan="1" colspan="1">
                  <bold>PT (<italic>n</italic> = 11)</bold>
                </th>
                <th valign="top" align="center" rowspan="1" colspan="1">
                  <bold>Healthy (<italic>n</italic> = 8)</bold>
                </th>
                <th rowspan="1" colspan="1"/>
              </tr>
            </thead>
            <tbody>
              <tr style="border-bottom: thin solid #000000;">
                <td valign="top" align="left" rowspan="1" colspan="1">
                  <bold>Demographic data</bold>
                </td>
                <td valign="top" align="center" rowspan="1" colspan="1"><bold>Mean</bold>
<bold>&#xB1;</bold>
<bold>SEM;</bold></td>
                <td valign="top" align="center" rowspan="1" colspan="1"><bold>Mean</bold>
<bold>&#xB1;</bold>
<bold>SEM;</bold></td>
                <td valign="top" align="center" rowspan="1" colspan="1">
                  <italic>
                    <bold>p</bold>
                  </italic>
                  <bold>-value</bold>
                </td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td valign="top" align="center" rowspan="1" colspan="1">
                  <bold>median</bold>
                </td>
                <td valign="top" align="center" rowspan="1" colspan="1">
                  <bold>median</bold>
                </td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td valign="top" align="center" rowspan="1" colspan="1">
                  <bold>(min.&#x2013;max.)</bold>
                </td>
                <td valign="top" align="center" rowspan="1" colspan="1">
                  <bold>(min.&#x2013;max.)</bold>
                </td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">44.5 &#xB1; 3.9; 49 (21&#x2013;63)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">42.4 &#xB1; 5.4; 42 (25&#x2013;64)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n.s.</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Sex, m/f (n)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">9/2</td>
                <td valign="top" align="center" rowspan="1" colspan="1">5/3</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n.s.</td>
              </tr>
              <tr>
                <td valign="top" align="left" colspan="4" rowspan="1">
                  <bold>Injury severity and clinical course</bold>
                </td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">ISS</td>
                <td valign="top" align="center" rowspan="1" colspan="1">35.9 &#xB1; 1.5; 34 (27&#x2013;43)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">GCS</td>
                <td valign="top" align="center" rowspan="1" colspan="1">4.9 &#xB1; 1.2; 3 (3&#x2013;15)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">ICU stay (d)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">10.4 &#xB1; 3.0; 10 (1&#x2013;32)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Death, <italic>n</italic> (%)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">4 (36%)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Nosocomial infection, <italic>n</italic> (%)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">6 (54%)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" colspan="4" rowspan="1">
                  <bold>Mechanism of injury</bold>
                </td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Car crash <italic>n</italic> (%)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">5 (45%)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Bicycle&#x2014;car collision <italic>n</italic> (%)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">3 (27%)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Fall <italic>n</italic> (%)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">3 (27%)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" colspan="4" rowspan="1">
                  <bold>Clinical parameters</bold>
                </td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Systolic RR (mmHg) min/max</td>
                <td valign="top" align="center" rowspan="1" colspan="1">65.9/103.3 &#xB1; 6.1/6.2;65/110 (40/60&#x2013;110/120)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">BE</td>
                <td valign="top" align="center" rowspan="1" colspan="1">&#x2212;1.7 &#xB1; 0.8; &#x2212;2.7 (-4.8&#x2013;3)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Initial Lactate (mmol/l)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">2.2 &#xB1; 0.3; 1.7 (0.8&#x2013;3.7)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">INR</td>
                <td valign="top" align="center" rowspan="1" colspan="1">1.4 &#xB1; 0.1; 1.3 (0.9&#x2013;2.8)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Initial Quick (%)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">65.3 &#xB1; 10.8; 58 (24&#x2013;124)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Initial PTT (sec)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">40.1 &#xB1; 4.9; 37 (21&#x2013;77)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">RBC transfusion 0 &#x2265; 24 h (unit)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">3.8 &#xB1; 1.43; 2 (0&#x2013;15)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">TASH score</td>
                <td valign="top" align="center" rowspan="1" colspan="1">8.4 &#xB1; 1.0; 8 (2&#x2013;13)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">Initial leukocytes (cells/nl)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">14.3 &#xB1; 1.9; 14 (4.9&#x2013;26.1)</td>
                <td valign="top" align="center" rowspan="1" colspan="1">n/a</td>
                <td rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p><italic>Central clinical data of study participants. Ages were compared using Student's t-test, and sexes were compared using Fisher's Exact test</italic>.</p>
            <p><italic>BE, base excess, GCS, Glasgow Coma Scale, ICU, intensive care unit, INR, international normalized ratio; ISS, injury severity score, PT, polytrauma; PTT, partial thromboplastin time; RBC, red blood cell; RR, Riva-Rocci, SEM, standard error of the mean; TASH score, trauma associated severe hemorrhage score</italic>.</p>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec>
        <title>Microvesicle Enrichment in Plasma Samples</title>
        <p>For flow cytometric analyses of CD66b and C5aR1 on the surface, MVs were enriched in patients' plasma samples. Plasma was thawed and centrifuged at 20,000 &#xD7; g for 45 min. Subsequently, the pelleted MV fraction was resuspended in Annexin V-binding buffer (BD Pharmingen) and stored at &#x2212;80&#xB0;C until further analysis.</p>
      </sec>
      <sec>
        <title>MV Flow Cytometric Analysis</title>
        <p>For identification of MVs, flow cytometry (FACSCanto II, BD) was used to define a MV-specific gate by size calibration beads and presence of Annexin V (AV). AV binding buffer was filtered twice (0.2 &#x3BC;m pore membrane filter). Five microliter of enriched or non- enriched plasma samples were used per measurement. MVs were stained with mouse anti-human C5aR1-FITC antibody (MCA2059F, Bio-Rad) and mouse anti-human CD66b-APC-Cy7 (305126, Biolegend) or the respective isotype controls in AV binding buffer. Gates to define size were set using 0.3, 0.5, and 1 &#x3BC;m latex beads (latex beads polystyrene 0.3 &#x3BC;m Kat: LB3-1ML; latex beads, carboxylate-modified polystyrene, fluorescent red, 0.5 &#x3BC;m, Kat: L3280-1ML; latex beads, amine-modified polystyrene, fluorescent red 1.0 &#x3BC;m, Kat: L2778-1ML; all Sigma Aldrich). The lowest detection limit for digital flow cytometry based on size calibration beads is 0.2 &#x3BC;m; since MVs are defined as AV-positive vesicles ranging from 0.2 to 0.9 &#x3BC;m, the MV gate was set at this limit. Gate borders of Q1 to Q4 were defined according to isotype controls. A known quantity of counting beads of a 4.2 &#x3BC;m diameter (C36950, Thermo Fisher Scientific) was used and the absolute number of MV per plasma volume was calculated based on counting beads using the following formula: MV/&#x3BC;l = (MV count/bead count) &#xD7; (total number of beads/test volume).</p>
      </sec>
      <sec>
        <title>PMN Isolation and Stimulation</title>
        <p>After written informed consent was collected human blood was drawn by peripheral venous puncture into sodium citrate monovettes (approval by the Local Independent Ethics Committee of the University of Ulm (number 459/18 and 462/18). Subjects were healthy males and females between 18 and 35 years without signs of infection or any current medical problems or medication. PMNs were isolated from whole blood by Ficoll-Hypaque gradient centrifugation (GE Healthcare) and dextran sedimentation (Dextran from Leuconostoc spp.; Sigma), followed by hypotonic lysis of residual red blood cells. PMNs were counted and adjusted to 5 &#xD7; 10<sup>6</sup> cells/mL in HBSS++ (Gibco) or in RPMI buffer (Gibco). PMNs were incubated with 100 ng/ml C5a (Complement Technology, USA) or human C5a<sup>desArg</sup> (Sigma, USA), human C3a (Complement Technology), 500 pg/ml human recombinant IL-6 (Biomol), 200 pg/ml human recombinant IL-8 (Biomol), 150 pg/ml human recombinant IL-1&#x3B2; (PeproTech), or 5 &#x3BC;g/ml LPS (Sigma, USA). Untreated cells served as controls. To further investigate the C5a-mediated effects, we used 10 &#x3BC;M of the selective small peptide C5aR1 antagonist PMX53 (kind gift of John Lambris, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, United States) and the Arf6-selective inhibitor NAV2729 (5986, Tocris). All experiments were performed on a rotating wheel at 37&#xB0;C and 80 rpm; after incubation, cells were centrifuged at 340 &#xD7; g for 5 min. Supernatants were stored at &#x2212;80&#xB0;C for MV analysis. The pelleted cells were washed with PBS twice, stained with anti-human C5aR1 antibody (1:100 dilution) for 20 min at 4&#xB0;C, washed and fixed with CellFix (BD) and analyzed by flow cytometry after gating based on light scatter characteristics.</p>
        <p>Moreover, PMNs from healthy volunteers were incubated in HBSS++ containing 20% of human serum from either polytraumatized patients or from healthy donors. For this purpose, sera from three patients or three healthy donors were pooled, respectively. Since PMN supernatants were analyzed for MV shedding, we removed MVs in sera by centrifugation at 20,000 &#xD7; g at 4&#xB0;C for 45 min. PMNs were incubated for 1 h at 37&#xB0;C.</p>
        <p>For further <italic>in vitro</italic> stimulation experiments, the supernatant after PMN stimulation with 100 ng/ml C5a &#xB1; 10 &#x3BC;M C5aR1 antagonist was centrifuged at 3,000 &#xD7; g for 10 min; MVs were pelleted by centrifugation at 20,000 &#xD7; g for 45 min. The supernatant was discarded and the MV&#x2013;containing pellet was washed twice with PBS and centrifuged again at 20,000 &#xD7; g for 45 min. MVs were resuspended in PBS and stored at &#x2212;80&#xB0;C. PMNs were stimulated with the generated MV from autologous donors for 1 h at 37&#xB0;C. Subsequently functional PMN assays including NADPH oxidase activity, ROS generation, and MPO release were investigated.</p>
      </sec>
      <sec>
        <title>Western Blotting</title>
        <p>PMNs were resuspended in cold RIPA buffer containing a protease- and phosphatase inhibitor cocktail (Thermo Fisher). Cells were gently resuspended, sonicated and stored on ice for 20 min. After a second sonication step, 4x Laemmli buffer including beta-mercaptoethanol (Sigma) was added. Samples were denatured for 5 min at 95&#xB0;C. For electrophoresis, precast 4&#x2013;20% gradient gels (Bio-Rad) were used. After electrophoresis, proteins were transferred on a PDVF membrane (GE Healthcare) and membranes were blocked in BSA/TBST for 1 h. Subsequently, membranes were incubated with rabbit anti-human phospho-p47<sup>phox</sup> (Ser345) antibody (Invitrogen, 1:500 dilution in BSA/TBST) overnight at 4&#xB0;C. After washing, membranes were incubated with anti-rabbit-IgG-HRP secondary antibody (Cell Signaling, 1:1500 dilution in BSA/TBST). Western clarity ECL solution (Bio-Rad) was used for development. A Chemidoc XRS+ (Bio-Rad) was used for detection of bands. Protein expression was normalized to total protein using ImageLab (Bio-Rad). For C5a immunoblots, washed MV from PMN supernatants were equally loaded on 4&#x2013;20% gradient gels. After protein transfer, PVDF membranes were blocked in 5% milk/TBST and incubated with the primary antibody rabbit anti-human C5a (Calbiochem) overnight at 4&#xB0;C. After washing, membranes were incubated in anti-rabbit-IgG-HRP secondary antibody (Cell Signaling, 1:1500 dilution in 5% milk/TBST).</p>
      </sec>
      <sec>
        <title>ROS Detection</title>
        <p>Isolated PMNs were adjusted to 5 &#xD7; 10<sup>6</sup> cells/mL in HBSS++ and were incubated with Dihydrorhodamine (DHR) 123 (Santa Cruz, 1:1000 dilution) at 37&#xB0;C for 30 min protected from light. After incubation, cells were washed and resuspended in HBSS++ containing 0.1% BSA (Sigma). PMNs were seeded on 96-well plates and incubated for 10 min at 37&#xB0;C. After incubation, baseline fluorescence was determined with a fluorescence reader (Fluoroskan Ascent, Thermo Fisher). PMNs were stimulated with 5 &#x3BC;l MV preparations and incubated at 37&#xB0;C protected from light. Measurements were performed directly, 10, 30, 60, and 120 min after incubation.</p>
      </sec>
      <sec>
        <title>Myeloperoxidase Assay</title>
        <p>For assessment of myeloperoxidase (MPO) activity, neutrophil supernatant or standard human MPO (Merck) was incubated with tetramethylbenzidine (100 &#x3BC;g/ml) and H<sub>2</sub>O<sub>2</sub> (0.0016%) at 37&#xB0;C. After 5 min, the reaction was terminated by the addition of 2 M H<sub>2</sub>SO<sub>4</sub>, and the absorbance at 450 nm was determined using a spectrophotometric reader (Sunrise, Tecan).</p>
      </sec>
      <sec>
        <title>Whole Blood Model and Experiments</title>
        <p>For <italic>ex vivo</italic> experiments, we used a recently published human whole blood model employing lepirudin at a final concentration of 50 &#x3BC;g/ml; in contrast to heparin, lepirudin does not inhibit complement activation (<xref rid="B25" ref-type="bibr">25</xref>). For whole blood model experiments, PMN-derived MVs were added to 1 ml of whole lepirudin blood from autologous donors and incubated at 37&#xB0;C and 80 rpm. After incubation for 1 and 4 h, this reaction was supplemented with 10 mM EDTA and plasma was obtained by centrifugation at 800 &#xD7; g for 15 min followed by a second centrifugation step at 16,000 &#xD7; g for 2 min to remove cellular debris. Plasma was stored at &#x2212;80&#xB0;C until ELISA analysis. Human IL-6 ELISA (R&amp;D Systems) was performed with plasma samples according to the manufactures' instructions.</p>
      </sec>
      <sec>
        <title>RNA Isolation and Microarray Analysis</title>
        <p>Since eosinophils are more transcriptionally active cells than neutrophils and thus can affect transcriptome analysis (<xref rid="B26" ref-type="bibr">26</xref>), we performed depletion of eosinophils with CD9-selective beads (Miltenyi) to gain higher purity of neutrophils. Purified neutrophils were untreated or C5a-stimulated for 1 h at 37&#xB0;C on a rotating wheel. After stimulation, RNA extraction was performed by Guanidinium Thiocyanate&#x2013;Phenol&#x2013;Chloroform (TRIZOL) and resuspended in nuclease-free water. Microarray analyses were performed using 200 ng total RNA as starting material and 5.5 &#x3BC;g ssDNA per hybridization (GeneChip Fluidics Station 450; Affymetrix, Santa Clara, CA). Total RNAs were amplified and labeled following the Whole Transcript (WT) Sense Target Labeling Assay (<ext-link ext-link-type="uri" xlink:href="http://www.affymetrix.com">http://www.affymetrix.com</ext-link>). Labeled ssDNA was hybridized to Human Gene 1.0 ST GeneChip arrays (Affymetrix, Santa Clara, CA). The chips were scanned with a Affymetrix GeneChip Scanner 3000 and subsequent images analyzed using Affymetrix&#xAE; Expression ConsoleTM Software (Affymetrix).</p>
        <p>Transcriptome analysis: Transcriptome analysis was performed using BRB-ArrayTools developed by Dr. Richard Simon and BRB- ArrayTools Development Team (<ext-link ext-link-type="uri" xlink:href="http://linus.nci.nih.gov/BRB-ArrayTools.html">http://linus.nci.nih.gov/BRB-ArrayTools.html</ext-link>). Raw feature data were normalized and log 2 intensity expression summary values for each probe set were calculated using robust multiarray average (<xref rid="B27" ref-type="bibr">27</xref>). Filtering: Genes showing minimal variation across the set of arrays were excluded from the analysis. Genes whose expression differed by at least 1.5-fold from the median in at least 20% of the arrays were retained.</p>
        <p>Class comparison: Genes were identified as differentially expressed among the two classes using a 2 sample <italic>t</italic>-test. Genes were considered statistically significant if their <italic>p</italic> &lt; 0.05 (FDR &lt; 0.1) and displayed a fold change between the two groups of at least 1.5-fold. Benjamini and Hochberg correction was used to calculate the false discovery rate (<xref rid="B28" ref-type="bibr">28</xref>). Complete microarray data are available at Gene Expression Omnibus (GEO accession number: GSE150902).</p>
      </sec>
      <sec>
        <title>Gene Ontology Analysis</title>
        <p>Gene Ontology Analysis of differentially expressed genes: To identify the most affected biological processes, as defined by Gene Ontology annotation, we used the GoMINER analysis tool (<xref rid="B29" ref-type="bibr">29</xref>). This package allows the automatic analysis of multiple microarrays and then integrates the results, across all of them, to find the GO categories that were significantly over- or under-represented.</p>
      </sec>
      <sec>
        <title>Generation of Heat Maps</title>
        <p>A heat map was designed with selected, and MV-relevant genes using Genesis (Alexander Sturn and Rene Snajder, TU Graz, version 1.8.1). Gene expression was normalized, sorted by trend of expression value and displayed with a set upper maximum value of +0.9 and a lower maximum value of &#x2212;0.9.</p>
      </sec>
      <sec>
        <title>Statistical Analysis</title>
        <p>All results are shown as mean &#xB1; SEM. Groups were compared using one-way ANOVA if not indicated otherwise. Student-Newman-Keuls <italic>post hoc</italic> testing was performed in SigmaPlot (Version 14, Systat, Germany). Results were considered statistically significant where <italic>p</italic> &lt; 0.05.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s3">
      <title>Results</title>
      <sec>
        <title>MV Detection by Flow Cytometry</title>
        <p>The size of MVs is described to range between 100 nm to 1 &#x3BC;m. To exclude contaminant exosomes (50&#x2013;100 nm) and apoptotic bodies (&gt;1 &#x3BC;m) in our samples, we defined the MV-specific gate by using size calibration beads ranging from 0.3 to 1 &#x3BC;m (<xref ref-type="fig" rid="F1">Figure 1A</xref>). Moreover, to quantify MV counts, plasma samples included a known number of counting beads <italic>per set</italic> volume, which were used to stop sample analysis after 500 events allowing a quantification of MV counts per plasma volume. Since phosphatidylserine (PS) is an established marker for MVs, samples were stained with AV, which binds calcium-dependently to PS. Calcium chelation by EDTA served as control of AV specificity (<xref ref-type="fig" rid="F1">Figure 1B</xref>).</p>
        <fig id="F1" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Gating strategy for detection of MVs in plasma samples. <bold>(A)</bold> Size calibration beads ranging from 0.3 to 1 &#x3BC;m were used to define a MV gate. <bold>(B)</bold> AV staining was further included to specifically detect MVs due to their PS surface expression. EDTA control was included to block specific binding of AV to PS. Counting beads were used to quantify the amount of shed MVs in samples as described in the text.</p>
          </caption>
          <graphic xlink:href="fimmu-11-01789-g0001"/>
        </fig>
      </sec>
      <sec>
        <title>Post-traumatic C5aR1 Expression Kinetics on Neutrophil and MV Surfaces</title>
        <p><xref ref-type="fig" rid="F2">Figure 2A</xref> shows representative samples of a healthy donor and a multiple injured patient, respectively. AV<sup>+</sup> MV fraction was determined from the MV gate and used for further analysis. For AV<sup>+</sup> MVs, Q2 contains CD66b<sup>+</sup>C5aR1<sup>+</sup> MVs, while the sum of Q2+Q3 represents the total amount of PMN-derived MVs. Quantitative analysis revealed that plasma samples from patients after polytrauma showed a significant time-dependent increase of granulocyte-derived MVs compared to healthy controls (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Furthermore, we detected significantly more C5aR1<sup>+</sup> neutrophil-derived MVs after trauma and C5aR1 levels on these MVs were significantly increased at the time points 24 and 120 h, respectively (<xref ref-type="fig" rid="F2">Figure 2C</xref>), while MFI values were significantly increased at all time points after PT (<xref ref-type="fig" rid="F2">Figure 2D</xref>). In concordance, PMNs from these patients showed a significant and time-dependent reduction of the C5aR1 (<xref ref-type="supplementary-material" rid="SM2">Supplemental Figure 1A</xref>) in line with our previous study (<xref rid="B5" ref-type="bibr">5</xref>).</p>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Expression profile of shed MVs in multiple trauma. <bold>(A)</bold> Representative dot plot of a healthy control (left) and a multiple trauma patient (right). Annexin V- positive MV fraction was analyzed for CD66b and C5aR1 expression. FITC was used for C5aR1 staining, and APC-Cy7 for CD66b. Q2 represents AnnexinV<sup>+</sup>, C5aR1<sup>+</sup>, CD66b<sup>+</sup> MVs positive MV fraction. <bold>(B)</bold> Quantitative analysis for granulocyte-derived MVs and <bold>(C,D)</bold> granulocyte-derived MVs expressing C5aR1 in 5 &#x3BC;l of MV enriched plasma, respectively. <italic>n</italic> = 8&#x2013;10, *<italic>p</italic> &lt; 0.05 compared to healthy.</p>
          </caption>
          <graphic xlink:href="fimmu-11-01789-g0002"/>
        </fig>
      </sec>
      <sec>
        <title>C5a Induces Shedding of PMN-Derived MVs <italic>in vitro</italic></title>
        <p>After severe trauma, there is an excessive complement activation and C5a generation (<xref rid="B1" ref-type="bibr">1</xref>), and we investigated whether C5a stimulation of neutrophils results in shedding of MVs. While resting cells showed the lowest amount of MVs, C5a significantly increased MV shedding in a time-dependent manner (<xref ref-type="fig" rid="F3">Figure 3A</xref>). LPS, which has been described as a potent inducer of MV shedding in neutrophils (<xref rid="B30" ref-type="bibr">30</xref>), resulted in an even stronger induction of PMN-derived MVs compared to C5a (<xref ref-type="fig" rid="F3">Figure 3A</xref>). Characterization of the MVs showed that C5a induced shedding of C5aR1<sup>+</sup> MVs, which was not observed for LPS (<xref ref-type="fig" rid="F3">Figure 3B</xref>). To further compare C5a with other pro-inflammatory mediators, we incubated neutrophils with trauma-relevant concentrations of IL- 6, IL-1&#x3B2;, IL-8, and C3a. The shedding of PMN-derived MVs and C5aR1 on MVs was specific to C5a and was not observed for any of the other cytokines and chemokines (<xref ref-type="supplementary-material" rid="SM3">Supplemental Figure 2A</xref>).</p>
        <fig id="F3" position="float">
          <label>Figure 3</label>
          <caption>
            <p>C5a alters MV shedding in PMNs. <bold>(A)</bold> PMNs were stimulated for 0, 10, 30, 60, and 240 min with C5a (100 ng/ml) or LPS (5 &#x3BC;g/ml) and supernatants were analyzed by FACS. Untreated cells served as control. <italic>n</italic> = 10, One-Way ANOVA followed by Student-Neuman-Keuls <italic>post-hoc</italic> testing was performed for each time point, *<italic>p</italic> &lt; 0.05. <bold>(B)</bold> MVs from supernatants were further analyzed for expression of C5aR1 by FACS. <italic>n</italic> = 3 per group, *<italic>p</italic> &lt; 0.05. <bold>(C)</bold> Heat map and gene list of selected and differentially regulated genes upon C5a treatment in in neutrophils after 1 h (<italic>n</italic> = 3 per group).</p>
          </caption>
          <graphic xlink:href="fimmu-11-01789-g0003"/>
        </fig>
        <p>To identify the underlying mechanisms, we performed a microarray analysis of gene expression in C5a-stimulated neutrophils. <xref ref-type="fig" rid="F3">Figure 3C</xref> illustrates a heat map of selected genes. We found significant alterations in genes associated with generation of extracellular vesicles including small GTPases and genes encoding for regulatory proteins of GTPases and Arf proteins; fold change expression patterns in response to C5a are listed in the lower panel of <xref ref-type="fig" rid="F3">Figure 3C</xref>. While the microarray experiment does not show a significant change in expression of classical MV-forming proteins including Arf1, Arf6, and Rab22 GTPases, the expression of other important members of small GTPases was significantly increased including Ras homolog family member Q (RHOQ), ADP ribosylation factor like GTPase 11 (Arl11), and Ras related GTP binding C (RRAGC). We also found significant changes in the expression of genes described to regulate GTPase activity. Among them, we identified increased expression in RAB guanine nucleotide exchange factor 1 (RabGEF1), pleckstrin homology and RhoGEF domain containing G3 (Plekhg3), and phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1 (PIP4P1). Furthermore, we found increased expression of genes playing crucial roles for lipid composition of MVs, including galactosidase alpha, glucosylceramidase beta, and <italic>SPHK1</italic> encoding for sphingosine kinase 1.</p>
      </sec>
      <sec>
        <title>Gene Ontology Enrichment Analysis</title>
        <p>Among the altered processes in C5a-treated neutrophils, we found MV- relevant processes, such as catabolic and metabolic processes of glycosyl- and glyco-lipids, phospholipids and ceramids as well as activation and regulation of small GTPases (<xref ref-type="supplementary-material" rid="SM1">Supplemental Table 1</xref>). Further MV-relevant changes in pathways involve cytoskeleton-based processes (<xref rid="B31" ref-type="bibr">31</xref>), cell shape changes, and MAPK activity (<xref rid="B32" ref-type="bibr">32</xref>) (<xref ref-type="supplementary-material" rid="SM1">Supplemental Table 1</xref>).</p>
      </sec>
      <sec>
        <title>Influence of the C5aR1-Antagonist PMX53 on C5a-Mediated MV Shedding in PMNs</title>
        <p>To investigate whether the observed C5a effects were mediated by C5aR1, human neutrophils were treated with the C5aR1-specific antagonist PMX53 (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). Cytoskeleton staining shows morphological changes including reorganization of actin cables into filopodia and cell spreading with vesicle-resembling structures after C5a stimulation, which were almost absent in the presence of PMX53 (<xref ref-type="fig" rid="F4">Figure 4A</xref>). Quantitative analysis of the supernatants confirmed a dose-dependent increase of MV generation induced by C5a, which was blocked by PMX53 (<xref ref-type="fig" rid="F4">Figure 4B</xref>). Flow cytometric analysis of C5aR1 surface expression on PMNs showed that PMX53 completely blocked the C5a-induced loss of the C5aR1 through MV shedding (<xref ref-type="fig" rid="F5">Figures 5A&#x2013;D</xref>). To discover a potential link between C5aR1 signaling and MV shedding, we used the Arf-6-selective inhibitor NAV2729 since Arf6 activity is described in MV formation (<xref rid="B35" ref-type="bibr">35</xref>). Indeed, NAV2729 was able to completely block C5a-mediated loss of C5aR1 signal on PMNs and the shedding of C5aR1<sup>+</sup> MVs as shown in <xref ref-type="fig" rid="F5">Figures 5E,F</xref>.</p>
        <fig id="F4" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Effect of the C5aR1-antagonist PMX53 on vesicle shedding. <bold>(A)</bold> Upper panel shows merged image of F-actin staining (red, Phalloidin-Alexa Flour 568) and nuclei staining (DAPI) of fixed PMNs, untreated, after treatment with native human C5a (100 ng/ml), and C5a treatment in combination with PMX53 (10 &#x3BC;M) for 1 h, respectively at 630x magnification. Lower panel with further zoom-in on PMNs from the upper panel, white arrows indicate shed MVs. Experiment was repeated at least three times. <bold>(B)</bold> Quantitative analysis of shed MV at different C5a concentrations and in presence of the PMX53 together and alone in 10 &#x3BC;l supernatant (<italic>n</italic> = 3). *<italic>p</italic> &lt; 0.05.</p>
          </caption>
          <graphic xlink:href="fimmu-11-01789-g0004"/>
        </fig>
        <fig id="F5" position="float">
          <label>Figure 5</label>
          <caption>
            <p>PMX53 and NAV2729 show similar effects in blocking C5aR1-positive MV shedding. Representative flow cytometry panels for C5aR1 expression (FITC) <bold>(A)</bold> on PMNs or <bold>(B)</bold> in PMN supernatants including C5aR1<sup>+</sup> MV counts in Q2 after 1 h stimulation in the presence of PMX53. Quantitative analysis of flow cytometry data showing <bold>(C)</bold> C5aR1 expression on PMN surfaces (FITC MFI) and <bold>(D)</bold> C5aR1<sup>+</sup> MV counts. Quantitative flow cytometry analysis including the MV-specific inhibitor NAV2729 (10 &#x3BC;M) <bold>(E)</bold> for C5aR1 expression (FITC MFI) on PMNs and <bold>(F)</bold> C5aR1<sup>+</sup> MV counts in 10 &#x3BC;l PMN supernatants after 1 h, <italic>n</italic> = 4 per group, respectively. * <italic>p</italic> &lt; 0.05.</p>
          </caption>
          <graphic xlink:href="fimmu-11-01789-g0005"/>
        </fig>
      </sec>
      <sec>
        <title>Incubation of Human Neutrophils With Serum From Multiple Injury Patients Induces Loss of C5aR1</title>
        <p>To verify the C5a-mediated effects on neutrophils, we further incubated human PMNs from healthy donors in HBSS++ buffer containing 20% MV-free serum from polytraumatized patients. We observed a reduction of the C5aR1- signal on PMNs. Moreover, we included PMX53 before adding serum to PMNs and blocked C5aR1 reduction on PMNs (<xref ref-type="fig" rid="F6">Figure 6A</xref>). MV analysis in supernatants revealed that loss of PMN C5aR1 was due to shedding of C5aR1<sup>+</sup> MVs, which again was blocked by PMX53 and which was nearly absent when incubated with healthy serum (<xref ref-type="fig" rid="F6">Figure 6B</xref>). Since complement is a heat- labile system (<xref rid="B36" ref-type="bibr">36</xref>), we also incubated PMNs with heat-inactivated serum and again could block loss of the C5aR1 (<xref ref-type="supplementary-material" rid="SM4">Supplemental Figure 3A</xref>). Carboxypeptidases, which are present in serum can further process C5a to desarginated C5a (C5a<sup>desArg</sup>) (<xref rid="B37" ref-type="bibr">37</xref>), which can also induce cell responses via C5aR1 (<xref rid="B38" ref-type="bibr">38</xref>). Therefore, we additionally incubated isolated PMNs with 100 ng/ml human C5a<sup>desArg</sup> and found comparable results to native human C5a (<xref ref-type="supplementary-material" rid="SM4">Supplemental Figures 3B,C</xref>).</p>
        <fig id="F6" position="float">
          <label>Figure 6</label>
          <caption>
            <p>C5aR1 expression and MV shedding after incubation of PMNs with serum obtained from PT patients (S PT) and healthy donors (S Healthy). PMNs were incubated in HBSS++ buffer supplemented with 20% of pooled human serum from PT patients or from healthy donors for 1 h. <bold>(A)</bold> Quantification of C5aR1 expression on PMNs and <bold>(B)</bold> C5aR1<sup>+</sup> MV counts in 10 &#x3BC;l of PMN supernatants after incubation. <italic>n</italic> = 4, *<italic>p</italic> &lt; 0.05.</p>
          </caption>
          <graphic xlink:href="fimmu-11-01789-g0006"/>
        </fig>
      </sec>
      <sec>
        <title>Inflammatory Features of C5a-Generated PMN-MVs</title>
        <p>With regard to the functional effects of C5a-generated MVs for inflammation, we assessed central antimicrobial neutrophil functions including myeloperoxidase (MPO) release and reactive oxygen species (ROS) generation. For this purpose, resting PMNs were incubated with C5a-generated MVs from autologous donors. MVs derived from PMNs after C5a stimulation induced activation of p47<sup>phox</sup>, a key component of the NADPH oxidase (<xref ref-type="fig" rid="F7">Figures 7A,B</xref>). As a result, C5a-generated MVs induced a significant increase in ROS production in PMNs (<xref ref-type="fig" rid="F7">Figure 7C</xref>). Furthermore, MPO secretion was significantly increased in the presence of C5a-MVs (<xref ref-type="fig" rid="F7">Figure 7D</xref>). To further characterize the impact of MVs on inflammation, we incubated whole blood with the C5a-generated MVs for 1 and 4 h and detected a significant increase of the secreted pro-inflammatory cytokine IL-6 at both time points compared to control MVs (<xref ref-type="fig" rid="F7">Figure 7E</xref>). Western blotting revealed no residual C5a in MV preparations, ruling out a direct contribution of C5a to the observed pro-inflammatory effects (<xref ref-type="supplementary-material" rid="SM5">Supplemental Figure 4</xref>).</p>
        <fig id="F7" position="float">
          <label>Figure 7</label>
          <caption>
            <p>Inflammatory feature of PMN-derived MVs. <bold>(A)</bold> One representative immunoblot probed for phospho-p47<sup>phox</sup> of whole cell lysates from PMNs. PMNs were treated with C5a, C5a and PMX53, and PMX53 only. Untreated PMNs served as control. Afterwards, PMNs from autologous donors were incubated with the generated MVs for 1h at 37&#xB0;C. PMNs without MV stimulation served as control. <bold>(B)</bold> Quantification of phospho-p47<sup>phox</sup> signal intensity of PMNs whole cell lysates from three donors. *<italic>p</italic> &lt; 0.05 compared to PMN without MV control. <bold>(C)</bold> Time-dependent ROS generation in PMNs incubated with MVs, <italic>n</italic> = 3, *<italic>p</italic> &lt; 0.05. <bold>(D)</bold> MPO amount in PMN supernatants after incubation with MVs, <italic>n</italic> = 3 *<italic>p</italic> &lt; 0.05. <bold>(E)</bold> C5a-gerenerated MVs were incubated in whole blood from autologous donors for 1 h and for 4 h, respectively. IL-6 was determined in plasma by ELISA. <italic>n</italic> = 5 per group, *<italic>p</italic> &lt; 0.05.</p>
          </caption>
          <graphic xlink:href="fimmu-11-01789-g0007"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s4">
      <title>Discussion</title>
      <p>Trauma induces tissue injury, characterized by disruption of micro-and macrobarriers, which releases danger-associated molecular patterns (DAMPs) including histones, DNA, and HMGB1 from mechanically damaged or necrotic cells. Furthermore, loss of barrier integrity exposes the host to pathogen-associated molecular patterns including LPS. As first line of defense, the complement system promptly initiates a complex cascade of activation pathways resulting in early generation of anaphylatoxins (<xref rid="B39" ref-type="bibr">39</xref>). Immune complexes initiate activation of the classical pathway of complement (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>), while foreign surfaces and pathogen-specific proteins activate the lectin (<xref rid="B42" ref-type="bibr">42</xref>) and alternative pathway (<xref rid="B43" ref-type="bibr">43</xref>). Moreover, acidic environments due to tissue hypoperfusion have been described to activate the alternative pathway of complement (<xref rid="B44" ref-type="bibr">44</xref>). Besides the three established pathways of complement activation, extensive crosstalk between the complement and the coagulation system further activates complement via thrombin generation (<xref rid="B45" ref-type="bibr">45</xref>). Both systems are further triggered by surgical interventions and several biomaterials implanted for fracture care (<xref rid="B46" ref-type="bibr">46</xref>).</p>
      <p>The anaphylatoxin C5a is widely described for detrimental effects in the context of inflammation and trauma. In neutrophils, C5a induced significant morphological changes including calcium-independent actin polymerization, ruffling, and cell polarization (<xref rid="B47" ref-type="bibr">47</xref>). In a previous study, we have shown changes in the cell shape by increased length and decreased width, decreased cell circularity, and enhanced deformability (<xref rid="B10" ref-type="bibr">10</xref>). Besides changes in cellular morphology, C5a is also described to enhance neutrophil adhesion to endothelial and epithelial cells (<xref rid="B48" ref-type="bibr">48</xref>). Especially, high C5a levels are associated with neutrophil dysfunction, resulting in impaired immune responses including chemotaxis (<xref rid="B14" ref-type="bibr">14</xref>) and phagocytosis (<xref rid="B4" ref-type="bibr">4</xref>). Moreover, high concentrations of C5a (0.5&#x2013;2 &#x3BC;g/ml) have prevented caspase-9 activity and thus delayed apoptosis in neutrophils (<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>). To date, C5a-induced loss of the C5aR1 on neutrophils is suspected to be responsible for post-traumatic cell paralysis and thus, among other factors, could explain the high susceptibility of trauma patients to infectious complications (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). The role of C5aR2 still remains unclear and is controversially discussed in the literature. While a study showed that C5aR2 may act as negative regulator of C5a-C5aR1-mediated responses (<xref rid="B51" ref-type="bibr">51</xref>), another study described pro-inflammatory features of C5aR2 in C5a-primed neutrophils (<xref rid="B52" ref-type="bibr">52</xref>). In our study, C5aR2 expression on PMNs was unaltered after PT during the early phase after injury; in addition, C5a signaling inducing MV-dependent C5a complement receptor shedding was specifically mediated via the C5aR1, suggesting that C5aR1 is the main receptor involved in mediating C5a-induced neutrophil dysfunction. This highly specific role of C5a in PMN MV shedding is also supported by our data: increased C5aR1<sup>+</sup> MV generation and loss of C5aR1 from neutrophils after stimulation with PT serum was completely abolished after C5aR1 blockade; furthermore, stimulation of PMN with trauma-relevant concentrations of other pro-inflammatory cytokines and chemokines (<xref rid="B53" ref-type="bibr">53</xref>) did not have any effects on MV generation or cellular C5aR1 content. Furthermore, we point to a promising therapeutic strategy since PMX53, a potent C5aR1 antagonist, completely blocked shedding of C5aR1-positive MVs (<xref ref-type="fig" rid="F8">Figure 8</xref>). The pharmacological profile of PMX53 have been extensively studied in several animal models including mice (<xref rid="B54" ref-type="bibr">54</xref>) and rats (<xref rid="B55" ref-type="bibr">55</xref>). Also in humans, oral and topical administration was found to be safe and well-tolerated and successfully completed phase I clinical trials (<xref rid="B33" ref-type="bibr">33</xref>). Currently, PMX53 is evaluated in clinical studies addressing inflammatory disorders including patients with rheumatoid arthritis and psoriasis (<xref rid="B56" ref-type="bibr">56</xref>). In trauma patients, no clinical data is available so far. Considering an administration time point after PT, early application of PMX53 (at the 0 h time point), could provide a therapeutic benefit in future clinical studies.</p>
      <fig id="F8" position="float">
        <label>Figure 8</label>
        <caption>
          <p>Model for C5a-mediated alterations on MV shedding for neutrophils after PT. PT causes an early activation of complement generating increased C5a concentrations. C5a induces activity of the small GTPase Arf6, which is dependent on C5aR1 signaling. Additionally, specific changes in gene expression pattern are involved in MV shedding. Resting PMNs show physiological MV shedding and composition, which have no inflammatory potential. In contrast, PMNs incubated with C5a loose C5aR1 surface expression induced by C5aR1 signaling and Arf6-mediated shedding of C5aR1-positive MVs. Furthermore, these MVs show increased CD66b and C5aR1 expression, which show pro-inflammatory features when incubated with resting PMNs. C5a induces shedding of MVs, which lead to NAPDH oxidase activation, ROS generation and MPO release in resting PMNs. Moreover, IL-6 generation was observed when these MVs were incubated in whole blood. PMX53 and the Arf6-selective compound NAV2729 can block the shedding of C5aR1-positive MVs from PMN surfaces and its inflammatory effects.</p>
        </caption>
        <graphic xlink:href="fimmu-11-01789-g0008"/>
      </fig>
      <p>Changes in circulating MV levels and their cellular origin have previously been described in inflammatory conditions including trauma and sepsis (<xref rid="B57" ref-type="bibr">57</xref>). The cellular and tissue origin of circulating MVs can provide important insights into disease pathogenesis. Severe injury causes changes of MV phenotypes including increased shedding of platelet-, erythrocyte-, endothelial-, and monocyte-derived MVs, which are able to promote coagulation (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>) and inflammation in trauma (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B60" ref-type="bibr">60</xref>). Moreover, erythrocyte-derived MV have been shown to activate pulmonary endothelial cells by increase of ELAM-1 and ICAM-1 expression as well as leukocyte-recruitment into the lung, which aggravated lung injury (<xref rid="B61" ref-type="bibr">61</xref>). Although elevated numbers of granulocyte-derived MVs after trauma, major burn, and sepsis have been reported (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>), there is still little knowledge about their role in trauma and sepsis. Since neutrophil dysfunction has been observed early after injury in trauma patients, we focused on neutrophil-derived MVs and further characterized their inflammatory features by functional PMN assays. There is emerging evidence that complement activation products can influence MV shedding while simultaneously changing their features, which can boost an imbalanced inflammatory responses (<xref rid="B64" ref-type="bibr">64</xref>). In the present study, we demonstrated for the first time a direct mechanistic link between complement C5a and the MV shedding profile in neutrophils. These effects are likely of importance for the observed neutrophil dysfunction on the one hand and for aggravation of inflammation after multiple injury on the other hand. As in our previous study in a different trauma cohort (<xref rid="B5" ref-type="bibr">5</xref>), we found a post-traumatic loss of the C5aR1 on human neutrophils compared to healthy volunteers starting during the first 24 h after injury. Furthermore, we observed a clear and marked elevation of circulating granulocyte-derived MV numbers in polytraumatized patients. However, the relatively small number of patients did not allow us to perform reliable correlation analyses; for that reason, future studies need to include a larger number of patients to assess a possible connection between increased post-traumatic C5a plasma levels (<xref rid="B1" ref-type="bibr">1</xref>) and an increase in PMN-derived C5aR1 positive MVs. Moreover, we observed a higher variability in MV counts in PT patients, which could be explained by the high variability in the clinical cohort including injury mechanism, pattern, and severity as well as the extent of blood loss and need for transfusion, which could all influence the number of MVs (<xref rid="T1" ref-type="table">Table 1</xref>).</p>
      <p>Furthermore, it is well-established that MV budding depends on ADP-ribosylation factor 6 (Arf6), regulating selective recruitment of proteins into MVs, and promoting MV release (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B65" ref-type="bibr">65</xref>). Expression of a constitutively active form of Arf6 also induces a significant increase in RhoA activity, both resulting in significantly increased MV formation (<xref rid="B66" ref-type="bibr">66</xref>). We were able to block both MV secretion and loss of surface C5aR1 by specific blockade of Arf6, demonstrating a so far unknown interaction between C5aR1 signaling and Arf-6-mediated downstream effects in MV shedding (<xref ref-type="fig" rid="F8">Figure 8</xref>).</p>
      <p>Besides Arf6, other members of small GTPases are also involved in vesicular trafficking and MV formation. Both cargo sorting and MV shedding are tightly regulated by several small GTPases, including members of the Arf (Arf6 and Arf1), Rab, and Rho (Rac1 and RhoA) families (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B67" ref-type="bibr">67</xref>). To unravel intracellular events following activation of the C5a/C5aR1 axis, we performed whole genome microarray analyses. Although we could not find changes in the expression pattern of Arf proteins, we detected significant alterations in other small GTPases including <italic>RHOQ</italic> and <italic>RRAGC</italic>, also known to be involved in MV generation. We also found significantly increased expression of Arf-like (Arl) genes including Arl11, which belong to another family of small GTPases and are involved in regulation of vesicular transport, membrane trafficking, and cytoskeletal remodeling (<xref rid="B68" ref-type="bibr">68</xref>). The GTP-GDP cycle in small GTPases is tightly regulated by guanine nucleotide exchange factors (GEFs) (<xref rid="B69" ref-type="bibr">69</xref>). We identified significant changes in GEF expression, which are involved in regulating GTPases and thus downstream MV shedding. Furthermore, we observed significant upregulation of <italic>PIP4P1</italic> expression after C5a stimulation, a known interaction partner of Arf6 and MV formation (<xref rid="B70" ref-type="bibr">70</xref>). MVs possess a specific lipid composition enriched in phospholipids including PS, phosphatidylcholine, and sphingolipids (<xref rid="B71" ref-type="bibr">71</xref>), which seems to critically promote uptake by recipient cells (<xref rid="B72" ref-type="bibr">72</xref>). In this context, we found changes in expression of <italic>GLA, GBA</italic>, and <italic>SPHK1</italic> encoding for proteins which can act to regulate the lipid composition in the plasma membrane, playing a crucial role in sphingo- and phospholipid metabolism (<xref rid="B73" ref-type="bibr">73</xref>). <italic>SPHK1</italic> is also described to be involved in sorting of vesicle cargoes of extracellular vesicles including MVs and exosomes (<xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B75" ref-type="bibr">75</xref>). A future lipidomic approach might reveal here more mechanistic insights.</p>
      <p>Beyond the functional activation, our study reveals that C5a-induced MVs possess pro-inflammatory features and are able to activate resting neutrophils by inducing NADPH oxidase activity, ROS production, and MPO release as central mechanisms in the defense against bacterial and fungal pathogens. As a translational effort, we were able to demonstrate significant IL-6 generation in an <italic>ex vivo</italic> whole-blood model after addition of C5a-induced MVs. Besides monocytes and macrophages, mast cells and basophils (<xref rid="B76" ref-type="bibr">76</xref>), antigen-presenting cells and T cells including CD4<sup>+</sup> T cells (<xref rid="B77" ref-type="bibr">77</xref>) and T-helper 17 cells have been described to produce IL-6 during inflammation (<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B79" ref-type="bibr">79</xref>), while neutrophils have shown limited capacity in generating IL-6 (<xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B81" ref-type="bibr">81</xref>). Concerning our <italic>ex-vivo</italic> whole-blood model, it can be assumed that C5a-generated MVs induce IL-6 secretion mainly by monocytes, basophils and CD4<sup>+</sup> T cells. Previous studies addressing the inflammatory features of PMN-derived MVs (PMN-MVs) did not show uniform results so far (<xref rid="B82" ref-type="bibr">82</xref>). Some cartilage-protective features of PMN-MVs in the context of joint inflammation have been proposed (<xref rid="B83" ref-type="bibr">83</xref>); furthermore, PMN-MVs were shown to limit the inflammatory response in macrophages (<xref rid="B84" ref-type="bibr">84</xref>). However, the type of stimulus seems to influence the inflammatory properties of PMN-MVs. In the context of acute lung injury, neutrophils have been described to release MVs which can induce activation of the endothelium (<xref rid="B85" ref-type="bibr">85</xref>), platelets (<xref rid="B86" ref-type="bibr">86</xref>), and other inflammatory cells (<xref rid="B18" ref-type="bibr">18</xref>). In the present study, it remains unclear which component of the C5a-generated MVs may be responsible for their considerable pro-inflammatory features. Our results clearly show that C5a-generated MVs did not contain residual C5a, indicating that these pro-inflammatory effects are not C5a-mediated and rather may originate from an altered MV composition. C5a stimulation may have affected the MV cargo and composition in comparison with those released during physiologic conditions or from unstimulated granulocytes (<xref rid="B87" ref-type="bibr">87</xref>, <xref rid="B88" ref-type="bibr">88</xref>). Furthermore, extracellular vesicles in general have a comparably large and distinct lipid composition, harboring lipid mediators such as cholesterol, sphingomyelin, phosphatidylserine, and glycosphingolipid, and this phospholipid content is proportionally richer compared to their cellular sources (<xref rid="B89" ref-type="bibr">89</xref>). In a previous study, we could demonstrate that <italic>in vitro</italic> stimulation of monocytes with LPS led to changes in their MV phospholipid composition (<xref rid="B90" ref-type="bibr">90</xref>). More likely, the observed shedding of C5aR1 from the cellular surface to circulating MVs could represent a compensatory mechanism of activated neutrophils in order to reduce cellular effects of C5a as well as increase circulating C5aR1, as a decoy receptor to scavenge excessive C5a. Taken together, our findings confirm the hypothesis that C5a can induce MV shedding and significantly alter inflammatory MV features through C5aR1 signaling and subsequent Arf6 involvement. Thus, our study provides a better understanding how MVs act on the pathophysiology of multiple trauma. Inhibition or reduction of neutrophil MV shedding by targeting C5aR1 may represent a promising approach in order to protect PMN functionality and restore the MV balance during systemic inflammatory conditions such as PT and sepsis.</p>
    </sec>
    <sec sec-type="data-availability" id="s5">
      <title>Data Availability Statement</title>
      <p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="supplementary-material" rid="SM1">Supplementary Material</xref>.</p>
    </sec>
    <sec id="s6">
      <title>Ethics Statement</title>
      <p>The studies involving human participants were reviewed and approved by the Independent Local Ethics Committee of the University of Ulm, Helmholtzstrasse 20 (Oberer Eselsberg), 89081 Ulm, Germany. The patients/participants provided their written informed consent to participate in this study.</p>
    </sec>
    <sec id="s7">
      <title>Author Contributions</title>
      <p>EK, JD, SK, and RH performed the research experiments. EK and RH planned the experimental procedures, analyzed the data, and wrote the paper. MH-L contributed to the interpretation of data. KH performed microarray analysis, analyzed, and interpreted the data. MK, SK, and FG provided PT patient samples and clinical data for analysis. CS and JK critically reviewed the manuscript. All authors read and approved the manuscript.</p>
    </sec>
    <sec id="s8">
      <title>Conflict of Interest</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Bettina Klohs and Anke Schultze for excellent technical assistance.</p>
    </ack>
    <fn-group>
      <fn fn-type="financial-disclosure">
        <p><bold>Funding.</bold> This work was supported by the German Research Foundation by a grant assigned to the Collaborative Research Centre 1149 (A01, INST40/479-2) to MH-L.</p>
      </fn>
    </fn-group>
    <sec sec-type="supplementary-material" id="s9">
      <title>Supplementary Material</title>
      <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2020.01789/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2020.01789/full#supplementary-material</ext-link></p>
      <supplementary-material content-type="local-data" id="SM1">
        <media xlink:href="Table_1.DOCX">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SM2">
        <media xlink:href="Image_1.TIF">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SM3">
        <media xlink:href="Image_2.TIF">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SM4">
        <media xlink:href="Image_3.TIF">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SM5">
        <media xlink:href="Image_4.TIF">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burk</surname><given-names>AM</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Flierl</surname><given-names>MA</given-names></name><name><surname>Rittirsch</surname><given-names>D</given-names></name><name><surname>Helm</surname><given-names>M</given-names></name><name><surname>Lampl</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Early complementopathy after multiple injuries in humans</article-title>. <source>Shock.</source> (<year>2012</year>) <volume>37</volume>:<fpage>348</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1097/SHK.0b013e3182471795</pub-id><pub-id pub-id-type="pmid">22258234</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charchaflieh</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Labaze</surname><given-names>G</given-names></name><name><surname>Hou</surname><given-names>YJ</given-names></name><name><surname>Babarsh</surname><given-names>B</given-names></name><name><surname>Stutz</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>The role of complement system in septic shock</article-title>. <source>Clin Dev Immunol.</source> (<year>2012</year>) <volume>2012</volume>:<fpage>407324</fpage>. <pub-id pub-id-type="doi">10.1155/2012/407324</pub-id><pub-id pub-id-type="pmid">23049598</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unnewehr</surname><given-names>H</given-names></name><name><surname>Rittirsch</surname><given-names>D</given-names></name><name><surname>Sarma</surname><given-names>JV</given-names></name><name><surname>Zetoune</surname><given-names>F</given-names></name><name><surname>Flierl</surname><given-names>MA</given-names></name><name><surname>Perl</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Changes and regulation of the C5a receptor on neutrophils during septic shock in humans</article-title>. <source>J Immunol.</source> (<year>2013</year>) <volume>190</volume>:<fpage>4215</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1200534</pub-id><pub-id pub-id-type="pmid">23479227</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber-Lang</surname><given-names>MS</given-names></name><name><surname>Younkin</surname><given-names>EM</given-names></name><name><surname>Sarma</surname><given-names>JV</given-names></name><name><surname>McGuire</surname><given-names>SR</given-names></name><name><surname>Lu</surname><given-names>KT</given-names></name><name><surname>Guo</surname><given-names>RF</given-names></name><etal/></person-group>. <article-title>Complement-induced impairment of innate immunity during sepsis</article-title>. <source>J Immunol.</source> (<year>2002</year>) <volume>169</volume>:<fpage>3223</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.169.6.3223</pub-id><pub-id pub-id-type="pmid">12218141</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amara</surname><given-names>U</given-names></name><name><surname>Kalbitz</surname><given-names>M</given-names></name><name><surname>Perl</surname><given-names>M</given-names></name><name><surname>Flierl</surname><given-names>MA</given-names></name><name><surname>Rittirsch</surname><given-names>D</given-names></name><name><surname>Weiss</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Early expression changes of complement regulatory proteins and C5A receptor (CD88) on leukocytes after multiple injury in humans</article-title>. <source>Shock.</source> (<year>2010</year>) <volume>33</volume>:<fpage>568</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1097/SHK.0b013e3181c799d4</pub-id><pub-id pub-id-type="pmid">19864971</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rittirsch</surname><given-names>D</given-names></name><name><surname>Flierl</surname><given-names>MA</given-names></name><name><surname>Nadeau</surname><given-names>BA</given-names></name><name><surname>Day</surname><given-names>DE</given-names></name><name><surname>Huber-Lang</surname><given-names>M</given-names></name><name><surname>Mackay</surname><given-names>CR</given-names></name><etal/></person-group>. <article-title>Functional roles for C5a receptors in sepsis</article-title>. <source>Nat Med.</source> (<year>2008</year>) <volume>14</volume>:<fpage>551</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nm1753</pub-id><pub-id pub-id-type="pmid">18454156</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flierl</surname><given-names>MA</given-names></name><name><surname>Rittirsch</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>AJ</given-names></name><name><surname>Nadeau</surname><given-names>BA</given-names></name><name><surname>Day</surname><given-names>DE</given-names></name><name><surname>Sarma</surname><given-names>JV</given-names></name><etal/></person-group>. <article-title>The complement anaphylatoxin C5a induces apoptosis in adrenomedullary cells during experimental sepsis</article-title>. <source>PLoS ONE.</source> (<year>2008</year>) <volume>3</volume>:<fpage>e2560</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0002560</pub-id><pub-id pub-id-type="pmid">18648551</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dick</surname><given-names>J</given-names></name><name><surname>Gan</surname><given-names>PY</given-names></name><name><surname>Ford</surname><given-names>SL</given-names></name><name><surname>Odobasic</surname><given-names>D</given-names></name><name><surname>Alikhan</surname><given-names>MA</given-names></name><name><surname>Loosen</surname><given-names>SH</given-names></name><etal/></person-group>. <article-title>C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis</article-title>. <source>Kidney Int.</source> (<year>2018</year>) <volume>93</volume>:<fpage>615</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.kint.2017.09.018</pub-id><pub-id pub-id-type="pmid">29241626</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengelov</surname><given-names>H</given-names></name></person-group>. <article-title>Complement receptors in neutrophils</article-title>. <source>Crit Rev Immunol.</source> (<year>1995</year>) <volume>15</volume>:<fpage>107</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1615/CritRevImmunol.v15.i2.10</pub-id><pub-id pub-id-type="pmid">8573284</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denk</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>RP</given-names></name><name><surname>Wiegner</surname><given-names>R</given-names></name><name><surname>Cook</surname><given-names>EM</given-names></name><name><surname>Lindorfer</surname><given-names>MA</given-names></name><name><surname>Pfeiffer</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Complement C5a-induced changes in neutrophil morphology during inflammation</article-title>. <source>Scand J Immunol.</source> (<year>2017</year>) <volume>86</volume>:<fpage>143</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1111/sji.12580</pub-id><pub-id pub-id-type="pmid">28671713</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denk</surname><given-names>S</given-names></name><name><surname>Neher</surname><given-names>MD</given-names></name><name><surname>Messerer</surname><given-names>DAC</given-names></name><name><surname>Wiegner</surname><given-names>R</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Rittirsch</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Complement C5a functions as a master switch for the ph balance in neutrophils exerting fundamental immunometabolic effects</article-title>. <source>J Immunol.</source> (<year>2017</year>) <volume>198</volume>:<fpage>4846</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1700393</pub-id><pub-id pub-id-type="pmid">28490576</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messerer</surname><given-names>DAC</given-names></name><name><surname>Denk</surname><given-names>S</given-names></name><name><surname>Fohr</surname><given-names>KJ</given-names></name><name><surname>Halbgebauer</surname><given-names>R</given-names></name><name><surname>Braun</surname><given-names>CK</given-names></name><name><surname>Hones</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Complement C5a alters the membrane potential of neutrophils during hemorrhagic shock</article-title>. <source>Mediat Inflamm.</source> (<year>2018</year>) <volume>2018</volume>:<fpage>2052356</fpage>. <pub-id pub-id-type="doi">10.1155/2018/2052356</pub-id><pub-id pub-id-type="pmid">30002598</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>F</given-names></name><name><surname>Bao</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Complement 5a receptor-mediated neutrophil dysfunction is associated with a poor outcome in sepsis</article-title>. <source>Cell Mol Immunol.</source> (<year>2016</year>) <volume>13</volume>:<fpage>103</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/cmi.2014.136</pub-id><pub-id pub-id-type="pmid">25726869</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname><given-names>MA</given-names></name><name><surname>Kefala</surname><given-names>K</given-names></name><name><surname>Wilkinson</surname><given-names>TS</given-names></name><name><surname>Dhaliwal</surname><given-names>K</given-names></name><name><surname>Farrell</surname><given-names>L</given-names></name><name><surname>Walsh</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>C5a mediates peripheral blood neutrophil dysfunction in critically ill patients</article-title>. <source>Am J Respir Crit Care Med.</source> (<year>2009</year>) <volume>180</volume>:<fpage>19</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200812-1928OC</pub-id><pub-id pub-id-type="pmid">19324972</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>AC</given-names></name><name><surname>Brittan</surname><given-names>M</given-names></name><name><surname>Wilkinson</surname><given-names>TS</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Antonelli</surname><given-names>J</given-names></name><name><surname>McCulloch</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>C5a-mediated neutrophil dysfunction is RhoA-dependent and predicts infection in critically ill patients</article-title>. <source>Blood.</source> (<year>2011</year>) <volume>117</volume>:<fpage>5178</fpage>&#x2013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2010-08-304667</pub-id><pub-id pub-id-type="pmid">21292772</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santy</surname><given-names>LC</given-names></name><name><surname>Casanova</surname><given-names>JE</given-names></name></person-group>. <article-title>Activation of ARF6 by ARNO stimulates epithelial cell migration through downstream activation of both Rac1 and phospholipase D</article-title>. <source>J Cell Biol.</source> (<year>2001</year>) <volume>154</volume>:<fpage>599</fpage>&#x2013;<lpage>610</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200104019</pub-id><pub-id pub-id-type="pmid">11481345</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>JG</given-names></name><name><surname>Jackson</surname><given-names>CL</given-names></name></person-group>. <article-title>ARF family G proteins and their regulators: roles in membrane transport, development and disease</article-title>. <source>Nat Rev Mol Cell Biol.</source> (<year>2011</year>) <volume>12</volume>:<fpage>362</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3117</pub-id><pub-id pub-id-type="pmid">21587297</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McVey</surname><given-names>M</given-names></name><name><surname>Tabuchi</surname><given-names>A</given-names></name><name><surname>Kuebler</surname><given-names>WM</given-names></name></person-group>. <article-title>Microparticles and acute lung injury</article-title>. <source>Am J Physiol Lung Cell Mol Physiol.</source> (<year>2012</year>) <volume>303</volume>:<fpage>L364</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00354.2011</pub-id><pub-id pub-id-type="pmid">22728467</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>PD</given-names></name><name><surname>Dorronsoro</surname><given-names>A</given-names></name><name><surname>Booker</surname><given-names>CN</given-names></name></person-group>. <article-title>Regulation of chronic inflammatory and immune processes by extracellular vesicles</article-title>. <source>J Clin Invest.</source> (<year>2016</year>) <volume>126</volume>:<fpage>1173</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1172/JCI81131</pub-id><pub-id pub-id-type="pmid">27035808</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>PD</given-names></name><name><surname>Morelli</surname><given-names>AE</given-names></name></person-group>. <article-title>Regulation of immune responses by extracellular vesicles</article-title>. <source>Nat Rev Immunol.</source> (<year>2014</year>) <volume>14</volume>:<fpage>195</fpage>&#x2013;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1038/nri3622</pub-id><pub-id pub-id-type="pmid">24566916</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manek</surname><given-names>R</given-names></name><name><surname>Moghieb</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Kobessiy</surname><given-names>F</given-names></name><name><surname>Sarkis</surname><given-names>GA</given-names></name><etal/></person-group>
<article-title>Protein biomarkers and neuroproteomics characterization of microvesicles/exosomes from human cerebrospinal fluid following traumatic brain injury</article-title>. <source>Mol Neurobiol.</source> (<year>2018</year>) <volume>55</volume>:<fpage>6112</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-017-0821-y</pub-id><pub-id pub-id-type="pmid">29188495</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>DD</given-names></name><name><surname>Gercel-Taylor</surname><given-names>C</given-names></name></person-group>. <article-title>Exosome platform for diagnosis and monitoring of traumatic brain injury</article-title>. <source>Philos Trans R Soc Lond B Biol Sci.</source> (<year>2014</year>) <volume>369</volume>:<fpage>20130503</fpage>. <pub-id pub-id-type="doi">10.1098/rstb.2013.0503</pub-id><pub-id pub-id-type="pmid">25135964</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raeven</surname><given-names>P</given-names></name><name><surname>Zipperle</surname><given-names>J</given-names></name><name><surname>Drechsler</surname><given-names>S</given-names></name></person-group>. <article-title>Extracellular vesicles as markers and mediators in sepsis</article-title>. <source>Theranostics.</source> (<year>2018</year>) <volume>8</volume>:<fpage>3348</fpage>&#x2013;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.7150/thno.23453</pub-id><pub-id pub-id-type="pmid">29930734</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Dea</surname><given-names>KP</given-names></name><name><surname>Porter</surname><given-names>JR</given-names></name><name><surname>Tirlapur</surname><given-names>N</given-names></name><name><surname>Katbeh</surname><given-names>U</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Handy</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Circulating microvesicles are elevated acutely following major burns injury and associated with clinical severity</article-title>. <source>PLoS ONE.</source> (<year>2016</year>) <volume>11</volume>:<fpage>e0167801</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0167801</pub-id><pub-id pub-id-type="pmid">27936199</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollnes</surname><given-names>TE</given-names></name><name><surname>Brekke</surname><given-names>OL</given-names></name><name><surname>Fung</surname><given-names>M</given-names></name><name><surname>Fure</surname><given-names>H</given-names></name><name><surname>Christiansen</surname><given-names>D</given-names></name><name><surname>Bergseth</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Essential role of the C5a receptor in <italic>E coli</italic>-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation</article-title>. <source>Blood.</source> (<year>2002</year>) <volume>100</volume>:<fpage>1869</fpage>&#x2013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1182/blood.V100.5.1869.h81702001869_1869_1877</pub-id><pub-id pub-id-type="pmid">12176911</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stejskal</surname><given-names>S</given-names></name><name><surname>Koutna</surname><given-names>I</given-names></name><name><surname>Rucka</surname><given-names>Z</given-names></name></person-group>
<article-title>Isolation of granulocytes: which transcriptome do we analyse - neutrophils or eosinophils?</article-title>
<source>Folia Biol.</source> (<year>2010</year>) <volume>56</volume>:<fpage>252</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation>
      </ref>
      <ref id="B27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Hobbs</surname><given-names>B</given-names></name><name><surname>Collin</surname><given-names>F</given-names></name><name><surname>Beazer-Barclay</surname><given-names>YD</given-names></name><name><surname>Antonellis</surname><given-names>KJ</given-names></name><name><surname>Scherf</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Exploration, normalization, and summaries of high density oligonucleotide array probe level data</article-title>. <source>Biostatistics.</source> (<year>2003</year>) <volume>4</volume>:<fpage>249</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1093/biostatistics/4.2.249</pub-id><pub-id pub-id-type="pmid">12925520</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Drai</surname><given-names>D</given-names></name><name><surname>Elmer</surname><given-names>G</given-names></name><name><surname>Kafkafi</surname><given-names>N</given-names></name><name><surname>Golani</surname><given-names>I</given-names></name></person-group>. <article-title>Controlling the false discovery rate in behavior genetics research</article-title>. <source>Behav Brain Res.</source> (<year>2001</year>) <volume>125</volume>:<fpage>279</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/S0166-4328(01)00297-2</pub-id><pub-id pub-id-type="pmid">11682119</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeeberg</surname><given-names>BR</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>MD</given-names></name><name><surname>Fojo</surname><given-names>AT</given-names></name><name><surname>Sunshine</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>GoMiner: a resource for biological interpretation of genomic and proteomic data</article-title>. <source>Genome Biol.</source> (<year>2003</year>) <volume>4</volume>:<fpage>R28</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2003-4-4-r28</pub-id><pub-id pub-id-type="pmid">12702209</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>BL III</given-names></name><name><surname>Kuethe</surname><given-names>JW</given-names></name><name><surname>Caldwell</surname><given-names>CC</given-names></name></person-group>. <article-title>Neutrophil derived microvesicles: emerging role of a key mediator to the immune response</article-title>. <source>Endocr Metab Immune Disord Drug Targets.</source> (<year>2014</year>) <volume>14</volume>:<fpage>210</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.2174/1871530314666140722083717</pub-id><pub-id pub-id-type="pmid">25051983</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holliday</surname><given-names>LS</given-names></name><name><surname>Faria</surname><given-names>LP</given-names></name><name><surname>Rody</surname><given-names>WJ</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Actin and actin-associated proteins in extracellular vesicles shed by osteoclasts</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>21</volume>:<fpage>158</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21010158</pub-id><pub-id pub-id-type="pmid">31881680</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thyagarajan</surname><given-names>A</given-names></name><name><surname>Kadam</surname><given-names>SM</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Kelly</surname><given-names>LE</given-names></name><name><surname>Rapp</surname><given-names>CM</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Gemcitabine induces microvesicle particle release in a platelet-activating factor-receptor-dependent manner via modulation of the MAPK pathway in pancreatic cancer cells</article-title>. <source>Int J Mol Sci.</source> (<year>2018</year>) <volume>20</volume>:<fpage>32</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20010032</pub-id><pub-id pub-id-type="pmid">30577630</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohl</surname><given-names>J</given-names></name></person-group>. <article-title>Drug evaluation: the C5a receptor antagonist PMX-53</article-title>. <source>Curr Opin Mol Ther.</source> (<year>2006</year>) <volume>8</volume>:<fpage>529</fpage>&#x2013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">17243489</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>H</given-names></name><name><surname>Kashem</surname><given-names>SW</given-names></name><name><surname>Collington</surname><given-names>SJ</given-names></name><name><surname>Qu</surname><given-names>H</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name><name><surname>Ali</surname><given-names>H</given-names></name></person-group>. <article-title>PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells</article-title>. <source>Mol Pharmacol.</source> (<year>2011</year>) <volume>79</volume>:<fpage>1005</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1124/mol.111.071472</pub-id><pub-id pub-id-type="pmid">21441599</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tricarico</surname><given-names>C</given-names></name><name><surname>Clancy</surname><given-names>J</given-names></name><name><surname>D'Souza-Schorey</surname><given-names>C</given-names></name></person-group>. <article-title>Biology and biogenesis of shed microvesicles</article-title>. <source>Small GTPases.</source> (<year>2017</year>) <volume>8</volume>:<fpage>220</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1080/21541248.2016.1215283</pub-id><pub-id pub-id-type="pmid">27494381</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <label>36.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>MA</given-names></name></person-group>. <article-title>The human complement system: assembly of the classical pathway C3 convertase</article-title>. <source>Biochem J.</source> (<year>1980</year>) <volume>189</volume>:<fpage>173</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1042/bj1890173</pub-id><pub-id pub-id-type="pmid">6906228</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <label>37.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bokisch</surname><given-names>VA</given-names></name><name><surname>Muller-Eberhard</surname><given-names>HJ</given-names></name></person-group>. <article-title>Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase</article-title>. <source>J Clin Invest.</source> (<year>1970</year>) <volume>49</volume>:<fpage>2427</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1172/JCI106462</pub-id><pub-id pub-id-type="pmid">4098172</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <label>38.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reis</surname><given-names>ES</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Sfyroera</surname><given-names>G</given-names></name><name><surname>Monk</surname><given-names>PN</given-names></name><name><surname>Kohl</surname><given-names>J</given-names></name><name><surname>Ricklin</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>C5a receptor-dependent cell activation by physiological concentrations of desarginated C5a: insights from a novel label-free cellular assay</article-title>. <source>J Immunol.</source> (<year>2012</year>) <volume>189</volume>:<fpage>4797</fpage>&#x2013;<lpage>805</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1200834</pub-id><pub-id pub-id-type="pmid">23041570</pub-id></mixed-citation>
      </ref>
      <ref id="B39">
        <label>39.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber-Lang</surname><given-names>M</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name><name><surname>Ward</surname><given-names>PA</given-names></name></person-group>. <article-title>Innate immune responses to trauma</article-title>. <source>Nat Immunol.</source> (<year>2018</year>) <volume>19</volume>:<fpage>327</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-018-0064-8</pub-id><pub-id pub-id-type="pmid">29507356</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <label>40.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>NR</given-names></name></person-group>. <article-title>The classical complement pathway: activation and regulation of the first complement component</article-title>. <source>Adv Immunol.</source> (<year>1985</year>) <volume>37</volume>:<fpage>151</fpage>&#x2013;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1016/S0065-2776(08)60340-5</pub-id><pub-id pub-id-type="pmid">3890478</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <label>41.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohlson</surname><given-names>SS</given-names></name><name><surname>Fraser</surname><given-names>DA</given-names></name><name><surname>Tenner</surname><given-names>AJ</given-names></name></person-group>. <article-title>Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-term protective immune functions</article-title>. <source>Mol Immunol.</source> (<year>2007</year>) <volume>44</volume>:<fpage>33</fpage>&#x2013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2006.06.021</pub-id><pub-id pub-id-type="pmid">16908067</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <label>42.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiel</surname><given-names>S</given-names></name></person-group>. <article-title>Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins</article-title>. <source>Mol Immunol.</source> (<year>2007</year>) <volume>44</volume>:<fpage>3875</fpage>&#x2013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2007.06.005</pub-id><pub-id pub-id-type="pmid">17768106</pub-id></mixed-citation>
      </ref>
      <ref id="B43">
        <label>43.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pangburn</surname><given-names>MK</given-names></name><name><surname>Muller-Eberhard</surname><given-names>HJ</given-names></name></person-group>. <article-title>The alternative pathway of complement</article-title>. <source>Springer Semin Immunopathol.</source> (<year>1984</year>) <volume>7</volume>:<fpage>163</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1007/BF01893019</pub-id><pub-id pub-id-type="pmid">6238433</pub-id></mixed-citation>
      </ref>
      <ref id="B44">
        <label>44.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenawy</surname><given-names>HI</given-names></name><name><surname>Boral</surname><given-names>I</given-names></name><name><surname>Bevington</surname><given-names>A</given-names></name></person-group>. <article-title>Complement-coagulation cross-talk: a potential mediator of the physiological activation of complement by low pH</article-title>. <source>Front Immunol.</source> (<year>2015</year>) <volume>6</volume>:<fpage>215</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2015.00215</pub-id><pub-id pub-id-type="pmid">25999953</pub-id></mixed-citation>
      </ref>
      <ref id="B45">
        <label>45.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amara</surname><given-names>U</given-names></name><name><surname>Rittirsch</surname><given-names>D</given-names></name><name><surname>Flierl</surname><given-names>M</given-names></name><name><surname>Bruckner</surname><given-names>U</given-names></name><name><surname>Klos</surname><given-names>A</given-names></name><name><surname>Gebhard</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Interaction between the coagulation and complement system</article-title>. <source>Adv Exp Med Biol.</source> (<year>2008</year>) <volume>632</volume>:<fpage>71</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/978-0-387-78952-1_6</pub-id><pub-id pub-id-type="pmid">19025115</pub-id></mixed-citation>
      </ref>
      <ref id="B46">
        <label>46.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiegner</surname><given-names>R</given-names></name><name><surname>Chakraborty</surname><given-names>S</given-names></name><name><surname>Huber-Lang</surname><given-names>M</given-names></name></person-group>. <article-title>Complement-coagulation crosstalk on cellular and artificial surfaces</article-title>. <source>Immunobiology.</source> (<year>2016</year>) <volume>221</volume>:<fpage>1073</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.imbio.2016.06.005</pub-id><pub-id pub-id-type="pmid">27371975</pub-id></mixed-citation>
      </ref>
      <ref id="B47">
        <label>47.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lepidi</surname><given-names>H</given-names></name><name><surname>Zaffran</surname><given-names>Y</given-names></name><name><surname>Ansaldi</surname><given-names>JL</given-names></name><name><surname>Mege</surname><given-names>JL</given-names></name><name><surname>Capo</surname><given-names>C</given-names></name></person-group>. <article-title>Morphological polarization of human polymorphonuclear leucocytes in response to three different chemoattractants: an effector response independent of calcium rise and tyrosine kinases</article-title>. <source>J Cell Sci.</source> (<year>1995</year>) <volume>108</volume>(<issue>Pt. 4</issue>):<fpage>1771</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">7615691</pub-id></mixed-citation>
      </ref>
      <ref id="B48">
        <label>48.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jagels</surname><given-names>MA</given-names></name><name><surname>Daffern</surname><given-names>PJ</given-names></name><name><surname>Hugli</surname><given-names>TE</given-names></name></person-group>. <article-title>C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion</article-title>. <source>Immunopharmacology.</source> (<year>2000</year>) <volume>46</volume>:<fpage>209</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/S0162-3109(99)00178-2</pub-id><pub-id pub-id-type="pmid">10741901</pub-id></mixed-citation>
      </ref>
      <ref id="B49">
        <label>49.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perianayagam</surname><given-names>MC</given-names></name><name><surname>Balakrishnan</surname><given-names>VS</given-names></name><name><surname>King</surname><given-names>AJ</given-names></name><name><surname>Pereira</surname><given-names>BJ</given-names></name><name><surname>Jaber</surname><given-names>BL</given-names></name></person-group>. <article-title>C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway</article-title>. <source>Kidney Int.</source> (<year>2002</year>) <volume>61</volume>:<fpage>456</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1755.2002.00139.x</pub-id><pub-id pub-id-type="pmid">11849385</pub-id></mixed-citation>
      </ref>
      <ref id="B50">
        <label>50.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perianayagam</surname><given-names>MC</given-names></name><name><surname>Balakrishnan</surname><given-names>VS</given-names></name><name><surname>Pereira</surname><given-names>BJ</given-names></name><name><surname>Jaber</surname><given-names>BL</given-names></name></person-group>. <article-title>C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase and Bad-mediated signalling pathway</article-title>. <source>Eur J Clin Invest.</source> (<year>2004</year>) <volume>34</volume>:<fpage>50</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2362.2004.01273.x</pub-id><pub-id pub-id-type="pmid">14984438</pub-id></mixed-citation>
      </ref>
      <ref id="B51">
        <label>51.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Gerard</surname><given-names>C</given-names></name><name><surname>Gerard</surname><given-names>NP</given-names></name></person-group>. <article-title>Disruption of the complement anaphylatoxin receptor C5L2 exacerbates inflammation in allergic contact dermatitis</article-title>. <source>J Immunol.</source> (<year>2013</year>) <volume>191</volume>:<fpage>4001</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1301626</pub-id><pub-id pub-id-type="pmid">24043888</pub-id></mixed-citation>
      </ref>
      <ref id="B52">
        <label>52.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>MH</given-names></name></person-group>. <article-title>A pro-inflammatory role of C5L2 in C5a-primed neutrophils for ANCA-induced activation</article-title>. <source>PLoS ONE.</source> (<year>2013</year>) <volume>8</volume>:<fpage>e66305</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0066305</pub-id><pub-id pub-id-type="pmid">23785491</pub-id></mixed-citation>
      </ref>
      <ref id="B53">
        <label>53.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hengartner</surname><given-names>NE</given-names></name><name><surname>Fiedler</surname><given-names>J</given-names></name><name><surname>Schrezenmeier</surname><given-names>H</given-names></name><name><surname>Huber-Lang</surname><given-names>M</given-names></name><name><surname>Brenner</surname><given-names>RE</given-names></name></person-group>. <article-title>Crucial role of IL1beta and C3a in the <italic>in vitro</italic>-response of multipotent mesenchymal stromal cells to inflammatory mediators of polytrauma</article-title>. <source>PLoS ONE.</source> (<year>2015</year>) <volume>10</volume>:<fpage>e0116772</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0116772</pub-id><pub-id pub-id-type="pmid">25562599</pub-id></mixed-citation>
      </ref>
      <ref id="B54">
        <label>54.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>JD</given-names></name><name><surname>Clark</surname><given-names>RJ</given-names></name><name><surname>Noakes</surname><given-names>PG</given-names></name><name><surname>Taylor</surname><given-names>SM</given-names></name><name><surname>Woodruff</surname><given-names>TM</given-names></name></person-group>. <article-title>Preclinical pharmacokinetics of complement C5a receptor antagonists PMX53 and PMX205 in mice</article-title>. <source>ACS Omega.</source> (<year>2020</year>) <volume>5</volume>:<fpage>2345</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.9b03735</pub-id><pub-id pub-id-type="pmid">32064396</pub-id></mixed-citation>
      </ref>
      <ref id="B55">
        <label>55.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>M</given-names></name><name><surname>Bulmer</surname><given-names>AC</given-names></name><name><surname>Woodruff</surname><given-names>TM</given-names></name><name><surname>Proctor</surname><given-names>LM</given-names></name><name><surname>Williams</surname><given-names>HM</given-names></name><name><surname>Stocks</surname><given-names>SZ</given-names></name><etal/></person-group>. <article-title>Pharmacokinetics of a C5a receptor antagonist in the rat after different sites of enteral administration</article-title>. <source>Eur J Pharm Sci.</source> (<year>2008</year>) <volume>33</volume>:<fpage>390</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejps.2008.01.009</pub-id><pub-id pub-id-type="pmid">18337070</pub-id></mixed-citation>
      </ref>
      <ref id="B56">
        <label>56.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergunst</surname><given-names>CE</given-names></name><name><surname>Gerlag</surname><given-names>DM</given-names></name><name><surname>Dinant</surname><given-names>H</given-names></name><name><surname>Schulz</surname><given-names>L</given-names></name><name><surname>Vinkenoog</surname><given-names>M</given-names></name><name><surname>Smeets</surname><given-names>TJ</given-names></name><etal/></person-group>. <article-title>Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation</article-title>. <source>Rheumatology.</source> (<year>2007</year>) <volume>46</volume>:<fpage>1773</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/kem222</pub-id><pub-id pub-id-type="pmid">17965442</pub-id></mixed-citation>
      </ref>
      <ref id="B57">
        <label>57.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuravi</surname><given-names>SJ</given-names></name><name><surname>Yates</surname><given-names>CM</given-names></name><name><surname>Foster</surname><given-names>M</given-names></name><name><surname>Harrison</surname><given-names>P</given-names></name><name><surname>Hazeldine</surname><given-names>J</given-names></name><name><surname>Hampson</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Changes in the pattern of plasma extracellular vesicles after severe trauma</article-title>. <source>PLoS ONE.</source> (<year>2017</year>) <volume>12</volume>:<fpage>e0183640</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0183640</pub-id><pub-id pub-id-type="pmid">28837705</pub-id></mixed-citation>
      </ref>
      <ref id="B58">
        <label>58.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matijevic</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>YW</given-names></name><name><surname>Holcomb</surname><given-names>JB</given-names></name><name><surname>Kozar</surname><given-names>R</given-names></name><name><surname>Cardenas</surname><given-names>JC</given-names></name><name><surname>Wade</surname><given-names>CE</given-names></name></person-group>. <article-title>Microvesicle phenotypes are associated with transfusion requirements and mortality in subjects with severe injuries</article-title>. <source>J Extracell Vesicles.</source> (<year>2015</year>) <volume>4</volume>:<fpage>29338</fpage>. <pub-id pub-id-type="doi">10.3402/jev.v4.29338</pub-id><pub-id pub-id-type="pmid">26689982</pub-id></mixed-citation>
      </ref>
      <ref id="B59">
        <label>59.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Der Meijden</surname><given-names>PE</given-names></name><name><surname>Van SM Van</surname><given-names>OR</given-names></name><name><surname>Renne</surname><given-names>T</given-names></name><name><surname>ten</surname><given-names>CH</given-names></name><name><surname>Spronk</surname><given-names>HM</given-names></name></person-group>. <article-title>Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa</article-title>. <source>J Thromb Haemost.</source> (<year>2012</year>) <volume>10</volume>:<fpage>1355</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1111/j.1538-7836.2012.04758.x</pub-id><pub-id pub-id-type="pmid">22537188</pub-id></mixed-citation>
      </ref>
      <ref id="B60">
        <label>60.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frohlich</surname><given-names>M</given-names></name><name><surname>Schafer</surname><given-names>N</given-names></name><name><surname>Caspers</surname><given-names>M</given-names></name><name><surname>Bohm</surname><given-names>JK</given-names></name><name><surname>Sturmer</surname><given-names>EK</given-names></name><name><surname>Bouillon</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Temporal phenotyping of circulating microparticles after trauma: a prospective cohort study</article-title>. <source>Scand J Trauma Resusc Emerg Med.</source> (<year>2018</year>) <volume>26</volume>:<fpage>33</fpage>. <pub-id pub-id-type="doi">10.1186/s13049-018-0499-9</pub-id><pub-id pub-id-type="pmid">29703240</pub-id></mixed-citation>
      </ref>
      <ref id="B61">
        <label>61.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>AL</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Seitz</surname><given-names>AP</given-names></name><name><surname>Schuster</surname><given-names>RM</given-names></name><name><surname>Lentsch</surname><given-names>AB</given-names></name><name><surname>Pritts</surname><given-names>TA</given-names></name></person-group>. <article-title>Erythrocyte-derived microparticles activate pulmonary endothelial cells in a murine model of transfusion</article-title>. <source>Shock.</source> (<year>2017</year>) <volume>47</volume>:<fpage>632</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/SHK.0000000000000780</pub-id><pub-id pub-id-type="pmid">27792124</pub-id></mixed-citation>
      </ref>
      <ref id="B62">
        <label>62.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimi</surname><given-names>S</given-names></name><name><surname>Ogura</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Koh</surname><given-names>T</given-names></name><name><surname>Hosotsubo</surname><given-names>H</given-names></name><name><surname>Nakamori</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Increased production of leukocyte microparticles with enhanced expression of adhesion molecules from activated polymorphonuclear leukocytes in severely injured patients</article-title>. <source>J Trauma.</source> (<year>2003</year>) <volume>54</volume>:<fpage>114</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/00005373-200301000-00014</pub-id><pub-id pub-id-type="pmid">12544906</pub-id></mixed-citation>
      </ref>
      <ref id="B63">
        <label>63.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danesh</surname><given-names>A</given-names></name><name><surname>Inglis</surname><given-names>HC</given-names></name><name><surname>Abdel-Mohsen</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Adelman</surname><given-names>A</given-names></name><name><surname>Schechtman</surname><given-names>KB</given-names></name><etal/></person-group>. <article-title>Granulocyte-derived extracellular vesicles activate monocytes and are associated with mortality in intensive care unit patients</article-title>. <source>Front Immunol.</source> (<year>2018</year>) <volume>9</volume>:<fpage>956</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00956</pub-id><pub-id pub-id-type="pmid">29867942</pub-id></mixed-citation>
      </ref>
      <ref id="B64">
        <label>64.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karasu</surname><given-names>E</given-names></name><name><surname>Eisenhardt</surname><given-names>SU</given-names></name><name><surname>Harant</surname><given-names>J</given-names></name><name><surname>Huber-Lang</surname><given-names>M</given-names></name></person-group>. <article-title>Extracellular vesicles: packages sent with complement</article-title>. <source>Front Immunol.</source> (<year>2018</year>) <volume>9</volume>:<fpage>721</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00721</pub-id><pub-id pub-id-type="pmid">29696020</pub-id></mixed-citation>
      </ref>
      <ref id="B65">
        <label>65.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akers</surname><given-names>JC</given-names></name><name><surname>Gonda</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Carter</surname><given-names>BS</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name></person-group>. <article-title>Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies</article-title>. <source>J Neurooncol.</source> (<year>2013</year>) <volume>113</volume>:<fpage>1</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-013-1084-8</pub-id><pub-id pub-id-type="pmid">23456661</pub-id></mixed-citation>
      </ref>
      <ref id="B66">
        <label>66.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedgwick</surname><given-names>AE</given-names></name><name><surname>Clancy</surname><given-names>JW</given-names></name><name><surname>Olivia</surname><given-names>BM</given-names></name><name><surname>D'Souza-Schorey</surname><given-names>C</given-names></name></person-group>. <article-title>Extracellular microvesicles and invadopodia mediate non-overlapping modes of tumor cell invasion</article-title>. <source>Sci Rep.</source> (<year>2015</year>) <volume>5</volume>:<fpage>14748</fpage>. <pub-id pub-id-type="doi">10.1038/srep14748</pub-id><pub-id pub-id-type="pmid">26458510</pub-id></mixed-citation>
      </ref>
      <ref id="B67">
        <label>67.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beer</surname><given-names>KB</given-names></name><name><surname>Wehman</surname><given-names>AM</given-names></name></person-group>. <article-title>Mechanisms and functions of extracellular vesicle release <italic>in vivo</italic>-What we can learn from flies and worms</article-title>. <source>Cell Adh Migr.</source> (<year>2017</year>) <volume>11</volume>:<fpage>135</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1080/19336918.2016.1236899</pub-id><pub-id pub-id-type="pmid">27689411</pub-id></mixed-citation>
      </ref>
      <ref id="B68">
        <label>68.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavrier</surname><given-names>P</given-names></name><name><surname>Menetrey</surname><given-names>J</given-names></name></person-group>. <article-title>Toward a structural understanding of arf family:effector specificity</article-title>. <source>Structure.</source> (<year>2010</year>) <volume>18</volume>:<fpage>1552</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2010.11.004</pub-id><pub-id pub-id-type="pmid">21134634</pub-id></mixed-citation>
      </ref>
      <ref id="B69">
        <label>69.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>TS</given-names></name><name><surname>Lin</surname><given-names>MC</given-names></name><name><surname>Tsai</surname><given-names>MC</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Jang</surname><given-names>LT</given-names></name><name><surname>Lee</surname><given-names>FS</given-names></name></person-group>. <article-title>ADP-ribosylation factor-like 4A interacts with Robo1 to promote cell migration by regulating Cdc42 activation</article-title>. <source>Mol Biol Cell.</source> (<year>2019</year>) <volume>30</volume>:<fpage>69</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.E18-01-0001</pub-id><pub-id pub-id-type="pmid">30427759</pub-id></mixed-citation>
      </ref>
      <ref id="B70">
        <label>70.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krauss</surname><given-names>M</given-names></name><name><surname>Kinuta</surname><given-names>M</given-names></name><name><surname>Wenk</surname><given-names>MR</given-names></name><name><surname>De</surname><given-names>CP</given-names></name><name><surname>Takei</surname><given-names>K</given-names></name><name><surname>Haucke</surname><given-names>V</given-names></name></person-group>. <article-title>ARF6 stimulates clathrin/AP-2 recruitment to synaptic membranes by activating phosphatidylinositol phosphate kinase type Igamma</article-title>. <source>J Cell Biol.</source> (<year>2003</year>) <volume>162</volume>:<fpage>113</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200301006</pub-id><pub-id pub-id-type="pmid">12847086</pub-id></mixed-citation>
      </ref>
      <ref id="B71">
        <label>71.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haraszti</surname><given-names>RA</given-names></name><name><surname>Didiot</surname><given-names>MC</given-names></name><name><surname>Sapp</surname><given-names>E</given-names></name><name><surname>Leszyk</surname><given-names>J</given-names></name><name><surname>Shaffer</surname><given-names>SA</given-names></name><name><surname>Rockwell</surname><given-names>HE</given-names></name><etal/></person-group>. <article-title>High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources</article-title>. <source>J Extracell Vesicles.</source> (<year>2016</year>) <volume>5</volume>:<fpage>32570</fpage>. <pub-id pub-id-type="doi">10.3402/jev.v5.32570</pub-id><pub-id pub-id-type="pmid">27863537</pub-id></mixed-citation>
      </ref>
      <ref id="B72">
        <label>72.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Surface phosphatidylserine is responsible for the internalization on microvesicles derived from hypoxia-induced human bone marrow mesenchymal stem cells into human endothelial cells</article-title>. <source>PLoS ONE.</source> (<year>2016</year>) <volume>11</volume>:<fpage>e0147360</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0147360</pub-id><pub-id pub-id-type="pmid">26808539</pub-id></mixed-citation>
      </ref>
      <ref id="B73">
        <label>73.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verderio</surname><given-names>C</given-names></name><name><surname>Gabrielli</surname><given-names>M</given-names></name><name><surname>Giussani</surname><given-names>P</given-names></name></person-group>. <article-title>Role of sphingolipids in the biogenesis and biological activity of extracellular vesicles</article-title>. <source>J Lipid Res.</source> (<year>2018</year>) <volume>59</volume>:<fpage>1325</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.R083915</pub-id><pub-id pub-id-type="pmid">29853528</pub-id></mixed-citation>
      </ref>
      <ref id="B74">
        <label>74.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>S</given-names></name><name><surname>Milstien</surname><given-names>S</given-names></name><name><surname>Spiegel</surname><given-names>S</given-names></name></person-group>. <article-title>Sphingosine and sphingosine kinase 1 involvement in endocytic membrane trafficking</article-title>. <source>J Biol Chem.</source> (<year>2017</year>) <volume>292</volume>:<fpage>3074</fpage>&#x2013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.762377</pub-id><pub-id pub-id-type="pmid">28049734</pub-id></mixed-citation>
      </ref>
      <ref id="B75">
        <label>75.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clancy</surname><given-names>JW</given-names></name><name><surname>Sedgwick</surname><given-names>A</given-names></name><name><surname>Rosse</surname><given-names>C</given-names></name><name><surname>Muralidharan-Chari</surname><given-names>V</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name><name><surname>Method</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Regulated delivery of molecular cargo to invasive tumour-derived microvesicles</article-title>. <source>Nat Commun.</source> (<year>2015</year>) <volume>6</volume>:<fpage>6919</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms7919</pub-id><pub-id pub-id-type="pmid">25897521</pub-id></mixed-citation>
      </ref>
      <ref id="B76">
        <label>76.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruger-Krasagakes</surname><given-names>S</given-names></name><name><surname>Moller</surname><given-names>A</given-names></name><name><surname>Kolde</surname><given-names>G</given-names></name><name><surname>Lippert</surname><given-names>U</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Henz</surname><given-names>BM</given-names></name></person-group>. <article-title>Production of interleukin-6 by human mast cells and basophilic cells</article-title>. <source>J Invest Dermatol.</source> (<year>1996</year>) <volume>106</volume>:<fpage>75</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/1523-1747.ep12327815</pub-id><pub-id pub-id-type="pmid">8592085</pub-id></mixed-citation>
      </ref>
      <ref id="B77">
        <label>77.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rincon</surname><given-names>M</given-names></name><name><surname>Anguita</surname><given-names>J</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Fikrig</surname><given-names>E</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group>. <article-title>Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells</article-title>. <source>J Exp Med.</source> (<year>1997</year>) <volume>185</volume>:<fpage>461</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1084/jem.185.3.461</pub-id><pub-id pub-id-type="pmid">9053446</pub-id></mixed-citation>
      </ref>
      <ref id="B78">
        <label>78.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogura</surname><given-names>H</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Okuyama</surname><given-names>Y</given-names></name><name><surname>Tsuruoka</surname><given-names>M</given-names></name><name><surname>Kitabayashi</surname><given-names>C</given-names></name><name><surname>Kanamoto</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction</article-title>. <source>Immunity.</source> (<year>2008</year>) <volume>29</volume>:<fpage>628</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2008.07.018</pub-id><pub-id pub-id-type="pmid">18848474</pub-id></mixed-citation>
      </ref>
      <ref id="B79">
        <label>79.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>W</given-names></name></person-group>. <article-title>IL-6: a multifunctional regulator of immunity and inflammation</article-title>. <source>Jpn J Cancer Res.</source> (<year>1991</year>) <volume>82</volume>:<fpage>1458</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">1778773</pub-id></mixed-citation>
      </ref>
      <ref id="B80">
        <label>80.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delfino</surname><given-names>D</given-names></name><name><surname>Cianci</surname><given-names>L</given-names></name><name><surname>Lupis</surname><given-names>E</given-names></name><name><surname>Celeste</surname><given-names>A</given-names></name><name><surname>Petrelli</surname><given-names>ML</given-names></name><name><surname>Curro</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Interleukin-6 production by human monocytes stimulated with <italic>Cryptococcus neoformans</italic> components</article-title>. <source>Infect Immun.</source> (<year>1997</year>) <volume>65</volume>:<fpage>2454</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.65.6.2454-2456.1997</pub-id><pub-id pub-id-type="pmid">9169790</pub-id></mixed-citation>
      </ref>
      <ref id="B81">
        <label>81.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Arruda-Silva</surname><given-names>F</given-names></name><name><surname>Bianchetto-Aguilera</surname><given-names>F</given-names></name><name><surname>Finotti</surname><given-names>G</given-names></name><name><surname>Calzetti</surname><given-names>F</given-names></name><name><surname>Scapini</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>IFNalpha enhances the production of IL-6 by human neutrophils activated via TLR8</article-title>. <source>Sci Rep.</source> (<year>2016</year>) <volume>6</volume>:<fpage>19674</fpage>. <pub-id pub-id-type="doi">10.1038/srep19674</pub-id><pub-id pub-id-type="pmid">26790609</pub-id></mixed-citation>
      </ref>
      <ref id="B82">
        <label>82.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>CW</given-names></name></person-group>. <article-title>Extracellular vesicles of neutrophils</article-title>. <source>Immune Netw.</source> (<year>2018</year>) <volume>18</volume>:<fpage>e43</fpage>. <pub-id pub-id-type="doi">10.4110/in.2018.18.e43</pub-id><pub-id pub-id-type="pmid">30619629</pub-id></mixed-citation>
      </ref>
      <ref id="B83">
        <label>83.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Headland</surname><given-names>SE</given-names></name><name><surname>Jones</surname><given-names>HR</given-names></name><name><surname>Norling</surname><given-names>LV</given-names></name><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Souza</surname><given-names>PR</given-names></name><name><surname>Corsiero</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory arthritis</article-title>. <source>Sci Transl Med.</source> (<year>2015</year>) <volume>7</volume>:<fpage>315ra190</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aac5608</pub-id><pub-id pub-id-type="pmid">26606969</pub-id></mixed-citation>
      </ref>
      <ref id="B84">
        <label>84.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhys</surname><given-names>HI</given-names></name><name><surname>Dell'Accio</surname><given-names>F</given-names></name><name><surname>Pitzalis</surname><given-names>C</given-names></name><name><surname>Moore</surname><given-names>A</given-names></name><name><surname>Norling</surname><given-names>LV</given-names></name><name><surname>Perretti</surname><given-names>M</given-names></name></person-group>. <article-title>Neutrophil microvesicles from healthy control and rheumatoid arthritis patients prevent the inflammatory activation of macrophages</article-title>. <source>EBioMedicine.</source> (<year>2018</year>) <volume>29</volume>:<fpage>60</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2018.02.003</pub-id><pub-id pub-id-type="pmid">29449195</pub-id></mixed-citation>
      </ref>
      <ref id="B85">
        <label>85.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samapati</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Stoerger</surname><given-names>C</given-names></name><name><surname>Arenz</surname><given-names>C</given-names></name><name><surname>Dietrich</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Lung endothelial Ca2+ and permeability response to platelet-activating factor is mediated by acid sphingomyelinase and transient receptor potential classical 6</article-title>. <source>Am J Respir Crit Care Med.</source> (<year>2012</year>) <volume>185</volume>:<fpage>160</fpage>&#x2013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201104-0717OC</pub-id><pub-id pub-id-type="pmid">22246702</pub-id></mixed-citation>
      </ref>
      <ref id="B86">
        <label>86.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>J</given-names></name><name><surname>Marathe</surname><given-names>GK</given-names></name><name><surname>Neilsen</surname><given-names>PO</given-names></name><name><surname>Weyrich</surname><given-names>AS</given-names></name><name><surname>Harrison</surname><given-names>KA</given-names></name><name><surname>Murphy</surname><given-names>RC</given-names></name><etal/></person-group>. <article-title>Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles</article-title>. <source>J Biol Chem.</source> (<year>2003</year>) <volume>278</volume>:<fpage>33161</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M305321200</pub-id><pub-id pub-id-type="pmid">12810708</pub-id></mixed-citation>
      </ref>
      <ref id="B87">
        <label>87.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalli</surname><given-names>J</given-names></name><name><surname>Montero-Melendez</surname><given-names>T</given-names></name><name><surname>Norling</surname><given-names>LV</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name><name><surname>Hinds</surname><given-names>C</given-names></name><name><surname>Haskard</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Heterogeneity in neutrophil microparticles reveals distinct proteome and functional properties</article-title>. <source>Mol Cell Proteomics.</source> (<year>2013</year>) <volume>12</volume>:<fpage>2205</fpage>&#x2013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.M113.028589</pub-id><pub-id pub-id-type="pmid">23660474</pub-id></mixed-citation>
      </ref>
      <ref id="B88">
        <label>88.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorincz</surname><given-names>AM</given-names></name><name><surname>Schutte</surname><given-names>M</given-names></name><name><surname>Timar</surname><given-names>CI</given-names></name><name><surname>Veres</surname><given-names>DS</given-names></name><name><surname>Kittel</surname><given-names>A</given-names></name><name><surname>McLeish</surname><given-names>KR</given-names></name><etal/></person-group>. <article-title>Functionally and morphologically distinct populations of extracellular vesicles produced by human neutrophilic granulocytes</article-title>. <source>J Leukoc Biol.</source> (<year>2015</year>) <volume>98</volume>:<fpage>583</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.3VMA1014-514R</pub-id><pub-id pub-id-type="pmid">25986013</pub-id></mixed-citation>
      </ref>
      <ref id="B89">
        <label>89.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boilard</surname><given-names>E</given-names></name></person-group>. <article-title>Extracellular vesicles and their content in bioactive lipid mediators: more than a sack of microRNA</article-title>. <source>J Lipid Res.</source> (<year>2018</year>) <volume>59</volume>:<fpage>2037</fpage>&#x2013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.R084640</pub-id><pub-id pub-id-type="pmid">29678959</pub-id></mixed-citation>
      </ref>
      <ref id="B90">
        <label>90.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braig</surname><given-names>D</given-names></name><name><surname>Nero</surname><given-names>TL</given-names></name><name><surname>Koch</surname><given-names>HG</given-names></name><name><surname>Kaiser</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Thiele</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites</article-title>. <source>Nat Commun.</source> (<year>2017</year>) <volume>8</volume>:<fpage>14188</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms14188</pub-id><pub-id pub-id-type="pmid">28112148</pub-id></mixed-citation>
      </ref>
    </ref-list>
    <glossary>
      <def-list>
        <title>Abbreviations</title>
        <def-item>
          <term>Arf6</term>
          <def>
            <p>ADP-ribosylation factor 6</p>
          </def>
        </def-item>
        <def-item>
          <term>AV</term>
          <def>
            <p>annexin V</p>
          </def>
        </def-item>
        <def-item>
          <term>C5a<sup>desArg</sup></term>
          <def>
            <p>desarginated C5a</p>
          </def>
        </def-item>
        <def-item>
          <term>C5aR1</term>
          <def>
            <p>complement anaphylatoxin 5a receptor 1</p>
          </def>
        </def-item>
        <def-item>
          <term>C5aR2</term>
          <def>
            <p>complement anaphylatoxin 5a receptor 2</p>
          </def>
        </def-item>
        <def-item>
          <term>EDTA</term>
          <def>
            <p>ethylenediamine tetraacetic acid</p>
          </def>
        </def-item>
        <def-item>
          <term>GDP</term>
          <def>
            <p>guanosine-diphosphate</p>
          </def>
        </def-item>
        <def-item>
          <term>GEF</term>
          <def>
            <p>nucleotide exchange factors</p>
          </def>
        </def-item>
        <def-item>
          <term>GTP</term>
          <def>
            <p>guanosine-triphosphate</p>
          </def>
        </def-item>
        <def-item>
          <term>MFI</term>
          <def>
            <p>mean fluorescence intensity</p>
          </def>
        </def-item>
        <def-item>
          <term>MPO</term>
          <def>
            <p>myeloperoxidase</p>
          </def>
        </def-item>
        <def-item>
          <term>MV</term>
          <def>
            <p>microvesicles</p>
          </def>
        </def-item>
        <def-item>
          <term>PMN</term>
          <def>
            <p>polymorphonuclear neutrophils</p>
          </def>
        </def-item>
        <def-item>
          <term>PS</term>
          <def>
            <p>phosphatidylserine</p>
          </def>
        </def-item>
        <def-item>
          <term>PT</term>
          <def>
            <p>polytrauma</p>
          </def>
        </def-item>
        <def-item>
          <term>ROS</term>
          <def>
            <p>reactive oxygen species.</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Biol Sex Differ</journal-id>
      <journal-id journal-id-type="iso-abbrev">Biol Sex Differ</journal-id>
      <journal-title-group>
        <journal-title>Biology of Sex Differences</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2042-6410</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32503637</article-id>
      <article-id pub-id-type="pmc">7275616</article-id>
      <article-id pub-id-type="publisher-id">308</article-id>
      <article-id pub-id-type="doi">10.1186/s13293-020-00308-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Sex differences in pharmacokinetics predict adverse drug reactions in women</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8431-5370</contrib-id>
          <name>
            <surname>Zucker</surname>
            <given-names>Irving</given-names>
          </name>
          <address>
            <email>irvzuck@berkeley.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Prendergast</surname>
            <given-names>Brian J.</given-names>
          </name>
          <address>
            <email>prendergast@uchicago.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.47840.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 7878</institution-id><institution>Department of Psychology, </institution><institution>University of California, Berkeley, </institution></institution-wrap>2121 Berkeley Way West, Berkeley, CA 94720 USA </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.47840.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2181 7878</institution-id><institution>Department of Integrative Biology, </institution><institution>University of California, Berkeley, </institution></institution-wrap>3040 VLSB, Berkeley, CA 94720 USA </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.170205.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7822</institution-id><institution>Department of Psychology and Committee on Neurobiology, </institution><institution>University of Chicago, </institution></institution-wrap>Chicago, IL 60637 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>5</day>
        <month>6</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>5</day>
        <month>6</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>11</volume>
      <elocation-id>32</elocation-id>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>3</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>5</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2020</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p id="Par1">Women experience adverse drug reactions, ADRs, nearly twice as often as men, yet the role of sex as a biological factor in the generation of ADRs is poorly understood. Most drugs currently in use were approved based on clinical trials conducted on men, so women may be overmedicated. We determined whether sex differences in drug pharmacokinetics, PKs, predict sex differences in ADRs.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p id="Par2">Searches of the ISI Web of Science and PubMed databases were conducted with combinations of the terms: drugs, sex or gender, pharmacokinetics, pharmacodynamics, drug safety, drug dose, and adverse drug reaction, which yielded over 5000 articles with considerable overlap. We obtained information from each relevant article on significant sex differences in PK measures, predominantly area under the curve, peak/maximum concentrations, and clearance/elimination rates. ADRs were identified from every relevant article and recorded categorically as female-biased, male-biased, or not sex-biased.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p id="Par3">For most of the&#xA0;FDA-approved drugs examined, elevated blood concentrations and longer elimination times were manifested by women, and these PKs were strongly linked to sex differences in ADRs. Of the 86 drugs evaluated, 76 had higher PK values in women; for 59 drugs with clinically identifiable ADRs, sex-biased PKs predicted the direction of sex-biased ADRs in 88% of cases. Ninety-six percent of drugs with female-biased PK values were associated with a higher incidence of ADRs in women than men, but only 29% of male-biased PKs predicted male-biased ADRs. Accessible PK information is available for only a small fraction of all drugs</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p id="Par4">Sex differences in pharmacokinetics strongly predict sex-specific ADRs for women but not men. This sex difference was not explained by sex differences in body weight. The absence of sex-stratified PK information in public records for hundreds of drugs raises the concern that sex differences in PK values are widespread and of clinical significance. The common practice of prescribing equal drug doses to women and men neglects sex differences in pharmacokinetics and dimorphisms in body weight, risks overmedication of women, and contributes to female-biased adverse drug reactions. We recommend evidence-based dose reductions for women to counteract this sex bias.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Sex differences</kwd>
        <kwd>Drugs</kwd>
        <kwd>Adverse drug reactions</kwd>
        <kwd>Pharmacokinetics</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par5">Women historically were excluded from clinical pharmaceutical trials because of potential risks to individuals of childbearing potential. The now discredited belief that studies of men apply without modification to women also contributed to this oversight. Remediation by the US National Institute of Health (NIH) Revitalization Act of 1993 mandated enrollment of women in federally supported phase III clinical trials; a European Union initiative provided practical tools regarding sex differences in drug study design [<xref ref-type="bibr" rid="CR1">1</xref>]. Although the inclusion of women in clinical research subsequently increased in the USA, the EU, and Australia [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref>], most studies did not provide sex-specific data analyses [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. A 2018 review of 107 NIH funded randomized control trial studies that enrolled both men and women found that only 26% reported even one outcome by sex or included both sexes as a covariate [<xref ref-type="bibr" rid="CR7">7</xref>]; 72% simply did not include sex in their analyses. NIH policies mandated over a quarter century ago have yet to yield the intended increases in reporting by sex.</p>
      <p id="Par6">A consequence of this sex inequality hides in plain sight today: most drugs are prescribed to women and men at the same dose. Many currently prescribed drugs were approved by the US Food and Drug Administration (FDA) prior to 1993, with inadequate enrollment of female animals in preclinical research and of women in clinical trials [<xref ref-type="bibr" rid="CR8">8</xref>]. An illustrative example is found in the sedative-hypnotic drug zolpidem, which has been marketed under several names (e.g., Ambien, Edluar, Zolpimist) since it was first approved by the FDA, 1&#x2009;year before the NIH Revitalization Act. Only after decades of post-marketing reports of cognitive deficits in women given the standard male dose were sex-based dose adjustments developed (NDA 021774). Many other drugs administered in equal doses to women and men likely require re-evaluation for sex-specific dose adjustment. Even within sex, dosing is not usually weight-adjusted in adults [<xref ref-type="bibr" rid="CR9">9</xref>]; it remains uncertain whether weight-adjusted doses will suffice to offset the majority of sex-specific ADRs. One survey of clinical pharmacology data for 300 new drug applications (NDAs) evaluated by the FDA between 1994 and 2000 [<xref ref-type="bibr" rid="CR10">10</xref>] indicated that 31% of studies showed a possible sex effect based on pharmacokinetic (PK) sex differences greater than 20%. In the same report, 11 drugs showed a &gt; 40% difference between males and females in PK measures, yet no dosing recommendations to consider sex were issued, implicitly based on the unsubstantiated grounds that these differences were not clinically relevant. The existing knowledge base for sex-aware prescribing lacks information on sex differences for one-third of all drugs [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Pharmaceutical companies responsible for generating pre-approval data often fail to include information on sex differences in NDA documents, and the FDA has previously failed to enforce its own requirements before approving new drugs [<xref ref-type="bibr" rid="CR11">11</xref>]. Consequently, potential sex differences in PK measures and their relation to unwanted side effects often remain unknown. Most of the data submitted to the FDA by drug companies are not publicly available and not subject to peer-review by the broader scientific community [<xref ref-type="bibr" rid="CR9">9</xref>]. Regulatory agencies have historically paid insufficient attention to differences between women and men in terms of both sex and gender, which perpetuates inequalities by neglecting drug safety problems that are sex-specific. In addition, this disparity allows for misleading drug marketing [<xref ref-type="bibr" rid="CR11">11</xref>].</p>
      <p id="Par7">The present review study inventories drugs that elicit different responses in women and men and considers sex differences in adverse drug reactions (ADRs) that occur in individuals treated with therapeutic doses of medications. The range of ADRs included, but was not limited to, nausea, headache, drowsiness, depression, excessive weight gain, cognitive deficits, seizures, hallucinations, agitation, and cardiac anomalies. Sex differentiated ADRs were operationally defined as statistically significant differences in unintended drug effects in one sex, as reported in peer-reviewed literature or in NDAs. Supplementary evidence of ADRs was obtained from <italic>VigiBase</italic> [<xref ref-type="bibr" rid="CR12">12</xref>], the World Health Organization (WHO) global database of individual case safety reports (ICSRs), which since 1968 has aggregated ICSRs from member countries of the WHO Programme for International Drug Monitoring. It is important to note that pharmacovigilance datasets, including but not limited to <italic>VigiBase</italic>, have a number of shortcomings: the information in <italic>VigiBase</italic> comes from a variety of sources, and the probability that the suspected ADR is, in fact, drug-related is not the same in all cases. Thus, it cannot be proven that a specific drug caused an ADR, rather than an underlying illness or other concomitant medication. Reports submitted to <italic>VigiBase</italic> come from both regulated and voluntary sources, and the volume of reports about a given substance may be influenced by extent of use of the product, the nature of the ADR, and/or publicity. Lastly, many drugs are disproportionately prescribed to one sex, and <italic>VigiBase</italic> data do not account for the number of patients of each sex exposed to the drug [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
      <p id="Par8">In contrast, much stronger and less confounded evidence comes from clinical trials and experimentally controlled empirical studies of drugs, in which ADRs can be quantified in the context of a known number of subjects administered the drug. Because the present report is, to our knowledge, the most comprehensive attempt yet to identify sex-biased ADRs using clinically identified ADR data, it also provided an opportunity to evaluate the accuracy of <italic>VigiBase</italic> data in estimating sex differences in ADRs compared to estimates obtained under more controlled experimental conditions.</p>
      <sec id="Sec2">
        <title>Reasons why men and women respond differently to drugs</title>
        <p id="Par9">Women have a nearly 2-fold greater risk than men for exhibiting ADRs across all drug classes and are significantly more likely to be hospitalized secondary to an ADR [<xref ref-type="bibr" rid="CR14">14</xref>&#x2013;<xref ref-type="bibr" rid="CR16">16</xref>]. This disparity is pervasive: among 668 drugs of the 20 most frequent treatment regimens in the USA, 307 (46%) report significant sex differences in ADRs [<xref ref-type="bibr" rid="CR17">17</xref>]. In an analysis of cohort studies on 48 drugs completed between 1982 and 1997, compiling data from &gt; 500,000 patients, Martin et al. [<xref ref-type="bibr" rid="CR18">18</xref>] concluded that women over the age of 19 were 43 to 69% more likely to have an ADR recorded by their general practitioner. ADRs also peaked earlier in development among women (30&#x2013;39&#x2009;years of age) than men (50&#x2013;59&#x2009;years of age [<xref ref-type="bibr" rid="CR18">18</xref>];). Women are also more likely than men to use two or more medications concurrently (polypharmacy), and women use more unique medications per year (5.0 vs. 3.7, respectively), which may contribute to increased female ADRs [<xref ref-type="bibr" rid="CR19">19</xref>] but also renders the issue of sex-aware dosing all the more critical.</p>
        <p id="Par10">A comprehensive survey of the chemical and biological processes that underlie PKs and pharmacodynamics (PDs), and sex differences therein, is beyond the scope of the present work. We refer the reader to several thorough reviews of mechanisms relevant to PKs and PDs [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] and sex differences in drug disposition [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Here we discuss biophysical and molecular mechanisms only as required for illustration. Future analyses of drug elimination mechanisms (e.g., via CYP3A4) may facilitate extrapolation of the present results to a larger sample of drugs.</p>
        <p id="Par11">In general, drug disposition occurs through separate phases: absorption, distribution, bioavailability, metabolism, and excretion, and sex differences have been documented for each phase [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Women generally have a lower body weight and organ size and a higher percentage of body fat, which affects the absorption and distribution of drugs. The larger the volume of distribution (V<sub>d</sub>), the more likely the drug will be found in body tissues.</p>
        <p id="Par12">A number of biological, psychological, and cultural factors may contribute to why sex is such a&#xA0;strong risk factors for ADRs, including the following: sex differences in PKs and PDs, sex-specific organizational (early life) and activational (peripubertal through adulthood) endogenous steroid hormone exposure, and sex differences in exogenously administered steroids, higher rates of polypharmacy in women, sex differences in the expression of somatoform disorders, and sex differences in reporting rates [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
        <p id="Par13">Drug clearance is strongly linked to sex-specific expression of metabolic enzyme systems [<xref ref-type="bibr" rid="CR25">25</xref>&#x2013;<xref ref-type="bibr" rid="CR27">27</xref>]; renal clearance of drugs is decreased in women because of a relatively lower glomerular filtration rate compared to men [<xref ref-type="bibr" rid="CR28">28</xref>]. Women have a slower gastric emptying time and lower gastric pH, lower plasma volume, body mass index, average organ blood flow, and total body water differences, all of which affect drug distribution and PKs [<xref ref-type="bibr" rid="CR29">29</xref>]. Responses to drugs are also affected by physiological changes during the menstrual cycle. The striking hormonal variations across days over the course of the human menstrual have no parallel in men in which hormonal variations largely occur within rather than across days [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
        <p id="Par14">The anticoagulant drug lepirudin is excreted by the kidney with systemic clearance in women about 25% lower than in men (NDA 020807 [<xref ref-type="bibr" rid="CR31">31</xref>]). But PK variables do not translate linearly into phenotypes; thus, in women lepirudin is detectible in the circulation for up to 48&#x2009;h, compared to just 2&#x2009;h in men, which greatly increases the potential for undesired bleeding [<xref ref-type="bibr" rid="CR32">32</xref>]; indeed, in this example, low molecular weight heparin-induced thrombocytopenia is a clinically important ADR which occurs more frequently in women than men [<xref ref-type="bibr" rid="CR33">33</xref>], a difference that corresponded to much higher drug exposure as indicated by female-bias in multiple PK measures.</p>
        <p id="Par15">Arpon et al. [<xref ref-type="bibr" rid="CR34">34</xref>] maintain that dosing adjusted according to a range of patient-specific factors is of large and increasing clinical and financial concern but lament that the amount of body weight adjusted dosing change that occurs in clinical practice is presently unknown. Adjustments for body mass in most cases do not ameliorate the high incidence of female ADRs. Thus, a multivariate regression analysis controlling for age, body mass index, and number of prescribed drugs identified a strong and significant effect of female sex on the increased risk of encountering ADRs, indicating that the sex disparity in ADRs does not merely reflect body mass masquerading as an effect of sex [<xref ref-type="bibr" rid="CR35">35</xref>].</p>
        <p id="Par16">Most drugs are not administered on a milligram/kilogram basis but as a &#x201C;one size fits all&#x201D; dose, leading to higher exposures in women [<xref ref-type="bibr" rid="CR10">10</xref>]. Under optimal circumstances, the dose should be based on milligram/kilogram body weight, or titrated to the desired clinical effect [<xref ref-type="bibr" rid="CR36">36</xref>]. Correction for height, weight, surface area, or body composition eliminates a minority of sex-dependent PK differences [<xref ref-type="bibr" rid="CR10">10</xref>]. The inference that weight-corrected PKs are comparable between men and women is not generally warranted but must be examined on a case-by-case basis, if data on both sexes exist. If for a given drug with a sexually differentiated pattern of ADR expression, correction for body weight eliminates the sex differences in PKs, this may or may not have bearing on PK-driven exposure leading to sex-differentiated ADRs. In short, sex differences in PK may be sufficient but not necessary for the manifestation of sex differences in ADRs.</p>
        <p id="Par17">PKs differ in men and women for many drugs [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#x2013;<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR37">37</xref>&#x2013;<xref ref-type="bibr" rid="CR40">40</xref>]; this impacts drug efficacy and toxicity [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Data from bioequivalence trials identified significant sex differences in PKs in ~ 28% of data sets [<xref ref-type="bibr" rid="CR43">43</xref>]. Despite these differences, sex-specific dosing recommendations are absent for most drugs [<xref ref-type="bibr" rid="CR37">37</xref>]. When women consistently experience less therapeutic effect or more adverse effects, a change in dosing regimen may be necessary.</p>
        <p id="Par18">Sex-related differences in PKs present a more significant challenge for medications with a low therapeutic index, i.e., those in which the lowest effective dose approaches toxic concentrations [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. If the therapeutic index is narrow, these differences are more likely to become clinically significant. A detailed study of sex differences for drugs with either steep dose response curves or narrow therapeutic indices is warranted [<xref ref-type="bibr" rid="CR46">46</xref>]. For drugs with a relatively wide therapeutic index, a fixed dosing regimen is less of an impediment, but even in these instances, selecting the lowest effective dose would be prudent in women, at a minimum to decrease the potential for ADRs, as women are more likely than men to be prescribed more than one drug at a time.</p>
        <p id="Par19">Population PK studies often rely on sparse blood sampling collected from many subjects in phase II and III clinical trials. PK information is included in only a small minority of approved drug labels [<xref ref-type="bibr" rid="CR10">10</xref>]; among &gt; 2500 compounds listed in the Physicians Desk Reference (PDR), only 88 (fewer than 4%) presented population PK information in labelling [<xref ref-type="bibr" rid="CR47">47</xref>]. PK sex difference data routinely are derived from small clinical pharmacology studies, typically enrolling 12&#x2013;24 healthy subjects. Studies with such relatively small sample sizes have lower statistical power: they may be adequate to detect only very large sex differences in PK attributes, but as effect sizes decrease, these under-powered experimental designs generate widespread type II statistical errors&#x2014;they become less and less capable of identifying real sex differences.</p>
      </sec>
      <sec id="Sec3">
        <title>Aims</title>
        <p id="Par20">Here we examine relations between sex differences in drug PKs and ADRs to critically evaluate the hypothesis that drug exposure (PKs) and bodily responses to drugs (PDs; more specifically, clinically unintended effects, or ADRs) should be considered in the development of rational, feasible sex-based dosing adjustments. We conclude that such considerations are presently missing and recommend that sex-based dosing recommendations be disseminated to physicians and appear on drug labels. In many cases, these changes can be implemented at little cost. As demonstrated below, the data required to implement these procedures already exist for a number of drugs but have been ignored.</p>
        <p id="Par21">To determine the extent to which sex as a biological variable has been incorporated in the development of therapeutic pharmaceuticals, we reviewed whether sex differences in PK data were identified for any given drug and, where present, if such differences were incorporated into recommendations for sex-aware dosing/prescribing. Additionally, we reviewed an extensive literature on sex-specific ADRs, to evaluate whether sex differences in PK data predict sex disparities in ADRs. The hypothesis tested was that sex differences in PKs, specifically higher drug exposure in women than men, would be associated with clinically significant sex differences in ADRs. Support for this hypothesis, based on the broad net cast in the present investigation, would support dose reductions in women for the drugs under investigation here, and perhaps warrant extrapolation to any drugs for which sex differences in PKs exist. Several recent comprehensive reviews have addressed sex differences in drug treatment targeting specific diseases [<xref ref-type="bibr" rid="CR48">48</xref>&#x2013;<xref ref-type="bibr" rid="CR53">53</xref>]. Here we report, for the first time, substantial sex differences in PKs and ADRs for 86 drugs, spanning multiple (&gt; 10) therapeutic categories that support dose adjustments for women.</p>
      </sec>
    </sec>
    <sec id="Sec4">
      <title>Methods</title>
      <sec id="Sec5">
        <title>Objective</title>
        <p id="Par22">To examine whether sex differences in PKs are related to sex differences in ADRs, we reviewed empirical studies that measured PKs in females and males treated with FDA-approved drugs and quantitative reports documenting ADRs in both sexes.</p>
      </sec>
      <sec id="Sec6">
        <title>Search strategy, analysis steps, and criteria for study inclusion</title>
        <p id="Par23">Multiple searches of the ISI Web of Science database (core collection, basic search; Thompson Scientific) were conducted throughout 2018&#x2013;19 with the terms: <italic>drugs</italic> and <italic>sex differences</italic> and <italic>pharmacokinetics</italic> (848 articles), <italic>drugs</italic> and <italic>gender</italic> and <italic>pharmacokinetics</italic> (1548 articles), <italic>drugs</italic> and <italic>sex differences</italic> and <italic>pharmacodynamics</italic> (385 articles), <italic>drug safety</italic> and <italic>dose</italic> and <italic>sex</italic> (651 article), <italic>drug safety</italic> and <italic>dose</italic> and <italic>gender</italic> (462 articles), <italic>adverse drug reactions</italic> and <italic>sex</italic> (912 articles), <italic>adverse drug reaction</italic> and <italic>gender</italic> (687 articles), which yielded 5493 articles, with considerable overlap. All years were included in the Web of Science and Pub Med searches. Only English language articles were accessed. For a publication to be included in the survey, it had to contain data on sex differences in pharmacokinetics and/or adverse drug responses. The Thompson Reuters Web of Science and the NCBI PubMed databases were searched with no date restrictions; the last search was completed in January 2020. The WHO&#x2019;s VigiBase database was searched with no date or geographic restrictions.</p>
      </sec>
      <sec id="Sec7">
        <title>Data extraction</title>
        <sec id="FPar1">
          <title>PK measures</title>
          <p id="Par24">Each article was examined for relevance with additional searches conducted in PubMed and Web of Science for specific drugs; relevant publications identified in target articles were also inspected. Many drugs do not have a sex bias in pharmacokinetics. In an unknown number of instances, this reflects a true absence of sex differences based on empirical findings. For many drugs, however, the available PK data are lacking because female subjects were either not included in study design, or data were not reported by sex. Only studies of drugs that have a sex bias in pharmacokinetics were considered. Risk bias was examined in all articles to determine whether both sexes were included, whether sample size was adequate, and if subjects enrolled were adults or children. Sample size was considered adequate if there were 10&#x2013;12 subjects/group. Several articles reporting statistically significant results with smaller sample sizes were reported but flagged with a disclaimer. From each relevant article, data on sex differences in PK measures was extracted; the majority of these measures were in units of either area under the curve [AUC] or peak/maximum concentration [C<sub>max</sub>]; less frequently, data were available for drug half-life [<italic>t</italic><sub>1/2</sub>], clearance/elimination measures conducted over fixed time intervals, systemic exposure, V<sub>d</sub>, and T<sub>max</sub>.</p>
        </sec>
        <sec id="FPar2">
          <title>ADR measures</title>
          <p id="Par25">ADRs were identified from every relevant article and recorded categorically as female-biased or male-biased. The EU database of ADR reports and the WHO&#x2019;s ADR monitoring website, also known as <italic>VigiBase</italic>, were searched. ADR data from this site are listed in instances where we were unable to find primary reports of ADRs for a specific drug. The ratio of women:men reporting ADRs was computed, and a value that deviated by more than 20% from 1.0 in either direction indicated that <italic>VigiBase</italic> reports were sex biased: values &gt; 1.2 and &lt; 0.80 indicated female and male sex biases, respectively. Values between 0.80&#x2013;1.20 (inclusive) were interpreted as indicating no sex bias in ADRs. As discussed above, a major limitation of <italic>VigiBase</italic> is that it does not account for differences in the frequency with which women and men are treated with a specific drug. To directly examine this limitation in the context of sex differences in ADRs, we separately compared the prevalence of clinical ADRs (from data in the literature) with sex-specific reporting rates in <italic>VigiBase</italic>.</p>
          <p id="Par26">Label information and PK and PD data, where available, were obtained from the <italic>Drugs@FDA</italic> database [<xref ref-type="bibr" rid="CR54">54</xref>]. Only data from human subjects were considered. Recreational drugs including alcohol, cocaine, nicotine, heroin, most psychedelics, and drugs involved in treatment of AIDS were beyond the scope of this review. For each drug, we report information published in peer-reviewed journals, from FDA NDA forms, and approved product labels. PK data are presented first, followed by ADRs.</p>
          <p id="Par27">Generally, sex differences refer to differences between women and men in the gonads, genitals, hormones, chromosome, and gene complements. Gender differences are more difficult to define and usually encompass gender roles and gender identity. With a few exceptions, we use the term sex differences to describe differences in pharmacokinetics, pharmacodynamics, and adverse drug reactions.</p>
        </sec>
      </sec>
      <sec id="Sec8">
        <title>Data reduction</title>
        <p id="Par28">Results are provided in the form of a descriptive analyses of whether studies with sex-specific patterns of PK bias predict sex-specific patterns of ADR bias. Only studies with clear sex differences in pharmacokinetics were included in the data synthesis. Chi-square analyses also evaluated whether PK biases predicted VigiBase data.</p>
        <p id="Par29">Among the 86 drugs that were identified as having sex-specific PK data, one compound, tirilazad (ATC code N07XX01), exhibited clear sex-biased PK values (greater exposure in men), but neither clinical ADRs nor sufficient entries in <italic>VigiBase</italic> existed; as a result, tirilizad is discussed below but not included in final tabular calculations. Another drug, theophylline (R03DA04), exhibited conflicting PK data (i.e., some PK measures indicated greater exposure in women whereas others indicated greater exposure in men), no experimentally identified ADRs, but clear sex-biased adverse responses in post marketing reports and is therefore included in both the discussion and tabular calculations below. Lastly, for 4 drugs (mirabegron, sertraline, aspirin, and clozapine), ADRs were not uniformly present in one sex. For mirabegron, a&#xA0;number of publications indicated a female bias in ADRs, and for aspirin and sertraline, the overall number of ADRs reported was greater for women; these drugs were classified as having female-biased ADRs. For clozapine, empirical reports and meta-analyses identified over a dozen sexually differentiated ADRs, but overall, more ADRs occurred in men than in women, so clozapine was classified as having a male-biased ADR profile.</p>
      </sec>
    </sec>
    <sec id="Sec9">
      <title>Results</title>
      <p id="Par30">Data for all drugs are contained in Additional file <xref rid="MOESM1" ref-type="media">1</xref> which lists sex-specific PKs for drugs from every individual report. Full information is included in this file narrative, along with measures of central tendency (mean, median) and variance (SD, SEM, range) from the original reports where available. These results are summarized in Tables <xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref>, and <xref rid="Tab3" ref-type="table">3</xref>, which list the specific PK measures for each drug, their direction of sex bias, whether ADRs were female- or male-biased, and whether PK findings and ADR data were sex-concordant or sex-discordant.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of sex-biased PK measures and concordance with clinical ADRs</p></caption><table frame="hsides" rules="groups"><thead><tr><th>WHO ATC category</th><th>Drug<sup>a</sup></th><th>PK measure<sup>b</sup></th><th>Female-biased ADRs</th><th>Male-biased ADRs</th><th>PK vs ADR</th></tr></thead><tbody><tr><td rowspan="3">Alimentary tract, metabolism</td><td>Liraglutide</td><td>CL<sub>T</sub></td><td>headache, vomiting, nausea</td><td>--</td><td>Concordant</td></tr><tr><td><bold>Ranitidine</bold></td><td><bold><italic>AUC</italic></bold><bold>, T</bold><sub><bold>max</bold></sub></td><td>--</td><td><bold>Duodenal damage</bold></td><td>Concordant</td></tr><tr><td>Rosiglitazone</td><td>CL<sub>T</sub></td><td>Fracture</td><td>--</td><td>Concordant</td></tr><tr><td rowspan="5">Blood and blood forming organs</td><td>Heparin</td><td>CL<sub>T</sub></td><td>blood disorders, lymphatic disorders, bleeding (60 yoa)</td><td>--</td><td>Concordant</td></tr><tr><td>Aspirin</td><td><italic>AUC</italic>, Cl<sub>T</sub>, t<sub>1/2</sub></td><td>elevated fibrinogen, CVD in T2D</td><td><bold>Bleeding</bold></td><td>Concordant</td></tr><tr><td>Warfarin</td><td>CL<sub>T</sub></td><td>Bleeding</td><td>--</td><td>Concordant</td></tr><tr><td>Clopidogrel</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>fracture, bleeding, GI symptoms, IBD</td><td>--</td><td>Concordant</td></tr><tr><td>Dabigatran</td><td><italic>AUC</italic></td><td>Bleeding</td><td>--</td><td>Concordant</td></tr><tr><td rowspan="7">Cardiovascular system</td><td>Torasemide</td><td><italic>AUC</italic>, C<sub>max</sub>, Cl<sub>T</sub>,t<sub>1/2</sub></td><td>Hospitalization</td><td>--</td><td>Concordant</td></tr><tr><td>Pravastatin</td><td>AUC, C<sub>max</sub></td><td>CHD</td><td>--</td><td>Concordant</td></tr><tr><td><bold>Amlodipine</bold></td><td><bold>CL</bold><sub><bold>T</bold></sub></td><td>Edema, flushing, palpitations</td><td>--</td><td>Discordant</td></tr><tr><td>Digoxin</td><td>CL<sub>T</sub></td><td>Mortality</td><td>--</td><td>Concordant</td></tr><tr><td>Verapamil</td><td>CL<sub>T</sub></td><td>Constipation, edema, fatigue, headache</td><td>--</td><td>Concordant</td></tr><tr><td>Aliskiren</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>Diarrhea</td><td>--</td><td>Concordant</td></tr><tr><td>Losartan</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>--</td><td><bold>Angina, mortality</bold></td><td>Discordant</td></tr><tr><td rowspan="2"/><td>Propranolol</td><td><italic>AUC,</italic> C<sub>max</sub>, Cl<sub>T</sub></td><td>dizziness muscle pain headache dry mouth</td><td>--</td><td>Concordant</td></tr><tr><td>Dofetilide</td><td>SysExp</td><td>TdP</td><td>--</td><td>Concordant</td></tr><tr><td rowspan="3">Genito-urinary system, sex hormones</td><td>Mirabegron</td><td><italic>AUC</italic>, C<sub>max</sub>, SysExp</td><td>Treatment discontinuation (CAN), treatment discontinuation (CZE)</td><td><bold>Treatment discontinuation (UK)</bold></td><td>Concordant</td></tr><tr><td>Darifenacin</td><td><italic>AUC</italic>, C<sub>max</sub>, Cl<sub>T</sub></td><td>F &gt; M, ADRs not specified</td><td>--</td><td>Concordant</td></tr><tr><td>Trospium</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>Cognitive impairments</td><td>--</td><td>Concordant</td></tr><tr><td>Systemic hormonal preparations</td><td>Prednisone</td><td><italic>AUC,</italic> Cl<sub>T</sub></td><td>Depression, fatigue, hair loss, mood swings, weight gain</td><td>--</td><td>Concordant</td></tr><tr><td rowspan="3">Anti-infectives</td><td>Levofloxacin</td><td>Cl<sub>T</sub>, SysExp</td><td>Fluoroquinolone toxicity</td><td>--</td><td>Concordant</td></tr><tr><td><bold>Erythromycin</bold></td><td><bold>CL</bold><sub><bold>T</bold></sub></td><td>TdP</td><td>--</td><td>Discordant</td></tr><tr><td>Voriconazole</td><td><italic>AUC,</italic> C<sub>max</sub></td><td>cardiac QTc symptoms</td><td>--</td><td>Concordant</td></tr><tr><td rowspan="6">Antineoplastics, immunomodulators</td><td><bold>Cyclosporin</bold></td><td><bold>CL</bold><sub><bold>T</bold></sub></td><td>--</td><td>--</td><td>Discordant*</td></tr><tr><td>Fluorouracil</td><td><italic>AUC</italic>, Cl<sub>T</sub></td><td>Stomatitis, leukopenia, alopecia, diarrhea, mucositis</td><td>--</td><td>Concordant</td></tr><tr><td>Paclitaxel</td><td>CL<sub>T</sub></td><td>Myocardial infarction, death, lesion revascularization</td><td>--</td><td>Concordant</td></tr><tr><td>Capecitabine</td><td><italic>AUC</italic></td><td>Dose-limiting toxicity</td><td>--</td><td>Concordant</td></tr><tr><td>Infliximab</td><td>CL<sub>T</sub></td><td>Allergic reactions</td><td>--</td><td>Concordant</td></tr><tr><td>Adalimumab</td><td>CL<sub>T</sub></td><td>Allergic reactions</td><td>--</td><td>Concordant</td></tr><tr><td rowspan="6">Anesthetics, analgesics</td><td>Morphine</td><td>CL<sub>T</sub></td><td>Respiratory depression, hypoxic sensitivity, emesis, nausea</td><td>--</td><td>Concordant</td></tr><tr><td>Oxycodone</td><td>CL<sub>T</sub></td><td>Nausea, pruritus, negative affect</td><td>--</td><td>Concordant</td></tr><tr><td>Buprenorphine</td><td><italic>AUC,</italic> C<sub>max</sub></td><td>Sleep disturbance</td><td>--</td><td>Concordant</td></tr><tr><td>Tramadol</td><td><italic>AUC,</italic> C<sub>max</sub></td><td>Treatment discontinuation</td><td>--</td><td>Concordant</td></tr><tr><td>Zolmitriptan</td><td><italic>AUC,</italic> C<sub>max</sub></td><td>Face and neck presure</td><td>--</td><td>Concordant</td></tr><tr><td><bold>Ketamine</bold></td><td><bold>Cl</bold><sub><bold>T</bold></sub></td><td>--</td><td><bold>Verbal learning, subjective memory</bold></td><td>Concordant</td></tr><tr><td rowspan="4">Anti-epileptics, anti-Parkinson&#x2019;s</td><td><bold>Carbamazepine</bold></td><td><bold>Cl</bold><sub><bold>T</bold></sub><bold>, t</bold><sub><bold>1/2</bold></sub></td><td>Cognitive impairment, elevated LDL/HDL</td><td>--</td><td>Discordant</td></tr><tr><td>Gabapentin</td><td>C<sub>max</sub></td><td>Dizziness, somnolescence, nausea</td><td>--</td><td>Concordant</td></tr><tr><td>Perampanel</td><td><italic>AUC</italic>, Cl<sub>T</sub></td><td>Dizziness, headache, treatment discontinuation</td><td>--</td><td>Concordant</td></tr><tr><td>Pramipexole</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>Nausea, fatigue</td><td>--</td><td>Concordant</td></tr><tr><td rowspan="7">Psycholeptics</td><td>Olanzapine</td><td>CL<sub>T</sub></td><td>Severe weight gain</td><td/><td>Concordant</td></tr><tr><td>Clozapine</td><td>CL<sub>T</sub></td><td>Blood glucose, laxative use, obesity, type II diabetes, neutropenia, leukopenia, weight gain</td><td><bold>Hypertension, increases in BMI, elevated homocysteine, increased basal metabolic rate, increased plasma lipids, QTc symptoms, blood dyscrasias, myocarditis, cardiomyopathy</bold></td><td>Discordant</td></tr><tr><td>Risperidone</td><td>CL<sub>T</sub></td><td>Hyperprolactinemia, neurological effects, headache, hypotension</td><td>--</td><td>Concordant</td></tr><tr><td>Aripiprazol</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>Blood pressure, heart rate, elongated QTc</td><td>--</td><td>Concordant</td></tr><tr><td>Diazepam</td><td>t<sub>1/2</sub></td><td>Psychomotor impairment</td><td>--</td><td>Concordant</td></tr><tr><td>Zolpidem</td><td><italic>AUC</italic>, C<sub>max</sub>, Cl<sub>T</sub></td><td>Cognitive impairment, driving impairment</td><td>--</td><td>Concordant</td></tr><tr><td>Eszopiclone</td><td><italic>AUC</italic></td><td>Dysgeusia</td><td>--</td><td>Concordant</td></tr><tr><td rowspan="7">Psychoanaleptics</td><td>Imipramine</td><td>CL<sub>T</sub></td><td>Dry mouth, constipation, sweating, tremor, treatment discontinuation</td><td>--</td><td>Concordant</td></tr><tr><td>Nortriptyline</td><td>CL<sub>T</sub></td><td>Dry mouth</td><td>--</td><td>Concordant</td></tr><tr><td>Fluoxetine</td><td>CL<sub>T</sub></td><td>Hypercortisolemia, elevated albumin, elevated tryptophan, suicidal ideation</td><td>--</td><td>Concordant</td></tr><tr><td>Citalopram</td><td>CL<sub>T</sub></td><td>Elevated ADH</td><td>--</td><td>Concordant</td></tr><tr><td>Sertraline</td><td><italic>AUC</italic>, Cl<sub>T</sub>, t<sub>1/2</sub></td><td>Cholesterol, nausea, dizziness, delusions</td><td><bold>Dyspepsia, sexual dysfunction, urinary frequency</bold></td><td>Concordant</td></tr><tr><td>Bupropion</td><td><italic>AUC</italic>, C<sub>max</sub>, t<sub>1/2</sub></td><td>EEG abnormalities, seizure</td><td>--</td><td>Concordant</td></tr><tr><td><bold>Methylphenidate</bold></td><td><bold><italic>AUC</italic></bold></td><td>Anxiety disorder</td><td>--</td><td>Discordant</td></tr><tr><td>Antiparasitics</td><td>Primaquine</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>Nausea</td><td>--</td><td>Concordant</td></tr><tr><td rowspan="2">Respiratory</td><td>Terfenadine</td><td>C<sub>max</sub></td><td>TdP</td><td>--</td><td>Concordant</td></tr><tr><td>Fexofenadine</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>Visual attention deficits, reaction time deficits, driving impairments</td><td>--</td><td>Concordant</td></tr><tr><td>Miscellaneous</td><td>MDMA</td><td>CL<sub>T</sub></td><td>Elevated copeptin, hyponatremia</td><td>--</td><td>Concordant</td></tr><tr><td/><td>Cannabis</td><td>CL<sub>T</sub></td><td>Increased subjective emotional responses, problematic useintrovertive anhedonia</td><td>--</td><td>Concordant</td></tr></tbody></table><table-wrap-foot><p>PK abbreviations: <italic>AUC</italic> area under the curve, <italic>C</italic><sub><italic>max</italic></sub> maximum circulating concentration<italic>, T</italic><sub><italic>max</italic></sub> time required to reach C<sub>max</sub> value, <italic>t</italic><sub><italic>1/2</italic></sub> elimination half-life, <italic>Cl</italic><sub><italic>T</italic></sub> clearance time, exposure, or plasma concentration after a fixed time interval, <italic>SysExp</italic> systemic exposure</p><p>*No evidence of sex differences in ADRs</p><p><sup>a</sup>Font style of drug name indicates direction of PK drug exposure bias: (normal font: F &gt; M; <bold>bold font</bold>: M &gt; F)</p><p><sup>b</sup>Font style of PK measure indicates direction of greater drug exposure (normal: F &gt; M; <bold>bold</bold>: M &gt; F)</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Concordance between sex-biased PKs and VigiBase sex ratios</p></caption><table frame="hsides" rules="groups"><thead><tr><th>WHO ATC category</th><th>Drug name/PK bias<sup>a</sup></th><th>PK measure<sup>b</sup></th><th>VB ratio<sup>c</sup></th><th>Concordance</th></tr></thead><tbody><tr><td>Alimentary tract, metabolism</td><td>Ondansetron</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>2.14</td><td>Concordant</td></tr><tr><td>Blood and blood forming organs</td><td>Icatibant</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>3.18</td><td>Concordant</td></tr><tr><td rowspan="4">Cardiovascular system</td><td>Metoprolol</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>1.26</td><td>Concordant</td></tr><tr><td>Labetalol</td><td>C<sub>max</sub>, Cl<sub>T</sub></td><td>1.50</td><td>Concordant</td></tr><tr><td><bold>Nifedipine</bold></td><td><bold>Cl</bold><sub><bold>T</bold></sub></td><td>1.29</td><td>Discordant<sup>1</sup></td></tr><tr><td>Pitavastatin</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>1.12</td><td>Discordant<sup>2</sup></td></tr><tr><td>Systemic hormonal preparations</td><td><bold>Methylprednisolone</bold></td><td><bold><italic>AUC</italic></bold><bold>, t</bold><sub><bold>1/2</bold></sub><bold>, Cl</bold><sub><bold>T</bold></sub></td><td>1.38</td><td>Discordant<sup>1</sup></td></tr><tr><td>Musculoskeletal</td><td><bold>Ibuprofen</bold></td><td><bold><italic>AUC,</italic></bold><bold>C</bold><sub><bold>max</bold></sub><bold>, t</bold><sub><bold>1/2</bold></sub><bold>, Cl</bold><sub><bold>T</bold></sub></td><td>1.46</td><td>Discordant<sup>1</sup></td></tr><tr><td rowspan="4">Anesthetics, analgesics</td><td>Lignocaine</td><td>Cl<sub>T</sub></td><td>1.64</td><td>Condordant</td></tr><tr><td>Propofol</td><td><italic>AUC,</italic><bold>Cl</bold><sub><bold>T</bold></sub></td><td>1.45</td><td>Concordant</td></tr><tr><td>Butorphanol</td><td><italic>AUC,</italic> C<sub>max</sub></td><td>3.23</td><td>Concordant</td></tr><tr><td>Paracetamol</td><td>Cl<sub>T</sub></td><td>1.68</td><td>Concordant</td></tr><tr><td>Anti-epileptics</td><td>Ezogabine</td><td><italic>AUC,</italic> C<sub>max</sub>, <italic>Cl</italic><sub><italic>T</italic></sub></td><td>0.90</td><td>Discordant<sup>2</sup></td></tr><tr><td rowspan="6">Psycholeptics</td><td>Clobazam</td><td>t<sub>1/2</sub></td><td>1.11</td><td>Discordant<sup>2</sup></td></tr><tr><td>Sertindole</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>1.06</td><td>Discordant<sup>2</sup></td></tr><tr><td>Thiothixene</td><td>Cl<sub>T</sub></td><td>1.35</td><td>Concordant</td></tr><tr><td>Oxazepam</td><td>Cl<sub>T</sub></td><td>1.31</td><td>Concordant</td></tr><tr><td>Temazepam</td><td>t<sub>1/2</sub>, Cl<sub>T</sub></td><td>1.34</td><td>Concordant</td></tr><tr><td>Zopiclone</td><td><italic>AUC</italic>, C<sub>max</sub></td><td>1.55</td><td>Concordant</td></tr><tr><td rowspan="6">Psychoanaleptics</td><td>Memantine</td><td>SysExp</td><td>1.50</td><td>Condordant</td></tr><tr><td>Desipramine</td><td><italic>AUC</italic>, Cl<sub>T</sub></td><td>1.59</td><td>Concordant</td></tr><tr><td>Clomipramine</td><td>Cl<sub>T</sub></td><td>1.57</td><td>Concordant</td></tr><tr><td>Paroxetine</td><td>Cl<sub>T</sub></td><td>2.00</td><td>Concordant</td></tr><tr><td>Fluvoxamine</td><td>Cl<sub>T</sub></td><td>1.73</td><td>Concordant</td></tr><tr><td>Mirtazapine</td><td>Cl<sub>T</sub></td><td>1.53</td><td>Concordant</td></tr><tr><td>Respiratory</td><td>Cetirizine</td><td>Cl<sub>T</sub></td><td>1.76</td><td>Concordant</td></tr></tbody></table><table-wrap-foot><p>PK abbreviations: <italic>AUC</italic> area under the curve, <italic>Cmax</italic> maximum circulating concentration, <italic>Tmax</italic> time required to reach Cmax value, <italic>t1/2</italic> elimination half-life, <italic>ClT</italic> clearance time, exposure, or plasma concentration after a fixed time interval, <italic>SysExp</italic> systemic exposure, <italic>DurAbs</italic> duration of absorption</p><p><sup>a</sup>Font style of drug name indicates direction of PK drug exposure bias: (normal: F &gt; M; <bold>bold</bold>: M &gt; F)</p><p><sup>b</sup>Font style of PK measure indicates direction of greater PK drug exposure: (normal: F &gt; M; <bold>bold</bold>: M &gt; F; <italic>italic</italic>: inconsistent)</p><p><sup>c</sup>F-to-M reporting ratio of suspected ADRs. Threshold for designation of sex bias = &#xB1; 20%</p><p><sup>1</sup>False positive</p><p><sup>2</sup>False negative</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Sex ratios of adverse drug event reports in <italic>VigiBase</italic> among 59 drugs with sex-biased ADRs</p></caption><table frame="hsides" rules="groups"><thead><tr><th>WHO ATC category</th><th>Drug name/PK bias<sup><bold>a</bold></sup></th><th>ADR bias</th><th>VB ratio<sup><bold>b</bold></sup></th><th>ADR-VB relation</th></tr></thead><tbody><tr><td rowspan="3">Alimentary tract, metabolism</td><td>Liraglutide</td><td>Females</td><td>1.79</td><td>Concordant</td></tr><tr><td><bold>Ranitidine</bold></td><td>Males</td><td>1.52</td><td>Discordant<sup>1</sup></td></tr><tr><td>Rosiglitazone</td><td>Females</td><td>0.79</td><td>Discordant<sup>1</sup></td></tr><tr><td rowspan="5">Blood and blood forming organ</td><td>Heparin</td><td>Females</td><td>0.92</td><td>Discordant<sup>2</sup></td></tr><tr><td>Aspirin</td><td>Females</td><td>0.85</td><td>Discordant<sup>2</sup></td></tr><tr><td>Warfarin</td><td>Females</td><td>0.91</td><td>Discordant<sup>2</sup></td></tr><tr><td>Clopidogrel</td><td>Females</td><td>0.69</td><td>Discordant<sup>2</sup></td></tr><tr><td>Dabigatran</td><td>Females</td><td>0.93</td><td>Discordant<sup>2</sup></td></tr><tr><td rowspan="9">Cardiovascular system</td><td>Torasemide</td><td>Females</td><td>1.15</td><td>Discordant<sup>2</sup></td></tr><tr><td>Pravastatin</td><td>Females</td><td>1.13</td><td>Discordant<sup>2</sup></td></tr><tr><td><bold>Amlodipine</bold></td><td>Females</td><td>1.41</td><td>Concordant</td></tr><tr><td>Digoxin</td><td>Females</td><td>1.26</td><td>Concordant</td></tr><tr><td>Verapimil</td><td>Females</td><td>1.56</td><td>Concordant</td></tr><tr><td>Aliskiren</td><td>Females</td><td>1.27</td><td>Concordant</td></tr><tr><td>Losartan</td><td>Males</td><td>1.41</td><td>Discordant<sup>1</sup></td></tr><tr><td>Propranolol</td><td>Females</td><td>1.72</td><td>Concordant</td></tr><tr><td>Dofetilide</td><td>Females</td><td>0.92</td><td>Discordant<sup>2</sup></td></tr><tr><td rowspan="3">Genito-urinary system, sex hormones</td><td>Mirabegron</td><td>Females</td><td>1.95</td><td>Concordant</td></tr><tr><td>Darifenacin</td><td>Females</td><td>2.48</td><td>Concordant</td></tr><tr><td>Trospium</td><td>Females</td><td>2.14</td><td>Concordant</td></tr><tr><td>Systemic hormonal preparations</td><td>Prednisone</td><td>Females</td><td>1.17</td><td>Discordant<sup>2</sup></td></tr><tr><td rowspan="3">Anti-infectives</td><td>Levofloxacin</td><td>Females</td><td>1.26</td><td>Concordant</td></tr><tr><td><bold>Erythromycin</bold></td><td>Females</td><td>1.70</td><td>Concordant</td></tr><tr><td>Voriconazole</td><td>Females</td><td>0.65</td><td>Discordant<sup>1</sup></td></tr><tr><td rowspan="6">Antineoplastics, immunomodulators</td><td><bold>Cyclosporin</bold></td><td>Neither</td><td>1.25</td><td>Discordant<sup>1</sup></td></tr><tr><td>Fluorouracil</td><td>Females</td><td>1.00</td><td>Discordant<sup>2</sup></td></tr><tr><td>Paclitaxel</td><td>Females</td><td>2.66</td><td>Concordant</td></tr><tr><td>Capecitabine</td><td>Females</td><td>1.77</td><td>Concordant</td></tr><tr><td>Infliximab</td><td>Females</td><td>1.51</td><td>Concordant</td></tr><tr><td>Adalimumab</td><td>Females</td><td>2.02</td><td>Concordant</td></tr><tr><td rowspan="6">Anesthetics, analgesics</td><td>Morphine</td><td>Females</td><td>1.57</td><td>Concordant</td></tr><tr><td>Oxycodone</td><td>Females</td><td>1.01</td><td>Discordant<sup>2</sup></td></tr><tr><td>Buprenorphine</td><td>Females</td><td>1.61</td><td>Concordant</td></tr><tr><td>Tramadol</td><td>Females</td><td>1.71</td><td>Concordant</td></tr><tr><td>Zolmitriptan</td><td>Females</td><td>5.14</td><td>Concordant</td></tr><tr><td><bold>Ketamine</bold></td><td>Males</td><td>1.07</td><td>Discordant<sup>2</sup></td></tr><tr><td rowspan="4">Anti-epileptics, anti-Parkinson&#x2019;s</td><td><bold>Carbamazepine</bold></td><td>Females</td><td>1.26</td><td>Concordant</td></tr><tr><td>Gabapentin</td><td>Females</td><td>1.84</td><td>Concordant</td></tr><tr><td>Perampanel</td><td>Females</td><td>1.18</td><td>Discordant<sup>2</sup></td></tr><tr><td>Pramipexole</td><td>females</td><td>1.19</td><td>Discordant<sup>2</sup></td></tr><tr><td rowspan="7">Psycholeptics</td><td>Olanzapine</td><td>Females</td><td>0.92</td><td>Discordant<sup>2</sup></td></tr><tr><td>Clozapine</td><td>Males</td><td>0.61</td><td>Concordant</td></tr><tr><td>Risperidone</td><td>Females</td><td>0.53</td><td>Discordant<sup>1</sup></td></tr><tr><td>Aripiprazol</td><td>Females</td><td>1.27</td><td>Concordant</td></tr><tr><td>Diazepam</td><td>Females</td><td>1.17</td><td>Discordant<sup>2</sup></td></tr><tr><td>Zolpidem</td><td>Females</td><td>1.48</td><td>Concordant</td></tr><tr><td>Eszopiclone</td><td>Females</td><td>1.85</td><td>Concordant</td></tr><tr><td rowspan="7">Psychoanaleptics</td><td>Imipramine</td><td>Females</td><td>1.61</td><td>Concordant</td></tr><tr><td>Nortriptyline</td><td>Females</td><td>2.10</td><td>Concordant</td></tr><tr><td>Fluoxetine</td><td>Females</td><td>2.29</td><td>Concordant</td></tr><tr><td>Citalopram</td><td>Females</td><td>1.95</td><td>Concordant</td></tr><tr><td>Sertraline</td><td>Females</td><td>2.00</td><td>Concordant</td></tr><tr><td>Bupropion</td><td>Females</td><td>1.79</td><td>Concordant</td></tr><tr><td><bold>Methylphenidate</bold></td><td>Females</td><td>0.47</td><td>Discordant<sup>1</sup></td></tr><tr><td>Antiparasitics</td><td>Primaquine</td><td>Females</td><td>0.55</td><td>Discordant<sup>1</sup></td></tr><tr><td rowspan="2">Respiratory</td><td>Terfenadine</td><td>Females</td><td>1.66</td><td>Concordant</td></tr><tr><td>Fexofenadine</td><td>Females</td><td>2.05</td><td>Concordant</td></tr><tr><td rowspan="2">Miscellaneous</td><td>MDMA</td><td>females</td><td>0.43</td><td>Discordant<sup>1</sup></td></tr><tr><td>Cannabis</td><td>females</td><td>0.51</td><td>Discordant<sup>1</sup></td></tr></tbody></table><table-wrap-foot><p>Threshold for designation of a <italic>VigiBase</italic> reporting sex bias was set at &#xB1; 20%</p><p><sup>a</sup>Font style of drug name indicates direction of PK drug exposure bias: (normal: F &gt; M; <bold>bold</bold>: M &gt; F)</p><p><sup>b</sup>Female-to-male (F:M) ratio of suspected ADRs</p><p><sup>1</sup>&#x201C;false sex&#x201D; error</p><p><sup>2</sup>&#x201C;false null&#x201D; error</p></table-wrap-foot></table-wrap></p>
      <p id="Par31">We identified 86 drugs with significant sex differences in PKs, based on C<sub>max</sub> and AUC values or drug distribution and elimination rates. Many drugs with striking sex differences in ADRs did not make it onto this list because there were no available PK data, almost always because drugs were approved prior to the year 2000, and thus the relevant information is not available in the online FDA database.</p>
      <p id="Par32">The correspondence of sex differences in PKs with sex differences in ADRs was striking. In 88% of instances, a sex difference in PKs was linked to a similar sex difference in ADRs (52 of 59 drugs were PK-ADR &#x201C;concordant,&#x201D; summarized in Table <xref rid="Tab1" ref-type="table">1</xref>), a substantially higher incidence than the 46% sex difference in ADRs across all drugs assessed without regard to PK differences [<xref ref-type="bibr" rid="CR17">17</xref>]; thus, including PK data in the consideration of ADRs, and stratifying analyses of drugs both by the presence, and by the direction, of PK differences greatly clarifies patterns of sex differences in ADRs. Overall, 76 of 86 drugs (88%) had higher PK values in women than men (Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>), and among the 59 drugs for which ADR data were available. Of course, it remains possible that sex differences in PK parallel sex differences in ADRs independently. Ninety-six percent with higher PK values in women also induced a higher incidence of ADRs in women. For 7 drugs, male PK values exceeded those of females, but this sex difference positively predicted male-biased ADRs in only 2 of 7 instances (29%;&#xA0;4 exhibited female-biased ADRs and 1 no bias; Table <xref rid="Tab2" ref-type="table">2</xref>). In the absence of any obvious reason to suspect that our sample is not representative of the more than thousands of drugs approved for human use by the FDA (US-FDA, 2019), the present data suggest that elevated drug concentrations and decreased elimination times are far more prevalent in women than men and present a quantifiable and major health risk for women.</p>
      <sec id="Sec10">
        <title>Comparison of VigiBase adverse event reporting with empirical clinical data</title>
        <p id="Par33">For 27 of the 86 drugs surveyed, <italic>VigiBase</italic> was the only source available for data on sex differences in ADRs (Table <xref rid="Tab2" ref-type="table">2</xref>). Similar to the drugs summarized in Table <xref rid="Tab1" ref-type="table">1</xref>, 24 of these 27 drugs (89%) exhibited female-biased PK values (Table <xref rid="Tab1" ref-type="table">1</xref>, 52/59; Table <xref rid="Tab2" ref-type="table">2</xref>, 24/27; &#x3C7;<sup>2</sup> = 0.01, <italic>P</italic> &gt; 0.9), among these drugs, sex-biased PKs predicted sex-biased VigiBase ADR reporting ratios (hereafter, &#x201C;VB ratios&#x201D;) in 74% of instances (20 of 27 drugs were PK&#x2013;VB ratio &#x201C;concordant,&#x201D; Table <xref rid="Tab2" ref-type="table">2</xref>). To examine how closely estimates of sex differences in ADRs inferred from VB ratios corresponded to actual sex differences in ADRs gathered from the empirical clinical literature, we calculated VB ratios for the 59 compounds in Table <xref rid="Tab1" ref-type="table">1</xref>, i.e., drugs for which actual ADR information was available. This analysis indicates that sex-biased patterns of case reports in the <italic>VigiBase</italic> pharmacovigilance database correctly predict actual sex differences in ADRs in only 33 of 59 cases (56% of drugs were ADR&#x2013;VB ratio &#x201C;concordant,&#x201D; Table <xref rid="Tab3" ref-type="table">3</xref>); concordance between ADR bias and VB ratios did not differ between drugs that had male- vs. female-biased PK values: 3 of 7 drugs (43%) with male-biased PKs were ADR&#x2013;VB ratio concordant, 30 of 52 drugs (58%) with female-biased PKs were ADR&#x2013;VB ratio concordant; &#x3C7;<sup>2</sup> = 0.55, <italic>P</italic> &gt; 0.4. <italic>VigiBase</italic> indicated no sex bias in adverse event reporting (VB ratios between 0.80 and 1.20, as defined above, a &#x201C;false null&#x201D; error) for 15 of 26 (58%) ADR&#x2013;VB ratio discordant drugs, and a sex-biased VB ratio in a direction opposite to that of the actual ADR bias (e.g., a male-biased VB ratio, when real ADRs are female biased, a &#x201C;false sex&#x201D; error) in 11 of 26 (42%) discordant drugs (Table <xref rid="Tab3" ref-type="table">3</xref>). Pharmacovigilance databases are useful as broad indicators, but the present analysis underscores the limitations inherent in <italic>VigiBase</italic> ADRs.</p>
      </sec>
    </sec>
    <sec id="Sec11">
      <title>Discussion</title>
      <sec id="Sec12">
        <title>PK values predict ADRs but only in women</title>
        <p id="Par34">The present results reveal a striking sex difference in pharmacokinetics: among patients administered a standard drug dose, females are exposed to higher blood drug concentrations and longer drug elimination times than males. This likely contributes to the near doubling of adverse drug reactions in female patients, raising the possibility that women are routinely overmedicated. Whether this relation also holds for the thousands of drugs for which sex-stratified PK data are not publicly available remains to be investigated, but an affirmative answer would be consistent with&#xA0;our analysis. The present results also support the argument that for drugs with a sufficiently broad therapeutic index, dose reductions in women would yield a reduction in side effects.</p>
        <p id="Par35">A number of reports have identified links between sex-specific patterns of PK values, PDs, and ADRs [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR55">55</xref>], but to our knowledge, the present analysis is the first to document that sex differences in PKs positively predict sex differences in ADRs broadly across multiple categories of FDA-approved pharmaceuticals. These data indicate that if a significant, female-biased PK sex difference is identified, then there is an overwhelmingly high probability that a clinically identifiable female-biased ADR will co-occur. Although it remains to be definitively established that women routinely are overmedicated, the present data are consistent with this conjecture for the drugs reviewed here, as well as for the thousands of drugs administered in equivalent doses to women and men. The intended efficacy of drugs in relation to sex remains in need of intensive investigation.</p>
      </sec>
      <sec id="Sec13">
        <title>Limitations</title>
        <p id="Par36">Among the 27 drugs for which VB ratios were the only format of adverse event data, sex-biased PKs predicted sex-biased <italic>VigiBase</italic> ADR reporting ratios in 74% of instances (20 of 27 drugs were PK&#x2013;VB ratio &#x201C;concordant,&#x201D; Table <xref rid="Tab2" ref-type="table">2</xref>). In all but a few instances, <italic>VigiBase</italic> contained thousands of ADR reports, but as noted above, the number of men and women treated with each drug was not specified, nor are the links between the drug and specific ADRs known. It remains likely that some ADR sex differences in the <italic>VigiBase</italic> reflect unequal numbers of women and men treated with a given drug.</p>
        <p id="Par37">To definitively establish a cause effect relation between higher blood drug concentrations and ADRs requires concurrent measurement of PKs&#xA0;and ADRs in the same subjects. This has been accomplished infrequently (but see [<xref ref-type="bibr" rid="CR56">56</xref>]).</p>
        <p id="Par38">Some have argued that what we ascribe to sex differences in the genesis of ADRs is causally related to differences in body weight. In reference to the sex difference in ADRs among patients taking zolpidem, Richardson et al. [<xref ref-type="bibr" rid="CR57">57</xref>] stated &#x201C;body weight, not sex, is the culprit.&#x201D; They contend that body weight eliminates the statistical significance of sex as a variable in clearance of zolpidem, referencing a study by Greenblatt et al. [<xref ref-type="bibr" rid="CR58">58</xref>]. However, the cited paper makes no such claim, instead stating that &#x201C;AUC averaged 40% to 50% higher in females than in males receiving the same dose, and the sex effect was incompletely explained by body weight&#x201D;. In a more recent review, Greenblatt et al. [<xref ref-type="bibr" rid="CR59">59</xref>] note that women had on average 35% lower apparent clearance of zolpidem than men and that this difference was not explained by body weight. They conclude instead that the pharmacodynamic effects of zolpidem are greater in women due to a combination of higher plasma concentrations and greater intrinsic sensitivity [<xref ref-type="bibr" rid="CR58">58</xref>]. The present analysis indicates that many sex differences in ADRs persist after corrections for body weight are made.</p>
        <p id="Par39">Lastly, while we appreciate the difficulties in conducting clinical research, the standards of evidence encountered in many reports cited herein were disappointing, especially so in the clinical trials submitted to, and approved by, the FDA: reports of no statistical differences between the sexes were routinely not supported by <italic>F</italic> statistics or <italic>p</italic> values, and were further complicated by small sample sizes and inflated type II error. Estimates of treatment effect size were also largely absent.</p>
        <sec id="Sec14">
          <title>Recommendations</title>
          <sec id="FPar3">
            <title>Recommendation #1</title>
            <p id="Par40">For all drugs currently in use, the FDA should post, on their website, PK data that were submitted as part of the drug approval process (i.e., NDAs) and associated peer reviewed publications. Generally, this information is unavailable for drugs approved prior to 2000. Once this information becomes accessible, scores if not hundreds of drugs with substantial PK sex differences will be revealed, which can facilitate corrective measures that will reduce female ADRs.</p>
          </sec>
          <sec id="FPar4">
            <title>Recommendation #2</title>
            <p id="Par41">Credible evidence of sex differences in PKs should be made available in drug labels. In popular websites directed at the public either by drug companies, or by sites such as <italic>WebMD</italic>, the list of adverse effects should include known sex differences.</p>
          </sec>
          <sec id="FPar5">
            <title>Recommendation #3</title>
            <p id="Par42">Almost all ADRs emerge from post-marketing reports, sometimes years after a drug appears on the market. The high correlation between elevated PKs in women and increased ADRs suggests that for drugs with higher female PKs, the initial dose should be lower for women than men and increased only if the lower dose fails to achieve the desired therapeutic effect. We anticipate this would eliminate or ameliorate many sex differences in adverse drug reactions. For orally administered drugs, pill splitting can begin to approximate a correction to the current practice where &#x201C;one dose fits all.&#x201D; Wherever feasible, drugs should be administered on a body weight adjusted basis (mg/kg) for men as well as women.</p>
          </sec>
          <sec id="FPar6">
            <title>Recommendation #4</title>
            <p id="Par43">The FDA should require all empirical NDA data to be accompanied by documentation of statistical analyses which should meet requirements for publication in a peer-reviewed journal. Experiments reported in NDAs are less likely to be subjected to replication attempts by the scientific community, and therefore methodological or interpretive errors are less likely to be rapidly corrected by the iterative scientific process. Standards of evidence should be accordingly maintained high. At a minimum, this should include mandatory reporting of information on: a priori power analyses, measures of central tendency, variance, treatment of outlier data, statistical tests used to support statements regarding drug effects and lack thereof, specific <italic>P</italic> values, corrections deployed to control type I and type II error, and post hoc estimates of treatment effect magnitude. Such information is essential if clinicians are to develop informed decisions regarding sex differences in drug effects.</p>
          </sec>
          <sec id="FPar7">
            <title>Recommendation #5</title>
            <p id="Par44">An appropriate understanding of the clinical relevance of sex-differences in drug treatment should be part of the board certification process for healthcare providers and reinforced in continuing medical education courses.</p>
          </sec>
          <sec id="FPar8">
            <title>Recommendation #6</title>
            <p id="Par45">Establishing sex parity in the drug approval process should be explicitly identified as a long-term goal of the Department of Health and Human Services. The decades-long pattern of neglect of female animals in preclinical research and underrepresentation of women in clinical trials and research must be corrected, and the recent NIH oversight and vigilance must be maintained.</p>
          </sec>
          <sec id="FPar9">
            <title>Recommendation #7</title>
            <p id="Par46">Pharmaceutical companies should pay more attention, beginning in the early drug development phases to sex-appropriate dosing [<xref ref-type="bibr" rid="CR60">60</xref>]. Drug development commonly begins with pre-clinical modelling, in vitro experiments, and in vivo studies in mouse models. Recent analyses indicate that the overwhelming majority of basic research in mammalian physiology and pharmacology is based on work in male animals [<xref ref-type="bibr" rid="CR6">6</xref>]. If, during the early stages of pre-clinical development, a compound is titrated or optimized specifically in male cells or in male mice, then any sex biases inherent in such models may be passed forward into later stages of drug development. The disproportionate expression of increased PKs and ADRs in women may be one result of this continued neglect.</p>
          </sec>
        </sec>
      </sec>
    </sec>
    <sec id="Sec15">
      <title>Perspectives and significance</title>
      <p id="Par47">The substantially elevated incidence of adverse drug reactions in women is undisputed, but the biological basis for this sex difference is poorly understood. The present study tested the hypothesis that sex differences in pharmacokinetics contributes to the female sex bias in adverse drug reactions. The analyses indicate that for many drugs administration of the same standard drug dose to women and men results in higher blood concentrations and/or longer elimination times in women and that these female-biased pharmacokinetics are a striking predictor of adverse drug reactions in women. Pharmaceutical pipelines that optimize drugs using males in vitro (male cells) and in vivo (male preclinical animal models) may contribute to the prevalence of these PK-ADR relations. Pervasive unintended and adverse drug responses may reflect routine overmedication of women for many drugs. Measures to ameliorate the sex difference in adverse drug reactions include reducing drug doses for women.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <sec id="Sec16">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13293_2020_308_MOESM1_ESM.docx"><caption><p><bold>Additional file 1:.</bold> Supplementary Results.</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <sec>
      <title>Supplementary information</title>
      <p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s13293-020-00308-5.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>We are grateful to Annaliese Beery, Alison Fleming, David Greenblatt, Gary Kraemer, Lance Kriegsfeld, and Ellen Zucker for constructive criticism and helpful suggestions.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; contributions</title>
      <p>BJP and IZ collected and analyzed the data; BJP and IZ approved the manuscript. IZ conceived of the study; IZ and BJP participated in study design and coordination; IZ and BJP wrote the manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>The authors received no funding to perform this work.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Availability of data and materials</title>
      <p>The datasets used and/or analyzed during the current study are available from either author and described in Additional file <xref rid="MOESM1" ref-type="media">1</xref>.</p>
    </notes>
    <notes id="FPar10">
      <title>Ethics approval and consent to participate</title>
      <p id="Par48">Not applicable</p>
    </notes>
    <notes id="FPar11">
      <title>Consent for publication</title>
      <p id="Par49">Not applicable.</p>
    </notes>
    <notes id="FPar12" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par50">The authors declare that they have no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klinge</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Gender perspectives in European research</article-title>
          <source>Pharmacol Res.</source>
          <year>2008</year>
          <volume>58</volume>
          <issue>3&#x2013;4</issue>
          <fpage>183</fpage>
          <lpage>189</lpage>
          <pub-id pub-id-type="pmid">18761409</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wetherington</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>Sex-gender differences in drug abuse: a shift in the burden of proof?</article-title>
          <source>Exp Clin Psychopharmacol.</source>
          <year>2007</year>
          <volume>15</volume>
          <issue>5</issue>
          <fpage>411</fpage>
          <lpage>417</lpage>
          <pub-id pub-id-type="pmid">17924775</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rogers</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Ballantyne</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Exclusion of women from clinical research: myth or reality?</article-title>
          <source>Mayo Clin Proc.</source>
          <year>2008</year>
          <volume>83</volume>
          <issue>5</issue>
          <fpage>536</fpage>
          <lpage>542</lpage>
          <pub-id pub-id-type="pmid">18452682</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soldin</surname>
              <given-names>OP</given-names>
            </name>
            <name>
              <surname>Mattison</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Sex differences in pharmacokinetics and pharmacodynamics</article-title>
          <source>Clin Pharmacokinet.</source>
          <year>2009</year>
          <volume>48</volume>
          <issue>3</issue>
          <fpage>143</fpage>
          <lpage>157</lpage>
          <pub-id pub-id-type="pmid">19385708</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="other">Hayes SN, Redberg RF. Dispelling the myths: calling for sex-specific reporting of trial results. Mayo Clin Proc. 2008;83:523&#x2013;5.</mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beery</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Zucker</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Sex bias in neuroscience and biomedical research</article-title>
          <source>Neurosci Biobehav Rev.</source>
          <year>2011</year>
          <volume>35</volume>
          <issue>3</issue>
          <fpage>565</fpage>
          <lpage>572</lpage>
          <pub-id pub-id-type="pmid">20620164</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Geller</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Roesch</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Filut</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hallgren</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Carnes</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The more things change, the more they stay the same: a study to evaluate compliance with inclusion and assessment of women and minorities in randomized controlled trials</article-title>
          <source>Acad Med.</source>
          <year>2018</year>
          <volume>93</volume>
          <issue>4</issue>
          <fpage>630</fpage>
          <lpage>635</lpage>
          <pub-id pub-id-type="pmid">29053489</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zucker</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Beery</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Males still dominate animal studies</article-title>
          <source>Nature.</source>
          <year>2010</year>
          <volume>465</volume>
          <issue>7299</issue>
          <fpage>690</fpage>
          <pub-id pub-id-type="pmid">20535186</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karlsson Lind</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>von Euler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Korkmaz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schenck-Gustafsson</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Sex differences in drugs: the development of a comprehensive knowledge base to improve gender awareness prescribing</article-title>
          <source>Biol Sex Differ.</source>
          <year>2017</year>
          <volume>8</volume>
          <issue>1</issue>
          <fpage>32</fpage>
          <pub-id pub-id-type="pmid">29065918</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Fadiran</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Harrison-Woolrych</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Effects of sex differences in the pharmacokinetics of drugs and their impact on the safety of medicines in women</article-title>
          <source>Medicines for women</source>
          <year>2015</year>
          <publisher-loc>Cham</publisher-loc>
          <publisher-name>Springer International Publishing</publisher-name>
          <fpage>41</fpage>
          <lpage>68</lpage>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fisher</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Ronald</surname>
              <given-names>LM</given-names>
            </name>
          </person-group>
          <article-title>Sex, gender, and pharmaceutical politics: from drug development to marketing</article-title>
          <source>Gend Med.</source>
          <year>2010</year>
          <volume>7</volume>
          <issue>4</issue>
          <fpage>357</fpage>
          <lpage>370</lpage>
          <pub-id pub-id-type="pmid">20869636</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="other">WHO. <ext-link ext-link-type="uri" xlink:href="http://www.vigiaccess.org">http://www.vigiaccess.org</ext-link>.</mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="other">WHO. <ext-link ext-link-type="uri" xlink:href="http://who-umc.org/vigibase/vigibase/">http://who-umc.org/vigibase/vigibase/</ext-link>.</mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="other">Tharpe N. Adverse drug reactions in women&#x2019;s health care. J Midwifery Womens Health. 2011;56(3):205-13.</mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakagawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kajiwara</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Female sex as a risk factor for adverse drug reactions</article-title>
          <source>Nihon Rinsho.</source>
          <year>2015</year>
          <volume>73</volume>
          <issue>4</issue>
          <fpage>581</fpage>
          <lpage>585</lpage>
          <pub-id pub-id-type="pmid">25936145</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Damien</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Patural</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Trombert-Paviot</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Beyens</surname>
              <given-names>M-N</given-names>
            </name>
          </person-group>
          <article-title>Adverse drug reactions in children: 10&#x2009;years of pharmacovigilance</article-title>
          <source>Arch Pediatr.</source>
          <year>2016</year>
          <volume>23</volume>
          <issue>5</issue>
          <fpage>468</fpage>
          <lpage>476</lpage>
          <pub-id pub-id-type="pmid">27062190</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Systematic analysis of adverse event reports for sex differences in adverse drug events</article-title>
          <source>Sci Rep.</source>
          <year>2016</year>
          <volume>6</volume>
          <issue>1</issue>
          <fpage>24955</fpage>
          <pub-id pub-id-type="pmid">27102014</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martin</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Biswas</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Freemantle</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Pearce</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies</article-title>
          <source>Br J Clin Pharmacol.</source>
          <year>1998</year>
          <volume>46</volume>
          <issue>5</issue>
          <fpage>505</fpage>
          <lpage>511</lpage>
          <pub-id pub-id-type="pmid">9833605</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manteuffel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Verbrugge</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Pittman</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Steinkellner</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines</article-title>
          <source>J Women&#x2019;s Heal.</source>
          <year>2014</year>
          <volume>23</volume>
          <issue>2</issue>
          <fpage>112</fpage>
          <lpage>119</lpage>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holford</surname>
              <given-names>NHG</given-names>
            </name>
            <name>
              <surname>Sheiner</surname>
              <given-names>LB</given-names>
            </name>
          </person-group>
          <article-title>Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models</article-title>
          <source>Clin Pharmacokinet.</source>
          <year>1981</year>
          <volume>6</volume>
          <issue>6</issue>
          <fpage>429</fpage>
          <lpage>453</lpage>
          <pub-id pub-id-type="pmid">7032803</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="other">Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics?: Clin Pharmacokinet. 2002;41(5):329&#x2013;42.</mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harris</surname>
              <given-names>RZ</given-names>
            </name>
            <name>
              <surname>Benet</surname>
              <given-names>LZ</given-names>
            </name>
          </person-group>
          <article-title>Schwartz JB</article-title>
          <source>Gender effects in pharmacokinetics and pharmacodynamics: Drugs.</source>
          <year>1995</year>
          <volume>50</volume>
          <issue>2</issue>
          <fpage>222</fpage>
          <lpage>239</lpage>
          <pub-id pub-id-type="pmid">8521756</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gandhi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aweeka</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Greenblatt</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Blaschke</surname>
              <given-names>TF</given-names>
            </name>
          </person-group>
          <article-title>Sex differences in pharmacokinetics and pharmacodynamics</article-title>
          <source>Annu Rev Pharmacol Toxicol.</source>
          <year>2004</year>
          <volume>44</volume>
          <fpage>499</fpage>
          <lpage>523</lpage>
          <pub-id pub-id-type="pmid">14744256</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kando</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Yonkers</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title>Cole JO</article-title>
          <source>Gender as a risk factor for adverse events to medications: Drugs.</source>
          <year>1995</year>
          <volume>50</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">7588082</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beierle</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Meibohm</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Derendorf</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Gender differences in pharmacokinetics and pharmacodynamics</article-title>
          <source>Int J Clin Pharmacol Ther.</source>
          <year>1999</year>
          <volume>37</volume>
          <issue>11</issue>
          <fpage>529</fpage>
          <lpage>547</lpage>
          <pub-id pub-id-type="pmid">10584975</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cotreau</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>von Moltke</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Greenblatt</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>The influence of age and sex on the clearance of cytochrome P450 3A substrates</article-title>
          <source>Clin Pharmacokinet.</source>
          <year>2005</year>
          <volume>44</volume>
          <issue>1</issue>
          <fpage>33</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">15634031</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greenblatt</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>von Moltke</surname>
              <given-names>LL</given-names>
            </name>
          </person-group>
          <article-title>Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs</article-title>
          <source>J Clin Pharmacol.</source>
          <year>2008</year>
          <volume>48</volume>
          <issue>11</issue>
          <fpage>1350</fpage>
          <lpage>1355</lpage>
          <pub-id pub-id-type="pmid">18757784</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>GD</given-names>
            </name>
          </person-group>
          <source>Chapter 1 gender differences in pharmacological response</source>
          <year>2008</year>
          <publisher-loc>In</publisher-loc>
          <publisher-name>International review of neurobiology. Elsevier</publisher-name>
          <fpage>1</fpage>
          <lpage>10</lpage>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Islam</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Iqbal</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Walther</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>P-A</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y-C</given-names>
            </name>
            <name>
              <surname>Dubey</surname>
              <given-names>NK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gender-based personalized pharmacotherapy: a systematic review</article-title>
          <source>Arch Gynecol Obstet.</source>
          <year>2017</year>
          <volume>295</volume>
          <issue>6</issue>
          <fpage>1305</fpage>
          <lpage>1317</lpage>
          <pub-id pub-id-type="pmid">28378180</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brambilla</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>O'Donnell</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>McKinlay</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men</article-title>
          <source>Clin Endocrinol</source>
          <year>2007</year>
          <volume>67</volume>
          <issue>6</issue>
          <fpage>853</fpage>
          <lpage>862</lpage>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petros</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Lepirudin in the management of patients with heparin-induced thrombocytopenia</article-title>
          <source>Biologics.</source>
          <year>2008</year>
          <volume>2</volume>
          <issue>3</issue>
          <fpage>481</fpage>
          <lpage>490</lpage>
          <pub-id pub-id-type="pmid">19707378</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdel-Rahman</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>Influence of sex on cardiovascular drug responses: role of estrogen</article-title>
          <source>Curr Opin Pharmacol.</source>
          <year>2017</year>
          <volume>33</volume>
          <fpage>1</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">28340373</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>J-AI</given-names>
            </name>
            <name>
              <surname>Sigouin</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Kohlmann</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Eichler</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Greinacher</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia</article-title>
          <source>Blood.</source>
          <year>2006</year>
          <volume>108</volume>
          <issue>9</issue>
          <fpage>2937</fpage>
          <lpage>2941</lpage>
          <pub-id pub-id-type="pmid">16857993</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <mixed-citation publication-type="other">Arpon DR, Gandhi MK, Martin JH. A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug. Br J Clin Pharmacol. 2014;78(2):274&#x2013;81.</mixed-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zopf</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Rabe</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Neubert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hahn</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Dormann</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Risk factors associated with adverse drug reactions following hospital admission: a prospective analysis of 907 patients in two German university hospitals</article-title>
          <source>Drug Saf.</source>
          <year>2008</year>
          <volume>31</volume>
          <issue>9</issue>
          <fpage>789</fpage>
          <lpage>798</lpage>
          <pub-id pub-id-type="pmid">18707193</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vree</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Dammers</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Valducci</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60&#x2009;mg) after repeated oral administration of two different original prolonged release formulations</article-title>
          <source>Int J Clin Pharmacol Ther.</source>
          <year>2004</year>
          <volume>42</volume>
          <issue>8</issue>
          <fpage>463</fpage>
          <lpage>472</lpage>
          <pub-id pub-id-type="pmid">15366327</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <mixed-citation publication-type="other">Schwartz JB. The influence of sex on pharmacokinetics: Clin Pharmacokinet. 2003;42(2):107&#x2013;21.</mixed-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <mixed-citation publication-type="other">Franconi F, Campesi I. Sex impact on biomarkers, pharmacokinetics and pharmacodynamics. Curr Med Chem. 2017;24(24).</mixed-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>The current state of knowledge on age, sex, and their interactions on clinical pharmacology</article-title>
          <source>Clin Pharmacol Ther.</source>
          <year>2007</year>
          <volume>82</volume>
          <issue>1</issue>
          <fpage>87</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="pmid">17495875</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franconi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Campesi</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women: Pharmacological differences between sexes</article-title>
          <source>Br J Pharmacol.</source>
          <year>2014</year>
          <volume>171</volume>
          <issue>3</issue>
          <fpage>580</fpage>
          <lpage>594</lpage>
          <pub-id pub-id-type="pmid">23981051</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amacher</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>Female gender as a susceptibility factor for drug-induced liver injury</article-title>
          <source>Hum Exp Toxicol.</source>
          <year>2014</year>
          <volume>33</volume>
          <issue>9</issue>
          <fpage>928</fpage>
          <lpage>939</lpage>
          <pub-id pub-id-type="pmid">24299907</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <mixed-citation publication-type="other">Institute of Medicine. Committee on Understanding the Biology of Sex and Gender Differences. Exploring the biological contributions to human health. Does sex matter? 2001.</mixed-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics</article-title>
          <source>Clin Pharmacol Ther.</source>
          <year>2000</year>
          <volume>68</volume>
          <issue>5</issue>
          <fpage>510</fpage>
          <lpage>521</lpage>
          <pub-id pub-id-type="pmid">11103754</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fife</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Maibach</surname>
              <given-names>HI</given-names>
            </name>
          </person-group>
          <article-title>Gender differences in the pharmacokinetics of oral dermatologic medications</article-title>
          <source>J Toxicol Cutan Ocul Toxicol.</source>
          <year>2005</year>
          <volume>23</volume>
          <issue>2</issue>
          <fpage>119</fpage>
          <lpage>133</lpage>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <mixed-citation publication-type="other">Polasek TM, Shakib S, Rostami-Hodjegan A. Precision dosing in clinical medicine: present and future. Expert Rev Clin Pharmacol. 2018;11:743&#x2013;6.</mixed-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <mixed-citation publication-type="other">Panetta JA, Srinivasan U. Gender based medicine. In: Annual reports in medicinal chemistry. Elsevier; 1998. p. 355&#x2013;63.</mixed-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duan</surname>
              <given-names>JZ</given-names>
            </name>
          </person-group>
          <article-title>Applications of population pharmacokinetics in current drug labelling</article-title>
          <source>J Clin Pharm Ther.</source>
          <year>2007</year>
          <volume>32</volume>
          <issue>1</issue>
          <fpage>57</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="pmid">17286790</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tamargo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rosano</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Walther</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Duarte</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Niessner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kaski</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gender differences in the effects of cardiovascular drugs</article-title>
          <source>Eur Hear J - Cardiovasc Pharmacother.</source>
          <year>2017</year>
          <volume>3</volume>
          <issue>3</issue>
          <fpage>163</fpage>
          <lpage>182</lpage>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <mixed-citation publication-type="other">Regitz-Zagrosek V, Kararigas G. Mechanistic pathways of sex differences in cardiovascular disease. Physiol Rev. 2017;97:1-37.</mixed-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crawford</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>DeLisi LE</article-title>
          <source>Issues related to sex differences in antipsychotic treatment: Curr Opin Psychiatry.</source>
          <year>2016</year>
          <volume>29</volume>
          <issue>3</issue>
          <fpage>211</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="pmid">26906336</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <mixed-citation publication-type="other">Salzano A, Demelo-Rodriguez P, Marra AM, Proietti M. A focused review of gender differences in antithrombotic therapy. Curr Med Chem. 2017;24(24).</mixed-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ofotokun</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Chuck</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Hitti</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Antiretroviral pharmacokinetic profile: a review of sex differences</article-title>
          <source>Gend Med.</source>
          <year>2007</year>
          <volume>4</volume>
          <issue>2</issue>
          <fpage>106</fpage>
          <lpage>119</lpage>
          <pub-id pub-id-type="pmid">17707845</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sramek</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Cutler</surname>
              <given-names>NR</given-names>
            </name>
          </person-group>
          <article-title>Sex differences in the psychopharmacological treatment of depression</article-title>
          <source>Dialogues Clin Neurosci.</source>
          <year>2016</year>
          <volume>18</volume>
          <issue>4</issue>
          <fpage>11</fpage>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <mixed-citation publication-type="other">FDA. <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/">https://www.accessdata.fda.gov/scripts/cder/daf/</ext-link>.</mixed-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Humphries</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Izadnegahdar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sedlak</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Saw</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Schenck-Gustafsson</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sex differences in cardiovascular disease &#x2013; impact on care and outcomes</article-title>
          <source>Front Neuroendocrinol.</source>
          <year>2017</year>
          <volume>46</volume>
          <fpage>46</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="pmid">28428055</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <mixed-citation publication-type="other">Greenblatt DJ, Legangneux E, Harmatz JS, Weinling E, Freeman J, Rice K, et al. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol. 2006;46(12):1469&#x2013;80.</mixed-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Richardson</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Reiches</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shattuck-Heidorn</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>LaBonte</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Consoli</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Opinion: focus on preclinical sex differences will not address women&#x2019;s and men&#x2019;s health disparities</article-title>
          <source>Proc Natl Acad Sci.</source>
          <year>2015</year>
          <volume>112</volume>
          <issue>44</issue>
          <fpage>13419</fpage>
          <lpage>13420</lpage>
          <pub-id pub-id-type="pmid">26534989</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <mixed-citation publication-type="other">Greenblatt DJ, Harmatz JS, Singh NN, Steinberg F, Roth T, Moline ML, et al. Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration: &#xA0;J Clin Pharmacol. 2014;54(3):282&#x2013;90.</mixed-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greenblatt</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Harmatz</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Zolpidem and gender: are women really at risk?</article-title>
          <source>J Clin Psychopharmacol.</source>
          <year>2019</year>
          <volume>39</volume>
          <issue>3</issue>
          <fpage>189</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="pmid">30939589</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <mixed-citation publication-type="other">Colombo D, Banfi G, Cassano N, Graziottin A, Vena GA, et al. The GENDER ATTENTION observational study: gender and hormonal status differences in the incidence of adverse events during cyclosporine treatment in psoriatic patients. Adv Ther. 2017;34(6):1349&#x2013;63.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
      <journal-title-group>
        <journal-title>Scientific Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2045-2322</issn>
      <publisher>
        <publisher-name>Nature Publishing Group UK</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33188246</article-id>
      <article-id pub-id-type="pmc">7666225</article-id>
      <article-id pub-id-type="publisher-id">76715</article-id>
      <article-id pub-id-type="doi">10.1038/s41598-020-76715-w</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cell-free synthesis of the hirudin variant 1 of the blood-sucking leech <italic>Hirudo medicinalis</italic></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>W&#xFC;stenhagen</surname>
            <given-names>Doreen A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Lukas</surname>
            <given-names>Phil</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>M&#xFC;ller</surname>
            <given-names>Christian</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aubele</surname>
            <given-names>Simone A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hildebrandt</surname>
            <given-names>Jan-Peter</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Kubick</surname>
            <given-names>Stefan</given-names>
          </name>
          <address>
            <email>Stefan.kubick@izi-bb.fraunhofer.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.418008.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0494 3022</institution-id><institution>Fraunhofer Institute for Cell Therapy and Immunology (IZI), </institution><institution>Branch Bioanalytics and Bioprocesses Potsdam-Golm (IZI-BB), </institution></institution-wrap>14476 Potsdam, Germany </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.5603.0</institution-id><institution>Animal Physiology and Biochemistry, Zoological Institute and Museum, </institution><institution>University of Greifswald, </institution></institution-wrap>17489 Greifswald, Germany </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.11348.3f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0942 1117</institution-id><institution>Faculty of Health Sciences, Joint Faculty of the Brandenburg University of Technology Cottbus &#x2013; Senftenberg, </institution><institution>The Brandenburg Medical School Theodor Fontane and the University of Potsdam, </institution></institution-wrap>16816 Neuruppin, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>11</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>13</day>
        <month>11</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>10</volume>
      <elocation-id>19818</elocation-id>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>4</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>10</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2020</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">Synthesis and purification of peptide drugs for medical applications is a challenging task. The leech-derived factor hirudin is in clinical use as an alternative to heparin in anticoagulatory therapies. So far, recombinant hirudin is mainly produced in bacterial or yeast expression systems. We describe the successful development and application of an alternative protocol for the synthesis of active hirudin based on a cell-free protein synthesis approach. Three different cell lysates were compared, and the effects of two different signal peptide sequences on the synthesis of mature hirudin were determined. The combination of K562 cell lysates and the endogenous wild-type signal peptide sequence was most effective. Cell-free synthesized hirudin showed a considerably higher anti-thrombin activity compared to recombinant hirudin produced in bacterial cells.</p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
        <title>Subject terms</title>
        <kwd>Expression systems</kwd>
        <kwd>Cardiovascular biology</kwd>
        <kwd>Proteases</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002347</institution-id>
              <institution>Bundesministerium f&#xFC;r Bildung und Forschung</institution>
            </institution-wrap>
          </funding-source>
          <award-id>031B0078A</award-id>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>Projekt DEAL</institution>
          </funding-source>
        </award-group>
        <open-access>
          <p>Open Access funding enabled and organized by Projekt DEAL.</p>
        </open-access>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par2">Hirudin is a secretory protein produced in the salivary gland cells of sanguivorous leeches of the genus <italic>Hirudo</italic><sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup> and one of the most effective natural thrombin inhibitors. First described by Haycraft in 1884, it took almost 80&#xA0;years until Markwardt et al. were able to successfully isolate and purify hirudin from crude extracts of <italic>Hirudo&#xA0;medicinalis</italic><sup><xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref></sup>. However, extraction of native hirudin was very time consuming, costly and inefficient and required sacrificing a large number of leeches<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>. The availability of mRNA/cDNA sequence data of hirudin completely altered the situation and enabled the production of large amounts of recombinant hirudin in prokaryotic and eukaryotic expression systems. Bacterial expression systems include <italic>Escherichia&#xA0;coli</italic> (<italic>E. coli</italic>)<sup><xref ref-type="bibr" rid="CR7">7</xref>&#x2013;<xref ref-type="bibr" rid="CR10">10</xref></sup>, <italic>Bacillus subtilis</italic>, <italic>Lactococcus lactis</italic> and <italic>Streptomyces lividans</italic><sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>, whereas in fungi hirudin could be successfully synthesized in <italic>Acremonium&#xA0;chrysogenum</italic>, <italic>Ogataea&#xA0;angusta</italic>, <italic>Pichia&#xA0;pastoris</italic> and <italic>Saccharomyces&#xA0;cerevisiae</italic><sup><xref ref-type="bibr" rid="CR13">13</xref>&#x2013;<xref ref-type="bibr" rid="CR16">16</xref></sup>, respectively. Eukaryotic expression systems, beside fungi, include insect cell lines, Chinese hamster ovary (CHO) cells, mouse fibroblast cells, porcine endothelial cells and pituitary secretory cell lines<sup><xref ref-type="bibr" rid="CR17">17</xref>&#x2013;<xref ref-type="bibr" rid="CR19">19</xref></sup>. In addition, a cell-free synthesis approach with rabbit reticulocyte lysate was described as well<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Commercially available hirudin variants like Desirudin and the discontinued Lepirudin are nowadays expressed in <italic>Saccharomyces cerevisiae</italic><sup><xref ref-type="bibr" rid="CR21">21</xref>&#x2013;<xref ref-type="bibr" rid="CR23">23</xref></sup>, whereas for research applications usually protocols based on <italic>E. coli</italic> or <italic>Pichia&#xA0;pastoris</italic> are applied<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR23">23</xref>&#x2013;<xref ref-type="bibr" rid="CR25">25</xref></sup>.</p>
      <p id="Par3">The expression of recombinant hirudin in bacteria or yeast usually results in products with a lower activity compared to leech-derived hirudin. One explanation for this phenomenon is the absence of sulfatation at the amino acid residue Tyr-63 (Tys-63) or other post-translational modifications like glycosylations<sup><xref ref-type="bibr" rid="CR26">26</xref>&#x2013;<xref ref-type="bibr" rid="CR29">29</xref></sup>. In only a few reports the successful synthesis of sulfo-hirudin using chemical synthesis, expression in baby hamster kidney (BHK) cells or even in <italic>E.&#xA0;coli</italic> cells was described<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>.</p>
      <p id="Par4">Misfolding of recombinant proteins in general and hirudin in particular is a major concern as well. In addition to the lower activity, misfolded proteins applied in patients may cause or amplify unwanted immunogenic reactions or other side effects<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Misfolding mostly happens during inclusion body formation, which is typically a consequence of high yield expression in bacterial systems<sup><xref ref-type="bibr" rid="CR33">33</xref>&#x2013;<xref ref-type="bibr" rid="CR36">36</xref></sup>. Another important aspect of recombinant protein expression especially for medical applications is the presence of endotoxins or other byproducts in the final extracts. Such contaminations have to be detected and carefully removed prior to application<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. Taken together, the synthesis of sufficient amounts of native (sulfo) hirudin for research or clinical applications is still a challenging task.</p>
      <p id="Par5">Cell-free protein synthesis approaches might be a promising alternative to the conventional methods described above. In cell-free systems, protein synthesis is based on the presence of the translational apparatus of the cells only, while other cell components like the nuclei, mitochondria or the outer membrane are removed<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. By choosing specific lysates, unwanted byproducts like endotoxins can be easily avoided. In eukaryotic cell lysates, the complex translational characteristics remain intact and thus the chance of correct protein folding and posttranslational modifications like sulfatation and glycosylation is significantly enhanced<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. During the lysate production process, endogenous microsomal vesicles based on the endoplasmic reticulum (ER) are obtained. The native translocon remains in an active state and proteins with signal sequences can be translocated into the lumen of the microsomes. Furthermore, endogenous disulfide isomerases are located in the lumen of the microsomes and N-glycosylation (core) also takes place here<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup>. These are important prerequisites for correctly folded and active proteins.</p>
      <p id="Par6">In the present study we describe a new experimental approach to the cell-free synthesis of hirudin variant 1 (HV1 or hirudin-VV) of <italic>Hirudo medicinalis</italic>. The efficiencies of three different eukaryotic cell-free systems based on <italic>Spodoptera frugiperda</italic> (<italic>Sf</italic>21), Chinese hamster ovary (CHO) and human K562 cell lines and the effects of two different cleavable signal peptide sequences on the synthesis and correct processing of mature hirudin were examined. In vitro assays were performed for the functional characterization of cell-free synthesized hirudin in comparison to hirudin that has been conventionally synthesized in bacterial expression systems. Our data indicate a considerably higher anti-thrombin activity of the cell-free produced hirudin. Given the scalability of cell-free protein synthesis, which has already been demonstrated in <italic>E. coli</italic> cell-free systems<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup>, this approach could be a promising alternative for the production of highly active hirudin (and other protein drugs with complex molecular structures).</p>
    </sec>
    <sec id="Sec2">
      <title>Results</title>
      <sec id="Sec3">
        <title>Cell-free synthesis of hirudin in three different eukaryotic cell lysates</title>
        <p id="Par7">We have previously demonstrated the performance of cell-free protein synthesis systems based on translationally active <italic>Sf</italic>21, CHO and K562 cell lysates<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR44">44</xref>&#x2013;<xref ref-type="bibr" rid="CR47">47</xref></sup>. All three cell-free lysate systems contain endogenous microsomes derived from the ER. An advantage of these microsomes is the co-translational translocation of proteins harbouring a signal peptide into the lumen of the microsomes. Thereby, subsequent post-translational modifications such as cleavage of signal peptides, formation of disulfide bridges, <italic>N</italic>-glycosylation etc. takes place as in living cells<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Chaperones, which play an important role in protein folding are also present in the microsomes. In order to obtain correctly folded and thus active hirudin, we have decided to use the potential of the microsomes, since hirudin is very sensitive to any modifications at the N-terminus and also at the C-terminus, such as the addition of a His-tag for protein purification<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>.</p>
        <p id="Par8">We have constructed two different vectors to express hirudin HV1. The first construct contained the endogenous wild-type signal peptide sequence of hirudin (wild-type hirudin, WT-HV1) and the second contained hirudin fused to the heterologous signal peptide sequence of melittin (Mel-HV1) instead of the endogenous sequence (see Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>Sequence comparison of hirudin with its endogenous signal peptide (WT-HV1) or with the melittin signal (Mel-HV1). The signal sequence is underlined, while the conserved six cysteines are bolded, basic amino acids are indicated as blue, acid amino acids as red and tyrosine at position 63 as purple. The sequence is given in one-letter code according to IUPAC.</p></caption><graphic xlink:href="41598_2020_76715_Fig1_HTML" id="MO1"/></fig></p>
        <p id="Par9">In a first evaluation (&#x201C;proof of concept&#x201D;) only WT-HV1 was tested for expression and processing in three different cell lysate systems, the insect cell line <italic>Sf</italic>21, the human cell line K562 and the hamster cell line CHO-K1. Total protein yields and the secretion efficiencies were determined and quantified by scintillation and autoradiography. The term secretion efficiency refers to the processed protein that was translocated into the lumen of the ER-based microsomes and released from the microsomes using a mild detergent after completion of protein synthesis (see preparation of SN2 in methods section). For better comparability all calculations were normalized to the molecular mass of mature hirudin without signal peptide (7&#xA0;kDa).</p>
        <p id="Par10">As shown in Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>, WT-HV1 was successfully expressed in all three cell free expression systems and mainly appeared as a dimer (26&#xA0;kDa) or monomers (13&#xA0;kDa) on autoradiographs of protein blots. The relative abundances of monomers and dimers were slightly different with monomers being the major forms in cell free synthesis reactions using CHO extracts. Dimers appeared to be more abundant than monomers in reactions using <italic>Sf</italic>21 or K562 extracts. Both, the dimer and the monomer were also detectable using Coomassie staining of bacterial expressed hirudin (see Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>Autoradiography of translocated and released WT-HV1 (SN2 fraction) in three different eukaryotic cell-free systems derived from <italic>Sf</italic>21, K562 and CHO cells, respectively. For comparison, the Coomassie staining of bacterial hirudin is shown, which was analyzed on the same SDS gel. All three cell-free systems displayed two bands indicating full length hirudin (FL) at approx. 13&#xA0;kDa and a putative dimer of hirudin (DM) at approx. 26&#xA0;kDa. The same protein bands can be detected in the bacterial hirudin. Additional debris (DB) could be observed between 3 and 6&#xA0;kDa. The shown image consists of two different gels, which contained the used protein ladder and HV1 from <italic>Sf</italic>21-lysate (Gel1) and the protein ladder together with HV1 from K562-lysate, from CHO-lysate and the bacterial hirudin (Gel2). The autoradiographs are based on the SDS gels.</p></caption><graphic xlink:href="41598_2020_76715_Fig2_HTML" id="MO2"/></fig></p>
        <p id="Par11">However, both the total protein yield, the amount of secreted hirudin (final processed protein without the signal peptide; SN2 fraction) and the secretion efficiency (ratio between total protein yield and released protein) markedly differed (Table <xref rid="Tab1" ref-type="table">1</xref>). The highest total protein yield with 1065&#xA0;nmol/l (7.5&#xA0;&#xB5;g/ml) was obtained in the K562 cell-free system with a secretion amount of translocated and released hirudin of about 50&#xA0;nmol/l (0.4&#xA0;&#xB5;g/ml). The CHO cell-free system was less productive in terms of total yield (211&#xA0;nmol/l; 1.5&#xA0;&#xB5;g/ml), but it resulted in an equal amount of secreted hirudin (about 51&#xA0;nmol/l or 0.4&#xA0;&#xB5;g/ml, final concentration) in comparison to the K562 system. Using the <italic>Sf</italic>21 cell-free system a total protein yield of 838&#xA0;nmol/l (5.9&#xA0;&#xB5;g/ml) and a secreted amount of hirudin of about 70&#xA0;nmol/l (0.5&#xA0;&#xB5;g/ml) was obtained.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Synthesis of wild-type hirudin (WT-HV1) in three different eukaryotic cell-free systems: total protein yield and secreted/released amount of hirudin (SN2 fraction) in nmol/l and &#xB5;g/ml; ratio between total protein yield and secreted/released amount of hirudin represents the secretion efficiency.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">K562</th><th align="left"><italic>Sf</italic>21</th><th align="left">CHO</th></tr></thead><tbody><tr><td align="left" rowspan="2">Total protein yield</td><td align="left">1065&#xA0;nmol/l</td><td align="left">838&#xA0;nmol/l</td><td align="left">211&#xA0;nmol/l</td></tr><tr><td align="left">7.5&#xA0;&#xB5;g/ml</td><td align="left">5.9&#xA0;&#xB5;g/ml</td><td align="left">1.5&#xA0;&#xB5;g/ml</td></tr><tr><td align="left" rowspan="2">Secreted amount</td><td align="left">50&#xA0;nmol/l</td><td align="left">70&#xA0;nmol/l</td><td align="left">51&#xA0;nmol/l</td></tr><tr><td align="left">0.4&#xA0;&#xB5;g/ml</td><td align="left">0.5&#xA0;&#xB5;g/ml</td><td align="left">0.4&#xA0;&#xB5;g/ml</td></tr><tr><td align="left">Ratio</td><td align="left">4.7%</td><td align="left">8.4%</td><td align="left">24.1%</td></tr></tbody></table><table-wrap-foot><p>Determination was performed by double determination (n&#x2009;=&#x2009;2).</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec4">
        <title>Anti-coagulatory activity of cell-free synthesized hirudin</title>
        <p id="Par12">The processed and released hirudin preparations (SN2 fractions) obtained from all three cell-free systems were independently tested for their anti-coagulatory activities in two different coagulation assays (&#x201C;proof of principle&#x201D;): the activated partial thromboplastin time (aPTT) test as well as the thrombin time (TT) test. Whereas the aPTT test is used to determine the functionality of the intrinsic and common pathways of the coagulation cascade, the TT is applied to specifically test for activity of thrombin. 10&#xA0;&#xB5;l of each SN2 fraction were added to the respective coagulation assays and the time until onset of coagulation was measured. SN2 fractions of the respective no-template control reactions (NTC) served as negative controls. In all cases, SN2 fractions containing hirudin clearly prolonged the coagulation time in the TT test, whereas the NTC did not negatively affect the coagulation times (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a). The anti-coagulatory effect caused by hirudin was most pronounced for hirudin synthesized in the human K562 cell-free lysate system (clotting time about 242&#xA0;s), whereas the expression of hirudin in the CHO (94&#xA0;s) and <italic>Sf</italic>21 cell-free lysate system (50&#xA0;s) were less effective. The results for the aPTT assays were similar, apart from the fact that all hirudin-containing SN2 fractions were evenly increasing aPTT while the NTC fractions prolonged the coagulation times just marginally above the upper tolerance limit at 28.9&#xA0;s (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>b).<fig id="Fig3"><label>Figure 3</label><caption><p>Anti-coagulatory potencies of translocated and released WT-HV1 samples (SN2) synthesized in <italic>Sf</italic>21, K562 and CHO cell-free systems tested in the thrombin time assay (<bold>a</bold>), activated partial thromboplastin time assay (<bold>b</bold>) and anti-coagulatory potencies of equimolar amounts of HV1 synthesized by bacterial expression (rHV1) and synthesized in <italic>Sf</italic>21, K562 and CHO cell-free systems (WT-HV1, SN2) determined by the thrombin time test assay (<bold>c</bold>). Final concentrations are given in nmol/l. For the equimolar measurement samples were tested at a final concentration of 3.1&#xA0;nmol/l. rHV1 was additionally tested at a concentration of 31.0&#xA0;nmol/l. Data for the activity of rHV1 at a concentration of 310&#xA0;nmol/l were taken from M&#xFC;ller et al.<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. For determination of clotting times double determination was used as &#x201C;proof of principle&#x201D; (n&#x2009;=&#x2009;2).</p></caption><graphic xlink:href="41598_2020_76715_Fig3_HTML" id="MO3"/></fig></p>
      </sec>
      <sec id="Sec5">
        <title>Comparison of cell-free vs. bacterially synthesized hirudin samples</title>
        <p id="Par13">So far, variants of both hirudins and hirudin-like factors were produced and purified solely from <italic>E.&#xA0;coli</italic>-based expression systems in our lab. To directly compare the anti-coagulatory activities of both bacterially (rHV1) and cell-free synthesized HV1 samples, we performed thrombin time tests with equimolar concentrations (3.1&#xA0;nmol/l) of each sample. In previous investigations, rHV1 was routinely tested in concentrations of 3100 and 310&#xA0;nmol/l, respectively. Thus we decided to test also rHV1 at concentrations of 31&#xA0;nmol/l and 3.1&#xA0;nmol/l to cover the wider range of four orders of magnitude. Compared with rHV1 expressed in bacteria the WT-HV1 expressed with extracts of <italic>Sf</italic>21 lysate was at least twice as effective in elongation of TT (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>c). WT-HV1 expressed using extracts of CHO-lysate was even more efficient and elongated TT approximately ninefold more efficiently compared with protein expressed in bacteria. The most potent WT-HV1 was that expressed using extracts of K562 cells. This variant was approximately 100 times more effective as an anti-coagulant than rHV1 expressed in bacteria (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>c).</p>
      </sec>
      <sec id="Sec6">
        <title>Comparison of cell-free synthesis of WT-HV1 and Mel-HV1</title>
        <p id="Par14">We also synthesized and functionally tested Mel-HV1. The signal peptide sequence of melittin is commonly used for labelling, subsequent processing and highly efficient secretion of proteins in heterologous expression systems<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. For cell-free protein synthesis, especially for efficient translocation of proteins into the lumen of microsomes, the use of the melittin signal peptide sequence has already been described and is firmly established in our lab<sup><xref ref-type="bibr" rid="CR38">38</xref>&#x2013;<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>. Based on the results of the evaluation of the synthesis of WT-HV1 in the three eukaryotic cell-free lysate systems, only the human K562 system was used for this study. The resulting total protein yields and secreted/released amounts of WT-HV1 and Mel-HV1 are listed in Table <xref rid="Tab2" ref-type="table">2</xref>. The total yield of WT-HV1 (1245&#xA0;nmol/l or 8.8&#xA0;&#xB5;g/ml) was approximately the same compared to the first synthesis reaction, but the secreted/released amount of hirudin (158&#xA0;nmol/l or 1.1&#xA0;&#xB5;g/ml) and hence the secretion efficiency (12.7%) was nearly three-times higher. In contrast, both the total protein yield of Mel-HV1 (6150&#xA0;nmol/l or 43.2&#xA0;&#xB5;g/ml) and the secreted/released amount of hirudin (510&#xA0;nmol/l or 3.6&#xA0;&#xB5;g/ml) were considerably higher compared to WT-HV1, whereas the secretion efficiency (8.3%) was slightly lower.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Cell-free synthesis of WT-HV1 and Mel-HV1 in K562 cell lysate system: total protein yield and secreted/released amount of hirudin (SN2 fraction) in nmol/l and &#xB5;g/ml; ratio between total protein yield and secreted/released amount of hirudin represents the secretion efficiency.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Total yield</th><th align="left">Secreted amount</th><th align="left">Ratio (%)</th></tr></thead><tbody><tr><td align="left" rowspan="2">WT-HV1</td><td align="left">1245&#xA0;nmol/l</td><td align="left">158&#xA0;nmol/l</td><td align="left" rowspan="2">12.7</td></tr><tr><td align="left">8.8&#xA0;&#xB5;g/ml</td><td align="left">1.1&#xA0;&#xB5;g/ml</td></tr><tr><td align="left" rowspan="2">Mel-HV1</td><td align="left">6150&#xA0;nmol/l</td><td align="left">509&#xA0;nmol/l</td><td align="left" rowspan="2">8.3</td></tr><tr><td align="left">43.2&#xA0;&#xB5;g/ml</td><td align="left">3.6&#xA0;&#xB5;g/ml</td></tr></tbody></table><table-wrap-foot><p>Determination was performed by double determination (n&#x2009;=&#x2009;2).</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec7">
        <title>Processing of hirudin samples containing either the endogenous wild-type or the heterologous melittin signal peptide</title>
        <p id="Par15">As hirudins still containing their signal peptides are not able to function as anti-coagulants<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR51">51</xref></sup>, the high anti-coagulatory and anti-thrombin potencies of WT-HV1 variants generated by cell-free protein synthesis indicates that the endogenous wild-type signal peptide had been removed by the signal peptidase present in all three cell lysates. To verify the correct processing of both the endogenous wild-type and the heterologous melittin signal peptides, we analysed the SN2 fractions of WT-HV1, Mel-HV1 and NTC, based on the cell-free synthesis in the K562 cell lysate system, by MALDI-TOF. The spectra of both WT-HV1 and Mel-HV1 SN2 fractions revealed the presence of additional peaks at a molecular mass of about 7026&#xA0;Da compared to the spectrum of NTC SN2 fraction (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). The predicted molecular mass of HV1 is 7026.6&#xA0;Da, which is almost identical to the observed values (arrows). These data strongly support the assumption that not only WT-HV1, but also Mel-HV1 is correctly processed during cell-free synthesis in K562 cell lysates.<fig id="Fig4"><label>Figure 4</label><caption><p>Mass spectrometric analyses of SN2 fractions derived from K562 cell-free system expressing either no hirudin (NTC as negative control) (<bold>a</bold>), hirudin HV1 containing the endogenous wild-type (<bold>b</bold>) or the heterologous melittin signal peptide (<bold>c</bold>). Each sample was analysed by three independent measurements. The predicted AVG of HV1 is 7026.6&#xA0;Da. The additional peaks indicated by arrows represent masses of 7025.6&#x2009;&#xB1;&#x2009;6.0&#xA0;Da (<bold>b</bold>) or 7027.5&#x2009;&#xB1;&#x2009;5.0&#xA0;Da (<bold>c</bold>), respectively.</p></caption><graphic xlink:href="41598_2020_76715_Fig4_HTML" id="MO4"/></fig></p>
      </sec>
      <sec id="Sec8">
        <title>Anti-thrombin activities of WT-HV1 and Mel-HV1 synthesized in the human K562 cell-free system</title>
        <p id="Par16">To test the anti-coagulatory potency of WT-HV1 or Mel-HV1 we performed comparative thrombin time test assays with concentrations of 9.8&#xA0;nmol/l (highest achievable concentration of WT-HV1), 4.9&#xA0;nmol/l and 1&#xA0;nmol/l of each of the inhibitors, respectively. For Mel-HV1, we additionally tested the highest achievable concentration of 31.8&#xA0;nmol/l. The results are summarized in Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref> and clearly show that the anti-coagulatory potency of WT-HV1 was much more pronounced (at least by a factor of 10) compared with that of Mel-HV1. Additionally, at the highest concentration of 31.8&#xA0;nmol/l, Mel-HV1&#x2019;s anti-thrombin activity reached just the same level as the bacterially expressed rHV1 at nearly the same concentration (see Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>c). A further comparison between the SN1-fraction of the HV1 showed lower influence on clotting times, while concentration of the SN1-fraction was at least twice as high as the SN2-fraction (see <xref rid="MOESM1" ref-type="media">Supplementary Files</xref>). <fig id="Fig5"><label>Figure 5</label><caption><p>Anti-coagulatory activities of SN2 fractions containing either WT-HV1 or Mel-HV1 synthesized in the K562 cell-free system as determined by the thrombin time test assay. A cell-free reaction without synthesized hirudin was used as a negative control (NTC). Final concentrations of test proteins are given in nmol/l (n&#x2009;=&#x2009;3).</p></caption><graphic xlink:href="41598_2020_76715_Fig5_HTML" id="MO5"/></fig></p>
      </sec>
      <sec id="Sec9">
        <title>Posttranslational modifications of hirudin synthesized in the human K562 cell-free lysate system</title>
        <p id="Par17">The hirudin variants of the European medicinal leeches contain a tyrosine residue at position 63 (Tyr-63 in HV1 and HV2) or 64 (Tyr-64 in HV3) at the C-termini (see above). The respective residues are sulfated, but only in hirudins that are purified directly from salivary glands of leeches. Except from only very few counterexamples<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>, neither hirudins expressed in eukaryotic nor in bacterial systems contain this modification. The sulfatation of Tyr-63/Tyr-64 enhances the negative charge of the C-terminal tail of hirudin and stabilizes its interaction with thrombin, thereby promoting the inhibitory activity<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. To evaluate the putative post-translational modification of cell-free synthesized hirudins we performed Western blot analysis using antibodies that were raised against either hirudin (whole protein antibody) or sulfo-tyrosine. Bacterially expressed rHV1 served as a control for whole protein detection, NTC SN2 fraction as the negative control. The anti-hirudin antibody detected its target in SN2 fractions of WT-HV1 and Mel-HV1, but not in NTC (Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>). However, no evidence could be found for sulfatation of Tyr-63/64 in any of the fractions (data not shown).<fig id="Fig6"><label>Figure 6</label><caption><p>Western-blot analysis of different hirudin preparations. rHV1: bacterially expressed hirudin; WT-HV1 and Mel-HV1: cell-free synthesized in K562 lysate; NTC: no template control (cell-free reaction without synthesized hirudin). The SN2-fractions of the microsomes were used for all cell-free produced protein samples. The image of the Western Blot was cropped from the same Western Blot exposed by two different shutter times (5&#xA0;s and 50&#xA0;s), to avoid overexposure as well as faded bands. The corresponding blot areas were delineated by boxes. The images of all exposure times are summarized in the <xref rid="MOESM1" ref-type="media">Supplementary Material</xref>.</p></caption><graphic xlink:href="41598_2020_76715_Fig6_HTML" id="MO6"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec10">
      <title>Discussion</title>
      <p id="Par18">The present study describes the successful synthesis of hirudin variant HV1 in three different eukaryotic cell-free systems. The impacts of either the endogenous wild-type or the heterologous melittin signal peptides on synthesis, processing and secretion of hirudin was evaluated. Finally, the anti-coagulatory activity of different cell-free synthesized hirudin samples was determined.</p>
      <p id="Par19">The large-scale synthesis and purification of hirudin for scientific, commercial and medical purposes remains a challenging task<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>. Preparations of hirudin from whole leeches may lead to ethical concerns (death of innumerable animals) and/or limitations due to the collapse of natural populations<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup>. The biotechnological production of hirudin in bacteria, yeast and animal cells is hence an attractive alternative<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. However, there are major drawbacks and limitations in heterologous expression, too<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. Putative contaminations with bacterial endotoxins in animal cells may serve as examples<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. Cell-free synthesis of proteins in general and hirudin in particular has the potential to avoid most of the problems mentioned above. The efficiency of cell-free protein synthesis largely depends on the appropriate expression system with the matching vector construct and the background of the corresponding subcellular machinery as the main components<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR55">55</xref></sup>. We have examined lysates of three different eukaryotic cell lines, namely human K562, insect <italic>Sf</italic>21 and CHO-K1, for the expression of hirudin variant 1 (HV1). In all three eukaryotic cell-free systems, hirudin was successfully synthesized and secreted. However, there were obvious differences between the individual cell lysates. Lysate derived from the human cell line K562 was best suited in terms of total yield and amount of secreted protein, whereas the CHO lysate displayed the highest secretion efficiency. One might expect that the lysate derived from the cell line <italic>Sf</italic>21 would have performed best due to the closer phylogenetic relationship of <italic>Insecta</italic> and <italic>Annelida</italic>. However, this was the case only for the secreted/released amount of hirudin, but neither for the total yield nor the ratio between total yield and secreted/released protein (see Table <xref rid="Tab1" ref-type="table">1</xref>).</p>
      <p id="Par20">The signal peptide sequence of the honey bee toxin melittin is often used for the efficient secretion of proteins in heterologous cell-based and cell-free expression systems<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup>. We have compared the synthesis and secretion of hirudin containing either its endogenous wild-type signal peptide (WT-HV1) or the heterologous melittin signal peptide (Mel-HV1) in K562 cell lysates. Both the total protein yield and the amount of secreted hirudin were considerably higher for Mel-HV1. The secretion efficiency, however, was slightly lower. These observations are in good agreement with previous reports<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR56">56</xref></sup>. The total protein yield of synthesized hirudin in the translation reaction was about 6150&#xA0;nmol/l (43.2&#xA0;&#xB5;g/ml) for Mel-HV1 and 1245&#xA0;nmol/l (8.8&#xA0;&#xB5;g/ml) for WT-HV1. Both quantities are in the typical range of cell-free synthesized luciferase<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup> and membrane proteins<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. Taken together, we successfully conducted cell-free synthesis of hirudin both with its endogenous wild-type signal peptide (WT-HV1) as well as with the heterologous melittin signal peptide (Mel-HV1).</p>
      <p id="Par21">The anti-coagulatory and anti-thrombin potencies of hirudin can be determined and quantified by several coagulation assays, among them the aPTT and the TT tests<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. Since we did not purify hirudin from the cell lysates, we performed all assays with the respective SN2 fractions that contained proteins that were translocated into the lumen of the ER-based microsomes during the cell free synthesis reaction and subsequently released by treatment of the microsomes with the mild detergent DDM. In all assays, the hirudin-containing SN2 fractions considerably prolonged the coagulation times in comparison to the respective NTC samples (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). Hence, all WT-HV1 SN2 fractions contained biologically active hirudin. However, there were differences between the lysates. The K562 cell lysate displayed by far the strongest impact on the coagulation time in the TT test, despite the lowest concentration of secreted hirudin (3.1&#xA0;nmol/l). In contrast, the <italic>Sf</italic>21 SN2 fraction contained the highest concentration of secreted hirudin (4.4&#xA0;nmol/l), but displayed only a comparably low anti-coagulatory potency (see Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a,b). Differences in the yield of active protein between lysates of the three cell lines have already been described for the firefly luciferase<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. In addition to that clotting times of the bacterial expressed hirudin variant rHV1 were in good accordance with respective values of the commercially available lepirudin as described in previous studies<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR61">61</xref></sup>. Based on this data the anti-thrombin activity of hirudin in all three cell lysates was additionally compared to the activity of the bacterially expressed rHV1. Anyway, in respect to the concentration of the SN2 fractions a concentration range of 3100&#xA0;nmol/l to 3.1&#xA0;nmol/l was tested for rHV1, which included 100&#x2013;1000-fold amounts of rHV1 which were usually tested. As can be seen in Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>c, all cell-free synthesized hirudins seem to display higher anti-thrombin potencies compared to rHV1 expressed in bacteria. Again, hirudin synthesized in the K562 cell lysate had the strongest impact.</p>
      <p id="Par22">The differences of anti-coagulatory potencies among the cell-free synthesized hirudin samples and, even more important, in comparison to rHV1 expressed in bacteria might be explained by differences in folding of the mature protein. Activity of hirudin critically depends on the correct formation of three disulphide bonds within the central globular domain<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>. It seems very likely that the cellular machinery of eukaryotic cells performs better in expression and handling of heterologous proteins of eukaryotic origin in comparison to the bacterial cell machinery<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. Moreover, protein misfolding and formation of inclusion bodies remain a serious problem and a technological challenge for the production of recombinant proteins in bacterial cells<sup><xref ref-type="bibr" rid="CR33">33</xref>&#x2013;<xref ref-type="bibr" rid="CR35">35</xref></sup>. Cell-free protein synthesis could be a promising alternative harbouring the potential to overcome these problems. However, not all cell lysates are equally well suited for all target proteins<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>. Accordingly the selection of the appropriate cell-free system (e.g. K562 cell lysate in case of hirudin) and the optimization of the reaction conditions<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup> to the needs of the respective protein should be carried out in form of evaluation studies.</p>
      <p id="Par23">One parameter for optimization might be the choice of the appropriate signal peptide sequence. For secretory proteins, the signal peptide sequence of melittin (Mel-SP), a honey bee toxin, is quite regularly used and works well for a broad variety of proteins<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>. Interestingly, the Mel-SP did not improve our results for hirudin significantly. Mel-HV1 was synthesized in considerably larger amounts in the K562 cell-free system compared to WT-HV1 and the secretory amount was more than three times higher, too (see Table <xref rid="Tab2" ref-type="table">2</xref>). The anti-thrombin potency of Mel-HV1, however, was lower compared to that of WT-HV1 (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). At equimolar concentrations, WT-HV1 had a clearly detectable anti-coagulatory effect, whereas Mel-HV1 had almost none (at 4.9&#xA0;nmol/l) or a very weak effect (at 9.8&#xA0;nmol/l).</p>
      <p id="Par24">A possible explanation for the lower effectivity of Mel-HV1 compared to WT-HV1 as an anti-coagulant might be an incorrect processing of the Mel-SP. The activity of hirudin is negatively influenced by alterations of the N-terminal five amino acid residues<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR64">64</xref></sup>. However, the mass determinations of WT-HV1 and Mel-HV1 by MALDI-TOF analyses did not reveal any evidence for an incorrect processing of the signal peptides. Both spectra contained a clearly visible peak at a position that exactly corresponds to the expected molecular mass of hirudin. Alternatively, the lower potency of Mel-HV1 compared to that of WT-HV1 as an anti-coagulant may be explained by incorrect folding of the respective protein. Our data indicate that a heterologous signal peptide might somehow affect and even hamper the correct folding of a protein upon secretion. A similar observation on the influence of the endogenous signal peptide on the correct folding of a bacterial autotransporter has been made by other researchers<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>. The authors concluded that some types of signal peptides play major roles in preventing misfolding of mature proteins. Hence, possible negative effects of a heterologous signal peptide on the activity of the cell-free synthesized "protein of interest" should therefore be considered and, consequently, tested.</p>
      <p id="Par25">Hirudins of European medicinal leeches of the genus <italic>Hirudo</italic> are usually sulphated at tyrosine residues at positions 63 or 64, respectively. With only a very few exceptions<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>, hirudins of biotechnological origin do not contain the respective sulphates. In addition, hirudins of the Asian medicinal leech <italic>Hirudinaria manillensis</italic> are glycosylated as well<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR66">66</xref></sup>. Neither WT-HV1 nor Mel-HV1 displayed any signs of post-translational modifications like the addition of a sulphate groups or of carbohydrate residues (Figs. <xref rid="Fig4" ref-type="fig">4</xref>, <xref rid="Fig6" ref-type="fig">6</xref>).</p>
    </sec>
    <sec id="Sec11">
      <title>Conclusion</title>
      <p id="Par26">Hirudin is a drug of medical relevance in clinical use for decades<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref></sup>. So far, the biotechnological production of recombinant hirudin depends on either bacterial or yeast expression systems<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Both systems have major drawbacks in terms of putative contaminations and limitations in terms of yield of biologically active product<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>. In the present study, we investigated further promising ways to produce hirudin in its active form. The cell-free human K562 system in particular shows a high potential to produce active hirudin. Although the syntheses reactions were performed in our laboratory on an analytical scale, cell-free synthesis in general offers an interesting alternative for the production of active pharmaceutical ingredients. The scalability of cell-free synthesis points out the outstanding potential of this technology and paves the way to future industrial applications.</p>
    </sec>
    <sec id="Sec12">
      <title>Methods</title>
      <sec id="Sec13">
        <title>Sequences and template preparation</title>
        <p id="Par27">The sequence of hirudin-variant 1 (HV1, GenBank Acc. No. KR066903.1) of <italic>Hirudo medicinalis</italic><sup><xref ref-type="bibr" rid="CR60">60</xref></sup> was used as the reference. Expression vectors contain the coding sequence of hirudin, the internal ribosomal entry site (IRES) of the cricket paralysis virus (CRPV), the T7-promoter and a signal peptide encoding sequence<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup>. All templates are based on the pMA backbone and were generated by gene synthesis (GeneArt, Thermo Fischer). Two different templates were designed: the first construct contained the coding sequence of the original signal peptide of HV1 (WT-HV1), while the second contained the signal peptide of honey bee melittin (Mel-HV1)<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>.</p>
      </sec>
      <sec id="Sec14">
        <title>Cell-free and bacterial synthesis of hirudin</title>
        <p id="Par28">Cell-free protein synthesis was performed based on translationally active eukaryotic lysates from CHO-K1 (ECACC 85051005), <italic>Sf</italic> 21 (DSM ACC 119) and K562 (InVivo BioTech GmbH, Hennigsdorf, Germany) cell lines as previously described<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup>. In seeking to find the most suitable lysate system for hirudin synthesis, the batch reaction mode for the cell-free protein synthesis were used. The reaction mixture contained 40% (v/v) of the respective cell lysate (<italic>Sf</italic>21 or CHO or K562), 60&#xA0;ng/&#xB5;l plasmid DNA, 20&#xA0;mmol/l HEPES (pH 7.6), 70&#xA0;&#xB5;mol/l amino acids, 1.45&#xA0;mmol/l ATP, 0.25&#xA0;mmol/l GTP, 0.25&#xA0;mmol/l CTP, 0.25&#xA0;mmol/l UTP, 83&#xA0;&#xB5;mol/l m7G(ppp)G-CAP-analoga, 95&#xA0;mmol/l KOAc, 2.7&#xA0;mmol/l Mg(OAc)<sub>2</sub>, 20&#xA0;&#xB5;mol/l Poly-G Primer, and 1&#xA0;U/&#xB5;l&#xA0;T7 RNA Polymerase. To monitor protein quality and quantity, an aliquot of the reaction mixture was supplemented with <sup>14</sup>C-labelled leucine (310.0&#xA0;mCi/mmol, Perkin Elmer, Germany). After preparing the reaction mixture, the volume for the incubation step was divided into aliquots of 50&#xA0;&#xB5;l each. Protein synthesis reactions were incubated at 27&#xA0;&#xB0;C (<italic>Sf</italic>21 lysate) or at 30&#xA0;&#xB0;C (CHO, K562) for 3&#xA0;h and at 500&#xA0;rpm (Thermomixer comfort, Eppendorf, Hamburg, Germany). A reaction mixture without plasmid (no-template control, NTC) was prepared as the negative control. After incubation, the <sup>14</sup>C-leucine labelled reaction mixtures were frozen at&#x2009;&#x2212;&#x2009;20&#xA0;&#xB0;C until radiometric analysis.</p>
        <p id="Par29">The bacterial hirudin was expressed in <italic>E. coli</italic>. While the exact methods are already described in other places<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup>. An additional hexahistidin-tag was fused to hirudin for purification, afterwards the tag was removed completely removed due to a factor-Xa cleavage-site and a digest with factor-Xa. The final hirudin was dialysed and kept in elution buffer (20&#xA0;mmol/l Tris/HCl, 100&#xA0;mmol/l NaCl, 2&#xA0;mmol/l CaCl2, pH8.0).</p>
      </sec>
      <sec id="Sec15">
        <title>Preparation of SN2 fraction harbouring the translocated hirudin</title>
        <p id="Par30">The reaction mixtures were fractionated after completion of protein synthesis into TM (total reaction mixture), SN1 (supernatant-1) and MF1 (microsomal fraction). For fractionation, the total reaction mixture was centrifuged for 10&#xA0;min at 16,000&#xD7;<italic>g</italic> and 4&#xA0;&#xB0;C (5415R microcentrifuge, Eppendorf, Hamburg, Germany). The supernatant-1 (SN1) was separated and the pellet was re-suspended with PBS (pH 7.4) to obtain the MF1. To release translocated hirudin from the lumen of the microsomes, MF1 was treated with 0.02% (w/v)&#xA0;DDM (<italic>n</italic>-Dodecyl-&#x3B2;-<sc>d</sc>-maltoside) in elution buffer and incubated for 1&#xA0;h at 25&#xA0;&#xB0;C. An additional centrifugation step at 16,000&#xD7;<italic>g</italic>, 4&#xA0;&#xB0;C and 10&#xA0;min was performed to obtain the released protein in the SN2 (supernatant-2)<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. The SN2 fraction was separated and used for further studies.</p>
      </sec>
      <sec id="Sec16">
        <title>Analysis of <sup>14</sup>C-labeled proteins</title>
        <p id="Par31">The total yield (TM), soluble protein (SN1), microsomal fraction (MF1), translocated and released protein (SN2) were determined by hot trichloroacetic acid (TCA)-precipitation. Aliquots of 5&#xA0;&#x3BC;l of each fraction were taken from the solution, mixed with 3&#xA0;ml TCA (10% solution with 2% casein hydrolysate) and incubated in a water bath for 15&#xA0;min, followed by incubation on ice for 30&#xA0;min. The TCA-precipitated proteins were collected on filters (MN GF-3, Machery-Nagel, D&#xFC;ren, Germany) and washed with 5% TCA using a vacuum filtration system (Hoefer Scientific, Holliston, MA, USA) to remove non-incorporated <sup>14</sup>C-leucin from the protein solution. Protein loaded filters were placed in scintillation vials and 3&#xA0;ml scintillation cocktail (Quicksafe A, Zinsser Analytic, Eschborn, Germany) was added. The incorporation of <sup>14</sup>C-leucine into cell-free expressed hirudin was measured by liquid scintillation counting by double determination (n&#x2009;=&#x2009;2) using the LS6500 Multi Purpose Scintillation Counter (Beckmann Coulter, Krefeld, Germany).</p>
        <p id="Par32">To determine the homogeneity and molecular size of cell-free synthesized hirudin, 5&#xA0;&#xB5;l aliquots of the corresponding fractions were precipitated with 150&#xA0;&#xB5;l ice-cold acetone and the samples were incubated on ice for 15&#xA0;min. Subsequently the samples were centrifuged at 16,000&#xD7;<italic>g</italic> for 5&#xA0;min at 4&#xA0;&#xB0;C. Protein pellets were re-suspended in 20&#xA0;&#xB5;l sample buffer (LDS-sample buffer, Life Technologies, Thermo Fischer, Schwerte, Germany), incubated for 15&#xA0;min at RT with gentle shaking and heated for 10&#xA0;min at 70&#xA0;&#xB0;C. Samples were loaded onto precast SDS-PAGE gels (10% Bis&#x2013;Tris NuPAGE Novex gel, Life Technologies) and run for 35&#xA0;min at 200&#xA0;V. After electrophoresis, the gels were stained with Coomassie Blue (SimplyBlue SafeStain, Life Technologies), dried for 1&#xA0;h on Whatman paper at 70&#xA0;&#xB0;C (Unigeldryer 3545, Uniequip, Planegg, Germany) and exposed to storage phosphor screens (Mounted GP, GE Healthcare, Solingen, Germany). Radioactively labelled proteins were visualized using a phosphor imager (Typhoon Trio&#x2009;+&#x2009;, GE Healthcare). The determination of radioactively labelled proteins is based on our previous works<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup>.</p>
      </sec>
      <sec id="Sec17">
        <title>Coagulation assays</title>
        <p id="Par33">To verify the anti-coagulatory activity of the different HV1 preparations, two blood coagulation assays were performed: the activated partial thromboplastin time test (aPTT; reference range 22.7&#x2013;28.9&#xA0;s) and the thrombin time test (TT; reference range 16.8&#x2013;21.4&#xA0;s) using a BFT II analyzer (Siemens Healthcare, Erlangen, Germany). All steps followed the instructions outlined by the manufacturer and were described in detail in our previous works with small deviations<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR71">71</xref></sup>. 10&#xA0;&#xB5;l of the respective SN2 fraction of the cell-free expressed protein were directly transferred into the cuvette immediately before the plasma was added. Dade Ci-Trol 1 (Siemens Healthcare, Erlangen, Germany) was used as standardized human plasma. The incubation of reaction mixtures was carried out at 37.4&#xA0;&#xB0;C. Measurements that lasted up to 300&#xA0;s were stopped and declared as a complete inhibition of clot formation. Clot formation was additionally controlled by eye to exclude technical errors. All samples where measured within 48&#xA0;h after cell-free synthesis. During this time period all samples were kept at 4&#xA0;&#xB0;C to avoid freeze&#x2013;thaw circles. HV1 expressed in bacteria was kept in aliquots and thawed on ice immediately before the measurements.</p>
        <p id="Par34">Samples were either used directly or diluted in 0.02% (w/v) DDM-solution to adjust the final concentration.</p>
      </sec>
      <sec id="Sec18">
        <title>Immunoblotting</title>
        <p id="Par35">Immunoblotting was performed to evaluate whether or not the single tyrosine residue at position 63 (Tyr-63) in cell-free synthesized HV1 is sulfated. 10&#xA0;&#xB5;l of undiluted SN2 fraction which contains either the protein or the background control (NTC) were denatured by mixing with 3&#x2009;&#xD7;&#x2009;SDS-sample buffer (0.27&#xA0;mol/l Tris, 60% (v/v) glycerol, 12% (v/v) &#x3B2;-Mercaptoethanol, 3%&#xA0;(w/v) SDS, 0.6% (w/v) bromophenol blue) and incubation for 10&#xA0;min at 105&#xA0;&#xB0;C. Samples were cooled down and subsequently loaded on self-casted 20% polyacrylamide gels twice in a mirrored arrangement. After the run at 60&#xA0;V for 4&#xA0;h in a Mini-PROTEAN Tetra Cell (BioRad, Feldkirchen, Germany), proteins were blotted from the gels onto Roti-NC nitrocellulose membrane (Roth, Karlsruhe, Germany) using a Trans-Blot SD semi-dry transfer cell (BioRad, Feldkirchen, Germany) at 400&#xA0;mA for 15&#xA0;min.</p>
        <p id="Par36">The membranes were cut into two halves in a way, that each side contained the same arrangement of samples. Both halves were first blocked with 3% milk-TTBS, and one half was subsequently incubated over night at 4&#xA0;&#xB0;C with 10&#xA0;&#xB5;l of an anti-sulfotyrosine antibody [Sulfo-1C-A2] (Abcam, Cambridge, UK) whereas the other was incubated with 10&#xA0;&#xB5;l of an anti-hirudin antibody [2D7] (Abcam, Cambridge, UK). An anti-mouse IgG HRP-linked antibody (Cell Signaling Technology, Frankfurt&#xA0;/M., Germany) was used as the secondary antibody<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. Blots were incubated with WesternBright ECL HRP reagent (Biozym, Hessisch Oldendorf, Germany) and the bands were detected using a ChemoStar ECL &amp; Fluorescence Imager (Intas Science Imaging Instruments, G&#xF6;ttingen, Germany).</p>
      </sec>
      <sec id="Sec19">
        <title>MALDI-TOF</title>
        <p id="Par37">Samples for MALDI-TOF mass spectrometric analysis were prepared using HyperSep-C18-tips (Thermo Scientific, Schwerte, Germany) according to the manufacturer&#x2019;s recommendations. Sample application was performed via dried-droplet on MSP 96 target ground steel (Bruker Daltonics, Bremen, Germany) with 1&#xA0;&#xB5;l sinapinic-matrix (45&#xA0;mmol/l sinapinic acid in 70% (v/v) H<sub>2</sub>O, 30% (v/v) acetonitrile, 0.3% (v/v) trifluoroacetic acid). After drying under vacuum, samples were analyzed using the LP-mode and 60&#x2013;90% laser intensity by a Microflex device (Bruker Daltonics, Bremen, Germany). The free software mMass v. 5.5.0 was used to evaluate the mass spectra<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>.</p>
      </sec>
      <sec id="Sec20">
        <title>Ethical approval</title>
        <p id="Par38">We declare that the experiments described in this paper comply with the current laws in Germany. This article does not contain any studies with human participants performed by any of the authors.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <sec id="Sec21">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2020_76715_MOESM1_ESM.pdf"><caption><p>Supplementary Information.</p></caption></media></supplementary-material></p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher's note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>These authors contributed equally: Doreen A. W&#xFC;stenhagen and Phil Lukas.</p>
      </fn>
    </fn-group>
    <sec>
      <title>Supplementary information</title>
      <p>is available for this paper at 10.1038/s41598-020-76715-w.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>This work was supported by German Ministry of Education and Research, BMBF (BMBF, Nos. 031B0078A and 031B0831C). We would like to acknowledge Ms. Dana Wenzel (Fraunhofer IZI-BB, Potsdam-Golm, Germany) for technical support. The authors would like to thank Prof. Dr. Sabine M&#xFC;ller and her working group &#x2019;Organic Biochemistry&#x2019; at the University of Greifswald for providing the equipment for MALDI-TOF analysis. Phil Lukas received a doctoral stipend from the Friedrich-Ebert-Stiftung, Germany.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>P.L., D.W. and C.M. designed the study and prepared the manuscript. P.L., D.W. and S.A. performed the experiments and analyzed the data. J.-P.H. and S.K. supervised the practical and theoretical works. All authors contributed to the preparation of the final manuscript and gave approval for publication.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>Open Access funding enabled and organized by Projekt DEAL.</p>
    </notes>
    <notes id="FPar1" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par39">The authors declare no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References
</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markwardt</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Untersuchungen &#xFC;ber Hirudin</article-title>
          <source>Naturwissenschaften</source>
          <year>1955</year>
          <volume>42</volume>
          <fpage>537</fpage>
          <lpage>538</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00630151</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markwardt</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Die Isolierung und chemische Charakterisierung des Hirudins</article-title>
          <source>Hoppe-Seylers Z. Physiol. Chem.</source>
          <year>1957</year>
          <volume>308</volume>
          <fpage>147</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="doi">10.1515/bchm2.1957.308.1.147</pub-id>
          <pub-id pub-id-type="pmid">13474656</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haycraft</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>&#xDC;ber die Einwirkung eines Sekretes des officinellen Blutegels auf die Gerinnbarkeit des Blutes</article-title>
          <source>Arch. f&#xFC;r Exp. Pathol. Pharmakol.</source>
          <year>1884</year>
          <volume>18</volume>
          <fpage>209</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="doi">10.1007/BF01833843</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nowak</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schr&#xF6;r</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Hirudin&#x2014;The long and stony way from an anticoagulant peptide in the saliva of medicinal leech to a recombinant drug and beyond</article-title>
          <source>Thromb. Haemost.</source>
          <year>2007</year>
          <volume>98</volume>
          <fpage>116</fpage>
          <lpage>119</lpage>
          <pub-id pub-id-type="doi">10.1160/TH07-05-0364</pub-id>
          <pub-id pub-id-type="pmid">17598001</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rigbi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Orevi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eldor</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Platelet aggregation and coagulation inhibitors in leech saliva and their roles in leech therapy</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <year>1996</year>
          <volume>22</volume>
          <fpage>273</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2007-999019</pub-id>
          <pub-id pub-id-type="pmid">8836013</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Markwardt</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Walsmann</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Reindarstellung und analyse des thrombininhibitors hirudin</article-title>
          <source>Hoppe-Seylers Z. Physiol. Chem.</source>
          <year>1967</year>
          <volume>348</volume>
          <fpage>1381</fpage>
          <lpage>1386</lpage>
          <pub-id pub-id-type="doi">10.1515/bchm2.1967.348.1.1381</pub-id>
          <pub-id pub-id-type="pmid">4869965</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fortkamp</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rieger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Heisterberg-Moustes</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schweitzer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sommer</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Cloning and expression in <italic>Escherichia coli</italic> of a synthetic DNA for hirudin, the blood coagulation inhibitor in the leech</article-title>
          <source>DNA</source>
          <year>1986</year>
          <volume>5</volume>
          <fpage>511</fpage>
          <lpage>517</lpage>
          <pub-id pub-id-type="doi">10.1089/dna.1.1986.5.511</pub-id>
          <pub-id pub-id-type="pmid">3545721</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bergmann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dodt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>K&#xF6;hler</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fink</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gassen</surname>
              <given-names>HG</given-names>
            </name>
          </person-group>
          <article-title>Chemical synthesis and expression of a gene coding for hirudin, the thrombin-specific inhibitor from the leech <italic>Hirudo medicinalis</italic></article-title>
          <source>Biol. Chem. Hoppe Seyler</source>
          <year>1986</year>
          <volume>367</volume>
          <fpage>731</fpage>
          <lpage>740</lpage>
          <pub-id pub-id-type="doi">10.1515/bchm3.1986.367.2.731</pub-id>
          <pub-id pub-id-type="pmid">3533117</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harvey</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Degryse</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Stefani</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schamber</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cazenave</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Courtney</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tolstoshev</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lecocq</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, <italic>Hirudo medicinalis</italic></article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <year>1986</year>
          <volume>83</volume>
          <fpage>1084</fpage>
          <lpage>1088</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.83.4.1084</pub-id>
          <pub-id pub-id-type="pmid">3513162</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scacheri</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nitti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Valsasina</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Orsini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Visco</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ferrera</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sawyer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sarmientos</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Novel hirudin variants from the leech <italic>Hirudinaria manillensis.</italic> Amino acid sequence, cDNA cloning and genomic organization</article-title>
          <source>Eur. J. Biochem.</source>
          <year>1993</year>
          <volume>214</volume>
          <fpage>295</fpage>
          <lpage>304</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1432-1033.1993.tb17924.x</pub-id>
          <pub-id pub-id-type="pmid">7685281</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Qi</surname>
              <given-names>XH</given-names>
            </name>
            <name>
              <surname>Geng</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>QG</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>ZR</given-names>
            </name>
          </person-group>
          <article-title>Expression, purification and characterization of the recombinant hirudin variant iii in the <italic>Bacillus subtilis</italic></article-title>
          <source>Prep. Biochem. Biotechnol.</source>
          <year>2011</year>
          <volume>34</volume>
          <fpage>239</fpage>
          <lpage>252</lpage>
          <pub-id pub-id-type="doi">10.1081/PB-200026807</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lv</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Extracellular secretion of anticoagulant peptide hirudin in <italic>Lactococcus lactis</italic> using SP310mut2 signal peptide</article-title>
          <source>Biotechnol. Lett.</source>
          <year>2012</year>
          <volume>34</volume>
          <fpage>61</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="doi">10.1007/s10529-011-0740-3</pub-id>
          <pub-id pub-id-type="pmid">21901343</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hou</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tyo</surname>
              <given-names>KEJ</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Petranovic</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Metabolic engineering of recombinant protein secretion by <italic>Saccharomyces cerevisiae</italic></article-title>
          <source>FEMS Yeast Res.</source>
          <year>2012</year>
          <volume>12</volume>
          <fpage>491</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1567-1364.2012.00810.x</pub-id>
          <pub-id pub-id-type="pmid">22533807</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lehman</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Joyce</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Markus</surname>
              <given-names>HZ</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Dunwiddie</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
          <article-title>Expression, purification and characterization of multigram amounts of a recombinant hybrid HV1-HV2 hirudin variant expressed in <italic>Saccharomyces cerevisiae</italic></article-title>
          <source>Protein Expr. Purif.</source>
          <year>1993</year>
          <volume>4</volume>
          <fpage>247</fpage>
          <lpage>255</lpage>
          <pub-id pub-id-type="doi">10.1006/prep.1993.1032</pub-id>
          <pub-id pub-id-type="pmid">8518563</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Otto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Seckler</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Characterization, stability and refolding of recombinant hirudin</article-title>
          <source>Eur. J. Biochem.</source>
          <year>1991</year>
          <volume>202</volume>
          <fpage>67</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1432-1033.1991.tb16345.x</pub-id>
          <pub-id pub-id-type="pmid">1935981</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lan</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Hirudin variants production by genetic engineered microbial factory</article-title>
          <source>Biotchnol. Genet. Eng.</source>
          <year>2018</year>
          <volume>34</volume>
          <fpage>261</fpage>
          <lpage>280</lpage>
          <pub-id pub-id-type="doi">10.1080/02648725.2018.1506898</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benatti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Scacheri</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bishop</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Sarmientos</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Secretion of biologically active leech hirudin from baculovirus-infected insect cells</article-title>
          <source>Gene</source>
          <year>1991</year>
          <volume>101</volume>
          <fpage>255</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="doi">10.1016/0378-1119(91)90420-G</pub-id>
          <pub-id pub-id-type="pmid">1647362</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riesbeck</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kemball-Cook</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mcvey</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tuddenham</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lechler</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Expression of hirudin fusion proteins in mammalian cells: A strategy for prevention of intravascular thrombosis</article-title>
          <source>Circulation</source>
          <year>1998</year>
          <volume>98</volume>
          <fpage>2744</fpage>
          <lpage>2752</lpage>
          <pub-id pub-id-type="doi">10.1161/01.CIR.98.24.2744</pub-id>
          <pub-id pub-id-type="pmid">9851962</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Chou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kuan</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Expression of recombinant anticoagulant hirudin in the differentiated cultures of the porcine mammary epithelial cellline SI-PMEC</article-title>
          <source>Cell Biol. Int.</source>
          <year>2008</year>
          <volume>32</volume>
          <fpage>739</fpage>
          <lpage>747</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cellbi.2008.02.004</pub-id>
          <pub-id pub-id-type="pmid">18406177</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hempel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wirsching</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schober</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schwienhorst</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>A new reporter gene system suited for cell-free protein synthesis and high-throughput screening in small reaction volumes</article-title>
          <source>Anal. Biochem.</source>
          <year>2001</year>
          <volume>15</volume>
          <fpage>177</fpage>
          <lpage>182</lpage>
          <pub-id pub-id-type="doi">10.1006/abio.2001.5322</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liebe</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Br&#xFC;ckmann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>K-G</given-names>
            </name>
            <name>
              <surname>Haase</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Borggrefe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Huhle</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Biological relevance of anti-recombinant hirudin antibodies&#x2014;Results from in vitro and in vivo studies</article-title>
          <source>Thromb. Haemost.</source>
          <year>2002</year>
          <volume>28</volume>
          <fpage>483</fpage>
          <lpage>489</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2002-35289</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frame</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Rice</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bartholomew</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Whelton</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Rationale and design of the PREVENT-HIT study: A randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis</article-title>
          <source>Clin. Ther.</source>
          <year>2010</year>
          <volume>32</volume>
          <fpage>626</fpage>
          <lpage>636</lpage>
          <pub-id pub-id-type="doi">10.1016/j.clinthera.2010.04.012</pub-id>
          <pub-id pub-id-type="pmid">20435232</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sohn</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Rhee</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Current status of the anticoagulant hirudin: Its biotechnological production and clinical practice</article-title>
          <source>Appl. Microbiol. Biotechnol.</source>
          <year>2001</year>
          <volume>57</volume>
          <fpage>606</fpage>
          <lpage>613</lpage>
          <pub-id pub-id-type="doi">10.1007/s00253-001-0856-9</pub-id>
          <pub-id pub-id-type="pmid">11778867</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Expression, purification and characterization of recombinant targeting bifunctional hirudin in <italic>Pichia pastoris</italic></article-title>
          <source>Afr. J. Biotechnol.</source>
          <year>2009</year>
          <volume>8</volume>
          <fpage>5582</fpage>
          <lpage>5588</lpage>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Badran</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Al-Fadal</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Production and purification of constructed recombinant hirudin in BL21(DE3) strain</article-title>
          <source>JBEI</source>
          <year>2017</year>
          <volume>3</volume>
          <fpage>62</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.5430/jbei.v3n1p62</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stone</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Hofsteenge</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Kinetics of the inhibition of thrombin by hirudin</article-title>
          <source>Biochemistry</source>
          <year>1986</year>
          <volume>25</volume>
          <fpage>4622</fpage>
          <lpage>4628</lpage>
          <pub-id pub-id-type="doi">10.1021/bi00364a025</pub-id>
          <pub-id pub-id-type="pmid">3768302</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Steiner</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Knecht</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>B&#xF6;rnsen</surname>
              <given-names>KO</given-names>
            </name>
            <name>
              <surname>Gassmann</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Raschdorf</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schlaeppi</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Maschler</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Primary structure and function of novel O-glycosylated hirudins from the leech <italic>Hirudinaria manillensis</italic></article-title>
          <source>Biochemistry</source>
          <year>1992</year>
          <volume>31</volume>
          <fpage>2294</fpage>
          <lpage>2298</lpage>
          <pub-id pub-id-type="doi">10.1021/bi00123a012</pub-id>
          <pub-id pub-id-type="pmid">1540584</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hsieh</surname>
              <given-names>YSY</given-names>
            </name>
            <name>
              <surname>Wijeyewickrema</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Pike</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Payne</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Total synthesis of homogeneous variants of hirudin P6: A post-translationally modified anti-thrombotic leech-derived protein</article-title>
          <source>Angew. Chem. Int. Ed. Engl.</source>
          <year>2014</year>
          <volume>53</volume>
          <fpage>3947</fpage>
          <lpage>3951</lpage>
          <pub-id pub-id-type="doi">10.1002/anie.201310777</pub-id>
          <pub-id pub-id-type="pmid">24615823</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Schindler</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chatrenet</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>The disulfide structures of scrambled hirudins</article-title>
          <source>J. Biol. Chem.</source>
          <year>1995</year>
          <volume>270</volume>
          <fpage>11992</fpage>
          <lpage>11997</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.270.20.11992</pub-id>
          <pub-id pub-id-type="pmid">7744849</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Skern</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bischoff</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jallat</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dott</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Alihadji</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Clesse</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Courtney</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Sulphation of hirudin in BHK cells</article-title>
          <source>FEBS Lett.</source>
          <year>1990</year>
          <volume>275</volume>
          <fpage>36</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="doi">10.1016/0014-5793(90)81433-o</pub-id>
          <pub-id pub-id-type="pmid">2261997</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
          <article-title>Recombinant expression of selectively sulfated proteins in <italic>Escherichia coli</italic></article-title>
          <source>Nat. Biotechnol.</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>1436</fpage>
          <lpage>1440</lpage>
          <pub-id pub-id-type="doi">10.1038/nbt1254</pub-id>
          <pub-id pub-id-type="pmid">17072302</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ratanji</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Derrick</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Dearman</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Kimber</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Immunogenicity of therapeutic proteins: Influence of aggregation</article-title>
          <source>J. Immunotoxicol.</source>
          <year>2014</year>
          <volume>11</volume>
          <fpage>99</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="doi">10.3109/1547691X.2013.821564</pub-id>
          <pub-id pub-id-type="pmid">23919460</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elena Garc&#xED;a-Fruit&#xF3;s</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gonz&#xE1;lez-Montalb&#xE1;n</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Morell</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vera</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ferraz</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Ar&#xED;s</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ventura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Villaverde</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins</article-title>
          <source>Microb. Cell Fact.</source>
          <year>2005</year>
          <volume>4</volume>
          <fpage>1</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1186/1475-2859-4-27</pub-id>
          <pub-id pub-id-type="pmid">15629064</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomas</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Baneyx</surname>
              <given-names>FO</given-names>
            </name>
          </person-group>
          <article-title>Protein misfolding and inclusion body formation in recombinant <italic>Escherichia coli</italic> cells overexpressing heat-shock proteins</article-title>
          <source>J. Biol. Chem.</source>
          <year>1996</year>
          <volume>271</volume>
          <fpage>11141</fpage>
          <lpage>11147</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.271.19.11141</pub-id>
          <pub-id pub-id-type="pmid">8626659</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baneyx</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mujacic</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Recombinant protein folding and misfolding in <italic>Escherichia coli</italic></article-title>
          <source>Nat. Biotechnol.</source>
          <year>2004</year>
          <volume>22</volume>
          <fpage>1399</fpage>
          <lpage>1408</lpage>
          <pub-id pub-id-type="doi">10.1038/nbt1029</pub-id>
          <pub-id pub-id-type="pmid">15529165</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mukherjee</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>MN</given-names>
            </name>
          </person-group>
          <article-title>Paradigm shifts in our views on inclusion bodies</article-title>
          <source>Curr. Biochem. Eng.</source>
          <year>2016</year>
          <volume>3</volume>
          <fpage>47</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="doi">10.2174/2212711902666150302212051</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mamat</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Wilke</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bramhill</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Schromm</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Lindner</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kohl</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Corchero</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Villaverde</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schaffer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Head</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Souvignier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Meredith</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Woodard</surname>
              <given-names>RW</given-names>
            </name>
          </person-group>
          <article-title>Detoxifying <italic>Escherichia coli</italic> for endotoxin-free production of recombinant proteins</article-title>
          <source>Microb. Cell Fact.</source>
          <year>2015</year>
          <volume>14</volume>
          <fpage>1</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1186/s12934-015-0241-5</pub-id>
          <pub-id pub-id-type="pmid">25567661</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Br&#xF6;del</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Sonnabend</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Cell-free protein expression based on extracts from CHO cells</article-title>
          <source>Biotechnol. Bioeng.</source>
          <year>2013</year>
          <volume>111</volume>
          <fpage>25</fpage>
          <lpage>36</lpage>
          <pub-id pub-id-type="doi">10.1002/bit.25013</pub-id>
          <pub-id pub-id-type="pmid">24018795</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zemella</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thoring</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hoffmeister</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>&#x160;amal&#xED;kov&#xE1;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ehren</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>W&#xFC;stenhagen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Cell-free protein synthesis as a novel tool for directed glycoengineering of active erythropoietin</article-title>
          <source>Sci. Rep.</source>
          <year>2018</year>
          <volume>8</volume>
          <fpage>1</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1038/s41598-018-26936-x</pub-id>
          <pub-id pub-id-type="pmid">29311619</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stech</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nikolaeva</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Thoring</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>St&#xF6;cklein</surname>
              <given-names>WFM</given-names>
            </name>
            <name>
              <surname>W&#xFC;stenhagen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Hust</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>D&#xFC;bel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Cell-free synthesis of functional antibodies using a coupled in vitro transcription-translation system based on CHO cell lysates</article-title>
          <source>Sci. Rep.</source>
          <year>2017</year>
          <volume>7</volume>
          <fpage>1</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1038/s41598-017-12364-w</pub-id>
          <pub-id pub-id-type="pmid">28127051</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramm</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Dondapati</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Thoring</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zemella</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>W&#xFC;stenhagen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Frentzel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Mammalian cell-free protein expression promotes the functional characterization of the tripartite non-hemolytic enterotoxin from <italic>Bacillus cereus</italic></article-title>
          <source>Sci. Rep.</source>
          <year>2020</year>
          <volume>10</volume>
          <fpage>2887</fpage>
          <pub-id pub-id-type="doi">10.1038/s41598-020-59634-8</pub-id>
          <pub-id pub-id-type="pmid">32076011</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swartz</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Developing cell-free biology for industrial applications</article-title>
          <source>J. Ind. Microbiol. Biotechnol.</source>
          <year>2006</year>
          <volume>33</volume>
          <fpage>476</fpage>
          <lpage>485</lpage>
          <pub-id pub-id-type="doi">10.1007/s10295-006-0127-y</pub-id>
          <pub-id pub-id-type="pmid">16761165</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zawada</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Steiner</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Naresh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Gold</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Heinsohn</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Microscale to manufacturing scale-up of cell-free cytokine production&#x2014;A new approach for shortening protein production development timelines</article-title>
          <source>Biotechnol. Bioeng.</source>
          <year>2011</year>
          <volume>108</volume>
          <issue>7</issue>
          <fpage>1570</fpage>
          <lpage>1578</lpage>
          <pub-id pub-id-type="doi">10.1002/bit.23103</pub-id>
          <pub-id pub-id-type="pmid">21337337</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Br&#xF6;del</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Sonnabend</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>LO</given-names>
            </name>
            <name>
              <surname>Stech</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>W&#xFC;stenhagen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>IRES-mediated translation of membrane proteins and glycoproteins in eukaryotic cell-free systems</article-title>
          <source>PLoS ONE</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>1</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0082234</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thoring</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dondapati</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Stech</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>W&#xFC;stenhagen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>High-yield production of &#x201C;difficult-to-express&#x201D; proteins in a continuous exchange cell-free system based on CHO cell lysates</article-title>
          <source>Sci. Rep.</source>
          <year>2017</year>
          <volume>7</volume>
          <fpage>11710</fpage>
          <pub-id pub-id-type="doi">10.1038/s41598-017-12188-8</pub-id>
          <pub-id pub-id-type="pmid">28916746</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quast</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ballion</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Stech</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sonnabend</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Varga</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>W&#xFC;stenhagen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Kele</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Schiller</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Cell-free synthesis of functional human epidermal growth factor receptor: Investigation of ligand-independent dimerization in <italic>Sf</italic>21 microsomal membranes using non-canonical amino acids</article-title>
          <source>Sci. Rep.</source>
          <year>2016</year>
          <volume>6</volume>
          <fpage>34048</fpage>
          <pub-id pub-id-type="doi">10.1038/srep34048</pub-id>
          <pub-id pub-id-type="pmid">27670253</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zemella</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grossmann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sachse</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sonnabend</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schaefer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Qualifying a eukaryotic cell-free system for fluorescence based GPCR analyses</article-title>
          <source>Sci. Rep.</source>
          <year>2017</year>
          <volume>7</volume>
          <fpage>3740</fpage>
          <pub-id pub-id-type="doi">10.1038/s41598-017-03955-8</pub-id>
          <pub-id pub-id-type="pmid">28623260</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lukas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rauch</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>J-P</given-names>
            </name>
            <name>
              <surname>M&#xFC;ller</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Hirudins of the Asian medicinal leech, <italic>Hirudinaria manillensis</italic>: Same same but different</article-title>
          <source>Parasitol. Res.</source>
          <year>2019</year>
          <volume>18</volume>
          <fpage>2223</fpage>
          <lpage>2233</lpage>
          <pub-id pub-id-type="doi">10.1007/s00436-019-06365-z</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tessier</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>DY</given-names>
            </name>
            <name>
              <surname>Khouri</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Lalibert&#xE9;</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Vernet</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Enhanced secretion from insect cells of a foreign protein fused to the honeybee melittin signal peptide</article-title>
          <source>Gene</source>
          <year>1991</year>
          <volume>98</volume>
          <fpage>177</fpage>
          <lpage>183</lpage>
          <pub-id pub-id-type="doi">10.1016/0378-1119(91)90171-7</pub-id>
          <pub-id pub-id-type="pmid">2016060</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thoring</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zemella</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>W&#xFC;stenhagen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Accelerating the production of druggable targets: Eukaryotic cell-free systems come into focus</article-title>
          <source>Methods Protoc.</source>
          <year>2019</year>
          <pub-id pub-id-type="doi">10.3390/mps2020030</pub-id>
          <pub-id pub-id-type="pmid">31164610</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loison</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Findeli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bernard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nguyen-Juilleret</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marquet</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Riehl-Bellon</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Carvallo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Guerra-Santos</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Courtney</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Roitsch</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lemoine</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Expression and secretion in <italic>S. cerevisiae </italic>of biologically active leech hirudin</article-title>
          <source>Bio/Technology</source>
          <year>1988</year>
          <volume>6</volume>
          <fpage>72</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="doi">10.1038/nbt0188-72</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Brustad</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of a biosynthetic sulfo-hirudin complexed to thrombin</article-title>
          <source>J. Am. Chem. Soc.</source>
          <year>2007</year>
          <volume>129</volume>
          <fpage>10648</fpage>
          <lpage>10649</lpage>
          <pub-id pub-id-type="doi">10.1021/ja0735002</pub-id>
          <pub-id pub-id-type="pmid">17685615</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baskova</surname>
              <given-names>IP</given-names>
            </name>
            <name>
              <surname>Cherkesova</surname>
              <given-names>DU</given-names>
            </name>
            <name>
              <surname>Mosolov</surname>
              <given-names>VV</given-names>
            </name>
          </person-group>
          <article-title>Hirudin from leech heads and whole leeches and "Pseudo-Hirudin" from leech bodies</article-title>
          <source>Thromb. Res.</source>
          <year>1983</year>
          <volume>30</volume>
          <fpage>459</fpage>
          <lpage>467</lpage>
          <pub-id pub-id-type="doi">10.1016/0049-3848(83)90180-9</pub-id>
          <pub-id pub-id-type="pmid">6612679</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khow</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Suntrarachun</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Strategies for production of active eukaryotic proteins in bacterial expression system</article-title>
          <source>Asian Pac. J. Trop. Biomed.</source>
          <year>2012</year>
          <volume>2</volume>
          <fpage>159</fpage>
          <lpage>162</lpage>
          <pub-id pub-id-type="doi">10.1016/S2221-1691(11)60213-X</pub-id>
          <pub-id pub-id-type="pmid">23569889</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bechlars</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>W&#xFC;stenhagen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Dr&#xE4;gert</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dieckmann</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Strauch</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Cell-free synthesis of functional thermostable direct hemolysins of <italic>Vibrio parahaemolyticus</italic></article-title>
          <source>Toxicon</source>
          <year>2013</year>
          <volume>76</volume>
          <fpage>132</fpage>
          <lpage>142</lpage>
          <pub-id pub-id-type="doi">10.1016/j.toxicon.2013.09.012</pub-id>
          <pub-id pub-id-type="pmid">24060377</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soejima</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Nagata</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mon</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Iiyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kitano</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Matsuyama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kusakabe</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Comparison of signal peptides for efficient protein secretion in the baculovirus-silkworm system</article-title>
          <source>Cent. Eur. J. Biol.</source>
          <year>2013</year>
          <volume>8</volume>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.2478/s11535-012-0112-6</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Br&#xF6;del</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>W&#xFC;stenhagen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Cell-free protein synthesis systems derived from cultured mammalian cells</article-title>
          <source>Methods Mol. Biol.</source>
          <year>2015</year>
          <volume>1261</volume>
          <fpage>129</fpage>
          <lpage>140</lpage>
          <pub-id pub-id-type="doi">10.1007/978-1-4939-2230-7_7</pub-id>
          <pub-id pub-id-type="pmid">25502197</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quast</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Kortt</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Henkel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dondapati</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>W&#xFC;stenhagen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Stech</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Automated production of functional membrane proteins using eukaryotic cell-free translation systems</article-title>
          <source>J. Biotechnol.</source>
          <year>2015</year>
          <volume>203</volume>
          <fpage>45</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbiotec.2015.03.015</pub-id>
          <pub-id pub-id-type="pmid">25828454</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walenga</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Hoppensteadt</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Koza</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wallock</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pifarre</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fareed</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Laboratory assays for the evaluation of recombinant hirudin</article-title>
          <source>Haemostasis</source>
          <year>1991</year>
          <volume>21</volume>
          <fpage>49</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="doi">10.1159/000216263</pub-id>
          <pub-id pub-id-type="pmid">1894197</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>M&#xFC;ller</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Meschke</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Liebig</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mahfound</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lemke</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>J-P</given-names>
            </name>
          </person-group>
          <article-title>More than just one: Multiplicity of hirudins and hirudin like factors in the medicinal leech, <italic>Hirudo medicinalis</italic></article-title>
          <source>Mol. Genet. Genomics</source>
          <year>2016</year>
          <volume>291</volume>
          <fpage>227</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="doi">10.1007/s00438-015-1100-0</pub-id>
          <pub-id pub-id-type="pmid">26267058</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>M&#xFC;ller</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Haase</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lemke</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>J-P</given-names>
            </name>
          </person-group>
          <article-title>Hirudins and hirudin-like factors in Hirudinidae: Implications for function and phylogenetic relationships</article-title>
          <source>Parasitol. Res.</source>
          <year>2017</year>
          <volume>116</volume>
          <fpage>313</fpage>
          <lpage>325</lpage>
          <pub-id pub-id-type="doi">10.1007/s00436-016-5294-9</pub-id>
          <pub-id pub-id-type="pmid">27785600</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tokmakov</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Kurotani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shirouzu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fukami</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yokoyama</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Bioinformatics analysis and optimization of cell-free protein synthesis</article-title>
          <source>Methods Mol. Biol.</source>
          <year>2014</year>
          <volume>1118</volume>
          <fpage>17</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="doi">10.1007/978-1-62703-782-2_2</pub-id>
          <pub-id pub-id-type="pmid">24395407</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gregorio</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>MZ</given-names>
            </name>
            <name>
              <surname>Oza</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>A user&#x2019;s guide to cell-free protein synthesis</article-title>
          <source>Methods Protoc.</source>
          <year>2019</year>
          <volume>2</volume>
          <fpage>24</fpage>
          <pub-id pub-id-type="doi">10.3390/mps2010024</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wallace</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dennis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hofsteenge</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Contribution of the N-terminal region of hirudin to its interaction with thrombin</article-title>
          <source>Biochemistry</source>
          <year>1989</year>
          <volume>28</volume>
          <fpage>10079</fpage>
          <lpage>10084</lpage>
          <pub-id pub-id-type="doi">10.1021/bi00452a030</pub-id>
          <pub-id pub-id-type="pmid">2620063</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szabady</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Skillman</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Bernstein</surname>
              <given-names>HD</given-names>
            </name>
          </person-group>
          <article-title>An unusual signal peptide facilitates late steps in the biogenesis of a bacterial autotransporter</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <year>2005</year>
          <volume>102</volume>
          <fpage>221</fpage>
          <lpage>226</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0406055102</pub-id>
          <pub-id pub-id-type="pmid">15615856</pub-id>
        </element-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shabareesh</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kaur</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Structural and functional characterization of hirudin P6 derived novel bivalent thrombin inhibitors&#x2014;Studying the effect of linker length and glycosylation on their function</article-title>
          <source>Chem. Biol. Drug Des.</source>
          <year>2016</year>
          <volume>88</volume>
          <fpage>129</fpage>
          <lpage>141</lpage>
          <pub-id pub-id-type="doi">10.1111/cbdd.12742</pub-id>
          <pub-id pub-id-type="pmid">26850929</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
          </person-group>
          <article-title>Bivalent direct thrombin inhibitors: Hirudin and bivalirudin</article-title>
          <source>Best. Pract. Res. Clin. Haematol.</source>
          <year>2004</year>
          <volume>17</volume>
          <fpage>105</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="doi">10.1016/j.beha.2004.02.002</pub-id>
          <pub-id pub-id-type="pmid">15171961</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greinacher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lubenow</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Recombinant hirudin in clinical practice: Focus on lepirudin</article-title>
          <source>Circulation</source>
          <year>2001</year>
          <volume>103</volume>
          <fpage>1479</fpage>
          <lpage>1484</lpage>
          <pub-id pub-id-type="doi">10.1161/01.cir.103.10.1479</pub-id>
          <pub-id pub-id-type="pmid">11245656</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quast</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Sonnabend</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stech</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>W&#xFC;stenhagen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>High-yield cell-free synthesis of human EGFR by IRES-mediated protein translation in a continuous exchange cell-free reaction format</article-title>
          <source>Sci. Rep.</source>
          <year>2016</year>
          <pub-id pub-id-type="doi">10.1038/srep30399</pub-id>
          <pub-id pub-id-type="pmid">27670253</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stech</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Merk</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Schenk</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>St&#xF6;cklein</surname>
              <given-names>WFM</given-names>
            </name>
            <name>
              <surname>W&#xFC;stenhagen</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Micheel</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Duschl</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bier</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Kubick</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Production of functional antibody fragments in a vesicle-based eukaryotic cell-free translation system</article-title>
          <source>J. Biotechnol.</source>
          <year>2012</year>
          <volume>164</volume>
          <fpage>220</fpage>
          <lpage>231</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbiotec.2012.08.020</pub-id>
          <pub-id pub-id-type="pmid">22982167</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>M&#xFC;ller</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lukas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>B&#xF6;hmert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hildebrandt</surname>
              <given-names>J-P</given-names>
            </name>
          </person-group>
          <article-title>Hirudin or hirudin-like factor&#x2014;That is the question</article-title>
          <source>FEBS Lett.</source>
          <year>2020</year>
          <volume>594</volume>
          <fpage>841</fpage>
          <lpage>850</lpage>
          <pub-id pub-id-type="doi">10.1002/1873-3468.13683</pub-id>
          <pub-id pub-id-type="pmid">31733150</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Saunders</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schussler</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Rios</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Insaidoo</surname>
              <given-names>FK</given-names>
            </name>
            <name>
              <surname>Fridman</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>YH</given-names>
            </name>
          </person-group>
          <article-title>Characterization of a novel modification of a CHO-produced mAb: Evidence for the presence of tyrosine sulfation</article-title>
          <source>mAbs</source>
          <year>2017</year>
          <volume>9</volume>
          <fpage>985</fpage>
          <lpage>995</lpage>
          <pub-id pub-id-type="doi">10.1080/19420862.2017.1332552</pub-id>
          <pub-id pub-id-type="pmid">28590151</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niedermeyer</surname>
              <given-names>THJ</given-names>
            </name>
            <name>
              <surname>Strohalm</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>mMass as a software tool for the annotation of cyclic peptide tandem mass spectra</article-title>
          <source>PLoS ONE</source>
          <year>2012</year>
          <volume>7</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0044913</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Cardiovasc Drugs Ther</journal-id>
      <journal-id journal-id-type="iso-abbrev">Cardiovasc Drugs Ther</journal-id>
      <journal-title-group>
        <journal-title>Cardiovascular Drugs and Therapy</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0920-3206</issn>
      <issn pub-type="epub">1573-7241</issn>
      <publisher>
        <publisher-name>Springer US</publisher-name>
        <publisher-loc>New York</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32870433</article-id>
      <article-id pub-id-type="pmc">7459262</article-id>
      <article-id pub-id-type="publisher-id">7066</article-id>
      <article-id pub-id-type="doi">10.1007/s10557-020-07066-x</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Aliter</surname>
            <given-names>Kholoud F.</given-names>
          </name>
          <address>
            <email>kal-horani@dillard.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9146-2662</contrib-id>
          <name>
            <surname>Al-Horani</surname>
            <given-names>Rami A.</given-names>
          </name>
          <address>
            <email>ralhoran@xula.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.255097.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2233 734X</institution-id><institution>Department of Chemistry, School of STEM, </institution><institution>Dillard University, </institution></institution-wrap>New Orleans, LA 70122 USA </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.268355.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9679 3586</institution-id><institution>Division of Basic Pharmaceutical Sciences, College of Pharmacy, </institution><institution>Xavier University of Louisiana, </institution></institution-wrap>1 Drexel Drive, New Orleans, LA 70125-1089 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>1</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <fpage>1</fpage>
      <lpage>9</lpage>
      <history>
        <date date-type="accepted">
          <day>27</day>
          <month>8</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer Science+Business Media, LLC, part of Springer Nature 2020</copyright-statement>
        <license>
          <license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">Thrombin is a trypsin-like serine protease with multiple physiological functions. Its role in coagulation and thrombosis is well-established. Nevertheless, thrombin also plays a major role in inflammation by activating protease-activated receptors. In addition, thrombin is also involved in angiogenesis, fibrosis, and viral infections. Considering the pathogenesis of COVID-19 pandemic, thrombin inhibitors may exert multiple potential therapeutic benefits including antithrombotic, anti-inflammatory, and antiviral activities. In this review, we describe the clinical features of COVID-19, the thrombin&#x2019;s roles in various pathologies, and the potential of argatroban in COVID-19 patients. Argatroban is a synthetic, small molecule, direct, competitive, and selective inhibitor of thrombin. It is approved to parenterally prevent and/or treat heparin-induced thrombocytopenia in addition to other thrombotic conditions. Argatroban also possesses anti-inflammatory and antiviral activities and has a well-established pharmacokinetics profile. It also appears to lack a significant risk of drug&#x2013;drug interactions with therapeutics currently being evaluated for COVID-19. Thus, argatroban presents a substantial promise in treating severe cases of COVID-19; however, this promise is yet to be established in randomized, controlled clinical trials.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>COVID-19</kwd>
        <kwd>SARS-CoV-2</kwd>
        <kwd>Argatroban</kwd>
        <kwd>Coagulopathy</kwd>
        <kwd>Inflammation</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>National Institute of General Medical Sciences</institution>
          </funding-source>
          <award-id>SC3GM131986</award-id>
          <principal-award-recipient>
            <name>
              <surname>Al-Horani</surname>
              <given-names>Rami A.</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par2">Coronavirus disease of 2019 (COVID-19) continues to evolve as a deadly pandemic with more than 25 million people infected worldwide and more than 840 thousand individuals died because of the disease and/or its associated complications [<xref ref-type="bibr" rid="CR1">1</xref>]. COVID-19 is a viral infection caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The pathogen is a single-stranded RNA virus which, upon infecting the respiratory system, can cause pneumonia and acute respiratory distress syndrome. The most common symptoms at the illness onset appear to be fever, cough, fatigue, and myalgia [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Nevertheless, the disease is also associated with several extra-pulmonary manifestations. Gastrointestinal symptoms appear to be common and reported in about 40% of patients in some studies [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Neurological manifestations such as headache, dizziness, and altered consciousness have also been reported [<xref ref-type="bibr" rid="CR6">6</xref>]. Some COVID-19 patients also reported skin and ocular symptoms [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>] as well as taste or olfactory disorders [<xref ref-type="bibr" rid="CR9">9</xref>].</p>
      <p id="Par3">Although the initial clinical cases from China involved hospitalized patients with severe pneumonia, yet overall data have suggested that ~&#x2009;80% of COVID-19 patients only experience a mild disease [<xref ref-type="bibr" rid="CR10">10</xref>]. Many reports indicated that patients who require hospital admission initially appear stable, but they rapidly deteriorate with severe hypoxia leading to severe acute distress syndrome which requires ICU admission and mechanical ventilation [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Myocardial injury also appears to be high among these patients [<xref ref-type="bibr" rid="CR12">12</xref>]. The progression of illness in hospitalized patients has been attributed to excessive systemic inflammatory response including the excessive release of pro-inflammatory cytokines, which may eventually lead to multiorgan failure and death. Along these lines, the progression of COVID-19 has been found to be associated with a decrease in lymphocytes and an increase in neutrophils. A number of inflammatory markers are reported to significantly increase during the severe stage of the illness including C-reactive protein, ferritin, interleukin-6 (IL-6), interferon gamma-induced protein-10 (IP-10), granulocyte-colony stimulating factor (G-CSF), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1&#x3B1; (MIP-1&#x3B1;), and tissue necrosis factor-&#x3B1; (TNF-&#x3B1;) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR13">13</xref>&#x2013;<xref ref-type="bibr" rid="CR15">15</xref>].</p>
      <p id="Par4">Furthermore, several cardiovascular, hematologic, and thrombotic complications have also been attributed to the (in)direct effects of the viral disease [<xref ref-type="bibr" rid="CR16">16</xref>&#x2013;<xref ref-type="bibr" rid="CR18">18</xref>]. Several studies reported thrombotic complications in COVID-19 patients with rates of venous thromboembolic events as high as 30%, particularly in critically ill and mechanically ventilated patients [<xref ref-type="bibr" rid="CR19">19</xref>&#x2013;<xref ref-type="bibr" rid="CR21">21</xref>]. Cardiovascular and thrombotic complications include intravascular disseminated coagulopathy, pulmonary embolism, stroke, acute limb ischemia, and acute coronary syndromes [<xref ref-type="bibr" rid="CR22">22</xref>&#x2013;<xref ref-type="bibr" rid="CR26">26</xref>]. In fact, the hypercoagulable state of these patients was reflected by the elevated measured levels of D-dimer and fibrinogen as well as the prolonged measured prothrombin time [<xref ref-type="bibr" rid="CR27">27</xref>]. Similar to the systemic inflammation, the hypercoagulable state appears to be associated with poor clinical outcomes [<xref ref-type="bibr" rid="CR22">22</xref>&#x2013;<xref ref-type="bibr" rid="CR26">26</xref>].</p>
      <p id="Par5">Unfortunately, there are currently neither approved vaccines to protect people against the infection nor highly effective approved therapeutics to treat it. However, the evolving understanding of the virus life cycle and the infection pathogenicity is catalyzing the development of the urgently needed vaccines and therapeutics. In this direction, several viral and host proteins are being considered as&#xA0;drug targets to develop anti-COVID-19 therapeutics. In this review, we put forward thrombin, a trypsin-like serine protease belonging to the coagulation process, as a potential drug target to develop adjunct therapeutics for COVID-19, particularly for the critically ill patients. While the pivotal role of thrombin in coagulation and thrombosis is well established, thrombin also has a documented role in inflammation as well as a significant link to viral infections.</p>
    </sec>
    <sec id="Sec2">
      <title>Thrombin in Coagulation, Inflammation, Angiogenesis, Fibrosis, and Viral Infections</title>
      <sec id="Sec3">
        <title>Coagulation</title>
        <p id="Par6">Thrombin, also known as factor IIa, is a ~&#x2009;36&#xA0;kD globular, trypsin-like serine protease in the common coagulation pathway. Thrombin is a pivotal protein in both hemostasis and thrombosis. Thrombin initiates the formation of fibrin clots and promotes platelet activation. It is enzymatically generated from its precursor i.e., prothrombin by the action of factor Xa of prothrombinase complex, which also includes phospholipids, calcium, and factor Va. Physiologically, thrombin converts fibrinogen to fibrin which ultimately leads to the formation of blood clot. Thrombin also activates factor XIII which subsequently cross-links fibrin so as to strengthen the formed clot. Thrombin also contributes to the propagation of the coagulation process by providing a positive feedback in which it activates other factors including factors V, VIII, and XI [<xref ref-type="bibr" rid="CR28">28</xref>&#x2013;<xref ref-type="bibr" rid="CR33">33</xref>]. Thrombin can also activate platelets by binding to platelet glycoprotein Ib&#x3B1; [<xref ref-type="bibr" rid="CR34">34</xref>] and/or protease-activated receptors (PARs) [<xref ref-type="bibr" rid="CR35">35</xref>]. Thrombin is also reported to activate thrombin-activatable fibrinolysis inhibitor and eventually downregulates fibrinolysis [<xref ref-type="bibr" rid="CR36">36</xref>]. Together, thrombin is a key procoagulant protein and its excessive generation often leads to arterial or venous thrombosis. Under certain conditions, thrombin can exhibit an anticoagulant role by forming a complex with thrombomodulin. The resulting complex activates protein C which in turn cleaves factors Va and VIIIa resulting in a feedback inhibition of the coagulation process [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
      </sec>
      <sec id="Sec4">
        <title>Inflammation, Angiogenesis, and Fibrosis</title>
        <p id="Par7">Beyond coagulation, thrombin&#x2019;s pro-inflammatory effects are also well documented. Thrombin can initiate and amplify inflammation by activating PARs. PARs are G protein-coupled receptors that are expressed in a variety of tissues and cells including platelets, endothelial cells, leukocytes, and fibroblasts. These receptors can be activated by tissue factor: factor VIIa complex, factor Xa, and/or thrombin. Particularly, PARs (1, 3, and 4) modulate a variety of responses to thrombin including thrombosis and inflammation [<xref ref-type="bibr" rid="CR38">38</xref>&#x2013;<xref ref-type="bibr" rid="CR40">40</xref>].</p>
        <p id="Par8">Thrombin was shown to upregulate the expression of cytokines, chemokines, and other proteins in different types of cells. In human adipocytes, thrombin stimulated the secretion of interleukin (IL)-1&#x3B2;, IL-6, TNF-&#x3B1;, MCP-1, and vascular endothelial cell growth factor [<xref ref-type="bibr" rid="CR41">41</xref>]. Likewise, thrombin increased the release of macrophage migration inhibitory factor in urothelial cell, which can mediate bladder inflammation [<xref ref-type="bibr" rid="CR42">42</xref>]. On endothelial cells, thrombin initiated the production of a number of pro-inflammatory mediators including IL-6, IL-8, transforming growth factor-&#x3B2;, MCP-1, platelet-derived growth factor, intracellular adhesion molecule (ICAM)-1, and P-selectin, mainly through the NF-&#x3BA;B (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway. Disrupting this pathway was shown to inhibit the ability of thrombin to induce the expression of adhesion molecules including ICAM-1 and vascular cell adhesion molecule and to reduce the thrombin-dependent adhesion of monocytes to endothelial cells [<xref ref-type="bibr" rid="CR43">43</xref>&#x2013;<xref ref-type="bibr" rid="CR45">45</xref>]. Macrophage migration inhibitory factor secretion and ERK phosphorylation were implicated in thrombin effect on endothelium&#x2019;s NF-&#x3BA;B activation [<xref ref-type="bibr" rid="CR46">46</xref>]. At high concentrations, thrombin also increased endothelial permeability which is a feature of inflammation [<xref ref-type="bibr" rid="CR47">47</xref>]. Thrombin has also been shown to induce the expression of IL-6 and C-X-C motif chemokine ligand-8 (aka IL-8) from human aortic smooth muscle cells [<xref ref-type="bibr" rid="CR48">48</xref>]. With monocytes or monocyte-derived macrophages, thrombin enhanced adhesiveness, increased the production of IL-1, TNF-&#x3B1;, IL-6, MCP-1, and IL-10, and downregulated IL-12 secretion [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Earlier, it was also shown that thrombin enhanced IL-1 and TNF-&#x3B1; induced polymorphonuclear leukocyte migration [<xref ref-type="bibr" rid="CR51">51</xref>]. Likewise, thrombin enhanced the production of MCP-1 and macrophage inflammatory protein-2 in cultured rat glomerular epithelial cells [<xref ref-type="bibr" rid="CR52">52</xref>]. Along these lines, thrombin inhibition was found to reduce the expression of brain inflammatory markers upon systemic lipopolysaccharide treatment of mice. In this model, inhibition of thrombin activity by a specific inhibitor reported as NAPAP (mostly likely is dabigatran) immediately led to a reduction in the expression of inflammatory markers of TNF-&#x3B1;, C-X-C motif chemokine ligand-9 (CXL9), and C-C motif chemokine ligand-1 (CCL1) and in the expression of the coagulation markers of factor X and PAR-1 in the brain [<xref ref-type="bibr" rid="CR53">53</xref>].</p>
        <p id="Par9">Furthermore, thrombin can also directly activate the complement components C3 and C5 [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>] as well as modulate innate immune responses by altering cytokine secretion and receptor expression by antigen-presenting cells [<xref ref-type="bibr" rid="CR56">56</xref>]. Thrombin was also found to promote angiogenesis and to increase the expression of angiogenic growth factors including fibroblast growth factor-2, platelet-derived growth factor, and vascular endothelial growth factor in human adipose cells and these effects were prevented by lepirudin, a direct thrombin inhibitor [<xref ref-type="bibr" rid="CR41">41</xref>]. Thrombin-mediated regulation of platelet-derived growth factor influenced the migration and proliferation of vascular smooth muscle cells leading to plaque formation [<xref ref-type="bibr" rid="CR57">57</xref>]. Thrombin was also shown to regulate the expression and release of platelet-derived growth factor activity from cultured renal microvascular endothelial cells, and thus, was proposed to in vivo stimulate mitogen to induce perivascular cell proliferation [<xref ref-type="bibr" rid="CR58">58</xref>]. Subsequently, thrombin was shown to regulate the expression of proangiogenic cytokines by activating PAR-1 [<xref ref-type="bibr" rid="CR59">59</xref>].</p>
        <p id="Par10">Importantly, thrombin was also shown to be involved in several experimental animal models of diseases including lipopolysaccharide-induced endotoxemia [<xref ref-type="bibr" rid="CR39">39</xref>], glomerulonephritis [<xref ref-type="bibr" rid="CR60">60</xref>], and lung fibrosis [<xref ref-type="bibr" rid="CR61">61</xref>]. In the lung, thrombin mediated the expression of mucin and stimulated the expression of tissue factor from nasal epithelial cells through PAR-1 activation [<xref ref-type="bibr" rid="CR62">62</xref>]. Recently, a study also showed that thrombin activates IL-1&#x3B1;, a pro-inflammatory cytokine that mediates innate immune responses and thrombopoiesis, following ectoderm injury in mice. Interestingly, thrombin-cleaved IL-1&#x3B1; was identified in humans with sepsis-associated adult respiratory distress syndrome suggesting a strong link between thrombin and inflammation [<xref ref-type="bibr" rid="CR63">63</xref>]. Furthermore, idiopathic pulmonary fibrosis produced in a vascular leak&#x2013;dependent mouse model was found to be highly dependent on thrombin activity and its downstream signaling pathways. Inhibition of thrombin by dabigatran, and not by warfarin, significantly inhibited PAR-1 activation, integrin &#x3B1;v&#x3B2;6 induction, transforming growth factor-&#x3B2; activation, and the development of pulmonary fibrosis in this model [<xref ref-type="bibr" rid="CR64">64</xref>].</p>
      </sec>
      <sec id="Sec5">
        <title>Viral Infections</title>
        <p id="Par11">Considering microbial infections, thrombin has been reported to be involved in the pathogenesis of several viruses by different mechanisms [<xref ref-type="bibr" rid="CR65">65</xref>&#x2013;<xref ref-type="bibr" rid="CR75">75</xref>]. These viruses include hepatitis E virus [<xref ref-type="bibr" rid="CR66">66</xref>], respiratory syncytial virus [<xref ref-type="bibr" rid="CR67">67</xref>], human metapneumovirus [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR71">71</xref>], influenza viruses [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR72">72</xref>&#x2013;<xref ref-type="bibr" rid="CR74">74</xref>], coxsackievirus B3 [<xref ref-type="bibr" rid="CR65">65</xref>], herpes simplex virus [<xref ref-type="bibr" rid="CR68">68</xref>], cytomegalovirus [<xref ref-type="bibr" rid="CR69">69</xref>], human immunodeficiency virus [<xref ref-type="bibr" rid="CR70">70</xref>], and porcine circovirus-1 [<xref ref-type="bibr" rid="CR75">75</xref>]. For example, thrombin has been implicated in the replication of hepatitis E virus, nonenveloped positive-sense and single-stranded RNA virus, by facilitating pORF1 polyprotein processing [<xref ref-type="bibr" rid="CR66">66</xref>]. Data also showed that herpes simplex viruses-1 and -2 initiate thrombin production to increase the susceptibility of cells to infection through a mechanism involving PAR1-mediated cell modulation [<xref ref-type="bibr" rid="CR68">68</xref>]. Thrombin was also found to increase influenza virus-induced inflammation. In fact, influenza viruses could induce thrombin generation leading to platelet activation-mediated lung inflammation [<xref ref-type="bibr" rid="CR72">72</xref>&#x2013;<xref ref-type="bibr" rid="CR74">74</xref>]. Studies also linked thrombin to human metapneumovirus and respiratory syncytial virus, two enveloped, negative-sense, and single-stranded RNA viruses that cause respiratory infections. In these studies, thrombin was shown to increase the replication of these viruses and to exacerbate the associated inflammation [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR71">71</xref>].</p>
        <p id="Par12">Together, considering thrombin&#x2019;s roles in thrombosis, inflammation, and viral infections (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>), it is plausible to expect that inhibiting thrombin activity may eventually promote not only anticoagulant effect, but also anti-inflammatory and antiviral effects. These effects provide a strong rationale for the use of thrombin inhibitors in treating COVID-19 patients.<fig id="Fig1"><label>Fig. 1</label><caption><p>Thrombin plays a pivotal role in thrombosis, inflammation, angiogenesis, fibrosis, and viral infection. Therefore, thrombin inhibitors may eventually promote not only anticoagulant effect, but also anti-inflammatory and antiviral effects. Thrombin&#x2019;s effect on protein C pathway is not presented</p></caption><graphic xlink:href="10557_2020_7066_Fig1_HTML" id="MO1"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec6">
      <title>Current Thrombin Inhibitors</title>
      <p id="Par13">Current drugs that inhibit thrombin are classified into direct and indirect inhibitors (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). In one hand, the indirect inhibitors include unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) which activate the endogenous serpin antithrombin to eventually inhibit thrombin in a template- or bridging-based mechanism. UFH and LMWHs also antithrombin-dependently inhibit factor Xa [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR77">77</xref>]. Warfarin, a vitamin K antagonist, also affects thrombin indirectly by inhibiting the hepatic biosynthesis of its precursor prothrombin by targeting vitamin K epoxide reductase and vitamin K quinone reductase [<xref ref-type="bibr" rid="CR77">77</xref>]. In the other hand, hirudin, dabigatran etexilate, and argatroban are direct inhibitors of thrombin. Hirudin is a naturally occurring polypeptide isolated from the salivary glands of blood-sucking leeches of <italic>Hirudo medicinalis</italic> and possesses a blood anticoagulant property. Hirudin inhibits thrombin by binding to its active site as well as its allosteric exosite I, and thus, it is described as a bivalent inhibitor. Hirudin-related drugs that are in clinical use are lepirudin, desirudin, and bivalirudin [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. Dabigatran and argatroban are small molecule, active site, and selective inhibitors of thrombin [<xref ref-type="bibr" rid="CR78">78</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>The chemical structures of <bold>a</bold> indirect inhibitors (UFH, LMWHs, and warfarin) and <bold>b</bold> direct inhibitors of thrombin (bivalirudin, dabigatran etexilate, and argatroban). UFH, LMWHs, bivalirudin, and argatroban are parenterally used anticoagulants, whereas warfarin and dabigatran etexilate are orally used anticoagulants. Argatroban is the focus of this review</p></caption><graphic xlink:href="10557_2020_7066_Fig2_HTML" id="MO2"/></fig></p>
      <p id="Par14">Generally, all the above drugs are approved for clinical use as prophylaxis or treatment of thrombotic conditions. Some of them are used parenterally while the others are orally active. UFH and LMWHs are heterogenous mixtures of sulfated glycosaminoglycans that are clinically used via the parenteral route of administration [<xref ref-type="bibr" rid="CR79">79</xref>]. Lepirudin and desirudin are recombinant hirudins that were developed by recombinant technology in <italic>Saccharomyces cerevisiae</italic> [<xref ref-type="bibr" rid="CR80">80</xref>]. Bivalirudin is an engineered 20-amino acid, synthetic analogue of hirudin [<xref ref-type="bibr" rid="CR81">81</xref>]. All hirudin derivatives are also used parenterally. Argatroban is a synthetic tetrahydroquinolinyl-sulfonyl-L-arginyl-piperidine-carboxylic acid derivative that is also used parenterally. Warfarin is orally active coumarin derivative, whereas dabigatran etexilate is orally active, double prodrug that is derivative of benzimidazole methylamine-benzamidine [<xref ref-type="bibr" rid="CR77">77</xref>&#x2013;<xref ref-type="bibr" rid="CR80">80</xref>].</p>
      <p id="Par15">In the ongoing pandemic, UFH and LMWHs appear to be gaining a momentum in treating COVID-19 [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. They are widely available and affordable anticoagulants with well-known pharmacological profiles and approved antidote to address potential bleeding events. However, a recent study has documented evidence of heparin resistance in critically ill COVID-19 patients [<xref ref-type="bibr" rid="CR84">84</xref>]. In many cases, heparin resistance can be attributed to antithrombin deficiency. In fact, another recent study reported that antithrombin values were moderately, yet significantly lower in COVID-19 patients compared with control group [<xref ref-type="bibr" rid="CR85">85</xref>]. Thus, this review focuses on argatroban which may serve as a potential alternative anticoagulant in COVID-19 patients. In fact, argatroban demonstrates anti-inflammatory and antiviral activities, in addition to its established anticoagulant properties. Argatroban is also associated with a favorable drug&#x2013;drug interaction profile considering treatments currently under evaluation in COVID-19 patients [<xref ref-type="bibr" rid="CR86">86</xref>].</p>
    </sec>
    <sec id="Sec7">
      <title>Potential Therapeutic Benefits of Argatroban in COVID-19 Patients</title>
      <p id="Par16">Argatroban is a synthetic small molecule and peptidomimetic inhibitor of thrombin with a <italic>K</italic><sub>i</sub> value of ~&#x2009;39&#xA0;nM. It is a reversible, parenterally used, highly selective, and competitive inhibitor of thrombin. In contrast to heparins, it directly inhibits the physiological function of the free as well as the clot-bound thrombin without the need for antithrombin. It inhibits fibrin formation as well as the thrombin-mediated activation of coagulation factors V, VIII, and XIII. It also inhibits the activation of protein C and platelet aggregation [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. Argatroban was first approved by the US FDA in 2000 as a prophylaxis or a treatment of thrombosis in adults with heparin-induced thrombocytopenia. It is also used as an anticoagulant for percutaneous coronary intervention in adults who have or are at risk of developing heparin-induced thrombocytopenia [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. Similar indications are approved by the Canadian authorities. However, argatroban has been approved for other thrombotic conditions in Japan and Korea. It was first clinically used in Japan for the treatment of peripheral arterial occlusive disease in the early 1980s. It was then approved for the treatment of arterial thrombosis, acute cerebral thrombosis, and anticoagulation of antithrombin-deficient patients undergoing hemodialysis. Argatroban is also approved in Korea for use in chronic arterial occlusion and acute cerebral thrombosis [<xref ref-type="bibr" rid="CR88">88</xref>]. Given the high risk of coagulopathy in severe and critically ill COVID-19 patients, the anticoagulant activity of argatroban is of enormous benefit, particularly that anticoagulation has been found to increase survival in these patients [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>].</p>
      <p id="Par17">Given the established role of thrombin in inflammation, angiogenesis, and fibrosis, thrombin inhibitors are likely to protect against these pathologies. As mentioned before, lepirudin was found to prevent thrombin-mediated angiogenesis and to prevent thrombin-mediated expression of angiogenic growth factors [<xref ref-type="bibr" rid="CR41">41</xref>]. Dabigatran reduced the expression of inflammatory markers of TNF-&#x3B1;, CXL9, and CCL1 and the expression of the coagulation markers of factor X and PAR-1 in mouse brain [<xref ref-type="bibr" rid="CR53">53</xref>]. Dabigatran significantly inhibited PAR-1 activation, integrin &#x3B1;v&#x3B2;6 induction, transforming growth factor-&#x3B2; activation, and the development of pulmonary fibrosis in a vascular-leak mouse model [<xref ref-type="bibr" rid="CR64">64</xref>]. Similar to lepirudin [<xref ref-type="bibr" rid="CR41">41</xref>] and dabigatran [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR64">64</xref>], argatroban is likely to protect against these pathologies. Furthermore, continuous infusion of argatroban was also found to increase the plasma levels of nitric oxide and nitrosyl hemoglobin in patients with peripheral arterial obstructive disease, and thus, to improve microcirculation compared with a placebo-treated group [<xref ref-type="bibr" rid="CR91">91</xref>]. Moreover, plasma samples collected from heparin-induced thrombocytopenia patients indicated that treatment with argatroban significantly decreased the circulatory levels of inflammation markers including myeloperoxidase, CD40L, and functional microparticles. Nitric oxide levels measured in platelets were also increased with argatroban treatment [<xref ref-type="bibr" rid="CR92">92</xref>]. Interestingly, none of the above effects was observed with lepirudin or bivalirudin [<xref ref-type="bibr" rid="CR92">92</xref>], suggesting a greater potential benefit of argatroban.</p>
      <p id="Par18">In a diabetic cardiomyopathy rat model, argatroban treatment reduced plasma levels of glucose and cholesterol, alleviated ventricular dysfunctions by improving systolic and diastolic functions, decreased cardiac fibrosis, and reduced apoptosis. In this model, argatroban significantly reduced the expression of PAR-1 and PAR-4. Protein kinase B, glycogen synthase kinase-3&#x3B2;, p-65 NF-&#x138;B phosphorylation, transforming growth factor-&#x3B2;, cyclooxygenase-2, and caspase-3 expression were also reduced significantly in rats treated with argatroban, along with a substantial increase in sarco/endoplasmic reticulum calcium&#x2014;ATPase expression suggesting a significant anti-fibrotic, anti-inflammatory, and anti-apoptotic potential of argatroban [<xref ref-type="bibr" rid="CR93">93</xref>]. Argatroban also decreased the production of MCP-1 and macrophage inflammatory protein-2 in cultured rat glomerular epithelial cells [<xref ref-type="bibr" rid="CR52">52</xref>]. Thrombin inhibition by argatroban also decreased neurodegeneration and cerebral edema following bilateral common carotid artery occlusion and reperfusion in male Mongolian gerbils [<xref ref-type="bibr" rid="CR94">94</xref>].</p>
      <p id="Par19">Literature has also reported on the antiviral activity of argatroban. Human metapneumovirus, which belongs to the family of <italic>Pneumoviridae</italic>, is non-segmented, negative-stranded, enveloped RNA virus. It can cause upper and lower respiratory diseases particularly among young children, older adults, and people with compromised immune systems. In mice studies, it was found that immediate injections of argatroban after the virus challenge protected mice against human metapneumovirus infection and substantially reduced mortality, weight loss, viral load, and lung inflammation. In particular, the results showed that there was no weight loss or mortality in the infected mice that received immediate treatment with argatroban post-infection followed by 4&#xA0;days of treatment. A significant decrease in lung viral titers was detected on day 5 post-infection. Argatroban also significantly reduced thrombin generation and leukocyte recruitment during the infection. It also induced significant decreases in the levels of G-CSF, interferon-&#x3B3;, IL-3, IL-4, IL-6, IL-12 p70, and MCP-1 in the bronchoalveolar lavage of the infected mice, as compared with controls. It also decreased the virus-induced lung tissue damage [<xref ref-type="bibr" rid="CR71">71</xref>].</p>
      <p id="Par20">As far as COVID-19, argatroban was recently identified via bioinformatics approach as a potential blocker of angiotensin converting enzyme-2 (ACE2), yet the finding was not experimentally confirmed. ACE2 is the human cell receptor to which the viral spike S protein binds [<xref ref-type="bibr" rid="CR95">95</xref>]. A homology modeling and virtual screening also identified argatroban as a potential inhibitor of the viral 3-chymotrypsin-like protease (also known as the main protease), a viral protease with an essential role in processing the polyproteins that are translated from the viral RNA [<xref ref-type="bibr" rid="CR96">96</xref>]. Another computational work identified argatroban as a potential inhibitor of transmembrane protease, serine-2 (TMPRSS2), a serine protease that facilitates the viral fusion and entry into the host cell [<xref ref-type="bibr" rid="CR97">97</xref>]. Importantly, although promising, the above computational results remain to be theoretical in nature.</p>
    </sec>
    <sec id="Sec8">
      <title>Pharmacokinetics, Toxicities, and Potential Drug&#x2013;Drug Interactions of Argatroban</title>
      <p id="Par21">Because argatroban is administered via IV infusion, it promotes an immediate action. It has a volume of distribution of 174&#xA0;mL/kg and binds to plasma proteins including albumin (~&#x2009;20%) and &#x3B1;<sub>1</sub>-acid glycoprotein (~&#x2009;34%). Its plasma half-life is 39&#x2013;51&#xA0;min, which is extended to 181&#xA0;min in patients with hepatic impairment. The time to reach steady state peak is 1&#x2013;3&#xA0;h. Its clearance rate in adults is about 5.1&#xA0;mL/kg/min, which is decreased to 1.9&#xA0;mL/kg/min in patients with hepatic impairment. The main route of argatroban metabolism is hydroxylation and aromatization of the tetrahydro-quinoline ring in the liver. The formation of metabolites is catalyzed in vitro by CYP450 3A4/5. Thus, the dosage of argatroban should be decreased in patients with hepatic impairment. Argatroban is excreted primarily in the feces, and thus, no dosage adjustment is necessary in patients with renal dysfunction [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR98">98</xref>&#x2013;<xref ref-type="bibr" rid="CR100">100</xref>].</p>
      <p id="Par22">Argatroban was not genotoxic in a host of tests. Argatroban also had no effect on fertility or reproductive function of male and female rats at IV doses up to 27&#xA0;mg/kg/day [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR88">88</xref>, <xref ref-type="bibr" rid="CR98">98</xref>&#x2013;<xref ref-type="bibr" rid="CR100">100</xref>]. Argatroban&#x2019;s adverse reactions are generally mild and appear to resolve upon treatment discontinuation. In heparin-induced thrombocytopenia patients, the most common adverse reactions were dyspnea, hypotension, fever, and diarrhea. In percutaneous coronary intervention patients, the most common adverse reactions were chest pain, hypotension, back pain, nausea, vomiting, and headache [<xref ref-type="bibr" rid="CR98">98</xref>]. As with all anticoagulants, bleeding is also a potential adverse effect of argatroban. There is no specific antidote for argatroban. Given its short-half life, management of bleeding is recommended via the cessation of treatment and general hemostatic measures [<xref ref-type="bibr" rid="CR100">100</xref>].</p>
      <p id="Par23">Considering drug&#x2013;drug interactions, the concomitant use of argatroban and warfarin was found to lead to prothrombin time prolongation. If argatroban is to be initiated after cessation of heparin therapy, sufficient time should be allowed prior to initiation of argatroban therapy. No drug&#x2013;drug interactions have been demonstrated between argatroban and concomitantly administered aspirin, acetaminophen, digoxin, or azithromycin. The safety and effectiveness of argatroban with thrombolytic agents do not appear to have been established [<xref ref-type="bibr" rid="CR98">98</xref>]. Interestingly, there appear no potential interactions between argatroban and drugs being currently tested for COVID-19 including lopinavir/ritonavir, remdesivir, ribavirin, hydroxychloroquine, tocilizumab, sarilumab, methylprednisolone, and anakinra [<xref ref-type="bibr" rid="CR86">86</xref>].</p>
    </sec>
    <sec id="Sec9">
      <title>Conclusion</title>
      <p id="Par24">The potential therapeutic benefits of argatroban as a treatment for COVID-19 infection and/or its complications can be attributed to its antithrombotic, anti-inflammatory, and antiviral properties. These properties have been supported by a large number of studies in cellular settings, animal models, and humans. Owing to these properties, argatroban could potentially assist in treating the coagulopathy, dampen the excessive inflammation, and halting the viral replication, particularly in severe and critically ill COVID-19 patients. Encouraging aspects also include&#xA0;the worldwide availability of the drug, its well-established pharmacokinetics and safety profiles, and the apparent lack of drug&#x2013;drug interactions with potential anti-COVID-19 therapeutics under evaluation. In this direction, successful anticoagulation with argatroban was very recently reported in a small number of severely ill COVID-19 patients (<italic>N</italic>&#x2009;=&#x2009;10) with acute antithrombin deficiency [<xref ref-type="bibr" rid="CR101">101</xref>]. Nevertheless, the potential benefits of argatroban in COVID-19 patients remain largely hypothetical and will have to be clinically established via large, randomized, double-blinded, and controlled clinical trials. Currently, argatroban is being studied in a phase 4 trial of anticoagulation in critically ill patients with COVID-19 (NCT04406389).</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <ack>
      <p>The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; Contribution</title>
      <p>RAAH: conceptualized the project; RAAH and KFA: reviewed the relevant literature; KFA: wrote the first draft; RAAH: supervised, revised, and finalized the manuscript; RAAH: provided all resources; RAAH: visualized the project aspect.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>RAAH is supported by NIGMS/NIH under award number SC3GM131986 and by IDeA program from NIGMS/NIH under grant number P20GM103424.</p>
    </notes>
    <notes>
      <title>Compliance with Ethical Standards</title>
      <notes id="FPar1" notes-type="COI-statement">
        <title>Conflict of Interest</title>
        <p id="Par25">The authors declare that they have no conflict of interest.</p>
      </notes>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="other">Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533&#x2013;4.</mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title>
          <source>Lancet.</source>
          <year>2020</year>
          <volume>395</volume>
          <issue>10229</issue>
          <fpage>1054</fpage>
          <lpage>1062</lpage>
          <pub-id pub-id-type="pmid">32171076</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="other">Kluytmans-vanden Bergh MFQ, Buiting AGM, Pas SD, et al. Prevalence and clinical presentation of health care workers with symptoms of coronavirus disease 2019 in 2 Dutch hospitals during an early phase of the pandemic. JAMA Netw Open. 2020;3(5):e209673 <ext-link ext-link-type="uri" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2766228">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2766228</ext-link>. Accessed 25 Aug 2020.</mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Rao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Qi</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus</article-title>
          <source>Gut.</source>
          <year>2020</year>
          <volume>69</volume>
          <issue>6</issue>
          <fpage>1141</fpage>
          <lpage>1143</lpage>
          <pub-id pub-id-type="pmid">32102928</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>YD</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>YB</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>YQ</given-names>
            </name>
            <name>
              <surname>Akdis</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>YD</given-names>
            </name>
          </person-group>
          <article-title>Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China</article-title>
          <source>Allergy</source>
          <year>2020</year>
          <volume>75</volume>
          <issue>7</issue>
          <fpage>1730</fpage>
          <lpage>1741</lpage>
          <pub-id pub-id-type="pmid">32077115</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mao</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Miao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China</article-title>
          <source>JAMA Neurol</source>
          <year>2020</year>
          <volume>77</volume>
          <issue>6</issue>
          <fpage>1</fpage>
          <lpage>9</lpage>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Recalcati</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous manifestations in COVID-19: a first perspective</article-title>
          <source>J Eur Acad Dermatol Venereol</source>
          <year>2020</year>
          <volume>34</volume>
          <issue>5</issue>
          <fpage>e212</fpage>
          <lpage>e213</lpage>
          <pub-id pub-id-type="pmid">32215952</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Duan</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Qu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China</article-title>
          <source>JAMA Ophthalmol</source>
          <year>2020</year>
          <volume>138</volume>
          <issue>5</issue>
          <fpage>575</fpage>
          <lpage>578</lpage>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giacomelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pezzati</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Conti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bernacchia</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Siano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oreni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rusconi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gervasoni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ridolfo</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Rizzardini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Antinori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Galli</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study</article-title>
          <source>Clin Infect Dis</source>
          <year>2020</year>
          <volume>71</volume>
          <issue>15</issue>
          <fpage>889</fpage>
          <lpage>890</lpage>
          <pub-id pub-id-type="pmid">32215618</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Epidemiology Working Group for NCIP Epidemic Response</collab>
          </person-group>
          <article-title>Chinese Center for Disease Control and Prevention</article-title>
          <source>Zhonghua Liu Xing Bing Xue Za Zhi</source>
          <year>2020</year>
          <volume>41</volume>
          <issue>2</issue>
          <fpage>145</fpage>
          <lpage>151</lpage>
          <pub-id pub-id-type="pmid">32064853</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Xiang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title>
          <source>JAMA</source>
          <year>2020</year>
          <volume>323</volume>
          <issue>11</issue>
          <fpage>1061</fpage>
          <lpage>1069</lpage>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>YT</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>COVID-19 and the cardiovascular system</article-title>
          <source>Nat Rev Cardiol</source>
          <year>2020</year>
          <volume>17</volume>
          <issue>5</issue>
          <fpage>259</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="pmid">32139904</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Dysregulation of immune response in patients with COVID-19 in Wuhan, China</article-title>
          <source>Clin Infect Dis</source>
          <year>2020</year>
          <volume>71</volume>
          <issue>15</issue>
          <fpage>762</fpage>
          <lpage>768</lpage>
          <pub-id pub-id-type="pmid">32161940</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zheng</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Functional exhaustion of antiviral lymphocytes in COVID-19 patients</article-title>
          <source>Cell Mol Immunol</source>
          <year>2020</year>
          <volume>17</volume>
          <fpage>533</fpage>
          <lpage>535</lpage>
          <pub-id pub-id-type="pmid">32203188</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mehta</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>McAuley</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sanchez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tattersall</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Manson</surname>
              <given-names>JJ</given-names>
            </name>
            <collab>HLH Across Speciality Collaboration, UK</collab>
          </person-group>
          <article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title>
          <source>Lancet.</source>
          <year>2020</year>
          <volume>395</volume>
          <issue>10229</issue>
          <fpage>1033</fpage>
          <lpage>1034</lpage>
          <pub-id pub-id-type="pmid">32192578</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Driggin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Madhavan</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Bikdeli</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Chuich</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Laracy</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Biondi-Zoccai</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>der Nigoghossian</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zidar</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Haythe</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brodie</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Beckman</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Kirtane</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Krumholz</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Parikh</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2020</year>
          <volume>75</volume>
          <issue>18</issue>
          <fpage>2352</fpage>
          <lpage>2371</lpage>
          <pub-id pub-id-type="pmid">32201335</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clerkin</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Fried</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Raikhelkar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sayer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Masoumi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Burkhoff</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kumaraiah</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rabbani</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Uriel</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>COVID-19 and cardiovascular disease</article-title>
          <source>Circulation.</source>
          <year>2020</year>
          <volume>141</volume>
          <issue>20</issue>
          <fpage>1648</fpage>
          <lpage>1655</lpage>
          <pub-id pub-id-type="pmid">32200663</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bikdeli</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Madhavan</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Jimenez</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chuich</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dreyfus</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Driggin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nigoghossian</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ageno</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Madjid</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Giri</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cushman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Qu&#xE9;r&#xE9;</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Dimakakos</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Lippi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Favaloro</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Fareed</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Caprini</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Tafur</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Burton</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Francese</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>EY</given-names>
            </name>
            <name>
              <surname>Falanga</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>McLintock</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hunt</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Spyropoulos</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Eikelboom</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Weinberg</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Schulman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Carrier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Piazza</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Beckman</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Steg</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Rosenkranz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Goldhaber</surname>
              <given-names>SZ</given-names>
            </name>
            <name>
              <surname>Parikh</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Monreal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Krumholz</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Konstantinides</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Weitz</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Lip</surname>
              <given-names>GYH</given-names>
            </name>
            <collab>Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function</collab>
          </person-group>
          <article-title>COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2020</year>
          <volume>75</volume>
          <issue>23</issue>
          <fpage>2950</fpage>
          <lpage>2973</lpage>
          <pub-id pub-id-type="pmid">32311448</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cui</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia</article-title>
          <source>J Thromb Haemost</source>
          <year>2020</year>
          <volume>18</volume>
          <issue>6</issue>
          <fpage>1421</fpage>
          <lpage>1424</lpage>
          <pub-id pub-id-type="pmid">32271988</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klok</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Kruip</surname>
              <given-names>MJHA</given-names>
            </name>
            <name>
              <surname>van der Meer</surname>
              <given-names>NJM</given-names>
            </name>
            <name>
              <surname>Arbous</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Gommers</surname>
              <given-names>DAMPJ</given-names>
            </name>
            <name>
              <surname>Kant</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Kaptein</surname>
              <given-names>FHJ</given-names>
            </name>
            <name>
              <surname>van Paassen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stals</surname>
              <given-names>MAM</given-names>
            </name>
            <name>
              <surname>Huisman</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Endeman</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Incidence of thrombotic complications in critically ill ICU patients with COVID-19</article-title>
          <source>Thromb Res</source>
          <year>2020</year>
          <volume>191</volume>
          <fpage>145</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="pmid">32291094</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Helms</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tacquard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Severac</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study</article-title>
          <source>Intensive Care Med</source>
          <year>2020</year>
          <volume>46</volume>
          <issue>6</issue>
          <fpage>1089</fpage>
          <lpage>1098</lpage>
          <pub-id pub-id-type="pmid">32367170</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oxley</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Mocco</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Majidi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kellner</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Shoirah</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>IP</given-names>
            </name>
            <name>
              <surname>de Leacy</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Shigematsu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ladner</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Yaeger</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Skliut</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weinberger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dangayach</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Bederson</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Tuhrim</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fifi</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Large-vessel stroke as a presenting feature of Covid-19 in the young</article-title>
          <source>N Engl J Med</source>
          <year>2020</year>
          <volume>382</volume>
          <issue>20</issue>
          <fpage>e60</fpage>
          <pub-id pub-id-type="pmid">32343504</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bangalore</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Slotwiner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yatskar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Harari</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ibrahim</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Alviar</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Chadow</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Fishman</surname>
              <given-names>GI</given-names>
            </name>
            <name>
              <surname>Reynolds</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Keller</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hochman</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>ST-segment elevation in patients with Covid-19-a case series</article-title>
          <source>N Engl J Med</source>
          <year>2020</year>
          <volume>382</volume>
          <issue>25</issue>
          <fpage>2478</fpage>
          <lpage>2480</lpage>
          <pub-id pub-id-type="pmid">32302081</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="other">Bellosta R, Luzzani L, Natalini G, et al. Acute limb ischemia in patients with COVID-19 pneumonia. J Vasc Surg. 2020;S0741-5214(20):31080&#x2013;6 <ext-link ext-link-type="uri" xlink:href="https://www.jvascsurg.org/article/S0741-5214(20)31080-6/fulltext">https://www.jvascsurg.org/article/S0741-5214(20)31080-6/fulltext</ext-link>. Accessed 10 June 2020.</mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <mixed-citation publication-type="other">Bompard F, Monnier H, Saab I, et al. Pulmonary embolism in patients with Covid-19 pneumonia. Eur Respir J. 2020;2001365.</mixed-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title>
          <source>J Thromb Haemost</source>
          <year>2020</year>
          <volume>18</volume>
          <issue>4</issue>
          <fpage>844</fpage>
          <lpage>847</lpage>
          <pub-id pub-id-type="pmid">32073213</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Demelo-Rodr&#xED;guez</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cervilla-Mu&#xF1;oz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ordieres-Ortega</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Parra-Virto</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Toledano-Mac&#xED;as</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Toledo-Samaniego</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a-Garc&#xED;a</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Garc&#xED;a-Fern&#xE1;ndez-Bravo</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>de-Miguel-Diez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>&#xC1;lvarez-Sala-Walther</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>del-Toro-Cervera</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Galeano-Valle</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels</article-title>
          <source>Thromb Res</source>
          <year>2020</year>
          <volume>192</volume>
          <fpage>23</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="pmid">32405101</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Green</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Coagulation cascade</article-title>
          <source>Hemodial Int</source>
          <year>2006</year>
          <volume>10</volume>
          <issue>Suppl 2</issue>
          <fpage>S2</fpage>
          <lpage>S4</lpage>
          <pub-id pub-id-type="pmid">17022746</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davie</surname>
              <given-names>EW</given-names>
            </name>
            <name>
              <surname>Fujikawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kisiel</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>The coagulation cascade: initiation, maintenance, and regulation</article-title>
          <source>Biochemistry.</source>
          <year>1991</year>
          <volume>30</volume>
          <fpage>10363</fpage>
          <lpage>10370</lpage>
          <pub-id pub-id-type="pmid">1931959</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gladner</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Chemistry and physiology of the fibrinogen-fibrin transition</article-title>
          <source>Physiol Rev</source>
          <year>1964</year>
          <volume>44</volume>
          <fpage>127</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="pmid">14152903</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Versteeg</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Heemskerk</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>New fundamentals in hemostasis</article-title>
          <source>Physiol Rev</source>
          <year>2013</year>
          <volume>93</volume>
          <fpage>327</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="pmid">23303912</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>von dem Borne</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Meijers</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Bouma</surname>
              <given-names>BN</given-names>
            </name>
          </person-group>
          <article-title>Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis</article-title>
          <source>Blood.</source>
          <year>1995</year>
          <volume>86</volume>
          <fpage>3035</fpage>
          <lpage>3042</lpage>
          <pub-id pub-id-type="pmid">7579397</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Horani</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Kar</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism</article-title>
          <source>Eur J Med Chem</source>
          <year>2020</year>
          <volume>200</volume>
          <fpage>112442</fpage>
          <pub-id pub-id-type="pmid">32502864</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruggeri</surname>
              <given-names>ZM</given-names>
            </name>
            <name>
              <surname>Zarpellon</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Mc Clintock</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Jing</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Mendolicchio</surname>
              <given-names>GL</given-names>
            </name>
          </person-group>
          <article-title>Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib</article-title>
          <source>Thromb Haemost</source>
          <year>2010</year>
          <volume>104</volume>
          <issue>5</issue>
          <fpage>894</fpage>
          <lpage>902</lpage>
          <pub-id pub-id-type="pmid">20941453</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sambrano</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>YW</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Coughlin</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
          <article-title>Role of thrombin signalling in platelets in haemostasis and thrombosis</article-title>
          <source>Nature.</source>
          <year>2001</year>
          <volume>413</volume>
          <issue>6851</issue>
          <fpage>74</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="pmid">11544528</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bouma</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Mosnier</surname>
              <given-names>LO</given-names>
            </name>
          </person-group>
          <article-title>Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?</article-title>
          <source>Ann Med</source>
          <year>2006</year>
          <volume>38</volume>
          <issue>6</issue>
          <fpage>378</fpage>
          <lpage>388</lpage>
          <pub-id pub-id-type="pmid">17008302</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Esmon</surname>
              <given-names>CT</given-names>
            </name>
          </person-group>
          <article-title>The roles of protein C and thrombomodulin in the regulation of blood coagulation</article-title>
          <source>J Biol Chem</source>
          <year>1989</year>
          <volume>264</volume>
          <fpage>4743</fpage>
          <lpage>4746</lpage>
          <pub-id pub-id-type="pmid">2538457</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dorling</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Critical roles for thrombin in acute and chronic inflammation</article-title>
          <source>J Thromb Haemost</source>
          <year>2009</year>
          <volume>7</volume>
          <issue>Suppl 1</issue>
          <fpage>122</fpage>
          <lpage>126</lpage>
          <pub-id pub-id-type="pmid">19630783</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dorling</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The roles of thrombin and protease-activated receptors in inflammation</article-title>
          <source>Semin Immunopathol</source>
          <year>2012</year>
          <volume>34</volume>
          <issue>1</issue>
          <fpage>63</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">21809138</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Popovi&#x107;</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Smiljani&#x107;</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dobutovi&#x107;</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Syrovets</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Simmet</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Isenovi&#x107;</surname>
              <given-names>ER</given-names>
            </name>
          </person-group>
          <article-title>Thrombin and vascular inflammation</article-title>
          <source>Mol Cell Biochem</source>
          <year>2012</year>
          <volume>359</volume>
          <issue>1&#x2013;2</issue>
          <fpage>301</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="pmid">21858738</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strande</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Phillips</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Thrombin increases inflammatory cytokine and angiogenic growth factor secretion in human adipose cells in vitro</article-title>
          <source>J Inflamm (Lond)</source>
          <year>2009</year>
          <volume>6</volume>
          <fpage>4</fpage>
          <pub-id pub-id-type="pmid">19267924</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vera</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Wolfe</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Braley</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Meyer-Siegler</surname>
              <given-names>KL</given-names>
            </name>
          </person-group>
          <article-title>Thrombin induces macrophage migration inhibitory factor release and upregulation in urothelium: a possible contribution to bladder inflammation</article-title>
          <source>PLoS One</source>
          <year>2010</year>
          <volume>5</volume>
          <fpage>e15904</fpage>
          <pub-id pub-id-type="pmid">21209875</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minami</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sugiyama</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>SQ</given-names>
            </name>
            <name>
              <surname>Abid</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kodama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Aird</surname>
              <given-names>WC</given-names>
            </name>
          </person-group>
          <article-title>Thrombin and phenotypic modulation of the endothelium</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <year>2004</year>
          <volume>24</volume>
          <fpage>41</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="pmid">14551154</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fazal</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Hug tightly and say goodbye: role of endothelial ICAM-1 in leukocyte transmigration</article-title>
          <source>Antioxid Redox Signal</source>
          <year>2009</year>
          <volume>11</volume>
          <fpage>823</fpage>
          <lpage>839</lpage>
          <pub-id pub-id-type="pmid">18808323</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miho</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ishida</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kuwaba</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Role of the JNK pathway in thrombin-induced ICAM-1 expression in endothelial cells</article-title>
          <source>Cardiovasc Res</source>
          <year>2005</year>
          <volume>68</volume>
          <issue>2</issue>
          <fpage>289</fpage>
          <lpage>298</lpage>
          <pub-id pub-id-type="pmid">15979056</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wadgaonkar</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Somnay</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Thrombin induced secretion of macrophage migration inhibitory factor (MIF) and its effect on nuclear signaling in endothelium</article-title>
          <source>J Cell Biochem</source>
          <year>2008</year>
          <volume>105</volume>
          <issue>5</issue>
          <fpage>1279</fpage>
          <lpage>1288</lpage>
          <pub-id pub-id-type="pmid">18821572</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feistritzer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Riewald</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation</article-title>
          <source>Blood.</source>
          <year>2005</year>
          <volume>105</volume>
          <issue>8</issue>
          <fpage>3178</fpage>
          <lpage>3184</lpage>
          <pub-id pub-id-type="pmid">15626732</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chung</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Eo</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Thrombin promotes proinflammatory phenotype in human vascular smooth muscle cell</article-title>
          <source>Biochem Biophys Res Commun</source>
          <year>2010</year>
          <volume>396</volume>
          <fpage>748</fpage>
          <lpage>754</lpage>
          <pub-id pub-id-type="pmid">20451499</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kastl</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Speidl</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Katsaros</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Kaun</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rega</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Assadian</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hagmueller</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Hoeth</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>de Martin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Maurer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wojta</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation</article-title>
          <source>Blood.</source>
          <year>2009</year>
          <volume>114</volume>
          <fpage>2812</fpage>
          <lpage>2818</lpage>
          <pub-id pub-id-type="pmid">19652200</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colotta</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sciacca</surname>
              <given-names>FL</given-names>
            </name>
            <name>
              <surname>Sironi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Luini</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Rabiet</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Mantovani</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin</article-title>
          <source>Am J Pathol</source>
          <year>1994</year>
          <volume>144</volume>
          <issue>5</issue>
          <fpage>975</fpage>
          <lpage>985</lpage>
          <pub-id pub-id-type="pmid">8178946</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drake</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>NN</given-names>
            </name>
            <name>
              <surname>Fenton</surname>
              <given-names>JW</given-names>
              <suffix>2nd</suffix>
            </name>
            <name>
              <surname>Issekutz</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Thrombin enhancement of interleukin-1 and tumor necrosis factor-alpha induced polymorphonuclear leukocyte migration</article-title>
          <source>Lab Investig</source>
          <year>1992</year>
          <volume>67</volume>
          <issue>5</issue>
          <fpage>617</fpage>
          <lpage>627</lpage>
          <pub-id pub-id-type="pmid">1434539</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujita</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamabe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shimada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kumasaka</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Osawa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Okumura</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Thrombin enhances the production of monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 in cultured rat glomerular epithelial cells</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>2008</year>
          <volume>23</volume>
          <issue>11</issue>
          <fpage>3412</fpage>
          <lpage>3417</lpage>
          <pub-id pub-id-type="pmid">18622025</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shavit Stein</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ben Shimon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Artan Furman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Golderman</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Chapman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Maggio</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Thrombin inhibition reduces the expression of brain inflammation markers upon systemic LPS treatment</article-title>
          <source>Neural Plast</source>
          <year>2018</year>
          <volume>2018</volume>
          <fpage>7692182</fpage>
          <pub-id pub-id-type="pmid">30018633</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huber-Lang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sarma</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Zetoune</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Rittirsch</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Neff</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>McGuire</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Lambris</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Warner</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Flierl</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Hoesel</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Gebhard</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Younger</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Drouin</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Wetsel</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Generation of C5a in the absence of C3: a new complement activation pathway</article-title>
          <source>Nat Med</source>
          <year>2006</year>
          <volume>12</volume>
          <issue>6</issue>
          <fpage>682</fpage>
          <lpage>687</lpage>
          <pub-id pub-id-type="pmid">16715088</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clark</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Weymann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hartman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Turmelle</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Carroll</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Thurman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Holers</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Hourcade</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Rudnick</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Evidence for non-traditional activation of complement factor C3 during murine liver regeneration</article-title>
          <source>Mol Immunol</source>
          <year>2008</year>
          <volume>45</volume>
          <issue>11</issue>
          <fpage>3125</fpage>
          <lpage>3132</lpage>
          <pub-id pub-id-type="pmid">18452991</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naldini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aarden</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pucci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bernini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Carraro</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of interleukin-12 expression by alpha-thrombin in human peripheral blood mononuclear cells: a potential mechanism for modulating Th1/Th2 responses</article-title>
          <source>Br J Pharmacol</source>
          <year>2003</year>
          <volume>140</volume>
          <issue>5</issue>
          <fpage>980</fpage>
          <lpage>986</lpage>
          <pub-id pub-id-type="pmid">14517182</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Noda-Heiny</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sobel</surname>
              <given-names>BE</given-names>
            </name>
          </person-group>
          <article-title>Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor</article-title>
          <source>Am J Phys</source>
          <year>1995</year>
          <volume>268</volume>
          <issue>5 Pt 1</issue>
          <fpage>C1195</fpage>
          <lpage>C1201</lpage>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Daniel TO</collab>
            <name>
              <surname>Gibbs</surname>
              <given-names>VC</given-names>
            </name>
            <name>
              <surname>Milfay</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Garovoy</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>LT</given-names>
            </name>
          </person-group>
          <article-title>Thrombin stimulates c-sis gene expression in microvascular endothelial cells</article-title>
          <source>J Biol Chem</source>
          <year>1986</year>
          <volume>261</volume>
          <issue>21</issue>
          <fpage>9579</fpage>
          <lpage>9582</lpage>
          <pub-id pub-id-type="pmid">2426251</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naldini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carney</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Pucci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pasquali</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carraro</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Thrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1</article-title>
          <source>Gen Pharmacol</source>
          <year>2000</year>
          <volume>35</volume>
          <issue>5</issue>
          <fpage>255</fpage>
          <lpage>259</lpage>
          <pub-id pub-id-type="pmid">11888681</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cunningham</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Rondeau</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Coughlin</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Holdsworth</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Tipping</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
          <article-title>Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis</article-title>
          <source>J Exp Med</source>
          <year>2000</year>
          <volume>191</volume>
          <fpage>455</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="pmid">10662791</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Howell</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Johns</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Lasky</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Shan</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Scotton</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis</article-title>
          <source>Am J Pathol</source>
          <year>2005</year>
          <volume>166</volume>
          <fpage>1353</fpage>
          <lpage>1365</lpage>
          <pub-id pub-id-type="pmid">15855637</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimizu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Morser</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamaguchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Toda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>D&#x2019;Alessandro-Gabazza</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takagi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yano</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sumida</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takei</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Taguchi</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gabazza</surname>
              <given-names>EC</given-names>
            </name>
          </person-group>
          <article-title>Role of the coagulation system in allergic inflammation in the upper airways</article-title>
          <source>Clin Immunol</source>
          <year>2008</year>
          <volume>129</volume>
          <fpage>365</fpage>
          <lpage>371</lpage>
          <pub-id pub-id-type="pmid">18789772</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <mixed-citation publication-type="other">Burzynski LC, Humphry M, Pyrillou K, et al. The coagulation and immune systems are directly linked through the activation of interleukin-1&#x3B1; by thrombin. Immunity. 2019;50(4):1033&#x2013;1042.e6.</mixed-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shea</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Probst</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Brazee</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Rotile</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Blasi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Weinreb</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Black</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Sosnovik</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>van Cott</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Violette</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Caravan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tager</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis</article-title>
          <source>JCI Insight</source>
          <year>2017</year>
          <volume>2</volume>
          <issue>9</issue>
          <fpage>e86608</fpage>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Antoniak</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Owens</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Baunacke</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>RD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PAR-1 contributes to the innate immune response during viral infection</article-title>
          <source>J Clin Invest</source>
          <year>2013</year>
          <volume>123</volume>
          <fpage>1310</fpage>
          <lpage>1322</lpage>
          <pub-id pub-id-type="pmid">23391721</pub-id>
        </element-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kanade</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Pingale</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Karpe</surname>
              <given-names>YA</given-names>
            </name>
          </person-group>
          <article-title>Activities of thrombin and factor Xa are essential for replication of hepatitis E virus and are possibly implicated in ORF1 polyprotein processing</article-title>
          <source>J Virol</source>
          <year>2018</year>
          <volume>92</volume>
          <issue>6</issue>
          <fpage>e01853</fpage>
          <lpage>e01817</lpage>
          <pub-id pub-id-type="pmid">29321328</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xEA;</surname>
              <given-names>VB</given-names>
            </name>
            <name>
              <surname>Riteau</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Alessi</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Couture</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jandrot-Perrus</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rh&#xE9;aume</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hamelin</surname>
              <given-names>M&#xC8;</given-names>
            </name>
            <name>
              <surname>Boivin</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections</article-title>
          <source>Br J Pharmacol</source>
          <year>2018</year>
          <volume>175</volume>
          <issue>2</issue>
          <fpage>388</fpage>
          <lpage>403</lpage>
          <pub-id pub-id-type="pmid">29105740</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sutherland</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Pryzdial</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
          <article-title>Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1</article-title>
          <source>J Thromb Haemost</source>
          <year>2007</year>
          <volume>5</volume>
          <fpage>1055</fpage>
          <lpage>1061</lpage>
          <pub-id pub-id-type="pmid">17461934</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scholz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>JU</given-names>
            </name>
            <name>
              <surname>H&#xF6;ver</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kotchetkov</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Cinatl</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thrombin stimulates IL-6 and IL-8 expression in cytomegalovirus-infected human retinal pigment epithelial cells</article-title>
          <source>Int J Mol Med</source>
          <year>2004</year>
          <volume>13</volume>
          <fpage>327</fpage>
          <lpage>331</lpage>
          <pub-id pub-id-type="pmid">14719142</pub-id>
        </element-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ling</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Usami</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Hattori</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Thrombin activates envelope glycoproteins of HIV type 1 and enhances fusion</article-title>
          <source>Microbes Infect</source>
          <year>2004</year>
          <volume>6</volume>
          <fpage>414</fpage>
          <lpage>420</lpage>
          <pub-id pub-id-type="pmid">15109955</pub-id>
        </element-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#xEA;</surname>
              <given-names>BV</given-names>
            </name>
            <name>
              <surname>Jandrot-Perrus</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Couture</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Checkmahomed</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Venable</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Hamelin</surname>
              <given-names>M&#xC8;</given-names>
            </name>
            <name>
              <surname>Boivin</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of anticoagulant agents for the treatment of human metapneumovirus infection in mice</article-title>
          <source>J Gen Virol</source>
          <year>2018</year>
          <volume>99</volume>
          <issue>10</issue>
          <fpage>1367</fpage>
          <lpage>1380</lpage>
          <pub-id pub-id-type="pmid">30102144</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Le</surname>
              <given-names>VB</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Boergeling</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Berri</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ducatez</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Platelet activation and aggregation promote lung inflammation and influenza virus pathogenesis</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2015</year>
          <volume>191</volume>
          <fpage>804</fpage>
          <lpage>819</lpage>
          <pub-id pub-id-type="pmid">25664391</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boilard</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pare</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rousseau</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cloutier</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Dubuc</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Influenza virus H1N1 activates platelets through FcgRIIA signaling and thrombin generation</article-title>
          <source>Blood.</source>
          <year>2014</year>
          <volume>123</volume>
          <fpage>2854</fpage>
          <lpage>2863</lpage>
          <pub-id pub-id-type="pmid">24665136</pub-id>
        </element-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keller</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>van der Sluijs</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>de Kruif</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Gerdes</surname>
              <given-names>VEA</given-names>
            </name>
            <name>
              <surname>Meijers</surname>
              <given-names>JCM</given-names>
            </name>
            <name>
              <surname>Florquin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>van der Poll</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>van Gorp</surname>
              <given-names>ECM</given-names>
            </name>
            <name>
              <surname>Brandjes</surname>
              <given-names>DPM</given-names>
            </name>
            <name>
              <surname>B&#xFC;ller</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1</article-title>
          <source>Circ Res</source>
          <year>2006</year>
          <volume>99</volume>
          <issue>11</issue>
          <fpage>1261</fpage>
          <lpage>1269</lpage>
          <pub-id pub-id-type="pmid">17068293</pub-id>
        </element-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marks</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Reck</surname>
              <given-names>J</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Corr&#xEA;a</surname>
              <given-names>AMR</given-names>
            </name>
            <name>
              <surname>Driemeier</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Barcellos</surname>
              <given-names>DESN</given-names>
            </name>
            <name>
              <surname>Guimar&#xE3;es</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Termignoni</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Canal</surname>
              <given-names>CW</given-names>
            </name>
          </person-group>
          <article-title>Porcine circovirus 2 (PCV2) induces a procoagulant state in naturally infected swine and in cultured endothelial cells</article-title>
          <source>Vet Microbiol</source>
          <year>2010</year>
          <volume>141</volume>
          <issue>1&#x2013;2</issue>
          <fpage>22</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">19733020</pub-id>
        </element-citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gray</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mulloy</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Barrowcliffe</surname>
              <given-names>TW</given-names>
            </name>
          </person-group>
          <article-title>Heparin and low-molecular-weight heparin</article-title>
          <source>Thromb Haemost</source>
          <year>2008</year>
          <volume>99</volume>
          <issue>5</issue>
          <fpage>807</fpage>
          <lpage>818</lpage>
          <pub-id pub-id-type="pmid">18449410</pub-id>
        </element-citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harter</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Henderson</surname>
              <given-names>SO</given-names>
            </name>
          </person-group>
          <article-title>Anticoagulation drug therapy: a review</article-title>
          <source>West J Emerg Med</source>
          <year>2015</year>
          <volume>16</volume>
          <issue>1</issue>
          <fpage>11</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="pmid">25671002</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Ansell</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Direct thrombin inhibitors</article-title>
          <source>Br J Clin Pharmacol</source>
          <year>2011</year>
          <volume>72</volume>
          <issue>4</issue>
          <fpage>581</fpage>
          <lpage>592</lpage>
          <pub-id pub-id-type="pmid">21241354</pub-id>
        </element-citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <mixed-citation publication-type="other">Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S&#x2013;43S <ext-link ext-link-type="uri" xlink:href="https://journal.chestnet.org/article/S0012-3692(12)60118-4/fulltext">https://journal.chestnet.org/article/S0012-3692(12)60118-4/fulltext</ext-link>. Accessed 10 June 2020.</mixed-citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alban</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Pharmacological strategies for inhibition of thrombin activity</article-title>
          <source>Curr Pharm Des</source>
          <year>2008</year>
          <volume>14</volume>
          <issue>12</issue>
          <fpage>1152</fpage>
          <lpage>1175</lpage>
          <pub-id pub-id-type="pmid">18473863</pub-id>
        </element-citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Steinmetzer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>St&#xFC;rzebecher</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Von Fibrinogen und Hirudin zu synthetischen Antikoagulanzien. Rationales Design von Thrombinhemmstoffen [From fibrinogen and hirudin to synthetic anticoagulants. Rational design of thrombin inhibitors]</article-title>
          <source>Pharm Unserer Zeit</source>
          <year>2004</year>
          <volume>33</volume>
          <issue>3</issue>
          <fpage>196</fpage>
          <lpage>205</lpage>
          <pub-id pub-id-type="pmid">15208908</pub-id>
        </element-citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <mixed-citation publication-type="other">Lindahl U, Li JP. Heparin-an old drug with multiple potential targets in Covid-19 therapy. J Thromb Haemost. 2020:10.1111/jth.14898.</mixed-citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Belen-Apak</surname>
              <given-names>FB</given-names>
            </name>
            <name>
              <surname>Sarialioglu</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>The old but new: can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?</article-title>
          <source>Med Hypotheses</source>
          <year>2020</year>
          <volume>142</volume>
          <fpage>109743</fpage>
          <pub-id pub-id-type="pmid">32335456</pub-id>
        </element-citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>White</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>MacDonald</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bull</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hayman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>de Monteverde-Robb</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sapsford</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lavinio</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Varley</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Besser</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Heparin resistance in COVID-19 patients in the intensive care unit</article-title>
          <source>J Thromb Thrombolysis</source>
          <year>2020</year>
          <volume>50</volume>
          <issue>2</issue>
          <fpage>287</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="pmid">32445064</pub-id>
        </element-citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>XH</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>Prominent changes in blood coagulation of patients with SARS-CoV-2 infection</article-title>
          <source>Clin Chem Lab Med</source>
          <year>2020</year>
          <volume>58</volume>
          <issue>7</issue>
          <fpage>1116</fpage>
          <lpage>1120</lpage>
          <pub-id pub-id-type="pmid">32172226</pub-id>
        </element-citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bikdeli</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Madhavan</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jimenez</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Burton</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>der Nigoghossian</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chuich</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nouri</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Dreyfus</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Driggin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sethi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sehgal</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Chatterjee</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ageno</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Madjid</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Bertoletti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Giri</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cushman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Qu&#xE9;r&#xE9;</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Dimakakos</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Lippi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Favaloro</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Fareed</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tafur</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Francese</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Batra</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Falanga</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Clerkin</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Uriel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kirtane</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>McLintock</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hunt</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Spyropoulos</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Eikelboom</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Weinberg</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Schulman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Carrier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Piazza</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Beckman</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Leon</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Rosenkranz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Goldhaber</surname>
              <given-names>SZ</given-names>
            </name>
            <name>
              <surname>Parikh</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Monreal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Krumholz</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Konstantinides</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Weitz</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Lip</surname>
              <given-names>GYH</given-names>
            </name>
            <collab>The Global COVID-19 Thrombosis Collaborative Group</collab>
          </person-group>
          <article-title>Pharmacological agents targeting thrombo-inflammation in COVID-19: review and implications for future research</article-title>
          <source>Thromb Haemost</source>
          <year>2020</year>
          <volume>120</volume>
          <issue>7</issue>
          <fpage>1004</fpage>
          <lpage>1024</lpage>
          <pub-id pub-id-type="pmid">32473596</pub-id>
        </element-citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <mixed-citation publication-type="other">Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S&#x2013;530S <ext-link ext-link-type="uri" xlink:href="https://journal.chestnet.org/article/S0012-3692(12)60130-5/fulltext">https://journal.chestnet.org/article/S0012-3692(12)60130-5/fulltext</ext-link>. Accessed 10 June 2020.</mixed-citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walenga</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>An overview of the direct thrombin inhibitor argatroban</article-title>
          <source>Pathophysiol Haemost Thromb</source>
          <year>2002</year>
          <volume>32</volume>
          <issue>Suppl 3</issue>
          <fpage>9</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="pmid">12811006</pub-id>
        </element-citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Gong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy</article-title>
          <source>J Thromb Haemost</source>
          <year>2020</year>
          <volume>18</volume>
          <issue>5</issue>
          <fpage>1094</fpage>
          <lpage>1099</lpage>
          <pub-id pub-id-type="pmid">32220112</pub-id>
        </element-citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paranjpe</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Fuster</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Lala</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Russak</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Glicksberg</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Levin</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Charney</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Narula</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fayad</surname>
              <given-names>ZA</given-names>
            </name>
            <name>
              <surname>Bagiella</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nadkarni</surname>
              <given-names>GN</given-names>
            </name>
          </person-group>
          <article-title>Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2020</year>
          <volume>76</volume>
          <issue>1</issue>
          <fpage>122</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="pmid">32387623</pub-id>
        </element-citation>
      </ref>
      <ref id="CR91">
        <label>91.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ueki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kizaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsunaga</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Miyake</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tominaga</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Eguchi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: placebo-controlled study</article-title>
          <source>J Thromb Thrombolysis</source>
          <year>1999</year>
          <volume>8</volume>
          <issue>2</issue>
          <fpage>131</fpage>
          <lpage>137</lpage>
          <pub-id pub-id-type="pmid">10436143</pub-id>
        </element-citation>
      </ref>
      <ref id="CR92">
        <label>92.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fareed</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hoppensteadt</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bansal</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Walenga</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lale</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bick</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>The anti-inflammatory effects of argatroban can be differentiated from other direct thrombin inhibitors: experimental and clinical observations</article-title>
          <source>Blood.</source>
          <year>2006</year>
          <volume>108</volume>
          <issue>11</issue>
          <fpage>4132</fpage>
        </element-citation>
      </ref>
      <ref id="CR93">
        <label>93.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bulani</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
          <article-title>Argatroban attenuates diabetic cardiomyopathy in rats by reducing fibrosis, inflammation, apoptosis, and protease-activated receptor expression</article-title>
          <source>Cardiovasc Drugs Ther</source>
          <year>2017</year>
          <volume>31</volume>
          <issue>3</issue>
          <fpage>255</fpage>
          <lpage>267</lpage>
          <pub-id pub-id-type="pmid">28695302</pub-id>
        </element-citation>
      </ref>
      <ref id="CR94">
        <label>94.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohyama</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hosomi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mizushige</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kohno</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia</article-title>
          <source>Brain Res</source>
          <year>2001</year>
          <volume>902</volume>
          <issue>2</issue>
          <fpage>264</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="pmid">11384620</pub-id>
        </element-citation>
      </ref>
      <ref id="CR95">
        <label>95.</label>
        <mixed-citation publication-type="other">Kim J, Zhang J, Cha Y, Kolitz S, Funt J, Escalante Chong R, et al. Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19). 2020;18(1):257 <ext-link ext-link-type="uri" xlink:href="https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02430-9">https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02430-9</ext-link>. Accessed 25 Aug 2020.</mixed-citation>
      </ref>
      <ref id="CR96">
        <label>96.</label>
        <mixed-citation publication-type="other">Nguyen DD, Gao K, Chen J, Wang R, Wei GW. Potentially highly potent drugs for 2019-nCoV. Preprint. bioRxiv. 2020;2020.02.05.936013. <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.02.05.936013v1">https://www.biorxiv.org/content/10.1101/2020.02.05.936013v1</ext-link>. Accessed 10 June 2020.</mixed-citation>
      </ref>
      <ref id="CR97">
        <label>97.</label>
        <mixed-citation publication-type="other">Sheikh HK, Arshad T, Mohammad ZS, Arshad I, Hassan M. Repurposed single inhibitor for serine protease and spike glycoproteins of SAR-CoV-2. Preprint. chemRxiv. 2020. <ext-link ext-link-type="uri" xlink:href="https://chemrxiv.org/articles/preprint/Repurposed_Single_Inhibitor_for_Serine_Protease_and_Spike_Glycoproteins_of_SAR-CoV-2/12192660/1">https://chemrxiv.org/articles/preprint/Repurposed_Single_Inhibitor_for_Serine_Protease_and_Spike_Glycoproteins_of_SAR-CoV-2/12192660/1</ext-link>. Accessed 10 June 2020.</mixed-citation>
      </ref>
      <ref id="CR98">
        <label>98.</label>
        <mixed-citation publication-type="other">The U.S. Food and Drug Administration. In: Argatroban label. ARGATROBAN INJECTION. 2011. <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022485lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022485lbl.pdf</ext-link>. Accessed on 7 June 2020.</mixed-citation>
      </ref>
      <ref id="CR99">
        <label>99.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Swan</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Hursting</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction</article-title>
          <source>Pharmacotherapy.</source>
          <year>2000</year>
          <volume>20</volume>
          <issue>3</issue>
          <fpage>318</fpage>
          <lpage>329</lpage>
          <pub-id pub-id-type="pmid">10730687</pub-id>
        </element-citation>
      </ref>
      <ref id="CR100">
        <label>100.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Makris</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Van Veen</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Tait</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Mumford</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Laffan</surname>
              <given-names>M</given-names>
            </name>
            <collab>British Committee for Standards in Haematology</collab>
          </person-group>
          <article-title>Guideline on the management of bleeding in patients on antithrombotic agents</article-title>
          <source>Br J Haematol</source>
          <year>2013</year>
          <volume>160</volume>
          <issue>1</issue>
          <fpage>35</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">23116425</pub-id>
        </element-citation>
      </ref>
      <ref id="CR101">
        <label>101.</label>
        <mixed-citation publication-type="other">Arachchillage DJ, Remmington C, Rosenberg A, et al. Anticoagulation with argatroban in patients with acute antithrombin deficiency in severe COVID-19. Br J Haematol. 2020:10.1111/bjh.16927.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Curr Anesthesiol Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Curr Anesthesiol Rep</journal-id>
      <journal-title-group>
        <journal-title>Current Anesthesiology Reports</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1523-3855</issn>
      <issn pub-type="epub">2167-6275</issn>
      <publisher>
        <publisher-name>Springer US</publisher-name>
        <publisher-loc>New York</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32904403</article-id>
      <article-id pub-id-type="pmc">7455512</article-id>
      <article-id pub-id-type="publisher-id">405</article-id>
      <article-id pub-id-type="doi">10.1007/s40140-020-00405-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Blood Management (KA Tanaka, Section Editor)</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Heparin Induced Thrombocytopenia for the Perioperative and Critical Care Clinician</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Moreno-Duarte</surname>
            <given-names>Ingrid</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9287-7541</contrib-id>
          <name>
            <surname>Ghadimi</surname>
            <given-names>Kamrouz</given-names>
          </name>
          <address>
            <email>kamrouz.ghadimi@duke.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.26009.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7961</institution-id><institution>Department of Anesthesiology &amp; Critical Care, </institution><institution>Duke University School of Medicine, </institution></institution-wrap>DUMC Box 3094, Durham, NC 27710 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>29</day>
        <month>8</month>
        <year>2020</year>
      </pub-date>
      <fpage>1</fpage>
      <lpage>11</lpage>
      <permissions>
        <copyright-statement>&#xA9; Springer Science+Business Media, LLC, part of Springer Nature 2020</copyright-statement>
        <license>
          <license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Purpose of Review</title>
          <p id="Par1">This review will illustrate the importance of heparin-induced thrombocytopenia in the intraoperative and critical care settings.</p>
        </sec>
        <sec>
          <title>Recent Findings</title>
          <p id="Par2">Heparin-induced thrombocytopenia (HIT) occurs more frequently in surgical patients compared with medical patients due to the inflammatory release of platelet factor 4 and perioperative heparin exposure. Recognition of this disease requires a high index of suspicion. Diagnostic tools and therapeutic strategies have been expanded and refined in recent years.</p>
        </sec>
        <sec>
          <title>Summary</title>
          <p id="Par3">HIT is a condition where antibodies against the heparin/platelet factor 4 complex interact with platelet receptors to promote platelet activation, aggregation, and thrombus formation. Our review will focus on intraoperative and postoperative considerations related to HIT to help the clinician better manage this rare but often devastating hypercoagulable disease process.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Heparin</kwd>
        <kwd>Thrombocytopenia</kwd>
        <kwd>Surgery</kwd>
        <kwd>Limb ischemia</kwd>
        <kwd>Thrombosis</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id>
              <institution>National Institute of General Medical Sciences</institution>
            </institution-wrap>
          </funding-source>
          <award-id>T32008600</award-id>
          <principal-award-recipient>
            <name>
              <surname>Ghadimi</surname>
              <given-names>Kamrouz</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par4">Heparin-induced thrombocytopenia (HIT) is a prothrombotic disease where antibodies against the molecular complex of heparin-to-platelet factor 4 (PF4/H) interact with platelet receptors to promote platelet activation, aggregation, and removal from circulation [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>&#x2022;]. PF4 is secreted by platelet granules or displaced from the endothelium. HIT antibodies against the heparin/PF4 complex will trigger downstream thrombin generation and catastrophic thrombus formation. The prevalence of HIT is rare in both medical and surgical patients, and the incidence in most population-based studies ranges between 0.3 and 3.0%. However, the occurrence of HIT in the operating theater or the postoperative critical care setting can be swift and devastating. In this review, we will discuss standard definitions, scoring systems, epidemiology, and pathogenesis that is relevant to the perioperative and critical care environments. For our review, we will be referring to the type 2 variety of HIT, where an immune-mediated disorder emerges typically 4&#x2013;10&#xA0;days after heparin exposure to heparin and has life- and limb-threatening thrombotic complications [<xref ref-type="bibr" rid="CR2">2</xref>&#x2022;, <xref ref-type="bibr" rid="CR3">3</xref>]. There will be a limited focus on the less clinically important type 1, which is a non-immune process that presents within the first 2&#xA0;days after heparin exposure with correction of thrombocytopenia despite continuation of heparin therapy [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
    </sec>
    <sec id="Sec2">
      <title>Definition and Epidemiology</title>
      <p id="Par5">Approximately 20&#x2013;50% of critically ill patients present with thrombocytopenia in the intensive care unit (ICU), whereby a reduced platelet count below 150,000 platelets per microliter of blood is noted on laboratory testing [<xref ref-type="bibr" rid="CR4">4</xref>]. Heparinoid exposure by syringe flush, subcutaneous prophylaxis, or therapeutic anticoagulation is common in the operative room (OR) and ICU environments [<xref ref-type="bibr" rid="CR5">5</xref>] .Only a fraction of those with low platelet counts will develop HIT, which presents in approximately 0.3&#x2013;0.5% of critically ill patients exposed to heparin [<xref ref-type="bibr" rid="CR6">6</xref>]. These statistics suggest that around 1 in 100 ICU patients will develop thrombocytopenia due to HIT [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. HIT is paradoxically linked to a high risk for arterial and venous thromboses. Almost half of the critically ill patients diagnosed with HIT will present with thrombotic events [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p id="Par6">HIT presents in the setting of higher concentrations of platelet factor 4 (PF4) leading to the formation of PF4/H complexes. Surgery can trigger the release of massive amounts of PF4 [<xref ref-type="bibr" rid="CR9">9</xref>]. Therefore, the frequency of HIT varies with the type of surgery. Five percent of orthopedic surgical patients exposed to heparin for 10&#x2013;14&#xA0;days present with HIT [<xref ref-type="bibr" rid="CR10">10</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>]. Shorter courses of heparin treatment seem to decrease the risk of HIT development [<xref ref-type="bibr" rid="CR13">13</xref>]. Preferential use of low molecular weight heparin (LMWH) as opposed to unfractionated heparin (UFH) is associated with lower rates of HIT [<xref ref-type="bibr" rid="CR14">14</xref>&#x2022;]. In cardiac surgery patients, the frequency of HIT is approximately 2% [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x2022;]. Although HIT is less frequent in cardiac surgical patients compared with orthopedic patients, cardiac surgical patients have a higher frequency of HIT immunization (positive antibody formation) [<xref ref-type="bibr" rid="CR15">15</xref>], potentially due to the high intraoperative UFH doses required for anticoagulation on cardiopulmonary bypass [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. HIT presents in trauma patients with a frequency of around 2.2% [<xref ref-type="bibr" rid="CR18">18</xref>]. Patients with major trauma showed higher rates of seroconversion compared with patients with minor trauma (OR 7.98 [95% CI 2.06&#x2013;31.00]; <italic>P</italic>&#x2009;=&#x2009;0.003). In these patients, HIT incidence was lower when using LMWH versus UFH, although the difference was not statistically significant (LMWH 1.3% vs. UFH 0.3%; <italic>P</italic>&#x2009;=&#x2009;0.37).</p>
      <p id="Par7">HIT occurs more frequently in surgical patients compared with medical patients [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Medical patients present a HIT prevalence of around 0.8&#x2013;2.0% [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Gender seems to be a risk factor for HIT and females are more affected than men (OR, 9.22 vs. 1.83; <italic>P</italic>&#x2009;=&#x2009;.020) [<xref ref-type="bibr" rid="CR19">19</xref>]. HIT is uncommon in obstetric patients [<xref ref-type="bibr" rid="CR22">22</xref>].</p>
      <p id="Par8">The type of heparin used is a well-described risk factor for HIT. A small study with patients undergoing first-time CABG reported a seroconversion rate of 44.4% for bovine heparin and 30.6% for porcine heparin. Intraoperatively, bovine heparin is less frequently used compared with porcine heparin, and in the setting of HIT, both should be avoided [<xref ref-type="bibr" rid="CR23">23</xref>]. Unfractionated heparin has been significantly associated with a higher incidence of HIT (almost 10-fold higher), [<xref ref-type="bibr" rid="CR2">2</xref>&#x2022;] compared with LMWH and selective factor Xa inhibitors like fondaparinux [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR24">24</xref>] likely due to the difference of the polysaccharide chain lengths and the degree of sulfation of each medication [<xref ref-type="bibr" rid="CR25">25</xref>]. Of importance, dosing seems to be correlated to the risk of developing HIT. Prophylactic UFH is more frequently associated with HIT compared with therapeutic UFH, due to the fluctuations in the PF4/H ratio. LMWH and fondaparinux are less likely to form multimolecular complexes with PF4 and, consequently, less likely to induce HIT.</p>
      <p id="Par9">The variability in the reported frequency of HIT is due to the multiple factors. Differences in the studied populations (medical vs. surgical) [<xref ref-type="bibr" rid="CR15">15</xref>], type of heparin used [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], duration of therapy, [<xref ref-type="bibr" rid="CR10">10</xref>] and female over-representation [<xref ref-type="bibr" rid="CR19">19</xref>] have been strongly correlated with such variability. Other limitations of the studies include selection bias, inconsistency in the definitions used for thrombocytopenia and HIT, discrepancy/inconsistency of tests performed for confirmation, and differences in baseline patient characteristics (including baseline platelet counts, inclusion of patients with early thrombocytopenia, and the failure to exclude patient whose platelet counts recovered during continue heparin treatment) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR26">26</xref>&#x2013;<xref ref-type="bibr" rid="CR28">28</xref>].</p>
      <p id="Par10">In the ICU, exposure to UFH occurs from flushes and heparin-bonded devices. Although rare, Swan-Ganz catheters and extracorporeal circuits may be heparin coated to avoid thrombus formation during routine standard use. Even minor heparin exposures can elicit the formation of HIT antibodies [<xref ref-type="bibr" rid="CR29">29</xref>], but not all antibodies will trigger the development of HIT. The estimated frequency of catheter-associated HIT is around 0.4% [<xref ref-type="bibr" rid="CR30">30</xref>]. Patients with central catheters and HIT antibodies are at a higher risk for both upper-extremity and lower-extremity DVT occurring at the catheter site [<xref ref-type="bibr" rid="CR31">31</xref>]. The larger devices (i.e., VAD, ECMO, intra-aortic balloon pump) require high doses of systemic UFH, increasing the risk of seroconversion and clinically apparent HIT. Interestingly, the incidence of HIT in this population is around 8% [<xref ref-type="bibr" rid="CR32">32</xref>], while the rate of seroconversion by immunoassay has been reported between 25 and 75% [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Such a wide range depends on the criteria used to define HIT, the populations included, and the difference in confirmatory tests used for diagnosis.</p>
    </sec>
    <sec id="Sec3">
      <title>Pathogenesis</title>
      <p id="Par11">The binding specificity of heparin is determined by its negative charge, molecular size, molecular weight, and chain length [<xref ref-type="bibr" rid="CR34">34</xref>&#x2022;&#x2022;]. Heparin binding to the platelet surface can trigger the release of PF4, a positively charged chemokine secreted from the &#x3B1; granules of activated platelets [<xref ref-type="bibr" rid="CR35">35</xref>]. PF4 readily binds negatively charged proteins on the endothelium and also to soluble proteins such as heparin [<xref ref-type="bibr" rid="CR36">36</xref>]. Excess PF4 binding can alter the usual configuration of the endothelial proteins, expressing new antigens and inducing an immune response [<xref ref-type="bibr" rid="CR34">34</xref>&#x2022;&#x2022;, <xref ref-type="bibr" rid="CR37">37</xref>].</p>
      <p id="Par12">To be immunogenic, the PF4-heparin complexes must be soluble and sizable [<xref ref-type="bibr" rid="CR25">25</xref>] to interact with the Fc &#x3B3; receptors present on platelets and monocytes [<xref ref-type="bibr" rid="CR38">38</xref>]. As a result of this interaction, these cells are activated and potentiate thrombin generation.</p>
      <p id="Par13">In HIT, high-affinity IgG antibodies are produced soon after heparin exposure along with IgA and IgM antibodies [<xref ref-type="bibr" rid="CR39">39</xref>]. In contrast to other conditions, HIT does not present with an initial IgM phase [<xref ref-type="bibr" rid="CR40">40</xref>]. This rapid response with IgG might be related to exposure early in life to bacteria or host cells with PF4 bound to surface polyanions [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Repeated exposure to heparin does not necessarily lead to recurrent episodes of HIT (e.g., non-anamnestic), suggesting that these antibodies disappear within a short time [<xref ref-type="bibr" rid="CR43">43</xref>&#x2013;<xref ref-type="bibr" rid="CR45">45</xref>] due to a lack of a robust increase in memory B-cells [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p>
      <p id="Par14">The fine balance between molar concentrations of PF4 relative to heparin determines the immune response in HIT. Molar concentrations where one component exceeds the other will promote the formation of complexes that are non-immunogenic and that will not be favorable for platelet binding [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. This may explain why seropositive HIT does not necessarily translate to clinically apparent HIT. The immunogenic ultralarge PF4-heparin complexes form in the presence of a 1:1&#xA0;M ratio. The optimal concentration of PF4 needed to shift antigenicity to higher levels seems to be related to heparin dosing in the setting of platelet activation (i.e., surgery, trauma, diabetes, inflammation, etc.) [<xref ref-type="bibr" rid="CR42">42</xref>]. Patients exposed intraoperatively to very high doses of heparin (e.g., cardiovascular surgery and cardiopulmonary bypass), where there is more heparin compared to PF4, are less likely to develop HIT [<xref ref-type="bibr" rid="CR25">25</xref>]. Conversely, standard postoperative doses (e.g., orthopedic surgery) seem to produce a more favorable PF4/heparin ratio for clinically significant HIT [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
      <p id="Par15">HIT antibodies can develop even in the absence of heparin exposure, suggesting the presence of a group of B-cells that are triggered by inflammation and lack of immune regulation [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Although rare, spontaneous or autoimmune HIT can occur through the binding of PF4 to other major anionic proteins including nucleic acids and bacterial lipopolysaccharides [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Thrombocytopenia from autoimmune HIT may persist for weeks, even after the initiation of an alternative drug for anticoagulation [<xref ref-type="bibr" rid="CR50">50</xref>].</p>
      <p id="Par16">HIT is characterized by thrombocytopenia or a fall of more than 50% in the baseline platelet count measured after surgery [<xref ref-type="bibr" rid="CR11">11</xref>]. Around 85&#x2013;90% of the patients diagnosed with HIT present with thrombocytopenia [<xref ref-type="bibr" rid="CR51">51</xref>]. Thrombocytopenia (or the 50% fall in the platelet count) classically starts between 4 and 10&#xA0;days of heparin exposure and more commonly between 6 and 15&#xA0;days after the first heparin exposure in more than 90% of the patients with HIT [<xref ref-type="bibr" rid="CR52">52</xref>]. By several reports, the platelet count reaches nadir values by day 8 and the first evidence of thrombosis usually starts by day 10. Some patients develop thrombocytopenia earlier (within 2&#xA0;days of exposure), but those patients have usually been exposed to heparin before, typically within 2&#x2013;3&#xA0;weeks, yet sometimes within 100&#xA0;days before heparin re-exposure [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR50">50</xref>].</p>
      <p id="Par17">Thrombosis is common in HIT patients. It is estimated that around 50% of patients diagnosed with HIT in the postoperative period will present with thrombotic complications that might be a threat to life and/or limb [<xref ref-type="bibr" rid="CR2">2</xref>&#x2022;]. Venous thromboembolic disease, such as deep vein thrombosis or pulmonary embolus, is more common than arterial thrombosis (two&#x2013;fourfold higher), particularly in surgical patients [<xref ref-type="bibr" rid="CR53">53</xref>]. Patients with vascular disease are an exception as they tend to have similar rates of venous and arterial thrombosis in the setting of HIT [<xref ref-type="bibr" rid="CR54">54</xref>]. Arterial thrombosis is also common in cardiac surgery patients [<xref ref-type="bibr" rid="CR55">55</xref>]. In vascular patients, postoperative HIT is associated with longer hospitalizations, higher cost of stay, and higher rates of non-routine home discharges [<xref ref-type="bibr" rid="CR56">56</xref>].</p>
      <p id="Par18">Venous thromboembolism (VTE) occurs with a range of incidence between 17 and 55% in postsurgical cardiac, orthopedic, oncologic, and neurosurgical patients [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. If HIT goes untreated, then the frequency of thrombosis increases by 6.1% each day until cessation of heparin and the initiation of alternative anticoagulant therapy [<xref ref-type="bibr" rid="CR58">58</xref>]. Other manifestations that may present with seropositive HIT include necrotizing skin lesions at heparin injection sites [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>], adrenal vein thrombosis with hemorrhagic necrosis [<xref ref-type="bibr" rid="CR61">61</xref>], cavernous sinus thrombosis [<xref ref-type="bibr" rid="CR62">62</xref>], acute systemic reactions within 30&#xA0;min of an intravenous heparin bolus injection [<xref ref-type="bibr" rid="CR60">60</xref>], and disseminated intravascular coagulation (DIC) [<xref ref-type="bibr" rid="CR63">63</xref>&#x2013;<xref ref-type="bibr" rid="CR66">66</xref>]. DIC is perhaps the most feared complication if it were to occur along with a HIT diagnosis because clinical manifestations may be similar and the presence of DIC may often suggest HIT has progressed from localized thrombus formation to a systemic thromboinflammatory response [<xref ref-type="bibr" rid="CR67">67</xref>].</p>
    </sec>
    <sec id="Sec4">
      <title>Screening Systems</title>
      <p id="Par19">Multiple scoring systems can be used for HIT probability estimation. Only the 4&#xA0;T score (4Ts) has been validated. The 4Ts comprises four variables evaluated and scored from 0 to 2 (Table <xref rid="Tab1" ref-type="table">1</xref>). The positive (PPV) and negative (NPV) predictive values for this score were assessed in a pooled analysis from 2012 that included approximately 3000 patients. A low score (0&#x2013;3) has a NPV 0.99 [95% CI, 0.99&#x2013;1.00], which essentially rules out HIT. An intermediate score (4&#x2013;5) has a PPV of 0.48 [95% CI 0.42&#x2013;0.55], and a high score (6&#x2013;8) has a PPV of 0.12 [95% CI 0.10&#x2013;0.14]. Intermediate and high scores are not as reliable as only 48% of the patients with an intermediate score and 12% of patients with a high score will be accurately diagnosed with HIT with these criteria [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR68">68</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>4Ts score for pretest evaluation of HIT<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Definition</th><th>2</th><th>1</th><th>0</th></tr></thead><tbody><tr><td>Thrombocytopenia</td><td>Magnitude</td><td>&gt;&#x2009;50% platelet count decrease or nadir &gt;&#x2009;=&#x2009;20&#x2009;&#xD7;&#x2009;10<sup>3</sup> platelets/&#x3BC;L</td><td>Fall of 30&#x2013;50% or nadir 10-19&#x2009;&#xD7;&#x2009;10<sup>3</sup> platelets/&#x3BC;L</td><td>&lt;&#x2009;30% decrease or nadir &lt;&#x2009;10&#x2009;&#xD7;&#x2009;10<sup>3</sup> platelets/&#x3BC;L</td></tr><tr><td>Timing</td><td>Onset</td><td>5&#x2013;10&#xA0;days after heparin or reduced platelet count occurs &lt;&#x2009;1&#xA0;day after heparin exposure if heparin exposure prior 30&#xA0;days</td><td>5&#x2013;10&#xA0;days fall but not clear or onset after day 10 or fall starting &lt;&#x2009;1&#xA0;day after if heparin exposure prior 30&#x2013;100&#xA0;days</td><td>Platelet count fall &lt;&#x2009;4&#xA0;days without recent heparin exposure</td></tr><tr><td>Confirmed OR suspected thrombosis</td><td>Presence</td><td>New thrombosis, skin necrosis at heparin injection sites, or acute systemic reaction after heparin exposure</td><td>Progressive recurrent thrombosis, non-necrotizing skin lesions, or suspected thrombosis</td><td>None</td></tr><tr><td>Other</td><td>Alternative causes</td><td>None</td><td>Possible (sepsis, drug-induced, ITP)</td><td>Definite (within 72&#xA0;h of surgery, bacteremia, chemotherapy in the past 20&#xA0;days, DIC, post-transfusion purpura, TTP, non-necrotizing skin lesions at heparin injection sites)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Table modified from original iteration [<xref ref-type="bibr" rid="CR68">68</xref>]</p></table-wrap-foot></table-wrap></p>
      <p id="Par20">The HIT expert probability score (HEP score) was developed according to expert opinion to offer another option for guiding clinical decision making, as previous scores had limited predictive capacities [<xref ref-type="bibr" rid="CR69">69</xref>]. The score showed good agreement with the serotonin release assay, but greater inter-observer variability. However, the predictive values were not different than the 4&#xA0;Ts&#x2019; score (positive predictive value of 0.55 (95% CI 0.25&#x2013;0.82) and a negative predictive value of 0.97 [95% CI 0.85&#x2013;1.00] for a cutoff &gt;&#x2009;5). This score has not been prospectively validated.</p>
      <p id="Par21">The Lillo-Le Lou&#xEB;t model [<xref ref-type="bibr" rid="CR70">70</xref>] is intended for estimation of the likelihood of HIT in patients following cardiopulmonary bypass (CPB) for cardiac surgery. A low score (&lt;&#x2009;2) suggests a low probability of HIT, while a high score (&#x2265;2) is associated with a high probability. The negative predictive value of this model was comparable with both the HEP and 4&#xA0;T scores (~ 97%), but this model has not been prospectively validated.</p>
    </sec>
    <sec id="Sec5">
      <title>Differential Diagnosis</title>
      <p id="Par22">HIT is a challenging diagnosis in the ICU setting. Critically ill patients can often present with thrombocytopenia resulting from diagnoses other than HIT. The timing of thrombocytopenia is tremendously helpful in the diagnosis. The etiology of platelet depletion can be classified as consumptive and destructive (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Differential diagnosis for HIT</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Platelet consumption</th><th>Platelet destruction</th></tr></thead><tbody><tr><td>Thrombolytics [<xref ref-type="bibr" rid="CR71">71</xref>]</td><td>Drug-induced thrombocytopenia [<xref ref-type="bibr" rid="CR72">72</xref>&#x2022;&#x2022;]</td></tr><tr><td><sup>a</sup>GPIIb/IIIa antagonists [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]</td><td>Post-transfusion purpura [<xref ref-type="bibr" rid="CR72">72</xref>&#x2022;&#x2022;]</td></tr><tr><td>DIC [<xref ref-type="bibr" rid="CR72">72</xref>&#x2022;&#x2022;]</td><td>Multiorgan failure</td></tr><tr><td>Sepsis (purpura fulminans) [<xref ref-type="bibr" rid="CR72">72</xref>&#x2022;&#x2022;]</td><td>Paroxysmal nocturnal hemoglobinuria (PNH) [<xref ref-type="bibr" rid="CR75">75</xref>]</td></tr><tr><td><sup>b</sup>Postoperative thrombocytopenic purpura [<xref ref-type="bibr" rid="CR72">72</xref>&#x2022;&#x2022;]</td><td>Lupus/antiphospholipid syndrome [<xref ref-type="bibr" rid="CR76">76</xref>]</td></tr><tr><td>Multiorgan failure</td><td><sup>c</sup>COVID-19 [<xref ref-type="bibr" rid="CR77">77</xref>]</td></tr><tr><td>Infective endocarditis [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]</td><td/></tr><tr><td>Pulmonary embolism [<xref ref-type="bibr" rid="CR80">80</xref>]</td><td/></tr><tr><td>Liver failure [<xref ref-type="bibr" rid="CR81">81</xref>&#x2022;&#x2022;]</td><td/></tr><tr><td>Diabetic ketoacidosis [<xref ref-type="bibr" rid="CR82">82</xref>]</td><td/></tr><tr><td>Lupus/antiphospholipid syndrome [<xref ref-type="bibr" rid="CR76">76</xref>]</td><td/></tr><tr><td>Cancer (mucin-producing adenocarcinomas) [<xref ref-type="bibr" rid="CR83">83</xref>]</td><td/></tr><tr><td><sup>c</sup>COVID-19[<xref ref-type="bibr" rid="CR77">77</xref>]</td><td/></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Antibodies that recognize GPIIb/IIIa in the presence of the provoking drug can cross-react with platelet-activating receptors [<xref ref-type="bibr" rid="CR74">74</xref>]</p><p><sup>b</sup>Postoperative thrombotic thrombocytopenic purpura is due to abnormality on the clearance of ultralarge vWF multimers released from endothelium leads to increased platelet consumption [<xref ref-type="bibr" rid="CR84">84</xref>] and severe thrombocytopenia (&lt;&#x2009;20&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L) [<xref ref-type="bibr" rid="CR72">72</xref>&#x2022;&#x2022;]</p><p><sup>c</sup>At the time of this composition, the exact mechanisms for COVID-19-associated hypercoagulability and thrombocytopenia are yet to be elucidated. The current prevailing conceptual framework involves dysregulated endothelial inflammation and upregulation of thrombin generation [<xref ref-type="bibr" rid="CR77">77</xref>]</p></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="Sec6">
      <title>Laboratory Tests</title>
      <p id="Par23">HIT is a challenging clinical diagnosis as critically ill patients often present thrombocytopenia and are almost ubiquitously exposed to heparin. There are two varieties of laboratory tests for HIT: Immunoassays (ELISA, IgG) and functional assays (serotonin release assay-SRA, heparin-induced platelet activation-HIPA) [<xref ref-type="bibr" rid="CR85">85</xref>].</p>
      <p id="Par24">Immunoassays detect anti-PF4/H antibodies (platelet-activating and non-activating) and have high sensitivity (&gt;&#x2009;95%) but low specificity (i.e., high rate of false positives) [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. These tests are widely available. Enzyme immunoassays (EIA) identify antibody presence by days 4&#x2013;5 reaching maximum reactivity on days 10&#x2013;12 [<xref ref-type="bibr" rid="CR40">40</xref>]. These assays use a solid surface with heparin coating to which the patient&#x2019;s plasma is added. Antibody isotypes are measured using a combination of anti-immunoglobulins (Anti-IgG, -IgM, and IgA) or a single isotype (Anti-IgG) [<xref ref-type="bibr" rid="CR66">66</xref>]. The main limitation of EIAs in HIT is the detection of antibodies that are not necessarily pathogenic (e.g., IgM and IgA antibodies). IgG- focused EIAs seem to be more specific but are likewise limited for identification of clinically relevant HIT antibodies [<xref ref-type="bibr" rid="CR2">2</xref>&#x2022;, <xref ref-type="bibr" rid="CR26">26</xref>].</p>
      <p id="Par25">Immunization (presence of PF4/H antibodies) does not necessarily mean the development of a clinical picture of HIT. In fact, seroconversion (or immunization) occurs frequently without thrombocytopenia or thrombosis [<xref ref-type="bibr" rid="CR86">86</xref>]. A patient with a low pretest probability of HIT and a positive EIA requires confirmation with a functional assay [<xref ref-type="bibr" rid="CR2">2</xref>&#x2022;, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>&#x2022;&#x2022;]. The goal is to avoid over-diagnosis and over-treatment. A positive EIA does not automatically translate into a HIT diagnosis. Polyclonal immunoassays that detect IgA, IgM, and IgG isotypes can result in false positives for HIT, even when there are no clinical symptoms [<xref ref-type="bibr" rid="CR89">89</xref>]. It is generally recommended to not pursue said test unless there is a high clinical suspicion of HIT. Treatment based on such results may be unnecessary and potentially harmful [<xref ref-type="bibr" rid="CR90">90</xref>].</p>
      <p id="Par26">IgG-specific assays are more promising, but cutoffs for optical densities (OD) for HIT have not been clearly defined. OD values are arbitrary units and vary among laboratories [<xref ref-type="bibr" rid="CR91">91</xref>]. Strongly reactive ODs (more than 1.0) are usually correlated with clinically apparent HIT [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. High ODs are also associated with positive functional assays [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. It has been suggested that an intermediate or high score on the 4&#xA0;T&#x2019;s plus a high OD (above 1.0) has a similar accuracy in diagnosing HIT compared with a functional assay, but validation studies are needed [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>&#x2022;&#x2022;]. An intermediate OD (0.4&#x2013;1.0) should be confirmed with a functional assay [<xref ref-type="bibr" rid="CR2">2</xref>&#x2022;, <xref ref-type="bibr" rid="CR87">87</xref>]. HIT assays should be used in the setting of an intermediate-high pretest probability of HIT [<xref ref-type="bibr" rid="CR88">88</xref>&#x2022;&#x2022;]. This level of pretest probability warrants transition to or the initiation of non-heparinoid anticoagulant therapy until serologic data returns (see below for Treatment).</p>
      <p id="Par27">Functional assays (i.e., SRA, HIPA) detect platelet-activating anti-PF4/H antibodies and have high specificity (80&#x2013;100%) [<xref ref-type="bibr" rid="CR92">92</xref>] but restricted availability due to technical requirements (i.e., require human platelets from known reactive donors, use of radioactive compounds) [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. SRA only detects antibodies that are capable of activating platelets and can detect antibodies by day 5 after heparin initiation [<xref ref-type="bibr" rid="CR12">12</xref>]. The proportion of immunized patients who develop HIT is highest among the patients who have a positive SRA [<xref ref-type="bibr" rid="CR94">94</xref>].</p>
      <p id="Par28">Titers of PF4/H antibodies decrease by 3&#x2013;4 months [<xref ref-type="bibr" rid="CR45">45</xref>]. These patients are still at risk for developing rapid-onset HIT on heparin re-exposure during this period unless the functional assays/EIA are negative [<xref ref-type="bibr" rid="CR87">87</xref>].</p>
    </sec>
    <sec id="Sec7">
      <title>Treatment</title>
      <p id="Par29">HIT treatments aim to reduce thrombin generation, treat any thrombotic events, and interrupt platelet activation triggered by heparin. The mainstay of HIT treatment is the cessation of all forms of heparin and initiation of alternative anticoagulation (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Vitamin K antagonists should be avoided until HIT has resolved and the platelet count has recovered and plateaued. This is due to the increased risk of venous limb gangrene and limb loss with the inhibition of Protein C [<xref ref-type="bibr" rid="CR2">2</xref>&#x2022;].<fig id="Fig1"><label>Fig. 1</label><caption><p>Management of heparin-induced thrombocytopenia (HIT) in the intraoperative and the postoperative settings. <italic>IVIg</italic> intravenous immunoglobulin, <italic>VKA</italic> vitamin K antagonists</p></caption><graphic xlink:href="40140_2020_405_Fig1_HTML" id="MO1"/></fig></p>
      <p id="Par30">There are options for alternative anticoagulation. Direct thrombin inhibitors (DTI), including argatroban, lepirudin, and bivalirudin, inhibit both free and clot-bound thrombin facilitating the action of antithrombin, preventing the conversion of fibrinogen to fibrin, and preventing the activation of factor XIII [<xref ref-type="bibr" rid="CR95">95</xref>]. The inhibition is selective and reversible for argatroban and bivalirudin. These drugs have a short half-life (less than 2&#xA0;h) and are monitored by PTT. However, there is a risk for falsely supratherapeutic PTT in the setting of coagulopathy (e.g., DIC, decreased liver function) leading to DTI underdosing [<xref ref-type="bibr" rid="CR63">63</xref>&#x2013;<xref ref-type="bibr" rid="CR65">65</xref>]. DTIs (particularly argatroban) increase INR values and interfere with the protein C pathway [<xref ref-type="bibr" rid="CR95">95</xref>], so transitioning to warfarin requires specific protocols with an overlap of the two drugs for 5&#xA0;days to maintain an INR&#x2009;&gt;&#x2009;4 [<xref ref-type="bibr" rid="CR16">16</xref>&#x2022;, <xref ref-type="bibr" rid="CR87">87</xref>]. Argatroban is useful for patients with renal insufficiency due to its hepatobiliary excretion [<xref ref-type="bibr" rid="CR4">4</xref>] and requires parenteral administration. Lepirudin has to be monitored by ecarin clotting time (ECT) during cardiopulmonary bypass and with unexpected bleeding [<xref ref-type="bibr" rid="CR96">96</xref>].</p>
      <p id="Par31">Bivalirudin is a better option for cardiac surgery as it has a quick onset and short half-life and can be monitored with the activated clotting time (ACT) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). However, bivalirudin carries a risk for excessive bleeding as there is no specific reversal agent available to date. Monitoring its effect can be challenging due to a lack of standardized methods. Currently, ACT or aPTT are used as surrogates of the degree of anticoagulation. For surgeries that require the use of cardiopulmonary bypass, stagnant blood should be avoided at all times due to the increased risk of clotting as bivalirudin is cleaved by thrombin [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Bivalirudin metabolism and clearance can be unpredictable with changes in renal function, core temperature, or repeated doses during a long procedure [<xref ref-type="bibr" rid="CR99">99</xref>].</p>
      <p id="Par32">Indirect thrombin inhibitors (danaparoid, fondaparinux) work by enhancing the anti-Xa activity of antithrombin III. Danaparoid is not available in the USA since 2002, but it is available in other countries. Fondaparinux has a long half-life (17&#xA0;h), requires monitoring with anti-Xa levels, has no effect on INR, and does not interfere with the activation of the protein C pathway [<xref ref-type="bibr" rid="CR100">100</xref>]. These drugs undergo renal excretion [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR101">101</xref>] and subcutaneously administered. Both direct and indirect thrombin inhibitors lack a reversal agent.</p>
      <p id="Par33">Platelet transfusions are not indicated in HIT unless the patient has uncontrolled hemorrhage or is undergoing an invasive procedure as it increases the risk of thrombosis [<xref ref-type="bibr" rid="CR102">102</xref>]. IVC filters are also relatively contraindicated in HIT as there is an increased risk of IVC thrombosis, pulmonary embolism, and limb ischemia [<xref ref-type="bibr" rid="CR103">103</xref>].</p>
      <p id="Par34">HIT patients with thrombosis or a moderate-high pretest probability should be started on a non-heparin anticoagulant while awaiting the results of confirmatory testing. These patients will require therapeutic anticoagulation for at least 3&#xA0;months [<xref ref-type="bibr" rid="CR2">2</xref>&#x2022;].</p>
      <sec id="Sec8">
        <title>Treatment of Isolated HIT (Non-thrombotic)</title>
        <p id="Par35">Patients with a strong suspicion of isolated HIT or with a confirmed diagnosis should receive therapeutic dose anticoagulation with a non-heparin alternative. The treatment should be continued until platelets recover to a stable plateau [<xref ref-type="bibr" rid="CR104">104</xref>]. The risk of major bleeding with a DTI for HIT is around 1% for lepirudin (mean treatment period: 14&#xA0;days) and 0.6&#x2013;1% for argatroban (mean treatment period: 5&#xA0;days).</p>
      </sec>
      <sec id="Sec9">
        <title>Treatment of Patients with a Low Probability of HIT</title>
        <p id="Par36">Patients with a 4&#xA0;T score of equal or less than 3 that do not have a reason for therapeutic dose anticoagulation should continue prophylactic treatment with heparin or an alternative [<xref ref-type="bibr" rid="CR87">87</xref>]. Patients with an intermediate probability (4Ts score 4&#x2013;5) without the need for therapeutic anticoagulation should continue prophylactic treatment with a non-heparin alternative.</p>
      </sec>
      <sec id="Sec10">
        <title>Adjuvant Treatments</title>
        <p id="Par37">Intravenous immunoglobulin (IVIg) blocks the platelet Fc &#x3B3; receptors at high doses (2&#xA0;g/kg over 2&#xA0;days) and, consequently, inhibits antibody-mediated platelet activation [<xref ref-type="bibr" rid="CR105">105</xref>]. It can be an option in patients at high risk for autoimmune HIT or life-threatening thrombosis and bleeding (e.g., cavernous sinus thrombosis, pregnancy, severe limb ischemia) [<xref ref-type="bibr" rid="CR106">106</xref>]. IVIG has been used successfully in the preoperative period. It was shown to reduce the activity of HIT antibodies and also decreased the risk of thrombosis while rapidly increasing the platelet count shortly after initiation of therapy [<xref ref-type="bibr" rid="CR107">107</xref>].</p>
        <p id="Par38">Plasma exchange has been described as an adjunctive therapy for life-threatening HIT, particularly in the setting of urgent cardiac surgery requiring full heparinization. Its mechanism has not been fully determined, but it is thought to remove pathogenic immune complexes and potentially correct coagulopathy with FFP replacement [<xref ref-type="bibr" rid="CR108">108</xref>]. In cardiac surgery, the removal of prothrombotic complexes facilitates heparin use at high doses [<xref ref-type="bibr" rid="CR16">16</xref>]. A single plasmapheresis session reduces EIA reactivity with a loss of SRA reactivity [<xref ref-type="bibr" rid="CR109">109</xref>]. The anti-PF4/heparin antibody titer decreases by approximately 50&#x2013;80%. In a case series describing 11 cardiac surgery patients with HIT managed with intraoperative plasmapheresis before heparin administration for cardiopulmonary bypass, none of the patients with reduced titers developed clinical HIT [<xref ref-type="bibr" rid="CR108">108</xref>]. To date, only a few institutions are using plasma exchange for HIT antibody elimination [<xref ref-type="bibr" rid="CR110">110</xref>].</p>
        <p id="Par39">Intravenous epoprostenol (IV prostacyclin) is a prostaglandin that is FDA-approved as a pulmonary vasodilator for patients with pulmonary arterial hypertension. Intravenous prostacyclins inhibit platelet aggregation by activating intracellular adenylate cyclase to increase cAMP in the platelets. In a small case series, intravenous epoprostenol was administered in an &#x201C;off-label&#x201D; manner, in conjunction with heparin, to facilitate anticoagulation during cardiopulmonary bypass [<xref ref-type="bibr" rid="CR111">111</xref>]. The authors deemed the use of IV epoprostenol to be safe and effective, especially for patients with impaired renal function where bivalirudin-induced anticoagulation may have lingered and been associated with harm after separation from cardiopulmonary bypass. To date, there is a paucity of robust pharmacokinetic/pharmacodynamic studies to further evaluate the use of IV prostacyclins for this indication.</p>
      </sec>
      <sec id="Sec11">
        <title>Patients Requiring Surgical Procedures with Heparinization</title>
        <p id="Par40">In patients with a history of HIT with positive antibodies requiring non-emergent surgical procedures with heparinization (e.g., cardiac and vascular procedures, PCI, etc.), the current recommendation is to delay surgery until the functional assay is negative [<xref ref-type="bibr" rid="CR112">112</xref>] and then to use heparin [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR87">87</xref>]. If surgery is urgent or emergent, bivalirudin is the recommended drug of choice [<xref ref-type="bibr" rid="CR87">87</xref>], although plasmapheresis or therapeutic plasma exchange (TPE) followed by heparin anticoagulation has been safely used at our institution for more than a decade in cardiac surgical operations that require systemic anticoagulation for cardiopulmonary bypass (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR108">108</xref>]. This off-label use of TPE has been supported as a potential option for antibody removal in non-surgical patients [<xref ref-type="bibr" rid="CR109">109</xref>]. Intraoperative TPE is a valuable adjunct in the management of antibody-mediated syndromes including HIT and is FDA-approved for the treatment of thrombotic thrombocytopenic purpura. TPE permits heparin use by removing immune complexes and HIT antibodies [<xref ref-type="bibr" rid="CR113">113</xref>]. Intraoperative TPE can also allow for the routine reversal of post-cardiopulmonary bypass heparin reversal using protamine. In a retrospective study of 11 HIT or heparin/PF4 seropositive patients undergoing TPE in preparation for cardiac surgery, a single TPE treatment reduced heparin/PF4 titers by 50&#x2013;84%, and 7 of 9 patients had normal anti-heparin/PF4 levels after treatment [<xref ref-type="bibr" rid="CR108">108</xref>]. Following re-exposure to heparin, no serious adverse complications of HIT or to TPE were noted.</p>
      </sec>
    </sec>
    <sec id="Sec12">
      <title>Conclusions</title>
      <p id="Par41">HIT is a devastating clinical condition that will lead to loss of life and/or limb if it is not quickly recognized, diagnosed, and managed in patients that have undergone surgery. The incidence of HIT development is higher in surgical patients than it is in non-surgical patients owing to the inflammatory milieu generated during surgery as well as the potential for heparin exposure, especially in select patients such as those that have undergone orthopedic or cardiac surgery. While the recognition and understanding of the pathogenesis of HIT has dramatically improved over the past several decades due to important basic and translational studies evaluating disease biology, there remains a paucity of information regarding optimal treatment modalities. Current therapy pivots on heparin avoidance and alternative non-heparinoid anticoagulation. Although therapeutic plasma exchange has been used as a means of quickly removing antibodies, comparative effectiveness studies have not been performed to assign a high level of evidence to the use of TPE in the setting of HIT management.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>This article is part of the Topical Collection on <italic>Blood Management</italic></p>
      </fn>
      <fn>
        <p>
          <bold>Publisher&#x2019;s Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>IMD: None</p>
        <p>KG: Consultant for Uptodate&#xAE; for coagulation and blood management; Receives grant support from NIH T32GM008600 and Duke Health; Previous support from Octapharma&#xAE;</p>
      </fn>
    </fn-group>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>Kamrouz Ghadimi has received research funding from Octapharma, the National Institutes of Health (grant #T32GM008600), and Duke Health, and has received compensation from UpToDate for service as a consultant.</p>
    </notes>
    <notes>
      <title>Compliance with Ethical Standards</title>
      <notes id="FPar1" notes-type="COI-statement">
        <title>Conflict of Interest</title>
        <p id="Par42">Ingrid Moreno-Duarte declares that she has no conflict of interest.</p>
      </notes>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref-list id="BSec1">
        <title>Papers of particular interest, published recently, have been highlighted as: &#x2022; Of importance &#x2022;&#x2022; Of major importance</title>
        <ref id="CR1">
          <label>1.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>HIT: lessons learned</article-title>
            <source>Pathophysiol Haemost Thromb</source>
            <year>2006</year>
            <volume>35</volume>
            <issue>1&#x2013;2</issue>
            <fpage>50</fpage>
            <lpage>57</lpage>
            <pub-id pub-id-type="doi">10.1159/000093544</pub-id>
            <pub-id pub-id-type="pmid">16855347</pub-id>
          </element-citation>
        </ref>
        <ref id="CR2">
          <label>2.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice. Heparin-induced thrombocytopenia</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <volume>373</volume>
            <issue>3</issue>
            <fpage>252</fpage>
            <lpage>261</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMcp1411910</pub-id>
            <pub-id pub-id-type="pmid">26176382</pub-id>
          </element-citation>
        </ref>
        <ref id="CR3">
          <label>3.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy</article-title>
            <source>Chest.</source>
            <year>2004</year>
            <volume>126</volume>
            <issue>3 Suppl</issue>
            <fpage>311S</fpage>
            <lpage>337S</lpage>
            <pub-id pub-id-type="doi">10.1378/chest.126.3_suppl.311S</pub-id>
            <pub-id pub-id-type="pmid">15383477</pub-id>
          </element-citation>
        </ref>
        <ref id="CR4">
          <label>4.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Napolitano</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Almahameed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nasraway</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management</article-title>
            <source>Crit Care Med</source>
            <year>2006</year>
            <volume>34</volume>
            <issue>12</issue>
            <fpage>2898</fpage>
            <lpage>2911</lpage>
            <pub-id pub-id-type="doi">10.1097/01.CCM.0000248723.18068.90</pub-id>
            <pub-id pub-id-type="pmid">17075368</pub-id>
          </element-citation>
        </ref>
        <ref id="CR5">
          <label>5.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Wester</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Biesma</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Leusink</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Veth</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients</article-title>
            <source>Intensive Care Med</source>
            <year>2004</year>
            <volume>30</volume>
            <issue>10</issue>
            <fpage>1927</fpage>
            <lpage>1934</lpage>
            <pub-id pub-id-type="doi">10.1007/s00134-004-2334-1</pub-id>
            <pub-id pub-id-type="pmid">15156309</pub-id>
          </element-citation>
        </ref>
        <ref id="CR6">
          <label>6.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Crowther</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Meade</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Granton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Skrobik</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Langevin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hebert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Geerts</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rabbat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Douketis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zytaruk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <collab>Canadian Critical Care Trials Group</collab>
            </person-group>
            <article-title>The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients</article-title>
            <source>J Crit Care</source>
            <year>2010</year>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>287</fpage>
            <lpage>293</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jcrc.2009.12.006</pub-id>
            <pub-id pub-id-type="pmid">20149589</pub-id>
          </element-citation>
        </ref>
        <ref id="CR7">
          <label>7.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Selleng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malowsky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Strobel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Wessel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ittermann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wollert</surname>
                <given-names>HG</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive</article-title>
            <source>J Thromb Haemost</source>
            <year>2010</year>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <lpage>36</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1538-7836.2009.03626.x</pub-id>
            <pub-id pub-id-type="pmid">19793190</pub-id>
          </element-citation>
        </ref>
        <ref id="CR8">
          <label>8.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Trehel-Tursis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Louvain-Quintard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zarrouki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Imbert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Doubine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stephan</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Clinical and biologic features of patients suspected or confirmed to have heparin-induced thrombocytopenia in a cardiothoracic surgical ICU</article-title>
            <source>Chest.</source>
            <year>2012</year>
            <volume>142</volume>
            <issue>4</issue>
            <fpage>837</fpage>
            <lpage>844</lpage>
            <pub-id pub-id-type="doi">10.1378/chest.11-3074</pub-id>
            <pub-id pub-id-type="pmid">22406956</pub-id>
          </element-citation>
        </ref>
        <ref id="CR9">
          <label>9.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Marder</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization</article-title>
            <source>J Thromb Haemost</source>
            <year>2010</year>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>504</fpage>
            <lpage>512</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1538-7836.2009.03735.x</pub-id>
            <pub-id pub-id-type="pmid">20050998</pub-id>
          </element-citation>
        </ref>
        <ref id="CR10">
          <label>10.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Hirsh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Horsewood</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Gent</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin</article-title>
            <source>N Engl J Med</source>
            <year>1995</year>
            <volume>332</volume>
            <issue>20</issue>
            <fpage>1330</fpage>
            <lpage>1335</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJM199505183322003</pub-id>
            <pub-id pub-id-type="pmid">7715641</pub-id>
          </element-citation>
        </ref>
        <ref id="CR11">
          <label>11.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Hirsh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients</article-title>
            <source>Arch Intern Med</source>
            <year>2003</year>
            <volume>163</volume>
            <issue>20</issue>
            <fpage>2518</fpage>
            <lpage>2524</lpage>
            <pub-id pub-id-type="doi">10.1001/archinte.163.20.2518</pub-id>
            <pub-id pub-id-type="pmid">14609790</pub-id>
          </element-citation>
        </ref>
        <ref id="CR12">
          <label>12.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Sigouin</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?</article-title>
            <source>J Lab Clin Med</source>
            <year>2005</year>
            <volume>146</volume>
            <issue>6</issue>
            <fpage>341</fpage>
            <lpage>346</lpage>
            <pub-id pub-id-type="doi">10.1016/j.lab.2005.08.003</pub-id>
            <pub-id pub-id-type="pmid">16310517</pub-id>
          </element-citation>
        </ref>
        <ref id="CR13">
          <label>13.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Smythe</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Koerber</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mattson</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital</article-title>
            <source>Chest.</source>
            <year>2007</year>
            <volume>131</volume>
            <issue>6</issue>
            <fpage>1644</fpage>
            <lpage>1649</lpage>
            <pub-id pub-id-type="doi">10.1378/chest.06-2109</pub-id>
            <pub-id pub-id-type="pmid">17400685</pub-id>
          </element-citation>
        </ref>
        <ref id="CR14">
          <label>14.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Junqueira</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Zorzela</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Perini</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <volume>4</volume>
            <fpage>CD007557</fpage>
            <pub-id pub-id-type="doi">10.1002/14651858.CD007557.pub3</pub-id>
            <pub-id pub-id-type="pmid">28431186</pub-id>
          </element-citation>
        </ref>
        <ref id="CR15">
          <label>15.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Horsewood</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Impact of the patient population on the risk for heparin-induced thrombocytopenia</article-title>
            <source>Blood.</source>
            <year>2000</year>
            <volume>96</volume>
            <issue>5</issue>
            <fpage>1703</fpage>
            <lpage>1708</lpage>
            <pub-id pub-id-type="doi">10.1182/blood.V96.5.1703</pub-id>
            <pub-id pub-id-type="pmid">10961867</pub-id>
          </element-citation>
        </ref>
        <ref id="CR16">
          <label>16.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ivascu</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghadimi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Goeddel</surname>
                <given-names>LA</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia: a review for cardiac anesthesiologists and intensivists</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2019</year>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>511</fpage>
            <lpage>520</lpage>
            <pub-id pub-id-type="doi">10.1053/j.jvca.2018.10.035</pub-id>
            <pub-id pub-id-type="pmid">30502310</pub-id>
          </element-citation>
        </ref>
        <ref id="CR17">
          <label>17.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Pouplard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gueret</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fouassier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ternisien</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trossaert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Regina</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Prospective evaluation of the &#x201C;4Ts&#x201D; score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia</article-title>
            <source>J Thromb Haemost</source>
            <year>2007</year>
            <volume>5</volume>
            <issue>7</issue>
            <fpage>1373</fpage>
            <lpage>1379</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1538-7836.2007.02524.x</pub-id>
            <pub-id pub-id-type="pmid">17362241</pub-id>
          </element-citation>
        </ref>
        <ref id="CR18">
          <label>18.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Lubenow</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hinz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thomaschewski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lietz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vogler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ladwig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>J&#xFC;nger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nauck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schellong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wander</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ekkernkamp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia</article-title>
            <source>Blood.</source>
            <year>2010</year>
            <volume>115</volume>
            <issue>9</issue>
            <fpage>1797</fpage>
            <lpage>1803</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2009-07-231506</pub-id>
            <pub-id pub-id-type="pmid">19965682</pub-id>
          </element-citation>
        </ref>
        <ref id="CR19">
          <label>19.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sigouin</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kohlmann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eichler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia</article-title>
            <source>Blood.</source>
            <year>2006</year>
            <volume>108</volume>
            <issue>9</issue>
            <fpage>2937</fpage>
            <lpage>2941</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2005-11-012450</pub-id>
            <pub-id pub-id-type="pmid">16857993</pub-id>
          </element-citation>
        </ref>
        <ref id="CR20">
          <label>20.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Girolami</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Prandoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stefani</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Tanduo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sabbion</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Eichler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ramon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baggio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fabris</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Girolami</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study</article-title>
            <source>Blood.</source>
            <year>2003</year>
            <volume>101</volume>
            <issue>8</issue>
            <fpage>2955</fpage>
            <lpage>2959</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2002-07-2201</pub-id>
            <pub-id pub-id-type="pmid">12480713</pub-id>
          </element-citation>
        </ref>
        <ref id="CR21">
          <label>21.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Yamamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koide</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ohtaka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saika</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia in hemodialysis patients</article-title>
            <source>Am J Kidney Dis</source>
            <year>1996</year>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>82</fpage>
            <lpage>85</lpage>
            <pub-id pub-id-type="doi">10.1016/s0272-6386(96)90134-1</pub-id>
            <pub-id pub-id-type="pmid">8712226</pub-id>
          </element-citation>
        </ref>
        <ref id="CR22">
          <label>22.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Fausett</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Vogtlander</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Esplin</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Branch</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia is rare in pregnancy</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2001</year>
            <volume>185</volume>
            <issue>1</issue>
            <fpage>148</fpage>
            <lpage>152</lpage>
            <pub-id pub-id-type="doi">10.1067/mob.2001.114690</pub-id>
            <pub-id pub-id-type="pmid">11483919</pub-id>
          </element-citation>
        </ref>
        <ref id="CR23">
          <label>23.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Francis</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Moroose</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Drexler</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery</article-title>
            <source>Ann Thorac Surg</source>
            <year>2003</year>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <lpage>22</lpage>
            <pub-id pub-id-type="doi">10.1016/s0003-4975(02)04349-7</pub-id>
            <pub-id pub-id-type="pmid">12537186</pub-id>
          </element-citation>
        </ref>
        <ref id="CR24">
          <label>24.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Marder</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>BI</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin</article-title>
            <source>Blood.</source>
            <year>2005</year>
            <volume>106</volume>
            <issue>12</issue>
            <fpage>3791</fpage>
            <lpage>3796</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2005-05-1938</pub-id>
            <pub-id pub-id-type="pmid">16109780</pub-id>
          </element-citation>
        </ref>
        <ref id="CR25">
          <label>25.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Rauova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Poncz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McKenzie</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Arepally</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Weisel</surname>
                <given-names>JW</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia</article-title>
            <source>Blood.</source>
            <year>2005</year>
            <volume>105</volume>
            <issue>1</issue>
            <fpage>131</fpage>
            <lpage>138</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2004-04-1544</pub-id>
            <pub-id pub-id-type="pmid">15304392</pub-id>
          </element-citation>
        </ref>
        <ref id="CR26">
          <label>26.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Juhl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Strobel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Wessel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lubenow</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Selleng</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes</article-title>
            <source>J Thromb Haemost</source>
            <year>2007</year>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>1666</fpage>
            <lpage>1673</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1538-7836.2007.02617.x</pub-id>
            <pub-id pub-id-type="pmid">17488345</pub-id>
          </element-citation>
        </ref>
        <ref id="CR27">
          <label>27.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Lo</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Sigouin</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>What is the potential for overdiagnosis of heparin-induced thrombocytopenia?</article-title>
            <source>Am J Hematol</source>
            <year>2007</year>
            <volume>82</volume>
            <issue>12</issue>
            <fpage>1037</fpage>
            <lpage>1043</lpage>
            <pub-id pub-id-type="doi">10.1002/ajh.21032</pub-id>
            <pub-id pub-id-type="pmid">17722079</pub-id>
          </element-citation>
        </ref>
        <ref id="CR28">
          <label>28.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sigouin</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays</article-title>
            <source>J Thromb Haemost</source>
            <year>2008</year>
            <volume>6</volume>
            <issue>8</issue>
            <fpage>1304</fpage>
            <lpage>1312</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1538-7836.2008.03025.x</pub-id>
            <pub-id pub-id-type="pmid">18489711</pub-id>
          </element-citation>
        </ref>
        <ref id="CR29">
          <label>29.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Ling</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Intraoperative heparin flushes and subsequent acute heparin-induced thrombocytopenia</article-title>
            <source>Anesthesiology.</source>
            <year>1998</year>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>1567</fpage>
            <lpage>1569</lpage>
            <pub-id pub-id-type="doi">10.1097/00000542-199812000-00037</pub-id>
            <pub-id pub-id-type="pmid">9856734</pub-id>
          </element-citation>
        </ref>
        <ref id="CR30">
          <label>30.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Laster</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Heparin-coated catheters and heparin-induced thrombocytopenia</article-title>
            <source>J Vasc Surg</source>
            <year>1988</year>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>667</fpage>
            <lpage>672</lpage>
            <pub-id pub-id-type="doi">10.1067/mva.1988.avs0070667</pub-id>
            <pub-id pub-id-type="pmid">3367431</pub-id>
          </element-citation>
        </ref>
        <ref id="CR31">
          <label>31.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Hong</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sigouin</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia</article-title>
            <source>Blood.</source>
            <year>2003</year>
            <volume>101</volume>
            <issue>8</issue>
            <fpage>3049</fpage>
            <lpage>3051</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2002-05-1448</pub-id>
            <pub-id pub-id-type="pmid">12506031</pub-id>
          </element-citation>
        </ref>
        <ref id="CR32">
          <label>32.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Koster</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huebler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Potapov</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Jurmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pasic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drews</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kuppe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Loebe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hetzer</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Impact of heparin-induced thrombocytopenia on outcome in patients with ventricular assist device support: single-institution experience in 358 consecutive patients</article-title>
            <source>Ann Thorac Surg</source>
            <year>2007</year>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <lpage>76</lpage>
            <pub-id pub-id-type="doi">10.1016/j.athoracsur.2006.05.077</pub-id>
            <pub-id pub-id-type="pmid">17184633</pub-id>
          </element-citation>
        </ref>
        <ref id="CR33">
          <label>33.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Schroder</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Daneshmand</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Villamizar</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Blue</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Welsby</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Lodge</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ortel</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients</article-title>
            <source>Ann Thorac Surg</source>
            <year>2007</year>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>841</fpage>
            <lpage>845</lpage>
            <pub-id pub-id-type="doi">10.1016/j.athoracsur.2007.03.049</pub-id>
            <pub-id pub-id-type="pmid">17720387</pub-id>
          </element-citation>
        </ref>
        <ref id="CR34">
          <label>34.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Khandelwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arepally</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Immune pathogenesis of heparin-induced thrombocytopenia</article-title>
            <source>Thromb Haemost</source>
            <year>2016</year>
            <volume>116</volume>
            <issue>5</issue>
            <fpage>792</fpage>
            <lpage>798</lpage>
            <pub-id pub-id-type="doi">10.1160/TH16-01-0074</pub-id>
            <pub-id pub-id-type="pmid">27465274</pub-id>
          </element-citation>
        </ref>
        <ref id="CR35">
          <label>35.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>O'Brien</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Etherington</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Pashley</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The heparin-mobilisable pool of platelet factor 4: a comparison of intravenous and subcutaneous heparin and Kabi heparin fragment 2165</article-title>
            <source>Thromb Haemost</source>
            <year>1985</year>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>735</fpage>
            <lpage>738</lpage>
            <pub-id pub-id-type="doi">10.1055/s-0038-1660121</pub-id>
            <pub-id pub-id-type="pmid">4089807</pub-id>
          </element-citation>
        </ref>
        <ref id="CR36">
          <label>36.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Visentin</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Aster</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells</article-title>
            <source>J Clin Invest</source>
            <year>1994</year>
            <volume>93</volume>
            <issue>1</issue>
            <fpage>81</fpage>
            <lpage>88</lpage>
            <pub-id pub-id-type="doi">10.1172/JCI116987</pub-id>
            <pub-id pub-id-type="pmid">8282825</pub-id>
          </element-citation>
        </ref>
        <ref id="CR37">
          <label>37.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Poncz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Mechanistic basis of heparin-induced thrombocytopenia</article-title>
            <source>Semin Thorac Cardiovasc Surg</source>
            <year>2005</year>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <lpage>79</lpage>
            <pub-id pub-id-type="doi">10.1053/j.semtcvs.2004.12.007</pub-id>
            <pub-id pub-id-type="pmid">16104364</pub-id>
          </element-citation>
        </ref>
        <ref id="CR38">
          <label>38.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Horne</surname>
                <given-names>MK</given-names>
                <suffix>3rd</suffix>
              </name>
              <name>
                <surname>Alkins</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Platelet binding of IgG from patients with heparin-induced thrombocytopenia</article-title>
            <source>J Lab Clin Med</source>
            <year>1996</year>
            <volume>127</volume>
            <issue>5</issue>
            <fpage>435</fpage>
            <lpage>442</lpage>
            <pub-id pub-id-type="doi">10.1016/s0022-2143(96)90060-8</pub-id>
            <pub-id pub-id-type="pmid">8621980</pub-id>
          </element-citation>
        </ref>
        <ref id="CR39">
          <label>39.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Studies of the immune response in heparin-induced thrombocytopenia</article-title>
            <source>Blood.</source>
            <year>2009</year>
            <volume>113</volume>
            <issue>20</issue>
            <fpage>4963</fpage>
            <lpage>4969</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2008-10-186064</pub-id>
            <pub-id pub-id-type="pmid">19144981</pub-id>
          </element-citation>
        </ref>
        <ref id="CR40">
          <label>40.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kohlmann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Strobel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>The temporal profile of the anti-PF4/heparin immune response</article-title>
            <source>Blood.</source>
            <year>2009</year>
            <volume>113</volume>
            <issue>20</issue>
            <fpage>4970</fpage>
            <lpage>4976</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2008-08-173062</pub-id>
            <pub-id pub-id-type="pmid">19109231</pub-id>
          </element-citation>
        </ref>
        <ref id="CR41">
          <label>41.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Krauel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Potschke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Furll</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ittermann</surname>
                <given-names>T</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia</article-title>
            <source>Blood.</source>
            <year>2011</year>
            <volume>117</volume>
            <issue>4</issue>
            <fpage>1370</fpage>
            <lpage>1378</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2010-08-301424</pub-id>
            <pub-id pub-id-type="pmid">20959601</pub-id>
          </element-citation>
        </ref>
        <ref id="CR42">
          <label>42.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Rauova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kowalska</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Arepally</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Cines</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Poncz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications</article-title>
            <source>Blood.</source>
            <year>2006</year>
            <volume>107</volume>
            <issue>6</issue>
            <fpage>2346</fpage>
            <lpage>2353</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2005-08-3122</pub-id>
            <pub-id pub-id-type="pmid">16304054</pub-id>
          </element-citation>
        </ref>
        <ref id="CR43">
          <label>43.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>P&#xF6;tschke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Selleng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Br&#xF6;ker</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia: further evidence for a unique immune response</article-title>
            <source>Blood.</source>
            <year>2012</year>
            <volume>120</volume>
            <issue>20</issue>
            <fpage>4238</fpage>
            <lpage>4245</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2012-04-419424</pub-id>
            <pub-id pub-id-type="pmid">22932802</pub-id>
          </element-citation>
        </ref>
        <ref id="CR44">
          <label>44.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia</article-title>
            <source>J Thromb Haemost</source>
            <year>2009</year>
            <volume>7</volume>
            <issue>Suppl 1</issue>
            <fpage>9</fpage>
            <lpage>12</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1538-7836.2009.03385.x</pub-id>
            <pub-id pub-id-type="pmid">19630757</pub-id>
          </element-citation>
        </ref>
        <ref id="CR45">
          <label>45.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Temporal aspects of heparin-induced thrombocytopenia</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <volume>344</volume>
            <issue>17</issue>
            <fpage>1286</fpage>
            <lpage>1292</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJM200104263441704</pub-id>
            <pub-id pub-id-type="pmid">11320387</pub-id>
          </element-citation>
        </ref>
        <ref id="CR46">
          <label>46.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Lubenow</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kempf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eichner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eichler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin</article-title>
            <source>Chest.</source>
            <year>2002</year>
            <volume>122</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <lpage>42</lpage>
            <pub-id pub-id-type="doi">10.1378/chest.122.1.37</pub-id>
            <pub-id pub-id-type="pmid">12114336</pub-id>
          </element-citation>
        </ref>
        <ref id="CR47">
          <label>47.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Krauel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schulze</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jouni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hackbarth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hietkamp</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Selleng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koster</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jensch</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schwertz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bakchoul</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hundt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Further insights into the anti-PF4/heparin IgM immune response</article-title>
            <source>Thromb Haemost</source>
            <year>2016</year>
            <volume>115</volume>
            <issue>4</issue>
            <fpage>752</fpage>
            <lpage>761</lpage>
            <pub-id pub-id-type="doi">10.1160/TH15-08-0654</pub-id>
            <pub-id pub-id-type="pmid">26467272</pub-id>
          </element-citation>
        </ref>
        <ref id="CR48">
          <label>48.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Satoh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Okazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kaburaki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuwana</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Heparin-dependent and -independent anti-platelet factor 4 autoantibodies in patients with systemic lupus erythematosus</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2012</year>
            <volume>51</volume>
            <issue>9</issue>
            <fpage>1721</fpage>
            <lpage>1728</lpage>
            <pub-id pub-id-type="doi">10.1093/rheumatology/kes145</pub-id>
            <pub-id pub-id-type="pmid">22718864</pub-id>
          </element-citation>
        </ref>
        <ref id="CR49">
          <label>49.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Krauel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brandt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zahringer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mamat</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Platelet factor 4 binding to lipid a of gram-negative bacteria exposes PF4/heparin-like epitopes</article-title>
            <source>Blood.</source>
            <year>2012</year>
            <volume>120</volume>
            <issue>16</issue>
            <fpage>3345</fpage>
            <lpage>3352</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2012-06-434985</pub-id>
            <pub-id pub-id-type="pmid">22942185</pub-id>
          </element-citation>
        </ref>
        <ref id="CR50">
          <label>50.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin</article-title>
            <source>Blood.</source>
            <year>2014</year>
            <volume>123</volume>
            <issue>16</issue>
            <fpage>2485</fpage>
            <lpage>2493</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2013-10-533083</pub-id>
            <pub-id pub-id-type="pmid">24516044</pub-id>
          </element-citation>
        </ref>
        <ref id="CR51">
          <label>51.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentation of heparin-induced thrombocytopenia</article-title>
            <source>Semin Hematol</source>
            <year>1998</year>
            <volume>35</volume>
            <issue>4 Suppl 5</issue>
            <fpage>9</fpage>
            <lpage>16</lpage>
            <pub-id pub-id-type="pmid">9855179</pub-id>
          </element-citation>
        </ref>
        <ref id="CR52">
          <label>52.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>King</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Heparin-associated thrombocytopenia</article-title>
            <source>Ann Intern Med</source>
            <year>1984</year>
            <volume>100</volume>
            <issue>4</issue>
            <fpage>535</fpage>
            <lpage>540</lpage>
            <pub-id pub-id-type="doi">10.7326/0003-4819-100-4-535</pub-id>
            <pub-id pub-id-type="pmid">6367579</pub-id>
          </element-citation>
        </ref>
        <ref id="CR53">
          <label>53.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>A 14-year study of heparin-induced thrombocytopenia</article-title>
            <source>Am J Med</source>
            <year>1996</year>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>502</fpage>
            <lpage>507</lpage>
            <pub-id pub-id-type="doi">10.1016/s0002-9343(96)00258-6</pub-id>
            <pub-id pub-id-type="pmid">8948273</pub-id>
          </element-citation>
        </ref>
        <ref id="CR54">
          <label>54.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Almeida</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liem</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Silver</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome</article-title>
            <source>J Vasc Surg</source>
            <year>1998</year>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>309</fpage>
            <lpage>314</lpage>
            <pub-id pub-id-type="doi">10.1016/s0741-5214(98)70361-1</pub-id>
            <pub-id pub-id-type="pmid">9510285</pub-id>
          </element-citation>
        </ref>
        <ref id="CR55">
          <label>55.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Singer</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Mannion</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Armenti</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Edie</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass</article-title>
            <source>Chest.</source>
            <year>1993</year>
            <volume>104</volume>
            <issue>5</issue>
            <fpage>1436</fpage>
            <lpage>1440</lpage>
            <pub-id pub-id-type="doi">10.1378/chest.104.5.1436</pub-id>
            <pub-id pub-id-type="pmid">8222802</pub-id>
          </element-citation>
        </ref>
        <ref id="CR56">
          <label>56.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Subahi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Osman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adegbala</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Abubakar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kheiri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yassin</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Khalid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akintoye</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eljack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Osman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alkhouli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical and economic burden of heparin-induced thrombocytopenia in hospitalized patients undergoing percutaneous peripheral arterial interventions</article-title>
            <source>Vascular.</source>
            <year>2020</year>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>81</fpage>
            <lpage>86</lpage>
            <pub-id pub-id-type="doi">10.1177/1708538119868615</pub-id>
            <pub-id pub-id-type="pmid">31382836</pub-id>
          </element-citation>
        </ref>
        <ref id="CR57">
          <label>57.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Nand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yetter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schmulbach</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution</article-title>
            <source>Am J Hematol</source>
            <year>1997</year>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <lpage>16</lpage>
            <pub-id pub-id-type="doi">10.1002/(sici)1096-8652(199709)56:1&lt;12::aid-ajh3&gt;3.0.co;2-5</pub-id>
            <pub-id pub-id-type="pmid">9298861</pub-id>
          </element-citation>
        </ref>
        <ref id="CR58">
          <label>58.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eichler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lubenow</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kwasny</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Luz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range</article-title>
            <source>Blood.</source>
            <year>2000</year>
            <volume>96</volume>
            <issue>3</issue>
            <fpage>846</fpage>
            <lpage>851</lpage>
            <pub-id pub-id-type="doi">10.1182/blood.V96.3.846</pub-id>
            <pub-id pub-id-type="pmid">10910895</pub-id>
          </element-citation>
        </ref>
        <ref id="CR59">
          <label>59.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced skin lesions</article-title>
            <source>Br J Haematol</source>
            <year>1996</year>
            <volume>92</volume>
            <issue>2</issue>
            <fpage>494</fpage>
            <lpage>497</lpage>
            <pub-id pub-id-type="doi">10.1046/j.1365-2141.1996.d01-1481.x</pub-id>
            <pub-id pub-id-type="pmid">8603024</pub-id>
          </element-citation>
        </ref>
        <ref id="CR60">
          <label>60.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Hirsh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study</article-title>
            <source>Chest.</source>
            <year>2005</year>
            <volume>127</volume>
            <issue>5</issue>
            <fpage>1857</fpage>
            <lpage>1861</lpage>
            <pub-id pub-id-type="doi">10.1378/chest.127.5.1857</pub-id>
            <pub-id pub-id-type="pmid">15888871</pub-id>
          </element-citation>
        </ref>
        <ref id="CR61">
          <label>61.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Tan</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>Bilateral adrenal hemorrhage secondary to heparin-induced thrombocytopenia</article-title>
            <source>Am J Med</source>
            <year>2020</year>
            <volume>133</volume>
            <fpage>e376</fpage>
            <lpage>e377</lpage>
            <pub-id pub-id-type="doi">10.1016/j.amjmed.2019.11.027</pub-id>
            <pub-id pub-id-type="pmid">31926140</pub-id>
          </element-citation>
        </ref>
        <ref id="CR62">
          <label>62.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Meyer-Lindenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quenzel</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Bierhoff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wolff</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schindler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Biniek</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Fatal cerebral venous sinus thrombosis in heparin-induced thrombotic thrombocytopenia</article-title>
            <source>Eur Neurol</source>
            <year>1997</year>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>191</fpage>
            <lpage>192</lpage>
            <pub-id pub-id-type="doi">10.1159/000117434</pub-id>
            <pub-id pub-id-type="pmid">9137932</pub-id>
          </element-citation>
        </ref>
        <ref id="CR63">
          <label>63.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>The direct thrombin inhibitor hirudin</article-title>
            <source>Thromb Haemost</source>
            <year>2008</year>
            <volume>99</volume>
            <issue>5</issue>
            <fpage>819</fpage>
            <lpage>829</lpage>
            <pub-id pub-id-type="doi">10.1160/TH07-11-0693</pub-id>
            <pub-id pub-id-type="pmid">18449411</pub-id>
          </element-citation>
        </ref>
        <ref id="CR64">
          <label>64.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia in critically ill patients</article-title>
            <source>Crit Care Clin</source>
            <year>2011</year>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>805</fpage>
            <lpage>823</lpage>
            <pub-id pub-id-type="doi">10.1016/j.ccc.2011.08.001</pub-id>
            <pub-id pub-id-type="pmid">22082515</pub-id>
          </element-citation>
        </ref>
        <ref id="CR65">
          <label>65.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>HIT paradigms and paradoxes</article-title>
            <source>J Thromb Haemost</source>
            <year>2011</year>
            <volume>9</volume>
            <issue>Suppl 1</issue>
            <fpage>105</fpage>
            <lpage>117</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1538-7836.2011.04322.x</pub-id>
            <pub-id pub-id-type="pmid">21781246</pub-id>
          </element-citation>
        </ref>
        <ref id="CR66">
          <label>66.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Linkins</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>The approach to heparin-induced thrombocytopenia</article-title>
            <source>Semin Respir Crit Care Med</source>
            <year>2008</year>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <lpage>74</lpage>
            <pub-id pub-id-type="doi">10.1055/s-2008-1047564</pub-id>
            <pub-id pub-id-type="pmid">18302088</pub-id>
          </element-citation>
        </ref>
        <ref id="CR67">
          <label>67.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Levy</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ghadimi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Faraoni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>van Diepen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hotchkiss</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Ischemic limb necrosis in septic shock: what is the role of high-dose vasopressor therapy?</article-title>
            <source>J Thromb Haemost</source>
            <year>2019</year>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>1973</fpage>
            <lpage>1978</lpage>
            <pub-id pub-id-type="doi">10.1111/jth.14566</pub-id>
            <pub-id pub-id-type="pmid">31334603</pub-id>
          </element-citation>
        </ref>
        <ref id="CR68">
          <label>68.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Lo</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Juhl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Sigouin</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Eichler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings</article-title>
            <source>J Thromb Haemost</source>
            <year>2006</year>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>759</fpage>
            <lpage>765</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1538-7836.2006.01787.x</pub-id>
            <pub-id pub-id-type="pmid">16634744</pub-id>
          </element-citation>
        </ref>
        <ref id="CR69">
          <label>69.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Cuker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arepally</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Datko</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hook</surname>
                <given-names>K</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>The HIT expert probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion</article-title>
            <source>J Thromb Haemost</source>
            <year>2010</year>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>2642</fpage>
            <lpage>2650</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1538-7836.2010.04059.x</pub-id>
            <pub-id pub-id-type="pmid">20854372</pub-id>
          </element-citation>
        </ref>
        <ref id="CR70">
          <label>70.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Lillo-Le Louet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boutouyrie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alhenc-Gelas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Beller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gautier</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Aiach</surname>
                <given-names>M</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass</article-title>
            <source>J Thromb Haemost</source>
            <year>2004</year>
            <volume>2</volume>
            <issue>11</issue>
            <fpage>1882</fpage>
            <lpage>1888</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1538-7836.2004.00949.x</pub-id>
            <pub-id pub-id-type="pmid">15550015</pub-id>
          </element-citation>
        </ref>
        <ref id="CR71">
          <label>71.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sane</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Califf</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Sigmon</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Abbottsmith</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Candela</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Topol</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The thrombolysis and angioplasty in myocardial infarction study group</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1994</year>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>891</fpage>
            <lpage>898</lpage>
            <pub-id pub-id-type="doi">10.1016/0735-1097(94)90634-3</pub-id>
            <pub-id pub-id-type="pmid">8106694</pub-id>
          </element-citation>
        </ref>
        <ref id="CR72">
          <label>72.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Skeith</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baumann Kreuziger</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>A practical approach to evaluating postoperative thrombocytopenia</article-title>
            <source>Blood Adv</source>
            <year>2020</year>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>776</fpage>
            <lpage>783</lpage>
            <pub-id pub-id-type="doi">10.1182/bloodadvances.2019001414</pub-id>
            <pub-id pub-id-type="pmid">32097460</pub-id>
          </element-citation>
        </ref>
        <ref id="CR73">
          <label>73.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Weitz</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hudoba</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors</article-title>
            <source>Circulation.</source>
            <year>1998</year>
            <volume>97</volume>
            <issue>6</issue>
            <fpage>544</fpage>
            <lpage>552</lpage>
            <pub-id pub-id-type="doi">10.1161/01.cir.97.6.544</pub-id>
            <pub-id pub-id-type="pmid">9494024</pub-id>
          </element-citation>
        </ref>
        <ref id="CR74">
          <label>74.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Bougie</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Wilker</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Wuitschick</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lind</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aster</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa</article-title>
            <source>Blood.</source>
            <year>2002</year>
            <volume>100</volume>
            <issue>6</issue>
            <fpage>2071</fpage>
            <lpage>2076</lpage>
            <pub-id pub-id-type="doi">10.1182/blood.V100.6.2071</pub-id>
            <pub-id pub-id-type="pmid">12200368</pub-id>
          </element-citation>
        </ref>
        <ref id="CR75">
          <label>75.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Wiedmer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Ortel</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Rosse</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Sims</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria</article-title>
            <source>Blood.</source>
            <year>1993</year>
            <volume>82</volume>
            <issue>4</issue>
            <fpage>1192</fpage>
            <lpage>1196</lpage>
            <pub-id pub-id-type="doi">10.1182/blood.V82.4.1192.1192</pub-id>
            <pub-id pub-id-type="pmid">7688991</pub-id>
          </element-citation>
        </ref>
        <ref id="CR76">
          <label>76.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Lipp</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>von Felten</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sax</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Muller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Berchtold</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia</article-title>
            <source>Eur J Haematol</source>
            <year>1998</year>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>283</fpage>
            <lpage>288</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1600-0609.1998.tb01041.x</pub-id>
            <pub-id pub-id-type="pmid">9654157</pub-id>
          </element-citation>
        </ref>
        <ref id="CR77">
          <label>77.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Thromboinflammation and the hypercoagulability of COVID-19</article-title>
            <source>J Thromb Haemost</source>
            <year>2020</year>
            <volume>18</volume>
            <fpage>1559</fpage>
            <lpage>1561</lpage>
            <pub-id pub-id-type="doi">10.1111/jth.14849</pub-id>
            <pub-id pub-id-type="pmid">32302453</pub-id>
          </element-citation>
        </ref>
        <ref id="CR78">
          <label>78.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Arnold</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Smaill</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Christjanson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Cardiobacterium hominis endocarditis associated with very severe thrombocytopenia and platelet autoantibodies</article-title>
            <source>Am J Hematol</source>
            <year>2004</year>
            <volume>76</volume>
            <issue>4</issue>
            <fpage>373</fpage>
            <lpage>377</lpage>
            <pub-id pub-id-type="doi">10.1002/ajh.20127</pub-id>
            <pub-id pub-id-type="pmid">15282672</pub-id>
          </element-citation>
        </ref>
        <ref id="CR79">
          <label>79.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Selleng</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Heggtveit</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Eichler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cybulsky</surname>
                <given-names>IJ</given-names>
              </name>
            </person-group>
            <article-title>Very severe thrombocytopenia and fragmentation hemolysis mimicking thrombotic thrombocytopenic purpura associated with a giant intracardiac vegetation infected with Staphylococcus epidermidis: role of monocyte procoagulant activity induced by bacterial supernatant</article-title>
            <source>Am J Hematol</source>
            <year>2007</year>
            <volume>82</volume>
            <issue>8</issue>
            <fpage>766</fpage>
            <lpage>771</lpage>
            <pub-id pub-id-type="doi">10.1002/ajh.20821</pub-id>
            <pub-id pub-id-type="pmid">17160989</pub-id>
          </element-citation>
        </ref>
        <ref id="CR80">
          <label>80.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Kitchens</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Thrombocytopenia due to acute venous thromboembolism and its role in expanding the differential diagnosis of heparin-induced thrombocytopenia</article-title>
            <source>Am J Hematol</source>
            <year>2004</year>
            <volume>76</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <lpage>73</lpage>
            <pub-id pub-id-type="doi">10.1002/ajh.20009</pub-id>
            <pub-id pub-id-type="pmid">15114601</pub-id>
          </element-citation>
        </ref>
        <ref id="CR81">
          <label>81.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia in critically ill patients</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2015</year>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <lpage>60</lpage>
            <pub-id pub-id-type="doi">10.1055/s-0034-1398381</pub-id>
            <pub-id pub-id-type="pmid">25590528</pub-id>
          </element-citation>
        </ref>
        <ref id="CR82">
          <label>82.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Sudic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Razmara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Forslund</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Hjemdahl</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>High glucose levels enhance platelet activation: involvement of multiple mechanisms</article-title>
            <source>Br J Haematol</source>
            <year>2006</year>
            <volume>133</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <lpage>322</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1365-2141.2006.06012.x</pub-id>
            <pub-id pub-id-type="pmid">16643434</pub-id>
          </element-citation>
        </ref>
        <ref id="CR83">
          <label>83.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Elavathil</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Hayward</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Russett</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia</article-title>
            <source>Ann Intern Med</source>
            <year>1997</year>
            <volume>127</volume>
            <issue>9</issue>
            <fpage>804</fpage>
            <lpage>812</lpage>
            <pub-id pub-id-type="doi">10.7326/0003-4819-127-9-199711010-00005</pub-id>
            <pub-id pub-id-type="pmid">9382401</pub-id>
          </element-citation>
        </ref>
        <ref id="CR84">
          <label>84.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Pavlovsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Thrombotic thrombocytopenic purpura following coronary artery bypass graft surgery: prospective observations of an emerging syndrome</article-title>
            <source>J Clin Apher</source>
            <year>1997</year>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>159</fpage>
            <lpage>164</lpage>
            <pub-id pub-id-type="doi">10.1002/(sici)1098-1101(1997)12:4&lt;159::aid-jca1&gt;3.0.co;2-9</pub-id>
            <pub-id pub-id-type="pmid">9483176</pub-id>
          </element-citation>
        </ref>
        <ref id="CR85">
          <label>85.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Francis</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2004</year>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>359</fpage>
            <lpage>368</lpage>
            <pub-id pub-id-type="doi">10.1055/s-2004-831049</pub-id>
            <pub-id pub-id-type="pmid">15282659</pub-id>
          </element-citation>
        </ref>
        <ref id="CR86">
          <label>86.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Amiral</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boyer-Neumann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vissac</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia</article-title>
            <source>Br J Haematol</source>
            <year>1996</year>
            <volume>92</volume>
            <issue>4</issue>
            <fpage>954</fpage>
            <lpage>959</lpage>
            <pub-id pub-id-type="doi">10.1046/j.1365-2141.1996.407945.x</pub-id>
            <pub-id pub-id-type="pmid">8616093</pub-id>
          </element-citation>
        </ref>
        <ref id="CR87">
          <label>87.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Linkins</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Dans</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Moores</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Bona</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</article-title>
            <source>Chest.</source>
            <year>2012</year>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e495S</fpage>
            <lpage>e530S</lpage>
            <pub-id pub-id-type="doi">10.1378/chest.11-2303</pub-id>
            <pub-id pub-id-type="pmid">22315270</pub-id>
          </element-citation>
        </ref>
        <ref id="CR88">
          <label>88.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Cuker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arepally</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Cines</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gruel</surname>
                <given-names>Y</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia</article-title>
            <source>Blood Adv</source>
            <year>2018</year>
            <volume>2</volume>
            <issue>22</issue>
            <fpage>3360</fpage>
            <lpage>3392</lpage>
            <pub-id pub-id-type="doi">10.1182/bloodadvances.2018024489</pub-id>
            <pub-id pub-id-type="pmid">30482768</pub-id>
          </element-citation>
        </ref>
        <ref id="CR89">
          <label>89.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Husseinzadeh</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Gimotty</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Pishko</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Cuker</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis</article-title>
            <source>J Thromb Haemost</source>
            <year>2017</year>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>1203</fpage>
            <lpage>1212</lpage>
            <pub-id pub-id-type="doi">10.1111/jth.13692</pub-id>
            <pub-id pub-id-type="pmid">28374939</pub-id>
          </element-citation>
        </ref>
        <ref id="CR90">
          <label>90.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Harada</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Zaw</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Murry</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Volod</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Nu&#xF1;o</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Margulies</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Ley</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Overtreatment of heparin-induced thrombocytopenia in the surgical ICU</article-title>
            <source>Crit Care Med</source>
            <year>2017</year>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <lpage>34</lpage>
            <pub-id pub-id-type="doi">10.1097/CCM.0000000000002002</pub-id>
            <pub-id pub-id-type="pmid">27513533</pub-id>
          </element-citation>
        </ref>
        <ref id="CR91">
          <label>91.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ittermann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bagemuhl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Althaus</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Furll</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Selleng</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests</article-title>
            <source>J Thromb Haemost</source>
            <year>2010</year>
            <volume>8</volume>
            <issue>9</issue>
            <fpage>2025</fpage>
            <lpage>2031</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1538-7836.2010.03974.x</pub-id>
            <pub-id pub-id-type="pmid">20626620</pub-id>
          </element-citation>
        </ref>
        <ref id="CR92">
          <label>92.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Michels</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kiefel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mueller-Eckhardt</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia</article-title>
            <source>Thromb Haemost</source>
            <year>1991</year>
            <volume>66</volume>
            <issue>6</issue>
            <fpage>734</fpage>
            <lpage>736</lpage>
            <pub-id pub-id-type="doi">10.1055/s-0038-1646493</pub-id>
            <pub-id pub-id-type="pmid">1796420</pub-id>
          </element-citation>
        </ref>
        <ref id="CR93">
          <label>93.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Hayward</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia</article-title>
            <source>J Lab Clin Med</source>
            <year>1992</year>
            <volume>120</volume>
            <issue>3</issue>
            <fpage>371</fpage>
            <lpage>379</lpage>
            <pub-id pub-id-type="pmid">1517683</pub-id>
          </element-citation>
        </ref>
        <ref id="CR94">
          <label>94.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nazi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kelton</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>The platelet serotonin-release assay</article-title>
            <source>Am J Hematol</source>
            <year>2015</year>
            <volume>90</volume>
            <issue>6</issue>
            <fpage>564</fpage>
            <lpage>572</lpage>
            <pub-id pub-id-type="doi">10.1002/ajh.24006</pub-id>
            <pub-id pub-id-type="pmid">25775976</pub-id>
          </element-citation>
        </ref>
        <ref id="CR95">
          <label>95.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Di Nisio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buller</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Direct thrombin inhibitors</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <volume>353</volume>
            <issue>10</issue>
            <fpage>1028</fpage>
            <lpage>1040</lpage>
            <pub-id pub-id-type="doi">10.1056/NEJMra044440</pub-id>
            <pub-id pub-id-type="pmid">16148288</pub-id>
          </element-citation>
        </ref>
        <ref id="CR96">
          <label>96.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Lubenow</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Eichler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lietz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <collab>Hit Investigators G</collab>
            </person-group>
            <article-title>Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3</article-title>
            <source>J Thromb Haemost</source>
            <year>2005</year>
            <volume>3</volume>
            <issue>11</issue>
            <fpage>2428</fpage>
            <lpage>2436</lpage>
            <pub-id pub-id-type="doi">10.1111/j.1538-7836.2005.01623.x</pub-id>
            <pub-id pub-id-type="pmid">16241940</pub-id>
          </element-citation>
        </ref>
        <ref id="CR97">
          <label>97.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Koster</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Faraoni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery</article-title>
            <source>Anesthesiology.</source>
            <year>2018</year>
            <volume>128</volume>
            <issue>2</issue>
            <fpage>390</fpage>
            <lpage>400</lpage>
            <pub-id pub-id-type="doi">10.1097/ALN.0000000000001976</pub-id>
            <pub-id pub-id-type="pmid">29206646</pub-id>
          </element-citation>
        </ref>
        <ref id="CR98">
          <label>98.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Dyke</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Smedira</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Koster</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>HL</given-names>
                <suffix>2nd</suffix>
              </name>
              <name>
                <surname>Kirshner</surname>
                <given-names>R</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the evolution -on study</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2006</year>
            <volume>131</volume>
            <issue>3</issue>
            <fpage>533</fpage>
            <lpage>539</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jtcvs.2005.09.057</pub-id>
            <pub-id pub-id-type="pmid">16515902</pub-id>
          </element-citation>
        </ref>
        <ref id="CR99">
          <label>99.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Koster</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dyke</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Aldea</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Smedira</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>S</given-names>
              </name>
              <etal/>
            </person-group>
            <article-title>Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the choose-on trial</article-title>
            <source>Ann Thorac Surg</source>
            <year>2007</year>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>572</fpage>
            <lpage>577</lpage>
            <pub-id pub-id-type="doi">10.1016/j.athoracsur.2006.09.038</pub-id>
            <pub-id pub-id-type="pmid">17257990</pub-id>
          </element-citation>
        </ref>
        <ref id="CR100">
          <label>100.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Lobo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Finch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Minhas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia</article-title>
            <source>Thromb Haemost</source>
            <year>2008</year>
            <volume>99</volume>
            <issue>1</issue>
            <fpage>208</fpage>
            <lpage>214</lpage>
            <pub-id pub-id-type="doi">10.1160/TH07-04-0252</pub-id>
            <pub-id pub-id-type="pmid">18217156</pub-id>
          </element-citation>
        </ref>
        <ref id="CR101">
          <label>101.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Pappalardo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scandroglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maj</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zangrillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Angelo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment of heparin-induced thrombocytopenia after cardiac surgery: preliminary experience with fondaparinux</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2010</year>
            <volume>139</volume>
            <issue>3</issue>
            <fpage>790</fpage>
            <lpage>792</lpage>
            <pub-id pub-id-type="doi">10.1016/j.jtcvs.2008.11.032</pub-id>
            <pub-id pub-id-type="pmid">19660283</pub-id>
          </element-citation>
        </ref>
        <ref id="CR102">
          <label>102.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Goel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ness</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Takemoto</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Krishnamurti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Tobian</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality</article-title>
            <source>Blood.</source>
            <year>2015</year>
            <volume>125</volume>
            <issue>9</issue>
            <fpage>1470</fpage>
            <lpage>1476</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2014-10-605493</pub-id>
            <pub-id pub-id-type="pmid">25588677</pub-id>
          </element-citation>
        </ref>
        <ref id="CR103">
          <label>103.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Nitta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shitara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nozaki</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Heparin-induced thrombocytopenia in a glioblastoma multiforme patient with inferior vena cava filter placement for deep venous thrombosis</article-title>
            <source>Neurol Med Chir (Tokyo)</source>
            <year>2011</year>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>445</fpage>
            <lpage>448</lpage>
            <pub-id pub-id-type="doi">10.2176/nmc.51.445</pub-id>
            <pub-id pub-id-type="pmid">21701111</pub-id>
          </element-citation>
        </ref>
        <ref id="CR104">
          <label>104.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Lewis</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Wallis</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hursting</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Leya</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia</article-title>
            <source>Chest.</source>
            <year>2006</year>
            <volume>129</volume>
            <issue>6</issue>
            <fpage>1407</fpage>
            <lpage>1416</lpage>
            <pub-id pub-id-type="doi">10.1378/chest.129.6.1407</pub-id>
            <pub-id pub-id-type="pmid">16778256</pub-id>
          </element-citation>
        </ref>
        <ref id="CR105">
          <label>105.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liebenhoff</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kiefel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Presek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mueller-Eckhardt</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Heparin-associated thrombocytopenia: the effects of various intravenous IgG preparations on antibody mediated platelet activation--a possible new indication for high dose i.v. IgG</article-title>
            <source>Thromb Haemost</source>
            <year>1994</year>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>641</fpage>
            <lpage>645</lpage>
            <pub-id pub-id-type="doi">10.1055/s-0038-1642496</pub-id>
            <pub-id pub-id-type="pmid">8091393</pub-id>
          </element-citation>
        </ref>
        <ref id="CR106">
          <label>106.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Tvito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bakchoul</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Greinacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ganzel</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment</article-title>
            <source>Am J Hematol</source>
            <year>2015</year>
            <volume>90</volume>
            <issue>7</issue>
            <fpage>675</fpage>
            <lpage>678</lpage>
            <pub-id pub-id-type="doi">10.1002/ajh.23971</pub-id>
            <pub-id pub-id-type="pmid">25683147</pub-id>
          </element-citation>
        </ref>
        <ref id="CR107">
          <label>107.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review</article-title>
            <source>Expert Rev Hematol</source>
            <year>2019</year>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>685</fpage>
            <lpage>698</lpage>
            <pub-id pub-id-type="doi">10.1080/17474086.2019.1636645</pub-id>
            <pub-id pub-id-type="pmid">31274032</pub-id>
          </element-citation>
        </ref>
        <ref id="CR108">
          <label>108.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Welsby</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Um</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ortel</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Arepally</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia</article-title>
            <source>Anesth Analg</source>
            <year>2010</year>
            <volume>110</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <lpage>35</lpage>
            <pub-id pub-id-type="doi">10.1213/ANE.0b013e3181c3c1cd</pub-id>
            <pub-id pub-id-type="pmid">19933539</pub-id>
          </element-citation>
        </ref>
        <ref id="CR109">
          <label>109.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>FV</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gangji</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities</article-title>
            <source>Blood.</source>
            <year>2015</year>
            <volume>125</volume>
            <issue>1</issue>
            <fpage>195</fpage>
            <lpage>198</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2014-07-590844</pub-id>
            <pub-id pub-id-type="pmid">25406354</pub-id>
          </element-citation>
        </ref>
        <ref id="CR110">
          <label>110.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Onwuemene</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Zantek</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Rollins-Raval</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Raval</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ipe</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Kuchibhatla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pagano</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>ECC</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic plasma exchange for management of heparin-induced thrombocytopenia: results of an international practice survey</article-title>
            <source>J Clin Apher</source>
            <year>2019</year>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>545</fpage>
            <lpage>554</lpage>
            <pub-id pub-id-type="doi">10.1002/jca.21709</pub-id>
            <pub-id pub-id-type="pmid">31116461</pub-id>
          </element-citation>
        </ref>
        <ref id="CR111">
          <label>111.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Mertzlufft</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kuppe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Koster</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: use of heparin and epoprostenol combined with on-line monitoring of platelet function</article-title>
            <source>J Cardiothorac Vasc Anesth</source>
            <year>2000</year>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>304</fpage>
            <lpage>308</lpage>
            <pub-id pub-id-type="doi">10.1053/cr.2000.5846</pub-id>
            <pub-id pub-id-type="pmid">10890486</pub-id>
          </element-citation>
        </ref>
        <ref id="CR112">
          <label>112.</label>
          <element-citation publication-type="journal">
            <person-group person-group-type="author">
              <name>
                <surname>Warkentin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>How I treat patients with a history of heparin-induced thrombocytopenia</article-title>
            <source>Blood.</source>
            <year>2016</year>
            <volume>128</volume>
            <issue>3</issue>
            <fpage>348</fpage>
            <lpage>359</lpage>
            <pub-id pub-id-type="doi">10.1182/blood-2016-01-635003</pub-id>
            <pub-id pub-id-type="pmid">27114458</pub-id>
          </element-citation>
        </ref>
        <ref id="CR113">
          <label>113.</label>
          <mixed-citation publication-type="other">Kanellopoulou T, Kostelidou T. Literature review of apheresis procedures performed perioperatively in cardiac surgery for ASFA category indications. J Clin Apher. 2018. 10.1002/jca.21676.</mixed-citation>
        </ref>
      </ref-list>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
      <journal-title-group>
        <journal-title>Frontiers in Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1663-9812</issn>
      <publisher>
        <publisher-name>Frontiers Media S.A.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32848750</article-id>
      <article-id pub-id-type="pmc">7396678</article-id>
      <article-id pub-id-type="doi">10.3389/fphar.2020.01132</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Pharmacology</subject>
          <subj-group>
            <subject>Review</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bordon</surname>
            <given-names>Karla de Castro Figueiredo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/423555"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cologna</surname>
            <given-names>Camila Takeno</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/430512"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fornari-Baldo</surname>
            <given-names>Elisa Corr&#xEA;a</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1035928"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinheiro-J&#xFA;nior</surname>
            <given-names>Ernesto Lopes</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/953307"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cerni</surname>
            <given-names>Felipe Augusto</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/764581"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Amorim</surname>
            <given-names>Fernanda Gobbi</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1022421"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Anjolette</surname>
            <given-names>Fernando Antonio Pino</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1003619"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cordeiro</surname>
            <given-names>Francielle Almeida</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/866955"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wiezel</surname>
            <given-names>Gisele Adriano</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1036170"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cardoso</surname>
            <given-names>Iara Aim&#xEA;</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1003651"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferreira</surname>
            <given-names>Isabela Gobbo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1037030"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Oliveira</surname>
            <given-names>Isadora Sousa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/765310"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Boldrini-Fran&#xE7;a</surname>
            <given-names>Johara</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1036187"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pucca</surname>
            <given-names>Manuela Berto</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/41350"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Baldo</surname>
            <given-names>Mateus Amaral</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1035934"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Arantes</surname>
            <given-names>Eliane Candiani</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/423558"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">
<sup>1</sup>
<institution>Laboratory of Animal Toxins, Department of BioMolecular Sciences, School of Pharmaceutical Sciences of Ribeir&#xE3;o Preto, University of S&#xE3;o Paulo</institution>, <addr-line>Ribeir&#xE3;o Preto</addr-line>, <country>Brazil</country>
</aff>
      <aff id="aff2">
<sup>2</sup>
<institution>Health and Science Institute, Paulista University</institution>, <addr-line>S&#xE3;o Jos&#xE9; do Rio Pardo</addr-line>, <country>Brazil</country>
</aff>
      <aff id="aff3">
<sup>3</sup>
<institution>Postgraduate Program in Pharmaceutical Sciences, Vila Velha University</institution>, <addr-line>Vila Velha</addr-line>, <country>Brazil</country>
</aff>
      <aff id="aff4">
<sup>4</sup>
<institution>Department of Pharmacy, Federal Institute of Education, Science and Technology of Paran&#xE1;</institution>, <addr-line>Palmas</addr-line>, <country>Brazil</country>
</aff>
      <aff id="aff5">
<sup>5</sup>
<institution>Postgraduate Program in Ecosystem Ecology, Vila Velha University</institution>, <addr-line>Vila Velha</addr-line>, <country>Brazil</country>
</aff>
      <aff id="aff6">
<sup>6</sup>
<institution>Medical School, Federal University of Roraima</institution>, <addr-line>Boa Vista</addr-line>, <country>Brazil</country>
</aff>
      <author-notes>
        <fn fn-type="edited-by">
          <p>Edited by: Yuri N. Utkin, Institute of Bioorganic Chemistry (RAS), Russia</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Reviewed by: Sakthivel Vaiyapuri, University of Reading, United Kingdom; Helena Safavi, The University of Utah, United States; Zhonghua Liu, Hunan Normal University, China</p>
        </fn>
        <corresp id="fn001">*Correspondence: Karla de Castro Figueiredo Bordon, <email xlink:href="mailto:karla@fcfrp.usp.br" xlink:type="simple">karla@fcfrp.usp.br</email>; Eliane Candiani Arantes, <email xlink:href="mailto:ecabraga@fcfrp.usp.br" xlink:type="simple">ecabraga@fcfrp.usp.br</email>
</corresp>
        <fn fn-type="other" id="fn002">
          <p>This article was submitted to Translational Pharmacology, a section of the journal Frontiers in Pharmacology</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>7</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>11</volume>
      <elocation-id>1132</elocation-id>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>4</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>7</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2020 Bordon, Cologna, Fornari-Baldo, Pinheiro-J&#xFA;nior, Cerni, Amorim, Anjolette, Cordeiro, Wiezel, Cardoso, Ferreira, Oliveira, Boldrini-Fran&#xE7;a, Pucca, Baldo and Arantes</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder>Bordon, Cologna, Fornari-Baldo, Pinheiro-J&#xFA;nior, Cerni, Amorim, Anjolette, Cordeiro, Wiezel, Cardoso, Ferreira, Oliveira, Boldrini-Fran&#xE7;a, Pucca, Baldo and Arantes</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Animal poisons and venoms are comprised of different classes of molecules displaying wide-ranging pharmacological activities. This review aims to provide an in-depth view of toxin-based compounds from terrestrial and marine organisms used as diagnostic tools, experimental molecules to validate postulated therapeutic targets, drug libraries, prototypes for the design of drugs, cosmeceuticals, and therapeutic agents. However, making these molecules applicable requires extensive preclinical trials, with some applications also demanding clinical trials, in order to validate their molecular target, mechanism of action, effective dose, potential adverse effects, as well as other fundamental parameters. Here we go through the pitfalls for a toxin-based potential therapeutic drug to become eligible for clinical trials and marketing. The manuscript also presents an overview of the current picture for several molecules from different animal venoms and poisons (such as those from amphibians, cone snails, hymenopterans, scorpions, sea anemones, snakes, spiders, tetraodontiformes, bats, and shrews) that have been used in clinical trials. Advances and perspectives on the therapeutic potential of molecules from other underexploited animals, such as caterpillars and ticks, are also reported. The challenges faced during the lengthy and costly preclinical and clinical studies and how to overcome these hindrances are also discussed for that drug candidates going to the bedside. It covers most of the drugs developed using toxins, the molecules that have failed and those that are currently in clinical trials. The article presents a detailed overview of toxins that have been used as therapeutic agents, including their discovery, formulation, dosage, indications, main adverse effects, and pregnancy and breastfeeding prescription warnings. Toxins in diagnosis, as well as cosmeceuticals and atypical therapies (bee venom and leech therapies) are also reported. The level of cumulative and detailed information provided in this review may help pharmacists, physicians, biotechnologists, pharmacologists, and scientists interested in toxinology, drug discovery, and development of toxin-based products.</p>
      </abstract>
      <kwd-group>
        <kwd>poison</kwd>
        <kwd>venom</kwd>
        <kwd>toxin</kwd>
        <kwd>drug discovery</kwd>
        <kwd>scorpion</kwd>
        <kwd>snake</kwd>
        <kwd>toad</kwd>
        <kwd>
          <italic>Conus</italic>
        </kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source id="cn001">Funda&#xE7;&#xE3;o de Amparo &#xE0; Pesquisa do Estado de S&#xE3;o Paulo<named-content content-type="fundref-id">10.13039/501100001807</named-content></funding-source>
          <award-id rid="cn001">2019/10173-6</award-id>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="2"/>
        <equation-count count="0"/>
        <ref-count count="307"/>
        <page-count count="29"/>
        <word-count count="15457"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>Animal poisons and venoms are rich sources of proteins, peptides, neurotransmitters, among other compounds. Together, these molecules can induce major damages in the prey&#x2019;s body, being one of the mechanisms employed by these animals to subdue and/or kill their preys or predators. The main difference between the terms &#x201C;poison&#x201D; and &#x201C;venom&#x201D; is the delivery method. Poisons are generated by specialized cells or tissues or are acquired from the diet, causing prey toxicity by ingestion or contact with the poisonous animal. On the other hand, venoms are produced by a tissue or organ (venom gland) and are parenterally introduced into the prey by the venomous animal, with a specialized apparatus (fang, stinger, teeth, nematocysts, among others) (<xref rid="B82" ref-type="bibr">Fox and Serrano, 2007</xref>). The word &#x201C;toxin&#x201D; will be used for both compounds from animal poisons and venoms in the whole article.</p>
      <p>As a result of evolution and natural selection, toxins from animal poisons and venoms display wide-ranging pharmacological activities. Since the toxin targets are related to biological functions, with many of them playing important roles in human diseases, several venom components were used in the design of new therapeutic agents. They were also employed as cosmeceuticals, diagnostic tools, and experimental molecules to validate postulated therapeutic targets, improving several drug libraries (<xref rid="B93" ref-type="bibr">Ghosh et&#xA0;al., 2019</xref>; <xref rid="B271" ref-type="bibr">Utkin et&#xA0;al., 2019</xref>).</p>
      <p>Although several biologically active toxins have been reported from terrestrial and marine organisms, there is a large gap between the initial drug discovery phase, including their validation as drug models, and their use in a clinical study. Drug candidates must pass through an extensive range of <italic>in vitro</italic>&#xA0;and <italic>in vivo</italic> tests to establish their pharmacology and biochemistry, carcinogenicity, and effects on the reproductive system, to assess their safety before moving on to the clinical phases (<xref rid="B255" ref-type="bibr">Tamimi and Ellis, 2009</xref>). In other words, drug development includes the discovery of a candidate molecule, preclinical and clinical studies, which are usually costly and takes a significant amount of time to attend the requirements stated by the regulatory agencies throughout the world.</p>
      <p>This review aims to highlight the key successes and some examples of the obstacles and challenges faced when developing toxin-based drugs. It covers toxins from poisonous and venomous animals, drugs that target diverse pathological conditions, the molecules that have failed, and those that are currently in clinical trials. It also aims to encourage scientists to&#xA0;elucidate the mechanism of action of the already known venom components, discover new molecules with innovative therapeutic potential, and develop strategies to improve their pharmacokinetic and pharmacodynamic properties. Moreover, perspectives on the research and development of a wide range of toxins from several underexploited animal poisons and venoms are also discussed.</p>
    </sec>
    <sec id="s2">
      <title>Achievements With Animal Toxin-Based Molecules</title>
      <p>Readers and scientists looking for approved drugs must consider the databases from regulatory agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Furthermore, valuable information for health professionals and general public can be found at the Drug Information Database. However, the information provided by these databases is significantly limited, since biotechnology companies and pharmaceutical industries usually perform the drug development processes. Thus, much of the information relevant to drug development is not published and/or quite difficult to access.</p>
      <p>Therefore, the subsections <italic>Approved Drugs</italic> to <italic>Venom Therapies</italic> will address the toxin-based approved drugs, diagnostic tools, cosmeceuticals and venom therapies, respectively, with the currently available details found at these databases.</p>
      <sec id="s2_1">
        <title>Approved Drugs</title>
        <p>Among the 11 approved toxin-based molecules marketed, one molecule (ziconotide) is obtained from cone snails, two from lizards (exenatide and lixisenatide), two from leeches (bivalirudin and desirudin), and six from snakes (captopril, enalapril, tirofiban, eptifibatide, batroxobin, and cobratide). Batroxobin and cobratide are native compounds purified from snake venoms, desirudin is a recombinant molecule, and the other drugs (bivalirudin, captopril, enalapril, eptifibatide, exenatide, tirofiban, and ziconotide) are synthetic molecules (<xref rid="T1" ref-type="table">
<bold>Table 1</bold>
</xref>).</p>
        <table-wrap id="T1" position="float">
          <label>Table 1</label>
          <caption>
            <p>Approved drugs and therapies for human use.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th valign="top" align="left" rowspan="1" colspan="1">Molecule(brand name)</th>
                <th valign="top" align="center" rowspan="1" colspan="1">Species origin of venom toxin</th>
                <th valign="top" align="center" rowspan="1" colspan="1">Production</th>
                <th valign="top" align="center" rowspan="1" colspan="1">Formulation</th>
                <th valign="top" align="center" rowspan="1" colspan="1">Mechanism of action</th>
                <th valign="top" align="center" rowspan="1" colspan="1">Use</th>
                <th valign="top" align="center" rowspan="1" colspan="1">Dosage(maximum dose per day)*</th>
                <th valign="top" align="center" rowspan="1" colspan="1">More frequently reported adverse effects, pregnancy and breastfeeding warnings*</th>
                <th valign="top" align="center" rowspan="1" colspan="1">Reference</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Batroxobin (Defibrase<sup>&#xAE;</sup>) <sup>(1)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Brazilian lancehead snake (<italic>Bothrops moojeni</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Purified from venom</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Ampoule contains 10 batroxobin units, NaCl, chlorobutanol, and partially hydrolyzed gelatin in water</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Cleaves A&#x3B1;-chain of fibrinogen</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Acute cerebral infarction; unspecific angina pectoris; sudden deafness</td>
                <td valign="top" align="left" rowspan="1" colspan="1">40 batroxobin units by i.v. infusion over 1&#xA0;h.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Microvascular thrombosis</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B249" ref-type="bibr">Stocker, 1978</xref>; <xref rid="B284" ref-type="bibr">Vu et&#xA0;al., 2013</xref>; <xref rid="B202" ref-type="bibr">Pentapharm DSM Nutritional Products Ltd, 2018</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Batroxobin (Plateltex-Act<sup>&#xAE;</sup>) <sup>(1)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Common lancehead snake (<italic>Bothrops atrox</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Purified from venom</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Vial of batroxobin (5 batroxobin units/1&#xA0;ml), and 1 vial of calcium gluconate (940 mg gluconate/10&#xA0;ml)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Cleaves A&#x3B1;-chain of fibrinogen</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Gelification of blood for topical applications</td>
                <td valign="top" align="left" rowspan="1" colspan="1">1 ml (or maximum of 1.5&#xA0;ml) of calcium gluconate mixed with batroxobin (5 U). This mixture is mixed with 6-10 ml of platelet concentrate. After gel formation (7-10 min), it is applied on the area or in the site to be treated.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">No toxicity phenomena are described in the tissues treated with the gel.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B206" ref-type="bibr">Plateltex, 2018</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Batroxobin - Fibrin sealant (Vivostat<sup>&#xAE;</sup>) <sup>(1)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Brazilian lancehead snake (<italic>Bothrops moojeni</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Purified from venom</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Medical device used for the preparation of an autologous fibrin; citrate</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Cleaves A&#x3B1;-chain of fibrinogen</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Autologous fibrin sealant in surgery</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Citrate is added to the device (during surgery or 24&#xA0;h before), where is drawn 120&#xA0;ml of the patient&#x2019;s blood. After 25&#xA0;min, an autologous fibrin is ready for use.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">The sealant has no known adverse effects.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B132" ref-type="bibr">Kjaergard and Trumbull, 1998</xref>; <xref rid="B283" ref-type="bibr">Vivostat A/S, 2018</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Bee venom therapy (Apitox<sup>&#xAE;</sup>)</bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Honeybee<break/>
<italic>Apis mellifera</italic>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Whole venom</td>
                <td valign="top" align="left" rowspan="1" colspan="1">100 &#xB5;g/1&#xA0;ml (bee venom in 0.9% NaCl)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Anti-inflammatory action; alteration of the immune response <italic>via</italic> antigen competition</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Pain associated with osteoarthritis and multiple sclerosis</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Monthly s.c. injections; twice weekly range from 1 to 20 intradermal injections (100 &#xB5;g/0.1&#xA0;ml saline)&#x2014;at acupuncture points</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Irritation, swollen, reddened skin and severe allergic reactions that can be life-threatening.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B95" ref-type="bibr">Gotter, 2019</xref>; <xref rid="B270" ref-type="bibr">US National Library of Medicine, 2020</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Bivalirudin (Angiomax<sup>&#xAE;</sup>) <sup>(2)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">European medicinal leech (<italic>Hirudo medicinalis</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Powder for injection, 250 mg, (bivalirudin trifluoroactetate, mannitol and sodium hidroxide)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Reversible direct thrombin inhibitor</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Anticoagulant in percutaneous coronary intervention</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.75 mg/kg by direct IV injection, followed by 1.75 mg/kg per hour<break/>(300-325 mg daily)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Hemorragic events, back pain, pain (unspecified), nausea, headache, hyper/hypotension, injection site pain, insomnia, vomiting, pelvic pain, anxiety, bradycardia, dyspepsia, abdominal pain, fever, nervouness, urinary retention; pregnancy risk factor B</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B269" ref-type="bibr">US Food and Drug Administration, 2020</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Captopril (Capoten<sup>&#xAE;</sup>) <sup>(3)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Jararaca pit viper snake (<italic>Bothrops jararaca</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Oral tablets: 12.5, 25, 50, and 100 mg (inactive ingredients: anhydrous lactose, colloidal silicon dioxide, crospovidone, microcrystalline cellulose, and stearic acid)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Angiotensin-converting enzyme inhibitor</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Hypertension, cardiac failure</td>
                <td valign="top" align="left" rowspan="1" colspan="1">50 or 100 mg orally 3 times a day (maximum dose: 450 mg/day)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Cough and skin rash; US FDA pregnancy category D; excreted into human milk&#x2014;discontinue breastfeeding or discontinue the drug, since the effects in the nursing infant are unknown</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B269" ref-type="bibr">US Food and Drug Administration, 2020</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Cobratide (Ketongning, cobrotoxin) <sup>(2)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Chinese cobra (<italic>Naja naja atra</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Purified from venom</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Freeze-dried powder (70 or 140 &#x3BC;g/vial) with dextran and glycine as excipient, for injection and cobratide enteric coated capsule</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Blockage of nicotinic receptors</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Chronic arthralgia, sciatica, neuropathic headache</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Minimum and maximum daily dose are 280 &#x3BC;g and 840 &#x3BC;g, respectively&#x2014;enteric coated capsule (CN101381408B)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Fatal side effects, such as respiration inhibition, can<break/>occur when it is injected at higher dosage levels.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B45" ref-type="bibr">Chen et&#xA0;al., 2016</xref>; <xref rid="B193" ref-type="bibr">Orientoxin Biotech Co. Ltd., 2019</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Desirudin (Iprivask<sup>&#xAE;</sup>) <sup>(2)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">European medicinal leech (<italic>Hirudo medicinalis</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Recombinant</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Sterile powder for injection (desirudin-15.75 mg, anhydrous magnesium chloride-1.31 mg, and sodium hydroxide for injection USP)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Selective and near-irreversible<break/>inhibitor of thrombin</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Prevention of venous thrombotic events</td>
                <td valign="top" align="left" rowspan="1" colspan="1">15 mg (5-15 min prior surgery), followed by 15 mg every 12&#xA0;h up to 12 days</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Bleeding, deep vein thrombophlebitis, wound secretion, nausea, vomiting, fever, hematoma, anemia; pregnancy risk factor C; no breastfeeding when using desirudin</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B269" ref-type="bibr">US Food and Drug Administration, 2020</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Enalapril (Vasotec<sup>&#xAE;</sup>) <sup>(3)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Jararaca pit viper snake (<italic>Bothrops jararaca</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Oral Tablets, 2.5, 5, 10, and 20 mg; 1.25 mg/ml i.v. (with benzyl alcohol 0.9%)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Angiotensin-converting enzyme inhibitor</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Hypertension, cardiac failure</td>
                <td valign="top" align="left" rowspan="1" colspan="1">2.5 mg twice daily up to 10-20 mg twice daily. Increased dosage up to 40 mg/day (1 or 2 divided doses)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Increased serum creatinine,hypotension, dizziness, headache, fatigue, skin rash, abdominal pain, anorexia, constipation, diarrhea, nausea, vomiting, cough, dyspnea; US FDA pregnancy category D; excreted into human milk&#x2014;discontinue breastfeeding or discontinue the drug, since the effects in the nursing infant are unknown</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B269" ref-type="bibr">US Food and Drug Administration, 2020</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Eptifibatide (Integrilin<sup>&#xAE;</sup>) <sup>(2)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Pigmy rattlesnake (<italic>Sistrurus miliarius</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
                <td valign="top" align="left" rowspan="1" colspan="1">I.v. bolus injection (20 mg/10&#xA0;ml); i.v. infusion (75 mg/100&#xA0;ml); i.v. infusion (200 mg/100&#xA0;ml); Each vial of any dose also contains 5.25 mg/ml citric acid and NaOH to adjust to pH 5.35.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Prevents binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GPIIb/IIIa</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Acute coronary syndrome; percutaneous coronary intervention</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Initial dose of 180 &#xB5;g/kg intravenous bolus administered and for maintenance 2 &#xB5;g/kg/min by a continuous infusion until hospital discharge, or for up 18 to 24&#xA0;h, whichever comes first. A minimum of 12&#xA0;h of infusion is recommended by the manufacturer.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Bleeding, dizziness; US FDA pregnancy category B; not known if distributed into human milk</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B221" ref-type="bibr">RxList, 2019</xref>; <xref rid="B73" ref-type="bibr">European Medicines Agency, 2020</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Exenatide (Byetta<sup>&#xAE;</sup>) <sup>(2)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Gila monster lizard (<italic>Heloderma suspectum</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Prefilled cartridge pen (250 &#xB5;g/ml; s.c. injection)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Glucagon-like peptide-1 receptor agonist</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Type 2 diabetes mellitus</td>
                <td valign="top" align="left" rowspan="1" colspan="1">5 or 10 &#xB5;g twice daily 60&#xA0;min before two main meals of the day, ~6 h apart</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Hypoglycemia, nausea, vomiting, diarrhea, jittery feeling, dizziness, headache, dyspepsia, asthenia, gastroesophageal reflux disease, hyperhidrosis, constipation, abdominal distention, decreased appetite, flatulence; data lacking on the use in pregnancy; not known if excreted into human milk</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B269" ref-type="bibr">US Food and Drug Administration, 2020</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Extended-release exenatide (Bydureon<sup>&#xAE;</sup>) <sup>(2)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Gila monster lizard<break/>(<italic>Heloderma suspectum</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Exenatide (2 mg) and diluent</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Glucagon-like peptide-1 receptor agonist</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Type 2 diabetes mellitus</td>
                <td valign="top" align="left" rowspan="1" colspan="1">2 mg weekly at any time of the dosing day, with or without meals</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Hypoglycemia, nausea, diarrhea, injection-site reactions (pruritus, nodule, erythema, hematoma), vomiting, constipation, headache, viral gastroenteritis, gastroesophageal reflux disease, dyspepsia, fatigue, decreased appetite; data lacking on the use in pregnancy; not known if excreted into human milk</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B73" ref-type="bibr">European Medicines Agency, 2020</xref>; <xref rid="B269" ref-type="bibr">US Food and Drug Administration, 2020</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Leech therapy</bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">European medicinal leech (<italic>Hirudo medicinalis</italic>) or other species</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Leech</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Leeches drain blood from tissue</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Inhibits platelet aggregation and the coagulation cascade</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Skin grafts and reattachment surgery</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Usually 1&#x2013;10 leeches are used for each treatment, while at the beginning, the patient might need two or more treatments per day. Leeches should be applied on the darker spots of the reattached body parts or flaps. Usually the treatment lasts for 2&#x2013;6 days.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Lymphadenitis, slight swelling, pain of regional lymph nodes on the side of leech application and subfebrile temperature. Leech therapy is not recommended in pregnancy, lactation and in patients with an unstable medical status and disposition to keloid scar formation.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B181" ref-type="bibr">Mumcuoglu, 2014</xref>; <xref rid="B269" ref-type="bibr">US Food and Drug Administration, 2020</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Lixisenatide (Lyxumia<sup>&#xAE;</sup> and Adlyxin<sup>&#xAE;</sup>) <sup>(2)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Gila monster lizard<break/>(<italic>Heloderma suspectum</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
                <td valign="top" align="left" rowspan="1" colspan="1">0.15 mg/3&#xA0;ml (0.05 mg/ml)&#x2014;s.c.<break/>0.3 mg/3&#xA0;ml (0.1 mg/ml)&#x2014;s.c.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Glucagon-like peptide-1 receptor agonist</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Type 2 diabetes mellitus</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Initial dose: 10 &#xB5;g by s.c. injection once a day. Increase to 20 &#xB5;g on day 15. This drug should be administered 1&#xA0;h before the first meal of the day. Concurrent use with short acting insulin has not been studied and is not recommended.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Nausea, vomiting, diarrhea, headache, dizziness, low blood sugar; data lacking on the use in pregnancy; not known if distributed into human milk, but its use is not recommended.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B73" ref-type="bibr">European Medicines Agency, 2020</xref>; <xref rid="B269" ref-type="bibr">US Food and Drug Administration, 2020</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Tirofiban (Aggrastat<sup>&#xAE;</sup>) <sup>(3)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Saw-scaled viper snake (<italic>Echis carinatus</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
                <td valign="top" align="left" rowspan="1" colspan="1">I.v. bolus (3.75 mg in 15 ml&#x2014;vial); i.v. bolus and infusion (5 mg in 100 ml&#x2014;vial); i.v. bolus and infusion (12.5 mg/250 ml&#x2014;bag)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Antagonist of fibrinogen binding to the GPlIb/lIla receptor</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Acute coronary syndrome</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Initial dose: 25 &#xB5;g/kg i.v. within 5&#xA0;min. Maintenance dose: 0.15 &#xB5;g/kg/min i.v. infusion for up to 18 h</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Dizziness, slow heart rate, leg pain, pelvic pain, swelling, increased sweating; US FDA pregnancy category B; not known if distributed into human milk.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B170" ref-type="bibr">Medicure Pharma, 2016</xref>)</td>
              </tr>
              <tr>
                <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Ziconotide (Prialt<sup>&#xAE;</sup>) <sup>(2)</sup></bold>
</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Magical cone marine snail (<italic>Conus magus</italic>)</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
                <td valign="top" align="left" rowspan="1" colspan="1">25 or 100 &#xB5;g/ml (aqueous pH adjusted solution pH 4-5, L-methionine and NaCl); i.t.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Cav2.2 channel antagonist</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Severe chronic pain</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Initial dose: &#x2264; 2.4 &#xB5;g/day (&#x2264; 0.1 &#xB5;g/h) less than 2 to 3 times/week. Maximum dose: 19.2 &#xB5;g/day (0.8 &#xB5;g/h) by day 21.</td>
                <td valign="top" align="left" rowspan="1" colspan="1">Dizziness, confusion, drowsiness,abnormal gait, memory impairment, ataxia, speech disorder, headache, aphasia, hallucination, thinking abnormality, amnesia, anxiety, blurred vision, increased creatine phosphokinase, anorexia, nystagmus, fever; pregnancy risk factor C</td>
                <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B269" ref-type="bibr">US Food and Drug Administration, 2020</xref>)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>*For complete and detailed information, we suggest consulting Drugs.com and the patient information leaflets provided by the medicine manufacturer; 1), enzyme; 2), peptide; 3), non-protein molecule; i.t., intrathecal; i.v., intravenous; s.c., subcutaneous.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Most toxin-based approved drugs are derived from snake venoms. One of the possible reasons for this scenario is the larger amount of venoms produced by snakes in comparison to small animals (e.g. scorpions, spiders, and snails) (<xref rid="B130" ref-type="bibr">King, 2011</xref>; <xref rid="B131" ref-type="bibr">King, 2013</xref>). In parallel, the effect of snake venoms on hemostasis evidenced the cardiovascular system as a pharmacological target for snake venom toxins. Furthermore, the analytical techniques capable of characterizing limited amounts of venom components from small animals were only developed recently. These are some issues that boosted the initial toxinological studies primarly on snake venoms. The advent of more sensitive techniques and the improvement in experimental models in the last years have allowed the study of poorly expressed toxins and their novel pharmacological targets (<xref rid="B25" ref-type="bibr">Boldrini-Fran&#xE7;a et&#xA0;al., 2017</xref>). Additionally, the discovery of many ion channels in the 1970-1980s, and the better understanding of the nervous system, which houses the main molecular targets of small venomous invertebrates, opened up the field to new therapeutic leads for non-cardiovascular targets (<xref rid="B131" ref-type="bibr">King, 2013</xref>).</p>
        <p>The first animal toxin-based drug approved for human use was captopril in 1981. Captopril (Capoten<sup>&#xAE;</sup>, Bristol-Myers Squibb) was developed based on the bradykinin potentiating factor (BPF) present in <italic>Bothrops jararaca</italic> snake venom (<xref rid="B80" ref-type="bibr">Ferreira, 1965</xref>; <xref rid="B39" ref-type="bibr">Camargo et&#xA0;al., 2012</xref>). BPF is a nonapeptide that acts by blocking the activity of the angiotensin-converting enzyme (ACE), inhibiting the production of the hypertensive molecule angiotensin II and potentiating the action of the hypotensive peptide bradykinin (<xref rid="B80" ref-type="bibr">Ferreira, 1965</xref>; <xref rid="B76" ref-type="bibr">Ferreira and Rocha e Silva, 1965</xref>; <xref rid="B77" ref-type="bibr">Ferreira et&#xA0;al., 1970a</xref>; <xref rid="B78" ref-type="bibr">Ferreira et&#xA0;al., 1970b</xref>).</p>
        <p>Since the native peptide found in this venom was quite expensive to be synthesized and impossible to be orally administered (<xref rid="B81" ref-type="bibr">Ferreira, 2000</xref>), captopril was designed by the miniaturization of the original molecule, and by the addition of a succinyl group to a proline residue, which allowed its oral administration. This amino acid residue located at the C-terminal of BPP5a (one of the most active peptides in the bradykinin potentiating factor) is responsible for interacting with ACE (<xref rid="B52" ref-type="bibr">Cushman et&#xA0;al., 1977</xref>; <xref rid="B39" ref-type="bibr">Camargo et&#xA0;al., 2012</xref>). Captopril (alone or in combination with other drugs) is suitable and widely used for hypertension treatment (<xref rid="B287" ref-type="bibr">Weber et&#xA0;al., 2014</xref>).</p>
        <p>After captopril, enalapril (MK-421, enalapril maleate) was approved by the FDA in 1985 for hypertension and congestive heart failure treatments (<xref rid="B197" ref-type="bibr">Patchett, 1984</xref>). The mercapto group in captopril structure was believed to be responsible for the skin rash and loss of taste reported as common adverse effects when using this drug. Therefore, the main challenge in enalapril development was to substitute the mercapto by an alkyl group, keeping the interaction with ACE (<xref rid="B197" ref-type="bibr">Patchett, 1984</xref>). Enalapril (Vasotec<sup>&#xAE;</sup>, Merck) is produced as a prodrug that undergoes <italic>in vivo</italic> de-esterification to give rise to enalaprilat (MK-422), whose potency is greater than captopril, but has limited oral bioavailability (<xref rid="B20" ref-type="bibr">Biollaz et&#xA0;al., 1981</xref>; <xref rid="B197" ref-type="bibr">Patchett, 1984</xref>). Historically, captopril and enalapril are the hallmark in the development of ACE inhibitors for the treatment of hypertension.</p>
        <p>The antiplatelet drug tirofiban (Aggrastat<sup>&#xAE;</sup>, Medicure International, Inc.) is based on the RGD motif (Arg-Gly-Asp) from echistatin, a disintegrin found in the venom of the saw-scaled viper <italic>Echis carinatus</italic> (<xref rid="B262" ref-type="bibr">Topol et&#xA0;al., 1999</xref>). Tirofiban was approved by the FDA in 1998 for acute coronary syndrome treatment (<xref rid="B105" ref-type="bibr">Hartman et&#xA0;al., 1992</xref>). It mimics the RGD sequence and possesses a (S)-NHSO<sub>2</sub>-C<sub>4</sub>H<sub>9</sub> group that enhanced the interactions with the platelet glycoprotein GPIIb/IIIa receptor (<xref rid="B90" ref-type="bibr">Gan et&#xA0;al., 1988</xref>). The competition with fibrinogen for the RGD recognition sites on the GPIIb/IIIa complex results in the inhibition of platelet aggregation and other antithrombotic properties (<xref rid="B262" ref-type="bibr">Topol et&#xA0;al., 1999</xref>; <xref rid="B144" ref-type="bibr">Lang et&#xA0;al., 2012</xref>).</p>
        <p>Eptifibatide (Integrilin<sup>&#xAE;</sup>, Millennium Pharmaceuticals, Inc.) is another antiplatelet drug approved by the FDA in 1998 and licensed to Schering-Plough in 2005. It was developed during the efforts to create synthetic analogues of barbourin, a disintegrin isolated from <italic>Sistrurus miliarius barbouri</italic> snake venom. Due to its conservative amino acid substitution of arginine (R) for lysine (K), barbourin presents more specificity for platelet glycoprotein GPIIb/IIIa complex than other disintegrins containing the RGD motif (<xref rid="B227" ref-type="bibr">Scarborough et&#xA0;al., 1991</xref>). Also, it was verified that the affinity for GPIIb/IIIa is highly influenced by the amino acid residues adjacent to the KGD sequence and the size of the peptide ring created through the disulfide bond formation. From this information, different synthetic peptides with potential clinical use were designed, including eptifibatide (<xref rid="B229" ref-type="bibr">Scarborough, 1999</xref>). Eptifibatide is a cyclic heptapeptide (deamino-Cys(1)-hArg-Gly-Asp-Trp-Pro-Cys(1)-NH<sub>2</sub>) more resistant to proteolysis due the introduction of a ring in the structure (<xref rid="B228" ref-type="bibr">Scarborough et&#xA0;al., 1993</xref>; <xref rid="B260" ref-type="bibr">Tcheng and O&#x2019;Shea, 2002</xref>).</p>
        <p>In the middle of 1900s, hirudin was isolated from <italic>Hirudo medicinalis</italic> leech saliva (<xref rid="B145" ref-type="bibr">Lee and Ansell, 2011</xref>). This 65-amino acid peptide presents an anticoagulant effect, through direct thrombin inhibition, and it was the only molecule to prevent blood coagulation until the discovery of heparin (<xref rid="B63" ref-type="bibr">Dodt et&#xA0;al., 1984</xref>; <xref rid="B165" ref-type="bibr">Markwardt, 1991</xref>). The removal of a sulfate group at Tyr63 residue gave rise to desulfatohirudin and increased in 10 times the complex formation with thrombin; however, obtaining this molecule with high activity and yield was a challenge to be overcome to allow clinical studies (<xref rid="B121" ref-type="bibr">Johnson et&#xA0;al., 1989</xref>; <xref rid="B165" ref-type="bibr">Markwardt, 1991</xref>). Desirudin (Iprivask<sup>&#xAE;</sup>, Bausch Health), the recombinant 63-desulfohirudin (variant HV-1) produced in <italic>Saccharomyces cerevisiae</italic> (strain TR 1456), was approved by the FDA in 2003 for prophylaxis of deep vein thrombosis after hip replacement surgery (<xref rid="B285" ref-type="bibr">Warkentin, 2004</xref>). Revasc<sup>&#xAE;</sup> (Novartis) was approved by EMA in 1997, but it was withdrawn from the market in 2014 for commercial reasons.</p>
        <p>In general, hirudins inactivate irreversibly thrombin, causing more bleeding than heparin (<xref rid="B220" ref-type="bibr">R&#xF6;misch et&#xA0;al., 1993</xref>). Therefore, some analogues were developed with the aim of optimizing the therapeutic profile of hirudin based on the interaction with the active site of thrombin (<xref rid="B285" ref-type="bibr">Warkentin, 2004</xref>). Bivalirudin (Angiomax<sup>&#xAE;</sup>, The Medicines Company) is a synthetic peptide resulted from rational drug design, comprised of 20 amino acids: 4 N-terminal residues from native hirudin which interact with the active site, connected by 4 glycine residues to the last 12 residues present in its C-terminal responsible to interact with the anion exosite (<xref rid="B163" ref-type="bibr">Maraganore et&#xA0;al., 1990</xref>). This drug binds reversibly to thrombin, which decreased the risk of bleeding reported to other hirudins (<xref rid="B187" ref-type="bibr">Nutescu and Wittkowsky, 2004</xref>). Angiomax<sup>&#xAE;</sup> was approved by the FDA in 2000 to patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (<xref rid="B23" ref-type="bibr">Bittl et&#xA0;al., 2001</xref>). In Europe it is marketed as Angiox<sup>&#xAE;</sup> (<xref rid="B171" ref-type="bibr">Mehrzad et&#xA0;al., 2017</xref>).</p>
        <p>In 2004, ziconotide (Prialt<sup>&#xAE;</sup>, Elan Pharmaceuticals, Inc.) was approved for the management of severe chronic pain by the FDA and by the EMA (<xref rid="B243" ref-type="bibr">Smith and Deer, 2009</xref>). Ziconotide (SNX-111) is a synthetic analogue of the omega-conotoxin MVIIA isolated from the venom of the fish-hunting snail <italic>Conus magus</italic>. It is a 25-amino acid peptide that blocks Ca<sub>v</sub>2.2 channels (N-type voltage-sensitive calcium channels) and, consequently, inhibits the conduction of nerve impulse and release of neurotransmitters into the thalamus, leading to antinociception (<xref rid="B168" ref-type="bibr">McGivern, 2007</xref>; <xref rid="B282" ref-type="bibr">Vink and Alewood, 2012</xref>). Ziconotide does not induce dependence or tolerance, which is a valuable advantage in comparison to morphine, which is also less effective than ziconotide (<xref rid="B232" ref-type="bibr">Scott et&#xA0;al., 2002</xref>). However, the main limitations of ziconotide use are its intrathecal administration route, which impairs the patient&#x2019;s adherence to the treatment (<xref rid="B243" ref-type="bibr">Smith and Deer, 2009</xref>), and narrow therapeutic index (<xref rid="B232" ref-type="bibr">Scott et&#xA0;al., 2002</xref>). Recently, the intranasal route has been studied to overcome the challenge of administering ziconotide (<xref rid="B162" ref-type="bibr">Manda et&#xA0;al., 2016</xref>).</p>
        <p>Exenatide (synthetic exendin-4 from Gila monster, <italic>Heloderma suspectum</italic>) is the first glucagon-like-peptide-1 (GLP-1) analogue (<xref rid="B88" ref-type="bibr">Furman, 2012</xref>) and has been used as an adjuvant in the treatment of type 2 diabetes mellitus (<xref rid="B183" ref-type="bibr">Nauck et&#xA0;al., 2007</xref>; <xref rid="B109" ref-type="bibr">Henry et&#xA0;al., 2014</xref>). It presents a combination of actions: stimulation of insulin and suppression of glucagon secretion that result in blood glucose control, and reduction of body weight and cardiovascular risk factors (<xref rid="B70" ref-type="bibr">Eng et&#xA0;al., 1992</xref>; <xref rid="B99" ref-type="bibr">Greig et&#xA0;al., 1999</xref>; <xref rid="B7" ref-type="bibr">Alves et&#xA0;al., 2017</xref>).</p>
        <p>Since GLP-1 is rapidly degraded by serum proteases presenting a very short lifetime, the key point was the development of GLP-1analogues resistant to these enzymes (<xref rid="B157" ref-type="bibr">Lorenz et&#xA0;al., 2013</xref>). Indeed the N-terminal (HGE) of exendin-4 is more resistant to peptidases that degrade the endogenous GLP-1 which make that more potent and longer-lasting than GLP-1 (<xref rid="B70" ref-type="bibr">Eng et&#xA0;al., 1992</xref>; <xref rid="B99" ref-type="bibr">Greig et&#xA0;al., 1999</xref>). The first pharmaceutical form of exenatide (Byetta<sup>&#xAE;</sup>) was approved by the FDA in 2005 and in 2009 by the EMA. Even with the N-terminal more resistant to proteases, Byetta<sup>&#xAE;</sup> has a half-life of ~2.4 h after administration (<xref rid="B157" ref-type="bibr">Lorenz et&#xA0;al., 2013</xref>).</p>
        <p>Lixisenatide (Lyxumia<sup>&#xAE;</sup> in the Europe and Adlyxin<sup>&#xAE;</sup> in the USA., Sanofi S.A.) is a 44-amino acid peptide, with an amide group on its C-terminus. It is comprised of the first 39 amino acids of exendin-4, with a deletion of proline at position 38 and addition of six lysine residues (<xref rid="B47" ref-type="bibr">Christensen et&#xA0;al., 2009</xref>). Lixisenatide was approved in 2013 and 2016 by the EMA and the FDA, respectively, as the first once-daily injectable GLP-1 receptor agonist for the treatment of diabetes type II, presenting a half-life of ~3 h (<xref rid="B69" ref-type="bibr">Elkinson and Keating, 2013</xref>; <xref rid="B157" ref-type="bibr">Lorenz et&#xA0;al., 2013</xref>; <xref rid="B268" ref-type="bibr">US Food and Drug Administration, 2016</xref>).</p>
        <p>In addition, there is an extended-release form of exenatide (Bydureon<sup>&#xAE;</sup>), approved in 2011 and 2012 by the EMA and the FDA, respectively. It has a half-life of 5-6 days due to its encapsulation into poly (D,L-lactide-<italic>co</italic>-glycolide) microspheres, which hydrate <italic>in situ</italic> and slowly degrade to release the drug over time, resulting in less peak-trough variation (<xref rid="B60" ref-type="bibr">DeYoung et&#xA0;al., 2011</xref>; <xref rid="B157" ref-type="bibr">Lorenz et&#xA0;al., 2013</xref>). Long-acting exenatide has also been developed in a ready-to-use auto injector to facilitate the administration since the former pharmaceutical form needs to be diluted prior to administration (<xref rid="B295" ref-type="bibr">Wysham et&#xA0;al., 2017</xref>).</p>
        <p>Apart from the marketed drugs in the USA and Europe, there are also those approved by the National Medical Products Administration (NMPA, formerly State FDA and China FDA&#x2014;SFDA and CFDA, respectively). Batroxobin (also known as hemocoagulase, reptilase, and botropase) is a thrombin-like serine protease obtained from <italic>B. atrox</italic> and <italic>B. moojeni</italic> snake venoms (<xref rid="B116" ref-type="bibr">Itoh et&#xA0;al., 1987</xref>; <xref rid="B68" ref-type="bibr">Earps and Shoolingin-Jordan, 1998</xref>). It cleaves fibrinogen, resulting in the formation of non-cross-linked fibrin clots. Unlike thrombin, which releases fibrinopeptides A and B from fibrinogen, batroxobin releases only fibrinopeptide A (<xref rid="B111" ref-type="bibr">Holleman and Weiss, 1976</xref>). Although the enzyme is not clinically approved in the USA, its defibrinogenating effect is clinically used in other countries for the treatment of various thrombotic diseases including deep vein thrombosis, myocardial infarction, pulmonary embolism, and acute ischemic stroke (<xref rid="B301" ref-type="bibr">You et&#xA0;al., 2004</xref>).</p>
        <p>Currently, batroxobin has been commercialized with the brand names: Batroxobin and Reptilase (Tobishi Pharmaceutical, China), Defibrase (Tobishi Pharmaceutical, China and DSM Nutritional Products Ltd Branch Pentapharm, Switzerland), Botropase (Hanlim, South Korea and Juggat Pharma, India), Botroclot (Juggat Pharma, India) (<xref rid="B65" ref-type="bibr">Drugs.com, 2020</xref>), Plateltex-Act<sup>&#xAE;</sup> (Plateltex S.R.O., Czech Republic) (<xref rid="B206" ref-type="bibr">Plateltex, 2018</xref>), and Vivostat System (<xref rid="B283" ref-type="bibr">Vivostat A/S, 2018</xref>). Therapeutic applications of Defibrase<sup>&#xAE;</sup> include acute cerebral infarction, unspecific angina pectoris, and sudden deafness (<xref rid="B202" ref-type="bibr">Pentapharm DSM Nutritional Products Ltd, 2018</xref>). Plateltex-Act<sup>&#xAE;</sup> is used to prepare autologous platelet-gel, an emerging biotechnology in current tissue engineering and cellular therapy (<xref rid="B167" ref-type="bibr">Mazzucco et&#xA0;al., 2008</xref>). Batroxobin from Plateltex-Act<sup>&#xAE;</sup> converts fibrinogen into fibrin in the presence of Ca<sup>2+</sup> ions, and forms a fibrin reticulum that causes the gelling of the product and cooperates with the regenerative and reparative processes of damaged tissues (<xref rid="B167" ref-type="bibr">Mazzucco et&#xA0;al., 2008</xref>; <xref rid="B205" ref-type="bibr">Plateltex, 2016</xref>). The Vivostat System (Vivostat A/S, Denmark) is a medical device used for the preparation of an autologous fibrin sealant in the operating room by the action of batroxobin upon the fibrinogen in the patient&#x2019;s plasma (<xref rid="B283" ref-type="bibr">Vivostat A/S, 2018</xref>).</p>
        <p>In 1998, cobratide (a short-chain post-synaptic &#x3B1;-neurotoxin isolated from <italic>Naja naja atra</italic> snake venom, also known as ketongning and cobrotoxin) was approved in combination with synthetic drugs as a pain killer for the treatment of moderate to severe pain (<xref rid="B92" ref-type="bibr">Gazerani and Cairns, 2014</xref>; <xref rid="B306" ref-type="bibr">Zhang, 2015</xref>). However, pharmacokinetics studies <italic>in vivo</italic> of cobratide injection (China Approval no. H53022101) are still necessary to adjust drug plasma concentrations and to reduce the risk of drug accumulation and fatal side effects (e.g., respiration inhibition) (<xref rid="B45" ref-type="bibr">Chen et&#xA0;al., 2016</xref>).</p>
        <p>A detailed description of mechanism, pharmacology, pharmacokinetics, and clinical development of most approved toxin-based drugs can be found in specific reviews already published for each compound (<xref rid="B34" ref-type="bibr">Brogden et&#xA0;al., 1988</xref>; <xref rid="B254" ref-type="bibr">Tabacova and Kimmel, 2001</xref>; <xref rid="B294" ref-type="bibr">Wong, 2005</xref>; <xref rid="B304" ref-type="bibr">Zeymer, 2007</xref>; <xref rid="B96" ref-type="bibr">Graetz et&#xA0;al., 2011</xref>; <xref rid="B207" ref-type="bibr">Pope and Deer, 2013</xref>; <xref rid="B234" ref-type="bibr">Serrano, 2013</xref>; <xref rid="B133" ref-type="bibr">Knop et&#xA0;al., 2017</xref>; <xref rid="B266" ref-type="bibr">Trujillo and Goldman, 2017</xref>; <xref rid="B300" ref-type="bibr">Yang et&#xA0;al., 2019</xref>).</p>
      </sec>
      <sec id="s2_2">
        <title>Diagnostic Tools</title>
        <p>Besides its therapeutic applications, batroxobin (Reptilase<sup>&#xAE;</sup>) has also been used for decades as a laboratory reagent to measure fibrinogen levels and blood coagulation capability through the <italic>in vitro</italic> clotting time using serine proteases instead of thrombin (Reptilase<sup>&#xAE;</sup> time) (<xref rid="B87" ref-type="bibr">Funk et&#xA0;al., 1971</xref>). Since Reptilase<sup>&#xAE;</sup> does not need Ca<sup>2+</sup> and phospholipids, some coagulation factors (V, VIII, XI, and XIII) are not activated and the platelet aggregation is not induced, cleaving only the fibrinopeptide A. Both Reptilase<sup>&#xAE;</sup> time and thrombin time are complementary tests to evaluate coagulation disorders. Reptilase<sup>&#xAE;</sup> is also used to detect antithrombin activity (<xref rid="B83" ref-type="bibr">Francischetti and Gil, 2019</xref>).</p>
        <p>RVV-V (Pefakit<sup>&#xAE;</sup>) is a 27 kDa factor V-activating serine protease from the Russel&#x2019;s viper (<italic>Daboia russelii</italic>) venom, used to identify factor V levels in plasma (<xref rid="B261" ref-type="bibr">Tokunaga et&#xA0;al., 1988</xref>). It is widely used in assays for the diagnosis of resistance to activated protein C, which does not cleaves factors Va and VIIIa (<xref rid="B83" ref-type="bibr">Francischetti and Gil, 2019</xref>).</p>
        <p>RVV-X (Stypven<sup>&#xAE;</sup>) is a 120 kDa factor X-activating metalloprotease from <italic>D. russelii</italic> venom that converts factor X quantitatively into factor Xa (<xref rid="B257" ref-type="bibr">Tans and Rosing, 2001</xref>; <xref rid="B179" ref-type="bibr">Morita, 2005</xref>). This toxin is dependent of Ca<sup>2+</sup>, factor V, phospholipids and prothrombin (<xref rid="B83" ref-type="bibr">Francischetti and Gil, 2019</xref>).</p>
        <p>Ecarin, from <italic>E. carinatus</italic> venom, is a 55 kDa metalloprotease able to activate prothrombin and detect its abnormal types (<xref rid="B178" ref-type="bibr">Morita et&#xA0;al., 1976</xref>; <xref rid="B290" ref-type="bibr">Weinger et&#xA0;al., 1980</xref>; <xref rid="B30" ref-type="bibr">Braud et&#xA0;al., 2000</xref>). Contrary to RVV-X, ecarin is independent of factor V, phospholipids or Ca<sup>2+</sup>, detecting thrombin with chromogenic substrates (Ecarin chromogenic assay&#x2014;ECA) or in a clotting assay (Ecarin clotting time&#x2014;ECT) (<xref rid="B83" ref-type="bibr">Francischetti and Gil, 2019</xref>).</p>
        <p>RVV-V, RVV-X, and ecarin are used to the diagnosis of lupus anticoagulant (<xref rid="B83" ref-type="bibr">Francischetti and Gil, 2019</xref>), one of the clinical manifestations of Antiphospholipid Syndrome, characterized by the presence of antiphospholipid antibodies (<xref rid="B74" ref-type="bibr">Favaloro and Wong, 2014</xref>).</p>
        <p>Other snake venom toxins used as diagnostic tools include Botrocetin<sup>&#xAE;</sup> and Protac<sup>&#xAE;</sup>. Venom coagglutinin (Botrocetin<sup>&#xAE;</sup>) isolated from <italic>B. jararaca</italic> venom is a 22 kDa C-type lectin-like protein that aggregates platelets by increasing the affinity between the receptor GPIb&#x3B1; and von Willebrand factor (<xref rid="B33" ref-type="bibr">Brinkhous et&#xA0;al., 1983</xref>; <xref rid="B17" ref-type="bibr">Beeton, 2013</xref>), independent of von Willebrand factor molecule size (<xref rid="B83" ref-type="bibr">Francischetti and Gil, 2019</xref>).</p>
        <p>ACC-C (Protac<sup>&#xAE;</sup>) from <italic>A. contortrix contortrix</italic> venom is a plasma protein C-activating serine protease used to quantify protein S and C levels (<xref rid="B248" ref-type="bibr">Stocker et&#xA0;al., 1988</xref>) with chromogenic substrates or by prolongation of the activated partial thromboplastin time (aPTT). These protein levels are used to investigate the cause of a blood clot (thromboembolism), linked to deep vein thrombosis or pulmonary embolism. AAC-C activity is not compromised by the inhibitor of protein C from plasma (<xref rid="B83" ref-type="bibr">Francischetti and Gil, 2019</xref>).</p>
      </sec>
      <sec id="s2_3">
        <title>Cosmeceuticals</title>
        <p>The cosmeceutical field is a profitable venture. For example, the anti-wrinkling effect of the botulinum toxin (Botox<sup>&#xAE;</sup>), a toxin isolated from <italic>Clostridium botulinum</italic> bacteria, accounts for striking global sales of about $3 billion per year (<xref rid="B49" ref-type="bibr">Clark et&#xA0;al., 2019</xref>). Among the biologically active compounds from animal venoms showing cosmeceuticals applications, we can cite the use of bee venom-containing cosmetics on facial wrinkles in human skin (<xref rid="B104" ref-type="bibr">Han et&#xA0;al., 2015</xref>), and the inhibitory activity of melanogenesis of Argiotoxine-636 (ArgTX-636), a polyamine isolated from <italic>Argiope lobata</italic> spider venom (<xref rid="B278" ref-type="bibr">Verdoni et&#xA0;al., 2016</xref>), including a deposited patent (US10064814B2) for skin whitening/depigmenting (<xref rid="B160" ref-type="bibr">Mabrouk et&#xA0;al., 2018</xref>). Another example is the synthetic tripeptide [dipeptide diaminobutyroyl benzylamide diacetate (H-&#x3B2;-Ala-Pro-Dab-NHBzl x 2 AcOH)], commercialized as the cosmeceutical SYN<sup>&#xAE;</sup>-AKE (Pentapharm). It mimics the activity of waglerin 1, a 22-amino acid peptide from <italic>Tropidolaemus wagleri</italic> snake venom, and reduces wrinkles by inhibiting muscle contractions (<xref rid="B305" ref-type="bibr">Zhang and Falla, 2009</xref>).</p>
      </sec>
      <sec id="s2_4">
        <title>Venom Therapies</title>
        <p>Bee venom therapy is an ancient therapy which uses this toxin arsenal as a cream, liniment, ointment, injection, acupuncture, or directly <italic>via</italic> stings of live bees to treat several disorders (<xref rid="B5" ref-type="bibr">Ali, 2012</xref>). Those treatments rely on the fact that bee venom is composed of a wide range of components, such as biogenic amines, enzymes (mostly PLA<sub>2</sub>s), basic peptides, and non-enzyme proteins (mainly melittin and apamin) (<xref rid="B224" ref-type="bibr">Santos et&#xA0;al., 2011</xref>). Bee venom acupuncture corresponds to the most common used method, especially in the Koreas, and can be employed as an alternative treatment to pain, rheumatoid arthritis, osteoarthritis, and multiple sclerosis. The treatment consists of using bee venom in the relevant sites according to the disease or acupuncture points (<xref rid="B147" ref-type="bibr">Lee et&#xA0;al., 2014</xref>). A phase II randomized study to evaluate the effects of bee venom acupuncture in 68 participants with adhesive capsulitis (frozen shoulder) (NCT01526031) and another one in 60 patients with chronic cervicalgia (NCT01922466) were completed in 2012 and 2015, respectively.</p>
        <p>Bee venom designated as apitoxin (Apitox<sup>&#xAE;</sup>) has been marketed by Apimeds, Inc. for osteoarthritis in South Korea since 2016.&#xA0;A phase III randomized study (NCT01112722) in 363 patients with diagnosed osteoarthritis of the knee was completed in 2016 and a phase III randomized study (NCT03710655) for multiple sclerosis is not yet recruiting patients (last update 2018). Apitox<sup>&#xAE;</sup> diminishes the pain and swelling associated with rheumatoid arthritis, tendinitis, bursitis, and multiple sclerosis (<xref rid="B14" ref-type="bibr">Bastos et&#xA0;al., 2011</xref>; <xref rid="B177" ref-type="bibr">Moreno and Giralt, 2015</xref>).</p>
        <p>Another therapy for medicinal purposes is the hirudotherapy (medicinal leech therapy), approved in 2004 by the FDA. Since the beginning of civilization, leeches have been used for therapeutic purposes (<xref rid="B134" ref-type="bibr">Koh and Kini, 2008</xref>; <xref rid="B1" ref-type="bibr">Abdualkader et&#xA0;al., 2013</xref>). They are hematophagous animals that possess about 100 biologically active compounds in their saliva, especially the anticoagulants, but also components with anti-inflammatory, bacteriostatic, and analgesic properties (<xref rid="B241" ref-type="bibr">Singh, 2010</xref>). Many of the compounds responsible for those activities have already been identified (<xref rid="B238" ref-type="bibr">Sig et&#xA0;al., 2017</xref>), such as hirudin, kallikrein inhibitors, calin, hyaluronidase, collagenase, histamine-like substances, and antimicrobial peptides (e. g. theromacin, theromyzin, peptide B and lumbricin) (<xref rid="B51" ref-type="bibr">Cooper and Mologne, 2017</xref>). <italic>H. medicinalis</italic>, also known as the healing leech, is the main species used in the therapy (<xref rid="B1" ref-type="bibr">Abdualkader et&#xA0;al., 2013</xref>). The hirudotherapy has been shown to produce statistically significant improvement of arthritic conditions (<xref rid="B51" ref-type="bibr">Cooper and Mologne, 2017</xref>) and has also been applied in cardiovascular diseases, reconstructive and microsurgery, cancer and metastasis, diabetes mellitus and its complications, infectious diseases, arthritis, and as analgesic (<xref rid="B241" ref-type="bibr">Singh, 2010</xref>; <xref rid="B1" ref-type="bibr">Abdualkader et&#xA0;al., 2013</xref>). For an extensive review regarding these venom therapies, please see (<xref rid="B181" ref-type="bibr">Mumcuoglu, 2014</xref>; <xref rid="B118" ref-type="bibr">Jagua-Gualdr&#xF3;n et&#xA0;al., 2020</xref>).</p>
        <p>The hirudotherapy and all the toxin-based drugs approved by the FDA are chronologically shown in the next timeline (<xref ref-type="fig" rid="f1">
<bold>Figure 1</bold>
</xref>).</p>
        <fig id="f1" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Timeline showing the animal toxin-based drugs and hirudotherapy approved by the FDA.</p>
          </caption>
          <graphic xlink:href="fphar-11-01132-g001"/>
        </fig>
      </sec>
    </sec>
    <sec id="s3">
      <title>Animal Toxin-Based Drug Development Challenges</title>
      <p>Animal toxins are most often useful as pharmacological tools for target validation. However, in section <italic>Achievements With Animal Toxin-Based Molecules</italic> it was shown that they have also been successfully used as therapeutic agents.</p>
      <p>Although there are examples of success, there is a gap between the number of compounds with interesting pharmacological properties obtained from animal poisons and venoms and those that are approved. Drug development programs may be discontinued due to several factors, like intellectual property disputes, changes in the program leadership, lack of funding, among other business decisions. The lack of publications regarding important data, during the different stages of their development, also contributes to several program discontinuations. While we sought to retrieve this information from the scientific literature, this fact impairs most of the process, concealing most of the key events.</p>
      <p>The subsections <italic>Challenges Regarding Basic Research</italic> to <italic>Challenges Regarding Clinical Trials</italic> will address the challenges related to basic research, preclinical evaluation and clinical trials during the development of animal toxin-based drugs. However, many challenges faced during these stages are not available in the scientific literature, since much of this information is under intellectual property law for compounds that are still being developed or for which the development stopped because of internal issues.</p>
      <sec id="s3_1">
        <title>Challenges Regarding Basic Research</title>
        <p>One of the bottlenecks when studying toxins from small or rare venomous species, such as scorpions and spiders, is the hardship in obtaining large amounts of venom and purified toxins. For example, the venom glands from <italic>Cupiennius salei</italic> spider contain only 10 &#x3BC;l of venom, and the venom regeneration in milked animals requires from 8 to 16 days (<xref rid="B292" ref-type="bibr">Wigger et&#xA0;al., 2002</xref>). On the other hand, the snake <italic>Lachesis muta muta</italic> is able of injecting large venom amounts (milliliters of venom yielding 200-400 mg of toxins) (<xref rid="B250" ref-type="bibr">Stransky et&#xA0;al., 2018</xref>). The higher amount of collected snake venom is one of the reasons that may explain why most of the approved animal toxins-based drugs come from these animals.</p>
        <p>Mucus-rich samples, such as toad and frog poisons, is also another issue, which may hinder the use of omic approaches (<xref rid="B237" ref-type="bibr">Shibao et&#xA0;al., 2018</xref>). In this context, studies comprising animal toxins are not a simple task since many challenges must be addressed. The small amount obtained from different poisonous and venomous animals, together with the nature of the venom/poison allied with the difficulty in isolating specific toxins, are the main limitations faced during basic research. Overcoming these limitations is thoroughly discussed in section <italic>Filling the Gap Between the Drug Discovery and Its Commercialization&#x2014;Future Trends</italic>.</p>
      </sec>
      <sec id="s3_2">
        <title>Challenges Regarding Preclinical Evaluation</title>
        <p>Problems in the development of toxin-based drugs encompass selectivity, mechanism of action, formulation, stability, and production cost (<xref rid="B305" ref-type="bibr">Zhang and Falla, 2009</xref>). Besides the modern approaches using omic techniques, molecular biology, bioconjugation, and nanomaterials in animal venom research, venom components do not always meet all the requirements for a potential therapeutic application. Drug metabolism and pharmacokinetics properties of animal toxins, for instance, are key factors that need to be carefully optimized (<xref rid="B140" ref-type="bibr">Kovalainen et&#xA0;al., 2015</xref>).</p>
        <p>In this regard, after overcoming the challenges imposed during the basic research, like obtaining enough amount of the toxin, it becomes necessary to stand up against some pitfalls faced during preclinical evaluation. Some compounds lack the ability of crossing pivotal barriers in the organism, including the blood-brain barrier, which may interfere in their delivery. Additionally, the susceptibility to blood proteases, as well as their immunogenicity, which are directly linked to biopharmaceutical degradation <italic>in vivo</italic>, are also important factors to be considered. Due to the relatively large size and other specific physicochemical properties, parenteral administration is currently the most used delivery route for approved venom-based drugs (<xref rid="T1" ref-type="table">
<bold>Table 1</bold>
</xref>) (<xref rid="B113" ref-type="bibr">Ibraheem et&#xA0;al., 2014</xref>; <xref rid="B67" ref-type="bibr">Duskey et&#xA0;al., 2017</xref>).</p>
        <p>Considering all the challenges at this phase, preclinical studies are usually costly and lengthy, since they must attend all the requirements stated by the regulatory agencies throughout the world. In this respect, regulatory issues, together with problems related to lack of funding, and manufacturing problems, have been a hindrance for academics pursuing to advance their drug candidates into the clinical trials.</p>
      </sec>
      <sec id="s3_3">
        <title>Challenges Regarding Clinical Trials</title>
        <p>Randomized clinical trials are the gold standard to evaluate specific drug-related issues such as the efficacy and, to a lesser extent, the safety of new medicines before marketing approval. But these studies are not often able to evaluate special populations, such as children, pregnant women, and the elderly (<xref rid="B265" ref-type="bibr">Trifiro et&#xA0;al., 2019</xref>). To overcome these limitations, studies using electronic healthcare records (EHRs) of post-marketing comparative drug safety may complement traditional spontaneous reporting systems to predict which drugs require further epidemiological investigation. For instance, a multi-country healthcare database network identified new signals of potentially drug-induced acute liver injury in children using EHRs (<xref rid="B75" ref-type="bibr">Ferrajolo et&#xA0;al., 2014</xref>). A method of enhancing effectiveness of therapeutic agents using taxane nanoparticle co-administered with the therapeutic agent has been recently patented (US10660965B2).</p>
        <p>On this point, the obstacles faced during the process of approving a new drug are harder to overcome than just improving its drugability, with two mainly issues contributing at this stage. First, new therapeutic drugs must achieve very high standards to be accepted, since they may have to compete with older and well-known drugs on the market, which may be more effective and cheaper, in most cases (because of the expired patent, for instance) (<xref rid="B226" ref-type="bibr">Scannell et&#xA0;al., 2012</xref>). Another problem is when the role of the toxin&#x2019;s target on the disease state is less relevant than previously thought for the manifestation of a particular disease, resulting in low efficacy. Even more, unexpected and unwanted effects could be observed <italic>in vivo</italic> if the target is expressed at different cells or if the toxin binds promiscuously to other targets (<xref rid="B226" ref-type="bibr">Scannell et&#xA0;al., 2012</xref>; <xref rid="B107" ref-type="bibr">Harvey, 2014</xref>; <xref rid="B279" ref-type="bibr">Vetter et&#xA0;al., 2017</xref>). In this context, adverse effects, lack of efficacy and dose-limiting toxicity are responsible for the interruption of many clinical trials (<xref rid="B107" ref-type="bibr">Harvey, 2014</xref>; <xref rid="B149" ref-type="bibr">Lewis, 2015</xref>).</p>
      </sec>
    </sec>
    <sec id="s4">
      <title>Learning From Discontinued Toxin-Based Drugs</title>
      <p>Most cases of drugs withdrawn from the market (voluntarily or prohibited by regulatory agencies) are related to different events, ranging from safety issues, like serious side effects, to several non-safety issues, encompassing those related to the manufacturing process, regulatory or business issues, or lack of efficacy. The foreseen toxicity of some toxin-based drugs may not be completely avoided, impairing the process at different stages of drug development. Therefore, understanding the mechanisms of toxicity is of utmost importance as an attempt to prevent post-marketing withdrawals (<xref rid="B242" ref-type="bibr">Siramshetty et&#xA0;al., 2016</xref>).</p>
      <p>A mimetic peptide isolated from <italic>Naja</italic> spp. cobra venom, ximelagatran (Exanta<sup>&#xAE;</sup>, AstraZeneca), was discontinued in 2006, due to hepatotoxic potential (<xref rid="B130" ref-type="bibr">King, 2011</xref>). This prodrug anticoagulant agent, orally administered, had been approved in Europe and South America for thrombin inhibition (<xref rid="B71" ref-type="bibr">Eriksson et&#xA0;al., 2003</xref>; <xref rid="B136" ref-type="bibr">Koh et&#xA0;al., 2006</xref>; <xref rid="B82" ref-type="bibr">Fox and Serrano, 2007</xref>; <xref rid="B130" ref-type="bibr">King, 2011</xref>). While Ximelagatran was mostly well tolerated in specific trial populations, a small proportion of the treated patients developed elevated liver enzyme levels, during phase II of clinical trials, which caused the FDA to reject its approval.</p>
      <p>A phase III study of agkisacutacin (also known as hemocoagulase) in perioperative bleeding (<xref rid="B289" ref-type="bibr">Wei et&#xA0;al., 2010</xref>) was ceased due to anaphylactic reactions (<xref rid="B298" ref-type="bibr">Xu et&#xA0;al., 2016</xref>). The enzyme, which acts on fibrinogen and fibrin, is a heterodimeric serine protease from <italic>Deinagkistrodon acutus</italic> venom whose monomers A and B are comprised of 123 and 129 amino acid residues, respectively, linked by a disulfide bond (<xref rid="B289" ref-type="bibr">Wei et&#xA0;al., 2010</xref>). On the other hand, a phase IV randomized study (NCT03270735) to evaluate the efficacy and safety of hemocoagulase injection in the treatment of moderate to severe hemoptysis is recruiting patients since 2017. However, updated information regarding the evolution of this study could not be retrieved.</p>
      <p>Pexiganan, also known as MSI-78 (a 22-residue linear peptide analogue of magainin-2), isolated from the skin of <italic>Xenopus laevis</italic> frog, is an antimicrobial peptide with therapeutic potential in treatment of infected foot ulcers in diabetic patients. The molecule presents <italic>in vitro</italic> activity against both Gram-positive and Gram-negative bacteria. The company Dipexium Pharmaceuticals, Inc. patented a 0.8% pexiganan acetate cream (Locilex<sup>&#xAE;</sup> or Cytolex) but, in 1999, FDA denied the approval of this medicine arguing that its efficacy was not proven superior to that of the conventional treatment in any of the clinical trials (<xref rid="B142" ref-type="bibr">Ladram and Nicolas, 2016</xref>; <xref rid="B94" ref-type="bibr">Gomes et&#xA0;al., 2017</xref>).</p>
      <p>Following the approval of ziconotide, other conotoxins, such as leconotide and Xen2174, were synthesized, studied and advanced to clinical trials. Leconotide (AM336 or &#x3C9;-conotoxin CVID from <italic>Conus catus</italic>) caused side effects when intrathecally administered and would be intravenously evaluated, but the developer company went bankrupt (<xref rid="B107" ref-type="bibr">Harvey, 2014</xref>). Xen2174 (&#x3C7;-CTX MrIA from <italic>C. marmoreus</italic>) progressed to Phase IIb trial (<xref rid="B149" ref-type="bibr">Lewis, 2015</xref>), but it showed dose-limiting toxicity in pharmacodynamics and cerebrospinal fluid pharmacokinetics assays. Thus, it is unlikely that this conotoxin can be used for the treatment of acute pain in humans (<xref rid="B191" ref-type="bibr">Okkerse et&#xA0;al., 2017</xref>).</p>
      <p>Alfimeprase, a recombinant zinc metalloprotease fibrolase from <italic>Agkistrodon contortrix</italic> with 203 residues and three disulfide bonds, cleaves the A&#x3B1;- and B&#x3B2;-chains of fibrin, releasing fibrinopeptides A and B, respectively (<xref rid="B130" ref-type="bibr">King, 2011</xref>; <xref rid="B135" ref-type="bibr">Koh and Kini, 2012</xref>; <xref rid="B253" ref-type="bibr">Swenson and Markland, 2013</xref>). This molecule reached phase III of clinical trials in catheter occlusion and stroke; however, it was discontinued due to the lack of effectiveness (<xref rid="B235" ref-type="bibr">Shah and Scher, 2007</xref>; <xref rid="B164" ref-type="bibr">Markland and Swenson, 2010</xref>).</p>
      <p>Among the several reasons for the interruption of many drug development programs are also intellectual property conflicts, lack of funding, business issues or changes in development leadership. In the case of lepirudin (Refludan<sup>&#xAE;</sup>), for instance, its marketing was discontinued by Bayer in 2012 because the third-party manufacturer of the product had permanently ceased production of the drug (<xref rid="B15" ref-type="bibr">Bayer Healthcare, 2012</xref>). But the reasons that led to the manufacturing interruption have not been published, which prevents the proposal of solutions. Lepirudin is a recombinant peptide similar to hirudin, with an isoleucine instead of a leucine at N-terminal region and also lacking a sulfate group at Tyr63. It was marketed for prophylaxis or treatment of thrombosis complicating heparin-induced thrombocytopenia (<xref rid="B145" ref-type="bibr">Lee and Ansell, 2011</xref>).</p>
      <p>The process of looking for information on drug removals from the market or haltered developments is a difficult task, since some of them are not available for several reasons aforementioned, and the data retrieved from public databases are significantly limited. In other words, factors that have not been published could have contributed to the discontinuation of the program.</p>
    </sec>
    <sec id="s5">
      <title>Promising Animal Toxins in Preclinical Stage and Clinical Trials</title>
      <p>The database search for toxin-based drugs on clinical trials is challenging. One needs to know the acronym or the abbreviation of the desired active ingredient, since sometimes neither the species nor the generic name is cited to allow a broad search. Furthermore, most of the information on these drugs is confidential and thus not available in the public domain. Another problem is that a lot of available data for some drugs have not been updated for several years, which makes it difficult to find accurate details.</p>
      <p>Clinical development is a lengthy and costly process that includes phases I to III of clinical trials (previous regulatory review and approval) and phase IV (post-marketing surveillance) (<xref rid="B46" ref-type="bibr">Chow and Chang, 2008</xref>). Phase I recruits healthy volunteers to assess primarily pharmacokinetics, safety and tolerability; phase II evaluates a cohort of patients with the target disease to establish efficacy and dose-response relationship, and the large-scale phase III studies confirm safety and efficacy (<xref rid="B255" ref-type="bibr">Tamimi and Ellis, 2009</xref>). Phase IV clinical development focus on the safety rather than efficacy (<xref rid="B46" ref-type="bibr">Chow and Chang, 2008</xref>).</p>
      <p>The following subsections will address the clinical trial status of some toxin-based drugs from different animal species and additional information about these drugs is available in <xref rid="T2" ref-type="table">
<bold>Table 2</bold>
</xref>.</p>
      <table-wrap id="T2" position="float">
        <label>Table 2</label>
        <caption>
          <p>Toxin-based drugs in clinical trials.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">Molecule (NCT number)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Species origin of venom toxin</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Production</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Formulation</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Mechanism of action</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Use</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Status(last update)</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Reference</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>ACV-1 (&#x3B1;-Vc1.1) &#x2013; Discontinued <sup>(1)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Conus victoriae</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
              <td valign="top" align="left" rowspan="1" colspan="1">S.c. injection</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Activation of GABA<sub>B</sub> receptors</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Neuropathic pain</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase II&#x2014;discontinued (lack of efficacy)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B48" ref-type="bibr">Clark et&#xA0;al., 2010</xref>; <xref rid="B130" ref-type="bibr">King, 2011</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Agkisacutacin, Hemocoagulase, Recothrom<sup>&#xAE;</sup> (NCT not available; NCT03270735) <sup>(2)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Deinagkistrodon acutus</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recombinant</td>
              <td valign="top" align="left" rowspan="1" colspan="1">I.v. infusion (2U)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Fibrinogen and fibrin cleavage</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Perioperative bleeding; moderate to severe hemoptysis</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase III ceased (2016); phase IV recruiting (September 1, 2017)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B289" ref-type="bibr">Wei et&#xA0;al., 2010</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Alfimeprase &#x2013; Discontinued (NCT00338585) <sup>(2)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Agkistrodon contortrix contortrix</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recombinant</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Parenteral administration (up to 0.5 mg/kg was tolerated)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Cleaves A&#x3B1;-chain of fibrin and fibrinogen</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Catheter occlusion and stroke</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase III terminated (based upon preliminary safety and efficacy results from a similar study) (January 15, 2008);</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B252" ref-type="bibr">Swenson et&#xA0;al., 2004</xref>; <xref rid="B195" ref-type="bibr">Ouriel et&#xA0;al., 2005</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Ancrod (Viprinex<sup>&#xAE;</sup>) (NCT01621256) <sup>(2)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Calloselasma rhodostoma</italic>
<break/>(Malasyan pit viper)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recombinant</td>
              <td valign="top" align="left" rowspan="1" colspan="1">I.v. infusion (0.167 IU/kg for 6&#xA0;h)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Reduce fibrinogen</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Sudden sensorineural hearing loss</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phases I/II completed (December 21, 2018)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B108" ref-type="bibr">Hennerici et&#xA0;al., 2006</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Bombesin (NCT02440308) <sup>(1)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Bombina bombina</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
              <td valign="top" align="left" rowspan="1" colspan="1">I.v.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Attaches to prostate tumor cells with specific receptors on their surfaces</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Imaging agent for positron emission tomography/magnetic resonance imaging</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase II completed (April 11, 2017)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B270" ref-type="bibr">US National Library of Medicine, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Cenderitide, CD-NP (NCT00482937, NCT02603614, NCT02359227 and NCT02071602) <sup>(1)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Dendroaspis angusticeps</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Chimeric natriuretic peptide</td>
              <td valign="top" align="left" rowspan="1" colspan="1">I.v. infusion (10, 25, 50, 100, 200, and 300 ng/kg/min over 4&#xA0;h) or subcutaneous infusion (0.5, 1.0, 2.0, and 3.0 ng/kg/min) or IV infusion (5 and 10 ng/kg/min over 72&#xA0;h)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Connection to natriuretic peptide receptor</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Congestive cardiac failure, heart failure and myocardial infarction</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase I completed (June 6, 2007; February 11, 2020 and January 4, 2019)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B146" ref-type="bibr">Lee et&#xA0;al., 2009</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Chlorotoxin derivates - Tozuleristide (BLZ-100) (NCT02234297) and 131-I-TM-601 (NCT00379132) <sup>(1)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Leiurus quinquestriatus quinquestriatus</italic> (Deathstalker yellow scorpion)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">BLZ-100: Synthetic/131-I-TM-601: Recombinant</td>
              <td valign="top" align="left" rowspan="1" colspan="1">I.v. infusion (BLZ-100: dose unknown/31-I-TM-601: 0.2, 0.4, and 0.6 mg)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Binds to different targets (membrane type-2 matrix metalloprotease, annexin A2, and CLC-3 chloride channels in glioma cells and other tumors of neuroectodermal origin)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Tumor paint for intraoperative visualization of solid cancer cells</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase I completed (April 6, 2016 and March 31, 2009)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B198" ref-type="bibr">Patil et&#xA0;al., 2019</xref>; <xref rid="B270" ref-type="bibr">US National Library of Medicine, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Cinobufacini (Buformin<sup>&#xAE;</sup>) (NCT02871869)</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Bufo gargarizans</italic> or <italic>Duttaphrynus melanostictus</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Sterilized water extract of dried toad skin (Chansu)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.3 g per tablet, three tablets per time</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Induction of apoptosis; inhibition of cancer cells</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Several types of cancer</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase II/III recruiting (July 17, 2017)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B270" ref-type="bibr">US National Library of Medicine, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Conantokin-G (CGX-1007) &#x2013; Discontinued <sup>(1)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Conus geographus</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Intrathecal</td>
              <td valign="top" align="left" rowspan="1" colspan="1">NMDA receptor antagonist</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Intractable epilepsy</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase I&#x2014;discontinued (the developer company went bankrupt)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B103" ref-type="bibr">Han et&#xA0;al., 2008</xref>; <xref rid="B130" ref-type="bibr">King, 2011</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Contulakin-G (CGX-1160) &#x2013; Discontinued <sup>(1)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Conus geographus</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Intrathecal</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Neurotensin receptor agonist</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Neuropathic pain</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase II&#x2014;discontinued (the developer company went bankrupt)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B103" ref-type="bibr">Han et&#xA0;al., 2008</xref>; <xref rid="B130" ref-type="bibr">King, 2011</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Dalazatide, ShK-186, Stichodactyla toxin ShK (NCT02435342) <sup>(1)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Stichodactyla helianthus</italic>
<break/>(Sun sea anemone)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
              <td valign="top" align="left" rowspan="1" colspan="1">S.c. injection twice per week for a total of nine doses</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Kv1.3 channel antagonist</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Autoimmune diseases (psoriatic arthritis, multiple sclerosis, lupus, rheumatoid arthritis, etc.)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase I completed (May 6, 2015)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B270" ref-type="bibr">US National Library of Medicine, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Desmoteplase (NCT00790920 and NCT00111852) <sup>(2)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Common vampire bat<break/>(<italic>Desmodus rotundus</italic>)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Recombinant</td>
              <td valign="top" align="left" rowspan="1" colspan="1">I.v. single bolus (90 or 125 &#xB5;g/kg of body weight)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Plasminogen activator a1 with high fibrin specificity</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Acute ischemic stroke</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase III completed (September 18, 2015 and March 20, 2012)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B270" ref-type="bibr">US National Library of Medicine, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Fibrin glue, fibrin sealant <sup>(2 and 3)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Crotalus durissus terrificus</italic> and <italic>Bubalus bubalis</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Thrombin-like serine protease from snake venom and fibrinogen-rich cryoprecipitate from buffalo blood</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Topically</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Fibrinogen cleavage</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Adhesive, sealant, and hemostatic effects</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase I/II completed by the Clinic of Chronic Ulcers of the Dermatology Service at the Botucatu Medical School, UNESP (November, 11, 2019)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B79" ref-type="bibr">Ferreira et&#xA0;al., 2017</xref>; <xref rid="B36" ref-type="bibr">Buchaim et&#xA0;al., 2019</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Huachansu (NCT00837239 and NCT02647125)</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Bufo gargarizans</italic> or <italic>Duttaphrynus melanostictus</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Sterilized water extract of dried toad skin (Chansu)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">20 ml/m<sup>2</sup> for total 500&#xA0;ml given as a 2-h infusion</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Induction of apoptosis; inhibition of cancer cells</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Several types of cancer</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase II completed (July 12, 2012) and active, not recruiting (April 30, 2020)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B270" ref-type="bibr">US National Library of Medicine, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Leconotide (AM336 or &#x3C9;-conotoxin CVID) &#x2013; Discontinued <sup>(1)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Conus catus</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
              <td valign="top" align="left" rowspan="1" colspan="1">3&#x2013;6 &#xB5;g/h (intrathecal)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Selective blocker of Ca<sub>V</sub>2.2 channel</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Neuropathic pain</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase I/IIa&#x2014;discontinued (the developer company went bankrupt)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B138" ref-type="bibr">Kolosov et&#xA0;al., 2010</xref>; <xref rid="B130" ref-type="bibr">King, 2011</xref>; <xref rid="B107" ref-type="bibr">Harvey, 2014</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>RPI-78M (Receptin<sup>&#xAE;</sup>) (NCT not avaiable) <sup>(3)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Naja kaouthia</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Detoxified or chemically modified</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Orally (with benzalkonium chloride)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Connetion to nicotinic acetylcholine receptors (nAChRs)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Analgesic applications and multiple sclerosis</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Manufacturing for clinical trials (October 28, 2018)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B130" ref-type="bibr">King, 2011</xref>; <xref rid="B64" ref-type="bibr">Drug discovery and development, 2016</xref>; <xref rid="B3" ref-type="bibr">Adis Insight, 2018</xref>; <xref rid="B190" ref-type="bibr">Ojeda et&#xA0;al., 2018</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>RPI-MN (Pepteron<sup>&#xAE;</sup>) (NCT not avaiable)<sup>(3)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Naja naja atra</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Detoxified or chemically modified</td>
              <td valign="top" align="left" rowspan="1" colspan="1">S.c. injection</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Connection to nicotinic acetylcholine receptors (nAChRs) and can protect cells due to its ability to inhibit viral replication</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Analgesic applications and HIV</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase I and II completed (January 28, 2020)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B19" ref-type="bibr">Biocentury, 2007</xref>; <xref rid="B130" ref-type="bibr">King, 2011</xref>; <xref rid="B4" ref-type="bibr">Adis Insight, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Shk-192 &#x2013; Discontinued <sup>(1)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Stichodactyla helianthus</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
              <td valign="top" align="center" rowspan="1" colspan="1">10 or 100 &#xB5;g/kg by s.c. injection once daily</td>
              <td valign="top" align="left" rowspan="1" colspan="1">K<sub>V</sub>1.3 channel blocker</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Autoimmune disease</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase I</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B200" ref-type="bibr">Pennington et&#xA0;al., 2009</xref>; <xref rid="B130" ref-type="bibr">King, 2011</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Soricidin, SOR-C13 (NCT01578564 and NCT03784677) <sup>(1)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Blarina brevicauda</italic>
<break/>(Northern short-tailed shrew)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
              <td valign="top" align="left" rowspan="1" colspan="1">I.v. infusion (dose range from 1.375 to 6.12 mg/kg)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Inhibitor of the Ca<sup>2+</sup>-selective transient receptor potential channel TRPV6</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Ovarian (and other) cancers</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase I completed (June 23, 2016) and recruiting (August 6, 2019)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B270" ref-type="bibr">US National Library of Medicine, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Tetrodotoxin (Tectin<sup>&#xAE;</sup>) (NCT01655823) <sup>(4)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Pufferfish, marine animals and phylogenetically unrelated terrestrial organisms</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Different injectable dosages (1&#xA0;ml), twice a day for four consecutive days</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Sodium channel blocker</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Neuropathic pain caused by chemotherapy</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase II terminated (decided to proceed to Phase III) (October 30, 2018)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B270" ref-type="bibr">US National Library of Medicine, 2020</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Xen 2174 (&#x3C7;-CTX MrIA) &#x2013; Discontinued <sup>(1)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Conus marmoreus</italic>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Intrathecal</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Interacts with a large hydrophobic pocket within the norepinephrine transporter</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Postoperative pain</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase IIb (2015)&#x2014; discontinued</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B35" ref-type="bibr">Brust et&#xA0;al., 2009</xref>; <xref rid="B130" ref-type="bibr">King, 2011</xref>; <xref rid="B149" ref-type="bibr">Lewis, 2015</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Ximelagatran (Exanta<sup>&#xAE;</sup>) &#x2013; Discontinued (NCT00206089) <sup>(4)</sup></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">
<italic>Naja</italic> spp.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Synthetic</td>
              <td valign="top" align="center" rowspan="1" colspan="1">36 mg orally twice daily.</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Direct thrombin inhibitor</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Prevention of venous thromboembolic events</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Phase III terminated (November 15, 2010)&#x2014;withdrawn from the market and clinical development in February 2006 in the interest of patient safety (hepatic toxicity)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B101" ref-type="bibr">Gulseth, 2005</xref>; <xref rid="B130" ref-type="bibr">King, 2011</xref>)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>1), peptide; 2), enzyme; 3), non-enzyme protein; 4), organic molecule; i.v., intravenous; NCT, ClinicalTrials.gov identifier; s.c., subcutaneous.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <sec id="s5_1">
        <title>Amphibians</title>
        <p>Chansu, the dried toad venom secreted by the skin glands of <italic>Bufo gargarizans</italic> (previously <italic>B. bufo gargarizans</italic>) or <italic>Duttaphrynus melanostictus</italic> (previously <italic>B. melanostictus</italic>), has been used in the Traditional Chinese Medicine for more than 1000 years (<xref rid="B209" ref-type="bibr">Qi et&#xA0;al., 2011</xref>). Bufalin, the major digoxin-like immunoreactive component of Chansu, is a cardiotonic glycoside (bufadienolide) present in toad poisons and has demonstrated anticancer activities in several preclinical studies (<xref rid="B175" ref-type="bibr">Miao et&#xA0;al., 2013</xref>). Cinobufagin and resibufogenin are also bufadienolides present in Chansu, capable of inhibiting cancer cells growth <italic>in vitro</italic> (<xref rid="B296" ref-type="bibr">Xie et&#xA0;al., 2012</xref>; <xref rid="B150" ref-type="bibr">Li et&#xA0;al., 2013</xref>).</p>
        <p>Huachansu (also known as cinobufacini) is a sterilized aqueous extract of Chansu, designed for intravenous injection, and has been widely used in oncological clinics in China to treat patients with several types of cancer, being approved by the NMPA (formerly China FDA) (<xref rid="B209" ref-type="bibr">Qi et&#xA0;al., 2011</xref>; <xref rid="B155" ref-type="bibr">Liu et&#xA0;al., 2015</xref>). The major biologically active components present in huachansu are steroidal cardiac glycosides, such as bufalin, resibufogenin, cinobufagin, cinobufotalin, marinobufagin (also known as marinobufagenin) and bufotalin, and indole alkaloids, like bufotenine, bufotenidine, cinobufotenine, and serotonin (<xref rid="B251" ref-type="bibr">Su et&#xA0;al., 2003</xref>).</p>
        <p>During a phase I clinical study, huachansu was tolerable even at doses 6 times higher than those normally administered, and could slow disease progression in some cancer patients, with no observed significant cardiac toxicity (<xref rid="B172" ref-type="bibr">Meng et&#xA0;al., 2009</xref>).</p>
        <p>The efficacy and safety of gemcitabine-oxaliplatin (Gemox) combined with huachansu chemotherapy is an effective and well-tolerated regimen for advanced and metastatic gallbladder carcinoma (<xref rid="B210" ref-type="bibr">Qin et&#xA0;al., 2008</xref>). Another study showed that huachansu combined with chemotherapy reduced the occurrence of gastrointestinal side effects and leukocytopenia in patients with advanced gastric cancer (<xref rid="B297" ref-type="bibr">Xie et&#xA0;al., 2013</xref>).</p>
        <p>Many <italic>in vitro</italic> studies demonstrating anticancer properties of huachansu justify its continued evaluation in clinical trials. Phases II and III studies started recruiting participants, in 2016, to evaluate if cinobufacini tablets have synergistic effect in the treatment of diffuse large B cell lymphoma, the most common subtype of non-Hodgkin lymphoma. The estimated date of conclusion of the study is December 2021 (NCT02871869).</p>
        <p>Bombesin is a peptide composed of 14 amino acids (EQRLGNQWAVGHLM-NH<sub>2</sub>), isolated from the poisonous skin of the frog <italic>Bombina bombina</italic>, that shows high affinity for gastrin-releasing peptide-receptors (<xref rid="B263" ref-type="bibr">Tornesello et&#xA0;al., 2017</xref>; <xref rid="B272" ref-type="bibr">Utkin, 2017</xref>). Overexpression of members of this receptor family has been documented in several human neoplasms, such as prostate cancer, breast cancer, and small cell lung cancer. In this way, these receptors represent a molecular target for radiolabeled bombesin analogues as diagnostic or radiotherapeutic applications in these tumors (<xref rid="B231" ref-type="bibr">Schwartsmann et&#xA0;al., 2006</xref>; <xref rid="B291" ref-type="bibr">Wieser et&#xA0;al., 2014</xref>). Gallium-68 (68Ga)-DOTA-bombesin completed phase II in 2017 with 10 patients presenting prostate cancer. It is an imaging agent for positron emission tomography/magnetic resonance imaging and attaches to tumor cells with specific receptors on their surfaces (NCT02440308).</p>
        <p>Different chemical modifications have been introduced in the synthetic bombesin to stabilize its structure, increase the binding affinity and to potentiate its agonist/antagonist properties (<xref rid="B41" ref-type="bibr">Cescato et&#xA0;al., 2008</xref>; <xref rid="B263" ref-type="bibr">Tornesello et&#xA0;al., 2017</xref>). A large variety of bombesin receptor ligands have been preclinically tested, most of which were bombesin agonists (<xref rid="B12" ref-type="bibr">Baratto et&#xA0;al., 2018</xref>). However, most of these ligands demonstrated high gastrointestinal uptake and limited metabolic stability <italic>in vivo</italic>, and can cause acute side effects (nausea, abdominal pain and emesis) when administered at higher doses (<xref rid="B2" ref-type="bibr">Accardo et&#xA0;al., 2016</xref>).</p>
        <p>A synthetic bombesin/gastrin-releasing peptide-receptor antagonist (RC-3095) was able to produce long-lasting tumor regressions in murine and human tumor models <italic>in vitro</italic> and <italic>in vivo</italic>. Due to the occurrence of local toxicity at the injection site during a phase I trial in patients with advanced solid malignancies, a recommended dose of RC-3095 for Phase II trials could not be clearly established (<xref rid="B231" ref-type="bibr">Schwartsmann et&#xA0;al., 2006</xref>). Considering its mechanism of action and preclinical antitumor activity, further studies exploiting new formulations of RC-3095 for human use, such as slow-release preparations and analogues with a more favorable pharmacokinetics, are justified.</p>
        <p>Epibatidine is an alkaloid extracted from the skin of the Ecuadorian frog <italic>Epipedobatus tricolor</italic> (poison-dart frog). This molecule binds to several nAChR subtypes, including &#x3B1;7, &#x3B1;4&#x3B2;2, and the neuromuscular &#x3B1;1&#x3B2;1&#x3B4;&#x3B3; subtype. Antinociceptive efficacy of epibatidine is about 100 times more powerful than morphine, but it has induced adverse effects, revealing high toxicity to be used as a pain-relieving drug (<xref rid="B264" ref-type="bibr">Traynor, 1998</xref>; <xref rid="B222" ref-type="bibr">Salehi et&#xA0;al., 2019</xref>).</p>
        <p>Many compounds based on the chemical structure of epibatidine have been developed and tested to become new, powerful pain-reducing drugs (<xref rid="B53" ref-type="bibr">Daly, 2004</xref>; <xref rid="B267" ref-type="bibr">Umana et&#xA0;al., 2013</xref>). An example is ABT-594 (tebanicline or ebanicline) (<xref rid="B222" ref-type="bibr">Salehi et&#xA0;al., 2019</xref>). ABT-594 is of particular interest once it is more powerful than morphine showing no morphine-associated side effects and only mild cardiovascular side effects (<xref rid="B82" ref-type="bibr">Fox and Serrano, 2007</xref>). Due to severe gastrointestinal side effects caused by this first analogue of epibatidine, it has not been included in pain therapies in humans (<xref rid="B222" ref-type="bibr">Salehi et&#xA0;al., 2019</xref>).</p>
      </sec>
      <sec id="s5_2">
        <title>Cone Snails</title>
        <p>Conotoxins, isolated from different species of cone snails (<italic>Conus</italic> ssp.), comprise a large family of small cysteine-rich peptides (10&#x2013;30 amino acid residues) organized in subfamilies according to their structure (cysteine framework) and their mechanism of action (<xref rid="B148" ref-type="bibr">Lewis et&#xA0;al., 2012</xref>; <xref rid="B196" ref-type="bibr">Ovsepian et&#xA0;al., 2019</xref>). Undoubtedly, omega-conotoxins represent the most notable and famous conotoxin subfamily, in which omega-MVIIA [ziconotide (Prialt<sup>&#xAE;</sup>)], previously reported in the section <italic>Achievements With Animal Toxin-Based Molecules</italic>, belongs to.</p>
        <p>KCP-400 (also known as RgIA4), derived from Vc1.1, the first toxin isolated from <italic>C. regius</italic> venom, is a novel non-opioid drug for the treatment of chronic pain. Vc1.1 is a highly potent toxin that targets &#x3B1;9&#x3B1;10 nAChR, blocking pain signaling at the site of nerve injury, producing analgesic, anti-inflammatory and neuroprotective effects (<xref rid="B219" ref-type="bibr">Romero et&#xA0;al., 2017</xref>). The preclinical safety and efficacy studies of KCP-400 had been conducted by Kineta Inc., which is currently developing the non-opioid KCP-506 (<xref rid="B128" ref-type="bibr">Kineta Inc., 2020</xref>).</p>
        <p>Because of their high potency and specificity, novel conotoxins can provide additional information on the pharmacology of ion channels, receptors, and transporters (<xref rid="B148" ref-type="bibr">Lewis et&#xA0;al., 2012</xref>; <xref rid="B91" ref-type="bibr">Gao et&#xA0;al., 2017</xref>).</p>
      </sec>
      <sec id="s5_3">
        <title>Hymenopterans</title>
        <p>The whole venom of bees (Alyostal ST <italic>Apis mellifera</italic>) completed a randomized phase II study, in 2014, to evaluate its efficacy and potential effects in 50 participants presenting motor symptoms of Parkinson&#x2019;s disease (NCT01341431). The administration of bee venom showed to be safe in non-allergic patients (<xref rid="B106" ref-type="bibr">Hartmann et&#xA0;al., 2016</xref>). Following the same direction of bee venom, the whole venom of ants has been employed in therapeutic use. For instance, the extracted material from venom sacs of <italic>Pseudomyrmex triplarinus</italic> could be helpful in relieving the pain caused by rheumatoid arthritis (WO1990003178A1, US4247540A).</p>
        <p>The whole venom of wasps, bees and ants are also being used in venom immunotherapy (VIT), which represents a treatment to allergic patients preventing further sting-induced anaphylactic reactions (<xref rid="B137" ref-type="bibr">Kolaczek et&#xA0;al., 2017</xref>). Several clinical protocols and guidelines were published and generally consist of injections of small but gradually increasing doses of a specific venom (<xref rid="B28" ref-type="bibr">Bonifazi et&#xA0;al., 2005</xref>).</p>
        <p>Despite those studies published employing hymenoptera whole venoms, little has been reported on the therapeutic applications of purified toxins. Thus far, the most explored hymenoptera venom components are melittin, apamin (both isolated from bees), and mastoparan (isolated from wasps) (<xref rid="B177" ref-type="bibr">Moreno and Giralt, 2015</xref>). All those three components arise as promising drug candidates for several conditions or therapeutic applications, such as antitumor agents (<xref rid="B89" ref-type="bibr">Gajski and Garaj-Vrhovac, 2013</xref>; <xref rid="B56" ref-type="bibr">de Azevedo et&#xA0;al., 2015</xref>), learning disabilities (<xref rid="B174" ref-type="bibr">Messier et&#xA0;al., 1991</xref>; <xref rid="B115" ref-type="bibr">Ikonen and Riekkinen, 1999</xref>), antimicrobial and antiviral activity (<xref rid="B281" ref-type="bibr">Vila-Farres et&#xA0;al., 2012</xref>; <xref rid="B223" ref-type="bibr">Sample et&#xA0;al., 2013</xref>), cell penetrating-peptides (<xref rid="B122" ref-type="bibr">Jones and Howl, 2012</xref>), among other applications.</p>
        <p>Concerning melittin, a phase II study of ARC-520 in 79 participants with chronic hepatitis B virus (HBV) was terminated for regulatory and business reasons in 2019 (NCT02577029). The Dynamic Polyconjugate<sup>&#xAE;</sup> technology, developed by Arrowhead Therapeutics, uses melittin as an endosomolytic agent to facilitate the delivery of siRNA conjugates to hepatocytes (US8313772; US8501930; US8618277; WO2013003520A1).</p>
      </sec>
      <sec id="s5_4">
        <title>Scorpions</title>
        <p>Chlorotoxin (CTx) is the only toxin from scorpion venoms undergoing clinical phase trials. The evidence of a venom molecule that interacts with chloride (Cl<sup>-</sup>) channels was firstly demonstrated by DeBin and Strichartz, which showed that <italic>Leiurus quinquestriatus quinquestriatus</italic> (the yellow scorpion from the Middle East, also known as death stalker) venom was able to block Cl<sup>-</sup> channels of reconstituted rat epithelia and embryonic rat brain (<xref rid="B58" ref-type="bibr">DeBin and Strichartz, 1991</xref>). CTx is a peptide with 36 amino acids presenting 4070 Da, 4 disulfide bonds and it is positively charged in pH 7. Moreover its structure was solved by nuclear magnetic resonance spectroscopy: three-stranded antiparallel &#x3B2;-sheet packed against an &#x3B1;-helix (<xref rid="B152" ref-type="bibr">Lippens et&#xA0;al., 1995</xref>). The synthetic CTx was also produced successfully (<xref rid="B189" ref-type="bibr">Ojeda et&#xA0;al., 2016</xref>).</p>
        <p>CTx discovery was marked by a substantial rise of publications using this molecule for different applications, such as insecticide (<xref rid="B59" ref-type="bibr">DeBin et&#xA0;al., 1993</xref>), antiangiogenic (<xref rid="B117" ref-type="bibr">Jacoby et&#xA0;al., 2010</xref>), and tumor binding (<xref rid="B50" ref-type="bibr">Cohen-Inbar and Zaaroor, 2016</xref>). CTx has demonstrated the capability to bind to different targets including chloride channels, membrane type-2 matrix metalloprotease (MMP-2) and annexin A2 (<xref rid="B189" ref-type="bibr">Ojeda et&#xA0;al., 2016</xref>). However, a milestone in the CTx discovery was the production of fluorescent molecular probes such as the tumor paint (CTx conjugated with Cy5.5 or CTx : Cy5.5). This bioconjugate can detect cancer foci and metastases from malignant glioma, sarcoma medulloblastoma and prostate and intestinal cancers using mouse models. The specific identification by this fluorescent molecular beacon (CTx : Cy5.5) increases the precision of surgical resection (image guidance) and improves patient prognosis (<xref rid="B277" ref-type="bibr">Veiseh et&#xA0;al., 2007</xref>). CTx:800CW (an infrared dye conjugate) was also produced; however, it has failed since the integrity of the blood-brain barrier was compromised even in the early stages of medulloblastoma tumor (<xref rid="B141" ref-type="bibr">Kovar et&#xA0;al., 2013</xref>).</p>
        <p>Tozuleristide (BLZ-100), a CTx indocyanine green conjugate, demonstrated to bind to tumor cells while sparing healthy tissues (<xref rid="B38" ref-type="bibr">Butte et&#xA0;al., 2014</xref>). Phase I studies of BLZ-100 in 17 patients with glioma undergoing surgery were finished in 2016 (NCT02234297). The 131-I-TM-601 is the recombinant version of chlorotoxin (TM-601) radioconjugated with iodine 131 (<xref rid="B110" ref-type="bibr">Hockaday et&#xA0;al., 2005</xref>; <xref rid="B127" ref-type="bibr">Kesavan et&#xA0;al., 2010</xref>). It has been tested against different cancers (breast cancer, non-small cell lung cancer, melanoma, colorectal cancer, pancreatic cancer, prostate adenocarcinoma, glioma primary and solid tumors). The Phase I with 60 patients presenting recurrent or refractory somatic and/or cerebral metastatic solid tumors was completed in 2009 (NCT00379132). Regarding intellectual property, many patents applications can be detected relating to CTx variants, bioconjugates and methods for use, with an extensive list of records (e.g. WO2011142858A2; WO20006115633A2; US20030021810A1; US20160096869A1; US20080260639A1).</p>
        <p>Although solely CTx reached clinical phase so far, other scorpion toxins have demonstrated therapeutic potential. For instance, the scorpion venom active polypeptide (SVAP) from <italic>Mesobuthus martensii</italic> (formerly <italic>B. martensii</italic>) has completed preclinical phase as a potential antithrombotic peptide. The results demonstrated that SVAP (0.125, 0.25, 0.5 mg/ml) inhibited rabbit platelet aggregation <italic>in vitro</italic>. Moreover, this peptide (0.32 and 0.64 mg/kg, intravenous administration) prolonged the occlusion time of carotid artery thrombosis in rats. Thus, SVAP may be considered an interesting molecule to be used in the treatment of cardiocerebral vascular diseases (<xref rid="B244" ref-type="bibr">Song et&#xA0;al., 2005</xref>).</p>
        <p>Cancer treatment is also explored with other scorpion toxins. Besides CTx, BmKCT, a CTx-like molecule from <italic>M. martensii</italic> venom, reversibly inhibits chloride currents of glioma cells (<xref rid="B299" ref-type="bibr">Yang et&#xA0;al., 2005</xref>). BmkTa, also a CTx-like from <italic>M. martensii</italic> venom, is able to abolish the human glioma cells growth in a dose-dependent manner, with an IC<sub>50</sub> of approximately 0.28 &#xB5;M (<xref rid="B84" ref-type="bibr">Fu et&#xA0;al., 2007</xref>). Although some peptides must be highlighted (AmmTx3, BmTx3, Bekm-1, BmHyA, and IbTx), the list of scorpion toxins with antiproliferative activities is extensive (<xref rid="B54" ref-type="bibr">Das Gupta et&#xA0;al., 2007</xref>; <xref rid="B85" ref-type="bibr">Fu et&#xA0;al., 2012</xref>; <xref rid="B61" ref-type="bibr">Ding et&#xA0;al., 2014</xref>; <xref rid="B194" ref-type="bibr">Ortiz et&#xA0;al., 2015</xref>).</p>
        <p>Scorpion toxins blocking potassium channels have also been widely investigated. In particular, those inhibiting K<sub>v</sub>1.3 currents are considered potential bioactive molecules to treat autoimmune diseases (<xref rid="B307" ref-type="bibr">Zhao et&#xA0;al., 2015</xref>). To the best of our knowledge, there are 81 scorpion toxins with positive results in inhibiting K<sub>v</sub>1.3 (<xref rid="B192" ref-type="bibr">Oliveira et&#xA0;al., 2019</xref>). Nevertheless, only eight of them present <italic>in vivo</italic> assays (i.e. most of them were studied using solely <italic>in vitro</italic> electrophysiological experiments). 1) HsTX1 from <italic>Heterometrus spinifer</italic> venom demonstrated to reduce inflammation in an active delayed-type hypersensitivity model and in the pristane-induced arthritis using rat models (<xref rid="B256" ref-type="bibr">Tanner et&#xA0;al., 2017</xref>). 2) ImKTX88 from <italic>Isometrus maculatus</italic> venom ameliorates pathological severity in rat experimental autoimmune encephalomyelitis (<xref rid="B112" ref-type="bibr">Huang et&#xA0;al., 2017</xref>). 3) Kaliotoxin (Ktx) from <italic>Androctonus mauretanicus mauretanicus</italic> venom showed the ability of preventing bone loss through a receptor activator of NF-&#x3BA;B ligand (RANKL)-dependent osteoclastogenesis mechanism, using rat periodontal disease model. Thus, Ktx has been tested to treat periodontal disease and rheumatoid arthritis (<xref rid="B273" ref-type="bibr">Valverde et&#xA0;al., 2004</xref>). 4) Margatoxin (MgTX) from <italic>Centruroides margaritatus</italic> venom caused a reduction of tumor volume into a xenograft model using nude mice by blocking K<sub>v</sub>1.3 channels, and it is being considered as a novel therapeutic target for lung adenocarcinoma therapy (<xref rid="B119" ref-type="bibr">Jang et&#xA0;al., 2011</xref>). 5) OSK1 from <italic>Orthochirus scrobilosus</italic> venom displayed blocking activity of K<sub>v</sub>1.3; however, during <italic>in vivo</italic> experiments, it demonstrated to be neurotoxic since it can diffuse immediately throughout the mouse brain (<xref rid="B180" ref-type="bibr">Mouhat et&#xA0;al., 2005</xref>). 6-7) Ts6 and Ts15 from <italic>Tityus serrulatus</italic> venom inhibit the proliferation of effector memory T cells and reduce inflammation in delayed-type hypersensitivity response using mice model (<xref rid="B208" ref-type="bibr">Pucca et&#xA0;al., 2016</xref>). 8) Vm24 from <italic>Vaejovis mexicanus smithi</italic> venom reduces delayed-type hypersensitivity reactions in rats (<xref rid="B274" ref-type="bibr">Varga et&#xA0;al., 2012</xref>), as well as impairs the synthesis and secretion of T cell cytokines in response to T-cell receptor engagement (<xref rid="B280" ref-type="bibr">Veytia-Bucheli et&#xA0;al., 2018</xref>).</p>
        <p>Some reports have shown that maurocalcine from the scorpion <italic>Maurus palmatus</italic>, a toxin active on ryanodine receptors, goes into the cells and can also be used as a vector for the penetration of cell-impermeable cargo molecules. Mutated analogues of maurocalcine have been produced as leads to develop better cell-penetrating peptides (CPPs) (<xref rid="B72" ref-type="bibr">Esteve et&#xA0;al., 2005</xref>; <xref rid="B211" ref-type="bibr">Ram et&#xA0;al., 2009</xref>). CPPs are short (9-35 residues) cationic or amphipathic molecules with the capability of being rapidly internalized across cell membranes. In this way, they can mediate the translocation of a conjugated drug across plasma membranes, being considered an effective and non-toxic mechanism for drug delivery (<xref rid="B212" ref-type="bibr">Ramsey and Flynn, 2015</xref>). The first Ca<sup>2+</sup> channel toxin from <italic>T. serrulatus</italic> venom, designated as CPP-Ts, exhibited selective internalization properties and specific nuclear delivery, being a potential intranuclear delivery tool to target cancerous cells (<xref rid="B57" ref-type="bibr">de Oliveira-Mendes et&#xA0;al., 2018</xref>).</p>
      </sec>
      <sec id="s5_5">
        <title>Sea Anemones</title>
        <p>Sea anemones, the polyp form of marine coelenterates of the phylum Cnidaria (<xref rid="B286" ref-type="bibr">Watters, 2005</xref>), are poorly studied, but represent a rich source of new compounds. ShK-186, originally isolated from <italic>Stichodactyla helianthus</italic> sea anemone venom, inspired the design of dalazatide, a synthetic peptide composed of 37 amino acids, acting as a K<sub>v</sub>1.3 inhibitor (<xref rid="B16" ref-type="bibr">Beeton et&#xA0;al., 2006</xref>). In preclinical tests, dalazatide have significantly reduced the clinical score of rat model of multiple sclerosis (<xref rid="B259" ref-type="bibr">Tarcha et&#xA0;al., 2012</xref>). Dalazatide completed phase I trials in 2015 to examine the safety of systemic multiple ascending dose administration in 32 healthy volunteers (NCT02446340) and in 24 patients with plaque psoriasis (NCT02435342). No phase II study has been started since then. However, public databases (e.g., the FDA, Drugs.com, etc.) do not mention what happened to this drug lead.</p>
      </sec>
      <sec id="s5_6">
        <title>Snakes</title>
        <p>Recently, collinein-1, a SVSP from <italic>Crotalus durissus collilineatus</italic> venom (<xref rid="B24" ref-type="bibr">Boldrini-Fran&#xE7;a et&#xA0;al., 2015</xref>) was recombinantly expressed in <italic>Pichia pastoris</italic> system (<xref rid="B26" ref-type="bibr">Boldrini-Franca et&#xA0;al., 2019</xref>) and demonstrated to block, independently from its catalytic activity, the hEAG1 ion channel, which is overexpressed in several cell cancer lines. Collinein-1 reduced the viability of human breast cancer cell line MCF7, which displays high expression of hEAG1, but does not affect the HepG2 and MCF10A cell lines, which present low expression of this ion channel, demonstrating that the reduction of cell viability might be connected with hEAG1 inhibition by this protein (<xref rid="B27" ref-type="bibr">Boldrini-Fran&#xE7;a et&#xA0;al., 2020</xref>).</p>
        <p>Isolated from the Malayan pit viper (<italic>Calloselasma rhodostoma</italic>), ancrod is a thrombin-like enzyme able to release fibrinopeptide A from fibrinogen A&#x3B1; chain, causing hypofibrinogenemia in humans (<xref rid="B214" ref-type="bibr">Reid, 1971</xref>). Structurally, it is composed of 234 amino acids and presents six disulfide bonds (<xref rid="B37" ref-type="bibr">Burkhart et&#xA0;al., 1992</xref>). Because of its enzyme activity on fibrinogen (<xref rid="B42" ref-type="bibr">Chan et&#xA0;al., 2016</xref>), this toxin was used in stroke treatment (<xref rid="B204" ref-type="bibr">Pizzo et&#xA0;al., 1972</xref>), marketed for several decades by Knoll Pharma in Germany and Austria, until it was withdrawn in the 1980s (<xref rid="B42" ref-type="bibr">Chan et&#xA0;al., 2016</xref>). In 2002 the rights of this drug were licensed. Two parallel trials (NCT00141001 and NCT00300196) were in phase III of clinical trials by Neurobiological Technologies (NTI), but both studies were terminated due to low efficacy, suboptimal and inconsistent results which led to the dissolution of NTI in 2009 (<xref rid="B130" ref-type="bibr">King, 2011</xref>; <xref rid="B154" ref-type="bibr">Liu et&#xA0;al., 2011</xref>). A randomized study involving this molecule completed phase II trial in 31 patients with sudden hearing loss to check its effectiveness, safety, and tolerance for this kind of pathology in 2018 (NCT01621256).</p>
        <p>The association of 15 residues of the C-terminal portion of <italic>Dendroaspis</italic> natriuretic peptide, isolated from <italic>D. angusticeps</italic> venom, with 22 residues of a human C-type natriuretic peptide, formed the chimeric natriuretic peptide, cenderitide (CD-NP) (<xref rid="B153" ref-type="bibr">Lisy et&#xA0;al., 2008</xref>; <xref rid="B146" ref-type="bibr">Lee et&#xA0;al., 2009</xref>). It can be applied in congestive heart failure, and its mechanism of action is associated with the connection to natriuretic peptide receptors, leading to hypotension (<xref rid="B288" ref-type="bibr">Wei et&#xA0;al., 1993</xref>; <xref rid="B146" ref-type="bibr">Lee et&#xA0;al., 2009</xref>). Studies with this peptide completed phase I in 2007, in a non-randomized way, to check its efficacy, safety, and pharmacodynamics in 22 healthy participants (NCT00482937) (<xref rid="B146" ref-type="bibr">Lee et&#xA0;al., 2009</xref>; <xref rid="B114" ref-type="bibr">Ichiki et&#xA0;al., 2019</xref>). A phase II study in 14 patients with stable chronic heart failure (NCT02359227) and a phase I/II randomized study in 8 patients with chronic stable heart failure and moderate renal impairment (NCT02603614) were completed in February 2020. Another phase I randomized study to maintain the function of left ventricle in 30 participants with myocardial infarction was completed in 2019 (NCT02071602).</p>
        <p>Fibrin sealant or fibrin glue, a bioproduct formed by a thrombin-like serine protease from <italic>C. d. terrificus</italic> venom and fibrinogen-rich cryoprecipitate from humans, could transmit infectious diseases and was suspended by the FDA in 1978 (<xref rid="B247" ref-type="bibr">Spotnitz, 2014</xref>; <xref rid="B79" ref-type="bibr">Ferreira et&#xA0;al., 2017</xref>). To overcome this drawback, the Center for the Study of Venoms and Venomous Animals (CEVAP) at S&#xE3;o Paulo State University (UNESP), in Brazil, started studying the aforementioned fibrin sealant using a fibrinogen-rich cryoprecipitate from <italic>Bubalus bubalis</italic> buffaloes blood (<xref rid="B13" ref-type="bibr">Barros et&#xA0;al., 2009</xref>; <xref rid="B79" ref-type="bibr">Ferreira et&#xA0;al., 2017</xref>), and this bioproduct completed phase I/II of clinical trials with 10 patients in phase I and 30 patients in phase II (<xref rid="B79" ref-type="bibr">Ferreira et&#xA0;al., 2017</xref>). The fibrin glue displays adhesive, sealant and hemostatic effects due to its proteolytic activity on fibrinogen, producing fibrin monomers, which forms a clot in the presence of calcium (<xref rid="B13" ref-type="bibr">Barros et&#xA0;al., 2009</xref>; <xref rid="B79" ref-type="bibr">Ferreira et&#xA0;al., 2017</xref>). Similarly, preliminary studies have been conducted to evaluate the effect of direct application of Vivostat<sup>&#xAE;</sup> (autologous fibrin sealant) in controlling cerebral bleeding (<xref rid="B97" ref-type="bibr">Graziano et&#xA0;al., 2015</xref>; <xref rid="B98" ref-type="bibr">Graziano et&#xA0;al., 2016</xref>).</p>
        <p>A 33 kDa-batroxobin from <italic>B. atrox</italic> and <italic>B. moojeni</italic> venoms (<xref rid="B116" ref-type="bibr">Itoh et&#xA0;al., 1987</xref>; <xref rid="B68" ref-type="bibr">Earps and Shoolingin-Jordan, 1998</xref>) was expressed in <italic>P. pastoris</italic> and exhibited biochemical activities similar to those of native protein (<xref rid="B301" ref-type="bibr">You et&#xA0;al., 2004</xref>). The recombinant batroxobin used with a medical adhesive synergistically accelerated hemostasis in the mouse liver and femoral artery models, reducing bleeding time and blood loss. Hemostasis was more rapidly achieved with increasing concentrations of batroxobin (<xref rid="B302" ref-type="bibr">You et&#xA0;al., 2014</xref>). Other dressings using collagen and chitosan with recombinant batroxobin also controlled bleeding and improved the hemostatic properties of collagen and chitosan pads used alone (<xref rid="B233" ref-type="bibr">Seon et&#xA0;al., 2017</xref>).</p>
        <p>An analgesic preparation containing cobratide and oxycodone for cancer-related pain (CN104645312) and a keluoqu tablet preparation method using tramadol hydrochloride, ibuprofen and cobratide (also known as ketongning and cobrotoxin) (CN105769791) have been patented. The anti-nociceptive effects of cobrotoxin (the <italic>N. n. atra</italic> snake venom short-chain post-synaptic &#x3B1;-neurotoxin cobratide) do not involve muscarinic acetylcholine or opioid receptors and the molecule has high affinity for the &#x3B1;<sub>1</sub> subunit of the nicotinic acetylcholine receptors (nAChR) (<xref rid="B92" ref-type="bibr">Gazerani and Cairns, 2014</xref>). Cobratoxin, a long-chain post-synaptic &#x3B1;-neurotoxin isolated from the Thailand cobra (<italic>N. kaouthia</italic>), produces anti-nociceptive and anti-inflammatory effects through decreased production of inflammatory cytokines, for example, TNF-&#x3B1;, IL-1, and IL-2, <italic>via</italic> its high affinity for the &#x3B1;<sub>7</sub> subtype of nAChR (<xref rid="B92" ref-type="bibr">Gazerani and Cairns, 2014</xref>).</p>
        <p>RPI-78M (Receptin<sup>&#xAE;</sup>) and RPI-MN (Pepteron<sup>&#xAE;</sup>) are detoxified and chemically modified forms of cobratoxin and cobrotoxin, respectively (<xref rid="B130" ref-type="bibr">King, 2011</xref>; <xref rid="B107" ref-type="bibr">Harvey, 2014</xref>). RPI-78M has 71 amino acid residues with five disulfide bonds and completed phase I of clinical trials for multiple sclerosis, while RPI-MN presents 62 amino acid residues and four disulfide bonds (<xref rid="B130" ref-type="bibr">King, 2011</xref>). Both molecules show analgesic applications and present the nAChRs as molecular target (<xref rid="B42" ref-type="bibr">Chan et&#xA0;al., 2016</xref>). Although RPI-MN is parenterally administered <italic>via</italic> subcutaneous injection, RPI-78M can be orally administered, since its absorption through the oral mucosa occurs when it is formulated with benzalkonium chloride (<xref rid="B213" ref-type="bibr">Reid and Raymond, 2010</xref>). Chemical modifications that detoxify these molecules can alter their affinity to nAChRs. They may include their oxidation with ozone, formate (also known as methanoate) and hydrogen peroxide, being the latter more adopted (<xref rid="B215" ref-type="bibr">Reid, 2007</xref>). RPI-MN has also completed preclinical studies against Human Immunodeficiency Virus (HIV), protecting cells due to its ability to inhibit viral replication (<xref rid="B215" ref-type="bibr">Reid, 2007</xref>; <xref rid="B130" ref-type="bibr">King, 2011</xref>; <xref rid="B107" ref-type="bibr">Harvey, 2014</xref>). However, its mechanism of action has not been elucidated yet (<xref rid="B213" ref-type="bibr">Reid and Raymond, 2010</xref>).</p>
        <p>Crotamine, a highly cationic and cysteine-rich CPP from <italic>C. d. terrificus</italic> snake venom, displays membrane translocation capabilities, penetrates into the cell and presents cytoplasmatic, vesicular, and nuclear distribution (<xref rid="B126" ref-type="bibr">Kerkis et&#xA0;al., 2004</xref>). This toxin is specifically uptaken by actively proliferating cells, being able to permeate several lineages <italic>in vitro</italic> (<xref rid="B182" ref-type="bibr">Nascimento et&#xA0;al., 2007</xref>). Additionally, several molecules based on crotamine structure, including fluorescent derivatives (<xref rid="B258" ref-type="bibr">Tansi et&#xA0;al., 2019</xref>) and functionalized with gold nanoparticles (<xref rid="B124" ref-type="bibr">Karpel et&#xA0;al., 2018</xref>), for instance, are being developed. Crotamine and its analogues have been tested in healthy and tumorous cell lines, and the results indicate they can be used as selective delivery tools of anticancer molecules (<xref rid="B161" ref-type="bibr">Mambelli-Lisboa et&#xA0;al., 2018</xref>).</p>
        <p>Another component isolated from <italic>C. d. terrificus</italic> venom is crotalphine (<xref rid="B139" ref-type="bibr">Konno et&#xA0;al., 2008</xref>), a potent analgesic comprised of 14 amino acid residues. It acts at peripheral opioid receptors (<xref rid="B102" ref-type="bibr">Gutierrez et&#xA0;al., 2008</xref>) and selectively targets TRPA1 ion channels (<xref rid="B31" ref-type="bibr">Bressan et&#xA0;al., 2016</xref>), being more potent under conditions of acute peripheral sensitization (<xref rid="B303" ref-type="bibr">Zambelli et&#xA0;al., 2014</xref>). The potent and long lasting opioid-mediated antinociception of crotalphine has been evaluated in cancer pain (<xref rid="B32" ref-type="bibr">Brigatte et&#xA0;al., 2013</xref>).</p>
      </sec>
      <sec id="s5_7">
        <title>Spiders</title>
        <p>The toxin &#x3C0;-theraphotoxin-Pc1a or &#x3C0;-TRTX-Pc1a (also known as psalmotoxin 1 or PcTx1), obtained from the <italic>Psalmopoeus cambridgei</italic> (Trinidad chevron tarantula) venom, is considered a novel therapeutic molecule for treating pain (<xref rid="B176" ref-type="bibr">Monge-Fuentes et&#xA0;al., 2018</xref>). Classified as a specific inhibitor of ASIC1a, the most abundant acid-sensing ion channel, the toxin &#x3C0;-TRTX-Pc1 demonstrated an effective analgesic effect comparable to morphine in rat models of acute pain (<xref rid="B166" ref-type="bibr">Mazzuca et&#xA0;al., 2007</xref>). Recently, PcTx1 was also reported as a valuable tool for understanding the functional role of ASIC2a heteromeric channels (ASIC1a/2a) (<xref rid="B156" ref-type="bibr">Liu et&#xA0;al., 2018</xref>) and had no effect on acid-induced transient or chronic hyperalgesia in a mouse model of fibromyalgia (<xref rid="B43" ref-type="bibr">Chang et&#xA0;al., 2019</xref>).</p>
        <p>Hi1a, a PcTx1-related toxin isolated from the Australian funnel-web spider <italic>Hadronyche infensa</italic>, partially inhibits ASIC1a and does not affect ASIC1b (<xref rid="B159" ref-type="bibr">Maatuf et&#xA0;al., 2019</xref>). This toxin strongly attenuates brain damage after stroke and could be used to protect the brain from ischemic injury (<xref rid="B44" ref-type="bibr">Chassagnon et&#xA0;al., 2017</xref>), being considered as a lead for development of neuroprotective agents (<xref rid="B217" ref-type="bibr">Ren et&#xA0;al., 2018</xref>).</p>
        <p>Purotoxin-1 (PT1), obtained from the central Asian spider <italic>Geolycosa</italic> sp. venom, has also been studied to pain treatment (<xref rid="B176" ref-type="bibr">Monge-Fuentes et&#xA0;al., 2018</xref>). Characterized as a specific antagonist of P2X3 purinergic receptor, which is the most-studied subtype of P2X receptor related to pain, PT1 was able to inhibit nociceptive effect in different rat pain models (<xref rid="B100" ref-type="bibr">Grishin et&#xA0;al., 2010</xref>).</p>
        <p>
<italic>Phoneutria nigriventer</italic> (the armed spider) presents different toxins with potential pharmaceutical application and under preclinical tests (<xref rid="B199" ref-type="bibr">Peigneur et&#xA0;al., 2018</xref>). The toxin Ph&#x3B1;1&#x3B2;, classified as P/Q- and N-type voltage-gated calcium channel blocker, and its recombinant form (produced in <italic>E. coli</italic>) demonstrated analgesic effects in rodent models of pain (<xref rid="B246" ref-type="bibr">Souza et&#xA0;al., 2008</xref>). Recently, the same toxin (Ph&#x3B1;1&#x3B2;) together with PhTx3-3 (also a voltage-gated calcium channel blocker) demonstrated significant inhibitory effects on the proliferation and viability of different glioma cell lines (M059J, U-138MG and U-251MG) at low concentrations (0.3-100 pM). In the same study, Ph&#x3B1;1&#x3B2; and its recombinant form named CTK 01512-2 caused significant reductions of tumor areas <italic>in vivo</italic> using mouse glioblastoma model (<xref rid="B184" ref-type="bibr">Nicoletti et&#xA0;al., 2017</xref>). Moreover, Ph&#x3B1;1&#x3B2; and its recombinant version were able to reduce the inflammatory phase of the formalin-induced nociceptive behavior in rats, to decrease neuropathic pain caused by chronic constriction injury of sciatic nerve in rats, and to reduce the hyperalgesia caused by melanoma cancer model in mice (<xref rid="B218" ref-type="bibr">Rigo et&#xA0;al., 2017</xref>).</p>
        <p>
<italic>P. nigriventer</italic> venom became attractive because of its induced-priapism effect. The &#x3B4;-ctenitoxin-Pn2a toxin, also known as &#x3B4;-CNTX-Pn2a or Tx2-6, modulates voltage-gated sodium (Na<sub>v</sub>) channels and demonstrated an erectile effect in rats (12 &#xB5;g/kg, subcutaneous or intravenous injection) (<xref rid="B186" ref-type="bibr">Nunes et&#xA0;al., 2008</xref>). Interestingly, a minimum dose of 0.006 &#xB5;g/kg directly injected into the corpus cavernosum can cause erection in mice (<xref rid="B8" ref-type="bibr">Andrade et&#xA0;al., 2008</xref>). A synthetic 19-amino acid peptide, PnPP-19, designed from active core of PnTx2-6 tertiary structure, potentiated erection <italic>in vivo</italic> and <italic>ex vivo via</italic> the nitric oxide/cyclic guanosine monophosphate pathway. PnPP-19 is a promising candidate for erectile dysfunction treatment in patients that do not respond to the usual therapies (<xref rid="B239" ref-type="bibr">Silva et&#xA0;al., 2015</xref>). Biozeus Biopharmaceutical S.A performed pilot tests with the topical peptide (renamed BZ371) on healthy human beings and has been performing a pilot test with voluntary men with erectile dysfunction associated to hypertension or diabetes. The regulatory toxicological preclinical tests have already started. The next steps involve the final marketing formulation and future clinical trials (Phases 1 and 2) (<xref rid="B21" ref-type="bibr">Biozeus Biopharmaceutical SA, 2018</xref>; <xref rid="B120" ref-type="bibr">Johnson &amp; Johnson, 2019</xref>){Johnson &amp; Johnson, 2019, Champions of Science&#xAE;&#xA0;Storytelling Challenge: Latin America and Caribbean Edition;Biozeus Biopharmaceutical SA, 2018, First clinical trial sponsored by Biozeus concluded!}.</p>
        <p>Although antimicrobial activities with spider toxins are well documented (for detail see Spider Toxin Database, <uri xlink:type="simple" xlink:href="http://arachnoserver.org">http://arachnoserver.org</uri>), their therapeutic use are limited due to their susceptibility to proteolysis.</p>
      </sec>
      <sec id="s5_8">
        <title>Tetraodontiformes</title>
        <p>Tetrodotoxin (TTX), a guanidinium neurotoxin with high affinity for voltage-gated sodium (Na<sub>v</sub>) channels, had traditionally been known for many years as the main toxin from Tetraodontidae pufferfish (<xref rid="B143" ref-type="bibr">Lago et&#xA0;al., 2015</xref>). However, the toxin was present not only in other marine animals such as octopuses, gobies and sea stars, but also in phylogenetically unrelated terrestrial and aquatic organisms, including a dinoflagellate <italic>Alexandrium tamarense</italic>, red calcareous algae, arthropods, echinoderms, molluscs, worms, newts, frogs, and bacteria <italic>Actinomyces</italic>, <italic>Aeromonas</italic>, <italic>Alteromonas</italic>, <italic>Bacillus</italic> and <italic>Pseudomonas</italic> (<xref rid="B143" ref-type="bibr">Lago et&#xA0;al., 2015</xref>; <xref rid="B10" ref-type="bibr">Assuncao et&#xA0;al., 2017</xref>). The blockage of Na<sup>+</sup> into the cell inhibits the action potentials&#x2019; propagation in the excitable cell membranes, which causes neuromuscular paralysis (<xref rid="B66" ref-type="bibr">Duran-Riveroll and Cembella, 2017</xref>). TTX has been used for the development of analgesic and anesthetic drugs (<xref rid="B10" ref-type="bibr">Assuncao et&#xA0;al., 2017</xref>; <xref rid="B279" ref-type="bibr">Vetter et&#xA0;al., 2017</xref>) and, under the trade name Tectin<sup>&#xAE;</sup> (Wex Pharmaceuticals Inc.), proceeded to phase III of the clinical trials for the treatment of pain resulting from chemotherapy treatment in 2018 (NCT01655823).</p>
      </sec>
      <sec id="s5_9">
        <title>Other Animals</title>
        <p>The salivary secretion from different animals, such as bats, leeches, lizards, shrews and ticks are considered important sources of biologically active compounds. Other animals, such as caterpillars, have biologically active compounds in their bristles. Many of these compounds are still underexploited, lacking information on their chemical structure, physiological role and therapeutic application. Thus, the study of these compounds increases the chances of discovering new compounds with great pharmaceutical potential. The subsections <bold><italic>Bats</italic></bold> to <bold><italic>Ticks</italic></bold> will address some potential therapeutic molecules found in the saliva or bristles of these animals.</p>
        <sec id="s5_9_1">
          <title>Bats</title>
          <p>Desmoteplase, also known as &#x201C;<italic>Desmodus rotundus</italic> salivary plasminogen activator&#x201D; (DPSA), is a thrombolytic agent for acute ischemic stroke derived from vampire-bat saliva (<xref rid="B169" ref-type="bibr">Medcalf, 2012</xref>; <xref rid="B236" ref-type="bibr">Shi et&#xA0;al., 2016</xref>). This fibrin-dependent plasminogen activator is composed of 441 amino acids with high fibrin specificity, long half-life, low bleeding tendency, nonactivation by &#x3B2;-amyloid and lack of neurotoxicity (<xref rid="B169" ref-type="bibr">Medcalf, 2012</xref>; <xref rid="B236" ref-type="bibr">Shi et&#xA0;al., 2016</xref>; <xref rid="B151" ref-type="bibr">Li et&#xA0;al., 2017</xref>). A phase III randomized study in 492 participants with acute ischemic stroke was completed in 2015. Currently, there is no drug based on desmoteplase available for commercialization.</p>
        </sec>
        <sec id="s5_9_2">
          <title>Caterpillars</title>
          <p>Caterpillars from different South American countries, such as Venezuela, Brazil, French Guyana, Peru, Paraguay, Argentina and Colombia, are responsible for a severe bleeding syndrome in humans who touch their bristles (<xref rid="B9" ref-type="bibr">Arocha-Pinango and Guerrero, 2001</xref>). <italic>Lonomia obliqua</italic> is the main species of caterpillar found in Southern Brazil and its venom is comprised of molecules with antiviral, procoagulant, fibrinolytic and wound healing activities (<xref rid="B275" ref-type="bibr">Veiga et&#xA0;al., 2005</xref>; <xref rid="B216" ref-type="bibr">Reis et&#xA0;al., 2006</xref>; <xref rid="B6" ref-type="bibr">Alvarez-Flores et&#xA0;al., 2011</xref>; <xref rid="B40" ref-type="bibr">Carmo et&#xA0;al., 2015</xref>; <xref rid="B225" ref-type="bibr">Sato et&#xA0;al., 2016</xref>). Their toxic compounds are found in the bristle extract, hemolymph, cryosecretion (a crude venomous fluid ejected by the whole secretory tegument of caterpillars, stored at -20&#xB0;C for 24&#xA0;h) and tegument extract (<xref rid="B203" ref-type="bibr">Pinto et&#xA0;al., 2006</xref>; <xref rid="B276" ref-type="bibr">Veiga et&#xA0;al., 2009</xref>). Some compounds with potential therapeutic applications were identified in <italic>Lonomia</italic> sp, e.g. prothrombin or factor X activators, such as Lopap (<italic>L. obliqua</italic> prothrombim activator protease) and Losac (<italic>L. obliqua</italic> Stuart factor activator protease), PLA<sub>2</sub>-like, proteases, hyaluronidases, &#x3B1;-fibrinogenases (e.g. Lonofibrase), protease inhibitors, serpins, lipocalins, and lectins (<xref rid="B276" ref-type="bibr">Veiga et&#xA0;al., 2009</xref>). Currently, there are three clinical studies on caterpillars recorded at the Clinical Trials website (<xref rid="B270" ref-type="bibr">US National Library of Medicine, 2020</xref>). However, these studies are related to their use as a source of protein in the diet and none of them involves the genus <italic>Lonomia</italic>.</p>
        </sec>
        <sec id="s5_9_3">
          <title>Leeches</title>
          <p>Two phase II randomized studies involving leech therapy in 118 (NCT00435773) and 60 participants (NCT02612974) with knee osteoarthritis were completed in 2007 and 2015, respectively. Additional information on FDA-approved hirudin analogues from <italic>H. medicinalis</italic> leech saliva and hirudotherapy was reported in section <italic>Achievements With Animal Toxin-Based Molecules</italic>.</p>
        </sec>
        <sec id="s5_9_4">
          <title>Lizards</title>
          <p>Exenatide is the synthetic version of the native peptide exendin-4 isolated from the saliva of Gila monster lizard (<italic>H. suspectum</italic>) (<xref rid="B70" ref-type="bibr">Eng et&#xA0;al., 1992</xref>; <xref rid="B88" ref-type="bibr">Furman, 2012</xref>). According to the Clinical Trials website, there are more than 300 clinical studies about exenatide. So far, there are 207 completed studies, 12 terminated, 25 whose status has not changed for 2 years, 47 recruiting volunteers, 11 that are not yet recruiting, and three enrolled by invitation. Among the clinical studies, exenatide has been used in patients with Parkinson&#x2019;s disease, showing beneficial effects on nerve cells by slowing down or stopping the degenerative process of this disease (NCT03456687). For an extensive review regarding clinical trials involving this drug, please see (<xref rid="B188" ref-type="bibr">Odegard and Desantis, 2009</xref>; <xref rid="B18" ref-type="bibr">Bhavsar et&#xA0;al., 2013</xref>). Additional information on exenatide was described in section <italic>Achievements With Animal Toxin-Based Molecules</italic>.</p>
        </sec>
        <sec id="s5_9_5">
          <title>Shrews</title>
          <p>SOR-C13 is a synthetic selective peptide inhibitor of Transient Receptor Potential Vanilloid 6 (TRPV6) calcium oncochannel (<xref rid="B201" ref-type="bibr">Pennington et&#xA0;al., 2017</xref>; <xref rid="B245" ref-type="bibr">Soricimed, 2018</xref>). It is comprised of 13 amino acids derived from the C-terminal region of the paralytic peptide soricidin (UniProtKB&#x2014;P0C2P6), from the submaxillary and sublingual salivary glands of the Northern Short-tailed shrew (<italic>Blarina brevicauda</italic>) (<xref rid="B29" ref-type="bibr">Bowen et&#xA0;al., 2013</xref>; <xref rid="B86" ref-type="bibr">Fu et&#xA0;al., 2017</xref>). It inhibits the activation of nuclear factor of activated T-cell (NFAT) transcription complex, and induces apoptosis in TRPV6-overexpressing cells (<xref rid="B185" ref-type="bibr">NIH National Cancer Institute, 2018</xref>). A phase I of study (NCT01578564) in 23 advanced cancer patients with TRPV6 channel overexpression was completed in 2016 and a phase I study (NCT03784677) started recruiting patients with advanced refractory solid tumors in 2019.</p>
        </sec>
        <sec id="s5_9_6">
          <title>Ticks</title>
          <p>There are several studies addressing the importance of tick saliva components. The use of evasins in the treatment of heart diseases, such as myocarditis (<xref rid="B240" ref-type="bibr">Singh et&#xA0;al., 2017</xref>) and the use of ixolaris, an anticoagulant protein from <italic>Ixodes scapularis</italic> tick saliva, to reduce HIV-driven coagulopathy, for instance (<xref rid="B230" ref-type="bibr">Schechter et&#xA0;al., 2017</xref>).</p>
          <p>However, although tick saliva contains many components with therapeutic and biotechnological potentials, there are neither clinical studies involving the use of substances isolated from tick saliva nor drugs available for therapeutic purposes. The 101 clinical studies currently registered on the Clinical Trial website in respect to ticks are related to the development of vaccines against ticks or the use of different antibiotics in Lyme disease.</p>
        </sec>
      </sec>
    </sec>
    <sec id="s6">
      <title>Filling the Gap Between the Drug Discovery and Its Commercialization&#x2014;Future Trends</title>
      <p>Animal poisons and venoms are comprised of a cocktail of bioactive components with a gamut of different activities. Company pipelines worldwide are expanding the number of peptide-based products currently in development mainly because of the diversity of their application and activity. However, industrial production of toxin-related drugs from natural sources is quite challenging, laborious and presents restricted yield (<xref rid="B25" ref-type="bibr">Boldrini-Fran&#xE7;a et&#xA0;al., 2017</xref>). To overcome these limitations, the main options are the chemical synthesis of peptides and the production of biopharmaceuticals <italic>via</italic> heterologous expression using biotechnological tools.</p>
      <p>Recent data reinforces the advances in transcriptomics, proteomics and heterologous expression techniques, which allowed the characterization and potential production of low abundant active venom components, presenting low or high molecular mass (<xref rid="B25" ref-type="bibr">Boldrini-Fran&#xE7;a et&#xA0;al., 2017</xref>). Additionally, pharmacomics has been gaining ground by integrating &#x201C;omic&#x201D; approaches to study dynamic molecular states and monitors disease states and drug responses, improving the development of novel drugs (<xref rid="B293" ref-type="bibr">Wilson and Daly, 2018</xref>).</p>
      <p>The industry has focused on heterologous expression systems as an interesting alternative for manufacturing biopharmaceuticals of high molecular mass (<xref rid="B173" ref-type="bibr">Merlin et&#xA0;al., 2014</xref>). Recombinant protein production processes require extensive design and regulatory control before therapeutic products become commercially available. Regarding heterologous expression, the accurate cysteine bond formation and the proper incorporation of post-translational modifications remain a challenge, and new technologies to assess and mitigate immunogenicity risk of engineered proteins are becoming more common. Therefore, a special attempt should be made to ensure that the recombinant protein presents comparable three-dimensional folding and consistent pharmacological properties when compared to its corresponding native form.</p>
      <p>Native chemoselective reaction has been employed in the production of animal toxins with potential therapeutic application, such as mambalgin-2, a 57-amino acid analgesic peptide from three-finger toxins family, from <italic>Dendroaspis polylepis polylepis</italic> venom (<xref rid="B62" ref-type="bibr">Diochot et&#xA0;al., 2012</xref>; <xref rid="B107" ref-type="bibr">Harvey, 2014</xref>). This approach allows the synthesis of large proteins, since it is based in the production of different unprotected linear peptide fragments, which are condensed in solution <italic>via</italic> chemoselective reactions to originate the entire polypeptide (<xref rid="B125" ref-type="bibr">Kent et&#xA0;al., 2012</xref>). Studies to improve the protecting groups, resins, linkers, and activation and coupling reagents may enable the manufacture of larger peptides and even small proteins for therapeutic applications. However, the development of cheaper reagents and methods for the synthesis and purification of peptides are necessary.</p>
      <p>Concerning the limitations of peptides in terms of their biopharmaceutical properties, designed approaches that will find molecules with intrinsically more favorable properties will need to be devised. As mentioned earlier in section <italic>Achievements With Animal Toxin-Based Molecules</italic>, the drug design of captopril made oral administration possible. Additionally, designed cationicity-enhanced analogues of natural antimicrobial peptides have exhibited higher potency and spectra of antimicrobial activity (<xref rid="B158" ref-type="bibr">Luna-Ramirez et&#xA0;al., 2017</xref>).</p>
      <p>Achievements towards successful oral delivery of proteins and peptides by protecting them against degradation and increasing their absorption remain as an active area of research. Regarding toxin-based formulations, intranasal inoculation of hyaluronidase from <italic>T. serrulatus</italic> venom induced mononuclear increase in the bronchoalveolar space and became a promising tool for the treatment of pulmonary fibrosis (<xref rid="B22" ref-type="bibr">Bitencourt et&#xA0;al., 2011</xref>).</p>
      <p>Some approaches to improve biopharmaceuticals delivery, such as alternative delivery routes, PEGylation and conjugation to (nano)carriers, represent a relevant step towards targeted delivery of toxin-based drugs. It is sobering to realize how little alternative delivery routes and bioconjugation strategies have been exploited to deliver toxin-based drugs, suggesting that studies on routes of distribution, delivery vehicles, cargo molecules, and targeting strategies are fruitful fields for future research.</p>
      <p>Collinein-1, a thrombin-like serine protease from <italic>C. d. collilineatus</italic>, was successfully modified by site-specific PEGylation with maleimide-mPEG of 5 kDa and exhibited higher catalytic efficiency and affinity for the substrate than the native form (<xref rid="B55" ref-type="bibr">da-Silva-Freitas et&#xA0;al., 2015</xref>). The PEGylated peptide HsTX1[R14A] from <italic>Heterometrus spinnifer</italic> scorpion venom showed higher plasma circulating half-life in rodents compared to the native peptide, which resulted in sustained efficacy in rodent models of multiple sclerosis and rheumatoid arthritis (<xref rid="B256" ref-type="bibr">Tanner et&#xA0;al., 2017</xref>).</p>
      <p>In the drug development process, formulation patents using advanced drug release systems extend the market exclusivity of drugs, because of the high technical barrier to be overcome by generic manufacturers after the expiration of patents. Focusing on competitiveness, pharmaceutical companies have established strategic partnerships with leading academic institutions that have deep scientific expertise in novel concepts in the main areas of biology or chemistry. Some reports have shown the antitumor potential, among other applications, of animal venoms or their toxins conjugated with a wide variety of nanomaterials, such as silica, gold, chitosan, poly(D,L-Lactide)-based, and supermagnetic iron oxide nanoparticles (<xref rid="B11" ref-type="bibr">Badr et&#xA0;al., 2014</xref>; <xref rid="B272" ref-type="bibr">Utkin, 2017</xref>).</p>
      <p>Studies on cell penetrating peptides (CPPs) have open unprecedented possibilities for vector applications in several fields, such as basic research, therapeutics, technology, and medical imaging. CPP-Ts, the first Ca<sup>2+</sup> channel toxin from <italic>T. serrulatus</italic> venom, showed to be a potential intranuclear delivery tool to target cancerous cells (<xref rid="B57" ref-type="bibr">de Oliveira-Mendes et&#xA0;al., 2018</xref>). WaTx, a cell-penetrating toxin from the Australian black rock scorpion <italic>U. manicatus</italic>, reduced the permeability of the TRPA1 ion channel to Ca<sup>2+</sup> ions and can be used as a tool to study the mechanisms involved in chronic pain (<xref rid="B129" ref-type="bibr">King et&#xA0;al., 2019</xref>).</p>
      <p>Another field in ever-growing demand is the cosmeceutical industry, especially in Asia, where Korea is at the forefront of cosmeceutical development. Efficacy and safety studies on these products in humans are on high demand (<xref rid="B123" ref-type="bibr">Juh&#xE1;sz et&#xA0;al., 2018</xref>).</p>
    </sec>
    <sec id="s7">
      <title>Conclusion</title>
      <p>Animal poisons and venoms are rich sources of molecules with a wide range of applications. However, to make the use of these molecules feasible, extensive preclinical trials are necessary, with some applications also requiring clinical trials (<xref ref-type="fig" rid="f2">
<bold>Figure 2</bold>
</xref>).</p>
      <fig id="f2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Animal poisons and venoms as sources of candidate molecules for wide-ranging applications, after extensive characterization during preclinical and clinical trials.</p>
        </caption>
        <graphic xlink:href="fphar-11-01132-g002"/>
      </fig>
      <p>Although the research in the field of toxinology tends to be quite challenging and time-consuming, the high selectivity of animal toxins for their targets turns them into promising leads for the development of effective therapeutic drugs. Studies on new engineered molecules with reduced side effects can be reached by untangling the interaction of venom peptides with their target. Therefore, we are still at a beginning phase in comprehending the complexity of animal venoms and poisons. While very few species have been extensively studied, we still have thousands of unexploited organisms, especially marine ones. Novel methods to produce and deliver biopharmaceuticals are expected to be developed in the near future. With that in mind, we can get a glimpse of how much work on toxinology and drug discovery is yet to come in the next years.</p>
    </sec>
    <sec id="s8">
      <title>Author Contributions</title>
      <p>KB and EA contributed to the conception and design of the study. KB and EP-J wrote the first draft of the manuscript. KB, CC, EF-B, EP-J, FCe, FGA, FPA, FCo, GW, IC, IF, IO, JB-F, MP, MB, and EA wrote sections of the manuscript. FCe created the figures. KB, GW, IC, and IO created the tables. All authors contributed to manuscript revision, read, and approved the submitted version.</p>
    </sec>
    <sec sec-type="funding-information" id="s9">
      <title>Funding</title>
      <p>This study was supported by the S&#xE3;o Paulo Research Foundation (FAPESP, grants 2017/04724-4 and 2019/10173-6, and scholarships to CC 2013/26200-6, EP-J 2016/04761-4; FCe 2017/14035-1 and 2018/14158-9; GW 2017/00586-6; ISO 2017/03580-9 and 2018/21233-7; KB 2013/26619-7), the National Council for Scientific and Technological Development (CNPq, grants 306479/2017-6 and 307155/2017-0 and scholarships to FCo 155276/2018-2 and FGA 150037/2018-0) and the Coordination for the Improvement of Higher Education Personnel (Coordena&#xE7;&#xE3;o de Aperfei&#xE7;oamento de Pessoal de N&#xED;vel Superior&#x2014;Brasil, CAPES, Finance Code 001, scholarships to EP-J 88881.186830/2018-01, GW, IF, IO, and JB-F).</p>
    </sec>
    <sec id="s10">
      <title>Conflict of Interest</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abdualkader</surname><given-names>A. M.</given-names></name><name><surname>Ghawi</surname><given-names>A. M.</given-names></name><name><surname>Alaama</surname><given-names>M.</given-names></name><name><surname>Awang</surname><given-names>M.</given-names></name><name><surname>Merzouk</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Leech therapeutic applications</article-title>. <source>Indian J. Pharm. Sci.</source>
<volume>75</volume> (<issue>2</issue>), <fpage>127</fpage>. <pub-id pub-id-type="doi">10.4103/0250-474X.115456</pub-id>
<pub-id pub-id-type="pmid">24019559</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Accardo</surname><given-names>A.</given-names></name><name><surname>Galli</surname><given-names>F.</given-names></name><name><surname>Mansi</surname><given-names>R.</given-names></name><name><surname>Del Pozzo</surname><given-names>L.</given-names></name><name><surname>Aurilio</surname><given-names>M.</given-names></name><name><surname>Morisco</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for <italic>in vivo</italic> targeting of receptor-expressing tumors</article-title>. <source>EJNMMI Res.</source>
<volume>6</volume> (<issue>1</issue>):<fpage>17</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1186/s13550-016-0175-x</pub-id>
<pub-id pub-id-type="pmid">26897133</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Adis Insight</collab></person-group> (<year>2018</year>). <source>RPI-78M</source>. Available at: <uri xlink:type="simple" xlink:href="https://adisinsight.springer.com/drugs/800020844">https://adisinsight.springer.com/drugs/800020844</uri> (Accessed <date-in-citation>June 22, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Adis Insight</collab></person-group> (<year>2020</year>). <source>RPI-MN</source>. Available at: <uri xlink:type="simple" xlink:href="https://adisinsight.springer.com/drugs/800025141">https://adisinsight.springer.com/drugs/800025141</uri> (Accessed <date-in-citation>June 22, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ali</surname><given-names>M.A.A.-S.M.</given-names></name></person-group> (<year>2012</year>). <article-title>Studies on bee venom and its medical uses</article-title>. <source>Int. J. Adv. Res. Technol.</source>
<volume>1</volume> (<issue>2</issue>), <fpage>69</fpage>&#x2013;<lpage>83</lpage>.</mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alvarez-Flores</surname><given-names>M. P.</given-names></name><name><surname>Furlin</surname><given-names>D.</given-names></name><name><surname>Ramos</surname><given-names>O. H. P.</given-names></name><name><surname>Balan</surname><given-names>A.</given-names></name><name><surname>Konno</surname><given-names>K.</given-names></name><name><surname>Chudzinski-Tavassi</surname><given-names>A. M.</given-names></name></person-group> (<year>2011</year>). <article-title>Losac, the first hemolin that exhibits procogulant activity through selective factor X proteolytic activation</article-title>. <source>J. Biol. Chem.</source>
<volume>286</volume> (<issue>9</issue>), <fpage>6918</fpage>&#x2013;<lpage>6928</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1074/jbc.M110.167718</pub-id>
<pub-id pub-id-type="pmid">21177860</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alves</surname><given-names>P. L.</given-names></name><name><surname>Abdalla</surname><given-names>F. M. F.</given-names></name><name><surname>Alponti</surname><given-names>R. F.</given-names></name><name><surname>Silveira</surname><given-names>P. F.</given-names></name></person-group> (<year>2017</year>). <article-title>Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from the saliva of the Gila monster</article-title>. <source>Toxicon</source>
<volume>135</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2017.06.001</pub-id>
<pub-id pub-id-type="pmid">28579479</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andrade</surname><given-names>E.</given-names></name><name><surname>Villanova</surname><given-names>F.</given-names></name><name><surname>Borra</surname><given-names>P.</given-names></name><name><surname>Leite</surname><given-names>K.</given-names></name><name><surname>Troncone</surname><given-names>L.</given-names></name><name><surname>Cortez</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Penile erection induced <italic>in vivo</italic> by a purified toxin from the Brazilian spider <italic>Phoneutria nigriventer</italic>
</article-title>. <source>BJU Int.</source>
<volume>102</volume> (<issue>7</issue>), <fpage>835</fpage>&#x2013;<lpage>857</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/j.1464-410X.2008.07762.x</pub-id>
<pub-id pub-id-type="pmid">18537953</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arocha-Pinango</surname><given-names>C. L.</given-names></name><name><surname>Guerrero</surname><given-names>B.</given-names></name></person-group> (<year>2001</year>). <article-title>
<italic>Lonomia</italic> genus caterpillar envenomation: Clinical and biological aspects</article-title>. <source>Haemostasis</source>
<volume>31</volume> (<issue>3-6</issue>), <fpage>288</fpage>&#x2013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1159/000048075</pub-id>
<pub-id pub-id-type="pmid">11910197</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Assuncao</surname><given-names>J.</given-names></name><name><surname>Guedes</surname><given-names>A. C.</given-names></name><name><surname>Malcata</surname><given-names>F. X.</given-names></name></person-group> (<year>2017</year>). <article-title>Biotechnological and pharmacological applications of biotoxins and other bioactive molecules from dinoflagellates</article-title>. <source>Mar. Drugs</source>
<volume>15</volume> (<issue>12</issue>), <fpage>393</fpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/md15120393</pub-id>
</mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Badr</surname><given-names>G.</given-names></name><name><surname>Sayed</surname><given-names>D.</given-names></name><name><surname>Maximous</surname><given-names>D.</given-names></name><name><surname>Mohamed</surname><given-names>A. O.</given-names></name><name><surname>Gul</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Increased susceptibility to apoptosis and growth arrest of human breast cancer cells treated by a snake venom-loaded silica nanoparticles</article-title>. <source>Cell Physiol. Biochem.</source>
<volume>34</volume> (<issue>5</issue>), <fpage>1640</fpage>&#x2013;<lpage>1651</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1159/000366366</pub-id>
<pub-id pub-id-type="pmid">25401286</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baratto</surname><given-names>L.</given-names></name><name><surname>Jadvar</surname><given-names>H.</given-names></name><name><surname>Iagaru</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Prostate cancer theranostics targeting gastrin-releasing peptide receptors</article-title>. <source>Mol. Imaging Biol.</source>
<volume>20</volume> (<issue>4</issue>), <fpage>501</fpage>&#x2013;<lpage>509</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s11307-017-1151-1</pub-id>
<pub-id pub-id-type="pmid">29256046</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barros</surname><given-names>L. C.</given-names></name><name><surname>Ferreira</surname><given-names>R. S.</given-names><suffix>Jr.</suffix></name><name><surname>Barraviera</surname><given-names>S. R. C. S.</given-names></name><name><surname>Stolf</surname><given-names>H. O.</given-names></name><name><surname>Thomazini-Santos</surname><given-names>I. A.</given-names></name><name><surname>Mendes-Giannini</surname><given-names>M. J. S.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>A new fibrin sealant from <italic>Crotalus durissus terrificus</italic> venom: applications in medicine</article-title>. <source>J. Toxicol. Environ. Health B Crit. Rev.</source>
<volume>12</volume> (<issue>8</issue>), <fpage>553</fpage>&#x2013;<lpage>571</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1080/10937400903442514</pub-id>
<pub-id pub-id-type="pmid">20183534</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Bastos</surname><given-names>E. M. A. F.</given-names></name><name><surname>Heneine</surname><given-names>L. G. D.</given-names></name><name><surname>Pesquero</surname><given-names>J. L.</given-names></name><name><surname>Merlo</surname><given-names>L. A.</given-names></name></person-group> (<year>2011</year>). <source>Pharmaceutical composition containing an Apitoxin fraction and use thereof</source>, WO/2011/041865 patent application.</mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Bayer Healthcare</collab></person-group> (<year>2012</year>). <source>Discontinuation of Refludan&#xAE;&#xA0;[lepirudin (rDNA) for injection]</source>. Available at: <uri xlink:type="simple" xlink:href="https://www.hrsa.gov/sites/default/files/opa/programrequirements/manufacturerletters/2012/refludan05312012.pdf">https://www.hrsa.gov/sites/default/files/opa/programrequirements/manufacturerletters/2012/refludan05312012.pdf</uri> (Accessed <date-in-citation>March 19, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beeton</surname><given-names>C.</given-names></name><name><surname>Wulff</surname><given-names>H.</given-names></name><name><surname>Standifer</surname><given-names>N. E.</given-names></name><name><surname>Azam</surname><given-names>P.</given-names></name><name><surname>Mullen</surname><given-names>K. M.</given-names></name><name><surname>Pennington</surname><given-names>M. W.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>103</volume> (<issue>46</issue>), <fpage>17414</fpage>&#x2013;<lpage>17419</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1073/pnas.0605136103</pub-id>
<pub-id pub-id-type="pmid">17088564</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Beeton</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>). &#x201C;<article-title>Targets and therapeutic properties</article-title>,&#x201D; in <source>Handbook of biologically active peptides</source>, <edition>2nd ed.</edition> Ed. <person-group person-group-type="editor"><name><surname>Kastin</surname><given-names>A. J.</given-names></name></person-group> (<publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>), <fpage>473</fpage>&#x2013;<lpage>482</lpage>.</mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhavsar</surname><given-names>S.</given-names></name><name><surname>Mudaliar</surname><given-names>S.</given-names></name><name><surname>Cherrington</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Evolution of exenatide as a diabetes therapeutic</article-title>. <source>Curr. Diabetes Rev.</source>
<volume>9</volume> (<issue>2</issue>), <fpage>161</fpage>&#x2013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.2174/1573399811309020007</pub-id>
<pub-id pub-id-type="pmid">23256660</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Biocentury</collab></person-group> (<year>2007</year>). <source>Pepteron (RPI-MN)</source>. Available at: <uri xlink:type="simple" xlink:href="https://bciq.biocentury.com/products/pepteron_(rpi-mn)">https://bciq.biocentury.com/products/pepteron_(rpi-mn)</uri> (Accessed <date-in-citation>March 19, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Biollaz</surname><given-names>J.</given-names></name><name><surname>Burnier</surname><given-names>M.</given-names></name><name><surname>Turini</surname><given-names>G. A.</given-names></name><name><surname>Brunner</surname><given-names>D. B.</given-names></name><name><surname>Porchet</surname><given-names>M.</given-names></name><name><surname>Gomez</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>1981</year>). <article-title>Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I</article-title>. <source>Clin. Pharmacol. Ther.</source>
<volume>29</volume> (<issue>5</issue>), <fpage>665</fpage>&#x2013;<lpage>670</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.1981.92</pub-id>
<pub-id pub-id-type="pmid">6260419</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Biozeus Biopharmaceutical SA</collab></person-group> (<year>2018</year>). <source>First clinical trial sponsored by Biozeus concluded!</source>. Available at: <uri xlink:type="simple" xlink:href="http://biozeus.com.br/first-clinical-trial-sponsored-by-biozeus-concluded/">http://biozeus.com.br/first-clinical-trial-sponsored-by-biozeus-concluded/</uri> (Accessed <date-in-citation>March 29, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bitencourt</surname><given-names>C. S.</given-names></name><name><surname>Pereira</surname><given-names>P. A.</given-names></name><name><surname>Ramos</surname><given-names>S. G.</given-names></name><name><surname>Sampaio</surname><given-names>S. V.</given-names></name><name><surname>Arantes</surname><given-names>E. C.</given-names></name><name><surname>Aronoff</surname><given-names>D. M.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Hyaluronidase recruits mesenchymal-like cells to the lung and ameliorates fibrosis</article-title>. <source>Fibrogenesis Tissue Repair</source>
<volume>4</volume>(<issue>1</issue>), <fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/1755-1536-4-3</pub-id>
<pub-id pub-id-type="pmid">21232095</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bittl</surname><given-names>J. A.</given-names></name><name><surname>Chaitman</surname><given-names>B. R.</given-names></name><name><surname>Feit</surname><given-names>F.</given-names></name><name><surname>Kimball</surname><given-names>W.</given-names></name><name><surname>Topol</surname><given-names>E. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study</article-title>. <source>Am. Heart J.</source>
<volume>142</volume> (<issue>6</issue>), <fpage>952</fpage>&#x2013;<lpage>959</lpage>. <pub-id pub-id-type="doi">10.1067/mhj.2001.119374</pub-id>
<pub-id pub-id-type="pmid">11717596</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boldrini-Fran&#xE7;a</surname><given-names>J.</given-names></name><name><surname>Santos Rodrigues</surname><given-names>R.</given-names></name><name><surname>Santos-Silva</surname><given-names>L. K.</given-names></name><name><surname>de Souza</surname><given-names>D. L.</given-names></name><name><surname>Gomes</surname><given-names>M. S.</given-names></name><name><surname>Cologna</surname><given-names>C. T.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Expression of a new serine protease from C<italic>rotalus durissus collilineatus v</italic>enom in P<italic>ichia pastoris</italic> and functional comparison with the native enzyme</article-title>. <source>Appl. Microbiol. Biotechnol.</source>
<volume>99</volume> (<issue>23</issue>), <fpage>9971</fpage>&#x2013;<lpage>9986</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s00253-015-6836-2</pub-id>
<pub-id pub-id-type="pmid">26227411</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boldrini-Fran&#xE7;a</surname><given-names>J.</given-names></name><name><surname>Cologna</surname><given-names>C. T.</given-names></name><name><surname>Pucca</surname><given-names>M. B.</given-names></name><name><surname>Bordon</surname><given-names>K. C. F.</given-names></name><name><surname>Amorim</surname><given-names>F. G.</given-names></name><name><surname>Anjolette</surname><given-names>F. A. P.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Minor snake venom proteins: Structure, function and potential applications</article-title>. <source>Biochim. Biophys. Acta Gen. Subj.</source>
<volume>1861</volume> (<issue>4</issue>), <fpage>824</fpage>&#x2013;<lpage>838</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.bbagen.2016.12.022</pub-id>
<pub-id pub-id-type="pmid">28012742</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boldrini-Franca</surname><given-names>J.</given-names></name><name><surname>Pinheiro-Junior</surname><given-names>E. L.</given-names></name><name><surname>Arantes</surname><given-names>E. C.</given-names></name></person-group> (<year>2019</year>). <article-title>Functional and biological insights of rCollinein-1, a recombinant serine protease from C<italic>rotalus durissus collilineatus</italic>
</article-title>. <source>J. Venom. Anim. Toxins Incl. Trop. Dis.</source>
<volume>25</volume>, <fpage>e147118</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1590/1678-9199-jvatitd-1741-18</pub-id>
<pub-id pub-id-type="pmid">31131001</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boldrini-Fran&#xE7;a</surname><given-names>J.</given-names></name><name><surname>Pinheiro-Junior</surname><given-names>E. L.</given-names></name><name><surname>Peigneur</surname><given-names>S.</given-names></name><name><surname>Pucca</surname><given-names>M. B.</given-names></name><name><surname>Cerni</surname><given-names>F. A.</given-names></name><name><surname>Borges</surname><given-names>R. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Beyond hemostasis: a snake venom serine protease with potassium channel blocking and potential antitumor activities</article-title>. <source>Sci. Rep.</source>
<volume>10</volume>, 4476 (<issue>2020</issue>). &#xA0;<pub-id pub-id-type="doi">10.1038/s41598-020-61258-x</pub-id>
</mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bonifazi</surname><given-names>F.</given-names></name><name><surname>Jutel</surname><given-names>M.</given-names></name><name><surname>Bilo</surname><given-names>B. M.</given-names></name><name><surname>Birnbaum</surname><given-names>J.</given-names></name><name><surname>Muller</surname><given-names>U.</given-names></name><name><surname>Hy</surname><given-names>E.I.G.I.V.</given-names></name></person-group> (<year>2005</year>). <article-title>Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice</article-title>. <source>Allergy</source>
<volume>60</volume> (<issue>12</issue>), <fpage>1459</fpage>&#x2013;<lpage>1470</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/j.1398-9995.2005.00960.x</pub-id>
<pub-id pub-id-type="pmid">16266376</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bowen</surname><given-names>C. V.</given-names></name><name><surname>DeBay</surname><given-names>D.</given-names></name><name><surname>Ewart</surname><given-names>H. S.</given-names></name><name><surname>Gallant</surname><given-names>P.</given-names></name><name><surname>Gormley</surname><given-names>S.</given-names></name><name><surname>Ilenchuk</surname><given-names>T. T.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>I<italic>n vivo</italic> detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin</article-title>. <source>PloS One</source>
<volume>8</volume> (<issue>3</issue>), <elocation-id>e58866</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1371/journal.pone.0058866</pub-id>
<pub-id pub-id-type="pmid">23554944</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braud</surname><given-names>S.</given-names></name><name><surname>Bon</surname><given-names>C.</given-names></name><name><surname>Wisner</surname><given-names>A.</given-names></name></person-group> (<year>2000</year>). <article-title>Snake venom proteins acting on hemostasis</article-title>. <source>Biochimie</source>
<volume>82</volume> (<issue>9-10</issue>), <fpage>851</fpage>&#x2013;<lpage>859</lpage>. <pub-id pub-id-type="doi">10.1016/S0300-9084(00)01178-0</pub-id>
<pub-id pub-id-type="pmid">11086215</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bressan</surname><given-names>E.</given-names></name><name><surname>Touska</surname><given-names>F.</given-names></name><name><surname>Vetter</surname><given-names>I.</given-names></name><name><surname>Kistner</surname><given-names>K.</given-names></name><name><surname>Kichko</surname><given-names>T. I.</given-names></name><name><surname>Teixeira</surname><given-names>N. B.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Crotalphine desensitizes TRPA1 ion channels to alleviate inflammatory hyperalgesia</article-title>. <source>Pain</source>
<volume>157</volume> (<issue>11</issue>), <fpage>2504</fpage>&#x2013;<lpage>2516</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1097/j.pain.0000000000000669</pub-id>
<pub-id pub-id-type="pmid">27434506</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brigatte</surname><given-names>P.</given-names></name><name><surname>Konno</surname><given-names>K.</given-names></name><name><surname>Gutierrez</surname><given-names>V. P.</given-names></name><name><surname>Sampaio</surname><given-names>S. C.</given-names></name><name><surname>Zambelli</surname><given-names>V. O.</given-names></name><name><surname>Picolo</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Peripheral kappa and delta opioid receptors are involved in the antinociceptive effect of crotalphine in a rat model of cancer pain</article-title>. <source>Pharmacol. Biochem. Behav.</source>
<volume>109</volume>, <fpage>1</fpage>&#x2013;<lpage>7</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.pbb.2013.04.012</pub-id>
<pub-id pub-id-type="pmid">23628488</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brinkhous</surname><given-names>K. M.</given-names></name><name><surname>Read</surname><given-names>M. S.</given-names></name><name><surname>Fricke</surname><given-names>W. A.</given-names></name><name><surname>Wagner</surname><given-names>R. H.</given-names></name></person-group> (<year>1983</year>). <article-title>Botrocetin (venom coagglutinin) - Reaction with a broad-spectrum of multimeric forms of factor VIII macromolecular complex</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A. -Biol. Sci.</source>
<volume>80</volume> (<issue>5</issue>), <fpage>1463</fpage>&#x2013;<lpage>1466</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1073/pnas.80.5.1463</pub-id>
</mixed-citation>
      </ref>
      <ref id="B34">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brogden</surname><given-names>R. N.</given-names></name><name><surname>Todd</surname><given-names>P. A.</given-names></name><name><surname>Sorkin</surname><given-names>E. M.</given-names></name></person-group> (<year>1988</year>). <article-title>Captopril - an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart-failure</article-title>. <source>Drugs</source>
<volume>36</volume> (<issue>5</issue>), <fpage>540</fpage>&#x2013;<lpage>600</lpage>. &#xA0;<pub-id pub-id-type="doi">10.2165/00003495-198836050-00003</pub-id>
<pub-id pub-id-type="pmid">3063499</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brust</surname><given-names>A.</given-names></name><name><surname>Palant</surname><given-names>E.</given-names></name><name><surname>Croker</surname><given-names>D. E.</given-names></name><name><surname>Colless</surname><given-names>B.</given-names></name><name><surname>Drinkwater</surname><given-names>R.</given-names></name><name><surname>Patterson</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>&#x3C7;-conopeptide pharmacophore development: toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain</article-title>. <source>J. Med. Chem.</source>
<volume>52</volume> (<issue>22</issue>), <fpage>6991</fpage>&#x2013;<lpage>7002</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1021/jm9003413</pub-id>
<pub-id pub-id-type="pmid">19860431</pub-id></mixed-citation>
      </ref>
      <ref id="B36">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buchaim</surname><given-names>D. V.</given-names></name><name><surname>Cassaro</surname><given-names>C. V.</given-names></name><name><surname>Shindo</surname><given-names>J.</given-names></name><name><surname>Della Coletta</surname><given-names>B. B.</given-names></name><name><surname>Pomini</surname><given-names>K. T.</given-names></name><name><surname>Rosso</surname><given-names>M. P. D.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Unique heterologous fibrin biopolymer with hemostatic, adhesive, sealant, scaffold and drug delivery properties: a systematic review</article-title>. <source>J. Venom. Anim. Toxins Incl. Trop. Dis.</source>
<volume>25</volume>, <fpage>e20190038</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1590/1678-9199-jvatitd-2019-0038</pub-id>
<pub-id pub-id-type="pmid">31839802</pub-id></mixed-citation>
      </ref>
      <ref id="B37">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burkhart</surname><given-names>W.</given-names></name><name><surname>Smith</surname><given-names>G. F.</given-names></name><name><surname>Su</surname><given-names>J. L.</given-names></name><name><surname>Parikh</surname><given-names>I.</given-names></name><name><surname>LeVine</surname><given-names>H.</given-names></name></person-group> (<year>1992</year>). <article-title>Amino acid sequence determination of ancrod, the thrombin-like alpha-fibrinogenase from the venom of A<italic>gkistrodon rhodostoma</italic>
</article-title>. <source>FEBS Lett.</source>
<volume>297</volume> (<issue>3</issue>), <fpage>297</fpage>&#x2013;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1016/0014-5793(92)80559-Y</pub-id>
<pub-id pub-id-type="pmid">1544412</pub-id></mixed-citation>
      </ref>
      <ref id="B38">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butte</surname><given-names>P. V.</given-names></name><name><surname>Mamelak</surname><given-names>A.</given-names></name><name><surname>Parrish-Novak</surname><given-names>J.</given-names></name><name><surname>Drazin</surname><given-names>D.</given-names></name><name><surname>Shweikeh</surname><given-names>F.</given-names></name><name><surname>Gangalum</surname><given-names>P. R.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Near-infrared imaging of brain tumors using the Tumor Paint BLZ-100 to achieve near-complete resection of brain tumors</article-title>. <source>Neurosurg. Focus</source>
<volume>36</volume> (<issue>2</issue>), <fpage>E1</fpage>. &#xA0;<pub-id pub-id-type="doi">10.3171/2013.11.FOCUS13497</pub-id>
</mixed-citation>
      </ref>
      <ref id="B39">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Camargo</surname><given-names>A. C. M.</given-names></name><name><surname>Ianzer</surname><given-names>D.</given-names></name><name><surname>Guerreiro</surname><given-names>J. R.</given-names></name><name><surname>Serrano</surname><given-names>S. M. T.</given-names></name></person-group> (<year>2012</year>). <article-title>Bradykinin-potentiating peptides: Beyond captopril</article-title>. <source>Toxicon</source>
<volume>59</volume> (<issue>4</issue>), <fpage>516</fpage>&#x2013;<lpage>523</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2011.07.013</pub-id>
<pub-id pub-id-type="pmid">21835190</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carmo</surname><given-names>A. C. V.</given-names></name><name><surname>Yamasaki</surname><given-names>L. H. T.</given-names></name><name><surname>Figueiredo</surname><given-names>C. A.</given-names></name><name><surname>Giovanni</surname><given-names>D.</given-names></name><name><surname>de Oliveira</surname><given-names>M. I.</given-names></name><name><surname>dos Santos</surname><given-names>F. C. P.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Discovery of a new antiviral protein isolated L<italic>onomia obliqua</italic> analysed by bioinformatics and real-time approaches</article-title>. <source>Cytotechnology</source>
<volume>67</volume> (<issue>6</issue>), <fpage>1011</fpage>&#x2013;<lpage>1022</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s10616-014-9740-1</pub-id>
<pub-id pub-id-type="pmid">24908059</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cescato</surname><given-names>R.</given-names></name><name><surname>Maina</surname><given-names>T.</given-names></name><name><surname>Nock</surname><given-names>B.</given-names></name><name><surname>Nikolopoulou</surname><given-names>A.</given-names></name><name><surname>Charalambidis</surname><given-names>D.</given-names></name><name><surname>Piccand</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Bombesin receptor antagonists may be preferable to agonists for tumor targeting</article-title>. <source>J. Nucl. Med.</source>
<volume>49</volume> (<issue>2</issue>), <fpage>318</fpage>&#x2013;<lpage>326</lpage>. &#xA0;<pub-id pub-id-type="doi">10.2967/jnumed.107.045054</pub-id>
<pub-id pub-id-type="pmid">18199616</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chan</surname><given-names>Y. S.</given-names></name><name><surname>Cheung</surname><given-names>R. C.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name><name><surname>Wong</surname><given-names>J. H.</given-names></name><name><surname>Ng</surname><given-names>T. B.</given-names></name><name><surname>Chan</surname><given-names>W. Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Snake venom toxins: toxicity and medicinal applications</article-title>. <source>Appl. Microbiol. Biotechnol.</source>
<volume>100</volume> (<issue>14</issue>), <fpage>6165</fpage>&#x2013;<lpage>6181</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s00253-016-7610-9</pub-id>
<pub-id pub-id-type="pmid">27245678</pub-id></mixed-citation>
      </ref>
      <ref id="B43">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>C. T.</given-names></name><name><surname>Fong</surname><given-names>S. W.</given-names></name><name><surname>Lee</surname><given-names>C. H.</given-names></name><name><surname>Chuang</surname><given-names>Y. C.</given-names></name><name><surname>Lin</surname><given-names>S. H.</given-names></name><name><surname>Chen</surname><given-names>C. C.</given-names></name></person-group> (<year>2019</year>). <article-title>Involvement of acid-sensing ion channel 1b in the development of acid-induced chronic muscle pain</article-title>. <source>Front. Neurosci.</source>
<volume>13</volume>:<elocation-id>1247</elocation-id>:<elocation-id>1247</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.3389/fnins.2019.01247</pub-id>
<pub-id pub-id-type="pmid">31824248</pub-id></mixed-citation>
      </ref>
      <ref id="B44">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chassagnon</surname><given-names>I. R.</given-names></name><name><surname>McCarthy</surname><given-names>C. A.</given-names></name><name><surname>Chin</surname><given-names>Y. K. Y.</given-names></name><name><surname>Pineda</surname><given-names>S. S.</given-names></name><name><surname>Keramidas</surname><given-names>A.</given-names></name><name><surname>Mobli</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>114</volume> (<issue>14</issue>), <fpage>3750</fpage>&#x2013;<lpage>3755</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1073/pnas.1614728114</pub-id>
<pub-id pub-id-type="pmid">28320941</pub-id></mixed-citation>
      </ref>
      <ref id="B45">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>C. W.</given-names></name><name><surname>Hu</surname><given-names>Y. Q.</given-names></name><name><surname>Shi</surname><given-names>X. W.</given-names></name><name><surname>Tao</surname><given-names>C. H.</given-names></name><name><surname>Zheng</surname><given-names>H. Y.</given-names></name><name><surname>Fei</surname><given-names>W. D.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>A single-label fluorescent derivatization method for quantitative determination of neurotoxin i<italic>n vivo</italic> by capillary electrophoresis coupled with laser-induced fluorescence detection</article-title>. <source>Analyst</source>
<volume>141</volume> (<issue>14</issue>), <fpage>4495</fpage>&#x2013;<lpage>4501</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1039/c6an00327c</pub-id>
<pub-id pub-id-type="pmid">27175860</pub-id></mixed-citation>
      </ref>
      <ref id="B46">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chow</surname><given-names>S. C.</given-names></name><name><surname>Chang</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Adaptive design methods in clinical trials - a review</article-title>. <source>Orphanet J. Rare Dis.</source>
<volume>3</volume>, <fpage>11</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1186/1750-1172-3-11</pub-id>
<pub-id pub-id-type="pmid">18454853</pub-id></mixed-citation>
      </ref>
      <ref id="B47">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Christensen</surname><given-names>M.</given-names></name><name><surname>Knop</surname><given-names>F. K.</given-names></name><name><surname>Holst</surname><given-names>J. J.</given-names></name><name><surname>Vilsboll</surname><given-names>T.</given-names></name></person-group> (<year>2009</year>). <article-title>Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus</article-title>. <source>Idrugs</source>
<volume>12</volume> (<issue>8</issue>), <fpage>503</fpage>&#x2013;<lpage>513</lpage>.<pub-id pub-id-type="pmid">19629885</pub-id></mixed-citation>
      </ref>
      <ref id="B48">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clark</surname><given-names>R. J.</given-names></name><name><surname>Jensen</surname><given-names>J.</given-names></name><name><surname>Nevin</surname><given-names>S. T.</given-names></name><name><surname>Callaghan</surname><given-names>B. P.</given-names></name><name><surname>Adams</surname><given-names>D. J.</given-names></name><name><surname>Craik</surname><given-names>D. J.</given-names></name></person-group> (<year>2010</year>). <article-title>The engineering of an orally active conotoxin for the treatment of neuropathic pain</article-title>. <source>Angew. Chem. Int. Ed</source>
<volume>49</volume> (<issue>37</issue>), <fpage>6545</fpage>&#x2013;<lpage>6548</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/anie.201000620</pub-id>
</mixed-citation>
      </ref>
      <ref id="B49">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clark</surname><given-names>G. C.</given-names></name><name><surname>Casewell</surname><given-names>N. R.</given-names></name><name><surname>Elliott</surname><given-names>C. T.</given-names></name><name><surname>Harvey</surname><given-names>A. L.</given-names></name><name><surname>Jamieson</surname><given-names>A. G.</given-names></name><name><surname>Strong</surname><given-names>P. N.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Friends or foes? Emerging impacts of biological toxins</article-title>. <source>Trends Biochem. Sci.</source>
<volume>44</volume> (<issue>4</issue>), <fpage>365</fpage>&#x2013;<lpage>379</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.tibs.2018.12.004</pub-id>
<pub-id pub-id-type="pmid">30651181</pub-id></mixed-citation>
      </ref>
      <ref id="B50">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cohen-Inbar</surname><given-names>O.</given-names></name><name><surname>Zaaroor</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Glioblastoma multiforme targeted therapy: The Chlorotoxin story</article-title>. <source>J. Clin. Neurosci.</source>
<volume>33</volume>, <fpage>52</fpage>&#x2013;<lpage>58</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jocn.2016.04.012</pub-id>
<pub-id pub-id-type="pmid">27452128</pub-id></mixed-citation>
      </ref>
      <ref id="B51">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cooper</surname><given-names>E. L.</given-names></name><name><surname>Mologne</surname><given-names>N.</given-names></name></person-group> (<year>2017</year>). <article-title>Exploiting leech saliva to treat osteoarthritis: A provocative perspective</article-title>. <source>J. Tradit. Complement Med.</source>
<volume>7</volume> (<issue>3</issue>), <fpage>367</fpage>&#x2013;<lpage>369</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jtcme.2016.11.005</pub-id>
<pub-id pub-id-type="pmid">28725633</pub-id></mixed-citation>
      </ref>
      <ref id="B52">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cushman</surname><given-names>D. W.</given-names></name><name><surname>Cheung</surname><given-names>H. S.</given-names></name><name><surname>Sabo</surname><given-names>E. F.</given-names></name><name><surname>Ondetti</surname><given-names>M. A.</given-names></name></person-group> (<year>1977</year>). <article-title>Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids</article-title>. <source>Biochemistry</source>
<volume>16</volume> (<issue>25</issue>), <fpage>5484</fpage>&#x2013;<lpage>5491</lpage>. <pub-id pub-id-type="doi">10.1021/bi00644a014</pub-id>
<pub-id pub-id-type="pmid">200262</pub-id></mixed-citation>
      </ref>
      <ref id="B53">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Daly</surname><given-names>J.</given-names></name></person-group> (<year>2004</year>). <source>Chlorine compound of the month: Eptibatidine - natural frog poison with a surprising benefit to humans</source>. Available at: <uri xlink:type="simple" xlink:href="https://chlorine.americanchemistry.com/Science-Center/Chlorine-Compound-of-the-Month-Library/Epibatidine-Natural-Frog-Poison-with-a-Surprising-Benefit-to-Humans/">https://chlorine.americanchemistry.com/Science-Center/Chlorine-Compound-of-the-Month-Library/Epibatidine-Natural-Frog-Poison-with-a-Surprising-Benefit-to-Humans/</uri> (Accessed <date-in-citation>March 19, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B54">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Das Gupta</surname><given-names>S.</given-names></name><name><surname>Debnath</surname><given-names>A.</given-names></name><name><surname>Saha</surname><given-names>A.</given-names></name><name><surname>Giri</surname><given-names>B.</given-names></name><name><surname>Tripathi</surname><given-names>G.</given-names></name><name><surname>Vedasiromoni</surname><given-names>J. R.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Indian black scorpion (H<italic>eterometrus bengalensis</italic> Koch) venom induced antiproliferative and apoptogenic activity against human leukemic cell lines U937 and K562</article-title>. <source>Leuk. Res.</source>
<volume>31</volume> (<issue>6</issue>), <fpage>817</fpage>&#x2013;<lpage>825</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.leukres.2006.06.004</pub-id>
<pub-id pub-id-type="pmid">16876244</pub-id></mixed-citation>
      </ref>
      <ref id="B55">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>da-Silva-Freitas</surname><given-names>D.</given-names></name><name><surname>Boldrini-Franca</surname><given-names>J.</given-names></name><name><surname>Arantes</surname><given-names>E. C.</given-names></name></person-group> (<year>2015</year>). <article-title>PEGylation: A successful approach to improve the biopharmaceutical potential of snake venom thrombin-like serine protease</article-title>. <source>Protein Pept. Lett.</source>
<volume>22</volume> (<issue>12</issue>), <fpage>1133</fpage>&#x2013;<lpage>1139</lpage>. &#xA0;<pub-id pub-id-type="doi">10.2174/0929866522666151013130742</pub-id>
<pub-id pub-id-type="pmid">26458403</pub-id></mixed-citation>
      </ref>
      <ref id="B56">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Azevedo</surname><given-names>R. A.</given-names></name><name><surname>Figueiredo</surname><given-names>C. R.</given-names></name><name><surname>Ferreira</surname><given-names>A. K.</given-names></name><name><surname>Matsuo</surname><given-names>A. L.</given-names></name><name><surname>Massaoka</surname><given-names>M. H.</given-names></name><name><surname>Girola</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Mastoparan induces apoptosis in B1 6F10-Nex2 melanoma cells via the intrinsic mitochondrial pathway and displays antitumor activity i<italic>n vivo</italic>
</article-title>. <source>Peptides</source>
<volume>68</volume>, <fpage>113</fpage>&#x2013;<lpage>119</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.peptides.2014.09.024</pub-id>
<pub-id pub-id-type="pmid">25305549</pub-id></mixed-citation>
      </ref>
      <ref id="B57">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Oliveira-Mendes</surname><given-names>B. B. R.</given-names></name><name><surname>Horta</surname><given-names>C. C. R.</given-names></name><name><surname>do Carmo</surname><given-names>A. O.</given-names></name><name><surname>Biscoto</surname><given-names>G. L.</given-names></name><name><surname>Sales-Medina</surname><given-names>D. F.</given-names></name><name><surname>Leal</surname><given-names>H. G.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>CPP-Ts: a new intracellular calcium channel modulator and a promising tool for drug delivery in cancer cells</article-title>. <source>Sci. Rep.</source>
<volume>8</volume>, <fpage>14739</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1038/s41598-018-33133-3</pub-id>
<pub-id pub-id-type="pmid">30282983</pub-id></mixed-citation>
      </ref>
      <ref id="B58">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeBin</surname><given-names>J. A.</given-names></name><name><surname>Strichartz</surname><given-names>G. R.</given-names></name></person-group> (<year>1991</year>). <article-title>Chloride channel inhibition by the venom of the scorpion L<italic>eiurus quinquestriatus</italic>
</article-title>. <source>Toxicon</source>
<volume>29</volume> (<issue>11</issue>), <fpage>1403</fpage>&#x2013;<lpage>1408</lpage>. <pub-id pub-id-type="doi">10.1016/0041-0101(91)90128-E</pub-id>
<pub-id pub-id-type="pmid">1726031</pub-id></mixed-citation>
      </ref>
      <ref id="B59">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeBin</surname><given-names>J. A.</given-names></name><name><surname>Maggio</surname><given-names>J. E.</given-names></name><name><surname>Strichartz</surname><given-names>G. R.</given-names></name></person-group> (<year>1993</year>). <article-title>Purification and characterization of chlorotoxin, a chloride channel ligand from the venom of the scorpion</article-title>. <source>Am. J. Physiol.</source>
<volume>264</volume> (<issue>2 Pt 1</issue>), <fpage>C361</fpage>&#x2013;<lpage>C369</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.1993.264.2.C361</pub-id>
<pub-id pub-id-type="pmid">8383429</pub-id></mixed-citation>
      </ref>
      <ref id="B60">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeYoung</surname><given-names>M. B.</given-names></name><name><surname>MacConell</surname><given-names>L.</given-names></name><name><surname>Sarin</surname><given-names>V.</given-names></name><name><surname>Trautmann</surname><given-names>M.</given-names></name><name><surname>Herbert</surname><given-names>P.</given-names></name></person-group> (<year>2011</year>). <article-title>Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes</article-title>. <source>Diabetes Technol. Ther.</source>
<volume>13</volume> (<issue>11</issue>), <fpage>1145</fpage>&#x2013;<lpage>1154</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1089/dia.2011.0050</pub-id>
<pub-id pub-id-type="pmid">21751887</pub-id></mixed-citation>
      </ref>
      <ref id="B61">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Chua</surname><given-names>P. J.</given-names></name><name><surname>Bay</surname><given-names>B. H.</given-names></name><name><surname>Gopalakrishnakone</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>Scorpion venoms as a potential source of novel cancer therapeutic compounds</article-title>. <source>Exp. Biol. Med. (Maywood)</source>
<volume>239</volume> (<issue>4</issue>), <fpage>387</fpage>&#x2013;<lpage>393</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1177/1535370213513991</pub-id>
<pub-id pub-id-type="pmid">24599885</pub-id></mixed-citation>
      </ref>
      <ref id="B62">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diochot</surname><given-names>S.</given-names></name><name><surname>Baron</surname><given-names>A.</given-names></name><name><surname>Salinas</surname><given-names>M.</given-names></name><name><surname>Douguet</surname><given-names>D.</given-names></name><name><surname>Scarzello</surname><given-names>S.</given-names></name><name><surname>Dabert-Gay</surname><given-names>A. S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Black mamba venom peptides target acid-sensing ion channels to abolish pain</article-title>. <source>Nature</source>
<volume>490</volume> (<issue>7421</issue>), <fpage>552</fpage>&#x2013;<lpage>555</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1038/nature11494</pub-id>
<pub-id pub-id-type="pmid">23034652</pub-id></mixed-citation>
      </ref>
      <ref id="B63">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dodt</surname><given-names>J.</given-names></name><name><surname>M&#xFC;ller</surname><given-names>H.-P.</given-names></name><name><surname>Seem&#xFC;ller</surname><given-names>U.</given-names></name><name><surname>Chang</surname><given-names>J.-Y.</given-names></name></person-group> (<year>1984</year>). <article-title>The complete amino acid sequence of hirudin, a thrombin specific inhibitor. Application of colour carboxymethylation</article-title>. <source>FEBS</source>
<volume>165</volume> (<issue>2</issue>), <fpage>180</fpage>&#x2013;<lpage>184</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/0014-5793(84)80165-9</pub-id>
</mixed-citation>
      </ref>
      <ref id="B64">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Drug discovery and development</collab></person-group> (<year>2016</year>). <source>Nutra Pharma announces manufacturing alliance with Omnia Biologics to produce RPI-78M for clinical trials in pediatric multiple sclerosis</source>. Available at: <uri xlink:type="simple" xlink:href="https://www.drugdiscoverytrends.com/nutra-pharma-omnias-manufacturing-alliance-to-produce-pediatric-ms-treatment/">https://www.drugdiscoverytrends.com/nutra-pharma-omnias-manufacturing-alliance-to-produce-pediatric-ms-treatment/</uri> (Accessed <date-in-citation>March 19, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B65">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Drugs.com</collab></person-group> (<year>2020</year>). <source>Search</source>. Available at: <uri xlink:type="simple" xlink:href="https://www.drugs.com/">https://www.drugs.com/</uri> (Accessed <date-in-citation>June 25, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B66">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duran-Riveroll</surname><given-names>L. M.</given-names></name><name><surname>Cembella</surname><given-names>A. D.</given-names></name></person-group> (<year>2017</year>). <article-title>Guanidinium toxins and their interactions with voltage-gated sodium ion channels</article-title>. <source>Mar Drugs</source>
<volume>15</volume> (<issue>10</issue>), <fpage>303</fpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/md15100303</pub-id>
</mixed-citation>
      </ref>
      <ref id="B67">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duskey</surname><given-names>J. T.</given-names></name><name><surname>Belletti</surname><given-names>D.</given-names></name><name><surname>Pederzoli</surname><given-names>F.</given-names></name><name><surname>Vandelli</surname><given-names>M. A.</given-names></name><name><surname>Forni</surname><given-names>F.</given-names></name><name><surname>Ruozi</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Current strategies for the delivery of therapeutic proteins and enzymes to treat brain disorders</article-title>. <source>Int. Rev. Neurobiol.</source>
<volume>137</volume>, <fpage>1</fpage>&#x2013;<lpage>28</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/bs.irn.2017.08.006</pub-id>
<pub-id pub-id-type="pmid">29132540</pub-id></mixed-citation>
      </ref>
      <ref id="B68">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Earps</surname><given-names>L.</given-names></name><name><surname>Shoolingin-Jordan</surname><given-names>P. M.</given-names></name></person-group> (<year>1998</year>). <article-title>Molecular modelling of batroxobin on kallikreins</article-title>. <source>Biochem. Soc. Trans.</source>
<volume>26</volume> (<issue>3</issue>), <fpage>S283</fpage>&#x2013;<lpage>S283</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1042/bst026s283</pub-id>
<pub-id pub-id-type="pmid">9766002</pub-id></mixed-citation>
      </ref>
      <ref id="B69">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elkinson</surname><given-names>S.</given-names></name><name><surname>Keating</surname><given-names>G. M.</given-names></name></person-group> (<year>2013</year>). <article-title>Lixisenatide: First global approval</article-title>. <source>Drugs</source>
<volume>73</volume> (<issue>4</issue>), <fpage>383</fpage>&#x2013;<lpage>391</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s40265-013-0033-3</pub-id>
<pub-id pub-id-type="pmid">23558600</pub-id></mixed-citation>
      </ref>
      <ref id="B70">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eng</surname><given-names>J.</given-names></name><name><surname>Kleinman</surname><given-names>W. A.</given-names></name><name><surname>Singh</surname><given-names>L.</given-names></name><name><surname>Singh</surname><given-names>G.</given-names></name><name><surname>Raufman</surname><given-names>J. P.</given-names></name></person-group> (<year>1992</year>). <article-title>Isolation and characterization of exendin-4, an exendin-3 analogue, from H<italic>eloderma suspectum</italic> venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas</article-title>. <source>J. Biol. Chem.</source>
<volume>267</volume> (<issue>11</issue>), <fpage>7402</fpage>&#x2013;<lpage>7405</lpage>.<pub-id pub-id-type="pmid">1313797</pub-id></mixed-citation>
      </ref>
      <ref id="B71">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>U. G.</given-names></name><name><surname>Bredberg</surname><given-names>U.</given-names></name><name><surname>Gisl&#xE9;n</surname><given-names>K.</given-names></name><name><surname>Johansson</surname><given-names>L. C.</given-names></name><name><surname>Frison</surname><given-names>L.</given-names></name><name><surname>Ahnoff</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects</article-title>. <source>Eur. J. Clin. Pharmacol.</source>
<volume>59</volume> (<issue>1</issue>), <fpage>35</fpage>&#x2013;<lpage>43</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s00228-003-0565-7</pub-id>
<pub-id pub-id-type="pmid">12743672</pub-id></mixed-citation>
      </ref>
      <ref id="B72">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Esteve</surname><given-names>E.</given-names></name><name><surname>Mabrouk</surname><given-names>K.</given-names></name><name><surname>Dupuis</surname><given-names>A.</given-names></name><name><surname>Smida-Rezgui</surname><given-names>S.</given-names></name><name><surname>Altafaj</surname><given-names>X.</given-names></name><name><surname>Grunwald</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Transduction of the scorpion toxin maurocalcine into cells - Evidence that the toxin crosses the plasma membrane</article-title>. <source>J. Biol. Chem.</source>
<volume>280</volume> (<issue>13</issue>), <fpage>12833</fpage>&#x2013;<lpage>12839</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1047/jbc.M412521200</pub-id>
<pub-id pub-id-type="pmid">15653689</pub-id></mixed-citation>
      </ref>
      <ref id="B73">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group> (<year>2020</year>). <source>Search for medicines: Search our database of medicines - including human medicines, veterinary medicines and herbal medicines</source>. Available at: <uri xlink:type="simple" xlink:href="https://www.ema.europa.eu/en">https://www.ema.europa.eu/en</uri> (Accessed <date-in-citation>June 25, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B74">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Favaloro</surname><given-names>E. J.</given-names></name><name><surname>Wong</surname><given-names>R. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Antiphospholipid antibody testing for the antiphospholipid syndrome: a comprehensive practical review including a synopsis of challenges and recent guidelines</article-title>. <source>Pathology</source>
<volume>46</volume> (<issue>6</issue>), <fpage>481</fpage>&#x2013;<lpage>495</lpage>. <pub-id pub-id-type="doi">10.1097/PAT.0000000000000142</pub-id>
<pub-id pub-id-type="pmid">25158812</pub-id></mixed-citation>
      </ref>
      <ref id="B75">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferrajolo</surname><given-names>C.</given-names></name><name><surname>Coloma</surname><given-names>P. M.</given-names></name><name><surname>Verhamme</surname><given-names>K. M. C.</given-names></name><name><surname>Schuemie</surname><given-names>M. J.</given-names></name><name><surname>de Bie</surname><given-names>S.</given-names></name><name><surname>Gini</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network</article-title>. <source>Drug Saf.</source>
<volume>37</volume> (<issue>2</issue>), <fpage>99</fpage>&#x2013;<lpage>108</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s40264-013-0132-9</pub-id>
<pub-id pub-id-type="pmid">24446276</pub-id></mixed-citation>
      </ref>
      <ref id="B76">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>S. H.</given-names></name><name><surname>Rocha e Silva</surname><given-names>M.</given-names></name></person-group> (<year>1965</year>). <article-title>Potentiation of bradykinin and eledoisin by BPF (bradykinin potentiating factor) from <italic>Bothrops jararaca</italic> venom</article-title>. <source>Experientia</source>
<volume>21</volume> (<issue>6</issue>), <fpage>347</fpage>&#x2013;<lpage>349</lpage>. <pub-id pub-id-type="doi">10.1007/BF02144709</pub-id>
<pub-id pub-id-type="pmid">5870517</pub-id></mixed-citation>
      </ref>
      <ref id="B77">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>S. H.</given-names></name><name><surname>Bartelt</surname><given-names>D. C.</given-names></name><name><surname>Greene</surname><given-names>L. J.</given-names></name></person-group> (<year>1970</year>a). <article-title>Isolation of bradykinin-potentiating peptides from B<italic>othrops jararaca</italic> venom</article-title>. <source>Biochemistry</source>
<volume>9</volume> (<issue>13</issue>), <fpage>2583</fpage>&#x2013;<lpage>2593</lpage>. <pub-id pub-id-type="doi">10.1021/bi00815a005</pub-id>
<pub-id pub-id-type="pmid">4317874</pub-id></mixed-citation>
      </ref>
      <ref id="B78">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>S. H.</given-names></name><name><surname>Greene</surname><given-names>L. H.</given-names></name><name><surname>Alabaster</surname><given-names>V. A.</given-names></name><name><surname>Bakhle</surname><given-names>Y. S.</given-names></name><name><surname>Vane</surname><given-names>J. R.</given-names></name></person-group> (<year>1970</year>b). <article-title>Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme</article-title>. <source>Nature</source>
<volume>225</volume> (<issue>5230</issue>), <fpage>379</fpage>&#x2013;<lpage>380</lpage>. <pub-id pub-id-type="doi">10.1038/225379a0</pub-id>
<pub-id pub-id-type="pmid">4312128</pub-id></mixed-citation>
      </ref>
      <ref id="B79">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>R. S.</given-names></name><name><surname>de Barros</surname><given-names>L. C.</given-names></name><name><surname>Abbade</surname><given-names>L. P. F.</given-names></name><name><surname>Barraviera</surname><given-names>S. R. C. S.</given-names></name><name><surname>Silvares</surname><given-names>M. R. C.</given-names></name><name><surname>de Pontes</surname><given-names>L. G.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Heterologous fibrin sealant derived from snake venom: from bench to bedside - an overview</article-title>. <source>J. Venom. Anim. Toxins Incl. Trop. Dis.</source>
<volume>23</volume>, <fpage>21</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1186/s40409-017-0109-8</pub-id>
<pub-id pub-id-type="pmid">28396682</pub-id></mixed-citation>
      </ref>
      <ref id="B80">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>S. H.</given-names></name></person-group> (<year>1965</year>). <article-title>A bradykinin-potentiating factor (BPF) present in the venom of B<italic>othrops jararaca</italic>
</article-title>. <source>Br. J. Pharmacol. Chemother.</source>
<volume>24</volume>, <fpage>163</fpage>&#x2013;<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.1965.tb02091.x</pub-id>
<pub-id pub-id-type="pmid">14302350</pub-id></mixed-citation>
      </ref>
      <ref id="B81">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>S. H.</given-names></name></person-group> (<year>2000</year>). <article-title>Angiotensin converting enzyme: history and relevance</article-title>. <source>Semin. Perinatol.</source>
<volume>24</volume> (<issue>1</issue>), <fpage>7</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/S0146-0005(00)80046-4</pub-id>
<pub-id pub-id-type="pmid">10709850</pub-id></mixed-citation>
      </ref>
      <ref id="B82">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fox</surname><given-names>J. W.</given-names></name><name><surname>Serrano</surname><given-names>S. M. T.</given-names></name></person-group> (<year>2007</year>). <article-title>Approaching the golden age of natural product pharmaceuticals from venom libraries: An overview of toxins and toxin-derivatives currently involved in therapeutic or diagnostic applications</article-title>. <source>Curr. Pharm. Des.</source>
<volume>13</volume> (<issue>28</issue>), <fpage>2927</fpage>&#x2013;<lpage>2934</lpage>. &#xA0;<pub-id pub-id-type="doi">10.2174/138161207782023739</pub-id>
<pub-id pub-id-type="pmid">17979737</pub-id></mixed-citation>
      </ref>
      <ref id="B83">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Francischetti</surname><given-names>I. M.</given-names></name><name><surname>Gil</surname><given-names>M. R.</given-names></name></person-group> (<year>2019</year>). &#x201C;<article-title>Diagnostic use of venoms</article-title>,&#x201D; in <source>Transfusion Medicine and Hemostasis</source>, <edition>3rd ed.</edition> Eds. <person-group person-group-type="editor"><name><surname>Shaz</surname><given-names>B. H.</given-names></name><name><surname>Hillyer</surname><given-names>C. D.</given-names></name><name><surname>Gil</surname><given-names>M. R.</given-names></name></person-group> (<publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>), <fpage>969</fpage>&#x2013;<lpage>975</lpage>.</mixed-citation>
      </ref>
      <ref id="B84">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y. J.</given-names></name><name><surname>Yin</surname><given-names>L. T.</given-names></name><name><surname>Liang</surname><given-names>A. H.</given-names></name><name><surname>Zhang</surname><given-names>C. F.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Chai</surname><given-names>B. F.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Therapeutic potential of chlorotoxin-like neurotoxin from the Chinese scorpion for human gliomas</article-title>. <source>Neurosci. Lett.</source>
<volume>412</volume> (<issue>1</issue>), <fpage>62</fpage>&#x2013;<lpage>67</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.neulet.2006.10.056</pub-id>
<pub-id pub-id-type="pmid">17166663</pub-id></mixed-citation>
      </ref>
      <ref id="B85">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>An</surname><given-names>N.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>A potential strategy for high-grade gliomas: combination treatment with lithium chloride and BmK CT</article-title>. <source>Biotechnol. Lett.</source>
<volume>34</volume> (<issue>1</issue>), <fpage>9</fpage>&#x2013;<lpage>17</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s10529-011-0741-2</pub-id>
<pub-id pub-id-type="pmid">21932030</pub-id></mixed-citation>
      </ref>
      <ref id="B86">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>S.</given-names></name><name><surname>Hirte</surname><given-names>H.</given-names></name><name><surname>Welch</surname><given-names>S.</given-names></name><name><surname>Ilenchuk</surname><given-names>T. T.</given-names></name><name><surname>Lutes</surname><given-names>T.</given-names></name><name><surname>Rice</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors</article-title>. <source>Invest. New Drugs</source>
<volume>35</volume> (<issue>3</issue>), <fpage>324</fpage>&#x2013;<lpage>333</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s10637-017-0438-z</pub-id>
<pub-id pub-id-type="pmid">28150073</pub-id></mixed-citation>
      </ref>
      <ref id="B87">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Funk</surname><given-names>C.</given-names></name><name><surname>Gmur</surname><given-names>J.</given-names></name><name><surname>Herold</surname><given-names>R.</given-names></name><name><surname>Straub</surname><given-names>P. W.</given-names></name></person-group> (<year>1971</year>). <article-title>Reptilase&#xAE; - a new reagent in blood coagulation</article-title>. <source>Br. J. Haematol.</source>
<volume>21</volume> (<issue>1</issue>), <fpage>43</fpage>&#x2013;<lpage>&amp;</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/j.1365-2141.1971.tb03415.x</pub-id>
<pub-id pub-id-type="pmid">5105276</pub-id></mixed-citation>
      </ref>
      <ref id="B88">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Furman</surname><given-names>B. L.</given-names></name></person-group> (<year>2012</year>). <article-title>The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent</article-title>. <source>Toxicon</source>
<volume>59</volume> (<issue>4</issue>), <fpage>464</fpage>&#x2013;<lpage>471</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2010.12.016</pub-id>
<pub-id pub-id-type="pmid">21194543</pub-id></mixed-citation>
      </ref>
      <ref id="B89">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gajski</surname><given-names>G.</given-names></name><name><surname>Garaj-Vrhovac</surname><given-names>V.</given-names></name></person-group> (<year>2013</year>). <article-title>Melittin: A lytic peptide with anticancer properties</article-title>. <source>Environ. Toxicol. Pharmacol.</source>
<volume>36</volume> (<issue>2</issue>), <fpage>697</fpage>&#x2013;<lpage>705</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.etap.2013.06.009</pub-id>
<pub-id pub-id-type="pmid">23892471</pub-id></mixed-citation>
      </ref>
      <ref id="B90">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gan</surname><given-names>Z. R.</given-names></name><name><surname>Gould</surname><given-names>R. J.</given-names></name><name><surname>Jacobs</surname><given-names>J. W.</given-names></name><name><surname>Friedman</surname><given-names>P. A.</given-names></name><name><surname>Polokoff</surname><given-names>M. A.</given-names></name></person-group> (<year>1988</year>). <article-title>). Echistatin. A potent platelet aggregation inhibitor from the venom of the viper E<italic>chis carinatus</italic>
</article-title>. <source>J. Biol. Chem.</source>
<volume>263</volume> (<issue>36</issue>), <fpage>19827</fpage>&#x2013;<lpage>19832</lpage>.<pub-id pub-id-type="pmid">3198653</pub-id></mixed-citation>
      </ref>
      <ref id="B91">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>B.</given-names></name><name><surname>Peng</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Yi</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>Q.</given-names></name></person-group> (<year>2017</year>). <article-title>Cone snails: a big store of conotoxins for novel drug discovery</article-title>. <source>Toxins</source>
<volume>9</volume> (<issue>12</issue>):<fpage>397</fpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/toxins9120397</pub-id>
</mixed-citation>
      </ref>
      <ref id="B92">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gazerani</surname><given-names>P.</given-names></name><name><surname>Cairns</surname><given-names>B. E.</given-names></name></person-group> (<year>2014</year>). <article-title>Venom-based biotoxins as potential analgesics</article-title>. <source>Expert Rev. Neurother.</source>
<volume>14</volume> (<issue>11</issue>), <fpage>1261</fpage>&#x2013;<lpage>1274</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1586/14737175.2014.962518</pub-id>
<pub-id pub-id-type="pmid">25234848</pub-id></mixed-citation>
      </ref>
      <ref id="B93">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>A.</given-names></name><name><surname>Roy</surname><given-names>R.</given-names></name><name><surname>Nandi</surname><given-names>M.</given-names></name><name><surname>Mukhopadhyay</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Scorpion venom-toxins that aid in drug development: a review</article-title>. <source>Int. J. Pept. Res. Ther.</source>
<volume>25</volume> (<issue>1</issue>), <fpage>27</fpage>&#x2013;<lpage>37</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s10989-018-9721-x</pub-id>
<pub-id pub-id-type="pmid">32214927</pub-id></mixed-citation>
      </ref>
      <ref id="B94">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gomes</surname><given-names>A.</given-names></name><name><surname>Teixeira</surname><given-names>C.</given-names></name><name><surname>Ferraz</surname><given-names>R.</given-names></name><name><surname>Prudencio</surname><given-names>C.</given-names></name><name><surname>Gomes</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Wound-healing peptides for treatment of chronic diabetic foot ulcers and other infected skin injuries</article-title>. <source>Molecules</source>
<volume>22</volume> (<issue>10</issue>), <fpage>1743</fpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/molecules22101743</pub-id>
</mixed-citation>
      </ref>
      <ref id="B95">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Gotter</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <source>Apitherapy</source>. Available at: <uri xlink:type="simple" xlink:href="https://www.healthline.com/health/apitherapy">https://www.healthline.com/health/apitherapy</uri> (Accessed <date-in-citation>June 25, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B96">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Graetz</surname><given-names>T. J.</given-names></name><name><surname>Tellor</surname><given-names>B. R.</given-names></name><name><surname>Smith</surname><given-names>J. R.</given-names></name><name><surname>Avidan</surname><given-names>M. S.</given-names></name></person-group> (<year>2011</year>). <article-title>Desirudin: a review of the pharmacology and clinical application for the prevention of deep vein thrombosis</article-title>. <source>Expert Rev. Cardiovasc. Ther.</source>
<volume>9</volume> (<issue>9</issue>), <fpage>1101</fpage>&#x2013;<lpage>1109</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1586/erc.11.131</pub-id>
<pub-id pub-id-type="pmid">21932952</pub-id></mixed-citation>
      </ref>
      <ref id="B97">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Graziano</surname><given-names>F.</given-names></name><name><surname>Certo</surname><given-names>F.</given-names></name><name><surname>Basile</surname><given-names>L.</given-names></name><name><surname>Maugeri</surname><given-names>R.</given-names></name><name><surname>Grasso</surname><given-names>G.</given-names></name><name><surname>Meccio</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Autologous fibrin sealant (Vivostat&#xAE;<sup>)</sup> in the neurosurgical practice: Part I: Intracranial surgical procedure</article-title>. <source>Surg. Neurol. Int.</source>
<volume>6</volume>, <fpage>77</fpage>. &#xA0;<pub-id pub-id-type="doi">10.4103/2152-7806.156871</pub-id>
<pub-id pub-id-type="pmid">25984391</pub-id></mixed-citation>
      </ref>
      <ref id="B98">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Graziano</surname><given-names>F.</given-names></name><name><surname>Maugeri</surname><given-names>R.</given-names></name><name><surname>Basile</surname><given-names>L.</given-names></name><name><surname>Meccio</surname><given-names>F.</given-names></name><name><surname>Iacopino</surname><given-names>D. G.</given-names></name></person-group> (<year>2016</year>). <article-title>Aulogous fibrin sealant (Vivostat&#xAE;<sup>)</sup> in the neurosurgical practice: Part II: Vertebro-spinal procedures</article-title>. <source>Surg. Neurol. Int.</source>
<volume>7</volume> (<issue>Suppl 3</issue>), <fpage>S77</fpage>&#x2013;<lpage>S82</lpage>. &#xA0;<pub-id pub-id-type="doi">10.4103/2152-7806.174894</pub-id>
<pub-id pub-id-type="pmid">26904371</pub-id></mixed-citation>
      </ref>
      <ref id="B99">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Greig</surname><given-names>N. H.</given-names></name><name><surname>Holloway</surname><given-names>H. W.</given-names></name><name><surname>De Ore</surname><given-names>K. A.</given-names></name><name><surname>Jani</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations</article-title>. <source>Diabetologia</source>
<volume>42</volume> (<issue>1</issue>), <fpage>45</fpage>&#x2013;<lpage>50</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s001250051111</pub-id>
</mixed-citation>
      </ref>
      <ref id="B100">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grishin</surname><given-names>E. V.</given-names></name><name><surname>Savchenko</surname><given-names>G. A.</given-names></name><name><surname>Vassilevski</surname><given-names>A. A.</given-names></name><name><surname>Korolkova</surname><given-names>Y. V.</given-names></name><name><surname>Boychuk</surname><given-names>Y. A.</given-names></name><name><surname>Viatchenko-Karpinski</surname><given-names>V. Y.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Novel peptide from spider venom inhibits P2X3 receptors and inflammatory pain</article-title>. <source>Ann. Neurol.</source>
<volume>67</volume> (<issue>5</issue>), <fpage>680</fpage>&#x2013;<lpage>683</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/ana.21949</pub-id>
<pub-id pub-id-type="pmid">20437566</pub-id></mixed-citation>
      </ref>
      <ref id="B101">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gulseth</surname><given-names>M. P.</given-names></name></person-group> (<year>2005</year>). <article-title>Ximelagatran: An orally active direct thrombin inhibitor</article-title>. <source>Am. J. Health Syst. Pharm.</source>
<volume>62</volume> (<issue>14</issue>), <fpage>1451</fpage>&#x2013;<lpage>1467</lpage>. &#xA0;<pub-id pub-id-type="doi">10.2146/ajhp040534</pub-id>
<pub-id pub-id-type="pmid">15998925</pub-id></mixed-citation>
      </ref>
      <ref id="B102">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gutierrez</surname><given-names>V. P.</given-names></name><name><surname>Konno</surname><given-names>K.</given-names></name><name><surname>Chacur</surname><given-names>M.</given-names></name><name><surname>Sampaio</surname><given-names>S. C.</given-names></name><name><surname>Picolo</surname><given-names>G.</given-names></name><name><surname>Brigatte</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Crotalphine induces potent antinociception in neuropathic pain by acting at peripheral opioid receptors</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>594</volume> (<issue>1-3</issue>), <fpage>84</fpage>&#x2013;<lpage>92</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.ejphar.2008.07.053</pub-id>
<pub-id pub-id-type="pmid">18703042</pub-id></mixed-citation>
      </ref>
      <ref id="B103">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>T. S.</given-names></name><name><surname>Teichert</surname><given-names>R. W.</given-names></name><name><surname>Olivera</surname><given-names>B. M.</given-names></name><name><surname>Bulaj</surname><given-names>G.</given-names></name></person-group> (<year>2008</year>). <article-title>Conus venoms - A rich source of peptide-based therapeutics</article-title>. <source>Curr. Pharm. Des.</source>
<volume>14</volume> (<issue>24</issue>), <fpage>2462</fpage>&#x2013;<lpage>2479</lpage>. &#xA0;<pub-id pub-id-type="doi">10.2174/138161208785777469</pub-id>
<pub-id pub-id-type="pmid">18781995</pub-id></mixed-citation>
      </ref>
      <ref id="B104">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>S. M.</given-names></name><name><surname>Hong</surname><given-names>I. P.</given-names></name><name><surname>Woo</surname><given-names>S. O.</given-names></name><name><surname>Chun</surname><given-names>S. N.</given-names></name><name><surname>Park</surname><given-names>K. K.</given-names></name><name><surname>Nicholls</surname><given-names>Y. M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>The beneficial effects of honeybee-venom serum on facial wrinkles in humans</article-title>. <source>Clin. Interv. Aging</source>
<volume>10</volume>, <fpage>1587</fpage>&#x2013;<lpage>1592</lpage>. &#xA0;<pub-id pub-id-type="doi">10.2147/cia.s84940</pub-id>
<pub-id pub-id-type="pmid">26491274</pub-id></mixed-citation>
      </ref>
      <ref id="B105">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartman</surname><given-names>G. D.</given-names></name><name><surname>Egbertson</surname><given-names>M. S.</given-names></name><name><surname>Halczenko</surname><given-names>W.</given-names></name><name><surname>Laswell</surname><given-names>W. L.</given-names></name><name><surname>Duggan</surname><given-names>M. E.</given-names></name><name><surname>Smith</surname><given-names>R. L.</given-names></name><etal/></person-group> (<year>1992</year>). <article-title>Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors</article-title>. <source>J. Med. Chem.</source>
<volume>35</volume> (<issue>24</issue>), <fpage>4640</fpage>&#x2013;<lpage>4642</lpage>. <pub-id pub-id-type="doi">10.1021/jm00102a020</pub-id>
<pub-id pub-id-type="pmid">1469694</pub-id></mixed-citation>
      </ref>
      <ref id="B106">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>A.</given-names></name><name><surname>Mullner</surname><given-names>J.</given-names></name><name><surname>Meier</surname><given-names>N.</given-names></name><name><surname>Hesekamp</surname><given-names>H.</given-names></name><name><surname>van Meerbeeck</surname><given-names>P.</given-names></name><name><surname>Habert</surname><given-names>M. O.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Bee venom for the treatment of Parkinson disease - A randomized controlled clinical trial</article-title>. <source>PloS One</source>
<volume>11</volume> (<issue>7</issue>), <elocation-id>e0158235</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1371/journal.pone.0158235</pub-id>
<pub-id pub-id-type="pmid">27403743</pub-id></mixed-citation>
      </ref>
      <ref id="B107">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harvey</surname><given-names>A. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Toxins and drug discovery</article-title>. <source>Toxicon</source>
<volume>92</volume>, <fpage>193</fpage>&#x2013;<lpage>200</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2014.10.020</pub-id>
<pub-id pub-id-type="pmid">25448391</pub-id></mixed-citation>
      </ref>
      <ref id="B108">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hennerici</surname><given-names>M. G.</given-names></name><name><surname>Kay</surname><given-names>R.</given-names></name><name><surname>Bogousslavsky</surname><given-names>J.</given-names></name><name><surname>Lenzi</surname><given-names>G. L.</given-names></name><name><surname>Verstraete</surname><given-names>M.</given-names></name><name><surname>Orgogozo</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial</article-title>. <source>Lancet</source>
<volume>368</volume> (<issue>9550</issue>), <fpage>1871</fpage>&#x2013;<lpage>1878</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/S0140-6736(06)69776-6</pub-id>
<pub-id pub-id-type="pmid">17126719</pub-id></mixed-citation>
      </ref>
      <ref id="B109">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henry</surname><given-names>R. R.</given-names></name><name><surname>Rosenstock</surname><given-names>J.</given-names></name><name><surname>Logan</surname><given-names>D.</given-names></name><name><surname>Alessi</surname><given-names>T.</given-names></name><name><surname>Luskey</surname><given-names>K.</given-names></name><name><surname>Baron</surname><given-names>M. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes</article-title>. <source>J. Diabetes Complicat.</source>
<volume>28</volume> (<issue>3</issue>), <fpage>393</fpage>&#x2013;<lpage>398</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jdiacomp.2013.12.009</pub-id>
<pub-id pub-id-type="pmid">24631129</pub-id></mixed-citation>
      </ref>
      <ref id="B110">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hockaday</surname><given-names>D. C.</given-names></name><name><surname>Shen</surname><given-names>S.</given-names></name><name><surname>Fiveash</surname><given-names>J.</given-names></name><name><surname>Raubitschek</surname><given-names>A.</given-names></name><name><surname>Colcher</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Imaging glioma extent with 131I-TM-601</article-title>. <source>J. Nucl. Med.</source>
<volume>46</volume> (<issue>4</issue>), <fpage>580</fpage>&#x2013;<lpage>586</lpage>.<pub-id pub-id-type="pmid">15809479</pub-id></mixed-citation>
      </ref>
      <ref id="B111">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Holleman</surname><given-names>W. H.</given-names></name><name><surname>Weiss</surname><given-names>L. J.</given-names></name></person-group> (<year>1976</year>). <article-title>The thrombin-like enzyme from B<italic>othrops atrox</italic> snake venom. Properties of the enzyme purified by affinity chromatography on p-aminobenzamidine-substituted agarose</article-title>. <source>J. Biol. Chem.</source>
<volume>251</volume> (<issue>6</issue>), <fpage>1663</fpage>&#x2013;<lpage>1669</lpage>.<pub-id pub-id-type="pmid">1254591</pub-id></mixed-citation>
      </ref>
      <ref id="B112">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>Q.</given-names></name><name><surname>Zhao</surname><given-names>Y. P.</given-names></name><name><surname>Liu</surname><given-names>J. C.</given-names></name><name><surname>Yuan</surname><given-names>X. L.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Kv1.3 channel blocker (ImKTx88) maintains blood-brain barrier in experimental autoimmune encephalomyelitis</article-title>. <source>CellBiosci</source>
<volume>7</volume>, <fpage>31</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1186/s13578-017-0158-2</pub-id>
</mixed-citation>
      </ref>
      <ref id="B113">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ibraheem</surname><given-names>D.</given-names></name><name><surname>Elaissari</surname><given-names>A.</given-names></name><name><surname>Fessi</surname><given-names>H.</given-names></name></person-group> (<year>2014</year>). <article-title>Administration strategies for proteins and peptides</article-title>. <source>Int. J. Pharm.</source>
<volume>477</volume>, <fpage>578</fpage>&#x2013;<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.10.059</pub-id>
<pub-id pub-id-type="pmid">25445533</pub-id></mixed-citation>
      </ref>
      <ref id="B114">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ichiki</surname><given-names>T.</given-names></name><name><surname>Dzhoyashvili</surname><given-names>N.</given-names></name><name><surname>Burnett</surname><given-names>J. C.</given-names></name></person-group> (<year>2019</year>). <article-title>Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide</article-title>. <source>Int. J. Cardiol.</source>
<volume>281</volume>, <fpage>166</fpage>&#x2013;<lpage>171</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.ijcard.2018.06.002</pub-id>
<pub-id pub-id-type="pmid">29941213</pub-id></mixed-citation>
      </ref>
      <ref id="B115">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ikonen</surname><given-names>S.</given-names></name><name><surname>Riekkinen</surname><given-names>P.</given-names></name></person-group> (<year>1999</year>). <article-title>Effects of apamin on memory processing of hippocampal-lesioned mice</article-title>. <source>Eur. JPharmacol.</source>
<volume>382</volume> (<issue>3</issue>), <fpage>151</fpage>&#x2013;<lpage>156</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/s0014-2999(99)00616-0</pub-id>
<pub-id pub-id-type="pmid">10556665</pub-id></mixed-citation>
      </ref>
      <ref id="B116">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Itoh</surname><given-names>N.</given-names></name><name><surname>Tanaka</surname><given-names>N.</given-names></name><name><surname>Mihashi</surname><given-names>S.</given-names></name><name><surname>Yamashina</surname><given-names>I.</given-names></name></person-group> (<year>1987</year>). <article-title>Molecular cloning and sequence analysis of cDNA for batroxobin, a thrombin-like snake venom enzyme</article-title>. <source>J. Biol. Chem.</source>
<volume>262</volume> (<issue>7</issue>), <fpage>3132</fpage>&#x2013;<lpage>3135</lpage>.<pub-id pub-id-type="pmid">3546302</pub-id></mixed-citation>
      </ref>
      <ref id="B117">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jacoby</surname><given-names>D. B.</given-names></name><name><surname>Dyskin</surname><given-names>E.</given-names></name><name><surname>Yalcin</surname><given-names>M.</given-names></name><name><surname>Kesavan</surname><given-names>K.</given-names></name><name><surname>Dahlberg</surname><given-names>W.</given-names></name><name><surname>Ratliff</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide</article-title>. <source>Anticancer Res.</source>
<volume>30</volume> (<issue>1</issue>), <fpage>39</fpage>&#x2013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">20150615</pub-id></mixed-citation>
      </ref>
      <ref id="B118">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jagua-Gualdr&#xF3;n</surname><given-names>A.</given-names></name><name><surname>Pe&#xF1;a-Latorre</surname><given-names>J. A.</given-names></name><name><surname>Fernadez-Bernal</surname><given-names>R. E.</given-names></name></person-group> (<year>2020</year>). <article-title>Apitherapy for osteoarthritis: perspectives from basic research</article-title>. <source>Complement Med. Res.</source>
<volume>27</volume> (<issue>3</issue>), <fpage>184</fpage>&#x2013;<lpage>192</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1159/000505015</pub-id>
<pub-id pub-id-type="pmid">31896107</pub-id></mixed-citation>
      </ref>
      <ref id="B119">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jang</surname><given-names>S. H.</given-names></name><name><surname>Choi</surname><given-names>S. Y.</given-names></name><name><surname>Ryu</surname><given-names>P. D.</given-names></name><name><surname>Lee</surname><given-names>S. Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Anti-proliferative effect of Kv1.3 blockers in A549 human lung adenocarcinoma i<italic>n vitro</italic> and i<italic>n vivo</italic>
</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>651</volume> (<issue>1-3</issue>), <fpage>26</fpage>&#x2013;<lpage>32</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.ejphar.2010.10.066</pub-id>
<pub-id pub-id-type="pmid">21087602</pub-id></mixed-citation>
      </ref>
      <ref id="B120">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Johnson &amp; Johnson</collab></person-group> (<year>2019</year>). <source>Champions of Science&#xAE; Storytelling Challenge: Latin America and Caribbean Edition</source>. Available at: <uri xlink:type="simple" xlink:href="https://www.jnj.com/latin-america-caribbean-storytelling-challenge/maria-elena-de-lima">https://www.jnj.com/latin-america-caribbean-storytelling-challenge/maria-elena-de-lima</uri> (Accessed <date-in-citation>March 29, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B121">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>P. H.</given-names></name><name><surname>Sze</surname><given-names>P.</given-names></name><name><surname>Winant</surname><given-names>R.</given-names></name><name><surname>Payne</surname><given-names>P. W.</given-names></name><name><surname>Lazar</surname><given-names>J. B.</given-names></name></person-group> (<year>1989</year>). <article-title>Biochemistry and genetic-engineering of hirudin</article-title>. <source>Semin. Thromb. Hemost.</source>
<volume>15</volume> (<issue>3</issue>), <fpage>302</fpage>&#x2013;<lpage>315</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1055/s-2007-1002723</pub-id>
<pub-id pub-id-type="pmid">2688103</pub-id></mixed-citation>
      </ref>
      <ref id="B122">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>S.</given-names></name><name><surname>Howl</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Enantiomer-specific bioactivities of peptidomimetic analogues of mastoparan and mitoparan: Characterization of inverso mastoparan as a highly efficient cell penetrating peptide</article-title>. <source>Bioconj. Chem.</source>
<volume>23</volume> (<issue>1</issue>), <fpage>47</fpage>&#x2013;<lpage>56</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1021/bc2002924</pub-id>
</mixed-citation>
      </ref>
      <ref id="B123">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Juh&#xE1;sz</surname><given-names>M. L.</given-names></name><name><surname>Levin</surname><given-names>M. K.</given-names></name><name><surname>Marmur</surname><given-names>E. S.</given-names></name></person-group> (<year>2018</year>). <article-title>The use of natural ingredients in innovative Korean cosmeceuticals</article-title>. <source>J. Cosmet. Dermatol.</source>
<volume>17</volume>, <fpage>1</fpage>&#x2013;<lpage>8</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/jocd.12492</pub-id>
</mixed-citation>
      </ref>
      <ref id="B124">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karpel</surname><given-names>R. L.</given-names></name><name><surname>Liberato</surname><given-names>M. D.</given-names></name><name><surname>Campeiro</surname><given-names>J. D.</given-names></name><name><surname>Bergeon</surname><given-names>L.</given-names></name><name><surname>Szychowski</surname><given-names>B.</given-names></name><name><surname>Butler</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Design and characterization of crotamine-functionalized gold nanoparticles</article-title>. <source>Colloids Surf B Biointerfaces</source>
<volume>163</volume>, <fpage>1</fpage>&#x2013;<lpage>8</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.colsurfb.2017.12.013</pub-id>
<pub-id pub-id-type="pmid">29268209</pub-id></mixed-citation>
      </ref>
      <ref id="B125">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kent</surname><given-names>S.</given-names></name><name><surname>Sohma</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Bang</surname><given-names>D.</given-names></name><name><surname>Pentelute</surname><given-names>B.</given-names></name><name><surname>Mandal</surname><given-names>K.</given-names></name></person-group> (<year>2012</year>). <article-title>Through the looking glass - a new world of proteins enabled by chemical synthesis</article-title>. <source>J. Pept. Sci.</source>
<volume>18</volume> (<issue>7</issue>), <fpage>428</fpage>&#x2013;<lpage>436</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/psc.2421</pub-id>
<pub-id pub-id-type="pmid">22674813</pub-id></mixed-citation>
      </ref>
      <ref id="B126">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kerkis</surname><given-names>A.</given-names></name><name><surname>Kerkis</surname><given-names>I.</given-names></name><name><surname>Radis-Baptista</surname><given-names>G.</given-names></name><name><surname>Oliveira</surname><given-names>E. B.</given-names></name><name><surname>Vianna-Morgante</surname><given-names>A. M.</given-names></name><name><surname>Pereira</surname><given-names>L. V.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Crotamine is a novel cell-penetrating protein from the venom of rattlesnake Crotalus durissus terrificus</article-title>. <source>FASEB J.</source>
<volume>18</volume> (<issue>10</issue>), <fpage>1407</fpage>&#x2013;<lpage>140+</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1096/fj.03-1459fje</pub-id>
<pub-id pub-id-type="pmid">15231729</pub-id></mixed-citation>
      </ref>
      <ref id="B127">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kesavan</surname><given-names>K.</given-names></name><name><surname>Ratliff</surname><given-names>J.</given-names></name><name><surname>Johnson</surname><given-names>E. W.</given-names></name><name><surname>Dahlberg</surname><given-names>W.</given-names></name><name><surname>Asara</surname><given-names>J. M.</given-names></name><name><surname>Misra</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects</article-title>. <source>J. Biol. Chem.</source>
<volume>285</volume> (<issue>7</issue>), <fpage>4366</fpage>&#x2013;<lpage>4374</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1074/jbc.M109.066092</pub-id>
<pub-id pub-id-type="pmid">20018898</pub-id></mixed-citation>
      </ref>
      <ref id="B128">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Kineta Inc</collab></person-group> (<year>2020</year>). <source>KCP-506 - A novel non-opioid for the treatment of chronic pain</source>. Available at: <uri xlink:type="simple" xlink:href="https://kinetabio.com/neuroscience/">https://kinetabio.com/neuroscience/</uri> (Accessed <date-in-citation>March 29, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B129">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>King</surname><given-names>J. V. L.</given-names></name><name><surname>Emrick</surname><given-names>J. J.</given-names></name><name><surname>Kelly</surname><given-names>M. J. S.</given-names></name><name><surname>Herzig</surname><given-names>V.</given-names></name><name><surname>King</surname><given-names>G. F.</given-names></name><name><surname>Medzihradszky</surname><given-names>K. F.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>A cell-penetrating scorpion toxin enables mode-specific modulation of TRPA1 and pain</article-title>. <source>Cell</source>
<volume>178</volume> (<issue>6</issue>), <fpage>1362</fpage>&#x2013;<lpage>136+</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.cell.2019.07.014</pub-id>
<pub-id pub-id-type="pmid">31447178</pub-id></mixed-citation>
      </ref>
      <ref id="B130">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>King</surname><given-names>G. F.</given-names></name></person-group> (<year>2011</year>). <article-title>Venoms as a platform for human drugs: translating toxins into therapeutics</article-title>. <source>Expert Opin. Biol. Ther.</source>
<volume>11</volume> (<issue>11</issue>), <fpage>1469</fpage>&#x2013;<lpage>1484</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1517/14712598.2011.621940</pub-id>
<pub-id pub-id-type="pmid">21939428</pub-id></mixed-citation>
      </ref>
      <ref id="B131">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>King</surname><given-names>G. F.</given-names></name></person-group> (<year>2013</year>). <article-title>Venoms to drugs: translating venom peptides into therapeutics</article-title>. <source>Aust. Biochem.</source>
<volume>44</volume> (<issue>3</issue>), <fpage>13</fpage>&#x2013;<lpage>16</lpage>.</mixed-citation>
      </ref>
      <ref id="B132">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kjaergard</surname><given-names>H. K.</given-names></name><name><surname>Trumbull</surname><given-names>H. R.</given-names></name></person-group> (<year>1998</year>). <article-title>Vivostat system autologous fibrin sealant: Preliminary study in elective coronary bypass grafting</article-title>. <source>Ann. Thorac. Surg.</source>
<volume>66</volume> (<issue>2</issue>), <fpage>482</fpage>&#x2013;<lpage>486</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/s0003-4975(98)00470-6</pub-id>
<pub-id pub-id-type="pmid">9725389</pub-id></mixed-citation>
      </ref>
      <ref id="B133">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Knop</surname><given-names>F. K.</given-names></name><name><surname>Bronden</surname><given-names>A.</given-names></name><name><surname>Vilsboll</surname><given-names>T.</given-names></name></person-group> (<year>2017</year>). <article-title>Exenatide: pharmacokinetics, clinical use, and future directions</article-title>. <source>Expert Opin. Pharmacother.</source>
<volume>18</volume> (<issue>6</issue>), <fpage>555</fpage>&#x2013;<lpage>571</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1080/14656566.2017.1282463</pub-id>
<pub-id pub-id-type="pmid">28085521</pub-id></mixed-citation>
      </ref>
      <ref id="B134">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koh</surname><given-names>C. Y.</given-names></name><name><surname>Kini</surname><given-names>R. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Anticoagulants from hematophagous animals</article-title>. <source>Expert Rev. Hematol.</source>
<volume>1</volume> (<issue>2</issue>), <fpage>135</fpage>&#x2013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1586/17474086.1.2.135</pub-id>
<pub-id pub-id-type="pmid">21082917</pub-id></mixed-citation>
      </ref>
      <ref id="B135">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koh</surname><given-names>C. Y.</given-names></name><name><surname>Kini</surname><given-names>R. M.</given-names></name></person-group> (<year>2012</year>). <article-title>From snake venom toxins to therapeutics - cardiovascular examples</article-title>. <source>Toxicon</source>
<volume>59</volume> (<issue>4</issue>), <fpage>497</fpage>&#x2013;<lpage>506</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2011.03.017</pub-id>
<pub-id pub-id-type="pmid">21447352</pub-id></mixed-citation>
      </ref>
      <ref id="B136">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koh</surname><given-names>D. C. I.</given-names></name><name><surname>Armugam</surname><given-names>A.</given-names></name><name><surname>Jeyaseelan</surname><given-names>K.</given-names></name></person-group> (<year>2006</year>). <article-title>Snake venom components and their applications in biomedicine</article-title>. <source>Cell Mol. Life Sci.</source>
<volume>63</volume> (<issue>24</issue>), <fpage>3030</fpage>&#x2013;<lpage>3041</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s00018-006-6315-0</pub-id>
<pub-id pub-id-type="pmid">17103111</pub-id></mixed-citation>
      </ref>
      <ref id="B137">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kolaczek</surname><given-names>A.</given-names></name><name><surname>Skorupa</surname><given-names>D.</given-names></name><name><surname>Antczak-Marczak</surname><given-names>M.</given-names></name><name><surname>Kuna</surname><given-names>P.</given-names></name><name><surname>Kupczyk</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Safety and efficacy of venom immunotherapy: a real life study</article-title>. <source>Postepy DermatolAlergol.</source>
<volume>34</volume> (<issue>2</issue>), <fpage>159</fpage>&#x2013;<lpage>167</lpage>. &#xA0;<pub-id pub-id-type="doi">10.5114/ada.2017.67082</pub-id>
</mixed-citation>
      </ref>
      <ref id="B138">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kolosov</surname><given-names>A.</given-names></name><name><surname>Goodchild</surname><given-names>C. S.</given-names></name><name><surname>Cooke</surname><given-names>I.</given-names></name></person-group> (<year>2010</year>). <article-title>CNSB004 (leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain</article-title>. <source>Pain Med.</source>
<volume>11</volume> (<issue>2</issue>), <fpage>262</fpage>&#x2013;<lpage>273</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/j.1526-4637.2009.00741.x</pub-id>
<pub-id pub-id-type="pmid">20002322</pub-id></mixed-citation>
      </ref>
      <ref id="B139">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konno</surname><given-names>K.</given-names></name><name><surname>Picolo</surname><given-names>G.</given-names></name><name><surname>Gutierrez</surname><given-names>V. P.</given-names></name><name><surname>Brigatte</surname><given-names>P.</given-names></name><name><surname>Zambelli</surname><given-names>V. O.</given-names></name><name><surname>Camargo</surname><given-names>A. C. M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Crotalphine, a novel potent analgesic peptide from the venom of the South American rattlesnake C<italic>rotalus durissus terrificus</italic>
</article-title>. <source>Peptides</source>
<volume>29</volume> (<issue>8</issue>), <fpage>1293</fpage>&#x2013;<lpage>1304</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.peptides.2008.04.003</pub-id>
<pub-id pub-id-type="pmid">18495297</pub-id></mixed-citation>
      </ref>
      <ref id="B140">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kovalainen</surname><given-names>M.</given-names></name><name><surname>Monkare</surname><given-names>J.</given-names></name><name><surname>Riikonen</surname><given-names>J.</given-names></name><name><surname>Pesonen</surname><given-names>U.</given-names></name><name><surname>Vlasova</surname><given-names>M.</given-names></name><name><surname>Salonen</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Novel delivery systems for improving the clinical use of peptides</article-title>. <source>Pharmacol. Rev.</source>
<volume>67</volume> (<issue>3</issue>), <fpage>541</fpage>&#x2013;<lpage>561</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1124/pr.113.008367</pub-id>
<pub-id pub-id-type="pmid">26023145</pub-id></mixed-citation>
      </ref>
      <ref id="B141">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kovar</surname><given-names>J. L.</given-names></name><name><surname>Curtis</surname><given-names>E.</given-names></name><name><surname>Othman</surname><given-names>S. F.</given-names></name><name><surname>Simpson</surname><given-names>M. A.</given-names></name><name><surname>Olive</surname><given-names>D. M.</given-names></name></person-group> (<year>2013</year>). <article-title>Characterization of IRDye 800CW chlorotoxin as a targeting agent for brain tumors</article-title>. <source>Anal. Biochem.</source>
<volume>440</volume> (<issue>2</issue>), <fpage>212</fpage>&#x2013;<lpage>219</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.ab.2013.05.013</pub-id>
<pub-id pub-id-type="pmid">23711726</pub-id></mixed-citation>
      </ref>
      <ref id="B142">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ladram</surname><given-names>A.</given-names></name><name><surname>Nicolas</surname><given-names>P.</given-names></name></person-group> (<year>2016</year>). <article-title>Antimicrobial peptides from frog skin: biodiversity and therapeutic promises</article-title>. <source>Front. Biosci.</source>
<volume>21</volume>, <fpage>1341</fpage>&#x2013;<lpage>1371</lpage>. &#xA0;<pub-id pub-id-type="doi">10.2741/4461</pub-id>
</mixed-citation>
      </ref>
      <ref id="B143">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lago</surname><given-names>J.</given-names></name><name><surname>Rodriguez</surname><given-names>L. P.</given-names></name><name><surname>Blanco</surname><given-names>L.</given-names></name><name><surname>Vieites</surname><given-names>J. M.</given-names></name><name><surname>Cabado</surname><given-names>A. G.</given-names></name></person-group> (<year>2015</year>). <article-title>Tetrodotoxin, an extremely potent marine neurotoxin: distribution, toxicity, origin and therapeutical uses</article-title>. <source>Mar Drugs</source>
<volume>13</volume> (<issue>10</issue>), <fpage>6384</fpage>&#x2013;<lpage>6406</lpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/md13106384</pub-id>
<pub-id pub-id-type="pmid">26492253</pub-id></mixed-citation>
      </ref>
      <ref id="B144">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lang</surname><given-names>S.</given-names></name><name><surname>Manning</surname><given-names>N.</given-names></name><name><surname>Armstrong</surname><given-names>N.</given-names></name><name><surname>Misso</surname><given-names>K.</given-names></name><name><surname>Allen</surname><given-names>A.</given-names></name><name><surname>Di Nisio</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis</article-title>. <source>Curr. Med. Res. Opin.</source>
<volume>28</volume> (<issue>3</issue>), <fpage>351</fpage>&#x2013;<lpage>370</lpage>. <pub-id pub-id-type="doi">10.1185/03007995.2012.657299</pub-id>
<pub-id pub-id-type="pmid">22292469</pub-id></mixed-citation>
      </ref>
      <ref id="B145">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>C. J.</given-names></name><name><surname>Ansell</surname><given-names>J. E.</given-names></name></person-group> (<year>2011</year>). <article-title>Direct thrombin inhibitors</article-title>. <source>Br. JClin. Pharmacol.</source>
<volume>72</volume> (<issue>4</issue>), <fpage>581</fpage>&#x2013;<lpage>592</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/j.1365-2125.2011.03916.x</pub-id>
<pub-id pub-id-type="pmid">21241354</pub-id></mixed-citation>
      </ref>
      <ref id="B146">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>C. Y.</given-names></name><name><surname>Chen</surname><given-names>H. H.</given-names></name><name><surname>Lisy</surname><given-names>O.</given-names></name><name><surname>Swan</surname><given-names>S.</given-names></name><name><surname>Cannon</surname><given-names>C.</given-names></name><name><surname>Lieu</surname><given-names>H. D.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects</article-title>. <source>J. Clin. Pharmacol.</source>
<volume>49</volume> (<issue>6</issue>), <fpage>668</fpage>&#x2013;<lpage>673</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1177/0091270009336233</pub-id>
<pub-id pub-id-type="pmid">19395584</pub-id></mixed-citation>
      </ref>
      <ref id="B147">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. A.</given-names></name><name><surname>Son</surname><given-names>M. J.</given-names></name><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Jun</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>J. I.</given-names></name><name><surname>Lee</surname><given-names>M. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Bee venom acupuncture for rheumatoid arthritis: a systematic review of randomised clinical trials</article-title>. <source>BMJ Open</source>
<volume>4</volume>, <elocation-id>e006140</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1136/bmjopen-2014-006140</pub-id>
</mixed-citation>
      </ref>
      <ref id="B148">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>R. J.</given-names></name><name><surname>Dutertre</surname><given-names>S.</given-names></name><name><surname>Vetter</surname><given-names>I.</given-names></name><name><surname>Christie</surname><given-names>M. J.</given-names></name></person-group> (<year>2012</year>). <article-title>C<italic>onus</italic> venom peptide pharmacology</article-title>. <source>Pharmacol. Rev.</source>
<volume>64</volume> (<issue>2</issue>), <fpage>259</fpage>&#x2013;<lpage>298</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1124/pr.111.005322</pub-id>
<pub-id pub-id-type="pmid">22407615</pub-id></mixed-citation>
      </ref>
      <ref id="B149">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>R. J.</given-names></name></person-group> (<year>2015</year>). &#x201C;<article-title>Case study 1: development of the analgesic drugs Prialt&#xAE; and Xen2174 from cone snail venoms</article-title>,&#x201D; in <source>Venoms to drugs: venom as a source for the development of human therapeutics</source>. Ed. <person-group person-group-type="editor"><name><surname>King</surname><given-names>G. F.</given-names></name></person-group> (<publisher-loc>London</publisher-loc>: <publisher-name>Royal Society of Chemistry</publisher-name>), <fpage>245</fpage>&#x2013;<lpage>254</lpage>.</mixed-citation>
      </ref>
      <ref id="B150">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Hashimi</surname><given-names>S. M.</given-names></name><name><surname>Cao</surname><given-names>S.</given-names></name><name><surname>Mellick</surname><given-names>A. S.</given-names></name><name><surname>Duan</surname><given-names>W.</given-names></name><name><surname>Good</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>The mechanisms of chansu in inducing efficient apoptosis in colon cancer cells</article-title>. <source>Evid. Based Complement Alternat. Med.</source>
<volume>2013</volume>:<elocation-id>849054</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1155/2013/849054</pub-id>
<pub-id pub-id-type="pmid">23818933</pub-id></mixed-citation>
      </ref>
      <ref id="B151">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ling</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name></person-group> (<year>2017</year>). <article-title>Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis</article-title>. <source>Medicine</source>
<volume>96</volume> (<issue>18</issue>), <elocation-id>e6667</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1097/md.0000000000006667</pub-id>
<pub-id pub-id-type="pmid">28471961</pub-id></mixed-citation>
      </ref>
      <ref id="B152">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lippens</surname><given-names>G.</given-names></name><name><surname>Najib</surname><given-names>J.</given-names></name><name><surname>Wodak</surname><given-names>S. J.</given-names></name><name><surname>Tartar</surname><given-names>A.</given-names></name></person-group> (<year>1995</year>). <article-title>NMR sequential assignments and solution structure of chlorotoxin, a small scorpion toxin that blocks chloride channels</article-title>. <source>Biochemistry</source>
<volume>34</volume> (<issue>1</issue>), <fpage>13</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1021/bi00001a003</pub-id>
<pub-id pub-id-type="pmid">7819188</pub-id></mixed-citation>
      </ref>
      <ref id="B153">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lisy</surname><given-names>O.</given-names></name><name><surname>Huntley</surname><given-names>B. K.</given-names></name><name><surname>McCormick</surname><given-names>D. J.</given-names></name><name><surname>Kurlansky</surname><given-names>P. A.</given-names></name><name><surname>Burnett</surname><given-names>J. C.</given-names></name></person-group> (<year>2008</year>). <article-title>). Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP</article-title>. <source>J. Am. Coll. Cardiol.</source>
<volume>52</volume> (<issue>1</issue>), <fpage>60</fpage>&#x2013;<lpage>68</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jacc.2008.02.077</pub-id>
<pub-id pub-id-type="pmid">18582636</pub-id></mixed-citation>
      </ref>
      <ref id="B154">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Marder</surname><given-names>V. J.</given-names></name><name><surname>Levy</surname><given-names>D. E.</given-names></name><name><surname>Wang</surname><given-names>S. J.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Paganini-Hill</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Ancrod and fibrin formation: perspectives on mechanisms of action</article-title>. <source>Stroke</source>
<volume>42</volume> (<issue>11</issue>), <fpage>3277</fpage>&#x2013;<lpage>3280</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1161/STROKEAHA.111.622753</pub-id>
<pub-id pub-id-type="pmid">21868728</pub-id></mixed-citation>
      </ref>
      <ref id="B155">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Ban</surname><given-names>L. Y.</given-names></name><name><surname>Su</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>J. W.</given-names></name><name><surname>Cui</surname><given-names>X. N.</given-names></name></person-group> (<year>2015</year>). <article-title>Effects of cinobufacini injection on cell proliferation and the expression of topoisomerases in human HepG-2 hepatocellular carcinoma cells</article-title>. <source>Mol. Med. Rep.</source>
<volume>12</volume> (<issue>1</issue>), <fpage>1598</fpage>&#x2013;<lpage>1604</lpage>. &#xA0;<pub-id pub-id-type="doi">10.3892/mmr.2015.3552</pub-id>
<pub-id pub-id-type="pmid">25815590</pub-id></mixed-citation>
      </ref>
      <ref id="B156">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Hagan</surname><given-names>R.</given-names></name><name><surname>Schoellerman</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>Dual actions of Psalmotoxin at ASIC1a and ASIC2a heteromeric channels (ASIC1a/2a)</article-title>. <source>Sci. Rep.</source>
<volume>8</volume>, <fpage>7179</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1038/s41598-018-25386-9</pub-id>
<pub-id pub-id-type="pmid">29739981</pub-id></mixed-citation>
      </ref>
      <ref id="B157">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lorenz</surname><given-names>M.</given-names></name><name><surname>Evers</surname><given-names>A.</given-names></name><name><surname>Wagner</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity</article-title>. <source>Bioorg. Med. Chem. Lett.</source>
<volume>23</volume> (<issue>14</issue>), <fpage>4011</fpage>&#x2013;<lpage>4018</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.bmcl.2013.05.022</pub-id>
<pub-id pub-id-type="pmid">23743288</pub-id></mixed-citation>
      </ref>
      <ref id="B158">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luna-Ramirez</surname><given-names>K.</given-names></name><name><surname>Tonk</surname><given-names>M.</given-names></name><name><surname>Rahnamaeian</surname><given-names>M.</given-names></name><name><surname>Vilcinskas</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Bioactivity of natural and engineered antimicrobial peptides from venom of the scorpions U<italic>rodacus yaschenkoi a</italic>nd U<italic>. manicatus</italic>
</article-title>. <source>Toxins</source>
<volume>9</volume> (<issue>1</issue>), 22. &#xA0;<pub-id pub-id-type="doi">10.3390/toxins9010022</pub-id>
</mixed-citation>
      </ref>
      <ref id="B159">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maatuf</surname><given-names>Y.</given-names></name><name><surname>Geron</surname><given-names>M.</given-names></name><name><surname>Priel</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>The role of toxins in the pursuit for novel analgesics</article-title>. <source>Toxins</source>
<volume>11</volume> (<issue>2</issue>):<fpage>131</fpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/toxins11020131</pub-id>
</mixed-citation>
      </ref>
      <ref id="B160">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Mabrouk</surname><given-names>K.</given-names></name><name><surname>Luis</surname><given-names>J.</given-names></name><name><surname>De Pomyers</surname><given-names>H.</given-names></name><name><surname>Bertin</surname><given-names>D.</given-names></name><name><surname>Bengeloune</surname><given-names>A. H.</given-names></name><name><surname>Verdoni</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <source>Use of spider venoms for skin whitening/depigmenting and composition comprising spider venoms molecules or synthetic analogs</source>, WO/2014/037111 patent application.</mixed-citation>
      </ref>
      <ref id="B161">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mambelli-Lisboa</surname><given-names>N. C.</given-names></name><name><surname>Sciani</surname><given-names>J. M.</given-names></name><name><surname>da Silva</surname><given-names>A.</given-names></name><name><surname>Kerkis</surname><given-names>I.</given-names></name></person-group> (<year>2018</year>). <article-title>Co-localization of crotamine with internal membranes and accentuated accumulation in tumor cells</article-title>. <source>Molecules</source>
<volume>23</volume> (<issue>4</issue>), 968. &#xA0;<pub-id pub-id-type="doi">10.3390/molecules23040968</pub-id>
</mixed-citation>
      </ref>
      <ref id="B162">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manda</surname><given-names>P.</given-names></name><name><surname>Kushwaha</surname><given-names>A. S.</given-names></name><name><surname>Kundu</surname><given-names>S.</given-names></name><name><surname>Shivakumar</surname><given-names>H. N.</given-names></name><name><surname>Jo</surname><given-names>S. B.</given-names></name><name><surname>Murthy</surname><given-names>S. N.</given-names></name></person-group> (<year>2016</year>). <article-title>Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain</article-title>. <source>J. Control Release</source>
<volume>224</volume>, <fpage>69</fpage>&#x2013;<lpage>76</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jconrel.2015.12.044</pub-id>
<pub-id pub-id-type="pmid">26732557</pub-id></mixed-citation>
      </ref>
      <ref id="B163">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maraganore</surname><given-names>J. M.</given-names></name><name><surname>Bourdon</surname><given-names>P.</given-names></name><name><surname>Jablonski</surname><given-names>J.</given-names></name><name><surname>Ramachandran</surname><given-names>K. L.</given-names></name><name><surname>Fenton</surname><given-names>J. W.</given-names></name></person-group> (<year>1990</year>). <article-title>Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin</article-title>. <source>Biochemistry</source>
<volume>29</volume> (<issue>30</issue>), <fpage>7095</fpage>&#x2013;<lpage>7101</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1021/bi00482a021</pub-id>
<pub-id pub-id-type="pmid">2223763</pub-id></mixed-citation>
      </ref>
      <ref id="B164">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Markland</surname><given-names>F. S.</given-names></name><name><surname>Swenson</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Fibrolase: trials and tribulations</article-title>. <source>Toxins</source>
<volume>2</volume> (<issue>4</issue>), <fpage>793</fpage>&#x2013;<lpage>808</lpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/toxins2040793</pub-id>
<pub-id pub-id-type="pmid">22069611</pub-id></mixed-citation>
      </ref>
      <ref id="B165">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Markwardt</surname><given-names>F.</given-names></name></person-group> (<year>1991</year>). <article-title>Past, present and future of hirudin</article-title>. <source>Haemostasis</source>
<volume>21 Suppl 1</volume>, <fpage>11</fpage>&#x2013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1159/000216258</pub-id>
<pub-id pub-id-type="pmid">1894186</pub-id></mixed-citation>
      </ref>
      <ref id="B166">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mazzuca</surname><given-names>M.</given-names></name><name><surname>Heurteaux</surname><given-names>C.</given-names></name><name><surname>Alloui</surname><given-names>A.</given-names></name><name><surname>Diochot</surname><given-names>S.</given-names></name><name><surname>Baron</surname><given-names>A.</given-names></name><name><surname>Voilley</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>A tarantula peptide against pain via ASIC1a channels and opioid mechanisms</article-title>. <source>Nat. Neurosci.</source>
<volume>10</volume> (<issue>8</issue>), <fpage>943</fpage>&#x2013;<lpage>945</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1038/nn1940</pub-id>
<pub-id pub-id-type="pmid">17632507</pub-id></mixed-citation>
      </ref>
      <ref id="B167">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mazzucco</surname><given-names>L.</given-names></name><name><surname>Balbo</surname><given-names>V.</given-names></name><name><surname>Cattana</surname><given-names>E.</given-names></name><name><surname>Borzini</surname><given-names>P.</given-names></name></person-group> (<year>2008</year>). <article-title>Platelet-rich plasma and platelet gel preparation using Plateltex&#xAE;</article-title>. <source>Vox Sang</source>
<volume>94</volume> (<issue>3</issue>), <fpage>202</fpage>&#x2013;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1111/j.1423-0410.2007.01027.x</pub-id>
<pub-id pub-id-type="pmid">18179680</pub-id></mixed-citation>
      </ref>
      <ref id="B168">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McGivern</surname><given-names>J. G.</given-names></name></person-group> (<year>2007</year>). <article-title>Ziconotide: a review of its pharmacology and use in the treatment of pain</article-title>. <source>Neuropsychiatr. Dis. Treat</source>
<volume>3</volume> (<issue>1</issue>), <fpage>69</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.2147/nedt.2007.3.1.69</pub-id>
<pub-id pub-id-type="pmid">19300539</pub-id></mixed-citation>
      </ref>
      <ref id="B169">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Medcalf</surname><given-names>R. L.</given-names></name></person-group> (<year>2012</year>). <article-title>Desmoteplase: discovery, insights and opportunities for ischaemic stroke</article-title>. <source>Br. J. Pharmacol.</source>
<volume>165</volume> (<issue>1</issue>), <fpage>75</fpage>&#x2013;<lpage>89</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01514.x</pub-id>
<pub-id pub-id-type="pmid">21627637</pub-id></mixed-citation>
      </ref>
      <ref id="B170">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>Medicure Pharma</collab></person-group> (<year>2016</year>). <source>Aggrastat (Tirofiban hydrochloride) injection premixed and injection prescribing information</source> (<publisher-loc>Somerset, USA</publisher-loc>). Available at: <uri xlink:type="simple" xlink:href="https://www.aggrastathdb.com/product-formats">https://www.aggrastathdb.com/product-formats</uri> (Accessed <date-in-citation>March 19, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B171">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mehrzad</surname><given-names>M.</given-names></name><name><surname>Tuktamyshov</surname><given-names>R.</given-names></name><name><surname>Mehrzad</surname><given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>Safety, efficiency and cost effectiveness of Bivalirudin: A systematic review</article-title>. <source>World J. Cardiol.</source>
<volume>9</volume> (<issue>9</issue>), <fpage>761</fpage>&#x2013;<lpage>772</lpage>. &#xA0;<pub-id pub-id-type="doi">10.4330/wjc.v9.i9.761</pub-id>
<pub-id pub-id-type="pmid">29081910</pub-id></mixed-citation>
      </ref>
      <ref id="B172">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meng</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Bei</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Ge</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer</article-title>. <source>Cancer</source>
<volume>115</volume> (<issue>22</issue>), <fpage>5309</fpage>&#x2013;<lpage>5318</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/cncr.24602</pub-id>
<pub-id pub-id-type="pmid">19701908</pub-id></mixed-citation>
      </ref>
      <ref id="B173">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Merlin</surname><given-names>M.</given-names></name><name><surname>Gecchele</surname><given-names>E.</given-names></name><name><surname>Capaldi</surname><given-names>S.</given-names></name><name><surname>Pezzotti</surname><given-names>M.</given-names></name><name><surname>Avesani</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>Comparative evaluation of recombinant protein production in different biofactories: the green perspective</article-title>. <source>BioMed. Res. Int.</source>
<volume>2014</volume>:<fpage>14</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1155/2014/136419</pub-id>
</mixed-citation>
      </ref>
      <ref id="B174">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Messier</surname><given-names>C.</given-names></name><name><surname>Mourre</surname><given-names>C.</given-names></name><name><surname>Bontempi</surname><given-names>B.</given-names></name><name><surname>Sif</surname><given-names>J.</given-names></name><name><surname>Lazdunski</surname><given-names>M.</given-names></name><name><surname>Destrade</surname><given-names>C.</given-names></name></person-group> (<year>1991</year>). <article-title>Effect of apamin, a toxin that inhibits Ca2<sup>+-</sup>dependent K+ channels, on learning and memory processes</article-title>. <source>Brain Res.</source>
<volume>551</volume> (<issue>1-2</issue>), <fpage>322</fpage>&#x2013;<lpage>326</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/0006-8993(91)90950-z</pub-id>
<pub-id pub-id-type="pmid">1913161</pub-id></mixed-citation>
      </ref>
      <ref id="B175">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miao</surname><given-names>Q.</given-names></name><name><surname>Bi</surname><given-names>L. L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Miao</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Anticancer effects of bufalin on human hepatocellular carcinoma HepG2 cells: roles of apoptosis and autophagy</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>14</volume> (<issue>1</issue>), <fpage>1370</fpage>&#x2013;<lpage>1382</lpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/ijms14011370</pub-id>
<pub-id pub-id-type="pmid">23344047</pub-id></mixed-citation>
      </ref>
      <ref id="B176">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Monge-Fuentes</surname><given-names>V.</given-names></name><name><surname>Arenas</surname><given-names>C.</given-names></name><name><surname>Galante</surname><given-names>P.</given-names></name><name><surname>Goncalves</surname><given-names>J. C.</given-names></name><name><surname>Mortari</surname><given-names>M. R.</given-names></name><name><surname>Schwartz</surname><given-names>E. F.</given-names></name></person-group> (<year>2018</year>). <article-title>Arthropod toxins and their antinociceptive properties: From venoms to painkillers</article-title>. <source>Pharmacol. Ther.</source>
<volume>188</volume>, <fpage>176</fpage>&#x2013;<lpage>185</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.pharmthera.2018.03.007</pub-id>
<pub-id pub-id-type="pmid">29605457</pub-id></mixed-citation>
      </ref>
      <ref id="B177">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moreno</surname><given-names>M.</given-names></name><name><surname>Giralt</surname><given-names>E.</given-names></name></person-group> (<year>2015</year>). <article-title>Three valuable peptides from bee and wasp venoms for therapeutic and biotechnological use: melittin, apamin and mastoparan</article-title>. <source>Toxins</source>
<volume>7</volume> (<issue>4</issue>), <fpage>1126</fpage>&#x2013;<lpage>1150</lpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/toxins7041126</pub-id>
<pub-id pub-id-type="pmid">25835385</pub-id></mixed-citation>
      </ref>
      <ref id="B178">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morita</surname><given-names>T.</given-names></name><name><surname>Iwanaga</surname><given-names>S.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name></person-group> (<year>1976</year>). <article-title>The mechanism of activation of bovine prothrombin by an activator isolated from E<italic>chis carinatus v</italic>enon and characterization of the new active intermediates</article-title>. <source>J. Biochem.</source>
<volume>79</volume> (<issue>5</issue>), <fpage>1089</fpage>&#x2013;<lpage>1108</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a131150</pub-id>
<pub-id pub-id-type="pmid">956136</pub-id></mixed-citation>
      </ref>
      <ref id="B179">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morita</surname><given-names>T.</given-names></name></person-group> (<year>2005</year>). <article-title>Structures and functions of snake venom CLPs (C-type lectin-like proteins) with anticoagulant-, procoagulant-, and platelet-modulating activities</article-title>. <source>Toxicon</source>
<volume>45</volume> (<issue>8</issue>), <fpage>1099</fpage>&#x2013;<lpage>1114</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2005.02.021</pub-id>
<pub-id pub-id-type="pmid">15922777</pub-id></mixed-citation>
      </ref>
      <ref id="B180">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mouhat</surname><given-names>S.</given-names></name><name><surname>Visan</surname><given-names>V.</given-names></name><name><surname>Ananthakrishnan</surname><given-names>S.</given-names></name><name><surname>Wulff</surname><given-names>H.</given-names></name><name><surname>Andreotti</surname><given-names>N.</given-names></name><name><surname>Grissmer</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>K+ channel types targeted by synthetic OSK1, a toxin from O<italic>rthochirus scrobiculosus</italic> scorpion venom</article-title>. <source>Biochem. J.</source>
<volume>385</volume> (<issue>Pt 1</issue>), <fpage>95</fpage>&#x2013;<lpage>104</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1042/BJ20041379</pub-id>
<pub-id pub-id-type="pmid">15588251</pub-id></mixed-citation>
      </ref>
      <ref id="B181">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mumcuoglu</surname><given-names>K. Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Recommendations for the use of leeches in reconstructive plastic surgery</article-title>. <source>Evid. Based Complement Alternat. Med.</source>
<volume>2014</volume>, <fpage>205929</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1155/2014/205929</pub-id>
<pub-id pub-id-type="pmid">24653746</pub-id></mixed-citation>
      </ref>
      <ref id="B182">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nascimento</surname><given-names>F. D.</given-names></name><name><surname>Hayashi</surname><given-names>M. A. F.</given-names></name><name><surname>Kerkis</surname><given-names>A.</given-names></name><name><surname>Oliveira</surname><given-names>V.</given-names></name><name><surname>Oliveira</surname><given-names>E. B.</given-names></name><name><surname>Radis-Baptista</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Crotamine mediates gene delivery into cells through the binding to heparan sulfate proteoglycans</article-title>. <source>J. Biol. Chem.</source>
<volume>282</volume> (<issue>29</issue>), <fpage>21349</fpage>&#x2013;<lpage>21360</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1074/jbc.M604876200</pub-id>
<pub-id pub-id-type="pmid">17491023</pub-id></mixed-citation>
      </ref>
      <ref id="B183">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nauck</surname><given-names>M. A.</given-names></name><name><surname>Duran</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Johns</surname><given-names>D.</given-names></name><name><surname>Northrup</surname><given-names>J.</given-names></name><name><surname>Festa</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study</article-title>. <source>Diabetologia</source>
<volume>50</volume> (<issue>2</issue>), <fpage>259</fpage>&#x2013;<lpage>267</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s00125-006-0510-2</pub-id>
<pub-id pub-id-type="pmid">17160407</pub-id></mixed-citation>
      </ref>
      <ref id="B184">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nicoletti</surname><given-names>N. F.</given-names></name><name><surname>Erig</surname><given-names>T. C.</given-names></name><name><surname>Zanin</surname><given-names>R. F.</given-names></name><name><surname>Roxo</surname><given-names>M. R.</given-names></name><name><surname>Ferreira</surname><given-names>N. P.</given-names></name><name><surname>Gomez</surname><given-names>M. V.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Pre-clinical evaluation of voltage-gated calcium channel blockers derived from the spider P. <italic>nigriventer in</italic> glioma progression</article-title>. <source>Toxicon</source>
<volume>129</volume>, <fpage>58</fpage>&#x2013;<lpage>67</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2017.02.001</pub-id>
<pub-id pub-id-type="pmid">28202361</pub-id></mixed-citation>
      </ref>
      <ref id="B185">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>NIH National Cancer Institute</collab></person-group> (<year>2018</year>). <source>NCI Drug Dictionary - TRPV6 calcium channel inhibitor SOR-C13</source>. Available at: <uri xlink:type="simple" xlink:href="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/trpv6-calcium-channel-inhibitor-sor-c13">https://www.cancer.gov/publications/dictionaries/cancer-drug/def/trpv6-calcium-channel-inhibitor-sor-c13</uri> (Accessed <date-in-citation>April 19, 2018</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B186">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nunes</surname><given-names>K. P.</given-names></name><name><surname>Costa-Goncalves</surname><given-names>A.</given-names></name><name><surname>Lanza</surname><given-names>L. F.</given-names></name><name><surname>Cortes</surname><given-names>S. F.</given-names></name><name><surname>Cordeiro</surname><given-names>M. N.</given-names></name><name><surname>Richardson</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Tx2-6 toxin of the P<italic>honeutria nigriventer</italic> spider potentiates rat erectile function</article-title>. <source>Toxicon</source>
<volume>51</volume> (<issue>7</issue>), <fpage>1197</fpage>&#x2013;<lpage>1206</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2008.02.010</pub-id>
<pub-id pub-id-type="pmid">18397797</pub-id></mixed-citation>
      </ref>
      <ref id="B187">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nutescu</surname><given-names>E. A.</given-names></name><name><surname>Wittkowsky</surname><given-names>A. K.</given-names></name></person-group> (<year>2004</year>). <article-title>Direct thrombin inhibitors for anticoagulation</article-title>. <source>Ann. Pharmacother.</source>
<volume>38</volume> (<issue>1</issue>), <fpage>99</fpage>&#x2013;<lpage>109</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1345/aph.1D066</pub-id>
<pub-id pub-id-type="pmid">14742803</pub-id></mixed-citation>
      </ref>
      <ref id="B188">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Odegard</surname><given-names>P. S.</given-names></name><name><surname>Desantis</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes</article-title>. <source>Diabetes Metab. Syndr. Obes.</source>
<volume>2</volume>, <fpage>135</fpage>&#x2013;<lpage>144</lpage>. <pub-id pub-id-type="doi">10.2147/DMSO.S4444</pub-id>
<pub-id pub-id-type="pmid">21437127</pub-id></mixed-citation>
      </ref>
      <ref id="B189">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ojeda</surname><given-names>P. G.</given-names></name><name><surname>Wang</surname><given-names>C. K.</given-names></name><name><surname>Craik</surname><given-names>D. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Chlorotoxin: Structure, activity, and potential uses in cancer therapy</article-title>. <source>Biopolymers</source>
<volume>106</volume> (<issue>1</issue>), <fpage>25</fpage>&#x2013;<lpage>36</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/bip.22748</pub-id>
<pub-id pub-id-type="pmid">26418522</pub-id></mixed-citation>
      </ref>
      <ref id="B190">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ojeda</surname><given-names>P. G.</given-names></name><name><surname>Ramirez</surname><given-names>D.</given-names></name><name><surname>Alzate-Morales</surname><given-names>J.</given-names></name><name><surname>Caballero</surname><given-names>J.</given-names></name><name><surname>Kaas</surname><given-names>Q.</given-names></name><name><surname>Gonzalez</surname><given-names>W.</given-names></name></person-group> (<year>2018</year>). <article-title>Computational studies of snake venom toxins</article-title>. <source>Toxins</source>
<volume>10</volume> (<issue>1</issue>), 8. &#xA0;<pub-id pub-id-type="doi">10.3390/toxins10010008</pub-id>
</mixed-citation>
      </ref>
      <ref id="B191">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okkerse</surname><given-names>P.</given-names></name><name><surname>Hay</surname><given-names>J. L.</given-names></name><name><surname>Sitsen</surname><given-names>E.</given-names></name><name><surname>Dahan</surname><given-names>A.</given-names></name><name><surname>Klaassen</surname><given-names>E.</given-names></name><name><surname>Houghton</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties</article-title>. <source>Br. J. Clin. Pharmacol.</source>
<volume>83</volume> (<issue>4</issue>), <fpage>751</fpage>&#x2013;<lpage>763</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/bcp.13176</pub-id>
<pub-id pub-id-type="pmid">27987228</pub-id></mixed-citation>
      </ref>
      <ref id="B192">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>I. S.</given-names></name><name><surname>Ferreira</surname><given-names>I. G.</given-names></name><name><surname>Alexandre-Silva</surname><given-names>G. M.</given-names></name><name><surname>Cerni</surname><given-names>F. A.</given-names></name><name><surname>Cremonez</surname><given-names>C. M.</given-names></name><name><surname>Arantes</surname><given-names>E. C.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Scorpion toxins targeting Kv1.3 channels: insights into immunosuppression</article-title>. <source>J. Venom. Anim. Toxins Incl. Trop. Dis.</source> (<issue>25</issue>), <fpage>e148118</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1590/1678-9199-JVATITD-1481-18</pub-id>
<pub-id pub-id-type="pmid">31131004</pub-id></mixed-citation>
      </ref>
      <ref id="B193">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Orientoxin Biotech Co. Ltd</collab></person-group> (<year>2019</year>). <source>Medicine, cobratide for injection</source>. Available at: <uri xlink:type="simple" xlink:href="https://orientoxin.en.ec21.com/Medicine_Cobratide_for_Injection&#x2013;9761674.html">https://orientoxin.en.ec21.com/Medicine_Cobratide_for_Injection&#x2013;9761674.html</uri> (Accessed <date-in-citation>December 19, 2019</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B194">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ortiz</surname><given-names>E.</given-names></name><name><surname>Gurrola</surname><given-names>G. B.</given-names></name><name><surname>Schwartz</surname><given-names>E. F.</given-names></name><name><surname>Possani</surname><given-names>L. D.</given-names></name></person-group> (<year>2015</year>). <article-title>Scorpion venom components as potential candidates for drug development</article-title>. <source>Toxicon</source>
<volume>93</volume>, <fpage>125</fpage>&#x2013;<lpage>135</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2014.11.233</pub-id>
<pub-id pub-id-type="pmid">25432067</pub-id></mixed-citation>
      </ref>
      <ref id="B195">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ouriel</surname><given-names>K.</given-names></name><name><surname>Cynamon</surname><given-names>J.</given-names></name><name><surname>Weaver</surname><given-names>F. A.</given-names></name><name><surname>Dardik</surname><given-names>H.</given-names></name><name><surname>Akers</surname><given-names>D.</given-names></name><name><surname>Blebea</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>A phase I trial of alfimeprase for peripheral arterial thrombolysis</article-title>. <source>J. Vasc. Interv. Radiol.</source>
<volume>16</volume> (<issue>8</issue>), <fpage>1075</fpage>&#x2013;<lpage>1083</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1097/01.RVI.0000167863.10122.2A</pub-id>
<pub-id pub-id-type="pmid">16105919</pub-id></mixed-citation>
      </ref>
      <ref id="B196">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ovsepian</surname><given-names>S. V.</given-names></name><name><surname>O&#x2019;Leary</surname><given-names>V. B.</given-names></name><name><surname>Ayvazyan</surname><given-names>N. M.</given-names></name><name><surname>Al-Sabi</surname><given-names>A.</given-names></name><name><surname>Ntziachristos</surname><given-names>V.</given-names></name><name><surname>Dolly</surname><given-names>J. O.</given-names></name></person-group> (<year>2019</year>). <article-title>Neurobiology and therapeutic applications of neurotoxins targeting transmitter release</article-title>. <source>Pharmacol. Ther.</source>
<volume>193</volume>, <fpage>135</fpage>&#x2013;<lpage>155</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.pharmthera.2018.08.016</pub-id>
<pub-id pub-id-type="pmid">30149105</pub-id></mixed-citation>
      </ref>
      <ref id="B197">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patchett</surname><given-names>A. A.</given-names></name></person-group> (<year>1984</year>). <article-title>The chemistry of enalapril</article-title>. <source>Br. J. Clin. Pharmacol.</source>
<volume>18 Suppl 2</volume>, <fpage>201S</fpage>&#x2013;<lpage>207S</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2125.1984.tb02599.x</pub-id>
<pub-id pub-id-type="pmid">6085275</pub-id></mixed-citation>
      </ref>
      <ref id="B198">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patil</surname><given-names>C. G.</given-names></name><name><surname>Walker</surname><given-names>D. G.</given-names></name><name><surname>Miller</surname><given-names>D. M.</given-names></name><name><surname>Butte</surname><given-names>P.</given-names></name><name><surname>Morrison</surname><given-names>B.</given-names></name><name><surname>Kittle</surname><given-names>D. S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Phase 1 safety, pharmacokinetics, and fluorescence imaging study of tozuleristide (BLZ-100) in adults with newly diagnosed or recurrent gliomas</article-title>. <source>Neurosurgery</source>
<volume>85</volume> (<issue>4</issue>), <fpage>E641</fpage>&#x2013;<lpage>E648</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1093/neuros/nyz125</pub-id>
<pub-id pub-id-type="pmid">31069381</pub-id></mixed-citation>
      </ref>
      <ref id="B199">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peigneur</surname><given-names>S.</given-names></name><name><surname>de Lima</surname><given-names>M. E.</given-names></name><name><surname>Tytgat</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>P<italic>honeutria nigriventer</italic> venom: A pharmacological treasure</article-title>. <source>Toxicon</source>
<volume>151</volume>, <fpage>96</fpage>&#x2013;<lpage>110</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2018.07.008</pub-id>
<pub-id pub-id-type="pmid">30003916</pub-id></mixed-citation>
      </ref>
      <ref id="B200">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pennington</surname><given-names>M. W.</given-names></name><name><surname>Beeton</surname><given-names>C.</given-names></name><name><surname>Galea</surname><given-names>C. A.</given-names></name><name><surname>Smith</surname><given-names>B. J.</given-names></name><name><surname>Chi</surname><given-names>V.</given-names></name><name><surname>Monaghan</surname><given-names>K. P.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes</article-title>. <source>Mol. Pharmacol.</source>
<volume>75</volume> (<issue>4</issue>), <fpage>762</fpage>&#x2013;<lpage>773</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1124/mol.108.052704</pub-id>
<pub-id pub-id-type="pmid">19122005</pub-id></mixed-citation>
      </ref>
      <ref id="B201">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pennington</surname><given-names>M. W.</given-names></name><name><surname>Czerwinski</surname><given-names>A.</given-names></name><name><surname>Norton</surname><given-names>R. S.</given-names></name></person-group> (<year>2017</year>). <article-title>Peptide therapeutics from venom: Current status and potential</article-title>. <source>Bioorg. Med. Chem.</source>
<volume>26</volume>, <fpage>2738</fpage>&#x2013;<lpage>2758</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.bmc.2017.09.029</pub-id>
<pub-id pub-id-type="pmid">28988749</pub-id></mixed-citation>
      </ref>
      <ref id="B202">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Pentapharm DSM Nutritional Products Ltd</collab></person-group> (<year>2018</year>). <source>Defibrase&#xAE;</source>. Available at: <uri xlink:type="simple" xlink:href="http://www.pentapharm.com/content.cfm?nav=21&amp;content=39&amp;CFID=31651415&amp;CFTOKEN=27339979&amp;jsessionid=ae30b7ebec2f381e5bb64c68363f73c6f813">http://www.pentapharm.com/content.cfm?nav=21&amp;content=39&amp;CFID=31651415&amp;CFTOKEN=27339979&amp;jsessionid=ae30b7ebec2f381e5bb64c68363f73c6f813</uri> (Accessed <date-in-citation>March 15, 2018</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B203">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pinto</surname><given-names>A. F. M.</given-names></name><name><surname>Silva</surname><given-names>K.</given-names></name><name><surname>Guimaraes</surname><given-names>J. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Proteases from L<italic>onomia obliqua</italic> venomous secretions: Comparison of procoagulant, fibrin(ogen)olytic and amidolytic activities</article-title>. <source>Toxicon</source>
<volume>47</volume> (<issue>1</issue>), <fpage>113</fpage>&#x2013;<lpage>121</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2005.10.004</pub-id>
<pub-id pub-id-type="pmid">16360724</pub-id></mixed-citation>
      </ref>
      <ref id="B204">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pizzo</surname><given-names>S. V.</given-names></name><name><surname>Schwartz</surname><given-names>M. L.</given-names></name><name><surname>Hill</surname><given-names>R. L.</given-names></name><name><surname>McKee</surname><given-names>P. A.</given-names></name></person-group> (<year>1972</year>). <article-title>Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin</article-title>. <source>J. Clin. Invest.</source>
<volume>51</volume> (<issue>11</issue>), <fpage>2841</fpage>&#x2013;<lpage>2850</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1172/JCI107107</pub-id>
<pub-id pub-id-type="pmid">4263497</pub-id></mixed-citation>
      </ref>
      <ref id="B205">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Plateltex</surname><given-names>S. R. O.</given-names></name></person-group> (<year>2016</year>). <source>Plateltex - Device for the activation (gelification) of blood components destined to the topical non-transfusional use</source> (<publisher-loc>Czech Republic</publisher-loc>: <publisher-name>Praha</publisher-name>). Available at: <uri xlink:type="simple" xlink:href="http://www.plateltex.com/data/pdf/IFU4.3plateltexACTJUNE2016ENG.pdf">http://www.plateltex.com/data/pdf/IFU4.3plateltexACTJUNE2016ENG.pdf</uri> (Accessed <date-in-citation>March 19, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B206">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Plateltex</surname><given-names>S. R. O.</given-names></name></person-group> (<year>2018</year>). <source>Plateltex - biologicals, clinical use, information sheet</source> (<publisher-loc>Prague, Czech Republic</publisher-loc>). Available at: <uri xlink:type="simple" xlink:href="https://www.plateltex.com/">https://www.plateltex.com/</uri> (Accessed <date-in-citation>April 19, 2018</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B207">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pope</surname><given-names>J. E.</given-names></name><name><surname>Deer</surname><given-names>T. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Ziconotide: a clinical update and pharmacologic review</article-title>. <source>Expert Opin. Pharmacother.</source>
<volume>14</volume> (<issue>7</issue>), <fpage>957</fpage>&#x2013;<lpage>966</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1517/14656566.2013.784269</pub-id>
<pub-id pub-id-type="pmid">23537340</pub-id></mixed-citation>
      </ref>
      <ref id="B208">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pucca</surname><given-names>M. B.</given-names></name><name><surname>Bertolini</surname><given-names>T. B.</given-names></name><name><surname>Cerni</surname><given-names>F. A.</given-names></name><name><surname>Bordon</surname><given-names>K. C. F.</given-names></name><name><surname>Peigneur</surname><given-names>S.</given-names></name><name><surname>Tytgat</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Immunosuppressive evidence of T<italic>ityus serrulatus</italic> toxins Ts6 and Ts15: insights of a novel K+ channel pattern in T cells</article-title>. <source>Immunology</source>
<volume>147</volume> (<issue>2</issue>), <fpage>240</fpage>&#x2013;<lpage>250</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/imm.12559</pub-id>
<pub-id pub-id-type="pmid">26595158</pub-id></mixed-citation>
      </ref>
      <ref id="B209">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>A.</given-names></name><name><surname>Inagaki</surname><given-names>Y.</given-names></name><name><surname>Kokudo</surname><given-names>N.</given-names></name><name><surname>Tamura</surname><given-names>S.</given-names></name><name><surname>Nakata</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Antitumor activity of extracts and compounds from the skin of the toad B<italic>ufo bufo gargarizans</italic> Cantor</article-title>. <source>Int. Immunopharmacol.</source>
<volume>11</volume> (<issue>3</issue>), <fpage>342</fpage>&#x2013;<lpage>349</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.intimp.2010.12.007</pub-id>
<pub-id pub-id-type="pmid">21185919</pub-id></mixed-citation>
      </ref>
      <ref id="B210">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qin</surname><given-names>T. J.</given-names></name><name><surname>Zhao</surname><given-names>X. H.</given-names></name><name><surname>Yun</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L. X.</given-names></name><name><surname>Ruan</surname><given-names>Z. P.</given-names></name><name><surname>Pan</surname><given-names>B. R.</given-names></name></person-group> (<year>2008</year>). <article-title>Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma</article-title>. <source>World J. Gastroenterol.</source>
<volume>14</volume> (<issue>33</issue>), <fpage>5210</fpage>&#x2013;<lpage>5216</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.14.5210</pub-id>
<pub-id pub-id-type="pmid">18777599</pub-id></mixed-citation>
      </ref>
      <ref id="B211">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Ram</surname><given-names>N.</given-names></name><name><surname>Jaumain</surname><given-names>E.</given-names></name><name><surname>Ronjat</surname><given-names>M.</given-names></name><name><surname>Pirollet</surname><given-names>F.</given-names></name><name><surname>De Waard</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). &#x201C;<article-title>Maurocalcine-derivatives as biotechnological tools for the penetration of cell-impermeable compounds</article-title>,&#x201D; in <source>Animal toxins: state of the art-perspectives in health and biotechnology</source>, <edition>1st ed.</edition> Eds. <person-group person-group-type="editor"><name><surname>Lima</surname><given-names>M. E. D.</given-names></name><name><surname>Pimenta</surname><given-names>A. M. D. C.</given-names></name><name><surname>Martin-Eauclaire</surname><given-names>M. F.</given-names></name><name><surname>Zingali</surname><given-names>R. B.</given-names></name><name><surname>Rochat</surname><given-names>H.</given-names></name></person-group> (<publisher-loc>Belo Horizonte</publisher-loc>: <publisher-name>Editora UFMG</publisher-name>), <fpage>715</fpage>&#x2013;<lpage>732</lpage>.</mixed-citation>
      </ref>
      <ref id="B212">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>J. D.</given-names></name><name><surname>Flynn</surname><given-names>N. H.</given-names></name></person-group> (<year>2015</year>). <article-title>Cell-penetrating peptides transport therapeutics into cells</article-title>. <source>Pharmacol. Ther.</source>
<volume>154</volume>, <fpage>78</fpage>&#x2013;<lpage>86</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.pharmthera.2015.07.003</pub-id>
<pub-id pub-id-type="pmid">26210404</pub-id></mixed-citation>
      </ref>
      <ref id="B213">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Reid</surname><given-names>P. F.</given-names></name><name><surname>Raymond</surname><given-names>L. N.</given-names></name></person-group> (<year>2010</year>). <source>Modified elapid venoms as stimulators of the immune reaction</source>, 11/592896 application number.</mixed-citation>
      </ref>
      <ref id="B214">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reid</surname><given-names>H. A.</given-names></name></person-group> (<year>1971</year>). <article-title>Therapeutic defibrination by ancrod (Arvin)</article-title>. <source>Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch.</source>
<volume>95</volume> (<issue>2</issue>), <fpage>209</fpage>&#x2013;<lpage>215</lpage>.<pub-id pub-id-type="pmid">4106010</pub-id></mixed-citation>
      </ref>
      <ref id="B215">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reid</surname><given-names>P. F.</given-names></name></person-group> (<year>2007</year>). <article-title>Alpha-cobratoxin as a possible therapy for multiple sclerosis: a review of the literature leading to its development for this application</article-title>. <source>Crit. Rev. Immunol.</source>
<volume>27</volume> (<issue>4</issue>), <fpage>291</fpage>&#x2013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1615/CritRevImmunol.v27.i4.10</pub-id>
<pub-id pub-id-type="pmid">18197810</pub-id></mixed-citation>
      </ref>
      <ref id="B216">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reis</surname><given-names>C. V.</given-names></name><name><surname>Andrade</surname><given-names>S. A.</given-names></name><name><surname>Ramos</surname><given-names>O. H. P.</given-names></name><name><surname>Ramos</surname><given-names>C. R. R.</given-names></name><name><surname>Ho</surname><given-names>P. L.</given-names></name><name><surname>Batista</surname><given-names>I. D. C.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Lopap, a prothrombin activator from L<italic>onomia obliqua</italic> belonging to the lipocalin family: recombinant production, biochemical characterization and structure-function insights</article-title>. <source>Biochem. J.</source>
<volume>398</volume>, <fpage>295</fpage>&#x2013;<lpage>302</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1042/bj20060325</pub-id>
<pub-id pub-id-type="pmid">16734589</pub-id></mixed-citation>
      </ref>
      <ref id="B217">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ren</surname><given-names>Y. D.</given-names></name><name><surname>Li</surname><given-names>C. C.</given-names></name><name><surname>Chang</surname><given-names>J. L.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>Y. H.</given-names></name><name><surname>Chu</surname><given-names>X. P.</given-names></name></person-group> (<year>2018</year>). <article-title>Hi1a as a novel neuroprotective agent for ischemic stroke by inhibition of acid-sensing ion channel 1a</article-title>. <source>Transl. Stroke Res.</source>
<volume>9</volume> (<issue>2</issue>), <fpage>96</fpage>&#x2013;<lpage>98</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s12975-017-0575-x</pub-id>
<pub-id pub-id-type="pmid">29027122</pub-id></mixed-citation>
      </ref>
      <ref id="B218">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rigo</surname><given-names>F. K.</given-names></name><name><surname>Trevisan</surname><given-names>G.</given-names></name><name><surname>De Pra</surname><given-names>S. D. T.</given-names></name><name><surname>Cordeiro</surname><given-names>M. N.</given-names></name><name><surname>Borges</surname><given-names>M. H.</given-names></name><name><surname>Silva</surname><given-names>J. F.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The spider toxin Ph&#x3B1;1&#x3B2; recombinant possesses strong analgesic activity</article-title>. <source>Toxicon</source>
<volume>133</volume>, <fpage>145</fpage>&#x2013;<lpage>152</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2017.05.018</pub-id>
<pub-id pub-id-type="pmid">28526335</pub-id></mixed-citation>
      </ref>
      <ref id="B219">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Romero</surname><given-names>H. K.</given-names></name><name><surname>Christensen</surname><given-names>S. B.</given-names></name><name><surname>Mannelli</surname><given-names>L. D.</given-names></name><name><surname>Gajewiak</surname><given-names>J.</given-names></name><name><surname>Ramachandra</surname><given-names>R.</given-names></name><name><surname>Elmslie</surname><given-names>K. S.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Inhibition of&#xA0;&#x3B1;9&#x3B1;10&#xA0;nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>114</volume> (<issue>10</issue>), <fpage>E1825</fpage>&#x2013;<lpage>E1832</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1073/pnas.1621433114</pub-id>
<pub-id pub-id-type="pmid">28223528</pub-id></mixed-citation>
      </ref>
      <ref id="B220">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>R&#xF6;misch</surname><given-names>J.</given-names></name><name><surname>Diehl</surname><given-names>K. H.</given-names></name><name><surname>Hoffmann</surname><given-names>D.</given-names></name><name><surname>Krahl-Mateblowski</surname><given-names>U.</given-names></name><name><surname>Reers</surname><given-names>M.</given-names></name><name><surname>St&#xFC;ber</surname><given-names>W.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Comparison of <italic>in vitro</italic> and <italic>in vivo</italic> properties of rhirudin (HBW 023) and a synthetic analogous peptide</article-title>. <source>Haemostasis</source>
<volume>23</volume> (<issue>5</issue>), <fpage>249</fpage>&#x2013;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1159/000216883</pub-id>
<pub-id pub-id-type="pmid">8175045</pub-id></mixed-citation>
      </ref>
      <ref id="B221">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>RxList</collab></person-group> (<year>2019</year>). <source>Search</source>. Available at: <uri xlink:type="simple" xlink:href="https://www.rxlist.com/script/main/hp.asp">https://www.rxlist.com/script/main/hp.asp</uri> (Accessed <date-in-citation>December 19, 2019</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B222">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Salehi</surname><given-names>B.</given-names></name><name><surname>Sestito</surname><given-names>S.</given-names></name><name><surname>Rapposelli</surname><given-names>S.</given-names></name><name><surname>Peron</surname><given-names>G.</given-names></name><name><surname>Calina</surname><given-names>D.</given-names></name><name><surname>Sharifi-Rad</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Epibatidine: a promising natural alkaloid in health</article-title>. <source>Biomolecules</source>
<volume>9</volume> (<issue>1</issue>):<fpage>6</fpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/biom9010006</pub-id>
</mixed-citation>
      </ref>
      <ref id="B223">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sample</surname><given-names>C. J.</given-names></name><name><surname>Hudak</surname><given-names>K. E.</given-names></name><name><surname>Barefoot</surname><given-names>B. E.</given-names></name><name><surname>Koci</surname><given-names>M. D.</given-names></name><name><surname>Wanyonyi</surname><given-names>M. S.</given-names></name><name><surname>Abraham</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses</article-title>. <source>Peptides</source>
<volume>48</volume>, <fpage>96</fpage>&#x2013;<lpage>105</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.peptides.2013.07.014</pub-id>
<pub-id pub-id-type="pmid">23891650</pub-id></mixed-citation>
      </ref>
      <ref id="B224">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Santos</surname><given-names>L. D.</given-names></name><name><surname>Pieroni</surname><given-names>M.</given-names></name><name><surname>Menegasso</surname><given-names>A. R. S.</given-names></name><name><surname>Pinto</surname><given-names>J.</given-names></name><name><surname>Palma</surname><given-names>M. S.</given-names></name></person-group> (<year>2011</year>). <article-title>A new scenario of bioprospecting of Hymenoptera venoms through proteomic approach</article-title>. <source>J. Venom. Anim. Toxins Incl. Trop. Dis.</source>
<volume>17</volume> (<issue>4</issue>), <fpage>364</fpage>&#x2013;<lpage>377</lpage>. <pub-id pub-id-type="doi">10.1590/S1678-91992011000300004</pub-id>
</mixed-citation>
      </ref>
      <ref id="B225">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sato</surname><given-names>A. C.</given-names></name><name><surname>Bosch</surname><given-names>R. V.</given-names></name><name><surname>Will</surname><given-names>S. E. A.</given-names></name><name><surname>Alvarez-Flores</surname><given-names>M. P.</given-names></name><name><surname>Goldfeder</surname><given-names>M. B.</given-names></name><name><surname>Pasqualoto</surname><given-names>K. F. M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Exploring the i<italic>n vivo</italic> wound healing effects of a recombinant hemolin from the caterpillar L<italic>onomia obliqua</italic>
</article-title>. <source>J. Venom. Anim. Toxins Incl. Trop. Dis.</source>
<volume>22</volume>, <fpage>36</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1186/s40409-016-0093-4</pub-id>
<pub-id pub-id-type="pmid">28031734</pub-id></mixed-citation>
      </ref>
      <ref id="B226">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scannell</surname><given-names>J. W.</given-names></name><name><surname>Blanckley</surname><given-names>A.</given-names></name><name><surname>Boldon</surname><given-names>H.</given-names></name><name><surname>Warrington</surname><given-names>B.</given-names></name></person-group> (<year>2012</year>). <article-title>Diagnosing the decline in pharmaceutical R&amp;D efficiency</article-title>. <source>Nat. Rev. Drug Discovery</source>
<volume>11</volume> (<issue>3</issue>), <fpage>191</fpage>&#x2013;<lpage>200</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1038/nrd3681</pub-id>
<pub-id pub-id-type="pmid">22378269</pub-id></mixed-citation>
      </ref>
      <ref id="B227">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scarborough</surname><given-names>R. M.</given-names></name><name><surname>Rose</surname><given-names>J. W.</given-names></name><name><surname>Hsu</surname><given-names>M. A.</given-names></name><name><surname>Phillips</surname><given-names>D. R.</given-names></name><name><surname>Fried</surname><given-names>V. A.</given-names></name><name><surname>Campbell</surname><given-names>A. M.</given-names></name><etal/></person-group> (<year>1991</year>). <article-title>Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of S<italic>istrurus m. barbouri</italic>
</article-title>. <source>J. Biol. Chem.</source>
<volume>266</volume> (<issue>15</issue>), <fpage>9359</fpage>&#x2013;<lpage>9362</lpage>.<pub-id pub-id-type="pmid">2033037</pub-id></mixed-citation>
      </ref>
      <ref id="B228">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scarborough</surname><given-names>R. M.</given-names></name><name><surname>Naughton</surname><given-names>M. A.</given-names></name><name><surname>Teng</surname><given-names>W.</given-names></name><name><surname>Rose</surname><given-names>J.</given-names></name><name><surname>Phillips</surname><given-names>D.</given-names></name><name><surname>Nannizzi</surname><given-names>L.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa</article-title>. <source>J. Biol. Chem.</source>
<volume>268</volume> (<issue>2</issue>), <fpage>1066</fpage>&#x2013;<lpage>1073</lpage>.<pub-id pub-id-type="pmid">8419315</pub-id></mixed-citation>
      </ref>
      <ref id="B229">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scarborough</surname><given-names>R. M.</given-names></name></person-group> (<year>1999</year>). <article-title>Development of eptifibatide</article-title>. <source>Am. Heart J.</source>
<volume>138</volume> (<issue>6</issue>), <fpage>1093</fpage>&#x2013;<lpage>1104</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/s0002-8703(99)70075-x</pub-id>
<pub-id pub-id-type="pmid">10577440</pub-id></mixed-citation>
      </ref>
      <ref id="B230">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schechter</surname><given-names>M. E.</given-names></name><name><surname>Andrade</surname><given-names>B. B.</given-names></name><name><surname>He</surname><given-names>T.</given-names></name><name><surname>Richter</surname><given-names>G. H.</given-names></name><name><surname>Tosh</surname><given-names>K. W.</given-names></name><name><surname>Policicchio</surname><given-names>B. B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Inflammatory monocytes expressing tissue factor drive SIV and HIV coagulopathy</article-title>. <source>Sci. Transl. Med.</source>
<volume>9</volume> (<issue>405</issue>), <elocation-id>eaam5441</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1126/scitranslmed.aam5441</pub-id>
<pub-id pub-id-type="pmid">28855397</pub-id></mixed-citation>
      </ref>
      <ref id="B231">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwartsmann</surname><given-names>G.</given-names></name><name><surname>DiLeone</surname><given-names>L. P.</given-names></name><name><surname>Horowitz</surname><given-names>M.</given-names></name><name><surname>Schunemann</surname><given-names>D.</given-names></name><name><surname>Cancella</surname><given-names>A.</given-names></name><name><surname>Pereira</surname><given-names>A. S.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies</article-title>. <source>Invest. New Drugs</source>
<volume>24</volume> (<issue>5</issue>), <fpage>403</fpage>&#x2013;<lpage>412</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s10637-006-6886-5</pub-id>
<pub-id pub-id-type="pmid">16505950</pub-id></mixed-citation>
      </ref>
      <ref id="B232">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scott</surname><given-names>D. A.</given-names></name><name><surname>Wright</surname><given-names>C. E.</given-names></name><name><surname>Angus</surname><given-names>J. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>451</volume> (<issue>3</issue>), <fpage>279</fpage>&#x2013;<lpage>286</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-2999(02)02247-1</pub-id>
<pub-id pub-id-type="pmid">12242089</pub-id></mixed-citation>
      </ref>
      <ref id="B233">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seon</surname><given-names>G. M.</given-names></name><name><surname>Lee</surname><given-names>M. H.</given-names></name><name><surname>Kwon</surname><given-names>B. J.</given-names></name><name><surname>Kim</surname><given-names>M. S.</given-names></name><name><surname>Koo</surname><given-names>M. A.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Functional improvement of hemostatic dressing by addition of recombinant batroxobin</article-title>. <source>Acta Biomater.</source>
<volume>48</volume>, <fpage>175</fpage>&#x2013;<lpage>185</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.actbio.2016.10.024</pub-id>
<pub-id pub-id-type="pmid">27769944</pub-id></mixed-citation>
      </ref>
      <ref id="B234">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serrano</surname><given-names>S. M. T.</given-names></name></person-group> (<year>2013</year>). <article-title>The long road of research on snake venom serine proteinases</article-title>. <source>Toxicon</source>
<volume>62</volume>, <fpage>19</fpage>&#x2013;<lpage>26</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2012.09.003</pub-id>
<pub-id pub-id-type="pmid">23010164</pub-id></mixed-citation>
      </ref>
      <ref id="B235">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shah</surname><given-names>A. R.</given-names></name><name><surname>Scher</surname><given-names>L.</given-names></name></person-group> (<year>2007</year>). <article-title>Drug evaluation: alfimeprase, a plasminogen-independent thrombolytic</article-title>. <source>IDrugs</source>
<volume>10</volume> (<issue>5</issue>), <fpage>329</fpage>&#x2013;<lpage>335</lpage>.<pub-id pub-id-type="pmid">17487785</pub-id></mixed-citation>
      </ref>
      <ref id="B236">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Liang</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Shao</surname><given-names>A.</given-names></name><name><surname>Zhou</surname><given-names>K.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Desmoteplase for acute ischemic stroke within 3 to 9&#x2009;Hours after symptom onset: Evidence from randomized controlled trials</article-title>. <source>Sci. Rep.</source>
<volume>6</volume>:<elocation-id>33989</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1038/srep33989</pub-id>
<pub-id pub-id-type="pmid">27671010</pub-id></mixed-citation>
      </ref>
      <ref id="B237">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shibao</surname><given-names>P. Y. T.</given-names></name><name><surname>Cologna</surname><given-names>C. T.</given-names></name><name><surname>Morandi</surname><given-names>R.</given-names></name><name><surname>Wiezel</surname><given-names>G. A.</given-names></name><name><surname>Fujimura</surname><given-names>P. T.</given-names></name><name><surname>Ueira-Vieira</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Deep sequencing analysis of toad R<italic>hinella schneideri</italic> skin glands and partial biochemical characterization of its cutaneous secretion</article-title>. <source>J. Venom. Anim. Toxins Incl. Trop. Dis.</source>
<volume>24</volume>, 36. &#xA0;<pub-id pub-id-type="doi">10.1186/s40409-018-0173-8</pub-id>
</mixed-citation>
      </ref>
      <ref id="B238">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sig</surname><given-names>A. K.</given-names></name><name><surname>Guney</surname><given-names>M.</given-names></name><name><surname>Uskudar Guclu</surname><given-names>A.</given-names></name><name><surname>Ozmen</surname><given-names>E.</given-names></name></person-group> (<year>2017</year>). <article-title>Medicinal leech therapy - an overall perspective</article-title>. <source>Integr. Med. Res.</source>
<volume>6</volume> (<issue>4</issue>), <fpage>337</fpage>&#x2013;<lpage>343</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.imr.2017.08.001</pub-id>
<pub-id pub-id-type="pmid">29296560</pub-id></mixed-citation>
      </ref>
      <ref id="B239">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Silva</surname><given-names>C. N.</given-names></name><name><surname>Nunes</surname><given-names>K. P.</given-names></name><name><surname>Torres</surname><given-names>F. S.</given-names></name><name><surname>Cassoli</surname><given-names>J. S.</given-names></name><name><surname>Santos</surname><given-names>D. M.</given-names></name><name><surname>Almeida</surname><given-names>F. D.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>PnPP-19, a synthetic and nontoxic peptide designed from a P<italic>honeutria nigriventer</italic> toxin, potentiates erectile function via NO/cGMP</article-title>. <source>J. Urol</source>
<volume>194</volume> (<issue>5</issue>), <fpage>1481</fpage>&#x2013;<lpage>1490</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.juro.2015.06.081</pub-id>
<pub-id pub-id-type="pmid">26119670</pub-id></mixed-citation>
      </ref>
      <ref id="B240">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Davies</surname><given-names>G.</given-names></name><name><surname>Alenazi</surname><given-names>Y.</given-names></name><name><surname>Eaton</surname><given-names>J. R. O.</given-names></name><name><surname>Kawamura</surname><given-names>A.</given-names></name><name><surname>Bhattacharya</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Yeast surface display identifies a family of evasins from ticks with novel polyvalent CC chemokine-binding activities</article-title>. <source>Sci. Rep.</source>
<volume>7</volume> (<issue>1</issue>), <fpage>4267</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1038/s41598-017-04378-1</pub-id>
<pub-id pub-id-type="pmid">28655871</pub-id></mixed-citation>
      </ref>
      <ref id="B241">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>A. P.</given-names></name></person-group> (<year>2010</year>). <article-title>Medicinal leech therapy (hirudotherapy): a brief overview</article-title>. <source>Complement Ther. Clin. Pract.</source>
<volume>16</volume> (<issue>4</issue>), <fpage>213</fpage>&#x2013;<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1016/j.ctcp.2009.11.005</pub-id>
<pub-id pub-id-type="pmid">20920805</pub-id></mixed-citation>
      </ref>
      <ref id="B242">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siramshetty</surname><given-names>V. B.</given-names></name><name><surname>Nickel</surname><given-names>J.</given-names></name><name><surname>Omieczynski</surname><given-names>C.</given-names></name><name><surname>Gohlke</surname><given-names>B. O.</given-names></name><name><surname>Drwal</surname><given-names>M. N.</given-names></name><name><surname>Preissner</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>Withdrawn - a resource for withdrawn and discontinued drugs</article-title>. <source>Nucleic Acids Res.</source>
<volume>44</volume> (<issue>D1</issue>), <fpage>D1080</fpage>&#x2013;<lpage>D1086</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1093/nar/gkv1192</pub-id>
<pub-id pub-id-type="pmid">26553801</pub-id></mixed-citation>
      </ref>
      <ref id="B243">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>H. S.</given-names></name><name><surname>Deer</surname><given-names>T. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain</article-title>. <source>Ther. Clin. Risk Manag.</source>
<volume>5</volume> (<issue>3</issue>), <fpage>521</fpage>&#x2013;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.2147/TCRM.S4438</pub-id>
<pub-id pub-id-type="pmid">19707262</pub-id></mixed-citation>
      </ref>
      <ref id="B244">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>Y. M.</given-names></name><name><surname>Tang</surname><given-names>X. X.</given-names></name><name><surname>Chen</surname><given-names>X. G.</given-names></name><name><surname>Gao</surname><given-names>B. B.</given-names></name><name><surname>Gao</surname><given-names>E.</given-names></name><name><surname>Bai</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Effects of scorpion venom bioactive polypolypeptides on platelet aggregation and thrombosis and plasma 6-keto-PG F1alpha and TXB2 in rabbits and rats</article-title>. <source>Toxicon</source>
<volume>46</volume> (<issue>2</issue>), <fpage>230</fpage>&#x2013;<lpage>235</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.toxicon.2005.04.012</pub-id>
<pub-id pub-id-type="pmid">15975616</pub-id></mixed-citation>
      </ref>
      <ref id="B245">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>Soricimed</collab></person-group> (<year>2018</year>). <source>SOR-C13 clinical development program -&#xA0;A first-in-class drug candidate in development for the treatment of solid-tumor cancer</source>. Available at: <uri xlink:type="simple" xlink:href="https://www.soricimed.com/sor-c13.htm">https://www.soricimed.com/sor-c13.htm</uri> (Accessed <date-in-citation>April 19, 2018</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B246">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Souza</surname><given-names>A. H.</given-names></name><name><surname>Ferreira</surname><given-names>J.</given-names></name><name><surname>Cordeiro Mdo</surname><given-names>N.</given-names></name><name><surname>Vieira</surname><given-names>L. B.</given-names></name><name><surname>De Castro</surname><given-names>C. J.</given-names></name><name><surname>Trevisan</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Analgesic effect in rodents of native and recombinant Ph&#x3B1;1&#x3B2; toxin, a high-voltage-activated calcium channel blocker isolated from armed spider venom</article-title>. <source>Pain</source>
<volume>140</volume> (<issue>1</issue>), <fpage>115</fpage>&#x2013;<lpage>126</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.pain.2008.07.014</pub-id>
<pub-id pub-id-type="pmid">18774645</pub-id></mixed-citation>
      </ref>
      <ref id="B247">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spotnitz</surname><given-names>W. D.</given-names></name></person-group> (<year>2014</year>). <article-title>Fibrin sealant: The only approved hemostat, sealant, and adhesive - a laboratory and clinical perspective</article-title>. <source>ISRN Surg.</source>
<volume>2014</volume>:<elocation-id>203943</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1155/2014/203943</pub-id>
<pub-id pub-id-type="pmid">24729902</pub-id></mixed-citation>
      </ref>
      <ref id="B248">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stocker</surname><given-names>K.</given-names></name><name><surname>Fischer</surname><given-names>H.</given-names></name><name><surname>Meier</surname><given-names>J.</given-names></name></person-group> (<year>1988</year>). <article-title>Practical application of the protein C activator Protac from A<italic>gkistrodon contortrix</italic> venom</article-title>. <source>Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch.</source>
<volume>115</volume> (<issue>3</issue>), <fpage>260</fpage>&#x2013;<lpage>264</lpage>.<pub-id pub-id-type="pmid">2465212</pub-id></mixed-citation>
      </ref>
      <ref id="B249">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Stocker</surname><given-names>K.</given-names></name></person-group> (<year>1978</year>). &#x201C;<article-title>Defibrinogenation with thrombin-like snake venom enzymes</article-title>,&#x201D; in <source>Fibrinolytics and antifibrinolytics</source>. Ed. <person-group person-group-type="editor"><name><surname>Markwardt</surname><given-names>F.</given-names></name></person-group> (<publisher-loc>Berlin, Heidelberg, New York</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>), <fpage>451</fpage>&#x2013;<lpage>484</lpage>.</mixed-citation>
      </ref>
      <ref id="B250">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stransky</surname><given-names>S.</given-names></name><name><surname>Costal-Oliveira</surname><given-names>F.</given-names></name><name><surname>Lopes-de-Souza</surname><given-names>L.</given-names></name><name><surname>Guerra-Duarte</surname><given-names>C.</given-names></name><name><surname>Chavez-Olortegui</surname><given-names>C.</given-names></name><name><surname>Braga</surname><given-names>V. M. M.</given-names></name></person-group> (<year>2018</year>). <article-title>In vitro assessment of cytotoxic activities of L<italic>achesis muta muta</italic> snake venom</article-title>. <source>PloS Negl. Trop. Dis.</source>
<volume>12</volume> (<issue>4</issue>), <fpage>e0006427</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1371/journal.pntd.0006427</pub-id>
<pub-id pub-id-type="pmid">29659601</pub-id></mixed-citation>
      </ref>
      <ref id="B251">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Linh</surname><given-names>C.</given-names></name></person-group> (<year>2003</year>). <article-title>HPLC separation and determination of bufadienolide in cinobufacini injection</article-title>. <source>Chin. Tradit. Pat. Med.</source>
<volume>25</volume>, <fpage>24</fpage>&#x2013;<lpage>27</lpage>.</mixed-citation>
      </ref>
      <ref id="B252">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swenson</surname><given-names>S.</given-names></name><name><surname>Toombs</surname><given-names>C. F.</given-names></name><name><surname>Pena</surname><given-names>L.</given-names></name><name><surname>Johansson</surname><given-names>J.</given-names></name><name><surname>Markland</surname><given-names>F. S.</given-names></name></person-group> (<year>2004</year>). <article-title>Alpha-fibrinogenases</article-title>. <source>Curr. Drug Targets Cardiovasc. Haematol. Disord.</source>
<volume>4</volume> (<issue>4</issue>), <fpage>417</fpage>&#x2013;<lpage>435</lpage>. <pub-id pub-id-type="doi">10.2174/1568006043335754</pub-id>
<pub-id pub-id-type="pmid">15578961</pub-id></mixed-citation>
      </ref>
      <ref id="B253">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Swenson</surname><given-names>S.</given-names></name><name><surname>Markland</surname><given-names>F. S.</given-names></name></person-group> (<year>2013</year>). &#x201C;<article-title>Fibrolase</article-title>,&#x201D; in <source>Handbook of proteolytic enzymes</source>. Eds. <person-group person-group-type="editor"><name><surname>Rawlings</surname><given-names>N. D.</given-names></name><name><surname>Salvesen</surname><given-names>G.</given-names></name></person-group> (<publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>), <fpage>972</fpage>&#x2013;<lpage>976</lpage>.</mixed-citation>
      </ref>
      <ref id="B254">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tabacova</surname><given-names>S. A.</given-names></name><name><surname>Kimmel</surname><given-names>C. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity - A review</article-title>. <source>Reprod. Toxicol.</source>
<volume>15</volume> (<issue>5</issue>), <fpage>467</fpage>&#x2013;<lpage>478</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/s0890-6238(01)00161-7</pub-id>
<pub-id pub-id-type="pmid">11780954</pub-id></mixed-citation>
      </ref>
      <ref id="B255">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tamimi</surname><given-names>N. A. M.</given-names></name><name><surname>Ellis</surname><given-names>P.</given-names></name></person-group> (<year>2009</year>). <article-title>Drug development: from concept to marketing</article-title>! <source>Nephron Clin. Pract.</source>
<volume>113</volume> (<issue>3</issue>), <fpage>C125</fpage>&#x2013;<lpage>C131</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1159/000232592</pub-id>
<pub-id pub-id-type="pmid">19729922</pub-id></mixed-citation>
      </ref>
      <ref id="B256">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tanner</surname><given-names>M. R.</given-names></name><name><surname>Tajhya</surname><given-names>R. B.</given-names></name><name><surname>Huq</surname><given-names>R.</given-names></name><name><surname>Gehrmann</surname><given-names>E. J.</given-names></name><name><surname>Rodarte</surname><given-names>K. E.</given-names></name><name><surname>Atik</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1 R14A and its PEGylated analog</article-title>. <source>Clin. Immunol.</source>
<volume>180</volume>, <fpage>45</fpage>&#x2013;<lpage>57</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.clim.2017.03.014</pub-id>
<pub-id pub-id-type="pmid">28389388</pub-id></mixed-citation>
      </ref>
      <ref id="B257">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tans</surname><given-names>G.</given-names></name><name><surname>Rosing</surname><given-names>J.</given-names></name></person-group> (<year>2001</year>). <article-title>Snake venom activators of factor X: an overview</article-title>. <source>Haemostasis</source>
<volume>31</volume> (<issue>3-6</issue>), <fpage>225</fpage>&#x2013;<lpage>233</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1159/000048067</pub-id>
<pub-id pub-id-type="pmid">11910189</pub-id></mixed-citation>
      </ref>
      <ref id="B258">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tansi</surname><given-names>F. L.</given-names></name><name><surname>Filatova</surname><given-names>M. P.</given-names></name><name><surname>Koroev</surname><given-names>D. O.</given-names></name><name><surname>Volpina</surname><given-names>O. M.</given-names></name><name><surname>Lange</surname><given-names>S.</given-names></name><name><surname>Schumann</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>New generation CPPs show distinct selectivity for cancer and noncancer cells</article-title>. <source>J. Cell Biochem.</source>
<volume>120</volume> (<issue>4</issue>), <fpage>6528</fpage>&#x2013;<lpage>6541</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/jcb.27943</pub-id>
<pub-id pub-id-type="pmid">30362167</pub-id></mixed-citation>
      </ref>
      <ref id="B259">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tarcha</surname><given-names>E. J.</given-names></name><name><surname>Chi</surname><given-names>V.</given-names></name><name><surname>Munoz-Elias</surname><given-names>E. J.</given-names></name><name><surname>Bailey</surname><given-names>D.</given-names></name><name><surname>Londono</surname><given-names>L. M.</given-names></name><name><surname>Upadhyay</surname><given-names>S. K.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>342</volume> (<issue>3</issue>), <fpage>642</fpage>&#x2013;<lpage>653</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1124/jpet.112.191890</pub-id>
<pub-id pub-id-type="pmid">22637724</pub-id></mixed-citation>
      </ref>
      <ref id="B260">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tcheng</surname><given-names>J. E.</given-names></name><name><surname>O&#x2019;Shea</surname><given-names>J. C.</given-names></name></person-group> (<year>2002</year>). <article-title>Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa</article-title>. <source>Expert OpinPharmacother.</source>
<volume>3</volume> (<issue>8</issue>), <fpage>1199</fpage>&#x2013;<lpage>1210</lpage>. <pub-id pub-id-type="doi">10.1517/14656566.3.8.1199</pub-id>
</mixed-citation>
      </ref>
      <ref id="B261">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tokunaga</surname><given-names>F.</given-names></name><name><surname>Nagasawa</surname><given-names>K.</given-names></name><name><surname>Tamura</surname><given-names>S.</given-names></name><name><surname>Miyata</surname><given-names>T.</given-names></name><name><surname>Iwanaga</surname><given-names>S.</given-names></name><name><surname>Kisiel</surname><given-names>W.</given-names></name></person-group> (<year>1988</year>). <article-title>The factor V-activating enzyme (RVV-V) from Russell&#x2019;s viper venom. Identification of isoproteins RVV-V alpha, -V beta, and -V gamma and their complete amino acid sequences</article-title>. <source>J. Biol. Chem.</source>
<volume>263</volume> (<issue>33</issue>), <fpage>17471</fpage>&#x2013;<lpage>17481</lpage>.<pub-id pub-id-type="pmid">3053712</pub-id></mixed-citation>
      </ref>
      <ref id="B262">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Topol</surname><given-names>E. J.</given-names></name><name><surname>Byzova</surname><given-names>T. V.</given-names></name><name><surname>Plow</surname><given-names>E. F.</given-names></name></person-group> (<year>1999</year>). <article-title>Platelet GPIIb-IIIa blockers</article-title>. <source>Lancet</source>
<volume>353</volume> (<issue>9148</issue>), <fpage>227</fpage>&#x2013;<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(98)11086-3</pub-id>
<pub-id pub-id-type="pmid">9923894</pub-id></mixed-citation>
      </ref>
      <ref id="B263">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tornesello</surname><given-names>A. L.</given-names></name><name><surname>Buonaguro</surname><given-names>L.</given-names></name><name><surname>Tornesello</surname><given-names>M. L.</given-names></name><name><surname>Buonaguro</surname><given-names>F. M.</given-names></name></person-group> (<year>2017</year>). <article-title>New insights in the design of bioactive peptides and chelating agents for imaging and therapy in oncology</article-title>. <source>Molecules</source>
<volume>22</volume> (<issue>8</issue>):<fpage>1282</fpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/molecules22081282</pub-id>
</mixed-citation>
      </ref>
      <ref id="B264">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Traynor</surname><given-names>J. R.</given-names></name></person-group> (<year>1998</year>). <article-title>Epibatidine and pain</article-title>. <source>Br. J. Anaesth.</source>
<volume>81</volume> (<issue>1</issue>), <fpage>69</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1093/bja/81.1.69</pub-id>
<pub-id pub-id-type="pmid">9771274</pub-id></mixed-citation>
      </ref>
      <ref id="B265">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trifiro</surname><given-names>G.</given-names></name><name><surname>Gini</surname><given-names>R.</given-names></name><name><surname>Barone-Adesi</surname><given-names>F.</given-names></name><name><surname>Beghi</surname><given-names>E.</given-names></name><name><surname>Cantarutti</surname><given-names>A.</given-names></name><name><surname>Capuano</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand</article-title>? <source>Drug Safe</source>
<volume>42</volume> (<issue>3</issue>), <fpage>347</fpage>&#x2013;<lpage>363</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s40264-018-0732-5</pub-id>
</mixed-citation>
      </ref>
      <ref id="B266">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trujillo</surname><given-names>J. M.</given-names></name><name><surname>Goldman</surname><given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist for the treatment of adults with type 2 diabetes</article-title>. <source>Pharmacotherapy</source>
<volume>37</volume> (<issue>8</issue>), <fpage>927</fpage>&#x2013;<lpage>943</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/phar.1962</pub-id>
<pub-id pub-id-type="pmid">28556176</pub-id></mixed-citation>
      </ref>
      <ref id="B267">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Umana</surname><given-names>I. C.</given-names></name><name><surname>Daniele</surname><given-names>C. A.</given-names></name><name><surname>McGehee</surname><given-names>D. S.</given-names></name></person-group> (<year>2013</year>). <article-title>Neuronal nicotinic receptors as analgesic targets: it&#x2019;s a winding road</article-title>. <source>Biochem. Pharmacol.</source>
<volume>86</volume> (<issue>8</issue>), <fpage>1208</fpage>&#x2013;<lpage>1214</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.bcp.2013.08.001</pub-id>
<pub-id pub-id-type="pmid">23948066</pub-id></mixed-citation>
      </ref>
      <ref id="B268">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group> (<year>2016</year>). <source>FDA approves Adlyxin to treat type 2 diabetes</source> (Accessed <date-in-citation>March 30, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B269">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group> (<year>2020</year>). <source>Drugs FDA: FDA approved drug products</source>. Available at: <uri xlink:type="simple" xlink:href="https://www.accessdata.fda.gov/scripts/cder/daf/">https://www.accessdata.fda.gov/scripts/cder/daf/</uri> (Accessed <date-in-citation>June 25, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B270">
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><collab>US National Library of Medicine</collab></person-group> (<year>2020</year>). <source>ClinicalTrials.gov - Find a study</source>. Available at: <uri xlink:type="simple" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</uri> (Accessed <date-in-citation>June 25, 2020</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B271">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Utkin</surname><given-names>Y. N.</given-names></name><name><surname>Vassilevski</surname><given-names>A. A.</given-names></name><name><surname>Kudryavtsev</surname><given-names>D.</given-names></name><name><surname>Undheim</surname><given-names>E. A. B.</given-names></name></person-group> (<year>2019</year>). <article-title>Animal toxins as comprehensive pharmacological tools to identify diverse ion channels</article-title>. <source>Front. Pharmacol.</source>
<volume>10</volume>, <elocation-id>423</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.3389/fphar.2019.00423</pub-id>
<pub-id pub-id-type="pmid">31068819</pub-id></mixed-citation>
      </ref>
      <ref id="B272">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Utkin</surname><given-names>Y. N.</given-names></name></person-group> (<year>2017</year>). <article-title>Modern trends in animal venom research - omics and nanomaterials</article-title>. <source>World J. Biol. Chem.</source>
<volume>8</volume> (<issue>1</issue>), <fpage>4</fpage>&#x2013;<lpage>12</lpage>. &#xA0;<pub-id pub-id-type="doi">10.4331/wjbc.v8.i1.4</pub-id>
<pub-id pub-id-type="pmid">28289514</pub-id></mixed-citation>
      </ref>
      <ref id="B273">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Valverde</surname><given-names>P.</given-names></name><name><surname>Kawai</surname><given-names>T.</given-names></name><name><surname>Taubman</surname><given-names>M. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease</article-title>. <source>J. Bone Miner. Res.</source>
<volume>19</volume> (<issue>1</issue>), <fpage>155</fpage>&#x2013;<lpage>164</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1359/JBMR.0301213</pub-id>
<pub-id pub-id-type="pmid">14753747</pub-id></mixed-citation>
      </ref>
      <ref id="B274">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varga</surname><given-names>Z.</given-names></name><name><surname>Gurrola-Briones</surname><given-names>G.</given-names></name><name><surname>Papp</surname><given-names>F.</given-names></name><name><surname>Rodriguez de la Vega</surname><given-names>R. C.</given-names></name><name><surname>Pedraza-Alva</surname><given-names>G.</given-names></name><name><surname>Tajhya</surname><given-names>R. B.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells</article-title>. <source>Mol. Pharmacol.</source>
<volume>82</volume> (<issue>3</issue>), <fpage>372</fpage>&#x2013;<lpage>382</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1124/mol.112.078006</pub-id>
<pub-id pub-id-type="pmid">22622363</pub-id></mixed-citation>
      </ref>
      <ref id="B275">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veiga</surname><given-names>A. B.</given-names></name><name><surname>Ribeiro</surname><given-names>J. M.</given-names></name><name><surname>Guimar&#xE3;es</surname><given-names>J. A.</given-names></name><name><surname>Francischetti</surname><given-names>I. M.</given-names></name></person-group> (<year>2005</year>). <article-title>A catalog for the transcripts from the venomous structures of the caterpillar L<italic>onomia obliqua:</italic> identification of the proteins potentially involved in the coagulation disorder and hemorrhagic syndrome</article-title>. <source>Gene</source>
<volume>355</volume>, <fpage>11</fpage>&#x2013;<lpage>27</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.gene.2005.05.002</pub-id>
<pub-id pub-id-type="pmid">16023793</pub-id></mixed-citation>
      </ref>
      <ref id="B276">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Veiga</surname><given-names>A. B. G.</given-names></name><name><surname>Berger</surname><given-names>M.</given-names></name><name><surname>Guimar&#xE3;es</surname><given-names>J. A.</given-names></name></person-group> (<year>2009</year>). <article-title>&#x201C;Lonomia obliqua venom: pharmaco-toxicological effects and biotechnological perspectives,&#x201D;</article-title> in <source>Animal toxins: state of the art - perspectives in health and biotechnology</source>, <edition>1st ed.</edition> Eds. <person-group person-group-type="editor"><name><surname>Lima</surname><given-names>M. E. D.</given-names></name><name><surname>Pimenta</surname><given-names>A. M. D. C.</given-names></name><name><surname>Martin-Eauclaire</surname><given-names>M. F.</given-names></name><name><surname>Zingali</surname><given-names>R. B.</given-names></name><name><surname>Rochat</surname><given-names>H.</given-names></name></person-group> (<publisher-loc>Belo Horizonte</publisher-loc>: <publisher-name>Editora UFMG</publisher-name>), <fpage>371</fpage>&#x2013;<lpage>390</lpage>.</mixed-citation>
      </ref>
      <ref id="B277">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veiseh</surname><given-names>M.</given-names></name><name><surname>Gabikian</surname><given-names>P.</given-names></name><name><surname>Bahrami</surname><given-names>S. B.</given-names></name><name><surname>Veiseh</surname><given-names>O.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Hackman</surname><given-names>R. C.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci</article-title>. <source>Cancer Res.</source>
<volume>67</volume> (<issue>14</issue>), <fpage>6882</fpage>&#x2013;<lpage>6888</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3948</pub-id>
<pub-id pub-id-type="pmid">17638899</pub-id></mixed-citation>
      </ref>
      <ref id="B278">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Verdoni</surname><given-names>M.</given-names></name><name><surname>Roudaut</surname><given-names>H.</given-names></name><name><surname>De Pomyers</surname><given-names>H.</given-names></name><name><surname>Gigmes</surname><given-names>D.</given-names></name><name><surname>Bertin</surname><given-names>D.</given-names></name><name><surname>Luis</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>ArgTX-636, a polyamine isolated from spider venom: A novel class of melanogenesis inhibitors</article-title>. <source>Bioorgan. Med. Chem.</source>
<volume>24</volume> (<issue>22</issue>), <fpage>5685</fpage>&#x2013;<lpage>5692</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.bmc.2016.08.023</pub-id>
</mixed-citation>
      </ref>
      <ref id="B279">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vetter</surname><given-names>I.</given-names></name><name><surname>Deuis</surname><given-names>J. R.</given-names></name><name><surname>Mueller</surname><given-names>A.</given-names></name><name><surname>Israel</surname><given-names>M. R.</given-names></name><name><surname>Starobova</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Na<sub>V</sub>1.7 as a pain target - From gene to pharmacology</article-title>. <source>Pharmacol. Ther.</source>
<volume>172</volume>, <fpage>73</fpage>&#x2013;<lpage>100</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.pharmthera.2016.11.015</pub-id>
<pub-id pub-id-type="pmid">27916648</pub-id></mixed-citation>
      </ref>
      <ref id="B280">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veytia-Bucheli</surname><given-names>J. I.</given-names></name><name><surname>Jimenez-Vargas</surname><given-names>J. M.</given-names></name><name><surname>Melchy-Perez</surname><given-names>E. I.</given-names></name><name><surname>Sandoval-Hernandez</surname><given-names>M. A.</given-names></name><name><surname>Possani</surname><given-names>L. D.</given-names></name><name><surname>Rosenstein</surname><given-names>Y.</given-names></name></person-group> (<year>2018</year>). <article-title>Kv1.3 channel blockade with the Vm24 scorpion toxin attenuates the CD4+ effector memory T cell response to TCR stimulation</article-title>. <source>J. Cell Commun. Signal</source>
<volume>16</volume>, 45. &#xA0;<pub-id pub-id-type="doi">10.1186/s12964-018-0257-7</pub-id>
</mixed-citation>
      </ref>
      <ref id="B281">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vila-Farres</surname><given-names>X.</given-names></name><name><surname>Giralt</surname><given-names>E.</given-names></name><name><surname>Vila</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Update of peptides with antibacterial activity</article-title>. <source>Curr. Med. Chem.</source>
<volume>19</volume> (<issue>36</issue>), <fpage>6188</fpage>&#x2013;<lpage>6198</lpage>. &#xA0;<pub-id pub-id-type="doi">10.2174/092986712804485818</pub-id>
<pub-id pub-id-type="pmid">22978329</pub-id></mixed-citation>
      </ref>
      <ref id="B282">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vink</surname><given-names>S.</given-names></name><name><surname>Alewood</surname><given-names>P. F.</given-names></name></person-group> (<year>2012</year>). <article-title>Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain</article-title>. <source>Br. J. Pharmacol.</source>
<volume>167</volume> (<issue>5</issue>), <fpage>970</fpage>&#x2013;<lpage>989</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.02082.x</pub-id>
<pub-id pub-id-type="pmid">22725651</pub-id></mixed-citation>
      </ref>
      <ref id="B283">
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>Vivostat A/S</collab></person-group> (<year>2018</year>). <source>Vivostat autologous fibrin sealant</source> (<publisher-loc>Medicon Valley</publisher-loc>: <publisher-name>Scandinavia</publisher-name>). Available at: <uri xlink:type="simple" xlink:href="https://www.vivostat.com/products/vivostat-fibrin-sealant">https://www.vivostat.com/products/vivostat-fibrin-sealant</uri> (Accessed <date-in-citation>April 19, 2018</date-in-citation>).</mixed-citation>
      </ref>
      <ref id="B284">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vu</surname><given-names>T. T.</given-names></name><name><surname>Stafford</surname><given-names>A. R.</given-names></name><name><surname>Leslie</surname><given-names>B. A.</given-names></name><name><surname>Kim</surname><given-names>P. Y.</given-names></name><name><surname>Fredenburgh</surname><given-names>J. C.</given-names></name><name><surname>Weitz</surname><given-names>J. I.</given-names></name></person-group> (<year>2013</year>). <article-title>Batroxobin binds fibrin with higher affinity and promotes clot expansion to a greater extent than thrombin</article-title>. <source>J. Biol. Chem.</source>
<volume>288</volume> (<issue>23</issue>), <fpage>16862</fpage>&#x2013;<lpage>16871</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1074/jbc.M113.464750</pub-id>
<pub-id pub-id-type="pmid">23612970</pub-id></mixed-citation>
      </ref>
      <ref id="B285">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Warkentin</surname><given-names>T. E.</given-names></name></person-group> (<year>2004</year>). <article-title>Bivalent direct thrombin inhibitors: hirudin and bivalirudin</article-title>. <source>Best Pract. Res. Clin. Haematol.</source>
<volume>17</volume> (<issue>1</issue>), <fpage>105</fpage>&#x2013;<lpage>125</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.beha.2004.02.002</pub-id>
<pub-id pub-id-type="pmid">15171961</pub-id></mixed-citation>
      </ref>
      <ref id="B286">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watters</surname><given-names>M. R.</given-names></name></person-group> (<year>2005</year>). <article-title>Tropical marine neurotoxins: Venoms to drugs</article-title>. <source>Semin. Neurol.</source>
<volume>25</volume> (<issue>3</issue>), <fpage>278</fpage>&#x2013;<lpage>289</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1055/s-2005-917664</pub-id>
<pub-id pub-id-type="pmid">16170740</pub-id></mixed-citation>
      </ref>
      <ref id="B287">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weber</surname><given-names>M. A.</given-names></name><name><surname>Schiffrin</surname><given-names>E. L.</given-names></name><name><surname>White</surname><given-names>W. B.</given-names></name><name><surname>Mann</surname><given-names>S.</given-names></name><name><surname>Lindholm</surname><given-names>L. H.</given-names></name><name><surname>Kenerson</surname><given-names>J. G.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension</article-title>. <source>J. Clin. Hypertens.</source>
<volume>16</volume> (<issue>1</issue>), <fpage>14</fpage>&#x2013;<lpage>26</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/jch.12237</pub-id>
</mixed-citation>
      </ref>
      <ref id="B288">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>C. M.</given-names></name><name><surname>Aarhus</surname><given-names>L. L.</given-names></name><name><surname>Miller</surname><given-names>V. M.</given-names></name><name><surname>Burnett</surname><given-names>J. C.</given-names></name></person-group> (<year>1993</year>). <article-title>Action of C-type natriuretic peptide in isolated canine arteries and veins</article-title>. <source>Am. J. Physiol.</source>
<volume>264</volume> (<issue>1 Pt 2</issue>), <fpage>H71</fpage>&#x2013;<lpage>H73</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.1993.264.1.H71</pub-id>
<pub-id pub-id-type="pmid">8430863</pub-id></mixed-citation>
      </ref>
      <ref id="B289">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>J. M.</given-names></name><name><surname>Zhu</surname><given-names>M. W.</given-names></name><name><surname>Zhang</surname><given-names>Z. T.</given-names></name><name><surname>Jia</surname><given-names>Z. G.</given-names></name><name><surname>He</surname><given-names>X. D.</given-names></name><name><surname>Wan</surname><given-names>Y. L.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>A multicenter, phase III trial of hemocoagulase A<italic>gkistrodon:</italic> hemostasis, coagulation, and safety in patients undergoing abdominal surgery</article-title>. <source>Chin. Med. J. (Engl)</source>
<volume>123</volume> (<issue>5</issue>), <fpage>589</fpage>&#x2013;<lpage>593</lpage>.<pub-id pub-id-type="pmid">20367987</pub-id></mixed-citation>
      </ref>
      <ref id="B290">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weinger</surname><given-names>R. S.</given-names></name><name><surname>Rudy</surname><given-names>C.</given-names></name><name><surname>Moake</surname><given-names>J. L.</given-names></name><name><surname>Olson</surname><given-names>J. D.</given-names></name><name><surname>Cimo</surname><given-names>P. L.</given-names></name></person-group> (<year>1980</year>). <article-title>Prothrombin Houston: a dysprothrombin identifiable by crossed immunoelectrofocusing and abnormal <italic>Echis carinatus</italic> venom activation</article-title>. <source>Blood</source>
<volume>55</volume> (<issue>5</issue>), <fpage>811</fpage>&#x2013;<lpage>816</lpage>.<pub-id pub-id-type="pmid">7362870</pub-id></mixed-citation>
      </ref>
      <ref id="B291">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wieser</surname><given-names>G.</given-names></name><name><surname>Mansi</surname><given-names>R.</given-names></name><name><surname>Grosu</surname><given-names>A. L.</given-names></name><name><surname>Schultze-Seemann</surname><given-names>W.</given-names></name><name><surname>Dumont-Walter</surname><given-names>R. A.</given-names></name><name><surname>Meyer</surname><given-names>P. T.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist - from mice to men</article-title>. <source>Theranostics</source>
<volume>4</volume> (<issue>4</issue>), <fpage>412</fpage>&#x2013;<lpage>419</lpage>. &#xA0;<pub-id pub-id-type="doi">10.7150/thno.7324</pub-id>
<pub-id pub-id-type="pmid">24578724</pub-id></mixed-citation>
      </ref>
      <ref id="B292">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wigger</surname><given-names>E.</given-names></name><name><surname>Kuhn-Nentwig</surname><given-names>L.</given-names></name><name><surname>Nentwig</surname><given-names>W.</given-names></name></person-group> (<year>2002</year>). <article-title>The venom optimisation hypothesis: a spider injects large venom quantities only into difficult prey types</article-title>. <source>Toxicon</source>
<volume>40</volume> (<issue>6</issue>), <fpage>749</fpage>&#x2013;<lpage>752</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/s0041-0101(01)00277-x</pub-id>
<pub-id pub-id-type="pmid">12175611</pub-id></mixed-citation>
      </ref>
      <ref id="B293">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilson</surname><given-names>D.</given-names></name><name><surname>Daly</surname><given-names>N. L.</given-names></name></person-group> (<year>2018</year>). <article-title>Venomics: A mini-review</article-title>. <source>High Throughput</source>
<volume>7</volume> (<issue>3</issue>), 19. &#xA0;<pub-id pub-id-type="doi">10.3390/ht7030019</pub-id>
</mixed-citation>
      </ref>
      <ref id="B294">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>C. K.</given-names></name></person-group> (<year>2005</year>). <article-title>Should bivalirudin be the anticoagulant of choice for percutaneous coronary intervention</article-title>? <source>Nat. Clin. Pract. Cardiovasc. Med.</source>
<volume>2</volume> (<issue>8</issue>), <fpage>384</fpage>&#x2013;<lpage>385</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1038/ncpcardio0277</pub-id>
<pub-id pub-id-type="pmid">16119695</pub-id></mixed-citation>
      </ref>
      <ref id="B295">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wysham</surname><given-names>C. H.</given-names></name><name><surname>Rosenstock</surname><given-names>J.</given-names></name><name><surname>Vetter</surname><given-names>M. L.</given-names></name><name><surname>Dong</surname><given-names>F.</given-names></name><name><surname>&#xD6;hman</surname><given-names>P.</given-names></name><name><surname>Iqbal</surname><given-names>N.</given-names></name></person-group> (<year>2017</year>). <article-title>Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes</article-title>. <source>Diabetes Obes. Metab.</source>
<volume>20</volume>, <fpage>165</fpage>&#x2013;<lpage>172</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1111/dom.13056</pub-id>
<pub-id pub-id-type="pmid">28685973</pub-id></mixed-citation>
      </ref>
      <ref id="B296">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>X. B.</given-names></name><name><surname>Yin</surname><given-names>J. Q.</given-names></name><name><surname>Wen</surname><given-names>L. L.</given-names></name><name><surname>Gao</surname><given-names>Z. H.</given-names></name><name><surname>Zou</surname><given-names>C. Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research</article-title>. <source>PloS One</source>
<volume>7</volume> (<issue>10</issue>), <elocation-id>e47375</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1371/journal.pone.0047375</pub-id>
<pub-id pub-id-type="pmid">23091618</pub-id></mixed-citation>
      </ref>
      <ref id="B297">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Lv</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Efficacy and safety of Huachansu combined with chemotherapy in advanced gastric cancer: a meta-analysis</article-title>. <source>Med. Hypotheses</source>
<volume>81</volume> (<issue>2</issue>), <fpage>243</fpage>&#x2013;<lpage>250</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.mehy.2013.04.038</pub-id>
<pub-id pub-id-type="pmid">23692970</pub-id></mixed-citation>
      </ref>
      <ref id="B298">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y. Y.</given-names></name><name><surname>Ma</surname><given-names>X. H.</given-names></name><name><surname>Zhang</surname><given-names>S. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Hemocoagulase agkistrodon-induced anaphylactic shock: A case report and literature review</article-title>. <source>Int. J. Clin. Pharmacol. Ther.</source>
<volume>54</volume> (<issue>2</issue>), <fpage>129</fpage>&#x2013;<lpage>134</lpage>. &#xA0;<pub-id pub-id-type="doi">10.5414/CP202296</pub-id>
<pub-id pub-id-type="pmid">26636421</pub-id></mixed-citation>
      </ref>
      <ref id="B299">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Peng</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Cao</surname><given-names>Z. J.</given-names></name><name><surname>Li</surname><given-names>W. X.</given-names></name><name><surname>Mao</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Functional analysis of a gene encoding a chlorotoxin-like peptide derived from scorpion toxin</article-title>. <source>Chin. J. Biochem. Mol. Biol.</source>
<volume>21</volume> (<issue>1</issue>), <fpage>19</fpage>&#x2013;<lpage>23</lpage>.</mixed-citation>
      </ref>
      <ref id="B300">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Huo</surname><given-names>X. C.</given-names></name><name><surname>Miao</surname><given-names>Z. R.</given-names></name><name><surname>Wang</surname><given-names>Y. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban in acute ischemic stroke</article-title>. <source>Drugs</source>
<volume>79</volume> (<issue>5</issue>), <fpage>515</fpage>&#x2013;<lpage>529</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/s40265-019-01078-0</pub-id>
<pub-id pub-id-type="pmid">30838514</pub-id></mixed-citation>
      </ref>
      <ref id="B301">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>You</surname><given-names>W. K.</given-names></name><name><surname>Choi</surname><given-names>W. S.</given-names></name><name><surname>Koh</surname><given-names>Y. S.</given-names></name><name><surname>Shin</surname><given-names>H. C.</given-names></name><name><surname>Jang</surname><given-names>Y.</given-names></name><name><surname>Chung</surname><given-names>K. H.</given-names></name></person-group> (<year>2004</year>). <article-title>Functional characterization of recombinant batroxobin, a snake venom thrombin-like enzyme, expressed from P<italic>ichia pastoris</italic>
</article-title>. <source>FEBS Lett.</source>
<volume>571</volume> (<issue>1-3</issue>), <fpage>67</fpage>&#x2013;<lpage>73</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.febslet.2004.06.060</pub-id>
<pub-id pub-id-type="pmid">15280019</pub-id></mixed-citation>
      </ref>
      <ref id="B302">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>You</surname><given-names>K. E.</given-names></name><name><surname>Koo</surname><given-names>M. A.</given-names></name><name><surname>Lee</surname><given-names>D. H.</given-names></name><name><surname>Kwon</surname><given-names>B. J.</given-names></name><name><surname>Lee</surname><given-names>M. H.</given-names></name><name><surname>Hyon</surname><given-names>S. H.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>The effective control of a bleeding injury using a medical adhesive containing batroxobin</article-title>. <source>BioMed. Mat.</source>
<volume>9</volume> (<issue>2</issue>):<elocation-id>25002</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1088/1748-6041/9/2/025002</pub-id>
</mixed-citation>
      </ref>
      <ref id="B303">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zambelli</surname><given-names>V. O.</given-names></name><name><surname>Fernandes</surname><given-names>A. C. D.</given-names></name><name><surname>Gutierrez</surname><given-names>V. P.</given-names></name><name><surname>Ferreira</surname><given-names>J. C. B.</given-names></name><name><surname>Parada</surname><given-names>C. A.</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Peripheral sensitization increases opioid receptor expression and activation by crotalphine in rats</article-title>. <source>PloS One</source>
<volume>9</volume> (<issue>3</issue>), <elocation-id>e90576</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1371/journal.pone.0090576</pub-id>
<pub-id pub-id-type="pmid">24594607</pub-id></mixed-citation>
      </ref>
      <ref id="B304">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeymer</surname><given-names>U.</given-names></name></person-group> (<year>2007</year>). <article-title>The role of eptifibatide in patients undergoing percutaneous coronary intervention</article-title>. <source>Expert Opin. Pharmacother.</source>
<volume>8</volume> (<issue>8</issue>), <fpage>1147</fpage>&#x2013;<lpage>1154</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1517/14656566.8.8.1147</pub-id>
<pub-id pub-id-type="pmid">17516878</pub-id></mixed-citation>
      </ref>
      <ref id="B305">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L. J.</given-names></name><name><surname>Falla</surname><given-names>T. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Cosmeceuticals and peptides</article-title>. <source>Clin. Dermatol.</source>
<volume>27</volume> (<issue>5</issue>), <fpage>485</fpage>&#x2013;<lpage>494</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.clindermatol.2009.05.013</pub-id>
<pub-id pub-id-type="pmid">19695481</pub-id></mixed-citation>
      </ref>
      <ref id="B306">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Why do we study animal toxins</article-title>? <source>Zool Res.</source>
<volume>36</volume> (<issue>4</issue>), <fpage>183</fpage>&#x2013;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.13918/j.issn.2095-8137.2015.4.183</pub-id>
<pub-id pub-id-type="pmid">26228472</pub-id></mixed-citation>
      </ref>
      <ref id="B307">
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>X.</given-names></name><name><surname>Peng</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Toxins targeting the Kv1.3 channel: Potential immunomodulators for autoimmune diseases</article-title>. <source>Toxins</source>
<volume>7</volume> (<issue>5</issue>), <fpage>1749</fpage>&#x2013;<lpage>1764</lpage>. &#xA0;<pub-id pub-id-type="doi">10.3390/toxins7051749</pub-id>
<pub-id pub-id-type="pmid">25996605</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="methods-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
      <journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
      <journal-title-group>
        <journal-title>Frontiers in Immunology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1664-3224</issn>
      <publisher>
        <publisher-name>Frontiers Media S.A.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33178198</article-id>
      <article-id pub-id-type="pmc">7592114</article-id>
      <article-id pub-id-type="doi">10.3389/fimmu.2020.571992</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Immunology</subject>
          <subj-group>
            <subject>Methods</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Animal-Free Human Whole Blood Sepsis Model to Study Changes in Innate Immunity</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Messerer</surname>
            <given-names>David Alexander Christian</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn001">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vidoni</surname>
            <given-names>Laura</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Erber</surname>
            <given-names>Maike</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stratmann</surname>
            <given-names>Alexander Elias Paul</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1103489"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bauer</surname>
            <given-names>Jonas Martin</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1104115"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Braun</surname>
            <given-names>Christian Karl</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/785153"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hug</surname>
            <given-names>Stefan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1103282"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Adler</surname>
            <given-names>Anna</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/880958"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nilsson Ekdahl</surname>
            <given-names>Kristina</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/579730"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nilsson</surname>
            <given-names>Bo</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/289238"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barth</surname>
            <given-names>Eberhard</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Radermacher</surname>
            <given-names>Peter</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/580485"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Huber-Lang</surname>
            <given-names>Markus</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/378510"/>
        </contrib>
      </contrib-group>
      <aff id="aff1"><sup>1</sup><institution>Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm</institution>, <addr-line>Ulm</addr-line>, <country>Germany</country></aff>
      <aff id="aff2"><sup>2</sup><institution>Department of Anesthesiology and Intensive Care Medicine, University Hospital of Ulm</institution>, <addr-line>Ulm</addr-line>, <country>Germany</country></aff>
      <aff id="aff3"><sup>3</sup><institution>Rudbeck Laboratory, Department of Immunology, Genetics and Pathology</institution>, <addr-line>Uppsala</addr-line>, <country>Sweden</country></aff>
      <aff id="aff4"><sup>4</sup><institution>Centre of Biomaterials Chemistry, Linnaeus University</institution>, <addr-line>Kalmar</addr-line>, <country>Sweden</country></aff>
      <aff id="aff5"><sup>5</sup><institution>Institute for Anesthesiologic Pathophysiology and Process Engineering, Ulm University</institution>, <addr-line>Ulm</addr-line>, <country>Germany</country></aff>
      <author-notes>
        <fn fn-type="edited-by">
          <p>Edited by: Fabrice Cognasse, Groupe Sur L&#x2019;immunit&#xE9; Des Muqueuses Et Agents Pathog&#xE8;nes (GIMAP), France</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Reviewed by: Charles E. McCall, Wake Forest Baptist Medical Center, United States; Rafael Agust&#xED;n Burgos, Austral University of Chile, Chile</p>
        </fn>
        <corresp id="fn001">*Correspondence: David Alexander Christian Messerer, <email xlink:href="mailto:david.messerer@uni-ulm.de" xlink:type="simple">david.messerer@uni-ulm.de</email></corresp>
        <fn fn-type="other" id="fn002">
          <p>This article was submitted to Inflammation, a section of the journal Frontiers in Immunology</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>10</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>11</volume>
      <elocation-id>571992</elocation-id>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>6</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>9</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2020 Messerer, Vidoni, Erber, Stratmann, Bauer, Braun, Hug, Adler, Nilsson Ekdahl, Nilsson, Barth, Radermacher and Huber-Lang</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder>Messerer, Vidoni, Erber, Stratmann, Bauer, Braun, Hug, Adler, Nilsson Ekdahl, Nilsson, Barth, Radermacher and Huber-Lang</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Studying innate immunity in humans is crucial for understanding its role in the pathophysiology of systemic inflammation, particularly in the complex setting of sepsis. Therefore, we standardized a step-by-step process from the venipuncture to the transfer in a human model system, while closely monitoring the inflammatory response for up to three hours. We designed an animal-free, human whole blood sepsis model using a commercially available, simple to use, tubing system. First, we analyzed routine clinical parameters, including cell count and blood gas analysis. Second, we demonstrated that extracellular activation markers (e.g., CD11b and CD62l) as well as intracellular metabolic (intracellular pH) and functional (generation of radical oxygen species) features remained stable after incubation in the whole blood model. Third, we mimicked systemic inflammation during early sepsis by exposure of whole blood to pathogen-associated molecular patterns. Stimulation with lipopolysaccharide revealed the capability of the model system to evoke a sepsis-like inflammatory phenotype of innate immunity. In summary, the presented model serves as a convenient, economic, and reliable platform to study innate immunity in human whole blood, which may yield clinically important insights.</p>
      </abstract>
      <kwd-group>
        <kwd>inflammation</kwd>
        <kwd>neutrophil granulocytes</kwd>
        <kwd>lipopolysaccharide (LPS)</kwd>
        <kwd>blood physiology</kwd>
        <kwd>sepsis</kwd>
        <kwd>ex vivo whole blood model</kwd>
        <kwd>principles of the 3Rs</kwd>
      </kwd-group>
      <counts>
        <fig-count count="7"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="54"/>
        <page-count count="12"/>
        <word-count count="5715"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>Innate immunity plays a vital role as the vanguard against numerous harmful carriers of damage- and pathogen associated molecular patterns (DAMPs and PAMPs, respectively). An appropriate inflammatory response efficiently clears pathogens and initiates subsequent healing processes. However, an excessive and dysregulated inflammation is a matter of both increasing interest and concern, particularly during trauma (<xref rid="B1" ref-type="bibr">1</xref>) and sepsis (<xref rid="B2" ref-type="bibr">2</xref>). A recent study estimated the annual global incidence of sepsis at approximately 50 million (<xref rid="B3" ref-type="bibr">3</xref>). Moreover, the latest consensus definition of sepsis underscored the importance of appropriate regulated (innate) immunity in the successful clearance of pathogens (<xref rid="B2" ref-type="bibr">2</xref>).</p>
      <p>To study the complex innate immune response to PAMP exposure, various small or large, simple or complex animal models are used (<xref rid="B4" ref-type="bibr">4</xref>&#x2013;<xref rid="B6" ref-type="bibr">6</xref>). However, ethical considerations, including the aspect of replacement within the 3R-principles (<xref rid="B7" ref-type="bibr">7</xref>), possible limitations in translation into real-world patients (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>), and the expense of personal and material resources, may limit the validity and attractiveness of animal-based models. In addition, whole blood samples or tissue specimens of patients suffering from sepsis can only be obtained at the cost of additional burden and risk to the patients. Moreover, the samples originate from different etiological, microbiological, and genetic backgrounds, and thus cannot be standardized precisely. For example, the exact exposure time and the amount of pathogens within the blood during sepsis cannot be determined with certainty. Therefore, as another alternative, injection of immune-stimulants, including lipopolysaccharide (LPS), has been performed and investigated in healthy human volunteers (<xref rid="B8" ref-type="bibr">8</xref>&#x2013;<xref rid="B10" ref-type="bibr">10</xref>). On the one hand, this approach provides the intriguing opportunity to study the immunological response directly in human organisms. On the other hand, obvious ethical considerations limit the possibilities of this method, for example, constraining the severity of the induced inflammation or being restricted to young and healthy individuals (<xref rid="B9" ref-type="bibr">9</xref>). However, because excessive inflammation during sepsis remains a major clinical and scientific challenge, there is an unabated research need to elucidate the underlying immunological pathomechanisms, for example, by utilizing human whole blood in a standardized and reliable manner.</p>
      <p>Exposure of blood to DAMPs, PAMPs, and/or defined pathogens outside the human body surmounts several limitations indicated above. Notwithstanding, there are some cellular and humoral components in the blood that become rapidly activated when losing their contact with intact endothelium, which under homeostatic conditions acts as an anti-inflammatory, anti-adhesive, and anti-coagulatory regulator. In particular, platelets and serine cascades are controlled by an intact endothelium (<xref rid="B11" ref-type="bibr">11</xref>). To address the issue of &#x201C;hemoincompatibility&#x201D; of artificial materials, whole blood is frequently completely anticoagulated, for example, either by heparin-based anticoagulants or cation-chelators, including citrate, both of which can alter the ability of humoral and cellular immunity to adequately respond to stimulation.</p>
      <p>To prevent stimulation after venipuncture <italic>ex vivo</italic>, a variety of models have been previously proposed of whole blood being supplemented with an anticoagulant and/or being encased in a specially coated system. Human whole blood models of coated circuits or whole blood cultures in combination with defined anticoagulation, for example, heparin or hirudin, have been widely used and characterized in recent years (<xref rid="B12" ref-type="bibr">12</xref>&#x2013;<xref rid="B18" ref-type="bibr">18</xref>). In general, these models address a specific focus and produced the respective specific answers. For example, they were used to elucidate the interaction of whole blood stimulated with various bacteria, revealing the significance of the complement factors 3a and 5a (C3a, C5a) as well as CD14 for the crosstalk of pathogens and leukocytes (<xref rid="B12" ref-type="bibr">12</xref>&#x2013;<xref rid="B15" ref-type="bibr">15</xref>).</p>
      <p>However, to our knowledge, the description of hitherto existing models focused on the characterization of humoral immunity and other protease systems such as the coagulation cascade, without elucidating the impact of exposition to an <italic>ex vivo</italic> circuit to general (patho-)physiological and metabolic responses in association with cellular innate immunity. For example, global blood parameters (e.g. pH and glucose concentration) have frequently not been reported, making it difficult to interpret the presented data and to transfer them into the physiological <italic>in vivo</italic> context of the human body (<xref rid="B12" ref-type="bibr">12</xref>&#x2013;<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B18" ref-type="bibr">18</xref>&#x2013;<xref rid="B21" ref-type="bibr">21</xref>). There is also a concomitant research gap with regards to a comprehensive study of blood physiology <italic>ex vivo</italic> while synchronically assessing important immunological functions and activation markers.</p>
      <p>Here, we 1) standardized the handling of an easy-to-use whole blood model, 2) determined a myriad of global blood parameters with a comprehensive focus on extra- and intracellular parameters of innate immunity, and 3) mimicked septic conditions and subsequent systemic inflammation in blood in an animal-free research setup by stimulation with LPS.</p>
    </sec>
    <sec id="s2">
      <title>Methods</title>
      <sec id="s2_1">
        <title>Blood Sampling</title>
        <p>Healthy human volunteers of both genders aged 21&#x2013;30 years served as blood donors. All experiments were conducted in accordance with the declaration of Helsinki (<xref rid="B22" ref-type="bibr">22</xref>). Following ethical approval (number 459/18, Local Independent Ethics Committee of the University of Ulm) and written informed consent, blood was drawn by peripheral venipuncture in accordance with the guidelines of the World Health Organization (<xref rid="B23" ref-type="bibr">23</xref>). In detail, blood stasis was limited to a maximum of 30 s before puncture and the first 2&#x2013;3 ml were immediately discarded. The blood was collected in neutral monovettes (Sarstedt, N&#xFC;rnbrecht, Germany), which had been supplemented with heparin (B. Braun Melsungen AG, Melsungen, Germany) and either LPS (Sigma Aldrich, Steinheim, Germany) or phosphate-buffered saline (PBS<sup>++</sup>, as control), respectively. In total, 9&#xA0;ml blood was collected per tube, with a final concentration of 0.5 IU/ml of heparin and when present, 100 ng/ml of LPS.</p>
      </sec>
      <sec id="s2_2">
        <title>Whole Blood Model</title>
        <p>Immediately after sampling, the blood was transferred carefully using 10&#xA0;ml tips (Eppendorf, Hamburg, Germany) into the following described system. The whole blood model consisted of a heparin coated tubing system (Cortiva, #M999413C, Medtronic, Meerbusch, Germany), being cut into approximately 33&#xA0;cm long pieces. Both ends of the tube were added to a circuit using a similarly coated connector (Cortiva, #CB4629, Medtronic), leaving an air bubble of approximately 1.5&#xA0;ml inside the system. The loops were attached to a spinning wheel (Snijders Labs, Tilburg, Netherlands) rotating at 5 rpm, causing the air bubble to generate a continuous circulation of the blood. As described previously, the combination of heparin-coating and continuous circulation mediated by a small air bubble allows incubating whole blood with a low-dose of heparin (<xref rid="B24" ref-type="bibr">24</xref>). Another option would be the application of higher doses of heparin, however, this interferes with important immunological systems such as the complement system (<xref rid="B24" ref-type="bibr">24</xref>) or the leukocytes (<xref rid="B25" ref-type="bibr">25</xref>). The authors actively decided against to use a mechanic pump, as this causes mechanical stress, that among other consequences results in hemolysis and platelet activation (<xref rid="B26" ref-type="bibr">26</xref>).</p>
        <p>The system was incubated for 0 (depicted as &#x201C;0<sup>&#x2212;</sup>&#x201D; indicating no contact with the tubing system), 10, 60, or 180&#xA0;min as indicated in an incubator at 37&#xB0;C without additional CO<sub>2</sub>. Following the incubation period, the tubing loops were cut open. Initially, 95 &#xB5;l blood were directly drawn into dry-heparin anticoagulated glass capillary tubes (Radiometer GmbH, Krefeld, Germany). Subsequently, 1&#xA0;ml of the blood was transferred into a heparin anticoagulated tube (Sarstedt) for the analysis of phagocytotic activity and radical generation. The remaining blood was transferred into citrate anticoagulated monovettes (Sarstedt) for the analysis of all other parameters. Sodium, potassium, ionized calcium, lactate, glucose, and blood pH were determined using a standard blood gas analyzer (ABL 800 Flex, Radiometer GmbH). To calculate the difference in the amount of lactate generated or the consumption of glucose, the respective value after 60&#xA0;min with or without incubation with LPS was subtracted from the corresponding baseline (0<sup>&#x2212;</sup>). Differential blood count and global coagulation parameters (activated partial thromboplastin time, aPTT, and international normal ratio (INR)) were determined using a standard hematology (Sysmex CN 2000, Sysmex, Kobe, Japan) and coagulation (BCS XP, Siemens, Marburg, Germany) analyzer, respectively, each according to the manufacturer&#x2019;s standard protocol.</p>
      </sec>
      <sec id="s2_3">
        <title>Flow Cytometry</title>
        <p>For antibody staining, 10 &#xB5;l citrate anticoagulated blood were added to 40 &#xB5;l PBS<sup>++</sup> adjusted to pH 7.3 and stimulated with 100 ng/ml C5a (Complement Technology, Tyler, Texas, USA) or PBS as control for 15&#xA0;min in a water bath at 37&#xB0;C. Subsequently, the cells were stained as indicated with anti-CD11b (APC, dilution 1:82 #101212, BioLegend, San Diego, California, USA), anti-CD14 (APC-Cy7, dilution 1:200 #301820, BioLegend), anti-CD62l (PE, dilution 1:33 #304806, BioLegend), anti-CD88 (APC, dilution 1:250 #344310, BioLegend), or corresponding isotype controls (all from BioLegend), respectively, for 15&#xA0;min at room temperature. All markers were assessed by monoclonal mouse anti-human antibodies. Cellular viability was analyzed by identifying necrotic cells with the Zombie Violet Fixable Viability Kit (dilution 1:4000, #423114, BioLegend) and apoptotic cells using Apotracker Green (final concentration 200 nM, #427402, BioLegend).</p>
        <p>The generation of radical oxygen species (ROS) was determined by staining 40 &#xB5;l heparin anticoagulated blood with 0.29 mM (100 &#xB5;g/ml) dihydrorhodamine 123 (DHR, Santa Cruz Biotechnology, Dallas, Texas, USA). Phagocytosis was analyzed using fluorescent microspheres (Fluoresbrite&#x2122; Carboxylate YG 0.75 Microspheres, Polysciences, Inc., Warrington, Pennsylvania, USA). The microspheres were dissolved 1:20 in PBS<sup>++</sup> followed by a washing procedure (3&#xD7; at 1000&#xA0;g for 5&#xA0;min). Of this microsphere solution, 10 &#xB5;l was added onto 100 &#xB5;l heparin anticoagulated whole blood. Whole blood stained with either DHR or incubated with microspheres was incubated for 20 and 30&#xA0;min, respectively, at 37&#xB0;C in the dark. In all experiments, after stimulation and staining of whole blood, the erythrocytes were lysed and the leukocytes fixed by filling up the sample volume to 1&#xA0;ml with 1&#xD7; BD FACS lysing solution&#x2122; (BD Biosciences, San Jose, California, USA) for 30&#xA0;min at room temperature in the dark. Following centrifugation of the samples for 5&#xA0;min at 340&#xA0;g, the specimens were resuspended in 100 &#xB5;l PBS + 0.1% bovine serum albumin and stored at 4&#xB0;C until further analysis (normally within 1&#xA0;h).</p>
        <p>For the analysis of living granulocytes and plasma, citrate anticoagulated whole blood was centrifuged for 10&#xA0;min at 400&#xA0;g at room temperature. The supernatant plasma was carefully removed from the hematocrit and stored at &#x2212;80&#xB0;C until further use for enzyme-linked immunosorbent assay (ELISA) analysis. The remaining blood cells were subjected to dextran sedimentation followed by hypotonic lysis of the erythrocytes. Forward scatter (FSC) area was used as a surrogate for cellular shape (<xref rid="B27" ref-type="bibr">27</xref>). The intracellular pH was determined using the fluorescent dye SNARF (Thermo Fisher Scientific, Waltheim, Massachusetts, USA) with nigericin-based calibration curves as described previously (<xref rid="B28" ref-type="bibr">28</xref>).</p>
        <p>For all flow cytometry experiments, neutrophils and monocytes were gated based on their forward and sideward scatter (SSC) area properties. Doublets were removed by plotting forward scatter area versus height. Spillover between fluorescence channels was corrected by a compensation matrix. For all antigens, appropriate isotype controls (see figures) and single-staining controls were performed (data not shown). For all experiments, a minimum of 300 monocytes and 1000 neutrophils were recorded using a FACS Canto II (BD Biosciences).</p>
      </sec>
      <sec id="s2_4">
        <title>Determination of Platelet-Neutrophil-Complexes</title>
        <p>Platelet-neutrophil-complexes (PNC) were analyzed by light microscopy (<xref rid="B29" ref-type="bibr">29</xref>). In brief, 100 &#xB5;l citrate anticoagulated blood was diluted with 100 &#xB5;l PBS<sup>++</sup>. Blood smears were stained with the &#x201C;Hemacolor<sup>&#xAE;</sup> Rapid staining of blood smear - staining set for microscopy&#x201D; (Merck KGaA, Darmstadt, Germany). A minimum of 50 neutrophils per specimen were analyzed by two independent and blinded individuals. Each neutrophil with at least one thrombocyte in direct proximity was counted as a PNC.</p>
      </sec>
      <sec id="s2_5">
        <title>ELISA</title>
        <p>Determination of plasma levels of C3a, matrix metallopeptidase 9 (MMP9), interleukin 6 (Il6), and interleukin 8 (Il8) was conducted by standard ELISA as indicated by the manufacturer (MMP9: R&amp;D Systems, Minneapolis, Minnesota, USA; Il6: BD Biosciences; Il8: R&amp;D Systems; C3a: Quidel Corporation, San Diego, California, USA).</p>
      </sec>
      <sec id="s2_6">
        <title>Data Analysis and Statistics</title>
        <p>All data is presented as median with error bars indicating the interquartile range (IQR). When informative (e.g. to assess donor heterogeneity in cellular immunity), additional scatter plots are presented as overlay. The sampling strategy consisted of an initial experiment series with n = 3 for all time points (0<sup>&#x2212;</sup>, 10&#xA0;min, 60&#xA0;min, 180&#xA0;min, 60&#xA0;min with LPS, 180&#xA0;min with LPS) focusing on blood gas analysis, whole blood count, and humoral inflammation. Because blood glucose, pH, and lactate level became unphysiological beyond 1&#xA0;h and previous literature indicated that the neutrophil phenotype as measured by CD11b/CD62l expression reached its final alteration after exposure to LPS for 1&#xA0;h (<xref rid="B30" ref-type="bibr">30</xref>), cellular immunity was analyzed for this time point from at least five independent specimen. Data analysis was performed with licensed versions of Microsoft Excel 2019 (Microsoft, Redmond, Washington, USA) and GraphPad Prism 8 (GraphPad Software Inc, San Diego, California, USA). In statistical testing, data was considering as paired and non-normally distributed: For comparison of two groups, a Wilcoxon matched-pairs signed rank test was conducted (<xref ref-type="fig" rid="f4"><bold>Figures 4</bold></xref>, <xref ref-type="fig" rid="f5"><bold>5</bold></xref>, comparison of control vs. C5a within the respective condition). Multiple-group comparison was performed by the Friedman test for paired data (<xref ref-type="fig" rid="f4"><bold>Figures 4</bold></xref>&#x2013;<xref ref-type="fig" rid="f6"><bold>6A, B</bold></xref>, comparison of 0<sup>&#x2212;</sup> vs. Ctrl vs. LPS) or Kruskal-Wallis test for unpaired data (<xref ref-type="fig" rid="f6"><bold>Figures 6C, D</bold></xref>, comparison of 0<sup>&#x2212;</sup> vs. Ctrl vs. LPS), respectively, followed by Dunns&#x2019; multiple comparison test. A <italic>p</italic>-value &lt;0.05 was considered to be significant and marked by * or **, indicating &lt;0.05 or 0.01, respectively.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s3">
      <title>Results</title>
      <sec id="s3_1">
        <title>Stability of Global Physiological Parameters in the <italic>Ex Vivo</italic> Whole Blood Model During the First Hour</title>
        <p>In the present whole blood model, the leukocyte and erythrocyte cell counts remained stable for up to 3&#xA0;h after circulation in comparison to baseline values (directly after venipuncture, <xref ref-type="fig" rid="f1"><bold>Figures 1A, B</bold></xref>). In accordance, the amount of necrotic and/or apoptotic cells for neutrophils, monocytes, and lymphocytes was determined to be &lt;2% (n = 3, data not shown). Furthermore, the activity of hemostasis and the coagulation system was monitored: platelet count (<xref ref-type="fig" rid="f1"><bold>Figure 1C</bold></xref>) and the formation of PNCs (<xref ref-type="fig" rid="f1"><bold>Figure 1D</bold></xref>) indicated no initiation of cellular coagulation. As expected, after the addition of 0.5 IU heparin/ml and incubation for 60&#xA0;min, humoral coagulation was inhibited as indication by an INR of 2.1 (1.8; 2.3, n = 4) and an aPTT of &gt;180 s in all four analyzed samples (data not shown). No visible clot formation was detected in any of the analyzed specimens.</p>
        <fig id="f1" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Cell counts of leukocytes <bold>(A)</bold>, erythrocytes <bold>(B)</bold>, platelets <bold>(C)</bold>, and platelet-neutrophil complexes (PNC) <bold>(D)</bold> before and after contact of blood with the tubing system. Cell counts and PNC formation remained stable during the first 3&#xA0;h after exposure of whole blood in the ex vivo model. LPS (100 ng/ml) was used as a potent PAMP stimulus. n = 3. Results are presented as median with error bars indicating the interquartile range.</p>
          </caption>
          <graphic xlink:href="fimmu-11-571992-g001"/>
        </fig>
        <p>Electrolyte concentrations including sodium, potassium, and ionized calcium were stable throughout the 3-h period of interest (<xref ref-type="fig" rid="f2"><bold>Figures 2A&#x2013;C</bold></xref>). Because the potassium levels did not increase and the red blood cell count and hemoglobin did not decrease, no considerable hemolysis had occurred in the system.</p>
        <fig id="f2" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Sodium <bold>(A)</bold>, potassium <bold>(B)</bold>, ionized calcium <bold>(C)</bold>, glucose <bold>(D)</bold>, lactate <bold>(E)</bold>, pH <bold>(F)</bold>, oxygen partial pressure (pO<sub>2</sub>) <bold>(G)</bold>, carbon dioxide partial pressure (pCO<sub>2</sub>) <bold>(H)</bold>, and acid-base balance <bold>(I)</bold> before and after exposure of whole blood to the circuit system. Plasma parameters remain widely stable during the first 60&#xA0;min but show deviations after 3&#xA0;h. LPS (100 ng/ml) served as PAMP exposure. n = 3 for 10&#xA0;min and 180&#xA0;min, n = 10 for all other time points. Results are presented as median with error bars indicating interquartile range.</p>
          </caption>
          <graphic xlink:href="fimmu-11-571992-g002"/>
        </fig>
        <p>Regarding metabolic changes, there was an expected glucose consumption over time. The glucose concentration (<xref ref-type="fig" rid="f2"><bold>Figure 2D</bold></xref>) decreased within the first hour of incubation with a median of &#x2013;16% (&#x2013;12%; &#x2013;17%, n = 10), with a glucose consumption rate of 0.80 mmol/L/h (0.60; 0.92, n = 10). The lactate (<xref ref-type="fig" rid="f2"><bold>Figure 2E</bold></xref>) concentration almost doubled (+94%, 88%; 126%) within the first hour, accounting for a generation rate of lactate of 1.4 mmol/L/h (1.1; 1.6, n = 10). The pH (<xref ref-type="fig" rid="f2"><bold>Figure 2F</bold></xref>) and acid-base balance (<xref ref-type="fig" rid="f2"><bold>Figure 2I</bold></xref>) changed accordingly. Partial pressure of oxygen (pO<sub>2</sub>, <xref ref-type="fig" rid="f2"><bold>Figure 2G</bold></xref>) increased slightly within the first 10&#xA0;min, while partial pressure of carbon dioxide (pCO<sub>2</sub>, <xref ref-type="fig" rid="f2"><bold>Figure 2H</bold></xref>) remained stable. Both parameters indicated that the tubing system was airtight when connected firmly.</p>
      </sec>
      <sec id="s3_2">
        <title>Contact With the Tubing System Does Not Trigger an Inflammatory Response</title>
        <p>To assess inflammatory processes induced in the present model system, key inflammatory markers were determined (<xref ref-type="fig" rid="f3"><bold>Figure 3</bold></xref>). Of note, the plasma Il8, MMP9, and C3a concentrations remained in a stable range during the monitored incubation period of 3&#xA0;h. In parallel, Il6 levels were mostly not detectable. Despite the complement system has not been broadly evaluated, it was unlikely that massive C5a generation occurred. It is established, that neutrophils respond on exposure to C5a with downregulation of CD88 ((<xref rid="B31" ref-type="bibr">31</xref>), <xref ref-type="fig" rid="f5"><bold>Figure 5B</bold></xref>). However, in the present model system, neutrophil CD88 expression was not significantly altered within the first hour of incubation, indicating excessive complement activity to be unlikely.</p>
        <fig id="f3" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Assessment of humoral inflammatory activity during contact of whole blood with the tubing system by determining the plasma concentrations of Il6 <bold>(A)</bold>, Il8 <bold>(B)</bold>, C3a <bold>(C)</bold>, and MMP9 <bold>(D)</bold>. Incubation with LPS 100 ng/ml reflected the presence of PAMPs. n = 3 for 10&#xA0;min and 180&#xA0;min, n = 10 for all other time points. Results are presented as median with error bars indicating the interquartile range.</p>
          </caption>
          <graphic xlink:href="fimmu-11-571992-g003"/>
        </fig>
      </sec>
      <sec id="s3_3">
        <title>Preservation of the Immune and Metabolic Response in the <italic>Ex Vivo</italic> Situation During the First Hour</title>
        <p>Monitoring of the activation of monocytes and neutrophils was performed by simultaneously analyzing the expression patterns of CD11b, CD88, CD621, and CD14 as well-established markers of the innate immune response after LPS exposure and/or during sepsis. <xref ref-type="fig" rid="f4"><bold>Figures 4</bold></xref>, <xref ref-type="fig" rid="f5"><bold>5</bold></xref> summarize the findings for the incubation period of 1&#xA0;h, showing no significant alterations after contact within the whole blood model. Additionally, the cellular response pattern of monocytes and neutrophils to <italic>in vitro</italic> stimulation with C5a either directly after venipuncture or during a defined period in the whole blood model was multi-parametrically evaluated. For all activation markers, there was no relevant change in the cellular response of monocytes or neutrophils before or after incubation in the whole blood model after subsequent <italic>in vitro</italic> stimulation with C5a.</p>
        <fig id="f4" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Profiling of activation markers CD11b <bold>(A)</bold>, CD88 <bold>(B)</bold>, CD62l <bold>(C)</bold>, CD14 <bold>(D)</bold> of monocytes directly after venipuncture (0) and after 60&#xA0;min of incubation in the whole blood model with or without LPS (100 ng/ml). Following phlebotomy or after the given stimulation period <italic>ex vivo</italic>, monocytes were stimulated with C5a (100 ng/ml) <italic>in vitro</italic> for 15&#xA0;min. n = 9, results are presented as scatter plot and median with error bars indicating interquartile range. * = <italic>p</italic> &lt;0.05, ** = <italic>p</italic> &lt;0.01.</p>
          </caption>
          <graphic xlink:href="fimmu-11-571992-g004"/>
        </fig>
        <fig id="f5" position="float">
          <label>Figure 5</label>
          <caption>
            <p>Profiling of the activation markers CD11b <bold>(A)</bold>, CD88 <bold>(B)</bold>, CD62l <bold>(C)</bold>, CD14 <bold>(D)</bold> of neutrophil granulocytes directly after venipuncture (0) and after 60&#xA0;min of incubation in the whole blood model with or without LPS (100 ng/ml). Following phlebotomy or after the given stimulation period <italic>ex vivo</italic>, neutrophils were stimulated with C5a (100 ng/ml) <italic>in vitro</italic> for 15&#xA0;min. n = 9, results are presented as scatter plot and median with error bars indicating the interquartile range. * = <italic>p</italic> &lt;0.05, ** = <italic>p</italic> &lt;0.01.</p>
          </caption>
          <graphic xlink:href="fimmu-11-571992-g005"/>
        </fig>
        <p>In addition to the reported extracellular parameters, neutrophils were analyzed regarding the cellular physiology and functionality. As presented in <xref ref-type="fig" rid="f6"><bold>Figures 6A, B</bold></xref>, the intracellular pH and the cellular size of neutrophils were not changed after contact with the whole blood model, apart from a slight intracellular acidification being in accordance with the changes noted in the extracellular pH. Moreover, vital key functions of neutrophil granulocytes remained intact: ROS generation (<xref ref-type="fig" rid="f6"><bold>Figure 6C</bold></xref>) and phagocytotic activity (<xref ref-type="fig" rid="f6"><bold>Figure 6D</bold></xref>) remained largely stable when comparing neutrophils before and after exposure to the whole blood model, besides a small shift in intracellular pH and FSC.</p>
        <fig id="f6" position="float">
          <label>Figure 6</label>
          <caption>
            <p>Characterization of intracellular pH <bold>(A)</bold>, size <bold>(B)</bold>, generation of reactive oxygen species <bold>(C)</bold>, and phagocytotic activity <bold>(D)</bold> of neutrophils after venipuncture (0<sup>&#x2212;</sup>, n = 5 &#x2013; 7) and after incubation in the whole blood model for 1&#xA0;h with LPS 100 ng/ml or without further stimulation (Ctrl, both n = 7), results are presented as scatter plot and median with error bars indicating the interquartile range. * = <italic>p</italic> &lt;0.05, ** = <italic>p</italic> &lt;0.01.</p>
          </caption>
          <graphic xlink:href="fimmu-11-571992-g006"/>
        </fig>
      </sec>
      <sec id="s3_4">
        <title>Stimulation With LPS Causes Sepsis-Like Changes of the Immunologic Phenotype <italic>Ex Vivo</italic></title>
        <p>LPS (100 ng/ml) was used as a well-described and potent activator of innate immunity, demonstrating that the whole blood model is fully capable of generating a proinflammatory immunologic phenotype. Incubation of the whole blood system with LPS for 1&#xA0;h activated the cellular metabolism. Glucose utilization was significantly enhanced by 24% (15%; 49%; Ctrl: &#x2212;13 mM/h; &#x2212;16; &#x2212;11; vs. LPS &#x2212;17 mM/h; &#x2212;20; &#x2212;15; <italic>p</italic> &lt; 0.01, n = 10). Similarly, lactate generation was significantly increased by 27% (22%; 33%; Ctrl: +1.3 mM/h; 1.1; 1.6; vs. LPS: +1.7 mM/h; 1.5; 1.9; <italic>p</italic> &lt; 0.01, n = 10). Otherwise, global parameters of differential blood count and blood gas analysis remained widely unchanged. As a subsequent step, we compared the C3a, Il6, Il8, and MMP9 levels after stimulation of the whole blood <italic>ex vivo</italic> with LPS. LPS induced a tremendous increase in Il6 and MMP9, while Il8 and C3a were slightly increased (<xref ref-type="fig" rid="f3"><bold>Figure 3</bold></xref>). Interestingly, LPS-induced generation of MMP9 attained a maximum level within the first hour with a concentration that was 10&#x2013;20-fold increased after 1 and 3&#xA0;h of stimulation in comparison with the control specimens (data not shown). By contrast, LPS-induced generation of Il6 continued to increase beyond 1&#xA0;h, resulting in a greatly higher level after 3&#xA0;h (1&#xA0;h: 45 pg/ml; 31; 75, vs. 3&#xA0;h: 2523 pg/ml; 2271;2889, data not shown, n = 10 and n = 3, respectively).</p>
        <p>On the cellular site, monocytes and neutrophils responded to LPS exposure with an increase in the expression rates of CD11 and CD14, while CD62l was markedly decreased. The expression of CD88 was increased in monocytes and decreased in neutrophils after exposure to LPS (<xref ref-type="fig" rid="f4"><bold>Figures 4</bold></xref>, <xref ref-type="fig" rid="f5"><bold>5</bold></xref>). Furthermore, the cellular response pattern to additional stimulation <italic>in vitro</italic> with C5a was significantly impaired. In addition to extracellular activation markers, LPS incubation in the whole blood model altered intracellular parameters of neutrophils, increasing both intracellular pH and size (<xref ref-type="fig" rid="f6"><bold>Figures 6A, B</bold></xref>). Moreover, the activity of neutrophils regarding ROS production and phagocytosis was significantly enhanced (<xref ref-type="fig" rid="f6"><bold>Figures 6C, D</bold></xref>).</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s4">
      <title>Discussion</title>
      <sec id="s4_1">
        <title>Blood Physiology and Inflammation in Context</title>
        <p>In extracorporeal circulation, the blood system is subjected to various alterations because the interaction with other organ systems is interrupted while in parallel the continuous contact and interaction with the intact endothelium is lost. Furthermore, the <italic>ex vivo</italic> blood is exposed to artificial surfaces, resulting in activation of thromboinflammation (<xref rid="B32" ref-type="bibr">32</xref>). In the current model, the coagulation cascade was inhibited on the material surface and in the blood by a steady level of heparin, however, without administering an extensive amount. Of note, the platelet count and PNC formation remained stable (while still inducible by LPS), indicating no relevant activation of cellular coagulation. Nonetheless, one must consider, that heparins of both high and low molecular weight have been shown to directly interact with immune cells, for example, by increasing myeloperoxidase activity (<xref rid="B25" ref-type="bibr">25</xref>), although, a much lower concentration of heparin (0.5 IU/ml) was used in the present model. It is also noteworthy, that none of the activation markers assessed in this model were significantly elevated after 1&#xA0;h (<xref ref-type="fig" rid="f7"><bold>Figure 7</bold></xref>). Regarding metabolic changes of blood physiology, alterations in blood pH, glucose levels, and lactate were noted in the current model. While acidification and lactate levels were tolerable within the first hour, they cannot be considered physiological after 3&#xA0;h. In a similar manner, blood became hypoglycemic. Cellular innate immunity (particularly neutrophils) mainly relies on anaerobic glycolysis for its metabolism (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). Furthermore, cellular effector functions, including phagocytosis, require anaerobic glycolysis (<xref rid="B35" ref-type="bibr">35</xref>). Also, hypoglycemia has been shown to aggravate the response to inflammatory stimuli, including LPS (<xref rid="B36" ref-type="bibr">36</xref>). In parallel, (lactate) acidosis modulates many activities of the immune system, for example, reducing the phagocytotic capability of neutrophils while increasing their production of MMP9 (<xref rid="B37" ref-type="bibr">37</xref>).</p>
        <fig id="f7" position="float">
          <label>Figure 7</label>
          <caption>
            <p>Graphical abstract of the <italic>ex vivo</italic> whole blood model and the LPS-induced simulation of sepsis. Black symbols represent changes after 1&#xA0;h of contact with the tubing system, orange indicates a concomitant stimulation with LPS (100 ng/ml). pO<sub>2</sub> and pCO<sub>2</sub>, partial pressure of oxygen and carbon dioxide, respectively; Hb, hemoglobin; Hct, hematocrit; PNC, platelet-neutrophil-complexes; pH<sub>i</sub>, intracellular pH; C3a and C5a, complement factor 3a and 5a, respectively; MAC, membrane attack complex (sC5b-9); aPTT &amp; INR, activated partial thromboplastin time and international normalized ratio, respectively; Il, Interleukin; MMP9, matrix metallopeptidase 9; ROS, reactive oxygen species; Phago, phagocytosis; CRC, cellular response capacity (to subsequent additional stimulation with C5a.</p>
          </caption>
          <graphic xlink:href="fimmu-11-571992-g007"/>
        </fig>
        <p>Increased Il6 and MMP9 levels are well described in inflammation and during sepsis (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B39" ref-type="bibr">39</xref>). The Il6 levels after 1&#xA0;h of stimulation with LPS had almost attained the threshold level of septic patients (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). In this regard, it is, however, likely that Il6 during sepsis <italic>in realiter</italic> can be present longer and attain higher concentrations, because normally more than 1&#xA0;h elapses until the patient appears in the clinic with the diagnosis of sepsis. By contrast, the MMP9 levels in the model system were far above the concentrations described in sepsis (<xref rid="B38" ref-type="bibr">38</xref>) as early as 1&#xA0;h after incubation. It is tempting to speculate that the potent interactions of MMP9 with the glycocalyx of the endothelium, particularly during systemic inflammations that result in degradation of the glycocalyx, which was of course absent in the current <italic>ex vivo</italic> simulation, may induce higher MMP9 levels <italic>ex vivo</italic> in comparison with the <italic>in vivo</italic> situation.</p>
        <p>Overall, changes in cellular innate immunity closely resembled the described phenotype alterations in modeled systemic inflammation. For example, in two independent <italic>in vivo</italic> models of LPS administration in either rats or mice, neutrophil CD62l and CD11b expression appeared similar to the patterns found after LPS exposure in the <italic>ex vivo</italic> whole blood model (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). Reduced CD62l expression was also observed in neutrophils from patients with sepsis and endotoxin-challenged human volunteers (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Varying CD11b expression profiles of neutrophils have been reported in clinical sepsis (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>). These potential differences in CD11b expression (and the differences noted above regarding MMP9 and Il6) may either reflect some limitations of sepsis simulation by isolated LPS stimulation and/or the restricted observation period in the present model. However, the present results regarding the LPS-induced changes of neutrophil expression of CD11b, CD62l, and CD88 are perfectly in line with other whole blood models (<xref rid="B45" ref-type="bibr">45</xref>). Additionally, the reduced CD88 expression on leukocytes after simulation of inflammation in the whole blood model is corroborated by data from severely injured, sick, and septic patients (<xref rid="B46" ref-type="bibr">46</xref>&#x2013;<xref rid="B49" ref-type="bibr">49</xref>).</p>
        <p>In addition, LPS stimulation in the present model resulted in a similar shift of intracellular parameters in comparison with <italic>in vivo</italic> findings in recent literature. For example, an alkalization of neutrophils has been reported in septic shock patients (<xref rid="B28" ref-type="bibr">28</xref>). Likewise, a rise in size of granulocytes has been described in a murine model of cecum ligation and puncture-induced sepsis (<xref rid="B27" ref-type="bibr">27</xref>) and patients after trauma-induced inflammation (<xref rid="B50" ref-type="bibr">50</xref>).</p>
      </sec>
      <sec id="s4_2">
        <title>Whole Blood Models in Context</title>
        <p>Addressing the complex pathophysiology of systemic inflammation and blood stream infections requires models that can sufficiently portray the various cross-talk mechanisms between the blood cells, the endothelium, the humoral agents of immunity and hemostasis as well as blood physiology in terms of thermoregulation, acid-base-homeostasis, and blood-gas characteristics. Therefore, a plethora of different approaches and protocols were developed to allow the <italic>ex vivo</italic> investigation of the complex and highly sensitive organ &#x201C;blood&#x201D;. In this context, the term &#x201C;whole blood&#x201D; mostly represents an approach whereby blood, which has been somehow anticoagulated, retains the functionality of most if not, in principle, all its cellular and humoral components. Some protocols apply anticoagulated blood for studies which require an intact immune system, including simulating blood-stream infections (<xref rid="B16" ref-type="bibr">16</xref>), analyzing vaccine safety (<xref rid="B17" ref-type="bibr">17</xref>), and investigating leukocyte trafficking (<xref rid="B51" ref-type="bibr">51</xref>). These models usually add heparin or a hirudin-derived anticoagulant to mainly preserve the complement system as an important calcium-dependent humoral component of innate immunity. By contrast, citrate or Ethylenediaminetetraacetic acid addition interferes with the complement system (<xref rid="B32" ref-type="bibr">32</xref>).</p>
        <p>Blood models designed to investigate the coagulation cascade, particularly cellular hemostasis, normally use citrated blood including a protocol to resubstitute calcium in a stoichiometric manner; however, attempts have been undertaken with hirudin-based models (<xref rid="B52" ref-type="bibr">52</xref>). Other groups established a closed <italic>in-vivo</italic>-like setup by combining defined cell layers or cell culture-based organoids with whole blood (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>).</p>
      </sec>
      <sec id="s4_3">
        <title><italic>Ex Vivo</italic> Incubation of Human Whole Blood&#x2014;Advantages and Limitations</title>
        <p>The presented animal-free <italic>ex vivo</italic> whole blood model has various advantages: First, it is effortlessly transferable, widely accessible, and convenient to set up, because all the components are commercially available and can be delivered under sterile conditions. Moreover, the materials do not require any special treatment, for example, coating by the user, thus improving standardization and reducing the risk of any contamination. Second, particularly within the first hour, whole blood incubated in the circuit system remains stable regarding both blood physiology and cellular innate immunity. Third, the model allows incubation of several milliliters of blood, enabling the collection of a sufficient amount of specimen for endpoint analysis. The application of an <italic>ex vivo</italic> stimulation in general allows inclusion of older, frailer individuals, because they are generally underrepresented in inflammatory studies, especially in <italic>in vivo</italic> LPS challenges (<xref rid="B9" ref-type="bibr">9</xref>). Fourth, mimicking the inflammatory stimulus of sepsis with LPS resulted in an immunologic phenotype in accordance with preexisting literature. Last and most importantly, such a reliable model may help support disseminating the 3R-principles of animal research (<xref rid="B7" ref-type="bibr">7</xref>) by offering a valid reduction and/or replacement strategy for the investigation of blood-borne and blood-transferred inflammatory and infectious responses.</p>
        <p>There are also some limitations of the model. One restriction is the requirement of anticoagulation to reduce the activation of the blood while drawing and transferring it as well as presumably because of the shedding of at least some of the heparin coating into the system. Other whole blood models use different anticoagulants other than heparin, for example, hirudin, which inhibits the coagulation cascade further downstream than heparin. However, because of to the costs of hirudin-based drugs (e.g. lepirudin), and to adhere to the same substance as used for the coating of the tubing, we decided to apply a minimal dose of heparin systemically in the present model. Furthermore, the circulation of the continuously rotating air bubble only partially imitates the circulation forces in the human body without imitating the heterogeneous changes in pO<sub>2</sub>, CO<sub>2</sub>, or flow kinetics in the arterial and venous phases of circulation. Therefore, the changes in pO<sub>2</sub> and the stability of CO<sub>2</sub> are because of gas exchange with the remaining air bubble in the system, maintaining stable blood gas levels and being comparable to the venous environment. Another limitation is that the simulation of systemic inflammation occurs outside the human body, thereby excluding the blood-organ crosstalk, particularly the interactions with the endothelium, bone marrow, liver, and spleen. However, the current <italic>ex vivo</italic> setting allows the examination of inflammatory processes uniquely occurring in the blood itself. Finally, the timeframe for analyzing &#x201C;physiologic&#x201D; blood <italic>ex vivo</italic> is limited, because, for example, blood glucose is depleted and metabolic byproducts like lactate are not cleared. However, LPS-induced changes in the phenotype of neutrophils is a rather fast process, that starts within minutes and reached its ceiling as measured by CD62l and CD11b expression on neutrophils within 1&#xA0;h (<xref rid="B30" ref-type="bibr">30</xref>). Future development might overcome these issues, for example, by supplementing glucose during the experimental course, by connecting the system to a pulsatile pump allowing the circulation of the blood through various organoids such as liver or kidney cells. In addition, although the model in its current setup is easy to perform, a desirable automatization process of the blood handling would be rather complex to achieve.</p>
        <p>Overall, based on the data obtained from the synchronous monitoring of a comprehensive arsenal of physiological, metabolic, and immunologic blood parameters in an animal-free environment, we propose an <italic>ex vivo</italic> whole blood model of sepsis as a valuable addition to <italic>in vivo</italic> and clinical studies. Further studies need to validate the advantages of this model system in other inflammatory conditions and with blood from patients, for example, to test immunomodulatory treatments in blood from patients with systemic inflammation, cancer, or other diseases without putting patients at risk. Also, this model can be used as a screening tool, which may help to further reduce and/or replace animal experiments.</p>
      </sec>
    </sec>
    <sec sec-type="data-availability" id="s5">
      <title>Data Availability Statement</title>
      <p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
    </sec>
    <sec id="s6">
      <title>Ethics Statement</title>
      <p>The studies involving human participants were reviewed and approved by: Local Independent Ethics Committee of the University of Ulm. The participants provided their written informed consent to participate in this study.</p>
    </sec>
    <sec id="s7">
      <title>Author Contributions</title>
      <p>Conceptualization and supervision: DM and MH-L. Data curation and formal analysis: DM, LV, ME, AS, JB, SH, and MH-L. Methodology: DM, CB, AA, KN, BN, and MH-L. Validation and visualization: DM, LV, and ME. Writing&#x2014;original draft: DM, CB, and MH-L. Writing&#x2014;reviewing and editing. All authors contributed to the article and approved the submitted version.</p>
    </sec>
    <sec sec-type="funding-information" id="s8">
      <title>Funding</title>
      <p>The present work was funded by a research grant (&#x201C;Forum Gesundheitsstandort&#x201D;) of the Ministry of Science, Research, and Art Baden Wuerttemberg to DM and MH-L, a start-up grant and a position as Clinician Scientist to DM by the Collaborative Research Center 1149, project number 251293561, German Research Foundation, as well as grants to KN and BN (grants 2018- 04199, 2016-2075-5.1, and 2016-04519) provided by the Swedish Research Council. The funders had no role in the design of this study, data collection and interpretation, or decision to submit results.</p>
    </sec>
    <sec id="s9">
      <title>Conflict of Interest</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>The authors are indebted to Carina Kleimaier and Anke Schultze for outstanding technical assistance. In addition, the authors are grateful to the Department of Clinical Chemistry, University Hospital of Ulm, Ulm, Germany, for the measurement of differential blood count and coagulation parameters.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huber-Lang</surname><given-names>M</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name><name><surname>Ward</surname><given-names>PA</given-names></name></person-group>
<article-title>Innate immune responses to trauma</article-title>. <source>Nat Immunol</source> (<year>2018</year>) <volume>19</volume>:<page-range>327&#x2013;41</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1038/s41590-018-0064-8</pub-id>
</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Deutschman</surname><given-names>CS</given-names></name><name><surname>Seymour</surname><given-names>CW</given-names></name><name><surname>Shankar-Hari</surname><given-names>M</given-names></name><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)</article-title>. <source>JAMA</source> (<year>2016</year>) <volume>315</volume>:<fpage>801</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id>
<pub-id pub-id-type="pmid">26903338</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rudd</surname><given-names>KE</given-names></name><name><surname>Johnson</surname><given-names>SC</given-names></name><name><surname>Agesa</surname><given-names>KM</given-names></name><name><surname>Shackelford</surname><given-names>KA</given-names></name><name><surname>Tsoi</surname><given-names>D</given-names></name><name><surname>Kievlan</surname><given-names>DR</given-names></name><etal/></person-group>
<article-title>Global, regional, and national sepsis incidence and mortality, 1990&#x2013;2017: analysis for the Global Burden of Disease Study</article-title>. <source>Lancet</source> (<year>2020</year>) <volume>395</volume>:<page-range>200&#x2013;11</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1016/S0140-6736(19)32989-7</pub-id>
</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Poli-de-Figueiredo</surname><given-names>LF</given-names></name><name><surname>Garrido</surname><given-names>AG</given-names></name><name><surname>Nakagawa</surname><given-names>N</given-names></name><name><surname>Sannomiya</surname><given-names>P</given-names></name></person-group>
<article-title>EXPERIMENTAL MODELS OF SEPSIS AND THEIR CLINICAL RELEVANCE</article-title>. <source>Shock</source> (<year>2008</year>) <volume>30</volume>:<page-range>53&#x2013;9</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1097/SHK.0b013e318181a343</pub-id>
</mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fink</surname><given-names>MP</given-names></name></person-group>
<article-title>Animal models of sepsis</article-title>. <source>Virulence</source> (<year>2014</year>) <volume>5</volume>:<page-range>143&#x2013;53</page-range>. &#xA0;<pub-id pub-id-type="doi">10.4161/viru.26083</pub-id>
</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Osuchowski</surname><given-names>MF</given-names></name><name><surname>Ayala</surname><given-names>A</given-names></name><name><surname>Bahrami</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Boros</surname><given-names>M</given-names></name><name><surname>Cavaillon</surname><given-names>J-M</given-names></name><etal/></person-group>
<article-title>Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): An International Expert Consensus Initiative for Improvement of Animal Modeling in Sepsis</article-title>. <source>SHOCK</source> (<year>2018</year>) <volume>50</volume>:<page-range>377&#x2013;80</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1097/SHK.0000000000001212</pub-id>
</mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Russell</surname><given-names>WMS</given-names></name><name><surname>Burch</surname><given-names>RL</given-names></name></person-group>
<source>The principles of humane experimental technique</source>. <publisher-loc>Potters Bar</publisher-loc>: <publisher-name>UFAW</publisher-name> (<year>1992</year>). Special ed.
</mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pillay</surname><given-names>J</given-names></name><name><surname>Kamp</surname><given-names>VM</given-names></name><name><surname>van Hoffen</surname><given-names>E</given-names></name><name><surname>Visser</surname><given-names>T</given-names></name><name><surname>Tak</surname><given-names>T</given-names></name><name><surname>Lammers</surname><given-names>J-W</given-names></name><etal/></person-group>
<article-title>A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1</article-title>. <source>J Clin Invest</source> (<year>2012</year>) <volume>122</volume>:<page-range>327&#x2013;36</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1172/JCI57990</pub-id>
</mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Fullerton</surname><given-names>JN</given-names></name><name><surname>Segre</surname><given-names>E</given-names></name><name><surname>De Maeyer</surname><given-names>RPH</given-names></name><name><surname>Maini</surname><given-names>AAN</given-names></name><name><surname>Gilroy</surname><given-names>DW</given-names></name></person-group>
<article-title>Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation</article-title>. <source>J Vis Exp</source> (<year>2016</year>). &#xA0;<pub-id pub-id-type="doi">10.3791/53913</pub-id>
</mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grondman</surname><given-names>I</given-names></name><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>Koch</surname><given-names>RM</given-names></name><name><surname>Leijte</surname><given-names>GP</given-names></name><name><surname>Gerretsen</surname><given-names>J</given-names></name><name><surname>Bruse</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Frontline Science: Endotoxin-induced immunotolerance is associated with loss of monocyte metabolic plasticity and reduction of oxidative burst</article-title>. <source>J Leukoc Biol</source> (<year>2019</year>) <volume>106</volume>:<fpage>11</fpage>&#x2013;<lpage>25</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1002/JLB.5HI0119-018R</pub-id>
<pub-id pub-id-type="pmid">31169935</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamilos</surname><given-names>M</given-names></name><name><surname>Petousis</surname><given-names>S</given-names></name><name><surname>Parthenakis</surname><given-names>F</given-names></name></person-group>
<article-title>Interaction between platelets and endothelium: from pathophysiology to new therapeutic options</article-title>. <source>Cardiovasc Diagn Ther</source> (<year>2018</year>) <volume>8</volume>:<page-range>568&#x2013;80</page-range>. &#xA0;<pub-id pub-id-type="doi">10.21037/cdt.2018.07.01</pub-id>
</mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mollnes</surname><given-names>TE</given-names></name><name><surname>Brekke</surname><given-names>O-L</given-names></name><name><surname>Fung</surname><given-names>M</given-names></name><name><surname>Fure</surname><given-names>H</given-names></name><name><surname>Christiansen</surname><given-names>D</given-names></name><name><surname>Bergseth</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation</article-title>. <source>Blood</source> (<year>2002</year>) <volume>100</volume>:<page-range>1869&#x2013;77</page-range>.
</mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sprong</surname><given-names>T</given-names></name><name><surname>Brandtzaeg</surname><given-names>P</given-names></name><name><surname>Fung</surname><given-names>M</given-names></name><name><surname>Pharo</surname><given-names>AM</given-names></name><name><surname>H&#xF8;iby</surname><given-names>EA</given-names></name><name><surname>Michaelsen</surname><given-names>TE</given-names></name><etal/></person-group>
<article-title>Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis</article-title>. <source>Blood</source> (<year>2003</year>) <volume>102</volume>:<page-range>3702&#x2013;10</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1182/blood-2003-03-0703</pub-id>
</mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brekke</surname><given-names>O-L</given-names></name><name><surname>Christiansen</surname><given-names>D</given-names></name><name><surname>Fure</surname><given-names>H</given-names></name><name><surname>Fung</surname><given-names>M</given-names></name><name><surname>Mollnes</surname><given-names>TE</given-names></name></person-group>
<article-title>The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood</article-title>. <source>J Leukoc Biol</source> (<year>2007</year>) <volume>81</volume>:<page-range>1404&#x2013;13</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1189/jlb.0806538</pub-id>
</mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Egge</surname><given-names>KH</given-names></name><name><surname>Thorgersen</surname><given-names>EB</given-names></name><name><surname>Lindstad</surname><given-names>JK</given-names></name><name><surname>Pharo</surname><given-names>A</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name><name><surname>Barratt-Due</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Post challenge inhibition of C3 and CD14 attenuates <italic>Escherichia coli-</italic> induced inflammation in human whole blood</article-title>. <source>Innate Immun</source> (<year>2014</year>) <volume>20</volume>:<fpage>68</fpage>&#x2013;<lpage>77</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1177/1753425913482993</pub-id>
<pub-id pub-id-type="pmid">23669326</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>H&#xFC;nniger</surname><given-names>K</given-names></name><name><surname>Lehnert</surname><given-names>T</given-names></name><name><surname>Bieber</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name><name><surname>Figge</surname><given-names>MT</given-names></name><name><surname>Kurzai</surname><given-names>O</given-names></name></person-group>
<article-title>A Virtual Infection Model Quantifies Innate Effector Mechanisms and Candida albicans Immune Escape in Human Blood</article-title>. <source>PLoS Comput Biol</source> (<year>2014</year>) <volume>10</volume>:<elocation-id>e1003479</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1371/journal.pcbi.1003479</pub-id>
<pub-id pub-id-type="pmid">24586131</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hakimi</surname><given-names>J</given-names></name><name><surname>Aboutorabian</surname><given-names>S</given-names></name><name><surname>To</surname><given-names>F</given-names></name><name><surname>Ausar</surname><given-names>SF</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Brookes</surname><given-names>RH</given-names></name></person-group>
<article-title>Screening Vaccine Formulations in Fresh Human Whole Blood</article-title>. <source>Methods Mol Biol</source> (<year>2017</year>) <volume>1494</volume>:<fpage>295</fpage>&#x2013;<lpage>304</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1007/978-1-4939-6445-1_22</pub-id>
<pub-id pub-id-type="pmid">27718203</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Halbgebauer</surname><given-names>R</given-names></name><name><surname>Kellermann</surname><given-names>S</given-names></name><name><surname>Sch&#xE4;fer</surname><given-names>F</given-names></name><name><surname>Weckbach</surname><given-names>S</given-names></name><name><surname>Weiss</surname><given-names>M</given-names></name><name><surname>Barth</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Functional immune monitoring in severely injured patients-A pilot study</article-title>. <source>Scand J Immunol</source> (<year>2020</year>) <volume>91</volume>:<elocation-id>e12837</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1111/sji.12837</pub-id>
<pub-id pub-id-type="pmid">31622512</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>JE</given-names></name><name><surname>Solberg</surname><given-names>R</given-names></name><name><surname>Okkenhaug</surname><given-names>C</given-names></name><name><surname>J&#xF8;rgensen</surname><given-names>PF</given-names></name><name><surname>Krohn</surname><given-names>CD</given-names></name><name><surname>Aasen</surname><given-names>AO</given-names></name></person-group>
<article-title>Cytokine modulation in experimental endotoxemia: characterization of an ex vivo whole blood model</article-title>. <source>Eur Surg Res</source> (<year>2000</year>) <volume>32</volume>:<fpage>65</fpage>&#x2013;<lpage>73</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1159/000008743</pub-id>
<pub-id pub-id-type="pmid">10810211</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bexborn</surname><given-names>F</given-names></name><name><surname>Engberg</surname><given-names>AE</given-names></name><name><surname>Sandholm</surname><given-names>K</given-names></name><name><surname>Mollnes</surname><given-names>TE</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Nilsson Ekdahl</surname><given-names>K</given-names></name></person-group>
<article-title>Hirudin versus heparin for use in whole blood <italic>in vitro</italic> biocompatibility models</article-title>. <source>J BioMed Mater Res</source> (<year>2009</year>) <volume>89A</volume>:<page-range>951&#x2013;9</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1002/jbm.a.32034</pub-id>
</mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asif</surname><given-names>S</given-names></name><name><surname>Asawa</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Ishihara</surname><given-names>K</given-names></name><name><surname>Lindell</surname><given-names>B</given-names></name><name><surname>Holmgren</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Validation of an MPC Polymer Coating to Attenuate Surface-Induced Crosstalk between the Complement and Coagulation Systems in Whole Blood in In Vitro and In Vivo Models</article-title>. <source>Macromol Biosci</source> (<year>2019</year>) <volume>19</volume>:<elocation-id>1800485</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1002/mabi.201800485</pub-id>
</mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><collab>World Medical Association Declaration of Helsinki</collab></person-group>
<article-title>Ethical Principles for Medical Research Involving Human Subjects</article-title>. <source>JAMA</source> (<year>2013</year>) <volume>310</volume>:<fpage>2191</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1001/jama.2013.281053</pub-id>
<pub-id pub-id-type="pmid">24141714</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="webpage">
<person-group person-group-type="author"><name><surname>Dhingra</surname><given-names>N</given-names></name><collab>Safe Injection Global Network</collab><collab>World Health Organization</collab></person-group>
<source>WHO guidelines on drawing blood: best practices in phlebotomy</source> (<year>2010</year>). Available at: <uri xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK138650/">http://www.ncbi.nlm.nih.gov/books/NBK138650/</uri> (Accessed <date-in-citation>November 10, 2018</date-in-citation>).
</mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Larsson</surname><given-names>R</given-names></name><name><surname>Ekdahl</surname><given-names>KN</given-names></name><name><surname>Mollnes</surname><given-names>TE</given-names></name><name><surname>Nilsson</surname><given-names>U</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name></person-group>
<article-title>Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model</article-title>. <source>J Clin Immunol</source> (<year>1996</year>) <volume>16</volume>:<page-range>222&#x2013;9</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1007/BF01541228</pub-id>
</mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Videm</surname><given-names>V</given-names></name></person-group>
<article-title>Heparin in clinical doses &#x201C;primes&#x201D; granulocytes to subsequent activation as measured by myeloperoxidase release</article-title>. <source>Scand J Immunol</source> (<year>1996</year>) <volume>43</volume>:<page-range>385&#x2013;90</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1046/j.1365-3083.1996.d01-57.x</pub-id>
</mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borgdorff</surname><given-names>P</given-names></name><name><surname>Tangelder</surname><given-names>GJ</given-names></name></person-group>
<article-title>Pump-induced platelet aggregation with subsequent hypotension: Its mechanism and prevention with clopidogrel</article-title>. <source>J Thoracic Cardiovasc Surg</source> (<year>2006</year>) <volume>131</volume>:<fpage>813</fpage>&#x2013;<lpage>821.e2</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jtcvs.2005.10.021</pub-id>
</mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Denk</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>RP</given-names></name><name><surname>Wiegner</surname><given-names>R</given-names></name><name><surname>Cook</surname><given-names>EM</given-names></name><name><surname>Lindorfer</surname><given-names>MA</given-names></name><name><surname>Pfeiffer</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Complement C5a-induced changes in neutrophil morphology during inflammation</article-title>. <source>Scand J Immunol</source> (<year>2017</year>) <volume>86</volume>:<page-range>143&#x2013;55</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1111/sji.12580</pub-id>
</mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Denk</surname><given-names>S</given-names></name><name><surname>Neher</surname><given-names>MD</given-names></name><name><surname>Messerer</surname><given-names>DAC</given-names></name><name><surname>Wiegner</surname><given-names>R</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Rittirsch</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Complement C5a Functions as a Master Switch for the pH Balance in Neutrophils Exerting Fundamental Immunometabolic Effects</article-title>. <source>J Immunol</source> (<year>2017</year>) <volume>198</volume>:<page-range>4846&#x2013;54</page-range>. &#xA0;<pub-id pub-id-type="doi">10.4049/jimmunol.1700393</pub-id>
</mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mauler</surname><given-names>M</given-names></name><name><surname>Seyfert</surname><given-names>J</given-names></name><name><surname>Haenel</surname><given-names>D</given-names></name><name><surname>Seeba</surname><given-names>H</given-names></name><name><surname>Guenther</surname><given-names>J</given-names></name><name><surname>Stallmann</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Platelet-neutrophil complex formation&#x2014;a detailed in vitro analysis of murine and human blood samples</article-title>. <source>J Leukocyte Biol</source> (<year>2016</year>) <volume>99</volume>:<page-range>781&#x2013;9</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1189/jlb.3TA0315-082R</pub-id>
</mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vlkova</surname><given-names>M</given-names></name><name><surname>Chovancova</surname><given-names>Z</given-names></name><name><surname>Nechvatalova</surname><given-names>J</given-names></name><name><surname>Connelly</surname><given-names>AN</given-names></name><name><surname>Davis</surname><given-names>MD</given-names></name><name><surname>Slanina</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Neutrophil and Granulocytic Myeloid-Derived Suppressor Cell&#x2013;Mediated T Cell Suppression Significantly Contributes to Immune Dysregulation in Common Variable Immunodeficiency Disorders</article-title>. <source>J Immunol</source> (<year>2019</year>) <volume>202</volume>:<fpage>93</fpage>&#x2013;<lpage>104</lpage>. &#xA0;<pub-id pub-id-type="doi">10.4049/jimmunol.1800102</pub-id>
<pub-id pub-id-type="pmid">30487174</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van den Berg</surname><given-names>CW</given-names></name><name><surname>Tambourgi</surname><given-names>DV</given-names></name><name><surname>Clark</surname><given-names>HW</given-names></name><name><surname>Hoong</surname><given-names>SJ</given-names></name><name><surname>Spiller</surname><given-names>OB</given-names></name><name><surname>McGreal</surname><given-names>EP</given-names></name></person-group>
<article-title>Mechanism of Neutrophil Dysfunction: Neutrophil Serine Proteases Cleave and Inactivate the C5a Receptor</article-title>. <source>JI</source> (<year>2014</year>) <volume>192</volume>:<page-range>1787&#x2013;95</page-range>. &#xA0;<pub-id pub-id-type="doi">10.4049/jimmunol.1301920</pub-id>
</mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ekdahl</surname><given-names>KN</given-names></name><name><surname>Teramura</surname><given-names>Y</given-names></name><name><surname>Hamad</surname><given-names>OA</given-names></name><name><surname>Asif</surname><given-names>S</given-names></name><name><surname>Duehrkop</surname><given-names>C</given-names></name><name><surname>Fromell</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation</article-title>. <source>Immunol Rev</source> (<year>2016</year>) <volume>274</volume>:<page-range>245&#x2013;69</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1111/imr.12471</pub-id>
</mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kramer</surname><given-names>PA</given-names></name><name><surname>Ravi</surname><given-names>S</given-names></name><name><surname>Chacko</surname><given-names>B</given-names></name><name><surname>Johnson</surname><given-names>MS</given-names></name><name><surname>Darley-Usmar</surname><given-names>VM</given-names></name></person-group>
<article-title>A review of the mitochondrial and glycolytic metabolism in human platelets and leukocytes: Implications for their use as bioenergetic biomarkers</article-title>. <source>Redox Biol</source> (<year>2014</year>) <volume>2</volume>:<page-range>206&#x2013;10</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.redox.2013.12.026</pub-id>
</mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Loftus</surname><given-names>RM</given-names></name><name><surname>Finlay</surname><given-names>DK</given-names></name></person-group>
<article-title>Immunometabolism: Cellular Metabolism Turns Immune Regulator</article-title>. <source>J Biol Chem</source> (<year>2016</year>) <volume>291</volume>:<fpage>1</fpage>&#x2013;<lpage>10</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1074/jbc.R115.693903</pub-id>
<pub-id pub-id-type="pmid">26534957</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borregaard</surname><given-names>N</given-names></name><name><surname>Herlin</surname><given-names>T</given-names></name></person-group>
<article-title>Energy metabolism of human neutrophils during phagocytosis</article-title>. <source>J Clin Invest</source> (<year>1982</year>) <volume>70</volume>:<page-range>550&#x2013;7</page-range>.
</mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ratter</surname><given-names>JM</given-names></name><name><surname>Rooijackers</surname><given-names>HMM</given-names></name><name><surname>Tack</surname><given-names>CJ</given-names></name><name><surname>Hijmans</surname><given-names>AGM</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>de Galan</surname><given-names>BE</given-names></name><etal/></person-group>
<article-title>Proinflammatory Effects of Hypoglycemia in Humans With or Without Diabetes</article-title>. <source>Diabetes</source> (<year>2017</year>) <volume>66</volume>:<page-range>1052&#x2013;61</page-range>. &#xA0;<pub-id pub-id-type="doi">10.2337/db16-1091</pub-id>
</mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Erra D&#xED;az</surname><given-names>F</given-names></name><name><surname>Dantas</surname><given-names>E</given-names></name><name><surname>Geffner</surname><given-names>J</given-names></name></person-group>
<article-title>Unravelling the Interplay between Extracellular Acidosis and Immune Cells</article-title>. <source>Mediators Inflamm</source> (<year>2018</year>) <volume>2018</volume>:<fpage>1</fpage>&#x2013;<lpage>11</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1155/2018/1218297</pub-id>
</mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>M&#xFC;hl</surname><given-names>D</given-names></name><name><surname>Nagy</surname><given-names>B</given-names></name><name><surname>Woth</surname><given-names>G</given-names></name><name><surname>Falusi</surname><given-names>B</given-names></name><name><surname>Bog&#xE1;r</surname><given-names>L</given-names></name><name><surname>Weber</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis</article-title>. <source>J Crit Care</source> (<year>2011</year>) <volume>26</volume>:<page-range>550&#x2013;5</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.jcrc.2011.02.011</pub-id>
</mixed-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>DW</given-names></name><name><surname>Moon</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>H-J</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Seok</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions</article-title>. <source>BMC Infect Dis</source> (<year>2019</year>) <volume>19</volume>:<fpage>968</fpage>. &#xA0;<pub-id pub-id-type="doi">10.1186/s12879-019-4618-7</pub-id>
<pub-id pub-id-type="pmid">31718563</pub-id></mixed-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gentile</surname><given-names>LF</given-names></name><name><surname>Cuenca</surname><given-names>AG</given-names></name><name><surname>Vanzant</surname><given-names>EL</given-names></name><name><surname>Efron</surname><given-names>PA</given-names></name><name><surname>McKinley</surname><given-names>B</given-names></name><name><surname>Moore</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Is there value in plasma cytokine measurements in patients with severe trauma and sepsis</article-title>? <source>Methods</source> (<year>2013</year>) <volume>61</volume>:<fpage>3</fpage>&#x2013;<lpage>9</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.ymeth.2013.04.024</pub-id>
<pub-id pub-id-type="pmid">23669589</pub-id></mixed-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Wessem</surname><given-names>KJP</given-names></name><name><surname>Heeres</surname><given-names>M</given-names></name><name><surname>Leliefeld</surname><given-names>PHC</given-names></name><name><surname>Koenderman</surname><given-names>L</given-names></name><name><surname>Leenen</surname><given-names>LPH</given-names></name></person-group>
<article-title>Lipopolysaccharide and hemorrhagic shock cause systemic inflammation by different mechanisms</article-title>. <source>J Trauma Acute Care Surg</source> (<year>2013</year>) <volume>74</volume>:<fpage>37</fpage>&#x2013;<lpage>44</lpage>. &#xA0;<pub-id pub-id-type="doi">10.1097/TA.0b013e3182789489</pub-id>
<pub-id pub-id-type="pmid">23271075</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reber</surname><given-names>LL</given-names></name><name><surname>Gillis</surname><given-names>CM</given-names></name><name><surname>Starkl</surname><given-names>P</given-names></name><name><surname>J&#xF6;nsson</surname><given-names>F</given-names></name><name><surname>Sibilano</surname><given-names>R</given-names></name><name><surname>Marichal</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Neutrophil myeloperoxidase diminishes the toxic effects and mortality induced by lipopolysaccharide</article-title>. <source>J Exp Med</source> (<year>2017</year>) <volume>214</volume>:<page-range>1249&#x2013;58</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1084/jem.20161238</pub-id>
</mixed-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Demaret</surname><given-names>J</given-names></name><name><surname>Venet</surname><given-names>F</given-names></name><name><surname>Friggeri</surname><given-names>A</given-names></name><name><surname>Cazalis</surname><given-names>M-A</given-names></name><name><surname>Plassais</surname><given-names>J</given-names></name><name><surname>Jallades</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Marked alterations of neutrophil functions during sepsis-induced immunosuppression</article-title>. <source>J Leukocyte Biol</source> (<year>2015</year>) <volume>98</volume>:<page-range>1081&#x2013;90</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1189/jlb.4A0415-168RR</pub-id>
</mixed-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Groeneveld</surname><given-names>KM</given-names></name><name><surname>Koenderman</surname><given-names>L</given-names></name><name><surname>Warren</surname><given-names>BL</given-names></name><name><surname>Jol</surname><given-names>S</given-names></name><name><surname>Leenen</surname><given-names>LPH</given-names></name><name><surname>Hietbrink</surname><given-names>F</given-names></name></person-group>
<article-title>Early decreased neutrophil responsiveness is related to late onset sepsis in multitrauma patients: An international cohort study</article-title>. <source>PLoS One</source> (<year>2017</year>) <volume>12</volume>:<elocation-id>e0180145</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1371/journal.pone.0180145</pub-id>
<pub-id pub-id-type="pmid">28665985</pub-id></mixed-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maini</surname><given-names>AA</given-names></name><name><surname>George</surname><given-names>MJ</given-names></name><name><surname>Motwani</surname><given-names>MP</given-names></name><name><surname>Day</surname><given-names>RM</given-names></name><name><surname>Gilroy</surname><given-names>DW</given-names></name><name><surname>O&#x2019;Brien</surname><given-names>AJ</given-names></name></person-group>
<article-title>A Comparison of Human Neutrophils Acquired from Four Experimental Models of Inflammation</article-title>. <source>PLoS One</source> (<year>2016</year>) <volume>11</volume>:<elocation-id>e0165502</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.1371/journal.pone.0165502</pub-id>
<pub-id pub-id-type="pmid">27780229</pub-id></mixed-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Furebring</surname><given-names>M</given-names></name><name><surname>H&#xE5;kansson</surname><given-names>LD</given-names></name><name><surname>Venge</surname><given-names>P</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Sj&#xF6;lin</surname><given-names>J</given-names></name></person-group>
<article-title>Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis</article-title>. <source>Crit Care</source> (<year>2002</year>) <volume>6</volume>:<page-range>363&#x2013;70</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1186/cc1524</pub-id>
</mixed-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amara</surname><given-names>U</given-names></name><name><surname>Kalbitz</surname><given-names>M</given-names></name><name><surname>Perl</surname><given-names>M</given-names></name><name><surname>Flierl</surname><given-names>MA</given-names></name><name><surname>Rittirsch</surname><given-names>D</given-names></name><name><surname>Weiss</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Early Expression Changes of Complement Regulatory Proteins and C5a Receptor (Cd88) On Leukocytes After Multiple Injury In Humans</article-title>. <source>Shock</source> (<year>2010</year>) <volume>33</volume>:<page-range>568&#x2013;75</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1097/SHK.0b013e3181c799d4</pub-id>
</mixed-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morris</surname><given-names>AC</given-names></name><name><surname>Brittan</surname><given-names>M</given-names></name><name><surname>Wilkinson</surname><given-names>TS</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Antonelli</surname><given-names>J</given-names></name><name><surname>McCulloch</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>C5a-mediated neutrophil dysfunction is RhoA-dependent and predicts infection in critically ill patients</article-title>. <source>Blood</source> (<year>2011</year>) <volume>117</volume>:<page-range>5178&#x2013;88</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1182/blood-2010-08-304667</pub-id>
</mixed-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Unnewehr</surname><given-names>H</given-names></name><name><surname>Rittirsch</surname><given-names>D</given-names></name><name><surname>Sarma</surname><given-names>JV</given-names></name><name><surname>Zetoune</surname><given-names>F</given-names></name><name><surname>Flierl</surname><given-names>MA</given-names></name><name><surname>Perl</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Changes and Regulation of the C5a Receptor on Neutrophils during Septic Shock in Humans</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>190</volume>:<page-range>4215&#x2013;25</page-range>. &#xA0;<pub-id pub-id-type="doi">10.4049/jimmunol.1200534</pub-id>
</mixed-citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hesselink</surname><given-names>L</given-names></name><name><surname>Heeres</surname><given-names>M</given-names></name><name><surname>Paraschiakos</surname><given-names>F</given-names></name><name><surname>ten Berg</surname><given-names>M</given-names></name><name><surname>Huisman</surname><given-names>A</given-names></name><name><surname>Hoefer</surname><given-names>IE</given-names></name><etal/></person-group>
<article-title>A Rise in Neutrophil Cell Size Precedes Organ Dysfunction After Trauma</article-title>. <source>SHOCK</source> (<year>2019</year>) <volume>51</volume>:<page-range>439&#x2013;46</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1097/SHK.0000000000001200</pub-id>
</mixed-citation>
      </ref>
      <ref id="B51">
        <label>51</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamza</surname><given-names>B</given-names></name><name><surname>Irimia</surname><given-names>D</given-names></name></person-group>
<article-title>Whole blood human neutrophil trafficking in a microfluidic model of infection and inflammation</article-title>. <source>Lab Chip</source> (<year>2015</year>) <volume>15</volume>:<page-range>2625&#x2013;33</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1039/c5lc00245a</pub-id>
</mixed-citation>
      </ref>
      <ref id="B52">
        <label>52</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tiedemann Skipper</surname><given-names>M</given-names></name><name><surname>Rubak</surname><given-names>P</given-names></name><name><surname>Halfdan Larsen</surname><given-names>O</given-names></name><name><surname>Hvas</surname><given-names>A-M</given-names></name></person-group>
<article-title>Thrombocytopenia model with minimal manipulation of blood cells allowing whole blood assessment of platelet function</article-title>. <source>Platelets</source> (<year>2016</year>) <volume>27</volume>:<fpage>295</fpage>&#x2013;<lpage>300</lpage>. &#xA0;<pub-id pub-id-type="doi">10.3109/09537104.2015.1095873</pub-id>
<pub-id pub-id-type="pmid">26555800</pub-id></mixed-citation>
      </ref>
      <ref id="B53">
        <label>53</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmohl</surname><given-names>M</given-names></name><name><surname>Schneiderhan-Marra</surname><given-names>N</given-names></name><name><surname>Baur</surname><given-names>N</given-names></name><name><surname>Hefner</surname><given-names>K</given-names></name><name><surname>Blum</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>GM</given-names></name><etal/></person-group>
<article-title>Characterization of immunologically active drugs in a novel organotypic co-culture model of the human gut and whole blood</article-title>. <source>Int Immunopharmacol</source> (<year>2012</year>) <volume>14</volume>:<page-range>722&#x2013;8</page-range>. &#xA0;<pub-id pub-id-type="doi">10.1016/j.intimp.2012.10.010</pub-id>
</mixed-citation>
      </ref>
      <ref id="B54">
        <label>54</label>
        <mixed-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Nordling</surname><given-names>S</given-names></name><name><surname>Nilsson</surname><given-names>B</given-names></name><name><surname>Magnusson</surname><given-names>PU</given-names></name></person-group>
<article-title>A novel in vitro model for studying the interactions between human whole blood and endothelium</article-title>. <source>J Vis Exp</source> (<year>2014</year>), <elocation-id>e52112</elocation-id>. &#xA0;<pub-id pub-id-type="doi">10.3791/52112</pub-id>
<pub-id pub-id-type="pmid">25489671</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Am J Case Rep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Am J Case Rep</journal-id>
      <journal-id journal-id-type="publisher-id">amjcaserep</journal-id>
      <journal-title-group>
        <journal-title>The American Journal of Case Reports</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1941-5923</issn>
      <publisher>
        <publisher-name>International Scientific Literature, Inc.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32469847</article-id>
      <article-id pub-id-type="pmc">7286187</article-id>
      <article-id pub-id-type="doi">10.12659/AJCR.922498</article-id>
      <article-id pub-id-type="publisher-id">922498</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Myocardial Infarction with Limb Arterial and Venous Thrombosis in a Patient with Enoxaparin-Induced Thrombocytopenia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Singh</surname>
            <given-names>Navdeep</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn2-amjcaserep-21-e922498">
            <sup>B</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn5-amjcaserep-21-e922498">
            <sup>E</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn6-amjcaserep-21-e922498">
            <sup>F</sup>
          </xref>
          <xref ref-type="aff" rid="af1-amjcaserep-21-e922498">
            <sup>1</sup>
          </xref>
          <xref rid="c1-amjcaserep-21-e922498" ref-type="corresp"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lubana</surname>
            <given-names>Sandeep Singh</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn4-amjcaserep-21-e922498">
            <sup>D</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn5-amjcaserep-21-e922498">
            <sup>E</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn6-amjcaserep-21-e922498">
            <sup>F</sup>
          </xref>
          <xref ref-type="aff" rid="af2-amjcaserep-21-e922498">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tsai</surname>
            <given-names>Han-mou</given-names>
          </name>
          <xref ref-type="author-notes" rid="fn5-amjcaserep-21-e922498">
            <sup>E</sup>
          </xref>
          <xref ref-type="author-notes" rid="fn6-amjcaserep-21-e922498">
            <sup>F</sup>
          </xref>
          <xref ref-type="aff" rid="af2-amjcaserep-21-e922498">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="af1-amjcaserep-21-e922498">
<label>1</label>Department of Medicine, Division of Hospice and Palliative Care, North Shore University Hospital, Manhasset, NY, U.S.A.</aff>
      <aff id="af2-amjcaserep-21-e922498">
<label>2</label>Department of Medicine, Division of Hematology and Oncology, State University New York (SUNY) Downstate Medical Center, Brooklyn, NY, U.S.A.</aff>
      <author-notes>
        <corresp id="c1-amjcaserep-21-e922498">Corresponding Author: Navdeep Singh, e-mail: <email>imedsingh@gmail.com</email></corresp>
        <fn>
          <p>Authors&#x2019; Contribution:</p>
        </fn>
        <fn id="fn1-amjcaserep-21-e922498">
          <label>A</label>
          <p>Study Design</p>
        </fn>
        <fn id="fn2-amjcaserep-21-e922498">
          <label>B</label>
          <p>Data Collection</p>
        </fn>
        <fn id="fn3-amjcaserep-21-e922498">
          <label>C</label>
          <p>Statistical Analysis</p>
        </fn>
        <fn id="fn4-amjcaserep-21-e922498">
          <label>D</label>
          <p>Data Interpretation</p>
        </fn>
        <fn id="fn5-amjcaserep-21-e922498">
          <label>E</label>
          <p>Manuscript Preparation</p>
        </fn>
        <fn id="fn6-amjcaserep-21-e922498">
          <label>F</label>
          <p>Literature Search</p>
        </fn>
        <fn id="fn7-amjcaserep-21-e922498">
          <label>G</label>
          <p>Funds Collection</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Conflict of interest:</bold> None declared</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>29</day>
        <month>5</month>
        <year>2020</year>
      </pub-date>
      <volume>21</volume>
      <fpage>e922498-1</fpage>
      <lpage>e922498-7</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>12</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>3</month>
          <year>2020</year>
        </date>
        <date date-type="rev-recd">
          <day>07</day>
          <month>5</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Am J Case Rep, 2020</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license license-type="open-access">
          <license-p>This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0</ext-link>)</license-p>
        </license>
      </permissions>
      <abstract>
        <p>
          <bold>Patient: Female, 67-year-old</bold>
        </p>
        <p>
          <bold>Final Diagnosis: Enoxaparin induced thrombocytopenia with life threatening thrombosis</bold>
        </p>
        <p>
          <bold>Symptoms: Chest discomfort</bold>
        </p>
        <p>
          <bold>Medication:&#x2014;</bold>
        </p>
        <p>
          <bold>Clinical Procedure: &#x2014;</bold>
        </p>
        <p>
          <bold>Specialty: Hematology</bold>
        </p>
        <sec>
          <title>Objective:</title>
          <p>
            <bold>Educational purpose</bold>
          </p>
        </sec>
        <sec>
          <title>Background:</title>
          <p>Heparin, often used as an anticoagulant, acts by binding to antithrombin III. Indeed, heparin binds to a variety of proteins other than antithrombin III. Among them, platelet factor 4 can bind and neutralize the anticoagulant activity of heparin. Upon binding with heparin, platelet factor 4 undergoes a conformational change and expresses immunogenic neo-epitopes that induce the generation of antibodies of the platelet factor 4 heparin complex. This immune reaction may lead to thrombocytopenia and venous, arterial, or microvascular thrombosis. However, the risk of such complications is quite variable, as it is affected not only by the source and dose of heparin and the clinical condition (e.g., cardiovascular surgery and orthopedic surgery) of the patient, but also the molecular size of the heparin formulation. Venous, arterial, and small-vessel thrombosis can lead to leg swelling, pulmonary embolism, stroke, skin necrosis, or gangrene requiring limb amputation or intestinal resection. Myocardial infarction due to coronary thrombosis also occurs, although it is less common and can be readily recognized.</p>
        </sec>
        <sec>
          <title>Case Report:</title>
          <p>Heparin-induced thrombocytopenia (HIT) is a potentially life-threatening complication of heparin therapy. We report the case of a 67-year-old woman who developed ST-segment elevation myocardial infarction and thrombocytopenia within 10 days of prophylactic enoxaparin therapy after undergoing bilateral total knee replacement surgery. She also had peripheral arterial and venous thrombosis. With thrombolysis and argatroban anticoagulation therapy, she recovered without residual sequelae.</p>
        </sec>
        <sec>
          <title>Conclusions:</title>
          <p>Thrombocytopenia with coronary and other vascular thrombosis is a potentially serious complication of heparin therapy. A trend of decreased platelet count, decreased platelet count by 30% or more, and/or occurrence of any type of thrombosis should raise the suspicion of HIT. This case demonstrates that early recognition and prompt treatment of HIT can be life-saving.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>MeSH Keywords:</title>
        <kwd>Enoxaparin</kwd>
        <kwd>Platelet Factor 4</kwd>
        <kwd>Thrombocytopenia</kwd>
        <kwd>Thrombosis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Heparin, a naturally occurring, highly sulfated, and iduronic acid-rich form of heparan sulfate, is often used as an anticoagulant to stop or prevent thrombosis in the circulation. Heparin acts by binding via a sulfated pentasaccharide sequence to anti-thrombin III (AT3, encoded by <italic>SerpinC1</italic>), a plasma serine pro-tease inhibitor (serpin). This binding induces conformational transformation of the AT3 reactive site for interaction with coagulation proteases such as factors IIa (thrombin), IXa, and Xa. For inhibition of thrombin but not factor Xa, an additional 13 monomeric units of the heparin molecule are required [<xref rid="b1-amjcaserep-21-e922498" ref-type="bibr">1</xref>]. Due to this size difference, low-molecular-weight heparins (LMWH) are more effective in inhibiting factor Xa than is thrombin.</p>
      <p>Heparin is highly conserved evolutionarily, being synthesized in a variety of animal species, including those without a blood coagulation system [<xref rid="b2-amjcaserep-21-e922498" ref-type="bibr">2</xref>], indicating that it possesses biological functions other than anticoagulation.</p>
      <p>Indeed, heparin binds to a variety of proteins other than AT3 [<xref rid="b3-amjcaserep-21-e922498" ref-type="bibr">3</xref>]. Among them, platelet factor 4 (PF4), a positively-charged chemokine derived from the alpha granules of platelets, can bind and neutralize the anticoagulant activity of heparin. Upon binding with heparin, PF4 undergoes a conformational change and expresses immunogenic neo-epitopes that induce the generation of anti-PF4-heparin antibodies [<xref rid="b4-amjcaserep-21-e922498" ref-type="bibr">4</xref>]. This conformational change of PF4 also occurs upon its binding to other poly-anions such as polyphosphates. Occasionally, autoimmune anti-PF4 antibodies occur spontaneously to cause thrombosis without prior exposure to heparin [<xref rid="b5-amjcaserep-21-e922498" ref-type="bibr">5</xref>,<xref rid="b6-amjcaserep-21-e922498" ref-type="bibr">6</xref>].</p>
      <p>Heparin-induced immune reaction can lead to thrombocytopenia (type II HIT, or simply HIT) that is not easily distinguished from mild thrombocytopenia that is benign and self-limited (type I HIT) [<xref rid="b7-amjcaserep-21-e922498" ref-type="bibr">7</xref>]. The thrombocytopenia of HIT is rarely severe enough to cause spontaneous bleeding complications, even in the presence of heparin anticoagulation therapy; instead, the immune reaction may lead to venous or arterial thrombosis. However, the risk of such complications is quite variable, as it is affected not only by the source and dose of heparin, the clinical condition (e.g., cardiovascular surgery and orthopedic surgery) of the patient, but also the molecular size of the heparin formulation &#x2013; the risk is much lower with LMWH than with unfractionated heparin (UFH) [<xref rid="b8-amjcaserep-21-e922498" ref-type="bibr">8</xref>]. Venous, arterial, and small-vessel thrombosis can lead to leg swelling, pulmonary embolism, stroke, skin necrosis, or gangrene requiring limb amputation or intestinal resection. Myocardial infarction due to coronary thrombosis also occurs, although it is less common and is not widely known.</p>
      <p>We report a case of ST-segment elevation myocardial infarction (STEMI) with peripheral arterial and venous thrombosis a patient receiving prophylactic enoxaparin therapy after undergoing bilateral knee replacement surgery, which was successfully treated with thrombolysis, argatroban, and apixaban.</p>
    </sec>
    <sec sec-type="cases">
      <title>Case Report</title>
      <p>A 67-year-old woman with a past medical history of hyper-lipidemia but no known history of coronary artery disease or myocardial infarction was transferred to our facility with STEMI 10 days after undergoing bilateral total knee arthroplasty at an outside hospital.</p>
      <p>The patient&#x2019;s preoperative evaluation revealed an abnormal electrocardiogram (EKG) with right bundle branch block (RBBB) and age-indeterminate inferior myocardial infarction. An echo-cardiogram showed normal left ventricular wall motions with an ejection fraction of 60%. Myocardial imaging did not detect any perfusion defects. The preoperative laboratory tests were unremarkable. The platelet count was 209 000/microliter. The knee replacement surgery was uneventful. Prophylactic subcutaneous enoxaparin at 40 mg daily was started 1 day after the operation, before the patient was discharged on the next day. On day 9 of her enoxaparin therapy, she started to have retrosternal chest pain with diaphoresis and lightheadedness, prompting evaluation at her local emergency room (ER).</p>
      <p>In the ER, her physical examination was unremarkable other than the surgical incision wounds of her recent knee surgery. The EKG was notable for ST-segment elevation in leads II, III, and aVF along with old RBBB. Laboratory studies were significant for elevated troponin level (7.27 ng/mL), thrombocytopenia (39 000/microliter), and elevated D-dimer (20 microgram/L). The patient was treated with oral aspirin 325 mg, 1 inch of 2% nitroglycerin paste, tenecteplase 50 mg intravenously as a single bolus, and heparin 4000 units as a bolus followed by infusion at 12 U/kg/h before transfer to our institution.</p>
      <p>Upon arrival at our institution, a repeat laboratory test confirmed thrombocytopenia with a platelet count of 36 000/microliter. An echocardiogram demonstrated left ventricular ejection fraction of 55% to 60% with mild inferior wall hypokinesis. The troponins had increased to 238 ng/ml. Heparin-induced thrombocytopenia (HIT) with thrombosis was suspected. Her heparin infusion was discontinued and replaced with argatroban infusion at 2 microgram/kg/min after blood samples were obtained for anti-heparin-platelet factor 4 (anti-heparin-PF4) antibody test (GTI Elisa) and serotonin release assay (SRA), both of which later came back positive.</p>
      <p>A computerized tomography angiogram (CTA) of the chest was negative for pulmonary embolism. However, a Doppler ultra-sound examination detected an acute thrombosis of the left posterior tibial vein. In addition to argatroban infusion, she was treated with aspirin 81 mg daily, metoprolol 25 mg twice daily, and atorvastatin 80 mg daily. The troponin level rapidly trended downward to 14 ng/mL within 3 days. Serial EKG showed resolution of the ST-segment elevations. However, the patient&#x2019;s hospital course was complicated by extreme pain of the left foot, with toe discoloration on the 5<sup>th</sup> day. Run-off CTA of the abdominal aorta and lower extremities demonstrated bilateral non-occlusive thrombi of femoral and popliteal arteries. The pain improved with analgesics hydromor-phone as needed and continued argatroban anticoagulation therapy. Her platelet count was at its nadir of 36 000/micro-liter at admission and returned to normal on the 9<sup>th</sup> hospital day. The patient was discharged on hospital day 13 with apixaban 10 mg twice daily.</p>
      <p><italic>Timeline:</italic>
<list list-type="simple"><list-item><p>Day 0 &#x2013; Preoperative evaluation;</p></list-item><list-item><p>Day 8 &#x2013; Patient underwent bilateral knee replacement;</p></list-item><list-item><p>Day 9 &#x2013; Prophylactic enoxaparin started;</p></list-item><list-item><p>Day 10 &#x2013; Discharged on subcutaneous enoxaparin;</p></list-item><list-item><p>Day 17 &#x2013; Patient started to have retrosternal chest pain;</p></list-item><list-item><p>Day 18 (Outside ER) &#x2013; Diagnosed with STEMI, Tenecteplase was administered, Platelets 39000/microliter;</p></list-item><list-item><p>Day 18 (Our hospital) &#x2013; Heparin discontinued (HIT suspected), argatroban infusion started, heparin-PF4 antibody positive, positive deep vein thrombosis;</p></list-item><list-item><p>Day 20 &#x2013; SRA came back positive, confirming the diagnosis of HIT;</p></list-item><list-item><p>Day 25 &#x2013; CTA detected lower-extremities arterial thrombosis;</p></list-item><list-item><p>Day 26 &#x2013; Platelets returned normal;</p></list-item><list-item><p>Day 28 &#x2013; Argatroban switched to apixaban;</p></list-item><list-item><p>Day 30 &#x2013; Patient was discharged.</p></list-item></list></p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Heparin-induced thrombocytopenia (HIT) is a potentially serious adverse event of heparin anticoagulation therapy. It typically presents with thrombocytopenia or a decrease of the platelet count by more than 30&#x2013;50% on days 5&#x2013;15 of heparin therapy, accompanied with venous or arterial thrombosis in approximately 50% of patients. Although this complication occurs less frequently with low-molecular-weight heparin (LMWH) than with unfractionated heparin (UFH) [<xref rid="b4-amjcaserep-21-e922498" ref-type="bibr">4</xref>], the risk is not negligible, being 0.5&#x2013;5% for individuals treated with enoxaparin for at least 5 days [<xref rid="b9-amjcaserep-21-e922498" ref-type="bibr">9</xref>].</p>
      <p>Laboratory investigations have demonstrated that HIT antibodies are formed against the heparin- platelet factor 4 (PF4) complex [<xref rid="b10-amjcaserep-21-e922498" ref-type="bibr">10</xref>&#x2013;<xref rid="b13-amjcaserep-21-e922498" ref-type="bibr">13</xref>]. PF4 [<xref rid="b14-amjcaserep-21-e922498" ref-type="bibr">14</xref>], also known as CXCL4, is a 70-amino acid positively-charged protein that is released from the alpha granules of activated platelets. It binds to negatively-charged heparin and heparin-like molecules via electrostatic interactions on the surface of vascular endothelium. This binding keeps heparin from binding to antithrombin 3 (AT3), thereby preventing activation of AT3 by heparin for controlling the activity of factors IIa (thrombin), IXa, and Xa. As a consequence, PF4 is pro-coagulation and may be pro-thrombosis. PF4 may also be involved in the regulation of megakaryopoiesis [<xref rid="b15-amjcaserep-21-e922498" ref-type="bibr">15</xref>] and is a chemokine for various cell types, including neutrophils and fibroblasts.</p>
      <p>The binding of PF4 with heparin exposes neo-epitopes on PF4 that trigger the formation of anti-heparin-PF4 antibodies in approximately 8&#x2013;50% of patients treated with UFH, 1&#x2013;8% with LMWH, and 1&#x2013;3% with fondaparinux [<xref rid="b8-amjcaserep-21-e922498" ref-type="bibr">8</xref>,<xref rid="b16-amjcaserep-21-e922498" ref-type="bibr">16</xref>,<xref rid="b17-amjcaserep-21-e922498" ref-type="bibr">17</xref>]. The heparin-PF4 complex is most stable for the trigger of an immune reaction when PF4 and heparin are at stoichiometric molar ratios (&#x223C;1 for UFH and &#x223C;0.5 for LMWH) of electrostatic neutralization [<xref rid="b18-amjcaserep-21-e922498" ref-type="bibr">18</xref>,<xref rid="b19-amjcaserep-21-e922498" ref-type="bibr">19</xref>]. Thus, heparin formulation, dosage, and clinical conditions of the patients contribute to the wide variation of the incidence rate of immune reactions to heparin-PF4.</p>
      <p>Only a small fraction of patients with heparin-PF4 antibodies develop thrombocytopenia with or without thrombosis. This variation likely reflects the difference in the molecular size of the heparin formulations and the heterogeneity of antibodies produced. In laboratory studies, the higher affinity of the antibodies for heparin-PF4 complex or for PF4 alone correlates with greater platelet-activating ability [<xref rid="b20-amjcaserep-21-e922498" ref-type="bibr">20</xref>]. In addition to the type of heparin used, clinical conditions such as cardiac transplant and neurosurgery are associated with a higher risk of HIT.</p>
      <p>The mechanism of thrombocytopenia and thrombosis in HIT is complex and not fully established. In laboratory studies, Heparin-PF4 complex is deposited on the platelet surface. This deposition is suppressed by high concentrations of heparin, suggesting that the heparin-PF4 complex binds to platelets via its heparin component [<xref rid="b21-amjcaserep-21-e922498" ref-type="bibr">21</xref>]. HIT IgG binds via its Fab sequences to the PF4 component of heparin-PF4 complex on the platelet surface. The IgG molecule then binds via its Fc sequences to the Fcg receptor IIa of platelets, resulting in activation of the platelet and generation of pro-coagulant platelet microparticles. <italic>In vivo</italic>, P-selectin is expressed on circulating platelets, and platelet-derived microparticles are increased, confirming that platelets are activated in HIT [<xref rid="b22-amjcaserep-21-e922498" ref-type="bibr">22</xref>,<xref rid="b23-amjcaserep-21-e922498" ref-type="bibr">23</xref>]. Nevertheless, platelet activation alone is insufficient to cause thrombosis. Other studies further show that HIT sera cause IgG and C3 to deposit on endothelial cells [<xref rid="b24-amjcaserep-21-e922498" ref-type="bibr">24</xref>] and HIT IgG induces monocytes to express pro-coagulant tissue factor activity [<xref rid="b25-amjcaserep-21-e922498" ref-type="bibr">25</xref>]. These alterations create a prothrombotic state that can lead to thrombosis, especially in vessels with pre-existing injury. Attraction of neutrophils, possibly by PF4, and formation of neutrophil extracellular trap (NET) may contribute to the propagation of thrombus [<xref rid="b26-amjcaserep-21-e922498" ref-type="bibr">26</xref>,<xref rid="b27-amjcaserep-21-e922498" ref-type="bibr">27</xref>].</p>
      <p>In a typical case, there is no history of exposure to heparin within the preceding 3 months, thrombocytopenia occurs after 4 but usually within 15 days of heparin treatment, and there is no other potential cause of the thrombocytopenia. For such cases, the diagnosis of HIT is straightforward, especially when it is accompanied with evidence of new thrombosis and when the thrombocytopenia quickly resolves in a few days after heparin is discontinued, with or without starting alternative anticoagulation therapy. Our patient did not have prior exposure to heparin, her symptoms of myocardial infarction and thrombocytopenia were noted on day 9 of enoxaparin treatment, there were no other plausible causes of her thrombocytopenia, and she had myocardial infarction as well as arterial and venous thrombosis.</p>
      <sec>
        <title>Diagnosis of HIT</title>
        <p>The diagnosis of HIT can be quite challenging at the time of presentation. Several instruments have been designed to stratify the risk of HIT based on clinical features, including the 4T score and HIT Expert Probability (HEP) score [<xref rid="b28-amjcaserep-21-e922498" ref-type="bibr">28</xref>,<xref rid="b29-amjcaserep-21-e922498" ref-type="bibr">29</xref>]. However, the information necessary for determining clinical scores may be inaccurate or unavailable. Hence, incorrect assignment of scores may occur. In a study of more than 500 cases of suspected HIT, the sensitivity of an intermediate [<xref rid="b30-amjcaserep-21-e922498" ref-type="bibr">30</xref>,<xref rid="b31-amjcaserep-21-e922498" ref-type="bibr">31</xref>] or high [<xref rid="b32-amjcaserep-21-e922498" ref-type="bibr">32</xref>&#x2013;<xref rid="b34-amjcaserep-21-e922498" ref-type="bibr">34</xref>] 4T score was 81.3% for patients with HIT, while the specificity of a low 4T score (&#x2264;3) was 63.8% for exclusion of HIT. Consequently, the positive predictive value for HIT was 1.9%, 6.7%, and 36.6% for low, intermediate, and high 4T scores, respectively, according to one study [<xref rid="b35-amjcaserep-21-e922498" ref-type="bibr">35</xref>]. The performance of HEP score is similarly problematic [<xref rid="b30-amjcaserep-21-e922498" ref-type="bibr">30</xref>]. Overall, clinical scores alone are insufficient for diagnosis or exclusion of HIT, although a low score helps increase the negative predictive value of a negative HIT diagnostic test to nearly 100%.</p>
        <p>There are 2 types of laboratory tests for the diagnosis of HIT: those that detect antibodies of PF4 neo-epitopes (HIT antibodies [HIT Ab] or HIT IgG), and functional assays that detect the aggregation [<xref rid="b36-amjcaserep-21-e922498" ref-type="bibr">36</xref>] or serotonin release [<xref rid="b37-amjcaserep-21-e922498" ref-type="bibr">37</xref>] of platelets after incubation with patient serum or plasma samples in the presence of heparin. The specificity of the functional tests is increased by showing that platelet aggregation or serotonin release in the presence of heparin in the range of therapeutic concentrations is suppressed by high (10&#xD7; to 100&#xD7;) concentrations of heparin. The serotonin release assay (SRA) is used as the ultimate test for the diagnosis of HIT. SRA is technically demanding and requires the use of a radioisotope (<sup>14</sup>C serotonin). The test is only performed in a few reference laboratories and the turnaround time may be several days.</p>
        <p>Among the commercially available tests for detection of HIT Ab [<xref rid="b38-amjcaserep-21-e922498" ref-type="bibr">38</xref>,<xref rid="b39-amjcaserep-21-e922498" ref-type="bibr">39</xref>], the sensitivity ranges from &#x223C;70% to &#x223C;100%; the specificity ranges from &#x223C;80% to &#x223C;99%, and the turnaround time ranges from less than 20 minutes to hours or even days. In general, tests that only detect IgG are more specific but tend to be less sensitive than tests that detect all 3 classes of immunoglobulins (IgG, IgM, and IgA). In interpreting a test result, the performance of the test method used and the estimated pre-test probability (e.g., the patient&#x2019;s 4T score) should be taken into consideration. Specifically, among patients with a high pre-test probability, a negative test result may not completely exclude the diagnosis of HIT [<xref rid="b40-amjcaserep-21-e922498" ref-type="bibr">40</xref>]. Occasionally, even a negative test result in a patient with low 4T-score does not exclude the diagnosis of HIT [<xref rid="b41-amjcaserep-21-e922498" ref-type="bibr">41</xref>].</p>
        <p>Functional flow cytometry that detects annexin V (also referred to as annexin A5) binding or P-selectin (also known as CD62P) expression as an indicator of platelet activation may replace SRA if its preliminary promising performance is validated [<xref rid="b42-amjcaserep-21-e922498" ref-type="bibr">42</xref>,<xref rid="b43-amjcaserep-21-e922498" ref-type="bibr">43</xref>].</p>
      </sec>
      <sec>
        <title>Thrombosis</title>
        <p>HIT was first described in a patient presenting with arterial thrombosis [<xref rid="b44-amjcaserep-21-e922498" ref-type="bibr">44</xref>]. However, thrombosis may occur in any vascular bed, including arteries of the extremities, brain, aorta, heart, and other visceral organs; veins of the extremities, with or without pulmonary embolism; cerebral vein sinuses; jugular veins; cardiac chambers; and skin or venous gangrene, presumably due to microvascular thrombosis. The risk of thrombosis is 8- to 9-fold higher for patients with a platelet count decreased by more than 70% [<xref rid="b45-amjcaserep-21-e922498" ref-type="bibr">45</xref>]. Nevertheless, normal or mildly decreased platelet counts do not exclude the risk of thrombosis due to HIT. Thus, HIT should be suspected in all patients presenting with new thrombosis during heparin therapy or with heparin exposures via a vascular device.</p>
        <p>Coronary thrombosis with myocardial infarction is an uncommon complication of HIT, occurring in 2&#x2013;3% of patients with HIT and thrombosis [<xref rid="b45-amjcaserep-21-e922498" ref-type="bibr">45</xref>,<xref rid="b46-amjcaserep-21-e922498" ref-type="bibr">46</xref>]. Our review of the literature identified 9 case reports of coronary thrombosis [<xref rid="b32-amjcaserep-21-e922498" ref-type="bibr">32</xref>,<xref rid="b47-amjcaserep-21-e922498" ref-type="bibr">47</xref>]. Among these, only 2 cases occurred in patients without recent coronary intervention or bypass surgery. Although selective reporting of extraordinary events might have been a factor, the data along with the case series cited above support the common clinical impressions that myocardial infarction is an uncommon complication of HIT, especially in the absence of recent coronary intervention or bypass surgery.</p>
      </sec>
      <sec>
        <title>Screening for HIT</title>
        <p>HIT can lead to 20%&#x2013;30% mortality if it is not recognized early and treated appropriately [<xref rid="b48-amjcaserep-21-e922498" ref-type="bibr">48</xref>]. To minimize adverse effects of HIT, monitoring of the platelet count and high index of suspicion are critical (<xref rid="t1-amjcaserep-21-e922498" ref-type="table">Table 1</xref>). To detect HIT early before serious complications occur, the baseline platelet count should be determined before heparin treatment is initiated. The platelet count is monitored during the course of treatment, at least between day 4 and 15, daily to twice weekly, depending on the type and dose of heparin used. Another recommendation is to monitor the platelet count only when the estimated risk of HIT is more than minimal (e.g., &gt;0.1%) [<xref rid="b49-amjcaserep-21-e922498" ref-type="bibr">49</xref>]. Nevertheless, risk estimation for HIT is not consistently reliable. Our case demonstrates the risk of not screening for HIT in patients being treated with LMWH.</p>
        <p>HIT should be suspected when the platelet count shows a downward trend, decreases by more than 30%, or there is evidence of new venous and/or arterial thrombosis, or atypical presentations such as skin necrosis, adrenal hemorrhage, or venous limb gangrene [<xref rid="b50-amjcaserep-21-e922498" ref-type="bibr">50</xref>,<xref rid="b51-amjcaserep-21-e922498" ref-type="bibr">51</xref>].</p>
        <p>In practice, possibly due to the perceived lower risk of HIT, the platelet count is often not monitored for patients receiving prophylactic or therapeutic LMWH therapy. Furthermore, since HIT is not a widely known cause of myocardial infarction, its diagnosis was not immediately suspected in our case and the patient was treated with intravenous heparin when she presented with myocardial infarction. Fortunately, heparin was discontinued within a few hours before it caused further damage.</p>
      </sec>
      <sec>
        <title>Thrombosis</title>
        <sec>
          <title>Therapeutic options</title>
          <p>When HIT is suspected, all heparin administration and exposure should be discontinued. This includes Hep-Lock and heparin-coated vascular devices. With or without evidence of thrombosis, the patients should be treated with an alternative anticoagulant. The treatment options have expanded beyond vitamin K antagonists (e.g., warfarin) in recent years, as they now include 2 intravenous direct thrombin inhibitors, argatroban [<xref rid="b52-amjcaserep-21-e922498" ref-type="bibr">52</xref>] and bivalirudin [<xref rid="b53-amjcaserep-21-e922498" ref-type="bibr">53</xref>]; subcutaneous fondaparinux [<xref rid="b54-amjcaserep-21-e922498" ref-type="bibr">54</xref>], a pentasaccharide that is chemically related to heparin but does not cross-react with HIT antibodies; and direct oral anticoagulants such as dabigatran, rivaroxaban, apixaban, and edoxaban. Among these, only argatroban is approved for treatment of HIT. Bivalirudin is approved for use during percutaneous coronary intervention (PCI) in patients with the diagnosis of HIT, although it has been used off-label for the treatment of HIT. Two other FDA-approved anticoagulants &#x2013; danaparoid and lepirudin &#x2013; are no longer available in the USA.</p>
          <p>Argatroban is contraindicated in patients with impaired liver function. Argatroban treatment requires monitoring of PTT, which is often confounded by the levels of other clotting factors. Subcutaneous fondaparinux does not routinely require monitoring. When monitoring is necessary, chromogenic anti-Xa level assay, which is less affected by the levels of other clotting factors, is used to guide dose adjustment. A national, multicenter registry study has shown that the efficacy and safety of fondaparinux are far superior to those of argatroban [<xref rid="b54-amjcaserep-21-e922498" ref-type="bibr">54</xref>].</p>
          <p>Direct oral anticoagulants have also been increasingly used off-label for HIT, generally with favorably efficacy and safety, either as primary treatment or secondary treatment following initial treatment using a parenteral non-heparin anticoagulant [<xref rid="b55-amjcaserep-21-e922498" ref-type="bibr">55</xref>].</p>
          <p>Before the newer alternative anticoagulants became available, warfarin was the only option to provide anticoagulation for the treatment of HIT. Initiation of a vitamin K antagonist prior to platelet count recovery is contraindicated as it is associated with a heightened risk of venous limb gangrene, presumably due to the compounding effects of decreased protein C synthesis by vitamin K antagonists and the inhibition of protein C activation by HIT antibodies [<xref rid="b56-amjcaserep-21-e922498" ref-type="bibr">56</xref>]. Furthermore, the effect of vitamin K should be reversed if a patient is being treated with a vitamin K antagonist at the time of HIT diagnosis.</p>
          <p>In practice, unstable hospitalized patients are often treated with intravenous argatroban or bivalirudin, followed by one of the direct oral anticoagulants when the patients are stabilized or discharged.</p>
        </sec>
        <sec>
          <title>Duration of treatment</title>
          <p>For patients without thrombosis, the anticoagulation therapy should be continued at least until the platelet count normalizes or returns to its baseline level. The treatment is generally extended to 4 weeks to prevent delayed thrombosis [<xref rid="b57-amjcaserep-21-e922498" ref-type="bibr">57</xref>].</p>
          <p>For patients with thrombosis due to HIT, the anticoagulation therapy is continued for at least 3 months, preferably until the thrombosis has reached its optimal resolution, or longer as clinically indicated if the patients have other indications of long-term anticoagulation therapy.</p>
          <p>Thromboembolic events may continue to occur in HIT patients during non-heparin anticoagulation therapy. We speculate that the intense pain of the left foot with toe discoloration on day 5 of our case might have resulted from embolism of the dissolving thrombosis upstream in the femoral and popliteal arteries. We are uncertain whether the thrombosis in the left posterior tibial vein in this case was due to her knee surgery or due to HIT. In a clinical trial that included prophylactic enoxaparin at 40 mg daily after total knee arthroplasty, as was used in our patient, asymptomatic, mostly distal, DVT occurred in nearly one-quarter of the patients [<xref rid="b58-amjcaserep-21-e922498" ref-type="bibr">58</xref>].</p>
        </sec>
      </sec>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>In summary, we report a case of heparin-induced thrombocytopenia (HIT) that caused myocardial infarction on day 9 of prophylactic enoxaparin therapy after bilateral total knee arthroplasty. The patient also had bilateral lower-extremity artery thrombosis and a distal deep venous thrombosis. She was successfully treated with thrombolysis and argatroban followed by apixaban, with good recovery and no adverse events. Considering the seriousness of HIT, we propose that UFH or LMWH should be avoided when alternative options of anticoagulation are available. Among patients being treated with any formulation of heparin, the platelet count should be monitored to detect HIT before it causes serious complications. A trend of decrease of the platelet count, decrease of the platelet count by 30% or more, and/or occurrence of any type of thrombosis should raise the suspicion of HIT and prompt the discontinuation of all heparin exposures and institution of anticoagulation with a non-heparin alternative to prevent or treat thrombosis. The clinical HIT score should be determined. D-dimer measurement may help determine if there is active thrombosis. Further management is guided by the results of HIT diagnostic tests.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References:</title>
      <ref id="b1-amjcaserep-21-e922498">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petitou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>H&#xE9;rault</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Bernat</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Synthesis of thrombin-inhibiting heparin mimetics without side effects</article-title>
          <source>Nature</source>
          <year>1999</year>
          <volume>398</volume>
          <issue>6726</issue>
          <fpage>417</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="pmid">10201371</pub-id>
        </element-citation>
      </ref>
      <ref id="b2-amjcaserep-21-e922498">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flengsrud</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Disaccharide analysis of chondroitin and heparin from farmed Atlantic salmon</article-title>
          <source>Glycoconj J</source>
          <year>2016</year>
          <volume>33</volume>
          <fpage>121</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="pmid">26993287</pub-id>
        </element-citation>
      </ref>
      <ref id="b3-amjcaserep-21-e922498">
        <label>3.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Esko</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Linhardt</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Proteins that bind sulfated glycosaminoglucans</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Varki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cummings</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Esko</surname>
              <given-names>JD</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Essentials of Glycobiology</source>
          <edition>3rd edition</edition>
          <publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>
          <year>2015</year>
          <comment>chapter 38</comment>
        </element-citation>
      </ref>
      <ref id="b4-amjcaserep-21-e922498">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Krauel</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gottschalk</surname>
              <given-names>KE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Characterisation of the conformational changes in platelet factor 4 induced by polyanions: Towards <italic>in vitro</italic> prediction of antigenicity</article-title>
          <source>Thromb Haemost</source>
          <year>2014</year>
          <volume>112</volume>
          <issue>1</issue>
          <fpage>53</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="pmid">24671506</pub-id>
        </element-citation>
      </ref>
      <ref id="b5-amjcaserep-21-e922498">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Makris</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jay</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Kelton</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia</article-title>
          <source>Am J Med</source>
          <year>2008</year>
          <volume>121</volume>
          <issue>7</issue>
          <fpage>632</fpage>
          <lpage>36</lpage>
          <pub-id pub-id-type="pmid">18589060</pub-id>
        </element-citation>
      </ref>
      <ref id="b6-amjcaserep-21-e922498">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greinacher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Selleng</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
          </person-group>
          <article-title>Autoimmune heparin-induced thrombocytopenia</article-title>
          <source>J Thromb Haemost</source>
          <year>2017</year>
          <volume>15</volume>
          <issue>11</issue>
          <fpage>2099</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="pmid">28846826</pub-id>
        </element-citation>
      </ref>
      <ref id="b7-amjcaserep-21-e922498">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chong</surname>
              <given-names>BH</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia</article-title>
          <source>Blood Rev</source>
          <year>1988</year>
          <volume>2</volume>
          <issue>2</issue>
          <fpage>108</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="pmid">3042056</pub-id>
        </element-citation>
      </ref>
      <ref id="b8-amjcaserep-21-e922498">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Horsewood</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact of the patient population on the risk for heparin-induced thrombocytopenia</article-title>
          <source>Blood</source>
          <year>2000</year>
          <volume>96</volume>
          <issue>5</issue>
          <fpage>1703</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">10961867</pub-id>
        </element-citation>
      </ref>
      <ref id="b9-amjcaserep-21-e922498">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Hursting</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Reducing thrombotic complications in the perioperative setting: An update on heparin-induced thrombocytopenia</article-title>
          <source>Anesth Analg</source>
          <year>2007</year>
          <volume>105</volume>
          <issue>3</issue>
          <fpage>570</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">17717208</pub-id>
        </element-citation>
      </ref>
      <ref id="b10-amjcaserep-21-e922498">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amiral</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bridey</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Dreyfus</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia</article-title>
          <source>Thromb Haemost</source>
          <year>1992</year>
          <volume>68</volume>
          <issue>1</issue>
          <fpage>95</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="pmid">1514184</pub-id>
        </element-citation>
      </ref>
      <ref id="b11-amjcaserep-21-e922498">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>May</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>After-care services for schizophrenic patients</article-title>
          <source>Acta Psychiatr Belg</source>
          <year>1976</year>
          <volume>76</volume>
          <issue>5</issue>
          <fpage>778</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">193358</pub-id>
        </element-citation>
      </ref>
      <ref id="b12-amjcaserep-21-e922498">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Visentin</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Ford</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Aster</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells</article-title>
          <source>J Clin Invest</source>
          <year>1994</year>
          <volume>93</volume>
          <issue>1</issue>
          <fpage>81</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="pmid">8282825</pub-id>
        </element-citation>
      </ref>
      <ref id="b13-amjcaserep-21-e922498">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greinacher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>P&#xF6;tzsch</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Amiral</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen</article-title>
          <source>Thromb Haemost</source>
          <year>1994</year>
          <volume>71</volume>
          <issue>2</issue>
          <fpage>247</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="pmid">8191407</pub-id>
        </element-citation>
      </ref>
      <ref id="b14-amjcaserep-21-e922498">
        <label>14.</label>
        <element-citation publication-type="book">
          <source>PF4 platelet factor 4 [Homo sapiens (human)]</source>
          <publisher-loc>Bethesda (MD)</publisher-loc>
          <publisher-name>National Library of Medicine (US), National Center for Biotechnology Information</publisher-name>
          <year>2020</year>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gene/?term=5196">https://www.ncbi.nlm.nih.gov/gene/?term=5196</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="b15-amjcaserep-21-e922498">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lambert</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Rauova</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Platelet factor 4 is a negative auto-crine <italic>in vivo</italic> regulator of megakaryopoiesis: Clinical and therapeutic implications</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>110</volume>
          <issue>4</issue>
          <fpage>1153</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">17495129</pub-id>
        </element-citation>
      </ref>
      <ref id="b16-amjcaserep-21-e922498">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arepally</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Hursting</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: A literature analysis of commercial immunoassay results</article-title>
          <source>J Thromb Thrombolysis</source>
          <year>2008</year>
          <volume>26</volume>
          <issue>1</issue>
          <fpage>55</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">18369708</pub-id>
        </element-citation>
      </ref>
      <ref id="b17-amjcaserep-21-e922498">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maeda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wakasawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shima</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Role of polyamines derived from arginine in differentiation and proliferation of human blood cells</article-title>
          <source>Biol Pharm Bull</source>
          <year>2006</year>
          <volume>29</volume>
          <issue>2</issue>
          <fpage>234</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="pmid">16462024</pub-id>
        </element-citation>
      </ref>
      <ref id="b18-amjcaserep-21-e922498">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suvarna</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Espinasse</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Qi</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Determinants of PF4/heparin immunogenicity</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>110</volume>
          <issue>13</issue>
          <fpage>4253</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">17848616</pub-id>
        </element-citation>
      </ref>
      <ref id="b19-amjcaserep-21-e922498">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rauova</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Poncz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McKenzie</surname>
              <given-names>SE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>105</volume>
          <issue>1</issue>
          <fpage>131</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="pmid">15304392</pub-id>
        </element-citation>
      </ref>
      <ref id="b20-amjcaserep-21-e922498">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amiral</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pouplard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vissac</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: Biological characteristics and effects on platelet activation</article-title>
          <source>Br J Haematol</source>
          <year>2000</year>
          <volume>109</volume>
          <issue>2</issue>
          <fpage>336</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="pmid">10848821</pub-id>
        </element-citation>
      </ref>
      <ref id="b21-amjcaserep-21-e922498">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Horne</surname>
              <given-names>MK</given-names>
              <suffix>3rd</suffix>
            </name>
            <name>
              <surname>Hutchison</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Simultaneous binding of heparin and platelet factor-4 to platelets: Further insights into the mechanism of heparin-induced thrombocytopenia</article-title>
          <source>Am J Hematol</source>
          <year>1998</year>
          <volume>58</volume>
          <issue>1</issue>
          <fpage>24</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">9590145</pub-id>
        </element-citation>
      </ref>
      <ref id="b22-amjcaserep-21-e922498">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chong</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Berndt</surname>
              <given-names>MC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Plasma P-selectin is increased in thrombotic consumptive platelet disorders</article-title>
          <source>Blood</source>
          <year>1994</year>
          <volume>83</volume>
          <issue>6</issue>
          <fpage>1535</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="pmid">7510145</pub-id>
        </element-citation>
      </ref>
      <ref id="b23-amjcaserep-21-e922498">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Hayward</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Boshkov</surname>
              <given-names>LK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia</article-title>
          <source>Blood</source>
          <year>1994</year>
          <volume>84</volume>
          <issue>11</issue>
          <fpage>3691</fpage>
          <lpage>99</lpage>
          <pub-id pub-id-type="pmid">7949124</pub-id>
        </element-citation>
      </ref>
      <ref id="b24-amjcaserep-21-e922498">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cines</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Tomaski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tannenbaum</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Immune endothelial-cell injury in heparin-associated thrombocytopenia</article-title>
          <source>N Engl J Med</source>
          <year>1987</year>
          <volume>316</volume>
          <issue>10</issue>
          <fpage>581</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="pmid">3807952</pub-id>
        </element-citation>
      </ref>
      <ref id="b25-amjcaserep-21-e922498">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arepally</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Mayer</surname>
              <given-names>IM</given-names>
            </name>
          </person-group>
          <article-title>Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8</article-title>
          <source>Blood</source>
          <year>2001</year>
          <volume>98</volume>
          <issue>4</issue>
          <fpage>1252</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="pmid">11493478</pub-id>
        </element-citation>
      </ref>
      <ref id="b26-amjcaserep-21-e922498">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gollomp</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neutrophil accumulation and NET release contribute to thrombosis in HIT</article-title>
          <source>JCI Insight</source>
          <year>2018</year>
          <volume>3</volume>
          <issue>18</issue>
          <comment>pii:</comment>
          <fpage>99445</fpage>
          <pub-id pub-id-type="pmid">30232279</pub-id>
        </element-citation>
      </ref>
      <ref id="b27-amjcaserep-21-e922498">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perdomo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>HHL</given-names>
            </name>
            <name>
              <surname>Ahmadi</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia</article-title>
          <source>Nat Commun</source>
          <year>2019</year>
          <volume>10</volume>
          <issue>1</issue>
          <fpage>1322</fpage>
          <pub-id pub-id-type="pmid">30899022</pub-id>
        </element-citation>
      </ref>
      <ref id="b28-amjcaserep-21-e922498">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia: pathogenesis and management</article-title>
          <source>Br J Haematol</source>
          <year>2003</year>
          <volume>121</volume>
          <issue>4</issue>
          <fpage>535</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="pmid">12752095</pub-id>
        </element-citation>
      </ref>
      <ref id="b29-amjcaserep-21-e922498">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cuker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arepally</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Crowther</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The HIT Expert Probability (HEP) Score: A novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion</article-title>
          <source>J Thromb Haemost</source>
          <year>2010</year>
          <volume>8</volume>
          <issue>12</issue>
          <fpage>2642</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">20854372</pub-id>
        </element-citation>
      </ref>
      <ref id="b30-amjcaserep-21-e922498">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Levine</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Hirsh</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin</article-title>
          <source>N Engl J Med</source>
          <year>1995</year>
          <volume>332</volume>
          <issue>20</issue>
          <fpage>1330</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="pmid">7715641</pub-id>
        </element-citation>
      </ref>
      <ref id="b31-amjcaserep-21-e922498">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Almeqdadi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aoun</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Carrozza</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Native coronary artery thrombosis in the setting of heparin-induced thrombocytopenia: A case report</article-title>
          <source>Eur Heart J Case Rep</source>
          <year>2018</year>
          <volume>2</volume>
          <issue>4</issue>
          <fpage>yty138</fpage>
          <pub-id pub-id-type="pmid">31020214</pub-id>
        </element-citation>
      </ref>
      <ref id="b32-amjcaserep-21-e922498">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joost</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kurowski</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Radke</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
          <article-title>Anticoagulation in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary angiography and interventions</article-title>
          <source>Curr Pharm Des</source>
          <year>2008</year>
          <volume>14</volume>
          <issue>12</issue>
          <fpage>1176</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">18473864</pub-id>
        </element-citation>
      </ref>
      <ref id="b33-amjcaserep-21-e922498">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>JC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?</article-title>
          <source>J Lab Clin Med</source>
          <year>2005</year>
          <volume>146</volume>
          <issue>6</issue>
          <fpage>341</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">16310517</pub-id>
        </element-citation>
      </ref>
      <ref id="b34-amjcaserep-21-e922498">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arepally</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Ortel</surname>
              <given-names>TL</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia</article-title>
          <source>Annu Rev Med</source>
          <year>2010</year>
          <volume>61</volume>
          <fpage>77</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="pmid">20059332</pub-id>
        </element-citation>
      </ref>
      <ref id="b35-amjcaserep-21-e922498">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Linkins</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Bates</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>AY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combination of 4Ts score and PF4/HPaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study</article-title>
          <source>Blood</source>
          <year>2015</year>
          <volume>126</volume>
          <issue>5</issue>
          <fpage>597</fpage>
          <lpage>603</lpage>
          <pub-id pub-id-type="pmid">25926600</pub-id>
        </element-citation>
      </ref>
      <ref id="b36-amjcaserep-21-e922498">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chong</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Burgess</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ismail</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia</article-title>
          <source>Thromb Haemost</source>
          <year>1993</year>
          <volume>69</volume>
          <issue>4</issue>
          <fpage>344</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">8497847</pub-id>
        </element-citation>
      </ref>
      <ref id="b37-amjcaserep-21-e922498">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sheridan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kelton</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>A diagnostic test for heparin-induced thrombocytopenia</article-title>
          <source>Blood</source>
          <year>1986</year>
          <volume>67</volume>
          <issue>1</issue>
          <fpage>27</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">3940551</pub-id>
        </element-citation>
      </ref>
      <ref id="b38-amjcaserep-21-e922498">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leroux</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hezard</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lebreton</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert(&#xAE;) HIT) for the diagnosis of heparin-induced thrombocytopenia</article-title>
          <source>Br J Haematol</source>
          <year>2014</year>
          <volume>166</volume>
          <issue>5</issue>
          <fpage>774</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">24815503</pub-id>
        </element-citation>
      </ref>
      <ref id="b39-amjcaserep-21-e922498">
        <label>39.</label>
        <element-citation publication-type="webpage">
          <article-title>Immunocore PF4 Enhanced&#xAE; assay, User instructions</article-title>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://www.immucor.com/LIFECODES%20Documents/303288_IFUEN_PF4Enhanced_English_2017-04-04.pdf">https://www.immucor.com/LIFECODES%20Documents/303288_IFUEN_PF4Enhanced_English_2017-04-04.pdf</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="b40-amjcaserep-21-e922498">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Voudris</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Georgiadou</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kalogris</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Missed heparin-induced thrombocytopenia (HIT) diagnosis in a patient with acute stent thrombosis</article-title>
          <source>Am J Case Rep</source>
          <year>2019</year>
          <volume>20</volume>
          <fpage>753</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="pmid">31133634</pub-id>
        </element-citation>
      </ref>
      <ref id="b41-amjcaserep-21-e922498">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pouplard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gruel</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>A rapid test (STic Expert&#xAE;) for the diagnosis of heparin-induced thrombocytopenia &#x2013; response to De Cooman and Devreese</article-title>
          <source>Br J Haematol</source>
          <year>2016</year>
          <volume>172</volume>
          <issue>3</issue>
          <fpage>466</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="pmid">25959988</pub-id>
        </element-citation>
      </ref>
      <ref id="b42-amjcaserep-21-e922498">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Padmanabhan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Curtis</surname>
              <given-names>BR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A Novel PF4-dependent platelet activation assay identifies patients likely to have heparin-induced thrombocytopenia/thrombosis</article-title>
          <source>Chest</source>
          <year>2016</year>
          <volume>150</volume>
          <issue>3</issue>
          <fpage>506</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="pmid">26905366</pub-id>
        </element-citation>
      </ref>
      <ref id="b43-amjcaserep-21-e922498">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tomer</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia</article-title>
          <source>Br J Haematol</source>
          <year>1997</year>
          <volume>98</volume>
          <issue>3</issue>
          <fpage>648</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="pmid">9332321</pub-id>
        </element-citation>
      </ref>
      <ref id="b44-amjcaserep-21-e922498">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weismann</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Tobin</surname>
              <given-names>RW</given-names>
            </name>
          </person-group>
          <article-title>Arterial embolism occurring during systemic heparin therapy</article-title>
          <source>AMA Arch Surg</source>
          <year>1958</year>
          <volume>76</volume>
          <issue>2</issue>
          <fpage>219</fpage>
          <lpage>25</lpage>
          <comment>; discussion 225&#x2013;27</comment>
          <pub-id pub-id-type="pmid">13497418</pub-id>
        </element-citation>
      </ref>
      <ref id="b45-amjcaserep-21-e922498">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greinacher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Farner</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kroll</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients</article-title>
          <source>Thromb Haemost</source>
          <year>2005</year>
          <volume>94</volume>
          <issue>1</issue>
          <fpage>132</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="pmid">16113796</pub-id>
        </element-citation>
      </ref>
      <ref id="b46-amjcaserep-21-e922498">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boshkov</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Hayward</surname>
              <given-names>CP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies</article-title>
          <source>Br J Haematol</source>
          <year>1993</year>
          <volume>84</volume>
          <issue>2</issue>
          <fpage>322</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="pmid">8398837</pub-id>
        </element-citation>
      </ref>
      <ref id="b47-amjcaserep-21-e922498">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suzuki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tsunematsu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A case of heparin-induced thrombocytopenia with subacute stent thrombosis, multiple cerebral infarction, and acute limb ischemia</article-title>
          <source>J Cardiol Cases</source>
          <year>2017</year>
          <volume>15</volume>
          <issue>5</issue>
          <fpage>145</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="pmid">30279763</pub-id>
        </element-citation>
      </ref>
      <ref id="b48-amjcaserep-21-e922498">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lassen</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Raskob</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Gallus</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ADVANCE-2 investigators: Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial</article-title>
          <source>Lancet</source>
          <year>2010</year>
          <volume>375</volume>
          <issue>9717</issue>
          <fpage>807</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="pmid">20206776</pub-id>
        </element-citation>
      </ref>
      <ref id="b49-amjcaserep-21-e922498">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>LaMonte</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Hursting</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor</article-title>
          <source>Expert Rev Cardiovasc Ther</source>
          <year>2005</year>
          <volume>3</volume>
          <issue>1</issue>
          <fpage>31</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="pmid">15723573</pub-id>
        </element-citation>
      </ref>
      <ref id="b50-amjcaserep-21-e922498">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cuker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arepally</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Chong</surname>
              <given-names>BH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia</article-title>
          <source>Blood Adv</source>
          <year>2018</year>
          <volume>2</volume>
          <issue>22</issue>
          <fpage>3360</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="pmid">30482768</pub-id>
        </element-citation>
      </ref>
      <ref id="b51-amjcaserep-21-e922498">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Hirsh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kelton</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: A nested cohort study</article-title>
          <source>Chest</source>
          <year>2005</year>
          <volume>127</volume>
          <issue>5</issue>
          <fpage>1857</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">15888871</pub-id>
        </element-citation>
      </ref>
      <ref id="b52-amjcaserep-21-e922498">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hong</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Sigouin</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
          </person-group>
          <article-title>Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>101</volume>
          <issue>8</issue>
          <fpage>3049</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="pmid">12506031</pub-id>
        </element-citation>
      </ref>
      <ref id="b53-amjcaserep-21-e922498">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lewis</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Wallis</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Leya</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Argatroban-915 Investigators: Argatroban anticoagulation in patients with heparin-induced thrombocytopenia</article-title>
          <source>Arch Intern Med</source>
          <year>2003</year>
          <volume>163</volume>
          <issue>15</issue>
          <fpage>1849</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="pmid">12912723</pub-id>
        </element-citation>
      </ref>
      <ref id="b54-amjcaserep-21-e922498">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koster</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dyke</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Aldea</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: Results of the CHOOSE-ON trial</article-title>
          <source>Ann Thorac Surg</source>
          <year>2007</year>
          <volume>83</volume>
          <issue>2</issue>
          <fpage>572</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="pmid">17257990</pub-id>
        </element-citation>
      </ref>
      <ref id="b55-amjcaserep-21-e922498">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schindewolf</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Steindl</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Beyer-Westendorf</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia</article-title>
          <source>J Am Coll Cardiol</source>
          <year>2017</year>
          <volume>70</volume>
          <issue>21</issue>
          <fpage>2636</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="pmid">29169470</pub-id>
        </element-citation>
      </ref>
      <ref id="b56-amjcaserep-21-e922498">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Pai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Linkins</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>Direct oral anticoagulants for treatment of HIT: Update of Hamilton experience and literature review</article-title>
          <source>Blood</source>
          <year>2017</year>
          <volume>130</volume>
          <issue>9</issue>
          <fpage>1104</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">28646118</pub-id>
        </element-citation>
      </ref>
      <ref id="b57-amjcaserep-21-e922498">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kowalska</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Krishnaswamy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rauova</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: New insights into the prothrombotic nature of HIT</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <issue>10</issue>
          <fpage>2882</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="pmid">21772054</pub-id>
        </element-citation>
      </ref>
      <ref id="b58-amjcaserep-21-e922498">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Kelton</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Delayed-onset heparin-induced thrombocytopenia and thrombosis</article-title>
          <source>Ann Intern Med</source>
          <year>2001</year>
          <volume>135</volume>
          <issue>7</issue>
          <fpage>502</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">11578153</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <table-wrap id="t1-amjcaserep-21-e922498" position="float">
      <label>Table 1.</label>
      <caption>
        <p>Prevention and management of heparin-induced thrombocytopenia (HIT).</p>
      </caption>
      <table frame="hsides" rules="groups">
        <tbody>
          <tr>
            <td valign="middle" align="left" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Avoid use of UFH or LMWH when alternative anticoagulants are available.</p></list-item><list-item><p>If heparin has to be used.
<list list-type="simple"><list-item><p>&#x2013; obtain the baseline platelet count before it is initiated.</p></list-item><list-item><p>&#x2013; monitor the platelet count daily to twice weekly during the course of treatment, at least between days 4&#x2013;15, depending on the type of heparin and its dosage.</p></list-item></list></p></list-item><list-item><p>HIT is suspected when the platelet count trends downward, decreases by more than 30%, or new thrombosis occurs.</p></list-item><list-item><p>Determine the clinical HIT score (4T or HEP); check the D-dimer level; and venous ultrasound and other imaging studies as clinically indicated.</p></list-item><list-item><p>Diagnostic tests for HIT: HIT Ab tests with reflex for serotonin release assay.</p></list-item><list-item><p>Discontinued all heparin administration and exposure and institute anticoagulation therapy with a non-heparin alternative when HIT is suspected.
<list list-type="simple"><list-item><p>&#x2013; To minimize the risk of bleeding, prophylactic doses may be used for patients with thrombocytopenia but a low risk score (e.g., 4T &#x2264;3) and no other indication of anticoagulation therapy.</p></list-item></list></p></list-item><list-item><p>Alternative non-heparin anticoagulants include.
<list list-type="simple"><list-item><p>&#x2013; Direct thrombin or factor Xa inhibitors.
<list list-type="simple"><list-item><p>&#x25A0; Intravenous: argatroban<xref ref-type="table-fn" rid="tfn1-amjcaserep-21-e922498"><sup>1</sup></xref>, lepirudin<sup><xref ref-type="table-fn" rid="tfn1-amjcaserep-21-e922498">1</xref>,<xref ref-type="table-fn" rid="tfn2-amjcaserep-21-e922498">2</xref></sup>, bivalirudin<xref ref-type="table-fn" rid="tfn3-amjcaserep-21-e922498"><sup>3</sup></xref>.</p></list-item><list-item><p>&#x25A0; Oral<xref ref-type="table-fn" rid="tfn4-amjcaserep-21-e922498"><sup>4</sup></xref>: dabigatran, rivaroxaban, apixaban, edoxaban.</p></list-item></list></p></list-item><list-item><p>&#x2013; Chemically related to heparin (AT3 dependent): danaparoid<sup><xref ref-type="table-fn" rid="tfn1-amjcaserep-21-e922498">1</xref>,<xref ref-type="table-fn" rid="tfn2-amjcaserep-21-e922498">2</xref></sup>, fondaparinux<xref ref-type="table-fn" rid="tfn5-amjcaserep-21-e922498"><sup>5</sup></xref>.</p></list-item></list></p></list-item><list-item><p>Duration of anticoagulation therapy.
<list list-type="simple"><list-item><p>&#x2013; Patients without thrombosis and no indication of anticoagulation therapy otherwise.
<list list-type="simple"><list-item><p>&#x25A0;Treatment at least until the platelet count is normalized, preferably for 4 weeks to prevent delayed HIT thrombosis.</p></list-item></list></p></list-item><list-item><p>&#x2013; Patients with thrombosis and otherwise no indication of anticoagulation therapy.
<list list-type="simple"><list-item><p>&#x25A0;At least 3 months, until maximal clot resolution is achieved.</p></list-item></list></p></list-item><list-item><p>&#x2013; Patients with an indication of anticoagulation therapy other than HIT.
<list list-type="simple"><list-item><p>&#x25A0;Continue anticoagulation therapy for at least 3 months or longer as clinically indicated.</p></list-item></list></p></list-item></list></p></list-item></list></td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn1-amjcaserep-21-e922498">
          <label>1</label>
          <p>FDA-approved for the treatment of HIT;</p>
        </fn>
        <fn id="tfn2-amjcaserep-21-e922498">
          <label>2</label>
          <p>No longer available in the USA;</p>
        </fn>
        <fn id="tfn3-amjcaserep-21-e922498">
          <label>3</label>
          <p>FDA-approved for anticoagulation during percutaneous coronary intervention;</p>
        </fn>
        <fn id="tfn4-amjcaserep-21-e922498">
          <label>4</label>
          <p>These direct oral anticoagulants are increasingly used, with favorable efficacy and safety, but have not been rigorously investigated in large trials or are not FDA-approved for this indication;</p>
        </fn>
        <fn id="tfn5-amjcaserep-21-e922498">
          <label>5</label>
          <p>Chemically related to heparin but not associated with platelet activation.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id>
      <journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id>
      <journal-id journal-id-type="publisher-id">rbccv</journal-id>
      <journal-title-group>
        <journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0102-7638</issn>
      <issn pub-type="epub">1678-9741</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33306320</article-id>
      <article-id pub-id-type="pmc">7731847</article-id>
      <article-id pub-id-type="doi">10.21470/1678-9741-2019-0360</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Positive Heparin/PF4 Antibodies and High Mortality Rate: a Retrospective Case-Series Analysis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8423-5071</contrib-id>
          <name>
            <surname>Ezelsoy</surname>
            <given-names>Mehmet</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c1"/>
          <role>MD</role>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Saracoglu</surname>
            <given-names>Kemal Tolga</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
          <role>MD</role>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Oral</surname>
            <given-names>Kerem</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <role>MD</role>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Saracoglu</surname>
            <given-names>Ayten</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
          <role>MD</role>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Akpinar</surname>
            <given-names>Belhan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <role>MD</role>
        </contrib>
      </contrib-group>
      <aff id="aff1">
<label>1</label> Department of Cardiovascular Surgery, Istanbul Demiroglu Bilim University Medical School, Istanbul, Turkey.</aff>
      <aff id="aff2">
<label>2</label> Department of Anesthesiology and Intensive Care, Health Sciences University Medical School, Istanbul, Turkey.</aff>
      <aff id="aff3">
<label>3</label> Department of Anesthesiology and Intensive Care, Istanbul Marmara University Medical School, Istanbul, Turkey.</aff>
      <author-notes>
        <corresp id="c1">Correspondence Address: <bold>Mehmet Ezelsoy</bold><ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-8423-5071">https://orcid.org/0000-0002-8423-5071</ext-link> Sisli Florence Nightingale Hospital No: 164, Cardiovascular Surgery Department, Sisli, Istanbul,Turkey - Zip Code: 34387 E-mail: <email>mehmet_ezelsoy@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Nov-Dec</season>
        <year>2020</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2020</year>
      </pub-date>
      <volume>35</volume>
      <issue>6</issue>
      <fpage>950</fpage>
      <lpage>957</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>9</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>1</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Introduction</title>
          <p>Heparin-induced thrombocytopenia (HIT) is a potentially lethal complication of unfractionated or low-molecular weight heparin therapy. We aimed to determine the incidence and mortality rate of patients with positive heparin/platelet factor 4 (PF4) antibodies, which is a rapid detection test of HIT.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>Coronary artery bypass grafting and mitral and aortic valve surgeries were evaluated. Cardiopulmonary bypass was employed in all patients. The diagnosis of HIT was based on immunological assays. Postoperative complications, mortality rates, and the causes of death were specified in patients with positive heparin/PF4 antibodies.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>Postoperative thrombocytopenia was detected in 257 patients. Twenty of these patients undergoing open heart surgery were included in the final analysis. Antibodies against heparin/PF4 complex were positive in 20 patients. The mean body mass index was 28.8&#xB1;2.3 kg/m<sup>2</sup>, mean value of left ventricular ejection fraction was 48.3&#xB1;6.7%, cardiopulmonary bypass time was 113.0&#xB1;35.0 min, aortic cross-clamping time was 88.0&#xB1;32.7 min, mean intensive care unit length of stay was 10.9&#xB1;4.9 days, mean preoperative platelet count was 307.250&#xB1;88528 platelets/microliter, and mean postoperative platelet count was 243.050&#xB1;89.354 platelets/microliter. The mean duration of heparin exposure was 6.9&#xB1;2.9 days. The mortality rate was 45% (nine patients) and 1.2% (three patients) in heparin/PF4 complex positive and negative patients, respectively.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Although the incidence of HIT was low in patients undergoing open heart surgery, an increased rate of early mortality was observed in patients with positive heparin/PF4 antibodies.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Thrombocytopenia</kwd>
        <kwd>Heparin-adverse effects</kwd>
        <kwd>Cardiopulmonary Bypass</kwd>
        <kwd>Aortic Valve</kwd>
        <kwd>Incidence</kwd>
        <kwd>Cause of Death</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <table-wrap id="t10" orientation="portrait" position="anchor">
      <table frame="hsides" rules="groups">
        <colgroup span="1">
          <col width="10%" span="1"/>
          <col width="90%" span="1"/>
        </colgroup>
        <thead>
          <tr>
            <th colspan="2" align="left" style="background-color:#e6e7e8" rowspan="1">Abbreviations, acronyms &amp; symbols</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BMI</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Body mass index</td>
          </tr>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary bypass</td>
          </tr>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EF</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ejection fraction</td>
          </tr>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FFP</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Fresh frozen plasma</td>
          </tr>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HIT</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Heparin-induced thrombocytopenia</td>
          </tr>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive care unit</td>
          </tr>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LMWH</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Low-molecular weight heparin</td>
          </tr>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MOF</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Multiple organ failure</td>
          </tr>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PF4</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Platelet factor 4</td>
          </tr>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PLT</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Platelet</td>
          </tr>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RBC</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Red blood cell</td>
          </tr>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SD</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard deviation</td>
          </tr>
          <tr>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">UFH</td>
            <td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Unfractionated heparin</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The management of the cardiac patients suspected of having heparin-induced thrombocytopenia (HIT) may be challenging due to a number of reasons. The functional assay which is used to diagnose the disorder is not only expensive, but also time-consuming. However, heparin should be urgently discontinued in such patients. It is also necessary to decide within a few hours whether an alternative anticoagulant agent will be started or not. Whereas delayed discontinuation of heparin can be life-threatening for patients with HIT, several risks may arise from the use of alternative anticoagulants in patients without HIT<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p>
      <p>Related with the duration of heparin exposure, HIT occurs in about 0.1-5% of patients<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. The development of HIT carries greater risks in patients who require cardiac surgery compared to other patient populations. It has been documented that the risk for postoperative pneumonia or acute renal injury is twofold higher in patients requiring cardiac surgery, whereas the risk for thromboembolic complications is several times higher<sup>[<xref rid="r3" ref-type="bibr">3</xref>-<xref rid="r5" ref-type="bibr">5</xref>]</sup>. Because of a hypercoagulable state, the mortality rate may rise up to 5%-10%<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Although the risk of arterial thrombosis has been reported to be greater than the risk of venous thrombosis in cardiac surgery patients, unfractionated heparin (UFH) is associated with a five to 10 times higher risk of HIT compared to low-molecular weight heparin (LMWH)<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>. In addition, HIT generates nearly a 50% higher risk for in-hospital deaths in surgical patients<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p>
      <p>The aim of this study was to determine the rate of mortality and morbidity and the incidence of patients with positive heparin/platelet factor 4 (PF4) antibodies undergoing open heart surgery in early postoperative period.</p>
    </sec>
    <sec sec-type="methods">
      <title>METHODS</title>
      <p>Patients undergoing elective cardiac surgery between January 2014 and December 2016 were included. The data of 1583 patients were assessed for eligibility. Valve surgery and coronary artery bypass grafting were evaluated (<xref ref-type="fig" rid="f1">Figure 1</xref>). Cardiopulmonary bypass (CPB) was employed in all patients. HIT was considered when all the following criteria met: (1) a platelet count was defined as: either a drop of 50% from the initial level or an absolute count of &lt; 80.000 mm<sup>3</sup>; (2) no other apparent cause of thrombocytopenia; (3) positive anti-PF4 antibodies; and (4) recovery of the platelet count after the discontinuation of heparin treatment.</p>
      <fig id="f1" orientation="portrait" position="float">
        <label>Fig. 1</label>
        <caption>
          <p>Flow diagram of the study. PF4=platelet factor 4.</p>
        </caption>
        <graphic xlink:href="rbccv-35-06-0950-g01"/>
      </fig>
      <p>Clinical suspicion of HIT was based on postoperative thrombocytopenia, positive anti-PF4 antibodies, and/or the occurrence of a thrombotic event. The other possible causes of thrombocytopenia were excluded (<italic>e.g</italic>., intra-aortic balloon pump, severe disseminated intravascular coagulation, and non-heparin medication). Based on this clinical suspicion, anti-PF4 antibodies were then systematically determined. An alternative anticoagulant therapy of fondaparinux (Arixtra<sup>&#xAE;</sup>) was started, and UFH or LMWH was stopped.</p>
      <p>The variables including the duration of heparin therapy, CPB time, aortic cross-clamping time, duration of postoperative mechanical ventilation, and intensive care unit length of stay were determined and the Spearman&#x2019;s correlation analysis was performed to determine whether or not these variables were correlated with each other. Furthermore, postoperative complications, mortality rates, and the causes of death were specified. Potential correlations between the exposure to heparin and a number of variables, including transfusion volumes of red blood cell concentrates, volume of fresh frozen plasma, and platelet volume, were investigated.</p>
      <p>The study was performed in accordance with the Helsinki Declaration and approved by the Ethics Committee of Istanbul Demiroglu Bilim University. In addition, written informed consent was obtained from all study patients.</p>
      <sec>
        <title>Statistical Analysis</title>
        <p>Descriptive statistics were summarized as mean, median, minimum, maximum, frequency, ratio, and standard deviation. The distribution of the variables was analyzed using the Kolmogorov-Smirnov test. The Mann-Whitney U test was used to investigate qualitative data. In addition, repeated measurements were analyzed using the Wilcoxon test. The Spearman&#x2019;s correlation analysis was used to examine correlation between the variables. Study data was processed using the IBM Corp. Released 2013, IBM SPSS Statistics for Windows, Version 22.0, Armonk, NY: IBM Corp.</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>RESULTS</title>
      <p>The data of 1583 patients were analyzed. Postoperative thrombocytopenia was detected in 257 patients who underwent open heart surgery. Antibodies against heparin/PF4 complex were positive in 20 patients. The mean ejection fraction was 47.5% (48.3&#xB1;6.7%), mean CPB time was 110 min (113.0&#xB1;35.0 min), mean cross-clamping time was 82.5 min (88.0&#xB1;32.7 min), and mean intensive care unit length of stay was 10 days (10.9&#xB1;4.9 days).</p>
      <p>We compared the demographic characteristics of PF4+ and PF4- patients. There were no significant differences between the patients regarding their demographic characteristics and ejection fraction values (<xref rid="t1" ref-type="table">Table 1</xref>). The duration of mechanical ventilation was significantly longer in PF4+ patients: 9.95&#xB1;5.23 hours <italic>vs</italic>. 6.59&#xB1;1.41 hours in PF4+ and PF4- patients, respectively (<italic>P</italic>=0.001, <xref rid="t2" ref-type="table">Table 2</xref>). The &#x131;ntensive care unit length of stay was significantly longer in PF4+ patients: 10.85&#xB1;4.92 days <italic>vs</italic>. 1.24&#xB1;0.42 days in PF4+ and PF4- patients, respectively (<italic>P</italic>=0.001, <xref rid="t2" ref-type="table">Table 2</xref>). The CPB time and the cross-clamping time did not differ between patients.</p>
      <table-wrap id="t1" orientation="portrait" position="float">
        <label>Table 1</label>
        <caption>
          <p>Comparison between demographics of PF4+ and PF4- patients.</p>
        </caption>
        <table frame="hsides" rules="all">
          <colgroup span="1">
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" colspan="2" rowspan="1">&#xA0;</th>
              <th align="center" rowspan="1" colspan="1">PF4+<break/>(n=20)</th>
              <th align="center" rowspan="1" colspan="1">PF4-<break/>(n=237)</th>
              <th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="2" colspan="1">Sex</td>
              <td align="left" rowspan="1" colspan="1">Female</td>
              <td align="center" rowspan="1" colspan="1">11 (55%)</td>
              <td align="center" rowspan="1" colspan="1">75 (31.6%)</td>
              <td align="center" rowspan="2" colspan="1">0.039<xref ref-type="table-fn" rid="TFN1">*</xref></td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Male</td>
              <td align="center" rowspan="1" colspan="1">9 (45%)</td>
              <td align="center" rowspan="1" colspan="1">162 (68.4%)</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Age (years)</td>
              <td align="center" rowspan="1" colspan="1">67.55&#xB1;5.84 (66.5)</td>
              <td align="center" rowspan="1" colspan="1">63.9&#xB1;11.6 (65)</td>
              <td align="center" rowspan="1" colspan="1">0.171</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">BMI</td>
              <td align="center" rowspan="1" colspan="1">28.8&#xB1;2.31 (28.2)</td>
              <td align="center" rowspan="1" colspan="1">26.56&#xB1;1.89 (26)</td>
              <td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN1">*</xref></td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">EF</td>
              <td align="center" rowspan="1" colspan="1">48.3&#xB1;6.69 (47.5)</td>
              <td align="center" rowspan="1" colspan="1">50.38&#xB1;4.85 (50)</td>
              <td align="center" rowspan="1" colspan="1">0.090</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN1">
            <label>*</label>
            <p><italic>P</italic>&lt;0.05 is the statistically significant value between groups</p>
          </fn>
          <fn id="TFN2">
            <p>BMI=body mass &#x131;ndex; EF=ejection fraction; PF4=platelet factor 4</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="t2" orientation="portrait" position="float">
        <label>Table 2</label>
        <caption>
          <p>Comparison between outcomes of PF4+ and PF4- patients.</p>
        </caption>
        <table frame="hsides" rules="all">
          <colgroup span="1">
            <col width="40%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">&#xA0;</th>
              <th align="center" rowspan="1" colspan="1">PF4+<break/>(n=20)</th>
              <th align="center" rowspan="1" colspan="1">PF4-<break/>(n=237)</th>
              <th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">Cardiopulmonary bypass time (min)</td>
              <td align="center" rowspan="1" colspan="1">113.0&#xB1;35.0 (110)</td>
              <td align="center" rowspan="1" colspan="1">107.51&#xB1;46.16 (90)</td>
              <td align="center" rowspan="1" colspan="1">0.275</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Cross-clamping time (min)</td>
              <td align="center" rowspan="1" colspan="1">88.0&#xB1;32.74 (82.5)</td>
              <td align="center" rowspan="1" colspan="1">80.92&#xB1;33.38 (80)</td>
              <td align="center" rowspan="1" colspan="1">0.349</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Duration of mechanical ventilation (h)</td>
              <td align="center" rowspan="1" colspan="1">9.95&#xB1;5.23 (9.5)</td>
              <td align="center" rowspan="1" colspan="1">6.59&#xB1;1.41 (6)</td>
              <td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN3">*</xref></td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Intensive care unit length of stay (days)</td>
              <td align="center" rowspan="1" colspan="1">10.85&#xB1;4.92 (10)</td>
              <td align="center" rowspan="1" colspan="1">1.24&#xB1;0.42 (1)</td>
              <td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN3">*</xref></td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN3">
            <label>*</label>
            <p><italic>P</italic>&lt;0.05 is the statistically significant value between groups</p>
          </fn>
          <fn id="TFN4">
            <p>PF4=platelet factor 4</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>The amount of decrease in platelet was significantly higher in PF4+ patients: 246&#xB1;91.69/mm<sup>3</sup>
<italic>vs</italic>. 65.24&#xB1;40.99/mm<sup>3</sup> in PF4+ and PF4- patients, respectively (<italic>P</italic>=0.001, <xref rid="t3" ref-type="table">Table 3</xref>). The consumption rate of erythrocytes suspension was not different in groups. Perioperative fresh frozen plasma transfusion amount was significantly higher in PF4+ patients (6.9&#xB1;4.19 units,<italic>P</italic>=0.001, <xref rid="t3" ref-type="table">Table 3</xref>). Perioperative platelet transfusion rate was also higher in this group (6.8&#xB1;4.87).</p>
      <table-wrap id="t3" orientation="portrait" position="float">
        <label>Table 3</label>
        <caption>
          <p>Comparison between blood product consumption of PF4+ and PF4- patients.</p>
        </caption>
        <table frame="hsides" rules="all">
          <colgroup span="1">
            <col width="40%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">&#xA0;</th>
              <th align="center" rowspan="1" colspan="1">PF4+<break/>(n=20)</th>
              <th align="center" rowspan="1" colspan="1">PF4-<break/>(n=237)</th>
              <th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">Preoperative platelet count (per mm<sup>3</sup>)</td>
              <td align="center" rowspan="1" colspan="1">307.25&#xB1;88.53 (300)</td>
              <td align="center" rowspan="1" colspan="1">235.89&#xB1;67.49 (226)</td>
              <td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN5">*</xref></td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Amount of decrease in platelet (per mm<sup>3</sup>)</td>
              <td align="center" rowspan="1" colspan="1">246&#xB1;91.69 (233)</td>
              <td align="center" rowspan="1" colspan="1">65.24&#xB1;40.99 (61)</td>
              <td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN5">*</xref></td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Perioperative erythrocytes suspension (units)</td>
              <td align="center" rowspan="1" colspan="1">3.75&#xB1;2.69 (2.5)</td>
              <td align="center" rowspan="1" colspan="1">2.69&#xB1;2.39 (2)</td>
              <td align="center" rowspan="1" colspan="1">0.242</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Perioperative fresh frozen plasma transfusion (units)</td>
              <td align="center" rowspan="1" colspan="1">6.9&#xB1;4.19 (6)</td>
              <td align="center" rowspan="1" colspan="1">1.78&#xB1;1.77 (2)</td>
              <td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN5">*</xref></td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Perioperative platelet transfusion (units)</td>
              <td align="center" rowspan="1" colspan="1">6.8&#xB1;4.87 (8)</td>
              <td align="center" rowspan="1" colspan="1">0.78&#xB1;2.98 (0.0)</td>
              <td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN5">*</xref></td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN5">
            <label>*</label>
            <p><italic>P</italic>&lt;0.05 is the statistically significant value between groups</p>
          </fn>
          <fn id="TFN6">
            <p>PF4=platelet factor 4</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Among PF4+ patients, a total of eleven patients developed complications (<xref rid="t4" ref-type="table">Table 4</xref>). Out of these eleven patients, four patients developed atrial fibrillation, and thus, received heparin therapy. Furthermore, two patients had hypoxia while another two patients developed multiple organ failure (MOF). Refractory hypotension and intra-aortic balloon pump placement, sepsis, and cardiac arrest were other complications observed in this study.</p>
      <table-wrap id="t4" orientation="portrait" position="float">
        <label>Table 4</label>
        <caption>
          <p>Demographics and other outcomes of PF4+ patients.</p>
        </caption>
        <table frame="hsides" rules="all">
          <colgroup span="1">
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" colspan="2" rowspan="1">Parameters</th>
              <th align="center" rowspan="1" colspan="1">Min-max</th>
              <th align="center" rowspan="1" colspan="1">Median</th>
              <th align="center" rowspan="1" colspan="1">Mean&#xB1;SD/n-%</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" colspan="2" rowspan="1">Age (years)</td>
              <td align="center" rowspan="1" colspan="1">57-77</td>
              <td align="center" rowspan="1" colspan="1">66.5</td>
              <td align="center" rowspan="1" colspan="1">67.6&#xB1;5.8</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Sex</td>
              <td align="left" rowspan="1" colspan="1">Female</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">11 (55.0%)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Male</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">9 (45.0%)</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Body mass index</td>
              <td align="center" rowspan="1" colspan="1">25-32.4</td>
              <td align="center" rowspan="1" colspan="1">28.2</td>
              <td align="center" rowspan="1" colspan="1">28.8&#xB1;2.3</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Ejection fraction (%)</td>
              <td align="center" rowspan="1" colspan="1">39-60</td>
              <td align="center" rowspan="1" colspan="1">47.5</td>
              <td align="center" rowspan="1" colspan="1">48.3&#xB1;6.7</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Duration of cardiopulmonary bypass (min)</td>
              <td align="center" rowspan="1" colspan="1">75-180</td>
              <td align="center" rowspan="1" colspan="1">110</td>
              <td align="center" rowspan="1" colspan="1">113.0&#xB1;35.0</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Duration of aortic cross-clamping (min)</td>
              <td align="center" rowspan="1" colspan="1">50-155</td>
              <td align="center" rowspan="1" colspan="1">82.5</td>
              <td align="center" rowspan="1" colspan="1">88.0&#xB1;32.7</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Duration of mechanical ventilation (days)</td>
              <td align="center" rowspan="1" colspan="1">1-25</td>
              <td align="center" rowspan="1" colspan="1">9.5</td>
              <td align="center" rowspan="1" colspan="1">10.0&#xB1;5.2</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">ICU length of stay (days)</td>
              <td align="center" rowspan="1" colspan="1">5-25</td>
              <td align="center" rowspan="1" colspan="1">10</td>
              <td align="center" rowspan="1" colspan="1">10.9&#xB1;4.9</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Preoperative blood product</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Erythrocytes suspension (units)</td>
              <td align="center" rowspan="1" colspan="1">0-6</td>
              <td align="center" rowspan="1" colspan="1">2</td>
              <td align="center" rowspan="1" colspan="1">2.2&#xB1;1.8</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Fresh frozen plasma (units)</td>
              <td align="center" rowspan="1" colspan="1">0-8</td>
              <td align="center" rowspan="1" colspan="1">2</td>
              <td align="center" rowspan="1" colspan="1">2.7&#xB1;3.1</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Platelet (random units)</td>
              <td align="center" rowspan="1" colspan="1">0-8</td>
              <td align="center" rowspan="1" colspan="1">0</td>
              <td align="center" rowspan="1" colspan="1">2.1&#xB1;3.5</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Postoperative blood product</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Erythrocytes suspension (units)</td>
              <td align="center" rowspan="1" colspan="1">0-4</td>
              <td align="center" rowspan="1" colspan="1">1</td>
              <td align="center" rowspan="1" colspan="1">1.5&#xB1;1.7</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Fresh frozen plasma (units)</td>
              <td align="center" rowspan="1" colspan="1">0-8</td>
              <td align="center" rowspan="1" colspan="1">4</td>
              <td align="center" rowspan="1" colspan="1">4.0&#xB1;2.1</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Platelet concentrates (random donor)</td>
              <td align="center" rowspan="1" colspan="1">0-16</td>
              <td align="center" rowspan="1" colspan="1">7</td>
              <td align="center" rowspan="1" colspan="1">5.9&#xB1;4.5</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Platelet count (per mm<sup>3</sup>)</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Preoperative period</td>
              <td align="center" rowspan="1" colspan="1">165000-485000</td>
              <td align="center" rowspan="1" colspan="1">300000</td>
              <td align="center" rowspan="1" colspan="1">307250&#xB1;88528</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Postoperative period</td>
              <td align="center" rowspan="1" colspan="1">98000-410000</td>
              <td align="center" rowspan="1" colspan="1">233000</td>
              <td align="center" rowspan="1" colspan="1">243050&#xB1;89354</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Amount of decrease</td>
              <td align="center" rowspan="1" colspan="1">43000-85000</td>
              <td align="center" rowspan="1" colspan="1">64500</td>
              <td align="center" rowspan="1" colspan="1">64200&#xB1;12177</td>
            </tr>
            <tr>
              <td align="left" colspan="2" rowspan="1">Heparin exposure (days)</td>
              <td align="center" rowspan="1" colspan="1">3-13</td>
              <td align="center" rowspan="1" colspan="1">7</td>
              <td align="center" rowspan="1" colspan="1">6.9&#xB1;2.9</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Complication</td>
              <td align="left" rowspan="1" colspan="1">No</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">9 (45.0%)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Yes</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">11 (55.0%)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Status</td>
              <td align="left" rowspan="1" colspan="1">Lived</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">11 (55.0%)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">Died</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
              <td align="center" rowspan="1" colspan="1">9 (45.0%)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN7">
            <p>ICU=intensive care unit; PF4=platelet factor 4; SD=standard deviation</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Out of 20 patients with positive heparin/PF4 antibodies, nine patients (45%) died. The causes of death were cardiac failure in two patients, hypotensive shock in two patients, and postoperative bleeding in another two patients. Hypoxemia, sepsis, and MOF were identified as the other causes that contributed to mortality.</p>
      <p>In patients with positive heparin/PF4 antibodies, platelet counts significantly decreased during the postoperative period, compared to the preoperative period (<italic>P</italic>&gt;0.05, <xref rid="t5" ref-type="table">Table 5</xref>). None of the patients developed venous or arterial thrombosis.</p>
      <table-wrap id="t5" orientation="portrait" position="float">
        <label>Table 5</label>
        <caption>
          <p>Preoperative and postoperative platelet count in patients with positive heparin/PF4 antibodies.</p>
        </caption>
        <table frame="hsides" rules="all">
          <colgroup span="1">
            <col width="40%" span="1"/>
            <col width="15%" span="1"/>
            <col width="15%" span="1"/>
            <col width="15%" span="1"/>
            <col width="15%" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Platelet concentration (per mm<sup>3</sup>)</th>
              <th align="center" rowspan="1" colspan="1">Min-max</th>
              <th align="center" rowspan="1" colspan="1">Median</th>
              <th align="center" rowspan="1" colspan="1">Mean&#xB1;SD</th>
              <th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">Preoperative</td>
              <td align="center" rowspan="1" colspan="1">165000-485000</td>
              <td align="center" rowspan="1" colspan="1">300000</td>
              <td align="center" rowspan="1" colspan="1">307250&#xB1;88528</td>
              <td align="center" rowspan="1" colspan="1">0.000</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Postoperative</td>
              <td align="center" rowspan="1" colspan="1">98000-410000</td>
              <td align="center" rowspan="1" colspan="1">233000</td>
              <td align="center" rowspan="1" colspan="1">243050&#xB1;89354</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN8">
            <p>Wilcoxon test</p>
            <p>PF4=platelet factor 4; SD=standard deviation</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>There were no significant differences between females and males regarding their heparin exposure (<italic>P</italic>&gt;0.05). Moreover, the duration of heparin exposure did not show a significant difference between the patients who died and who stayed alive (<italic>P</italic>&gt;0.05). In addition, there was no significant difference between the patients who developed complications and who did not regarding their heparin exposure (<italic>P</italic>&gt;0.05, <xref rid="t6" ref-type="table">Table 6</xref>).</p>
      <table-wrap id="t6" orientation="portrait" position="float">
        <label>Table 6</label>
        <caption>
          <p>Factors related with heparin exposure.</p>
        </caption>
        <table frame="hsides" rules="all">
          <colgroup span="1">
            <col width="16%" span="1"/>
            <col width="16%" span="1"/>
            <col width="16%" span="1"/>
            <col width="16%" span="1"/>
            <col width="16%" span="1"/>
            <col width="16%" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" colspan="2" rowspan="1">Heparin exposure (days)</th>
              <th align="center" rowspan="1" colspan="1">Min-max</th>
              <th align="center" rowspan="1" colspan="1">Median</th>
              <th align="center" rowspan="1" colspan="1">Mean&#xB1;SD</th>
              <th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="2" colspan="1">Sex</td>
              <td align="center" rowspan="1" colspan="1">Female</td>
              <td align="center" rowspan="1" colspan="1">4-13</td>
              <td align="center" rowspan="1" colspan="1">6</td>
              <td align="center" rowspan="1" colspan="1">6.5&#xB1;2.7</td>
              <td align="center" rowspan="1" colspan="1">0.444</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">Male</td>
              <td align="center" rowspan="1" colspan="1">3-12</td>
              <td align="center" rowspan="1" colspan="1">8</td>
              <td align="center" rowspan="1" colspan="1">7.3&#xB1;3.2</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="2" colspan="1">Status</td>
              <td align="center" rowspan="1" colspan="1">Lived</td>
              <td align="center" rowspan="1" colspan="1">3-10</td>
              <td align="center" rowspan="1" colspan="1">6</td>
              <td align="center" rowspan="1" colspan="1">6.0&#xB1;2.0</td>
              <td align="center" rowspan="1" colspan="1">0.206</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">Died</td>
              <td align="center" rowspan="1" colspan="1">3-13</td>
              <td align="center" rowspan="1" colspan="1">8</td>
              <td align="center" rowspan="1" colspan="1">7.9&#xB1;3.5</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="2" colspan="1">Complication</td>
              <td align="center" rowspan="1" colspan="1">No</td>
              <td align="center" rowspan="1" colspan="1">3-13</td>
              <td align="center" rowspan="1" colspan="1">8</td>
              <td align="center" rowspan="1" colspan="1">7.9&#xB1;3.5</td>
              <td align="center" rowspan="1" colspan="1">0.206</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">Yes</td>
              <td align="center" rowspan="1" colspan="1">3-10</td>
              <td align="center" rowspan="1" colspan="1">6</td>
              <td align="center" rowspan="1" colspan="1">6.0&#xB1;2.0</td>
              <td align="center" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN9">
            <p>Mann-Whitney U test</p>
            <p>SD=standard deviation</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>There was no significant (<italic>P</italic>&gt;0.05) correlation between the duration of heparin exposure and age, body mass index, CPB time, cross-clamping time, duration of mechanical ventilation, and intensive care unit length of stay (<xref rid="t7" ref-type="table">Table 7</xref>).</p>
      <table-wrap id="t7" orientation="portrait" position="float">
        <label>Table 7</label>
        <caption>
          <p>Correlation between duration of heparin treatment and other factors.</p>
        </caption>
        <table frame="hsides" rules="all">
          <colgroup span="1">
            <col width="20%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" colspan="2" rowspan="1">&#xA0;</th>
              <th align="center" rowspan="1" colspan="1">Age<break/>(years)</th>
              <th align="center" rowspan="1" colspan="1">BMI </th>
              <th align="center" rowspan="1" colspan="1">EF<break/>(%)</th>
              <th align="center" rowspan="1" colspan="1">Duration of CPB<break/>(min)</th>
              <th align="center" rowspan="1" colspan="1">Duration of cross-clamping (min)</th>
              <th align="center" rowspan="1" colspan="1">Duration of mechanical ventilation<break/>(days)</th>
              <th align="center" rowspan="1" colspan="1">ICU length<break/>of stay<break/>(days)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="2" colspan="1">Heparin exposure (days)</td>
              <td align="center" rowspan="1" colspan="1">r</td>
              <td align="center" rowspan="1" colspan="1">0.268</td>
              <td align="center" rowspan="1" colspan="1">0.294</td>
              <td align="center" rowspan="1" colspan="1">0.244</td>
              <td align="center" rowspan="1" colspan="1">0.283</td>
              <td align="center" rowspan="1" colspan="1">0.355</td>
              <td align="center" rowspan="1" colspan="1">-0.004</td>
              <td align="center" rowspan="1" colspan="1">0.000</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">p</td>
              <td align="center" rowspan="1" colspan="1">0.253</td>
              <td align="center" rowspan="1" colspan="1">0.209</td>
              <td align="center" rowspan="1" colspan="1">0.300</td>
              <td align="center" rowspan="1" colspan="1">0.227</td>
              <td align="center" rowspan="1" colspan="1">0.124</td>
              <td align="center" rowspan="1" colspan="1">0.987</td>
              <td align="center" rowspan="1" colspan="1">0.999</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN10">
            <p>Spearman's correlation</p>
            <p>BMI=body mass index; CPB=cardiopulmonary bypass; EF=ejection fraction; ICU=intensive care unit</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Similarly, no significant correlations were found between the duration of heparin exposure and preoperative or postoperative use of blood products (<italic>P</italic>&gt;0.05, <xref rid="t8" ref-type="table">Table 8</xref>). Also, there were no significant correlations between the duration of heparin exposure and the pre/postoperative platelet counts and the alteration in these values (<italic>P</italic>&gt;0.05, <xref rid="t9" ref-type="table">Table 9</xref>).</p>
      <table-wrap id="t8" orientation="portrait" position="float">
        <label>Table 8</label>
        <caption>
          <p>Relation between heparin exposure and use of preoperative and postoperative blood.</p>
        </caption>
        <table frame="hsides" rules="all">
          <colgroup span="1">
            <col width="30%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
            <col width="10%" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="center" colspan="8" rowspan="1">Use of blood products</th>
            </tr>
            <tr>
              <th align="left" colspan="2" rowspan="1">&#xA0;</th>
              <th align="center" rowspan="1" colspan="1">Preoperative RBC</th>
              <th align="center" rowspan="1" colspan="1">Preoperative FFP</th>
              <th align="center" rowspan="1" colspan="1">Preoperative PLT</th>
              <th align="center" rowspan="1" colspan="1">Postoperative RBC</th>
              <th align="center" rowspan="1" colspan="1">Postoperative FFP</th>
              <th align="center" rowspan="1" colspan="1">Postoperative PLT</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="2" colspan="1">Heparin exposure (days)</td>
              <td align="center" rowspan="1" colspan="1">r</td>
              <td align="center" rowspan="1" colspan="1">0.377</td>
              <td align="center" rowspan="1" colspan="1">0.306</td>
              <td align="center" rowspan="1" colspan="1">0.316</td>
              <td align="center" rowspan="1" colspan="1">0.038</td>
              <td align="center" rowspan="1" colspan="1">0.087</td>
              <td align="center" rowspan="1" colspan="1">0.035</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">p</td>
              <td align="center" rowspan="1" colspan="1">0.101</td>
              <td align="center" rowspan="1" colspan="1">0.190</td>
              <td align="center" rowspan="1" colspan="1">0.174</td>
              <td align="center" rowspan="1" colspan="1">0.875</td>
              <td align="center" rowspan="1" colspan="1">0.716</td>
              <td align="center" rowspan="1" colspan="1">0.884</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN11">
            <p>FFP=fresh frozen plasma; PLT=platelet; RBC=red blood cell</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="t9" orientation="portrait" position="float">
        <label>Table 9</label>
        <caption>
          <p>Correlation between heparin exposure and pre and postoperative platelet count.</p>
        </caption>
        <table frame="hsides" rules="all">
          <colgroup span="1">
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
            <col width="20%" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" colspan="2" rowspan="1">&#xA0;</th>
              <th align="center" rowspan="1" colspan="1">Preoperative<break/>PLT</th>
              <th align="center" rowspan="1" colspan="1">Postoperative<break/>PLT</th>
              <th align="center" rowspan="1" colspan="1">PLT<break/>decrease</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="2" colspan="1">Heparin exposure (days)</td>
              <td align="center" rowspan="1" colspan="1">r</td>
              <td align="center" rowspan="1" colspan="1">0.040</td>
              <td align="center" rowspan="1" colspan="1">0.050</td>
              <td align="center" rowspan="1" colspan="1">0.021</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">p</td>
              <td align="center" rowspan="1" colspan="1">0.868</td>
              <td align="center" rowspan="1" colspan="1">0.833</td>
              <td align="center" rowspan="1" colspan="1">0.929</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN12">
            <p>PLT=platelet</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>In this study, the overall mortality in patients with positive heparin/PF4 antibodies undergoing cardiac surgery at our medical center was 45% (n=20). The risk for this complication was also high in patients who had been in the low-risk group during the preoperative period and tested positive for PF4 antigen in the postoperative period.</p>
      <p>The diagnosis of HIT may be challenging in patients undergoing open heart surgery. Patients undergoing CPB surgery receive large volumes of heparin infusion during this procedure, and their blood platelet counts can fall 30-50% within the first 72 hours of the postoperative period<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Thrombocytopenia was also reported to occur following transcatheter valve-in-valve &#x131;mplantation and aortic valve replacement<sup>[<xref rid="r10" ref-type="bibr">10</xref>,<xref rid="r11" ref-type="bibr">11</xref>]</sup>. Besides drug-induced thrombocytopenia, an extended platelet contact with artificial surfaces as a part of extracorporeal circulation is one of the major factors leading to low platelet counts<sup>[<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r13" ref-type="bibr">13</xref>]</sup>. For this reason, patients receiving oral anticoagulants were excluded from our study. Within the scope of the study, platelet counts were performed in all patients and a heparin/PF4 antibody test was performed in patients whose platelet counts were decreased significantly in the postoperative period. Patrick et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup> constructed a decision tree for the management of patients with HIT. They concluded that, in all thrombocytopenic critical care patients, the routine testing is not cost-effective. However, in the presence of risk factors, PF4 testing becomes reasonable.</p>
      <p>In addition, blood platelet counts were repeated in the 7<sup>th</sup> postoperative day, since a secondary fall of &#x2265; 50% in platelet counts that might occur between the 5<sup>th</sup> and 10<sup>th</sup> postoperative days has been reported to be a potential predictor of HIT<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p>
      <p>The risk for recurrent HIT appears to be high among patients who were previously diagnosed with HIT, and therefore, the use of heparin should be avoided in these patients. Nevertheless, there are only a few studies addressing the issue with small sample size, which forms the major limitation for drawing conclusions. If possible, patients who have a prior diagnosis of HIT should delay the surgery until they become negative for HIT antibodies. Relevant guidelines recommend the use of UFH over other anticoagulants during cardiac surgery for patients with a history of HIT who have become antibody-negative within the following 100 days. Preoperative and postoperative anticoagulation, on the other hand, should be provided with an agent other than UFH or LMWH. There are studies reporting the use of lepirudin, bivalirudin, and danaparoid as alternative anticoagulant agents in cardiac surgery<sup>[<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r18" ref-type="bibr">18</xref>]</sup>. Whereas prophylactic use of danaparoid is not recommended in HIT patients, it can be administered at therapeutic doses. Also, therapeutic-dose fondaparinux is an acceptable alternative anticoagulant. The 2012 American College of Chest Physicians, or ACCP, guideline recommends the use of bivalirudin as an alternative anticoagulant for the cases of HIT where cardiac surgery - whether urgent or not - is required<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. Nevertheless, the surgical team must be informed that the administration of bivalirudin causes coagulation of the blood accumulated in specific areas, such as pericardial sac. In patients with normal renal functions or abnormal hepatic functions, however, danaparoid or fondaparinux should be preferred (Level 2C). Argatroban, bivalirudin, danaparoid, and lepirudin are the anticoagulants commonly used in patients with HIT. In this study, we discontinued heparin in the patients who had positive heparin/PF4 antibodies during the postoperative period and we started fondaparinux (Arixtra<sup>&#xAE;</sup>) therapy. Fondaparinux increases the risk of bleeding and has a potential risk of causing epidural or spinal hematoma in patients undergoing neuraxial anesthesia. Fondaparinux has an anti-factor Xa activity and a prolonged activated partial thromboplastin time may occur at higher doses. However, postoperative bleeding resulted only in two patients out of 20 PF4(+) patients. Therefore, we could not explain this poor outcome just with the use of fondaparinux.</p>
      <p>Guidelines recommend platelet count monitoring from the 4<sup>th</sup> to the 14<sup>th</sup> postoperative day in patients with a history of CPB who receive LMWH. While HIT is more prevalent among surgical patients as compared to medical patients, a two times higher incidence has been noted in female patients<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>. However, we did not find a significant difference between female and male patients regarding the incidence of positive heparin/PF4 antibodies. In addition, HIT appears to be rare in patients aged &lt; 40 years and a higher risk of HIT has been reported in older patient populations<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. The average age of the patients with positive heparin/PF4 antibodies in our study was 66.5 years, which supports the evidences found in the literature.</p>
      <p>Autoimmune anti-PF4/heparin antibodies developed in HIT activate platelets and may ultimately lead to arterial or venous thrombosis. The reported mortality rate for thrombosis is nearly 20%<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>. However, various studies have reported different rates. In a study involving patients undergoing valvular heart surgery, the mortality rate was 1% in patients with HIT<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>. Pathak R et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup> noted that the risk ratio for the development of HIT after cardiac surgery was 0.53% and they stated that HIT was more common among female cardiac surgery patients. Moreover, the authors found a mortality rate of 9.63% in patients with HIT and the rate of patients with HIT accompanied by thrombosis was found to be 12.28%; however, the mortality rate among patients without HIT was only 2.19%.</p>
      <p>Although none of our patients had a venous or arterial thrombosis, the overall mortality in 20 patients with positive anti-PF4/heparin antibodies was found to be 45%. The reason might be that we did not wait the development of thrombosis for the diagnosis of HIT and stopped heparin exposures as soon as an early suspicion of HIT occured. After the discontinuation of heparin therapy, we immediately started fondaparinux which, in our opinion, had a role in the prevention of thrombosis. Nevertheless, hypoxemia, MOF, sepsis, cardiac arrest, and postoperative bleeding were among the etiological and contributing factors of mortality, in our study. Even though thrombosis is the leading cause of death, this study indicated that factors other than thrombosis, such as postoperative bleeding, can lead to mortality, as well.</p>
      <p>HIT is a rare but life-threatening complication in patients undergoing cardiac surgery. A high mortality rate has been reported in patients with HIT due to the development of venous or arterial thrombosis. However, it is possible to prevent thrombosis with early diagnosis. Particularly, platelet counts after the 5<sup>th</sup> postoperative day can be predictive even if the patient is asymptomatic. There are several other factors which can potentially contribute to mortality in HIT and which can be detected in the earlier stages. We need further studies with larger sample sizes to investigate these factors.</p>
      <p>Patients undergoing cardiac surgery or CPB have an incidence of 20% to 50% of anti-PF4/heparin antibody formation<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. In our study, we declared an incidence of 8% of anti-PF4/heparin antibody formation in thrombocytopenic surgical patients. Although the total count of PF4+ patients were low, the overall mortality rate was high. This result was unique for our study and revealed that the mortality rate increases significantly in patients with thrombocytopenia and positive PF4.</p>
      <p>Limitations</p>
      <p>Our analysis was based on thrombocytopenia as a quantitative value. We did not evaluate the duration of thrombocytopenia which can be an associate risk factor for HIT. This was the main limitation of this study.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>CONCLUSION</title>
      <p>In conclusion, according to HIT diagnosis criteria, we could not define HIT for all the 20 patients. Although the incidence of HIT was low in patients undergoing open heart surgery, an increased rate of early mortality was observed in patients with positive heparin/PF4 antibodies.</p>
      <table-wrap id="t11" orientation="portrait" position="anchor">
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col width="5%" span="1"/>
            <col width="95%" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" colspan="2" rowspan="1">Authors' roles &amp; responsibilities</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">ME</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">KTS</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">KO</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">AS</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it critically for important intellectual content; final approval of the version to be published</td>
            </tr>
            <tr>
              <td align="left" valign="top" rowspan="1" colspan="1">BA</td>
              <td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it critically for important intellectual content; final approval of the version to be published</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="other">
        <p>This study was carried out at the Department of Cardiovascular Surgery, Istanbul Demiroglu Bilim University Medical School, Istanbul, Turkey.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>No financial support.</p>
      </fn>
      <fn fn-type="COI-statement">
        <p>No conflict of interest.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bakchoul</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia</article-title>
          <source>Thromb Haemost</source>
          <year>2016</year>
          <volume>116</volume>
          <issue>5</issue>
          <fpage>823</fpage>
          <lpage>834</lpage>
          <pub-id pub-id-type="doi">10.1160/TH16-03-0240</pub-id>
          <pub-id pub-id-type="pmid">27604316</pub-id>
        </element-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pishko</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Cuker</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia in cardiac surgery patients</article-title>
          <source>Semin Thromb Hemost</source>
          <year>2017</year>
          <volume>43</volume>
          <issue>7</issue>
          <fpage>691</fpage>
          <lpage>698</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0037-1602664</pub-id>
          <pub-id pub-id-type="pmid">28597462</pub-id>
        </element-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kerendi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Thourani</surname>
              <given-names>VH</given-names>
            </name>
            <name>
              <surname>Puskas</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Kilgo</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Osgood</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Guyton</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact of heparin-induced thrombocytopenia on postoperative outcomes after cardiac surgery</article-title>
          <source>Ann Thorac Surg</source>
          <year>2007</year>
          <volume>84</volume>
          <issue>5</issue>
          <fpage>1548</fpage>
          <lpage>1553</lpage>
          <pub-id pub-id-type="doi">10.1016/j.athoracsur.2007.05.080</pub-id>
          <pub-id pub-id-type="pmid">17954061</pub-id>
        </element-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuitunen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Suojaranta-Ylinen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Raivio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kukkonen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lassila</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome</article-title>
          <source>J Cardiothorac Vasc Anesth</source>
          <year>2007</year>
          <volume>21</volume>
          <issue>1</issue>
          <fpage>18</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1053/j.jvca.2006.05.002</pub-id>
          <pub-id pub-id-type="pmid">17289474</pub-id>
        </element-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ortega-Loubon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fern&#xE1;ndez-Molina</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pa&#xF1;eda-Delgado</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jorge-Monjas</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Carrascal</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Predictors of postoperative acute kidney injury after coronary artery bypass graft surgery</article-title>
          <source>Braz J Cardiovasc Surg</source>
          <year>2018</year>
          <volume>33</volume>
          <issue>4</issue>
          <fpage>323</fpage>
          <lpage>329</lpage>
          <pub-id pub-id-type="doi">10.21470/1678-9741-2017-0251</pub-id>
          <pub-id pub-id-type="pmid">30184028</pub-id>
        </element-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prince</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wenham</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopaenia</article-title>
          <source>Postgrad Med J</source>
          <year>2018</year>
          <volume>94</volume>
          <issue>1114</issue>
          <fpage>453</fpage>
          <lpage>457</lpage>
          <pub-id pub-id-type="doi">10.1136/postgradmedj-2018-135702</pub-id>
          <pub-id pub-id-type="pmid">30126928</pub-id>
        </element-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krzych</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Nowacka</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Knapik</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia</article-title>
          <source>Anaesthesiol Intensive Ther</source>
          <year>2015</year>
          <volume>47</volume>
          <issue>1</issue>
          <fpage>63</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="doi">10.5603/AIT.2015.0006</pub-id>
          <pub-id pub-id-type="pmid">25751293</pub-id>
        </element-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rezende</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Morais</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Silva Junior</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Toledo</surname>
              <given-names>DO</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thrombocytopenia in cardiac surgery: diagnostic and prognostic importance</article-title>
          <source>Rev Bras Cir Cardiovasc</source>
          <year>2011</year>
          <volume>26</volume>
          <issue>1</issue>
          <fpage>47</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="doi">10.1590/s0102-76382011000100011</pub-id>
          <pub-id pub-id-type="pmid">21881711</pub-id>
        </element-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Keeling</surname>
              <given-names>D</given-names>
            </name>
            <collab>Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology</collab>
          </person-group>
          <article-title>Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition</article-title>
          <source>Br J Haematol</source>
          <year>2012</year>
          <volume>159</volume>
          <issue>5</issue>
          <fpage>528</fpage>
          <lpage>540</lpage>
          <pub-id pub-id-type="doi">10.1111/bjh.12059</pub-id>
          <pub-id pub-id-type="pmid">23043677</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Souza</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Paim</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Viotto</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Aprigio</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ara&#xFA;jo</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thrombocytopenia after transcatheter valve-in-valve implantation: prognostic marker or mere finding?</article-title>
          <source>Braz J Cardiovasc Surg</source>
          <year>2018</year>
          <volume>33</volume>
          <issue>4</issue>
          <fpage>362</fpage>
          <lpage>370</lpage>
          <pub-id pub-id-type="doi">10.21470/1678-9741-2018-0078</pub-id>
          <pub-id pub-id-type="pmid">30184033</pub-id>
        </element-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mujtaba</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Ledingham</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Schueler</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pillay</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Thrombocytopenia after aortic valve replacement: comparison between sutureless perceval S valve and perimount magna ease bioprosthesis</article-title>
          <source>Braz J Cardiovasc Surg</source>
          <year>2018</year>
          <volume>33</volume>
          <issue>2</issue>
          <fpage>169</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="doi">10.21470/1678-9741-2017-0157</pub-id>
          <pub-id pub-id-type="pmid">29898147</pub-id>
        </element-citation>
      </ref>
      <ref id="r12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selleng</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Malowsky</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Strobel</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Wessel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ittermann</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wollert</surname>
              <given-names>HG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive</article-title>
          <source>J Thromb Haemost</source>
          <year>2010</year>
          <volume>8</volume>
          <issue>1</issue>
          <fpage>30</fpage>
          <lpage>36</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2009.03626.x</pub-id>
          <pub-id pub-id-type="pmid">19793190</pub-id>
        </element-citation>
      </ref>
      <ref id="r13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gruel</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Pouplard</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Post-operative platelet count profile: the most reliable tool for identifying patients with true heparin-induced thrombocypenia after cardiac surgery</article-title>
          <source>J Thromb Haemost</source>
          <year>2010</year>
          <volume>8</volume>
          <issue>1</issue>
          <fpage>27</fpage>
          <lpage>29</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2009.03646.x</pub-id>
          <pub-id pub-id-type="pmid">19817999</pub-id>
        </element-citation>
      </ref>
      <ref id="r14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patrick</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Winkelmayer</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Avorn</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis</article-title>
          <source>Pharmacoeconomics</source>
          <year>2007</year>
          <volume>25</volume>
          <issue>11</issue>
          <fpage>949</fpage>
          <lpage>961</lpage>
          <pub-id pub-id-type="doi">10.2165/00019053-200725110-00005</pub-id>
          <pub-id pub-id-type="pmid">17960953</pub-id>
        </element-citation>
      </ref>
      <ref id="r15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pouplard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>May</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Regina</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Marchand</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fusciardi</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gruel</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies</article-title>
          <source>Br J Haematol</source>
          <year>2005</year>
          <volume>128</volume>
          <issue>6</issue>
          <fpage>837</fpage>
          <lpage>841</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2005.05381.x</pub-id>
          <pub-id pub-id-type="pmid">15755289</pub-id>
        </element-citation>
      </ref>
      <ref id="r16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lillo-Le Lou&#xEB;t</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Boutouyrie</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Alhenc-Gelas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Le Beller</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gautier</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Aiach</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass</article-title>
          <source>J Thromb Haemost</source>
          <year>2004</year>
          <volume>2</volume>
          <issue>11</issue>
          <fpage>1882</fpage>
          <lpage>1888</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2004.00949.x</pub-id>
          <pub-id pub-id-type="pmid">15550015</pub-id>
        </element-citation>
      </ref>
      <ref id="r17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lassila</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Antovic</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Baghaei</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Dalsgaard-Nielsen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hillarp</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia</article-title>
          <source>Semin Thromb Hemost</source>
          <year>2011</year>
          <volume>37</volume>
          <issue>3</issue>
          <fpage>328</fpage>
          <lpage>336</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0031-1274516</pub-id>
          <pub-id pub-id-type="pmid">21455867</pub-id>
        </element-citation>
      </ref>
      <ref id="r18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anna</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Boyan</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kader</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Catherine</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matthias</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>The HIT treatment in a cardiac surgery patient</article-title>
          <source>Int J Cardiol</source>
          <year>2010</year>
          <volume>144</volume>
          <issue>3</issue>
          <fpage>405</fpage>
          <lpage>407</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijcard.2009.03.027</pub-id>
          <pub-id pub-id-type="pmid">19324432</pub-id>
        </element-citation>
      </ref>
      <ref id="r19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Linkins</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Dans</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Moores</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Bona</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Schulman</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines</article-title>
          <source>Chest</source>
          <year>2012</year>
          <volume>141</volume>
          <issue>2 Suppl</issue>
          <fpage>e495S</fpage>
          <lpage>e530S</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.11-2303</pub-id>
          <pub-id pub-id-type="pmid">22315270</pub-id>
        </element-citation>
      </ref>
      <ref id="r20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Sigouin</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Kohlmann</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Eichler</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Greinacher</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia</article-title>
          <source>Blood</source>
          <year>2006</year>
          <volume>108</volume>
          <issue>9</issue>
          <fpage>2937</fpage>
          <lpage>2941</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2005-11-012450</pub-id>
          <pub-id pub-id-type="pmid">16857993</pub-id>
        </element-citation>
      </ref>
      <ref id="r21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stein</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Hull</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Matta</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Yaekoub</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism</article-title>
          <source>Am J Med</source>
          <year>2009</year>
          <volume>122</volume>
          <issue>10</issue>
          <fpage>919</fpage>
          <lpage>930</lpage>
          <pub-id pub-id-type="doi">10.1016/j.amjmed.2009.03.026</pub-id>
          <pub-id pub-id-type="pmid">19682670</pub-id>
        </element-citation>
      </ref>
      <ref id="r22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baroletti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hurwitz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Conti</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Fanikos</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Piazza</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Goldhaber</surname>
              <given-names>SZ</given-names>
            </name>
          </person-group>
          <article-title>Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels</article-title>
          <source>Am J Med</source>
          <year>2012</year>
          <volume>125</volume>
          <issue>1</issue>
          <fpage>44</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="doi">10.1016/j.amjmed.2011.06.025</pub-id>
          <pub-id pub-id-type="pmid">22075045</pub-id>
        </element-citation>
      </ref>
      <ref id="r23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arangalage</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lepage</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Faille</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cimadevilla</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dilly</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Papy</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Presentation, management and outcome of heparin-induced thrombocytopenia after valvular heart surgery</article-title>
          <source>Eur J Cardiothorac Surg</source>
          <year>2016</year>
          <volume>50</volume>
          <issue>6</issue>
          <fpage>1132</fpage>
          <lpage>1138</lpage>
          <pub-id pub-id-type="doi">10.1093/ejcts/ezw200</pub-id>
          <pub-id pub-id-type="pmid">27301386</pub-id>
        </element-citation>
      </ref>
      <ref id="r24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pathak</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bhatt</surname>
              <given-names>VR</given-names>
            </name>
            <name>
              <surname>Karmacharya</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Aryal</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Donato</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>Medical and economic burden of heparin-induced thrombocytopenia: a retrospective nationwide inpatient sample (NIS) study</article-title>
          <source>J Hosp Med</source>
          <year>2017</year>
          <volume>12</volume>
          <issue>2</issue>
          <fpage>94</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="doi">10.12788/jhm.2687</pub-id>
          <pub-id pub-id-type="pmid">28182804</pub-id>
        </element-citation>
      </ref>
      <ref id="r25">
        <label>25</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Whitlatch</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Metjian</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Arepally</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Ortel</surname>
              <given-names>TL</given-names>
            </name>
          </person-group>
          <source>Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytope</source>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Anesth Analg</journal-id>
      <journal-id journal-id-type="iso-abbrev">Anesth. Analg</journal-id>
      <journal-id journal-id-type="publisher-id">ANE</journal-id>
      <journal-title-group>
        <journal-title>Anesthesia and Analgesia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0003-2999</issn>
      <issn pub-type="epub">1526-7598</issn>
      <publisher>
        <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32371744</article-id>
      <article-id pub-id-type="pmc">7219828</article-id>
      <article-id pub-id-type="art-access-id">00010</article-id>
      <article-id pub-id-type="doi">10.1213/ANE.0000000000004949</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letters to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Falsely Low Fibrinogen Levels in COVID-19 Patients on Direct Thrombin Inhibitors</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Maier</surname>
            <given-names>Cheryl L.</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <aff id="aff1">Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia</aff>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Barker</surname>
            <given-names>Nicholas A.</given-names>
          </name>
          <degrees>PharmD</degrees>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <aff id="aff2">Department of Pharmacy, Emory St Joseph&#x2019;s Hospital, Atlanta, Georgia</aff>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Sniecinski</surname>
            <given-names>Roman M.</given-names>
          </name>
          <degrees>MD, MSc</degrees>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <aff id="aff3">Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, <email xlink:href="rsnieci@emory.edu">rsnieci@emory.edu</email></aff>
      </contrib-group>
      <pub-date pub-type="ppub">
        <day>12</day>
        <month>5</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>04</day>
        <month>5</month>
        <year>2020</year>
      </pub-date>
      <elocation-id>10.1213/ANE.0000000000004949</elocation-id>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2020 International Anesthesia Research Society</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license license-type="open-access">
          <license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="ane-publish-ahead-of-print-10.1213.ane.0000000000004949.pdf"/>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>To the Editor</title>
      <p>We read with great interest Ranucci et al&#x2019;s<sup><xref rid="R1" ref-type="bibr">1</xref></sup> review on the &#x201C;trials and tribulations&#x201D; of fibrinogen level determination that was recently published in <italic>Anesthesia &amp; Analgesia</italic>. This topic has become even more important with the rise of the coronavirus pandemic since severe hyperfibrinogenemia is a characteristic finding in patients critically ill with coronavirus disease 2019 (COVID-19) respiratory failure.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> We wanted to take this opportunity to bring another limitation of the Clauss method of fibrinogen determination to readers&#x2019; attention, as it can have important implications for care of these patients.</p>
      <p>Given the hypercoagulability seen in COVID-19 patients, anticoagulation with low-molecular-weight heparin has been recommended by the International Society of Thrombosis and Hemostasis.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> However, since antithrombin levels can be significantly lower than normal in this patient population,<sup><xref rid="R2" ref-type="bibr">2</xref></sup> heparin&#x2019;s effectiveness may be limited in some cases. Our institution has been selectively using direct thrombin inhibitors (DTIs) to overcome this problem. Unbeknownst to clinicians, this affected our laboratory&#x2019;s method for measuring fibrinogen levels, causing them to be vastly underestimated. An example of the magnitude in underestimation is provided in theFigure for illustrative purposes.</p>
      <fig id="F1" orientation="portrait" position="float">
        <label>Figure.</label>
        <caption>
          <p>The graph demonstrates an example of the magnitude of which an argatroban infusion can have upon the measurement of fibrinogen levels determined by the Clauss assay. The patient&#x2019;s initially reported levels (blue line) on the day argatroban was started (which were repeated for confirmation) were almost an order of magnitude lower from previous measurements taken while on a heparin infusion. These samples were diluted as described in the text to decrease the effects of the argatroban and rerun, producing a &#x201C;corrected&#x201D; fibrinogen level (orange line).</p>
        </caption>
        <graphic xlink:href="ane-publish-ahead-of-print-10.1213.ane.0000000000004949-g001"/>
      </fig>
      <p>The Clauss method of fibrinogen measurement is similar to a thrombin time. Platelet poor plasma is exposed to a reagent containing supraphysiologic concentrations of thrombin and clot formation is sensed by mechanical or photo-optical means. The time to clot detection is compared against reference plasma to generate a corresponding fibrinogen level. The concentration of thrombin in the Clauss reagent varies by manufacturer and what instrumentation is being used. When present in the patient sample, DTIs inhibit the thrombin in the Clauss reagent, prolonging the time to clot formation, and thus underestimating the fibrinogen concentration. Reagents with lower thrombin concentrations are more susceptible to DTI inference. This problem has been reported on several different commercial platforms with samples containing both bivalirudin and argatroban.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup></p>
      <p>The Clauss assay in our particular laboratory uses a reagent with the highest commercially available thrombin concentration&#x2014;100 NIH units (UNIH)/mL(QFA Thrombin, Instrumentation Laboratories, Bedford, MA). Despite this high level, &#x201C;inhibitors&#x201D; can still interfere with fibrinogen assessment. This can be assessed by performing a dilution procedure. This involves taking the patient plasma sample and performing a 1:1 dilution with HemosIL Factor Diluent (Instrumentation Laboratories), a nonactive buffer solution. This reduces the effect of the DTI. TheFigure provides an example of how large a difference this can make on the measurement of fibrinogen levels.</p>
      <p>Viscoelastic testing represents an alternative to the Clauss method for following fibrinogen levels in the setting of DTIs. The platelet&#x2013;fibrinogen interactions assessed by maximum amplitude on thromboelastography (TEG) (Haemonetics, Boston, MA) or maximum clot formation on rotational thromboelastometry (ROTEM) (Instrumentation Laboratories) are relatively unaffected by the presence of DTIs.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> In the example provided in theFigure, a ROTEM was obtained following the reported severe drop in fibrinogen on day 4 and resulted in the following notable parameters: EXTEM clottingtimeof 477 seconds (normal range 43&#x2013;82 seconds) and FIBTEM maximum clotfirmnessof 39 mm (normal range 7&#x2013;24 mm). The clottingtimewas appropriately prolonged, indicating thrombin inhibition by the argatroban, while the increased maximum clotfirmnesswas still able to reflect the hyperfibrinogenemia that was present. This discordance between the ROTEM findings and the reported fibrinogen level by the Clauss method prompted the initial investigations into diluting the DTI samples.</p>
      <p>The hypercoagulability caused by COVID-19 is still not wellunderstood. Fibrinogen levels are an important piece of the puzzle, not only from a research aspect but for patient care. However, it is important for both scientists and clinicians to understand that their measurement is not always entirely straightforward.</p>
    </sec>
    <sig-block>
      <sig>
        <bold>Cheryl L. Maier, MD, PhD</bold>
        <break/>
        <italic>Department of Pathology and Laboratory Medicine</italic>
        <break/>
        <italic>Emory University School of Medicine</italic>
        <break/>
        <italic>Atlanta, Georgia</italic>
      </sig>
      <sig>
        <bold>Nicholas A. Barker, PharmD</bold>
        <break/>
        <italic>Department of Pharmacy</italic>
        <break/>
        <italic>Emory St Joseph&#x2019;s Hospital</italic>
        <break/>
        <italic>Atlanta, Georgia</italic>
      </sig>
      <sig>
        <bold>Roman M. Sniecinski, MD, MSc</bold>
        <break/>
        <italic>Department of Anesthesiology</italic>
        <break/>
        <italic>Emory University School of Medicine</italic>
        <break/>
        <italic>Atlanta, Georgia</italic>
        <break/>
        <italic>rsnieci@emory.edu</italic>
      </sig>
    </sig-block>
  </body>
  <back>
    <fn-group>
      <fn fn-type="COI-statement">
        <p>Conflicts of Interest: R. M. Sniecinski has received research funding from Cerus and Grifols, and consulting fees from Octapharma. The remaining authors declare no conflicts of interest.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranucci</surname><given-names>M</given-names></name><name><surname>Di Dedda</surname><given-names>U</given-names></name><name><surname>Baryshnikova</surname><given-names>E</given-names></name></person-group>
<article-title>Trials and tribulations of viscoelastic-based determination of fibrinogen concentration.</article-title>
<source>Anesth Analg</source>. <year>2020</year>;<volume>130</volume>:<fpage>644</fpage>&#x2013;<lpage>653</lpage>.<pub-id pub-id-type="pmid">31725023</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name></person-group>
<article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.</article-title>
<source>J Thromb Haemost</source>. <year>2020</year>;<volume>18</volume>:<fpage>844</fpage>&#x2013;<lpage>847</lpage>.<pub-id pub-id-type="pmid">32073213</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thachil</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Gando</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>ISTH interim guidance on recognition and management of coagulopathy in COVID-19.</article-title>
<source>J Thromb Haemost</source>. <year>2020</year>;<volume>18</volume>:<fpage>1023</fpage>&#x2013;<lpage>1026</lpage>.<pub-id pub-id-type="pmid">32338827</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molinaro</surname><given-names>RJ</given-names></name><name><surname>Szlam</surname><given-names>F</given-names></name><name><surname>Levy</surname><given-names>JH</given-names></name><name><surname>Fantz</surname><given-names>CR</given-names></name><name><surname>Tanaka</surname><given-names>KA</given-names></name></person-group>
<article-title>Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin.</article-title>
<source>Anesthesiology</source>. <year>2008</year>;<volume>109</volume>:<fpage>160</fpage>&#x2013;<lpage>161</lpage>.<pub-id pub-id-type="pmid">18580197</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group>
<article-title>Influences of argatroban on five fibrinogen assays.</article-title>
<source>Int J Lab Hematol</source>. <year>2017</year>;<volume>39</volume>:<fpage>641</fpage>&#x2013;<lpage>644</lpage>.<pub-id pub-id-type="pmid">28766891</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beiderlinden</surname><given-names>M</given-names></name><name><surname>Werner</surname><given-names>P</given-names></name><name><surname>Bahlmann</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.</article-title>
<source>BMC Anesthesiol</source>. <year>2018</year>;<volume>18</volume>:<fpage>18</fpage>.<pub-id pub-id-type="pmid">29426286</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
      <journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
      <journal-title-group>
        <journal-title>Frontiers in Immunology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1664-3224</issn>
      <publisher>
        <publisher-name>Frontiers Media S.A.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">7843371</article-id>
      <article-id pub-id-type="doi">10.3389/fimmu.2020.565869</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Immunology</subject>
          <subj-group>
            <subject>Original Research</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Significant Differences in Host-Pathogen Interactions Between Murine and Human Whole Blood</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Machata</surname>
            <given-names>Silke</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/1063320"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sreekantapuram</surname>
            <given-names>Sravya</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/866317"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>H&#xFC;nniger</surname>
            <given-names>Kerstin</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kurzai</surname>
            <given-names>Oliver</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dunker</surname>
            <given-names>Christine</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schubert</surname>
            <given-names>Katja</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kr&#xFC;ger</surname>
            <given-names>Wibke</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schulze-Richter</surname>
            <given-names>Bianca</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="author-notes" rid="fn002">
<sup>&#x2020;</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Speth</surname>
            <given-names>Cornelia</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/758100"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rambach</surname>
            <given-names>G&#xFC;nter</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/950559"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jacobsen</surname>
            <given-names>Ilse D.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
          <xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
          <xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
          <uri xlink:type="simple" xlink:href="https://loop.frontiersin.org/people/148974"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">
<sup>1</sup>
<institution>Research Group Microbial Immunology, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knoell Institute</institution>, <addr-line>Jena</addr-line>, <country>Germany</country>
</aff>
      <aff id="aff2">
<sup>2</sup>
<institution>Research Group Fungal Septomics, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knoell Institute</institution>, <addr-line>Jena</addr-line>, <country>Germany</country>
</aff>
      <aff id="aff3">
<sup>3</sup>
<institution>Institute for Hygiene and Microbiology, University of W&#xFC;rzburg</institution>, <addr-line>W&#xFC;rzburg</addr-line>, <country>Germany</country>
</aff>
      <aff id="aff4">
<sup>4</sup>
<institution>Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck</institution>, <addr-line>Innsbruck</addr-line>, <country>Austria</country>
</aff>
      <aff id="aff5">
<sup>5</sup>
<institution>Institute of Microbiology, Friedrich Schiller University Jena</institution>, <addr-line>Jena</addr-line>, <country>Germany</country>
</aff>
      <author-notes>
        <fn fn-type="edited-by">
          <p>Edited by: Markus M. Heimesaat, Charit&#xE9;-Universit&#xE4;tsmedizin Berlin, Germany</p>
        </fn>
        <fn fn-type="edited-by">
          <p>Reviewed by: Caroline N. Jones, The University of Texas at Dallas, United States; Sunil Shaw, Brown University, United States</p>
        </fn>
        <corresp id="fn001">*Correspondence: Ilse D. Jacobsen, <email xlink:href="mailto:ilse.jacobsen@leibniz-hki.de" xlink:type="simple">ilse.jacobsen@leibniz-hki.de</email>
</corresp>
        <fn fn-type="present-address" id="fn002">
          <p>&#x2020;Present address: Bianca Schulze-Richter, Institute of Immunology, Molecular Pathogenesis, Center for Biotechnology and Biomedicine (BBZ), College of Veterinary Medicine, University of Leipzig, Leipzig, Germany</p>
        </fn>
        <fn fn-type="other" id="fn003">
          <p>This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>15</day>
        <month>1</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>11</volume>
      <elocation-id>565869</elocation-id>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>5</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>11</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2021 Machata, Sreekantapuram, H&#xFC;nniger, Kurzai, Dunker, Schubert, Kr&#xFC;ger, Schulze-Richter, Speth, Rambach and Jacobsen</copyright-statement>
        <copyright-year>2021</copyright-year>
        <copyright-holder>Machata, Sreekantapuram, H&#xFC;nniger, Kurzai, Dunker, Schubert, Kr&#xFC;ger, Schulze-Richter, Speth, Rambach and Jacobsen</copyright-holder>
        <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Murine infection models are widely used to study systemic candidiasis caused by <italic>C.&#xA0;albicans</italic>. Whole-blood models can help to elucidate host-pathogens interactions and have been used for several <italic>Candida</italic> species in human blood. We adapted the human whole-blood model to murine blood. Unlike human blood, murine blood was unable to reduce fungal burden and more substantial filamentation of <italic>C. albicans</italic> was observed. This coincided with less fungal association with leukocytes, especially neutrophils. The lower neutrophil number in murine blood only partially explains insufficient infection and filamentation control, as spiking with murine neutrophils had only limited effects on fungal killing. Furthermore, increased fungal survival is not mediated by enhanced filamentation, as a filament-deficient mutant was likewise not eliminated. We also observed host-dependent differences for interaction of platelets with <italic>C. albicans</italic>, showing enhanced platelet aggregation, adhesion and activation in murine blood. For human blood, opsonization was shown to decrease platelet interaction suggesting that complement factors interfere with fungus-to-platelet binding. Our results reveal substantial differences between murine and human whole-blood models infected with <italic>C. albicans</italic> and thereby demonstrate limitations in the translatability of this <italic>ex vivo</italic> model between hosts.</p>
      </abstract>
      <kwd-group>
        <kwd>whole blood ex vivo model</kwd>
        <kwd>host-pathogen interaction</kwd>
        <kwd>
          <italic>Candida albicans</italic>
        </kwd>
        <kwd>neutrophils</kwd>
        <kwd>mice</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source id="cn001">Leibniz-Gemeinschaft<named-content content-type="fundref-id">10.13039/501100001664</named-content></funding-source>
        </award-group>
        <award-group>
          <funding-source id="cn002">Austrian Science Fund<named-content content-type="fundref-id">10.13039/501100002428</named-content></funding-source>
        </award-group>
        <award-group>
          <funding-source id="cn003">Deutsche Forschungsgemeinschaft<named-content content-type="fundref-id">10.13039/501100001659</named-content></funding-source>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="9"/>
        <table-count count="1"/>
        <equation-count count="0"/>
        <ref-count count="65"/>
        <page-count count="15"/>
        <word-count count="8807"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s1">
      <title>Introduction</title>
      <p>Dissemination of pathogens from a primary site of colonization or infection can occur <italic>via</italic> different routes, including lymphatic vessels and the blood stream (<xref rid="B1" ref-type="bibr">1</xref>). The hematogenous is by far the most frequent route for systemic infections of various bacterial and fungal pathogens, in the most severe cases leading to blood stream infections (<xref rid="B2" ref-type="bibr">2</xref>). Survival in blood can thus be considered a major virulence trait in the development of systemic infections. However, our understanding of how pathogens interact with cellular and humoral host factors in blood is limited, mainly due to technical issues: While it is relatively easy to study the interaction of pathogens with isolated blood cells, or their survival in serum or plasma, such approaches lack the complexity of interactions between different types of immune cells and additional factors, e.g., complement, present in blood. Assessing host-pathogen interactions <italic>in vivo</italic> in patients is challenging due to ethical and logistic limitations. In mice, as the most commonly used laboratory animal for <italic>in vivo</italic> experiments, the blood volume that can be withdrawn repeatedly is very limited and thereby hampers in depth analysis of interactions within blood. Furthermore, if bacteremia or fungemia occurs transiently or intermittingly, pathogens might not be detectable in every blood sample during hematogenous dissemination (<xref rid="B3" ref-type="bibr">3</xref>). Therefore, we previously established an <italic>ex vivo</italic> human whole-blood infection model that allowed us to define which immune cells interact with the human fungal pathogen <italic>Candida albicans</italic> (<xref rid="B4" ref-type="bibr">4</xref>), to identify cross-talk between different components of the host response (<xref rid="B5" ref-type="bibr">5</xref>), and to detect substantial differences between related fungal pathogens (<xref rid="B6" ref-type="bibr">6</xref>).</p>
      <p>
<italic>Candida</italic> infections (candidiasis) caused by <italic>C. albicans</italic> commonly arise from endogenous strains that colonize mucosal surfaces as a commensal in healthy individuals. Risk factors for candidiasis are microbiota imbalance, impaired mucosal barrier function, and immunosuppression (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). In the majority of cases the fungus causes relatively benign mucosal infections such as oral and vaginal candidiasis (<xref rid="B9" ref-type="bibr">9</xref>). Life-threatening infections arise from dissemination <italic>via</italic> the blood stream resulting in deep-seated or systemic candidiasis (<xref rid="B8" ref-type="bibr">8</xref>). Disseminated candidiasis is associated with high mortality rates that can exceed 50% despite antifungal therapy (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). Dissemination from the gut into internal organs can be triggered in mice by a combination of intestinal barrier disruption and immunosuppression (<xref rid="B12" ref-type="bibr">12</xref>), but the most commonly used model to study systemic candidiasis is intravenous infection of mice (<xref rid="B13" ref-type="bibr">13</xref>). This model is considered a gold standard tool for detailed investigations of fungal virulence and of host immune responses, and largely resembles catheter-associated disseminated candidiasis in men (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). However, the initial interaction of <italic>C. albicans</italic> with murine blood and its impact on the development of systemic candidiasis is not well understood. Following intravenous infection, <italic>C.&#xA0;albicans</italic> rapidly disappears from circulating peripheral blood (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>), yet it is unknown whether this is due to killing of circulating fungal cells, adhesion to endothelium, rapid invasion of internal organs, or a combination of these factors.</p>
      <p>In the human whole-blood model, neutrophils predominantly associate with and phagocytose <italic>C.&#xA0;albicans</italic> (<xref rid="B4" ref-type="bibr">4</xref>). Fungal killing in the human whole-blood model is to 98% accountable to neutrophils (<xref rid="B4" ref-type="bibr">4</xref>) and mediated by phagocytosis, degranulation and formation of extracellular traps. However, murine blood differs significantly from human blood in the abundance of neutrophils: These cells are the most abundant leukocytes in human blood (55&#x2013;70%) while murine blood is dominated by lymphocytes (70&#x2013;80%) with neutrophils accounting only for 8% to 24% of all leukocytes (<xref rid="B17" ref-type="bibr">17</xref>). To elucidate whether these differences affect interaction of <italic>C.&#xA0;albicans</italic> with whole blood, we adapted our protocol established for human blood for application to mice. Our results show significant differences between humans and mice in the <italic>ex vivo</italic> model, including lower association of the fungus with leukocytes, higher association with thrombocytes, and substantially less killing of <italic>C.&#xA0;albicans</italic> in murine blood.</p>
    </sec>
    <sec sec-type="materials|methods" id="s2">
      <title>Materials and Methods</title>
      <sec id="s2_1">
        <title>Ethics Statement</title>
        <p>Human peripheral blood was collected from healthy volunteers with written informed consent. This study was conducted in accordance with the Declaration of Helsinki and all protocols were approved by the Ethics Committee of the University Hospital Jena (permit number: 273-12/09). All animals used for the project were held in accordance with the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes and the experiments performed in accordance with European and German regulations. The sacrifice of mice for blood withdrawal was performed under &#xA7;4 &#x201C;removal of organs&#x201D; of the German Animal Welfare Act and was approved by the local animal welfare officer (no specific permit number issued). The systemic candidiasis model was approved by the Thuringian authority and ethics committee (Th&#xFC;ringer Landesamt f&#xFC;r Verbraucherschutz, permit number 03-007/13 and HKI-19-003).</p>
      </sec>
      <sec id="s2_2">
        <title>Strains and Culture Conditions</title>
        <p>
<italic>C. albicans</italic> GFP-expressing strains M137 (<xref rid="B18" ref-type="bibr">18</xref>) (pACT1-GFP) and <italic>C. albicans</italic> &#x394;<italic>efg1</italic>&#x394;<italic>cph1</italic> + pADH1-GFP were used. To construct <italic>C. albicans</italic> &#x394;<italic>efg1</italic>&#x394;<italic>cph1</italic> + pADH1-GFP a CaGFP-caSAT1 construct with homology regions for the integration into the <italic>C. albicans ADH1</italic> locus was excised with <italic>Asc</italic>I/<italic>Sac</italic>I from the plasmid pSK-ADH1prom-CaGFP-SAT1 (<xref rid="B4" ref-type="bibr">4</xref>) and then transformed into the <italic>EFG1</italic>/<italic>CPH1</italic> double mutant HLC52 (<xref rid="B19" ref-type="bibr">19</xref>). Transformation was performed with the established lithium acetate protocol (<xref rid="B20" ref-type="bibr">20</xref>). Transformants were grown for two days on YPD with 200 mg/ml nourseothricine and verified by PCR and microscopy. For experiments <italic>C. albicans</italic> over-night cultures grown in YPD medium (2% peptone, 1% yeast extract, 2% glucose) at 30&#xB0;C and 180 rpm were diluted 1:50 in YPD medium and sub-cultured for another 3 to 4&#xA0;h into the mid-log phase under the same conditions. Yeast cells were washed three times with PBS, counted and diluted in PBS to 5&#xA0;&#xD7;&#xA0;10<sup>7</sup>/ml or 5&#xA0;&#xD7;&#xA0;10<sup>6</sup>/ml, as indicated.</p>
        <p>GFP-expressing <italic>S. aureus</italic> [6850/pALC1743 (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>)] and <italic>Escherichia coli</italic> ATCC 25922 (<xref rid="B23" ref-type="bibr">23</xref>) were cultivated overnight at 37&#xB0;C, 180 rpm in LB medium. The overnight culture was inoculated 1:100 into fresh LB medium and incubated at 37&#xB0;C, 180 rpm until O.D<sub>600</sub> 0.6 to 0.7 was reached. The cultures were then washed three times with PBS and bacterial cell numbers were calculated based on OD<sub>600</sub>&#x2013;CFU correlations. Cultures were diluted to desired concentrations with PBS before inoculation of whole blood.</p>
      </sec>
      <sec id="s2_3">
        <title>Whole-Blood Model</title>
        <p>Human peripheral blood from healthy donors was collected in hirudin-monovettes (Sarstedt, Germany, 2.7&#xA0;ml volume). Hirudin was used as an anti-coagulant as it was previously shown to have no effect on complement activation (<xref rid="B24" ref-type="bibr">24</xref>). Due to their size, direct use of the hirudin-monovettes was not feasible for the collection of murine blood. Therefore, three hirudin-monovettes were rinsed with total volume of 500 &#xB5;l sterile saline (0.9% NaCl) to solubilize the hirudin. Needles and syringes rinsed with hirudin-NaCl were then used to collected blood from female BALB/c mice (8&#x2013;12 weeks old, Charles River, Germany) or from C57BL/6J mice (8&#x2013;12 weeks old, Service Unit Experimental Biomedicine, Friedrich-Schiller-University Jena, Germany) by heart puncture immediately after sacrifice by intraperitoneal application of an overdose of ketamine (500 mg/kg) and xylazin (25 mg/kg). The blood was then immediately transferred to a falcon tube containing 500 &#xB5;l hirudin-NaCl, in which blood from ten animals was pooled for each experiment. Pilot experiments analyzing fungal CFU in whole blood of female and male C57BL/6J mice revealed no sex-specific differences; thus, both male and female mice were used for the experiments.</p>
        <p>The human whole-blood infection assay was performed as described previously (<xref rid="B4" ref-type="bibr">4</xref>), and murine blood was infected in the same way. Briefly, 1/50 volume fungal or bacterial suspensions prepared as described above were added to murine or human blood, resulting in an infectious dose of 1&#xA0;&#xD7;&#xA0;10<sup>6</sup>/ml for most experiments or 1&#xA0;&#xD7;&#xA0;10<sup>5</sup>/ml for lower infection dose experiments. The incubation of the whole blood was carried out at 37&#xB0;C under slow constant motion on a rolling device (Phoenix instrument RS_TR05) for time points from 10&#xA0;min to 480&#xA0;min. Survival of the pathogens was determined by plating on agar plates (YPD for <italic>C. albicans</italic>, LB for <italic>E. coli</italic> and <italic>S. aureus</italic>) using serial dilutions in PBS and counting colony forming units. To determine the effect of ketamine/xylazin on phagocytosis and association of <italic>C. albicans</italic> with immune cells, 40 &#xB5;g/ml ketamine and 2 &#xB5;g/ml xylazin were added to human blood directly before the experiment. 40 &#xB5;g/ml ketamine is equivalent to fivefold the maximal serum concentration in mice after intraperitoneal application of 100 mg/kg ketamine (<xref rid="B25" ref-type="bibr">25</xref>).</p>
      </sec>
      <sec id="s2_4">
        <title>Blood Analysis and Flow Cytometry</title>
        <p>Generally hematology analysis of murine samples was performed using a BC-5300Vet (Mindray) configured for murine blood. For murine samples, blood smears were prepared for each time point and stained by May-Gruenwald-Giemsa staining (Roth). Filamentation and interaction with platelets were observed by light microscopy. Further analyses were performed by differential staining and subsequent measurement with a flow cytometer. For murine blood, differential staining was performed with CD45-PerCP (Cat. no. 557235, clone 30-F11, 12 &#xB5;g/ml, BD Biosciences), CD19-APC-Cy7 (Cat. no. 115530, clone 1D3; 12 &#xB5;g/ml, Biolegend) for B-cells, CD3e-V500 (Cat. no. 560771, clone 500A2, 12 &#xB5;g/ml, BD Biosciences) for T-cells, Ly6G-PE (Cat. no. 127608, clone 1A8, 12 &#xB5;g/ml final conc; Biolegend) for neutrophils, NK1.1-BV421 (for C57BL/6J mice: Cat. no. 108731, clone PK136, 12 &#xB5;g/ml, Biolegend) or CD335-BV421 (for BALB/C mice: Cat. no. 562850, Clone 29A1.4, 12 &#xB5;g/ml, BD Biosciences) for NK cells, CD11b-APC (Cat. no. 130-091-241, clone M1/70.15.11.5, 30 &#xB5;g/ml, Miltenyi) for monocytes and neutrophils, CD41 (Cat. no. 133906, clone MWReg30, 12 &#xB5;g/ml, Biolegend) for platelets, and CD69-PE vio770 (Cat. no. 130-103-944, clone H1.2F3, 30 &#xB5;g/ml, Miltenyi) and CD62-PE-Vio779 (Cat. no. 130-105-537, clone REA 344, 30 &#xB5;g/ml, Miltenyi) as platelet activation markers. In parallel, staining with the appropriate isotype controls (APC Rat IgG2b, &#x3BA; Isotype Control, clone RTK5430, Cat. no. 400611, Biolegend; V500: Syrian hamster IgG2 &#x3BA; Isotype Control, clone B81-3, Cat. no. 560785, BD Bioscience; PE: rat IgG2a &#x3BA; Isotype Control, clone RTK2758, Cat. no. 400507, Biolegend; PerCP rat IgG2b &#x3BA; Isotype Control, clone A95-1, Cat. no. 552991, BD Bioscience; APC-Cy7 rat IgG2a &#x3BA; Isotype Control, clone RTK2758, Cat. no. 400524, Biolegend; V450 rat IgG2a &#x3BA; Isotype Control, clone R35-95, Cat. no. 560377, BD Bioscience; V450 mouse IgG2a &#x3BA; Isotype Control, clone G155-178, Cat. no. 560550, BD Bioscience; PE Vio770 hamster IgG1 Isotype Control, clone G235-2356, Cat. no. 553956, BD Bioscience; PE rat IgG1 &#x3BA; Isotype Control, clone RTK2071, Cat. no. 400407, Biolegend; APC human IgG1 Isotype Control, clone QA16A12, Cat. no. 403505, Biolegend) was performed as a binding specificity control. After staining the erythrocytes were removed using the BD FACS Lysing solution and fixed samples were analyzed on a FACSVerse (BD Biosciences) flow cytometer after two washing steps in PBS supplemented with 3% FCS.</p>
        <p>Human whole-blood was analyzed with a BD FACSCanto II flow cytometer. Platelets were specifically identified by CD42b<sup>+</sup> staining (mouse anti-human CD42b-APC antibody, clone HIP-1, Cat. no. 303912, BioLegend). Co-staining with mouse anti-human CD66b-V450 antibody (clone G10F5, Cat. no. 561649, BD Bioscience) identified platelets associated with neutrophils. Activation of human platelets was investigated by changes in surface CD62P expression (mouse anti-human CD62P-PE antibody, clone AK-4, Cat. no. 555524, BD Bioscience). In parallel, staining with the appropriate isotype controls (APC mouse IgG1, &#x3BA; Isotype Ctrl, clone MOPC-21, Cat. no. 400122, BioLegend; V450 mouse IgM, &#x3BA; Isotype Control, clone G155-228, Cat. no. 560861, BD Bioscience and PE Mouse IgG1, &#x3BA; Isotype Control, clone MOPC-21, Cat. no. 555749, BD Bioscience) was performed as a binding specificity control. Stained blood samples were treated with BD FACS Lysing solution followed by washing and harvesting cells in BD CellWASH solution. FlowJo10 was used for analysis of all samples.</p>
      </sec>
      <sec id="s2_5">
        <title>Neutrophil Isolation From Murine Bone Marrow</title>
        <p>Neutrophils were isolated from bone marrow of femur and tibia of three to four female 8- to 12-week-old BALB/c mice as previously described (<xref rid="B26" ref-type="bibr">26</xref>). Briefly, bone marrow was flushed with RPMI 1640 supplemented with Penicillin/Streptomycin (Sigma) and homogenized using a 40 &#xB5;m cell strainer. Lysis of erythrocytes was carried out for 1&#xA0;min on ice using a lysis buffer containing 8 mg/ml NH<sub>4</sub>Cl, 1 mg/ml K<sub>2</sub>CO<sub>3</sub> and 0.01% EDTA. Neutrophils were purified using a Percoll gradient of 52%, 69%, and 78% in PBS and cells were collected from the 69% to 78% interface. After washing with HBSS neutrophils were resuspended in HBSS, analyzed on a BC-5300Vet (Mindray) and stored on ice until usage for a maximum of 1&#xA0;h. The purity of isolated neutrophils was roughly 70%.</p>
      </sec>
      <sec id="s2_6">
        <title>Analysis of Platelets From Mice With Systemic Candidiasis</title>
        <p>Six- to eight-week-old female speci&#xFB01;c-pathogen-free BALB/c mice (16 to 18&#xA0;g) purchased from Charles River (Germany) were housed in groups of five in individually ventilated cages with free access to food and water. Mice were infected with 2.5&#xA0;&#xD7;&#xA0;10<sup>4</sup>
<italic>C. albicans</italic> CFU/g body weight in 100 &#xB5;l DPBS <italic>via</italic> the lateral tail vein at day 0. Groups of mice were sacrificed at the indicated time points post infection by intraperitoneal application of an overdose of ketamin (500 mg/kg) and xylazin (25 mg/kg). 100 &#xB5;l of blood were collected under terminal anesthesia by retro-orbital bleeding, immediately transferred into a tube containing 10 &#xB5;l EDTA solution (1.6 mg/ml), and gently mixed. 20 &#xB5;l of the sample were analyzed on a BC-5300Vet (Mindray) to determine platelet counts and mean platelet volume. Platelet-rich plasma (RPP) was prepared from 40 &#xB5;l of whole-blood by centrifugation at 135&#xA0;g for 15&#xA0;min at room temperature. To detect platelet activation, platelets were stained for 30&#xA0;min with fluorescence-labeled antibodies (BioLegend) directed against CD41 (clone HIP8, Cat. no. 303710, 0.1 &#xB5;g/ml) as platelet marker and CD63 (clone H5C6, Cat. no. 353006, 8 &#xB5;g/ml) as activation marker, followed by fixation with 1% formaldehyde. Surface expression of CD62P, fibrinogen binding and C3c binding were determined as described for CD63 using fluorescence-labeled antibodies (CD62P: BioLegend, clone AK4, Cat. no. 304906, 1.5 &#xB5;g/ml; fibrinogen: BioRad, polyclonal, Cat. no. 4440-8004F, 100 &#xB5;g/ml; C3c: Dako, polyclonal, Cat. no. F0201, 400 &#xB5;g/ml). Non-activated unstained cells and non-activated and activated stained cells were used to calibrate the flow cytometer using single stains and combined stains. Plasma was prepared by centrifugation of 40 &#xB5;l whole-blood at 1500&#xA0;g for 15&#xA0;min at room temperature. Plasma concentrations of soluble CD62P were determined using the Quantikine<sup>&#xAE;</sup> ELISA Mouse sP-Selectin/CD62P kit (R&amp;D Systems, USA) performed according to manufacturer instructions.</p>
      </sec>
      <sec id="s2_7">
        <title>Isolation of Platelets and Confrontation Assay</title>
        <p>Venous blood of healthy human volunteers was collected in sodium citrate monovettes (Sarstedt) and directly centrifuged at 80 &#xD7; g for 20&#xA0;min (without break). Supernatants were collected and treated with 0.25 mg/ml acetylsalicylic acid (Sigma Aldrich) for 30&#xA0;min followed by addition of 1&#xA0;mM Prostaglandin E1 (Sigma Aldrich), both to prevent pre-activation of the containing platelets. Centrifugation at 400 &#xD7; g for 8&#xA0;min pelleted platelets that were afterwards suspended in HEPES-Tyrodes buffer (10 mM HEPES, 137 mM NaCl, 2.8 mM KCl, 1 mM MgCl<sub>2</sub>6H<sub>2</sub>O, 12 mM NaHCO<sub>3</sub>, 0.4 mM Na<sub>2</sub>HPO<sub>4</sub>2H<sub>2</sub>O, 5.5 mM Glucose, 0.35% BSA, without Ca<sup>2+</sup>). Purified platelets were treated again with 1 mM Prostaglandin E1, centrifuged at 400 &#xD7; g for 10&#xA0;min and suspended either in RPMI 1640 medium containing 20% autologous active or heat-inactivated plasma. Autologous human plasma was collected after centrifugation of Hirudin-anticoagulated blood from the same donor at 16,000 &#xD7; g for 10&#xA0;min. To inactivate complement proteins, autologous human plasma was incubated for 1&#xA0;h at 56&#xB0;C. Murine platelets were prepared from freshly collected blood of healthy mice as concentrates by thrombocytapheresis with Amicus cell separator (Baxter, Vienna, Austria) by the Department of Immunology and Blood Transfusion (Innsbruck Medical University, Innsbruck, Austria). The platelet concentration was determined by a hemocytometer and adjusted to a concentration of 1.2 to 1.4&#xA0;&#xD7;&#xA0;10<sup>9</sup>/ml. Murine serum was collected by centrifugation of blood samples from (i) SPF mice without any treatment, (ii) mice systemically infected with a sublethal dose of 1&#xA0;&#xD7;&#xA0;10<sup>4</sup>
<italic>C. albicans</italic> CFU/g body weight on days 8 to 21 after infection (see 2.6), (iii) C3-deficient mice (B6.129S4-C3<sup>tm1Crr</sup>/J). Pooled serum of 5 to 12 mice per group was used for experiments with isolated platelets.</p>
        <p>Confrontation of isolated platelets with <italic>C. albicans</italic> was performed at a ratio of platelets to fungal cells of 10:1 for the indicated time points (37&#xB0;C, constant rolling at 5 rpm). Mock-infected platelets with the two different media served as controls.</p>
      </sec>
      <sec id="s2_8">
        <title>Quantification of Cytokines</title>
        <p>Plasma samples were generated from whole-blood aliquots that were incubated on ice for 45&#xA0;min to 1&#xA0;h and subsequently centrifuged at 4&#xB0;C for 10&#xA0;min at 10,000 &#xD7; g. Supernatants were stored at &#x2212;80&#xB0;C until further use. Concentration of IFN-&#x3B3;, IL-1&#x3B2;, TNF-&#x3B1;, IL-6, and KC (CXCL1) in murine samples was determined by ELISA (Invitrogen, Thermo Fisher Scientific) performed according to manufacturer&#x2019;s instructions.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s3">
      <title>Results</title>
      <sec id="s3_1">
        <title>
<italic>C. albicans</italic> Survives in Murine Whole Blood</title>
        <p>The fate of <italic>C. albicans</italic> upon exposure to murine blood was analyzed in whole blood collected from two of the most commonly used mouse strains for infection experiments, BALB/c and C57BL/6J. As described by H&#xFC;nniger et al. for the human whole-blood model (<xref rid="B4" ref-type="bibr">4</xref>), whole blood was inoculated with 1&#xA0;&#xD7;&#xA0;10<sup>6</sup>/ml of yeast-grown <italic>C. albicans</italic> and fungal survival was determined by counting colony forming units (CFU) at various time points over a time course of 3&#xA0;h. In contrast to human blood in which a 50% decrease of the initial CFUs within the first hour of contact was observed (<xref rid="B4" ref-type="bibr">4</xref>), the fungal burden did not decrease during incubation in neither BALB/c nor C57BL/6J mouse blood but remained stable throughout the experiment (<xref ref-type="fig" rid="f1">
<bold>Figures 1A, B</bold>
</xref>). Of note, ketamine and xylazin were used to euthanize mice prior to blood collection. As ketamine has been shown to affect antimicrobial functions of macrophages and neutrophils in a dose-dependent manner (<xref rid="B27" ref-type="bibr">27</xref>&#x2013;<xref rid="B30" ref-type="bibr">30</xref>), we added ketamine and xylazin to human blood and quantified fungal killing. At the used dose (40 &#xB5;g/ml ketamine and 2 &#xB5;g/ml xylazin) ketamine/xylazin treatment did not affect fungal killing (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S1</bold>
</xref>).</p>
        <fig id="f1" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Survival and association of <italic>C. albicans</italic> with leukocytes in murine whole blood. Colony forming units (CFU) were determined from infected blood of BALB/c <bold>(A)</bold> and C57BL/6J <bold>(B)</bold> mice. Each dot represents the data from an independent experiment; lines represent mean &#xB1; standard deviation (n = 3, except BALB/c 90&#xA0;min and 120&#xA0;min: n = 2). <bold>(C, D)</bold> The percentage of GFP-expressing <italic>Candida</italic> binding to immune cells of blood was calculated relative to total <italic>C. albicans</italic> cells in infected blood (set to 100%) during a time course of 3&#xA0;h. All values correspond to the means of three independent experiments with pooled whole blood from 10 mice. Left: BALB/c; right: C57BL/6. <bold>(E, F)</bold> The percentage of various immune cells associated with <italic>Candida</italic> was determined relative to their overall cell population in the blood. All values correspond to the means of three independent experiments with pooled whole blood from 10 mice. Left: BALB/c; right: C57BL/6.</p>
          </caption>
          <graphic xlink:href="fimmu-11-565869-g001"/>
        </fig>
      </sec>
      <sec id="s3_2">
        <title>Less Immune Cells Interact With <italic>C. albicans</italic> in Murine Compared to Human Blood</title>
        <p>In order to determine whether the higher fungal survival in murine compared to human blood was associated with differences in the interaction with immune cells, we analyzed the number of immune cells and association of <italic>C. albicans</italic> with leukocytes. Quantification of total leukocyte numbers using a hematology analyzer showed a moderate, non-significant decline over time in both mouse strains (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S2A</bold>
</xref>). While the numbers of CD45<sup>+</sup> leukocytes in relation to all blood cells showed no obvious changes throughout the infection (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S2B</bold>
</xref>), the numbers of neutrophils decreased by almost 50% within the first 10&#xA0;min after addition of <italic>C. albicans</italic> (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S2C</bold>
</xref>). This was not the case for mock-infected control samples (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S2D</bold>
</xref>). In contrast, the number of other types of leukocytes remained stable over time (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S3</bold>
</xref>). Note that the relative abundance of neutrophils was significantly lower in the blood of B57BL/6J (4.56 &#xB1; 1.3%) than of BALB/c mice (8.63 &#xB1; 1.58%; <italic>p</italic> = 0.02).</p>
        <p>Using a strain constitutively expressing green fluorescent protein the association of <italic>C.&#xA0;albicans</italic> with leukocytes was determined by flow cytometry. Within 30&#xA0;min, more than 50% of <italic>C. albicans</italic> cells were associated with immune cells in BALB/c whole blood (<xref ref-type="fig" rid="f1">
<bold>Figure 1C</bold>
</xref>). The proportion of fungal cells associated with immune cells remained relatively stable until the end of the experiments (<xref ref-type="fig" rid="f1">
<bold>Figure 1C</bold>
</xref>). A similar trend was observed in blood of C57BL/6J mice; however, the rate of association was lower and did not exceed 40%. Surprisingly, a large proportion of <italic>C. albicans</italic> cells were found to be associated with B- and T-cells in both mouse lines (<xref ref-type="fig" rid="f1">
<bold>Figures 1C, D</bold>
</xref>). This contrasts results from the human whole-blood model in which monocytes and neutrophils were the dominant types of immune cells physically interacting with <italic>C. albicans</italic> (<xref rid="B4" ref-type="bibr">4</xref>). Since the ratio of the different immune cell populations in blood differs significantly between humans and mice, we speculated that the association to lymphocytes could be the consequence of the higher abundance of these types of immune cells in murine blood rather than the result of specific interactions. We thus calculated the percentage of host cells interacting with <italic>C. albicans</italic> within the different immune cell populations (<xref ref-type="fig" rid="f1">
<bold>Figures 1E, F</bold>
</xref>). Although only a small fraction of <italic>C. albicans</italic> cells were associated with neutrophils, up to 50% and 40% of all neutrophils associated to fungal cells in blood from BALB/c and C57BL/6J mice, respectively. In contrast, only a minor fraction of the B- and T-cell populations interacted with the fungus, suggesting that the observed association is indeed a stochastic physical event rather than the result of specific interactions.</p>
      </sec>
      <sec id="s3_3">
        <title>The Reduced Fungal Killing in Murine Blood Is Only Partially Due to Lower Neutrophil Numbers</title>
        <p>Neutrophils are the most active immune cells interacting with <italic>C. albicans</italic> in both human and murine blood, and have been shown to be critical for killing of the fungus in the human whole-blood model (<xref rid="B4" ref-type="bibr">4</xref>). However, the absolute number of neutrophils is approximately 10-fold lower in murine (0.4&#xA0;&#xD7;&#xA0;10<sup>6</sup>/ml) than human blood (4&#xA0;&#xD7;&#xA0;10<sup>6</sup>/ml; according to reference values and determined by a hematology analyzer). Using the same infection dose (1&#xA0;&#xD7;&#xA0;10<sup>6/</sup>ml) in both models thus resulted in a pathogen to neutrophil ratio of 2.5 in murine but 0.25 in human blood. We hypothesized that the higher microbe to neutrophil ratio in the murine whole-blood model overwhelmed the capacity of the neutrophils to interact with and control <italic>C.&#xA0;albicans</italic>. Therefore, we analyzed fungal survival in whole blood of BALB/c mice using a 10-fold lower infection dose (1&#xA0;&#xD7;&#xA0;10<sup>5/</sup>ml), which is comparable to the ratio used previously in human whole blood (<xref rid="B4" ref-type="bibr">4</xref>). With the reduced infection dose there was a moderate reduction of the fungal burden by 30% within 3&#xA0;h of infection (<xref ref-type="fig" rid="f2">
<bold>Figure 2A</bold>
</xref>). A similar effect was observed when murine blood was supplemented with neutrophils isolated from bone marrow to reach cell numbers comparable to human blood (4.4 &#xB1; 0.51&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L of cells, determined by a hematology analyzer) (<xref ref-type="fig" rid="f2">
<bold>Figure 2B</bold>
</xref>). Thus, both the addition of external neutrophils and the lower infection dose led to increased fungal killing, but survival of <italic>C.&#xA0;albicans</italic> after 180&#xA0;min was still substantially higher (&gt;40%) than in a human whole-blood model (10% (<xref rid="B4" ref-type="bibr">4</xref>);). Furthermore, fungal burden decreased only slowly in murine blood, whereas 50% of fungal cells were killed within the first 60&#xA0;min in human blood (<xref rid="B4" ref-type="bibr">4</xref>). To exclude effects mediated by ketamine/xylazin, ketamine and xylazin were added to human blood; this did not affect association rates with neutrophils and monocytes (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S4</bold>
</xref>).</p>
        <fig id="f2" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Increased PMN - to - <italic>Candida</italic> ratio leads to a non-significant decrease of the fungal burden after 180&#xA0;min. <bold>(A)</bold> Colony forming units were determined on YPD plates from infected blood samples at various time points for 3&#xA0;h. All values correspond to the means of three independent experiments with pooled whole blood from 10 BALB/c mice infected <italic>ex vivo</italic> with 1&#xA0;&#xD7;&#xA0;10<sup>5</sup>/ml of <italic>C. albicans::gfp</italic>. Each dot represents the mean of an independent experiment &#xB1; standard deviation (n = 3). <bold>(B)</bold> Colony forming units were counted in murine whole blood as described for <bold>(A)</bold> with the following modifications: the infection dose was 1&#xA0;&#xD7;&#xA0;10<sup>6</sup>/ml and murine whole blood was supplemented with 4.5&#xA0;&#xD7;&#xA0;10<sup>6</sup>/ml neutrophils that were previously isolated from bone marrow of BALB/c mice. Although differences between control and neutrophil supplemented blood were observed at later time points, these were not statistically significant (p&gt;0.05, Wilcoxon matched-pairs signed rank test).</p>
          </caption>
          <graphic xlink:href="fimmu-11-565869-g002"/>
        </fig>
      </sec>
      <sec id="s3_4">
        <title>Filamentation of <italic>C. albicans</italic> in Whole Blood Is Not Effectively Inhibited by Murine Neutrophils but Fungal Survival Does Not Require Filamentation</title>
        <p>The lower number of neutrophils in murine compared to human blood did not fully explain the lower killing of <italic>C. albicans</italic> in murine blood. However, functional differences between human and murine neutrophils have been described: A previous study from Ermert et al. (<xref rid="B31" ref-type="bibr">31</xref>) described a reduced efficiency of murine neutrophils to kill <italic>Candida</italic> species due to the fact that mice lack &#x3B2;-defensins and produce lower amounts of myeloperoxidase. They also showed that internalized <italic>C. albicans</italic> can escape from murine but not from human neutrophils by outgrowing neutrophils through filamentation and subsequent rupture of the neutrophil membrane (<xref rid="B31" ref-type="bibr">31</xref>). We therefore analyzed <italic>C. albicans</italic> morphology in whole blood by microscopy. Following infection with yeast cells, after 60&#xA0;min the majority of <italic>C. albicans</italic> (~70%) in murine blood were hyphae and after 180&#xA0;min nearly all (&gt;90%) fungal cells grew as filaments (<xref ref-type="fig" rid="f3">
<bold>Figure 3A</bold>
</xref>). In contrast, hyphal morphology was observed only for 10% and 20% of all <italic>C. albicans</italic> cells in human blood after 60 and 180&#xA0;min, respectively (<xref ref-type="fig" rid="f3">
<bold>Figure 3B</bold>
</xref>).</p>
        <fig id="f3" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Morphology of <italic>C. albicans</italic> in murine and human blood during the course of infection. Blood smears were prepared at the given time points and the state of fungal filamentation was determined by counting yeast or hyphae form of <italic>Candida</italic> (n = 100 per time point) on an Axioplan 2 microscope (Zeiss) after staining of cells with Mai-Gruenwald- Giemsa.</p>
          </caption>
          <graphic xlink:href="fimmu-11-565869-g003"/>
        </fig>
        <p>
<italic>C. albicans</italic> morphology has been shown to affect recognition by neutrophils (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B32" ref-type="bibr">32</xref>) and monocytes (<xref rid="B33" ref-type="bibr">33</xref>). Furthermore, while human neutrophils prevent <italic>C. albicans</italic> filamentation and escape following phagocytosis (<xref rid="B31" ref-type="bibr">31</xref>), human monocytes and macrophages do not, and intracellular filamentation leads to immune cell lysis and fungal escape (<xref rid="B34" ref-type="bibr">34</xref>). Given the higher rate of <italic>C. albicans</italic> filamentation observed in murine blood, and the role of morphology for immune escape, we used a yeast-locked <italic>C. albicans</italic> &#x394;<italic>efg1</italic>/&#x394;<italic>cph1</italic> mutant expressing GFP (<xref rid="B19" ref-type="bibr">19</xref>) in the murine whole-blood infection model to determine if the higher filamentation rate could explain higher survival of <italic>C. albicans</italic> in murine blood. Surprisingly, no decrease in CFU counts was observed with this strain and fungal numbers even increased 2.5-fold from 60 to 180&#xA0;min (<xref ref-type="fig" rid="f4">
<bold>Figure 4A</bold>
</xref>). The increasing fungal burden correlated with a decrease in CD45<sup>+</sup> cells (<xref ref-type="fig" rid="f4">
<bold>Figure 4B</bold>
</xref>), and especially neutrophils (<xref ref-type="fig" rid="f4">
<bold>Figure 4C</bold>
</xref>), at later time points (150&#xA0;min and 180&#xA0;min). The percentage of <italic>C.&#xA0;albicans</italic> &#x394;<italic>efg1</italic>/&#x394;<italic>cph1</italic> cells not associated with any of type of immune cell (~80%, <xref ref-type="fig" rid="f4">
<bold>Figure 4D</bold>
</xref>) was significantly higher compared to the wild type strain (~50%, <xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S2A</bold>
</xref>). This is in contrast to experiments with human blood, in which similar association of wild type and mutant with immune cells was observed (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). However, more than 25% of all neutrophils were associated with this mutant after 2&#xA0;h (<xref ref-type="fig" rid="f4">
<bold>Figure 4E</bold>
</xref>), and the release of cytokines upon infection with the mutant was comparable to or higher than <italic>C. albicans</italic> wild type infection (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S4</bold>
</xref>). Thus, the large number of free &#x394;<italic>efg1</italic>/&#x394;<italic>cph1</italic> cells cannot be explained by an inability of immune cells to recognize mutant yeast cells.</p>
        <fig id="f4" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Survival and immune cell association of the yeast-locked <italic>C. albicans</italic> strain &#x394;<italic>efg1</italic>&#x394;<italic>cph1</italic> + pADH1-GFP in murine whole-blood of BALB/c mice. <bold>(A)</bold> Whole blood was pooled from 10 mice and infected <italic>ex vivo</italic> with 1&#xA0;&#xD7;&#xA0;10<sup>6</sup>/ml of the GFP-expressing <italic>C. albicans</italic> mutant. CFU were determined from infected blood at indicated time points. Each dot represents the mean of an independent experiment &#xB1; standard deviation (n = 3). <bold>(B</bold>, <bold>C)</bold> Immune cell stability during the course of infection, <bold>(B)</bold> relative number CD45<sup>+</sup> cells and <bold>(C)</bold> neutrophils as % of all cells. Asterisks indicate significant differences (**<italic>p</italic>&lt;0.005, ****<italic>p</italic>&lt;0.0005; 1-Way ANOVA and Holm-Sidak&#x2019;s multiple comparison test to compare each infected time point to 0&#xA0;min). <bold>(D)</bold> The percentage of GFP-expressing <italic>Candida</italic> binding to immune cells was calculated relative to total <italic>C. albicans</italic> cells in infected blood (set to 100%) during a time course of 3&#xA0;h. All values correspond to the means of three independent experiments with pooled whole blood from 10 mice. <bold>(E)</bold> The percentage of various immune cells associated with <italic>Candida</italic> was determined relative to their overall cell population in the blood. All values correspond to the means of three independent experiments with pooled whole blood from 10 mice.</p>
          </caption>
          <graphic xlink:href="fimmu-11-565869-g004"/>
        </fig>
      </sec>
      <sec id="s3_5">
        <title>Rapid Platelet Aggregation and Activation in Murine Blood Upon Exposure to <italic>C. albicans</italic>
</title>
        <p>In addition to fungal filamentation, microscopic analysis revealed aggregates of platelets around <italic>C.&#xA0;albicans</italic> cells (<xref ref-type="fig" rid="f5">
<bold>Figure 5A</bold>
</xref>). This interaction was confirmed and quantified by flow cytometry (<xref ref-type="fig" rid="f5">
<bold>Figure 5B</bold>
</xref>): Within 10&#xA0;min almost 60% of <italic>C. albicans</italic> cells were associated with platelets. The association rate slowly decreased over time to 40% after 3&#xA0;h. At early time points, over 35% of the fungal-associated platelets expressed the activation marker CD69 on their surface (<xref ref-type="fig" rid="f5">
<bold>Figure 5C</bold>
</xref>). We also observed increased expression of CD62 on the surface of <italic>C. albicans</italic> bound platelets, however in only 20% of all platelets (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S6</bold>
</xref>). To exclude that platelet activation was an artefact of the <italic>ex vivo</italic> situation, blood samples of intravenously (i. v.) infected mice were analyzed. <italic>In vivo</italic>, platelet counts increased significantly over a course of three days post infection (<xref ref-type="fig" rid="f6">
<bold>Figure 6A</bold>
</xref>). Transient platelet activation was observed at 6&#xA0;h post infection characterized by a significant increase of complement C3c, indicating opsonization, the platelet aggregation factor fibrinogen, and the activation markers CD63 and CD62P on the surface of platelets (<xref ref-type="fig" rid="f6">
<bold>Figures 6B&#x2013;E</bold>
</xref>). While at later time points expression of these markers was comparable to control samples, increased concentrations of soluble CD62 were detectable in the plasma of infected mice from 1 to 3 days post infection by ELISA (<xref ref-type="fig" rid="f6">
<bold>Figure 6F</bold>
</xref>). Taken together, these data demonstrate interaction and activation of platelets following infection with <italic>C.&#xA0;albicans</italic> in murine blood <italic>ex vivo</italic> and <italic>in vivo</italic>.</p>
        <fig id="f5" position="float">
          <label>Figure 5</label>
          <caption>
            <p>
<italic>C</italic>. <italic>albicans</italic>-induced platelet activation and aggregation <bold>(A)</bold> Fungal interactions with platelets were visualized in blood smears of <italic>ex vivo</italic> infected murine whole blood after staining with Mai-Gruenwald- Giemsa. Aggregates of thrombocytes (black arrow) surround <italic>Candida</italic> (white arrow) mostly during the first hour of infection. Flow cytometry analysis shows <bold>(B)</bold> strong binding of <italic>C. albicans</italic> to platelets almost immediately after infection and <bold>(C)</bold> induced expression of CD69 on the surface of platelets. Asterisks indicate significant differences (<italic>p</italic>&lt;0.05; 1-Way ANOVA and Holm-Sidak&#x2019;s multiple comparison test to compare each infected time point to 0&#xA0;min).</p>
          </caption>
          <graphic xlink:href="fimmu-11-565869-g005"/>
        </fig>
        <fig id="f6" position="float">
          <label>Figure 6</label>
          <caption>
            <p>Platelet activation in mice systemically infected with <italic>C. albicans</italic>. <bold>(A)</bold> The number of circulating platelets in peripheral murine blood was determined with an automated hematology analyzer. Deposition of complement factor C3 <bold>(B)</bold>, fibrinogen <bold>(C)</bold>, and surface expression of CD63 <bold>(D)</bold> and CD62P <bold>(E)</bold> was quantified by flow cytometry. <bold>(F)</bold> Soluble CD62 was measured in plasma by ELISA. CTRL: Samples from non-infected control animals. Time on X axis: Time after infection. Four to seven samples were analyzed per time point, data is presented as individual data points with bars indicating the mean &#xB1; standard deviation. Asterisks indicate significant differences (<italic>p</italic>&lt;0.05; 1-Way ANOVA and Holm-Sidak&#x2019;s multiple comparison test to compare each infected group to the control).</p>
          </caption>
          <graphic xlink:href="fimmu-11-565869-g006"/>
        </fig>
      </sec>
      <sec id="s3_6">
        <title>Opsonization of <italic>C. albicans</italic> in Human Blood Leads to Low Platelet Association</title>
        <p>Our next aim was to determine if interaction with thrombocytes also occurs in human blood. Consistent with previous findings (<xref rid="B4" ref-type="bibr">4</xref>), we observed decreasing numbers of <italic>C. albicans</italic> cells not associated with host cells in human blood over time (<xref ref-type="fig" rid="f7">
<bold>Figure 7A</bold>
</xref>). Only a small proportion (less than 10%) of fungal cells directly associated with platelets (<xref ref-type="fig" rid="f7">
<bold>Figure 7B</bold>
</xref>). This was in sharp contrast to the results we obtained in murine blood. To investigate the potential influence of human blood components on fungal-platelet interaction, confrontation of isolated human platelets with <italic>C. albicans</italic> cells was performed in the presence of non-treated (active) or heat-inactivated autologous plasma and showed a time-dependent increase in platelet-<italic>C. albicans</italic> interaction when plasma proteins were inactivated (<xref ref-type="fig" rid="f7">
<bold>Figure 7C</bold>
</xref>). In contrast, the presence of non-treated plasma containing active complement proteins resulted in a low platelet association. Consequently, we tested if opsonization of fungal cells interferes with platelet binding. Indeed, pre-opsonized <italic>C. albicans</italic> showed a significantly reduced interaction with isolated platelets compared to non-opsonized <italic>C. albicans</italic> (<xref ref-type="fig" rid="f7">
<bold>Figure 7D</bold>
</xref>) indicating that opsonization of extracellular <italic>C. albicans</italic> during human whole-blood infection prevents the binding of platelets. In a comparable experiment using isolated murine thrombocytes and murine serum, active but not inactive serum significantly increased the binding of thrombocytes to <italic>C. albicans</italic> (<xref ref-type="fig" rid="f8">
<bold>Figure 8A</bold>
</xref>).</p>
        <fig id="f7" position="float">
          <label>Figure 7</label>
          <caption>
            <p>Interaction of human platelets with <italic>C. albicans</italic> during whole-blood infection is influenced by complement opsonization. <bold>(A)</bold> The percentage of extracellular <italic>C.&#xA0;albicans</italic> during human whole-blood infection was investigated <italic>via</italic> flow cytometry and calculated relative to total fungal cells in blood (set to 100%) of five independent experiments with blood from different donors. A steady reduction of extracellular fungi over time was observed (1-Way ANOVA and Test for linear trend, <italic>p</italic>&lt;0.0001). <bold>(B)</bold> Less than 10% of extracellular <italic>C. albicans</italic> cells showed a CD42b<sup>+</sup> staining at each time point, reflecting a low platelet binding to <italic>C</italic>. <italic>albicans</italic> in human whole-blood (n = 5). <bold>(C)</bold> Isolated human platelets were confronted with <italic>C. albicans</italic> either in the presence of non-treated (active plasma) or heat-inactivated autologous plasma (inactive plasma). Co-incubation in medium containing active plasma prevented the time-dependent increase in platelet-<italic>C. albicans</italic> interaction as observed for heat-inactivated plasma. Significantly less CD42b-positive fungal cells were observed with active compared to inactive plasma at each time point (unpaired, two-tailed t-test, p&lt;0.0001, n = 7). <bold>(D)</bold>
<italic>C. albicans</italic> cells were either pre-incubated in non-treated (C3b-opsonized <italic>C. albicans</italic>) or heat-inactivated autologous plasma (non-opsonized <italic>C. albicans</italic>, no surface C3b) before confrontation with isolated human platelets in medium with inactive plasma for 1&#xA0;h. Opsonization of <italic>C. albicans</italic> resulted in a markedly lower association with platelets compared non-opsonized <italic>C. albicans</italic> (<italic>p</italic> = 0.035, unpaired, two-tailed t-test).</p>
          </caption>
          <graphic xlink:href="fimmu-11-565869-g007"/>
        </fig>
        <fig id="f8" position="float">
          <label>Figure 8</label>
          <caption>
            <p>Interaction of isolated murine platelets with <italic>C. albicans</italic>. <bold>(A)</bold> Binding of isolated platelets to <italic>C. albicans</italic> cells in the presence of heat-inactivated serum (inactive serum) or non-treated serum (active serum). The percentage of CD41-positive C. albicans cells was determined after 1&#xA0;h by flow cytometry. Active serum led to a significantly higher interaction with platelets compared inactive serum and a control without serum (asterisks indicate significant differences (<italic>p</italic>&lt;0.05) determined by 1-Way ANOVA and Holm-Sidak&#x2019;s multiple comparison test for pairwise comparisons of all groups). <bold>(B)</bold> Binding of isolated platelets to <italic>C. albicans</italic> cells in the presence of active serum from na&#xEF;ve mice, serum of mice collected after infection with <italic>C. albicans</italic> (reconvalescent) and serum from na&#xEF;ve C3-deficient mice analyzed after 1&#xA0;h and 2&#xA0;h. Reconvalescent serum led to significantly lower binding (significance determined by 1-Way ANOVA and Holm-Sidak&#x2019;s multiple comparison test for pairwise comparisons of all groups within one time point and indicated by asterisks).</p>
          </caption>
          <graphic xlink:href="fimmu-11-565869-g008"/>
        </fig>
        <p>The observation that inactivation of human plasma increases interaction of thrombocytes with <italic>C.&#xA0;albicans</italic> suggests that complement factors interfere with binding of human platelets to the fungus. While it remains unclear how complement becomes activated in active human plasma upon contact with <italic>C. albicans</italic>, the classical, antibody-mediated complement activation pathway might be involved. Specific-pathogen free mice, as used in this study, are usually not colonized by <italic>C. albicans</italic> (<xref rid="B35" ref-type="bibr">35</xref>) and show comparatively low colonization with fungi (<xref rid="B36" ref-type="bibr">36</xref>), resulting in very low detectable anti-<italic>Candida</italic> antibodies in SPF mice (<xref rid="B37" ref-type="bibr">37</xref>). Thus, due to the absence of antibodies, whole murine blood and serum might lack the level of opsonization mediated by normal human plasma and, in consequence, lower opsonization could result in higher interaction with platelets. To test this hypothesis, we compared the binding of isolated thrombocytes to <italic>C albicans</italic> in the presence of active serum from normal SPF mice (na&#xEF;ve mice) and mice that survived a sublethal systemic <italic>C. albicans</italic> infection (reconvalescent mice). The binding of thrombocytes to fungal cells was significantly higher with serum from na&#xEF;ve mice; furthermore, na&#xEF;ve serum and serum from C3-deficient mice induced similar binding of thrombocytes to <italic>C. albicans</italic> (<xref ref-type="fig" rid="f8">
<bold>Figure 8B</bold>
</xref>), supporting the hypothesis that the lack of prior contact to the fungus in SPF mice contributes to the observed differences between human and murine whole blood regarding interaction with thrombocytes.</p>
      </sec>
      <sec id="s3_7">
        <title>Whole Murine Blood Is Not Able to Clear Bacterial Infections <italic>Ex Vivo</italic>
</title>
        <p>In order to determine whether the inability of murine blood to control infections <italic>ex vivo</italic> is restricted to <italic>C. albicans</italic>, we performed infections with <italic>S. aureus</italic> and <italic>E. coli</italic> as models for Gram-positive and Gram-negative bacteria, respectively. Similar to our observations with the filament-deficient <italic>C. albicans</italic> strain, CFU counts for both bacterial pathogens remained stable for the first 90&#xA0;min followed by a steady increase (<xref ref-type="fig" rid="f9">
<bold>Figure 9A</bold>
</xref>). This increase in pathogen load was even more pronounced than that observed for <italic>C. albicans</italic> &#x394;<italic>efg1</italic> &#x394;<italic>cph1</italic> (<xref ref-type="fig" rid="f4">
<bold>Figure 4A</bold>
</xref>), and was also seen with a 10-fold lower infection dose, albeit at a lesser extent (<xref ref-type="supplementary-material" rid="SM1">
<bold>Figure S7</bold>
</xref>). Also similar to infection with the yeast-locked <italic>C. albicans</italic> mutant was the reduction of leukocyte numbers (<xref ref-type="fig" rid="f9">
<bold>Figure 9B</bold>
</xref>), and for <italic>S. aureus</italic> especially neutrophil counts (<xref ref-type="fig" rid="f9">
<bold>Figure 9C</bold>
</xref>), at late time points. The association of bacteria to immune cells varied quite drastically between both bacterial strains: While almost 60% of neutrophils were rapidly bound to <italic>S. aureus</italic> within 10&#xA0;min and almost all neutrophils were attached to these Gram-positive bacteria 1.5&#xA0;h post infection (<xref ref-type="fig" rid="f9">
<bold>Figure 9D</bold>
</xref>), bacterial host cell association occurred much later for <italic>E.&#xA0;coli</italic> and a maximum of 50% of neutrophils were attached to bacteria at 2&#xA0;h post infection (<xref ref-type="fig" rid="f9">
<bold>Figure 9E</bold>
</xref>).</p>
        <fig id="f9" position="float">
          <label>Figure 9</label>
          <caption>
            <p>Bacterial survival and immune cell association in murine whole blood. <bold>(A)</bold> Colony forming units of <italic>S. aureus</italic> and <italic>E. coli</italic> were determined from infected murine blood. All values correspond to the means of three independent experiments with pooled whole-blood from 10 BALB/c mice infected <italic>ex vivo</italic> with 1&#xA0;&#xD7;&#xA0;10<sup>6</sup>/ml of GFP-expressing bacteria. Each dot represents the mean of an independent experiment +/- standard deviation (n = 3). The relative numbers of CD45<sup>+</sup> cells <bold>(B)</bold> and of <bold>(C)</bold> neutrophils (Ly6G<sup>+</sup>/CD11b<sup>+</sup>) during the course of infection were measured by flow cytometry. <bold>(D)</bold> The percentage of various immune cells associated with GFP-expressing <italic>S. aureus</italic> or <bold>(E)</bold> with GFP-expressing <italic>E. coli</italic> was determined relative to their overall cell population in the blood. All values correspond to the means of three independent experiments with pooled whole blood from 10 mice.</p>
          </caption>
          <graphic xlink:href="fimmu-11-565869-g009"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s4">
      <title>Discussion</title>
      <p>Intravenous infection of mice is the most commonly used model to study candidiasis (<xref rid="B13" ref-type="bibr">13</xref>). It is known that <italic>C. albicans</italic> disappears quickly from circulating blood within a few minutes to hours after infection (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B38" ref-type="bibr">38</xref>), but the mechanisms underlying this phenomenon and the fungal interaction with blood components are not fully understood. We have previously employed a human whole-blood model to determine the interaction of <italic>C. albicans</italic> with leukocytes and the fate of the fungus. In this study, the model was adapted to mice to elucidate host-fungal interactions in whole blood over a period of 3&#xA0;h.</p>
      <p>One of the most striking differences observed between the murine and human whole-blood experiments was the lack of <italic>C. albicans</italic> killing in murine blood, both at the infectious dose used in our previous study on human blood (1&#xA0;&#xD7;&#xA0;10<sup>6</sup>/ml) and at a 10-fold lower dose (1 x 10<sup>5</sup>/ml). A commonly used infectious dose in the intravenous mouse model is 2.5&#xA0;&#xD7;&#xA0;10<sup>4</sup> CFU/g body weight, equivalent to 5&#xA0;&#xD7;&#xA0;10<sup>5</sup> CFU for a 20&#xA0;g mouse (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B16" ref-type="bibr">16</xref>). The approximate blood volume of a 20&#xA0;g mouse is 1.6&#xA0;ml (<xref rid="B39" ref-type="bibr">39</xref>), resulting in approximately 3&#xA0;&#xD7;&#xA0;10<sup>5</sup> CFU injected per ml of blood. Thus, the doses used in this study are relevant for the <italic>in vivo</italic> mouse model. Consequently, the inability of murine blood to effectively eliminate the fungus cannot be explained by an inadequately high infectious dose. Furthermore, as comparable results were obtained with blood from BALB/c and C57BL/6 mice, low fungal killing is unlikely to be a consequence of the specific genetic background.</p>
      <p>Differences were also observed in the interaction with immune cells: A higher proportion of fungal cells was not associated to any leukocytes in murine (40&#x2013;50%) compared to human blood (10&#x2013;20% (<xref rid="B4" ref-type="bibr">4</xref>),). Especially the proportion of <italic>C. albicans</italic> cells associated with neutrophils was substantially lower in mouse blood (&lt;30% compared to &gt;60% (<xref rid="B4" ref-type="bibr">4</xref>),). Neutrophils are known to be the major effector cells mediating <italic>C.&#xA0;albicans</italic> killing in human whole-blood infection (<xref rid="B4" ref-type="bibr">4</xref>), and they are essential for host defense against disseminated candidiasis both in humans (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>) and mice (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). It is unlikely that the low number of <italic>C.&#xA0;albicans</italic> interacting with neutrophils is due to insufficient recognition, as the high proportion of neutrophils associated with <italic>C. albicans</italic> indicated that these leukocytes responded to the fungus. The lower absolute numbers, however, lead to a pathogen-to-neutrophil ratio that might have been too high to allow efficient infection control. Contrary to this hypothesis, reducing the infectious dose did not substantially increase fungal killing. It is possible that the abundance of other immune cells blocked physical contact between neutrophils and <italic>Candida</italic>. Consistent with this, many fungal cells were associated with lymphocytes during high dose infection, even though the proportion of lymphocytes interacting with <italic>Candida</italic> was low, indicating limited directed activity. We therefore increased the absolute number of murine neutrophils to that in human blood, thereby also altering the neutrophil-lymphocyte ratio. As this had only a minor impact on fungal killing, functional differences between murine and human immune cells are likely to contribute to fungal survival in murine blood.</p>
      <p>While human and murine neutrophils share many characteristics, they differ in some functional aspects. For example, murine neutrophils do not produce defensins (<xref rid="B44" ref-type="bibr">44</xref>), express less myeloperoxidase and lysozyme (<xref rid="B45" ref-type="bibr">45</xref>), and differ in the expression and production of pattern recognition receptors, cytokines, and chemokines [summarized in (<xref rid="B46" ref-type="bibr">46</xref>)]. Ermert et&#xA0;al. showed that this translates into functional differences: Isolated murine neutrophils were less efficient in killing <italic>C.&#xA0;albicans in vitro</italic> than their human counterparts (<xref rid="B31" ref-type="bibr">31</xref>). Furthermore, while neutrophils were shown to be responsible for preventing hyphae development in human blood (<xref rid="B18" ref-type="bibr">18</xref>), isolated murine neutrophils fail to inhibit filamentation of phagocytosed yeast, resulting in fungal escape (<xref rid="B31" ref-type="bibr">31</xref>). Consistent with this, we observed substantial filamentation of <italic>C. albicans</italic> in murine, but not human blood. Thus, the higher filamentation rate in murine blood might be the consequence of an inability of murine neutrophils to control filamentation not only <italic>in vitro</italic> but also in the more complex <italic>ex vivo</italic> model. Killing of neutrophils by <italic>C. albicans</italic> filamentation after phagocytosis would furthermore explain the decline of neutrophil numbers over time in infected murine blood. However, extracellular filamentation has been shown to also occur in human blood (<xref rid="B4" ref-type="bibr">4</xref>), and we can therefore not exclude that the increased filamentation observed in murine blood is due to the lower number of fungal cells interacting with immune cells.</p>
      <p>Although long filaments are more difficult to phagocytose due to their size (<xref rid="B47" ref-type="bibr">47</xref>), it is unlikely that filamentation alone is responsible for the lack of fungal killing, as survival and even proliferation in murine whole blood was observed for a filament-deficient <italic>C.&#xA0;albicans</italic> mutant. This was surprising because mutants lacking either of the genes (<italic>EFG1</italic> and <italic>CPH1</italic>) deleted in the mutant used here were previously reported to display reduced survival in human blood (<xref rid="B18" ref-type="bibr">18</xref>), and the double mutant is avirulent in a systemic mouse infection model (<xref rid="B48" ref-type="bibr">48</xref>). The association rate of this mutant with leukocytes was however lower compared to wild type fungi (&lt;25% compared to up to 50%). This is indicative of lower phagocytosis rates and likely leads to less phagocytosis-dependent fungal killing. The lower association rates could be due to the generally less efficient recognition of yeast <italic>versus</italic> hyphal cells by neutrophils (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B49" ref-type="bibr">49</xref>). The specific gene deletions furthermore affect the exposure of cell wall components serving as pathogen-associated molecular patterns (<xref rid="B50" ref-type="bibr">50</xref>&#x2013;<xref rid="B52" ref-type="bibr">52</xref>). As the percentage of neutrophils interacting with the non-filamentous mutant was however only slightly less than for the wild type, it appears unlikely that altered recognition alone is responsible for proliferation of the filament-deficient mutant. This is supported by the cytokine measurements that demonstrate similar or higher responses of murine whole blood to the mutant compared to the wildtype, and is consistent with the higher cytokine release by monocytes and PBMCs in response to yeast cells observed by others (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B53" ref-type="bibr">53</xref>).</p>
      <p>While our results overall suggest a very limited capacity of murine neutrophils to control <italic>C.&#xA0;albicans</italic> in murine blood, it should be noted that we observed a reduction of fungal burden at late time points in murine whole blood with added neutrophils. Although not statistically significant, this is in agreement with other studies demonstrating some efficacy of isolated murine neutrophils against this fungus (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B54" ref-type="bibr">54</xref>). In this context it should be noted that neutrophils are primed during recruitment to a site of inflammation, leading to increased expression of pattern recognition receptors and enhanced effector functions (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). Thus, the limited impact of neutrophils in murine whole blood cannot be transferred to neutrophil efficacy in tissue <italic>in vivo</italic>. However, our results suggest that the rapid decline of <italic>C. albicans</italic> CFU numbers in the peripheral blood of intravenously infected mice is not due to fungal killing within circulating blood. Possibly, interaction between <italic>C.&#xA0;albicans</italic> and murine blood leukocytes <italic>in vivo</italic> occurs only after fungal attachment to endothelial cells (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>).</p>
      <p>Host-dependent differences in the interaction of <italic>C. albicans</italic> with leukocytes were also observed for platelets: In the murine whole-blood model, aggregation of platelets around and adhesion to fungal cells was observed which was associated with platelet activation. Transient activation of platelets was also observed <italic>in vivo</italic> in mice, consistent with previous observations by others (<xref rid="B38" ref-type="bibr">38</xref>). In contrast, only few platelets associated with <italic>C.&#xA0;albicans</italic> in human blood, supporting recent findings by Eberl et al. (<xref rid="B59" ref-type="bibr">59</xref>). The absence of the formation of obvious platelet aggregates around fungal elements in human blood is consistent with other studies (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B61" ref-type="bibr">61</xref>), and might be mediated by fungal chitin (<xref rid="B62" ref-type="bibr">62</xref>). Importantly, others showed that only those human platelets that bound to <italic>C. albicans</italic> became activated (<xref rid="B59" ref-type="bibr">59</xref>). The low number of bound platelets likely results in a very small increase of activation in the overall platelet population. This could explain why several studies described that this fungus does not activate human platelets (<xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>), whereas we detected a significant increase of released platelet effector molecules. Interestingly, we found that the physical interaction between <italic>C.&#xA0;albicans</italic> and human platelets was enhanced by plasma inactivation, suggesting that complement factors interfere with binding of human platelets to the fungus. In this context our observation that prior exposure of mice to <italic>C. albicans</italic> significantly affected the impact of their serum on the rate of interaction between the fungus and thrombocytes might be of relevance not only for this, but also for other studies and might have implications beyond <italic>C. albicans</italic> infection: SPF mice, which are commonly used to study infections, lack contact to common opportunistic pathogens and thus adaptive immune response to these microbes. As demonstrated here, this could explain some of the differences observed between mice and men, and might also contribute to the limited efficacy of murine whole blood to eliminate <italic>E. coli</italic> and <italic>S. aureus</italic> shown in this study. Even though <italic>S. aureus</italic> has been isolated from laboratory SPF mice colonies, over 70% of tested animals were found to be free of this opportunistic pathogen (<xref rid="B65" ref-type="bibr">65</xref>). It can also be assumed that SPF mouse colonies are free from pathogenic <italic>E. coli</italic> and thus na&#xEF;ve to the strain used in this study. Further research is clearly needed to investigate to which extent the lack of prior exposure affects host responses of mice in infection models.</p>
      <p>In summary, we present here a thorough analysis of host-pathogen interaction in a murine whole-blood model, the first point of fungal interaction with the host immune system in experimental candidiasis, and provide time-resolved data on fungal survival and association to immune cells. Our results indicate substantial differences to the host-fungal interactions shown in a human whole-blood model (summarized in <xref rid="T1" ref-type="table">
<bold>Table 1</bold>
</xref>), thereby limiting the translatability of data obtained in a murine whole-blood model to human infections&#x2014;even though the murine systemic infection model recapitulates several important aspects of systemic infection in humans. This could be at least in part due to the lack of <italic>C.&#xA0;albicans</italic> colonization of SPF mice.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Summary of the key differences between the murine and human whole-blood model for <italic>C. albicans</italic>.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="center" rowspan="1" colspan="1"/>
              <th valign="top" align="center" rowspan="1" colspan="1">Murine whole blood</th>
              <th valign="top" align="center" rowspan="1" colspan="1">Human whole blood</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold><italic>C. albicans</italic> killing</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Not detectable</td>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2265;50% within 60&#xA0;min, &#x2265;80% within 180&#xA0;min (<xref rid="B4" ref-type="bibr">4</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Association <italic>C. albicans</italic> with leukocytes</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Approx. 40&#x2013;60% max. (mouse strain-dependent)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Approx. 80% max (<xref rid="B4" ref-type="bibr">4</xref>).</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;<bold>Association with neutrophils relative to all leukocytes</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2265;50% (time point-dependent)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2265;80% (<xref rid="B4" ref-type="bibr">4</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>&#x2003;Association with monocytes relative to all leukocytes</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2265;25% (time point-dependent)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2264;15% (<xref rid="B4" ref-type="bibr">4</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>&#x2003;Association with lymphocytes relative to all leukocytes</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2265;50% (time point-dependent)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Not detectable (<xref rid="B4" ref-type="bibr">4</xref>)</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>% association neutrophils with <italic>C. albicans</italic></bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">40&#x2013;50% (mouse strain-dependent)</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Not determined</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Filamentation (% hyphae)</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2265;60% after 60&#xA0;min; &#x2265; 90% after 180 min</td>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2264;10% after 60&#xA0;min; &#x2264;20% after 180 min</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">
<bold>Interaction with platelets</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2003;<bold><italic>C. albicans</italic> association with platelets in whole blood</bold>
</td>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2264;60% after 10&#xA0;min; 40% after 180 min</td>
              <td valign="top" align="left" rowspan="1" colspan="1">&#x2264;10%</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec sec-type="data-availability" id="s5">
      <title>Data Availability Statement</title>
      <p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding author.</p>
    </sec>
    <sec id="s6">
      <title>Ethics Statement</title>
      <p>The studies involving human participants were reviewed and approved by Ethics Committee of the University Hospital Jena, permit number: 273-12/09. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Th&#xFC;ringer Landesamt f&#xFC;r Verbraucherschutz, permit number 03-007/13 and HKI-19-003.</p>
    </sec>
    <sec id="s7">
      <title>Author Contributions</title>
      <p>SM, SS, IJ, BS-R, OK, KH, and CS conceived the study. SM, SS, CD, KS, WK, KH, CS, and GR performed the experiments. SM, KH, CS, and IJ analyzed the data. SM, CD, and IJ drafted the manuscript. SM, SS, KH, OK, CD, KS, WK, BS-R, CS, GR, and IJ revised and approved the manuscript. All authors contributed to the article and approved the submitted version.</p>
    </sec>
    <sec sec-type="funding-information" id="s8">
      <title>Funding</title>
      <p>Part of this project was funded by the funding line Strategic Networking in the Leibniz Association within the framework of the Leibniz Science Campus &#x201C;InfectoOptics&#x201D; (Project BLOODi to IJ) in Jena. CS was supported by the FWF Austrian Science Fund (Project Nr. P26117-B20). Work in the lab of OK and IJ was supported by the German Research Foundation (DFG; TRR 124 FungiNet, &#x201C;Pathogenic fungi and their human host: Networks of Interaction,&#x201D; DFG project number 210879364, Project C3 to OK and C5 to IJ). Funders had no role in study design, analyses and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.</p>
    </sec>
    <sec sec-type="COI-statement" id="s9">
      <title>Conflict of Interest</title>
      <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank Joanna M. Niemiec for help with neutrophil isolation, and Phillipp Kaemmer for technical assistance. SS is a member of the Jena School for Microbial Communication (JSMC).</p>
    </ack>
    <sec id="s10" sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2020.565869/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2020.565869/full#supplementary-material</ext-link></p>
      <supplementary-material content-type="local-data" id="SM1">
        <media xlink:href="DataSheet_1.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Watson</surname><given-names>KG</given-names></name><name><surname>Holden</surname><given-names>DW</given-names></name></person-group>
<article-title>Dynamics of growth and dissemination of <italic>Salmonella in vivo</italic>
</article-title>. <source>Cell Microbiol</source> (<year>2010</year>) <volume>12</volume>:<page-range>1389&#x2013;97</page-range>. <pub-id pub-id-type="doi">10.1111/j.1462-5822.2010.01511.x</pub-id>
</mixed-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez</surname><given-names>RM</given-names></name><name><surname>Wolk</surname><given-names>DM</given-names></name></person-group>
<article-title>Bloodstream Infections</article-title>. <source>Microbiol Spectr</source> (<year>2016</year>) <volume>4</volume>. <pub-id pub-id-type="doi">10.1128/microbiolspec.DMIH2-0031-2016</pub-id>
</mixed-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reimer</surname><given-names>LG</given-names></name><name><surname>Wilson</surname><given-names>ML</given-names></name><name><surname>Weinstein</surname><given-names>MP</given-names></name></person-group>
<article-title>Update on detection of bacteremia and fungemia</article-title>. <source>Clin Microbiol Rev</source> (<year>1997</year>) <volume>10</volume>:<page-range>444&#x2013;65</page-range>. <pub-id pub-id-type="doi">10.1128/CMR.10.3.444</pub-id>
</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>H&#xFC;nniger</surname><given-names>K</given-names></name><name><surname>Lehnert</surname><given-names>T</given-names></name><name><surname>Bieber</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name><name><surname>Figge</surname><given-names>MT</given-names></name><name><surname>Kurzai</surname><given-names>O</given-names></name></person-group>
<article-title>A virtual infection model quantifies innate effector mechanisms and <italic>Candida albicans</italic> immune escape in human blood</article-title>. <source>PLoS Comput Biol</source> (<year>2014</year>) <volume>10</volume>:<fpage>e1003479</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pcbi.1003479</pub-id>
<pub-id pub-id-type="pmid">24586131</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>H&#xFC;nniger</surname><given-names>K</given-names></name><name><surname>Bieber</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name><name><surname>Lehnert</surname><given-names>T</given-names></name><name><surname>Figge</surname><given-names>MT</given-names></name><name><surname>L&#xF6;ffler</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a</article-title>. <source>J Immunol (Baltimore Md: 1950)</source> (<year>2015</year>) <volume>194</volume>:<page-range>1199&#x2013;210</page-range>. <pub-id pub-id-type="doi">10.4049/jimmunol.1401845</pub-id>
</mixed-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duggan</surname><given-names>S</given-names></name><name><surname>Essig</surname><given-names>F</given-names></name><name><surname>H&#xFC;nniger</surname><given-names>K</given-names></name><name><surname>Mokhtari</surname><given-names>Z</given-names></name><name><surname>Bauer</surname><given-names>L</given-names></name><name><surname>Lehnert</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Neutrophil activation by <italic>Candida glabrata</italic> but not <italic>Candida albicans</italic> promotes fungal uptake by monocytes</article-title>. <source>Cell Microbiol</source> (<year>2015</year>) <volume>17</volume>:<page-range>1259&#x2013;76</page-range>. <pub-id pub-id-type="doi">10.1111/cmi.12443</pub-id>
</mixed-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Viscoli</surname><given-names>C</given-names></name></person-group>
<article-title>Bloodstream Infections: The peak of the iceberg</article-title>. <source>Virulence</source> (<year>2016</year>) <volume>7</volume>:<page-range>248&#x2013;51</page-range>. <pub-id pub-id-type="doi">10.1080/21505594.2016.1152440</pub-id>
</mixed-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pappas</surname><given-names>PG</given-names></name><name><surname>Lionakis</surname><given-names>MS</given-names></name><name><surname>Arendrup</surname><given-names>MC</given-names></name><name><surname>Ostrosky-Zeichner</surname><given-names>L</given-names></name><name><surname>Kullberg</surname><given-names>BJ</given-names></name></person-group>
<article-title>Invasive candidiasis</article-title>. <source>Nat Rev Dis Primers</source> (<year>2018</year>) <volume>4</volume>:<fpage>18026</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2018.26</pub-id>
<pub-id pub-id-type="pmid">29749387</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vazquez</surname><given-names>JA</given-names></name><name><surname>Sobel</surname><given-names>JD</given-names></name></person-group>
<article-title>Mucosal candidiasis</article-title>. <source>Infect Dis Clin North Am</source> (<year>2002</year>) <volume>16</volume>:<fpage>793</fpage>&#x2013;<lpage>820, v</lpage>. <pub-id pub-id-type="doi">10.1016/S0891-5520(02)00042-9</pub-id>
<pub-id pub-id-type="pmid">12512182</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perlroth</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>B</given-names></name><name><surname>Spellberg</surname><given-names>B</given-names></name></person-group>
<article-title>Nosocomial fungal infections: epidemiology, diagnosis, and treatment</article-title>. <source>Med Mycol</source> (<year>2007</year>) <volume>45</volume>:<page-range>321&#x2013;46</page-range>. <pub-id pub-id-type="doi">10.1080/13693780701218689</pub-id>
</mixed-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pfaller</surname><given-names>M</given-names></name><name><surname>Neofytos</surname><given-names>D</given-names></name><name><surname>Diekema</surname><given-names>D</given-names></name><name><surname>Azie</surname><given-names>N</given-names></name><name><surname>Meier-Kriesche</surname><given-names>HU</given-names></name><name><surname>Quan</surname><given-names>SP</given-names></name><etal/></person-group>
<article-title>Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008</article-title>. <source>Diagn Microbiol Infect Dis</source> (<year>2012</year>) <volume>74</volume>:<page-range>323&#x2013;31</page-range>. <pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2012.10.003</pub-id>
</mixed-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koh</surname><given-names>AY</given-names></name><name><surname>K&#xF6;hler</surname><given-names>JR</given-names></name><name><surname>Coggshall</surname><given-names>KT</given-names></name><name><surname>Van Rooijen</surname><given-names>N</given-names></name><name><surname>Pier</surname><given-names>GB</given-names></name></person-group>
<article-title>Mucosal damage and neutropenia are required for <italic>Candida albicans</italic> dissemination</article-title>. <source>PloS Pathog</source> (<year>2008</year>) <volume>4</volume>:<fpage>e35</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.0040035</pub-id>
<pub-id pub-id-type="pmid">18282097</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>MacCallum</surname><given-names>DM</given-names></name></person-group>
<article-title>Hosting infection: experimental models to assay <italic>Candida</italic> virulence</article-title>. <source>Int J Microbiol</source> (<year>2012</year>) <volume>2012</volume>:<fpage>363764</fpage>. <pub-id pub-id-type="doi">10.1155/2012/363764</pub-id>
<pub-id pub-id-type="pmid">22235206</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lionakis</surname><given-names>MS</given-names></name></person-group>
<article-title>New insights into innate immune control of systemic candidiasis</article-title>. <source>Med Mycol</source> (<year>2014</year>) <volume>52</volume>:<page-range>555&#x2013;64</page-range>. <pub-id pub-id-type="doi">10.1093/mmy/myu029</pub-id>
</mixed-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lionakis</surname><given-names>MS</given-names></name><name><surname>Lim</surname><given-names>JK</given-names></name><name><surname>Lee</surname><given-names>CCR</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group>
<article-title>Organ-Specific Innate Immune Responses in a Mouse Model of Invasive Candidiasis</article-title>. <source>J Innate Immun</source> (<year>2011</year>) <volume>3</volume>:<page-range>180&#x2013;99</page-range>. <pub-id pub-id-type="doi">10.1159/000321157</pub-id>
</mixed-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>MacCallum</surname><given-names>DM</given-names></name><name><surname>Odds</surname><given-names>FC</given-names></name></person-group>
<article-title>Temporal events in the intravenous challenge model for experimental <italic>Candida albicans</italic> infections in female mice</article-title>. <source>Mycoses</source> (<year>2005</year>) <volume>48</volume>:<page-range>151&#x2013;61</page-range>. <pub-id pub-id-type="doi">10.1111/j.1439-0507.2005.01121.x</pub-id>
</mixed-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doeing</surname><given-names>DC</given-names></name><name><surname>Borowicz</surname><given-names>JL</given-names></name><name><surname>Crockett</surname><given-names>ET</given-names></name></person-group>
<article-title>Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods</article-title>. <source>BMC Clin Pathol</source> (<year>2003</year>) <volume>3</volume>:<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/1472-6890-3-3</pub-id>
<pub-id pub-id-type="pmid">12971830</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fradin</surname><given-names>C</given-names></name><name><surname>De Groot</surname><given-names>P</given-names></name><name><surname>MacCallum</surname><given-names>D</given-names></name><name><surname>Schaller</surname><given-names>M</given-names></name><name><surname>Klis</surname><given-names>F</given-names></name><name><surname>Odds</surname><given-names>FC</given-names></name><etal/></person-group>
<article-title>Granulocytes govern the transcriptional response, morphology and proliferation of <italic>Candida albicans</italic> in human blood</article-title>. <source>Mol Microbiol</source> (<year>2005</year>) <volume>56</volume>:<fpage>397</fpage>&#x2013;<lpage>415</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2958.2005.04557.x</pub-id>
<pub-id pub-id-type="pmid">15813733</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lo</surname><given-names>HJ</given-names></name><name><surname>Kohler</surname><given-names>JR</given-names></name><name><surname>DiDomenico</surname><given-names>B</given-names></name><name><surname>Loebenberg</surname><given-names>D</given-names></name><name><surname>Cacciapuoti</surname><given-names>A</given-names></name><name><surname>Fink</surname><given-names>GR</given-names></name></person-group>
<article-title>Nonfilamentous <italic>C. albicans</italic> mutants are avirulent</article-title>. <source>Cell</source> (<year>1997</year>) <volume>90</volume>:<page-range>939&#x2013;49</page-range>. <pub-id pub-id-type="doi">10.1016/S0092-8674(00)80358-X</pub-id>
</mixed-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walther</surname><given-names>A</given-names></name><name><surname>Wendland</surname><given-names>J</given-names></name></person-group>
<article-title>An improved transformation protocol for the human fungal pathogen <italic>Candida albicans</italic>
</article-title>. <source>Curr Genet</source> (<year>2003</year>) <volume>42</volume>:<page-range>339&#x2013;43</page-range>. <pub-id pub-id-type="doi">10.1007/s00294-002-0349-0</pub-id>
</mixed-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balwit</surname><given-names>JM</given-names></name><name><surname>van Langevelde</surname><given-names>P</given-names></name><name><surname>Vann</surname><given-names>JM</given-names></name><name><surname>Proctor</surname><given-names>RA</given-names></name></person-group>
<article-title>Gentamicin-Resistant Menadione and Hemin Auxotrophic Staphylococcus aureus Persist within Cultured Endothelial Cells</article-title>. <source>J Infect Dis</source> (<year>1994</year>) <volume>170</volume>:<page-range>1033&#x2013;7</page-range>. <pub-id pub-id-type="doi">10.1093/infdis/170.4.1033</pub-id>
</mixed-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kahl</surname><given-names>BC</given-names></name><name><surname>Goulian</surname><given-names>M</given-names></name><name><surname>van Wamel</surname><given-names>W</given-names></name><name><surname>Herrmann</surname><given-names>M</given-names></name><name><surname>Simon</surname><given-names>SM</given-names></name><name><surname>Kaplan</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Staphylococcus aureus RN6390 replicates and induces apoptosis in a pulmonary epithelial cell line</article-title>. <source>Infect Immun</source> (<year>2000</year>) <volume>68</volume>:<page-range>5385&#x2013;92</page-range>. <pub-id pub-id-type="doi">10.1128/IAI.68.9.5385-5392.2000</pub-id>
</mixed-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sreekantapuram</surname><given-names>S</given-names></name><name><surname>Lehnert</surname><given-names>T</given-names></name><name><surname>Prau&#xDF;e</surname><given-names>MTE</given-names></name><name><surname>Berndt</surname><given-names>A</given-names></name><name><surname>Berens</surname><given-names>C</given-names></name><name><surname>Figge</surname><given-names>MT</given-names></name><etal/></person-group>
<article-title>Dynamic Interplay of Host and Pathogens in an Avian Whole-Blood Model</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>500</elocation-id>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.00500</pub-id>
<pub-id pub-id-type="pmid">32296424</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mollnes</surname><given-names>TE</given-names></name><name><surname>Brekke</surname><given-names>OL</given-names></name><name><surname>Fung</surname><given-names>M</given-names></name><name><surname>Fure</surname><given-names>H</given-names></name><name><surname>Christiansen</surname><given-names>D</given-names></name><name><surname>Bergseth</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation</article-title>. <source>Blood</source> (<year>2002</year>) <volume>100</volume>:<page-range>1869&#x2013;77</page-range>.</mixed-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ganguly</surname><given-names>S</given-names></name><name><surname>Panetta</surname><given-names>JC</given-names></name><name><surname>Roberts</surname><given-names>JK</given-names></name><name><surname>Schuetz</surname><given-names>EG</given-names></name></person-group>
<article-title>Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice</article-title>. <source>Drug Metab Dispos</source> (<year>2018</year>) <volume>46</volume>:<page-range>1014&#x2013;22</page-range>. <pub-id pub-id-type="doi">10.1124/dmd.117.078360</pub-id>
</mixed-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ermert</surname><given-names>D</given-names></name><name><surname>Urban</surname><given-names>CF</given-names></name><name><surname>Laube</surname><given-names>B</given-names></name><name><surname>Goosmann</surname><given-names>C</given-names></name><name><surname>Zychlinsky</surname><given-names>A</given-names></name><name><surname>Brinkmann</surname><given-names>V</given-names></name></person-group>
<article-title>Mouse neutrophil extracellular traps in microbial infections</article-title>. <source>J Innate Immun</source> (<year>2009</year>) <volume>1</volume>:<page-range>181&#x2013;93</page-range>. <pub-id pub-id-type="doi">10.1159/000205281</pub-id>
</mixed-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davidson</surname><given-names>JA</given-names></name><name><surname>Boom</surname><given-names>SJ</given-names></name><name><surname>Pearsall</surname><given-names>FJ</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Ramsay</surname><given-names>G</given-names></name></person-group>
<article-title>Comparison of the effects of four i.v. anaesthetic agents on polymorphonuclear leucocyte function</article-title>. <source>Br J Anaesth</source> (<year>1995</year>) <volume>74</volume>:<page-range>315&#x2013;8</page-range>. <pub-id pub-id-type="doi">10.1093/bja/74.3.315</pub-id>
</mixed-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Heller</surname><given-names>A</given-names></name><name><surname>Heller</surname><given-names>S</given-names></name><name><surname>Blecken</surname><given-names>S</given-names></name><name><surname>Urbaschek</surname><given-names>R</given-names></name><name><surname>Koch</surname><given-names>T</given-names></name></person-group>
<article-title>Effects of intravenous anesthetics on bacterial elimination in human blood in vitro</article-title>. <source>Acta Anaesthesiol Scand</source> (<year>1998</year>) <volume>42</volume>:<page-range>518&#x2013;26</page-range>. <pub-id pub-id-type="doi">10.1111/j.1399-6576.1998.tb05160.x</pub-id>
</mixed-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishina</surname><given-names>K</given-names></name><name><surname>Akamatsu</surname><given-names>H</given-names></name><name><surname>Mikawa</surname><given-names>K</given-names></name><name><surname>Shiga</surname><given-names>M</given-names></name><name><surname>Maekawa</surname><given-names>N</given-names></name><name><surname>Obara</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>The inhibitory effects of thiopental, midazolam, and ketamine on human neutrophil functions</article-title>. <source>Anesth Analg</source> (<year>1998</year>) <volume>86</volume>:<page-range>159&#x2013;65</page-range>. <pub-id pub-id-type="doi">10.1097/00000539-199801000-00032</pub-id>
</mixed-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>TL</given-names></name><name><surname>Sheu</surname><given-names>JR</given-names></name><name><surname>Chen</surname><given-names>RM</given-names></name></person-group>
<article-title>Suppressive effects of ketamine on macrophage functions</article-title>. <source>Toxicol Appl Pharmacol</source> (<year>2005</year>) <volume>204</volume>:<fpage>27</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2004.08.011</pub-id>
<pub-id pub-id-type="pmid">15781291</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ermert</surname><given-names>D</given-names></name><name><surname>Niemiec</surname><given-names>MJ</given-names></name><name><surname>Rohm</surname><given-names>M</given-names></name><name><surname>Glenthoj</surname><given-names>A</given-names></name><name><surname>Borregaard</surname><given-names>N</given-names></name><name><surname>Urban</surname><given-names>CF</given-names></name></person-group>
<article-title>
<italic>Candida albicans</italic> escapes from mouse neutrophils</article-title>. <source>J Leukoc Biol</source> (<year>2013</year>) <volume>94</volume>:<page-range>223&#x2013;36</page-range>. <pub-id pub-id-type="doi">10.1189/jlb.0213063</pub-id>
</mixed-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wozniok</surname><given-names>I</given-names></name><name><surname>Hornbach</surname><given-names>A</given-names></name><name><surname>Schmitt</surname><given-names>C</given-names></name><name><surname>Frosch</surname><given-names>M</given-names></name><name><surname>Einsele</surname><given-names>H</given-names></name><name><surname>Hube</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Induction of ERK-kinase signalling triggers morphotype-specific killing of <italic>Candida albicans</italic> filaments by human neutrophils</article-title>. <source>Cell Microbiol</source> (<year>2008</year>) <volume>10</volume>:<page-range>807&#x2013;20</page-range>. <pub-id pub-id-type="doi">10.1111/j.1462-5822.2007.01086.x</pub-id>
</mixed-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mukaremera</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>KK</given-names></name><name><surname>Mora-Montes</surname><given-names>HM</given-names></name><name><surname>Gow</surname><given-names>NAR</given-names></name></person-group>
<article-title>
<italic>Candida albicans</italic> Yeast, Pseudohyphal, and Hyphal Morphogenesis Differentially Affects Immune Recognition</article-title>. <source>Front Immunol</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>629</elocation-id>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.00629</pub-id>
<pub-id pub-id-type="pmid">28638380</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jim&#xE9;nez-L&#xF3;pez</surname><given-names>C</given-names></name><name><surname>Lorenz</surname><given-names>MC</given-names></name></person-group>
<article-title>Fungal immune evasion in a model host-pathogen interaction: <italic>Candida albicans</italic> versus macrophages</article-title>. <source>PLoS Pathog</source> (<year>2013</year>) <volume>9</volume>:<fpage>e1003741</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1003741</pub-id>
<pub-id pub-id-type="pmid">24278014</pub-id></mixed-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iliev</surname><given-names>ID</given-names></name><name><surname>Funari</surname><given-names>VA</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Nguyen</surname><given-names>Q</given-names></name><name><surname>Reyes</surname><given-names>CN</given-names></name><name><surname>Strom</surname><given-names>SP</given-names></name><etal/></person-group>
<article-title>Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis</article-title>. <source>Science (New York NY)</source> (<year>2012</year>) <volume>336</volume>:<page-range>1314&#x2013;7</page-range>. <pub-id pub-id-type="doi">10.1126/science.1221789</pub-id>
</mixed-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yeung</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Lin</surname><given-names>JD</given-names></name><name><surname>Leung</surname><given-names>JM</given-names></name><name><surname>McCauley</surname><given-names>C</given-names></name><name><surname>Devlin</surname><given-names>JC</given-names></name><etal/></person-group>
<article-title>Altered Immunity of Laboratory Mice in the Natural Environment Is Associated with Fungal Colonization</article-title>. <source>Cell Host Microbe</source> (<year>2020</year>) <volume>27</volume>(<issue>5</issue>):<page-range>809&#x2013;22</page-range>. <pub-id pub-id-type="doi">10.1016/j.chom.2020.02.015</pub-id>
</mixed-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huertas</surname><given-names>B</given-names></name><name><surname>Prieto</surname><given-names>D</given-names></name><name><surname>Pitarch</surname><given-names>A</given-names></name><name><surname>Gil</surname><given-names>C</given-names></name><name><surname>Pla</surname><given-names>J</given-names></name><name><surname>D&#xED;ez-Orejas</surname><given-names>R</given-names></name></person-group>
<article-title>Serum Antibody Profile during Colonization of the Mouse Gut by <italic>Candida albicans</italic>: Relevance for Protection during Systemic Infection</article-title>. <source>J Proteome Res</source> (<year>2017</year>) <volume>16</volume>:<page-range>335&#x2013;45</page-range>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00383</pub-id>
</mixed-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Robert</surname><given-names>R</given-names></name><name><surname>Nail</surname><given-names>S</given-names></name><name><surname>Marot-Leblond</surname><given-names>A</given-names></name><name><surname>Cottin</surname><given-names>J</given-names></name><name><surname>Miegeville</surname><given-names>M</given-names></name><name><surname>Quenouillere</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Adherence of platelets to <italic>Candida</italic> species in vivo</article-title>. <source>Infect Immun</source> (<year>2000</year>) <volume>68</volume>:<page-range>570&#x2013;6</page-range>. <pub-id pub-id-type="doi">10.1128/IAI.68.2.570-576.2000</pub-id>
</mixed-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Mitruka</surname><given-names>BM</given-names></name><name><surname>Rawnsley</surname><given-names>HM</given-names></name></person-group>
<source>Clinical biochemical and hematological reference values in normal experimental animals</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Masson Publishing USA Inc.</publisher-name> (<year>1977</year>).</mixed-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Horn</surname><given-names>DL</given-names></name><name><surname>Neofytos</surname><given-names>D</given-names></name><name><surname>Anaissie</surname><given-names>EJ</given-names></name><name><surname>Fishman</surname><given-names>JA</given-names></name><name><surname>Steinbach</surname><given-names>WJ</given-names></name><name><surname>Olyaei</surname><given-names>AJ</given-names></name><etal/></person-group>
<article-title>Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry</article-title>. <source>Clin Infect Dis</source> (<year>2009</year>) <volume>48</volume>:<page-range>1695&#x2013;703</page-range>. <pub-id pub-id-type="doi">10.1086/599039</pub-id>
</mixed-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gazendam</surname><given-names>RP</given-names></name><name><surname>van de Geer</surname><given-names>A</given-names></name><name><surname>Roos</surname><given-names>D</given-names></name><name><surname>van den Berg</surname><given-names>TK</given-names></name><name><surname>Kuijpers</surname><given-names>TW</given-names></name></person-group>
<article-title>How neutrophils kill fungi</article-title>. <source>Immunol Rev</source> (<year>2016</year>) <volume>273</volume>:<fpage>299</fpage>&#x2013;<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12454</pub-id>
<pub-id pub-id-type="pmid">27558342</pub-id></mixed-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Romani</surname><given-names>L</given-names></name><name><surname>Mencacci</surname><given-names>A</given-names></name><name><surname>Cenci</surname><given-names>E</given-names></name><name><surname>Puccetti</surname><given-names>P</given-names></name><name><surname>Bistoni</surname><given-names>F</given-names></name></person-group>
<article-title>Neutrophils and the adaptive immune response to <italic>Candida albicans</italic>
</article-title>. <source>Res Immunol</source> (<year>1996</year>) <volume>147</volume>:<page-range>512&#x2013;8</page-range>. <pub-id pub-id-type="doi">10.1016/S0923-2494(97)85216-9</pub-id>
</mixed-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Cutler</surname><given-names>JE</given-names></name></person-group>
<article-title>Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals</article-title>. <source>J Infect Dis</source> (<year>1997</year>) <volume>175</volume>:<page-range>1169&#x2013;75</page-range>. <pub-id pub-id-type="doi">10.1086/516455</pub-id>
</mixed-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eisenhauer</surname><given-names>PB</given-names></name><name><surname>Lehrer</surname><given-names>RI</given-names></name></person-group>
<article-title>Mouse neutrophils lack defensins</article-title>. <source>Infect Immun</source> (<year>1992</year>) <volume>60</volume>:<page-range>3446&#x2013;7</page-range>. <pub-id pub-id-type="doi">10.1128/IAI.60.8.3446-3447.1992</pub-id>
</mixed-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rausch</surname><given-names>PG</given-names></name><name><surname>Moore</surname><given-names>TG</given-names></name></person-group>
<article-title>Granule enzymes of polymorphonuclear neutrophils: A phylogenetic comparison</article-title>. <source>Blood</source> (<year>1975</year>) <volume>46</volume>:<page-range>913&#x2013;9</page-range>. <pub-id pub-id-type="doi">10.1182/blood.V46.6.913.bloodjournal466913</pub-id>
</mixed-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tecchio</surname><given-names>C</given-names></name><name><surname>Micheletti</surname><given-names>A</given-names></name><name><surname>Cassatella</surname><given-names>MA</given-names></name></person-group>
<article-title>Neutrophil-derived cytokines: facts beyond expression</article-title>. <source>Front Immunol</source> (<year>2014</year>) <volume>5</volume>:<elocation-id>508</elocation-id>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00508</pub-id>
<pub-id pub-id-type="pmid">25374568</pub-id></mixed-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Branzk</surname><given-names>N</given-names></name><name><surname>Lubojemska</surname><given-names>A</given-names></name><name><surname>Hardison</surname><given-names>SE</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Gutierrez</surname><given-names>MG</given-names></name><name><surname>Brown</surname><given-names>GD</given-names></name><etal/></person-group>
<article-title>Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens</article-title>. <source>Nat Immunol</source> (<year>2014</year>) <volume>15</volume>:<page-range>1017&#x2013;25</page-range>. <pub-id pub-id-type="doi">10.1038/ni.2987</pub-id>
</mixed-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lo</surname><given-names>HJ</given-names></name><name><surname>K&#xF6;hler</surname><given-names>JR</given-names></name><name><surname>DiDomenico</surname><given-names>B</given-names></name><name><surname>Loebenberg</surname><given-names>D</given-names></name></person-group>
<article-title>A. Cacciapuoti, and G.R. Fink, Nonfilamentous <italic>C. albicans</italic> mutants are avirulent</article-title>. <source>Cell</source> (<year>1997</year>) <volume>90</volume>:<page-range>939&#x2013;49</page-range>. <pub-id pub-id-type="doi">10.1016/S0092-8674(00)80358-X</pub-id>
</mixed-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rudkin</surname><given-names>FM</given-names></name><name><surname>Bain</surname><given-names>JM</given-names></name><name><surname>Walls</surname><given-names>C</given-names></name><name><surname>Lewis</surname><given-names>LE</given-names></name><name><surname>Gow</surname><given-names>NA</given-names></name><name><surname>Erwig</surname><given-names>LP</given-names></name></person-group>
<article-title>Altered dynamics of <italic>Candida albicans</italic> phagocytosis by macrophages and PMNs when both phagocyte subsets are present</article-title>. <source>mBio</source> (<year>2013</year>) <volume>4</volume>:<page-range>e00810&#x2013;13</page-range>. <pub-id pub-id-type="doi">10.1128/mBio.00810-13</pub-id>
</mixed-citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zavrel</surname><given-names>M</given-names></name><name><surname>Majer</surname><given-names>O</given-names></name><name><surname>Kuchler</surname><given-names>K</given-names></name><name><surname>Rupp</surname><given-names>S</given-names></name></person-group>
<article-title>Transcription factor Efg1 shows a haploinsufficiency phenotype in modulating the cell wall architecture and immunogenicity of <italic>Candida albicans</italic>
</article-title>. <source>Eukaryot Cell</source> (<year>2012</year>) <volume>11</volume>:<page-range>129&#x2013;40</page-range>. <pub-id pub-id-type="doi">10.1128/EC.05206-11</pub-id>
</mixed-citation>
      </ref>
      <ref id="B51">
        <label>51</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cottier</surname><given-names>F</given-names></name><name><surname>Sherrington</surname><given-names>S</given-names></name><name><surname>Cockerill</surname><given-names>S</given-names></name><name><surname>Del Olmo Toledo</surname><given-names>V</given-names></name><name><surname>Kissane</surname><given-names>S</given-names></name><name><surname>Tournu</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Remasking of <italic>Candida albicans</italic> &#x3B2;-Glucan in Response to Environmental pH Is Regulated by Quorum Sensing</article-title>. <source>mBio</source> (<year>2019</year>) <volume>10</volume>. <pub-id pub-id-type="doi">10.1128/mBio.02347-19</pub-id>
</mixed-citation>
      </ref>
      <ref id="B52">
        <label>52</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wartenberg</surname><given-names>A</given-names></name><name><surname>Linde</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name><name><surname>Schreiner</surname><given-names>M</given-names></name><name><surname>Horn</surname><given-names>F</given-names></name><name><surname>Jacobsen</surname><given-names>ID</given-names></name><etal/></person-group>
<article-title>Microevolution of <italic>Candida albicans in</italic> macrophages restores filamentation in a nonfilamentous mutant</article-title>. <source>PLoS Genet</source> (<year>2014</year>) <volume>10</volume>:<fpage>e1004824</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1004824</pub-id>
<pub-id pub-id-type="pmid">25474009</pub-id></mixed-citation>
      </ref>
      <ref id="B53">
        <label>53</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Torosantucci</surname><given-names>A</given-names></name><name><surname>Chiani</surname><given-names>P</given-names></name><name><surname>Cassone</surname><given-names>A</given-names></name></person-group>
<article-title>Differential chemokine response of human monocytes to yeast and hyphal forms of <italic>Candida albicans</italic> and its relation to the beta-1,6 glucan of the fungal cell wall</article-title>. <source>J Leukoc Biol</source> (<year>2000</year>) <volume>68</volume>:<page-range>923&#x2013;32</page-range>.</mixed-citation>
      </ref>
      <ref id="B54">
        <label>54</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Behnsen</surname><given-names>J</given-names></name><name><surname>Narang</surname><given-names>P</given-names></name><name><surname>Hasenberg</surname><given-names>M</given-names></name><name><surname>Gunzer</surname><given-names>F</given-names></name><name><surname>Bilitewski</surname><given-names>U</given-names></name><name><surname>Klippel</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Environmental dimensionality controls the interaction of phagocytes with the pathogenic fungi Aspergillus fumigatus and Candida albicans</article-title>. <source>PLoS Pathog</source> (<year>2007</year>) <volume>3</volume>:<fpage>e13</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.0030013</pub-id>
<pub-id pub-id-type="pmid">17274685</pub-id></mixed-citation>
      </ref>
      <ref id="B55">
        <label>55</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Matsushima</surname><given-names>H</given-names></name><name><surname>Ohtola</surname><given-names>JA</given-names></name><name><surname>Geng</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Takashima</surname><given-names>A</given-names></name></person-group>
<article-title>Neutrophil priming occurs in a sequential manner and can be visualized in living animals by monitoring IL-1&#x3B2; promoter activation</article-title>. <source>J Immunol (Baltimore Md: 1950)</source> (<year>2015</year>) <volume>194</volume>:<page-range>1211&#x2013;24</page-range>. <pub-id pub-id-type="doi">10.4049/jimmunol.1402018</pub-id>
</mixed-citation>
      </ref>
      <ref id="B56">
        <label>56</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miralda</surname><given-names>I</given-names></name><name><surname>Uriarte</surname><given-names>SM</given-names></name><name><surname>McLeish</surname><given-names>KR</given-names></name></person-group>
<article-title>Multiple Phenotypic Changes Define Neutrophil Priming</article-title>. <source>Front Cell Infect Microbiol</source> (<year>2017</year>) <volume>7</volume>:<elocation-id>217</elocation-id>. <pub-id pub-id-type="doi">10.3389/fcimb.2017.00217</pub-id>
<pub-id pub-id-type="pmid">28611952</pub-id></mixed-citation>
      </ref>
      <ref id="B57">
        <label>57</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grubb</surname><given-names>SE</given-names></name><name><surname>Murdoch</surname><given-names>C</given-names></name><name><surname>Sudbery</surname><given-names>PE</given-names></name><name><surname>Saville</surname><given-names>SP</given-names></name><name><surname>Lopez-Ribot</surname><given-names>JL</given-names></name><name><surname>Thornhill</surname><given-names>MH</given-names></name></person-group>
<article-title>
<italic>Candida albicans</italic>-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis</article-title>. <source>Infect Immun</source> (<year>2008</year>) <volume>76</volume>:<page-range>4370&#x2013;7</page-range>. <pub-id pub-id-type="doi">10.1128/IAI.00332-08</pub-id>
</mixed-citation>
      </ref>
      <ref id="B58">
        <label>58</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Filler</surname><given-names>SG</given-names></name><name><surname>Pfunder</surname><given-names>AS</given-names></name><name><surname>Spellberg</surname><given-names>BJ</given-names></name><name><surname>Spellberg</surname><given-names>JP</given-names></name><name><surname>Edwards</surname><given-names>JE</given-names><suffix>Jr.</suffix></name></person-group>
<article-title>
<italic>Candida albicans</italic> stimulates cytokine production and leukocyte adhesion molecule expression by endothelial cells</article-title>. <source>Infect Immun</source> (<year>1996</year>) <volume>64</volume>:<page-range>2609&#x2013;17</page-range>. <pub-id pub-id-type="doi">10.1128/IAI.64.7.2609-2617.1996</pub-id>
</mixed-citation>
      </ref>
      <ref id="B59">
        <label>59</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eberl</surname><given-names>C</given-names></name><name><surname>Speth</surname><given-names>C</given-names></name><name><surname>Jacobsen</surname><given-names>ID</given-names></name><name><surname>Hermann</surname><given-names>M</given-names></name><name><surname>Hagleitner</surname><given-names>M</given-names></name><name><surname>Deshmukh</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>
<italic>Candida</italic>: Platelet Interaction and Platelet Activity in vitro</article-title>. <source>J Innate Immun</source> (<year>2019</year>) <volume>11</volume>:<fpage>52</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1159/000491030</pub-id>
<pub-id pub-id-type="pmid">30176656</pub-id></mixed-citation>
      </ref>
      <ref id="B60">
        <label>60</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schultz</surname><given-names>CM</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name><name><surname>Dunn</surname><given-names>A</given-names></name><name><surname>Knauss</surname><given-names>H</given-names></name><name><surname>Huss</surname><given-names>C</given-names></name><name><surname>Launder</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Stepping Up to the Plate(let) against <italic>Candida albicans</italic>
</article-title>. <source>Infect Immun</source> (<year>2020</year>) <volume>88</volume>:<fpage>00784-19</fpage>. <pub-id pub-id-type="doi">10.1128/IAI.00784-19</pub-id>
</mixed-citation>
      </ref>
      <ref id="B61">
        <label>61</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Willcox</surname><given-names>MD</given-names></name><name><surname>Webb</surname><given-names>BC</given-names></name><name><surname>Thakur</surname><given-names>A</given-names></name><name><surname>Harty</surname><given-names>DW</given-names></name></person-group>
<article-title>Interactions between <italic>Candida</italic> species and platelets</article-title>. <source>J Med Microbiol</source> (<year>1998</year>) <volume>47</volume>:<page-range>103&#x2013;10</page-range>. <pub-id pub-id-type="doi">10.1099/00222615-47-2-103</pub-id>
</mixed-citation>
      </ref>
      <ref id="B62">
        <label>62</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leroy</surname><given-names>J</given-names></name><name><surname>Bortolus</surname><given-names>C</given-names></name><name><surname>Lecointe</surname><given-names>K</given-names></name><name><surname>Parny</surname><given-names>M</given-names></name><name><surname>Charlet</surname><given-names>R</given-names></name><name><surname>Sendid</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Fungal Chitin Reduces Platelet Activation Mediated via TLR8 Stimulation</article-title>. <source>Front Cell Infect Microbiol</source> (<year>2019</year>) <volume>9</volume>:<elocation-id>383</elocation-id>. <pub-id pub-id-type="doi">10.3389/fcimb.2019.00383</pub-id>
<pub-id pub-id-type="pmid">31781518</pub-id></mixed-citation>
      </ref>
      <ref id="B63">
        <label>63</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bertling</surname><given-names>A</given-names></name><name><surname>Niemann</surname><given-names>S</given-names></name><name><surname>Uek&#xF6;tter</surname><given-names>A</given-names></name><name><surname>Fegeler</surname><given-names>W</given-names></name><name><surname>Lass-Fl&#xF6;rl</surname><given-names>C</given-names></name><name><surname>von Eiff</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>
<italic>Candida albicans</italic> and its metabolite gliotoxin inhibit platelet function via interaction with thiols</article-title>. <source>Thromb Haemost</source> (<year>2010</year>) <volume>104</volume>:<page-range>270&#x2013;8</page-range>. <pub-id pub-id-type="doi">10.1160/TH09-11-0769</pub-id>
</mixed-citation>
      </ref>
      <ref id="B64">
        <label>64</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woth</surname><given-names>G</given-names></name><name><surname>T&#x151;k&#xE9;s-F&#xFC;zesi</surname><given-names>M</given-names></name><name><surname>Magyarlaki</surname><given-names>T</given-names></name><name><surname>Kov&#xE1;cs</surname><given-names>GL</given-names></name><name><surname>Vermes</surname><given-names>I</given-names></name><name><surname>M&#xFC;hl</surname><given-names>D</given-names></name></person-group>
<article-title>Activated platelet-derived microparticle numbers are elevated in patients with severe fungal (<italic>Candida albicans</italic>) sepsis</article-title>. <source>Ann Clin Biochem</source> (<year>2012</year>) <volume>49</volume>:<page-range>554&#x2013;60</page-range>. <pub-id pub-id-type="doi">10.1258/acb.2012.011215</pub-id>
</mixed-citation>
      </ref>
      <ref id="B65">
        <label>65</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schulz</surname><given-names>D</given-names></name><name><surname>Grumann</surname><given-names>D</given-names></name><name><surname>Tr&#xFC;be</surname><given-names>P</given-names></name><name><surname>Pritchett-Corning</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Reppschl&#xE4;ger</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Laboratory Mice Are Frequently Colonized with <italic>Staphylococcus aureus and</italic> Mount a Systemic Immune Response-Note of Caution for <italic>In vivo</italic> Infection Experiments</article-title>. <source>Front Cell Infect Microbiol</source> (<year>2017</year>) <volume>7</volume>:<elocation-id>152</elocation-id>. <pub-id pub-id-type="doi">10.3389/fcimb.2017.00152</pub-id>
<pub-id pub-id-type="pmid">28512627</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Amino Acids</journal-id>
      <journal-id journal-id-type="iso-abbrev">Amino Acids</journal-id>
      <journal-title-group>
        <journal-title>Amino Acids</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0939-4451</issn>
      <issn pub-type="epub">1438-2199</issn>
      <publisher>
        <publisher-name>Springer Vienna</publisher-name>
        <publisher-loc>Vienna</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33398524</article-id>
      <article-id pub-id-type="pmc">7781173</article-id>
      <article-id pub-id-type="publisher-id">2921</article-id>
      <article-id pub-id-type="doi">10.1007/s00726-020-02921-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4933-3271</contrib-id>
          <name>
            <surname>Gorman</surname>
            <given-names>Declan M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9976-7396</contrib-id>
          <name>
            <surname>Lee</surname>
            <given-names>John</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9316-1465</contrib-id>
          <name>
            <surname>Payne</surname>
            <given-names>Colton D.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1382-911X</contrib-id>
          <name>
            <surname>Woodruff</surname>
            <given-names>Trent M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6807-5426</contrib-id>
          <name>
            <surname>Clark</surname>
            <given-names>Richard J.</given-names>
          </name>
          <address>
            <email>richard.clark@uq.edu.au</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.1003.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 9320 7537</institution-id><institution>School of Biomedical Sciences, </institution><institution>The University of Queensland, </institution></institution-wrap>Brisbane, Australia </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.1003.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 9320 7537</institution-id><institution>Queensland Brain Institute, </institution><institution>The University of Queensland, </institution></institution-wrap>Brisbane, Australia </aff>
      </contrib-group>
      <author-notes>
        <fn fn-type="com">
          <p>Handling Editor: J. D. Wade.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>4</day>
        <month>1</month>
        <year>2021</year>
      </pub-date>
      <fpage>1</fpage>
      <lpage>5</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>10</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>11</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer-Verlag GmbH Austria, part of Springer Nature 2021</copyright-statement>
        <license>
          <license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">The complement component C5 inhibitory peptide zilucoplan is currently in phase III clinical trials for myasthenia gravis (MG). Despite being at an advanced stage of clinical development, there have been no published reports in the literature detailing its chemical synthesis. In this work, we describe an approach for the chemical synthesis of zilucoplan and validate that the synthesised compound blocks LPS-induced C5a production from human blood.</p>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (10.1007/s00726-020-02921-5) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Peptides</kwd>
        <kwd>Zilucoplan</kwd>
        <kwd>RA101495</kwd>
        <kwd>Peptide synthesis</kwd>
        <kwd>Complement</kwd>
        <kwd>C5</kwd>
        <kwd>C5a</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id>
              <institution>National Health and Medical Research Council</institution>
            </institution-wrap>
          </funding-source>
          <award-id>APP8881111</award-id>
          <principal-award-recipient>
            <name>
              <surname>Woodruff</surname>
              <given-names>Trent M.</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par2">Zilucoplan (formerly RA3193/RA101495) is a 3.5&#xA0;kDa peptide therapeutic (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) developed by RA Pharmaceuticals targeting the complement component C5, with the purpose of preventing the cleavage of C5 into the downstream complement components C5a and C5b (Hoarty et al. <xref ref-type="bibr" rid="CR8">2015</xref>; Howard et al. <xref ref-type="bibr" rid="CR10">2020</xref>). Both metabolites are associated with host defence, with C5a propagating leukocyte chemotaxis and cytokine release through its receptors C5aR1 and C5aR2 (Pandey et al. <xref ref-type="bibr" rid="CR17">2020</xref>), and C5b initiating the formation of the membrane attack complex (MAC) (Denk et al. <xref ref-type="bibr" rid="CR6">2017</xref>; Podack <xref ref-type="bibr" rid="CR19">1984</xref>; Schindler et al. <xref ref-type="bibr" rid="CR21">1990</xref>; Scholz et al. <xref ref-type="bibr" rid="CR22">1990</xref>). Zilucoplan also binds to C5b, thereby competitively inhibiting C5b binding to C6 and further preventing assembly of the MAC (Yee et al. <xref ref-type="bibr" rid="CR27">2015</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Structure and analysis of synthetic zilucoplan. The structure of zilucoplan synthesized in this study (top). The RP-HPLC trace, ESI&#x2013;MS spectrum and MALDI-MS spectrum of zilucoplan (bottom). RP-HPLC was performed with an increasing gradient of 1% buffer B (90% ACN, 0.05% TFA) in buffer A (0.05% TFA) per minute. Sample&#x2009;&gt;&#x2009;99% pure</p></caption><graphic xlink:href="726_2020_2921_Fig1_HTML" id="MO1"/></fig></p>
      <p id="Par3">Zilucoplan has a similar mechanism of action to eculizumab (Soliris), an already approved therapeutic for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, neuromyelitis optica and MG (Brodsky et al. <xref ref-type="bibr" rid="CR3">2008</xref>; Cofiell et al. <xref ref-type="bibr" rid="CR5">2015</xref>; Howard et al. <xref ref-type="bibr" rid="CR9">2017</xref>; Legendre et al. <xref ref-type="bibr" rid="CR14">2013</xref>; Pittock et al. <xref ref-type="bibr" rid="CR18">2013</xref>). Both bind to C5 and prevent the pro-inflammatory and potentially cell-destructive activity elicited by C5 metabolites C5a and C5b (Beecher et al. <xref ref-type="bibr" rid="CR1">2019</xref>).</p>
      <p id="Par4">While zilucoplan and eculizumab inhibit C5 cleavage, several therapeutics have been developed specifically targeting the downstream complement interaction of C5a-C5aR1, enabling a more specific suppression of C5a-initiated systemic inflammation. This ligand&#x2013;receptor complex has been a target for the purposes of treating chronic inflammatory conditions such as inflammatory bowel disease and ANCA-associated vasculitis (Jayne et al. <xref ref-type="bibr" rid="CR11">2017</xref>; Woodruff et al. <xref ref-type="bibr" rid="CR25">2005</xref>). Recently, heightened C5a&#x2013;C5aR1 interaction, and the suppression of such, has also been of interest due to its association with more severe cases of COVID-19 (Carvelli et al. <xref ref-type="bibr" rid="CR4">2020</xref>; Lo et al. <xref ref-type="bibr" rid="CR15">2020</xref>; Woodruff and Shukla <xref ref-type="bibr" rid="CR24">2020</xref>).
</p>
      <p id="Par5">Zilucoplan is currently in phase III clinical trials for the treatment of MG following encouraging phase II trial results (Howard et al. <xref ref-type="bibr" rid="CR10">2020</xref>). However, despite this peptide being in advanced phase clinical trials, there is only a brief description of its synthesis presented in patent material (Hoarty et al. <xref ref-type="bibr" rid="CR8">2015</xref>). We, therefore, set out to undertake the chemical synthesis and experimental validation of our synthesised peptide. Here we report an approach for the solid-phase peptide synthesis of zilucoplan and verify it as a potent human C5 inhibitor.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Peptide synthesis and isolation</title>
        <p id="Par6">Peptides&#xA0;were synthesised using Fmoc (9-fluorenylmethyloxycarbonyl)-based solid-phase peptide synthesis (SPPS) on Wang resin using standard coupling protocols (Zhang et al. <xref ref-type="bibr" rid="CR28">2019</xref>). Four equivalents of standard amino acid, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and diisiopropylethylamine (DIPEA) were used for each coupling step. Non-standard amino acids used in this synthesis included Fmoc-Lysine(ivDde)-OH, Fmoc-L-cyclohexylglycine-OH, Fmoc-L-7-azatryptophan-OH, Fmoc-L-tbutyl-glycine-OH, Fmoc-N-Me-Asp(OtBu)-OH, Fmoc-Lys(Mtt)-OH, Fmoc-Asp(O-2-PhiPr)-OH, Fmoc-Glu(OH)-OtBu and Fmoc-NH-PEG24-CH<sub>2</sub>CH<sub>2</sub>COOH. All non-standard amino acids were coupled twice (30&#xA0;min for each reaction) using two equivalents of amino acid, two equivalents of HBTU and DIPEA in DMF.</p>
        <p id="Par7">Lactam bridge formation between Lys-1 to Asp-6 was achieved by selectively deprotecting the sidechains with 1% trifluoroacetic acid (TFA) in dichloromethane (15&#x2009;&#xD7;&#x2009;2&#xA0;min), to remove the MTT and O-2-PhiPr protecting groups, respectively. Following deprotection, two equivalents of 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) was dissolved in minimal dimethylformamide (DMF). HATU in DMF was added to the resin along with 15 equivalents DIPEA; resin was then shaken overnight (~&#x2009;16&#xA0;h). Lactam bridge formation was confirmed via test cleavage using electrospray mass spectrometry (ESI&#x2013;MS)&#xA0;(AB SCIEX API 2000). N-terminal acetylation was then carried out on-resin with a solution of acetic anhydride (5%) (Sigma-Aldrich) and DIPEA (3%) (Sigma-Aldrich) in DMF at 25&#xA0;&#xB0;C for 2&#x2009;&#xD7;&#x2009;10&#xA0;min. 10% hydrazine monohydrate (Sigma-Aldrich) in DMF was used for the removal of ivDde from the sidechain of the C-terminal lysine following the synthesis of the main-chain (2&#x2009;&#xD7;&#x2009;10-min treatments). Resin was split at this point, and one half was cleaved and purified for NMR analysis of the non-PEGylated/lipidated peptide. Fmoc-Glu(OH)-OtBu and Fmoc-PEG24-CH<sub>2</sub>CH<sub>2</sub>COOH were then coupled sequentially to the remaining resin.</p>
        <p id="Par8">Following synthesis, the peptides (with and without PEG group/lipid) were cleaved off resin and side chain protecting groups were removed by treatment with trifluoroacetic acid/TIPS/H<sub>2</sub>O at a ratio of 95:2.5:2.5 for 2&#xA0;h at room temperature. The peptide was then purified using reverse phase high-performance liquid chromatography (RP-HPLC) with an increasing gradient of 1% buffer B (90% ACN, 0.05% TFA) in buffer A (0.05% TFA) per minute. HPLC fractions were analysed by electrospray mass spectrometry (ESI&#x2013;MS) and fractions containing the desired product were combined. Peptide was purified until&#x2009;&gt;&#x2009;99% purity as assessed by analytical RP-HPLC (Agilent, 5&#xA0;&#xB5;M, 2.1&#x2009;&#xD7;&#x2009;150&#xA0;mm). Pure peptide was analysed by high-resolution mass spectrometry using MALDI-TOF MS (AB SCIEX TOF/TOF-5800).</p>
        <p id="Par9">Palmitic acid-NHS ester (Sigma-Aldrich) was used to label the free amine of the PEGylated peptide off-resin. Palmitic acid-NHS ester and peptide were prepared as stock solutions in DMSO at a concentration of 10&#xA0;mg/ml and 2.5&#xA0;mg/ml, respectively. NHS ester and peptide solutions were then combined at a ratio of 5:1 (NHS ester:peptide) and triethylamine (TEA) in DMSO was then added (two equivalents relative to peptide). The solution was stirred for 16&#xA0;h before confirming attachment of palmitic acid by ESI&#x2013;MS. The peptide was purified using RP-HPLC, fractions were lyophilised and confirmed&#x2009;&gt;&#x2009;99% pure via analytical RP-HPLC (Agilent). 12&#xA0;mg of pure peptide was obtained following synthesis, representing a yield of 2.7% of the theoretical maximum based on resin loading.</p>
      </sec>
      <sec id="Sec4">
        <title>Nuclear magnetic resonance (NMR)</title>
        <p id="Par10">Zilucoplan was prepared for NMR analysis by dissolving 1&#xA0;mg of peptide in 550&#xA0;&#x3BC;l of H<sub>2</sub>O/D<sub>2</sub>O (90:10), at pH&#x2009;~&#x2009;3.5. Two-Dimensional <sup>1</sup>H-<sup>1</sup>H TOCSY and NOESY experiments were recorded, with mixing times of 80 and 200&#xA0;ms respectively, at 298&#xA0;K on a 900&#xA0;MHz Bruker Avance III Spectrometer equipped with a cryoprobe (Braunschweiler and Ernst <xref ref-type="bibr" rid="CR2">1983</xref>; Jeener et al. <xref ref-type="bibr" rid="CR12">1979</xref>). The data were processed using Topspin 4.0.3 (Bruker), with the spectra being referenced to the solvent signal at 4.77&#xA0;ppm. Spectra were assigned using sequential assignment strategies with the program CARA (Keller <xref ref-type="bibr" rid="CR13">2004</xref>; W&#xFC;thrich <xref ref-type="bibr" rid="CR26">1986</xref>). Secondary structure was identified via the determination of secondary H&#x3B1; shifts from the closest naturally occurring residues random coil values (Wishart et al. <xref ref-type="bibr" rid="CR23">1995</xref>).</p>
      </sec>
      <sec id="Sec5">
        <title>Ex vivo human whole blood assay</title>
        <p id="Par11">Fresh human blood was collected from healthy volunteers with informed consent. Blood was collected using anticoagulant lepirudin at 50&#xA0;&#x3BC;g/mL. Blood samples were pre-treated with zilucoplan at ranging doses of 1&#xA0;nM to 1&#xA0;&#x3BC;M for 30&#xA0;min at 37&#xA0;&#xB0;C. Lipopolysaccharides from <italic>Echerichia coli</italic> O111:B4 at 200&#xA0;ng/mL was added to the pre-incubated blood samples for 24&#xA0;h at 37&#xA0;&#xB0;C. Blood samples were centrifuged at 2000&#xD7;<italic>g</italic> for 10&#xA0;min at 4&#xA0;&#xB0;C. Plasma C5a levels were determined using commercially available enzyme-linked immunosorbent assay kit (R&amp;D Systems).</p>
      </sec>
    </sec>
    <sec id="Sec6">
      <title>Results</title>
      <p id="Par12">We employed the structure of zilucoplan described in patent material for the basis of this work (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) (Hoarty et al. <xref ref-type="bibr" rid="CR8">2015</xref>). Zilucoplan consists of a cyclic backbone (from the sidechain of Lys-1 to the sidechain of Asp-6) alongside several non-natural amino acids (including cyclohexyl glycine, <sc>l</sc>-7-azatryptophan, <sc>l</sc>-butyl-glycine and N-methyl aspartate). PEG24, &#x3B3;-glutamic acid and an N-terminal palmitic acid moiety were attached to the sidechain of Lys-15. The cyclic core of zilucoplan was synthesised first using solid-phase peptide synthesis. The N-terminus was acetylated and then an on-resin cyclisation was performed between the sidechain of Lys-1 and Asp-6 overnight. The reaction was confirmed as completed by a loss of 18&#xA0;Da observed with ESI&#x2013;MS. Subsequent removal of the IvDde group on Lys-15 sidechain facilitated addition of PEG24 and &#x3B3;-glutamic acid to this position.</p>
      <p id="Par13">Following 95% TFA cleavage and RP-HPLC purification, palmitic acid was coupled onto the amine of &#x3B3;-glutamic acid on the sidechain extension of Lys-15 utilising palmitic acid-NHS ester. After purification by RP-HPLC, 12&#xA0;mg of zilucoplan was obtained (&gt;&#x2009;99% purity, 2.70% yield based on resin loading) and the monoisotopic mass (observed 3559.5891&#xA0;Da, calculated 3559.9694&#xA0;Da) was consistent with the reported value (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) (Hoarty et al. <xref ref-type="bibr" rid="CR8">2015</xref>). Secondary H&#x3B1; shifts were calculated according to the chemical shift assignments (Table S1) of the main chain of zilucoplan (not including PEG24, &#x3B3;-glutamic acid and palmitic acid). The deviation from random coil between residues 4 and 7 suggests that there might be local rigidity between Arg-4 and NMe-Asp-7 (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>a).</p>
      <p id="Par14">The ability of zilucoplan to inhibit LPS-induced increase in C5a plasma levels in human whole blood was then determined in a concentration&#x2013;response assay. Complete inhibition of LPS-induced C5a levels were observed at zilucoplan concentrations ranging from 10&#xA0;nM to 1&#xA0;&#xB5;M, with a 65.7% reduction in C5a plasma levels observed at a concentration of 1&#xA0;nM (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>b). An IC<sub>50</sub> of the synthesised zilucoplan was 474.5&#xA0;pM.<fig id="Fig2"><label>Fig. 2</label><caption><p>Structural analysis and biological activity of synthesized zilucoplan. <bold>a</bold> Calculated secondary H&#x3B1; shifts of the main chain of zilucoplan. Random coil values from the closest naturally occurring amino acid were used for nonstandard residues. <bold>b</bold> LPS-induced plasma C5a levels of human whole blood. <italic>n</italic>&#x2009;=&#x2009;3, data displayed as a mean&#x2009;&#xB1;&#x2009;SEM. ****<italic>p</italic>&#x2009;&lt;&#x2009;0.0001</p></caption><graphic xlink:href="726_2020_2921_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
    <sec id="Sec7">
      <title>Discussion</title>
      <p id="Par15">Prior to this work, there has been only a brief description of the synthesis of zilucoplan in the patent literature (Duda et al. <xref ref-type="bibr" rid="CR7">2020</xref>; Hoarty et al. <xref ref-type="bibr" rid="CR8">2015</xref>; Ma et al. <xref ref-type="bibr" rid="CR16">2020</xref>). Aside from being a promising therapeutic, zilucoplan is also a useful research tool in the study of complement component C5 activities. In this study, we have described an effective synthesis protocol for zilucoplan and validated the efficacy/potency of the resulting product. It has been previously reported that zilucoplan has little to no effect on rodent C5 cleavage, but does bind and inhibit human C5 cleavage (Hoarty et al. <xref ref-type="bibr" rid="CR8">2015</xref>; Ricardo et al. <xref ref-type="bibr" rid="CR20">2017</xref>). Consequently, as a measure of C5 cleavage inhibition, an LPS-induced C5a generation assay in whole human blood was assessed. Here we demonstrated a comparable inhibition of C5a formation with our synthesis compound (IC<sub>50</sub>&#x2009;=&#x2009;474.5&#xA0;pM), to the zilucoplan compound described in the patent literature (IC<sub>50</sub>&#x2009;=&#x2009;4.8&#xA0;nM) (Ricardo et al. <xref ref-type="bibr" rid="CR20">2017</xref>).</p>
      <p id="Par16">In conclusion, our effective synthesis of zilucoplan and its validation as a potent inhibitor of C5a production will be valuable to the research community to facilitate future studies on the complement system and for use as a benchmark molecule for future drug discovery efforts.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <sec id="Sec17">
        <p>Below is the link to the electronic supplementary material. <supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="726_2020_2921_MOESM1_ESM.pdf"><caption><p>Supplementary file1 (PDF 71 kb)</p></caption></media></supplementary-material></p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher's Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by DMG, JL and CDP. All authors contributed to the writing and revisions of the manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>This work was funded, in part, by a National Health and Medical Research Council Development Grant (APP8881111 to TMW and RJC).</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.</p>
    </notes>
    <notes notes-type="ethics">
      <title>Compliance with ethical standards</title>
      <notes id="FPar1" notes-type="COI-statement">
        <title>Conflict of interest</title>
        <p id="Par17">The authors declare that they have no conflict of interest.</p>
      </notes>
      <notes id="FPar2">
        <title>Ethical approval</title>
        <p id="Par18">Not applicable.</p>
      </notes>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beecher</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Putko</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Siddiqi</surname>
              <given-names>ZA</given-names>
            </name>
          </person-group>
          <article-title>Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status</article-title>
          <source>Drugs</source>
          <year>2019</year>
          <volume>79</volume>
          <fpage>353</fpage>
          <lpage>364</lpage>
          <pub-id pub-id-type="doi">10.1007/s40265-019-1065-0</pub-id>
          <pub-id pub-id-type="pmid">30762205</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braunschweiler</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ernst</surname>
              <given-names>RR</given-names>
            </name>
          </person-group>
          <article-title>Coherence transfer by isotropic mixing: Application to proton correlation spectroscopy</article-title>
          <source>J Magn Reson</source>
          <year>1969</year>
          <volume>53</volume>
          <fpage>521</fpage>
          <lpage>528</lpage>
          <pub-id pub-id-type="doi">10.1016/0022-2364(83)90226-3</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brodsky</surname>
              <given-names>RA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria</article-title>
          <source>Blood</source>
          <year>2008</year>
          <volume>111</volume>
          <fpage>1840</fpage>
          <lpage>1847</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2007-06-094136</pub-id>
          <pub-id pub-id-type="pmid">18055865</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carvelli</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Association of COVID-19 inflammation with activation of the C5a&#x2013;C5aR1 axis</article-title>
          <source>Nature</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1038/s41586-020-2600-6</pub-id>
          <pub-id pub-id-type="pmid">32726800</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cofiell</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS</article-title>
          <source>Blood</source>
          <year>2015</year>
          <volume>125</volume>
          <fpage>3253</fpage>
          <lpage>3262</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2014-09-600411</pub-id>
          <pub-id pub-id-type="pmid">25833956</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Denk</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Complement C5a-induced changes in neutrophil morphology during inflammation</article-title>
          <source>Scand J Immunol</source>
          <year>2017</year>
          <volume>86</volume>
          <fpage>143</fpage>
          <lpage>155</lpage>
          <pub-id pub-id-type="doi">10.1111/sji.12580</pub-id>
          <pub-id pub-id-type="pmid">28671713</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <mixed-citation publication-type="other">Duda P, Farzaneh-Far R, Ma Z, Zhu N, Thackaberry E, Ricardo A (2020) Neurological disease treatment with zilucoplan. WO2020086506A1</mixed-citation>
      </ref>
      <ref id="CR8">
        <mixed-citation publication-type="other">Hoarty MD et al. (2015) Modulation of complement activity. United States of America Patent, WO2015191951A2</mixed-citation>
      </ref>
      <ref id="CR9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Howard</surname>
              <given-names>JF</given-names>
              <suffix>Jr</suffix>
            </name>
            <etal/>
          </person-group>
          <article-title>Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study</article-title>
          <source>Lancet Neurol</source>
          <year>2017</year>
          <volume>16</volume>
          <fpage>976</fpage>
          <lpage>986</lpage>
          <pub-id pub-id-type="doi">10.1016/s1474-4422(17)30369-1</pub-id>
          <pub-id pub-id-type="pmid">29066163</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Howard</surname>
              <given-names>JF</given-names>
              <suffix>Jr</suffix>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized double-blind, placebo-controlled, multicenter clinical trial</article-title>
          <source>JAMA Neurol</source>
          <year>2020</year>
          <volume>77</volume>
          <fpage>582</fpage>
          <lpage>592</lpage>
          <pub-id pub-id-type="doi">10.1001/jamaneurol.2019.5125</pub-id>
          <pub-id pub-id-type="pmid">32065623</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jayne</surname>
              <given-names>DRW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2017</year>
          <volume>28</volume>
          <fpage>2756</fpage>
          <pub-id pub-id-type="doi">10.1681/ASN.2016111179</pub-id>
          <pub-id pub-id-type="pmid">28400446</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jeener</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Meier</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Bachmann</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ernst</surname>
              <given-names>RR</given-names>
            </name>
          </person-group>
          <article-title>Investigation of exchange processes by two-dimensional NMR spectroscopy</article-title>
          <source>J Chem Phys</source>
          <year>1979</year>
          <volume>71</volume>
          <fpage>4546</fpage>
          <lpage>4553</lpage>
          <pub-id pub-id-type="doi">10.1063/1.438208</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Keller</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <source>The computer aided resonance assignment tutorial</source>
          <year>2004</year>
          <publisher-loc>Seattle</publisher-loc>
          <publisher-name>CANTINA</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Legendre</surname>
              <given-names>CM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome</article-title>
          <source>N Engl J Med</source>
          <year>2013</year>
          <volume>368</volume>
          <fpage>2169</fpage>
          <lpage>2181</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1208981</pub-id>
          <pub-id pub-id-type="pmid">23738544</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lo</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Kemper</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Woodruff</surname>
              <given-names>TM</given-names>
            </name>
          </person-group>
          <article-title>COVID-19: complement, coagulation, and collateral damage</article-title>
          <source>J Immunol</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.4049/jimmunol.2000644</pub-id>
          <pub-id pub-id-type="pmid">32699160</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <mixed-citation publication-type="other">Ma Z, Zhu N, Thackaberry E, Farzaneh-Far R, Ricardo A (2020) Modulation of complement activity. WO2020185541</mixed-citation>
      </ref>
      <ref id="CR17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pandey</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Maharana</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>XX</given-names>
            </name>
            <name>
              <surname>Woodruff</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Shukla</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>Emerging insights into the structure and function of complement C5a receptors</article-title>
          <source>Trends Biochem Sci</source>
          <year>2020</year>
          <volume>45</volume>
          <fpage>693</fpage>
          <lpage>705</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tibs.2020.04.004</pub-id>
          <pub-id pub-id-type="pmid">32402749</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pittock</surname>
              <given-names>SJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study</article-title>
          <source>Lancet Neurol</source>
          <year>2013</year>
          <volume>12</volume>
          <fpage>554</fpage>
          <lpage>562</lpage>
          <pub-id pub-id-type="doi">10.1016/s1474-4422(13)70076-0</pub-id>
          <pub-id pub-id-type="pmid">23623397</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Podack</surname>
              <given-names>ER</given-names>
            </name>
          </person-group>
          <article-title>Molecular composition of the tubular structure of the membrane attack complex of complement</article-title>
          <source>J Biol Chem</source>
          <year>1984</year>
          <volume>259</volume>
          <fpage>8641</fpage>
          <lpage>8647</lpage>
          <pub-id pub-id-type="doi">10.1016/S0021-9258(17)39778-8</pub-id>
          <pub-id pub-id-type="pmid">6736043</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <mixed-citation publication-type="other">Ricardo A et al. (2017) Modulation of complement activity. United States of America Patent, WO2018106859 Al</mixed-citation>
      </ref>
      <ref id="CR21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schindler</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gelfand</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Dinarello</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself</article-title>
          <source>Blood</source>
          <year>1990</year>
          <volume>76</volume>
          <fpage>1631</fpage>
          <lpage>1638</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.V76.8.1631.1631</pub-id>
          <pub-id pub-id-type="pmid">2207333</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scholz</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>McClurg</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Cardenas</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Noonan</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Hugli</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
          <article-title>C5a-mediated release of interleukin 6 by human monocytes</article-title>
          <source>Clin Immunol Immunopathol</source>
          <year>1990</year>
          <volume>57</volume>
          <fpage>297</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="doi">10.1016/0090-1229(90)90043-p</pub-id>
          <pub-id pub-id-type="pmid">2208809</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wishart</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Bigam</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Holm</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hodges</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Sykes</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
          <article-title>1H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-neighbor effects</article-title>
          <source>J Biomol NMR</source>
          <year>1995</year>
          <volume>5</volume>
          <fpage>67</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00227471</pub-id>
          <pub-id pub-id-type="pmid">7881273</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Woodruff</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Shukla</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>The complement C5a&#x2013;C5aR1 GPCR axis in COVID-19 therapeutics</article-title>
          <source>Trends Immunol</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.it.2020.09.008</pub-id>
          <pub-id pub-id-type="pmid">33023856</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Woodruff</surname>
              <given-names>TM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>2005</year>
          <volume>314</volume>
          <fpage>811</fpage>
          <lpage>817</lpage>
          <pub-id pub-id-type="doi">10.1124/jpet.105.086835</pub-id>
          <pub-id pub-id-type="pmid">15879003</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>W&#xFC;thrich</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>NMR with proteins and nucleic acids</article-title>
          <source>Europhys News</source>
          <year>1986</year>
          <volume>17</volume>
          <fpage>11</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1051/epn/19861701011</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yee</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII</article-title>
          <source>Blood</source>
          <year>2015</year>
          <volume>126</volume>
          <fpage>939</fpage>
          <lpage>942</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2015-04-641696</pub-id>
          <pub-id pub-id-type="pmid">26065653</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An ancient peptide family buried within vicilin precursors</article-title>
          <source>ACS Chem Biol</source>
          <year>2019</year>
          <volume>14</volume>
          <fpage>979</fpage>
          <lpage>993</lpage>
          <pub-id pub-id-type="doi">10.1021/acschembio.9b00167</pub-id>
          <pub-id pub-id-type="pmid">30973714</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Adv Pharmacol Pharm Sci</journal-id>
      <journal-id journal-id-type="iso-abbrev">Adv Pharmacol Pharm Sci</journal-id>
      <journal-id journal-id-type="publisher-id">APS</journal-id>
      <journal-title-group>
        <journal-title>Advances in Pharmacological and Pharmaceutical Sciences</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2633-4682</issn>
      <issn pub-type="epub">2633-4690</issn>
      <publisher>
        <publisher-name>Hindawi</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33299984</article-id>
      <article-id pub-id-type="pmc">7707973</article-id>
      <article-id pub-id-type="doi">10.1155/2020/8890921</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Anticoagulant Utilization and Cost Analysis among Cardiology Inpatients in a Tertiary Care Teaching Hospital of Western Nepal</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7881-2864</contrib-id>
          <name>
            <surname>Sankhi</surname>
            <given-names>Sabina</given-names>
          </name>
          <email>sabinasankhi03@gmail.com</email>
          <xref ref-type="aff" rid="I1"/>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4353-382X</contrib-id>
          <name>
            <surname>Marasine</surname>
            <given-names>Nirmal Raj</given-names>
          </name>
          <xref ref-type="aff" rid="I1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thapa</surname>
            <given-names>Parbati</given-names>
          </name>
          <xref ref-type="aff" rid="I1"/>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1501-9196</contrib-id>
          <name>
            <surname>Dangi</surname>
            <given-names>Nim Bahadur</given-names>
          </name>
          <xref ref-type="aff" rid="I1"/>
        </contrib>
      </contrib-group>
      <aff id="I1">Pharmaceutical Sciences Program, School of Health and Allied Sciences, Pokhara University, Pokhara 30, Kaski, Nepal</aff>
      <author-notes>
        <fn fn-type="other">
          <p>Academic Editor: Gunawan Indrayanto</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>11</month>
        <year>2020</year>
      </pub-date>
      <volume>2020</volume>
      <elocation-id>8890921</elocation-id>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>4</month>
          <year>2020</year>
        </date>
        <date date-type="rev-recd">
          <day>23</day>
          <month>7</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>31</day>
          <month>10</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2020 Sabina Sankhi et al.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Introduction</title>
          <p> Anticoagulants have a wide spectrum of use and risks associated with their therapy due to their narrow therapeutic range. This study aimed to evaluate the anticoagulant utilization and cost analysis in patients admitted to the cardiology ward of a tertiary care hospital in western Nepal. </p>
        </sec>
        <sec>
          <title>Methods</title>
          <p> A prospective cohort study was conducted in patients admitted to the cardiology ward of Manipal Teaching Hospital (MTH), Pokhara, Kaski, Nepal, from August to November 2019. All patients (<italic>n</italic>&#x2009;=&#x2009;132) aged &#x2265;18 years of either gender receiving anticoagulants for any indication in the cardiology ward were included in the study. Anticoagulant utilization, the average prescribed daily dose (PDD/DDD) and the cost of anticoagulant per patient were calculated. Descriptive statistics were performed using IBM-SPSS 20.0. </p>
        </sec>
        <sec>
          <title>Results</title>
          <p> Acute coronary syndrome (66.67%) was a common indication, unfractionated heparin&#x2009;+&#x2009;enoxaparin (45.45%) and enoxaparin (27.3%) were the most frequently prescribed anticoagulants. The performance of monitoring parameters such as international normalized ratio (INR), prothrombin time (PT), activated partial thromboplastin time (aPTT), and renal function test were consistent with the American College of Chest Physician (ACCP) guidelines. The average prescribed daily dose of anticoagulants was 1.3 (unfractionated heparin), 2.25 (enoxaparin), 0.5 (warfarin), and 1.0 (dabigatran). Heparin was associated with the majority of cases of drug interactions (52 cases). Enoxaparin was the most expensive of all the anticoagulant drug classes. The median (IQR) cost of anticoagulants used per patient was US$79.92 ($46.32). </p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p> Our study suggests that the utilization of unfractionated heparin and enoxaparin and the cost of anticoagulants per patient were higher in the patients admitted to the cardiology ward of the hospital.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>1. Introduction</title>
      <p>Drug utilization has been defined as &#x201C;the marketing, distribution, prescription, and use of drugs in society, with special emphasis on the resulting medical, social, and economic consequences.&#x201D; It helps healthcare systems to understand, interpret, and improve the prescription, administration, and use of medications, which in turn improves patient therapeutic outcomes [<xref rid="B1" ref-type="bibr">1</xref>].</p>
      <p>About 7 million people worldwide are taking anticoagulants for the management of their chronic diseases [<xref rid="B2" ref-type="bibr">2</xref>]. Anticoagulants are frequently prescribed drugs in deep vein thrombosis, pulmonary embolism, myocardial infarction, unstable angina, atrial fibrillation, acute coronary syndrome, rheumatic heart disease, vascular surgery, and prosthetic heart valve, in both inpatient and outpatient settings [<xref rid="B3" ref-type="bibr">3</xref>]. They are divided into oral (coumarin derivatives: warfarin and acenocoumarol) and parenteral agents [indirect thrombin inhibitors: unfractionated heparin (UFH) and low molecular weight heparin (LMWH), such as enoxaparin, dalteparin, and direct thrombin inhibitor, lepirudin]. The latter is widely used for short-term therapy, basically when rapid anticoagulation is required [<xref rid="B4" ref-type="bibr">4</xref>].</p>
      <p>Historically, anticoagulation therapy with warfarin has been the cornerstone of oral anticoagulant therapy worldwide [<xref rid="B5" ref-type="bibr">5</xref>]. The ability to monitor the degree of anticoagulation, reversibility of effects, and low-cost generic availability of warfarin appealed both patients and physicians for its use. Despite its effectiveness in reducing thromboembolic events, it has several drawbacks, including a narrow therapeutic effect, a delayed onset and offset of action, complex dosing with genetic variances, potential drug interactions, and routine monitoring of international normalized ratio (INR), prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet count along with patient-specific dose adjustments [<xref rid="B6" ref-type="bibr">6</xref>&#x2013;<xref rid="B8" ref-type="bibr">8</xref>]. Additionally, these drug classes (both warfarin and unfractionated heparin) have a high chance of causing adverse effects such as bleeding, heparin-induced thrombocytopenia, osteoporosis, hemorrhagic stroke, and even death [<xref rid="B9" ref-type="bibr">9</xref>]. Lack of proper monitoring can result in inappropriate dosing and complications such as bleeding and thrombosis. This, as a whole, leads to increased duration of hospital stay, increased overall healthcare costs, decreased therapeutic outcome, and eventually increased mortality [<xref rid="B10" ref-type="bibr">10</xref>]. All these incidents motivated the development of newer oral anticoagulant therapy, called non-vitamin K antagonist oral anticoagulant (NOAC).</p>
      <p>Non-vitamin K antagonist oral anticoagulants (NOACs), such as direct factor Xa inhibitors: rivaroxaban and apixaban, and direct thrombin inhibitor: dabigatran, are newer agents approved by current guidelines for the prevention of stroke and systemic embolism in patients with atrial fibrillation and patients with venous thromboembolism [<xref rid="B6" ref-type="bibr">6</xref>&#x2013;<xref rid="B8" ref-type="bibr">8</xref>]. In contrast to warfarin, these newer agents do not require routine monitoring of anticoagulant effects because of their more predictable pharmacological profiles, rapid onset and offset of action, and fewer drug-drug and drug-food interactions [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B11" ref-type="bibr">11</xref>].</p>
      <p>There is a paucity of data on anticoagulant utilization and associated costs to the patients, especially in inpatients in Nepal. Evidence suggests that physicians familiarity, clinical experience, and efficacy have been influencing the prescription of anticoagulants. Determining the utilization of anticoagulants within a broader patient population could have a positive effect on patient outcomes and overall healthcare costs. Therefore, we aimed to assess the anticoagulant utilization and cost in patients admitted to the cardiology ward of a tertiary care teaching hospital in western Nepal.</p>
    </sec>
    <sec id="sec2">
      <title>2. Methodology</title>
      <sec id="sec2.1">
        <title>2.1. Ethics</title>
        <p>Ethical approval for this study was obtained from the Institutional Review Committee (IRC) of Pokhara University Research Center (PURC) (ref. no. 20/076/077). Prior permission to conduct the study was obtained from the Manipal Teaching Hospital, Pokhara, Nepal. The patients or caretakers were fully informed about the nature and purpose of the study in Nepali language, and their written consent was obtained prior to data collection. Personal details of the patients were kept confidential, and anonymity was maintained.</p>
      </sec>
      <sec id="sec2.2">
        <title>2.2. Study Design and Population</title>
        <p>A prospective cohort study was conducted between August 2019 and October 2019 among 132 patients in the cardiology ward of Manipal Teaching Hospital (MTH), Pokhara, Nepal. All patients aged &#x2265;18 years of either gender, receiving anticoagulants for any indication in the cardiology ward and those willing to participate were included in the study. Outpatients, patients admitted in a department other than the cardiology and those diagnosed with mental retardation were excluded from the study.</p>
      </sec>
      <sec id="sec2.3">
        <title>2.3. Data Collection</title>
        <p>Data were collected prospectively from the patients' Kardex. All patients were followed up until they stayed in the cardiology ward. Information on demographics (age, gender, occupation, and education), laboratory test results of parameters such as INR for warfarin, PT, and aPTT for UFH and renal function test before using enoxaparin, anticoagulant use (indication, prescribed anticoagulants, generic name, dose, dosage form, frequency, and route of administration of antibiotic), length of hospital stay, and anticoagulant cost at the time of the study were collected in a well-designed proforma. According to the World Health Organization (WHO), the prescribed daily dose (PDD) is the average dose prescribed according to a representative sample of prescriptions. It gives the average daily amount of a drug that is prescribed and expressed as the PDD:DDD ratio [<xref rid="B12" ref-type="bibr">12</xref>].</p>
        <p>PDD was calculated as<disp-formula id="EEq1"><label>(1)</label><mml:math id="M1"><mml:mtable><mml:mtr><mml:mtd><mml:mtext>PDD</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mtext>total&#x2009;dose&#x2009;of&#x2009;a&#x2009;drug&#x2009;over&#x2009;a&#x2009;specified&#x2009;period</mml:mtext></mml:mrow><mml:mrow><mml:mtext>number&#x2009;of&#x2009;days</mml:mtext></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p>
        <p>The calculated prescribed daily dose was compared with the respective WHO's precalculated defined daily dose (DDD) [<xref rid="B13" ref-type="bibr">13</xref>]. The individual anticoagulant cost was calculated by the multiplication of the cost per unit and the number of doses prescribed. The unit price of each anticoagulant used was obtained from the hospital pharmacy.</p>
      </sec>
      <sec id="sec2.4">
        <title>2.4. Data Analysis</title>
        <p>The data were entered in Microsoft Excel version 13 and analyzed using IBM-SPSS 20.0 (IBM Corporation, Armonk, NY, USA). Data were expressed as median and interquartile range (IQR), and descriptive statistics were used. The Kolmogorov&#x2013;Smirnov test was used to determine the normality of the numeric variables. Stockley's drug interactions, 9th Edition [<xref rid="B14" ref-type="bibr">14</xref>], was used for analyzing potential drug-drug interactions.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>3. Results and Discussion</title>
      <p>Among the total of 132 patients, more than half (77, 58.3%) were male. One-fourth of the study participants (34, 25.8%) aged 61&#x2013;70 years. The most frequently reported occupation was housewife or unemployed (70, 53%). Fifty-two (39.4%) of them were illiterate, and 38 (28.8%) of them had an elementary level of education, as shown in <xref rid="tab1" ref-type="table">Table 1</xref>.</p>
      <p>This represented that this patient population was at a higher risk of developing cardiovascular diseases. This finding was consistent with that of another study conducted in Pakistan [<xref rid="B15" ref-type="bibr">15</xref>]. Increased loneliness and stress in unemployed or housewife, business/job holders, poor control of pre-existing cardiovascular risk factors in farmers, and prolonged stable postures (sitting or standing) in builders, drivers, cooks, and tailors may increase the risk of cardiovascular diseases. The length of hospital stay ranged from 1 to 15 days, with a median (IQR) of 6 (3) days.</p>
      <p>The majority of the patients (81, 61.35%) were prescribed more than one anticoagulant medication, where unfractionated heparin and enoxaparin comprised a major proportion (60, 45.45%), followed by enoxaparin and warfarin (21, 15.90%). Enoxaparin (36, 27.3%) was the most frequently prescribed monotherapy compared to all other anticoagulants. In both monotherapy and combination therapy, use of enoxaparin was common. This might be due to its greater bioavailability, longer plasma half-life, predictable anticoagulant effect, and lower incidence of osteoporosis and heparin-induced thrombocytopenia [<xref rid="B16" ref-type="bibr">16</xref>]. The current availability of NOAC in Nepal along with the lack of clinical experience among physicians, higher cost, unavailability of antidotes, and contraindications in patients with severe kidney or liver disease might be the reason for the lower use of dabigatran (3.78%) than warfarin, which was used in monotherapy as well as in combination therapy in our study [<xref rid="B17" ref-type="bibr">17</xref>]. This was comparably lower than that of the studies from Canada [<xref rid="B18" ref-type="bibr">18</xref>] and Turkey [<xref rid="B19" ref-type="bibr">19</xref>], where dabigatran was used in 46.8% and 24% of the patients, respectively, and warfarin was the mainstay of the therapy (53.2% and 73%, respectively).</p>
      <p>As in a study done in Iran [<xref rid="B10" ref-type="bibr">10</xref>], acute coronary syndrome was the common clinical condition followed by congestive heart failure for which an anticoagulant was prescribed.</p>
      <p>Our study showed that there was a high variation in the cost of these utilized anticoagulants. The total cost of anticoagulants prescribed in all the patients was $8155.09, and the average individual anticoagulant cost was US$79.92, but it varied from US$0.03 to US$126.24, as illustrated in <xref rid="tab2" ref-type="table">Table 2</xref>. For example, enoxaparin 60&#x2009;mg/ml was prescribed twice a day for 5 days. Enoxaparin 60&#x2009;mg/ml costs NRs 911.52 during the study period. Within 5 days of hospital stay, 10 doses were used in patients, which cost 911.52&#x2009;&#xD7;&#x2009;10&#x2009;=&#x2009;Rs. 9115.20 ($79.92) for that individual. Similarly, during 1 day of hospital stay, only warfarin 2&#x2009;mg was prescribed once daily. Warfarin 2&#x2009;mg costs NRs 3 per tablet, and as only one tablet was used by the patient, the anticoagulant cost of that patient became 3&#x2009;&#xD7;&#x2009;1&#x2009;=&#x2009;3 ($0.03). In similar way, the cost was calculated in patients prescribed with more than one anticoagulant. Enoxaparin was the most expensive anticoagulant of all and further increases the burden when added to the cost of diagnosis and monitoring. A study in the United Kingdom [<xref rid="B20" ref-type="bibr">20</xref>] reported that the patients spent approximately US$726.58 on total anticoagulant cost per year. On the contrary, global comparisons of anticoagulant utilization costs could be often misleading due to the alteration of drug prices globally.</p>
      <p>As per the ACCP guidelines, monitoring parameters such as PT/INR/aPTT and renal function tests are important factors for monitoring and controlling anticoagulant use. During the study period, baseline PT/INR/aPTT was performed in the majority of the patients (87.9%). In the case of enoxaparin, a renal function test is a must since they are renally cleared drugs and was performed in 94.87% of enoxaparin users [<xref rid="B6" ref-type="bibr">6</xref>&#x2013;<xref rid="B8" ref-type="bibr">8</xref>], as depicted in <xref rid="tab3" ref-type="table">Table 3</xref>.</p>
      <p>In contrast, laboratory monitoring of PT/INR/aPTT was not performed in enoxaparin users, as they do not prolong aPTT/clotting time. Likewise, aPTT was monitored for unfractionated heparin every 6 hours and on every second day of warfarin therapy until the therapeutic goal (2-3) was reached. Moreover, it is recommended to carry out a kidney function test before initiation of any NOAC, to determine if dose reductions are necessary [<xref rid="B21" ref-type="bibr">21</xref>]. However, regular monitoring of PT/INR for dabigatran as like warfarin (i.e., on a 24-hour basis) was observed in our study, which might contribute to an increase in cost burden to the patients. In addition, in many patients, magnetic resonance imaging (MRI), angiography, and computerized tomography (CT) scans were performed to detect the presence of clots or thrombus formation.</p>
      <p>From the calculated PDD of each anticoagulant when compared with WHO's provided optimal dose, unfractionated heparin was prescribed more than the optimal dose, enoxaparin was prescribed more than double the optimal dose, and warfarin was prescribed half the optimal dose. In contrast, only dabigatran was prescribed within the WHO's provided optimal dose, as illustrated in <xref rid="tab4" ref-type="table">Table 4</xref>.</p>
      <p>These findings of our study were consistent with those of a study from our neighboring country, India [<xref rid="B3" ref-type="bibr">3</xref>], where unfractionated heparin and enoxaparin were prescribed above the optimal dose (1.3 and 1.1, respectively), warfarin was prescribed below the optimal dose (0.53), and NOAC (rivaroxaban) was prescribed within the WHOs provided optimal dose (1.0). The utilization of enoxaparin was more than twice in our study. This fluctuation in the utilization of anticoagulants might be due to variations in diagnosis, age, weight, and severity of the disease, which resulted in a marked difference in the dosing quantity and PDD differed from WHO's DDD [<xref rid="B12" ref-type="bibr">12</xref>].</p>
      <p>Of the total 65 cases of potential drug interactions analyzed during the study period, unfractionated heparin was the drug commonly involved in 52 (80%) of the cases (unfractionated heparin&#x2009;+&#x2009;aspirin: 44 and unfractionated heparin&#x2009;+&#x2009;telmisartan: 8), as depicted in <xref rid="tab5" ref-type="table">Table 5</xref>. Likewise, in a similar study conducted in Ethiopia [<xref rid="B22" ref-type="bibr">22</xref>], unfractionated heparin was found involved in 35% of the potential drug interaction cases and enoxaparin in only 10.7% of the cases.</p>
      <p>There are a number of limitations to this study. We explored the anticoagulant utilization pattern over a period of three months. Hence, the influence of seasonal variations on disease pattern and anticoagulant utilization could not be considered. Similarly, this study failed to examine confounding factors such as diet patterns, which could have influenced the significance of various factors on the utilization pattern. Likewise, the total healthcare costs of the individual patient was outside the scope of this study, and therefore we were only able to calculate the cost for anticoagulant use. Despite these limitations, this study provides an insight into the anticoagulant use among inpatients in the cardiology ward and the costs associated with it. The findings might be beneficial for policy formulation of anticoagulants use in Nepal. This is probably the first study on anticoagulants in the inpatient setting and first to calculate the prescribed daily dose for anticoagulants in Nepal. Thus, it can serve as baseline data for conducting studies in a similar set up in near future to identify the trends in drug consumption over the years.</p>
    </sec>
    <sec id="sec4">
      <title>4. Conclusion</title>
      <p>Our study suggests that the utilization of anticoagulants is not to the optimum except for dabigatran. Especially, enoxaparin use was more than twice as directed by the WHO. Moreover, anticoagulant costs per patient was also high. This highlights the need for development and implementation of standard treatment guidelines, protocols, and subsequent pharmacoeconomic evaluation of anticoagulation therapy for better patient outcomes and making treatments cost-effective and affordable to every socioeconomic community.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>The authors are equally thankful to the cardiologist, nurses, and all other staff of cardiology ward of Manipal Teaching Hospital for their help during data collection and to the patients and their relatives for their warm support and coordination throughout this study. The authors also acknowledge the School of Health and Allied Sciences, Pokhara University, for the necessary guidance and support. </p>
    </ack>
    <sec sec-type="data-availability">
      <title>Data Availability</title>
      <p>The raw data used to support the findings of this study are made available from the corresponding author upon request.</p>
    </sec>
    <sec>
      <title>Disclosure</title>
      <p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
    </sec>
    <sec sec-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors declare that they have no conflicts of interest.</p>
    </sec>
    <sec>
      <title>Authors' Contributions</title>
      <p>Sabina Sankhi was involved in the conceptualization and data curation. Sabina Sankhi and Nirmal Raj Marasine were involved in the formal analysis and investigation. Nim Bahadur Dangi supervised the study. Parbati Thapa co-supervised the study. Sabina Sankhi, Nirmal Raj Marasine, Parbati Thapa, and Nim Bahadur Dangi were responsible for the validation. Sabina Sankhi and Nirmal Raj Marasine were involved in writing, reviewing, and editing the original draft. All authors read and approved the final manuscript.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="book">
          <collab>World Health Organization</collab>
          <source>
            <italic toggle="yes">Introduction to Drug Utilization Research</italic>
          </source>
          <year>2003</year>
          <publisher-loc>Geneva, Switzerland</publisher-loc>
          <publisher-name>World Health Organization</publisher-name>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/42627/924156234X.pdf?sequence=1&amp;isAllowed=y">https://apps.who.int/iris/bitstream/handle/10665/42627/924156234X.pdf?sequence=1&amp;isAllowed=y</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia</surname>
              <given-names>D. A.</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>M. J.</given-names>
            </name>
          </person-group>
          <article-title>Warfarin therapy: tips and tools for better control</article-title>
          <source>
            <italic toggle="yes">The Journal of Family Practice</italic>
          </source>
          <year>2011</year>
          <volume>60</volume>
          <issue>2</issue>
          <fpage>p. 70</fpage>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chadalavada</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Mounika</surname>
              <given-names>G. V. N.</given-names>
            </name>
            <name>
              <surname>Saikiran</surname>
              <given-names>V. V. V.</given-names>
            </name>
            <name>
              <surname>Medha Sree</surname>
              <given-names>G. S.</given-names>
            </name>
          </person-group>
          <article-title>Drug utilization evaluation and assessment of economic burden of anticoagulants in a tertiary care hospital in South India</article-title>
          <source>
            <italic toggle="yes">Journal of Pharmaceutical and Scientific Innovation</italic>
          </source>
          <year>2018</year>
          <volume>7</volume>
          <issue>5</issue>
          <fpage>188</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="doi">10.7897/2277-4572.075106</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perez</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Eraso</surname>
              <given-names>L. H.</given-names>
            </name>
            <name>
              <surname>Merli</surname>
              <given-names>G. J.</given-names>
            </name>
          </person-group>
          <article-title>Implications of new anticoagulants in primary practice</article-title>
          <source>
            <italic toggle="yes">International Journal of Clinical Practice</italic>
          </source>
          <year>2013</year>
          <volume>67</volume>
          <issue>2</issue>
          <fpage>139</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="doi">10.1111/ijcp.12023</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84872356086</pub-id>
          <pub-id pub-id-type="pmid">23305476</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whitworth</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Haase</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Fike</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bharadwaj</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>MacLaughlin</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Utilization and prescribing patterns of direct oral anticoagulants</article-title>
          <source>
            <italic toggle="yes">International Journal of General Medicine</italic>
          </source>
          <year>2017</year>
          <volume>10</volume>
          <fpage>p. 87</fpage>
          <pub-id pub-id-type="doi">10.2147/ijgm.s129235</pub-id>
          <pub-id pub-id-type="other">2-s2.0-85016234751</pub-id>
          <pub-id pub-id-type="pmid">28331354</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ageno</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Gallus</surname>
              <given-names>A. S.</given-names>
            </name>
            <name>
              <surname>Wittkowsky</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Crowther</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hylek</surname>
              <given-names>E. M.</given-names>
            </name>
            <name>
              <surname>Palareti</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Oral anticoagulant therapy</article-title>
          <source>
            <italic toggle="yes">Chest</italic>
          </source>
          <year>2012</year>
          <volume>141</volume>
          <issue>2</issue>
          <fpage>e44S</fpage>
          <lpage>e88S</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.11-2292</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84856784474</pub-id>
          <pub-id pub-id-type="pmid">22315269</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>You</surname>
              <given-names>J. J.</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>D. E.</given-names>
            </name>
            <name>
              <surname>Howard</surname>
              <given-names>P. A.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antithrombotic therapy for atrial fibrillation</article-title>
          <source>
            <italic toggle="yes">Chest</italic>
          </source>
          <year>2012</year>
          <volume>141</volume>
          <issue>2</issue>
          <fpage>e531S</fpage>
          <lpage>e575S</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.11-2304</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84856745317</pub-id>
          <pub-id pub-id-type="pmid">22315271</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manning</surname>
              <given-names>W. H.</given-names>
            </name>
            <name>
              <surname>Bergqvist</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Pineo</surname>
              <given-names>G. F.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevention of venous thromboembolism</article-title>
          <source>
            <italic toggle="yes">Chest</italic>
          </source>
          <year>2008</year>
          <volume>133</volume>
          <issue>6</issue>
          <fpage>381S</fpage>
          <lpage>453S</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.08-0656</pub-id>
          <pub-id pub-id-type="other">2-s2.0-46049090201</pub-id>
          <pub-id pub-id-type="pmid">18574271</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heit</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Qato</surname>
              <given-names>D. M.</given-names>
            </name>
            <name>
              <surname>Kornfield</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Stafford</surname>
              <given-names>R. S.</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>G. C.</given-names>
            </name>
          </person-group>
          <article-title>National trends in oral anticoagulant use in the United States, 2007 to 2011</article-title>
          <source>
            <italic toggle="yes">Circulation: Cardiovascular Quality and Outcomes</italic>
          </source>
          <year>2012</year>
          <volume>5</volume>
          <issue>5</issue>
          <fpage>615</fpage>
          <lpage>621</lpage>
          <pub-id pub-id-type="doi">10.1161/circoutcomes.112.967299</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84868662780</pub-id>
          <pub-id pub-id-type="pmid">22949490</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khalili</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Dashti-Khavidaki</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Talasaz</surname>
              <given-names>A. H.-H.</given-names>
            </name>
            <name>
              <surname>Najmedin</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Hosseinpoor</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Anticoagulant utilization evaluation in a teaching hospital</article-title>
          <source>
            <italic toggle="yes">Journal of Pharmacy Practice</italic>
          </source>
          <year>2010</year>
          <volume>23</volume>
          <issue>6</issue>
          <fpage>579</fpage>
          <lpage>584</lpage>
          <pub-id pub-id-type="doi">10.1177/0897190010372808</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84971290837</pub-id>
          <pub-id pub-id-type="pmid">21507866</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Granger</surname>
              <given-names>C. B.</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>J. H.</given-names>
            </name>
            <name>
              <surname>McMurray</surname>
              <given-names>J. J. V.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>versus warfarin in patients with atrial fibrillation</article-title>
          <source>
            <italic toggle="yes">New England Journal of Medicine</italic>
          </source>
          <year>2011</year>
          <volume>365</volume>
          <issue>11</issue>
          <fpage>981</fpage>
          <lpage>992</lpage>
          <pub-id pub-id-type="doi">10.1056/nejmoa1107039</pub-id>
          <pub-id pub-id-type="other">2-s2.0-80052825103</pub-id>
          <pub-id pub-id-type="pmid">21870978</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="book">
          <collab>Diaz</collab>
          <source>
            <italic toggle="yes">WHO Collaborating Centre for Drug Statistics Methodology: Guidelines for ATC Classification and DDD Assignment 2020</italic>
          </source>
          <year>2020</year>
          <publisher-loc>Oslo, Norway</publisher-loc>
          <publisher-name>Norwegian Institute of Public Health</publisher-name>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Venkateshwarlu</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Joshua Jacinth</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Praneeth</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Anusha</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Rahul Goud</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Calculation of prescribed daily dose of anticoagulants in South Indian population</article-title>
          <source>
            <italic toggle="yes">Asian Journal of Pharmaceutical and Clinical Research</italic>
          </source>
          <year>2018</year>
          <volume>11</volume>
          <issue>6</issue>
          <fpage>158</fpage>
          <lpage>161</lpage>
          <pub-id pub-id-type="doi">10.22159/ajpcr.2018.v11i6.23467</pub-id>
          <pub-id pub-id-type="other">2-s2.0-85048219911</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Baxter</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <source>
            <italic toggle="yes">Stockley&#x2019;s Drug Interactions: A Source Book of Interactions, Their Mechanisms, Clinical Importance and Management, </italic>
          </source>
          <year>2010</year>
          <edition>9th</edition>
          <publisher-loc>London, UK</publisher-loc>
          <publisher-name>Pharmaceutical Press</publisher-name>
          <fpage>405</fpage>
          <lpage>532</lpage>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alam</surname>
              <given-names>S. H.</given-names>
            </name>
            <name>
              <surname>Baqir</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Naqvi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Drug utilization and economic impact of anticoagulants in unstable angina/non-st elevation myocardial infarction in Karachi</article-title>
          <source>
            <italic toggle="yes">International Journal of Pharmacy and Pharmaceutical Sciences</italic>
          </source>
          <year>2015</year>
          <volume>7</volume>
          <issue>3</issue>
          <fpage>183</fpage>
          <lpage>185</lpage>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Argenta</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>M. A. P.</given-names>
            </name>
            <name>
              <surname>Sander</surname>
              <given-names>G. B.</given-names>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>L. B.</given-names>
            </name>
          </person-group>
          <article-title>Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis</article-title>
          <source>
            <italic toggle="yes">Value in Health</italic>
          </source>
          <year>2011</year>
          <volume>14</volume>
          <issue>5</issue>
          <fpage>S89</fpage>
          <lpage>S92</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jval.2011.05.017</pub-id>
          <pub-id pub-id-type="other">2-s2.0-80052617359</pub-id>
          <pub-id pub-id-type="pmid">21839908</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Investigators</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Oral rivaroxaban for symptomatic venous thromboembolism</article-title>
          <source>
            <italic toggle="yes">New England Journal of Medicine</italic>
          </source>
          <year>2010</year>
          <volume>363</volume>
          <issue>26</issue>
          <fpage>2499</fpage>
          <lpage>2510</lpage>
          <pub-id pub-id-type="doi">10.1056/nejmoa1007903</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84055211897</pub-id>
          <pub-id pub-id-type="pmid">21128814</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Basaran</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Filiz Basaran</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Cekic</surname>
              <given-names>E. G.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PRescriptiOn PattERns of oral anticoagulants in nonvalvular atrial fibrillation (PROPER study)</article-title>
          <source>
            <italic toggle="yes">Clinical and Applied Thrombosis/Hemostasis</italic>
          </source>
          <year>2017</year>
          <volume>23</volume>
          <issue>4</issue>
          <fpage>384</fpage>
          <lpage>391</lpage>
          <pub-id pub-id-type="doi">10.1177/1076029615614395</pub-id>
          <pub-id pub-id-type="other">2-s2.0-85018379345</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ha</surname>
              <given-names>A. C. T.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>J. L.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Oral anticoagulation for stroke prevention in Canadian practice: stroke prevention and rhythm interventions in atrial fibrillation (SPRINT-AF) registry</article-title>
          <source>
            <italic toggle="yes">Canadian Journal of Cardiology</italic>
          </source>
          <year>2016</year>
          <volume>32</volume>
          <issue>2</issue>
          <fpage>204</fpage>
          <lpage>210</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cjca.2015.04.028</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84959078608</pub-id>
          <pub-id pub-id-type="pmid">26195228</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lightowlers</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>McGuire</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke</article-title>
          <source>
            <italic toggle="yes">Stroke</italic>
          </source>
          <year>1998</year>
          <volume>29</volume>
          <issue>9</issue>
          <fpage>1827</fpage>
          <lpage>1832</lpage>
          <pub-id pub-id-type="doi">10.1161/01.str.29.9.1827</pub-id>
          <pub-id pub-id-type="other">2-s2.0-0031716952</pub-id>
          <pub-id pub-id-type="pmid">9731603</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>January</surname>
              <given-names>C. T.</given-names>
            </name>
            <name>
              <surname>Wann</surname>
              <given-names>L. S.</given-names>
            </name>
            <name>
              <surname>Alpert</surname>
              <given-names>J. S.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation</article-title>
          <source>
            <italic toggle="yes">Journal of the American College of Cardiology</italic>
          </source>
          <year>2014</year>
          <volume>64</volume>
          <issue>21</issue>
          <fpage>e1</fpage>
          <lpage>e76</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jacc.2014.03.022</pub-id>
          <pub-id pub-id-type="other">2-s2.0-84908220640</pub-id>
          <pub-id pub-id-type="pmid">24685669</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stevenson</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lemma</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Molla</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Utilization patterns of anticoagulants at medical ward of hiwot fana Specialized university hospital, harar, Ethiopia</article-title>
          <source>
            <italic toggle="yes">Journal of Basic and Clinical Pharmacy</italic>
          </source>
          <year>2017</year>
          <volume>8</volume>
          <issue>4</issue>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <table-wrap id="tab1" orientation="portrait" position="float">
      <label>Table 1</label>
      <caption>
        <p>Sociodemographic characteristics of patients (<italic>n</italic>&#x2009;=&#x2009;132).</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Characteristics</th>
            <th align="center" rowspan="1" colspan="1">Categories</th>
            <th align="center" rowspan="1" colspan="1">
<italic>n</italic> (%)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="6" colspan="1">Age</td>
            <td align="center" rowspan="1" colspan="1">18&#x2013;40</td>
            <td align="center" rowspan="1" colspan="1">9 (6.8)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">41&#x2013;50</td>
            <td align="center" rowspan="1" colspan="1">11 (8.3)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">51&#x2013;60</td>
            <td align="center" rowspan="1" colspan="1">31 (23.5)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">61&#x2013;70</td>
            <td align="center" rowspan="1" colspan="1">34 (25.8)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">71&#x2013;80</td>
            <td align="center" rowspan="1" colspan="1">33 (25.0)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">&gt;80</td>
            <td align="center" rowspan="1" colspan="1">14 (10.6)</td>
          </tr>
          <tr>
            <td align="left" colspan="3" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="2" colspan="1">Gender</td>
            <td align="center" rowspan="1" colspan="1">Male</td>
            <td align="center" rowspan="1" colspan="1">77 (58.3)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Female</td>
            <td align="center" rowspan="1" colspan="1">55 (41.7)</td>
          </tr>
          <tr>
            <td align="left" colspan="3" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="5" colspan="1">Occupation</td>
            <td align="center" rowspan="1" colspan="1">Business</td>
            <td align="center" rowspan="1" colspan="1">21 (15.9)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Service</td>
            <td align="center" rowspan="1" colspan="1">12 (9.1)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Agriculture</td>
            <td align="center" rowspan="1" colspan="1">14 (10.6)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Housewife or unemployed</td>
            <td align="center" rowspan="1" colspan="1">70 (53.0)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Others</td>
            <td align="center" rowspan="1" colspan="1">15 (11.4)</td>
          </tr>
          <tr>
            <td align="left" colspan="3" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="5" colspan="1">Education</td>
            <td align="center" rowspan="1" colspan="1">Illiterate</td>
            <td align="center" rowspan="1" colspan="1">52 (39.4)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Literate but not attended formal classes</td>
            <td align="center" rowspan="1" colspan="1">19 (14.4)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Elementary level</td>
            <td align="center" rowspan="1" colspan="1">38 (28.8)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Secondary level</td>
            <td align="center" rowspan="1" colspan="1">17 (12.9)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Undergraduate and above</td>
            <td align="center" rowspan="1" colspan="1">6 (4.5)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">
<sup>&#x2020;</sup>Length of hospital stay (days)</td>
            <td align="center" rowspan="1" colspan="1">1 to 15</td>
            <td align="center" rowspan="1" colspan="1">6 (3)</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>
<sup>&#x2020;</sup>Median (IQR) instead of <italic>n</italic> (%); IQR: interquartile range.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tab2" orientation="portrait" position="float">
      <label>Table 2</label>
      <caption>
        <p>Anticoagulant use and cost in the cardiology unit (<italic>n</italic>&#x2009;=&#x2009;132).</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Characteristics</th>
            <th align="center" rowspan="1" colspan="1">Categories</th>
            <th align="center" rowspan="1" colspan="1">
<italic>n</italic> (%)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="6" colspan="1">Prescribed anticoagulants</td>
            <td align="center" rowspan="1" colspan="1">Unfractionated heparin (UFH)</td>
            <td align="center" rowspan="1" colspan="1">4 (3.03)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Unfractionated heparin&#x2009;+&#x2009;enoxaparin</td>
            <td align="center" rowspan="1" colspan="1">60 (45.45)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Enoxaparin</td>
            <td align="center" rowspan="1" colspan="1">36 (27.3)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Enoxaparin&#x2009;+&#x2009;warfarin</td>
            <td align="center" rowspan="1" colspan="1">21 (15.90)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Warfarin</td>
            <td align="center" rowspan="1" colspan="1">6 (4.54)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Dabigatran</td>
            <td align="center" rowspan="1" colspan="1">5 (3.78)</td>
          </tr>
          <tr>
            <td align="left" rowspan="3" colspan="1">Indication of anticoagulants use</td>
            <td align="center" rowspan="1" colspan="1">Acute coronary syndrome (ACS)</td>
            <td align="center" rowspan="1" colspan="1">88 (66.67)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Congestive heart failure (CHF)</td>
            <td align="center" rowspan="1" colspan="1">40 (30.30)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Rheumatic heart disease (RHD)</td>
            <td align="center" rowspan="1" colspan="1">4 (3.03)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">
<sup>&#x2020;</sup>Individual drug cost</td>
            <td align="center" rowspan="1" colspan="1">$0.03 to&#x2009;$126.24</td>
            <td align="center" rowspan="1" colspan="1">$79.92 ($46.32)</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>
<sup>&#x2020;</sup>Median (IQR) instead of <italic>n</italic> (%); IQR: interquartile range. 1$ (USD)&#x2009;=&#x2009;114.05 Nepalese rupees (NRs) during the study period.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tab3" orientation="portrait" position="float">
      <label>Table 3</label>
      <caption>
        <p>PT/INR/aPTT test and renal function test performance before enoxaparin</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Characteristics</th>
            <th align="center" rowspan="1" colspan="1">Categories</th>
            <th align="center" rowspan="1" colspan="1">
<italic>n</italic> (%)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="2" colspan="1">Whether PT/INR/aPTT was performed or not? (<italic>n</italic>&#x2009;=&#x2009;132)</td>
            <td align="center" rowspan="1" colspan="1">No</td>
            <td align="center" rowspan="1" colspan="1">16 (12.1)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Yes</td>
            <td align="center" rowspan="1" colspan="1">116 (87.9)</td>
          </tr>
          <tr>
            <td align="left" colspan="3" rowspan="1">
<hr/>
</td>
          </tr>
          <tr>
            <td align="left" rowspan="2" colspan="1">RFT performance before enoxaparin (<italic>n</italic>&#x2009;=&#x2009;117)</td>
            <td align="center" rowspan="1" colspan="1">No</td>
            <td align="center" rowspan="1" colspan="1">6 (5.13)</td>
          </tr>
          <tr>
            <td align="center" rowspan="1" colspan="1">Yes</td>
            <td align="center" rowspan="1" colspan="1">111 (94.87)</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>PT: prothrombin time; INR: international normalized ratio; aPTT: activated partial thromboplastin time; RFT: renal function test.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tab4" orientation="portrait" position="float">
      <label>Table 4</label>
      <caption>
        <p>Average prescribed daily dose (PDD/DDD) of anticoagulants.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Drug</th>
            <th align="center" rowspan="1" colspan="1">ATC code</th>
            <th align="center" rowspan="1" colspan="1">DDD</th>
            <th align="center" rowspan="1" colspan="1">PDD</th>
            <th align="center" rowspan="1" colspan="1">PDD/DDD</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="1" colspan="1">Unfractionated heparin</td>
            <td align="center" rowspan="1" colspan="1">B01AB01</td>
            <td align="center" rowspan="1" colspan="1">10 000 U&#x2009;(P)</td>
            <td align="center" rowspan="1" colspan="1">13 333 U</td>
            <td align="center" rowspan="1" colspan="1">1.3</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Enoxaparin</td>
            <td align="center" rowspan="1" colspan="1">B01AB05</td>
            <td align="center" rowspan="1" colspan="1">2000 U&#x2009;(P)</td>
            <td align="center" rowspan="1" colspan="1">4500 U</td>
            <td align="center" rowspan="1" colspan="1">2.25</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Warfarin</td>
            <td align="center" rowspan="1" colspan="1">B01AA03</td>
            <td align="center" rowspan="1" colspan="1">7.5&#x2009;mg (O)</td>
            <td align="center" rowspan="1" colspan="1">3.75&#x2009;mg</td>
            <td align="center" rowspan="1" colspan="1">0.5</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Dabigatran</td>
            <td align="center" rowspan="1" colspan="1">B01AEO7</td>
            <td align="center" rowspan="1" colspan="1">0.22&#x2009;g (O)</td>
            <td align="center" rowspan="1" colspan="1">0.22&#x2009;g</td>
            <td align="center" rowspan="1" colspan="1">1</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>ATC: Anatomical Therapeutic Chemical; DDD: defined daily dose; PDD: prescribed daily dose; P: parenteral; O: oral.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tab5" orientation="portrait" position="float">
      <label>Table 5</label>
      <caption>
        <p>Potential drug-drug interactions (<italic>n</italic>&#x2009;=&#x2009;132).</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Drug interaction found</th>
            <th align="center" rowspan="1" colspan="1">Number of cases</th>
            <th align="center" rowspan="1" colspan="1">Effect</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="1" colspan="1">Unfractionated heparin&#x2009;+&#x2009;aspirin (moderate)</td>
            <td align="center" rowspan="1" colspan="1">44</td>
            <td align="center" rowspan="1" colspan="1">May potentiate the risk of bleeding</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Unfractionated heparin&#x2009;+&#x2009;telmisartan (moderate)</td>
            <td align="center" rowspan="1" colspan="1">8</td>
            <td align="center" rowspan="1" colspan="1">May potentiate the risk of hyperkalemia</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Enoxaparin&#x2009;+&#x2009;aspirin (major)</td>
            <td align="center" rowspan="1" colspan="1">6</td>
            <td align="center" rowspan="1" colspan="1">May potentiate the risk of bleeding complications</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Enoxaparin&#x2009;+&#x2009;clopidogrel (major)</td>
            <td align="center" rowspan="1" colspan="1">5</td>
            <td align="center" rowspan="1" colspan="1">May potentiate the risk of bleeding</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Enoxaparin&#x2009;+&#x2009;telmisartan (moderate)</td>
            <td align="center" rowspan="1" colspan="1">2</td>
            <td align="center" rowspan="1" colspan="1">May increase the risk of hyperkalemia</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pharmacol Res Perspect</journal-id>
      <journal-id journal-id-type="iso-abbrev">Pharmacol Res Perspect</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)2052-1707</journal-id>
      <journal-id journal-id-type="publisher-id">PRP2</journal-id>
      <journal-title-group>
        <journal-title>Pharmacology Research &amp; Perspectives</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2052-1707</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33200888</article-id>
      <article-id pub-id-type="pmc">7670852</article-id>
      <article-id pub-id-type="doi">10.1002/prp2.686</article-id>
      <article-id pub-id-type="publisher-id">PRP2686</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Review</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Reviews</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy</article-title>
        <alt-title alt-title-type="left-running-head">ALVITIGALA et al.</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="prp2686-cr-0001" contrib-type="author" corresp="yes">
          <name>
            <surname>Alvitigala</surname>
            <given-names>Bhawani Yasassri</given-names>
          </name>
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6166-122X</contrib-id>
          <xref ref-type="aff" rid="prp2686-aff-0001">
<sup>1</sup>
</xref>
          <address>
            <email>yasassri.alvitigala@gmail.com</email>
          </address>
        </contrib>
        <contrib id="prp2686-cr-0002" contrib-type="author">
          <name>
            <surname>Gooneratne</surname>
            <given-names>Lallindra Viranjan</given-names>
          </name>
          <xref ref-type="aff" rid="prp2686-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="prp2686-cr-0003" contrib-type="author">
          <name>
            <surname>Constantine</surname>
            <given-names>Godwin Roger</given-names>
          </name>
          <xref ref-type="aff" rid="prp2686-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="prp2686-cr-0004" contrib-type="author">
          <name>
            <surname>Wijesinghe</surname>
            <given-names>Rajapaksha Arachchige Namal Kumarasiri</given-names>
          </name>
          <xref ref-type="aff" rid="prp2686-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="prp2686-cr-0005" contrib-type="author">
          <name>
            <surname>Arawwawala</surname>
            <given-names>Liyanage Dona Ashanthi Menuka</given-names>
          </name>
          <xref ref-type="aff" rid="prp2686-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="prp2686-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Medical Laboratory Science</named-content>
<named-content content-type="organisation-division">Faculty of Health Sciences</named-content>
<institution>The Open University of Sri Lanka</institution>
<city>Nugegoda</city>
<country country="LK">Sri Lanka</country>
</aff>
      <aff id="prp2686-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>University of Colombo</institution>
<city>Colombo</city>
<country country="LK">Sri Lanka</country>
</aff>
      <aff id="prp2686-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Clinical Medicine</named-content>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>University of Colombo</institution>
<city>Colombo</city>
<country country="LK">Sri Lanka</country>
</aff>
      <aff id="prp2686-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Clinical Sciences</named-content>
<named-content content-type="organisation-division">Faculty of Medicine</named-content>
<institution>General Sir John Kotelawala Defense University</institution>
<city>Ratmalana</city>
<country country="LK">Sri Lanka</country>
</aff>
      <aff id="prp2686-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Research &amp; Development Complex</named-content>
<institution>Industrial Technology Institute</institution>
<city>Malabe</city>
<country country="LK">Sri Lanka</country>
</aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Bhawani Yasassri Alvitigala, 125/A, Thalawathugoda Road, Pitakotte, Sri Lanka 10100.<break/>
Email: <email>yasassri.alvitigala@gmail.com</email><break/></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>11</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>12</month>
        <year>2020</year>
      </pub-date>
      <volume>8</volume>
      <issue>6</issue>
      <issue-id pub-id-type="doi">10.1002/prp2.v8.6</issue-id>
      <elocation-id>e00686</elocation-id>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>9</month>
          <year>2020</year>
        </date>
        <date date-type="rev-recd">
          <day>20</day>
          <month>10</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>10</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics <copyright-statement>-->
        <copyright-statement content-type="article-copyright">&#xA9; 2020 The Authors. <italic>Pharmacology Research &amp; Perspectives</italic> published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &amp; Sons Ltd</copyright-statement>
        <license license-type="creativeCommonsBy">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="file:PRP2-8-e00686.pdf"/>
      <abstract id="prp2686-abs-0001">
        <title>Abstract</title>
        <p>Clopidogrel is the most common and widely used antiplatelet agent for patients with coronary artery disease following confirmation by electrocardiographic studies. The nonresponsiveness of patients to clopidogrel and the possibility of testing for clopidogrel resistance by platelet function assays (PFA) are contentious issues. Light transmission aggregometry (LTA) is considered as the gold standard test among all PFA. In this review, the most commonly used PFA used for monitoring the effect of clopidogrel, LTA, vasodilator&#x2010;stimulated phosphoprotein assay phosphorylation, rotational thromboelastometry (ROTEM) delta and ROTEM platelet, thromboelastography, PFA&#x2010;100, VerifyNow P2Y12 assay, Multiplate analyzer, Plateletworks assay and pharmacogenetic studies, are comparatively discussed including their principles of action, advantages, and disadvantages. VerifyNow P2Y12 assay can be accepted as the ideal point of care test out of the discussed assays. However, modified assays are required which could overcome the limitations associated with currently available assays.</p>
      </abstract>
      <abstract abstract-type="graphical" id="prp2686-abs-0002">
        <p>This review article discuss the principles of pharmacokinetic, pharmacodynamic and pharmacogenetic assays used for monitoring clopidogrel therapy and comparatively discuss their advantages and disadvantages.<boxed-text position="anchor" content-type="graphic" id="prp2686-blkfxd-0001" orientation="portrait"><graphic xlink:href="PRP2-8-e00686-g005.jpg" position="anchor" id="nlm-graphic-1" orientation="portrait"/></boxed-text>
</p>
      </abstract>
      <kwd-group>
        <kwd id="prp2686-kwd-0001">clopidogrel</kwd>
        <kwd id="prp2686-kwd-0002">HPLC</kwd>
        <kwd id="prp2686-kwd-0003">platelet function assays</kwd>
        <kwd id="prp2686-kwd-0004">pharmacogenetic assays</kwd>
      </kwd-group>
      <counts>
        <fig-count count="5"/>
        <table-count count="2"/>
        <page-count count="18"/>
        <word-count count="13092"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>December 2020</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.4 mode:remove_FC converted:17.11.2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="prp2686-cit-1001">
<string-name>
<surname>Alvitigala</surname>
<given-names>BY</given-names>
</string-name>, <string-name>
<surname>Gooneratne</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Constantine</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Wijesinghe</surname>
<given-names>RANK</given-names>
</string-name>, <string-name>
<surname>Arawwawala</surname>
<given-names>LDAM</given-names>
</string-name>. <article-title>Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy</article-title>. <source xml:lang="en">Pharmacol Res Perspect</source>. <year>2020</year>;<volume>8</volume>:<elocation-id>e00686</elocation-id>
<pub-id pub-id-type="doi">10.1002/prp2.686</pub-id>
</mixed-citation>
</p>
      <fn-group id="prp2686-ntgp-0001">
        <fn id="prp2686-note-0001">
          <p>Bhawani Yasassri Alvitigala takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body id="prp2686-body-0001">
    <def-list list-content="abbreviations" id="prp2686-lp-0001">
      <title>Abbreviations</title>
      <def-item>
        <term>ADP</term>
        <def>
          <p>adenosine diphosphate</p>
        </def>
      </def-item>
      <def-item>
        <term>APTT</term>
        <def>
          <p>activated partial thromboplastin time</p>
        </def>
      </def-item>
      <def-item>
        <term>AU</term>
        <def>
          <p>aggregation units</p>
        </def>
      </def-item>
      <def-item>
        <term>CAD</term>
        <def>
          <p>coronary artery disease</p>
        </def>
      </def-item>
      <def-item>
        <term>CADP</term>
        <def>
          <p>collagen&#x2010;ADP</p>
        </def>
      </def-item>
      <def-item>
        <term>cAMP</term>
        <def>
          <p>cyclic adenosine monophosphate</p>
        </def>
      </def-item>
      <def-item>
        <term>CFT</term>
        <def>
          <p>clot formation time</p>
        </def>
      </def-item>
      <def-item>
        <term>CLPM</term>
        <def>
          <p>clopidogrel metabolite</p>
        </def>
      </def-item>
      <def-item>
        <term>CTM</term>
        <def>
          <p>converted to thiol metabolite of clopidogrel</p>
        </def>
      </def-item>
      <def-item>
        <term>EDTA&#x2010;K</term>
        <def>
          <p>ethylenediaminetetraacetic potassium salt</p>
        </def>
      </def-item>
      <def-item>
        <term>HPLC</term>
        <def>
          <p>high&#x2010;performance liquid chromatography</p>
        </def>
      </def-item>
      <def-item>
        <term>HTPR</term>
        <def>
          <p>high on&#x2010;treatment platelet reactivity</p>
        </def>
      </def-item>
      <def-item>
        <term>INR</term>
        <def>
          <p>international normalized ratio</p>
        </def>
      </def-item>
      <def-item>
        <term>LTA</term>
        <def>
          <p>light transmission aggregometry</p>
        </def>
      </def-item>
      <def-item>
        <term>MCF</term>
        <def>
          <p>maximum clot firmness</p>
        </def>
      </def-item>
      <def-item>
        <term>MFI</term>
        <def>
          <p>mean fluorescence intensity</p>
        </def>
      </def-item>
      <def-item>
        <term>ML</term>
        <def>
          <p>maximum lysis</p>
        </def>
      </def-item>
      <def-item>
        <term>MPV</term>
        <def>
          <p>mean platelet volume</p>
        </def>
      </def-item>
      <def-item>
        <term>MS</term>
        <def>
          <p>mass spectrometry</p>
        </def>
      </def-item>
      <def-item>
        <term>NSAID</term>
        <def>
          <p>nonsteroidal anti&#x2010;inflammatory drug</p>
        </def>
      </def-item>
      <def-item>
        <term>PCI</term>
        <def>
          <p>percutaneous coronary intervention</p>
        </def>
      </def-item>
      <def-item>
        <term>PFA</term>
        <def>
          <p>platelet function assay</p>
        </def>
      </def-item>
      <def-item>
        <term>PGE1</term>
        <def>
          <p>prostaglandin E1</p>
        </def>
      </def-item>
      <def-item>
        <term>POCT</term>
        <def>
          <p>point of care test</p>
        </def>
      </def-item>
      <def-item>
        <term>PRI</term>
        <def>
          <p>platelet reactivity index</p>
        </def>
      </def-item>
      <def-item>
        <term>PRP</term>
        <def>
          <p>platelet&#x2010;rich plasma</p>
        </def>
      </def-item>
      <def-item>
        <term>PRU</term>
        <def>
          <p>platelet reactivity units</p>
        </def>
      </def-item>
      <def-item>
        <term>PT</term>
        <def>
          <p>prothrombin time</p>
        </def>
      </def-item>
      <def-item>
        <term>ROTEM</term>
        <def>
          <p>rotational thromboelastometry</p>
        </def>
      </def-item>
      <def-item>
        <term>STEMI</term>
        <def>
          <p>ST&#x2010;elevated myocardial infarction</p>
        </def>
      </def-item>
      <def-item>
        <term>TEG</term>
        <def>
          <p>thromboelastography</p>
        </def>
      </def-item>
      <def-item>
        <term>UHPLC</term>
        <def>
          <p>ultra&#x2010;high&#x2010;performance liquid chromatography</p>
        </def>
      </def-item>
      <def-item>
        <term>VASP</term>
        <def>
          <p>vasodilator&#x2010;stimulated phosphoprotein</p>
        </def>
      </def-item>
      <def-item>
        <term>vWF</term>
        <def>
          <p>von Willebrand factor</p>
        </def>
      </def-item>
    </def-list>
    <sec id="prp2686-sec-0001">
      <label>1</label>
      <title>INTRODUCTION</title>
      <p>Clopidogrel is a second&#x2010;generation thienopyridine drug which acts as an inhibitor of platelet aggregation and hence used as an effective medication for coronary artery disease (CAD) and percutaneous coronary intervention (PCI).<xref rid="prp2686-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="prp2686-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> However, clopidogrel resistance among patients has become a significant concern. Hence, it has become important to decide whether the patient is clopidogrel resistant or not.<xref rid="prp2686-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> If resistant, then the optimum dose or changing/adding a different antiplatelet drug needs to be considered. In order to resolve this problem, platelet function tests (PFTs) play an important role in providing information for physicians regarding management of patients on clopidogrel therapy. This article reviews the role of platelet function assays (PFA) in monitoring clopidogrel therapy, together with the principles, applications, and limitations of the different tests discussed comparatively. Further, the future prospects of PFTs are also discussed.</p>
    </sec>
    <sec id="prp2686-sec-0002">
      <label>2</label>
      <title>ACTION OF CLOPIDOGREL</title>
      <p>Antiplatelet therapy is an essential pharmacological therapy given to patients with atherothrombotic disease to inhibit the platelet aggregation by blocking the platelet receptors involved in adhesion. Genetic variations between patients and delayed onset of action of clopidogrel result in the increase in resistance to clopidogrel therapy. Major reason for clopidogrel resistance was identified as the cytochrome P450 CYP2C19 polymorphism.<xref rid="prp2686-bib-0004" ref-type="ref">
<sup>4</sup>
</xref>, <xref rid="prp2686-bib-0005" ref-type="ref">
<sup>5</sup>
</xref>
</p>
      <p>When clopidogrel is ingested, 85% of prodrug is absorbed by liver and converted to its carboxylic acid derivative by carboxylic esterase. This is known as CLPM (clopidogrel metabolite), which is a major inactive metabolic product circulating in the blood and helps to determine the pharmacokinetics of the prodrug. Fifteen percent will be converted to thiol metabolite of clopidogrel (CTM) by the hepatic cytochrome isoenzymes (CYP P450 1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4). CTM involves in specific and irreversible blocking of P2Y12 receptors, inhibiting the adenosine diphosphate (ADP)&#x2010;induced platelet aggregation. CTM consists of four isomers; H1&#x2010;H4, where H3 (inactive form) and H4 (active circulating form) are mainly considered in monitoring the action of clopidogrel (Figure&#xA0;<xref rid="prp2686-fig-0001" ref-type="fig">1</xref>).<xref rid="prp2686-bib-0006" ref-type="ref">
<sup>6</sup>
</xref>, <xref rid="prp2686-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>, <xref rid="prp2686-bib-0008" ref-type="ref">
<sup>8</sup>
</xref>, <xref rid="prp2686-bib-0009" ref-type="ref">
<sup>9</sup>
</xref>, <xref rid="prp2686-bib-0010" ref-type="ref">
<sup>10</sup>
</xref>, <xref rid="prp2686-bib-0011" ref-type="ref">
<sup>11</sup>
</xref>
</p>
      <fig fig-type="FIGURE" xml:lang="en" id="prp2686-fig-0001" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Metabolic activation of clopidogrel prodrug in patients. CLPM, clopidogrel metabolite; CTM, converted to thiol metabolite of clopidogrel</p>
        </caption>
        <graphic id="nlm-graphic-3" xlink:href="PRP2-8-e00686-g001"/>
      </fig>
      <p>Thiol will irreversibly bind to P2Y12&#x2010;ADP receptor on platelets via a permanent disulfide bond with two cysteine residues (cys 17 and cys 270) on the receptor, thus inhibiting the ADP binding permanently and thereby activating adenylyl cyclase enzyme to increase cyclic adenosine monophosphate (cAMP). Thus, protein kinase level increases, stimulating phosphorylation of vasodilator&#x2010;stimulated phosphoprotein (VASP). Hence, inhibiting the activation of receptor complex gp IIb/III. Consequently, no thrombosis will occur. Furthermore, clopidogrel reduces secretions from dense granules in platelets and reduces arachidonic acid, collagen, and thrombin&#x2010;induced platelet activation. Clopidogrel also decreases the enzymatic activation of coagulation pathway, decreasing thrombin formation. Clopidogrel action solely depends on dose and time. Usually, 400&#x2010;600&#xA0;mg of dose is given and will take 2&#x2010;5&#xA0;hours for the platelet inhibition with 400&#xA0;mg dose. Seventy&#x2010;five milligram of daily dose will take about 7&#xA0;days for maximum platelet inhibition and management of atrial fibrillation. Half&#x2010;life of clopidogrel active metabolite is approximately 6&#xA0;hours.<xref rid="prp2686-bib-0012" ref-type="ref">
<sup>12</sup>
</xref>, <xref rid="prp2686-bib-0013" ref-type="ref">
<sup>13</sup>
</xref>, <xref rid="prp2686-bib-0014" ref-type="ref">
<sup>14</sup>
</xref>, <xref rid="prp2686-bib-0015" ref-type="ref">
<sup>15</sup>
</xref>
</p>
    </sec>
    <sec id="prp2686-sec-0003">
      <label>3</label>
      <title>CLOPIDOGREL RESISTANCE</title>
      <p>Although clopidogrel is widely used, it shows increased resistance/response variability among thrombosis patients as it is highly susceptible to drug interactions and CYP gene single nucleotide polymorphisms, thus reducing the in vitro enzyme activity inhibiting/reducing the conversion of clopidogrel into its active thiol metabolites. Therefore, it is difficult to decide the relevant dose without performing a PFT.<xref rid="prp2686-bib-0016" ref-type="ref">
<sup>16</sup>
</xref>, <xref rid="prp2686-bib-0017" ref-type="ref">
<sup>17</sup>
</xref> Degree of clopidogrel resistance may vary based on the laboratory method used.<xref rid="prp2686-bib-0014" ref-type="ref">
<sup>14</sup>
</xref> Prevalence of resistance with clopidogrel and aspirin has been studied by using different laboratory techniques. Expected prevalence of aspirin resistance by those studies was about 5.5% to 60%, while clopidogrel resistance was 16.8% to 21%. Hence, dual antiplatelet therapy or triple therapy along with another potent agent was required.<xref rid="prp2686-bib-0018" ref-type="ref">
<sup>18</sup>
</xref> Clopidogrel resistance is mainly associated with CYP2C19*2 genotype loss&#x2010;of&#x2010;function allele. Genetic variations regarding conversion to active metabolite by CYP P450 enzymes also play a major role in resistance.<xref rid="prp2686-bib-0017" ref-type="ref">
<sup>17</sup>
</xref>, <xref rid="prp2686-bib-0019" ref-type="ref">
<sup>19</sup>
</xref>, <xref rid="prp2686-bib-0020" ref-type="ref">
<sup>20</sup>
</xref> Conferring to the studies, clopidogrel resistance in population was about 4%&#x2010;30%, and the variation was due to the use of different platelet function studies.<xref rid="prp2686-bib-0021" ref-type="ref">
<sup>21</sup>
</xref>, <xref rid="prp2686-bib-0022" ref-type="ref">
<sup>22</sup>
</xref>, <xref rid="prp2686-bib-0023" ref-type="ref">
<sup>23</sup>
</xref> A study on clopidogrel resistance in India using optical aggregometry has shown that, in the population, 2.54% were resistant, 12.7% were semi&#x2010;responders, and 84.7% were responders to clopidogrel.<xref rid="prp2686-bib-0024" ref-type="ref">
<sup>24</sup>
</xref> There are several underlying causes for clopidogrel resistance. Age, gender, obesity, long&#x2010;term medications, and stress, such as individual factors, may contribute to clopidogrel resistance. Mainly, genetic factors such as mutations in P2Y12 gene, P450 CYP3A gene, and COX1 gene and polymorphism in platelet glycoprotein receptors affect the resistance. Further, overproduction of platelets by bone marrow, transfusion of platelets, failure in compliance, insufficient dose, and absorption by hepatic cells and certain drug interactions, such as nonsteroidal anti&#x2010;inflammatory drugs (NSAIDs), will also result in clopidogrel resistance.<xref rid="prp2686-bib-0025" ref-type="ref">
<sup>25</sup>
</xref>, <xref rid="prp2686-bib-0026" ref-type="ref">
<sup>26</sup>
</xref>, <xref rid="prp2686-bib-0027" ref-type="ref">
<sup>27</sup>
</xref>
</p>
    </sec>
    <sec id="prp2686-sec-0004">
      <label>4</label>
      <title>PLATELET FUNCTION TESTS TO MONITOR CLOPIDOGREL THERAPY</title>
      <p>Platelet function tests play a major role in determining the effect of antiplatelet drugs, such as clopidogrel, on inhibiting platelet aggregation. Although light transmission aggregometry (LTA) is considered as gold standard, it has many limitations. PFTs should possess several features for them to be ideal in use. They should be cost&#x2010;effective, less labor expertise, high sensitivity and specificity, produce quick results, and define the clinical situation more precisely. Further, they should have standardized test procedure with proper quality control, reference ranges to quantify the antiplatelet effect, and measure nonresponsiveness to antiplatelet drug, specific for the platelet receptor to measure the drug and its active metabolites. Importantly, they should have the capacity to monitor platelet activation&#x2010;induced physiologically relevant agonists and to detect high&#x2010;risk and low&#x2010;risk patients for antiplatelet drug resistance.<xref rid="prp2686-bib-0028" ref-type="ref">
<sup>28</sup>
</xref>
</p>
      <p>However, when most PFTs are considered they are less sensitive and cannot be performed in relation to normal physiological state. The reason is that, PFTs are performed on anticoagulated whole blood with relatively high concentrations of agonists including platelet aggregation. Further, the platelets will form more stabilized thrombus at high shear rate, which is difficult to be achieved by PFTs. Normal pathological shear rate is &gt;10&#xA0;000&#xA0;s<sup>&#x2212;1</sup>.<xref rid="prp2686-bib-0029" ref-type="ref">
<sup>29</sup>
</xref> At low shear rate of PFT, the effect of clopidogrel inhibitor is overrated, as the inhibitor fails to ban the platelet deposition on reactive surfaces due to shear gradient.<xref rid="prp2686-bib-0030" ref-type="ref">
<sup>30</sup>
</xref> In addition, PFTs have different cut&#x2010;off values to define the clopidogrel nonresponsiveness, hence it has become problematic to build up better correlation of results between different PFTs with different principles.<xref rid="prp2686-bib-0031" ref-type="ref">
<sup>31</sup>
</xref>
</p>
      <p>Most basic laboratory test is full blood count, where the mean platelet volume (MPV) parameter implies the platelet activation and clopidogrel resistance.<xref rid="prp2686-bib-0032" ref-type="ref">
<sup>32</sup>
</xref> ADP is the commonly used agonist for monitoring clopidogrel action by PFTs. There are two ADP receptors on the surface of platelets which involve in platelet aggregation. P2Y1 receptor stimulates ADP&#x2010;induced platelet aggregation via phospholipase C and phosphatidylinositol pathways. Second receptor is P2Y12, which stimulates platelet activation by inhibiting adenylyl cyclase signaling pathway. P2Y12 receptor essentially plays a role in producing more stabilized ADP&#x2010;induced platelet aggregation. Hence, the clopidogrel therapy mainly targets on blocking this P2Y12 receptors.<xref rid="prp2686-bib-0033" ref-type="ref">
<sup>33</sup>
</xref>
</p>
      <p>Platelet function tests are affected by many pre&#x2010;analytical variables, such as operator errors and phlebotomy errors, which may cause damage to the vessel walls inducing platelet coagulation. Other factors which affect the PFT results are age, gender, and clinical conditions (acquired platelet disorders, vWF, Hermansky&#x2010;Pudlak syndrome, and Chediak&#x2010;Higashi syndrome), certain foods&#x2014;garlic, turmeric, and cumin seeds&#x2014;and drugs such as aspirin, aspirin&#x2010;containing drugs, NSAIDs, tricyclic antidepressants, some antibiotics, and antihistamines, and other long&#x2010;term medications.<xref rid="prp2686-bib-0034" ref-type="ref">
<sup>34</sup>
</xref>
</p>
      <p>Prior to the PFT, the anticoagulated whole blood sample of the patient should be tested for full blood count/platelet count, to exclude pseudothrombocytopenia due to cold platelet agglutinin, and MPV, to identify high MPV which indicates platelet turnover and low values indicate bone marrow failure. Blood film and morphology will be used to confirm the conditions, such as primary platelet disorders (Gray platelet syndrome), presence of platelet clumps (pseudothrombocytopenia), and thrombocytopenia.<xref rid="prp2686-bib-0035" ref-type="ref">
<sup>35</sup>
</xref>, <xref rid="prp2686-bib-0036" ref-type="ref">
<sup>36</sup>
</xref>, <xref rid="prp2686-bib-0037" ref-type="ref">
<sup>37</sup>
</xref>
</p>
      <p>Plasma sample should be tested for prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (APTT), and fibrinogen levels to check the fibrinogen levels as they are important for platelet aggregation.<xref rid="prp2686-bib-0036" ref-type="ref">
<sup>36</sup>
</xref>, <xref rid="prp2686-bib-0037" ref-type="ref">
<sup>37</sup>
</xref> Collected samples should be performed within 30&#x2010;90&#xA0;minutes, which is known as the turnaround time, and be controlled by minimizing the sample transportation time, centrifugation time, and increasing the calibration ranges. It is vital to perform PFT immediately in the case of serious bleeding, &gt;6 units of red cells in 12&#xA0;hours.<xref rid="prp2686-bib-0035" ref-type="ref">
<sup>35</sup>
</xref>
</p>
      <sec id="prp2686-sec-0005">
        <label>4.1</label>
        <title>Anticoagulants used for PFTs</title>
        <p>Except for high&#x2010;performance liquid chromatography (HPLC), which requires whole blood collected in ethylenediaminetetraacetic potassium salt (EDTA&#x2010;K), other PFA could be performed on blood collected in 3.2% trisodium citrate anticoagulant at room temperature and physiological pH. Agonists play an important role by increasing the intracellular/cytosolic Ca<sup>2+</sup>, thereby inducing the platelet activation. Sodium citrate has the ability to chelate the extracellular calcium (Ca<sup>2+</sup>). Hence, citrate will have a slight chance to chelate the intracellular Ca<sup>2+</sup> as well as causing decreased platelet aggregation when the samples are taken for analysis 4&#xA0;hours after collection. Further, when citrated blood is used, blood sample becomes highly nonphysiological and has reduced the accuracy of results obtained via thromboelastogram (TEG).<xref rid="prp2686-bib-0038" ref-type="ref">
<sup>38</sup>
</xref> When citrated blood is used, the degree of platelet aggregation will not be changed up to 2&#xA0;hours; however, the aggregation gradually decreases thereafter. Even small rise in quantity of sodium citrate will show significant inhibition of platelet aggregation along with ADP, and collagen as sodium citrate acts as the major agent associated with ADP&#x2010;induced aggregation. At low plasma Ca<sup>2+</sup> (0.1&#xA0;mmol/L), citrated blood fails to generate thrombin, thus reduces the growth and stability of thrombus. Generally, 0.25&#xA0;&#xB1;&#xA0;0.05&#xA0;mmol/L free calcium is needed for thrombin generation. Thereby, citrated blood seem to affect the reproducibility and sensitivity of the assay to monitor the ADP&#x2010;induced platelet aggregation in patients under clopidogrel therapy.<xref rid="prp2686-bib-0039" ref-type="ref">
<sup>39</sup>
</xref>, <xref rid="prp2686-bib-0040" ref-type="ref">
<sup>40</sup>
</xref>
</p>
        <p>In order to overcome the faults, hirudin anticoagulant was introduced, which is extracted from leeches. Hirudin can directly inhibit the thrombin without changing the Ca<sup>2+</sup> levels in the sample. Since thrombin is inhibited, coagulation of the blood sample was also inhibited as a result of blocking the conversion of fibrinogen to fibrin. Further, hirudin can maintain the ADP levels in the samples for more than 4&#xA0;hours. In addition, the poor platelet impedance observed in citrated blood due to the effect from collagen and ADP was resolved when using hirudin anticoagulant. Moreover, Multiplate assay requires tight platelet aggregation for a remarkable change in impedance, which could not be strongly detected by citrated samples. Hence, hirudin is highly recommended for use while lepirudin, phenylalanyl&#x2010;L&#x2010;prolyl&#x2010;L&#x2010;arginine chloromethyl ketone also can be used.<xref rid="prp2686-bib-0041" ref-type="ref">
<sup>41</sup>
</xref>, <xref rid="prp2686-bib-0042" ref-type="ref">
<sup>42</sup>
</xref>, <xref rid="prp2686-bib-0043" ref-type="ref">
<sup>43</sup>
</xref> The assays (Figure&#xA0;<xref rid="prp2686-fig-0002" ref-type="fig">2</xref>) that are available to monitor the effect of clopidogrel on platelet activity are discussed comparatively under this review.</p>
        <fig fig-type="FIGURE" xml:lang="en" id="prp2686-fig-0002" orientation="portrait" position="float">
          <label>FIGURE 2</label>
          <caption>
            <p>PFA available to monitor the effect of clopidogrel in patients with CAD. HPLC&#x2010;MS, high performance liquid chromatography&#x2010;mass spectrometry; LTA, light transmission aggregometry; PFA, platelet function assay; ROTEM, rotational thromboelastometry; TEG, thromboelastography; VASP, vasodilator&#x2010;stimulated phosphoprotein</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="PRP2-8-e00686-g002"/>
        </fig>
      </sec>
      <sec id="prp2686-sec-0006">
        <label>4.2</label>
        <title>Assays performed in the laboratory (non&#x2010;point of care)</title>
        <sec id="prp2686-sec-0007">
          <title>Light transmission aggregometry</title>
          <p>Light transmission aggregometry is considered as the gold standard test performed on either whole blood or platelet&#x2010;rich plasma (PRP) and is used worldwide. The platelet function is measured by measuring the change in optical density when light passes through the PRP after the addition of the agonists, commonly used as ADP, arachidonic acid, collagen, epinephrine, and thrombin. ADP is regarded as the most common agonist to determine the effect of clopidogrel on inhibiting platelet aggregation. Low&#x2010;dose ADP (1, 2.5, or 5&#xA0;&#xB5;m) will initially bind to P2Y1 receptors on the platelet, inducing intracellular calcium efflux. Hence, results in altering the shape of platelets causing primary wave of platelet aggregation. Secondary wave is formed due to the release of ADP from platelet storage granules. Low&#x2010;dose ADP induces only the reversible primary wave. ADP has the capacity to bind for P2Y12 receptors. When high concentration of ADP agonist (10 and 20&#xA0;&#xB5;m) is added, it will bind to P2Y12 receptors, initiating the platelet aggregation, without changing the shape. P2Y12 receptor is the major receptor for ADP and is responsible for complete platelet aggregation. However, if the patient is a better clopidogrel responder, clopidogrel will block the binding of ADP to P2Y12 receptors, thus preventing the second wave of platelet aggregation. Such that, the percentage of light transmission in PRP will provide the percentage of maximum platelet aggregation (% MPA) and percentage inhibition of platelet aggregation (% IPA). When light passes through PRP, initially considered platelet aggregation is 0% (no aggregation), then the light transmission through the PRP is 0% (hence, 100% inhibition by clopidogrel). If aggregation initiates upon the addition of agonist, light transmission too increases. At platelet poor plasma (PPP), it is considered that 100% light transmission for 100% platelet aggregation (hence, 0% inhibition by clopidogrel). It could be interpreted that the decreased light transmission indicates the better clopidogrel responders. In order to overcome the limitations of above conventional method, a new method was developed where PRP was incubated with prostaglandin E1 (PGE1). Once pretreated with PGE1, prior to addition of ADP, the effect of P2Y1 receptors will be completely inhibited. Common ADP agonist doses are 5, 10, or 20&#xA0;&#xB5;mol/L. LTA is affected by pre&#x2010;analytical variables, such as anti&#x2010;inflammatory drugs, food stuff like garlic, turmeric, and caffeine, and high fat diet, and should adjust the count within 200&#x2010;400&#xA0;&#xD7;&#xA0;109/L. If high, adjust with PPP. Counts less than the range will reduce the aggregation responses.<xref rid="prp2686-bib-0022" ref-type="ref">
<sup>22</sup>
</xref>, <xref rid="prp2686-bib-0044" ref-type="ref">
<sup>44</sup>
</xref>, <xref rid="prp2686-bib-0045" ref-type="ref">
<sup>45</sup>
</xref>, <xref rid="prp2686-bib-0046" ref-type="ref">
<sup>46</sup>
</xref>, <xref rid="prp2686-bib-0047" ref-type="ref">
<sup>47</sup>
</xref>, <xref rid="prp2686-bib-0048" ref-type="ref">
<sup>48</sup>
</xref> Cut&#x2010;off value for suboptimal clopidogrel response in terms of percentage aggregation is &#x2265; 70% for 10&#xB5;M ADP and &#x2265; 50% for 5&#xB5;M ADP<xref rid="prp2686-bib-0049" ref-type="ref">
<sup>49</sup>
</xref>
</p>
        </sec>
        <sec id="prp2686-sec-0008">
          <title>Vasodilator&#x2010;stimulated phosphoprotein assay</title>
          <p>Vasodilator&#x2010;stimulated phosphoprotein is an actin regulatory protein and a substrate for both cAMP and cGMP (cyclic guanosine monophosphate)&#x2010;dependent protein kinases and involves in the filopodia formation and adhesion of platelets. When P2Y12 receptors are blocked by clopidogrel and PGE1 is stimulated, activated adenylyl cyclase will initiate the VASP phosphorylation. Hence, VASP phosphorylation will indicate the P2Y12 inhibition by clopidogrel.<xref rid="prp2686-bib-0050" ref-type="ref">
<sup>50</sup>
</xref>, <xref rid="prp2686-bib-0051" ref-type="ref">
<sup>51</sup>
</xref> However, still the direct relationship between the VASP phosphorylation and ADP&#x2010;induced in vivo platelet aggregation has not yet described.<xref rid="prp2686-bib-0052" ref-type="ref">
<sup>52</sup>
</xref>
</p>
          <p>Citrated anticoagulant blood samples are used along with the commercially available kit included with ADP and PGE1. Assay is based on the flow cytometric technique. Upon incubation of platelets with PGE1 and ADP, platelets will be reacted with CD61 phycoerythrin&#x2010;labeled platelet&#x2010;specific antibody and FITC&#x2010;labeled phosphorylated VASP&#x2010;specific mouse monoclonal antibody. The used antibody is specific for the phosphorylated form of VASP. Likely, pretreated samples will be analyzed via flow cytometer which produces results as geometric mean fluorescence intensity (MFI). The degree of phosphorylation of VASP will be directly proportional to the platelet inhibition by clopidogrel and is expressed as platelet reactivity index (PRI) derived from MFI [PRI(%)&#xA0;=&#xA0;100&#xA0;&#xD7;&#xA0;(MFI<sub>(PGE1)</sub>&#xA0;&#x2212;&#xA0;MFI<sub>(PGE1&#xA0;+&#xA0;ADP)</sub>)/MFI<sub>(PGE1)</sub>]. The main advantage associated with this assay is that it is highly specific for the P2Y12 receptors.<xref rid="prp2686-bib-0044" ref-type="ref">
<sup>44</sup>
</xref>
</p>
        </sec>
      </sec>
      <sec id="prp2686-sec-0009">
        <label>4.3</label>
        <title>Point of care tests</title>
        <p>Point of care tests (POCTs) are tests that can be performed on whole blood at or near the bedside of the patient, more easily, such that rapid results can be obtained without pipetting and pretreatments to the sample. Frequently, VerifyNow P2Y12 assay, Multiplate assay, PFA&#x2010;100, Plateletworks, TEG, and ROTEM are designed as POCTs and used to monitor the effect of clopidogrel. POCTs are developed to overcome the limitations associated with LTA, such as labor intensiveness, cost, and time. POCTs are generally at high cost than normal LTA, but they have the ability to provide clot quality and monitors clot formation and progression even after the point of clot formation.<xref rid="prp2686-bib-0035" ref-type="ref">
<sup>35</sup>
</xref>, <xref rid="prp2686-bib-0053" ref-type="ref">
<sup>53</sup>
</xref>, <xref rid="prp2686-bib-0054" ref-type="ref">
<sup>54</sup>
</xref>
</p>
        <sec id="prp2686-sec-0010">
          <label>4.3.1</label>
          <title>Rotational thromboelastometry: ROTEM delta and ROTEM platelet</title>
          <p>Blood collected within 4&#xA0;hours into 3.2% sodium citrate is needed to be incubated at 37&#xB0;C before examination. ROTEM delta uses viscoelastic measurement. Blood is filled into the cuvette and a cylindrical pin, known as the sensor, is immersed into the cuvette so that there is 1&#x2010;mm gap between pin and cuvette wall, bridge by the blood. Sensor is rotated sideways by a spring. The pin rotates till the blood is in liquid form; however, when blood starts clotting, rotation of the pin slows down. Kinetic motion of the pin is detected mechanically and computation is expressed via thromboelastometric curve and numerical parameters. ROTEM delta has the ability to identify hypo&#x2010; and hyperfunctional stages of clotting process. ROTEM can measure the parameters: clotting time, clot formation time (CFT), maximum clot firmness (MCF), and alpha angle, which use the angle between middle axis and tangent to the clotting curve through 2&#x2010;mm amplitude point. ROTEM has special techniques to monitor the coagulation pathway via intrinsic and extrinsic pathways, heparin action, and clot firmness after blocking hyperfibrinolysis by aprotinin. There are many variables that can be measured by ROTEM analysis. Commonly used parameters are coagulation time, CFT, &#x3B1;&#x2010;angle, amplitude at 10&#xA0;minutes after CT, MCF, maximum lysis (ML), EXTEM (measures extrinsic pathway), APTEM (measure clot firmness after blocking hyperfibrinolysis), FIBTEM (measure clot firmness after blocking the platelets), INTEM (measures intrinsic pathway), and HEPTEM (same as INTEM, but inhibits heparin).<xref rid="prp2686-bib-0055" ref-type="ref">
<sup>55</sup>
</xref>, <xref rid="prp2686-bib-0056" ref-type="ref">
<sup>56</sup>
</xref>, <xref rid="prp2686-bib-0057" ref-type="ref">
<sup>57</sup>
</xref>, <xref rid="prp2686-bib-0058" ref-type="ref">
<sup>58</sup>
</xref>, <xref rid="prp2686-bib-0059" ref-type="ref">
<sup>59</sup>
</xref> Assay should solely depend on the instructions provided by the manufacturer as the results may vary depending on the temperature, reagent status, sample stability, and instrument status.<xref rid="prp2686-bib-0057" ref-type="ref">
<sup>57</sup>
</xref> In monitoring the effect of clopidogrel, ROTEM analysis could be performed using EXTEM and FIBTEM reagents. Thus, produces the results CT, MCF, and CFT of EXTEM and FIBTEM, respectively.<xref rid="prp2686-bib-0056" ref-type="ref">
<sup>56</sup>
</xref>
</p>
          <p>However, ROTEM delta lacks the ability to monitor antiplatelet drug therapy due to increased production of thrombin during the assay. Thrombin thus produced stimulates platelets, preventing the detection of platelet inhibition by antiplatelet drugs. In order to overcome the above limitation, ROTEM platelet was combined to ROTEM delta such that single sample can be analyzed simultaneously with two techniques. ROTEM platelet consists of two channels which allow whole blood analysis via impedance principle. Sample cuvette is inserted into temperature&#x2010;controlled channel and then two wires of the electrodes are placed inside the cuvette. When the activated platelets aggregate around the surface of the electrode wires, impedance between wires increases producing an impedance curve. The magnetic stirrer inside the cuvette prevents the deposition of blood cells at the incubation. If the patient is effectively responding to clopidogrel therapy, the curve lies below the reference curve. Impedance curve provides three parameters, where area under curve (&#x3A9;&#xA0;&#xD7;&#xA0;min) gives overall platelet aggregation, amplitude at 6&#xA0;minutes (&#x3A9;/min) gives degree of platelet aggregation after activation, and maximum slope (&#x3A9;) indicates time taken for platelet aggregation. ROTEM platelet was specifically designed to monitor antiplatelet therapy by three assays. ARATEM assay monitors aspirin therapy by activator arachidonic acid, ADPTEM assay monitors clopidogrel using ADP, and TRAPTEM monitors thrombin by thrombin&#x2010;receptor activating peptide&#x2010;6.<xref rid="prp2686-bib-0056" ref-type="ref">
<sup>56</sup>
</xref>, <xref rid="prp2686-bib-0060" ref-type="ref">
<sup>60</sup>
</xref>
</p>
        </sec>
        <sec id="prp2686-sec-0011">
          <label>4.3.2</label>
          <title>Thromboelastography</title>
          <p>Thromboelastography is a rapid POCT performed on citrated whole blood. This technique quantitatively measures the viscoelastic properties of the platelets in forming the platelet plug. The principle will be same as that of ROTEM platelet, which has a disposable cup with a detection pin fixed at the center. Difference is that the TEG rotates the cup and ROTEM rotates the pin first when the clot forms. Prior to clotting, blood has the minimum viscosity. Therefore, the waves of the cup cannot induce the movement of the pin. When blood starts to coagulate, blood viscosity increases, and the clot gets attached to both the cup and pin causing the movement of the pin upon induced by the cup. When the viscosity increases gradually, amplitude of the pin movement also increases. Once the fibrinolysis starts, platelet clot dissolves decreasing the blood viscosity. Change of amplitude is expressed graphically against time.<xref rid="prp2686-bib-0061" ref-type="ref">
<sup>61</sup>
</xref>
</p>
          <p>Conventional TEG lacks the ability to determine the ADP receptor inhibition for the reason that the excess production of thrombin through the technique. Conventional TEG will show normal maximum amplitude for a patient under clopidogrel therapy who was shown to have an ultimate platelet inhibition via LTA, which was considered as a major problem associated with conventional TEG. ROTEM expresses CT, &#x3B1;&#x2010;angle, CFT, MCF, and clot lysis, whereas those parameters are expressed as reaction value (<italic>R</italic> value), &#x3B1;&#x2010;angle, <italic>K</italic>&#x2010;value, maximum amplitude, and amplitude at 30&#xA0;minutes (LY30) in TEG. However, by overcoming the above problem, modified TEG has the capability to monitor the clopidogrel action, without thrombin generation. ADP is used as the agonist to measure the degree of platelet aggregation of patients under clopidogrel therapy.<xref rid="prp2686-bib-0058" ref-type="ref">
<sup>58</sup>
</xref>
</p>
        </sec>
        <sec id="prp2686-sec-0012">
          <label>4.3.3</label>
          <title>VerifyNow P2Y12 assay</title>
          <p>VerifyNow assay is performed as a POCT on citrated whole blood as a turbidometry assay. When PGE1 is introduced, ADP induces platelet coagulation and aggregates with the help of fibrinogen&#x2010;coated beads. Most important fact is that, the assay is sensitive and specifically targets the P2Y12 receptors while inhibiting the action of P2Y1. As in LTA, the platelet aggregation is determined by the percentage of the light transmission and expressed in PRU (P2Y12 reaction units). Low PRU indicates the high P2Y12 receptor inhibition and better response to clopidogrel. Measurement of inhibition of P2Y12 receptor inhibition as a result of thrombin receptor&#x2010;activating peptide&#x2010;induced platelet aggregation has become an added advantage. Percentage inhibition is reported as [Base PRU&#xA0;&#x2212;&#xA0;Posttreatment PRU]/[Baseline PRU]&#xA0;&#xD7;&#xA0;100. VerifyNow assay is a rapid test which can be performed even at bedside within 5&#xA0;minutes, which has been an advantage when compared with LTA and VASP phosphorylation assays. VerifyNow assay also has the capability to monitor the effect of clopidogrel on P2Y12 receptors directly thereby helps to determine the adequacy of the loading dose of clopidogrel in patients who will be subjected to coronary stenting. Further, the assay has a simple technique and interpretation of results can be done easily.<xref rid="prp2686-bib-0051" ref-type="ref">
<sup>51</sup>
</xref>, <xref rid="prp2686-bib-0062" ref-type="ref">
<sup>62</sup>
</xref>, <xref rid="prp2686-bib-0063" ref-type="ref">
<sup>63</sup>
</xref> Cut&#x2010;off value for the suboptimal clopidogrel response in terms of percentage aggregation is &#x2265;70% for 10&#xB5;M ADP and &#x2265;50% for 5&#xB5;M ADP.<xref rid="prp2686-bib-0049" ref-type="ref">
<sup>49</sup>
</xref>
</p>
        </sec>
        <sec id="prp2686-sec-0013">
          <label>4.3.4</label>
          <title>Platelet function assay&#x2010;100</title>
          <p>Platelet function assay&#x2010;100 is another point of care assay to monitor the action of clopidogrel. This can be performed on less volume of citrated whole blood. This assay monitors the platelet aggregation and effect of antiplatelet drugs under higher shear stress. Hence, this assay can be performed rapidly in less time using less labor which is an added advantage when compared with conventional aggregation assays. PFA&#x2010;100 has cartridges coated with collagen and epinephrine or ADP. Blood drawn from the patient who is under clopidogrel therapy will flow under higher shear rate through the capillary and a small aperture of PFA&#x2010;100 analyzer toward the coated cartridge. Platelets will aggregate and form the ADP&#x2010;induced platelet plug by blocking the aperture. The time taken for complete occlusion of the aperture is recorded as closure time (CT). Collagen&#x2010;ADP (CADP) cartridge measures the platelet dysfunction due to clopidogrel. Prolonged CT indicates the better response to clopidogrel.<xref rid="prp2686-bib-0064" ref-type="ref">
<sup>64</sup>
</xref>, <xref rid="prp2686-bib-0065" ref-type="ref">
<sup>65</sup>
</xref>, <xref rid="prp2686-bib-0066" ref-type="ref">
<sup>66</sup>
</xref>, <xref rid="prp2686-bib-0067" ref-type="ref">
<sup>67</sup>
</xref> CT for CADP cartridge is 55&#x2010;137&#xA0;seconds.<xref rid="prp2686-bib-0068" ref-type="ref">
<sup>68</sup>
</xref>
</p>
        </sec>
        <sec id="prp2686-sec-0014">
          <label>4.3.5</label>
          <title>Multiplate analyzer</title>
          <p>Multiplate analyzer is a sensitive, novel, point of care platelet function analyzer which can be performed on citrated whole blood using electrical impedance aggregometry principle. The main aim of the assay was to monitor the platelet function inhibitors. When the samples obtained from the patients who are under clopidogrel therapy are exposed to ADP agonist, platelets will get stimulated and results in ADP&#x2010;induced platelet aggregation. Once the aggregated platelets attach tightly to the sensor wires in the Multiplate device, an electrical resistance will be created between the wires. ADP with 200&#x2010;&#x3BC;mol/L concentration interacts with P2Y1 and P2Y12 receptors inducing irreversible aggregation. However, ADP&#xA0;+&#xA0;PGE1: 200&#xA0;&#x3BC;mol/L&#xA0;+&#xA0;300&#xA0;nmol/L inhibits aggregation by P2Y1 receptor, thus increasing specificity for P2Y12 receptors. Change in the impedance can be shown by the graph; arbitrary aggregation units (AU) against time. In addition, the three parameters, area under the curve, height of the curve, and maximum slope, express the complete platelet reactivity, platelet aggregation, and velocity, respectively.<xref rid="prp2686-bib-0069" ref-type="ref">
<sup>69</sup>
</xref>, <xref rid="prp2686-bib-0070" ref-type="ref">
<sup>70</sup>
</xref>
</p>
        </sec>
        <sec id="prp2686-sec-0015">
          <label>4.3.6</label>
          <title>Plateletworks analyzer</title>
          <p>Plateletworks is a POCT device performed on whole blood. Plateletworks analyzer measures the platelet count of the sample before the addition of the ADP agonist and then after platelet aggregation upon addition of ADP. Usually, reference platelet count taken from the K3&#x2010;EDTA anticoagulant blood without ADP and other count is taken from citrated anticoagulant sample with ADP agonist.<xref rid="prp2686-bib-0071" ref-type="ref">
<sup>71</sup>
</xref>
</p>
          <p>In normal patients, the platelets get aggregated in the presence of agonist and the resultant platelet count is considered to be zero. When the blood flows through the aperture, the constant electric current will develop an electrical pulse which is amplified and converted to obtain the platelet count.<xref rid="prp2686-bib-0072" ref-type="ref">
<sup>72</sup>
</xref> When the platelet aggregates exceed the threshold limit for platelet size, such platelets are not considered for the resultant platelet count. Percentage inhibition of platelet aggregation provides the degree of platelet aggregation in the presence of clopidogrel. Percentage of inhibition is expressed as the ratio between platelet counts before and after exposure to ADP. Plateletworks is widely used for monitoring the effectiveness of antiplatelet drugs such as clopidogrel and aspirin.<xref rid="prp2686-bib-0053" ref-type="ref">
<sup>53</sup>
</xref>, <xref rid="prp2686-bib-0073" ref-type="ref">
<sup>73</sup>
</xref>, <xref rid="prp2686-bib-0074" ref-type="ref">
<sup>74</sup>
</xref>, <xref rid="prp2686-bib-0075" ref-type="ref">
<sup>75</sup>
</xref> Blood samples should be analyzed within 10&#xA0;minutes to obtain accurate results. There are studies to prove the significant correlation between Plateletworks and LTA. However LTA determines only macroaggregation while Plateletworks is sensitive for microaggregation. Minimum studies have been conducted to show the prediction of outcomes of cardiovascular diseases.<xref rid="prp2686-bib-0071" ref-type="ref">
<sup>71</sup>
</xref>, <xref rid="prp2686-bib-0073" ref-type="ref">
<sup>73</sup>
</xref>, <xref rid="prp2686-bib-0076" ref-type="ref">
<sup>76</sup>
</xref> In the determination of the cut&#x2010;off values for Plateletworks assay, it had shown 63% sensitivity and 58.5% specificity using ROC curve analysis.<xref rid="prp2686-bib-0074" ref-type="ref">
<sup>74</sup>
</xref>
</p>
        </sec>
      </sec>
      <sec id="prp2686-sec-0016">
        <label>4.4</label>
        <title>High&#x2010;performance liquid chromatography</title>
        <p>High&#x2010;performance liquid chromatography is generally used for identification and quantification of chemical compounds. HPLC consists of a stationary phase which is packed either with a resin or silica gel beads and mobile phase. Methanol and acetonitrile are used as solvents for the separation of analyte. Molecular interaction between stationary phase, analyte, and solvent decides the retention time. Separation of analytes in normal HPLC depends on the polarity where stationary phase is polar and mobile phase is nonpolar. However, in reverse phase HPLC, the separation is based on hydrophobic interactions between polar mobile phase and nonpolar stationary phase. During the separation and quantification of active metabolites, the internal diameter of the HPLC column, particle size, and pore size of the stationary phase and pump pressure should be considered for optimum performance.<xref rid="prp2686-bib-0077" ref-type="ref">
<sup>77</sup>
</xref>
</p>
        <p>Around 5%&#x2010;40% of patients who are under clopidogrel therapy may show resistance to clopidogrel and the cause may be due to impaired drug absorption by the hepatic cells or impaired drug metabolic activity. However, the cause can be clearly explained via analysis of drug metabolite levels in the patient's blood via HPLC method. However, due to low levels of the prodrug in plasma after ingestion and instability of thiol derivatives, it has become difficult to use HPLC method for determination of drug levels in patient plasma.<xref rid="prp2686-bib-0078" ref-type="ref">
<sup>78</sup>
</xref> Hence, most of the studies were conducted using plasma of healthy volunteers and spiking the samples with prepared concentrations of clopidogrel.<xref rid="prp2686-bib-0079" ref-type="ref">
<sup>79</sup>
</xref>, <xref rid="prp2686-bib-0080" ref-type="ref">
<sup>80</sup>
</xref> Thereby, those studies were only able to determine either the prodrug only or one of the derivates from CTM or CLPM. One such study was able to analyze the pharmacokinetic properties of only CTM isomers, but not the isomers or prodrug or CLPM. They have analyzed the H1&#x2010;H4 isomers using a reverse&#x2010;phase ultra&#x2010;high&#x2010;performance liquid chromatography and tandem mass spectrometry (MS) with a concentration accuracy for a range of 0.5&#x2010;250&#xA0;ng/mL.<xref rid="prp2686-bib-0081" ref-type="ref">
<sup>81</sup>
</xref>
</p>
        <p>Once the HPLC technique is validated by the means of the parameters linearity, stability, precision, and accuracy, it was identified as the most sensitive, specific analysis method to monitor the effect of clopidogrel on patient responsiveness.<xref rid="prp2686-bib-0082" ref-type="ref">
<sup>82</sup>
</xref>, <xref rid="prp2686-bib-0083" ref-type="ref">
<sup>83</sup>
</xref> Two studies have been found to analyze the clopidogrel and its metabolites in patients with myocardial infarction and PCI. One study has determined the plasma levels of clopidogrel, inactive carboxyl metabolite, and active H4 thiol metabolite in the plasma of ST&#x2010;elevated myocardial infarction patients.<xref rid="prp2686-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> The second study studied the plasma levels of clopidogrel, CLPM, active H4, and inactive H3 of patients under PCI. The study has found that the maximum absorption of 75&#xA0;mg of drug was 2&#xA0;ng/mL in 1.4&#xA0;hours and 300&#xA0;mg of drug was 4.5&#xA0;ng/mL in 1.2&#xA0;hours by intestines. Platelet aggregation with 75&#xA0;mg dose was found to be between 37 and 747&#xA0;AU/min. The significant correlation between maximum concentration of H4 isomer and platelet aggregation depicts the importance of use of both the above parameters in the detection of response to clopidogrel therapy.<xref rid="prp2686-bib-0078" ref-type="ref">
<sup>78</sup>
</xref>
</p>
      </sec>
      <sec id="prp2686-sec-0017">
        <label>4.5</label>
        <title>Pharmacogenetic assays</title>
        <p>CYPA1, CYP2B6, and CYP2C19 are CYP<sub>450</sub> enzymes that participate in the first step of converting clopidogrel prodrug to 2&#x2010;oxo&#x2010;clopidogrel. The second step which forms the thiol metabolite is catalyzed by the enzymes CYP2B6, CYP2C9, CYP3A4/5, and CYP2C19. CYP2C19 is considered as the main enzyme involved in the whole process as it provides 44.9% to the first step and 20.6% to the second step. In addition, CYP3A4 too contributes 39.8% to the second step.<xref rid="prp2686-bib-0084" ref-type="ref">
<sup>84</sup>
</xref>, <xref rid="prp2686-bib-0085" ref-type="ref">
<sup>85</sup>
</xref> Hence, bioactivation process of clopidogrel could be altered due to genetic polymorphisms of the genes <italic>CYP2C19</italic>, <italic>CYP3A4/5</italic>, <italic>CYP2C9</italic>, and <italic>CYP2B6</italic> that code for their respective enzymes. Out of these genes, <italic>CYP2C19</italic> gene polymorphism is studied mainly due its association with both the steps. <italic>CYP2C19</italic> is highly polymorphic, where *1/*1 allele is considered as normal and two loss of functional (LoF) alleles due to single nucleotide polymorphism are (*2) and (*3). These LoF alleles result in poor clopidogrel therapeutic outcome. Although <italic>CYP2C19</italic> and <italic>CYP2C9</italic> LoF cause poor clopidogrel outcome, <italic>CYP1A2</italic>,<italic>CYP2B6</italic>, and <italic>CYP3A4/5</italic> alleles have not shown any considerable effect on clopidogrel effect. The Clinical Pharmacogenetic Consortium has developed a guide to interpret CYP2C19 genetic test. It explained that *1/*17, *1/*17, and *17/*17 genotypes show normal enzyme activity and clopidogrel 75&#xA0;mg daily dose could be administered. Genotypes *1/*2, *1/*3, and *2/*17 indicate intermediate enzyme activity and genotypes *2/*2, *2/*3, and *3/*3 show absence of enzyme activity. Patients with these genotypes should be treated with either Prasugrel 10&#xA0;mg daily or Ticagrelor 90&#xA0;mg twice a day.<xref rid="prp2686-bib-0086" ref-type="ref">
<sup>86</sup>
</xref> Prasugrel and Ticagrelor are used for clopidogrel poor responders as these are not affected by <italic>CYP2C19</italic> LoF allele.<xref rid="prp2686-bib-0087" ref-type="ref">
<sup>87</sup>
</xref> It was found that <italic>CYP2C19*2</italic> resulted in poor platelet inhibition by clopidogrel and hence causes poor outcomes in PCI patients.<xref rid="prp2686-bib-0088" ref-type="ref">
<sup>88</sup>
</xref>
<italic>CYP2C19*17</italic> gene polymorphism too can be studied which results in enhanced enzyme activity due to increased gene transcription.<xref rid="prp2686-bib-0089" ref-type="ref">
<sup>89</sup>
</xref> Clopidogrel absorption in the intestine is controlled by a transporter protein called P&#x2010;glycoprotein multidrug resistance&#x2010;1, which is coded by the gene <italic>ABCB1</italic>. Polymorphism of <italic>ABCB1</italic> gene has shown poor absorption of clopidogrel by intestines.<xref rid="prp2686-bib-0090" ref-type="ref">
<sup>90</sup>
</xref>
<italic>CES1</italic> is another genetic polymorphism which could be studied as the CES1 enzyme synthesized by the gene results in the metabolism of clopidogrel. LoF of this allele causes increased concentration of active thiol metabolite,<xref rid="prp2686-bib-0091" ref-type="ref">
<sup>91</sup>
</xref> whereas polymorphism of <italic>PON1</italic> gene reduces the enzyme activity of PON1 esterase and results in reduction of active thiol metabolite concentration.<xref rid="prp2686-bib-0092" ref-type="ref">
<sup>92</sup>
</xref> Gain of functional haplotypes <italic>H2</italic> of <italic>P2Y12</italic> gene increases atherothrombotic events and affects the action of clopidogrel.<xref rid="prp2686-bib-0093" ref-type="ref">
<sup>93</sup>
</xref> However, due to the difficulty in predicting the outcome of every genetic variation associated with clopidogrel, Clinical Pharmacogenetics Implementation Consortium guidelines for <italic>CYP2C19</italic> genotype and clopidogrel therapy have not endorsed to follow <italic>CYP2C19</italic>&#x2010;guided therapy.</p>
        <p>Several pharmacogenetic tests are available to determine clopidogrel response by analyzing different <italic>CYP2C19</italic> variants. Whole blood is used for polymerase chain reaction and primer extension reaction, which is the underlying technique of the tests AccuType<sup>&#x2122;</sup> CP and Cytochrome P450 2C19 10 mutations assay (ARUP Laboratories, Salt Lake City, UT, USA). This technique is used by clopidogrel efficacy test (by 23andMe Company, Sunnyvale, CA, USA); however, it is performed for salivary samples. Medication panel (Navigenics, Inc, Foster City, CA, USA) and drug response test (Pathway Genomics, San Diego, CA, USA) use salivary samples on two different techniques: TaqMan SNP genotype assay and DNA testing, respectively. DNA testing is an underlying principle in many other tests such as Clopidogrel genetic test (TheranostiCs Lab, Auckland, New Zealand), CYP450 2C19 (Plavix<sup>&#x2122;</sup>) gene test for buccal swabs and Verigene CYP2C19 XP/CYP2C19 nucleic acid test. PlaVitest by Genelec Corporation can be performed on either whole blood or buccal swabs using extended CYP2C19 DNA mutation panel.<xref rid="prp2686-bib-0094" ref-type="ref">
<sup>94</sup>
</xref>
<italic>CYP2C19*2</italic> genetic test produced by Spartan Biosciences is a rapid test which could be performed within 1&#xA0;hour on buccal swab.<xref rid="prp2686-bib-0087" ref-type="ref">
<sup>87</sup>
</xref> Clopidogrel antiplatelet effect was studied by using a rapid test called Rapid Infinity analyzer. DNA extracted from the whole blood collected in EDTA was hybridized to BioFilmChip microarray in the analyzer, hence can be used to determine <italic>CYP19*2, *4 and CYP2C9*2, *3 polymorphisms</italic>.<xref rid="prp2686-bib-0095" ref-type="ref">
<sup>95</sup>
</xref> Rapid Verigene and classical TaqMan assays have been compared by analyzing <italic>CYP2C19*2, *3, *4, *5</italic> and <italic>*17</italic> polymorphisms. Study have found that turnaround time, labor requirement, and relative cost is less in the Verigene assay than TaqMan assay, although reagent cost of Verigene assay is considerably high. Hence, Verigene is considered having better performance.<xref rid="prp2686-bib-0096" ref-type="ref">
<sup>96</sup>
</xref>
</p>
      </sec>
    </sec>
    <sec id="prp2686-sec-0018">
      <label>5</label>
      <title>COMPARISON OF THE PFTS</title>
      <p>Light transmission aggregometry is the most acceptable method to determine the validity of other novel PFTs. In contrast to these advantages, the major disadvantage is that the higher concentrations of ADP agonist have the ability to induce the platelet aggregation without altering the shape of platelets. Other drawbacks of this assay are listed in Table&#xA0;<xref rid="prp2686-tbl-0002" ref-type="table">2</xref>.<xref rid="prp2686-bib-0025" ref-type="ref">
<sup>25</sup>
</xref>, <xref rid="prp2686-bib-0044" ref-type="ref">
<sup>44</sup>
</xref>, <xref rid="prp2686-bib-0097" ref-type="ref">
<sup>97</sup>
</xref>
</p>
      <p>A study conducted has shown that the traditional method of LTA cannot be used as a test to monitor the effect of clopidogrel. Conventional ADP represents platelet aggregation due to both P2Y1 and P2Y12 receptors, whereas modified method with PGE1 shows the platelet aggregation specific to PGE1 (Figure&#xA0;<xref rid="prp2686-fig-0003" ref-type="fig">3</xref>). Further, when comparing the VerifyNow P2Y12 assay, Modified ADP/PGE1 assay, and VASP phosphorylation assay, there was a 12%&#x2010;54% variation in the cut&#x2010;off values for clopidogrel nonresponsiveness between the above assays. Percentage of clopidogrel nonresponders detected by modified AD/PGE1 aggregation method and VerifyNow P2Y12 assay was much similar. When monitoring the clopidogrel active metabolite of clopidogrel in the plasma of patients, VASP assay was identified as more sensitive as the assay is more specific for P2Y12 assay. This study has concluded that the highest correlation was shown between the ADP/PGE1 aggregation assay and VASP phosphorylation assay and less correlation between conventional LTA and VerifyNow assay and VASP phosphorylation assay in monitoring the efficiency of action of clopidogrel.<xref rid="prp2686-bib-0044" ref-type="ref">
<sup>44</sup>
</xref> POCTs, such as VerifyNow P2Y12 assay, PFA&#x2010;100, Impact cone and Platelet analyzer, and Thromboelastograph Platelet Mapping System, were developed to overcome the limitations of the LTA technique although it is considered as the gold standard test.</p>
      <fig fig-type="FIGURE" xml:lang="en" id="prp2686-fig-0003" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Differentiation of results obtained from conventional and modifies light transmission aggregometry performed on clopidogrel responder and non&#x2010;responder patients (Bagoly et al, 2013).<xref rid="prp2686-bib-0044" ref-type="ref">
<sup>44</sup>
</xref>Conventional adenosine diphosphate (ADP) aggregation (without prostaglandin E1 [PGE1]) is shown in the left side and P2Y12 specific ADP aggregation with PGE1 is shown in right side. Top graphs shows the samples obtained from clopidogrel responder patients and below shows the samples obtained from clopidogrel resistant patient</p>
        </caption>
        <graphic id="nlm-graphic-7" xlink:href="PRP2-8-e00686-g003"/>
      </fig>
      <p>A study conducted to compare the effectiveness of LTA, modified TEG, and PFA&#x2010;100 has recruited 28 patients on clopidogrel therapy. The correlation between the LTA and TEG results was considerably acceptable (<italic>&#x3BA;</italic>&#xA0;=&#xA0;0.81). PFA&#x2010;100 had shown variable results for only two individuals who have been detected as resistant to clopidogrel by LTA and hence no relation was shown with either TEG or LTA. However, PFA&#x2010;100 was not recommended to demonstrate considerable difference in clopidogrel responses, but may be useful to demonstrate aspirin responses.<xref rid="prp2686-bib-0064" ref-type="ref">
<sup>64</sup>
</xref> As defined by the upper curve, Figure&#xA0;<xref rid="prp2686-fig-0004" ref-type="fig">4</xref>, <xref rid="prp2686-bib-0046" ref-type="ref">
<sup>46</sup>
</xref> depicts the platelet aggregation as a result of activation of P2Y1 receptor (till Point A). After point A, the platelet aggregation becomes stabilized due to the activation of P2Y12 receptors and the end point is noted as point C. Hence, points A and C are more likely in the same level due to the absence of clopidogrel. When clopidogrel is administered, the stabilization of P2Y12 decreases, initiating the disaggregation of the platelets, indicated by end point D. Absolute change in the peak level of the curve (Line E&#x2014;absolute inhibition at peak aggregations) and change in the levels of end points (Line F&#x2014;absolute inhibition at late aggregations) define the degree of nonresponsiveness to clopidogrel. Line G provides a measure of disaggregation. Points A and B indicate the peak points of platelet aggregation before and after clopidogrel administration, respectively. Points C and D reflect the late aggregation before and after clopidogrel administration, respectively.<xref rid="prp2686-bib-0046" ref-type="ref">
<sup>46</sup>
</xref>, <xref rid="prp2686-bib-0098" ref-type="ref">
<sup>98</sup>
</xref>
</p>
      <fig fig-type="FIGURE" xml:lang="en" id="prp2686-fig-0004" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>ADP&#x2010;induced platelet aggregation curve obtained from light transmission aggregometry before and after clopidogrel therapy (as cited by Lordkipanidze et al, 2009).<xref rid="prp2686-bib-0099" ref-type="ref">
<sup>99</sup>
</xref>ADP, adenosine diphosphate</p>
        </caption>
        <graphic id="nlm-graphic-9" xlink:href="PRP2-8-e00686-g004"/>
      </fig>
      <p>Both TEG and ROTEM have the capability to analyze the physical properties of the clot including the clot stability and strength, fibrin formation, clot formation, and clot lysis, but not thrombolysis or fibrinolysis. Moreover, both platelet function and defects associated with coagulation cascade are also monitored. Controversial result was obtained from the studies,<xref rid="prp2686-bib-0100" ref-type="ref">
<sup>100</sup>
</xref>, <xref rid="prp2686-bib-0101" ref-type="ref">
<sup>101</sup>
</xref>, <xref rid="prp2686-bib-0102" ref-type="ref">
<sup>102</sup>
</xref> that TEG has a very low ability in predicting the hemorrhage and guiding the transfusion of blood products, whereas. However, TEG platelet mapping can predict the excess hemorrhage in patients undergoing coronary artery bypass and under clopidogrel and aspirin therapy.<xref rid="prp2686-bib-0103" ref-type="ref">
<sup>103</sup>
</xref> The patients who were under clopidogrel therapy for 5&#xA0;days prior to bypass were shown 70% cut&#x2010;off value for platelet responsiveness for clopidogrel and had the capacity to determine the hemorrhage level at the surgery and transfusion guide.<xref rid="prp2686-bib-0104" ref-type="ref">
<sup>104</sup>
</xref>, <xref rid="prp2686-bib-0105" ref-type="ref">
<sup>105</sup>
</xref>
</p>
      <p>Vasodilator&#x2010;stimulated phosphoprotein phosphorylation assay has a higher ability to determine thienopyridine&#x2010;induced inhibition of platelets when compared with turbidimetric platelet aggregation assays. Flow cytometric analysis was able to define the associated clinical situation in detail. However, epinephrine action on &#x3B1;2A receptors can initiate the dephosphorylation of VASP, and nitric oxide donors can induce the VSP phosphorylation through cGMP causing false results in the analysis of the clopidogrel action.<xref rid="prp2686-bib-0106" ref-type="ref">
<sup>106</sup>
</xref>, <xref rid="prp2686-bib-0107" ref-type="ref">
<sup>107</sup>
</xref>, <xref rid="prp2686-bib-0108" ref-type="ref">
<sup>108</sup>
</xref> GRAVITAS trial (Gauging Responsiveness with a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety) has setup the cut&#x2010;off value for clopidogrel high on&#x2010;treatment platelet reactivity (HTPR) as &#x2265;208 P2Y12 PRU, which has been found in more than half of the selected subjects and has shown a &gt;5&#x2010;fold increased risk of cardiovascular death, myocardial infarction, and stent thrombosis at 60&#xA0;days.<xref rid="prp2686-bib-0109" ref-type="ref">
<sup>109</sup>
</xref>
</p>
      <p>Significant correlations were found between multiplate analyzer, PFA&#x2010;100, and LTA after ADP&#x2010;induced platelet aggregation in samples with clopidogrel therapy. However, sensitivity (78%), specificity (95%), accuracy (92%), positive predictive value (80%), and negative predictive value (95%) of Multiplate assay are significantly higher (&lt;0.0001) than LTA.<xref rid="prp2686-bib-0110" ref-type="ref">
<sup>110</sup>
</xref> Multiplate assay keeps the cellular environment unchanged, hence the assay becomes more rapid.<xref rid="prp2686-bib-0111" ref-type="ref">
<sup>111</sup>
</xref> Many studies have observed that PFA&#x2010;100 is more sensitive in determining the effect of clopidogrel rather than aspirin.<xref rid="prp2686-bib-0112" ref-type="ref">
<sup>112</sup>
</xref> However, a study has shown that PFA&#x2010;100 cannot be used in the determination of residual antiplatelet activity of clopidogrel. The actual platelet resistance in clopidogrel&#x2010;related HTPR can be detected by PFA&#x2010;100 when compared to aspirin.<xref rid="prp2686-bib-0113" ref-type="ref">
<sup>113</sup>
</xref>
</p>
      <p>Light transmission aggregometry had shown 60% sensitivity and specificity in HTPR once compared with VASP assay. Although both the assays have a high negative predictive value (94%), they lack a proper standardization technique.<xref rid="prp2686-bib-0114" ref-type="ref">
<sup>114</sup>
</xref> The cut&#x2010;off value for clopidogrel responsiveness when measured with Multiplate analyzer was found to be &gt;416 AU/min under 84% and 70% sensitivity and specificity, respectively.<xref rid="prp2686-bib-0115" ref-type="ref">
<sup>115</sup>
</xref>
</p>
      <p>Although there are many platelet function assays, none of the tests have been optimized or fully standardized to study the overall effect of clopidogrel and patient responsiveness to the drug. Reason is that, PFTs have their own pros and cons (Table&#xA0;<xref rid="prp2686-tbl-0001" ref-type="table">1</xref>).<xref rid="prp2686-bib-0036" ref-type="ref">
<sup>36</sup>
</xref>, <xref rid="prp2686-bib-0122" ref-type="ref">
<sup>122</sup>
</xref>
</p>
      <table-wrap id="prp2686-tbl-0001" xml:lang="en" content-type="TABLE" orientation="portrait" position="float">
        <label>TABLE 1</label>
        <caption>
          <p>Advantages and disadvantages of PFTs used for monitoring of clopidogrel effect</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <thead valign="top">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="top" rowspan="1" colspan="1">PFT</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Advantages</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Disadvantages</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">
<p>
<bold>VASP phosphorylation assay</bold>
</p>
<p>Principle: Flow cytometry</p>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0001"><list-item><p>Provides detail explanation on platelet glycoprotein receptors</p></list-item><list-item><p>Specific to assess the P2Y12 receptor inhibition</p></list-item><list-item><p>Perform on whole blood</p></list-item><list-item><p>Stable results can be obtained even after 24&#xA0;h of sample collection at room temperature</p></list-item><list-item><p>Low sample volume</p></list-item><list-item><p>Can monitor peak plasma levels of active thiol metabolite of clopidogrel. So, real in vivo biological activity of clopidogrel can be measured/more physiological</p></list-item><list-item><p>Possible to separate the &#x201C;Normal&#x201D; group from the patients with platelet inhibition effect</p></list-item><list-item><p>Not affected by platelet count. Hence, suitable for thrombocytopenic patients</p></list-item></list>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0002"><list-item><p>More time&#x2010;consuming</p></list-item><list-item><p>Need special expertise to perform</p></list-item><list-item><p>Cannot perform at/near bedside</p></list-item><list-item><p>Cannot produce rapid results</p></list-item><list-item><p>Expensive as it needs a flow cytometer</p></list-item><list-item><p>Special pretreatment to sample is required along with pipetting</p></list-item><list-item><p>Difficult to perform routinely</p></list-item><list-item><p>Cannot measure glycoprotein IIb/IIIa receptor</p></list-item><list-item><p>Affected by artifacts</p></list-item></list>
</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">
<p>
<bold>LTA</bold>
</p>
<p>Principle: Turbidimetric&#x2010;based optical detection of platelet aggregation under low shear rate</p>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0003"><list-item><p>Can be used to validate other novel platelet function tests</p></list-item><list-item><p>Possible to adjust the instrument to obtain many parameters</p></list-item><list-item><p>Good predictivity of clinical situation</p></list-item><list-item><p>Many studies are available to prove the efficacy of the assay, hence considered as gold standard</p></list-item><list-item><p>Measure overall platelet function and platelet surface glycoprotein including acquired and inherited defects</p></list-item><list-item><p>Monitoring clopidogrel drug effect</p></list-item></list>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0004"><list-item><p>Complex and time&#x2010;consuming</p></list-item><list-item><p>Poor standardization of the technique</p></list-item><list-item><p>Perform only platelet&#x2010;rich plasma. So, sample preparation steps are available; centrifugation and pipetting steps</p></list-item><list-item><p>Need more sample quantity</p></list-item><list-item><p>Cannot be performed at/near bedside</p></list-item><list-item><p>Operator errors affect the results</p></list-item><list-item><p>Measures AMC of clopidogrel only under high concentration of ADP (20&#xA0;&#xB5;mol/L)</p></list-item><list-item><p>Significant correlation with peak levels of AMC cannot be found with low ADP concentration (5&#xA0;&#xB5;mol/L). So, less sensitive to define clopidogrel responsiveness</p></list-item><list-item><p>Highly affected by pre&#x2010;analytical variables such as diet, hematocrit, operator errors, age, and gender</p></list-item><list-item><p>Results are affected by platelet count and not suitable for thrombocytopenic patients</p></list-item><list-item><p>P2Y1 receptors associated platelet aggregation will be induced under low&#x2010;dose ADP, unless they are blocked by PGE1</p></list-item><list-item><p>Assay performed under low shear rate. Hence, nonphysiological</p></list-item></list>
</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">
<p>
<bold>VerifyNow P2Y12 assay</bold>
</p>
<p>Principle: Turbidimetric assay</p>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0005"><list-item><p>Fully automated point of care device</p></list-item><list-item><p>Can be performed with whole blood</p></list-item><list-item><p>Produce rapid results</p></list-item><list-item><p>Simple technique. No expertise labor is required.</p></list-item><list-item><p>No pipetting, centrifugation steps, and sample processing</p></list-item><list-item><p>Small sample volume is required.</p></list-item><list-item><p>Widely used for monitoring clopidogrel effect</p></list-item><list-item><p>Results correlate considerably with LTA and other platelet function&#x2010;POCTs</p></list-item><list-item><p>Many disadvantages associated with LTA are addressed and rectified in the assay</p></list-item><list-item><p>Able to monitor clopidogrel efficacy and plasma levels of active thiol metabolite</p></list-item><list-item><p>Commonly used for monitoring the dual therapy with aspirin and clopidogrel</p></list-item><list-item><p>Assay is more physiological</p></list-item><list-item><p>Can be used for routine analysis</p></list-item><list-item><p>Most suitable device identified thus far to use as a POCT</p></list-item></list>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0006"><list-item><p>Assay cannot be adjusted to obtain different parameters or to predict the clinical condition more accurately</p></list-item><list-item><p>Cannot assess the other physiological platelet activation pathways</p></list-item><list-item><p>High cost for cartridges</p></list-item><list-item><p>Does not provide percentage inhibition of receptor or activity</p></list-item><list-item><p>Occasional failures in channels may occur</p></list-item><list-item><p>Though results can be delivered within 5&#xA0;min, it is recommended to incubate the sample for 10&#xA0;min for optimum results</p></list-item><list-item><p>Affected by hematocrit, platelet count, triglyceride, and fibrinogen levels</p></list-item></list>
</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">
<p>
<bold>PFA&#x2010;100</bold>
</p>
<p>Principle: Platelet aggregation is measured as the time required for closure of the aperture in the cartridge under high shear stress</p>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0007"><list-item><p>High sensitivity</p></list-item><list-item><p>Simple technique</p></list-item><list-item><p>Whole blood is used</p></list-item><list-item><p>3.8% sodium citrate anticoagulant will provide higher stability for CT results</p></list-item><list-item><p>Fully&#x2010;automated, point of care device</p></list-item><list-item><p>No sample pretreatment steps</p></list-item><list-item><p>Cartridge (CADP) is sensitive to measure P2Y12 receptor</p></list-item><list-item><p>Small volume of sample is needed</p></list-item><list-item><p>Produce rapid results</p></list-item><list-item><p>Standardized technique</p></list-item><list-item><p>Able to screen defects associated with primary hemostasis</p></list-item><list-item><p>More physiological than LTA</p></list-item><list-item><p>High negative predictive value</p></list-item><list-item><p>Insensitive to clotting factor deficiencies</p></list-item><list-item><p>More sensitive PFA&#x2010;P2Y cartridge has been developed which is more specific than collagen/ADP cartridge</p></list-item><list-item><p>Able to diagnose inherited and acquired platelet defects, bleeding, and thrombotic risk</p></list-item><list-item><p>Used to monitor antiplatelet therapy, mainly the effect of clopidogrel drug</p></list-item></list>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0008"><list-item><p>Assay cannot be adjusted</p></list-item><list-item><p>Requires sample pipetting only</p></list-item><list-item><p>Results may highly vary depending on the hematocrit level (&lt;50&#xA0;&#xD7;&#xA0;109/L and 25%) and vWF levels</p></list-item><list-item><p>Assay is affected by citrate concentration hematocrit, platelet count, certain drugs, certain food, and acquired platelet function defects</p></list-item><list-item><p>Less studies have conducted to prove the effectiveness of the assay</p></list-item><list-item><p>Collagen/ADP cartridge is relatively insensitive to thienopyridine effect. Hence, does not correlate with clopidogrel therapy</p></list-item><list-item><p>PFA&#x2010;P2Y cartridge is only available for research purposes</p></list-item><list-item><p>Not recommended to measure glycoprotein IIb/IIIa receptor</p></list-item></list>
</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">
<p>
<bold>Multiplate analyzer</bold>
</p>
<p>Principle: Impedance aggregometry</p>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0009"><list-item><p>Whole blood</p></list-item><list-item><p>Simple technique</p></list-item><list-item><p>Rapid results, within 10&#xA0;min</p></list-item><list-item><p>Standardized procedure</p></list-item><list-item><p>Point of care device</p></list-item><list-item><p>Less pretreatments to the sample</p></list-item><list-item><p>More physiological</p></list-item><list-item><p>Provides better correlation with LTA</p></list-item><list-item><p>Sensitive to monitor the clopidogrel effect</p></list-item><list-item><p>Able to monitor platelet surface glycoprotein receptors</p></list-item></list>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0010"><list-item><p>Semi&#x2010;automated</p></list-item><list-item><p>Samples should be analyzed as soon as collection.</p></list-item><list-item><p>Novel method. So, not much clinical studies to prove the effectiveness and evaluating the predictive value of the results obtained.</p></list-item><list-item><p>Need more sample volume</p></list-item><list-item><p>Expensive</p></list-item><list-item><p>Depend on hematocrit and platelet count</p></list-item></list>
</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">
<p>
<bold>TEG/ROTEM delta and ROTEM platelet</bold>
</p>
<p>Principle: Measures viscoelasticity under low shear stress</p>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0011"><list-item><p>Small volume of whole blood</p></list-item><list-item><p>Produce quick results within 5&#x2010;10&#xA0;min. ROTEM platelet provides results within 6&#xA0;min</p></list-item><list-item><p>Point of care device</p></list-item><list-item><p>Provide details regarding fibrinogen and clotting factors</p></list-item><list-item><p>Able to differentiate platelet disorders and clotting abnormalities</p></list-item><list-item><p>Measures the rate of clot formation and stability</p></list-item><list-item><p>Used to assess hemostasis worldwide</p></list-item><list-item><p>ROTEM platelet can monitor the effect of clopidogrel and other antiplatelet drugs</p></list-item></list>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0012"><list-item><p>Require labor expertise and expensive</p></list-item><list-item><p>Does not monitor warfarin effect</p></list-item><list-item><p>Artifacts in fibrin channel may affect percentage ADP estimates</p></list-item><list-item><p>Need calculations with three imprecise variables (CV&#xA0;~&#xA0;20%). Therefore, low precision. Co&#x2010;efficient of variance for TEG is 7.1%&#x2010;39.9% and ROTEM is 7%&#x2010;83.6% according to UK&#x2010;NEQAS data</p></list-item><list-item><p>TEG and ROTEM delta are not ideal test to monitor the effect of clopidogrel and other drugs</p></list-item><list-item><p>Requires pipetting</p></list-item><list-item><p>Results may be affected by the operator errors<xref rid="prp2686-bib-0123" ref-type="ref">
<sup>123</sup>
</xref>
</p></list-item></list>
</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">
<p>
<bold>Plateletworks</bold>
</p>
<p>Principle: Impedance aggregometry&#x2014;Measures platelet count before and after addition of ADP</p>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0013"><list-item><p>POCT</p></list-item><list-item><p>Small volume of citrated whole blood</p></list-item><list-item><p>Monitoring the response of platelets to antiplatelet therapy</p></list-item><list-item><p>Easy to perform</p></list-item><list-item><p>No sample preparation</p></list-item><list-item><p>No interaction of platelets with red cells and white cells</p></list-item><list-item><p>Can monitor clopidogrel effect and dual therapy along with aspirin</p></list-item><list-item><p>Glycoprotein IIb/IIIa receptors of platelets and predict outcomes</p></list-item></list>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0014"><list-item><p>Limited studies for assessing the effectiveness of the assay</p></list-item><list-item><p>More time due to sample preparation</p></list-item><list-item><p>Not standardized to define the antiplatelet resistance</p></list-item><list-item><p>Should perform within 10&#xA0;min</p></list-item><list-item><p>Affected by pre&#x2010;analytical variables</p></list-item><list-item><p>Does not have the ability to measure aggregation directly</p></list-item><list-item><p>Require adjunctive platelet count</p></list-item></list>
</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">
<bold>Pharmacogenetic assays</bold>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0015"><list-item><p>Predict the therapeutic outcome of clopidogrel as well as other drugs such as omeprazole, diazepam, and anti&#x2010;seizure drugs</p></list-item><list-item><p>Aid in genotype&#x2010;guided therapy where necessary</p></list-item><list-item><p>Determine the possible drug reactions</p></list-item><list-item><p>
<italic>CYP2C19</italic> polymorphism specifically determines clopidogrel efficacy</p></list-item><list-item><p>Whole blood, buccal swabs, and saliva can be used based on the test used</p></list-item><list-item><p>No patient preparation</p></list-item></list>
</td>
              <td align="left" rowspan="1" colspan="1">
<list list-type="order" id="prp2686-list-0016"><list-item><p>Expensive than PFTs</p></list-item><list-item><p>More time required for most techniques except for rapid genetic tests</p></list-item><list-item><p>Complex techniques which require skilled labor</p></list-item><list-item><p>Lack of studies to prove the relative cost&#x2010;effectiveness and efficacy to determine clopidogrel effect completely</p></list-item><list-item><p>Difficult to use routinely for every patient. Usually performed in high&#x2010;risk patients for poor response to standard dose of clopidogrel usually after PCI<xref rid="prp2686-bib-0094" ref-type="ref">
<sup>94</sup>
</xref> or if there is excess bleeding even after medication</p></list-item><list-item><p>Limited studies to prove the correlation between the results of different types of genetic tests available and with other PFTs</p></list-item><list-item><p>
<italic>CYP2C19</italic>&#x2010;guided therapy is not recommended to practice by ACA, AHA, and SCAI as clopidogrel nonresponsiveness may be associated with other genetic and nongenetic factors<xref rid="prp2686-bib-0085" ref-type="ref">
<sup>85</sup>
</xref>
</p></list-item></list>
</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="prp2686-ntgp-0002">
          <fn id="prp2686-note-0002">
            <p>Abbreviations: ACA, American College of Cardiology; ADP, adenosine diphosphate; AHA, American Heart Association; AMC, active thiol metabolite of clopidogrel; CV, coefficient of variation; LTA, light transmission aggregometry; PFA, platelet function assay; PGE1, prostaglandin E1; POCT; point of care test; ROTEM, rotational thromboelastometry; SCAI, society for cardiovascular angiography and interventions; TEG; thromboelastography; UK&#x2010;NEQAS, United Kingdom National External Quality Assessment Service; VASP, vasodilator&#x2010;stimulated phosphoprotein; vWF, von Willebrand factor.</p>
          </fn>
        </table-wrap-foot>
        <permissions>
          <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
        </permissions>
      </table-wrap>
      <p>By comparing the results obtained from the study, it was concluded that VASP phosphorylation assay, VerifyNow P2Y12 assay, and LTA with 20&#xA0;&#xB5;mol/L ADP are ideal PFTs to monitor clopidogrel responsiveness.<xref rid="prp2686-bib-0054" ref-type="ref">
<sup>54</sup>
</xref>, <xref rid="prp2686-bib-0066" ref-type="ref">
<sup>66</sup>
</xref>, <xref rid="prp2686-bib-0070" ref-type="ref">
<sup>70</sup>
</xref>, <xref rid="prp2686-bib-0117" ref-type="ref">
<sup>117</sup>
</xref>, <xref rid="prp2686-bib-0124" ref-type="ref">
<sup>124</sup>
</xref> When compared with LTA, VASP&#x2010;P assay was more suitable<xref rid="prp2686-bib-0125" ref-type="ref">
<sup>125</sup>
</xref> and out of LTA, Multiplate assay, Verify Now assay, and TEG, Multiplate assay was found to be ideal to monitor the clopidogrel.<xref rid="prp2686-bib-0126" ref-type="ref">
<sup>126</sup>
</xref> Limitations of LTA has paved the way for the development of standardized PFTs such as PFA&#x2010;100, Multiplate, and VerifyNow P2Y12 assays.<xref rid="prp2686-bib-0036" ref-type="ref">
<sup>36</sup>
</xref>
</p>
      <sec id="prp2686-sec-0019">
        <label>5.1</label>
        <title>Reference ranges</title>
        <p>High on&#x2010;treatment platelet reactivity on clopidogrel was defined by ROC curve analysis for VASP phosphorylation assay (PRI&#xA0;&gt;&#xA0;50%), VerifyNow P2Y12 assay (&gt;235&#x2010;240 PRU), LTA (&gt;46% for 5&#xA0;&#xB5;mol/L ADP), and Multiplate analysis (&gt;468 arbitrary AU/min).<xref rid="prp2686-bib-0067" ref-type="ref">
<sup>67</sup>
</xref>, <xref rid="prp2686-bib-0127" ref-type="ref">
<sup>127</sup>
</xref>, <xref rid="prp2686-bib-0128" ref-type="ref">
<sup>128</sup>
</xref> Table&#xA0;<xref rid="prp2686-tbl-0002" ref-type="table">2</xref> indicates the reference ranges to determine the clopidogrel responsiveness by different PFTs.</p>
        <table-wrap id="prp2686-tbl-0002" xml:lang="en" content-type="TABLE" orientation="portrait" position="float">
          <label>TABLE 2</label>
          <caption>
            <p>Reference ranges for clopidogrel responsiveness</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000" span="1"/>
            <thead valign="top">
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" valign="top" rowspan="1" colspan="1">Assay</th>
                <th align="left" valign="top" rowspan="1" colspan="1">Reference range</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">PFA&#x2010;100</td>
                <td align="left" rowspan="1" colspan="1">55&#x2010;137&#xA0;s for CADP cartridge</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">VerifyNow P2Y12 assay</td>
                <td align="left" rowspan="1" colspan="1">
<p>&gt;180&#x2010;376 PRU indicates that drug is not available in blood</p>
<p>10&#x2010;180 PRU indicates decreased platelet reactivity to P2Y12 inhibitor</p>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">ROTEM delta/TEG/ROTEM platelet</td>
                <td align="left" rowspan="1" colspan="1">
<p>Consider the impedance curve provided by ROTEM.</p>
<p>Reference ranges for CT (s), CFT (s), &#x3B1;&#x2010;angle (&#xB0;), A10 (MM), A20 (mm), MCF (mm), LI 30 (%), and ML (%) within 1&#xA0;h</p>
<p>For EXTEM: 38&#x2010;79&#xA0;s, 34&#x2010;159&#xA0;s, 63&#xB0;&#x2010;83&#xB0;, 43&#x2010;65&#xA0;mm, 50&#x2010;71&#xA0;mm, 50&#x2010;72&#xA0;mm, 94%&#x2010;100%,, and &lt;15%, respectively. For FIBTEM: A10 is 7&#x2010;23&#xA0;mm and A20 is 8&#x2010;24 mm<xref rid="prp2686-bib-0056" ref-type="ref">
<sup>56</sup>
</xref>, <xref rid="prp2686-bib-0129" ref-type="ref">
<sup>129</sup>
</xref>
</p>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">LTA</td>
                <td align="left" rowspan="1" colspan="1">Percentage optical density vs time graph will provide platelet aggregation traces. Based on the pattern, disease condition could be interpreted. Commonly encountered cases are Glanzmann's thrombasthenia, Bernard&#x2010;Soulier syndrome, storage pool disorder, the effect of aspirin, and the effect of clopidogrel</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Multiplate analyzer</td>
                <td align="left" rowspan="1" colspan="1">Interpretation is same as LTA</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">VASP Phosphorylation assay</td>
                <td align="left" rowspan="1" colspan="1">Need to study the scatterplot graphs to interpret the condition</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Plateletworks</td>
                <td align="left" rowspan="1" colspan="1">Provides percentage aggregation</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot id="prp2686-ntgp-0003">
            <fn id="prp2686-note-0003">
              <p>Abbreviations: A10, amplitude at 10&#xA0;s; CFT, clot formation time; clotting time; CT; LI, lysis index at 30&#xA0;min; MCF, maximum clot firmness; ML, maximum lysis; PFA; platelet function assay; PRU, platelet reactivity units; ROTEM, rotational thromboelastometry; TEG; thromboelastography.</p>
            </fn>
          </table-wrap-foot>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
          </permissions>
        </table-wrap>
      </sec>
    </sec>
    <sec id="prp2686-sec-0020">
      <label>6</label>
      <title>SUGGESTED IMPROVEMENTS FOR PLATELET FUNCTION TESTING</title>
      <p>An anticoagulant, such as hirudin, should be used instead of the 3.2% trisodium citrate when possible. The anticoagulant used must not interfere with the normal physiology of the sample.<xref rid="prp2686-bib-0054" ref-type="ref">
<sup>54</sup>
</xref>, <xref rid="prp2686-bib-0130" ref-type="ref">
<sup>130</sup>
</xref> An advanced principle with a simple technique which can be used globally for different agonists without altering the physiological environment of the sample would be ideal.<xref rid="prp2686-bib-0067" ref-type="ref">
<sup>67</sup>
</xref> Further, PFT should have the capacity to determine not only platelet aggregation, but also to measure the procoagulant activity of platelets. Most importantly, reference ranges need to be established to differentiate the normal from different clinical conditions and also identify low&#x2010;/high&#x2010;risk patients for clopidogrel and other antiplatelet drug nonresponsiveness. When the current clinical requirements are considered, the need for the PFT to be used as a screening test has increased, in order to obtain results and quick decisions.<xref rid="prp2686-bib-0131" ref-type="ref">
<sup>131</sup>
</xref> It would be better to develop more standardized and quality&#x2010;controlled PFT, minimizing the effect from pre&#x2010;analytical errors to the final result of the assay in addition to being cost&#x2010;effective. Assays more specifically assess the metabolism of clopidogrel and its thiol metabolites will help to study the increasing patterns of patient nonresponsiveness to clopidogrel. Performing large randomized clinical trials in different populations will benefit to identify the clinical outcomes of monitoring the effect of clopidogrel on individuals. At present, POCT assays, which use non&#x2010;anticoagulated finger prick blood with disposable cartridges, are available (such as PlaC or PFT).<xref rid="prp2686-bib-0066" ref-type="ref">
<sup>66</sup>
</xref> POCT&#x2010;PFTs should be developed to monitor the clopidogrel action on platelet inhibition via biomarkers, such as CD<sup>34+</sup>, which can be found in endothelial progenitor cells, chemokine CXCL12 (stromal cell&#x2010;derived factor&#x2010;1&#x3B1;, SDF&#x2010;1&#x3B1;), produced by platelet and stored in &#x3B1; granules. In future, there is a possibility for the development of sequencing assays to be used widely as screening tests to determine coagulation and hemorrhagic disorders.<xref rid="prp2686-bib-0132" ref-type="ref">
<sup>132</sup>
</xref>
</p>
    </sec>
    <sec sec-type="conclusions" id="prp2686-sec-0021">
      <label>7</label>
      <title>CONCLUSION</title>
      <p>In conclusion, at present no PFT has proved their optimum ideality for monitoring the platelet inhibition and efficacy by clopidogrel. Although new POCTs may be considered useful for the existing clinical setup, further prospective studies are required to determine the efficacy of them. For a PFT to become ideal, they should be able to use non&#x2010;anticoagulated whole blood to assess thrombus formation as wells as platelet aggregation/inhibition by clopidogrel. Further, assay should be able to perform on blood under high shear rate, to monitor in vivo thrombolysis and thrombus stability. Hence, the requirement for a new, ideal PFA as a point of care device which could overcome the limitations discussed has become an important need in the clinical setup globally. This would help in monitoring the effectiveness of clopidogrel on patients and helps to identify the responsiveness status and reasons for nonresponsiveness to the drug, thus aiding to develop proper treatment plans. Although determination of <italic>CYP2C19</italic> polymorphism is related to clopidogrel, it is not recommended to use <italic>CYP2C19</italic>&#x2010;guided therapy. Upon comparing the PFTs, VerifyNow P2Y12 assay seems to be the most suitable POCT for monitoring clopidogrel therapy at present. ROTEM platelet appears to have a good potential, however, lacks comparative studies. Performing PFT along with HPLC for clopidogrel levels in blood would provide a better understanding regarding clopidogrel therapy.</p>
    </sec>
    <sec sec-type="COI-statement" id="prp2686-sec-0022">
      <title>DISCLOSURES</title>
      <p>None declared.</p>
    </sec>
    <sec id="prp2686-sec-0023">
      <title>AUTHORS&#x2019; CONTRIBUTIONS</title>
      <p>All the authors have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data. Involved in drafting the manuscript and revising it critically for important intellectual content. All authors gave the final approval of the version to be published. Each author have participated sufficiently in the work to take public responsibility for appropriate portions of the content, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p>
    </sec>
  </body>
  <back>
    <sec sec-type="data-availability" id="prp2686-sec-0025">
      <title>DATA AVAILABILITY STATEMENT</title>
      <p>Data sharing is not applicable to this article as no new data were created or analyzed in this study.</p>
    </sec>
    <ref-list content-type="cited-references" id="prp2686-bibl-0001">
      <title>REFERENCES</title>
      <ref id="prp2686-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0001">
<string-name>
<surname>Michelson</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Bhatt</surname>
<given-names>DL</given-names>
</string-name>. <article-title>How I use laboratory monitoring of antiplatelet therapy</article-title>. <source xml:lang="en">Blood</source>. <year>2017</year>;<volume>130</volume>(<issue>6</issue>):<fpage>713</fpage>&#x2010;<lpage>721</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2017-03-742338</pub-id>
<pub-id pub-id-type="pmid">28600334</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0002">
<string-name>
<surname>Ohno</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Okada</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kitahara</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>Repetitive stent thrombosis in a patient who had resistance to both clopidogrel and prasugrel</article-title>. <source xml:lang="en">J Cardiol Cases</source>. <year>2016</year>;<volume>13</volume>(<issue>5</issue>):<fpage>139</fpage>&#x2010;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1016/j.jccase.2016.01.001</pub-id>
<pub-id pub-id-type="pmid">30546628</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0003">
<string-name>
<surname>Uchiyama</surname>
<given-names>S</given-names>
</string-name>. <article-title>Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment: clopidogrel resistance</article-title>. <source xml:lang="en">Cardiovasc Ther</source>. <year>2011</year>;<volume>29</volume>(<issue>6</issue>):<fpage>e100</fpage>&#x2010;<lpage>e111</lpage>. <pub-id pub-id-type="doi">10.1111/j.1755-5922.2010.00202.x</pub-id>
<pub-id pub-id-type="pmid">21883990</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0004">
<string-name>
<surname>Nishi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ariyoshi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Nakayama</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in Japanese patients with stable coronary artery disease</article-title>. <source xml:lang="en">Circ J</source>. <year>2015</year>;<volume>79</volume>(<issue>11</issue>):<fpage>2439</fpage>&#x2010;<lpage>2444</lpage>. <pub-id pub-id-type="doi">10.1253/circj.CJ-15-0546</pub-id>
<pub-id pub-id-type="pmid">26310876</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0005">
<string-name>
<surname>Kimura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Isshiki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ogawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yokoi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yamaguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ikeda</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Randomized, double&#x2010;blind, dose&#x2010;finding, phase ii study of prasugrel in japanese patients undergoing elective percutaneous coronary intervention</article-title>. <source xml:lang="en">J Atheroscler Thromb</source>. <year>2015</year>;<volume>22</volume>(<issue>6</issue>):<fpage>557</fpage>&#x2010;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.5551/jat.26013</pub-id>
<pub-id pub-id-type="pmid">25737192</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0006">
<string-name>
<surname>Sangkuhl</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>TE</given-names>
</string-name>, <string-name>
<surname>Altman</surname>
<given-names>RB</given-names>
</string-name>. <article-title>Clopidogrel pathway</article-title>. <source xml:lang="en">Pharmacogenet Genomics</source>. <year>2010</year>:<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e3283385420</pub-id>
<pub-id pub-id-type="pmid">19940802</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0007">
<string-name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Romero</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Ren</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Clopidogrel as a donor probe and thioenol derivatives as flexible promoieties for enabling H2S biomedicine</article-title>. <source xml:lang="en">Nat Commun</source>. <year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>3952</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-018-06373-0</pub-id>
<pub-id pub-id-type="pmid">30262863</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0008">
<string-name>
<surname>Kara&#x17A;niewicz&#x2010;Lada</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Danielak</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Burchardt</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Gl&#xF3;wka</surname>
<given-names>F</given-names>
</string-name>. <article-title>The influence of diabetic status on the pharmacokinetics of clopidogrel and its metabolites in patients suffered from cardiovascular diseases</article-title>. <source xml:lang="en">J Med Sci</source>. <year>2014</year>;<volume>83</volume>(<issue>3</issue>):<fpage>215</fpage>&#x2010;<lpage>221</lpage>.</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0009">
<string-name>
<surname>Kara&#x17A;niewicz&#x2010;&#x141;ada</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Danielak</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Rubi&#x15B;</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Burchardt</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Oszkinis</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>G&#x142;&#xF3;wka</surname>
<given-names>F</given-names>
</string-name>. <article-title>The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases</article-title>. <source xml:lang="en">J Clin Pharmacol</source>. <year>2014</year>;<volume>54</volume>(<issue>8</issue>):<fpage>874</fpage>&#x2010;<lpage>880</lpage>. <pub-id pub-id-type="doi">10.1002/jcph.323</pub-id>
<pub-id pub-id-type="pmid">24782221</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0010">
<string-name>
<surname>Kara&#x17A;niewicz&#x2010;&#x141;ada</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rze&#x17A;niczak</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>G&#x142;&#xF3;wka</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Influence of statin treatment on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites in patients after coronary angiography/angioplasty</article-title>. <source xml:lang="en">Biomed Pharmacother</source>. <year>2019</year>;<volume>116</volume>:<fpage>108991</fpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2019.108991</pub-id>
<pub-id pub-id-type="pmid">31136946</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0011">
<string-name>
<surname>Heestermans</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>de Boer</surname>
<given-names>M&#x2010;J</given-names>
</string-name>, <string-name>
<surname>van Werkum</surname>
<given-names>JW</given-names>
</string-name>, et al. <article-title>Higher efficacy of pre&#x2010;hospital tirofiban with longer pre&#x2010;treatment time to primary PCI: protection for the negative impact of time delay</article-title>. <source xml:lang="en">EuroIntervention</source>. <year>2011</year>;<volume>7</volume>(<issue>4</issue>):<fpage>442</fpage>&#x2010;<lpage>448</lpage>. <pub-id pub-id-type="doi">10.4244/EIJV7I4A73</pub-id>
<pub-id pub-id-type="pmid">21764662</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0012">
<string-name>
<surname>Mijajlovic</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Shulga</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Bloch</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Covickovic&#x2010;Sternic</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Aleksic</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Bornstein</surname>
<given-names>NM</given-names>
</string-name>. <article-title>Clinical consequences of aspirin and clopidogrel resistance: an overview</article-title>. <source xml:lang="en">Acta Neurol Scand</source>. <year>2013</year>;<volume>128</volume>(<issue>4</issue>):<fpage>213</fpage>&#x2010;<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1111/ane.12111</pub-id>
<pub-id pub-id-type="pmid">23432706</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0013">
<string-name>
<surname>Nguyen</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Diodati</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Pharand</surname>
<given-names>C</given-names>
</string-name>. <article-title>Resistance to clopidogrel: a review of the evidence</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2005</year>;<volume>45</volume>(<issue>8</issue>):<fpage>1157</fpage>&#x2010;<lpage>1164</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2005.01.034</pub-id>
<pub-id pub-id-type="pmid">15837243</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0014">
<string-name>
<surname>Qureshi</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Hobson</surname>
<given-names>AR</given-names>
</string-name>. <article-title>Clopidogrel &#x201C;resistance&#x201D;: where are we now?: Clopidogrel &#x2018;resistance&#x2019;</article-title>. <source xml:lang="en">Cardiovasc Ther</source>. <year>2013</year>;<volume>31</volume>(<issue>1</issue>):<fpage>3</fpage>&#x2010;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1111/j.1755-5922.2011.00296.x</pub-id>
<pub-id pub-id-type="pmid">21884029</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0015">
<string-name>
<surname>Ray</surname>
<given-names>S</given-names>
</string-name>. <article-title>Clopidogrel resistance: The way forward</article-title>. <source xml:lang="en">Indian Heart J</source>. <year>2014</year>;<volume>66</volume>(<issue>5</issue>):<fpage>530</fpage>&#x2010;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1016/j.ihj.2014.08.012</pub-id>
<pub-id pub-id-type="pmid">25443607</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0016">
<string-name>
<surname>Neki</surname>
<given-names>N</given-names>
</string-name>. <article-title>Clopidogrel resistance: current issues</article-title>. <source xml:lang="en">J Enam Med Coll</source>. <year>2016</year>;<volume>6</volume>(<issue>1</issue>):<fpage>38</fpage>&#x2010;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.3329/jemc.v6i1.26381</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0017">
<string-name>
<surname>Norgard</surname>
<given-names>NB</given-names>
</string-name>, <string-name>
<surname>DiNicolantonio</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes</article-title>. <source xml:lang="en">Postgrad Med</source>. <year>2013</year>;<volume>125</volume>(<issue>4</issue>):<fpage>91</fpage>&#x2010;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.3810/pgm.2013.07.2682</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0018">
<string-name>
<surname>Gasparyan</surname>
<given-names>AY</given-names>
</string-name>. <article-title>Aspirin and clopidogrel resistance: methodological challenges and opportunities</article-title>. <source xml:lang="en">Vasc Health Risk Manag</source>. <year>2010</year>:<fpage>109</fpage>
<pub-id pub-id-type="doi">10.2147/VHRM.S9087</pub-id>
<pub-id pub-id-type="pmid">20448796</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0019">
<string-name>
<surname>Holmes</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Dehmer</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Kaul</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>ACCF/AHA clopidogrel clinical alert: approaches to the FDA &#x201C;boxed warning&#x201D;: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents and the American Heart Association</article-title>. <source xml:lang="en">Circulation</source>. <year>2010</year>;<volume>122</volume>(<issue>5</issue>):<fpage>537</fpage>&#x2010;<lpage>557</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0b013e3181ee08ed</pub-id>
<pub-id pub-id-type="pmid">20585015</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0020">
<string-name>
<surname>Simon</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Verstuyft</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mary&#x2010;Krause</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Genetic determinants of response to clopidogrel and cardiovascular events</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>4</issue>):<fpage>363</fpage>&#x2010;<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0808227</pub-id>
<pub-id pub-id-type="pmid">19106083</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0021">
<string-name>
<surname>Jaremo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lindahl</surname>
<given-names>TL</given-names>
</string-name>, <string-name>
<surname>Fransson</surname>
<given-names>SG</given-names>
</string-name>, <string-name>
<surname>Richter</surname>
<given-names>A</given-names>
</string-name>. <article-title>Individual variations of platelet inhibition after loading doses of clopidogrel</article-title>. <source xml:lang="en">J Intern Med</source>. <year>2002</year>;<volume>252</volume>(<issue>3</issue>):<fpage>233</fpage>&#x2010;<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2796.2002.01027.x</pub-id>
<pub-id pub-id-type="pmid">12270003</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0022">
        <label>22</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0022">
<string-name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Bliden</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Hiatt</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>O&#x2019;Connor</surname>
<given-names>CM</given-names>
</string-name>. <article-title>Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity</article-title>. <source xml:lang="en">Circulation</source>. <year>2003</year>;<volume>107</volume>(<issue>23</issue>):<fpage>2908</fpage>&#x2010;<lpage>2913</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.0000072771.11429.83</pub-id>
<pub-id pub-id-type="pmid">12796140</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0023">
        <label>23</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0023">
<string-name>
<surname>Angiolillo</surname>
<given-names>D</given-names>
</string-name>. <article-title>High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2004</year>;<volume>25</volume>(<issue>21</issue>):<fpage>1903</fpage>&#x2010;<lpage>1910</lpage>. <pub-id pub-id-type="doi">10.1016/j.ehj.2004.07.036</pub-id>
<pub-id pub-id-type="pmid">15522469</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0024">
        <label>24</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0024">
<string-name>
<surname>Ivandic</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>Schlick</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Staritz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kurz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Katus</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Giannitsis</surname>
<given-names>E</given-names>
</string-name>. <article-title>Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor</article-title>. <source xml:lang="en">Clin Chem</source>. <year>2006</year>;<volume>52</volume>(<issue>3</issue>):<fpage>383</fpage>&#x2010;<lpage>388</lpage>. <pub-id pub-id-type="doi">10.1373/clinchem.2005.059535</pub-id>
<pub-id pub-id-type="pmid">16423907</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0025">
        <label>25</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0025">
<string-name>
<surname>Saraf</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bensalha</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Gorog</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Antiplatelet resistance&#x2014;does it exist and how to measure it?</article-title>
<source xml:lang="en">Clin Med Cardiol</source>. <year>2009</year>;<volume>3</volume>:<fpage>CMC.S2159</fpage>
<pub-id pub-id-type="doi">10.4137/CMC.S2159</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0026">
        <label>26</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0026">
<string-name>
<surname>Michos</surname>
<given-names>ED</given-names>
</string-name>, <string-name>
<surname>Ardehali</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Blumenthal</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Lange</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Ardehali</surname>
<given-names>H</given-names>
</string-name>. <article-title>Aspirin and clopidogrel resistance</article-title>. <source xml:lang="en">Mayo Clin Proc</source>. <year>2006</year>;<volume>81</volume>(<issue>4</issue>):<fpage>518</fpage>&#x2010;<lpage>526</lpage>. <pub-id pub-id-type="doi">10.4065/81.4.518</pub-id>
<pub-id pub-id-type="pmid">16610572</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0027">
        <label>27</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0027">
<string-name>
<surname>Maree</surname>
<given-names>AO</given-names>
</string-name>, <string-name>
<surname>Fitzgerald</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Variable platelet response to aspirin and clopidogrel in atherothrombotic disease</article-title>. <source xml:lang="en">Circulation</source>. <year>2007</year>;<volume>115</volume>(<issue>16</issue>):<fpage>2196</fpage>&#x2010;<lpage>2207</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.675991</pub-id>
<pub-id pub-id-type="pmid">17452618</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0028">
        <label>28</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0028">
<string-name>
<surname>Lui</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gardiner</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Arthur</surname>
<given-names>JF</given-names>
</string-name>, et al. <article-title>Novel stenotic microchannels to study thrombus formation in shear gradients: influence of shear forces and human platelet&#x2010;related factors</article-title>. <source xml:lang="en">Int J Mol Sci</source>. <year>2019</year>;<volume>20</volume>(<issue>12</issue>):<fpage>2967</fpage>
<pub-id pub-id-type="doi">10.3390/ijms20122967</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0029">
        <label>29</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0029">
<string-name>
<surname>Casa</surname>
<given-names>LDC</given-names>
</string-name>, <string-name>
<surname>Ku</surname>
<given-names>DN</given-names>
</string-name>. <article-title>Thrombus formation at high shear rates</article-title>. <source xml:lang="en">Annu Rev Biomed Eng</source>. <year>2017</year>;<volume>19</volume>(<issue>1</issue>):<fpage>415</fpage>&#x2010;<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-bioeng-071516-044539</pub-id>
<pub-id pub-id-type="pmid">28441034</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0030">
        <label>30</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0030">
<string-name>
<surname>Wang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hao</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Leeper</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>L</given-names>
</string-name>. <article-title>Thrombotic regulation from the endothelial cell perspectives</article-title>. <source xml:lang="en">Arterioscler Thromb Vasc Biol</source>. <year>2018</year>;<volume>38</volume>(<issue>6</issue>). <pub-id pub-id-type="doi">10.1161/ATVBAHA.118.310367</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0031">
        <label>31</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0031">
<string-name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Tantry</surname>
<given-names>US</given-names>
</string-name>. <article-title>Clopidogrel resistance?</article-title>
<source xml:lang="en">Thromb Res</source>. <year>2007</year>;<volume>120</volume>(<issue>3</issue>):<fpage>311</fpage>&#x2010;<lpage>321</lpage>. <pub-id pub-id-type="doi">10.1016/j.thromres.2006.08.012</pub-id>
<pub-id pub-id-type="pmid">17109936</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0032">
        <label>32</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0032">
<string-name>
<surname>Prisco</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Marcucci</surname>
<given-names>R</given-names>
</string-name>. <article-title>Antiplatelet drug&#x2019;s resistance</article-title>. <source xml:lang="en">Open Atheroscler Thromb J</source>. <year>2009</year>;<volume>2</volume>(<issue>2</issue>):<fpage>24</fpage>&#x2010;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.2174/1876506800902020024</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0033">
        <label>33</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0033">
<string-name>
<surname>Cattaneo</surname>
<given-names>M</given-names>
</string-name>. <article-title>P2Y12 receptors: structure and function</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2015</year>;<volume>13</volume>(<issue>S1</issue>):<fpage>S10</fpage>&#x2010;<lpage>S16</lpage>. <pub-id pub-id-type="doi">10.1111/jth.12952</pub-id>
<pub-id pub-id-type="pmid">26149010</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0034">
        <label>34</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0034">
<string-name>
<surname>Tanaka</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Bader</surname>
<given-names>SO</given-names>
</string-name>, <string-name>
<surname>Sturgil</surname>
<given-names>EL</given-names>
</string-name>. <article-title>Diagnosis of perioperative coagulopathy&#x2014;plasma versus whole blood testing</article-title>. <source xml:lang="en">J Cardiothorac Vasc Anesth</source>. <year>2013</year>;<volume>27</volume>(<issue>4</issue>):<fpage>S9</fpage>&#x2010;<lpage>S15</lpage>. <pub-id pub-id-type="doi">10.1053/j.jvca.2013.05.012</pub-id>
<pub-id pub-id-type="pmid">23910538</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0035">
        <label>35</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0035">
<string-name>
<surname>Rita Paniccia</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Maggini</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Assessment of platelet function: Laboratory and point&#x2010;of&#x2010;care methods</article-title>. <source xml:lang="en">World J Transl Med</source>. <year>2014</year>;<volume>3</volume>(<issue>2</issue>):<fpage>69</fpage>&#x2010;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.5528/wjtm.v3.i2.69</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0036">
        <label>36</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0036">
<string-name>
<surname>Choi</surname>
<given-names>J&#x2010;L</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>J&#x2010;Y</given-names>
</string-name>. <article-title>Platelet function tests: a review of progresses in clinical application</article-title>. <source xml:lang="en">BioMed Res Int</source>. <year>2014</year>;<volume>2014</volume>:<fpage>1</fpage>&#x2010;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1155/2014/456569</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0037">
        <label>37</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0037">
<string-name>
<surname>Hechler</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Dupuis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mangin</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Gachet</surname>
<given-names>C</given-names>
</string-name>. <article-title>Platelet preparation for function testing in the laboratory and clinic: Historical and practical aspects</article-title>. <source xml:lang="en">Res Pract Thromb Haemost</source>. <year>2019</year>;<volume>3</volume>(<issue>4</issue>):<fpage>615</fpage>&#x2010;<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1002/rth2.12240</pub-id>
<pub-id pub-id-type="pmid">31624781</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0038">
        <label>38</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0038">
<string-name>
<surname>Baumgartner</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Turitto</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>
<given-names>HJ</given-names>
</string-name>. <article-title>Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. II. Relationships among platelet adhesion, thrombus dimensions, and fibrin formation</article-title>. <source xml:lang="en">J Lab Clin Med</source>. <year>1980</year>;<volume>95</volume>(<issue>2</issue>):<fpage>208</fpage>&#x2010;<lpage>221</lpage>.<pub-id pub-id-type="pmid">7354233</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0039">
        <label>39</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0039">
<string-name>
<surname>Gilman</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Santrach</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Schears</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Karon</surname>
<given-names>BS</given-names>
</string-name>. <article-title>Fresh and citrated whole&#x2010;blood specimens can produce different thromboelastography results in patients on extracorporeal membrane oxygenation</article-title>. <source xml:lang="en">Am J Clin Pathol</source>. <year>2013</year>;<volume>140</volume>(<issue>2</issue>):<fpage>165</fpage>&#x2010;<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1309/AJCPYIQ9JNNSEN4Q</pub-id>
<pub-id pub-id-type="pmid">23897250</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0040">
        <label>40</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0040">
<string-name>
<surname>Silverberg</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tornqvist</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kander</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Comparison of citrated and fresh whole blood for viscoelastic coagulation testing during elective neurosurgery</article-title>. <source xml:lang="en">Thromb Res</source>. <year>2017</year>;<volume>156</volume>:<fpage>73</fpage>&#x2010;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.thromres.2017.05.033</pub-id>
<pub-id pub-id-type="pmid">28601642</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0041">
        <label>41</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0041">
<string-name>
<surname>Grau</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Reiners</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lichy</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Buggle</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ruf</surname>
<given-names>A</given-names>
</string-name>. <article-title>Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case&#x2010;crossover study</article-title>. <source xml:lang="en">Stroke</source>. <year>2003</year>;<volume>34</volume>(<issue>4</issue>):<fpage>849</fpage>&#x2010;<lpage>854</lpage>. <pub-id pub-id-type="doi">10.1161/01.STR.0000064326.65899.AC</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0042">
        <label>42</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0042">
<string-name>
<surname>T&#xF3;th</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Calatzis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Penz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Losonczy</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Siess</surname>
<given-names>W</given-names>
</string-name>. <article-title>Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood</article-title>. <source xml:lang="en">Thromb Haemost</source>. <year>2006</year>;<volume>96</volume>(<issue>12</issue>):<fpage>781</fpage>&#x2010;<lpage>788</lpage>. <pub-id pub-id-type="doi">10.1160/TH06-05-0242</pub-id>
<pub-id pub-id-type="pmid">17139373</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0043">
        <label>43</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0043">
<string-name>
<surname>Mani</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hellis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lindhoff&#x2010;Last</surname>
<given-names>E</given-names>
</string-name>. <article-title>Platelet function testing in hirudin and BAPA anticoagulated blood</article-title>. <source xml:lang="en">Clin Chem Lab Med</source>. <year>2010</year>;<volume>49</volume>(<issue>3</issue>):<fpage>501</fpage>&#x2010;<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1515/cclm.2011.074</pub-id>
<pub-id pub-id-type="pmid">21175382</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0044">
        <label>44</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0044">
<string-name>
<surname>Bagoly</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Sarkady</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Magyar</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Comparison of a New P2Y12 Receptor Specific Platelet Aggregation Test with Other Laboratory Methods in Stroke Patients on Clopidogrel Monotherapy</article-title>. <source xml:lang="en">PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>7</issue>):<elocation-id>e69417</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0069417</pub-id>
<pub-id pub-id-type="pmid">23844259</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0045">
        <label>45</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0045">
<string-name>
<surname>Wijeyeratne</surname>
<given-names>YD</given-names>
</string-name>, <string-name>
<surname>Heptinstall</surname>
<given-names>S</given-names>
</string-name>. <article-title>Anti&#x2010;platelet therapy: ADP receptor antagonists: Anti&#x2010;platelet therapy: ADP receptor antagonists</article-title>. <source xml:lang="en">Br J Clin Pharmacol</source>. <year>2011</year>;<volume>72</volume>(<issue>4</issue>):<fpage>647</fpage>&#x2010;<lpage>657</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2125.2011.03999.x</pub-id>
<pub-id pub-id-type="pmid">21518389</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0046">
        <label>46</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0046">
<string-name>
<surname>Labarthe</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Th&#xE9;roux</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Angio&#xEF;</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ghitescu</surname>
<given-names>M</given-names>
</string-name>. <article-title>Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2005</year>;<volume>46</volume>(<issue>4</issue>):<fpage>638</fpage>&#x2010;<lpage>645</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2005.02.092</pub-id>
<pub-id pub-id-type="pmid">16098428</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0047">
        <label>47</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0047">
<string-name>
<surname>Linnemann</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Schwonberg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mani</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Prochnow</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lindhoff&#x2010;Last</surname>
<given-names>E</given-names>
</string-name>. <article-title>Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2008</year>;<volume>6</volume>(<issue>4</issue>):<fpage>677</fpage>&#x2010;<lpage>683</lpage>. <pub-id pub-id-type="doi">10.1111/j.1538-7836.2008.02891.x</pub-id>
<pub-id pub-id-type="pmid">18182038</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0048">
        <label>48</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0048">
<string-name>
<surname>M&#xFC;ller&#x2010;Schunk</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Linn</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Monitoring of clopidogrel&#x2010;related platelet inhibition: correlation of nonresponse with clinical outcome in supra&#x2010;aortic stenting</article-title>. <source xml:lang="en">Am J Neuroradiol</source>. <year>2008</year>;<volume>29</volume>(<issue>4</issue>):<fpage>786</fpage>&#x2010;<lpage>791</lpage>. <pub-id pub-id-type="doi">10.3174/ajnr.A0917</pub-id>
<pub-id pub-id-type="pmid">18223094</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0049">
        <label>49</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0049">
<string-name>
<surname>Smock</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Saunders</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Rodgers</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Johari</surname>
<given-names>V</given-names>
</string-name>. <article-title>Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods</article-title>. <source xml:lang="en">Am J Hematol</source>. <year>2011</year>;<volume>86</volume>(<issue>12</issue>):<fpage>1032</fpage>&#x2010;<lpage>1034</lpage>. <pub-id pub-id-type="doi">10.1002/ajh.22112</pub-id>
<pub-id pub-id-type="pmid">21812020</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0050">
        <label>50</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0050">
<string-name>
<surname>Mallouk</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Varvat</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Assessment of a flow cytometry technique for studying signaling pathways in platelets: Monitoring of VASP phosphorylation in clinical samples</article-title>. <source xml:lang="en">Pract Lab Med</source>. <year>2018</year>;<volume>11</volume>:<fpage>10</fpage>&#x2010;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.plabm.2018.02.002</pub-id>
<pub-id pub-id-type="pmid">30202779</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0051">
        <label>51</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0051">
<string-name>
<surname>Godino</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mendolicchio</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Figini</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Comparison of VerifyNow&#x2010;P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut&#x2010;off value for identifying patients who are low responders to clopidogrel therapy?</article-title>
<source xml:lang="en">Thromb J</source>. <year>2009</year>;<volume>7</volume>(<issue>1</issue>):<fpage>4</fpage>
<pub-id pub-id-type="doi">10.1186/1477-9560-7-4</pub-id>
<pub-id pub-id-type="pmid">19419580</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0052">
        <label>52</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0052">
<string-name>
<surname>Aleil</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ravanat</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cazenave</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Rochoux</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Heitz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gachet</surname>
<given-names>C</given-names>
</string-name>. <article-title>Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2005</year>;<volume>3</volume>(<issue>1</issue>):<fpage>85</fpage>&#x2010;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1111/j.1538-7836.2004.01063.x</pub-id>
<pub-id pub-id-type="pmid">15634270</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0053">
        <label>53</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0053">
<string-name>
<surname>Ondondo</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Platelet</surname>
<given-names>B</given-names>
</string-name>. <article-title>Function testing for cardiac surgery patients on antiplatelet therapy: the extreme variability of point&#x2010;of&#x2010;care tests</article-title>. <source xml:lang="en">Biomed Pharmacol J</source>. <year>2018</year>;<volume>11</volume>(<issue>2</issue>):<fpage>593</fpage>&#x2010;<lpage>607</lpage>. <pub-id pub-id-type="doi">10.13005/bpj/1412</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0054">
        <label>54</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0054">
<string-name>
<surname>Gorog</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>RC</given-names>
</string-name>. <article-title>Point&#x2010;of&#x2010;care platelet function tests: relevance to arterial thrombosis and opportunities for improvement</article-title>. <source xml:lang="en">J Thromb Thrombolysis</source>. <year>2020</year>
<pub-id pub-id-type="doi">10.1007/s11239-020-02170-z</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0055">
        <label>55</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0055">
<string-name>
<surname>Lier</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Vorweg</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hanke</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>G&#xF6;rlinger</surname>
<given-names>K</given-names>
</string-name>. <article-title>Thromboelastometry guided therapy of severe bleeding: Essener Runde algorithm</article-title>. <source xml:lang="en">H&#xE4;mostaseologie</source>. <year>2013</year>;<volume>33</volume>(<issue>1</issue>):<fpage>51</fpage>&#x2010;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.5482/HAMO-12-05-0011</pub-id>
<pub-id pub-id-type="pmid">23258612</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0056">
        <label>56</label>
        <mixed-citation publication-type="book" id="prp2686-cit-0056">
<string-name>
<surname>G&#xF6;rlinger</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Dirkmann</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hanke</surname>
<given-names>AA</given-names>
</string-name>. <chapter-title>Rotational thromboelastometry (ROTEM<sup>&#xAE;</sup>)</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Gonzalez</surname><given-names>E</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Moore</surname><given-names>HB</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Moore</surname><given-names>EE</given-names></name></person-group>, eds. <source xml:lang="en">Trauma Induced Coagulopathy</source>. <publisher-name>Springer International Publishing</publisher-name>; <year>2016</year>:<fpage>267</fpage>&#x2010;<lpage>298</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-28308-1_18</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0057">
        <label>57</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0057">
<string-name>
<surname>Samo&#x161;</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stan&#x10D;iakov&#xE1;</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Duraj</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Monitoring the hemostasis with rotation thromboelastometry in patients with acute STEMI on dual antiplatelet therapy: First experiences</article-title>. <source xml:lang="en">Medicine</source>. <year>2017</year>;<volume>96</volume>(<issue>6</issue>):<elocation-id>e6045</elocation-id>
<pub-id pub-id-type="doi">10.1097/MD.0000000000006045</pub-id>
<pub-id pub-id-type="pmid">28178148</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0058">
        <label>58</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0058">
<string-name>
<surname>Tanaka</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Bolliger</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Vadlamudi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Nimmo</surname>
<given-names>A</given-names>
</string-name>. <article-title>Rotational thromboelastometry (ROTEM)&#x2010;based coagulation management in cardiac surgery and major trauma</article-title>. <source xml:lang="en">J Cardiothorac Vasc Anesth</source>. <year>2012</year>;<volume>26</volume>(<issue>6</issue>):<fpage>1083</fpage>&#x2010;<lpage>1093</lpage>. <pub-id pub-id-type="doi">10.1053/j.jvca.2012.06.015</pub-id>
<pub-id pub-id-type="pmid">22863406</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0059">
        <label>59</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0059">
<string-name>
<surname>Theusinger</surname>
<given-names>OM</given-names>
</string-name>, <string-name>
<surname>N&#xFC;rnberg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Asmis</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Seifert</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Spahn</surname>
<given-names>DR</given-names>
</string-name>. <article-title>Rotation thromboelastometry (ROTEM<sup>&#xAE;</sup>) stability and reproducibility over time&#x2606;</article-title>. <source xml:lang="en">Eur J Cardiothorac Surg</source>. <year>2010</year>;<volume>37</volume>(<issue>3</issue>):<fpage>677</fpage>&#x2010;<lpage>683</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejcts.2009.07.038</pub-id>
<pub-id pub-id-type="pmid">19747838</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0060">
        <label>60</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0060">
<string-name>
<surname>Bhardwaj</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Kapoor</surname>
<given-names>PM</given-names>
</string-name>. <article-title>Platelet aggregometry interpretation using rotem&#x2014;part&#x2010;II</article-title>. <source xml:lang="en">Ann Card Anaesth</source>. <year>2016</year>;<volume>19</volume>(<issue>4</issue>):<fpage>584</fpage>&#x2010;<lpage>586</lpage>. <pub-id pub-id-type="doi">10.4103/0971-9784.191559</pub-id>
<pub-id pub-id-type="pmid">27716685</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0061">
        <label>61</label>
        <mixed-citation publication-type="book" id="prp2686-cit-0061">
<string-name>
<surname>Shaydakov</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Sigmon</surname>
<given-names>DF</given-names>
</string-name>, <string-name>
<surname>Blebea</surname>
<given-names>J</given-names>
</string-name>. <source xml:lang="en">Thromboelastography (TEG)</source>. <publisher-loc>Treasure Island, FL</publisher-loc>: <publisher-name>StatPearls Publishing</publisher-name>; <year>2020</year>
<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK537061/">https://www.ncbi.nlm.nih.gov/books/NBK537061/</ext-link>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0062">
        <label>62</label>
        <mixed-citation publication-type="book" id="prp2686-cit-0062">
<string-name>
<surname>Munther</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Homoud</surname>
<given-names>MD</given-names>
</string-name>. <source xml:lang="en">Coronary Artery Disease Tufts</source>. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>New England Medical Center</publisher-name>; <year>2008</year>.</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0063">
        <label>63</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0063">
<string-name>
<surname>Jeong</surname>
<given-names>Y&#x2010;H</given-names>
</string-name>, <string-name>
<surname>Bliden</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Antonino</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>K&#x2010;S</given-names>
</string-name>, <string-name>
<surname>Tantry</surname>
<given-names>US</given-names>
</string-name>, <string-name>
<surname>Gurbel</surname>
<given-names>PA</given-names>
</string-name>. <article-title>Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies</article-title>. <source xml:lang="en">Am Heart J</source>. <year>2012</year>;<volume>164</volume>(<issue>1</issue>):<fpage>35</fpage>&#x2010;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.ahj.2012.03.022</pub-id>
<pub-id pub-id-type="pmid">22795280</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0064">
        <label>64</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0064">
<string-name>
<surname>Agarwal</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Coakely</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Reddy</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Riddell</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mallett</surname>
<given-names>S</given-names>
</string-name>. <article-title>Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA&#x2010;100<sup>&#xAE;</sup>) and modified thromboelastography (mTEG<sup>&#xAE;</sup>) with light transmission platelet aggregometry</article-title>. <source xml:lang="en">Anesthesiology</source>. <year>2006</year>;<volume>105</volume>(<issue>4</issue>):<fpage>676</fpage>&#x2010;<lpage>683</lpage>. <pub-id pub-id-type="doi">10.1097/00000542-200610000-00011</pub-id>
<pub-id pub-id-type="pmid">17006064</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0065">
        <label>65</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0065">
<string-name>
<surname>Benzon</surname>
<given-names>HT</given-names>
</string-name>, <string-name>
<surname>McCarthy</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Benzon</surname>
<given-names>HA</given-names>
</string-name>, et al. <article-title>Determination of residual antiplatelet activity of clopidogrel before neuraxial injections</article-title>. <source xml:lang="en">Br J Anaesth</source>. <year>2011</year>;<volume>107</volume>(<issue>6</issue>):<fpage>966</fpage>&#x2010;<lpage>971</lpage>. <pub-id pub-id-type="doi">10.1093/bja/aer298</pub-id>
<pub-id pub-id-type="pmid">21968250</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0066">
        <label>66</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0066">
<string-name>
<surname>Harrison</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lordkipanidz&#xE9;</surname>
<given-names>M</given-names>
</string-name>. <article-title>Testing platelet function</article-title>. <source xml:lang="en">Hematol Oncol Clin North Am</source>. <year>2013</year>;<volume>27</volume>(<issue>3</issue>):<fpage>411</fpage>&#x2010;<lpage>441</lpage>. <pub-id pub-id-type="doi">10.1016/j.hoc.2013.03.003</pub-id>
<pub-id pub-id-type="pmid">23714306</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0067">
        <label>67</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0067">
<string-name>
<surname>Gorog</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Fuster</surname>
<given-names>V</given-names>
</string-name>. <article-title>Platelet function tests in clinical cardiology</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2013</year>;<volume>61</volume>(<issue>21</issue>):<fpage>2115</fpage>&#x2010;<lpage>2129</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2012.11.080</pub-id>
<pub-id pub-id-type="pmid">23541972</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0068">
        <label>68</label>
        <mixed-citation publication-type="miscellaneous" id="prp2686-cit-0068">
<article-title>Platelet function testing: PFA&#x2010;100</article-title>. <ext-link ext-link-type="uri" xlink:href="https://practical-haemostasis.com/Platelets/pfa.html">https://practical&#x2010;haemostasis.com/Platelets/pfa.html</ext-link>. Accessed August 16, 2020</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0069">
        <label>69</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0069">
<string-name>
<surname>Kong</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Trimmings</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hutchinson</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Consensus recommendations for using the Multiplate<sup>&#xAE;</sup> for platelet function monitoring before cardiac surgery</article-title>. <source xml:lang="en">Int J Lab Hematol</source>. <year>2015</year>;<volume>37</volume>(<issue>2</issue>):<fpage>143</fpage>&#x2010;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1111/ijlh.12279</pub-id>
<pub-id pub-id-type="pmid">25055983</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0070">
        <label>70</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0070">
<string-name>
<surname>Paniccia</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Antonucci</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Maggini</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Assessment of platelet function on whole blood by multiple electrode aggregometry in high&#x2010;risk patients with coronary artery disease receiving antiplatelet therapy</article-title>. <source xml:lang="en">Am J Clin Pathol</source>. <year>2009</year>;<volume>131</volume>(<issue>6</issue>):<fpage>834</fpage>&#x2010;<lpage>842</lpage>. <pub-id pub-id-type="doi">10.1309/AJCPTE3K1SGAPOIZ</pub-id>
<pub-id pub-id-type="pmid">19461090</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0071">
        <label>71</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0071">
<string-name>
<surname>van Werkum</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Hackeng</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>de Korte</surname>
<given-names>FI</given-names>
</string-name>, <string-name>
<surname>Verheugt</surname>
<given-names>FWA</given-names>
</string-name>, <string-name>
<surname>ten Berg</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Point&#x2010;of&#x2010;care platelet function testing in patients undergoing PCI: between a rock and a hard place</article-title>. <source xml:lang="en">Neth Heart J</source>. <year>2007</year>;<volume>15</volume>(<issue>9</issue>):<fpage>299</fpage>&#x2010;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1007/BF03086004</pub-id>
<pub-id pub-id-type="pmid">18030318</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0072">
        <label>72</label>
        <mixed-citation publication-type="miscellaneous" id="prp2686-cit-0072">
<collab collab-type="authors">Plateletworks POC platelet function test: SPEP test: Helena.com</collab>
. <ext-link ext-link-type="uri" xlink:href="https://www.helena.com/plateletworks.html">https://www.helena.com/plateletworks.html</ext-link>. Accessed August 16, 2020</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0073">
        <label>73</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0073">
<string-name>
<surname>Campbell</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ridgway</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Carville</surname>
<given-names>D</given-names>
</string-name>. <article-title>Plateletworks<sup>&#xAE;</sup>
</article-title>. <source xml:lang="en">Mol Diagn Ther</source>. <year>2008</year>;<volume>12</volume>(<issue>4</issue>):<fpage>253</fpage>&#x2010;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1007/BF03256290</pub-id>
<pub-id pub-id-type="pmid">18652521</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0074">
        <label>74</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0074">
<string-name>
<surname>Breet</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>van Werkum</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Bouman</surname>
<given-names>HJ</given-names>
</string-name>, et al. <article-title>Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation</article-title>. <source xml:lang="en">JAMA</source>. <year>2010</year>;<volume>303</volume>(<issue>8</issue>):<fpage>754</fpage>&#x2010;<lpage>762</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2010.181</pub-id>
<pub-id pub-id-type="pmid">20179285</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0075">
        <label>75</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0075">
<string-name>
<surname>Dal&#xE9;n</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>van der Linden</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lindvall</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ivert</surname>
<given-names>T</given-names>
</string-name>. <article-title>Correlation between point&#x2010;of&#x2010;care platelet function testing and bleeding after coronary artery surgery</article-title>. <source xml:lang="en">Scand Cardiovasc J</source>. <year>2012</year>;<volume>46</volume>(<issue>1</issue>):<fpage>32</fpage>&#x2010;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.3109/14017431.2011.629677</pub-id>
<pub-id pub-id-type="pmid">21973169</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0076">
        <label>76</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0076">
<string-name>
<surname>Koltai</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kesmarky</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Feher</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Tibold</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Toth</surname>
<given-names>K</given-names>
</string-name>. <article-title>Platelet aggregometry testing: molecular mechanisms, techniques and clinical implications</article-title>. <source xml:lang="en">Int J Mol Sci</source>. <year>2017</year>;<volume>18</volume>(<issue>8</issue>):<fpage>1803</fpage>
<pub-id pub-id-type="doi">10.3390/ijms18081803</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0077">
        <label>77</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0077">
<string-name>
<surname>Malviya</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bansal</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Pal</surname>
<given-names>OP</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>PK</given-names>
</string-name>. <article-title>High performance liquid chromatography: a short review</article-title>. <source xml:lang="en">J Glob Pharma Technol</source>. <year>2010</year>;<volume>2</volume>(<issue>5</issue>):<fpage>22</fpage>&#x2010;<lpage>26</lpage>.</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0078">
        <label>78</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0078">
<string-name>
<surname>Kara&#x17A;niewicz&#x2010;&#x141;ada</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Danielak</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Burchardt</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases</article-title>. <source xml:lang="en">Clin Pharmacokinet</source>. <year>2014</year>;<volume>53</volume>(<issue>2</issue>):<fpage>155</fpage>&#x2010;<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1007/s40262-013-0105-2</pub-id>
<pub-id pub-id-type="pmid">24127209</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0079">
        <label>79</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0079">
<string-name>
<surname>ElTantawy</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Bebawy</surname>
<given-names>LI</given-names>
</string-name>, <string-name>
<surname>Shokry</surname>
<given-names>RF</given-names>
</string-name>. <article-title>Chromatographic determination of clopidogrel bisulfate; detection and quantification of counterfeit Plavix&#xAE; tablets</article-title>. <source xml:lang="en">Bull Fac Pharm Cairo Univ</source>. <year>2014</year>;<volume>52</volume>(<issue>1</issue>):<fpage>91</fpage>&#x2010;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.bfopcu.2014.04.003</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0080">
        <label>80</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0080">
<string-name>
<surname>Anuta</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Sarbu</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Mircioiu</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Velescu</surname>
<given-names>BS</given-names>
</string-name>. <article-title>Development of a new HPLC method for simultaneous determination of clopidogrel and its major metabolite using a chemometric approach</article-title>. <source xml:lang="en">Curr Health Sci J</source>. <year>2015</year>;<volume>41</volume>(<issue>1</issue>):<fpage>11</fpage>.<pub-id pub-id-type="pmid">30151245</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0081">
        <label>81</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0081">
<string-name>
<surname>Tuffal</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Roy</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lavisse</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma</article-title>. <source xml:lang="en">Thromb Haemost</source>. <year>2011</year>;<volume>105</volume>(<issue>4</issue>):<fpage>696</fpage>&#x2010;<lpage>705</lpage>.<pub-id pub-id-type="pmid">21301779</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0082">
        <label>82</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0082">
<string-name>
<surname>Vocilkova</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Opatrilova</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sramek</surname>
<given-names>V</given-names>
</string-name>. <article-title>Determination of clopidogrel by chromatography</article-title>. <source xml:lang="en">Curr Pharm Anal</source>. <year>2009</year>;<volume>5</volume>(<issue>4</issue>):<fpage>424</fpage>&#x2010;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.2174/157341209789649131</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0083">
        <label>83</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0083">
<string-name>
<surname>Croitoru</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Spiridon</surname>
<given-names>A&#x2010;M</given-names>
</string-name>, <string-name>
<surname>Belu</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Turcu&#x2010;&#x15E;tiolic&#x103;</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Neam&#x163;u</surname>
<given-names>J</given-names>
</string-name>. <article-title>Development and validation of an hplc method for simultaneous quantification of clopidogrel bisulfate, its carboxylic acid metabolite, and atorvastatin in human plasma: application to a pharmacokinetic study</article-title>. <source xml:lang="en">J Anal Methods Chem</source>. <year>2015</year>;<volume>2015</volume>:<fpage>1</fpage>&#x2010;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1155/2015/892470</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0084">
        <label>84</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0084">
<string-name>
<surname>Kazui</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nishiya</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ishizuka</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite</article-title>. <source xml:lang="en">Drug Metab Dispos</source>. <year>2010</year>;<volume>38</volume>(<issue>1</issue>):<fpage>92</fpage>&#x2010;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.109.029132</pub-id>
<pub-id pub-id-type="pmid">19812348</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0085">
        <label>85</label>
        <mixed-citation publication-type="book" id="prp2686-cit-0085">
<string-name>
<surname>Pereira</surname>
<given-names>NL</given-names>
</string-name>, <string-name>
<surname>Geske</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Mayr</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Rihal</surname>
<given-names>CS</given-names>
</string-name>. <source xml:lang="en">Pharmacogenetics of Clopidogrel</source>. <publisher-loc>Dallas, TX</publisher-loc>: <publisher-name>American Heart Association, Inc.</publisher-name>; <year>2016</year>.</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0086">
        <label>86</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0086">
<string-name>
<surname>Amin</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Sheau Chin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Azri Mohamed Noor</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Abdul Kader</surname>
<given-names>MASK</given-names>
</string-name>, <string-name>
<surname>Kah Hay</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ibrahim</surname>
<given-names>B</given-names>
</string-name>. <article-title>The personalization of clopidogrel antiplatelet therapy: the role of integrative pharmacogenetics and pharmacometabolomics</article-title>. <source xml:lang="en">Cardiol Res Pract</source>. <year>2017</year>;<volume>2017</volume>:<fpage>1</fpage>&#x2010;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1155/2017/8062796</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0087">
        <label>87</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0087">
<string-name>
<surname>Shahin</surname>
<given-names>MHA</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?</article-title>
<source xml:lang="en">Curr Opin Cardiol</source>. <year>2013</year>;<volume>28</volume>(<issue>3</issue>):<fpage>305</fpage>&#x2010;<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1097/HCO.0b013e32835f0bbc</pub-id>
<pub-id pub-id-type="pmid">23478884</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0088">
        <label>88</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0088">
<string-name>
<surname>Park</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>KW</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Genetic determinants of clopidogrel responsiveness in Koreans treated with drug&#x2010;eluting stents</article-title>. <source xml:lang="en">Int J Cardiol</source>. <year>2013</year>;<volume>163</volume>(<issue>1</issue>):<fpage>79</fpage>&#x2010;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2012.09.075</pub-id>
<pub-id pub-id-type="pmid">23260377</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0089">
        <label>89</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0089">
<string-name>
<surname>Sim</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Risinger</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dahl</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants</article-title>. <source xml:lang="en">Clin Pharmacol Ther</source>. <year>2006</year>;<volume>79</volume>(<issue>1</issue>):<fpage>103</fpage>&#x2010;<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1016/j.clpt.2005.10.002</pub-id>
<pub-id pub-id-type="pmid">16413245</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0090">
        <label>90</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0090">
<string-name>
<surname>Su</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta&#x2010;analysis</article-title>. <source xml:lang="en">PLoS One</source>. <year>2012</year>;<volume>7</volume>:<elocation-id>e46366</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0046366</pub-id>
<pub-id pub-id-type="pmid">23056288</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0091">
        <label>91</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0091">
<string-name>
<surname>Lewis</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Horenstein</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response</article-title>. <source xml:lang="en">Pharmacogenet Genomics</source>. <year>2013</year>;<volume>23</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2010;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/FPC.0b013e32835aa8a2</pub-id>
<pub-id pub-id-type="pmid">23111421</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0092">
        <label>92</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0092">
<string-name>
<surname>Bouman</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Sch&#xF6;mig</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>van Werkum</surname>
<given-names>JW</given-names>
</string-name>, et al. <article-title>Paraoxonase&#x2010;1 is a major determinant of clopidogrel efficacy</article-title>. <source xml:lang="en">Nat Med</source>. <year>2011</year>;<volume>17</volume>(<issue>1</issue>):<fpage>110</fpage>&#x2010;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2281</pub-id>
<pub-id pub-id-type="pmid">21170047</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0093">
        <label>93</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0093">
<string-name>
<surname>Staritz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kurz</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Stoll</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Giannitsis</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Katus</surname>
<given-names>HA</given-names>
</string-name>, <string-name>
<surname>Ivandic</surname>
<given-names>BT</given-names>
</string-name>. <article-title>Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12&#x2010;ADP receptor gene</article-title>. <source xml:lang="en">Int J Cardiol</source>. <year>2009</year>;<volume>133</volume>(<issue>3</issue>):<fpage>341</fpage>&#x2010;<lpage>345</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijcard.2007.12.118</pub-id>
<pub-id pub-id-type="pmid">18485500</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0094">
        <label>94</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0094">
<string-name>
<surname>Ma</surname>
<given-names>TKW</given-names>
</string-name>, <string-name>
<surname>Lam</surname>
<given-names>Y&#x2010;Y</given-names>
</string-name>, <string-name>
<surname>Tan</surname>
<given-names>VP</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>BP</given-names>
</string-name>. <article-title>Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?: Clopidogrel response variability</article-title>. <source xml:lang="en">Br J Clin Pharmacol</source>. <year>2011</year>;<volume>72</volume>(<issue>4</issue>):<fpage>697</fpage>&#x2010;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2125.2011.03949.x</pub-id>
<pub-id pub-id-type="pmid">21352268</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0095">
        <label>95</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0095">
<string-name>
<surname>Gladding</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Voss</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer</article-title>. <source xml:lang="en">JACC Cardiovasc Interv</source>. <year>2009</year>;<volume>2</volume>(<issue>11</issue>):<fpage>1095</fpage>&#x2010;<lpage>1101</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2009.08.018</pub-id>
<pub-id pub-id-type="pmid">19926050</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0096">
        <label>96</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0096">
<string-name>
<surname>Saracini</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Vestrini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Galora</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Armillis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Abbate</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Giusti</surname>
<given-names>B</given-names>
</string-name>. <article-title>Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing</article-title>. <source xml:lang="en">Genet Test Mol Biomark</source>. <year>2012</year>;<volume>16</volume>(<issue>6</issue>):<fpage>500</fpage>&#x2010;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1089/gtmb.2011.0259</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0097">
        <label>97</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0097">
<string-name>
<surname>Lenk</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Spannagl</surname>
<given-names>M</given-names>
</string-name>. <source xml:lang="en">Platelet Function Testing&#x2010;Guided Antiplatelet Therapy</source> (Vol <volume>24</volume>, <edition>3</edition>edn); <year>2014</year>: <fpage>90</fpage> . <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975182/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975182/</ext-link>.</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0098">
        <label>98</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0098">
<string-name>
<surname>Lordkipanidz&#xE9;</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pharand</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Palisaitis</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Schampaert</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Diodati</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel</article-title>. <source xml:lang="en">Thromb Res</source>. <year>2009</year>;<volume>124</volume>(<issue>5</issue>):<fpage>546</fpage>&#x2010;<lpage>553</lpage>. <pub-id pub-id-type="doi">10.1016/j.thromres.2009.04.003</pub-id>
<pub-id pub-id-type="pmid">19419755</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0099">
        <label>99</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0099">
<string-name>
<surname>Lordkipanidze</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pharand</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Schampaert</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Palisaitis</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Diodati</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2008</year>;<volume>29</volume>(<issue>23</issue>):<fpage>2877</fpage>&#x2010;<lpage>2885</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehn419</pub-id>
<pub-id pub-id-type="pmid">18826988</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0100">
        <label>100</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0100">
<string-name>
<surname>Dorman</surname>
<given-names>BH</given-names>
</string-name>, <string-name>
<surname>Spinale</surname>
<given-names>FG</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>aatz</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Roy</surname>
<given-names>RC</given-names>
</string-name>. <article-title>Identification of patients at risk for excessive blood loss during coronary artery bypass surgery: thromboelastograph versus coagulation screen</article-title>. <source xml:lang="en">Anesth Analg</source>. <year>1993</year>;<volume>76</volume>(<issue>4</issue>):<fpage>694</fpage>&#x2010;<lpage>700</lpage>.<pub-id pub-id-type="pmid">8466003</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0101">
        <label>101</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0101">
<string-name>
<surname>Dietrich</surname>
<given-names>GV</given-names>
</string-name>, <string-name>
<surname>Schueck</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Menges</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kiesenbauer</surname>
<given-names>NP</given-names>
</string-name>, <string-name>
<surname>Fruehauf</surname>
<given-names>A&#x2010;C</given-names>
</string-name>, <string-name>
<surname>Marquardt</surname>
<given-names>I</given-names>
</string-name>. <article-title>Comparison of four methods for the determination of platelet function in whole blood in cardiac surgery</article-title>. <source xml:lang="en">Thromb Res</source>. <year>1998</year>;<volume>89</volume>(<issue>6</issue>):<fpage>295</fpage>&#x2010;<lpage>301</lpage>.<pub-id pub-id-type="pmid">9669752</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0102">
        <label>102</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0102">
<string-name>
<surname>Ti</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Cheong</surname>
<given-names>K&#x2010;F</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>F&#x2010;G</given-names>
</string-name>. <article-title>Prediction of excessive bleeding after coronary artery bypass graft surgery: the influence of timing and heparinase on thromboelastography</article-title>. <source xml:lang="en">J Cardiothorac Vasc Anesth</source>. <year>2002</year>;<volume>16</volume>(<issue>5</issue>):<fpage>545</fpage>&#x2010;<lpage>550</lpage>.<pub-id pub-id-type="pmid">12407603</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0103">
        <label>103</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0103">
<string-name>
<surname>Preisman</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kogan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Itzkovsky</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Leikin</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Raanani</surname>
<given-names>E</given-names>
</string-name>. <article-title>Modified thromboelastography evaluation of platelet dysfunction in patients undergoing coronary artery surgery</article-title>. <source xml:lang="en">Eur J Cardiothorac Surg</source>. <year>2010</year>;<volume>37</volume>(<issue>6</issue>):<fpage>1367</fpage>&#x2010;<lpage>1374</lpage>.<pub-id pub-id-type="pmid">20181490</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0104">
        <label>104</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0104">
<string-name>
<surname>Kwak</surname>
<given-names>Y&#x2010;L</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>J&#x2010;C</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>Y&#x2010;S</given-names>
</string-name>, <string-name>
<surname>Yoo</surname>
<given-names>K&#x2010;J</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shim</surname>
<given-names>J&#x2010;K</given-names>
</string-name>. <article-title>Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off&#x2010;pump coronary artery bypass graft surgery</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2010</year>;<volume>56</volume>(<issue>24</issue>):<fpage>1994</fpage>&#x2010;<lpage>2002</lpage>.<pub-id pub-id-type="pmid">21126640</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0105">
        <label>105</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0105">
<string-name>
<surname>Corredor</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wasowicz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Karkouti</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>V</given-names>
</string-name>. <article-title>The role of point&#x2010;of&#x2010;care platelet function testing in predicting postoperative bleeding following cardiac surgery: a systematic review and meta&#x2010;analysis</article-title>. <source xml:lang="en">Anaesthesia</source>. <year>2015</year>;<volume>70</volume>(<issue>6</issue>):<fpage>715</fpage>&#x2010;<lpage>731</lpage>.<pub-id pub-id-type="pmid">25916344</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0106">
        <label>106</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0106">
<string-name>
<surname>Ito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ohno</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Morikawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tomizawa</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mizuno</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sugidachi</surname>
<given-names>A</given-names>
</string-name>. <article-title>Vasodilator&#x2010;stimulated phosphoprotein (VASP) is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and antiplatelet effect of prasugrel in rats</article-title>. <source xml:lang="en">Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2010;<lpage>11</lpage>.<pub-id pub-id-type="pmid">29311619</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0107">
        <label>107</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0107">
<string-name>
<surname>Fedor</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Simonova</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Fedorova</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Role of VASP phosphorylation assay in monitoring the antiplatelet therapy</article-title>. <source xml:lang="en">Acta Med Martin</source>. <year>2013</year>;<volume>13</volume>(<issue>1</issue>):<fpage>21</fpage>&#x2010;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.2478/acm-2013-0008</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0108">
        <label>108</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0108">
<string-name>
<surname>Ibrahim</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Oteh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Syukur</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hh</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>W</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Rahman</surname>
<given-names>MM</given-names>
</string-name>. <article-title>Evaluation of aspirin and clopidogrel resistance in patients with acute coronary syndrome by using adenosine diposphate test and aspirin test</article-title>. <source xml:lang="en">Pak J Med Sci</source>. <year>2012</year>;<volume>29</volume>(<issue>1</issue>). <pub-id pub-id-type="doi">10.12669/pjms.291.2820</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0109">
        <label>109</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0109">
<string-name>
<surname>Rade</surname>
<given-names>JJ</given-names>
</string-name>. <article-title>Platelet function testing in patients with coronary artery disease: is the who and the when any clearer than the what and the what then?</article-title>
<source xml:lang="en">Circulation</source>. <year>2012</year>;<volume>125</volume>(<issue>25</issue>):<fpage>3073</fpage>&#x2010;<lpage>3075</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.112094</pub-id>
<pub-id pub-id-type="pmid">22619281</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0110">
        <label>110</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0110">
<string-name>
<surname>Mueller</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dieplinger</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Poelz</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Haltmayer</surname>
<given-names>M</given-names>
</string-name>. <article-title>Utility of the PFA&#x2010;100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease</article-title>. <source xml:lang="en">Clin Appl Thromb</source>. <year>2009</year>;<volume>15</volume>(<issue>6</issue>):<fpage>652</fpage>&#x2010;<lpage>659</lpage>. <pub-id pub-id-type="doi">10.1177/1076029608322547</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0111">
        <label>111</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0111">
<string-name>
<surname>Janse van Rensburg</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>van der Merwe</surname>
<given-names>P</given-names>
</string-name>. <article-title>Comparison of commercially available blood collection tubes containing sodium citrate and hirudin in platelet aggregation testing</article-title>. <source xml:lang="en">Med Sci Monit Basic Res</source>. <year>2017</year>;<volume>23</volume>:<fpage>264</fpage>&#x2010;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.12659/MSMBR.905246</pub-id>
<pub-id pub-id-type="pmid">28747619</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0112">
        <label>112</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0112">
<string-name>
<surname>Linnemann</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Schwonberg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rechner</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Mani</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lindhoff&#x2010;Last</surname>
<given-names>E</given-names>
</string-name>. <article-title>Assessment of clopidogrel non&#x2010;response by the PFA&#x2010;100<sup>&#xAE;</sup> system using the new test cartridge INNOVANCE<sup>&#xAE;</sup> PFA P2Y</article-title>. <source xml:lang="en">Ann Hematol</source>. <year>2010</year>;<volume>89</volume>(<issue>6</issue>):<fpage>597</fpage>&#x2010;<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1007/s00277-009-0881-9</pub-id>
<pub-id pub-id-type="pmid">20049442</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0113">
        <label>113</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0113">
<string-name>
<surname>Kweon</surname>
<given-names>OJ</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>YK</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>M&#x2010;K</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>HR</given-names>
</string-name>. <article-title>Effectiveness of platelet function analyzer&#x2010;100 for laboratory detection of anti&#x2010;platelet drug&#x2010;induced platelet dysfunction</article-title>. <source xml:lang="en">Ann Lab Med</source>. <year>2019</year>;<volume>39</volume>(<issue>1</issue>):<fpage>23</fpage>
<pub-id pub-id-type="doi">10.3343/alm.2019.39.1.23</pub-id>
<pub-id pub-id-type="pmid">30215226</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0114">
        <label>114</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0114">
<string-name>
<surname>Pl&#xE1;&#x161;ek</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Homza</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gumulec</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ryz&#xED;</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stan&#x10D;&#xED;k</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>&#x160;ipula</surname>
<given-names>D</given-names>
</string-name>. <article-title>Resistance to antiplatelet treatment: the clinical relevance of platelet function assays</article-title>. <source xml:lang="en">Cor Vasa</source>. <year>2012</year>;<volume>54</volume>(<issue>9&#x2013;10</issue>):<fpage>e305</fpage>&#x2010;<lpage>e313</lpage>. <pub-id pub-id-type="doi">10.1016/j.crvasa.2012.08.003</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0115">
        <label>115</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0115">
<string-name>
<surname>Sibbing</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Braun</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jawansky</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Assessment of ADP&#x2010;induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment</article-title>. <source xml:lang="en">Thromb Haemost</source>. <year>2008</year>;<volume>99</volume>(<issue>01</issue>):<fpage>121</fpage>&#x2010;<lpage>126</lpage>. <pub-id pub-id-type="doi">10.1160/TH07-07-0478</pub-id>
<pub-id pub-id-type="pmid">18217143</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0116">
        <label>116</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0116">
<string-name>
<surname>Jiang</surname>
<given-names>X&#x2010;L</given-names>
</string-name>, <string-name>
<surname>Samant</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Lesko</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>
<given-names>S</given-names>
</string-name>. <article-title>Clinical pharmacokinetics and pharmacodynamics of clopidogrel</article-title>. <source xml:lang="en">Clin Pharmacokinet</source>. <year>2015</year>;<volume>54</volume>(<issue>2</issue>):<fpage>147</fpage>&#x2010;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1007/s40262-014-0230-6</pub-id>
<pub-id pub-id-type="pmid">25559342</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0117">
        <label>117</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0117">
<string-name>
<surname>Bouman</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Parlak</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Van werkum</surname>
<given-names>JW</given-names>
</string-name>, et al. <article-title>Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel</article-title>. <source xml:lang="en">J Thromb Haemost</source>. <year>2010</year>;<volume>8</volume>(<issue>3</issue>):<fpage>482</fpage>&#x2010;<lpage>488</lpage>.<pub-id pub-id-type="pmid">20040042</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0118">
        <label>118</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0118">
<string-name>
<surname>Collet</surname>
<given-names>J&#x2010;P</given-names>
</string-name>. <article-title>Current concepts in the clinical utility of platelet reactivity testing</article-title>. <source xml:lang="en">Interv Cardiol Rev</source>. <year>2013</year>;<volume>8</volume>(<issue>2</issue>):<fpage>100</fpage>&#x2010;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.15420/icr.2013.8.2.100</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0119">
        <label>119</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0119">
<string-name>
<surname>Hussein</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Emiru</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Georgiadis</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Qureshi</surname>
<given-names>AI</given-names>
</string-name>. <article-title>Assessment of platelet inhibition by point&#x2010;of&#x2010;care testing in neuroendovascular procedures</article-title>. <source xml:lang="en">Am J Neuroradiol</source>. <year>2013</year>;<volume>34</volume>(<issue>4</issue>):<fpage>700</fpage>&#x2010;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.3174/ajnr.A2963</pub-id>
<pub-id pub-id-type="pmid">22422188</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0120">
        <label>120</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0120">
<string-name>
<surname>Lordkipanidz&#xE9;</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pharand</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Schampaert</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Turgeon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Palisaitis</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Diodati</surname>
<given-names>JG</given-names>
</string-name>. <article-title>A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2007</year>;<volume>28</volume>(<issue>14</issue>):<fpage>1702</fpage>&#x2010;<lpage>1708</lpage>.<pub-id pub-id-type="pmid">17569678</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0121">
        <label>121</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0121">
<string-name>
<surname>Michelson</surname>
<given-names>AD</given-names>
</string-name>. <article-title>Antiplatelet therapies for the treatment of cardiovascular disease</article-title>. <source xml:lang="en">Nat Rev Drug Discov</source>. <year>2010</year>;<volume>9</volume>(<issue>2</issue>):<fpage>154</fpage>&#x2010;<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2957</pub-id>
<pub-id pub-id-type="pmid">20118963</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0122">
        <label>122</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0122">
<string-name>
<surname>Al Shamiri</surname>
<given-names>MQ</given-names>
</string-name>, <string-name>
<surname>Abdel Gader</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Bayoumy</surname>
<given-names>NM</given-names>
</string-name>. <article-title>Comparing light transmission aggregometry and PFA100 for monitoring antiplatelet therapy in patients with coronary heart disease</article-title>. <source xml:lang="en">J Taibah Univ Med Sci</source>. <year>2016</year>;<volume>11</volume>(<issue>5</issue>):<fpage>478</fpage>&#x2010;<lpage>484</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtumed.2016.08.002</pub-id>
</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0123">
        <label>123</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0123">
<string-name>
<surname>Sambu</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Curzen</surname>
<given-names>N</given-names>
</string-name>. <article-title>Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations: monitoring the effectiveness of antiplatelet therapy</article-title>. <source xml:lang="en">Br J Clin Pharmacol</source>. <year>2011</year>;<volume>72</volume>(<issue>4</issue>):<fpage>683</fpage>&#x2010;<lpage>696</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2125.2011.03955.x</pub-id>
<pub-id pub-id-type="pmid">21366666</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0124">
        <label>124</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0124">
<string-name>
<surname>Paniccia</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Priora</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Alessandrello Liotta</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Abbate</surname>
<given-names>R</given-names>
</string-name>. . <article-title>Platelet function tests: a comparative review</article-title>. <source xml:lang="en">Vasc Health Risk Manag</source>. <year>2015</year>:<fpage>133</fpage>
<pub-id pub-id-type="doi">10.2147/VHRM.S44469</pub-id>
<pub-id pub-id-type="pmid">25733843</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0125">
        <label>125</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0125">
<string-name>
<surname>Geiger</surname>
<given-names>J&#xF6;rg</given-names>
</string-name>, <string-name>
<surname>Teichmann</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Grossmann</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Monitoring of clopidogrel action: comparison of methods</article-title>. <source xml:lang="en">Clin Chem</source>. <year>2005</year>;<volume>51</volume>(<issue>6</issue>):<fpage>957</fpage>&#x2010;<lpage>965</lpage>. <pub-id pub-id-type="doi">10.1373/clinchem.2004.047050</pub-id>
<pub-id pub-id-type="pmid">15817818</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0126">
        <label>126</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0126">
<string-name>
<surname>Karon</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Tolan</surname>
<given-names>NV</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>CD</given-names>
</string-name>, et al. <article-title>Precision and reliability of 5 platelet function tests in healthy volunteers and donors on daily antiplatelet agent therapy</article-title>. <source xml:lang="en">Clin Chem</source>. <year>2014</year>;<volume>60</volume>(<issue>12</issue>):<fpage>1524</fpage>&#x2010;<lpage>1531</lpage>. <pub-id pub-id-type="doi">10.1373/clinchem.2014.226332</pub-id>
<pub-id pub-id-type="pmid">25281703</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0127">
        <label>127</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0127">
<string-name>
<surname>Bonello</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tantry</surname>
<given-names>US</given-names>
</string-name>, <string-name>
<surname>Marcucci</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Consensus and future directions on the definition of high on&#x2010;treatment platelet reactivity to adenosine diphosphate</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2010</year>;<volume>56</volume>(<issue>12</issue>):<fpage>919</fpage>&#x2010;<lpage>933</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2010.04.047</pub-id>
<pub-id pub-id-type="pmid">20828644</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0128">
        <label>128</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0128">
<string-name>
<surname>Brar</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>ten Berg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Marcucci</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta&#x2010;analysis of individual participant data</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2011</year>;<volume>58</volume>(<issue>19</issue>):<fpage>1945</fpage>&#x2010;<lpage>1954</lpage>.<pub-id pub-id-type="pmid">22032704</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0129">
        <label>129</label>
        <mixed-citation publication-type="book" id="prp2686-cit-0129">
<string-name>
<surname>Gonzalez</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>HB</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>EE</given-names>
</string-name>. <source xml:lang="en">Trauma Induced Coagulopathy</source>. <publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer</publisher-name>; <year>2016</year>.</mixed-citation>
      </ref>
      <ref id="prp2686-bib-0130">
        <label>130</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0130">
<string-name>
<surname>Gorog</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Sweeny</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Fuster</surname>
<given-names>V</given-names>
</string-name>. <article-title>Antiplatelet drug 'resistance&#x2019;. Part 2: laboratory resistance to antiplatelet drugs&#x2014;fact or artifact?</article-title>
<source xml:lang="en">Nat Rev Cardiol</source>. <year>2009</year>;<volume>6</volume>(<issue>5</issue>):<fpage>365</fpage>.<pub-id pub-id-type="pmid">19365406</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0131">
        <label>131</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0131">
<string-name>
<surname>Pencina</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>D&#x2019;Agostino</surname>
<given-names>RB</given-names>
<suffix>Sr</suffix>
</string-name>, <string-name>
<surname>D&#x2019;Agostino</surname>
<given-names>RB</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Vasan</surname>
<given-names>RS</given-names>
</string-name>. <article-title>Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond</article-title>. <source xml:lang="en">Stat Med</source>. <year>2008</year>;<volume>27</volume>(<issue>2</issue>):<fpage>157</fpage>&#x2010;<lpage>172</lpage>.<pub-id pub-id-type="pmid">17569110</pub-id></mixed-citation>
      </ref>
      <ref id="prp2686-bib-0132">
        <label>132</label>
        <mixed-citation publication-type="journal" id="prp2686-cit-0132">
<string-name>
<surname>Guyer</surname>
<given-names>KE</given-names>
</string-name>. <article-title>The present state of aspirin and clopidogrel resistance</article-title>. <source xml:lang="en">H&#xE4;mostaseologie</source>. <year>2009</year>;<volume>29</volume>(<issue>3</issue>):<fpage>285</fpage>&#x2010;<lpage>290</lpage>.<pub-id pub-id-type="pmid">19644597</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">EBioMedicine</journal-id>
      <journal-id journal-id-type="iso-abbrev">EBioMedicine</journal-id>
      <journal-title-group>
        <journal-title>EBioMedicine</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2352-3964</issn>
      <publisher>
        <publisher-name>Elsevier</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32927275</article-id>
      <article-id pub-id-type="pmc">7494683</article-id>
      <article-id pub-id-type="publisher-id">S2352-3964(20)30361-3</article-id>
      <article-id pub-id-type="doi">10.1016/j.ebiom.2020.102985</article-id>
      <article-id pub-id-type="publisher-id">102985</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Paper</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="au0001">
          <name>
            <surname>Niyonzima</surname>
            <given-names>Nathalie</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">a</xref>
          <xref rid="fn1" ref-type="fn">1</xref>
        </contrib>
        <contrib contrib-type="author" id="au0002">
          <name>
            <surname>Bakke</surname>
            <given-names>Siril S.</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">a</xref>
          <xref rid="fn1" ref-type="fn">1</xref>
        </contrib>
        <contrib contrib-type="author" id="au0003">
          <name>
            <surname>Gregersen</surname>
            <given-names>Ida</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">b</xref>
          <xref rid="aff0003" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author" id="au0004">
          <name>
            <surname>Holm</surname>
            <given-names>Sverre</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author" id="au0005">
          <name>
            <surname>Sandanger</surname>
            <given-names>&#xD8;ystein</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">b</xref>
          <xref rid="aff0003" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author" id="au0006">
          <name>
            <surname>Orrem</surname>
            <given-names>Hilde L.</given-names>
          </name>
          <xref rid="aff0004" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author" id="au0007">
          <name>
            <surname>Sporsheim</surname>
            <given-names>Bj&#xF8;rnar</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author" id="au0008">
          <name>
            <surname>Ryan</surname>
            <given-names>Liv</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author" id="au0009">
          <name>
            <surname>Kong</surname>
            <given-names>Xiang Yi</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author" id="au0010">
          <name>
            <surname>Dahl</surname>
            <given-names>Tuva B&#xF8;rresdatter</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author" id="au0011">
          <name>
            <surname>Skjelland</surname>
            <given-names>Mona</given-names>
          </name>
          <xref rid="aff0003" ref-type="aff">c</xref>
          <xref rid="aff0005" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author" id="au0012">
          <name>
            <surname>S&#xF8;rensen</surname>
            <given-names>Kirsten Krohg</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">b</xref>
          <xref rid="aff0003" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author" id="au0013">
          <name>
            <surname>Rokstad</surname>
            <given-names>Anne Mari</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author" id="au0014">
          <name>
            <surname>Yndestad</surname>
            <given-names>Arne</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">b</xref>
          <xref rid="aff0003" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author" id="au0015">
          <name>
            <surname>Latz</surname>
            <given-names>Eicke</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">a</xref>
          <xref rid="aff0006" ref-type="aff">f</xref>
        </contrib>
        <contrib contrib-type="author" id="au0016">
          <name>
            <surname>Gullestad</surname>
            <given-names>Lars</given-names>
          </name>
          <xref rid="aff0007" ref-type="aff">g</xref>
          <xref rid="aff0011" ref-type="aff">k</xref>
        </contrib>
        <contrib contrib-type="author" id="au0017">
          <name>
            <surname>Andersen</surname>
            <given-names>Geir &#xD8;.</given-names>
          </name>
          <xref rid="aff0007" ref-type="aff">g</xref>
        </contrib>
        <contrib contrib-type="author" id="au0018">
          <name>
            <surname>Dam&#xE5;s</surname>
            <given-names>Jan Kristian</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author" id="au0019">
          <name>
            <surname>Aukrust</surname>
            <given-names>P&#xE5;l</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">b</xref>
          <xref rid="aff0003" ref-type="aff">c</xref>
          <xref rid="aff0008" ref-type="aff">h</xref>
        </contrib>
        <contrib contrib-type="author" id="au0020">
          <name>
            <surname>Mollnes</surname>
            <given-names>Tom E.</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">a</xref>
          <xref rid="aff0009" ref-type="aff">i</xref>
          <xref rid="aff0010" ref-type="aff">j</xref>
          <xref rid="aff0013" ref-type="aff">m</xref>
        </contrib>
        <contrib contrib-type="author" id="au0021">
          <name>
            <surname>Halvorsen</surname>
            <given-names>Bente</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">b</xref>
          <xref rid="aff0003" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author" id="au0022">
          <name>
            <surname>Espevik</surname>
            <given-names>Terje</given-names>
          </name>
          <email>terje.espevik@ntnu.no</email>
          <xref rid="aff0001" ref-type="aff">a</xref>
          <xref rid="aff0012" ref-type="aff">l</xref>
          <xref rid="cor0001" ref-type="corresp">&#x204E;</xref>
        </contrib>
        <aff id="aff0001"><label>a</label>Centre of Molecular Inflammation Research, and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Olav Kyrres gate 17, Trondheim 7030, Norway</aff>
        <aff id="aff0002"><label>b</label>Research Institute of Internal Medicine, Oslo University Hospital, Norway</aff>
        <aff id="aff0003"><label>c</label>Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway</aff>
        <aff id="aff0004"><label>d</label>Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway</aff>
        <aff id="aff0005"><label>e</label>Department of Neurology, Oslo University Hospital, Norway</aff>
        <aff id="aff0006"><label>f</label>Institute of Innate Immunity, Biomedical Center, University of Bonn, Germany</aff>
        <aff id="aff0007"><label>g</label>Department of Cardiology, Oslo University Hospital, Norway</aff>
        <aff id="aff0008"><label>h</label>Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Norway</aff>
        <aff id="aff0009"><label>i</label>Department of Immunology, Oslo University Hospital, Norway</aff>
        <aff id="aff0010"><label>j</label>KG Jebsen TREC, Department of Clinical Medicine, University of Troms&#xF8;, Norway</aff>
        <aff id="aff0011"><label>k</label>KG Jebsen Center for Cardiac Research, and Center for Heart Failure Research, Oslo University Hospital, Norway</aff>
        <aff id="aff0012"><label>l</label>The Central Norway Regional Health Authority, St. Olavs Hospital HF, Norway</aff>
        <aff id="aff0013"><label>m</label>Research Laboratory, Norland Hospital, Norway</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor0001"><label>&#x204E;</label>Corresponding author at: Centre of Molecular Inflammation Research, and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Olav Kyrres gate 17, Trondheim 7030, Norway. <email>terje.espevik@ntnu.no</email></corresp>
        <fn id="fn1">
          <label>1</label>
          <p id="notep0001">These author contributed equally.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>11</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="collection">
        <month>10</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <volume>60</volume>
      <elocation-id>102985</elocation-id>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>2</month>
          <year>2020</year>
        </date>
        <date date-type="rev-recd">
          <day>19</day>
          <month>8</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>8</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2020 The Author(s)</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
        </license>
      </permissions>
      <abstract id="abs0001">
        <sec>
          <title>Background</title>
          <p>During atherogenesis, cholesterol precipitates into cholesterol crystals (CC) in the vessel wall, which trigger plaque inflammation by activating the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome. We investigated the relationship between CC, complement and NLRP3 in patients with cardiovascular disease.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>We analysed plasma, peripheral blood mononuclear cells (PBMC) and carotid plaques from patients with advanced atherosclerosis applying ELISAs, multiplex cytokine assay, qPCR, immunohistochemistry, and gene profiling.</p>
        </sec>
        <sec>
          <title>Findings</title>
          <p>Transcripts of interleukin (IL)-1beta(&#x3B2;) and NLRP3 were increased and correlated in PBMC from patients with acute coronary syndrome (ACS). Priming of these cells with complement factor 5a (C5a) and tumour necrosis factor (TNF) before incubation with CC resulted in increased IL-1&#x3B2; protein when compared to healthy controls. As opposed to healthy controls, systemic complement was significantly increased in patients with stable angina pectoris or ACS. In carotid plaques, complement C1q and C5b-9 complex accumulated around CC-clefts, and complement receptors <italic>C5aR1, C5aR2</italic> and <italic>C3aR1</italic> were higher in carotid plaques compared to control arteries. Priming human carotid plaques with C5a followed by CC incubation resulted in pronounced release of IL-1&#x3B2;, IL-18 and IL-1&#x3B1;. Additionally, mRNA profiling demonstrated that C5a and TNF priming followed by CC incubation upregulated plaque expression of NLRP3 inflammasome components.</p>
        </sec>
        <sec>
          <title>Interpretation</title>
          <p>We demonstrate that CC are important local- and systemic complement activators, and we reveal that the interaction between CC and complement could exert its effect by activating the NLRP3 inflammasome, thus promoting the progression of atherosclerosis.</p>
        </sec>
      </abstract>
      <kwd-group id="keys0001">
        <title>Keywords</title>
        <kwd>Cholesterol crystals</kwd>
        <kwd>Complement system</kwd>
        <kwd>NLRP3 inflammasome</kwd>
        <kwd>Coronary artery disease</kwd>
        <kwd>Carotid atherosclerosis</kwd>
        <kwd>Atherosclerosis</kwd>
        <kwd>Inflammation</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p id="para9001">
      <boxed-text id="tbox0002">
        <caption>
          <title>Research context</title>
        </caption>
        <sec id="sec0001a">
          <title>Evidence before the study</title>
          <p id="para0007">Atherosclerotic lesions are characterized by accumulation of lipids, cholesterol crystals (CC), and infiltration of immune cells. CC are present at all stages of atherogenesis and constitute primary endogenous danger signals that incite plaque inflammation. CC activate the NLRP3 inflammasome leading to IL-1&#x3B2; release and formation of atherosclerotic lesions. Based on these data a large clinical trial (CANTOS) inhibiting IL-1&#x3B2; by canakinumab was started, and this trial revealed a significant reduced risk of recurrent cardiovascular events. The CANTOS trial clearly demonstrates the important role of inflammation and IL-1&#x3B2; in atherosclerotic disorders. However, the interactions between inflammatory pathways leading to NLRP3 activation and IL-1&#x3B2; release in human clinical atherosclerosis are still not fully understood. We have earlier reported that complement activation is an important part of the inflammatory response induced by CC. However, data on interactions between CC, complement, and NLRP3 in patients with atherosclerotic disease are limited. Thus, we performed a detailed analysis of the relation between CC, complement and NLRP3 signaling pathways in patients with coronary artery disease - and carotid atherosclerosis.</p>
        </sec>
        <sec id="sec0002a">
          <title>Added value of this study</title>
          <p id="para0009">In <italic>in vitro, ex vivo</italic>, and using patient's samples, we show that complement contributes to the CC-driven inflammatory responses. Our data imply a positive association between CC-induced complement and NLRP3 activation, both systemically and within the atherosclerotic lesion, with disease severity and instability.</p>
        </sec>
        <sec id="sec0003a">
          <title>Implications of all the available evidence</title>
          <p id="para0011">The pathogenic loop between complement, CC and NLRP3 inflammasomes may represent a promising target for therapy of atherosclerotic disorders.</p>
        </sec>
        <notes notes-type="alt-text" specific-use="for-accessibility" id="alte1">
          <p>Alt-text: Unlabelled box</p>
        </notes>
      </boxed-text>
    </p>
    <sec id="sec0001">
      <label>1</label>
      <title>Introduction</title>
      <p id="para0012">Atherosclerosis is a progressive chronic disease with the bidirectional interaction between inflammation and lipids as its hallmark. Indeed, the atherosclerotic lesions are characterized by the accumulation of lipids together with infiltration of immune cells such as monocytes, macrophages, T cells and neutrophils <xref rid="bib0001" ref-type="bibr">[1]</xref>. When cholesterol accumulates in the vessel wall to the level that exceeds macrophage capacity for elimination, precipitation into cholesterol crystals (CC) will occur <xref rid="bib0002" ref-type="bibr">[2]</xref>. Oxidized low-density lipoprotein is endocytosed by CD36 that coordinates the intracellular conversion of this ligand to CC [<xref rid="bib0003" ref-type="bibr">3</xref>,<xref rid="bib0004" ref-type="bibr">4</xref>]. CC are present at all stages of atherogenesis, and constitute the primary endogenous danger signals that incite plaque inflammation, contributing to the development and progression of atherosclerosis and its complications like myocardial infarction and ischemic stroke [<xref rid="bib0005" ref-type="bibr">[5]</xref>, <xref rid="bib0006" ref-type="bibr">[6]</xref>, <xref rid="bib0007" ref-type="bibr">[7]</xref>]. Phagocytosis of CC causes lysosomal damage and this is sensed by the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome, leading to the release of interleukin (IL)-1&#x3B2; <xref rid="bib0005" ref-type="bibr">[5]</xref>. IL-1&#x3B2; is upregulated in atherosclerotic disorders and is associated with disease severity and outcome [<xref rid="bib0008" ref-type="bibr">8</xref>,<xref rid="bib0009" ref-type="bibr">9</xref>]. More recently, a large clinical trial on IL-1&#x3B2; inhibition by canakinumab, a monoclonal antibody against IL-1&#x3B2;, revealed a significant reduced risk of recurrent cardiovascular events demonstrating the important role of IL-1&#x3B2; in atherosclerotic disorders <xref rid="bib0010" ref-type="bibr">[10]</xref>. However, the mechanisms of enhanced release of IL-1&#x3B2; as well as the role of CC-induced NLRP3 inflammasome activation in clinical atherosclerosis are not fully understood.</p>
      <p id="para0013">Early studies have demonstrated the importance of both systemic and local complement in the progression of atherosclerosis, and depending on the stage of atherogenesis, complement can either promote or attenuate atherogenesis [<xref rid="bib0011" ref-type="bibr">[11]</xref>, <xref rid="bib0012" ref-type="bibr">[12]</xref>, <xref rid="bib0013" ref-type="bibr">[13]</xref>, <xref rid="bib0014" ref-type="bibr">[14]</xref>, <xref rid="bib0015" ref-type="bibr">[15]</xref>, <xref rid="bib0016" ref-type="bibr">[16]</xref>]. Complement is strongly activated by CC, with all three pathways involved, i.e., the classical (CP), the alternative (AP), and the lectin pathway (LP), leading to complement deposition on the surface and subsequent phagocytosis and stimulation of endothelial cells [<xref rid="bib0017" ref-type="bibr">[17]</xref>, <xref rid="bib0018" ref-type="bibr">[18]</xref>, <xref rid="bib0019" ref-type="bibr">[19]</xref>, <xref rid="bib0020" ref-type="bibr">[20]</xref>]. CC also employs complement to induce coagulation activation <xref rid="bib0021" ref-type="bibr">[21]</xref>. Complement activation leads to release of the anaphylatoxins C3a and C5a which trigger inflammatory signalling through their G-protein-coupled receptors, resulting in increased vascular permeability and chemotaxis <xref rid="bib0022" ref-type="bibr">[22]</xref>. CC generate C5a in whole blood which, in combination with tumour necrosis factor (TNF), works as signal 1 and is necessary for priming of monocytes for NLRP3 activation leading to IL-1&#x3B2; release (mature form 17KDa) <xref rid="bib0018" ref-type="bibr">[18]</xref>. The role of this interaction in clinical atherosclerosis is, however, not clear. Thus, the aim of the present study was to perform a detailed analysis of the relation between complement, NLRP3 signalling pathways and CC in patients with coronary artery disease and carotid atherosclerosis.</p>
    </sec>
    <sec id="sec0002">
      <label>2</label>
      <title>Materials and methods</title>
      <sec id="sec0003">
        <label>2.1</label>
        <title>Reagents</title>
        <p id="para0014">PBMC were isolated from whole-blood anticoagulated with lepirudin (Refludan&#xAE;, Celgene). Recombinant C5a, ultrapure cholesterol, 1-propanol were purchased from Sigma-Aldrich, and TNF from Genentech. The following reagents were used for qRT-PCR analyses: RNeasy Mini kit (Qiagen), DNase and High Capacity RNA-to-cDNA Kit (Applied Biosystems) and PerfeCTa&#xAE; qPCR FastMix&#x2122; (Quanta Biosciences). Assays were from Applied Biosystems: GAPDH (Hs99999905_m1), NLRP3 (Hs00918082_m1), TNF (Hs00174128_m1), and IL-1&#x3B2; (Hs01555410_m1) and primers from SYBR as shown in Supplementary Table I. Antibodies used for immunohistochemistry: polyclonal rabbit anti-human C1q (A0136, Dako), normal rabbit IgG (Ab105-C, R&amp;D systems), goat anti-mouse conjugated to Alexa 647 (Invitrogen), anti-C5b-9 (DIA-011, Antibodyshop), anti-CD68 (Dako Agilent M0814), anti-CD20 (Dako Agilent M0755), anti-CD3 (Dako Agilent A0452), anti-CD15 (BD Pharmingen 559045), control IgG2a (BD Pharmigen). Antibodies used for flow cytometry included anti-CD14 FITC (M5E2), anti-CD4 PerCP-CY 5.5 (RPA-T4), anti-CD8 BV605 (SK1) and anti-CD19 BV711 (SJ25C1) and were purchased from BD Pharmigen, and anti-CD3 APC (UCHT1) were from Invitrogen. Fluorescence-minus-one (FMO) was used as control.</p>
      </sec>
      <sec id="sec0004">
        <label>2.2</label>
        <title>Preparation of cholesterol crystals (CC)</title>
        <p id="para0015">CC were made as described in Samstad et al. <xref rid="bib0018" ref-type="bibr">[18]</xref> Briefly, Ultrapure cholesterol (100 mg) was dissolved in 1-propanol (50 ml). The solution was mixed with distilled water (1:1.5) and rested for at least ten minutes for monohydrate crystals to stabilize. 1-Propanol was removed by evaporation and CC were resuspended in PBS/0.05% HSA. All steps were performed at room temperature yielding CC with a size range of one&#x2013;two &#x3BC;m that were stored at 4&#xB0;C. CC were tested for endotoxin contamination using Limulus amebocyte lysate assay (LAL), and the LPS level was under the detection limit. Furthermore, treating whole blood with anti-CD14 Abs or lipid Iva did not reduce the CC-induced cytokines, whereas the LPS response was completely inhibited with the anti-CD14 Ab (data not shown).</p>
      </sec>
      <sec id="sec0005">
        <label>2.3</label>
        <title>Patient recruitment</title>
        <p id="para0016"><italic>Patients with coronary artery disease:</italic> Peripheral mononuclear cells (PBMC) and plasma were collected from a patient population with coronary artery disease (CAD). The study included only patients with CAD verified by coronary angiography (lesions with &#x2265;50% lumen reduction compared to reference segment). Patients were classified into either stable angina pectoris (SAP) referred to elective coronary angiography with at least one significant coronary stenosis or acute coronary syndrome (ACS). SAP was defined as episodes of reversible ischemic chest pain with significant CAD. ACS patients consisted of patients with unstable angina pectoris, defined as angina at rest or crescendo angina with a clinical indication of urgent (within 48 h) coronary angiography or non-ST elevation myocardial infarction. NSTEMI was defined according to the universal definition of MI as typical rise and fall of the cardiac specific biomarker troponin T (TnT) with at least one value above the 99th percentile of the upper reference limit in patients presenting with symptoms of ischemia without any ST elevation on ECG <xref rid="bib0023" ref-type="bibr">[23]</xref>. Mean age of the study population was about 65 years and around 82 % male. Exclusion criteria included clinically unstable patients with cardiac arrest, cardiogenic shock, hypotension or pulmonary congestion, active malignant disease, chronic inflammatory disease (e.g. inflammatory bowel disease, rheumatic arthritis, systemic lupus erythematosus), intercurrent infection or use of glucocorticosteroids. Controls in <xref rid="fig0001" ref-type="fig">Figs. 1</xref> and <xref rid="fig0003" ref-type="fig">3</xref> were apparently healthy based on disease history and biochemical markers within normal range, including CRP less than 4.5. Controls in <xref rid="fig0002" ref-type="fig">Fig. 2</xref> were healthy controls, age and gender matched. Clinical characteristics are presented in Supplementary Table II and III.<fig id="fig0001"><label>Fig. 1</label><caption><p><bold>Transcripts of IL-1&#x3B2;, NLRP3 and TNF in PBMC from controls and ACS and SAP patients.</bold> PBMC were isolated from blood from patients with SAP, ACS and healthy controls, RNA isolated and PCR run. Relative mRNA expression for IL-1&#x3B2; (a), NLRP3 (b) and TNF (c) is presented as mean &#xB1; SEM, <italic>n=</italic>21&#x2013;25. Furthermore, a correlation between IL-1&#x3B2; (y-axis) and NLRP3 (d) and TNF (e) (x-axes) mRNA expressions in PBMC from patients with ACS were found. ACS, acute coronary syndrome; IL, interleukin; NLRP3, NACHT, LRR and PYD domains-containing protein 3; SAP, Stable angina pectoris; TNF, tumour necrosis factor. *<italic>p&lt;</italic>0.05, **<italic>p&lt;</italic>0.01, ***<italic>p&lt;</italic>0.001. (a-c) Kruskal Wallis and Dunn's multiple comparison test, (d,e) Spearman's correlation.</p></caption><alt-text id="alt0001">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig><fig id="fig0002"><label>Fig. 2</label><caption><p><bold>Cytokine release from PBMC from patients with ACS and controls primed with combination of C5a and TNF and stimulated with CC.</bold> PBMC were isolated from blood from patients with ACS and healthy controls, primed with C5a+TNF or left unprimed prior to incubation with CC and supernatant collected. IL-1&#x3B2; and IL-1&#x3B1; released is presented for the two groups as mean &#xB1; SEM, <italic>n=</italic>9-10. Basal levels and control treatments are presented in Supplementary figure I. ACS, acute coronary syndrome; C, Complement factor; CC, cholesterol crystals; IL, interleukin; TNF, tumour necrosis factor. **<italic>p&lt;</italic>0.01 between controls and ACS with priming, Mann-Whitney two-tail test.</p></caption><alt-text id="alt0002">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p>
        <p id="para0017"><italic>Patients with carotid plaques:</italic> Patients with high-grade internal carotid stenosis (&#x2265;70%) or ischemic stroke within the last month were recruited at the Department of Neurology, Oslo University Hospital Rikshospitalet. Patients were classified into either symptomatic group including patients with ischemic stroke within the last month, or asymptomatic group without ischemic stroke the last month. The carotid stenosis was diagnosed and classified by precerebral colour duplex and CT angiography according to consensus criteria. As part of the ultrasound examination, the total extracranial part of the carotid artery was examined with B-mode and Doppler analyses. Ultrasound plaque appearance in terms of echogenicity was classified according to consensus criteria <xref rid="bib0024" ref-type="bibr">[24]</xref>. Mean age of the study population was about 67 years and around 65 % male. Exclusion criteria were heart failure, liver disease, kidney disease, and severe concomitant disease such as infection, connective tissue disease, or malignancy. Distal carotid arteries were disease free segments from the same patients. Normal renal arteries are taken post-mortem with no history of cardiovascular disease. Clinical characteristics are presented in Supplementary Table IV and V.</p>
      </sec>
      <sec id="sec0006">
        <label>2.4</label>
        <title>Cell isolation and culture</title>
        <p id="para0018">PBMC were separated from fresh heparinized blood by Isopaque-Ficoll gradient centrifugation using Lymphoprep (Nycomed, Oslo, Norway) or BD Vacutainer CPT (ref 362780 Becton, Dickinson and Company, Franklin Lakes). Data in <xref rid="fig0001" ref-type="fig">Fig. 1</xref> include patients with stable angina (SAP, <italic>N=</italic>21), acute coronary syndrome (ACS, <italic>N=</italic>25), or healthy donors (controls, <italic>N=</italic>25) and stored in liquid nitrogen until mRNA analyses. For protein analysis (in <xref rid="fig0002" ref-type="fig">Fig. 2</xref>), ten patients with ACS and nine healthy donors were recruited, and their PBMCs were used immediately for further in vitro experiments. Cells were maintained in RPMI supplemented with 10% heat inactivated pooled human A+ serum (The Blood Bank, St. Olav's Hospital, Trondheim, Norway) unless otherwise noted. Cells were primed with C5a (1&#xB5;g/ml), TNF (10 ng/ml) a combination of C5a and TNF or PBS for 2hrs prior to stimulation with CC (500 or 1000 &#x3BC;g/ml) for 16 hrs.</p>
      </sec>
      <sec id="sec0007">
        <label>2.5</label>
        <title>Culturing of human atherosclerotic plaques</title>
        <p id="para0019">Atherosclerotic carotid plaques were collected during carotid endarterectomy. Pieces of plaques used were dissected out as equal as possible in size. Plaques used for RNA analysis were rapidly frozen in liquid nitrogen and stored at -80&#xB0;C until further analyses, whereas plaques for culture and immunohistochemistry were kept in PBS until further processing. Biopsies from atherosclerotic carotid plaques were placed in Dulbecco's modified Eagle's medium (D-MEM/F12; Gibco) enriched with 30 mg/ml endotoxin-free and fatty acid-free bovine serum albumin (Sigma). The biopsies containing atherosclerotic plaques of each patient were split into macroscopically equal pieces and primed with C5a (1&#xB5;g/ml), TNF (10 ng/ml), a combination of C5a and TNF or PBS for 2hrs prior to stimulation with CC (1000 &#x3BC;g/ml) for 6 hrs. The plaque biopsies were placed in RNA Later (Qiagen) for RNA analysis and plaque supernatants were collected, centrifuged (1700 g for 5 min, 4&#xB0;C), and snap frozen before being stored at -80&#xB0;C until further analysis. Some results were presented as fold changes compared to PBS control, as the biopsies are heterogenous tissues with different cellular composition. The relative mRNA expression was presented when comparing atherosclerotic plaques to a distal area from the plaques or to normal arteries. Published gene expression profiles of 8 human carotid plaques <xref rid="bib0025" ref-type="bibr">[25]</xref> (Human Genome U133A 2.0 Array, Affymetrix) were analysed using CIBERSORT <xref rid="bib0026" ref-type="bibr">[26]</xref> to estimate the relative abundance of 22 infiltrating immune cell types, using the LM22 signature matrix and 1000 permutations (<xref rid="fig0008" ref-type="fig">Fig. 8</xref>).</p>
      </sec>
      <sec id="sec0008">
        <label>2.6</label>
        <title>Quantitative real time PCR</title>
        <p id="para0020">Total RNA was extracted from PBMC or human atherosclerotic plaques using RNeasy Mini kit as recommended by the manufacturer. Cell extracts were DNase treated before being reverse transcribed using High Capacity RNA-to-cDNA Kit and cycled in a StepOnePlus&#x2122; Real-Time PCR cycler (Applied Biosystems). Fold changes were calculated by delta Delta Ct methods using human GAPDH or actin as endogenous control for mRNA expression.</p>
      </sec>
      <sec id="sec0009">
        <label>2.7</label>
        <title>Immunohistochemistry</title>
        <p id="para0021">Immunohistochemistry was performed on human carotid tissue, where 4 &#x3BC;m paraffin embedded sections were cut onto SuperFrost Plus slides, dried over night at 37&#xB0;C and then 60 minutes at 60&#xB0;C. The slides&#xA0;were dewaxed in Tissue Clear, and taken through a series of descending ethanol to water in an automatic slide stainer (Sakura Tissue-Tek &#xA9; Prisma&#x2122;). The tissues were pre-treated in Target Retrieval Solution,&#xA0;High/Low pH (Dako K8004/5) in PT Link (Dako) for 20 minutes at 97&#xB0;C to facilitate antigen retrieval. The further staining was performed on Dako Autostainer. Following washes in wash buffer (Dako S3006),&#xA0;endogenous peroxidase activity was quenched by incubation in Peroxydase block (Dako S2023). Tissues were thereafter stained for complement C5-9 (TCC), and their isotype control, as well as for&#xA0;CD68, CD20, CD3 and CD15. The slides were then washed in wash buffer and incubated for 30 minutes in labelled polymer&#xA0;HRP anti-Rabbit (Dako K4003) and with DAB (Dako K3468) to develop the stain. In Sakura Tissue-Tek &#xA9; Prisma&#x2122; the slides were lightly counterstained with Hematoxylin, dehydrated through ascending grades of&#xA0;ethanol, cleared in Tissue Clear and mounted on cover slips. The sections were analysed using EVOS FL auto microscope (Thermo Fisher Scientific).</p>
      </sec>
      <sec id="sec0010">
        <label>2.8</label>
        <title>Measurements of systemic or local complement</title>
        <p id="para0022">The following complement activation products were measured by ELISA in EDTA plasma as described elsewhere. <xref rid="bib0027" ref-type="bibr">[27]</xref> soluble TCC, C3bc, C4bc and C3bBbP. These assays are based on monoclonal capture antibodies specific for neoepitopes expressed after a component is activated, and thus only the activated form is detected. An antibody (aE11) to a neoepitope expressed in C9 was used for the detection of soluble TCC. When C3 is activated, the C3b and subsequent C3c fragments both express a neoepitope recognized by the monoclonal antibody bH6. Thus, the ELISA detecting C3 activation is termed C3bc. The same principle applies for detection of C4 activation, which is denoted C4bc.</p>
      </sec>
      <sec id="sec0011">
        <label>2.9</label>
        <title>Gene expression and bioinformatic analyses</title>
        <p id="para0023">Plaques were homogenized using a FastPrep 24 instrument (&#x2248;6 m/s, MD Biomedicals) three times for 40 seconds with zirconium oxide beads (Bertin Tech) (six 2.8 mm beads and 0.8 g 1.4 mm beads per sample) in Isol-RNA Lysis Reagent (VWR, 5Prime). The aqueous phase was isolated after adding chloroform and centrifugation (13000 rpm, 15 min, 4&#xB0;C), and RNA was isolated further with RNeasy microkit (Qiagen). Nanodrop spectrophotometer (ND-1000, Saveen Werner) was used to measure RNA concentration. RNA expression analysis was run on the nCounter &#xAE; analysis system, running 12 samples at a time. The procedure was performed according to the manufacturer&#xB4;s instructions, applying about 100 ng mRNA. The kit used was a fixed code set for mRNA analysis with genes involved in human immunology nCounter GX Human Immunology Kit v2 (Nanostring Technologies). The number of mRNA molecules per gene was accounted for detection level &#x201C;average (negative control)&#xA0;+&#xA0;2SD (negative controls)&#x201D;, normalized against instrument variations (positive controls) and stable endogenous control genes (ABCF1, HPRT1, OAZ1, POLR2A and RPL19) using nSolver analysis software 2.5.34 (NanoString Technologies). The data detected were imported into Partek Genomics Suite 6.6 and Partek Pathway, log2 transformed and the data were batch corrected for patient variations. A cut-off at value &gt;10 normalized mRNA molecules was set and 503 genes were included in the analyses. ANOVA 3-way was performed for the comparisons of interest and p-value &lt;0.05 was considered significantly different between the groups. Finally, pathway enrichment analysis (Fisher's Exact test) was performed. Three gene lists were prepared with genes involved in the &#x201C;Regulation of inflammatory response&#x201D; (GO:0050727), &#x201C;NOD-like receptor signalling pathway&#x201D; (KEGG: hsa04621) and genes involved in the complement system. Induced genes were presented as Euclidian-clustered heat maps of genes involved in these lists with fold changes from the ANOVA. The expression of genes relevant for the NLRP3 inflammasome pathway were visualized in Partek Pathway and further visualized in Adobe Illustrator.</p>
      </sec>
      <sec id="sec0012">
        <label>2.10</label>
        <title>Cytokine and chemokine measurements</title>
        <p id="para0024">IL-1&#x3B2; and IL-1&#x3B1; from PBMC cultures were detected using IL-1&#x3B2; and IL-1&#x3B1; ELISAs (BD Biosciences). Supernatants from cultures of human atherosclerotic plaques were analysed using a multiplex cytokine assay (Bio-Plex; Bio-Rad Laboratories Inc.) for IL-1&#x3B2;, IL-1&#x3B1;, IL-18 and tumour necrosis factor (TNF). The analysis was performed according to the manufacturer's instructions.</p>
      </sec>
      <sec id="sec0013">
        <label>2.11</label>
        <title>Lactate dehydrogenase (LDH) assay</title>
        <p id="para0025">PBMC were cultured as indicated above. Cell death/cytotoxicity, as determined by LDH release, was measured in culture supernatant using a calorimetric LDH Assay Kit (Abcam) according to the manufacturer's instructions. For each assay, 10&#xB5;l of Triton-x 100 was used as positive control, and the spontaneous release was used for calculation of the % LDH activity.</p>
      </sec>
      <sec id="sec0014">
        <label>2.12</label>
        <title>Flow cytometry</title>
        <p id="para0026">PBMC from patients with ACS, or healthy donors (controls) were thawed and analyzed for cell composition using flow cytometry. The following controls were added: unstained cells, single-stained cells or dead cells monitored using the LIVE/DEAD fixable Aqua cell stain Assay (Life Technologies). Cells were treated with Fc receptor blocker (Miltenyi Inc.) prior to fixation. For cell surface staining, cells were fixed with 4% paraformaldehyde for 10 min followed by staining for the different cell population for 20 min with antibodies against CD14, CD3, CD4, CD8 and CD20. Results were analyzed by FlowJo 7.6, where cell debris, clustered cells and dead cells were excluded by gating.</p>
      </sec>
      <sec id="sec0015">
        <label>2.13</label>
        <title>Statistical analysis</title>
        <p id="para0027">GraphPad Prism (GraphPad Software) was used, and <italic>p</italic>&lt;0.05 was considered statistically significant. Results in <xref rid="fig0001" ref-type="fig">Fig. 1</xref> (a-c) was analysed using Kruskal Wallis and Dunn's multiple comparison test. <xref rid="fig0001" ref-type="fig">Figs. 1</xref>d, <xref rid="fig0001" ref-type="fig">1</xref>e and <xref rid="fig0003" ref-type="fig">3</xref>e were analysed with Spearman's correlation. <xref rid="fig0003" ref-type="fig">Fig. 3</xref> (a-d) was analysed using Bartlett's test for equal variance on log-transformed data with Bonferroni post-tests. <xref rid="fig0002" ref-type="fig">Figs. 2</xref>, <xref rid="fig0004" ref-type="fig">4</xref>a and Supplementary Fig. I were analysed using Mann-Whitney two-tail test (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>a on log-transformed data). <xref rid="fig0005" ref-type="fig">Fig. 5</xref> was analysed with ANOVA and Dunnett's&#x2019; multiple comparison test. Multiplex cytokine results in <xref rid="fig0006" ref-type="fig">Fig. 6</xref> were log2 transformed, batch corrected against patient variations and two-way ANOVA was performed in Partek Genomics Suite 6.6. Gene expression data in <xref rid="fig0007" ref-type="fig">Fig. 7</xref> and Supplementary Fig. IV, V and VI were analysed with Partek Genomics Suite 6.6 using 3-way ANOVA model as explained above.<fig id="fig0003"><label>Fig. 3</label><caption><p><bold>Complement activation products in plasma from controls and atherosclerotic patients with SAP and ACS.</bold> Presence of the end product of complement activation, TCC (a), the common complement component for the different pathways, C3bc (b), the activation product for both the classical and lectin pathway, C4bc (c), and the activation product for the alternative pathway, C3bBbP (d) in patients with SAP, ACS and healthy controls. Results are presented as mean &#xB1;SEM, <italic>n=</italic>21-23. e) Presence of activation product C4bc was correlated to IL-1&#x3B2; mRNA expression of controls, ACS and SAP combined, <italic>n=</italic>66. ACS, acute coronary syndrome; AU, arbitrary unit; C: Complement factor; IL, interleukin; SAP, Stable angina pectoris; TCC, terminal complement complex. ***<italic>p&lt;</italic>0.001, Bartlett's test for equal variance on log-transformed data with Bonferroni post-tests, (e) Spearman's correlation.</p></caption><alt-text id="alt0003">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig><fig id="fig0004"><label>Fig. 4</label><caption><p><bold>TCC in plasma from controls and patients with carotid plaques and accumulation of C1q and TCC around cholesterol crystal clefts in human carotid plaques.</bold> (a) TCC ELISA was performed on plasma collected from patients with carotid plaques and healthy controls. Results are presented as mean &#xB1; SEM, <italic>n=</italic>254 and 92, respectively. Immunohistochemistry was performed on paraffin embedded sectioned plaques which were stained for haematoxylin (HES) (b), C1q (c), TCC (d) and isotype control (e) and imaged using EVOS FL auto microscope. One representative image from 3 plaques from 3 patients. Arrows indicate crystal clefts. Scale bar is 50 &#x3BC;m. AU, arbitrary unit; C, Complement factor; TCC: terminal C5b-9 complement complex. ***<italic>p&lt;</italic>0.001, Mann-Whitney two-tail test.</p></caption><alt-text id="alt0004">Fig. 4</alt-text><graphic xlink:href="gr4"/></fig><fig id="fig0005"><label>Fig. 5</label><caption><p><bold>Transcripts of complement anaphylatoxin receptors in control arteries and human carotid plaques.</bold> Carotid plaques from asymptomatic, and symptomatic patients (symptoms for more than 2 months), distal area from the plaques and normal renal arteries were isolated from patients, <italic>n=</italic>115, 55, 14 and 8, respectively. RNA was isolated, and PCR run. mRNA expression for C5aR1 (a), C5aR2 (b), C3aR1 (c) and TNFR1 (d) is presented for the four groups as mean &#xB1; SEM. C*R, Complement factor receptor; TNFR, tumour necrosis factor receptor. *<italic>p&lt;</italic>0.05, **<italic>p&lt;</italic>0.01, ***<italic>p&lt;</italic>0.001 vs symptomatic, ANOVA and Dunnett's&#x2019; multiple comparison test.</p></caption><alt-text id="alt0005">Fig. 5</alt-text><graphic xlink:href="gr5"/></fig><fig id="fig0006"><label>Fig. 6</label><caption><p><bold>Release of pro-inflammatory cytokines from human carotid plaques upon CC stimulation and C5a priming.</bold> Carotid plaques were primed with C5a or left unprimed prior to stimulation with CC <italic>ex vivo</italic> and supernatants were collected. Multiplex cytokine assay was performed and amount of IL-1&#x3B2; (a), IL-18 (b), IL-1&#x3B1; (b) and TNF (d) is presented as mean fold induction compared to PBS, mean &#xB1; SEM, <italic>n=</italic>12 (for IL-1&#x3B1; <italic>n=</italic>8). Basal levels with exposure to PBS as mean &#xB1; SEM in pg/&#x3BC;l: IL-1&#x3B2;: 20&#xB1;6.1, IL-18 11&#xB1;4.1, IL-1&#x3B1; 1.8&#xB1;0.62, TNF 224&#xB1;66. CC, cholesterol crystals; IL, interleukin; TNF, tumour necrosis factor. *<italic>p&lt;</italic>0.05, **<italic>p&lt;</italic>0.01, *****<italic>p&lt;</italic>0.00001, 2-way ANOVA.</p></caption><alt-text id="alt0006">Fig. 6</alt-text><graphic xlink:href="gr6"/></fig><fig id="fig0007"><label>Fig. 7</label><caption><p><bold>Gene expression profiles from primed human carotid plaques incubated with CC.</bold> Carotid plaques were primed with C5a, C5a+TNF or left unprimed prior to incubation with CC or unstimulated <italic>ex vivo</italic>, before RNA isolation, Nanostring Technologies and Partek Genomics Suite analysis. Genes in the Kegg pathway &#x201C;NOD-like receptor signalling pathway&#x201D; are presented in a heat map (a) and genes linked to NLRP3 are presented in a graphical presentation (b). Basal levels in plaques treated with PBS as mean &#xB1; SEM normalized number of mRNAs: NLRP3 78&#xB1;34, ASC 101&#xB1;50, CASP1 125&#xB1;52, IL-1&#x3B2; 2601&#xB1;1186, IL-18 133&#xB1;66. Genes involved in the complement cascade are presented in a heatmap (c). Colour scale bar indicates mean fold change compared to PBS (red is higher and blue is lower), <italic>n=</italic>8. ASC/PYCARD, apoptotic speck protein containing a caspase recruitment domain; C, Complement factor; CASP1, Caspase-1; CC, cholesterol crystals; CLU, clusterin; ITGAM/CD11b, integrin alpha M; ITGAX/CD11c, integrin alpha X; ITGB2/CD18, integrin beta 2; IL, interleukin; NLRP3, NACHT, LRR and PYD domains-containing protein 3; NOD, nucleotide-binding oligomerization domain; SERPING1, complement 1 inhibitor; TNF, tumour necrosis factor. *<italic>p&lt;</italic>0.05, **<italic>p&lt;</italic>0.01, ***<italic>p&lt;</italic>0.001, 3-way ANOVA.</p></caption><alt-text id="alt0007">Fig. 7</alt-text><graphic xlink:href="gr7"/></fig></p>
      </sec>
      <sec id="sec0016">
        <label>2.14</label>
        <title>Ethics statement</title>
        <p id="para0028">Written informed consent was obtained from all participants and the study protocols were approved by the Regional Committees for Medical and Health Research Ethics in South-Eastern- and Western Norway. These committees approved the study protocols for human carotid plaques (REK No: 2014/2078), and the protocols for PBMC and plasma from patients with ACS, SAP and healthy controls (No: S-04114). The authors state that the study complies with the Declaration of Helsinki.</p>
      </sec>
    </sec>
    <sec id="sec0017">
      <label>3</label>
      <title>Results</title>
      <sec id="sec0018">
        <label>3.1</label>
        <title>PBMC from ACS patients showed increased transcripts of IL-1&#x3B2; and TNF</title>
        <p id="para0029">We first aimed to determine the relationships between NLRP3, IL-1&#x3B2; and TNF transcripts in PBMC from patients with verified CAD with stable (SAP) and unstable (ACS) disease. In accordance with previous reports <xref rid="bib0028" ref-type="bibr">[28]</xref> we observed that cells from patients with SAP and ACS had a marked increase in mRNA levels of IL-1&#x3B2; compared to the healthy controls (<italic>p</italic>&lt;0.001 and <italic>p</italic>&lt;0.05, respectively, Kruskal Wallis and Dunn's multiple comparison test, <xref rid="fig0001" ref-type="fig">Fig. 1</xref>a). Also, ACS patients had significant elevated IL-1&#x3B2; mRNA compared to the SAP group (<xref rid="fig0001" ref-type="fig">Fig. 1</xref>a). Furthermore, ACS patients had higher levels of NLRP3 transcripts as compared with SAP patients (<italic>p</italic>&lt;0.05, Kruskal Wallis and Dunn's multiple comparison test, <xref rid="fig0001" ref-type="fig">Fig. 1</xref>b). Moreover, ACS patients had significantly upregulated TNF transcript compared to both healthy controls (<italic>p</italic>&lt;0.001) and SAP (<italic>p</italic>&lt;0.01) (Kruskal Wallis and Dunn's multiple comparison test, <xref rid="fig0001" ref-type="fig">Fig. 1</xref>c). The upregulated TNF transcripts are also reflected by increase in plasma TNF in the ACS group<xref rid="bib0028" ref-type="bibr">[28]</xref>. Finally, in the ACS group there was a significant correlation between IL-1&#x3B2; and NLRP3 transcripts (r= 0.90, <italic>p</italic>&lt;0.0001; <xref rid="fig0001" ref-type="fig">Fig. 1</xref>d) and between IL-1&#x3B2; and TNF transcripts (<italic>r</italic>= 0.78, <italic>p</italic>&lt;0.0001; <xref rid="fig0001" ref-type="fig">Fig. 1</xref>e) (Spearman's correlation). These findings suggest a systemic inflammatory state occurring in ACS patients, potentially linked to NLRP3 inflammasomes.</p>
      </sec>
      <sec id="sec0019">
        <label>3.2</label>
        <title>PBMC from patients with ACS were highly responsive for priming with combination of C5a and TNF</title>
        <p id="para0030">We next examined if addition of CC with or without priming resulted in elevated IL-1&#x3B2; release in ACS patients compared to healthy controls. We have previously reported that C5a acts in synergy with TNF to induce IL-1&#x3B2; mRNA in human monocytes from healthy controls <xref rid="bib0018" ref-type="bibr">[18]</xref>. We found that when primed with a combination of C5a and TNF prior to CC stimulation, PBMC from ACS patients showed a higher IL-1&#x3B2; protein release (&gt;2-fold increase, <italic>p</italic>&lt;0.01, Mann-Whitney two-tail test) compared to PBMC from healthy controls (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>). It has been demonstrated that in a hyperlipidemic condition, CC will stimulate macrophages to produce IL-1&#x3B1;, contributing to atherosclerosis <xref rid="bib0029" ref-type="bibr">[29]</xref>. However, in our experiment, PBMC from healthy donors and ACS patients produced similar amount of IL-1&#x3B1; in response to CC with or without priming (<xref rid="fig0002" ref-type="fig">Fig. 2</xref>). Moreover, the cell viability was similar for all conditions applied (Supplementary Fig II). All control treatments are presented in Supplementary Fig. I<italic>.</italic> Correlations between the experimental results and clinical characteristics have been performed and no relevant observations were made (data not shown). The increase in transcripts in PBMC from the ACS patients compared to controls, as well as increase in responsiveness to C5a and TNF priming, were not due to differences in immune cell populations between the groups as the distributions of monocytes, T- and B-cells were similar in PBMC from ACS and controls (Supplementary Fig. III).</p>
      </sec>
      <sec id="sec0020">
        <label>3.3</label>
        <title>Higher complement activation was detected in plasma from patients with SAP and ACS</title>
        <p id="para0031">We have previously demonstrated that CC are potent activators of complement, both through the CP, LP and AP [<xref rid="bib0018" ref-type="bibr">18</xref>,<xref rid="bib0030" ref-type="bibr">30</xref>]. Thus, we next investigated the presence of complement activation products in plasma from patients with SAP and ACS. The end product of the three pathways, terminal C5b-9 complement complex (TCC) (<italic>p</italic>&lt;0.001, <xref rid="fig0003" ref-type="fig">Fig. 3</xref>a), and the common step product, C3bc (<italic>p</italic>&lt;0.001, <xref rid="fig0003" ref-type="fig">Fig. 3</xref>b), were significantly higher in the SAP and ACS groups compared to healthy controls (Bartlett's test for equal variance on log-transformed data with Bonferroni post-tests). Moreover, we also observed a significant increase in C4bc (<italic>p</italic>&lt;0.001, Bartlett's test for equal variance on log-transformed data with Bonferroni post-tests, <xref rid="fig0003" ref-type="fig">Fig. 3</xref>c), a marker of both the CP and the LP activation, in both SAP and ACS compared to healthy controls, suggesting that the CP and/or LP are involved in the CAD-related initial complement activation. The AP convertase C3bBbP was also significantly (<italic>p</italic>&lt;0.001, Bartlett's test for equal variance on log-transformed data with Bonferroni post-tests) increased in plasma from SAP patients, but not in ACS patients, compared to healthy controls (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>d). In addition, C4bc correlated to IL-1&#x3B2; mRNA levels when controls, SAP and ACS patients were combined (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>e). Our <italic>ex vivo</italic> experiments showed that C5a and TNF primed PBMC from ACS patients had a marked increase in IL-1&#x3B2; release upon subsequent CC exposure. Hence, the upregulation of the different components of this inflammatory loop i.e., TNF, NLRP3, IL-1&#x3B2; and complement in freshly isolated PBMC and plasma, suggest that these inflammatory interactions also could be operating <italic>in vivo</italic>.</p>
      </sec>
      <sec id="sec0021">
        <label>3.4</label>
        <title>Complement factor C1q and TCC were localized around CC clefts in carotid plaques</title>
        <p id="para0032">Complement products have been observed in atherosclerotic lesions <xref rid="bib0012" ref-type="bibr">[12]</xref>. To further elucidate the interaction between CC and complement activation in atherogenesis we next examined the expression of complement components in human atherosclerotic carotid plaques. Importantly, as for the ACS group (<xref rid="fig0003" ref-type="fig">Fig. 3</xref>a), plasma from patients with carotid atherosclerosis had also significantly higher (<italic>p</italic>&lt;0.001, Mann-Whitney two-tail test on log-transformed data, <xref rid="fig0004" ref-type="fig">Fig. 4</xref>a) TCC than plasma from healthy controls. Moreover, light microscopy of rehydrated carotid arteries showed &#x201C;CC clefts&#x201D; in proximity to &#x201C;foam-like&#x201D; cells and in the necrotic core (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>b). Importantly, C1q (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>c) and TCC (<xref rid="fig0004" ref-type="fig">Fig. 4</xref>d) localized around the CC-clefts. As complement activation is intended to propagate inflammatory responses, it is likely that complement activation at the surface of CC may facilitate the growth of the lesions by recruiting more immune cells to CC.</p>
      </sec>
      <sec id="sec0022">
        <label>3.5</label>
        <title>High expression of anaphylatoxin receptors were found in advanced human carotid plaques</title>
        <p id="para0033">We next determined whether patients with symptomatic or asymptomatic carotid atherosclerotic plaques expressed different local complement receptor profiles. Distal carotid samples, representing an early stage of atherosclerosis without macroscopically sign of atherosclerosis, and non-atherosclerotic common renal arteries of organ donors were used as controls. Symptomatic plaques had significantly higher transcripts of C5aR1 (<italic>p</italic>&lt;0.001), C5aR2 (<italic>p</italic>&lt;0.01) and C3aR1 (<italic>p</italic>&lt;0.001) than non-atherosclerotic control vessel or distal carotid samples suggesting that these anaphylatoxin receptors are associated with plaque severity of the disease (ANOVA and Dunnett's&#x2019; multiple comparison test, <xref rid="fig0005" ref-type="fig">Fig. 5</xref>a&#x2013;c). Of interest, minor, but significant difference between plaques from symptomatic- and asymptomatic patients were found for C5aR2 (<xref rid="fig0005" ref-type="fig">Fig. 5</xref>b). In contrast, no significant differences were observed for TNFR1 mRNA between patients with symptomatic and asymptomatic carotid plaques or between carotid plaques and the two control groups (<xref rid="fig0005" ref-type="fig">Fig. 5</xref>d). These findings suggest an important role for local complement and anaphylatoxin receptors in generating an inflammatory milieu in carotid atherosclerosis.</p>
      </sec>
      <sec id="sec0023">
        <label>3.6</label>
        <title>Carotid plaques showed enhanced sensitivity to C5a priming</title>
        <p id="para0034">Given that advanced carotid lesions are in an activated state, the cells present in the plaques may respond to stimulation by CC. Using freshly isolated carotid plaques, we and others have previously shown that incubation of carotid plaques with CC leads to high amount of IL-1&#x3B2;, confirming that the environment in plaques contains mediators (i.e. genes relevant to the NLRP3 inflammasome pathway) that may prime immune cells for CC-induced inflammation <xref rid="bib0031" ref-type="bibr">[31]</xref>. The spontaneously produced TNF is very high, which suggests that it might be present in high enough amounts for priming (224&#xB1;66 pg/ml). Hence, we addressed the effect of C5a as a priming signal in freshly isolated carotid plaques. In <xref rid="fig0006" ref-type="fig">Fig. 6</xref> we have normalized the stimulated plaques against their own controls and present fold changes rather than absolute values. In line with Varghese et&#xA0;al, <xref rid="bib0031" ref-type="bibr">[31]</xref> we found that IL-1&#x3B2; release was significantly increased in this <italic>ex vivo</italic> model of plaque stimulation during CC incubation (<italic>p</italic>&lt;0.01, 2-way ANOVA on log-transformed data, <xref rid="fig0006" ref-type="fig">Fig. 6</xref>a). Interestingly, priming with C5a prior to CC incubation significantly (<italic>p</italic>&lt;0.05, 2-way ANOVA on log-transformed data) increased both IL-1&#x3B2; and IL-18 release, the two major inflammatory products from NLRP3 activation (<xref rid="fig0006" ref-type="fig">Fig. 6</xref>a,b), whereas TNF did not change significantly (<xref rid="fig0006" ref-type="fig">Fig. 6</xref>d). This demonstrates the link between complement and CC-induced NLRP3 activation in atherosclerotic plaques. In murine models, CC have been shown to induce IL-1&#x3B1; by a mechanism involving fatty acid-induced mitochondrial uncoupling <xref rid="bib0029" ref-type="bibr">[29]</xref>. Likewise, addition of CC to human carotid plaques led to a significant (<italic>p</italic>&lt;0.01, 2-way ANOVA on log-transformed data) increase in IL-1&#x3B1; release in the presence of priming, illustrating the importance of a lipid rich and inflammatory microenvironment for IL-1&#x3B1; release (<xref rid="fig0006" ref-type="fig">Fig. 6</xref>c). Thus, these data suggest that C5a in atherosclerotic plaques may have an impact on the magnitude of the CC-induced inflammatory response with NLRP3 as a major target.</p>
      </sec>
      <sec id="sec0024">
        <label>3.7</label>
        <title>Combining C5a and TNF primed carotid plaques for NLRP3 and complement pathway genes</title>
        <p id="para0035">We next performed gene expression profiling on biopsies obtained from carotid endarterectomies. Gene expression profiling of a panel of human immune-related genes was performed in untreated plaques or plaques treated with CC alone, CC+C5a, C5a+TNF and CC+C5a+TNF. We found that the treatment affected many key genes in the GO term &#x201C;Regulation of inflammatory response&#x201D; (Supplementary Fig. IV). Of interest, pathway enrichment analysis revealed that the Kegg pathway &#x201C;NOD-like receptor-signalling pathway&#x201D; was significantly regulated in the data set (<xref rid="fig0007" ref-type="fig">Fig. 7</xref>a, Supplementary Fig. V). Incubating carotid plaques with CC increased many inflammatory genes including TNF receptor TNFRSF1B, the inflammatory chemokines CCL5, CCL3, CXCL2, CXCL1 as well as TLR2 and several other inflammatory genes such as IL-6, IL-8 and Cox-2 (<xref rid="fig0007" ref-type="fig">Fig. 7</xref>a, Supplementary Fig. IV and V). When biopsies were primed with C5a, CC induced upregulation of NLRP3 and apoptotic speck protein containing a caspase recruitment domain (ASC) with a corresponding significant increase of IL-1&#x3B2; gene expression (<italic>p</italic>&lt;0.05, 3-way ANOVA, <xref rid="fig0007" ref-type="fig">Fig. 7</xref>b). CC+C5a+TNF condition significantly increased both NLRP3, CASP1, IL-1&#x3B2; and IL-18 gene expression (<italic>p</italic>&lt;0.05, 3-way ANOVA, <xref rid="fig0007" ref-type="fig">Fig. 7</xref>b). Interestingly, mRNA expression of the anti-inflammatory cytokine IL-10 was markedly upregulated in C5a+TNF and CC-stimulated carotid plaques (Supplementary Fig. IV). Altogether, these data show that priming with the combination of C5a and TNF prior to stimulation with CC activates inflammation by inducing NLRP3-transcriptional programs in human plaques, as well as several other genes that are relevant to the inflammatory pathogenesis of atherosclerosis.</p>
        <p id="para0036">We also found that priming and stimuli with CC affected many key genes in the complement system (<xref rid="fig0007" ref-type="fig">Fig. 7</xref>c). Priming with C5a and TNF followed by CC stimulation lead to an increased expression of &#x201C;upstream genes&#x201D; of the complement activation cascade, such as C1q alpha- and beta chains (C1QA, C1QB), complement factor D (CFD), C2 and C3. Moreover, expression of phagocytic receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18) were increased (<xref rid="fig0007" ref-type="fig">Fig. 7</xref>c and Supplementary Fig. VI). In contrast, &#x201C;downstream activation genes&#x201D; like C5, C6, C7 and C9 were reduced by this treatment (<xref rid="fig0007" ref-type="fig">Fig. 7</xref>c and Supplementary Fig. IV). In addition, complement regulatory genes such as clusterin (CLU), CD59, CD46, CD55 and complement factor I (CFI) were also diminished by priming and CC treatment (<xref rid="fig0007" ref-type="fig">Fig. 7</xref>c and Supplementary Fig. VI). This indicates that priming and stimulation affects the gene expression of complement genes which again may reflect a shift in the balance that contributes to disease progression.</p>
        <p id="para0037">We identified immune cell types in 8 carotid plaques by using a CIBERSORT analysis <xref rid="bib0026" ref-type="bibr">[26]</xref> on microarray data previously published by our group <xref rid="bib0025" ref-type="bibr">[25]</xref>. Although the amount of different cell types varied between individual plaques, macrophages and monocytes were dominating immune cells (<xref rid="fig0008" ref-type="fig">Fig. 8</xref>). Also, neutrophils, T-cells and plasma cells were detected in the plaques. Immunohistochemistry of serial sections revealed that neutrophils (CD15<sup>+</sup>) were present in the necrotic zone of the plaque close to crystal clefts, whereas macrophages were located just outside the necrotic zone (Supplementary Fig. VII). T-cells (CD3<sup>+</sup>) and B-cells (CD20<sup>+</sup>) were also present in the immunohistochemistry sections of plaques, but these immune cells were less abundant compared to macrophages and neutrophils (Supplementary Fig. VII).<fig id="fig0008"><label>Fig. 8</label><caption><p><bold>Immune cell types detected in carotid plaques.</bold> CIBERSORT analysis was done on microarray results performed on RNA isolated from carotid plaques <xref rid="bib0026" ref-type="bibr">[26]</xref>. Presented are different cell types as relative % in relation to the total cell content. Results are shown for 8 different plaques from 8 different patients.</p></caption><alt-text id="alt0008">Fig. 8</alt-text><graphic xlink:href="gr8"/></fig></p>
      </sec>
    </sec>
    <sec id="sec0025">
      <label>4</label>
      <title>Discussion</title>
      <p id="para0038">In the present study, we propose a molecular mechanism that integrates systemic and local complement- and NLRP3 activation with CC-mediated inflammatory responses in patients with coronary- and carotid atherosclerosis. We show that complement contributes to the CC-driven inflammatory responses both in PBMC from ACS patients and within the atherosclerotic lesion in patients with carotid atherosclerosis. Our data imply a positive association between CC-induced complement and NLRP3 activation, both systemically and within the atherosclerotic lesion, with disease severity and instability.</p>
      <p id="para0039">Whereas much focus has been directed towards IL-1&#x3B2;, data on IL-1&#x3B1; in atherosclerotic disorders are scarce. Herein we show that CC induced marked IL-1&#x3B1; release in carotid plaques in the presence of C5a, while TNF and C5a priming increased IL-1&#x3B1; release in presence of CC in PBMC from ACS patients and controls. Baumer et al. recently suggested that TNF may also play an earlier role in CC formation <xref rid="bib0032" ref-type="bibr">[32]</xref>. We observed that neutrophils were present in lesions and these cells are potential sources for CC-induced IL-1&#x3B1; release. It is interesting that neutrophils were present in areas were CC clefts were detected. As CC are potent activators of complement, neutrophils may be attracted to this area. It has been reported that CC can trigger neutrophils to release neutrophil extracellular traps (NETs) <xref rid="bib0033" ref-type="bibr">[33]</xref>. Moreover, NETs are involved in production of mature IL-1&#x3B1;, which has been implicated in thrombosis caused by superficial erosion <xref rid="bib0034" ref-type="bibr">[34]</xref>. On the other side, Jiang et al. <xref rid="bib0009" ref-type="bibr">[9]</xref> recently found that inhibiting the NLRP3 inflammasome using MCC950 reduced LPS- or ATP-induced IL-1&#x3B1; release in plaque-derived tissue. The exact role of IL-1&#x3B1; in atherogenesis is still not clear, however, it seems to be of importance for metabolic-induced inflammation, as it was recently shown to promote vascular remodelling <xref rid="bib0035" ref-type="bibr">[35]</xref>.</p>
      <p id="para0040">In the current study we show that <italic>ex vivo</italic> priming of carotid plaques by C5a+TNF followed by CC activation induced mRNA expression of wide range of inflammatory genes. This was accompanied by enhanced expression of NLRP3, ASC and CASP1 with a corresponding significant increase of IL-1&#x3B2; and IL-18 gene expression and protein release, suggesting that these broad inflammatory responses within carotid plaques are driven by CC and complement activation. We found that monocytes, macrophages and T-cells were detected in plaques, and these cell types are likely to be major contributors to the inflammasome activation. Notably, also within CAD patients, we found an inflammatory response to C5a+ TNF and CC. PMBC from patients with ACS primed with C5a+TNF, and incubated with CC, showed a &gt;2-fold increase in IL-1&#x3B2; release as compared with PBMC from healthy controls. This result is in line with our data showing that PBMC from ACS patients also had upregulated NLRP3 and IL-1&#x3B2; mRNA. In accordance to our earlier findings <xref rid="bib0018" ref-type="bibr">[18]</xref>, these results suggest that both in carotid plaques and in PBMC from ACS patients, the proteins that are needed for NLRP3 complex assembly are upregulated, and when plaques and PBMC are exposed to C5a+TNF and CC, a marked enhanced inflammatory response occurs that may contribute to plaque progression and instability. Disparate results have emerged on the role of IL-1&#x3B2; in atherosclerosis when human and murine studies are compared. While a single cell study analysis of cells in human plaques recently showed that IL1&#x3B2; might be highly upregulated in plaque macrophages from asymptomatic than symptomatic patients <xref rid="bib0036" ref-type="bibr">[36]</xref>. The CANTOS trial <xref rid="bib0037" ref-type="bibr">[37]</xref>, demonstrated the benefits of IL-1&#x3B2; neutralization in patients post-myocardial infarction, thus, supporting the findings in murine studies showing the importance of IL-1&#x3B2; in driving inflammation and plaque formation in atherosclerosis [<xref rid="bib0005" ref-type="bibr">5</xref>,<xref rid="bib0038" ref-type="bibr">38</xref>].</p>
      <p id="para0041">Complement activation is highly induced in advanced atherosclerotic lesions, and studies have shown that cells in plaques express complement both at the mRNA and the protein level <xref rid="bib0016" ref-type="bibr">[16]</xref>. This fits well with our findings showing significantly higher levels of systemic TCC in plasma from patients with carotid plaques. Moreover, we show that carotid plaques had higher expression of C5aR1, C5aR2 and C3aR1 than control arteries. Hence, these results provide strong support for the hypothesis that the amplitude of local complement activation has a causal link to the disease progression. A recent study reported a higher expression of NLRP3 in symptomatic plaques compared to asymptomatic <xref rid="bib0009" ref-type="bibr">[9]</xref>. The prevalence of also a higher anaphylatoxin receptor expression in symptomatic compared to asymptomatic carotid arteries further underlines the relevance of local complement factors that reflect processes associated with atherosclerotic disease progression particularly in this group of patients with the highest &#x201C;inflammatory load&#x201D;. Although markers of inflammasome activation were different between SAP and ACS, the complement activation was equally high in these two groups. This might be due to the fact that complement activation is a quick response that is upstream the inflammasome activation. Recent studies have shown that complement can also be activated on intracellular compartments, and that this activation might exert functions that are different from systemic serum complement [<xref rid="bib0039" ref-type="bibr">39</xref>,<xref rid="bib0040" ref-type="bibr">40</xref>]. Future studies are needed to understand how this new location of complement affects the biology of atherosclerosis.</p>
      <p id="para0042">Interestingly, IL-10 expression was increased in the C5a+TNF and CC stimulated plaques. IL-10 is a potent anti-inflammatory cytokine with atheroprotective effects [<xref rid="bib0028" ref-type="bibr">28</xref>,<xref rid="bib0041" ref-type="bibr">41</xref>]. Moreover, IL-10 has been suggested to be a mediator in the resolution phase of an inflammatory response. The resolution phase of inflammation is characterized by efferocytosis, which is removal of dead cells. Important in this respect is our observation that stimulation of carotid plaques with C5a+TNF and CC resulted in upregulation of &#x201C;upstream&#x201D; complement genes such as C1Q and C3 as well as phagocytic receptors. These genes response may enhance phagocytosis of dead cells and debris in the plaque. Thus, both pro- and anti-inflammatory processes occur in carotid plaque, and the balance between these two pathways may be essential for disease development, and the CC-complement-NLRP3 axis seems to be a key regulator of these processes. Both our studies and previous work by others <xref rid="bib0036" ref-type="bibr">[36]</xref> have revealed the complex immune cell landscape of atherosclerotic plaques. We find a considerable amount of M2 macrophages that may contribute to IL-10 secretion and anti-inflammatory responses. Also, plasma cells are detected which can secrete antibodies which may enhance complement activation in the plaque. Future studies will be needed to clarify the important question as to which plaque-containing leucocyte group induces the observed cross-talk between complement and CC-induced NLRP3 in atherosclerosis.</p>
      <p id="para0043">Nevertheless, this study demonstrates a close relationship between complement and CC-induced NLRP3 inflammasome activation in the inflammatory processes both systemically and within the atherosclerotic lesion. Patients with atherosclerosis have increased levels of C3 and C4 in their plasma, which is a risk factor of cardiovascular events <xref rid="bib0042" ref-type="bibr">[42]</xref>. Most complement proteins, including C3 and C4 are acute phase proteins produced in the liver, supporting the idea that atherosclerosis is a systemic low-grade inflammatory disease. The increase in activation products, like C5a, has also been shown to predict cardiovascular events, particularly in patients with advanced atherosclerosis <xref rid="bib0043" ref-type="bibr">[43]</xref>. This increase in activation products, as we showed for components from the whole cascade, is most likely due to release of activation products from the continuously activated atherosclerotic arterial endothelium. Using <italic>ex vivo</italic> human atherosclerotic plaques together with plasma and PBMC isolated from whole blood of patients with SAP and ACS, we show that this cross talk plays a mechanistic role in the development of atherosclerosis. The pathogenic loop between complement, CC and NLRP3 inflammasomes may represent a promising target for therapy of atherosclerotic disorders.</p>
    </sec>
    <sec id="sec0026">
      <title>Funding sources</title>
      <p id="para0044">This work was supported by the Research Council of Norway [223255/F50, and 251255/F20], and the Liaison Committee in Central Norway [50052400]. The funders had no role in study design, data collection, data analysis, interpretation or writing of the manuscript.</p>
    </sec>
    <sec id="sec0027">
      <title>Declaration of Competing Interest</title>
      <p id="para0045">Dr. Latz is scientific co-founder and consultant to IFM Therapeutics, a biotech company that develops small molecule modulators of innate immune pathways. The other authors declare no competing interests with relevance to this study.</p>
    </sec>
    <sec id="sec0028">
      <title>Data sharing</title>
      <p id="para0046">The data, analytical methods, and study materials for the purposes of reproducing the results or replicating procedures can be made available on request to the corresponding author.</p>
    </sec>
    <sec id="sec0029">
      <title>Author contributions</title>
      <p id="para0047">NN, SSB, TE: conception and design of the study, literature search, figures, data collection, data analysis, writing of the article, final approval of the submitted version. IG, SH, &#xD8;S, HLO, LR, AMR, AY, XYK, TBD: data collection, editing, drafting of the article, final approval of the submitted version. BS: data collection, figures, editing, drafting of the article, final approval of the submitted version. MS, EL, LG, G&#xD8;A, JKD: conception and design of the study, data collection, editing, drafting of the article, final approval of the submitted version. PA, TEM, BH: conception and design of the study, data collection, data interpretation, editing, drafting of the article, editing, final approval of the submitted version.</p>
    </sec>
  </body>
  <back>
    <ref-list id="cebibl1">
      <title>References</title>
      <ref id="bib0001">
        <label>1</label>
        <element-citation publication-type="journal" id="sbref0001">
          <person-group person-group-type="author">
            <name>
              <surname>Hansson</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Hermansson</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>The immune system in atherosclerosis</article-title>
          <source>Nat Immunol</source>
          <volume>12</volume>
          <issue>3</issue>
          <year>2011</year>
          <fpage>204</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="pmid">21321594</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0002">
        <label>2</label>
        <element-citation publication-type="journal" id="sbref0002">
          <person-group person-group-type="author">
            <name>
              <surname>Katz</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Shipley</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Small</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Physical chemistry of the lipids of human atherosclerotic lesions. Demonstration of a lesion intermediate between fatty streaks and advanced plaques</article-title>
          <source>J Clin Invest</source>
          <volume>58</volume>
          <issue>1</issue>
          <year>1976</year>
          <fpage>200</fpage>
          <lpage>211</lpage>
          <pub-id pub-id-type="pmid">932206</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0003">
        <label>3</label>
        <element-citation publication-type="journal" id="sbref0003">
          <person-group person-group-type="author">
            <name>
              <surname>Sheedy</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Grebe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rayner</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation</article-title>
          <source>Nat Immunol</source>
          <volume>14</volume>
          <issue>8</issue>
          <year>2013</year>
          <fpage>812</fpage>
          <lpage>820</lpage>
          <pub-id pub-id-type="pmid">23812099</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0004">
        <label>4</label>
        <element-citation publication-type="journal" id="sbref0004">
          <person-group person-group-type="author">
            <name>
              <surname>Stewart</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Stuart</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer</article-title>
          <source>Nat Immunol</source>
          <volume>11</volume>
          <issue>2</issue>
          <year>2010</year>
          <fpage>155</fpage>
          <lpage>161</lpage>
          <pub-id pub-id-type="pmid">20037584</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0005">
        <label>5</label>
        <element-citation publication-type="journal" id="sbref0005">
          <person-group person-group-type="author">
            <name>
              <surname>Duewell</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kono</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rayner</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals</article-title>
          <source>Nature</source>
          <volume>464</volume>
          <issue>7293</issue>
          <year>2010</year>
          <fpage>1357</fpage>
          <lpage>1361</lpage>
          <pub-id pub-id-type="pmid">20428172</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0006">
        <label>6</label>
        <element-citation publication-type="journal" id="sbref0006">
          <person-group person-group-type="author">
            <name>
              <surname>Fujiyoshi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Minami</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ishida</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Incidence, factors, and clinical significance of cholesterol crystals in coronary plaque: An optical coherence tomography study</article-title>
          <source>Atherosclerosis</source>
          <volume>283</volume>
          <year>2019</year>
          <fpage>79</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">30802681</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0007">
        <label>7</label>
        <element-citation publication-type="journal" id="sbref0007">
          <person-group person-group-type="author">
            <name>
              <surname>Kataoka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Puri</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hammadah</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Cholesterol crystals associate with coronary plaque vulnerability in vivo</article-title>
          <source>J Am Coll Cardiol</source>
          <volume>65</volume>
          <issue>6</issue>
          <year>2015</year>
          <fpage>630</fpage>
          <lpage>632</lpage>
          <pub-id pub-id-type="pmid">25677323</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0008">
        <label>8</label>
        <element-citation publication-type="journal" id="sbref0008">
          <person-group person-group-type="author">
            <name>
              <surname>Kirii</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Niwa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <volume>23</volume>
          <issue>4</issue>
          <year>2003</year>
          <fpage>656</fpage>
          <lpage>660</lpage>
          <pub-id pub-id-type="pmid">12615675</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0009">
        <label>9</label>
        <element-citation publication-type="journal" id="sbref0009">
          <person-group person-group-type="author">
            <name>
              <surname>Jiang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Inflammasome-Driven Interleukin-1alpha and Interleukin-1beta Production in Atherosclerotic Plaques Relates to Hyperlipidemia and Plaque Complexity</article-title>
          <source>JACC Basic Transl Sci</source>
          <volume>4</volume>
          <issue>3</issue>
          <year>2019</year>
          <fpage>304</fpage>
          <lpage>317</lpage>
          <pub-id pub-id-type="pmid">31312755</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0010">
        <label>10</label>
        <element-citation publication-type="journal" id="sbref0010">
          <person-group person-group-type="author">
            <name>
              <surname>Ridker</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Everett</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Thuren</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease</article-title>
          <source>N Engl J Med</source>
          <volume>377</volume>
          <issue>12</issue>
          <year>2017</year>
          <fpage>1119</fpage>
          <lpage>1131</lpage>
          <pub-id pub-id-type="pmid">28845751</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0011">
        <label>11</label>
        <element-citation publication-type="journal" id="sbref0011">
          <person-group person-group-type="author">
            <name>
              <surname>Lewis</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>TR</given-names>
            </name>
          </person-group>
          <article-title>The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice</article-title>
          <source>Mol Immunol</source>
          <volume>47</volume>
          <issue>5</issue>
          <year>2010</year>
          <fpage>1098</fpage>
          <lpage>1105</lpage>
          <pub-id pub-id-type="pmid">19959238</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0012">
        <label>12</label>
        <element-citation publication-type="journal" id="sbref0012">
          <person-group person-group-type="author">
            <name>
              <surname>Meuwissen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>van der Wal</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Niessen</surname>
              <given-names>HW</given-names>
            </name>
          </person-group>
          <article-title>Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction</article-title>
          <source>J Clin Pathol</source>
          <volume>59</volume>
          <issue>2</issue>
          <year>2006</year>
          <fpage>196</fpage>
          <lpage>201</lpage>
          <pub-id pub-id-type="pmid">16443738</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0013">
        <label>13</label>
        <element-citation publication-type="journal" id="sbref0013">
          <person-group person-group-type="author">
            <name>
              <surname>Oksjoki</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kovanen</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Pentikainen</surname>
              <given-names>MO</given-names>
            </name>
          </person-group>
          <article-title>Role of complement activation in atherosclerosis</article-title>
          <source>Curr Opin Lipidol</source>
          <volume>14</volume>
          <issue>5</issue>
          <year>2003</year>
          <fpage>477</fpage>
          <lpage>482</lpage>
          <pub-id pub-id-type="pmid">14501586</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0014">
        <label>14</label>
        <element-citation publication-type="journal" id="sbref0014">
          <person-group person-group-type="author">
            <name>
              <surname>Seifert</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Kazatchkine</surname>
              <given-names>MD.</given-names>
            </name>
          </person-group>
          <article-title>Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position</article-title>
          <source>Mol Immunol</source>
          <volume>24</volume>
          <issue>12</issue>
          <year>1987</year>
          <fpage>1303</fpage>
          <lpage>1308</lpage>
          <pub-id pub-id-type="pmid">3431552</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0015">
        <label>15</label>
        <element-citation publication-type="journal" id="sbref0015">
          <person-group person-group-type="author">
            <name>
              <surname>Speidl</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Kastl</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Hutter</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>The complement component C5a is present in human coronary lesions in vivo and induces the expression of MMP-1 and MMP-9 in human macrophages in vitro</article-title>
          <source>FASEB J</source>
          <volume>25</volume>
          <issue>1</issue>
          <year>2011</year>
          <fpage>35</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="pmid">20813982</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0016">
        <label>16</label>
        <element-citation publication-type="journal" id="sbref0016">
          <person-group person-group-type="author">
            <name>
              <surname>Yasojima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schwab</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>McGeer</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>McGeer</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
          <article-title>Generation of C-reactive protein and complement components in atherosclerotic plaques</article-title>
          <source>Am J Pathol</source>
          <volume>158</volume>
          <issue>3</issue>
          <year>2001</year>
          <fpage>1039</fpage>
          <lpage>1051</lpage>
          <pub-id pub-id-type="pmid">11238052</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0017">
        <label>17</label>
        <mixed-citation publication-type="other" id="sbref0017">Pilely K, Rosbjerg A, Genster N. Cholesterol Crystals Activate the Lectin Complement Pathway via Ficolin-2 and Mannose-Binding Lectin: Implications for the Progression of Atherosclerosis. 2016;196(12):5064-74.</mixed-citation>
      </ref>
      <ref id="bib0018">
        <label>18</label>
        <element-citation publication-type="journal" id="sbref0018">
          <person-group person-group-type="author">
            <name>
              <surname>Samstad</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Niyonzima</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nymo</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release</article-title>
          <source>J Immunol</source>
          <volume>192</volume>
          <issue>6</issue>
          <year>2014</year>
          <fpage>2837</fpage>
          <lpage>2845</lpage>
          <pub-id pub-id-type="pmid">24554772</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0019">
        <label>19</label>
        <element-citation publication-type="journal" id="sbref0019">
          <person-group person-group-type="author">
            <name>
              <surname>Niyonzima</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Halvorsen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sporsheim</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Complement activation by cholesterol crystals triggers a subsequent cytokine response</article-title>
          <source>Mol Immunol</source>
          <volume>84</volume>
          <year>2017</year>
          <fpage>43</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">27692470</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0020">
        <label>20</label>
        <element-citation publication-type="journal" id="sbref0020">
          <person-group person-group-type="author">
            <name>
              <surname>Nymo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Niyonzima</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Espevik</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mollnes</surname>
              <given-names>TE</given-names>
            </name>
          </person-group>
          <article-title>Cholesterol crystal-induced endothelial cell activation is complement-dependent and mediated by TNF</article-title>
          <source>Immunobiology</source>
          <volume>219</volume>
          <issue>10</issue>
          <year>2014</year>
          <fpage>786</fpage>
          <lpage>792</lpage>
          <pub-id pub-id-type="pmid">25053140</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0021">
        <label>21</label>
        <element-citation publication-type="journal" id="sbref0021">
          <person-group person-group-type="author">
            <name>
              <surname>Gravastrand</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Steinkjer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Halvorsen</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocytic Tissue Factor</article-title>
          <source>J Immunol</source>
          <year>2019</year>
        </element-citation>
      </ref>
      <ref id="bib0022">
        <label>22</label>
        <element-citation publication-type="journal" id="sbref0022">
          <person-group person-group-type="author">
            <name>
              <surname>Ricklin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hajishengallis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lambris</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Complement: a key system for immune surveillance and homeostasis</article-title>
          <source>Nat Immunol</source>
          <volume>11</volume>
          <issue>9</issue>
          <year>2010</year>
          <fpage>785</fpage>
          <lpage>797</lpage>
          <pub-id pub-id-type="pmid">20720586</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0023">
        <label>23</label>
        <element-citation publication-type="journal" id="sbref0023">
          <person-group person-group-type="author">
            <name>
              <surname>Thygesen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Alpert</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Simoons</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Chaitman</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>HD</given-names>
            </name>
          </person-group>
          <article-title>Third universal definition of myocardial infarction</article-title>
          <source>Glob Heart</source>
          <volume>7</volume>
          <issue>4</issue>
          <year>2012</year>
          <fpage>275</fpage>
          <lpage>295</lpage>
          <pub-id pub-id-type="pmid">25689940</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0024">
        <label>24</label>
        <element-citation publication-type="journal" id="sbref0024">
          <person-group person-group-type="author">
            <name>
              <surname>Brott</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Halperin</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Abbara</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary</article-title>
          <source>J Neurointerv Surg</source>
          <volume>3</volume>
          <issue>2</issue>
          <year>2011</year>
          <fpage>100</fpage>
          <lpage>130</lpage>
          <pub-id pub-id-type="pmid">21990803</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0025">
        <label>25</label>
        <element-citation publication-type="journal" id="sbref0025">
          <person-group person-group-type="author">
            <name>
              <surname>Dahl</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Yndestad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Skjelland</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization</article-title>
          <source>Circulation</source>
          <volume>115</volume>
          <issue>8</issue>
          <year>2007</year>
          <fpage>972</fpage>
          <lpage>980</lpage>
          <pub-id pub-id-type="pmid">17283255</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0026">
        <label>26</label>
        <element-citation publication-type="journal" id="sbref0026">
          <person-group person-group-type="author">
            <name>
              <surname>Newman</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Robust enumeration of cell subsets from tissue expression profiles</article-title>
          <source>Nat Methods</source>
          <volume>12</volume>
          <issue>5</issue>
          <year>2015</year>
          <fpage>453</fpage>
          <lpage>457</lpage>
          <pub-id pub-id-type="pmid">25822800</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0027">
        <label>27</label>
        <element-citation publication-type="journal" id="sbref0027">
          <person-group person-group-type="author">
            <name>
              <surname>Bergseth</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ludviksen</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Kirschfink</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Giclas</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Nilsson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Mollnes</surname>
              <given-names>TE</given-names>
            </name>
          </person-group>
          <article-title>An international serum standard for application in assays to detect human complement activation products</article-title>
          <source>Mol Immunol</source>
          <volume>56</volume>
          <issue>3</issue>
          <year>2013</year>
          <fpage>232</fpage>
          <lpage>239</lpage>
          <pub-id pub-id-type="pmid">23787367</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0028">
        <label>28</label>
        <element-citation publication-type="journal" id="sbref0028">
          <person-group person-group-type="author">
            <name>
              <surname>Waehre</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yndestad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors</article-title>
          <source>Circulation</source>
          <volume>109</volume>
          <issue>16</issue>
          <year>2004</year>
          <fpage>1966</fpage>
          <lpage>1972</lpage>
          <pub-id pub-id-type="pmid">15051633</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0029">
        <label>29</label>
        <element-citation publication-type="journal" id="sbref0029">
          <person-group person-group-type="author">
            <name>
              <surname>Freigang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ampenberger</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Weiss</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1alpha and sterile vascular inflammation in atherosclerosis</article-title>
          <source>Nat Immunol</source>
          <volume>14</volume>
          <issue>10</issue>
          <year>2013</year>
          <fpage>1045</fpage>
          <lpage>1053</lpage>
          <pub-id pub-id-type="pmid">23995233</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0030">
        <label>30</label>
        <element-citation publication-type="journal" id="sbref0030">
          <person-group person-group-type="author">
            <name>
              <surname>Pilely</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rosbjerg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Genster</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Cholesterol crystals activate the Lectin complement pathway via ficolin-2 and mannose-binding lectin: implications for the progression of atherosclerosis</article-title>
          <source>J Immunol</source>
          <volume>196</volume>
          <issue>12</issue>
          <year>2016</year>
          <fpage>5064</fpage>
          <lpage>5074</lpage>
          <pub-id pub-id-type="pmid">27183610</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0031">
        <label>31</label>
        <element-citation publication-type="journal" id="sbref0031">
          <person-group person-group-type="author">
            <name>
              <surname>Paramel Varghese</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Folkersen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Strawbridge</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis</article-title>
          <source>J Am Heart Assoc</source>
          <volume>5</volume>
          <issue>5</issue>
          <year>2016</year>
        </element-citation>
      </ref>
      <ref id="bib0032">
        <label>32</label>
        <element-citation publication-type="journal" id="sbref0032">
          <person-group person-group-type="author">
            <name>
              <surname>Baumer</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Dey</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Gutierrez-Huerta</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Hyperlipidaemia and IFNgamma/TNFalpha synergism are associated with cholesterol crystal formation in endothelial cells partly through modulation of Lysosomal ph and cholesterol homeostasis</article-title>
          <source>EBioMedicine</source>
          <year>2020</year>
          <object-id pub-id-type="publisher-id">102876</object-id>
        </element-citation>
      </ref>
      <ref id="bib0033">
        <label>33</label>
        <element-citation publication-type="journal" id="sbref0033">
          <person-group person-group-type="author">
            <name>
              <surname>Warnatsch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ioannou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Papayannopoulos</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis</article-title>
          <source>Science</source>
          <volume>349</volume>
          <issue>6245</issue>
          <year>2015</year>
          <fpage>316</fpage>
          <lpage>320</lpage>
          <pub-id pub-id-type="pmid">26185250</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0034">
        <label>34</label>
        <element-citation publication-type="journal" id="sbref0034">
          <person-group person-group-type="author">
            <name>
              <surname>Folco</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Mawson</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Vromman</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil Extracellular traps induce endothelial cell activation and tissue factor production through interleukin-1alpha and cathepsin G</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <volume>38</volume>
          <issue>8</issue>
          <year>2018</year>
          <fpage>1901</fpage>
          <lpage>1912</lpage>
          <pub-id pub-id-type="pmid">29976772</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0035">
        <label>35</label>
        <element-citation publication-type="journal" id="sbref0035">
          <person-group person-group-type="author">
            <name>
              <surname>Vromman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ruvkun</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Shvartz</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis</article-title>
          <source>Eur Heart J</source>
          <volume>40</volume>
          <issue>30</issue>
          <year>2019</year>
          <fpage>2482</fpage>
          <lpage>2491</lpage>
          <pub-id pub-id-type="pmid">30698710</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0036">
        <label>36</label>
        <element-citation publication-type="journal" id="sbref0036">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>NF</given-names>
            </name>
          </person-group>
          <article-title>Single-cell immune landscape of human atherosclerotic plaques</article-title>
          <source>Nat Med</source>
          <volume>25</volume>
          <issue>10</issue>
          <year>2019</year>
          <fpage>1576</fpage>
          <lpage>1588</lpage>
          <pub-id pub-id-type="pmid">31591603</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0037">
        <label>37</label>
        <element-citation publication-type="journal" id="sbref0037">
          <person-group person-group-type="author">
            <name>
              <surname>Ridker</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Everett</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Thuren</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Antiinflammatory therapy with canakinumab for atherosclerotic disease</article-title>
          <source>N Engl J Med</source>
          <volume>377</volume>
          <issue>12</issue>
          <year>2017</year>
          <fpage>1119</fpage>
          <lpage>1131</lpage>
          <pub-id pub-id-type="pmid">28845751</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0038">
        <label>38</label>
        <element-citation publication-type="journal" id="sbref0038">
          <person-group person-group-type="author">
            <name>
              <surname>Alexander</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Moehle</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice</article-title>
          <source>J Clin Invest</source>
          <volume>122</volume>
          <issue>1</issue>
          <year>2012</year>
          <fpage>70</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="pmid">22201681</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0039">
        <label>39</label>
        <element-citation publication-type="journal" id="sbref0039">
          <person-group person-group-type="author">
            <name>
              <surname>Kolev</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Le Friec</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kemper</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Complement&#x2013;tapping into new sites and effector systems</article-title>
          <source>Nat Rev Immunol</source>
          <volume>14</volume>
          <issue>12</issue>
          <year>2014</year>
          <fpage>811</fpage>
          <lpage>820</lpage>
          <pub-id pub-id-type="pmid">25394942</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0040">
        <label>40</label>
        <element-citation publication-type="journal" id="sbref0040">
          <person-group person-group-type="author">
            <name>
              <surname>Liszewski</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Kolev</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Le Friec</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation</article-title>
          <source>Immunity</source>
          <volume>39</volume>
          <issue>6</issue>
          <year>2013</year>
          <fpage>1143</fpage>
          <lpage>1157</lpage>
          <pub-id pub-id-type="pmid">24315997</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0041">
        <label>41</label>
        <element-citation publication-type="journal" id="sbref0041">
          <person-group person-group-type="author">
            <name>
              <surname>Ouyang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Rutz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Crellin</surname>
              <given-names>NK</given-names>
            </name>
            <name>
              <surname>Valdez</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Hymowitz</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
          <article-title>Regulation and functions of the IL-10 family of cytokines in inflammation and disease</article-title>
          <source>Annu Rev Immunol</source>
          <volume>29</volume>
          <year>2011</year>
          <fpage>71</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="pmid">21166540</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0042">
        <label>42</label>
        <element-citation publication-type="journal" id="sbref0042">
          <person-group person-group-type="author">
            <name>
              <surname>Engstr&#xF6;m</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hedblad</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Janzon</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lindg&#xE4;rde</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study</article-title>
          <source>Eur J Cardiovasc Prev Rehabil</source>
          <volume>14</volume>
          <issue>3</issue>
          <year>2007</year>
          <fpage>392</fpage>
          <lpage>397</lpage>
          <pub-id pub-id-type="pmid">17568238</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0043">
        <label>43</label>
        <element-citation publication-type="journal" id="sbref0043">
          <person-group person-group-type="author">
            <name>
              <surname>Speidl</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Exner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Amighi</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis</article-title>
          <source>Eur Heart J</source>
          <volume>26</volume>
          <issue>21</issue>
          <year>2005</year>
          <fpage>2294</fpage>
          <lpage>2299</lpage>
          <pub-id pub-id-type="pmid">15917276</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="sec0031" sec-type="supplementary-material">
      <label>Appendix</label>
      <title>Supplementary materials</title>
      <p id="para0048a">
        <supplementary-material content-type="local-data" id="ecom0001">
          <media xlink:href="mmc1.pdf">
            <alt-text>Image, application 1</alt-text>
          </media>
        </supplementary-material>
      </p>
    </sec>
    <fn-group>
      <fn id="sec0030" fn-type="supplementary-material">
        <p id="para0006a">Supplementary material associated with this article can be found, in the online version, at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ebiom.2020.102985" id="interref0001">doi:10.1016/j.ebiom.2020.102985</ext-link>.</p>
      </fn>
    </fn-group>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Thromb J</journal-id>
      <journal-id journal-id-type="iso-abbrev">Thromb J</journal-id>
      <journal-title-group>
        <journal-title>Thrombosis Journal</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1477-9560</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">7467753</article-id>
      <article-id pub-id-type="publisher-id">229</article-id>
      <article-id pub-id-type="doi">10.1186/s12959-020-00229-8</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>SARS-CoV-2 and pulmonary embolism: who stole the platelets?</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Tran</surname>
            <given-names>Michael</given-names>
          </name>
          <address>
            <email>TRANM2@ccf.org</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sheth</surname>
            <given-names>Chirag</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bhandari</surname>
            <given-names>Rohan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9616-1540</contrib-id>
          <name>
            <surname>Cameron</surname>
            <given-names>Scott J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hornacek</surname>
            <given-names>Deborah</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.239578.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 0675 4725</institution-id><institution>Heart Vascular and Thoracic Institute, Department of Cardiovascular Medicine, Section of Vascular Medicine, Cleveland Clinic Foundation, </institution></institution-wrap>Desk J-35, Cleveland Clinic Foundation, Cleveland, OH 44195 USA </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.254293.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0435 0569</institution-id><institution>Department of Cardiovascular and Metabolic Sciences. Cleveland Clinic Lerner College of Medicine, </institution></institution-wrap>Cleveland, OH 44195 USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>3</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>3</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>18</volume>
      <elocation-id>16</elocation-id>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>5</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>7</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2020</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p id="Par1">Patients infected with&#xA0;SARS-CoV-2 often develop venous and arterial thrombosis. The high patient mortality is partly attributed to thrombotic events. An emerging trend is the presence of immunological phenomena including antiphospholipid antibodies which may promote thrombosis. The mechanism for these observations is not clear though many patients with SARS-CoV-2 develop thrombocytopenia.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p id="Par2">We describe a patient with SARS-CoV-2 pneumonitis who presented with intermediate risk pulmonary embolism (PE). Careful attention to his daily platelet count suggested the possibility of immune mediated heparin-induced thrombocytopenia (HIT) which was confirmed by laboratory testing and resolved when anticoagulation was switched to a direct thrombin inhibitor.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p id="Par3">Since excessive platelet activation and in situ thrombosis occur in HIT, this case underscores the need to consider that thrombocytopenia in patients with SARS-CoV-2&#x2014;most of whom receive heparinoids&#x2014;may be unrecognized HIT. A central role for the platelet in the etiology of thrombosis during the COVID-19 pandemic should be explored.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Pulmonary embolism</kwd>
        <kwd>HIT</kwd>
        <kwd>SARS-CoV-2</kwd>
        <kwd>COVID-19</kwd>
        <kwd>Thrombosis</kwd>
        <kwd>Heparin</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p id="Par4">Critically ill patients with COVID-19 infection often have multiple abnormalities in hemostasis and thrombosis. Recent literature documents hematologic derangements including mild thrombocytopenia [<xref ref-type="bibr" rid="CR1">1</xref>], elevated d-dimer [<xref ref-type="bibr" rid="CR2">2</xref>], prolonged activated partial-thromboplastin time (aPTT), and disseminated intravascular coagulation (DIC) [<xref ref-type="bibr" rid="CR3">3</xref>]. It is unclear whether these changes reflect SARS-CoV-2 infection, or an inflammatory state of acute illness. The recent medical literature reports multiple anticoagulation strategies to prevent thrombotic events in patients infected with SARS-CoV-2. Emerging reports suggest the possibility of HIT developing in SARS-CoV-2 patients receiving heparin anticoagulation [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. This case was a diagnostic dilemma since both thrombocytopenia and in situ pulmonary thrombosis are common features of SARS-CoV-2 infection [<xref ref-type="bibr" rid="CR6">6</xref>], making less common diagnoses, such as HIT, which shares similar features, more challenging to diagnose.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p id="Par5">A 62-year-old man with type 2 diabetes mellitus presented to the emergency department (ED) with 4-day history fever, cough, and dyspnea. The patient&#x2019;s vitals in the ED were as follows: Temperature 39.2&#x2009;&#xB0;C (102.6&#x2009;&#xB0;F), blood pressure 167/67&#x2009;mmHg, heart rate 135 beats per min, respiratory rate 22 breaths per minute, oxygen saturation 74% on room air. The SaO<sub>2</sub> improved to 96% with oxygen therapy at 10&#x2009;L/minute by non-rebreather mask. Relevant laboratory data was as follows: white blood count 13.9&#x2009;K/uL, platelet 412&#x2009;K/uL, sodium 126&#x2009;mmol/L, creatinine 0.7&#x2009;mg/dL. Chest radiography showed bilateral diffuse patchy airspace opacities. There was concern for COVID-19 which was confirmed by polymerase chain reaction (PCR) for the SARS-CoV-2 amplicon. The patient developed hypoxemic respiratory failure the following day and was placed on mechanical ventilation. Over a 10-day time period, the patient was treated with investigational therapies for COVID-19 including azithromycin, hydroxychloroquine, and convalescent plasma. The anticoagulation regimen consisted of subcutaneous enoxaparin (60&#x2009;mg once daily) for venous thromboembolism (VTE) prophylaxis. Intravenous unfractionated heparin (UFH) flushes were used to maintain patency of vascular access. The patient was subsequently transferred to our tertiary medical center on hospital day 12 for further management.</p>
      <p id="Par6">Bedside echocardiography suggested right ventricular (RV) dilation, raising the possibility of pulmonary embolism (PE). Venous Duplex of the lower extremities was unremarkable. Chest computed tomography angiography (CTA) demonstrated right upper lobe lobar and segmental PE (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Relevant laboratory data included hemoglobin 11.1&#x2009;g/dL, platelets 487&#x2009;k/uL, creatinine 0.93&#x2009;mg/dL, pro-BNP 7600&#x2009;pg/mL, troponin T&#x2009;&lt;&#x2009;0.01&#x2009;ng/mL, d-dimer 11,040&#x2009;ng/mL, activated partial thromboplastin time (aPTT) 24.2&#x2009;s, prothrombin time (PT) 14&#x2009;s, fibrinogen 661&#x2009;mg/dL. The patient had an equivocal cardiolipin IgM antibody of 15 IgG phospholipid units (MPL) since our reference range is &lt;&#x2009;12 MPL, and beta-2 glycoprotein antibodies were negative. Using the patient&#x2019;s PT, d-dimer, and measured fibrinogen concentration of 661&#x2009;mg/dL his DIC score is 6 which was&#xA0;compatible with overt DIC.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Computed tomography (CT) of chest showing a filling defect in the right upper labor pulmonary artery extending into the segmental and subsegmental pulmonary branches consistent with an acute pulmonary embolism (yellow arrowhead). Patchy infiltrates are indicated by the red arrowhead</p></caption><graphic xlink:href="12959_2020_229_Fig1_HTML" id="MO1"/></fig></p>
      <p id="Par7">A multidisciplinary pulmonary embolism response team (PERT) reviewed the patient&#x2019;s case and recommended therapeutic anticoagulation with intravenous UFH dosed at 18&#x2009;units/kg/hr and monitored by the anti-Xa chromogenic assay. The patient&#x2019;s platelet count decreased from 487&#x2009;k/uL to a nadir of 91&#x2009;k/uL over the following 4 days, raising the concern for heparin induced thrombocytopenia (HIT) with an intermediate pretest probability by the 4Ts score of 4 (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Heparin products were exchanged for the direct thrombin inhibitor (DTI) bivalirudin dosed at 0.19&#x2009;mg/kg/hr and&#xA0;monitored with activated partial thromboplastin time with a goal of 46 to 65&#x2009;s. IgG specific anti-platelet factor 4 (PF4)-heparin enzyme linked immunosorbent assay (ELISA) was quite positive (optical density 1.08, normal value &lt;&#x2009;0.4). The heparin induced platelet aggregation (HIPA) functional assay was also positive, confirming the diagnosis of HIT. The patient&#x2019;s platelet count increased to 279&#x2009;k/uL three days after the discontinuation of UFH (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). The patient responded favorably to anticoagulation with a DTI without new thrombotic complications.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>4Ts Score for Heparin-Induced Thrombocytopenia</p></caption><table frame="hsides" rules="groups"><thead><tr><th>4Ts pretest probability</th><th>Score</th><th>4</th></tr></thead><tbody><tr><td>Thrombocytopenia</td><td>Platelet count fall &gt;&#x2009;50% and platelet nadir &gt;&#x2009;20</td><td>2</td></tr><tr><td>Timing of platelet count fall</td><td>Onset after day 10 of heparin exposure</td><td>1</td></tr><tr><td>Thrombosis or other sequelae</td><td>No new thrombosis</td><td>0</td></tr><tr><td>Other causes for thrombocytopenia</td><td>Possible other causes</td><td>1</td></tr></tbody></table></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Platelet count and time points for anticoagulation administration and laboratory testing</p></caption><graphic xlink:href="12959_2020_229_Fig2_HTML" id="MO2"/></fig></p>
      <p id="Par8">HIT is an acquired immune-mediated complication associated with UFH or LMWH administration in which platelets become haptenized [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], creating a prothrombotic state that can be limb- or life-threatening due to venous or arterial thrombosis. The most common clinical manifestation of HIT is thrombocytopenia (platelet count &lt;&#x2009;150&#x2009;k/uL) in 85&#x2013;90% of patients between 5 and 10&#x2009;days after initiating heparin products. The incidence of HIT is &lt;&#x2009;0.1&#x2013;7% depending on clinical context, the heparin product used, and duration and dose of exposure [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p>
      <p id="Par9">HIT develops when immunoglobulin G (IgG) antibodies recognize PF4-heparin complexes and activate platelet surface Fc&#x3B3; receptors. This step activates platelets which degranulate and aggregate as thrombi [<xref ref-type="bibr" rid="CR10">10</xref>]. Laboratory evaluation includes an IgG-specific anti-PF4 immunoassay which has high sensitivity but sometimes low specificity for activated platelets. Interestingly, this assay also detects non-platelet activating anti-PF4/heparin antibodies [<xref ref-type="bibr" rid="CR11">11</xref>]. The diagnosis is supported by demonstrating IgG anti-PF4-heparin mediated platelet activation using washed platelets with functional assays such as the HIPA and serotonin release assay (SRA) [<xref ref-type="bibr" rid="CR12">12</xref>]. The assay performance of these two offers superior sensitivity and specificity in detection of pathogenic platelet activating antibodies. As a clinicopathologic syndrome, the diagnosis of HIT depends on taking a careful history and having temporal awareness of the exposure to heparinoids [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
    </sec>
    <sec id="Sec3">
      <title>Conclusions</title>
      <p id="Par10">It is clear that patients infected with SARS-CoV-2 have unusual immunological phenomena including the presence of anti-phospholipid antibodies [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The training of the internist is instinctually drawn to a broad differential diagnosis which is now more important than ever in the COVID-19 era. Early recognition and treatment for other immunologic phenomena such as HIT should be considered for every patient since thrombosis with thrombocytopenia often co-exist. Further study is required to determine if undiagnosed HIT contributes to the dramatically high number of thrombotic events in patients with SARS-CoV-2 infection.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher&#x2019;s Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; contributions</title>
      <p>All authors participated in writing of the manuscript and have reviewed and approved the submitted version.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>This study was not supported by external funds.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Availability of data and materials</title>
      <p>The datasets obtained and analyzed in the current study are available from the corresponding author on reasonable request.</p>
    </notes>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par11">Ethics approval was waived given there is no unique, identifiable information, and case reports do not require ethical approval in the United States. Our report adheres to the Ethical Guidelines for Medical and Health Research Involving Human Subjects established by the government Unites States.</p>
    </notes>
    <notes id="FPar2">
      <title>Ethics approval</title>
      <p id="Par12">No identifiable information or unique patient data is included.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par13">None.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lippi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Plebani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Henry</surname>
              <given-names>BM</given-names>
            </name>
          </person-group>
          <article-title>Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis</article-title>
          <source>Clinica chimica acta</source>
          <year>2020</year>
          <volume>506</volume>
          <fpage>145</fpage>
          <lpage>148</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cca.2020.03.022</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lippi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Favaloro</surname>
              <given-names>EJ</given-names>
            </name>
          </person-group>
          <article-title>D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis</article-title>
          <source>Thromb Haemost</source>
          <year>2020</year>
          <volume>120</volume>
          <issue>05</issue>
          <fpage>876</fpage>
          <lpage>878</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0040-1709650</pub-id>
          <pub-id pub-id-type="pmid">32246450</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title>
          <source>J Thromb Haemost</source>
          <year>2020</year>
          <volume>18</volume>
          <issue>4</issue>
          <fpage>844</fpage>
          <lpage>847</lpage>
          <pub-id pub-id-type="doi">10.1111/jth.14768</pub-id>
          <pub-id pub-id-type="pmid">32073213</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="other">Liu X, Zhang X, Xiao Y, Gao T, Wang G, Wang Z, et al. Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment. medRxiv. 2020:20076851.</mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="other">Riker RR, May TL, Fraser GL, Gagnon DJ, Bandara M, Zemrak W, et al. Heparin-induced Thrombocytopenia with Thrombosis in COVID-19 Adult Respiratory Distress Syndrome. Res Pract Thromb Haemost. 2020. 10.1002/rth2.12390.</mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="other">Wichmann D, Sperhake J-P, L&#xFC;tgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. 2020.</mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amiral</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bridey</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Dreyfus</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vissoc</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Fressinaud</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia</article-title>
          <source>Thromb Haemost</source>
          <year>1992</year>
          <volume>68</volume>
          <issue>1</issue>
          <fpage>95</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0038-1656329</pub-id>
          <pub-id pub-id-type="pmid">1514184</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>J-AI</given-names>
            </name>
            <name>
              <surname>Horsewood</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Kelton</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Impact of the patient population on the risk for heparin-induced thrombocytopenia</article-title>
          <source>Blood.</source>
          <year>2000</year>
          <volume>96</volume>
          <issue>5</issue>
          <fpage>1703</fpage>
          <lpage>1708</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.V96.5.1703</pub-id>
          <pub-id pub-id-type="pmid">10961867</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis</article-title>
          <source>Blood.</source>
          <year>2005</year>
          <volume>106</volume>
          <issue>8</issue>
          <fpage>2710</fpage>
          <lpage>2715</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2005-04-1546</pub-id>
          <pub-id pub-id-type="pmid">15985543</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greinacher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Eichler</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lubenow</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kwasny</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Luz</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range</article-title>
          <source>Blood.</source>
          <year>2000</year>
          <volume>96</volume>
          <issue>3</issue>
          <fpage>846</fpage>
          <lpage>851</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.V96.3.846</pub-id>
          <pub-id pub-id-type="pmid">10910895</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>WARKENTIN</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Greinacher</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gruel</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Rh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bh</surname>
              <given-names>C</given-names>
            </name>
            <collab>scientific obot</collab>
            <etal/>
          </person-group>
          <article-title>Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis</article-title>
          <source>J Thromb Haemost</source>
          <year>2011</year>
          <volume>9</volume>
          <issue>12</issue>
          <fpage>2498</fpage>
          <lpage>2500</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2011.04536.x</pub-id>
          <pub-id pub-id-type="pmid">22947414</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chong</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Burgess</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ismail</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia</article-title>
          <source>Thromb Haemost</source>
          <year>1993</year>
          <volume>69</volume>
          <issue>04</issue>
          <fpage>344</fpage>
          <lpage>350</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0038-1651610</pub-id>
          <pub-id pub-id-type="pmid">8497847</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
          </person-group>
          <article-title>Laboratory diagnosis of heparin-induced thrombocytopenia</article-title>
          <source>Int J Lab Hematol</source>
          <year>2019</year>
          <volume>41</volume>
          <issue>S1</issue>
          <fpage>15</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="doi">10.1111/ijlh.12993</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Coagulopathy and Antiphospholipid antibodies in patients with Covid-19</article-title>
          <source>N Engl J Med</source>
          <year>2020</year>
          <volume>382</volume>
          <issue>17</issue>
          <fpage>e38</fpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc2007575</pub-id>
          <pub-id pub-id-type="pmid">32268022</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="other">Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med. 2020.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Sensors (Basel)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Sensors (Basel)</journal-id>
      <journal-id journal-id-type="publisher-id">sensors</journal-id>
      <journal-title-group>
        <journal-title>Sensors (Basel, Switzerland)</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1424-8220</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32751629</article-id>
      <article-id pub-id-type="pmc">7435714</article-id>
      <article-id pub-id-type="doi">10.3390/s20154254</article-id>
      <article-id pub-id-type="publisher-id">sensors-20-04254</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Point-of-Care Diagnostics in Coagulation Management</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2030-0313</contrib-id>
          <name>
            <surname>Sahli</surname>
            <given-names>Sebastian D.</given-names>
          </name>
          <xref ref-type="aff" rid="af1-sensors-20-04254">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>R&#xF6;ssler</surname>
            <given-names>Julian</given-names>
          </name>
          <xref ref-type="aff" rid="af1-sensors-20-04254">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4284-6859</contrib-id>
          <name>
            <surname>Tscholl</surname>
            <given-names>David W.</given-names>
          </name>
          <xref ref-type="aff" rid="af1-sensors-20-04254">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Studt</surname>
            <given-names>Jan-Dirk</given-names>
          </name>
          <xref ref-type="aff" rid="af2-sensors-20-04254">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Spahn</surname>
            <given-names>Donat R.</given-names>
          </name>
          <xref ref-type="aff" rid="af1-sensors-20-04254">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kaserer</surname>
            <given-names>Alexander</given-names>
          </name>
          <xref ref-type="aff" rid="af1-sensors-20-04254">1</xref>
          <xref rid="c1-sensors-20-04254" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-sensors-20-04254"><label>1</label>Institute of Anesthesiology, University and University Hospital Zurich, 8091 Zurich, Switzerland; <email>sebastian.sahli@usz.ch</email> (S.D.S.); <email>julian.roessler@usz.ch</email> (J.R.); <email>david.tscholl@usz.ch</email> (D.W.T.); <email>donat.spahn@usz.ch</email> (D.R.S.)</aff>
      <aff id="af2-sensors-20-04254"><label>2</label>Division of Hematology, University and University Hospital Zurich, 8091 Zurich, Switzerland; <email>jan-dirk.studt@usz.ch</email></aff>
      <author-notes>
        <corresp id="c1-sensors-20-04254"><label>*</label>Correspondence: <email>alexander.kaserer@usz.ch</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>7</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>8</month>
        <year>2020</year>
      </pub-date>
      <volume>20</volume>
      <issue>15</issue>
      <elocation-id>4254</elocation-id>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>6</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>7</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2020 by the authors.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <license license-type="open-access">
          <license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>This review provides a comprehensive and up-to-date overview of point-of-care (POC) devices most commonly used for coagulation analyses in the acute settings. Fast and reliable assessment of hemostasis is essential for the management of trauma and other bleeding patients. Routine coagulation assays are not designed to visualize the process of clot formation, and their results are obtained only after 30&#x2013;90 m due to the requirements of sample preparation and the analytical process. POC devices such as viscoelastic coagulation tests, platelet function tests, blood gas analysis and other coagulometers provide new options for the assessment of hemostasis, and are important tools for an individualized, goal-directed, and factor-based substitution therapy. We give a detailed overview of the related tests, their characteristics and clinical implications. This review emphasizes the evident advantages of the speed and predictive power of POC clot measurement in the context of a goal-directed and algorithm-based therapy to improve the patient&#x2019;s outcome. Interpretation of viscoelastic tests is facilitated by a new visualization technology.</p>
      </abstract>
      <kwd-group>
        <kwd>hemorrhage</kwd>
        <kwd>coagulation management</kwd>
        <kwd>ROTEM<sup>&#xAE;</sup></kwd>
        <kwd>platelet function test</kwd>
        <kwd>point-of-care systems</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-sensors-20-04254">
      <title>1. Introduction</title>
      <p>Severe bleeding, e.g., after trauma or during surgery, requires adequate coagulation management [<xref rid="B1-sensors-20-04254" ref-type="bibr">1</xref>]. For this purpose, point-of-care (POC) tests allow a fast assessment of the hemostasis, and provide important guidance when a coagulation algorithm is used [<xref rid="B2-sensors-20-04254" ref-type="bibr">2</xref>,<xref rid="B3-sensors-20-04254" ref-type="bibr">3</xref>]. If bleeding is aggravated by coagulopathy, the negative impact on survival is significant [<xref rid="B4-sensors-20-04254" ref-type="bibr">4</xref>]. A factor-based coagulation management guided by POC diagnostics is therefore considered the gold standard in hemostatic resuscitation [<xref rid="B1-sensors-20-04254" ref-type="bibr">1</xref>]; it leads to a decreased transfusion requirement and improved outcome in patients with major trauma [<xref rid="B2-sensors-20-04254" ref-type="bibr">2</xref>,<xref rid="B5-sensors-20-04254" ref-type="bibr">5</xref>], undergoing cardiac surgery [<xref rid="B6-sensors-20-04254" ref-type="bibr">6</xref>,<xref rid="B7-sensors-20-04254" ref-type="bibr">7</xref>] or suffering from postpartum hemorrhage [<xref rid="B8-sensors-20-04254" ref-type="bibr">8</xref>,<xref rid="B9-sensors-20-04254" ref-type="bibr">9</xref>].</p>
      <p>This review provides a comprehensive and up-to-date overview of point-of-care (POC) devices most commonly used for coagulation analyses in the acute settings. POC testing refers to laboratory analyses that are performed at the site where the patient is treated. We divide the POC assays for coagulation management into three major groups: (1) combined assessment of clotting time and clot quality and stability (viscoelastic methods); (2) analyzers of the platelet function and (3) analyzers of the plasmatic coagulation (coagulometers). In addition, blood gas analyzers are addressed because they provide important physiological parameters. For a correct application, a detailed knowledge of the assay&#x2019;s functional characteristics and limitations is required. In addition to this, we will also focus on the important issue of their clinical application.</p>
      <p>While fundamental physiological parameters like acidosis, electrolyte shifts or anemia can be evaluated instantly in the extended blood gas analysis, the assessment of hemostasis is more challenging. Standard coagulation assays such as prothrombin time (PT), activated partial prothrombin time (aPTT) or thrombin time (TT) are not designed to visualize the process of clot formation or clot stability [<xref rid="B3-sensors-20-04254" ref-type="bibr">3</xref>]. Moreover, because of the processes of sample preparation and centrifugation, analysis and validation of the results standard laboratory results are available only after 30&#x2013;90 m [<xref rid="B10-sensors-20-04254" ref-type="bibr">10</xref>] or even later. They are therefore of limited value for coagulation management in the initial acute phase, especially if repetitive analyses are needed [<xref rid="B11-sensors-20-04254" ref-type="bibr">11</xref>]. A faster alternative is POC assays, which include viscoelastic coagulation tests, platelet function tests and coagulometers. They allow the assessment of clot formation, clot stability and clot lysis in real-time, also to evaluate for a possible intake of oral anticoagulants or platelet inhibitors. This review cannot present all of the available POC devices, and focuses on the most widely available and commonly used tests.</p>
    </sec>
    <sec id="sec2-sensors-20-04254">
      <title>2. Standard Laboratory Coagulation Tests</title>
      <p>The bleeding time was first used to assess the global hemostasis in vivo [<xref rid="B12-sensors-20-04254" ref-type="bibr">12</xref>]. Being an invasive test, its reproducibility is poor and it was therefore abandoned. A model of the plasmatic coagulation (see <xref ref-type="fig" rid="sensors-20-04254-f001">Figure 1</xref>) distinguishes an extrinsic pathway, which starts with tissue factor/factor VII activation, an intrinsic pathway that is activated by contact factors, and a common pathway comprising the coagulation factors II, V and X [<xref rid="B13-sensors-20-04254" ref-type="bibr">13</xref>]. The coagulation cascade is a tightly controlled series of enzymatic and cell-based reactions, designed to generate thrombin, which converts fibrinogen to fibrin, and requires co-factors such as phospholipids and calcium ions. It is usually subdivided into an initiation phase, an amplification phase and a propagation phase [<xref rid="B14-sensors-20-04254" ref-type="bibr">14</xref>].</p>
      <p>Global tests of coagulation are the prothrombin time (PT), which reflects the extrinsic pathway of the coagulation cascade, and the activated partial thromboplastin time (aPTT), which reflects the intrinsic pathway. PT, described first by Quick in 1935 [<xref rid="B15-sensors-20-04254" ref-type="bibr">15</xref>], is still referred as &#x201C;Quick&#x2019;s PT&#x201D; or &#x201C;Quick value&#x201D;. Originally developed to determine PT (factor II of the coagulation cascade), it is now clear that it depends especially on factor VII together with the factors X, V, II and fibrinogen. Changes over time have made the test more specific for the vitamin K dependent clotting factors (VII, X, V and II). The initiation of clotting, specifically of the intrinsic pathway, is naturally triggered by negatively charged phospholipid surfaces (platelet effect). This reaction is artificially replaced by contact phase activators. In the past through cephalin, currently through minerals as kaolin or celite and more rarely silica or glass dust. The aPTT depends initially on factor XII and XI and reflects the intrinsic pathway, especially factors VIII, IX and XI. Originally designed in 1953 by Langdell et al. [<xref rid="B16-sensors-20-04254" ref-type="bibr">16</xref>] as a simple one-stage test for hemophilia. At that time the test was activated by cephalin (phospholipid) and consequently replaced by kaolin (mineral) to optimize the contact phase [<xref rid="B17-sensors-20-04254" ref-type="bibr">17</xref>]. Both tests, PT and aPTT, reflect the common pathway of factors II, X and XIII. The thrombin time (TT) covers the final step of fibrin polymerization. These tests are however performed in a standardized and artificial setting. They reflect the situation in vivo only partially, and may be influenced by a variety of preanalytical factors. Similarly, fibrinogen according to Clauss [<xref rid="B18-sensors-20-04254" ref-type="bibr">18</xref>], which is a modification of TT and the most commonly used assay method may overestimate the fibrinogen concentration in the presence of hydroxyethyl starch (but not gelatin) [<xref rid="B19-sensors-20-04254" ref-type="bibr">19</xref>].</p>
    </sec>
    <sec id="sec3-sensors-20-04254">
      <title>3. Viscoelastic Tests</title>
      <p>Viscoelastic testing was first described by Hartert in 1948 [<xref rid="B20-sensors-20-04254" ref-type="bibr">20</xref>], and was established in the following years. Initially, a non-activated clot measurement was performed, which led to variability and longer measurement times. The test was also susceptible to vibration, which limited the use of viscoelastic tests. Today, the tests are initiated with citrated whole blood and defined activators or inhibitors. The thrombelastographic system (TEG<sup>&#xAE;</sup>) is in use more often in America, and the rotational thrombelastic system (ROTEM<sup>&#xAE;</sup>) in Europe. Different from standard coagulation assays, viscoelastic methods display clot formation and clot stability in real time. They permit detection of a delayed initiation of coagulation, a reduced fibrinogen level, an increased fibrinolytic activity and of the platelets&#x2019; contribution in whole blood. Viscoelastic assays are fast and give first results within 5&#x2013;10 m. In <xref ref-type="sec" rid="sec3dot4-sensors-20-04254">Section 3.4</xref> we focused on the clinical impact of these early parameters. Viscoelastic tests are of an advantage in acute situations such as trauma-induced coagulopathy, transfusions management, intra- and postoperative bleeding and targeted hemostatic therapy. Using guidance by viscoelastic tests, superior outcomes in trauma patients [<xref rid="B5-sensors-20-04254" ref-type="bibr">5</xref>,<xref rid="B11-sensors-20-04254" ref-type="bibr">11</xref>], cardiac surgery [<xref rid="B6-sensors-20-04254" ref-type="bibr">6</xref>,<xref rid="B7-sensors-20-04254" ref-type="bibr">7</xref>] and postpartum hemorrhage [<xref rid="B8-sensors-20-04254" ref-type="bibr">8</xref>,<xref rid="B9-sensors-20-04254" ref-type="bibr">9</xref>] are proved. Further, they allow the detection of a delayed coagulation initiation, diminished fibrinogen level, an increased fibrinolytic activity and of the platelet level in whole blood [<xref rid="B21-sensors-20-04254" ref-type="bibr">21</xref>]. They may also indicate the presence of anticoagulants, and give additional information in patients with hypercoagulability [<xref rid="B22-sensors-20-04254" ref-type="bibr">22</xref>] or substitution therapy in hemophiliacs [<xref rid="B23-sensors-20-04254" ref-type="bibr">23</xref>]. Commonly used viscoelastic assays and their clinical applications are described in the next chapters.</p>
      <sec id="sec3dot1-sensors-20-04254">
        <title>3.1. Rotational Thrombelastometry-ROTEM<sup>&#xAE;</sup></title>
        <p>Rotational thrombelastometry (ROTEM<sup>&#xAE;</sup>, Instrumentation Laboratory, Bedford, MA, USA) displays the processes of clot formation and subsequent clot lysis in a direct graphical manner. 300 &#xB5;L of citrated whole blood is incubated at 37 &#xB0;C in a cup using a software-controlled and self-guided pipette. The cuvette is fixed, and a pin is inserted into the blood and rotates alternately with an angle of 4&#xB0;75&#x2019; around its longitudinal axis. Recalcification activates the clotting in the cup. Different reagents are added to classify the hemostasis defect. A signal is generated, and translated from the pin via an optical detector into a visual graph [<xref rid="B22-sensors-20-04254" ref-type="bibr">22</xref>]. The ROTEM<sup>&#xAE;</sup> delta system provides four channels for parallel testing different aspects of the patient&#x2019;s hemostasis (see <xref ref-type="fig" rid="sensors-20-04254-f002">Figure 2</xref>). The new ROTEM<sup>&#xAE;</sup> sigma operates by the same principles. It is automated with ready-to-use cartridges for simultaneous testing.</p>
        <p>Compared with a monoanalysis, the simultaneous assessment of different assays allows a more comprehensive diagnosis [<xref rid="B24-sensors-20-04254" ref-type="bibr">24</xref>]. These assays are described in detail and summarized in <xref rid="sensors-20-04254-t001" ref-type="table">Table 1</xref>: For <bold>EXTEM</bold>, tissue thromboplastin is added to activate the extrinsic pathway of coagulation. The reaction depends on the activity of coagulation factors X, VII, V, II, fibrinogen and platelets. For <bold>INTEM</bold>, ellagic acid and phospholipids are added as contact phase activators. Beside the coagulation factors XII, XI, IX, VIII, X, V and II, clot firmness reflects both platelet and fibrin contribution [<xref rid="B25-sensors-20-04254" ref-type="bibr">25</xref>]. INTEM reflects the intrinsic coagulation pathway. <bold>FIBTEM</bold> is an EXTEM-based assay. Since it contains a potent platelet inhibitor (cytochalasin D), clot formation depends mostly on fibrinogen concentration and fibrin polymerization. Combining FIBTEM and EXTEM permits distinction of thrombocytopenia and hypofibrinogenemia [<xref rid="B26-sensors-20-04254" ref-type="bibr">26</xref>]. <bold>APTEM</bold> is also an EXTEM-based assay using the addition of an antifibrinolytic (earlier aprotinin, now tranexamic acid) to simulate an antifibrinolytic therapy. HEPTEM is an INTEM based assay with the same contact phase activator, and heparinase is added to discriminate between a heparin effect and a high dose of protamine [<xref rid="B27-sensors-20-04254" ref-type="bibr">27</xref>]. Additional assays are available, but are considered less clinically relevant (and therefore used only occasionally or for research purposes). ECATEM uses ecarin as an activator, a viper venom with a thrombin-like effect; this clotting time is altered by direct thrombin inhibitors such as argatroban, bivalirudin or dabigatran but not by heparin. At present, ECATEM is distributed only in Europe [<xref rid="B28-sensors-20-04254" ref-type="bibr">28</xref>]. NATEM does not use a specific activator and the coagulation process is only started by recalcification. It is sensitive to endogenous activators of coagulation, such as a tissue factor expressed on circulating monocytes. It may help to detect pathophysiological changes in trauma-induced coagulopathy and coagulation alterations in sepsis [<xref rid="B29-sensors-20-04254" ref-type="bibr">29</xref>].</p>
        <p>A set of parameters (see <xref ref-type="fig" rid="sensors-20-04254-f003">Figure 3</xref>) was used to characterize clot formation, clot firmness and clot lysis [<xref rid="B30-sensors-20-04254" ref-type="bibr">30</xref>]. These were compared with TEG<sup>&#xAE;</sup> parameters in the next section. During coagulation activation, the clotting time (CT) is defined as the time from the beginning of the test until a clot firmness amplitude of 2 mm was achieved, and reflected the velocity of thrombin generation. The clot formation time (CFT) indicates the time between a clot amplitude of 2 and 20 mm and reflects the kinetics of clot formation. The alpha angle (&#x3B1;) is the tangential angle of the curve between 0 and 20 mm. Clot firmness is described by the maximum clot firmness (MCF), which is the maximal clot amplitude reached and reflects the mechanical strength of the clot. Quickly available parameters are the amplitude of clot firmness 5, 10 or 20 m after CT (A5, A10 and A20, respectively). A5 and A10 correlate especially well with MCF, providing fast and reliable POC information [<xref rid="B31-sensors-20-04254" ref-type="bibr">31</xref>]. Finally, clot lysis is defined by the maximum lysis (ML) as the delta between MCF and the lowest amplitude following MCF. Likewise, the percentage of MCF (lysis index LI), which is present 30 or 60 m after CT (LI30 and LI60, respectively), provide faster information [<xref rid="B32-sensors-20-04254" ref-type="bibr">32</xref>].</p>
      </sec>
      <sec id="sec3dot2-sensors-20-04254">
        <title>3.2. Visual Clot</title>
        <p>Hospitals around the world are using viscoelastic tests for POC coagulation assessment. The way their results are displayed is however not self-explanatory, and their interpretation may be challenging. Visual Clot is a situation awareness-oriented visualization technology for thrombelastometric results [<xref rid="B33-sensors-20-04254" ref-type="bibr">33</xref>]. Examples are shown in <xref ref-type="fig" rid="sensors-20-04254-f004">Figure 4</xref> and <xref ref-type="fig" rid="sensors-20-04254-f005">Figure 5</xref>. An algorithm transforms parameters of rotational thrombelastometry into an animated model of the blood clot under investigation. In a prospective dual-center study [<xref rid="B33-sensors-20-04254" ref-type="bibr">33</xref>], 60 physicians interpreted results assisted by Visual Clot vs. standard procedures, and based therapeutic decisions on their interpretation. Visual Clot resulted in an overall of 100% correct decisions vs. 44% for standard procedures. The perceived cognitive workload using Visual Clot was less, and diagnostic confidence was rated higher. Additionally, the correct interpretation of Visual Clot did not depend on previous knowledge and experience with rotational thrombelastometry. This new technology resulted in a faster and more accurate detection of alterations, and a higher rate of correct therapeutic decisions in simulated cases [<xref rid="B33-sensors-20-04254" ref-type="bibr">33</xref>]. In a mixed qualitative/quantitative study, 92% percent of 42 physicians indicated a preference to have Visual Clot results displayed in addition to the standard result, and most described it as intuitive and easy to learn [<xref rid="B34-sensors-20-04254" ref-type="bibr">34</xref>]. This indicates a potential benefit by the situation awareness-oriented presentation of information, taking into account the capabilities and requirements of human operators. Visual clot was developed by the same research group at the University of Zurich as Visual Patient<sup>&#xAE;</sup>, and both rely on the same graphic principles (details can be found in a recent review article published in <italic>Sensors</italic>) [<xref rid="B35-sensors-20-04254" ref-type="bibr">35</xref>].</p>
        <p>An additional educational video was provided on Visual Clot with different clinical scenarios (e.g., bleeding, hyperfibrinolysis and heparin effect): <uri xlink:href="https://1drv.ms/v/s!AjkumfX_cNxMyiaZ9jV39Cvn1_rD?e=4TD7OO">https://1drv.ms/v/s!AjkumfX_cNxMyiaZ9jV39Cvn1_rD?e=4TD7OO</uri>.</p>
      </sec>
      <sec id="sec3dot3-sensors-20-04254">
        <title>3.3. Thrombelastography&#x2014;TEG<sup>&#xAE;</sup></title>
        <p>Thrombelastography (TEG<sup>&#xAE;</sup>, Haemonetics Corp., Boston, MA, USA) provides information similar to the ROTEM<sup>&#xAE;</sup>, but uses a different technique. While ROTEM<sup>&#xAE;</sup> uses a rotating pin, the TEG<sup>&#xAE;</sup> 5000 uses a cup oscillating by an angle of 4&#xB0;45&#x2019; around the pin. A torsion wire translates the movement into a signal and ultimately into a graph. The test uses citrated whole blood at 37 &#xB0;C. The formation of fibrin filaments between the cuvette wall of and the pin after recalcification and activation inhibits the cup&#x2019;s movement, which is recorded as a curve over time. The new TEG<sup>&#xAE;</sup> 6 s system detects the same physical properties of clot viscoelasticity as the TEG<sup>&#xAE;</sup> 5000 but uses a resonance method. The sample is exposed to vibration at a fixed frequency, which is detected by LED [<xref rid="B36-sensors-20-04254" ref-type="bibr">36</xref>]. This test is fully automated and uses prefabricated microfluid cartridges for simultaneous testing. No pipetting is required.</p>
        <p>Four main TEG<sup>&#xAE;</sup> assays and one native assay were used. An overview is given in <xref rid="sensors-20-04254-t002" ref-type="table">Table 2</xref>. A combination of these assays is important as well. RapidTEG&#x2122; assay contains a tissue factor together with kaolin as activators. Thereby, both the intrinsic and the extrinsic pathway are triggered, similarly to the activated clotting time (ACT). Kaolin assay initiates the contact activation of coagulation and reflects the intrinsic coagulation pathway. Clot firmness reflects the coagulation factors XII, XI, IX, VIII, X, V and II, also platelet and fibrin contribution. The functional fibrinogen assay contains tissue factor for activation together with abciximab, a potent inhibitor of the platelet fibrinogen receptor GPIIb-IIIa, thereby eliminating the contribution of platelets. In comparison with the kaolin assay, it permits a qualitative statement of the contribution of fibrinogen concentration and fibrin polymerization to clot formation. HTEG assay is based on the RapidTEG&#x2122; assay, additionally containing heparinase to neutralize an effect of unfractionated heparin. The Native assay only recalcifies whole blood, generating a long R time [<xref rid="B37-sensors-20-04254" ref-type="bibr">37</xref>].</p>
        <p>The initiation of coagulation is described by the reaction time (R value as the time between the starting of the test and the beginning of clot formation). The K value then describes the kinetics of clot formation, between the end of R until the clot reaches 20 mm. The widest vertical dimension of the graph defined as maximum amplitude (MA) represents the clot strength. Clot lysis (CL) is described by the percentage of the clot lysed after 30 and 60 m (CL30 and CL60).</p>
        <p>As presented in <xref rid="sensors-20-04254-t003" ref-type="table">Table 3</xref>, ROTEM<sup>&#xAE;</sup> and TEG<sup>&#xAE;</sup> parameters were comparable but not interchangeable. Ziegler et al. showed a high degree of correlation of ROTEM<sup>&#xAE;</sup> and TEG<sup>&#xAE;</sup> parameters using their most recent versions [<xref rid="B38-sensors-20-04254" ref-type="bibr">38</xref>]; however, device-specific algorithms for interpretation of the results are mandatory.</p>
      </sec>
      <sec id="sec3dot4-sensors-20-04254">
        <title>3.4. Early Viscoelastic Variables to Predict Transfusion and Mortality</title>
        <p>Bleeding is a leading cause of morbidity and mortality in trauma patients [<xref rid="B4-sensors-20-04254" ref-type="bibr">4</xref>,<xref rid="B39-sensors-20-04254" ref-type="bibr">39</xref>]. Hemorrhagic death within the first 24 h following trauma was 94%, as described in a prospective multicenter study conducted by Holcomb et al. [<xref rid="B40-sensors-20-04254" ref-type="bibr">40</xref>]. Interestingly, 60% of these bleeding patients died within the first 3 h after hospitalization. Consequently, rapid and targeted intervention is essential for the survival of bleeding patients.</p>
        <p>The prospective study by Hagemo et al. [<xref rid="B41-sensors-20-04254" ref-type="bibr">41</xref>] confirmed the ROTEM<sup>&#xAE;</sup> early parameter A5 in EXTEM and FIMBTEM assays as a marker for acute traumatic coagulopathy and predictor for massive transfusion. The systematic review by Veigas et al. 2016 [<xref rid="B32-sensors-20-04254" ref-type="bibr">32</xref>] supports the evidence that A5 and A10 in EXTEM and FIBTEM assays diagnose coagulopathy earlier and predict blood transfusion and mortality. In addition, an abnormal early clot lysis index LI30 associates with the presence of fibrinolysis.</p>
        <p>Additionally, for TEG<sup>&#xAE;</sup> assays, a strong correlation of early amplitudes (A5 and A10) in the rTEG, kTEG and TEG FF was confirmed [<xref rid="B42-sensors-20-04254" ref-type="bibr">42</xref>]. These early parameters A5 and A10 were significantly lower in transfused patients in rTEG and TEG FF assays (1&#x2013;9 units of red blood cells (RBC) as well as in the kTEG assay too, if more than 10 RBC were transfused. Even significant predictors of mortality were found in relation to the early amplitudes in the A10 kTEG and A5 TEG FF assays. Comparable data on early amplitudes were already shown 2014 by Meyer et al. [<xref rid="B43-sensors-20-04254" ref-type="bibr">43</xref>].</p>
      </sec>
      <sec id="sec3dot5-sensors-20-04254">
        <title>3.5. ClotPro<sup>&#xAE;</sup></title>
        <p>The viscoelastic analyzer ClotPro<sup>&#xAE;</sup> (Haemonetics Corporation, Boston, MA, USA; formerly enicor GmbH, Munich, Germany) provides six channels for parallel testing. It has a unique Active-Tip&#x2122; technology with the dried reagents contained in a sponge at the pipette tip. When a blood sample is pipetted the reagents dissolve and activate the sample. Thereby, manual handling of liquid reagents is obsolete. For testing, 340 &#xB5;L of citrated whole blood is pipetted into a cylindrical cup with an immersed pin. The cup rotates and the pin is fixed. Following activation blood adheres to the surfaces of cup and pin, and the strength of the clot is continuously detected and displayed graphically. Established parameters of thrombelastography (CT, CFT, A5, A10, MCF, ML, LT, &#x3B1; and CLI) are used. At present, ClotPro<sup>&#xAE;</sup> is not commercially available in the USA at current times [<xref rid="B44-sensors-20-04254" ref-type="bibr">44</xref>].</p>
        <p>It provides nine types of assays: for screening, EX-test, FIB-test, AP-test, IN-test and HI-test. New assays for drug monitoring are the RVV-test, ECA-test, TPA-test and NA-test. The EX-test assesses the extrinsic coagulation pathway and its interaction with platelets. A recalcified sample is activated with a tissue factor, and hexadimethrin bromide is added to neutralize heparin. The FIB-test determines the fibrinogen level and fibrin polymerization. The recalcified sample is again activated with the tissue factor, and platelets are inhibited by cytochalasin D and a GPIIb-IIIa antagonist, too. Hexadimethrin bromide is also added. The AP-test permits evaluation of the extrinsic coagulation pathway in a fibrinolysis-independent manner by adding a plasmin antagonist (aprotinin). The IN-test evaluates the intrinsic coagulation pathway and its interaction with platelets. The recalcified sample is activated by ellagic acid. It is sensitive to heparin and FVIII. The HI-test (IN-test based) offers evaluation of the intrinsic coagulation pathway insensitive to heparin by the addition of heparinase. There are new assays designed for drug monitoring: the RVV-test is sensitive to factor Xa-antagonists by using Russel Viper Venom, an activator of factor X. The ECA-test uses the prothrombin-activating viper venom ecarin. It detects thrombin inhibitors such as dabigatran. The TPA-test uses recombinant tissue plasminogen activator (r-tPA for the detection of antifibrinolytics. Finally, the NA-test assesses non-activated coagulation.</p>
      </sec>
      <sec id="sec3dot6-sensors-20-04254">
        <title>3.6. Sonoclot<sup>&#xAE;</sup></title>
        <p>Another viscoelastic analyzer is Sonoclot<sup>&#xAE;</sup> (Sienco Inc., Boulder, CO, USA). This test was described in 1975 by Kaulla [<xref rid="B45-sensors-20-04254" ref-type="bibr">45</xref>]. It was further developed and uses whole blood. At the beginning, a hollow disposable plastic is attached to an ultrasonic transducer. The blood sample is pipetted into a container with coagulation activators or inhibitors. The transducer is then inserted at a defined height and the sample is oscillated at 200 Hz with a vertical deflection of 1 &#xB5;m. There are different analyzers available, the one-channel SC1 and the two/four-channel SCP2/SCP4. Additional tests are available [<xref rid="B46-sensors-20-04254" ref-type="bibr">46</xref>]: The kACT Kit as a kaolin-activated clotting time intended for high dose heparin management providing quantitative ACT and clot rate results. The SonACT Kit is celite-activated and intended for high dose heparin management, too. The gbACT Kit is a glass bead activated clotting time, which is well designed for high dose heparin management. The gbACT+ Kit is glass bead activated and designed for use in non-heparinized patients. The H-gbACT+ Kit is glass bead activated and contains heparinase, intended for standard clotting assessment patients receiving heparin. The aiACT Kit uses celite and other minerals for contact activation, and is intended for high dose heparin anticoagulation management. A non-activated Kit is available, too. Parameters for initial fibrin formation (SonACT), clot rate (CR), maximum clot strength (peak amplitude and time to peak) and fibrinolysis (R3) are transmitted [<xref rid="B47-sensors-20-04254" ref-type="bibr">47</xref>].</p>
      </sec>
    </sec>
    <sec id="sec4-sensors-20-04254">
      <title>4. Point-of-Care Guided Therapy</title>
      <p>Targeted hemostasis management of trauma patients guided by POC diagnostics is defined as the gold standard in resuscitation [<xref rid="B1-sensors-20-04254" ref-type="bibr">1</xref>]. At least one in four trauma patients suffers from trauma-induced coagulopathy upon hospital admission [<xref rid="B48-sensors-20-04254" ref-type="bibr">48</xref>,<xref rid="B49-sensors-20-04254" ref-type="bibr">49</xref>]. POC guided hemostatic resuscitation with target guided coagulation factor therapy showed a higher probability of survival [<xref rid="B5-sensors-20-04254" ref-type="bibr">5</xref>,<xref rid="B50-sensors-20-04254" ref-type="bibr">50</xref>] and reduced transfusion of allogeneic blood products [<xref rid="B2-sensors-20-04254" ref-type="bibr">2</xref>,<xref rid="B11-sensors-20-04254" ref-type="bibr">11</xref>,<xref rid="B42-sensors-20-04254" ref-type="bibr">42</xref>]. Furthermore, empiric administration of fresh frozen plasma (FFP) induces dilution coagulopathy and hypofibrinogenemia [<xref rid="B51-sensors-20-04254" ref-type="bibr">51</xref>]. Transfusion itself is associated with increased mortality [<xref rid="B52-sensors-20-04254" ref-type="bibr">52</xref>] and a high risk of adverse events such as lung damage, volume overload and heart failure, kidney damage, transmission of infections and immunological activation [<xref rid="B53-sensors-20-04254" ref-type="bibr">53</xref>,<xref rid="B54-sensors-20-04254" ref-type="bibr">54</xref>]. Besides trauma, pathological changes can be caused through intra- and postoperative bleeding.</p>
      <sec id="sec4dot1-sensors-20-04254">
        <title>4.1. Viscoelastic Parameters for POC Guided Therapy</title>
        <p>Using ROTEM<sup>&#xAE;</sup> assays, Theusinger et al. [<xref rid="B21-sensors-20-04254" ref-type="bibr">21</xref>] showed in a retrospective study that the parameters CFT, &#x3B1;-angle and MCF in EXTEM, INTEM and APTEM are significantly (<italic>p</italic> &#x2264; 0.003) associated with fibrinogen and platelet levels, and FIBTEM MCF parameter significantly (<italic>p</italic> &#x2264; 0.003) with fibrinogen. A large retrospective study by Chow et al. [<xref rid="B55-sensors-20-04254" ref-type="bibr">55</xref>] proved through TEG<sup>&#xAE;</sup> assays that the kTEG parameter MA best diagnoses hypofibrinogenemia (fibrinogen &lt; 200 mg/dL, <italic>p</italic> &lt; 0.001) and accurately diagnoses all parameters (MA, k-time, and alpha-angle; <italic>p</italic> &lt; 0.001) of severe hypofibrinogenemia (fibrinogen &lt; 100 mg/dL). A further retrospective cohort study in cardiovascular surgery, G&#xF6;rlinger et al. demonstrated that the first-line administration of the coagulation factor concentrates combined with POC testing was associated with decreased transfusion of any allogeneic blood product (52.5 vs. 42.2%; <italic>p</italic> &lt; 0.0001), packed red blood cells (49.7 vs. 40.4%; <italic>p</italic> &lt; 0.0001) and fresh frozen plasma (19.4 vs. 1.1%; <italic>p</italic> &lt; 0.0001), whereas platelet transfusion increased (10.1 vs. 13.0%; <italic>p</italic> &lt; 0.0041) [<xref rid="B6-sensors-20-04254" ref-type="bibr">6</xref>]. These convincing results could be validated in a subsequent prospective, randomized clinical trial by Weber et al. Beside a significant lower erythrocyte transfusion rate, outcome parameters like length of intensive care unit stay, costs of hemostatic therapy and even 6-month mortality were lower in the POC treated group, too [<xref rid="B7-sensors-20-04254" ref-type="bibr">7</xref>]. Further, in a prospective trial on major obstetric hemorrhage, Mallaiah et al. showed superior outcomes and prompt correction of the coagulation deficit by ROTEM<sup>&#xAE;</sup> guided administration of fibrinogen concentrate [<xref rid="B9-sensors-20-04254" ref-type="bibr">9</xref>]. Due to the dynamics of coagulopathy, repetitive measurements are necessary. Standard coagulation parameters take 30&#x2013;90 or more minutes [<xref rid="B10-sensors-20-04254" ref-type="bibr">10</xref>] while results of viscoelastic testing can generate results within minutes [<xref rid="B56-sensors-20-04254" ref-type="bibr">56</xref>]. There are of course limitations to the clinical applicability of viscoelastic testing. Single coagulation factor deficiencies and the effect of their substitution are not displayed specifically [<xref rid="B57-sensors-20-04254" ref-type="bibr">57</xref>]. Additionally, detection and quantification of the effect of anticoagulants is insufficient. Platelet inhibitors can go unnoticed because of the high thrombin levels produced during viscoelastic testing. Platelets are stimulated strongest via their thrombin receptor pathway (e.g., protease-activated pathways (PAR)), which is activated by thrombin. Other pathways that are possibly blocked such as cyclooxygenase-1 (COX-1) or ADP (P2Y-12) pathways are bypassed [<xref rid="B58-sensors-20-04254" ref-type="bibr">58</xref>].</p>
      </sec>
      <sec id="sec4dot2-sensors-20-04254" sec-type="subjects">
        <title>4.2. Viscoelastic Parameters for Anticoagulated Patients</title>
        <p>Considering the large number of anticoagulated patients, the administration of viscoelastic methods is nevertheless useful, e.g., atrial fibrillation occurs during the life span of 1 out of 4 individuals [<xref rid="B59-sensors-20-04254" ref-type="bibr">59</xref>], and systemic anticoagulation with direct oral anticoagulants (DOAC&#x2019;s) or vitamin K antagonists is routinely recommended for the prevention of systemic embolism [<xref rid="B60-sensors-20-04254" ref-type="bibr">60</xref>]. As a consequence, the frequency of interventions associated with a high bleeding risk that is performed in anticoagulated patients is increasing [<xref rid="B61-sensors-20-04254" ref-type="bibr">61</xref>]. Global coagulation assays such as PT or aPTT do not reliably and precisely detect clinically relevant DOAC levels [<xref rid="B62-sensors-20-04254" ref-type="bibr">62</xref>]. Viscoelastic tests can indicate the presence of a DOAC. Although EXTEM CT of the ROTEM<sup>&#xAE;</sup> is progressively prolonged with increasing plasma concentrations of Xa or IIa inhibitors [<xref rid="B63-sensors-20-04254" ref-type="bibr">63</xref>], their quantification requires a calibrated anti-Xa- or anti-IIa assay by the laboratory [<xref rid="B64-sensors-20-04254" ref-type="bibr">64</xref>]. The impact of low DOAC plasma levels on ROTEM<sup>&#xAE;</sup> assays is poor. Nevertheless, a strong correlation of the LowTF CT between apixaban and rivaroxaban therapy with ascending drug plasma concentrations ranging from 50 to 400 ng/mL has been shown by Adelmann et al. [<xref rid="B65-sensors-20-04254" ref-type="bibr">65</xref>]. However, to double EXTEM CT the required DOAC concentration was 1042 &#xB1; 225 ng/mL for apixaban, 134 &#xB1; 38 ng/mL for edoxaban, 176 &#xB1; 26 ng/mL for rivaroxaban and 284 &#xB1; 73 ng/mL for dabigatran. Interestingly, MA remains unchanged [<xref rid="B63-sensors-20-04254" ref-type="bibr">63</xref>,<xref rid="B66-sensors-20-04254" ref-type="bibr">66</xref>]. A current study of Vedovati et al. was able to accurately identify the activity of apixaban, dabigatran and rivaroxaban by ROTEM<sup>&#xAE;</sup> by EXTEM and ECATEM-B assay [<xref rid="B67-sensors-20-04254" ref-type="bibr">67</xref>]. Furthermore, the parameters R time, K time, and &#x3B1;-angle of the TEG<sup>&#xAE;</sup> kaolin test were able to detect different concentrations of apixaban and dabigatran, also a higher concentration of rivaroxaban. The ACT parameter of the RapidTEG&#x2122; test of TEG<sup>&#xAE;</sup> was significantly and constantly different with varying concentrations of apixaban, dabigatran and rivaroxaban [<xref rid="B68-sensors-20-04254" ref-type="bibr">68</xref>]. Bliden et al. used two TEG<sup>&#xAE;</sup> 6S assays (DTI and AFXa assay) to detect the anticoagulant effects of dabigatran, rivaroxaban, apixaban and edoxaban. The R-time showed a strong correlation with each [<xref rid="B69-sensors-20-04254" ref-type="bibr">69</xref>]. The ClotPro<sup>&#xAE;</sup> analyzer is able to detect factor Xa antagonists using the RVV test, dabigatran using the ECA test and antifibrinolytics using the TPA test [<xref rid="B44-sensors-20-04254" ref-type="bibr">44</xref>]. Further validation is required.</p>
      </sec>
      <sec id="sec4dot3-sensors-20-04254">
        <title>4.3. Algorithm-Guided POC Therapy</title>
        <p>Correct application is crucial for successful POC diagnostics: no matter how fast and reliably a POC device generates results, it is of no use if it is not applied correctly. A predefined algorithm is therefore essential, from the complete acquisition of patient data to the subsequent targeted therapy. In summary, (A) patient-specific parameters must be generated, for which POC devices are of great use, (B) these parameters must be interpreted correctly, and very important (C) the identified abnormalities must be treated in a targeted manner. Standardization generates reproducibility, which is an advantage since it facilitates the identification of weak points in the process and promotes its continuous improvement. Several studies have shown an improved outcome of trauma patients with the generation of POC parameters and their application along with algorithms [<xref rid="B5-sensors-20-04254" ref-type="bibr">5</xref>,<xref rid="B70-sensors-20-04254" ref-type="bibr">70</xref>]. Such an algorithm is described and illustrated by Stein et al. [<xref rid="B3-sensors-20-04254" ref-type="bibr">3</xref>]. These findings are supported by a Cochrane Review of Wikkels&#xF8; et al. that considered studies until 2016 on the TEG<sup>&#xAE;</sup> or ROTEM<sup>&#xAE;</sup> monitoring of hemostatic therapies as compared to standard therapy in adults and children with bleeding. Compared with transfusion policies guided by any method, a TEG<sup>&#xAE;</sup> or ROTEM<sup>&#xAE;</sup> guided management reduced overall mortality. Additionally, a significant reduction of transfused pooled red blood cells (PRBCs), fresh frozen plasma (FFP) and platelets was registered [<xref rid="B71-sensors-20-04254" ref-type="bibr">71</xref>]. The impact of viscoelastic coagulation monitoring together with an algorithm-guided therapy has been shown in multiple meta-analyses [<xref rid="B72-sensors-20-04254" ref-type="bibr">72</xref>,<xref rid="B73-sensors-20-04254" ref-type="bibr">73</xref>,<xref rid="B74-sensors-20-04254" ref-type="bibr">74</xref>,<xref rid="B75-sensors-20-04254" ref-type="bibr">75</xref>,<xref rid="B76-sensors-20-04254" ref-type="bibr">76</xref>,<xref rid="B77-sensors-20-04254" ref-type="bibr">77</xref>,<xref rid="B78-sensors-20-04254" ref-type="bibr">78</xref>].</p>
        <p>The current COVID-19 pandemic illustrates the importance of using resources in a targeted manner. Several studies describe significant coagulation alterations in hospitalized COVID-19 patients [<xref rid="B79-sensors-20-04254" ref-type="bibr">79</xref>,<xref rid="B80-sensors-20-04254" ref-type="bibr">80</xref>]. POC based testing and subsequent algorithmically defined targeted therapy play a major role in the treatment of this population [<xref rid="B81-sensors-20-04254" ref-type="bibr">81</xref>].</p>
      </sec>
    </sec>
    <sec id="sec5-sensors-20-04254">
      <title>5. Platelet Function Tests</title>
      <p>Platelets play a crucial role in hemostasis. A variety of assay methods are available for the quantitative assessment of the platelet function. Light transmission aggregometry according to Born [<xref rid="B82-sensors-20-04254" ref-type="bibr">82</xref>] is considered the gold standard of platelet function testing. This method measures the increase of light transmission through a cuvette of platelet-rich plasma when platelets aggregate upon the addition of stimulants such as ADP, collagen, epinephrine, arachidonic acid or ristocetin. This method is labor-intensive and requires tightly controlled preanalytical conditions (e.g., manipulation and sample transport may preactivate platelets) [<xref rid="B83-sensors-20-04254" ref-type="bibr">83</xref>]. Available POC methods have important limitations. Moreover, in patients taking antiplatelet substances the platelet-inhibitory effect observed in vitro is not necessarily equivalent to that in vivo. Nevertheless, supplementary information for coagulation management in specific situations can be obtained, e.g., the determination of interindividual variation of platelet inhibition by P2Y<sub>12</sub>-receptor antagonists to prevent thrombotic events after coronary stenting [<xref rid="B84-sensors-20-04254" ref-type="bibr">84</xref>]. Regarding ROTEM<sup>&#xAE;</sup> platelet and Multiplate<sup>&#xAE;</sup>, there is evidence for a predictability of postoperative blood loss (e.g., chest tube drainage) and red blood cell transfusion in patients undergoing elective cardiac surgery [<xref rid="B85-sensors-20-04254" ref-type="bibr">85</xref>,<xref rid="B86-sensors-20-04254" ref-type="bibr">86</xref>]. However, the impact of drug-induced platelet inhibition on early postoperative bleeding is difficult to predict and in general, the tests are not sufficiently specific [<xref rid="B85-sensors-20-04254" ref-type="bibr">85</xref>,<xref rid="B87-sensors-20-04254" ref-type="bibr">87</xref>]. Regarding the therapy of bleeding trauma patients, current European guidelines assume only a subordinate role, adjunct to standard laboratory [<xref rid="B1-sensors-20-04254" ref-type="bibr">1</xref>]. Moenen et al. showed that Multiplate<sup>&#xAE;</sup> and PFA<sup>&#xAE;</sup> cannot discriminate between preoperative and referred patients with and without mild platelet function disorders (PFD&#x2019;s), indicating that they are not useful as screening tests for mild PFD&#x2019;s in these patients [<xref rid="B88-sensors-20-04254" ref-type="bibr">88</xref>].</p>
      <sec id="sec5dot1-sensors-20-04254">
        <title>5.1. Tests Based on Whole Blood Aggregometry</title>
        <p>Originally described by Cardinal and Flower 1980 for the measurement of platelet aggregation in platelet-rich plasma or whole blood [<xref rid="B89-sensors-20-04254" ref-type="bibr">89</xref>]. The serum is stirred at 37 &#xB0;C between two platinum electrodes set at a fixed distance. The position of electrodes in the cell is important, and both electrodes are facing the blood uniformly. Platelets adhere to the electrodes and cover their surface. Further adhesion of platelet aggregates depends on the addition of specific agonists, coating the electrodes and impairing the electric conduction. The magnitude of the response is proportional to the number of reacting platelets. This increase of the impedance can be displayed on any suitable chart recorder. Three principal systems are in discussion:</p>
        <p>The Multiplate<sup>&#xAE;</sup> Analyzer (F. Hoffmann-La Roche AG, Roche Diagnostics, Switzerland) consists of five channels for parallel measurements. Multiple electrode aggregometry (MEA) was introduced in 2006 by T&#xF3;th et al. [<xref rid="B90-sensors-20-04254" ref-type="bibr">90</xref>] for the measurement of platelet aggregation and platelet inhibition by aspirin or apyrase in diluted whole blood. Currently, for analysis, 300 &#xB5;L of citrated whole blood is pipetted in a computer-controlled manner into the specific cups. Generation of results takes 6&#x2013;10 m. Output aggregation curves describe the platelet reactivity, and an area under the curve (AUC) is determined for each assay [<xref rid="B91-sensors-20-04254" ref-type="bibr">91</xref>]. Several assays were available and demonstrated in <xref ref-type="fig" rid="sensors-20-04254-f006">Figure 6</xref>. The ADPtest detects platelets after stimulation with the agonist adenosine diphosphate (ADP) of the ADP receptor pathway P2Y<sub>12</sub>, which is blocked by antagonists such as clopidogrel, prasugrel or ticagrelor. The TRAPtest allows the measurement of the effect of glycoprotein IIb and IIIa (GPIIb/IIIa) antagonists (e.g., abciximab, eptifibatid and tirofiban). Determining the platelet function by the agonist thrombin receptor activator peptide-6 (TRAP-6) stimulating the protease activated receptor-1 pathway (PAR-1). The RISTOtest allows the determination of platelet aggregation dependent on the von Willebrand Factor (VWF) and glycoprotein Ib (GPIb) simulated by ristocetin. Ristocetin is an agonist of the glycoprotein Ib-IX-V (GPIb-IX-V) receptor pathway. The ASPItest detects platelets activated by arachidonic acid (AA). AA is converted to prostaglandin H<sub>2</sub> (PGH<sub>2</sub>) by cyclooxygenase-1 (COX-1), and PGH<sub>2</sub> is then converted to thromboxane A<sub>2</sub> (TXA<sub>2</sub>) by thromboxane synthase. TXA<sub>2</sub> increases platelet aggregation through the TXA<sub>2</sub> alpha (TP&#x3B1;) pathway. Non-steroidal anti-inflammatory drugs (NSAID&#x2019;s) like acetylic acid are COX inhibitors. Furthermore, the COLtest detects platelets activated by AA, too. Collagen is added to the sample and binds to collagen receptors GPVI and &#x3B1;<sub>2</sub>&#x3B2;<sub>1</sub>. Stimulating this pathways leads to a release of AA [<xref rid="B92-sensors-20-04254" ref-type="bibr">92</xref>].</p>
        <p>The ROTEM<sup>&#xAE;</sup> platelet module (Instrumentation Laboratory, Bedford, MA, USA) is a set of two channels, which can be added to the standard thromboelastometric system. Handling is similar. For analysis, 300 &#xB5;L of citrated whole blood is required and pipetted in a computer- controlled manner. AA (ARATEM), ADP (ADPTEM) and TRAP-6 (TRAPTEM) are used as agonists (activators) and detect the effect of COX inhibitors, ADP-receptor inhibitors or GpIIb-IIIa antagonists [<xref rid="B93-sensors-20-04254" ref-type="bibr">93</xref>].</p>
        <p>The TEG<sup>&#xAE;</sup> platelet mapping system (Haemonetics Corporation, Boston, MA, USA) is a modification of the original TEG<sup>&#xAE;</sup>. First, a kaolin-activated test is performed to evaluate the maximal hemostatic activity. Second, a test in the presence of reptilase and factor XIIIa produces a cross-linked fibrin clot. The addition of ADP or AA stimulates differentially the role of platelet ADP or TXA2 receptors in clot formation. The effect of therapy with aspirin<sup>&#xAE;</sup> (AA addition) or thienopyridines (e.g., clopidogrel, ADP addition) is evaluated by comparing the TEG<sup>&#xAE;</sup> kaolin-activated test curve with the AA or ADP-stimulated TEG<sup>&#xAE;</sup> curve. Modified TEG is with the addition of a GPIIb-IIIa receptor antagonist to assess the contribution of the fibrinogen-platelet interaction to TEG parameters.</p>
        <p>The platelet function is described by the clot formation time (ROTEM<sup>&#xAE;</sup>) or K Index (TEG<sup>&#xAE;</sup>). The fibrin formation is reproduced by the alpha-angle (&#x3B1;) in both systems. The clot formation contributed by the platelets is described by the maximum clot firmness (ROTEM<sup>&#xAE;</sup>) or maximum amplitude (TEG<sup>&#xAE;</sup>) [<xref rid="B94-sensors-20-04254" ref-type="bibr">94</xref>].</p>
      </sec>
      <sec id="sec5dot2-sensors-20-04254">
        <title>5.2. Tests Based on Platelet Adhesion under Shear Stress</title>
        <p>The Platelet Function Analyzer (PFA<sup>&#xAE;</sup>, Siemens Healthineers, Munich, Germany) is based on platelets aggregating under high shear force in the presence of collagen and other platelet agonists. In vivo, this is mediated by the von Willebrand factor. The test was first described in 1995 by Kratzer et al. (Thrombostat) to investigate the effect of different platelet inhibitors such as aspirin on primary hemostasis [<xref rid="B95-sensors-20-04254" ref-type="bibr">95</xref>]. PFA<sup>&#xAE;</sup> units are distributed as single use cartridges, which contain either ADP or epinephrine. A third cartridge is supplemented with P2Y<sub>12</sub> and is sensitive to the effect of clopidogrel. The test is automated. Citrated whole blood is aspirated through a capillary and placed on the membrane via a small aperture of 150 &#x3BC;m. The high velocity of the flow generates a shear force similar to the microcirculation where VWF binds to glycoprotein Ib. The time to closure of the aperture by platelet aggregates is registered (PFA closure time), and depends on VWF, platelet reactivity, the effect of platelet inhibitors, as well as platelet count and hematocrit [<xref rid="B94-sensors-20-04254" ref-type="bibr">94</xref>]. To a certain degree, the combination of the epinephrine and ADP units allows differentiation of severe intrinsic platelet defects (such as thrombasthenia Glanzmann or Bernard Soulier syndrome) or pronounced defects of VWF, from milder platelet function defects or the effect of antiplatelet substances such as acetylsalicylic acid [<xref rid="B96-sensors-20-04254" ref-type="bibr">96</xref>].</p>
      </sec>
      <sec id="sec5dot3-sensors-20-04254">
        <title>5.3. Tests Based on Optical Detection</title>
        <p>The VerifyNow<sup>&#xAE;</sup> Assay (ITC, Edison NJ, USA), formerly known as Ultegra Rapid Platelet Function Analyzer RPFA, uses a cartridge containing fibrinogen-coated beads and platelet agonists. It is a fully automated point-of-care test originally developed to monitor GPIIb-IIIa antagonists (abciximab; ReoPro) in the 1990s to prevent ischemic complications associated with unstable angina pectoris and percutaneous coronary interventions [<xref rid="B97-sensors-20-04254" ref-type="bibr">97</xref>]. A citrated whole blood sample is inserted into a closed system using optical detection. Proportionally to the expressed GPIIb-IIIa receptors, the activated platelets bind to a fibrinogen-covered layer in the assay. TRAP (iso-TRAP) is added to analyze the inhibitory effect of intravenous platelet GPIIb-IIIa antagonists. TRAP activates the platelets, resulting in GPIIb-IIIa exposure and binding of the fibrinogen-coated beads to the platelet receptors that are not blocked. Aggregation in response to the agonist is monitored by light transmission and results (percent inhibition) are available within a few minutes [<xref rid="B94-sensors-20-04254" ref-type="bibr">94</xref>]. There are two other cartridges available for monitoring either COX-1 (containing AA as agonist) or P2Y<sub>12</sub> (containing ADP as agonist) inhibition [<xref rid="B98-sensors-20-04254" ref-type="bibr">98</xref>].</p>
      </sec>
    </sec>
    <sec id="sec6-sensors-20-04254">
      <title>6. Point-of-Care Coagulometry</title>
      <p>PT as well as aPTT can be measured by POC coagulometers. There are several devices available. The CoaguChek<sup>&#xAE;</sup> (F. Hoffmann-La Roche AG, Roche Diagnostics, Switzerland) is frequently used. Its test strips include activators and a peptide substrate. Upon contact with (capillary) whole blood, the reagent (thromboplastin for PT or celite for aPTT) dissolves and initiates thrombin generation. Thrombin cleaves a synthetic peptide substrate generating an electrochemical signal, which is converted into INR or aPTT [<xref rid="B99-sensors-20-04254" ref-type="bibr">99</xref>]. The results must be interpreted with caution since they are altered by several factors, such as coagulation factor-deficiency including fibrinogen deficiency, impaired liver function, vitamin K deficiency or consumption coagulopathy [<xref rid="B100-sensors-20-04254" ref-type="bibr">100</xref>]. For this reason CoaguChek<sup>&#xAE;</sup> is approved only for the monitoring of anticoagulation with vitamin K antagonists (e.g., phenprocoumon) [<xref rid="B101-sensors-20-04254" ref-type="bibr">101</xref>]. POC measurement of PT and aPTT are of limited value in acute bleeding, such as trauma or surgery.</p>
    </sec>
    <sec id="sec7-sensors-20-04254">
      <title>7. Blood Gas Analysis</title>
      <p>In principle, all blood gas analyzers are POC devices. Due to the essential physiological parameters they determine promptly, we found them worth mentioning. Arterial blood sampling allows the precise assessment of oxygenation (PaO<sub>2</sub> and hemoglobin saturation), of ventilatory status (PaCO<sub>2</sub>) and of acid-base equilibrium (BE and pH) [<xref rid="B102-sensors-20-04254" ref-type="bibr">102</xref>]. The parameters hemoglobin (Hb), acid-base status (pH) and calcium (Ca<sup>2+</sup>) are particularly important for a comprehensive coagulation management as they reflect the essential physiologic basis. Depending on the number of parameters, between 40 and 120 &#xB5;L volume of whole blood is analyzed. A distinction is made between parameters which are measured (blood gases, electrolytes, CO-oximetry and metabolites) or calculated (e.g., HCO<sub>3</sub><sup>&#x2212;</sup>, BE) [<xref rid="B103-sensors-20-04254" ref-type="bibr">103</xref>]. The spectrum of methods is ample. The parameters of blood gases (pO<sub>2</sub>, pCO<sub>2</sub> and pH) are measured directly either electrochemically or optically. The measurement of electrolytes, especially ionized Ca<sup>2+</sup>, is done photometrically. Chemical sensors or fiber-optic chemical sensors are increasingly used as a standard [<xref rid="B104-sensors-20-04254" ref-type="bibr">104</xref>]. Schober et al. [<xref rid="B105-sensors-20-04254" ref-type="bibr">105</xref>] evaluated a portable blood gas analyzer (i-Stat 1, Abbott, Chicago, IL, USA) in prehospital helicopter medical service. Critically ill patients are managed with limited monitoring options during transport. They described benefits (e.g., portability and speed) and limitations (e.g., narrow operational temperature range).</p>
    </sec>
    <sec sec-type="conclusions" id="sec8-sensors-20-04254">
      <title>8. Conclusions</title>
      <p>Coagulation management is based on a reliable assessment of the hemostasis, which may be compromised by trauma-induced coagulopathy, of antithrombotic therapy or of other coagulopathies and during surgery. In the acute situation, POC devices are of great value as results are generated fast and reliable. Viscoelastic methods can be used for a real-time measurement of the clot formation rate and clot stability. They are of value in the early diagnosis of trauma-induced coagulopathy, for transfusion management, and a targeted hemostatic therapy within short time. Besides trauma, pathological changes can be caused by intra- and postoperative bleeding. Although platelet function plays a crucial role in hemostasis, the assessment by POC assays is unsatisfactory. Other disadvantages are the high cost of reagents, and a limited sample throughput as compared with standard laboratory assays. Additionally, an operator training is required covering the handling, test procedures, preanalytical and analytical conditions, and the interpretation of the results. Additionally, regular assay calibration is challenging.</p>
      <p>Overall, POC-guided treatment algorithms are an essential part of coagulation management in the acute situation. The introduction of viscoelastic methods to such algorithms improves mortality, reduces the transfusion of blood components and has a cost-saving effect in the context of transfusion and coagulation support as shown in several meta-analyses. For these reasons, coagulation assays are more often integrated in multifunctional POC systems. Additionally, improved visualization of the assay results (such as Visual Clot for the ROTEM<sup>&#xAE;</sup>) facilitates the fast and correct interpretation of results in critical situations.</p>
    </sec>
    <sec id="sec9-sensors-20-04254">
      <title>9. Patents</title>
      <p>- Visual Clot: U.S. Design Patent Application No. 29/725,001; Registered European Union design protection 007691399-0001 to 007691399-0012; European patent application 2019P01267EP &#x201C;Method and system for monitoring a patient&#x2019;s blood coagulation function.&#x201D;</p>
      <p>- Visual Patient: United States patent 10,702,214. &#x201C;Method for monitoring and visualizing a patient&#x2019;s medical condition&#x201D;; European Union trademark 1424812 &#x201C;Visual Patient&#x201D;; Swiss trademark 719318 Visual Patient&#x201D;; Registered European Union design protection 004064178-0001 and 004064178-0002; European patent application EP3311315A1 &#x201C;Method and system for monitoring a patient&#x2019;s medical condition&#x201D;.</p>
    </sec>
  </body>
  <back>
    <notes>
      <title>Author Contributions</title>
      <p>S.D.S. contributed to the writing&#x2014;original draft preparation, writing&#x2014;review, and editing. J.R., J.-D.S. and D.W.T. contributed to the writing&#x2014;original draft preparation, writing&#x2014;review. D.R.S. contributed to the conceptualization, writing&#x2014;original draft preparation, writing&#x2014;review and editing. A.K. contributed to the conceptualization, methodology, writing&#x2014;original draft preparation, writing&#x2014;review, editing, supervision and project administration. All authors have read and agreed to the published version of the manuscript.</p>
    </notes>
    <notes>
      <title>Funding</title>
      <p>This research received no external funding.</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>S.D.S. and J.R. have no conflict of interest to declare. J.-D.S. received lecture and advisory honoraria from Bayer (Switzerland), Shire/Takeda (Switzerland), Sanofi (Switzerland), and Siemens Healthineers (Switzerland). A.K. received honoraria for lecturing from Bayer AG Switzerland. The University of Zurich and Instrumentation Laboratory Company/Werfen Corporation, Bedford, MA, USA, signed a letter of intent regarding a joint development and licensing agreement to develop a product based on the concept of Visual Clot. Within the framework of this letter of intent and a potential later agreement, D.W.T. and D.R.S. might receive royalties as designated inventors. The University of Zurich and Philips Medizin Systeme B&#xF6;blingen GmbH, B&#xF6;blingen, Germany and Konikljike Philips N.V., Amsterdam, The Netherlands signed a joint development and licensing agreement to develop a product based on the concept of Visual Patient. Within the framework of this agreement, D.W.T. might receive royalties as designated inventor. D.W.T. received travel support for consulting Instrumentation Laboratory, Bedford, MA, USA and consults Philips Research/Philips Electronics Nederland B.V., Eindhoven, The Netherlands. Dr. Spahn&#x2019;s academic department is receiving grant support from the Swiss National Science Foundation, Berne, Switzerland, the Swiss Society of Anesthesiology and Reanimation (SGAR), Berne, Switzerland, the Swiss Foundation for Anesthesia Research, Zurich, Switzerland, Vifor SA, Villars-sur-Gl&#xE2;ne, Switzerland. Dr. Spahn is co-chair of the ABC-Trauma Faculty, sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland, CSL Behring GmbH, Marburg, Germany, LFB Biom&#xE9;dicaments, Courtaboeuf Cedex, France and Octapharma AG, Lachen, Switzerland. Dr. Spahn received honoraria/travel support for consulting or lecturing from: Danube University of Krems, Austria, US Department of Defense, Washington, USA, European Society of Anesthesiology, Brussels, BE, Korean Society for Patient Blood Management, Seoul, Korea, Korean Society of Anesthesiologists, Seoul, Korea, Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Paris, France, Baxalta Switzerland AG, Volketswil, Switzerland, Bayer AG, Z&#xFC;rich, Switzerland, B. Braun Melsungen AG, Melsungen, Germany, Boehringer Ingelheim GmbH, Basel, Switzerland, Bristol-Myers-Squibb, Rueil-Malmaison Cedex, France and Baar, Switzerland, CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland, Celgene International II S&#xE0;rl, Couvet, Switzerland, Daiichi Sankyo AG, Thalwil, Switzerland, Ethicon S&#xE0;rl, Neuch&#xE2;tel, Switzerland, Haemonetics, Braintree, MA, USA, Instrumentation Laboratory (Werfen), Bedford, MA, USA, LFB Biom&#xE9;dicaments, Courtaboeuf Cedex, France, Merck Sharp &amp; Dohme, Kenilworth, New Jersey, USA, PAION Deutschland GmbH, Aachen, Germany, Pharmacosmos A/S, Holbaek, Denmark, Photonics Healthcare B.V., Utrecht, Netherlands, Pfizer AG, Z&#xFC;rich, Switzerland, Pierre Fabre Pharma, Alschwil, Switzerland, Roche Diagnostics International Ltd., Reinach, Switzerland, Sarstedt AG &amp; Co., Sevelen, Switzerland and N&#xFC;mbrecht, Germany, Shire Switzerland GmbH, Zug, Switzerland, Tem International GmbH, Munich, Germany, Vifor Pharma, Munich, Germany, Neuilly sur Seine, France and Villars-sur-Gl&#xE2;ne, Switzerland, Vifor (International) AG, St. Gallen, Switzerland, Zuellig Pharma Holdings, Singapore, Singapore.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-sensors-20-04254">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spahn</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Bouillon</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Cerny</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Duranteau</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Filipescu</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hunt</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Komadina</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Maegele</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nardi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Riddez</surname>
              <given-names>L.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The european guideline on management of major bleeding and coagulopathy following trauma: Fifth edition</article-title>
          <source>Crit. Care</source>
          <year>2019</year>
          <volume>23</volume>
          <fpage>98</fpage>
          <pub-id pub-id-type="doi">10.1186/s13054-019-2347-3</pub-id>
          <pub-id pub-id-type="pmid">30917843</pub-id>
        </element-citation>
      </ref>
      <ref id="B2-sensors-20-04254">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stein</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kaserer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sprengel</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Wanner</surname>
              <given-names>G.A.</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Theusinger</surname>
              <given-names>O.M.</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>D.R.</given-names>
            </name>
          </person-group>
          <article-title>Change of transfusion and treatment paradigm in major trauma patients</article-title>
          <source>Anaesthesia</source>
          <year>2017</year>
          <volume>72</volume>
          <fpage>1317</fpage>
          <lpage>1326</lpage>
          <pub-id pub-id-type="doi">10.1111/anae.13920</pub-id>
          <pub-id pub-id-type="pmid">28542848</pub-id>
        </element-citation>
      </ref>
      <ref id="B3-sensors-20-04254">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stein</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kaserer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>G.H.</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>D.R.</given-names>
            </name>
          </person-group>
          <article-title>Point-of-care coagulation monitoring in trauma patients</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <year>2017</year>
          <volume>43</volume>
          <fpage>367</fpage>
          <lpage>374</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0037-1598062</pub-id>
          <pub-id pub-id-type="pmid">28297730</pub-id>
        </element-citation>
      </ref>
      <ref id="B4-sensors-20-04254">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Theusinger</surname>
              <given-names>O.M.</given-names>
            </name>
            <name>
              <surname>Wanner</surname>
              <given-names>G.A.</given-names>
            </name>
            <name>
              <surname>Emmert</surname>
              <given-names>M.Y.</given-names>
            </name>
            <name>
              <surname>Billeter</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Eismon</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Simmen</surname>
              <given-names>H.P.</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Baulig</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Hyperfibrinolysis diagnosed by rotational thromboelastometry (rotem) is associated with higher mortality in patients with severe trauma</article-title>
          <source>Anesth. Analg.</source>
          <year>2011</year>
          <volume>113</volume>
          <fpage>1003</fpage>
          <lpage>1012</lpage>
          <pub-id pub-id-type="doi">10.1213/ANE.0b013e31822e183f</pub-id>
          <pub-id pub-id-type="pmid">21918164</pub-id>
        </element-citation>
      </ref>
      <ref id="B5-sensors-20-04254">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gonzalez</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>E.E.</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>H.B.</given-names>
            </name>
            <name>
              <surname>Chapman</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Chin</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Ghasabyan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wohlauer</surname>
              <given-names>M.V.</given-names>
            </name>
            <name>
              <surname>Barnett</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Bensard</surname>
              <given-names>D.D.</given-names>
            </name>
            <name>
              <surname>Biffl</surname>
              <given-names>W.L.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: A pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays</article-title>
          <source>Ann. Surg.</source>
          <year>2016</year>
          <volume>263</volume>
          <fpage>1051</fpage>
          <lpage>1059</lpage>
          <pub-id pub-id-type="doi">10.1097/SLA.0000000000001608</pub-id>
          <pub-id pub-id-type="pmid">26720428</pub-id>
        </element-citation>
      </ref>
      <ref id="B6-sensors-20-04254">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>G&#xF6;rlinger</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Dirkmann</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hanke</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Kamler</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kottenberg</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Thielmann</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Jakob</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: A retrospective, single-center cohort study</article-title>
          <source>Anesthesiology</source>
          <year>2011</year>
          <volume>115</volume>
          <fpage>1179</fpage>
          <lpage>1191</lpage>
          <pub-id pub-id-type="doi">10.1097/ALN.0b013e31823497dd</pub-id>
          <pub-id pub-id-type="pmid">21970887</pub-id>
        </element-citation>
      </ref>
      <ref id="B7-sensors-20-04254">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>C.F.</given-names>
            </name>
            <name>
              <surname>G&#xF6;rlinger</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Meininger</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Herrmann</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Bingold</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Moritz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>L.H.</given-names>
            </name>
            <name>
              <surname>Zacharowski</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Point-of-care testing: A prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients</article-title>
          <source>Anesthesiology</source>
          <year>2012</year>
          <volume>117</volume>
          <fpage>531</fpage>
          <lpage>547</lpage>
          <pub-id pub-id-type="doi">10.1097/ALN.0b013e318264c644</pub-id>
          <pub-id pub-id-type="pmid">22914710</pub-id>
        </element-citation>
      </ref>
      <ref id="B8-sensors-20-04254">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mallaiah</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chevannes</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>McNamara</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Barclay</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>A reply</article-title>
          <source>Anaesthesia</source>
          <year>2015</year>
          <volume>70</volume>
          <fpage>760</fpage>
          <lpage>761</lpage>
          <pub-id pub-id-type="doi">10.1111/anae.13128</pub-id>
          <pub-id pub-id-type="pmid">25959192</pub-id>
        </element-citation>
      </ref>
      <ref id="B9-sensors-20-04254">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mallaiah</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Barclay</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Harrod</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Chevannes</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bhalla</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Introduction of an algorithm for rotem-guided fibrinogen concentrate administration in major obstetric haemorrhage</article-title>
          <source>Anaesthesia</source>
          <year>2015</year>
          <volume>70</volume>
          <fpage>166</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="doi">10.1111/anae.12859</pub-id>
          <pub-id pub-id-type="pmid">25289791</pub-id>
        </element-citation>
      </ref>
      <ref id="B10-sensors-20-04254">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haas</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Fries</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Asmis</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Curry</surname>
              <given-names>N.S.</given-names>
            </name>
            <name>
              <surname>Sch&#xF6;chl</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Usefulness of standard plasma coagulation tests in the management of perioperative coagulopathic bleeding: Is there any evidence</article-title>
          <source>Br. J. Anaesth.</source>
          <year>2015</year>
          <volume>114</volume>
          <fpage>217</fpage>
          <lpage>224</lpage>
          <pub-id pub-id-type="doi">10.1093/bja/aeu303</pub-id>
          <pub-id pub-id-type="pmid">25204698</pub-id>
        </element-citation>
      </ref>
      <ref id="B11-sensors-20-04254">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Da Luz</surname>
              <given-names>L.T.</given-names>
            </name>
            <name>
              <surname>Nascimento</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Shankarakutty</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Rizoli</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Adhikari</surname>
              <given-names>N.K.</given-names>
            </name>
          </person-group>
          <article-title>Effect of thromboelastography (teg<sup>&#xAE;</sup>) and rotational thromboelastometry (rotem<sup>&#xAE;</sup>) on diagnosis of coagulopathy, transfusion guidance and mortality in trauma: Descriptive systematic review</article-title>
          <source>Crit. Care</source>
          <year>2014</year>
          <volume>18</volume>
          <fpage>518</fpage>
          <pub-id pub-id-type="doi">10.1186/s13054-014-0518-9</pub-id>
          <pub-id pub-id-type="pmid">25261079</pub-id>
        </element-citation>
      </ref>
      <ref id="B12-sensors-20-04254">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duke</surname>
              <given-names>W.W.</given-names>
            </name>
          </person-group>
          <article-title>The relation of blood platelets to hemorrhagic disease: Description of a method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion</article-title>
          <source>J. Am. Med Assoc.</source>
          <year>1910</year>
          <volume>55</volume>
          <fpage>1185</fpage>
          <lpage>1192</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.1910.04330140029009</pub-id>
        </element-citation>
      </ref>
      <ref id="B13-sensors-20-04254">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davie</surname>
              <given-names>E.W.</given-names>
            </name>
            <name>
              <surname>Fujikawa</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kisiel</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>The coagulation cascade: Initiation, maintenance, and regulation</article-title>
          <source>Biochemistry</source>
          <year>1991</year>
          <volume>30</volume>
          <fpage>10363</fpage>
          <lpage>10370</lpage>
          <pub-id pub-id-type="doi">10.1021/bi00107a001</pub-id>
          <pub-id pub-id-type="pmid">1931959</pub-id>
        </element-citation>
      </ref>
      <ref id="B14-sensors-20-04254">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoffman</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Monroe</surname>
              <given-names>D.M.</given-names>
              <suffix>3rd</suffix>
            </name>
          </person-group>
          <article-title>A cell-based model of hemostasis</article-title>
          <source>Thromb. Haemost.</source>
          <year>2001</year>
          <volume>85</volume>
          <fpage>958</fpage>
          <lpage>965</lpage>
          <pub-id pub-id-type="pmid">11434702</pub-id>
        </element-citation>
      </ref>
      <ref id="B15-sensors-20-04254">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quick</surname>
              <given-names>A.J.</given-names>
            </name>
          </person-group>
          <article-title>The thromboplastin reagent for the determination of prothrombin</article-title>
          <source>Science</source>
          <year>1940</year>
          <volume>92</volume>
          <fpage>113</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="doi">10.1126/science.92.2379.113-a</pub-id>
        </element-citation>
      </ref>
      <ref id="B16-sensors-20-04254">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Langdell</surname>
              <given-names>R.D.</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>R.H.</given-names>
            </name>
            <name>
              <surname>Brinkhous</surname>
              <given-names>K.M.</given-names>
            </name>
          </person-group>
          <article-title>Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure</article-title>
          <source>J. Lab. Clin. Med.</source>
          <year>1953</year>
          <volume>41</volume>
          <fpage>637</fpage>
          <lpage>647</lpage>
          <pub-id pub-id-type="pmid">13045017</pub-id>
        </element-citation>
      </ref>
      <ref id="B17-sensors-20-04254">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tripodi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mannucci</surname>
              <given-names>P.M.</given-names>
            </name>
          </person-group>
          <article-title>Activated partial thromboplastin time (aptt). New indications for an old test</article-title>
          <source>J. Thromb. Haemost. JTH</source>
          <year>2006</year>
          <volume>4</volume>
          <fpage>750</fpage>
          <lpage>751</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2006.01857.x</pub-id>
          <pub-id pub-id-type="pmid">16634741</pub-id>
        </element-citation>
      </ref>
      <ref id="B18-sensors-20-04254">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clauss</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Rapid physiological coagulation method in determination of fibrinogen</article-title>
          <source>Acta Haematol.</source>
          <year>1957</year>
          <volume>17</volume>
          <fpage>237</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="doi">10.1159/000205234</pub-id>
          <pub-id pub-id-type="pmid">13434757</pub-id>
        </element-citation>
      </ref>
      <ref id="B19-sensors-20-04254">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kind</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Spahn-Nett</surname>
              <given-names>G.H.</given-names>
            </name>
            <name>
              <surname>Emmert</surname>
              <given-names>M.Y.</given-names>
            </name>
            <name>
              <surname>Eismon</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Theusinger</surname>
              <given-names>O.M.</given-names>
            </name>
          </person-group>
          <article-title>Is dilutional coagulopathy induced by different colloids reversible by replacement of fibrinogen and factor xiii concentrates</article-title>
          <source>Anesth. Analg.</source>
          <year>2013</year>
          <volume>117</volume>
          <fpage>1063</fpage>
          <lpage>1071</lpage>
          <pub-id pub-id-type="doi">10.1213/ANE.0b013e3182a52876</pub-id>
          <pub-id pub-id-type="pmid">24029856</pub-id>
        </element-citation>
      </ref>
      <ref id="B20-sensors-20-04254">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hartert</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Blutgerinnungsstudien mit der thrombelastographie, einem neuen untersuchungsverfahren</article-title>
          <source>Klin. Wochenschr.</source>
          <year>1948</year>
          <volume>26</volume>
          <fpage>577</fpage>
          <lpage>583</lpage>
          <pub-id pub-id-type="doi">10.1007/BF01697545</pub-id>
          <pub-id pub-id-type="pmid">18101974</pub-id>
        </element-citation>
      </ref>
      <ref id="B21-sensors-20-04254">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Theusinger</surname>
              <given-names>O.M.</given-names>
            </name>
            <name>
              <surname>Baulig</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>M&#xFC;ller</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Mariotti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>D.R.</given-names>
            </name>
          </person-group>
          <article-title>Changes in coagulation in standard laboratory tests and rotem in trauma patients between on-scene and arrival in the emergency department</article-title>
          <source>Anesth. Analg.</source>
          <year>2015</year>
          <volume>120</volume>
          <fpage>627</fpage>
          <lpage>635</lpage>
          <pub-id pub-id-type="doi">10.1213/ANE.0000000000000561</pub-id>
          <pub-id pub-id-type="pmid">25545751</pub-id>
        </element-citation>
      </ref>
      <ref id="B22-sensors-20-04254">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luddington</surname>
              <given-names>R.J.</given-names>
            </name>
          </person-group>
          <article-title>Thrombelastography/thromboelastometry</article-title>
          <source>Clin. Lab. Haematol.</source>
          <year>2005</year>
          <volume>27</volume>
          <fpage>81</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2257.2005.00681.x</pub-id>
          <pub-id pub-id-type="pmid">15784122</pub-id>
        </element-citation>
      </ref>
      <ref id="B23-sensors-20-04254">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aghighi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Riddell</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>S.A.</given-names>
            </name>
            <name>
              <surname>Tuddenham</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Chowdary</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Global coagulation assays in hemophilia a: A comparison to conventional assays</article-title>
          <source>Res. Pract. Thromb. Haemost.</source>
          <year>2020</year>
          <volume>4</volume>
          <fpage>298</fpage>
          <lpage>308</lpage>
          <pub-id pub-id-type="doi">10.1002/rth2.12295</pub-id>
          <pub-id pub-id-type="pmid">32110761</pub-id>
        </element-citation>
      </ref>
      <ref id="B24-sensors-20-04254">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larsen</surname>
              <given-names>O.H.</given-names>
            </name>
            <name>
              <surname>Fenger-Eriksen</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Christiansen</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Ingerslev</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>S&#xF8;rensen</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Diagnostic performance and therapeutic consequence of thromboelastometry activated by kaolin versus a panel of specific reagents</article-title>
          <source>Anesthesiology</source>
          <year>2011</year>
          <volume>115</volume>
          <fpage>294</fpage>
          <lpage>302</lpage>
          <pub-id pub-id-type="doi">10.1097/ALN.0b013e318220755c</pub-id>
          <pub-id pub-id-type="pmid">21691196</pub-id>
        </element-citation>
      </ref>
      <ref id="B25-sensors-20-04254">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>G&#xF6;rlinger</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Dirkmann</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Hanke</surname>
              <given-names>A.A.</given-names>
            </name>
          </person-group>
          <article-title>Fast interpretation of thromboelastometry in non-cardiac surgery: Reliability in patients with hypo-, normo-, and hypercoagulability</article-title>
          <source>Br. J. Anaesth.</source>
          <year>2013</year>
          <volume>110</volume>
          <fpage>222</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="doi">10.1093/bja/aes374</pub-id>
          <pub-id pub-id-type="pmid">23112213</pub-id>
        </element-citation>
      </ref>
      <ref id="B26-sensors-20-04254">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olde Engberink</surname>
              <given-names>R.H.</given-names>
            </name>
            <name>
              <surname>Kuiper</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Wetzels</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Nelemans</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Lance</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Beckers</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Henskens</surname>
              <given-names>Y.M.</given-names>
            </name>
          </person-group>
          <article-title>Rapid and correct prediction of thrombocytopenia and hypofibrinogenemia with rotational thromboelastometry in cardiac surgery</article-title>
          <source>J. Cardiothorac. Vasc. Anesth.</source>
          <year>2014</year>
          <volume>28</volume>
          <fpage>210</fpage>
          <lpage>216</lpage>
          <pub-id pub-id-type="doi">10.1053/j.jvca.2013.12.004</pub-id>
          <pub-id pub-id-type="pmid">24630470</pub-id>
        </element-citation>
      </ref>
      <ref id="B27-sensors-20-04254">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gronchi</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Perret</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Marcucci</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Fl&#xE8;che</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Crosset</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schoettker</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Marcucci</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Validation of rotational thromboelastometry during cardiopulmonary bypass: A prospective, observational in-vivo study</article-title>
          <source>Eur. J. Anaesthesiol.</source>
          <year>2014</year>
          <volume>31</volume>
          <fpage>68</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="doi">10.1097/EJA.0b013e328363171a</pub-id>
          <pub-id pub-id-type="pmid">23867776</pub-id>
        </element-citation>
      </ref>
      <ref id="B28-sensors-20-04254">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beiderlinden</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Werner</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bahlmann</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kemper</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Brezina</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sch&#xE4;fer</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>G&#xF6;rlinger</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Seidel</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kienbaum</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Treschan</surname>
              <given-names>T.A.</given-names>
            </name>
          </person-group>
          <article-title>Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry&#x2014;a prospectively controlled randomized double-blind clinical trial</article-title>
          <source>BMC Anesthesiol.</source>
          <year>2018</year>
          <volume>18</volume>
          <elocation-id>18</elocation-id>
          <pub-id pub-id-type="doi">10.1186/s12871-018-0475-y</pub-id>
          <pub-id pub-id-type="pmid">29426286</pub-id>
        </element-citation>
      </ref>
      <ref id="B29-sensors-20-04254">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>M&#xFC;ller</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Meijers</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Vroom</surname>
              <given-names>M.B.</given-names>
            </name>
            <name>
              <surname>Juffermans</surname>
              <given-names>N.P.</given-names>
            </name>
          </person-group>
          <article-title>Utility of thromboelastography and/or thromboelastometry in adults with sepsis: A systematic review</article-title>
          <source>Crit. Care</source>
          <year>2014</year>
          <volume>18</volume>
          <fpage>30</fpage>
          <pub-id pub-id-type="doi">10.1186/cc13721</pub-id>
        </element-citation>
      </ref>
      <ref id="B30-sensors-20-04254">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lang</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Bauters</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>P&#xF6;tzsch</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>von Pape</surname>
              <given-names>K.W.</given-names>
            </name>
            <name>
              <surname>Kolde</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>Lakner</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Multi-centre investigation on reference ranges for rotem thromboelastometry</article-title>
          <source>Blood Coagul. Fibrinolysis An Int. J. Haemost. Thromb.</source>
          <year>2005</year>
          <volume>16</volume>
          <fpage>301</fpage>
          <lpage>310</lpage>
          <pub-id pub-id-type="doi">10.1097/01.mbc.0000169225.31173.19</pub-id>
        </element-citation>
      </ref>
      <ref id="B31-sensors-20-04254">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelly</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Rizoli</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Veigas</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Hollands</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Min</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Using rotational thromboelastometry clot firmness at 5 minutes (rotem<sup>&#xAE;</sup>) extem a5) to predict massive transfusion and in-hospital mortality in trauma: A retrospective analysis of 1146 patients</article-title>
          <source>Anaesthesia</source>
          <year>2018</year>
          <volume>73</volume>
          <fpage>1103</fpage>
          <lpage>1109</lpage>
          <pub-id pub-id-type="doi">10.1111/anae.14297</pub-id>
          <pub-id pub-id-type="pmid">29658985</pub-id>
        </element-citation>
      </ref>
      <ref id="B32-sensors-20-04254">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Veigas</surname>
              <given-names>P.V.</given-names>
            </name>
            <name>
              <surname>Callum</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rizoli</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Nascimento</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>da Luz</surname>
              <given-names>L.T.</given-names>
            </name>
          </person-group>
          <article-title>A systematic review on the rotational thrombelastometry (rotem<sup>&#xAE;</sup>) values for the diagnosis of coagulopathy, prediction and guidance of blood transfusion and prediction of mortality in trauma patients</article-title>
          <source>Scand. J. Trauma Resusc. Emerg. Med.</source>
          <year>2016</year>
          <volume>24</volume>
          <fpage>114</fpage>
          <pub-id pub-id-type="doi">10.1186/s13049-016-0308-2</pub-id>
          <pub-id pub-id-type="pmid">27716278</pub-id>
        </element-citation>
      </ref>
      <ref id="B33-sensors-20-04254">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>R&#xF6;ssler</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Meybohm</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Zacharowski</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>N&#xF6;thiger</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Tscholl</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Improving decision making through presentation of viscoelastic tests as a 3d animated blood clot: The visual clot</article-title>
          <source>Anaesthesia</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1111/anae.14985</pub-id>
        </element-citation>
      </ref>
      <ref id="B34-sensors-20-04254">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roche</surname>
              <given-names>T.R.</given-names>
            </name>
            <name>
              <surname>Said</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>R&#xF6;ssler</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Godzik</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Meybohm</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Zacharowski</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>N&#xF6;thiger</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Tscholl</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>Physician perceptions of visual clot&#x2014;a situation awareness-oriented visualization technology for viscoelastic tests: A mixed methods study</article-title>
          <source>JMIR Prepr.</source>
          <year>2020</year>
          <volume>19036</volume>
          <pub-id pub-id-type="doi">10.2196/preprints.19036</pub-id>
        </element-citation>
      </ref>
      <ref id="B35-sensors-20-04254">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tscholl</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>R&#xF6;ssler</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Said</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kaserer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>N&#xF6;thiger</surname>
              <given-names>C.B.</given-names>
            </name>
          </person-group>
          <article-title>Situation awareness-oriented patient monitoring with visual patient technology: A qualitative review of the primary research</article-title>
          <source>Sensors</source>
          <year>2020</year>
          <volume>20</volume>
          <elocation-id>2112</elocation-id>
          <pub-id pub-id-type="doi">10.3390/s20072112</pub-id>
        </element-citation>
      </ref>
      <ref id="B36-sensors-20-04254">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gurbel</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Bliden</surname>
              <given-names>K.P.</given-names>
            </name>
            <name>
              <surname>Tantry</surname>
              <given-names>U.S.</given-names>
            </name>
            <name>
              <surname>Monroe</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Muresan</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Brunner</surname>
              <given-names>N.E.</given-names>
            </name>
            <name>
              <surname>Lopez-Espina</surname>
              <given-names>C.G.</given-names>
            </name>
            <name>
              <surname>Delmenico</surname>
              <given-names>P.R.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Raviv</surname>
              <given-names>G.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>First report of the point-of-care teg: A technical validation study of the teg-6s system</article-title>
          <source>Platelets</source>
          <year>2016</year>
          <volume>27</volume>
          <fpage>642</fpage>
          <lpage>649</lpage>
          <pub-id pub-id-type="doi">10.3109/09537104.2016.1153617</pub-id>
          <pub-id pub-id-type="pmid">27809712</pub-id>
        </element-citation>
      </ref>
      <ref id="B37-sensors-20-04254">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whiting</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>DiNardo</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Teg and rotem: Technology and clinical applications</article-title>
          <source>Am. J. Hematol.</source>
          <year>2014</year>
          <volume>89</volume>
          <fpage>228</fpage>
          <lpage>232</lpage>
          <pub-id pub-id-type="doi">10.1002/ajh.23599</pub-id>
          <pub-id pub-id-type="pmid">24123050</pub-id>
        </element-citation>
      </ref>
      <ref id="B38-sensors-20-04254">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ziegler</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Voelckel</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Zipperle</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Grottke</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Sch&#xF6;chl</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Comparison between the new fully automated viscoelastic coagulation analysers teg 6s and rotem sigma in trauma patients: A prospective observational study</article-title>
          <source>Eur. J. Anaesthesiol.</source>
          <year>2019</year>
          <volume>36</volume>
          <fpage>834</fpage>
          <lpage>842</lpage>
          <pub-id pub-id-type="doi">10.1097/EJA.0000000000001032</pub-id>
          <pub-id pub-id-type="pmid">31219873</pub-id>
        </element-citation>
      </ref>
      <ref id="B39-sensors-20-04254">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kauvar</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Lefering</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Wade</surname>
              <given-names>C.E.</given-names>
            </name>
          </person-group>
          <article-title>Impact of hemorrhage on trauma outcome: An overview of epidemiology, clinical presentations, and therapeutic considerations</article-title>
          <source>J. Trauma</source>
          <year>2006</year>
          <volume>60</volume>
          <fpage>3</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1097/01.ta.0000199961.02677.19</pub-id>
        </element-citation>
      </ref>
      <ref id="B40-sensors-20-04254">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holcomb</surname>
              <given-names>J.B.</given-names>
            </name>
            <name>
              <surname>del Junco</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Fox</surname>
              <given-names>E.E.</given-names>
            </name>
            <name>
              <surname>Wade</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Schreiber</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Alarcon</surname>
              <given-names>L.H.</given-names>
            </name>
            <name>
              <surname>Bai</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Brasel</surname>
              <given-names>K.J.</given-names>
            </name>
            <name>
              <surname>Bulger</surname>
              <given-names>E.M.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The prospective, observational, multicenter, major trauma transfusion (prommtt) study: Comparative effectiveness of a time-varying treatment with competing risks</article-title>
          <source>JAMA Surg.</source>
          <year>2013</year>
          <volume>148</volume>
          <fpage>127</fpage>
          <lpage>136</lpage>
          <pub-id pub-id-type="doi">10.1001/2013.jamasurg.387</pub-id>
          <pub-id pub-id-type="pmid">23560283</pub-id>
        </element-citation>
      </ref>
      <ref id="B41-sensors-20-04254">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hagemo</surname>
              <given-names>J.S.</given-names>
            </name>
            <name>
              <surname>Christiaans</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Stanworth</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Brohi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Johansson</surname>
              <given-names>P.I.</given-names>
            </name>
            <name>
              <surname>Goslings</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Naess</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Gaarder</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Detection of acute traumatic coagulopathy and massive transfusion requirements by means of rotational thromboelastometry: An international prospective validation study</article-title>
          <source>Crit. Care</source>
          <year>2015</year>
          <volume>19</volume>
          <fpage>97</fpage>
          <pub-id pub-id-type="doi">10.1186/s13054-015-0823-y</pub-id>
          <pub-id pub-id-type="pmid">25888032</pub-id>
        </element-citation>
      </ref>
      <ref id="B42-sensors-20-04254">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laursen</surname>
              <given-names>T.H.</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>M.A.S.</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>A.S.P.</given-names>
            </name>
            <name>
              <surname>Gaarder</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Naess</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Stensballe</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Ostrowski</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>Johansson</surname>
              <given-names>P.I.</given-names>
            </name>
          </person-group>
          <article-title>Thrombelastography early amplitudes in bleeding and coagulopathic trauma patients: Results from a multicenter study</article-title>
          <source>J. Trauma Acute Care Surg.</source>
          <year>2018</year>
          <volume>84</volume>
          <fpage>334</fpage>
          <lpage>341</lpage>
          <pub-id pub-id-type="doi">10.1097/TA.0000000000001735</pub-id>
          <pub-id pub-id-type="pmid">29112094</pub-id>
        </element-citation>
      </ref>
      <ref id="B43-sensors-20-04254">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meyer</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>S&#xF8;rensen</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Rasmussen</surname>
              <given-names>L.S.</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>M.B.</given-names>
            </name>
            <name>
              <surname>Holcomb</surname>
              <given-names>J.B.</given-names>
            </name>
            <name>
              <surname>Cotton</surname>
              <given-names>B.A.</given-names>
            </name>
            <name>
              <surname>Wade</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Ostrowski</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>Johansson</surname>
              <given-names>P.I.</given-names>
            </name>
          </person-group>
          <article-title>Thrombelastography and rotational thromboelastometry early amplitudes in 182 trauma patients with clinical suspicion of severe injury</article-title>
          <source>J. Trauma Acute Care Surg.</source>
          <year>2014</year>
          <volume>76</volume>
          <fpage>682</fpage>
          <lpage>690</lpage>
          <pub-id pub-id-type="doi">10.1097/TA.0000000000000134</pub-id>
          <pub-id pub-id-type="pmid">24553534</pub-id>
        </element-citation>
      </ref>
      <ref id="B44-sensors-20-04254">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hartmann</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dias</surname>
              <given-names>J.D.</given-names>
            </name>
          </person-group>
          <article-title>Viscoelastic hemostatic assays: Moving from the laboratory to the site of care-a review of established and emerging technologies</article-title>
          <source>Diagnostics</source>
          <year>2020</year>
          <volume>10</volume>
          <elocation-id>118</elocation-id>
          <pub-id pub-id-type="doi">10.3390/diagnostics10020118</pub-id>
          <pub-id pub-id-type="pmid">32098161</pub-id>
        </element-citation>
      </ref>
      <ref id="B45-sensors-20-04254">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>von Kaulla</surname>
              <given-names>K.N.</given-names>
            </name>
            <name>
              <surname>Ostendorf</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>von Kaulla</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>The impedance machine: A new bedside coagulation recording device</article-title>
          <source>J. Med.</source>
          <year>1975</year>
          <volume>6</volume>
          <fpage>73</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="pmid">1095678</pub-id>
        </element-citation>
      </ref>
      <ref id="B46-sensors-20-04254">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Curry</surname>
              <given-names>N.S.</given-names>
            </name>
            <name>
              <surname>Davenport</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Pavord</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mallett</surname>
              <given-names>S.V.</given-names>
            </name>
            <name>
              <surname>Kitchen</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Maybury</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>P.W.</given-names>
            </name>
            <name>
              <surname>Laffan</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>The use of viscoelastic haemostatic assays in the management of major bleeding: A british society for haematology guideline</article-title>
          <source>Br. J. Haematol.</source>
          <year>2018</year>
          <volume>182</volume>
          <fpage>789</fpage>
          <lpage>806</lpage>
          <pub-id pub-id-type="doi">10.1111/bjh.15524</pub-id>
          <pub-id pub-id-type="pmid">30073664</pub-id>
        </element-citation>
      </ref>
      <ref id="B47-sensors-20-04254">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ganter</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Hofer</surname>
              <given-names>C.K.</given-names>
            </name>
          </person-group>
          <article-title>Coagulation monitoring: Current techniques and clinical use of viscoelastic point-of-care coagulation devices</article-title>
          <source>Anesth. Analg.</source>
          <year>2008</year>
          <volume>106</volume>
          <fpage>1366</fpage>
          <lpage>1375</lpage>
          <pub-id pub-id-type="doi">10.1213/ane.0b013e318168b367</pub-id>
          <pub-id pub-id-type="pmid">18420846</pub-id>
        </element-citation>
      </ref>
      <ref id="B48-sensors-20-04254">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gando</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hayakawa</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiology of trauma-induced coagulopathy and management of critical bleeding requiring massive transfusion</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <year>2016</year>
          <volume>42</volume>
          <fpage>155</fpage>
          <lpage>165</lpage>
          <pub-id pub-id-type="pmid">26716498</pub-id>
        </element-citation>
      </ref>
      <ref id="B49-sensors-20-04254">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maegele</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sch&#xF6;chl</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>M.J.</given-names>
            </name>
          </person-group>
          <article-title>An update on the coagulopathy of trauma</article-title>
          <source>Shock</source>
          <year>2014</year>
          <volume>41</volume>
          <fpage>21</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="doi">10.1097/SHK.0000000000000088</pub-id>
          <pub-id pub-id-type="pmid">24192549</pub-id>
        </element-citation>
      </ref>
      <ref id="B50-sensors-20-04254">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sch&#xF6;chl</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Nienaber</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Hofer</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Voelckel</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Jambor</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Scharbert</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Kozek-Langenecker</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Solomon</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Goal-directed coagulation management of major trauma patients using thromboelastometry (rotem)-guided administration of fibrinogen concentrate and prothrombin complex concentrate</article-title>
          <source>Crit. Care</source>
          <year>2010</year>
          <volume>14</volume>
          <fpage>55</fpage>
          <pub-id pub-id-type="doi">10.1186/cc8948</pub-id>
        </element-citation>
      </ref>
      <ref id="B51-sensors-20-04254">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Theusinger</surname>
              <given-names>O.M.</given-names>
            </name>
            <name>
              <surname>Baulig</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Emmert</surname>
              <given-names>M.Y.</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Asmis</surname>
              <given-names>L.M.</given-names>
            </name>
          </person-group>
          <article-title>Relative concentrations of haemostatic factors and cytokines in solvent/detergent-treated and fresh-frozen plasma</article-title>
          <source>Br. J. Anaesth.</source>
          <year>2011</year>
          <volume>106</volume>
          <fpage>505</fpage>
          <lpage>511</lpage>
          <pub-id pub-id-type="doi">10.1093/bja/aer003</pub-id>
          <pub-id pub-id-type="pmid">21310721</pub-id>
        </element-citation>
      </ref>
      <ref id="B52-sensors-20-04254">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toy</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Popovsky</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ambruso</surname>
              <given-names>D.R.</given-names>
            </name>
            <name>
              <surname>Holness</surname>
              <given-names>L.G.</given-names>
            </name>
            <name>
              <surname>Kopko</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>McFarland</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Nathens</surname>
              <given-names>A.B.</given-names>
            </name>
            <name>
              <surname>Silliman</surname>
              <given-names>C.C.</given-names>
            </name>
            <name>
              <surname>Stroncek</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Transfusion-related acute lung injury: Definition and review</article-title>
          <source>Crit. Care Med.</source>
          <year>2005</year>
          <volume>33</volume>
          <fpage>721</fpage>
          <lpage>726</lpage>
          <pub-id pub-id-type="doi">10.1097/01.CCM.0000159849.94750.51</pub-id>
          <pub-id pub-id-type="pmid">15818095</pub-id>
        </element-citation>
      </ref>
      <ref id="B53-sensors-20-04254">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edens</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Haass</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Cumming</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Osinski</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>O&#x2019;Hearn</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Passanisi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Eaton</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Visintainer</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Savinkina</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kuehnert</surname>
              <given-names>M.J.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evaluation of the national healthcare safety network hemovigilance module for transfusion-related adverse reactions in the united states</article-title>
          <source>Transfusion</source>
          <year>2019</year>
          <volume>59</volume>
          <fpage>524</fpage>
          <lpage>533</lpage>
          <pub-id pub-id-type="doi">10.1111/trf.15008</pub-id>
          <pub-id pub-id-type="pmid">30427540</pub-id>
        </element-citation>
      </ref>
      <ref id="B54-sensors-20-04254">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andreu</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Morel</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Forestier</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Debeir</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Rebibo</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Janvier</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Herv&#xE9;</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Hemovigilance network in france: Organization and analysis of immediate transfusion incident reports from 1994 to 1998</article-title>
          <source>Transfusion</source>
          <year>2002</year>
          <volume>42</volume>
          <fpage>1356</fpage>
          <lpage>1364</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1537-2995.2002.00202.x</pub-id>
          <pub-id pub-id-type="pmid">12423521</pub-id>
        </element-citation>
      </ref>
      <ref id="B55-sensors-20-04254">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chow</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Morrison</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Galvagno</surname>
              <given-names>S.M.</given-names>
              <suffix>Jr.</suffix>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Madurska</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Rock</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Scalea</surname>
              <given-names>T.M.</given-names>
            </name>
            <name>
              <surname>Mazzeffi</surname>
              <given-names>M.A.</given-names>
            </name>
          </person-group>
          <article-title>Viscoelastic signals for optimal resuscitation in trauma: Kaolin thrombelastography cutoffs for diagnosing hypofibrinogenemia (visor study)</article-title>
          <source>Anesth. Analg.</source>
          <year>2019</year>
          <volume>129</volume>
          <fpage>1482</fpage>
          <lpage>1491</lpage>
          <pub-id pub-id-type="doi">10.1213/ANE.0000000000004315</pub-id>
          <pub-id pub-id-type="pmid">31743167</pub-id>
        </element-citation>
      </ref>
      <ref id="B56-sensors-20-04254">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Theusinger</surname>
              <given-names>O.M.</given-names>
            </name>
            <name>
              <surname>N&#xFC;rnberg</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Asmis</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Seifert</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>D.R.</given-names>
            </name>
          </person-group>
          <article-title>Rotation thromboelastometry (rotem) stability and reproducibility over time</article-title>
          <source>Eur. J. Cardio Thorac. Surg.</source>
          <year>2010</year>
          <volume>37</volume>
          <fpage>677</fpage>
          <lpage>683</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejcts.2009.07.038</pub-id>
        </element-citation>
      </ref>
      <ref id="B57-sensors-20-04254">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mackie</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lawrie</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kitchen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Laffan</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis</article-title>
          <source>Int. J. Lab. Hematol.</source>
          <year>2013</year>
          <volume>35</volume>
          <fpage>1</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1111/ijlh.12004</pub-id>
        </element-citation>
      </ref>
      <ref id="B58-sensors-20-04254">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ranucci</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Baryshnikova</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Sensitivity of viscoelastic tests to platelet function</article-title>
          <source>J. Clin. Med.</source>
          <year>2020</year>
          <volume>9</volume>
          <elocation-id>189</elocation-id>
          <pub-id pub-id-type="doi">10.3390/jcm9010189</pub-id>
        </element-citation>
      </ref>
      <ref id="B59-sensors-20-04254">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heeringa</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>van der Kuip</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Hofman</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kors</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>van Herpen</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Stricker</surname>
              <given-names>B.H.</given-names>
            </name>
            <name>
              <surname>Stijnen</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Lip</surname>
              <given-names>G.Y.</given-names>
            </name>
            <name>
              <surname>Witteman</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Prevalence, incidence and lifetime risk of atrial fibrillation: The rotterdam study</article-title>
          <source>Eur. Heart J.</source>
          <year>2006</year>
          <volume>27</volume>
          <fpage>949</fpage>
          <lpage>953</lpage>
          <pub-id pub-id-type="doi">10.1093/eurheartj/ehi825</pub-id>
          <pub-id pub-id-type="pmid">16527828</pub-id>
        </element-citation>
      </ref>
      <ref id="B60-sensors-20-04254">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bellin</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Berto</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Themistoclakis</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chandak</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Giusti</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cavalli</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Bakshi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tessarin</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Deambrosis</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Chinellato</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>New oral anti-coagulants versus vitamin k antagonists in high thromboembolic risk patients</article-title>
          <source>PLoS ONE</source>
          <year>2019</year>
          <volume>14</volume>
          <elocation-id>0222762</elocation-id>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0222762</pub-id>
        </element-citation>
      </ref>
      <ref id="B61-sensors-20-04254">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shoeb</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>M.C.</given-names>
            </name>
          </person-group>
          <article-title>Assessing bleeding risk in patients taking anticoagulants</article-title>
          <source>J. Thromb. Thrombolysis</source>
          <year>2013</year>
          <volume>35</volume>
          <fpage>312</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="doi">10.1007/s11239-013-0899-7</pub-id>
          <pub-id pub-id-type="pmid">23479259</pub-id>
        </element-citation>
      </ref>
      <ref id="B62-sensors-20-04254">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salmonson</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Dogn&#xE9;</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Janssen</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Garcia Burgos</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Blake</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Non-vitamin-k oral anticoagulants and laboratory testing: Now and in the future: Views from a workshop at the european medicines agency (ema)</article-title>
          <source>Eur. Heart J. Cardiovasc. Pharmacother.</source>
          <year>2017</year>
          <volume>3</volume>
          <fpage>42</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="doi">10.1093/ehjcvp/pvw032</pub-id>
          <pub-id pub-id-type="pmid">28025213</pub-id>
        </element-citation>
      </ref>
      <ref id="B63-sensors-20-04254">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seyve</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Richarme</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Polack</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Marlu</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Impact of four direct oral anticoagulants on rotational thromboelastometry (rotem)</article-title>
          <source>Int. J. Lab. Hematol.</source>
          <year>2018</year>
          <volume>40</volume>
          <fpage>84</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.1111/ijlh.12744</pub-id>
          <pub-id pub-id-type="pmid">28980758</pub-id>
        </element-citation>
      </ref>
      <ref id="B64-sensors-20-04254">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gosselin</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Adcock</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Dorgalaleh</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Favaloro</surname>
              <given-names>E.J.</given-names>
            </name>
            <name>
              <surname>Lippi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pego</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Regan</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Siguret</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>International council for standardization in haematology recommendations for hemostasis critical values, tests, and reporting</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <year>2020</year>
          <volume>46</volume>
          <fpage>398</fpage>
          <lpage>409</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0039-1697677</pub-id>
          <pub-id pub-id-type="pmid">31639855</pub-id>
        </element-citation>
      </ref>
      <ref id="B65-sensors-20-04254">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adelmann</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Wiegele</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wohlgemuth</surname>
              <given-names>R.K.</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Frantal</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Quehenberger</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Scharbert</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Kozek-Langenecker</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Schaden</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry</article-title>
          <source>Thromb. Res.</source>
          <year>2014</year>
          <volume>134</volume>
          <fpage>918</fpage>
          <lpage>923</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2014.08.006</pub-id>
          <pub-id pub-id-type="pmid">25179518</pub-id>
        </element-citation>
      </ref>
      <ref id="B66-sensors-20-04254">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fontana</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Alberio</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Angelillo-Scherrer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Asmis</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Korte</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Mendez</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Schmid</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Stricker</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Studt</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Tsakiris</surname>
              <given-names>D.A.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact of rivaroxaban on point-of-care assays</article-title>
          <source>Thromb. Res.</source>
          <year>2017</year>
          <volume>153</volume>
          <fpage>65</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2017.03.019</pub-id>
          <pub-id pub-id-type="pmid">28343143</pub-id>
        </element-citation>
      </ref>
      <ref id="B67-sensors-20-04254">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vedovati</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Mosconi</surname>
              <given-names>M.G.</given-names>
            </name>
            <name>
              <surname>Isidori</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Agnelli</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Becattini</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Global thromboelastometry in patients receiving direct oral anticoagulants: The ro-doa study</article-title>
          <source>J. Thromb. Thrombolysis</source>
          <year>2020</year>
          <volume>49</volume>
          <fpage>251</fpage>
          <lpage>258</lpage>
          <pub-id pub-id-type="doi">10.1007/s11239-019-01956-0</pub-id>
          <pub-id pub-id-type="pmid">31520364</pub-id>
        </element-citation>
      </ref>
      <ref id="B68-sensors-20-04254">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dias</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Norem</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Doorneweerd</surname>
              <given-names>D.D.</given-names>
            </name>
            <name>
              <surname>Thurer</surname>
              <given-names>R.L.</given-names>
            </name>
            <name>
              <surname>Popovsky</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Omert</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>Use of thromboelastography (teg) for detection of new oral anticoagulants</article-title>
          <source>Arch. Pathol. Lab. Med.</source>
          <year>2015</year>
          <volume>139</volume>
          <fpage>665</fpage>
          <lpage>673</lpage>
          <pub-id pub-id-type="doi">10.5858/arpa.2014-0170-OA</pub-id>
          <pub-id pub-id-type="pmid">25927150</pub-id>
        </element-citation>
      </ref>
      <ref id="B69-sensors-20-04254">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bliden</surname>
              <given-names>K.P.</given-names>
            </name>
            <name>
              <surname>Chaudhary</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Mohammed</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Muresan</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Lopez-Espina</surname>
              <given-names>C.G.</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Raviv</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Doubleday</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Zaman</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Mathew</surname>
              <given-names>B.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Determination of non-vitamin k oral anticoagulant (noac) effects using a new-generation thrombelastography teg 6s system</article-title>
          <source>J. Thromb. Thrombolysis</source>
          <year>2017</year>
          <volume>43</volume>
          <fpage>437</fpage>
          <lpage>445</lpage>
          <pub-id pub-id-type="doi">10.1007/s11239-017-1477-1</pub-id>
          <pub-id pub-id-type="pmid">28247290</pub-id>
        </element-citation>
      </ref>
      <ref id="B70-sensors-20-04254">
        <label>70.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nardi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Agostini</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Rondinelli</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Bastianini</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Bini</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Bulgarelli</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Cingolani</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Donato</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gambale</surname>
              <given-names>G.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Trauma-induced coagulopathy: Impact of the early coagulation support protocol on blood product consumption, mortality and costs</article-title>
          <source>Crit. Care</source>
          <year>2015</year>
          <volume>19</volume>
          <fpage>83</fpage>
          <pub-id pub-id-type="doi">10.1186/s13054-015-0817-9</pub-id>
          <pub-id pub-id-type="pmid">25880548</pub-id>
        </element-citation>
      </ref>
      <ref id="B71-sensors-20-04254">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wikkels&#xF8;</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wetterslev</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>M&#xF8;ller</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Afshari</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Thromboelastography (teg) or thromboelastometry (rotem) to monitor haemostatic treatment versus usual care in adults or children with bleeding</article-title>
          <source>Cochrane Database Syst. Rev.</source>
          <year>2016</year>
          <volume>2016</volume>
          <fpage>007871</fpage>
          <pub-id pub-id-type="doi">10.1002/14651858.CD007871.pub3</pub-id>
          <pub-id pub-id-type="pmid">27552162</pub-id>
        </element-citation>
      </ref>
      <ref id="B72-sensors-20-04254">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deppe</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Zimmermann</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>E.W.</given-names>
            </name>
            <name>
              <surname>Slottosch</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Liakopoulos</surname>
              <given-names>O.J.</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>Y.H.</given-names>
            </name>
            <name>
              <surname>Wahlers</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: A meta-analysis of 8332 patients</article-title>
          <source>J. Surg. Res.</source>
          <year>2016</year>
          <volume>203</volume>
          <fpage>424</fpage>
          <lpage>433</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jss.2016.03.008</pub-id>
          <pub-id pub-id-type="pmid">27363652</pub-id>
        </element-citation>
      </ref>
      <ref id="B73-sensors-20-04254">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santos</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>A.J.F.</given-names>
            </name>
            <name>
              <surname>Barbosa</surname>
              <given-names>M.C.L.</given-names>
            </name>
            <name>
              <surname>Nogueira</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Viscoelastic haemostatic assays in the perioperative period of surgical procedures: Systematic review and meta-analysis</article-title>
          <source>J. Clin. Anesth.</source>
          <year>2020</year>
          <volume>64</volume>
          <fpage>109809</fpage>
          <pub-id pub-id-type="doi">10.1016/j.jclinane.2020.109809</pub-id>
          <pub-id pub-id-type="pmid">32299044</pub-id>
        </element-citation>
      </ref>
      <ref id="B74-sensors-20-04254">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fahrendorff</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Oliveri</surname>
              <given-names>R.S.</given-names>
            </name>
            <name>
              <surname>Johansson</surname>
              <given-names>P.I.</given-names>
            </name>
          </person-group>
          <article-title>The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products&#x2014;a systematic review and meta-analysis</article-title>
          <source>Scand. J. Trauma Resusc. Emerg. Med.</source>
          <year>2017</year>
          <volume>25</volume>
          <fpage>39</fpage>
          <pub-id pub-id-type="doi">10.1186/s13049-017-0378-9</pub-id>
          <pub-id pub-id-type="pmid">28403868</pub-id>
        </element-citation>
      </ref>
      <ref id="B75-sensors-20-04254">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vlot</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Rigter</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Noordzij</surname>
              <given-names>P.G.</given-names>
            </name>
          </person-group>
          <article-title>Optimal patient blood management in cardiac surgery using viscoelastic point-of-care testing: Response to: Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery: Updated systematic review and meta-analysis</article-title>
          <source>Br. J. Anaesth.</source>
          <year>2017</year>
          <volume>119</volume>
          <fpage>544</fpage>
          <lpage>545</lpage>
          <pub-id pub-id-type="pmid">28969331</pub-id>
        </element-citation>
      </ref>
      <ref id="B76-sensors-20-04254">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Serraino</surname>
              <given-names>G.F.</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>G.J.</given-names>
            </name>
          </person-group>
          <article-title>Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery: Updated systematic review and meta-analysis</article-title>
          <source>Br. J. Anaesth.</source>
          <year>2017</year>
          <volume>118</volume>
          <fpage>823</fpage>
          <lpage>833</lpage>
          <pub-id pub-id-type="doi">10.1093/bja/aex100</pub-id>
          <pub-id pub-id-type="pmid">28475665</pub-id>
        </element-citation>
      </ref>
      <ref id="B77-sensors-20-04254">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lodewyks</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Heinrichs</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Grocott</surname>
              <given-names>H.P.</given-names>
            </name>
            <name>
              <surname>Karkouti</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Romund</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Arora</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Tangri</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Rabbani</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Abou-Setta</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Zarychanski</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Point-of-care viscoelastic hemostatic testing in cardiac surgery patients: A systematic review and meta-analysis</article-title>
          <source>Can. J. Anaesth.</source>
          <year>2018</year>
          <volume>65</volume>
          <fpage>1333</fpage>
          <lpage>1347</lpage>
          <pub-id pub-id-type="doi">10.1007/s12630-018-1217-9</pub-id>
          <pub-id pub-id-type="pmid">30194674</pub-id>
        </element-citation>
      </ref>
      <ref id="B78-sensors-20-04254">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ranucci</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Bank blood shortage, transfusion containment and viscoelastic point-of-care coagulation testing in cardiac surgery</article-title>
          <source>Br. J. Anaesth.</source>
          <year>2017</year>
          <volume>118</volume>
          <fpage>814</fpage>
          <lpage>815</lpage>
          <pub-id pub-id-type="doi">10.1093/bja/aex143</pub-id>
          <pub-id pub-id-type="pmid">28575337</pub-id>
        </element-citation>
      </ref>
      <ref id="B79-sensors-20-04254">
        <label>79.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title>
          <source>J. Thromb. Haemost. JTH</source>
          <year>2020</year>
          <volume>18</volume>
          <fpage>844</fpage>
          <lpage>847</lpage>
          <pub-id pub-id-type="doi">10.1111/jth.14768</pub-id>
          <pub-id pub-id-type="pmid">32073213</pub-id>
        </element-citation>
      </ref>
      <ref id="B80-sensors-20-04254">
        <label>80.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Xiang</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Gu</surname>
              <given-names>X.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical course and risk factors for mortality of adult inpatients with covid-19 in wuhan, china: A retrospective cohort study</article-title>
          <source>Lancet</source>
          <year>2020</year>
          <volume>395</volume>
          <fpage>1054</fpage>
          <lpage>1062</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id>
          <pub-id pub-id-type="pmid">32171076</pub-id>
        </element-citation>
      </ref>
      <ref id="B81-sensors-20-04254">
        <label>81.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baron</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Franchini</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Goobie</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Javidroozi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Lasocki</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Liumbruno</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Mu&#xF1;oz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Shander</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Spahn</surname>
              <given-names>D.R.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patient blood management during the covid-19 pandemic&#x2014;a narrative review</article-title>
          <source>Anaesthesia</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1111/anae.15095</pub-id>
        </element-citation>
      </ref>
      <ref id="B82-sensors-20-04254">
        <label>82.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Born</surname>
              <given-names>G.V.</given-names>
            </name>
          </person-group>
          <article-title>Aggregation of blood platelets by adenosine diphosphate and its reversal</article-title>
          <source>Nature</source>
          <year>1962</year>
          <volume>194</volume>
          <fpage>927</fpage>
          <lpage>929</lpage>
          <pub-id pub-id-type="doi">10.1038/194927b0</pub-id>
          <pub-id pub-id-type="pmid">13871375</pub-id>
        </element-citation>
      </ref>
      <ref id="B83-sensors-20-04254">
        <label>83.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winter</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Grove</surname>
              <given-names>E.L.</given-names>
            </name>
            <name>
              <surname>De Caterina</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Gorog</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Ahrens</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Geisler</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Gurbel</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Tantry</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Navarese</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Siller-Matula</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Advocating cardiovascular precision medicine with p2y12 receptor inhibitors</article-title>
          <source>Eur. Heart J. Cardiovasc. Pharmacother.</source>
          <year>2017</year>
          <volume>3</volume>
          <fpage>221</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="doi">10.1093/ehjcvp/pvw044</pub-id>
          <pub-id pub-id-type="pmid">28204303</pub-id>
        </element-citation>
      </ref>
      <ref id="B84-sensors-20-04254">
        <label>84.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials</article-title>
          <source>BMC Cardiovasc. Disord.</source>
          <year>2017</year>
          <volume>17</volume>
          <elocation-id>157</elocation-id>
          <pub-id pub-id-type="doi">10.1186/s12872-017-0582-6</pub-id>
          <pub-id pub-id-type="pmid">28619104</pub-id>
        </element-citation>
      </ref>
      <ref id="B85-sensors-20-04254">
        <label>85.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petricevic</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kopjar</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Biocina</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Milicic</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kolic</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Boban</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Skoric</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Lekic</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gasparovic</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>The predictive value of platelet function point-of-care tests for postoperative blood loss and transfusion in routine cardiac surgery: A systematic review</article-title>
          <source>Thorac. Cardiovasc. Surg.</source>
          <year>2015</year>
          <volume>63</volume>
          <fpage>2</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">24983736</pub-id>
        </element-citation>
      </ref>
      <ref id="B86-sensors-20-04254">
        <label>86.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petricevic</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Konosic</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Biocina</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Dirkmann</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mihaljevic</surname>
              <given-names>M.Z.</given-names>
            </name>
            <name>
              <surname>Ivancan</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Konosic</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Svetina</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>G&#xF6;rlinger</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Bleeding risk assessment in patients undergoing elective cardiac surgery using rotem(<sup>&#xAE;</sup>) platelet and multiplate(<sup>&#xAE;</sup>) impedance aggregometry</article-title>
          <source>Anaesthesia</source>
          <year>2016</year>
          <volume>71</volume>
          <fpage>636</fpage>
          <lpage>647</lpage>
          <pub-id pub-id-type="doi">10.1111/anae.13303</pub-id>
          <pub-id pub-id-type="pmid">26763378</pub-id>
        </element-citation>
      </ref>
      <ref id="B87-sensors-20-04254">
        <label>87.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Connelly</surname>
              <given-names>C.R.</given-names>
            </name>
            <name>
              <surname>Yonge</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>McCully</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Hilliard</surname>
              <given-names>T.C.</given-names>
            </name>
            <name>
              <surname>Lape</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Rick</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Houser</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Deloughery</surname>
              <given-names>T.G.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Assessment of three point-of-care platelet function assays in adult trauma patients</article-title>
          <source>J. Surg. Res.</source>
          <year>2017</year>
          <volume>212</volume>
          <fpage>260</fpage>
          <lpage>269</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jss.2017.01.008</pub-id>
          <pub-id pub-id-type="pmid">28550916</pub-id>
        </element-citation>
      </ref>
      <ref id="B88-sensors-20-04254">
        <label>88.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moenen</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Vries</surname>
              <given-names>M.J.A.</given-names>
            </name>
            <name>
              <surname>Nelemans</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>van Rooy</surname>
              <given-names>K.J.M.</given-names>
            </name>
            <name>
              <surname>Vranken</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Verhezen</surname>
              <given-names>P.W.M.</given-names>
            </name>
            <name>
              <surname>Wetzels</surname>
              <given-names>R.J.H.</given-names>
            </name>
            <name>
              <surname>Ten Cate</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Schouten</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Beckers</surname>
              <given-names>E.A.M.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Screening for platelet function disorders with multiplate and platelet function analyzer</article-title>
          <source>Platelets</source>
          <year>2019</year>
          <volume>30</volume>
          <fpage>81</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="doi">10.1080/09537104.2017.1371290</pub-id>
          <pub-id pub-id-type="pmid">29135309</pub-id>
        </element-citation>
      </ref>
      <ref id="B89-sensors-20-04254">
        <label>89.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cardinal</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Flower</surname>
              <given-names>R.J.</given-names>
            </name>
          </person-group>
          <article-title>The electronic aggregometer: A novel device for assessing platelet behavior in blood</article-title>
          <source>J. Pharmacol. Methods</source>
          <year>1980</year>
          <volume>3</volume>
          <fpage>135</fpage>
          <lpage>158</lpage>
          <pub-id pub-id-type="doi">10.1016/0160-5402(80)90024-8</pub-id>
          <pub-id pub-id-type="pmid">7392654</pub-id>
        </element-citation>
      </ref>
      <ref id="B90-sensors-20-04254">
        <label>90.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>T&#xF3;th</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Calatzis</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Penz</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Losonczy</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Siess</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood</article-title>
          <source>Thromb. Haemost.</source>
          <year>2006</year>
          <volume>96</volume>
          <fpage>781</fpage>
          <lpage>788</lpage>
          <pub-id pub-id-type="pmid">17139373</pub-id>
        </element-citation>
      </ref>
      <ref id="B91-sensors-20-04254">
        <label>91.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peerschke</surname>
              <given-names>E.I.</given-names>
            </name>
            <name>
              <surname>Castellone</surname>
              <given-names>D.D.</given-names>
            </name>
            <name>
              <surname>Stroobants</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Reference range determination for whole-blood platelet aggregation using the multiplate analyzer</article-title>
          <source>Am. J. Clin. Pathol.</source>
          <year>2014</year>
          <volume>142</volume>
          <fpage>647</fpage>
          <lpage>656</lpage>
          <pub-id pub-id-type="doi">10.1309/AJCPP43SEYCBJLHJ</pub-id>
          <pub-id pub-id-type="pmid">25319980</pub-id>
        </element-citation>
      </ref>
      <ref id="B92-sensors-20-04254">
        <label>92.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>W&#xFC;rtz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hvas</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>K.H.</given-names>
            </name>
            <name>
              <surname>Rubak</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kristensen</surname>
              <given-names>S.D.</given-names>
            </name>
            <name>
              <surname>Grove</surname>
              <given-names>E.L.</given-names>
            </name>
          </person-group>
          <article-title>Rapid evaluation of platelet function using the multiplate<sup>&#xAE;</sup> analyzer</article-title>
          <source>Platelets</source>
          <year>2014</year>
          <volume>25</volume>
          <fpage>628</fpage>
          <lpage>633</lpage>
          <pub-id pub-id-type="doi">10.3109/09537104.2013.849804</pub-id>
          <pub-id pub-id-type="pmid">24246241</pub-id>
        </element-citation>
      </ref>
      <ref id="B93-sensors-20-04254">
        <label>93.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kr&#xFC;ger</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Meves</surname>
              <given-names>S.H.</given-names>
            </name>
            <name>
              <surname>Kara</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>M&#xFC;gge</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Neubauer</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Monitoring asa and p2y12-specific platelet inhibition--comparison of conventional (single) and multiple electrode aggregometry</article-title>
          <source>Scand. J. Clin. Lab. Investig.</source>
          <year>2014</year>
          <volume>74</volume>
          <fpage>568</fpage>
          <lpage>574</lpage>
          <pub-id pub-id-type="doi">10.3109/00365513.2014.913305</pub-id>
          <pub-id pub-id-type="pmid">25296945</pub-id>
        </element-citation>
      </ref>
      <ref id="B94-sensors-20-04254">
        <label>94.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paniccia</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Priora</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Liotta</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Abbate</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Platelet function tests: A comparative review</article-title>
          <source>Vasc. Health Risk Manag.</source>
          <year>2015</year>
          <volume>11</volume>
          <fpage>133</fpage>
          <lpage>148</lpage>
          <pub-id pub-id-type="doi">10.2147/VHRM.S44469</pub-id>
          <pub-id pub-id-type="pmid">25733843</pub-id>
        </element-citation>
      </ref>
      <ref id="B95-sensors-20-04254">
        <label>95.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kratzer</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Negrescu</surname>
              <given-names>E.V.</given-names>
            </name>
            <name>
              <surname>Hirai</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Yeo</surname>
              <given-names>Y.K.</given-names>
            </name>
            <name>
              <surname>Franke</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Siess</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>The thrombostat system. A useful method to test antiplatelet drugs and diets</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <year>1995</year>
          <volume>21</volume>
          <fpage>25</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0032-1313599</pub-id>
          <pub-id pub-id-type="pmid">7660154</pub-id>
        </element-citation>
      </ref>
      <ref id="B96-sensors-20-04254">
        <label>96.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harrison</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Mackie</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Mumford</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Briggs</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Liesner</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Machin</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Guidelines for the laboratory investigation of heritable disorders of platelet function</article-title>
          <source>Br. J. Haematol.</source>
          <year>2011</year>
          <volume>155</volume>
          <fpage>30</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2011.08793.x</pub-id>
          <pub-id pub-id-type="pmid">21790527</pub-id>
        </element-citation>
      </ref>
      <ref id="B97-sensors-20-04254">
        <label>97.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smith</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Steinhubl</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>Lincoff</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Coleman</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>T.T.</given-names>
            </name>
            <name>
              <surname>Hillman</surname>
              <given-names>R.S.</given-names>
            </name>
            <name>
              <surname>Coller</surname>
              <given-names>B.S.</given-names>
            </name>
          </person-group>
          <article-title>Rapid platelet-function assay: An automated and quantitative cartridge-based method</article-title>
          <source>Circulation</source>
          <year>1999</year>
          <volume>99</volume>
          <fpage>620</fpage>
          <lpage>625</lpage>
          <pub-id pub-id-type="doi">10.1161/01.CIR.99.5.620</pub-id>
          <pub-id pub-id-type="pmid">9950658</pub-id>
        </element-citation>
      </ref>
      <ref id="B98-sensors-20-04254">
        <label>98.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jeong</surname>
              <given-names>Y.H.</given-names>
            </name>
            <name>
              <surname>Bliden</surname>
              <given-names>K.P.</given-names>
            </name>
            <name>
              <surname>Antonino</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>Tantry</surname>
              <given-names>U.S.</given-names>
            </name>
            <name>
              <surname>Gurbel</surname>
              <given-names>P.A.</given-names>
            </name>
          </person-group>
          <article-title>Usefulness of the verifynow p2y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies</article-title>
          <source>Am. Heart J.</source>
          <year>2012</year>
          <volume>164</volume>
          <fpage>35</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ahj.2012.03.022</pub-id>
          <pub-id pub-id-type="pmid">22795280</pub-id>
        </element-citation>
      </ref>
      <ref id="B99-sensors-20-04254">
        <label>99.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Plesch</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>van den Besselaar</surname>
              <given-names>A.M.</given-names>
            </name>
          </person-group>
          <article-title>Validation of the international normalized ratio (inr) in a new point-of-care system designed for home monitoring of oral anticoagulation therapy</article-title>
          <source>Int. J. Lab. Hematol.</source>
          <year>2009</year>
          <volume>31</volume>
          <fpage>20</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1751-553X.2007.00998.x</pub-id>
          <pub-id pub-id-type="pmid">19143869</pub-id>
        </element-citation>
      </ref>
      <ref id="B100-sensors-20-04254">
        <label>100.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ebner</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Birschmann</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Peter</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>H&#xE4;rtig</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Spencer</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Kuhn</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Blumenstock</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Zuern</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Ziemann</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Poli</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Emergency coagulation assessment during treatment with direct oral anticoagulants: Limitations and solutions</article-title>
          <source>Stroke</source>
          <year>2017</year>
          <volume>48</volume>
          <fpage>2457</fpage>
          <lpage>2463</lpage>
          <pub-id pub-id-type="doi">10.1161/STROKEAHA.117.017981</pub-id>
          <pub-id pub-id-type="pmid">28775134</pub-id>
        </element-citation>
      </ref>
      <ref id="B101-sensors-20-04254">
        <label>101.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drouet</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Bal Dit Sollier</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Steiner</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Purrucker</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Measuring non-vitamin k antagonist oral anticoagulant levels: When is it appropriate and which methods should be used</article-title>
          <source>Int. J. Stroke</source>
          <year>2016</year>
          <volume>11</volume>
          <fpage>748</fpage>
          <lpage>758</lpage>
          <pub-id pub-id-type="doi">10.1177/1747493016659671</pub-id>
          <pub-id pub-id-type="pmid">27412190</pub-id>
        </element-citation>
      </ref>
      <ref id="B102-sensors-20-04254">
        <label>102.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gattinoni</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Pesenti</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Matthay</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Understanding blood gas analysis</article-title>
          <source>Intensive Care Med.</source>
          <year>2018</year>
          <volume>44</volume>
          <fpage>91</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.1007/s00134-017-4824-y</pub-id>
          <pub-id pub-id-type="pmid">28497267</pub-id>
        </element-citation>
      </ref>
      <ref id="B103-sensors-20-04254">
        <label>103.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Massie</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>G.H.</given-names>
            </name>
            <name>
              <surname>Tzamaloukas</surname>
              <given-names>A.H.</given-names>
            </name>
          </person-group>
          <article-title>Discrepancy between measured serum total carbon dioxide content and bicarbonate concentration calculated from arterial blood gases</article-title>
          <source>Cureus</source>
          <year>2015</year>
          <volume>7</volume>
          <fpage>398</fpage>
          <pub-id pub-id-type="doi">10.7759/cureus.398</pub-id>
          <pub-id pub-id-type="pmid">26824002</pub-id>
        </element-citation>
      </ref>
      <ref id="B104-sensors-20-04254">
        <label>104.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Posp&#xED;&#x161;ilov&#xE1;</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kuncov&#xE1;</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Tr&#xF6;gl</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Fiber-optic chemical sensors and fiber-optic bio-sensors</article-title>
          <source>Sensors</source>
          <year>2015</year>
          <volume>15</volume>
          <fpage>25208</fpage>
          <lpage>25259</lpage>
          <pub-id pub-id-type="doi">10.3390/s151025208</pub-id>
          <pub-id pub-id-type="pmid">26437407</pub-id>
        </element-citation>
      </ref>
      <ref id="B105-sensors-20-04254">
        <label>105.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schober</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bossers</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Krage</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>De Leeuw</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Schwarte</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>Portable blood (gas) analyzer in a helicopter emergency medical service</article-title>
          <source>Air Med. J.</source>
          <year>2019</year>
          <volume>38</volume>
          <fpage>302</fpage>
          <lpage>304</lpage>
          <pub-id pub-id-type="doi">10.1016/j.amj.2019.04.006</pub-id>
          <pub-id pub-id-type="pmid">31248543</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="sensors-20-04254-f001" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Coagulation cascade and fibrin formation by the intrinsic and extrinsic pathways. The heavy arrows show the extrinsic pathway, triggered by vascular injury and the expression of tissue factor. On the left side, by light arrows, the intrinsic pathway is shown. In the common pathway, thrombin is generated, which converts fibrinogen to fibrin (heavy arrows, too). Reprinted with permission from [<xref rid="B13-sensors-20-04254" ref-type="bibr">13</xref>]. Copyright&#xA9; 1991 American Chemical Society, Washington, DC, USA.</p>
      </caption>
      <graphic xlink:href="sensors-20-04254-g001"/>
    </fig>
    <fig id="sensors-20-04254-f002" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Picture of the ROTEM<sup>&#xAE;</sup> temogram displaying the four channels <bold>EXTEM</bold>, <bold>INTEM</bold>, <bold>FIBTEM</bold> and <bold>APTEM</bold>. Reprinted with the kind permission from the Instrumentation Laboratory, Bedford, MA, USA.</p>
      </caption>
      <graphic xlink:href="sensors-20-04254-g002"/>
    </fig>
    <fig id="sensors-20-04254-f003" orientation="portrait" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Picture of ROTEM<sup>&#xAE;</sup> temogram illustrating the parameters characterizing clot formation. Reprinted with the kind permission from the Instrumentation Laboratory, Bedford, MA, USA.</p>
      </caption>
      <graphic xlink:href="sensors-20-04254-g003"/>
    </fig>
    <fig id="sensors-20-04254-f004" orientation="portrait" position="float">
      <label>Figure 4</label>
      <caption>
        <p>Coagulation factor deficiency: left, displayed by a four channel ROTEM<sup>&#xAE;</sup> report (EXTEM, INTEM, FIBTEM and APTEM); right, by Visual Clot visualization technology.</p>
      </caption>
      <graphic xlink:href="sensors-20-04254-g004"/>
    </fig>
    <fig id="sensors-20-04254-f005" orientation="portrait" position="float">
      <label>Figure 5</label>
      <caption>
        <p>Low fibrinogen level: left, displayed by a four channel ROTEM<sup>&#xAE;</sup> report (EXTEM, INTEM, FIBTEM and APTEM); right, by Visual Clot visualization technology.</p>
      </caption>
      <graphic xlink:href="sensors-20-04254-g005"/>
    </fig>
    <fig id="sensors-20-04254-f006" orientation="portrait" position="float">
      <label>Figure 6</label>
      <caption>
        <p>Illustration of Multiplate<sup>&#xAE;</sup> tests. The ADPtest detects platelets after stimulation of adenosine diphosphate (ADP) receptor pathway P2Y<sub>12</sub>. The TRAPtest detects platelets after stimulation with the agonist thrombin receptor activating peptide (TRAP) of the protease activated receptor-1 pathway (PAR-1). The RISTOtest detects platelets after stimulation with the agonist ristocetin of the glycoprotein Ib-IX-V (GPIb-IX-V) receptor pathway. The ASPItest detects platelets activated by arachidonic acid (AA). AA is finally converted to thromboxane A<sub>2</sub> (TXA<sub>2</sub>) by cyclooxygenase-1 (COX-1) and others. The COLtest detects platelets activated by AA, too. Collagen is added to the sample and stimulates the collagen receptor glycoprotein VI (GPVI) pathways. No direct Glycoprotein IIb-IIIa (GPIIb-IIIa) receptor measuring.</p>
      </caption>
      <graphic xlink:href="sensors-20-04254-g006"/>
    </fig>
    <table-wrap id="sensors-20-04254-t001" orientation="portrait" position="float">
      <object-id pub-id-type="pii">sensors-20-04254-t001_Table 1</object-id>
      <label>Table 1</label>
      <caption>
        <p>ROTEM<sup>&#xAE;</sup> Assays. The left column lists the main tests with the corresponding descriptions of content, activation, coagulation determinants and usage on the right column.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>EXTEM</bold>
</td>
            <td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x2022; Contains tissue factor (thromboplastin) as activator</p></list-item><list-item><p>&#x2022; Reflects the extrinsic coagulation pathway</p></list-item><list-item><p>&#x2022; Depends on the activity of the coagulation factors X, VII, V, II, fibrinogen and platelets</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>INTEM</bold>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x2022; Activated by ellagic acid and phospholipids</p></list-item><list-item><p>&#x2022; Imitates the contact activation, reflects the intrinsic coagulation pathway</p></list-item><list-item><p>&#x2022; Depends on the activity of the coagulation factors XII, XI, IX, VIII, X, V, II, fibrinogen and platelets</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>FIBTEM</bold>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x2022; Contains the platelet inhibitor cytochalasin D</p></list-item><list-item><p>&#x2022; EXTEM-based</p></list-item><list-item><p>&#x2022; Clot formation is dependent on fibrinogen concentration and fibrin polymerization independent of platelets</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>APTEM</bold>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x2022; Contains an antifibrinolytic drug (formerly aprotinin, currently tranexamic acid)</p></list-item><list-item><p>&#x2022; EXTEM-based</p></list-item><list-item><p>&#x2022; For in vitro simulation of antifibrinolytic therapy</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>HEPTEM</bold>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x2022; Contains heparinase</p></list-item><list-item><p>&#x2022; INTEM-based</p></list-item><list-item><p>&#x2022; To asses heparin effect</p></list-item></list>
</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="sensors-20-04254-t002" orientation="portrait" position="float">
      <object-id pub-id-type="pii">sensors-20-04254-t002_Table 2</object-id>
      <label>Table 2</label>
      <caption>
        <p>TEG<sup>&#xAE;</sup> assays. The left column lists the main tests with the corresponding descriptions of content, activation, coagulation determinants and usage on the right column.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>RapidTEG&#x2122;</bold>
</td>
            <td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x2022; Contains tissue factor and kaolin as activator</p></list-item><list-item><p>&#x2022; Reflects both, intrinsic and extrinsic coagulation pathways</p></list-item><list-item><p>&#x2022; Roughly analogous to activated clotting time (ACT)</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Kaolin</bold>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x2022; Activated by kaolin</p></list-item><list-item><p>&#x2022; Imitates the contact activation, reflects the intrinsic coagulation pathway</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Functional</bold>
<break/>
<bold>Fibrinogen</bold>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x2022; Contains tissue factor as activator and abciximab as platelet inhibitor</p></list-item><list-item><p>&#x2022; Clot formation is dependent on fibrinogen concentration and fibrin polymerization independent of platelets</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Native</bold>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x2022; Only re-calcification</p></list-item></list>
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>HTEG</bold>
</td>
            <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><p>&#x2022; Contains heparinase</p></list-item><list-item><p>&#x2022; Reflects the intrinsic coagulation pathway</p></list-item><list-item><p>&#x2022; To asses heparin effect</p></list-item></list>
</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap id="sensors-20-04254-t003" orientation="portrait" position="float">
      <object-id pub-id-type="pii">sensors-20-04254-t003_Table 3</object-id>
      <label>Table 3</label>
      <caption>
        <p>Comparison of ROTEM<sup>&#xAE;</sup> and TEG<sup>&#xAE;</sup> parameters.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ROTEM<sup>&#xAE;</sup></th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TEG<sup>&#xAE;</sup></th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Unit</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Explanation</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Significance</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Clot Activation Parameters</bold>
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Clotting Time (CT)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Reaction Time (R)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">s</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Time from test start to an amplitude of 2 mm</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Velocity of thrombin generation</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Clot Formation Time (CFT)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Kinetic Time (K)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">s</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Time between 2 and <break/>20 mm clot amplitude</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Kinetics of clot formation</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alpha-angle (&#x3B1;)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alpha-angle (&#x3B1;)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">degree (&#xB0;)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tangential angle at 2 mm amplitude (ROTEM<sup>&#xAE;</sup>) or slope between R and K (TEG<sup>&#xAE;</sup>)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Velocity of clot formation</td>
          </tr>
          <tr>
            <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Clot Firmness Parameters</bold>
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Amplitude at 5, 10 m (A5, 10)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Amplitude at 30, 60 m (A30, 60)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">mm</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Amplitude at set time</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Clot strength</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maximum Clot Firmness (MCF)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maximum Amplitude (MA)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mm</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Greatest width achieved </td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maximal cloth strength</td>
          </tr>
          <tr>
            <td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Clot Lysis Parameters</bold>
</td>
          </tr>
          <tr>
            <td align="center" valign="middle" rowspan="1" colspan="1">Lysis Index at 30, 60 m <break/>(LI30, 60)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Clot Lysis at 30, 60 m (CL30, 60)</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">%</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Residual clot firmness at set time, as % of MCF</td>
            <td align="center" valign="middle" rowspan="1" colspan="1">Clot stability and fibrinolysis</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maximum Lysis (ML)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">unestablished</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">%</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maximum lysis detected during the run time, <break/>as % of MCF</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Maximal clot stability and fibrinolysis</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Thromb Res</journal-id>
      <journal-id journal-id-type="iso-abbrev">Thromb Res</journal-id>
      <journal-title-group>
        <journal-title>Thrombosis Research</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0049-3848</issn>
      <issn pub-type="epub">1879-2472</issn>
      <publisher>
        <publisher-name>Published by Elsevier Ltd.</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32841919</article-id>
      <article-id pub-id-type="pmc">7416717</article-id>
      <article-id pub-id-type="pii">S0049-3848(20)30455-2</article-id>
      <article-id pub-id-type="doi">10.1016/j.thromres.2020.08.017</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>COVID-19 versus HIT hypercoagulability</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="au0005">
          <name>
            <surname>Warkentin</surname>
            <given-names>Theodore E.</given-names>
          </name>
          <xref rid="af0005" ref-type="aff">a</xref>
          <xref rid="af0010" ref-type="aff">b</xref>
          <xref rid="af0015" ref-type="aff">c</xref>
          <xref rid="af0020" ref-type="aff">d</xref>
          <xref rid="cr0005" ref-type="corresp">&#x204E;</xref>
        </contrib>
        <contrib contrib-type="author" id="au0010">
          <name>
            <surname>Kaatz</surname>
            <given-names>Scott</given-names>
          </name>
          <xref rid="af0025" ref-type="aff">e</xref>
        </contrib>
        <aff id="af0005"><label>a</label>Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada</aff>
        <aff id="af0010"><label>b</label>Department of Medicine, McMaster University, Hamilton, Ontario, Canada</aff>
        <aff id="af0015"><label>c</label>Hamilton Regional Laboratory Medicine Program (Transfusion Medicine), Hamilton, Ontario, Canada</aff>
        <aff id="af0020"><label>d</label>Service of Clinical Hematology, Hamilton Health Sciences (Hamilton General Hospital), Canada</aff>
        <aff id="af0025"><label>e</label>Division of Hospital Medicine, Henry Ford Hospital, Detroit, MI, United States of America</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cr0005"><label>&#x204E;</label>Corresponding author at: Room 1-270B, Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton General Hospital, 237 Barton St. East, Hamilton, Ontario L8L 2X2, Canada.</corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>10</day>
        <month>8</month>
        <year>2020</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>8</month>
        <year>2020</year>
      </pub-date>
      <volume>196</volume>
      <fpage>38</fpage>
      <lpage>51</lpage>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>7</month>
          <year>2020</year>
        </date>
        <date date-type="rev-recd">
          <day>5</day>
          <month>8</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>8</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2020 Published by Elsevier Ltd.</copyright-statement>
        <copyright-year>2020</copyright-year>
        <copyright-holder/>
        <license>
          <license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
        </license>
      </permissions>
      <abstract id="ab0005">
        <p>A striking feature of COVID-19 is the high frequency of thrombosis, particularly in patients who require admission to intensive care unit because of respiratory complications (pneumonia/adult respiratory distress syndrome). The spectrum of thrombotic events is wide, including in situ pulmonary thrombosis, deep-vein thrombosis and associated pulmonary embolism, as well as arterial thrombotic events (stroke, myocardial infarction, limb artery thrombosis). Unusual thrombotic events have also been reported, e.g., cerebral venous sinus thrombosis, mesenteric artery and vein thrombosis. Several hematology abnormalities have been observed in COVID-19 patients, including lymphopenia, neutrophilia, thrombocytopenia (usually mild), thrombocytosis, elevated prothrombin time and partial thromboplastin times (the latter abnormality often indicating lupus anticoagulant phenomenon), hyperfibrinogenemia, elevated von Willebrand factor levels, and elevated fibrin <sc>d</sc>-dimer. Many of these abnormal hematologic parameters&#x2014;even as early as the time of initial hospital admission&#x2014;indicate adverse prognosis, including greater frequency of progression to severe respiratory illness and death. Progression to overt disseminated intravascular coagulation in fatal COVID-19 has been reported in some studies, but not observed in others. We compare and contrast COVID-19 hypercoagulability, and associated increased risk of venous and arterial thrombosis, from the perspective of heparin-induced thrombocytopenia (HIT), including the dilemma of providing thromboprophylaxis and treatment recommendations when available data are limited to observational studies. The frequent use of heparin&#x2014;both low-molecular-weight and unfractionated&#x2014;in preventing and treating COVID-19 thrombosis, means that vigilance for HIT occurrence is required in this patient population.</p>
      </abstract>
      <abstract abstract-type="graphical" id="ab0010">
        <title>Graphical abstract</title>
        <p>
          <fig id="f0020" position="anchor">
            <alt-text id="al0040">Unlabelled Image</alt-text>
            <graphic xlink:href="ga1_lrg"/>
          </fig>
        </p>
      </abstract>
      <abstract abstract-type="author-highlights" id="ab0015">
        <title>Highlights</title>
        <p>
          <list list-type="simple" id="l0005">
            <list-item id="li0005">
              <label>&#x2022;</label>
              <p id="p0005">HIT and COVID-19 are associated with a high risk of thrombosis (venous &gt; arterial).</p>
            </list-item>
            <list-item id="li0010">
              <label>&#x2022;</label>
              <p id="p0010">HIT and COVID-19 both feature coagulation and &#x201C;pancellular&#x201D; activation.</p>
            </list-item>
            <list-item id="li0015">
              <label>&#x2022;</label>
              <p id="p0015">Therapeutic anticoagulation is indicated for HIT, but dosing unknown for COVID-19.</p>
            </list-item>
          </list>
        </p>
      </abstract>
      <kwd-group id="ks0005">
        <title>Keywords</title>
        <kwd>COVID-19</kwd>
        <kwd>Disseminated intravascular coagulation</kwd>
        <kwd>Heparin</kwd>
        <kwd>Thrombocytopenia</kwd>
        <kwd>Thrombosis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="s0005">
      <label>1</label>
      <title>COVID-19 as a hypercoagulable state</title>
      <p id="p0020">The emergence of the novel coronavirus, SARS-CoV-2 (abbreviation for <italic>severe acute respiratory syndrome coronavirus 2</italic>), in late 2019, and the resulting illness, COVID-19 (coronavirus disease, 2019), was declared a pandemic by the World Health Organization on March 11, 2020. At the time of writing (August 14, 2020), cases diagnosed world-wide have exceeded 21,000,000, with over 750,000 deaths (both values representing underestimates due to incomplete case ascertainment) [<xref rid="bb0005" ref-type="bibr">1</xref>]. Although clinical manifestations of COVID-19 are protean, the major clinical picture of pneumonia and adult respiratory distress syndrome (ARDS) is generally believed to account for the majority of deaths. However, it is increasingly apparent that there is a high frequency of hemostatic abnormalities, and thrombotic events, in COVID-19, with emerging consensus that this novel virus induces a hypercoagulable state beyond that expected in the &#x201C;typical&#x201D; critically ill patient. It is also likely that significant mortality is secondary to pulmonary thrombotic events, either local (in situ pulmonary thrombosis) or embolic (pulmonary embolism [PE]).</p>
      <p id="p8025">This review summarizes clinical and laboratory features of COVID-19 hypercoagulability. The viewpoint is from the perspectives of the two authors, one of whom has studied another hypercoagulable disorder&#x2014;heparin-induced thrombocytopenia (HIT)&#x2014;for over 30&#xA0;years (T.E.W.), and the other with a longstanding interest in anticoagulation (S.K). As in HIT, the challenge is to make appropriate thromboprophylaxis and treatment recommendations when available data are limited and largely observational.</p>
      <p id="p0025">SARS-CoV-2 is a positive-sense single-stranded RNA virus, i.e., its genetic material functions both as genome and messenger RNA that directs host ribosomes. The virus gains entry to human cells via its surface spike protein, which binds to host receptor angiotensin converting enzyme 2 (ACE2), highly expressed on human endothelial cells, among other cells (pneumocytes of the alveolar epithelium, renal tubular epithelium, hepatocytes, enterocytes, cardiomyocytes). Targeting vascular endothelium likely plays an important part in the prothrombotic diathesis of COVID-19, through endotheliilitis (endothelialitis), i.e., viral invasion of endothelial cells and resulting accumulation of inflammatory cells (host inflammatory response) [<xref rid="bb0010" ref-type="bibr">[2]</xref>, <xref rid="bb0015" ref-type="bibr">[3]</xref>, <xref rid="bb0020" ref-type="bibr">[4]</xref>].</p>
    </sec>
    <sec id="s0010">
      <label>2</label>
      <title>COVID-19: comparison with HIT and severe sepsis</title>
      <p id="p0030">
<xref rid="t0005" ref-type="table">Table 1</xref>
lists some comparisons between COVID-19 and HIT. Both severe COVID-19 and HIT occur in a minority of at-risk patients (those infected with SARS-CoV-2 and those exposed to heparin, respectively). Both feature a hypercoagulable state, including high frequency of thrombosis, and occurrence of unusual thrombotic events. Both feature abnormalities in blood cell counts (leukocytes, platelets), coagulation values indicating likely hemostasis activation&#x2014;elevations in prothrombin time (PT) and fibrin <sc>d</sc>-dimer&#x2014;and potential for &#x201C;high-fibrinogen disseminated intravascular coagulation (DIC)&#x201D;. One major distinction: while it is now widely accepted that treatment of acute HIT requires therapeutic-dose anticoagulation (even if no evidence of thrombosis is apparent) [<xref rid="bb0025" ref-type="bibr">5</xref>], the dosing of anticoagulation needed to prevent thrombosis in COVID-19 is controversial.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Comparison of COVID-19 and HIT.</p></caption><alt-text id="al0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>COVID-19</th><th>HIT</th></tr></thead><tbody><tr><td colspan="3"><italic>Similarities</italic></td></tr><tr><td>Risk of severe disease</td><td>1&#x2013;5% (?) infected patients develop severe disease</td><td>1&#x2013;5% heparin-exposed patients develop HIT</td></tr><tr><td>High frequency of thrombosis</td><td>~40&#x2013;50% of ICU patients</td><td>~40&#x2013;50% thrombosis rate</td></tr><tr><td>Higher frequency of thrombosis with greater disease severity</td><td>Thrombosis rate higher in ICU versus ward patients</td><td>Thrombosis rate higher in patients with more severe thrombocytopenia</td></tr><tr><td>Venous versus arterial thrombosis</td><td>Venous predominance</td><td>Venous predominance</td></tr><tr><td>Arterial thrombosis hierarchy</td><td>Stroke &gt; MI&#xA0;&gt;&#xA0;limb</td><td>Limb &gt; stroke &gt; MI</td></tr><tr><td>Occurrence of unusual thrombi</td><td>Yes (e.g., CVST, mesenteric artery or vein)</td><td>Yes (adrenal, CVST, mesenteric artery or vein, etc.)</td></tr><tr><td>Endothelial activation</td><td>Yes</td><td>Yes</td></tr><tr><td>Neutrophilia</td><td>Yes</td><td>Yes</td></tr><tr><td>Leukocyte activation</td><td>Yes</td><td>Yes</td></tr><tr><td colspan="3">&#x2028;&#x2028;</td></tr><tr><td colspan="3"><italic>Differences</italic></td></tr><tr><td>Prominent thrombocytopenia</td><td>No (mild thrombocytopenia common); moderate to severe thrombocytopenia occurs in some patients with fatal COVID-19</td><td>Yes (&gt;50% platelet fall in ~90% of patients with HIT; median platelet count nadir, 60&#x2013;70&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L)</td></tr><tr><td>In situ pulmonary thrombosis</td><td>Common</td><td>Uncommon</td></tr><tr><td>ARDS picture</td><td>Common</td><td>No</td></tr><tr><td>Pathological criterion indicating risk for thrombosis</td><td>No distinct marker for risk for thrombosis</td><td>Platelet-activating HIT antibodies detectable by platelet activation assay</td></tr><tr><td>Thromboprophylaxis and treatment consensus</td><td>No consensus re: anticoagulant dosing</td><td>Therapeutic-dose anticoagulation generally recommended (even in the absence of documented thrombosis)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbr.: ARDS, adult respiratory distress syndrome; COVID-19, coronavirus disease, 2019; CVST, cerebral venous sinus thrombosis; ICU, intensive care unit; HIT, heparin-induced thrombocytopenia; MI, myocardial infarction.</p></fn></table-wrap-foot></table-wrap></p>
      <p id="p0035">&#x201C;Pancellular&#x201D; activation in HIT involves platelets [<xref rid="bb0030" ref-type="bibr">6</xref>], monocytes [<xref rid="bb0035" ref-type="bibr">7</xref>], neutrophils [<xref rid="bb0040" ref-type="bibr">8</xref>,<xref rid="bb0045" ref-type="bibr">9</xref>], and endothelium [<xref rid="bb0050" ref-type="bibr">10</xref>,<xref rid="bb0055" ref-type="bibr">11</xref>]. Most striking in HIT is &#x201C;strong&#x201D; platelet activation&#x2014;including formation of procoagulant platelet-derived microparticles [<xref rid="bb0060" ref-type="bibr">12</xref>]&#x2014;that occurs when HIT antibodies recognize platelet factor 4 (PF4)/polyanion and activate platelets through their Fc&#x3B3;IIa receptors [<xref rid="bb0065" ref-type="bibr">13</xref>]. PF4 binds to monocytes, with resulting tissue factor expression [<xref rid="bb0070" ref-type="bibr">14</xref>]. Netosis of neutrophils is triggered by HIT antibodies [<xref rid="bb0040" ref-type="bibr">8</xref>,<xref rid="bb0045" ref-type="bibr">9</xref>]. Finally, numerous prothrombotic consequences of HIT antibody binding to endothelium has been reported, including perturbed protein C activation [<xref rid="bb0075" ref-type="bibr">15</xref>] and formation of von Willebrand factor (VWF) strings [<xref rid="bb0080" ref-type="bibr">16</xref>,<xref rid="bb0085" ref-type="bibr">17</xref>].</p>
      <p id="p0040">COVID-19 also has features of pancellular activation. As noted, SARS-CoV-2 invades endothelial cells, producing endotheliitis and an associated inflammatory response. Neutrophil infiltration occurs in the lungs [<xref rid="bb0090" ref-type="bibr">18</xref>], producing high levels of neutrophil extracellular traps (NETs) in many patients with COVID-19 [<xref rid="bb0095" ref-type="bibr">19</xref>]. Mild thrombocytopenia often occurs in patients with severe COVID-19 (discussed subsequently), and it is possible this represents platelet activation response, with or without associated activation of hemostasis.</p>
      <p id="p0045">Severe COVID-19 usually results in admission to the intensive care unit (ICU), and so comparisons with severe sepsis and (non-COVID-19) ARDS is apropos. Whereas DIC occurs frequently in sepsis [<xref rid="bb0100" ref-type="bibr">20</xref>], the frequency and clinical impact of DIC in COVID-19 is controversial. Systemic inflammation, including fibrinolytic shut-down (elevated plasminogen activator inhibitor-1 levels)&#x2014;common in sepsis [<xref rid="bb0105" ref-type="bibr">21</xref>]&#x2014;is likely a feature too of COVID-19 [<xref rid="bb0110" ref-type="bibr">22</xref>]. Substantial proinflammatory features indicating &#x201C;cytokine storm&#x201D; occur in many patients, contributing also to a prothrombotic phenotype [<xref rid="bb0115" ref-type="bibr">23</xref>]. As discussed later, some critically ill COVID-19 patients develop a clinical picture reminiscent of symmetrical peripheral gangrene (SPG), a disorder of acral microthrombosis that occurs in a minority of patients with sepsis or HIT, particularly when certain risk factors (&#x201C;shock liver&#x201D;, warfarin) compromise levels of natural anticoagulant proteins [<xref rid="bb0120" ref-type="bibr">24</xref>].</p>
    </sec>
    <sec id="s0015">
      <label>3</label>
      <title>Hematologic abnormalities in COVID-19: prognostic implications</title>
      <p id="p0050">Hematologic abnormalities of COVID-19 include leukocyte counts (neutrophilia, lymphopenia), platelet counts (thrombocytopenia, thrombocytosis), and markers of hemostasis (elevations in PT and partial thromboplastin time (PTT), fibrin <sc>d</sc>-dimer and other fibrin-specific markers). Moreover, various prognostic implications of these abnormalities have been demonstrated.</p>
      <sec id="s0020">
        <label>3.1</label>
        <title>Leukocyte abnormalities</title>
        <p id="p0055">Guan and colleagues [<xref rid="bb0125" ref-type="bibr">25</xref>] reported on almost 1100 patients diagnosed with COVID-19 in China. They evaluated admission laboratory findings, comparing these between patients with non-severe (<italic>N</italic>&#xA0;=&#xA0;926) and severe (<italic>N</italic>&#xA0;=&#xA0;173) pulmonary disease, and further comparing admission laboratory values among patients who subsequently developed one or more of the following (versus those who did not): death, mechanical ventilation, admission to ICU. Zhou et al. [<xref rid="bb0130" ref-type="bibr">26</xref>] similarly evaluated various admission laboratory abnormalities as risk factors for mortality in 191 COVID-19 patients, 54 of whom died.</p>
        <p id="p0060">Guan et al. found lymphopenia (&lt;1.5&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L) in 83% of COVID-19 patients, with a higher frequency among patients with severe versus non-severe disease (96% vs 80%, respectively) as well as a higher frequency among those who died, required mechanical ventilation or admission to ICU (93% vs 83%, respectively) [<xref rid="bb0125" ref-type="bibr">25</xref>]. Zhou et al. observed that 76% of non-survivors had a lymphocyte count &lt;0.8&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L on admission, versus only 26% of survivors; further, absolute lymphocyte counts tended to rise among survivors whereas they tended to decline further in non-survivors [<xref rid="bb0130" ref-type="bibr">26</xref>]. Although neither study reported on neutrophil levels, others have reported a high frequency of neutrophilia (approximately one-third of patients) in COVID-19 [<xref rid="bb0135" ref-type="bibr">27</xref>]; further, progressive increase in absolute neutrophil counts often occurs in non-survivors [<xref rid="bb0140" ref-type="bibr">28</xref>]. Fu and colleagues [<xref rid="bb0145" ref-type="bibr">29</xref>] found a high neutrophil/lymphocyte ratio to be associated with severe disease to a greater extent than other proinflammatory markers such as C-reactive protein (CRP) or procalcitonin.</p>
        <p id="p0065">For comparison, although HIT is considered a platelet activation disorder, neutrophilia is common, particularly in patients who develop thrombosis [<xref rid="bb0150" ref-type="bibr">30</xref>]. Acute neutrophilia can also accompany rapid-onset HIT post-intravenous heparin bolus administration [<xref rid="bb0150" ref-type="bibr">30</xref>].</p>
      </sec>
      <sec id="s0025">
        <label>3.2</label>
        <title>Thrombocytopenia and thrombocytosis</title>
        <p id="p0070">Mild thrombocytopenia is a common feature of COVID-19. Guan and coworkers [<xref rid="bb0125" ref-type="bibr">25</xref>] found the median (IQR) platelet count on admission to be 168 (132, 207)&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L, with one-third having a platelet count below 150&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L. The frequency of thrombocytopenia was higher in patients with severe versus non-severe COVID-19 (58% vs 32%). Zhou et al. [<xref rid="bb0130" ref-type="bibr">26</xref>] also found the admission platelet count to be significantly lower in non-survivors versus survivors (166 [107, 229] vs 220 [168, 271]&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L, respectively; <italic>P</italic>&#xA0;&lt;&#xA0;0.0001). Almost 20% of COVID-19 patients had thrombocytopenia on admission in another study [<xref rid="bb0135" ref-type="bibr">27</xref>].</p>
        <p id="p0075">Among survivors, the platelet count tended to rise during the second hospital week in one study, whereas among non-survivors, thrombocytopenia tended to persist or worsen [<xref rid="bb0155" ref-type="bibr">31</xref>]. Thrombocytosis (platelet count &gt;450&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L) was seen in 10% of patients on admission in a study of 5 Boston (Massachusetts) hospitals [<xref rid="bb0160" ref-type="bibr">32</xref>].</p>
        <p id="p0080">HIT features high thrombotic risk despite an oftentimes mild to moderate degree of thrombocytopenia. For example, the median platelet count nadir in HIT is approximately 55 to 70&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L [<xref rid="bb0165" ref-type="bibr">[33]</xref>, <xref rid="bb0170" ref-type="bibr">[34]</xref>, <xref rid="bb0175" ref-type="bibr">[35]</xref>], with a high proportion of patients (~30&#x2013;50%) with platelet count nadirs &gt;100&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L or even &gt;150&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L developing thrombotic events [<xref rid="bb0180" ref-type="bibr">36</xref>]. Perhaps, as in HIT, COVID-19 associated platelet count declines&#x2014;even within the &#x201C;normal&#x201D; range&#x2014;could portend progressive hypercoagulability and high thrombotic risk.</p>
      </sec>
      <sec id="s0030">
        <label>3.3</label>
        <title>Coagulation abnormalities</title>
        <p id="p0085">Guan and workers [<xref rid="bb0125" ref-type="bibr">25</xref>] reported on admission fibrin <sc>d</sc>-dimer levels, observing that 46% of COVID-19 patients had levels above the upper-limit of the reference range (0.5&#xA0;mg/L); further, the frequency of elevated <sc>d</sc>-dimer was higher in patients with severe (versus non-severe) disease (60% vs 43%), and higher in patients with severe illness (69% vs 44%). Zhou et al. [<xref rid="bb0130" ref-type="bibr">26</xref>] also found elevated <sc>d</sc>-dimer levels on hospital admission, with this representing a prognostic marker: 93% of non-surviving patients had a <sc>d</sc>-dimer over 0.5&#xA0;mg/L on admission versus only 57% of survivors; using a 1.0&#xA0;mg/L <sc>d</sc>-dimer cut-off, the mortality difference was even greater (81% vs 24%, respectively), a difference highlighted in the paper's abstract. Significantly higher <sc>d</sc>-dimer levels in critically-ill vs other COVID-19 patients were reported by others [<xref rid="bb0135" ref-type="bibr">27</xref>,<xref rid="bb0140" ref-type="bibr">28</xref>], with Wang et al. [<xref rid="bb0140" ref-type="bibr">28</xref>] and Li et al. [<xref rid="bb0185" ref-type="bibr">37</xref>] noting progressive increase in <sc>d</sc>-dimer levels among non-survivors.</p>
        <p id="p0090">Tang and colleagues [<xref rid="bb0190" ref-type="bibr">38</xref>] analyzed various coagulation markers in their study of COVID-19 in Wuhan, China, including a comparison of initial values and subsequent changes in survivors versus non-survivors. <xref rid="f0005" ref-type="fig">Fig. 1</xref>
shows that <sc>d</sc>-dimer levels were higher on admission among non-survivors versus survivors (median [IQR]: 2.12 [0.77, 5.27] vs 0.61 [0.35, 1.29]; <italic>P</italic>&#xA0;=&#xA0;0.001). Similar observations were made for fibrin degradation products.<fig id="f0005"><label>Fig. 1</label><caption><p>Progression to overt DIC in patients with fatal COVID-19.</p><p>Timeline charts illustrate the changes in coagulation parameters in 183 patients with COVID-19 pneumonia (21 non-survivors, 162 survivors). The error bars show medians and 25% and 75% percentiles. The horizontal lines show the upper normal limits of prothrombin time (PT) and <sc>d</sc>-dimer, and the lower normal limits of fibrinogen and antithrombin activity.</p><p><sup>a</sup>P&#xA0;&lt;&#xA0;0.05 for survivors versus non-survivors.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/><attrib>Reprinted from [<xref rid="bb0190" ref-type="bibr">38</xref>], with revisions, with permission.</attrib></fig></p>
        <p id="p0095">Tang et al. [<xref rid="bb0190" ref-type="bibr">38</xref>] also found elevated PT values in approximately one-quarter of COVID-19 patients upon admission (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). Remarkably, whereas approximately three-quarters of non-survivors had abnormal PTs on admission (in relation to normal range of 11.5 to 14.5&#xA0;s), the opposite was true for survivors (median [IQR]: 15.5 [14.4&#x2013;16.3] versus 13.6 [13.0&#x2013;14.3], respectively; <italic>P</italic>&#xA0;&lt;&#xA0;0.001).</p>
        <p id="p0100">Tang et al. also found PTT levels to be prolonged (PTT reference range, 29.0&#x2013;42.0&#xA0;s), with trend to higher values in non-survivors versus survivors (median [IQR]: 44.8 [40.2, 51.0] vs 41.2 [36.9, 44.0], respectively; <italic>p</italic>&#xA0;=&#xA0;0.096). Bowles and colleagues systematically investigated the cause for PTT prolongation in 35 COVID-19 patients [<xref rid="bb0195" ref-type="bibr">39</xref>]. Of 34 patients investigated for lupus anticoagulant, positive results were seen in 31 (91%). Further, factor XII levels tended to be low in COVID-19 patients (mean value, 55%), without any other factor deficiencies identified. Thus, as no bleeding tendency related to elevated PTT values would be expected, the authors argued that PTT prolongation per se should not be used to discourage anticoagulant prophylaxis or therapy. The authors were careful not to impute any prothrombotic implications to their findings.</p>
        <p id="p0105">Helms et al. also noted a high frequency of lupus anticoagulant in their COVID-19 patients admitted to ICU [<xref rid="bb0200" ref-type="bibr">40</xref>]. Harzallah and colleagues [<xref rid="bb0205" ref-type="bibr">41</xref>] found that 25/56 (45%) COVID-19 patients had lupus anticoagulant, with only 3 patients also testing positive for anticardiolipin or anti-&#x3B2;2-glycoprotein 1 antibodies. Heparin contamination did not appear to explain positive lupus anticoagulant testing [<xref rid="bb0195" ref-type="bibr">39</xref>,<xref rid="bb0205" ref-type="bibr">41</xref>]</p>
        <p id="p0110">Fibrinogen values are elevated&#x2014;often markedly&#x2014;in patients with COVID-19 [<xref rid="bb0160" ref-type="bibr">32</xref>,<xref rid="bb0190" ref-type="bibr">38</xref>,<xref rid="bb0210" ref-type="bibr">[42]</xref>, <xref rid="bb0215" ref-type="bibr">[43]</xref>, <xref rid="bb0220" ref-type="bibr">[44]</xref>]. This reflects the proinflammatory state, given that patients also have elevations in the other proinflammatory markers, procalcitonin [<xref rid="bb0125" ref-type="bibr">25</xref>,<xref rid="bb0130" ref-type="bibr">26</xref>,<xref rid="bb0160" ref-type="bibr">32</xref>], CRP [<xref rid="bb0125" ref-type="bibr">25</xref>,<xref rid="bb0160" ref-type="bibr">32</xref>], and ferritin [<xref rid="bb0130" ref-type="bibr">26</xref>,<xref rid="bb0160" ref-type="bibr">32</xref>]. Similarly, VWF levels are elevated in COVID-19 patients [<xref rid="bb0200" ref-type="bibr">40</xref>], often markedly [<xref rid="bb0220" ref-type="bibr">44</xref>]. ADAMTS13 levels tend to be normal [<xref rid="bb0215" ref-type="bibr">43</xref>] or mildly reduced [<xref rid="bb0220" ref-type="bibr">44</xref>], perhaps contributing to VWF-platelet microvascular thrombosis. Varatharajah and Rajah have speculated that endothelial-derived ultralarge VWF multimers could form large microthrombi &#x201C;strings&#x201D; comprised of platelets and large VWF complexes [<xref rid="bb0225" ref-type="bibr">45</xref>]. Pathologic evidence of complement deposition in lungs and skin suggests that vascular injury involves generalized activation of both alternative and lectin-based pathways [<xref rid="bb0230" ref-type="bibr">46</xref>].</p>
        <p id="p0115">Coagulation abnormalities are also a feature of severe HIT, including increase in PT [<xref rid="bb0235" ref-type="bibr">47</xref>], PTT [<xref rid="bb0235" ref-type="bibr">47</xref>,<xref rid="bb0240" ref-type="bibr">48</xref>], and fibrin <sc>d</sc>-dimer (with or without associated thrombosis) [<xref rid="bb0245" ref-type="bibr">49</xref>]. HIT-associated PTT prolongation in particular has therapeutic implications, as this phenomenon increases risk of &#x201C;PTT confounding&#x201D; with treatment failure resulting from systematic underdosing of PTT-adjusted anticoagulant therapy (argatroban, bivalirudin) [<xref rid="bb0240" ref-type="bibr">48</xref>]. Overt hypofibrinogenemia indicating decompensated DIC can also complicate HIT [<xref rid="bb0235" ref-type="bibr">47</xref>,<xref rid="bb0250" ref-type="bibr">50</xref>]. However, as discussed in the next section, typically elevated levels of fibrinogen in patients with HIT and COVID-19 complicate the diagnosis of DIC.</p>
      </sec>
    </sec>
    <sec id="s0035">
      <label>4</label>
      <title>Does severe COVID-19 cause DIC?</title>
      <p id="p0120">A controversial issue is whether progressively severe COVID-19 causes DIC in the absence of another superimposed DIC trigger, such as complicating bacterial sepsis. <sc>d</sc>-dimer elevation alone does not necessarily indicate DIC, but can simply indicate presence of thrombosis, such as deep-vein thrombosis (DVT) or PE [<xref rid="bb0255" ref-type="bibr">51</xref>]. This is relevant given the association between COVID-19 and thrombosis (discussed subsequently). It has been suggested that progressive lung disease with associated alveolitis and in situ pulmonary microthrombosis could also explain elevated <sc>d</sc>-dimer in COVID-19 [<xref rid="bb0260" ref-type="bibr">52</xref>,<xref rid="bb0265" ref-type="bibr">53</xref>], perhaps as a result of high pulmonary levels of lung urokinase [<xref rid="bb0270" ref-type="bibr">54</xref>].</p>
      <sec id="s0040">
        <label>4.1</label>
        <title>Progression to overt DIC in patients with fatal COVID-19</title>
        <p id="p0125">The most compelling study pointing to an association between COVID-19 and DIC is from Tang et al. [<xref rid="bb0190" ref-type="bibr">38</xref>] They reported a remarkable association between evolution to DIC in COVID-19 non-survivors versus survivors: whereas only 1/162 (0.6%) survivors met the International Society on Thrombosis and Haemostasis (ISTH) criteria for overt DIC [<xref rid="bb0275" ref-type="bibr">55</xref>], 15/21 (72%) non-survivors developed DIC. <xref rid="f0005" ref-type="fig">Fig. 1</xref> shows progressive rise in PT and <sc>d</sc>-dimers, and decline in fibrinogen and antithrombin levels, in non-survivors versus survivors. Further, the DIC criterion, &#x201C;thrombocytopenia&#x201D; (yielding 1 point for platelet count fall to &lt;100&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L, and 2 points if &lt;50&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L) [<xref rid="bb0275" ref-type="bibr">55</xref>], was met by 12/21 (57%) non-survivors. Despite these striking findings, they do not rule out the possibility of superimposed bacterial sepsis (a common trigger of overt DIC), rather than COVID-19 progression per se.</p>
        <p id="p0130">Helms and colleagues' experience [<xref rid="bb0200" ref-type="bibr">40</xref>] argues against overt DIC occurring in many COVID-19 patients. They reported 150 COVID-19 patients in 4 French ICUs. Although their patients typically had elevated <sc>d</sc>-dimer levels, none met ISTH criteria for DIC. Moreover, these authors noted that COVID-19 <sc>d</sc>-dimer levels were typically <italic>lower</italic> than seen in matched patients with (non-COVID-19) ARDS. Similarly, Al-Samkiri [<xref rid="bb0160" ref-type="bibr">32</xref>] found only 3/400 (0.75%) COVID-19 patients met DIC criteria.</p>
        <p id="p0135">There are several practical difficulties in standardizing the definition of DIC. The PT prolongation criteria (in seconds) result in different INR categories in different hospital laboratories. Also, given numerous available <sc>d</sc>-dimer assays, standardization is problematic. One of the authors (T.E.W) uses <sc>d</sc>-dimer cutoffs of 2.0 and 10.0&#xA0;mg/L to assign 2 points (moderate elevation, 2.0&#x2013;9.9) or 3 points (&#x2265;10.0&#xA0;mg/L), whereas Tang et al. [<xref rid="bb0190" ref-type="bibr">38</xref>] used cutoffs of 1.0 and 3.0 for assigning these categories. Nevertheless, DIC is usually characterized by marked consumption of coagulation factors&#x2014;both procoagulant and anticoagulant&#x2014;and this does not appear to occur in the majority of patients with COVID-19.</p>
      </sec>
      <sec id="s0045">
        <label>4.2</label>
        <title>High-fibrinogen DIC</title>
        <p id="p0140">Clinicians often rule out DIC when fibrinogen values are normal or elevated. However, fibrinogen levels are often normal in patients who otherwise meet criteria for DIC [<xref rid="bb0280" ref-type="bibr">56</xref>]. Indeed, one author (T.E.W.) has observed &#x201C;high-fibrinogen DIC&#x201D; in some patients who develop symmetrical peripheral gangrene [<xref rid="bb0285" ref-type="bibr">57</xref>]. Such patients can have high fibrinogen levels on hospital admission reflecting several days of prodromal illness (e.g., initial <italic>Klebsiella</italic> pneumonia evolving to pneumosepsis). A similar phenomenon occurs in HIT&#x2014;as approximately two-thirds of cases of HIT occur in postoperative patients [<xref rid="bb0175" ref-type="bibr">35</xref>,<xref rid="bb0290" ref-type="bibr">58</xref>]&#x2014;featuring high postoperative fibrinogen values&#x2014;occurrence of HIT can lead to fibrinogen consumption but with &#x201C;normal&#x201D; fibrinogen levels. Such &#x201C;high-fibrinogen DIC&#x201D; helps explain severe thrombotic events in patients with HIT and sepsis, and, potentially, in patients with COVID-19. However, progressive&#x2014;usually marked&#x2014;declines in platelet count are usually seen in patients with high-fibrinogen DIC associated with sepsis or HIT [<xref rid="bb0175" ref-type="bibr">35</xref>,<xref rid="bb0285" ref-type="bibr">57</xref>,<xref rid="bb0290" ref-type="bibr">58</xref>], and so absence of major platelet count declines in COVID-19 argues against this phenomenon.</p>
      </sec>
    </sec>
    <sec id="s0050">
      <label>5</label>
      <title>Thrombosis in COVID-19</title>
      <p id="p0145">Thrombosis complicating COVID-19 is emerging as a major explanation for patient morbidity and mortality. Just as greater severity of HIT (judged by lower platelet count nadirs) corresponds to higher thrombosis frequency [<xref rid="bb0165" ref-type="bibr">33</xref>,<xref rid="bb0170" ref-type="bibr">34</xref>], so too with COVID-19, greater severity of illness (judged by need for ICU vs ward admission) is associated with greater frequency of thrombosis.</p>
      <p id="p0150">We identified 16 cohort studies (<xref rid="t0010" ref-type="table">Table 2</xref>
) [<xref rid="bb0160" ref-type="bibr">32</xref>,<xref rid="bb0200" ref-type="bibr">40</xref>,<xref rid="bb0295" ref-type="bibr">[59]</xref>, <xref rid="bb0300" ref-type="bibr">[60]</xref>, <xref rid="bb0305" ref-type="bibr">[61]</xref>, <xref rid="bb0310" ref-type="bibr">[62]</xref>, <xref rid="bb0315" ref-type="bibr">[63]</xref>, <xref rid="bb0320" ref-type="bibr">[64]</xref>, <xref rid="bb0325" ref-type="bibr">[65]</xref>, <xref rid="bb0330" ref-type="bibr">[66]</xref>, <xref rid="bb0335" ref-type="bibr">[67]</xref>, <xref rid="bb0340" ref-type="bibr">[68]</xref>, <xref rid="bb0345" ref-type="bibr">[69]</xref>, <xref rid="bb0350" ref-type="bibr">[70]</xref>, <xref rid="bb0355" ref-type="bibr">[71]</xref>, <xref rid="bb0360" ref-type="bibr">[72]</xref>, <xref rid="bb0365" ref-type="bibr">[73]</xref>] that quantified rates of thromboembolic disease during hospitalization, from which several observations emerge. Although stroke, myocardial infarction/acute coronary syndrome (MI/ACS) and limb gangrene are apparent, venous thromboembolism (VTE) dominates. All studies still had patients in hospital (1 study did not report) and therefore, the true rates of thromboembolic complications during hospitalization are not known. Some studies use cumulative rates adjusted for competing risk of death to estimate the true rate (although this could underestimate the true frequency of thrombosis if deaths were caused by unrecognized thromboembolism) [<xref rid="bb0320" ref-type="bibr">64</xref>]. The rate and type of VTE prophylaxis varies widely among the studies, with some reporting no prophylaxis, other utilizing standard-dose pharmacologic prophylaxis on the wards and intermediate-dose prophylaxis in the ICU, to others with a predominance of therapeutic-dose anticoagulation.<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Proportion and rates of thromboembolic events in COVID-19.</p></caption><alt-text id="al0025">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Study [reference]</th><th>Setting</th><th>Baseline anticoagulation</th><th>N</th><th>DVT screening</th><th>Hospitalized at analysis</th><th>Proportion with TE event</th><th>Cumulative rate of thromboembolic event</th><th>Thrombosis predictors</th><th>Adjusted analysis</th></tr></thead><tbody><tr><td>Al-Samkari [<xref rid="bb0160" ref-type="bibr">32</xref>]</td><td>5 hospitals in U.S.</td><td>Proph. (89%); interm./ther. (9%); none (3%)</td><td>400<break/>(ICU: 144<break/>ward: 256)</td><td>None</td><td>37%</td><td>Total VTE: 24 (6%)<break/>ICU: 10%<break/>ward: 3.5%<break/>Total ATE: 11 (2.8%)<break/>ICU: 5.6%<break/>ward: 1.2%</td><td>Not reported</td><td><sc>d</sc>-dimer; platelet count; CRP</td><td>Yes</td></tr><tr><td>Criel [<xref rid="bb0295" ref-type="bibr">59</xref>]</td><td>1 hospital in Belgium</td><td>Proph. (ward)<break/>Interm. (ICU)<break/>none (2%)</td><td>82<break/>(ICU: 30<break/>ward: 52)</td><td>All</td><td>100%</td><td>Total DVT: 6 (7%)<break/>ICU DVT: 13%<break/>ward DVT: 4%</td><td>Not reported</td><td>NR</td><td>NA</td></tr><tr><td>Cui [<xref rid="bb0300" ref-type="bibr">60</xref>]</td><td>1 ICU in China</td><td>None</td><td>81</td><td>All</td><td>11%</td><td>DVT: 20 (25%)</td><td>Not reported</td><td>Age; lymphopenia; PTT; <sc>d</sc>-dimer</td><td>No</td></tr><tr><td>Demelo-Rodr&#xED;guez [<xref rid="bb0305" ref-type="bibr">61</xref>]</td><td>1 hospital in Spain</td><td>Proph.; none (2%)</td><td>156</td><td>All</td><td>100%</td><td>Total DVT: 23 (15%)<break/>1 proximal DVT<break/>22 distal DVT</td><td>Not reported</td><td><sc>d</sc>-dimer</td><td>Yes</td></tr><tr><td>Fraiss&#xE9; [<xref rid="bb0310" ref-type="bibr">62</xref>]</td><td>1 hospital in France</td><td>Proph. (47%); ther. (53%)</td><td>92</td><td>None</td><td>27%</td><td>Total TE: 39 in 37 pts. (40%)<break/>19 PE<break/>6 DVT<break/>6 PE&#xA0;+&#xA0;DVT<break/>2 stroke<break/>1 ACS<break/>2 limb ischemia<break/>3 mesenteric ischemia</td><td>Not reported</td><td><sc>d</sc>-dimer; PT</td><td>No</td></tr><tr><td>Helms [<xref rid="bb0200" ref-type="bibr">40</xref>]</td><td>4 ICUs in 4 French hospitals</td><td>Proph. (70%); ther. (30%)</td><td>150</td><td>None<xref rid="tf0005" ref-type="table-fn">a</xref></td><td>67%</td><td>Total TE: 27 (18%)<break/>25 PE<break/>3 DVT<break/>2 stroke/TIA<break/>1 limb ischemia<break/>1 mesenteric ischemia</td><td>Not reported</td><td>OR 2.6 for TE events versus non-COVID-19 ARDS</td><td>Yes</td></tr><tr><td>Klok [<xref rid="bb0315" ref-type="bibr">63</xref>,<xref rid="bb0320" ref-type="bibr">64</xref>]</td><td>ICUs in 3 hospitals in The Netherlands</td><td>Proph./interm; ther. continued on admission (9%)</td><td>184</td><td>None</td><td>35%</td><td>65 PE<break/>3 DVT<break/>7 ATE</td><td>Total (VTE&#xA0;+&#xA0;ATE): 57% (at 25&#xA0;days);<break/>Adjusted for competing risk of death: 49%</td><td>Age; PT; PTT; ther. anticoagulation</td><td>Yes</td></tr><tr><td>Llitjos [<xref rid="bb0325" ref-type="bibr">65</xref>]</td><td>2 ICUs in France</td><td>Proph. (31%); ther. (69%)</td><td>26</td><td>All</td><td>27%</td><td>Total VTE: 18 (69%)<break/>12 DVT<break/>6 PE</td><td>Not reported</td><td>Ther. anticoagulation</td><td>No</td></tr><tr><td>Lodigiani [<xref rid="bb0330" ref-type="bibr">66</xref>]</td><td>1 hospital in Italy</td><td>Proph./interm./ther.;<break/>none (25% of ward pts)</td><td>388<break/>(ICU: 61<break/>ward: 327)</td><td>None</td><td>7%<xref rid="tf0010" ref-type="table-fn">b</xref></td><td>Total TE: 28 (7.7%)<break/>16 VTE (10 with PE)<break/>4 MI<break/>9 stroke (1 stroke pt. also had PE)</td><td>ICU: 27.6% (mdn, 18&#xA0;days)<break/>Ward: 6.6% (mdn, 9&#xA0;days)</td><td>NR</td><td>NA</td></tr><tr><td>Maatman [<xref rid="bb0335" ref-type="bibr">67</xref>]</td><td>3 ICUs in U.S.</td><td>Proph.</td><td>109</td><td>None</td><td>6%</td><td>Total VTE: 31 (28%)<break/>26 DVT<break/>1 PE<break/>4 DVT&#xA0;+&#xA0;PE</td><td>Not reported</td><td><sc>d</sc>-dimer; platelet count</td><td>No</td></tr><tr><td>Middeldorp [<xref rid="bb0340" ref-type="bibr">68</xref>]</td><td>1 hospital in The Netherlands</td><td>Proph. (ward); proph./interm (ICU); ther. continued on admission (9.6%)</td><td>198<break/>(ICU: 75<break/>ward: 123)</td><td>Some in ICU</td><td>8%</td><td>Total VTE: 39 (20%)<break/>Total ICU: 35 (47%)<break/>Total ward: 4 (3.3%)<break/>Total sympt. VTE: 25 (13%)<break/>ICU sympt. VTE: 21 (28%)<break/>Ward sympt. VTE 4 (3.3%)</td><td>Total VTE: 42%<break/>Total ICU: 59%<break/>Ward sympt. VTE: NR<break/>At 21&#xA0;days, adjusted for competing risk of death<break/>Total sympt. VTE: 25%<break/>ICU sympt. VTE: 34%<break/>Ward sympt. VTE: NR</td><td>Neutrophil/<break/>lymphocyte ratio; <sc>d</sc>-dimer; ther. anticoagulation</td><td>Yes</td></tr><tr><td>Nahum [<xref rid="bb0345" ref-type="bibr">69</xref>]</td><td>1 ICU in France</td><td>Proph.</td><td>34</td><td>All</td><td>100%</td><td>Total DVT: 27 (79%)<break/>9 Proximal DVT<break/>23 Distal DVT</td><td>NR</td><td>NR</td><td>NA</td></tr><tr><td>Ren [<xref rid="bb0350" ref-type="bibr">70</xref>]</td><td>2 ICUs in China</td><td>Proph.; none (2%)</td><td>48</td><td>All</td><td>100%</td><td>Total DVT: 41 (85.4%)<break/>5 Proximal DVT<break/>36 Distal DVT</td><td>NR</td><td>NR</td><td>NA</td></tr><tr><td>Stoneham [<xref rid="bb0355" ref-type="bibr">71</xref>]</td><td>2 hospitals in United Kingdom</td><td>NR</td><td>274</td><td>NR</td><td>NR</td><td>Total VTE: 21 (8%)<break/>16 PE<break/>5 DVT</td><td>NR</td><td>WBC count; <sc>d</sc>-dimer; fibrinogen</td><td>Yes</td></tr><tr><td>Thomas [<xref rid="bb0360" ref-type="bibr">72</xref>]</td><td>1 ICU in United Kingdom</td><td>Proph.</td><td>63</td><td>No</td><td>44%</td><td>Total TE: 8 (13%)<break/>5 PE<break/>2 MI<break/>1 DVT</td><td>29%</td><td>NR</td><td>NA</td></tr><tr><td>Zhang [<xref rid="bb0365" ref-type="bibr">73</xref>]</td><td>1 hospital in China</td><td>Proph.; none (63%)</td><td>143</td><td>All</td><td>100%</td><td>Total DVT: 66 (46%)<break/>23 Proximal DVT<break/>43 Distal DVT</td><td>NR</td><td>CURB-65 score; Padua score; <sc>d</sc>-dimer</td><td>Yes</td></tr></tbody></table><table-wrap-foot><fn id="sp0070"><p>Abbr.: ATE, arterial thromboembolism; CT, computed tomography; DVT, deep-vein thrombosis; ICU, intensive care unit, Interm., intermediate-dose anticoagulation; NA, not applicable; NR, not reported; PE, pulmonary embolism; Proph., prophylactic-dose anticoagulation; pts., patients; sympt., symptomatic; TE, thromboembolic; Ther., therapeutic-dose anticoagulation; U.S., United States; VTE, venous thromboembolism.</p></fn><fn id="sp0075"><p>Footnotes:</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0005"><label>a</label><p id="np0005">99 patients had computed tomography imaging per clinical suspicion.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0010"><label>b</label><p id="np0010">TE proportions based on 362 patients discharged or died.</p></fn></table-wrap-foot></table-wrap></p>
      <p id="p0155">
<xref rid="f0010" ref-type="fig">Fig. 2</xref>
suggests that the frequency of thrombosis in isolated HIT [<xref rid="bb0290" ref-type="bibr">58</xref>] could be similar to that observed in severe COVID-19 requiring ICU admission [<xref rid="bb0315" ref-type="bibr">63</xref>,<xref rid="bb0320" ref-type="bibr">64</xref>,<xref rid="bb0340" ref-type="bibr">68</xref>].<fig id="f0010"><label>Fig. 2</label><caption><p>Cumulative thrombosis rates: HIT vs COVID-19 (ICU and ward patients).</p><p>A. Cumulative thrombosis frequency of isolated HIT (<italic>N</italic>&#xA0;=&#xA0;62). Reprinted from [<xref rid="bb0290" ref-type="bibr">58</xref>], with modifications, with permission.</p><p>B. Cumulative thrombosis in ICU patients with severe COVID-19 (<italic>N</italic>&#xA0;=&#xA0;184). Reprinted from [<xref rid="bb0320" ref-type="bibr">64</xref>], with permission.</p><p>C. Cumulative incidence of venous thromboembolism (VTE) in COVID-19: ICU patients (<italic>N</italic>&#xA0;=&#xA0;75) versus ward patients (<italic>N</italic>&#xA0;=&#xA0;123). Reprinted from [<xref rid="bb0340" ref-type="bibr">68</xref>], with permission.</p></caption><alt-text id="al0010">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p>
      <sec id="s0055">
        <label>5.1</label>
        <title>Frequency estimates of thrombosis complicating COVID-19</title>
        <p id="p0160">Since none of the 16 studies reported rates exclusively for patients who had completed hospitalization (discharged alive or died), the true rate of in-hospital thromboembolism is unknown. The cumulative rate was estimated in 4 studies [<xref rid="bb0320" ref-type="bibr">64</xref>,<xref rid="bb0330" ref-type="bibr">66</xref>,<xref rid="bb0340" ref-type="bibr">68</xref>,<xref rid="bb0360" ref-type="bibr">72</xref>], each reporting different follow-up times, and results differ from crude rates because of competing risk (death) or longer follow-up in sicker patients than those discharged earlier. Nearly half the studies screened all patients for DVT [<xref rid="bb0295" ref-type="bibr">[59]</xref>, <xref rid="bb0300" ref-type="bibr">[60]</xref>, <xref rid="bb0305" ref-type="bibr">[61]</xref>,<xref rid="bb0325" ref-type="bibr">65</xref>,<xref rid="bb0340" ref-type="bibr">[68]</xref>, <xref rid="bb0345" ref-type="bibr">[69]</xref>, <xref rid="bb0350" ref-type="bibr">[70]</xref>,<xref rid="bb0365" ref-type="bibr">73</xref>] and the importance of asymptomatic DVT likely is not the same as clinically symptomatic disease. Some studies reported arterial thromboembolism in addition to VTE, with venous disease predominating. HIT also features venous thrombosis predominance, with venous:arterial thrombosis ratio of approximately 4:1 in two studies [<xref rid="bb0175" ref-type="bibr">35</xref>,<xref rid="bb0290" ref-type="bibr">58</xref>]. Similarly, venous thrombosis predominance is seen in COVID-19; however, it is less clear whether pulmonary &#x201C;embolism&#x201D; reflects DVT-source embolism or rather in situ pulmonary artery thrombosis (discussed subsequently).</p>
      </sec>
      <sec id="s0060">
        <label>5.2</label>
        <title>Pulmonary embolism</title>
        <p id="p0165">Fatal COVID-19 outcomes could often reflect PE, as suggested by post-mortem studies of patients who have died of COVID-19. For example, Wichmann and colleagues [<xref rid="bb0370" ref-type="bibr">74</xref>] reported on twelve consecutive autopsies performed in Hamburg, Germany (minimizing selection bias since local law requires autopsies in patients dying with COVID-19). To their surprise, 7 of the 12 patients had previously unrecognized DVT identified at post-mortem, with 4 patients' deaths attributable to PE.</p>
        <p id="p0170">Faggiano and colleagues, in Italy, identified 7 patients with PE out of 25 COVID-19 patients admitted to their ICU over a 2-week period; 3 of the PE were already apparent at admission [<xref rid="bb0375" ref-type="bibr">75</xref>]. Poissy and colleagues [<xref rid="bb0380" ref-type="bibr">76</xref>], in France, identified 22 (21%) patients with PE among 107 consecutive patients admitted to ICU because of COVID-19. This high frequency of PE was approximately three-fold higher than that seen in the same time period one year earlier (6.1%), as well as in patients admitted during 2019 with influenza (7.5%).</p>
        <p id="p0175">Bompard and colleagues [<xref rid="bb0385" ref-type="bibr">77</xref>] found an overall 24% frequency of PE (segmental &gt; proximal &gt; subsegmental) in patients with COVID-19 pneumonia who underwent imaging because of clinical suspicion (including <sc>d</sc>-dimer elevation); the frequency was higher in ICU versus non-ICU patients (50% vs 18%). PE events occurred despite thromboprophylaxis in all patients including intermediate dosing in ICU patients. Similar findings were reported by Poyiadji and colleagues (Detroit, USA) [<xref rid="bb0390" ref-type="bibr">78</xref>], who found 72/328 (22%) COVID-19 patients investigated by pulmonary angiography to have confirmed PE.</p>
        <p id="p0180">Reported anecdotes have included asymptomatic or minimally symptomatic COVID-19 patients who presented abruptly with PE [<xref rid="bb0395" ref-type="bibr">79</xref>,<xref rid="bb0400" ref-type="bibr">80</xref>].</p>
      </sec>
      <sec id="s0065">
        <label>5.3</label>
        <title>In situ pulmonary thrombosis</title>
        <p id="p0185">Diffuse alveolar disease can be complicated by pulmonary microthrombosis, irrespective of cause. For example, a 1983 study on ARDS reported a high frequency of pulmonary microthrombosis [<xref rid="bb0405" ref-type="bibr">81</xref>]. In COVID-19 ARDS, there also is evidence for in situ pulmonary artery thrombosis involving small vessels (pulmonary microthrombosis) as well as larger arteries [<xref rid="bb0015" ref-type="bibr">3</xref>,<xref rid="bb0410" ref-type="bibr">82</xref>,<xref rid="bb0415" ref-type="bibr">83</xref>].</p>
        <p id="p0190">Lax and colleagues [<xref rid="bb0410" ref-type="bibr">82</xref>] reported an 11-patient autopsy study from Switzerland which showed diffuse alveolar damage in 11 randomly-selected autopsy patients who died of COVID-19. In the authors' words, &#x201C;Notably, the most striking and unexpected finding was the obstruction of pulmonary arteries by thrombotic material present at both the macroscopic and microscopic level in all cases. &#x2026; The key finding of thrombosis in small to mid-sized pulmonary arteries was unexpected. On the basis of the occurrence of this finding in all patients, we assume that these thrombotic events were disease-related and were the immediate cause of death, through acute pulmonary hypertension and cessation of pulmonary circulation. &#x2026; [w]e consider our findings to be caused by thrombosis rather than by thromboembolism, because most vessels were completely occluded by thrombotic material and small arteries were involved, with a diameter less than 1 mm.&#x201D;</p>
        <p id="p0195">Menter and colleagues [<xref rid="bb0415" ref-type="bibr">83</xref>] reported on 21 autopsies performed on patients who died of COVID-19. They noted that &#x201C;[i]n five of eleven cases where immunohistochemistry for fibrin was performed, microthrombi were detected in alveolar capillaries&#x201D;; moreover, &#x201C;[f]our cases presented with peripheral and prominent central pulmonary embolisms.&#x201D;</p>
        <p id="p0200">Ackermann and colleagues [<xref rid="bb0015" ref-type="bibr">3</xref>] reported on the lung pathology of 7 patients who died of COVID-19. They found features of lung injury common also to influenza-associated respiratory failure, namely diffuse alveolar damage with lymphocytic infiltration, as well as precapillary vessel pathology (microthrombi in small pulmonary arteries with diameter of 1 to 2&#xA0;mm); however, COVID-19 featured alveolar capillary microthrombi that were 9 times as prevalent as seen in control lungs with influenza respiratory failure.</p>
        <p id="p0205">Van Dam and colleagues [<xref rid="bb0420" ref-type="bibr">84</xref>] observed that the radiologic picture of PE features more peripheral (versus central) thrombosis, indirectly supporting a potential role for in situ thrombosis in the pathogenesis of pulmonary &#x201C;emboli&#x201D; in some COVID-19 patients.</p>
      </sec>
      <sec id="s0070">
        <label>5.4</label>
        <title>Arterial thrombosis: stroke, myocardial infarction, limb artery thrombosis</title>
        <p id="p0210">Several reports on COVID-19 have focused on arterial thrombosis, either together or as separate target organ sites, such as MI/ACS, ischemic stroke, and limb artery thrombosis. Evaluation of the relative frequency of target organ involvement can provide interesting perspectives: for example, in HIT, the rank order of arterial thrombosis (limb artery &gt; stroke &gt; MI/ACS) [<xref rid="bb0290" ref-type="bibr">58</xref>] is inverse to usual atherothrombosis (MI/ACS&#xA0;&gt;&#xA0;stroke &gt; limb artery). The most common arterial thrombotic event in COVID-19 appears to be thrombotic stroke. Cantador and colleagues [<xref rid="bb0425" ref-type="bibr">85</xref>] reported on 14 patients in Spain who developed arterial thrombosis complicating COVID-19, representing about 1% of 1419 admitted patients: 8 patients had cerebrovascular events (6 strokes, 2 TIAs), 3 had MI/ACS, and 3 had limb artery thrombosis. Similar findings were made by Rey and colleagues [<xref rid="bb0430" ref-type="bibr">86</xref>]: of 38 COVID-19 patients who developed arterial thrombosis, 24 had cerebral thrombosis, 10 peripheral artery thrombosis, and 4 patients had coronary artery thrombosis. Fibrinogen and <sc>d</sc>-dimer levels were generally high, and none of the patients met criteria for DIC. Based on these studies, one can tentatively propose the hierarchy of arterial thrombosis in COVID-19 to be: stroke &gt; limb artery &gt; MI/ACS. Thus, in contrast to HIT, COVID-19 hypercoagulability may be associated with a greater relative risk of thrombotic stroke versus limb artery thrombosis.</p>
        <p id="p0215">Several studies have focused on strokes complicating COVID-19. In a Chinese report [<xref rid="bb0435" ref-type="bibr">87</xref>] that reviewed 214 consecutive patients hospitalized with COVID-19, the frequency of stroke was higher in patients with severe versus non-severe COVID-19 (5/88 [6%] vs 1/126 [1%], respectively). Oxley and coauthors [<xref rid="bb0440" ref-type="bibr">88</xref>] reported 5 cases of acute ischemic stroke involving large cerebral arteries in COVID-19 outpatients under the age of 50 observed during a two-week period in New York city (at most, 1 young patient would have been expected during this time period); most patients had relatively mild symptoms of COVID-19. Jain et al. [<xref rid="bb0445" ref-type="bibr">89</xref>] reviewed neuroimaging studies performed on hospitalized COVID-19 patients also in New York City; approximately 1% (35/3218) had stroke (large infarct, <italic>n</italic>&#xA0;=&#xA0;17; lacunar infarct, <italic>n</italic>&#xA0;=&#xA0;9; hemorrhagic stroke, n&#xA0;=&#xA0;9). Another report from New York City by Merkler and coworkers [<xref rid="bb0450" ref-type="bibr">90</xref>] found that 31 (1.6%) of 1916 patients with COVID-19 had acute ischemic stroke, a frequency far higher than that observed (3/1486&#xA0;=&#xA0;0.2%) in patients with influenza; after adjustment for age, sex, and race, the likelihood of stroke was much higher with COVID-19 versus influenza (odds ratio, 7.6; 95%CI, 2.3&#x2013;25.2).</p>
        <p id="p0220">Among other studies reporting on various thrombotic manifestations, the frequency of ischemic strokes was also relatively high (approximately 2&#x2013;3%) in the studies of Klok [<xref rid="bb0315" ref-type="bibr">63</xref>,<xref rid="bb0320" ref-type="bibr">64</xref>] and Lodigiani [<xref rid="bb0330" ref-type="bibr">66</xref>]. The topic of cerebral venous sinus thrombosis (CVST) associated with COVID-19 is discussed later (see section 5.5 <italic>Unusual venous and arterial thromboses</italic>).</p>
        <p id="p0225">Peripheral limb artery thrombosis manifesting as limb ischemia with absent pulses is another potential complication of COVID-19, particularly in the critically ill. Bellosta and colleagues reported 20 patients who developed peripheral limb artery thrombosis after admission for COVID-19 pneumonia [<xref rid="bb0455" ref-type="bibr">91</xref>]. The frequency of acute limb ischemia was at least 5-fold greater than in the year earlier period, for which the authors proposed that COVID-19 produced a &#x201C;virus-related hypercoagulable state.&#x201D; Surgical revascularization was performed in 17 patients (3 were too ill), with successful outcomes infrequently seen. Mestres and colleagues, in Barcelona [<xref rid="bb0460" ref-type="bibr">92</xref>], described 4 patients who developed acute limb ischemia, 3 with infrapopliteal artery thrombosis in one or both limbs, and 1 patient with femoral-popliteal and radial-ulnar artery thromboses.</p>
        <p id="p0230">A clinical picture in keeping with symmetrical peripheral gangrene in COVID-19 ICU patients has also been reported [<xref rid="bb0465" ref-type="bibr">93</xref>]. Laboratory markers (falling platelet count, rising <sc>d</sc>-dimer levels to &gt;20.0&#xA0;mg/L, elevated PT) suggested possible overt DIC. However, the authors stated that the patients did not have elevated lactate levels and were not on vasopressors, thus somewhat unlike the typical patient with hemodynamic shock who develops DIC-associated ischemic limb injury [<xref rid="bb0120" ref-type="bibr">24</xref>]. Again, whether such patients have an unusual form of DIC that can lead to symmetrical peripheral gangrene or venous limb gangrene (as rarely occurs in severe HIT) [<xref rid="bb0120" ref-type="bibr">24</xref>] or whether these patients have superimposed bacterial sepsis is uncertain. In contrast, Helms et al. [<xref rid="bb0200" ref-type="bibr">40</xref>] noted that none of their 150 ICU patients with severe COVID-19 developed acral tissue necrosis.</p>
        <p id="p0235">Although MI/ACS in the conventional sense occur in a small minority of COVID-19 patients (discussed above), elevated cardiac biomarkers, such as troponin or creatine kinase MB, are commonly seen in COVID-19. One review of 26 studies estimated the prevalence of acute myocardial injury to be approximately 20% [<xref rid="bb0470" ref-type="bibr">94</xref>]. Plausible explanations for myocardial injury included: hyperinflammation/cytokine storm resulting in myocarditis; respiratory failure/hypoxemic cardiomyocyte injury; down-regulation of ACE2 expression with loss of protective signaling pathways in cardiac myocytes; hypercoagulability with resulting coronary microvascular thrombosis; &#x201C;endotheliitis&#x201D; involving cardiac vasculature; and inflammation and/or stress causing coronary plaque rupture or supply-demand mismatch with more conventional myocardial ischemia/infarction. Zhou and colleagues [<xref rid="bb0130" ref-type="bibr">26</xref>] found troponin levels &gt;28&#xA0;pg/mL in 17% of patients admitted with COVID-19, with almost half (23/50 [46%]) of patients with such elevated troponin levels dying versus patients with lower levels on admission (1/95 [1%]; <italic>P</italic>&#xA0;&lt;&#xA0;0.0001).</p>
      </sec>
      <sec id="s0075">
        <label>5.5</label>
        <title>Unusual venous and arterial thromboses</title>
        <p id="p0240">Hypercoagulable states can be characterized by a propensity for unusual sites of thrombosis. This is also a feature of COVID-19, where patients have developed such unusual thrombotic events as cerebral venous sinus thrombosis [<xref rid="bb0475" ref-type="bibr">[95]</xref>, <xref rid="bb0480" ref-type="bibr">[96]</xref>, <xref rid="bb0485" ref-type="bibr">[97]</xref>], mesenteric artery thrombosis [<xref rid="bb0490" ref-type="bibr">[98]</xref>, <xref rid="bb0495" ref-type="bibr">[99]</xref>, <xref rid="bb0500" ref-type="bibr">[100]</xref>], aortic graft thrombosis [<xref rid="bb0505" ref-type="bibr">101</xref>] and mesenteric vein thrombosis [<xref rid="bb0510" ref-type="bibr">102</xref>]. However, unlike HIT, adrenal vein thrombosis with secondary adrenal infarction/hemorrhage has not been reported in COVID-19. As with HIT [<xref rid="bb0515" ref-type="bibr">103</xref>], catheter-associated upper-limb DVT can complicate COVID-19 [<xref rid="bb0520" ref-type="bibr">104</xref>].</p>
      </sec>
      <sec id="s0080">
        <label>5.6</label>
        <title>Risk factors for thrombosis</title>
        <p id="p0245">Seven of the 16 studies in <xref rid="t0010" ref-type="table">Table 2</xref> reported adjusted analysis for laboratory thrombosis risk factors, with increased <sc>d</sc>-dimer the most consistent, identified in 5 studies. Al-Samkari and coworkers [<xref rid="bb0160" ref-type="bibr">32</xref>] found elevated <sc>d</sc>-dimer, platelet count and CRP at presentation were independent predictors of thrombosis. Adjusted odd ratios (OR) with 95% CI for <sc>d</sc>-dimer (expressed in ng/mL) were 3.04 (1.26&#x2013;7.31) for <sc>d</sc>-dimer levels of 1001&#x2013;2500 and 6.79 (2.39&#x2013;19.30) &gt;2500. Platelet count above 450&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L had an adjusted OR of 3.56 (1.27&#x2013;9.97) and CRP levels &gt;100, OR 2.71 (1.26&#x2013;5.86). Demelo-Rodr&#xED;guez et al. [<xref rid="bb0305" ref-type="bibr">61</xref>] showed <sc>d</sc>-dimer levels were higher in patients with DVT found by ultrasound screening with median levels of 4527 (IQR 1925&#x2013;9144) ng/mL vs 2050 (IQR 1428&#x2013;3235) in patient without DVT (<italic>P</italic>&#xA0;&lt;&#xA0;0.001) with an adjusted OR&#xA0;=&#xA0;9.8 (2.9&#x2013;33.7). Klok identified prolongation of PTs of &gt;3&#xA0;s or PTT&#xA0;&gt;&#xA0;5&#xA0;s as predictors of thrombotic complications, with adjusted hazard ratio 4.1 (1.9&#x2013;9.1) [<xref rid="bb0315" ref-type="bibr">63</xref>].</p>
        <p id="p0250">The subdistribution hazard ratio for elevated median neutrophil-to-lymphocyte ratio was 1.7 (1.2&#x2013;2.5) and 1.4 (1.1&#x2013;1.9) for <sc>d</sc>-dimer in the study by Middeldorp [<xref rid="bb0340" ref-type="bibr">68</xref>]. Stoneham [<xref rid="bb0355" ref-type="bibr">71</xref>] found elevations in white blood cell count, fibrinogen and <sc>d</sc>-dimer to be associated with VTE with OR of 1.18, 1.66 and 1.39 respectively. <sc>d</sc>-dimer &gt;1.0 at admission had an adjusted OR of 5.82 (1.42&#x2013;23.81) in the study led by Zhang [<xref rid="bb0365" ref-type="bibr">73</xref>] for screen-detected DVT.</p>
      </sec>
    </sec>
    <sec id="s0085">
      <label>6</label>
      <title>Illustrative case</title>
      <p id="p0255">
<xref rid="f0015" ref-type="fig">Fig. 3</xref>
illustrates clinical events and serial laboratory values in a patient with severe COVID-19 requiring intubation/mechanical ventilation. Despite routine thromboprophylaxis with enoxaparin (40&#xA0;mg/day) that was doubled (to 40&#xA0;mg twice-daily) upon ICU admission, symptomatic PE (proven by CT angiography) occurred in association with right internal jugular central line removal post-extubation. The patient also received treatment with hydroxychloroquine, high-dose corticosteroids, tocilizumab, remdesivir, and COVID-19 convalescent plasma (listed in order received). There are several noteworthy features of the case. First, the patient exhibit mild thrombocytopenia (platelet count, 103&#xA0;&#xD7;&#xA0;10<sup>9</sup>/L) and mild PT elevation (13.5&#xA0;s; reference range, 9.0&#x2013;13.0) at hospital admission, common features of severe COVID-19. However, neither parameter showed progressive worsening as might be expected if the infection had progressed to overt DIC. Second, the patient exhibited a rapid increase in <sc>d</sc>-dimer (which was normal on admission) on day 18 despite receiving intermediate-dose enoxaparin. In hindsight, the abrupt <sc>d</sc>-dimer increase may have been a marker of development of otherwise subclinical DVT that resulted in symptomatic PE a few days later. And third, the patient also evinced a 43% decline in platelet count beginning about 10&#xA0;days after starting enoxaparin thromboprophylaxis. It is possible that this platelet count fall, together with PE occurrence, reflects occurrence of HIT (not otherwise suspected nor investigated for).<fig id="f0015"><label>Fig. 3</label><caption><p>Illustrative case of pulmonary embolism (PE) complicating COVID-19.</p><p>Hemostasis abnormalities were evident at onset of symptomatic COVID-19 (mild thrombocytopenia, minor increase in PT and PTT), with subsequent improvement; however, an abrupt increase in <sc>d</sc>-dimer and decrease in platelet count preceded occurrence of symptomatic PE. See text for additional clinical details.</p><p>Abbr.: BID, twice-daily; PT, prothrombin time; PTT, partial thromboplastin time; QD, once-daily.</p></caption><alt-text id="al0015">Fig. 3</alt-text><graphic xlink:href="gr3_lrg"/></fig></p>
    </sec>
    <sec id="s0090">
      <label>7</label>
      <title>HIT as a potential complication of COVID-19</title>
      <p id="p0260">HIT occurrence reflects not only exposure to heparin but also the clinical setting, heparin type, and duration of exposure. For example, HIT occurs more often with unfractionated heparin (UFH) than with low-molecular-weight heparin (LMWH) [<xref rid="bb0525" ref-type="bibr">105</xref>], more often in surgical than medical patients [<xref rid="bb0530" ref-type="bibr">106</xref>], and more often with exposure beyond 10&#xA0;days than patients who receive 4 or fewer days [<xref rid="bb0535" ref-type="bibr">107</xref>]. Further, among immunized patients, higher heparin dosing can lead to greater frequency of HIT &#x201C;breakthrough&#x201D;, and so dosing increase from prophylactic to intermediate to therapeutic could also increase the HIT risk [<xref rid="bb0540" ref-type="bibr">108</xref>]. Inflammation is a risk factor for HIT [<xref rid="bb0545" ref-type="bibr">109</xref>], so it is possible that COVID-19 represents a high-than-usual risk for HIT than standard &#x201C;medical&#x201D; patients receiving thromboprophylaxis, especially as many COVID-19 patients are hospitalized for over 1&#xA0;week.</p>
      <p id="p0265">There are anecdotal reports of HIT occurrence in COVID-19 patients. Riker and colleagues [<xref rid="bb0550" ref-type="bibr">110</xref>] reported 3 cases of putative HIT observed among only 16 intubated patients receiving UFH. However, although all 3 patients tested positive by PF4-dependent enzyme-immunoassay (EIA), only 1 patient tested positive by serotonin-release assay (SRA), so the true frequency of HIT in this report is uncertain.</p>
      <p id="p0270">Lingamaneni and coworkers [<xref rid="bb0555" ref-type="bibr">111</xref>] reported 1 case of confirmed HIT (DVT, thrombocytopenia after switching from prophylactic-dose LMWH to therapeutic-dose UFH, SRA-positive) among 5 COVID-19 patients investigated for HIT who tested EIA-positive (the other 4 patients with weak-positive EIA results tested SRA-negative). The authors emphasized the potential for HIT &#x201C;overdiagnosis&#x201D; if EIA-positive status alone is used to diagnose HIT.</p>
      <p id="p0275">Patell and coworkers [<xref rid="bb0560" ref-type="bibr">112</xref>] reported 5 patients with possible HIT&#x2014;based upon suspicious platelet count decline and a positive latex immunoturbidimetric assay (LIA) for anti-PF4/heparin antibodies&#x2014;among 88 COVID-19 patients who received at least 5&#xA0;days of UFH (median, 11&#xA0;days of UFH exposure). This corresponded to a cumulative incidence of LIA positivity of 12% at 25&#xA0;days (95%CI, 4% to 26%). However, LIA reactivity was relatively weak (between 1.0 and 1.9&#xA0;units/mL) in 4 of the 5 patients, which corresponds to a relatively low (20&#x2013;30%) predictivity for SRA-positive status [<xref rid="bb0565" ref-type="bibr">113</xref>], and a clear positive SRA result was only observed in 1 patient (two patients had &#x201C;borderline&#x201D; SRA-positive results). One of the LIA-positive patients did not undergo SRA testing, but that patient's LIA result was strong-positive (&gt;16&#xA0;units/mL), which predicts for high (~90%) probability of HIT [<xref rid="bb0565" ref-type="bibr">113</xref>]. Although the true frequency of HIT in this study was unclear, the implication is that HIT is a definite potential complication of COVID-19 patients, particularly if there is prolonged exposure to UFH.</p>
      <p id="p0280">Given the importance of HIT ascertainment in this novel patient population, we recommend referral of EIA-positive or LIA-positive blood samples for testing by functional (platelet activation) assay, such as the SRA. However, given emerging data regarding occasional false-negative SRA results [<xref rid="bb0570" ref-type="bibr">114</xref>], we also suggest that SRA-negative blood samples (but with strong clinical suspicion of HIT corroborated by strong-positive EIA or LIA) be referred to a laboratory with experience in performing newer PF4-dependent platelet activation assays, such as the PF4-SRA [<xref rid="bb0570" ref-type="bibr">114</xref>], PF4/heparin-SRA [<xref rid="bb0575" ref-type="bibr">115</xref>], or the P-selectin expression assay [<xref rid="bb0580" ref-type="bibr">116</xref>].</p>
      <p id="p0285">Parzy and colleagues [<xref rid="bb0585" ref-type="bibr">117</xref>] reported 3 patients with laboratory-confirmed HIT among 13 critically-ill patients requiring venovenous extracorporeal membrane oxygenation (ECMO) with heparin anticoagulation. Since all 13 ECMO patients developed one or more venous thrombotic events, the contributory role of HIT in explaining thrombosis in this study is uncertain. Unfortunately, clinical and laboratory data supporting the HIT diagnoses were not provided.</p>
      <p id="p0290">A non-peer-reviewed paper from China found that non-surviving ICU patients frequently had progressive, severe thrombocytopenia [<xref rid="bb0590" ref-type="bibr">118</xref>]. Many of these patients were receiving LMWH. The authors found high levels of &#x201C;HIT antibodies&#x201D; by enzyme-immunoassay among ICU patients, and they speculated that HIT may have contributed to severe thrombocytopenia and adverse outcomes. In some patients, antibodies were detectable even before heparin treatment, raising the possibility of COVID-19-associated &#x201C;spontaneous&#x201D; HIT syndrome [<xref rid="bb0595" ref-type="bibr">119</xref>]. However, HIT antibody assays with higher specificity (e.g., SRA) were not performed, so the implications of these observations are uncertain.</p>
      <p id="p0295">Anticoagulant dosing in HIT offers an interesting perspective. Due to its (relative) rarity, heterogeneous clinical presentation, and (until recently) difficulty in achieving rapid real-time laboratory confirmation of a diagnosis of HIT, randomized trials evaluating different treatment approaches have not been available for HIT. Yet, the recognition of HIT as a profound hypercoagulable state, together with relevant observational studies, have led to the current treatment paradigm where&#x2014;in the absence of contraindications&#x2014;patients with HIT are typically treated with <italic>therapeutic-dose</italic> anticoagulation. An example of an observational study that informed this practice was one by Farner and colleagues, who reported their experience treating HIT with danaparoid [<xref rid="bb0600" ref-type="bibr">120</xref>]. Paradoxically, patients with HIT-associated thrombosis who were treated with danaparoid had a lower frequency of subsequent thrombosis than patients who had &#x201C;isolated&#x201D; HIT, i.e., HIT diagnosed on the basis of a platelet count fall rather than because of thrombosis occurrence that led to a diagnosis of HIT. The authors' explanation was that patients with HIT-associated thrombosis typically received therapeutic-dose danaparoid, whereas patients with isolated HIT were usually given lower (prophylactic-dose) danaparoid.</p>
    </sec>
    <sec id="s0095">
      <label>8</label>
      <title>Prevention and treatment of thrombosis in COVID-19</title>
      <p id="p0300">There is wide variation in dosing of pharmacologic VTE prophylaxis in COVID-19 patients. Of interest is the observation that continuation of pre-hospital therapeutic-dose anticoagulation may have an important effect on reducing development of VTE. Klok and coworkers [<xref rid="bb0320" ref-type="bibr">64</xref>] noted that the risk of VTE in patients on therapeutic anticoagulation prior to ICU admission was lower in a competing risk model (HR 0.29 [95%CI, 0.091&#x2013;0.92]), although no effect on mortality was seen. In another Dutch study, no patients receiving therapeutic anticoagulation prior to hospital admission developed VTE [<xref rid="bb0340" ref-type="bibr">68</xref>].</p>
      <p id="p0305">Paranjpe and colleagues studied 2773 patients hospitalized with COVID-19 within the Mount Sinai Health System (New York City), with 786 (28%) receiving therapeutic-dose anticoagulation at some point during hospitalization [<xref rid="bb0605" ref-type="bibr">121</xref>]. They used a Cox proportional hazards model to evaluate the effect of treatment-dose anticoagulation on in-hospital mortality, finding no difference. However, in patients who required mechanical ventilation (<italic>N</italic>&#xA0;=&#xA0;395), in-hospital mortality was 29.1% (with a median survival of 21&#xA0;days) for those treated with therapeutic-dose anticoagulation, as compared to 62.7% (with a median survival of 9&#xA0;days) in patients who did not. In a multivariate proportional hazards model, longer duration of anticoagulant treatment was associated with reduced mortality (adjusted HR, 0.86 per day, 95%CI, 0.82&#x2013;0.89, <italic>P</italic>&#xA0;&lt;&#xA0;0.001).</p>
      <p id="p0310">The effect of prophylactic-dose LMWH or UFH was evaluated in 449 Chinese patients with severe COVID-19, of whom 22% received an anticoagulant. There was no difference in 28-day mortality, however, in patients with a Sepsis Induced Coagulopathy (SIC) score&#xA0;&#x2265;&#xA0;4 and who received prophylactic-dose heparin, mortality was lower (40.0% vs 64.2%, <italic>P</italic>&#xA0;=&#xA0;0.029) [<xref rid="bb0610" ref-type="bibr">122</xref>]. These observations suggest anticoagulation may have a favorable effect on mortality in the sickest patients.</p>
      <p id="p0315">Several organizations have developed guidelines, guidance statements, answers to frequently asked questions, or state-of-the-art reviews (<xref rid="t0015" ref-type="table">Table 3</xref>
) [<xref rid="bb0615" ref-type="bibr">[123]</xref>, <xref rid="bb0620" ref-type="bibr">[124]</xref>, <xref rid="bb0625" ref-type="bibr">[125]</xref>, <xref rid="bb0630" ref-type="bibr">[126]</xref>, <xref rid="bb0635" ref-type="bibr">[127]</xref>, <xref rid="bb0640" ref-type="bibr">[128]</xref>]. There is general agreement that all patients should receive, or be evaluated for, pharmacologic VTE prophylaxis; none recommend therapeutic-dose VTE prophylaxis unless done in the context of a clinical trial. Recommendations to use usual prophylactic- or intermediate-dose anticoagulation varies, as does dose adjustment for extremes of body weight, and some organizations differentiate approaches depending on whether the patient is in the ICU. Some statements recommend LMWH over UFH because of less patient exposure and personal protective equipment utilization. There is not strong agreement for extended prophylaxis post-discharge, but several groups recommend considering. Randomized trials are needed to address the best anticoagulant dose for VTE prevention, and we identified 9 proposed or ongoing trials comparing different doses of LMWH or UFH (<xref rid="t0020" ref-type="table">Table 4</xref>
).<table-wrap position="float" id="t0015"><label>Table 3</label><caption><p>Organizational advice and comments re: anticoagulation of COVID-19.</p></caption><alt-text id="al0030">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Group</th><th colspan="3" align="center">Anticoagulant dose recommended<hr/></th><th rowspan="2">Pharmacologic and mechanical prophylaxis</th><th rowspan="2">Extremes of weight adjustment</th><th rowspan="2">Extended prophylaxis post-discharge</th></tr><tr><th>Prophylactic</th><th>Intermediate</th><th>Therapeutic</th></tr></thead><tbody><tr><td>Anticoagulation forum [<xref rid="bb0615" ref-type="bibr">123</xref>]</td><td>Ward</td><td>ICU</td><td>No</td><td>ICU</td><td>Yes</td><td>Case-by-case and low bleeding risk</td></tr><tr><td>International Society on Thrombosis and Haemostasis [<xref rid="bb0620" ref-type="bibr">124</xref>]</td><td>Ward, ICU</td><td>Ward (30% of respondents); ICU (50% of respondents)</td><td>No</td><td>ICU (60% of respondents)</td><td>Yes</td><td>LMWH (30% of respondents); DOAC (30% of respondents)</td></tr><tr><td>American College of Chest Physicians (ACCP) [<xref rid="bb0625" ref-type="bibr">125</xref>]</td><td>All</td><td>No</td><td>No</td><td>No</td><td>Not mentioned</td><td>No</td></tr><tr><td>Global COVID-19 Thrombosis Collaborative Group [<xref rid="bb0630" ref-type="bibr">126</xref>]</td><td>All</td><td>Insufficient data to consider</td><td>Insufficient data to consider</td><td>Not mentioned</td><td>Not mentioned</td><td>Not mentioned</td></tr><tr><td>American Society of Hematology [<xref rid="bb0635" ref-type="bibr">127</xref>]</td><td>Not specifically mentioned but implied for all</td><td>We encourage participation in clinical trials rather than empiric use of intermediate-dose heparin</td><td>We encourage participation in clinical trials rather than empiric use of therapeutic-dose heparin</td><td>Not generally recommended</td><td>May be used</td><td>It is reasonable to consider extended thromboprophylaxis after discharge using a regulatory approved regimen</td></tr><tr><td>National Institutes of Health [<xref rid="bb0640" ref-type="bibr">128</xref>]</td><td>Per standard of care for other hospitalized adults</td><td colspan="2">There are currently insufficient data to recommend for or against the use of thrombolytics or increasing anticoagulant doses for VTE prophylaxis in hospitalized COVID-19 patients outside the setting of a clinical trial</td><td>Not mentioned</td><td>Not mentioned</td><td>Hospitalized patients with COVID-19 should not routinely be discharged on VTE prophylaxis. Using FDA-approved regimens, extended VTE prophylaxis can be considered in patients who are at low risk for bleeding and high risk for VTE as per protocols for patients without COVID-19.</td></tr></tbody></table><table-wrap-foot><fn><p>Abbr: COVID-19, coronavirus disease, 2019; DOAC, direct oral anticoagulant; FDA, Food and Drug Administration; ICU, intensive care unit; LMWH, low-molecular-weight heparin; VTE, venous thromboembolism.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0020"><label>Table 4</label><caption><p>Clinical trials of anticoagulation for COVID-19.</p></caption><alt-text id="al0035">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Trial</th><th>Identifier</th><th>Sponsor</th><th>Patients</th><th>Intervention</th><th>Comparison</th><th>Outcome</th><th>Timeframe</th></tr></thead><tbody><tr><td>COVID-HEP</td><td>NCT0445848</td><td>University Hospital, Geneva</td><td>200 ward or ICU</td><td>Therapeutic enoxaparin or UFH</td><td>Prophylactic enoxaparin or UFH</td><td>Composite ATE, VTE, DIC and all-cause mortality</td><td>30&#xA0;days</td></tr><tr><td>X-covid 19</td><td><ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04366960" id="ir0005">NCT04366960</ext-link></td><td>Niguarda Hospital</td><td>2712 ward</td><td>Enoxaparin 40&#xA0;mg QD</td><td>Enoxaparin 40&#xA0;mg BID</td><td>DVT by serial ultrasound and PE</td><td>30&#xA0;days</td></tr><tr><td>Rapid COVID COAG</td><td><ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04362085" id="ir0010">NCT04362085</ext-link></td><td>St. Michael's Hospital, Toronto</td><td>462 ward with D-dimer &gt;2 time ULN</td><td>Therapeutic LMWH or UFH</td><td>Prophylactic LMWH, UFH or fondaparinux</td><td>Composite ICU admission, non-invasive positive pressure ventilation, mechanical ventilation or all-cause death</td><td>28&#xA0;days</td></tr><tr><td>Protect COVID 19</td><td><ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04359277" id="ir0015">NCT04359277</ext-link></td><td>NYU Langone Health</td><td>1000 ward or ICU</td><td>Therapeutic LMWH (adjusted for obesity) or UFH</td><td>Prophylactic LMWH or UFH (adjusted for obesity)</td><td>Composite all&#xA0;=&#xA0;cause mortality, cardiac arrest, VTE, ATE, MI, stroke or shock</td><td>30&#xA0;days</td></tr><tr><td>ATTACC</td><td><ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04372589" id="ir0020">NCT04372589</ext-link></td><td>University of Manitoba</td><td>3000 or less (adaptive design) ward and ICU</td><td>Therapeutic LMWH or UFH</td><td>Usual care</td><td>Intubation and mortality</td><td>30&#xA0;days</td></tr><tr><td>CORIMMUNO-COAG</td><td><ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04344756" id="ir0025">NCT04344756</ext-link></td><td>Assistance Pulique - Hopitaux de Paris</td><td>808 ward and ICU</td><td>Therapeutic tinzaparin or UFH</td><td>Prophylactic LMWH or UFH</td><td>Survival without ventilation</td><td>14&#xA0;days</td></tr><tr><td>COVI-DOSE</td><td><ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04373707" id="ir0030">NCT04373707</ext-link></td><td>Central Hospital, Nancy, France</td><td>602 ward and ICU</td><td>Intermediate LMWH</td><td>Prophylactic LMWH</td><td>VTE and VTE related death</td><td>28&#xA0;days</td></tr><tr><td>IMPROVE</td><td><ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04367831" id="ir0035">NCT04367831</ext-link></td><td>Columbia University</td><td>100 ICU</td><td>Intermediate LMWH or UFH</td><td>Prophylactic LMWH or UFH</td><td>VTE and ATE</td><td>30&#xA0;days</td></tr><tr><td>HEP-COVID</td><td><ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04401293" id="ir0040">NCT04401293</ext-link></td><td>Northwell Health</td><td>308 ward and ICU</td><td>Therapeutic LMWH</td><td>Prophylactic or intermediate LMWH or UFH</td><td>VTE, ATE and all-cause mortality</td><td>30&#xA0;days</td></tr></tbody></table><table-wrap-foot><fn><p>Abbr.: ATE, arterial thromboembolism; BID, twice-daily; COVID-19, coronavirus disease, 2019; DIC, disseminated intravascular coagulation; DVT, deep-vein thrombosis; ICU, intensive care unit; LMWH, low-molecular-weight heparin; QD, once-daily; UFH, unfractionated heparin; VTE, venous thromboembolism.</p></fn></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="s0100">
      <title>CRediT authorship contribution statement</title>
      <p id="p0320">Theodore E. Warkentin: Contributing to the literature review, writing and editing drafts of the manuscript (primarily responsible for sections 1 through 4, inclusive, and section 7).</p>
      <p id="p0325">Scott Kaatz: Contributing to the literature review, writing and editing drafts of the manuscript (primarily responsible for sections 5, 6, and 8).</p>
    </sec>
    <sec sec-type="COI-statement">
      <title>Declaration of competing interest</title>
      <p id="p0330">TEW has received royalties from Informa (Taylor &amp; Francis) and lecture honoraria from Alexion Canada and Instrumentation Laboratory; has provided consulting services to Aspen Global, Bayer, CSL Behring, Ergomed, Instrumentation Laboratory and Octapharma; has received research funding from <funding-source id="gts0005">Instrumentation Laboratory</funding-source>; and has provided expert witness testimony relating to HIT and non-HIT thrombocytopenic and coagulopathic disorders.</p>
      <p id="p0335">SK, Scott Kaatz has received research funding from <funding-source id="gts0010"><institution-wrap><institution-id institution-id-type="doi">10.13039/100014554</institution-id><institution>Janssen</institution></institution-wrap></funding-source> and <funding-source id="gts0015"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008021</institution-id><institution>Bristol-Myers Squibb</institution></institution-wrap></funding-source>, and has received consulting honoraria from Janssen, Bristol-Myers Squibb, and Portola.</p>
    </sec>
  </body>
  <back>
    <ref-list id="bi0005">
      <title>References</title>
      <ref id="bb0005">
        <label>1</label>
        <element-citation publication-type="other" id="rf0005">
          <article-title>Worldometer COVID-19</article-title>
          <comment>Available at</comment>
          <ext-link ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/" id="ir0045">https://www.worldometers.info/coronavirus/</ext-link>
        </element-citation>
      </ref>
      <ref id="bb0010">
        <label>2</label>
        <element-citation publication-type="journal" id="rf0010">
          <person-group person-group-type="author">
            <name>
              <surname>Varga</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Flammer</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Steiger</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Haberecker</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Andermatt</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Zinkernagel</surname>
              <given-names>A.S.</given-names>
            </name>
          </person-group>
          <article-title>Endothelial cell infection and endotheliitis in COVID-19</article-title>
          <source>Lancet</source>
          <volume>395</volume>
          <issue>10234</issue>
          <year>2020</year>
          <fpage>1417</fpage>
          <lpage>1418</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30937-5</pub-id>
          <comment>(Epub 2020 Apr 21)</comment>
          <pub-id pub-id-type="pmid">32325026</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0015">
        <label>3</label>
        <element-citation publication-type="journal" id="rf0015">
          <person-group person-group-type="author">
            <name>
              <surname>Ackermann</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Verleden</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Kuehnel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Haverich</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Welte</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Laenger</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19</article-title>
          <source>N. Engl. J. Med.</source>
          <volume>383</volume>
          <issue>2</issue>
          <year>2020</year>
          <fpage>120</fpage>
          <lpage>128</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa2015432</pub-id>
          <comment>(Epub 2020 May 21)</comment>
          <pub-id pub-id-type="pmid">32437596</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0020">
        <label>4</label>
        <element-citation publication-type="journal" id="rf0020">
          <person-group person-group-type="author">
            <name>
              <surname>Poncs</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fodil</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Azoulay</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Zafrani</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CiV-2 infection</article-title>
          <source>Crit. Care</source>
          <volume>24</volume>
          <issue>1</issue>
          <year>2020</year>
          <fpage>353</fpage>
          <pub-id pub-id-type="doi">10.1186/s13054-020-03062-7</pub-id>
          <pub-id pub-id-type="pmid">32546188</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0025">
        <label>5</label>
        <element-citation publication-type="journal" id="rf0025">
          <person-group person-group-type="author">
            <name>
              <surname>Cuker</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Arepally</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Chong</surname>
              <given-names>B.H.</given-names>
            </name>
            <name>
              <surname>Greinacher</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gruel</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Linkins</surname>
              <given-names>L.A.</given-names>
            </name>
          </person-group>
          <article-title>American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia</article-title>
          <source>Blood. Adv.</source>
          <volume>2</volume>
          <issue>22</issue>
          <year>2018</year>
          <fpage>3360</fpage>
          <lpage>3392</lpage>
          <pub-id pub-id-type="doi">10.1182/bloodadvances.2018024489</pub-id>
          <pub-id pub-id-type="pmid">30482768</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0030">
        <label>6</label>
        <element-citation publication-type="journal" id="rf0030">
          <person-group person-group-type="author">
            <name>
              <surname>Chong</surname>
              <given-names>B.H.</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Berndt</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Dunlop</surname>
              <given-names>L.C.</given-names>
            </name>
            <name>
              <surname>Brighton</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Chesterman</surname>
              <given-names>C.N.</given-names>
            </name>
          </person-group>
          <article-title>Plasma P-selectin is increased in thrombotic consumptive platelet disorders</article-title>
          <source>Blood</source>
          <volume>83</volume>
          <issue>6</issue>
          <year>1994</year>
          <fpage>1535</fpage>
          <lpage>1541</lpage>
          <pub-id pub-id-type="pmid">7510145</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0035">
        <label>7</label>
        <element-citation publication-type="journal" id="rf0035">
          <person-group person-group-type="author">
            <name>
              <surname>Rauova</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Hirsch</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Greene</surname>
              <given-names>T.K.</given-names>
            </name>
            <name>
              <surname>Zhai</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Hayes</surname>
              <given-names>V.M.</given-names>
            </name>
            <name>
              <surname>Kowalska</surname>
              <given-names>M.A.</given-names>
            </name>
          </person-group>
          <article-title>Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia</article-title>
          <source>Blood</source>
          <volume>116</volume>
          <issue>23</issue>
          <year>2010</year>
          <fpage>5021</fpage>
          <lpage>5031</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2010-03-276964</pub-id>
          <comment>(Epub 2010 Aug 19)</comment>
          <pub-id pub-id-type="pmid">20724543</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0040">
        <label>8</label>
        <element-citation publication-type="journal" id="rf0040">
          <person-group person-group-type="author">
            <name>
              <surname>Gollomp</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Hayes</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Welsh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Arepally</surname>
              <given-names>G.M.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil accumulation and NET release contribute to thrombosis in HIT</article-title>
          <source>JCI Insight</source>
          <volume>3</volume>
          <issue>18</issue>
          <year>2018</year>
          <fpage>e99445</fpage>
          <pub-id pub-id-type="doi">10.1172/jci.insight.99445</pub-id>
          <comment>(eCollection 2018 Sep 20)</comment>
        </element-citation>
      </ref>
      <ref id="bb0045">
        <label>9</label>
        <element-citation publication-type="journal" id="rf0045">
          <person-group person-group-type="author">
            <name>
              <surname>Perdomo</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>H.H.L.</given-names>
            </name>
            <name>
              <surname>Ahmadi</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Chong</surname>
              <given-names>J.J.H.</given-names>
            </name>
            <name>
              <surname>Passam</surname>
              <given-names>F.H.</given-names>
            </name>
            <name>
              <surname>Chong</surname>
              <given-names>B.H.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia</article-title>
          <source>Nat. Commun.</source>
          <volume>10</volume>
          <issue>1</issue>
          <year>2019</year>
          <fpage>1322</fpage>
          <pub-id pub-id-type="doi">10.1038/s41467-019-09160-7</pub-id>
          <pub-id pub-id-type="pmid">30899022</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0050">
        <label>10</label>
        <element-citation publication-type="journal" id="rf0050">
          <person-group person-group-type="author">
            <name>
              <surname>Madeeva</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Cines</surname>
              <given-names>D.B.</given-names>
            </name>
            <name>
              <surname>Poncz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rauova</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Role of monocytes and endothelial cells in heparin-induced thrombocytopenia</article-title>
          <source>Thromb. Haemost.</source>
          <volume>116</volume>
          <issue>5</issue>
          <year>2016</year>
          <fpage>806</fpage>
          <lpage>812</lpage>
          <pub-id pub-id-type="doi">10.1160/TH16-02-0162</pub-id>
          <pub-id pub-id-type="pmid">27487857</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0055">
        <label>11</label>
        <element-citation publication-type="journal" id="rf0055">
          <person-group person-group-type="author">
            <name>
              <surname>Hayes</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Arepally</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>McKenzie</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Cines</surname>
              <given-names>D.B.</given-names>
            </name>
            <name>
              <surname>Rauova</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia</article-title>
          <source>J. Clin. Invest.</source>
          <volume>127</volume>
          <issue>3</issue>
          <year>2017</year>
          <fpage>1090</fpage>
          <lpage>1098</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI90958</pub-id>
          <comment>(Epub 2017 Feb 20)</comment>
          <pub-id pub-id-type="pmid">28218620</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0060">
        <label>12</label>
        <element-citation publication-type="journal" id="rf0060">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Hayward</surname>
              <given-names>C.P.M.</given-names>
            </name>
            <name>
              <surname>Boshkov</surname>
              <given-names>L.K.</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>A.V.</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Bode</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Kelton</surname>
              <given-names>J.G.</given-names>
            </name>
          </person-group>
          <article-title>Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia</article-title>
          <source>Blood</source>
          <volume>84</volume>
          <issue>11</issue>
          <year>1994</year>
          <fpage>3691</fpage>
          <lpage>3699</lpage>
          <pub-id pub-id-type="pmid">7949124</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0065">
        <label>13</label>
        <element-citation publication-type="journal" id="rf0065">
          <person-group person-group-type="author">
            <name>
              <surname>Kelton</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Sheridan</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Steeves</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia: laboratory studies</article-title>
          <source>Blood</source>
          <volume>72</volume>
          <issue>3</issue>
          <year>1988</year>
          <fpage>925</fpage>
          <lpage>930</lpage>
          <pub-id pub-id-type="pmid">3416077</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0070">
        <label>14</label>
        <element-citation publication-type="journal" id="rf0070">
          <person-group person-group-type="author">
            <name>
              <surname>Pouplard</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Iochmann</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Renard</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Herault</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Colombat</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Amiral</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Gruel</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia</article-title>
          <source>Blood</source>
          <volume>97</volume>
          <issue>10</issue>
          <year>2001</year>
          <fpage>3300</fpage>
          <lpage>3302</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.v97.10.3300</pub-id>
          <pub-id pub-id-type="pmid">11342462</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0075">
        <label>15</label>
        <element-citation publication-type="journal" id="rf0075">
          <person-group person-group-type="author">
            <name>
              <surname>Kowalska</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Krishnaswamy</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rauova</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Zhai</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Hayes</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Amirikian</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT</article-title>
          <source>Blood</source>
          <volume>118</volume>
          <issue>10</issue>
          <year>2011</year>
          <fpage>2882</fpage>
          <lpage>2888</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2011-02-335208</pub-id>
          <pub-id pub-id-type="pmid">21772054</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0080">
        <label>16</label>
        <element-citation publication-type="journal" id="rf0080">
          <person-group person-group-type="author">
            <name>
              <surname>Johnson</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Sarkar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Hayes</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Koma</surname>
              <given-names>G.T.</given-names>
            </name>
            <name>
              <surname>Arepally</surname>
              <given-names>G.M.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contribute to thrombus propagation</article-title>
          <source>Blood</source>
          <volume>135</volume>
          <issue>15</issue>
          <year>2020</year>
          <fpage>1270</fpage>
          <lpage>1280</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.2018881607</pub-id>
          <pub-id pub-id-type="pmid">32077913</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0085">
        <label>17</label>
        <element-citation publication-type="journal" id="rf0085">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>HIT: still stringing us along</article-title>
          <source>Blood</source>
          <volume>135</volume>
          <issue>15</issue>
          <year>2020</year>
          <fpage>1193</fpage>
          <lpage>1194</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.2020005157.10.1182/blood.2020005157</pub-id>
          <comment>Apr 9</comment>
          <pub-id pub-id-type="pmid">32271906</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0090">
        <label>18</label>
        <element-citation publication-type="journal" id="rf0090">
          <person-group person-group-type="author">
            <name>
              <surname>Barnes</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Androver</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Baxter-Stoltzfus</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Borczuk</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Cools-Lartigue</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Targeting potential drivers of COVID-19: neutrophil extracellular traps</article-title>
          <source>J. Exp. Med.</source>
          <volume>217</volume>
          <issue>6</issue>
          <year>2020</year>
          <fpage>e20200652</fpage>
          <pub-id pub-id-type="doi">10.1084/jem.20200652</pub-id>
          <pub-id pub-id-type="pmid">32302401</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0095">
        <label>19</label>
        <element-citation publication-type="journal" id="rf7350">
          <person-group person-group-type="author">
            <name>
              <surname>Zuo</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Yalavarthi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Gockman</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Zuo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Madison</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil extracellular traps in COVID-19</article-title>
          <source>JCI Insight</source>
          <volume>5</volume>
          <issue>11</issue>
          <year>2020</year>
          <object-id pub-id-type="publisher-id">e138999</object-id>
          <pub-id pub-id-type="doi">10.1172/jci.insight.138999</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0100">
        <label>20</label>
        <element-citation publication-type="journal" id="rf0095">
          <person-group person-group-type="author">
            <name>
              <surname>Iba T</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Wada</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Thachil</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Differential diagnosis for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH</article-title>
          <source>J. Thromb. Haemost.</source>
          <volume>17</volume>
          <issue>2</issue>
          <year>2019</year>
          <fpage>415</fpage>
          <lpage>419</lpage>
          <pub-id pub-id-type="doi">10.1111/jth.14354</pub-id>
          <comment>(Epub 2019 Jan 7)</comment>
          <pub-id pub-id-type="pmid">30618150</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0105">
        <label>21</label>
        <element-citation publication-type="journal" id="rf0100">
          <person-group person-group-type="author">
            <name>
              <surname>Iba</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Raj</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Advance in the management of sepsis-induced coagulopathy and disseminated intravascular coagulation</article-title>
          <source>J. Clin. Med.</source>
          <volume>8</volume>
          <issue>5</issue>
          <year>2019</year>
          <pub-id pub-id-type="doi">10.3390/jcm8050728</pub-id>
          <comment>pii: E728</comment>
        </element-citation>
      </ref>
      <ref id="bb0110">
        <label>22</label>
        <mixed-citation publication-type="other" id="or0010">C.S. Whyte, G.B. Morrow, J.L. Mitchell, P. Chowdary, N.J. Mutch, Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19, J. Thromb. Haemost.. 18 (7) 1548&#x2013;1555. doi: <pub-id pub-id-type="doi">10.1111/jth.14872</pub-id>. (Epub 2020 Jun 3).</mixed-citation>
      </ref>
      <ref id="bb0115">
        <label>23</label>
        <element-citation publication-type="journal" id="rf0105">
          <person-group person-group-type="author">
            <name>
              <surname>McGonagle</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Sharif</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>O&#x2019;Regan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bridgewood</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease</article-title>
          <source>Autoimmun. Rev.</source>
          <volume>19</volume>
          <issue>6</issue>
          <year>2020</year>
          <fpage>102537</fpage>
          <pub-id pub-id-type="doi">10.1016/j.autrev.2020.102537</pub-id>
          <comment>(Epub 2020 Apr 3)</comment>
          <pub-id pub-id-type="pmid">32251717</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0120">
        <label>24</label>
        <element-citation publication-type="journal" id="rf0110">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Ischemic limb gangrene with pulses</article-title>
          <source>N. Engl. J. Med.</source>
          <volume>373</volume>
          <issue>7</issue>
          <year>2015</year>
          <fpage>642</fpage>
          <lpage>655</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra1316259</pub-id>
          <pub-id pub-id-type="pmid">26267624</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0125">
        <label>25</label>
        <element-citation publication-type="journal" id="rf0115">
          <person-group person-group-type="author">
            <name>
              <surname>Guan</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Ni</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Ou</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title>
          <source>N. Engl. J. Med.</source>
          <volume>382</volume>
          <issue>18</issue>
          <year>2020</year>
          <fpage>1708</fpage>
          <lpage>1720</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id>
          <comment>(Epub 2020 Feb 28)</comment>
          <pub-id pub-id-type="pmid">32109013</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0130">
        <label>26</label>
        <element-citation publication-type="journal" id="rf0120">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title>
          <source>Lancet</source>
          <volume>95</volume>
          <issue>10229</issue>
          <year>2020</year>
          <fpage>1054</fpage>
          <lpage>1062</lpage>
          <comment>Epub 2020 Mar 11</comment>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0135">
        <label>27</label>
        <element-citation publication-type="journal" id="rf0125">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China</article-title>
          <source>JAMA Intern. Med.</source>
          <volume>180</volume>
          <issue>7</issue>
          <year>2020</year>
          <fpage>1</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1001/jamainternmed.2020.0994</pub-id>
          <comment>([Epub ahead of print] Correction in: JAMA Intern. Med. 2020 May 11. E201429)</comment>
        </element-citation>
      </ref>
      <ref id="bb0140">
        <label>28</label>
        <element-citation publication-type="journal" id="rf2160">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title>
          <source>JAMA</source>
          <volume>323</volume>
          <issue>11</issue>
          <year>2020</year>
          <fpage>1061</fpage>
          <lpage>1069</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id>
          <pub-id pub-id-type="pmid">32031570</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0145">
        <label>29</label>
        <element-citation publication-type="journal" id="rf0130">
          <person-group person-group-type="author">
            <name>
              <surname>Fu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: a retrospective study in Suzhou China</article-title>
          <source>Thromb. Res.</source>
          <volume>192</volume>
          <year>2020</year>
          <fpage>3</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2020.05.006</pub-id>
          <comment>(Epub 2020 May 6)</comment>
          <pub-id pub-id-type="pmid">32407937</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0150">
        <label>30</label>
        <element-citation publication-type="journal" id="rf0135">
          <person-group person-group-type="author">
            <name>
              <surname>Hui</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Neutrophil and monocyte counts in heparin-induced thrombocytopenia</article-title>
          <source>Thromb. Haemost.</source>
          <volume>119</volume>
          <issue>6</issue>
          <year>2019</year>
          <fpage>941</fpage>
          <lpage>951</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0039-1683913</pub-id>
          <pub-id pub-id-type="pmid">31005061</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0155">
        <label>31</label>
        <element-citation publication-type="journal" id="rf0140">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China</article-title>
          <source>Crit. Care</source>
          <volume>24</volume>
          <issue>1</issue>
          <year>2020</year>
          <fpage>188</fpage>
          <pub-id pub-id-type="doi">10.1186/s13054-020-02895-6</pub-id>
          <pub-id pub-id-type="pmid">32354360</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0160">
        <label>32</label>
        <element-citation publication-type="journal" id="rf0145">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Samkari</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Leaf</surname>
              <given-names>R.K.</given-names>
            </name>
            <name>
              <surname>Dzik</surname>
              <given-names>W.H.</given-names>
            </name>
            <name>
              <surname>Carlson</surname>
              <given-names>J.C.T.</given-names>
            </name>
            <name>
              <surname>Fogerty</surname>
              <given-names>A.E.</given-names>
            </name>
            <name>
              <surname>Waheed</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection</article-title>
          <source>Blood</source>
          <volume>136</volume>
          <issue>4</issue>
          <year>2020</year>
          <fpage>489</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.2020006520</pub-id>
          <pub-id pub-id-type="pmid">32492712</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0165">
        <label>33</label>
        <element-citation publication-type="journal" id="rf0150">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia: pathogenesis and management</article-title>
          <source>Br. J. Haematol.</source>
          <volume>121</volume>
          <issue>4</issue>
          <year>2003</year>
          <fpage>535</fpage>
          <lpage>555</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2141.2003.04334.x</pub-id>
          <pub-id pub-id-type="pmid">12752095</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0170">
        <label>34</label>
        <element-citation publication-type="journal" id="rf0155">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced immune-mediated thrombocytopenia&#x2014;from purpura to thrombosis</article-title>
          <source>N. Engl. J. Med.</source>
          <volume>356</volume>
          <issue>9</issue>
          <year>2007</year>
          <fpage>891</fpage>
          <lpage>893</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMp068309</pub-id>
          <pub-id pub-id-type="pmid">17329695</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0175">
        <label>35</label>
        <element-citation publication-type="journal" id="rf0160">
          <person-group person-group-type="author">
            <name>
              <surname>Gruel</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Vayne</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rollin</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Faille</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bauters</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Comparative analysis of a French prospective series of 144 patients with heparin-induced thrombocytopenia (FRIGTIH) and the literature</article-title>
          <source>Thromb. Haemost.</source>
          <volume>120</volume>
          <issue>7</issue>
          <year>2020</year>
          <fpage>1096</fpage>
          <lpage>1107</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0040-1712957</pub-id>
          <pub-id pub-id-type="pmid">32572863</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0180">
        <label>36</label>
        <element-citation publication-type="journal" id="rf0165">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>R.S.</given-names>
            </name>
            <name>
              <surname>Hirsh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kelton</surname>
              <given-names>J.G.</given-names>
            </name>
          </person-group>
          <article-title>An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients</article-title>
          <source>Arch. Intern. Med.</source>
          <volume>163</volume>
          <issue>20</issue>
          <year>2003</year>
          <fpage>2518</fpage>
          <lpage>2524</lpage>
          <pub-id pub-id-type="doi">10.1001/archinte.163.20.2518</pub-id>
          <pub-id pub-id-type="pmid">14609790</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0185">
        <label>37</label>
        <element-citation publication-type="journal" id="rf0170">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Jia</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Dynamic relationship between D-dimer and COVID-19 severity</article-title>
          <source>Br. J. Haematol.</source>
          <volume>190</volume>
          <issue>1</issue>
          <year>2020</year>
          <fpage>e24</fpage>
          <lpage>e27</lpage>
          <pub-id pub-id-type="doi">10.1111/bjh.16811</pub-id>
          <comment>(Epub 2020 Jun 9)</comment>
          <pub-id pub-id-type="pmid">32420615</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0190">
        <label>38</label>
        <element-citation publication-type="journal" id="rf0175">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>Abnormal coagulation parameters are associated with poor prognosis in patients in novel coronavirus pneumonia</article-title>
          <source>J. Thromb. Haemost.</source>
          <volume>18</volume>
          <issue>4</issue>
          <year>2020</year>
          <fpage>844</fpage>
          <lpage>847</lpage>
          <comment>Epub 2020 Mar 13</comment>
          <pub-id pub-id-type="doi">10.1111/jth.14768</pub-id>
          <pub-id pub-id-type="pmid">32073213</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0195">
        <label>39</label>
        <element-citation publication-type="journal" id="rf0180">
          <person-group person-group-type="author">
            <name>
              <surname>Bowles</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Platton</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Yartey</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Dave</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>D.P.</given-names>
            </name>
          </person-group>
          <article-title>Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19</article-title>
          <source>N. Engl. J. Med.</source>
          <volume>383</volume>
          <issue>3</issue>
          <year>2020</year>
          <fpage>288</fpage>
          <lpage>290</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc2013656</pub-id>
          <pub-id pub-id-type="pmid">32369280</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0200">
        <label>40</label>
        <element-citation publication-type="journal" id="rf0185">
          <person-group person-group-type="author">
            <name>
              <surname>Helms</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Tacquard</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Severac</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Leonard-Lorant</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Ohana</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Delabranche</surname>
              <given-names>X.</given-names>
            </name>
          </person-group>
          <article-title>High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study</article-title>
          <source>Intensive Care Med.</source>
          <volume>46</volume>
          <issue>6</issue>
          <year>2020</year>
          <fpage>1089</fpage>
          <lpage>1098</lpage>
          <pub-id pub-id-type="doi">10.1007/s00134-020-06062-x</pub-id>
          <comment>(Epub 2020 May 4)</comment>
          <pub-id pub-id-type="pmid">32367170</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0205">
        <label>41</label>
        <element-citation publication-type="journal" id="rf0190">
          <person-group person-group-type="author">
            <name>
              <surname>Harzallah</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Debliquis</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Dr&#xE9;nou</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Frequency of lupus anticoagulant in Covid-19 patients</article-title>
          <source>J. Thromb. Haemost.</source>
          <year>2020 May</year>
          <fpage>29</fpage>
          <pub-id pub-id-type="doi">10.1111/jth.14937</pub-id>
          <comment>(doi: 10.1111/jth.14937)</comment>
        </element-citation>
      </ref>
      <ref id="bb0210">
        <label>42</label>
        <element-citation publication-type="journal" id="rf0195">
          <person-group person-group-type="author">
            <name>
              <surname>Escher</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Breakey</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Severe COVID-19 infection associated with endothelial activation</article-title>
          <source>Thromb. Res.</source>
          <volume>190</volume>
          <year>2020</year>
          <fpage>62</fpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2020.04.014</pub-id>
          <comment>(Epub 2020 Apr 15)</comment>
          <pub-id pub-id-type="pmid">32305740</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0215">
        <label>43</label>
        <element-citation publication-type="journal" id="rf0200">
          <person-group person-group-type="author">
            <name>
              <surname>Escher</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Breakey</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients</article-title>
          <source>Thromb. Res.</source>
          <volume>192</volume>
          <year>2020</year>
          <fpage>174</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2020.05.032</pub-id>
          <comment>(Epub 2020 May 23)</comment>
          <pub-id pub-id-type="pmid">32505009</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0220">
        <label>44</label>
        <element-citation publication-type="journal" id="rf0205">
          <person-group person-group-type="author">
            <name>
              <surname>Huisman</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Beun</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Sikma</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Westerink</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kusadasi</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SRAS-CoV-2</article-title>
          <source>Int. J. Lab. Hematol.</source>
          <volume>22</volume>
          <year>2020 May</year>
          <pub-id pub-id-type="doi">10.1111/ijlh.13244</pub-id>
          <comment>(doi: 10.1111/ijlh.13244. Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0225">
        <label>45</label>
        <element-citation publication-type="journal" id="rf0210">
          <person-group person-group-type="author">
            <name>
              <surname>Varatharajah</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Rajah</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Microthrombotic complications of COVID-19 are likely due to embolism of circulating endothelial derived ultralarge von Willebrand factor (eULVWF) decorated-platelet strings</article-title>
          <source>Fed. Pract.</source>
          <volume>37</volume>
          <issue>6</issue>
          <year>2020</year>
          <fpage>e1</fpage>
          <lpage>e2</lpage>
          <comment>(Epub 2020 May 15)</comment>
          <pub-id pub-id-type="pmid">32489244</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0230">
        <label>46</label>
        <element-citation publication-type="journal" id="rf0215">
          <person-group person-group-type="author">
            <name>
              <surname>Magro</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Mulvey</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Berlin</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Nuovo</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Salvatore</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Harp</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases</article-title>
          <source>Transl. Res.</source>
          <volume>220</volume>
          <year>2020</year>
          <fpage>1</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1016/j.trsl.2020.04.007</pub-id>
          <comment>(Epub 2020 Apr 15)</comment>
          <pub-id pub-id-type="pmid">32299776</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0235">
        <label>47</label>
        <element-citation publication-type="journal" id="rf0220">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia in critically ill patients</article-title>
          <source>Semin. Thromb. Hemost.</source>
          <volume>41</volume>
          <issue>1</issue>
          <year>2015</year>
          <fpage>49</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0034-1398381</pub-id>
          <pub-id pub-id-type="pmid">25590528</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0240">
        <label>48</label>
        <element-citation publication-type="journal" id="rf0225">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls</article-title>
          <source>Expert Opin. Drug Saf.</source>
          <volume>13</volume>
          <issue>1</issue>
          <year>2014</year>
          <fpage>25</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1517/14740338.2013.823946</pub-id>
          <pub-id pub-id-type="pmid">23971903</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0245">
        <label>49</label>
        <element-citation publication-type="journal" id="rf0230">
          <person-group person-group-type="author">
            <name>
              <surname>Chilver-Stainer</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Alberio</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems</article-title>
          <source>Thromb. Haemost.</source>
          <volume>91</volume>
          <issue>2</issue>
          <year>2004</year>
          <fpage>276</fpage>
          <lpage>282</lpage>
          <pub-id pub-id-type="doi">10.1160/TH03-07-0454</pub-id>
          <pub-id pub-id-type="pmid">14961154</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0250">
        <label>50</label>
        <element-citation publication-type="journal" id="rf0235">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Bernstein</surname>
              <given-names>R.A.</given-names>
            </name>
          </person-group>
          <article-title>Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin</article-title>
          <source>N. Engl. J. Med.</source>
          <volume>348</volume>
          <issue>11</issue>
          <year>2003</year>
          <fpage>1067</fpage>
          <lpage>1069</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM200303133481120</pub-id>
          <pub-id pub-id-type="pmid">12637624</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0255">
        <label>51</label>
        <element-citation publication-type="journal" id="rf0240">
          <person-group person-group-type="author">
            <name>
              <surname>Hart</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bate</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Dinh</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Elms</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bundesen</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Hillyard</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rylatt</surname>
              <given-names>D.B.</given-names>
            </name>
          </person-group>
          <article-title>The detection of <sc>d</sc>-dimer in plasma by enzyme immunoassay: improved discrimination is obtained with a more specific signal antibody</article-title>
          <source>Blood Coagul. Fibrinolysis</source>
          <volume>5</volume>
          <issue>2</issue>
          <year>1994</year>
          <fpage>227</fpage>
          <lpage>232</lpage>
          <pub-id pub-id-type="pmid">7519890</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0260">
        <label>52</label>
        <element-citation publication-type="journal" id="rf0245">
          <person-group person-group-type="author">
            <name>
              <surname>Iba</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Thachil</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Coagulopathy in COVID-19</article-title>
          <source>J.Thromb. Haemost.</source>
          <year>2020 Jun 18</year>
          <pub-id pub-id-type="doi">10.1111/jth.14975</pub-id>
          <comment>(Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0265">
        <label>53</label>
        <element-citation publication-type="journal" id="rf0250">
          <person-group person-group-type="author">
            <name>
              <surname>Saba</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Sverzellati</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Is COVID evolution due to occurrence of pulmonary vascular thrombosis?</article-title>
          <source>J. Thorac. Imaging</source>
          <year>2020 Apr 28</year>
          <pub-id pub-id-type="doi">10.1097/RTI.0000000000000530</pub-id>
          <comment>(doi: 10.1097/RTI.0000000000000530. Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0270">
        <label>54</label>
        <element-citation publication-type="journal" id="rf0255">
          <person-group person-group-type="author">
            <name>
              <surname>Hunt</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Re the source of elevated plasma D-dimer levels in COVID-19 infection</article-title>
          <source>Br. J. Haematol.</source>
          <volume>190</volume>
          <issue>3</issue>
          <year>2020</year>
          <fpage>e133</fpage>
          <lpage>e134</lpage>
          <pub-id pub-id-type="doi">10.1111/bjh.16907</pub-id>
          <pub-id pub-id-type="pmid">32484901</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0275">
        <label>55</label>
        <element-citation publication-type="journal" id="rf0260">
          <person-group person-group-type="author">
            <name>
              <surname>Taylor</surname>
              <given-names>F.B.</given-names>
              <suffix>Jr.</suffix>
            </name>
            <name>
              <surname>Toh</surname>
              <given-names>C.H.</given-names>
            </name>
            <name>
              <surname>Hoots</surname>
              <given-names>W.K.</given-names>
            </name>
            <name>
              <surname>Wada</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Levi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH)</article-title>
          <source>Thromb. Haemost.</source>
          <volume>86</volume>
          <issue>5</issue>
          <year>2001</year>
          <fpage>1327</fpage>
          <lpage>1330</lpage>
          <pub-id pub-id-type="pmid">11816725</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0280">
        <label>56</label>
        <element-citation publication-type="journal" id="rf0265">
          <person-group person-group-type="author">
            <name>
              <surname>Takemitsu</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Wada</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hatada</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ohmori</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ishikura</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation</article-title>
          <source>Thromb. Haemost.</source>
          <volume>105</volume>
          <issue>1</issue>
          <year>2011</year>
          <fpage>40</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="doi">10.1160/TH10-05-0293</pub-id>
          <comment>Jan</comment>
          <pub-id pub-id-type="pmid">20941463</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0285">
        <label>57</label>
        <element-citation publication-type="journal" id="rf4470">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Ischemic limb gangrene with pulses</article-title>
          <volume>373</volume>
          <issue>24</issue>
          <year>2015</year>
          <fpage>2386</fpage>
          <lpage>2388</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc1511750</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0290">
        <label>58</label>
        <element-citation publication-type="journal" id="rf0270">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Kelton</surname>
              <given-names>J.G.</given-names>
            </name>
          </person-group>
          <article-title>A 14-year study of heparin-induced thrombocytopenia</article-title>
          <source>Am. J. Med.</source>
          <volume>101</volume>
          <issue>5</issue>
          <year>1996</year>
          <fpage>502</fpage>
          <lpage>507</lpage>
          <pub-id pub-id-type="doi">10.1016/s0002-9343(96)00258-6</pub-id>
          <pub-id pub-id-type="pmid">8948273</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0295">
        <label>59</label>
        <element-citation publication-type="journal" id="rf0275">
          <person-group person-group-type="author">
            <name>
              <surname>Criel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Falter</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Jaeken</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Van Kerrebroeck</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lefere</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Meylaerts</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it?</article-title>
          <source>Eur. Resp. J.</source>
          <volume>56</volume>
          <issue>1</issue>
          <year>2020</year>
          <object-id pub-id-type="publisher-id">2001201</object-id>
          <pub-id pub-id-type="doi">10.1183/13993003.01201-2020</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0300">
        <label>60</label>
        <element-citation publication-type="journal" id="rf0280">
          <person-group person-group-type="author">
            <name>
              <surname>Cui</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia</article-title>
          <source>J. Thromb. Haemost.</source>
          <volume>18</volume>
          <issue>6</issue>
          <year>2020</year>
          <fpage>1421</fpage>
          <lpage>1424</lpage>
          <pub-id pub-id-type="doi">10.1111/jth.14830</pub-id>
          <comment>(Epub 2020 May 6)</comment>
          <pub-id pub-id-type="pmid">32271988</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0305">
        <label>61</label>
        <element-citation publication-type="journal" id="rf0285">
          <person-group person-group-type="author">
            <name>
              <surname>Demelo-Rodr&#xED;guez</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cervilla-Mu&#xF1;oz</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ordieres-Ortega</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Parra-Virto</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Toledano-Marc&#xED;as</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Toledo-Samaniego</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels</article-title>
          <source>Thromb. Res.</source>
          <volume>192</volume>
          <year>2020</year>
          <fpage>23</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2020.05.018</pub-id>
          <comment>(Epub 2020 May 13)</comment>
          <pub-id pub-id-type="pmid">32405101</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0310">
        <label>62</label>
        <element-citation publication-type="journal" id="rf0290">
          <person-group person-group-type="author">
            <name>
              <surname>Fraiss&#xE9;</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Logre</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Pajot</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Mentec</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Plantef&#xE8;ve</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Contou</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study</article-title>
          <source>Crit. Care</source>
          <volume>24</volume>
          <issue>1</issue>
          <year>2020</year>
          <fpage>275</fpage>
          <pub-id pub-id-type="doi">10.1186/s13054-020-03025-y</pub-id>
          <pub-id pub-id-type="pmid">32487122</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0315">
        <label>63</label>
        <element-citation publication-type="journal" id="rf0295">
          <person-group person-group-type="author">
            <name>
              <surname>Klok</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Kruip</surname>
              <given-names>M.J.H.A.</given-names>
            </name>
            <name>
              <surname>van der Meer</surname>
              <given-names>N.J.M.</given-names>
            </name>
            <name>
              <surname>Arbous</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Gommers</surname>
              <given-names>D.A.M.P.J.</given-names>
            </name>
            <name>
              <surname>Kant</surname>
              <given-names>K.M.</given-names>
            </name>
          </person-group>
          <article-title>Incidence of thrombotic complications in critically ill ICU patients with COVID-19</article-title>
          <source>Thromb. Res.</source>
          <volume>191</volume>
          <year>2020</year>
          <fpage>145</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2020.04.013</pub-id>
          <comment>(Epub 2020 Apr 10)</comment>
          <pub-id pub-id-type="pmid">32291094</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0320">
        <label>64</label>
        <element-citation publication-type="journal" id="rf0300">
          <person-group person-group-type="author">
            <name>
              <surname>Klok</surname>
              <given-names>F.A.</given-names>
            </name>
            <name>
              <surname>Kruip</surname>
              <given-names>M.J.H.A.</given-names>
            </name>
            <name>
              <surname>van der Meer</surname>
              <given-names>N.J.M.</given-names>
            </name>
            <name>
              <surname>Arbous</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Gommers</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kant</surname>
              <given-names>K.M.</given-names>
            </name>
          </person-group>
          <article-title>Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis</article-title>
          <source>Thromb. Res.</source>
          <volume>191</volume>
          <year>2020</year>
          <fpage>148</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2020.04.041</pub-id>
          <comment>(Epub 2020 Apr 30)</comment>
          <pub-id pub-id-type="pmid">32381264</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0325">
        <label>65</label>
        <element-citation publication-type="journal" id="rf0305">
          <person-group person-group-type="author">
            <name>
              <surname>Llitjos</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Leclerc</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Chochois</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Monsallier</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Ramakers</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Auvray</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Merouani</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients</article-title>
          <source>J. Thromb. Haemost.</source>
          <volume>18</volume>
          <issue>7</issue>
          <year>2020</year>
          <fpage>1743</fpage>
          <lpage>1746</lpage>
          <pub-id pub-id-type="doi">10.1111/jth.14869</pub-id>
          <comment>(Epub 2020 May 27)</comment>
          <pub-id pub-id-type="pmid">32320517</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0330">
        <label>66</label>
        <element-citation publication-type="journal" id="rf0310">
          <person-group person-group-type="author">
            <name>
              <surname>Lodigiani</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Iapichino</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Carenzo</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Cecconi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ferrazzi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Sebastian</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy</article-title>
          <source>Thromb. Res.</source>
          <volume>191</volume>
          <year>2020</year>
          <fpage>9</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2020.04.024</pub-id>
          <comment>(Epub 2020 Apr 23)</comment>
          <pub-id pub-id-type="pmid">32353746</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0335">
        <label>67</label>
        <element-citation publication-type="journal" id="rf0315">
          <person-group person-group-type="author">
            <name>
              <surname>Maatman</surname>
              <given-names>T.K.</given-names>
            </name>
            <name>
              <surname>Jalali</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Feizpour</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Douglas</surname>
              <given-names>A.</given-names>
              <suffix>II</suffix>
            </name>
            <name>
              <surname>McGuire</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Kinnaman</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019</article-title>
          <source>Crit. Care Med.</source>
          <year>2020 May 27</year>
          <pub-id pub-id-type="doi">10.1097/CCM.0000000000004466</pub-id>
          <comment>(doi: 10.1097/CCM.0000000000004466. Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0340">
        <label>68</label>
        <element-citation publication-type="journal" id="rf0320">
          <person-group person-group-type="author">
            <name>
              <surname>Middeldorp</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Coppens</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Van Happs</surname>
              <given-names>T.F.</given-names>
            </name>
            <name>
              <surname>Foppen</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Vlaar</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>M&#xFC;ller</surname>
              <given-names>M.C.A.</given-names>
            </name>
          </person-group>
          <article-title>Incidence of venous thromboembolism in hospitalized patients with COVID-19</article-title>
          <source>J. Thromb. Haemost.</source>
          <volume>18</volume>
          <issue>8</issue>
          <year>2020</year>
          <fpage>1995</fpage>
          <lpage>2002</lpage>
          <pub-id pub-id-type="doi">10.1111/jth.14888</pub-id>
          <pub-id pub-id-type="pmid">32369666</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0345">
        <label>69</label>
        <element-citation publication-type="journal" id="rf0325">
          <person-group person-group-type="author">
            <name>
              <surname>Nahum</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Morichau-Beauchant</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Daviaud</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Echegut</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Fichet</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Maillet</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19)</article-title>
          <source>JAMA Netw. Open</source>
          <volume>3</volume>
          <issue>5</issue>
          <year>2020</year>
          <object-id pub-id-type="publisher-id">e2010478</object-id>
          <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.10478</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0350">
        <label>70</label>
        <element-citation publication-type="journal" id="rf0330">
          <person-group person-group-type="author">
            <name>
              <surname>Ren</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan</article-title>
          <source>Circulation</source>
          <volume>142</volume>
          <issue>2</issue>
          <year>2020</year>
          <fpage>181</fpage>
          <lpage>183</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047407</pub-id>
          <pub-id pub-id-type="pmid">32412320</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0355">
        <label>71</label>
        <element-citation publication-type="journal" id="rf0335">
          <person-group person-group-type="author">
            <name>
              <surname>Stoneham</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Milne</surname>
              <given-names>K.M.</given-names>
            </name>
            <name>
              <surname>Nuttal</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Frew</surname>
              <given-names>G.H.</given-names>
            </name>
            <name>
              <surname>Sturrock</surname>
              <given-names>B.R.</given-names>
            </name>
            <name>
              <surname>Sivaloganathan</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Thrombotic risk in COVID-19: a case series and case-control study</article-title>
          <source>Clin Med (Lond)</source>
          <volume>20</volume>
          <issue>4</issue>
          <year>2020</year>
          <fpage>e76</fpage>
          <lpage>e81</lpage>
          <pub-id pub-id-type="doi">10.7861/clinmed.2020-0228</pub-id>
          <pub-id pub-id-type="pmid">32423903</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0360">
        <label>72</label>
        <element-citation publication-type="journal" id="rf0340">
          <person-group person-group-type="author">
            <name>
              <surname>Thomas</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Varley</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Symington</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sheares</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom</article-title>
          <source>Thromb. Res.</source>
          <volume>191</volume>
          <year>2020</year>
          <fpage>76</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2020.04.028</pub-id>
          <comment>(Epub 2020 Apr 25)</comment>
          <pub-id pub-id-type="pmid">32402996</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0365">
        <label>73</label>
        <element-citation publication-type="journal" id="rf0345">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Mei</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: prevalence, risk factors, and outcome</article-title>
          <source>Circulation</source>
          <volume>142</volume>
          <issue>2</issue>
          <year>2020</year>
          <fpage>114</fpage>
          <lpage>128</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.046702</pub-id>
          <pub-id pub-id-type="pmid">32421381</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0370">
        <label>74</label>
        <element-citation publication-type="journal" id="rf0350">
          <person-group person-group-type="author">
            <name>
              <surname>Wichmann</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Sperhake</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>L&#xFC;tgehetmann</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Steurer</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Edler</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Heinemann</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Autopsy findings and venous thromboembolism in patients with COVID-19. A prospective cohort study</article-title>
          <source>Ann. Intern. Med.</source>
          <year>2020 May 6</year>
          <fpage>M20</fpage>
          <lpage>2003</lpage>
          <pub-id pub-id-type="doi">10.7326/M20-2003</pub-id>
          <comment>(Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0375">
        <label>75</label>
        <element-citation publication-type="journal" id="rf0355">
          <person-group person-group-type="author">
            <name>
              <surname>Faggiano</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bonelli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Paris</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Milesi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Bisegna</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Acute pulmonary embolism in COVID-19 disease: preliminary report on seven patients</article-title>
          <source>Int. J. Cardiol.</source>
          <volume>313</volume>
          <year>2020</year>
          <fpage>129</fpage>
          <lpage>131</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijcard.2020.04.028</pub-id>
          <comment>(Epub 2020 May 26)</comment>
          <pub-id pub-id-type="pmid">32471650</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0380">
        <label>76</label>
        <element-citation publication-type="journal" id="rf0360">
          <person-group person-group-type="author">
            <name>
              <surname>Poissy</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Goutay</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Caplan</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Parmentier</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Duburq</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Lassalle</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence</article-title>
          <source>Circulation</source>
          <volume>142</volume>
          <issue>2</issue>
          <year>2020</year>
          <fpage>184</fpage>
          <lpage>186</lpage>
          <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047430</pub-id>
          <pub-id pub-id-type="pmid">32330083</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0385">
        <label>77</label>
        <element-citation publication-type="journal" id="rf0365">
          <person-group person-group-type="author">
            <name>
              <surname>Bompard</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Monnier</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Saab</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Tordjman</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Abdoul</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Fournier</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary embolism in patients with Covid-19 pneumonia</article-title>
          <source>Eur. Resp. J.</source>
          <volume>56</volume>
          <issue>1</issue>
          <year>2020</year>
          <object-id pub-id-type="publisher-id">2001365</object-id>
          <pub-id pub-id-type="doi">10.1183/13993003.01365-2020</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0390">
        <label>78</label>
        <element-citation publication-type="journal" id="rf0370">
          <person-group person-group-type="author">
            <name>
              <surname>Poyiadji</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Cormier</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Patel</surname>
              <given-names>P.Y.</given-names>
            </name>
            <name>
              <surname>Hadied</surname>
              <given-names>M.O.</given-names>
            </name>
            <name>
              <surname>Bhargava</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Khanna</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Acute pulmonary embolism and COVID-19</article-title>
          <source>Radiology</source>
          <year>2020 May 14</year>
          <fpage>201955</fpage>
          <pub-id pub-id-type="doi">10.1148/radiol.2020201955</pub-id>
          <comment>(Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0395">
        <label>79</label>
        <element-citation publication-type="journal" id="rf0375">
          <person-group person-group-type="author">
            <name>
              <surname>Vitali</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Minniti</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Caporali</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Del Papa</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Occurrence of pulmonary embolism in a patient with mild clinical expression of COVID-19 infection</article-title>
          <source>Thromb. Res.</source>
          <volume>192</volume>
          <year>2020</year>
          <fpage>21</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2020.05.002</pub-id>
          <comment>(Epub 2020 May 5)</comment>
          <pub-id pub-id-type="pmid">32416365</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0400">
        <label>80</label>
        <element-citation publication-type="journal" id="rf0380">
          <person-group person-group-type="author">
            <name>
              <surname>Polat</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Bostanci</surname>
              <given-names>G.I.</given-names>
            </name>
          </person-group>
          <article-title>Sudden death due to acute pulmonary embolism in a young woman with COVID-19</article-title>
          <source>J. Thromb. Thrombolysis</source>
          <volume>50</volume>
          <issue>1</issue>
          <year>2020</year>
          <fpage>239</fpage>
          <lpage>241</lpage>
          <pub-id pub-id-type="doi">10.1007/s11239-020-02132-5</pub-id>
          <pub-id pub-id-type="pmid">32394237</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0405">
        <label>81</label>
        <element-citation publication-type="journal" id="rf0385">
          <person-group person-group-type="author">
            <name>
              <surname>Tomashefski</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Boggis</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Greene</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Zapol</surname>
              <given-names>W.M.</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>L.M.</given-names>
            </name>
          </person-group>
          <article-title>The pulmonary vascular lesions of the adult respiratory distress syndrome</article-title>
          <source>Am. J. Pathol.</source>
          <volume>112</volume>
          <issue>1</issue>
          <year>1983</year>
          <fpage>112</fpage>
          <lpage>126</lpage>
          <pub-id pub-id-type="pmid">6859225</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0410">
        <label>82</label>
        <element-citation publication-type="journal" id="rf0390">
          <person-group person-group-type="author">
            <name>
              <surname>Lax</surname>
              <given-names>S.F.</given-names>
            </name>
            <name>
              <surname>Skok</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Zechner</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kessler</surname>
              <given-names>H.H.</given-names>
            </name>
            <name>
              <surname>Kaufmann</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Koeblinger</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series</article-title>
          <source>Ann. Intern. Med.</source>
          <year>2020 May 14</year>
          <fpage>M20</fpage>
          <lpage>2566</lpage>
          <pub-id pub-id-type="doi">10.7326/M20-2566</pub-id>
          <comment>(Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0415">
        <label>83</label>
        <element-citation publication-type="journal" id="rf0395">
          <person-group person-group-type="author">
            <name>
              <surname>Menter</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Haslbauer</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Nienhold</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Savic</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hopfer</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Deigendesch</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction</article-title>
          <source>Histopathology</source>
          <year>2020 May 4</year>
          <pub-id pub-id-type="doi">10.1111/his.14134</pub-id>
          <comment>(Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0420">
        <label>84</label>
        <element-citation publication-type="journal" id="rf0400">
          <person-group person-group-type="author">
            <name>
              <surname>van Dam</surname>
              <given-names>L.F.</given-names>
            </name>
            <name>
              <surname>Kroft</surname>
              <given-names>L.J.M.</given-names>
            </name>
            <name>
              <surname>van der Wal</surname>
              <given-names>L.I.</given-names>
            </name>
            <name>
              <surname>Cannegieter</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Eikenboom</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>de Jonge</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease</article-title>
          <source>Thromb. Res.</source>
          <volume>193</volume>
          <year>2020</year>
          <fpage>86</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2020.06.010</pub-id>
          <comment>(Online ahead of print)</comment>
          <pub-id pub-id-type="pmid">32531548</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0425">
        <label>85</label>
        <element-citation publication-type="journal" id="rf0405">
          <person-group person-group-type="author">
            <name>
              <surname>Cantador</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>N&#xFA;&#xF1;ez</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sobrino</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Espejo</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Fabia</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Vela</surname>
              <given-names>L.</given-names>
            </name>
          </person-group>
          <article-title>Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients</article-title>
          <source>J. Thromb. Thrombolysis</source>
          <year>2020 Jun 9</year>
          <fpage>1</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1007/s11239-020-02176-7</pub-id>
          <comment>(Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0430">
        <label>86</label>
        <element-citation publication-type="journal" id="rf0410">
          <person-group person-group-type="author">
            <name>
              <surname>Rey</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Caro-Cod&#xF3;n</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Pineda</surname>
              <given-names>D.P.</given-names>
            </name>
            <name>
              <surname>Merino</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Iniesta</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>L&#xF3;pez-Send&#xF3;n</surname>
              <given-names>J.L.</given-names>
            </name>
          </person-group>
          <article-title>Arterial thrombotic complications in hospitalized patients with COVID-19</article-title>
          <source>Rev. Esp. Cardiol. (Engl Ed)</source>
          <year>2020 May 23</year>
          <pub-id pub-id-type="doi">10.1016/j.rec.2020.05.008</pub-id>
          <comment>S1885-5857(20)30205-X. (Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0435">
        <label>87</label>
        <element-citation publication-type="journal" id="rf0415">
          <person-group person-group-type="author">
            <name>
              <surname>Mao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Q.</given-names>
            </name>
          </person-group>
          <article-title>Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China</article-title>
          <source>JAMA Neurol.</source>
          <volume>77</volume>
          <issue>6</issue>
          <year>2020</year>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1001/jamaneurol.2020.1127</pub-id>
          <comment>(Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0440">
        <label>88</label>
        <element-citation publication-type="journal" id="rf0420">
          <person-group person-group-type="author">
            <name>
              <surname>Oxley</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Mocco</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Majidi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kellner</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Shoirah</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>I.P.</given-names>
            </name>
          </person-group>
          <article-title>Large-vessel stroke as a presenting feature of Covid-19 in the young</article-title>
          <source>N. Engl. J. Med.</source>
          <volume>382</volume>
          <issue>20</issue>
          <year>2020</year>
          <fpage>e60</fpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc2009787</pub-id>
          <comment>(Epub 2020 Apr 28)</comment>
          <pub-id pub-id-type="pmid">32343504</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0445">
        <label>89</label>
        <element-citation publication-type="journal" id="rf0425">
          <person-group person-group-type="author">
            <name>
              <surname>Jain</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dogra</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kennedy</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>COVID-19 related neuroimaging findings: a signal of thromboembolic complications and a strong prognostic marker of poor patient outcome</article-title>
          <source>J. Neurol. Sci.</source>
          <volume>414</volume>
          <year>2020 Jul 15</year>
          <fpage>116923</fpage>
          <pub-id pub-id-type="doi">10.1016/j.jns.2020.116923</pub-id>
          <comment>(Epub 2020 May 19)</comment>
          <pub-id pub-id-type="pmid">32447193</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0450">
        <label>90</label>
        <element-citation publication-type="journal" id="rf0430">
          <person-group person-group-type="author">
            <name>
              <surname>Merkler</surname>
              <given-names>A.E.</given-names>
            </name>
            <name>
              <surname>Parikh</surname>
              <given-names>N.S.</given-names>
            </name>
            <name>
              <surname>Mir</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kamel</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Risk of ischemic stroke with coronavirus disease 2019 (COVID-19) vs patients with nfluenza</article-title>
          <source>JAMA Neurol.</source>
          <year>2020 Jul 2</year>
          <pub-id pub-id-type="doi">10.1001/jamaneurol.2020.2730</pub-id>
          <comment>(Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0455">
        <label>91</label>
        <element-citation publication-type="journal" id="rf0435">
          <person-group person-group-type="author">
            <name>
              <surname>Bellosta</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Luzzani</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Natalini</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pegorer</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Attisani</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Cossu</surname>
              <given-names>L.G.</given-names>
            </name>
          </person-group>
          <article-title>Acute limb ischemia in patients with COVID-19 pneumonia</article-title>
          <source>J. Vasc. Surg.</source>
          <year>2020 Apr 29</year>
          <pub-id pub-id-type="doi">10.1016/j.jvs.2020.04.483</pub-id>
          <comment>S0741-5214(20)31080-6. (Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0460">
        <label>92</label>
        <element-citation publication-type="journal" id="rf0440">
          <person-group person-group-type="author">
            <name>
              <surname>Mestres</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Puigmaci&#xE0;</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Blanco</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Yugueros</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Esturrica</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Riambau</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Risk of peripheral arterial thrombosis in COVID-19</article-title>
          <source>J. Vasc. Surg.</source>
          <volume>72</volume>
          <issue>2</issue>
          <year>2020</year>
          <fpage>756</fpage>
          <lpage>757</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jvs.2020.04.477</pub-id>
          <pub-id pub-id-type="pmid">32417015</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0465">
        <label>93</label>
        <element-citation publication-type="journal" id="rf0445">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y.J.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia</article-title>
          <comment>[Article in Chinese]</comment>
          <source>Zhonghua Xue Ye Xue Za Zhi</source>
          <volume>41</volume>
          <issue>0</issue>
          <year>2020 Mar 28</year>
          <fpage>E006</fpage>
          <pub-id pub-id-type="doi">10.3760/cma.j.issn.0253-2727.2020.0006</pub-id>
          <comment>(Online ahead of print)</comment>
          <pub-id pub-id-type="pmid">32220276</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0470">
        <label>94</label>
        <element-citation publication-type="journal" id="rf0450">
          <person-group person-group-type="author">
            <name>
              <surname>Bavishi</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>R.O.</given-names>
            </name>
            <name>
              <surname>Trivedi</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Abbott</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Messerli</surname>
              <given-names>F.H.</given-names>
            </name>
            <name>
              <surname>Bhatt</surname>
              <given-names>D.L.</given-names>
            </name>
          </person-group>
          <article-title>Acute myocardial injury in patients hospitalized with COVID-19 infection: a review</article-title>
          <source>Prog. Cardiovasc. Dis.</source>
          <year>2020 Jun 6</year>
          <pub-id pub-id-type="doi">10.1016/j.pcad.2020.05.013</pub-id>
          <comment>S0033-0620(20)30123-7. (Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0475">
        <label>95</label>
        <element-citation publication-type="journal" id="rf0455">
          <person-group person-group-type="author">
            <name>
              <surname>Hughes</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Nichols</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Pike</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Subbe</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Elghenzai</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Cerebral venous sinus thrombosis as a presentation of COVID-19</article-title>
          <source>Eur. J. Case. Rep. Intern. Med</source>
          <volume>7</volume>
          <issue>5</issue>
          <year>2020</year>
          <fpage>001691</fpage>
          <pub-id pub-id-type="doi">10.12890/2020_001691</pub-id>
          <comment>(eCollection 2020)</comment>
          <pub-id pub-id-type="pmid">32399457</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0480">
        <label>96</label>
        <element-citation publication-type="journal" id="rf0460">
          <person-group person-group-type="author">
            <name>
              <surname>Hemasian</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Ansari</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>First case of Covid-19 presented with cerebral venous thrombosis: a rare and dreaded case</article-title>
          <source>Rev. Neurol. (Paris)</source>
          <volume>176</volume>
          <issue>6</issue>
          <year>2020</year>
          <fpage>521</fpage>
          <lpage>523</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neurol.2020.04.013</pub-id>
          <comment>(Epub 2020 May 11)</comment>
          <pub-id pub-id-type="pmid">32414532</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0485">
        <label>97</label>
        <element-citation publication-type="journal" id="rf0465">
          <person-group person-group-type="author">
            <name>
              <surname>Klein</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Libman</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kirsch</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Arora</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Cerebral venous thrombosis: atypical presentation of COVID-19 in the young</article-title>
          <source>J. Stroke Cerebrovasc. Dis.</source>
          <volume>29</volume>
          <issue>8</issue>
          <year>2020</year>
          <fpage>104989</fpage>
          <pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2020.104989</pub-id>
          <pub-id pub-id-type="pmid">32689590</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0490">
        <label>98</label>
        <element-citation publication-type="journal" id="rf0470">
          <person-group person-group-type="author">
            <name>
              <surname>Vulliamy</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Jacob</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Davenport</surname>
              <given-names>R.A.</given-names>
            </name>
          </person-group>
          <article-title>Acute aortic-iliac and mesenteric arterial thromboses as presenting features of COVID-19</article-title>
          <source>Br. J. Haematol.</source>
          <volume>189</volume>
          <issue>6</issue>
          <year>2020</year>
          <fpage>1053</fpage>
          <lpage>1054</lpage>
          <pub-id pub-id-type="doi">10.1111/bjh.16760</pub-id>
          <comment>(Epub 2020 May 15)</comment>
          <pub-id pub-id-type="pmid">32353183</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0495">
        <label>99</label>
        <mixed-citation publication-type="other" id="or0025">E. Azouz, S. Yang, L. Monnier-Cholley, L. Arriv&#xE9;, Systemic arterial thrombosis and acute mesenteric ischemic in a patient with COVID-19, Intensive Care Med. 46 (7) 1464&#x2013;1465. doi: <pub-id pub-id-type="doi">10.1007/s00134-020-06079-2</pub-id>. (Epub 2020 May 18).</mixed-citation>
      </ref>
      <ref id="bb0500">
        <label>100</label>
        <element-citation publication-type="journal" id="rf0475">
          <person-group person-group-type="author">
            <name>
              <surname>Beccara</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Pacioni</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Ponton</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Francavilla</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Cuzzoli</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Acute mesenteric thrombosis as a complication of SARS-CoV-2 infection</article-title>
          <source>Eur. J. Case Rep. Intern. Med.</source>
          <volume>7</volume>
          <issue>5</issue>
          <year>2020</year>
          <fpage>001690</fpage>
          <pub-id pub-id-type="doi">10.12890/2020_001690</pub-id>
          <comment>(eCollection 2020)</comment>
          <pub-id pub-id-type="pmid">32399456</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0505">
        <label>101</label>
        <element-citation publication-type="journal" id="rf0480">
          <person-group person-group-type="author">
            <name>
              <surname>Giacomelli</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Dorigo</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Fargion</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Calugi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Cianchi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Pratesi</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Acute thrombosis of an aortic prosthetic graft in a patient with severe COVID-19-related pneumonia</article-title>
          <source>Ann. Vasc. Surg.</source>
          <volume>66</volume>
          <year>2020</year>
          <fpage>8</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1016/j.avsg.2020.04.040</pub-id>
          <comment>(Epub 2020 Apr 29)</comment>
          <pub-id pub-id-type="pmid">32360432</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0510">
        <label>102</label>
        <element-citation publication-type="journal" id="rf0485">
          <person-group person-group-type="author">
            <name>
              <surname>de Barry</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Mekki</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Diffre</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Seror</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>El Hajjam</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Carlier</surname>
              <given-names>R.-Y.</given-names>
            </name>
          </person-group>
          <article-title>Arterial and venous abdominal thrombosis in a 79-year-old woman with COVID-19 pneumonia</article-title>
          <source>Radiol. Case Rep.</source>
          <volume>15</volume>
          <issue>7</issue>
          <year>2020</year>
          <fpage>1054</fpage>
          <lpage>1057</lpage>
          <pub-id pub-id-type="doi">10.1016/j.radcr.2020.04.055</pub-id>
          <comment>(Online ahead of print)</comment>
          <pub-id pub-id-type="pmid">32351657</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0515">
        <label>103</label>
        <element-citation publication-type="journal" id="rf0490">
          <person-group person-group-type="author">
            <name>
              <surname>Hong</surname>
              <given-names>A.P.</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Sigouin</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <article-title>Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia</article-title>
          <source>Blood</source>
          <volume>101</volume>
          <issue>8</issue>
          <year>2003</year>
          <fpage>3049</fpage>
          <lpage>3051</lpage>
          <pub-id pub-id-type="pmid">12506031</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0520">
        <label>104</label>
        <element-citation publication-type="journal" id="rf0495">
          <person-group person-group-type="author">
            <name>
              <surname>Bozzani</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Arici</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Franciscone</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Danesino</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Cascina</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ticozzelli</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Ragni</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Severe acute respiratory syndrome coronavirus 2 infection and the upper limb deep vein thrombosis risk</article-title>
          <source>Ann. Vasc. Surg.</source>
          <volume>66</volume>
          <year>2020</year>
          <fpage>11</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1016/j.avsg.2020.04.037</pub-id>
          <comment>(Epub 2020 Apr 23)</comment>
          <pub-id pub-id-type="pmid">32335249</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0525">
        <label>105</label>
        <element-citation publication-type="journal" id="rf0500">
          <person-group person-group-type="author">
            <name>
              <surname>Martel</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>P.S.</given-names>
            </name>
          </person-group>
          <article-title>Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis</article-title>
          <source>Blood</source>
          <volume>106</volume>
          <issue>8</issue>
          <year>2005</year>
          <fpage>2710</fpage>
          <lpage>2715</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2005-04-1546</pub-id>
          <comment>Oct 15. (Epub 2005 Jun 28)</comment>
          <pub-id pub-id-type="pmid">15985543</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0530">
        <label>106</label>
        <element-citation publication-type="journal" id="rf0505">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Sigouin</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Kohlmann</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Eichler</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Greinacher</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia</article-title>
          <source>Blood.</source>
          <volume>108</volume>
          <issue>9</issue>
          <year>2006</year>
          <fpage>2937</fpage>
          <lpage>2941</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2005-11-012450</pub-id>
          <comment>(Epub 2006 Jul 20)</comment>
          <pub-id pub-id-type="pmid">16857993</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0535">
        <label>107</label>
        <element-citation publication-type="book" id="rf0510">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
          </person-group>
          <chapter-title>Clinical picture of heparin-induced thrombocytopenia</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Greinacher</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <source>Heparin-Induced Thrombocytopenia</source>
          <edition>5th ed.</edition>
          <year>2013</year>
          <publisher-name>CRC Press</publisher-name>
          <publisher-loc>Boca Raton, FL</publisher-loc>
          <fpage>24</fpage>
          <lpage>76</lpage>
        </element-citation>
      </ref>
      <ref id="bb0540">
        <label>108</label>
        <element-citation publication-type="journal" id="rf0515">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Heels-Ansdell</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>McIntyre</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>M.G.</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia in medical surgical critical illness</article-title>
          <source>Chest</source>
          <volume>144</volume>
          <issue>3</issue>
          <year>2013</year>
          <fpage>848</fpage>
          <lpage>858</lpage>
          <pub-id pub-id-type="doi">10.1378/chest.13-0057</pub-id>
          <pub-id pub-id-type="pmid">23722881</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0545">
        <label>109</label>
        <element-citation publication-type="journal" id="rf0520">
          <person-group person-group-type="author">
            <name>
              <surname>Paparella</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Scrascia</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Galeone</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Coviello</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Cappabianca</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Venneri</surname>
              <given-names>M.T.</given-names>
            </name>
          </person-group>
          <article-title>Formation of anti-platelet factor 4/heparin antibodies following cardiac surgery: influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status</article-title>
          <source>J. Thorac. Cardiovasc. Surg.</source>
          <volume>136</volume>
          <issue>6</issue>
          <year>2008 Dec</year>
          <fpage>1456</fpage>
          <lpage>1463</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jtcvs.2008.06.014</pub-id>
          <comment>(Epub 2008 Jul 24)</comment>
          <pub-id pub-id-type="pmid">19114189</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0550">
        <label>110</label>
        <element-citation publication-type="journal" id="rf0525">
          <person-group person-group-type="author">
            <name>
              <surname>Riker</surname>
              <given-names>R.R.</given-names>
            </name>
            <name>
              <surname>May</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>G.L.</given-names>
            </name>
            <name>
              <surname>Gagnon</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Bandara</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Zemrak</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia with thrombosis in COVID-19 adult respiratory distress syndrome</article-title>
          <source>Res. Pract. Thromb. Haemost.</source>
          <volume>4</volume>
          <issue>5</issue>
          <year>2020</year>
          <fpage>936</fpage>
          <lpage>941</lpage>
          <pub-id pub-id-type="doi">10.1002/rth2.12390</pub-id>
          <pub-id pub-id-type="pmid">32685905</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0555">
        <label>111</label>
        <element-citation publication-type="journal" id="rf0530">
          <person-group person-group-type="author">
            <name>
              <surname>Lingamaneni</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Gonakoti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Moturi</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Vohra</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Zia</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia in COVID-19</article-title>
          <source>J. Investig. Med. High Impact Case Rep.</source>
          <volume>8</volume>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1177/2324709620944091</pub-id>
          <comment>2324709620944091</comment>
        </element-citation>
      </ref>
      <ref id="bb0560">
        <label>112</label>
        <element-citation publication-type="journal" id="rf0535">
          <person-group person-group-type="author">
            <name>
              <surname>Patel</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bogue</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Merrill</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Koshy</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bindal</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Heparin induced antibodies in COVID-19</article-title>
          <source>Am. J. Hematol.</source>
          <year>2020 Jul 13</year>
          <pub-id pub-id-type="doi">10.1002/ajh.25935</pub-id>
          <comment>(Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0565">
        <label>113</label>
        <element-citation publication-type="journal" id="rf0540">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Linkins</surname>
              <given-names>L.A.</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>D.M.</given-names>
            </name>
            <name>
              <surname>Nazy</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL&#xAE; HIT-Ab<sub>(PF4-H)</sub>] for the diagnosis of immune heparin-induced thrombocytopenia</article-title>
          <source>Thromb. Res.</source>
          <volume>153</volume>
          <year>2017</year>
          <fpage>108</fpage>
          <lpage>117</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thromres.2017.03.010</pub-id>
          <pub-id pub-id-type="pmid">28391124</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0570">
        <label>114</label>
        <element-citation publication-type="journal" id="rf0545">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Nazy</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>J.I.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Kelton</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>Serotonin-release assay-negative heparin-induced thrombocytopenia</article-title>
          <source>Am. J. Hematol.</source>
          <volume>95</volume>
          <issue>1</issue>
          <year>2020</year>
          <fpage>38</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="doi">10.1002/ajh.25660</pub-id>
          <pub-id pub-id-type="pmid">31621093</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0575">
        <label>115</label>
        <element-citation publication-type="journal" id="rf0550">
          <person-group person-group-type="author">
            <name>
              <surname>Vayne</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Guery</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Kizlik-Masson</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rollin</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bauters</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gruel</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Pouplard</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies</article-title>
          <source>Br. J. Haematol.</source>
          <volume>179</volume>
          <issue>5</issue>
          <year>2017</year>
          <fpage>811</fpage>
          <lpage>819</lpage>
          <pub-id pub-id-type="doi">10.1111/bjh.14955</pub-id>
          <pub-id pub-id-type="pmid">29048130</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0580">
        <label>116</label>
        <element-citation publication-type="journal" id="rf0555">
          <person-group person-group-type="author">
            <name>
              <surname>Padmanabhan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>C.G.</given-names>
            </name>
            <name>
              <surname>G</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Curtis</surname>
              <given-names>B.R.</given-names>
            </name>
            <name>
              <surname>Bougie</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Peswani</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>A novel PF4-dependent platelet activation assay identifies patients likely to have heparin-induced thrombocytopenia/thrombosis</article-title>
          <source>Chest</source>
          <volume>150</volume>
          <issue>3</issue>
          <year>2016</year>
          <fpage>506</fpage>
          <lpage>515</lpage>
          <pub-id pub-id-type="doi">10.1016/j.chest.2016.02.641</pub-id>
          <pub-id pub-id-type="pmid">26905366</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0585">
        <label>117</label>
        <element-citation publication-type="journal" id="rf0560">
          <person-group person-group-type="author">
            <name>
              <surname>Parzy</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Daviet</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Puech</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Sylvestre</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Guervilly</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Porto</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Venous thromboembolism events following venovenous extracorporeal membrane oxygenation for severe acute respiratory syndrome coronavirus 2 based on CT scans</article-title>
          <source>Crit. Care. Med.</source>
          <year>2020 Jun 26</year>
          <pub-id pub-id-type="doi">10.1097/CCM.0000000000004504</pub-id>
          <comment>Online ahead of print</comment>
        </element-citation>
      </ref>
      <ref id="bb0590">
        <label>118</label>
        <element-citation publication-type="journal" id="rf5980">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-induced treatment</article-title>
          <source>MedRxiv</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1101/2020.04.23.20076851</pub-id>
          <comment>(preprint, not peer-reviewed)</comment>
        </element-citation>
      </ref>
      <ref id="bb0595">
        <label>119</label>
        <element-citation publication-type="journal" id="rf0565">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>T.E.</given-names>
            </name>
            <name>
              <surname>Basciano</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Knopman</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Bernstein</surname>
              <given-names>R.A.</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder</article-title>
          <source>Blood.</source>
          <volume>123</volume>
          <issue>23</issue>
          <year>2014</year>
          <fpage>3651</fpage>
          <lpage>3654</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2014-01-549741</pub-id>
          <comment>(Epub 2014 Mar 27)</comment>
          <pub-id pub-id-type="pmid">24677540</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0600">
        <label>120</label>
        <element-citation publication-type="journal" id="rf0570">
          <person-group person-group-type="author">
            <name>
              <surname>Farner</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Eichler</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kroll</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Greinacher</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia</article-title>
          <source>Thromb. Haemost.</source>
          <volume>85</volume>
          <issue>6</issue>
          <year>2001</year>
          <fpage>950</fpage>
          <lpage>957</lpage>
          <pub-id pub-id-type="pmid">11434701</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0605">
        <label>121</label>
        <element-citation publication-type="journal" id="rf0575">
          <person-group person-group-type="author">
            <name>
              <surname>Paranjpe</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Fuster</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Lala</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Russak</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Glicksberg</surname>
              <given-names>B.S.</given-names>
            </name>
            <name>
              <surname>Levin</surname>
              <given-names>M.A.</given-names>
            </name>
          </person-group>
          <article-title>Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19</article-title>
          <source>J. Am. Coll. Cardiol.</source>
          <volume>76</volume>
          <issue>1</issue>
          <year>2020</year>
          <fpage>122</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jacc.2020.05.001</pub-id>
          <comment>(Epub 2020 May 6)</comment>
          <pub-id pub-id-type="pmid">32387623</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0610">
        <label>122</label>
        <element-citation publication-type="journal" id="rf0580">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Bai</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Gong</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <article-title>Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy</article-title>
          <source>J. Thromb. Haemost.</source>
          <volume>18</volume>
          <issue>5</issue>
          <year>2020</year>
          <fpage>1094</fpage>
          <lpage>1099</lpage>
          <pub-id pub-id-type="doi">10.1111/jth.14817</pub-id>
          <comment>(Epub 2020 Apr 27)</comment>
          <pub-id pub-id-type="pmid">32220112</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0615">
        <label>123</label>
        <element-citation publication-type="journal" id="rf0585">
          <person-group person-group-type="author">
            <name>
              <surname>Barnes</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Burnett</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Allen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Blumenstein</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>N.P.</given-names>
            </name>
            <name>
              <surname>Cuker</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum</article-title>
          <source>J. Thromb. Thrombolysis</source>
          <volume>50</volume>
          <issue>1</issue>
          <year>2020</year>
          <fpage>72</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="doi">10.1007/s11239-020-02138-z</pub-id>
          <pub-id pub-id-type="pmid">32440883</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0620">
        <label>124</label>
        <element-citation publication-type="journal" id="rf0590">
          <person-group person-group-type="author">
            <name>
              <surname>Spyropoulos</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Levy</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Ageno</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Connors</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Hunt</surname>
              <given-names>B.J.</given-names>
            </name>
            <name>
              <surname>Iba</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19</article-title>
          <source>J. Thromb. Haemost.</source>
          <volume>18</volume>
          <issue>8</issue>
          <year>2020</year>
          <fpage>1859</fpage>
          <lpage>1865</lpage>
          <pub-id pub-id-type="doi">10.1111/jth.14929</pub-id>
          <comment>(Online ahead of print)</comment>
          <pub-id pub-id-type="pmid">32459046</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0625">
        <label>125</label>
        <element-citation publication-type="journal" id="rf0595">
          <person-group person-group-type="author">
            <name>
              <surname>Moores</surname>
              <given-names>L.K.</given-names>
            </name>
            <name>
              <surname>Tritschler</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Brosahan</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Carrier</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Collen</surname>
              <given-names>J.F.</given-names>
            </name>
            <name>
              <surname>Doerschug</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Prevention, diagnosis, and treatment of VTE in patients with COVID-19: CHEST guideline and expert panel report</article-title>
          <source>Chest</source>
          <year>2020 Jun 2</year>
          <pub-id pub-id-type="doi">10.1016/j.chest.2020.05.559</pub-id>
          <comment>S0012-3692(20)31625-1. (Online ahead of print)</comment>
        </element-citation>
      </ref>
      <ref id="bb0630">
        <label>126</label>
        <element-citation publication-type="journal" id="rf0600">
          <person-group person-group-type="author">
            <name>
              <surname>Bikdeli</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Madhavan</surname>
              <given-names>M.V.</given-names>
            </name>
            <name>
              <surname>Jimenez</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Chuich</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Dreyfus</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Driggin</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review</article-title>
          <source>J. Am. Coll. Cardiol.</source>
          <volume>75</volume>
          <issue>23</issue>
          <year>2020</year>
          <fpage>2950</fpage>
          <lpage>2973</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jacc.2020.04.031</pub-id>
          <comment>(Epub 2020 Apr 17)</comment>
          <pub-id pub-id-type="pmid">32311448</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0635">
        <label>127</label>
        <element-citation publication-type="other" id="rf0605">
          <ext-link ext-link-type="uri" xlink:href="https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation" id="ir0090">https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation</ext-link>
        </element-citation>
      </ref>
      <ref id="bb0640">
        <label>128</label>
        <element-citation publication-type="other" id="rf0610">
          <ext-link ext-link-type="uri" xlink:href="https://www.covid19treatmentguidelines.nih.gov/antithrombotic-therapy/" id="ir0095">https://www.covid19treatmentguidelines.nih.gov/antithrombotic-therapy/</ext-link>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
